Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,16867168,t1/2,The mean t1/2 of solifenacin was extended from 49.3 to 77.5 hr whereas time to Cmax did not change.,Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16867168/),h,49.3 to 77.5,435,DB00592,Piperazine
,9433654,Renal clearance,"Renal clearance was 0.50 +/- 0.05 ml/min/kg in healthy individuals vs 0.15 +/- 0.05 ml/min/kg in patients with severe renal impairment on day 1, while the corresponding values on day 7 were 0.46 +/- 0.04 ml/min/kg vs 0.14 +/- 0.08 ml/min/kg, respectively.",Effect of renal impairment on the pharmacokinetics of grepafloxacin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433654/),[ml] / [kg·min],0.50,794,DB00592,Piperazine
,9433654,Renal clearance,"Renal clearance was 0.50 +/- 0.05 ml/min/kg in healthy individuals vs 0.15 +/- 0.05 ml/min/kg in patients with severe renal impairment on day 1, while the corresponding values on day 7 were 0.46 +/- 0.04 ml/min/kg vs 0.14 +/- 0.08 ml/min/kg, respectively.",Effect of renal impairment on the pharmacokinetics of grepafloxacin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433654/),[ml] / [kg·min],0.15,795,DB00592,Piperazine
,9433654,Renal clearance,"Renal clearance was 0.50 +/- 0.05 ml/min/kg in healthy individuals vs 0.15 +/- 0.05 ml/min/kg in patients with severe renal impairment on day 1, while the corresponding values on day 7 were 0.46 +/- 0.04 ml/min/kg vs 0.14 +/- 0.08 ml/min/kg, respectively.",Effect of renal impairment on the pharmacokinetics of grepafloxacin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433654/),[ml] / [kg·min],0.46,796,DB00592,Piperazine
,9433654,Renal clearance,"Renal clearance was 0.50 +/- 0.05 ml/min/kg in healthy individuals vs 0.15 +/- 0.05 ml/min/kg in patients with severe renal impairment on day 1, while the corresponding values on day 7 were 0.46 +/- 0.04 ml/min/kg vs 0.14 +/- 0.08 ml/min/kg, respectively.",Effect of renal impairment on the pharmacokinetics of grepafloxacin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433654/),[ml] / [kg·min],0.14,797,DB00592,Piperazine
,9433654,percentage,The percentage of grepafloxacin excreted unchanged in urine on day 1 was 5.1 +/- 3.0 in the healthy individuals and 1.5 +/- 0.7 in those with severe renal impairment.,Effect of renal impairment on the pharmacokinetics of grepafloxacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433654/),,5.1,798,DB00592,Piperazine
,9433654,percentage,The percentage of grepafloxacin excreted unchanged in urine on day 1 was 5.1 +/- 3.0 in the healthy individuals and 1.5 +/- 0.7 in those with severe renal impairment.,Effect of renal impairment on the pharmacokinetics of grepafloxacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433654/),,1.5,799,DB00592,Piperazine
,9433654,excreted unchanged in,The percentage of grepafloxacin excreted unchanged in urine on day 1 was 5.1 +/- 3.0 in the healthy individuals and 1.5 +/- 0.7 in those with severe renal impairment.,Effect of renal impairment on the pharmacokinetics of grepafloxacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433654/),,5.1,800,DB00592,Piperazine
,9433654,excreted unchanged in,The percentage of grepafloxacin excreted unchanged in urine on day 1 was 5.1 +/- 3.0 in the healthy individuals and 1.5 +/- 0.7 in those with severe renal impairment.,Effect of renal impairment on the pharmacokinetics of grepafloxacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433654/),,1.5,801,DB00592,Piperazine
,9088588,peak concentration,"Itraconazole treatment did not significantly change the peak concentration of astemizole (0.74 vs 0.81 ng ml-1) but it increased the area under the curve from 0 to 24 h (5.46 to 9.95 ng ml-1 h) and from 0 to infinity (17.4 to 48.2 ng ml-1 h), and the elimination half-life (2.1 to 3.6 days).",Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088588/),[ng] / [ml],0.74,981,DB00592,Piperazine
,9088588,peak concentration,"Itraconazole treatment did not significantly change the peak concentration of astemizole (0.74 vs 0.81 ng ml-1) but it increased the area under the curve from 0 to 24 h (5.46 to 9.95 ng ml-1 h) and from 0 to infinity (17.4 to 48.2 ng ml-1 h), and the elimination half-life (2.1 to 3.6 days).",Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088588/),[ng] / [ml],0.81,982,DB00592,Piperazine
,9088588,area under the curve from 0 to 24 h,"Itraconazole treatment did not significantly change the peak concentration of astemizole (0.74 vs 0.81 ng ml-1) but it increased the area under the curve from 0 to 24 h (5.46 to 9.95 ng ml-1 h) and from 0 to infinity (17.4 to 48.2 ng ml-1 h), and the elimination half-life (2.1 to 3.6 days).",Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088588/),[h·ng] / [ml],5.46 to 9.95,983,DB00592,Piperazine
,9088588,from,"Itraconazole treatment did not significantly change the peak concentration of astemizole (0.74 vs 0.81 ng ml-1) but it increased the area under the curve from 0 to 24 h (5.46 to 9.95 ng ml-1 h) and from 0 to infinity (17.4 to 48.2 ng ml-1 h), and the elimination half-life (2.1 to 3.6 days).",Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088588/),[h·ng] / [ml],17.4 to 48.2,984,DB00592,Piperazine
,9088588,0 to infinity,"Itraconazole treatment did not significantly change the peak concentration of astemizole (0.74 vs 0.81 ng ml-1) but it increased the area under the curve from 0 to 24 h (5.46 to 9.95 ng ml-1 h) and from 0 to infinity (17.4 to 48.2 ng ml-1 h), and the elimination half-life (2.1 to 3.6 days).",Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088588/),[h·ng] / [ml],17.4 to 48.2,985,DB00592,Piperazine
,9088588,elimination half-life,"Itraconazole treatment did not significantly change the peak concentration of astemizole (0.74 vs 0.81 ng ml-1) but it increased the area under the curve from 0 to 24 h (5.46 to 9.95 ng ml-1 h) and from 0 to infinity (17.4 to 48.2 ng ml-1 h), and the elimination half-life (2.1 to 3.6 days).",Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088588/),d,2.1 to 3.6,986,DB00592,Piperazine
,11569531,Plasma clearances,"Plasma clearances in the male and female rat were high (120 and 54 ml min(-1) kg(-1)), giving rise to short elimination half-lives (0.2 and 0.3h respectively).","Pharmacokinetics and metabolism of a selective PDE5 inhibitor (UK-343,664) in rat and dog. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11569531/),[ml] / [kg·min],120,1342,DB00592,Piperazine
,11569531,Plasma clearances,"Plasma clearances in the male and female rat were high (120 and 54 ml min(-1) kg(-1)), giving rise to short elimination half-lives (0.2 and 0.3h respectively).","Pharmacokinetics and metabolism of a selective PDE5 inhibitor (UK-343,664) in rat and dog. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11569531/),[ml] / [kg·min],54,1343,DB00592,Piperazine
,11569531,elimination half-lives,"Plasma clearances in the male and female rat were high (120 and 54 ml min(-1) kg(-1)), giving rise to short elimination half-lives (0.2 and 0.3h respectively).","Pharmacokinetics and metabolism of a selective PDE5 inhibitor (UK-343,664) in rat and dog. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11569531/),h,0.2,1344,DB00592,Piperazine
,11569531,elimination half-lives,"Plasma clearances in the male and female rat were high (120 and 54 ml min(-1) kg(-1)), giving rise to short elimination half-lives (0.2 and 0.3h respectively).","Pharmacokinetics and metabolism of a selective PDE5 inhibitor (UK-343,664) in rat and dog. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11569531/),h,0.3,1345,DB00592,Piperazine
,11569531,clearance,Lower clearance in dog (14 ml min(-1) kg(-1)) was the primary factor resulting in a longer elimination half-life (3.7 h).,"Pharmacokinetics and metabolism of a selective PDE5 inhibitor (UK-343,664) in rat and dog. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11569531/),[ml] / [kg·min],14,1346,DB00592,Piperazine
,11569531,elimination half-life,Lower clearance in dog (14 ml min(-1) kg(-1)) was the primary factor resulting in a longer elimination half-life (3.7 h).,"Pharmacokinetics and metabolism of a selective PDE5 inhibitor (UK-343,664) in rat and dog. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11569531/),h,3.7,1347,DB00592,Piperazine
,11569531,volume of distribution,2. The volume of distribution was lower in rat (1.3-2.11 kg(-1)) compared with dog (4.61 kg(-1)) probably due to increased plasma protein binding in rat (96 versus 81% in dog).,"Pharmacokinetics and metabolism of a selective PDE5 inhibitor (UK-343,664) in rat and dog. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11569531/),1/[kg],1.3-2.11,1348,DB00592,Piperazine
,11569531,volume of distribution,2. The volume of distribution was lower in rat (1.3-2.11 kg(-1)) compared with dog (4.61 kg(-1)) probably due to increased plasma protein binding in rat (96 versus 81% in dog).,"Pharmacokinetics and metabolism of a selective PDE5 inhibitor (UK-343,664) in rat and dog. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11569531/),1/[kg],4.61,1349,DB00592,Piperazine
,11569531,plasma protein binding,2. The volume of distribution was lower in rat (1.3-2.11 kg(-1)) compared with dog (4.61 kg(-1)) probably due to increased plasma protein binding in rat (96 versus 81% in dog).,"Pharmacokinetics and metabolism of a selective PDE5 inhibitor (UK-343,664) in rat and dog. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11569531/),%,96,1350,DB00592,Piperazine
,11569531,plasma protein binding,2. The volume of distribution was lower in rat (1.3-2.11 kg(-1)) compared with dog (4.61 kg(-1)) probably due to increased plasma protein binding in rat (96 versus 81% in dog).,"Pharmacokinetics and metabolism of a selective PDE5 inhibitor (UK-343,664) in rat and dog. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11569531/),%,81,1351,DB00592,Piperazine
,11569531,Oral bioavailabilities,"3. Oral bioavailabilities were 2, 12 and 70% in the male and female rat and dog respectively.","Pharmacokinetics and metabolism of a selective PDE5 inhibitor (UK-343,664) in rat and dog. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11569531/),%,2,1352,DB00592,Piperazine
,11569531,Oral bioavailabilities,"3. Oral bioavailabilities were 2, 12 and 70% in the male and female rat and dog respectively.","Pharmacokinetics and metabolism of a selective PDE5 inhibitor (UK-343,664) in rat and dog. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11569531/),%,12,1353,DB00592,Piperazine
,11569531,Oral bioavailabilities,"3. Oral bioavailabilities were 2, 12 and 70% in the male and female rat and dog respectively.","Pharmacokinetics and metabolism of a selective PDE5 inhibitor (UK-343,664) in rat and dog. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11569531/),%,70,1354,DB00592,Piperazine
< or =,11569531,Tmax,Tmax < or = 0.5 h in all animals.,"Pharmacokinetics and metabolism of a selective PDE5 inhibitor (UK-343,664) in rat and dog. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11569531/),h,0.5,1355,DB00592,Piperazine
,3700520,detection limit,"Injection of 100 microliters of serum into the automated pre-column system, followed by high-performance liquid chromatography with electrochemical detection, gave a detection limit for urapidil and metabolites in serum of 5 ng/ml.",Determination of urapidil and its metabolites in human serum and urine: comparison of liquid-liquid and fully automated liquid-solid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3700520/),[ng] / [ml],5,1372,DB00592,Piperazine
,19293394,PFS,"Overall median PFS was 2 months (range, 0.7-34 months); 6M-PFS was 29.4%.",Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19293394/),month,2,1697,DB00592,Piperazine
,19293394,PFS,"For benign meningiomas, median PFS was 3 months (range, 1.1-34 months); 6M-PFS was 45%.",Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19293394/),month,3,1698,DB00592,Piperazine
,19293394,PFS,"For atypical and malignant meningiomas, median PFS was 2 months (range, 0.7-3.7 months); 6M-PFS was 0%.",Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19293394/),month,2,1699,DB00592,Piperazine
,19293394,trough concentrations,"Cycle 1 trough concentrations of imatinib and CGP74588 were 2,129 +/- 1,600 ng/ml and 517 +/- 326 ng/ml, respectively.",Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19293394/),[ng] / [ml],"2,129",1700,DB00592,Piperazine
,19293394,trough concentrations,"Cycle 1 trough concentrations of imatinib and CGP74588 were 2,129 +/- 1,600 ng/ml and 517 +/- 326 ng/ml, respectively.",Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19293394/),[ng] / [ml],517,1701,DB00592,Piperazine
,22732766,time to maximum plasma concentration (t(max)),The plasma vardenafil concentration increased rapidly and exhibited a median time to maximum plasma concentration (t(max)) of 1 h and a mean elimination half-life (t(1/2)) of 3.4 h.,High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22732766/),h,1,1895,DB00592,Piperazine
,22732766,elimination half-life (t(1/2)),The plasma vardenafil concentration increased rapidly and exhibited a median time to maximum plasma concentration (t(max)) of 1 h and a mean elimination half-life (t(1/2)) of 3.4 h.,High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22732766/),h,3.4,1896,DB00592,Piperazine
,22732766,peak plasma concentration (C(max)),"The geometric mean and standard deviation of (1) the peak plasma concentration (C(max)) was 21.4 ± 1.7 μg/L, (2) the normalized C(max) (C(max, norm)) 79.1 ± 1.6 g/L, (3) the area under the time-concentration curve (AUC) 71.5 ± 1.6 μg · h/L and (4) the normalized AUC (AUC(norm)) 261.6 ± 1.7 g · h/L.",High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22732766/),[μg] / [l],21.4,1897,DB00592,Piperazine
,22732766,normalized,"The geometric mean and standard deviation of (1) the peak plasma concentration (C(max)) was 21.4 ± 1.7 μg/L, (2) the normalized C(max) (C(max, norm)) 79.1 ± 1.6 g/L, (3) the area under the time-concentration curve (AUC) 71.5 ± 1.6 μg · h/L and (4) the normalized AUC (AUC(norm)) 261.6 ± 1.7 g · h/L.",High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22732766/),[g] / [l],79.1,1898,DB00592,Piperazine
,22732766,C(max) (C(max,"The geometric mean and standard deviation of (1) the peak plasma concentration (C(max)) was 21.4 ± 1.7 μg/L, (2) the normalized C(max) (C(max, norm)) 79.1 ± 1.6 g/L, (3) the area under the time-concentration curve (AUC) 71.5 ± 1.6 μg · h/L and (4) the normalized AUC (AUC(norm)) 261.6 ± 1.7 g · h/L.",High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22732766/),[g] / [l],79.1,1899,DB00592,Piperazine
,22732766,area under the time-concentration curve (AUC),"The geometric mean and standard deviation of (1) the peak plasma concentration (C(max)) was 21.4 ± 1.7 μg/L, (2) the normalized C(max) (C(max, norm)) 79.1 ± 1.6 g/L, (3) the area under the time-concentration curve (AUC) 71.5 ± 1.6 μg · h/L and (4) the normalized AUC (AUC(norm)) 261.6 ± 1.7 g · h/L.",High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22732766/),[h·μg] / [l],71.5,1900,DB00592,Piperazine
,22732766,normalized,"The geometric mean and standard deviation of (1) the peak plasma concentration (C(max)) was 21.4 ± 1.7 μg/L, (2) the normalized C(max) (C(max, norm)) 79.1 ± 1.6 g/L, (3) the area under the time-concentration curve (AUC) 71.5 ± 1.6 μg · h/L and (4) the normalized AUC (AUC(norm)) 261.6 ± 1.7 g · h/L.",High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22732766/),[g·h] / [l],261.6,1901,DB00592,Piperazine
,22732766,AUC (AUC(norm)),"The geometric mean and standard deviation of (1) the peak plasma concentration (C(max)) was 21.4 ± 1.7 μg/L, (2) the normalized C(max) (C(max, norm)) 79.1 ± 1.6 g/L, (3) the area under the time-concentration curve (AUC) 71.5 ± 1.6 μg · h/L and (4) the normalized AUC (AUC(norm)) 261.6 ± 1.7 g · h/L.",High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22732766/),[g·h] / [l],261.6,1902,DB00592,Piperazine
,11557914,heart rate,"As expected, heart rate increased from baseline (approximately 8-11 beats/min) at > or =8 mg reboxetine daily.",Lack of effect of reboxetine on cardiac repolarization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557914/),[beats] / [min],8-11,2265,DB00592,Piperazine
,11180024,unbound plasma level,"Ketoconazole significantly elevated ritonavir CSF concentration by 178% (95% CI, 59%-385%), from 2.4 to 6.6 ng/mL, with no change in paired unbound plasma level (26 ng/mL); this led to a commensurate 181% increase (95% CI, 47%-437%) in CSF/plasma unbound ratio.",Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180024/),[ng] / [ml],26,2307,DB00592,Piperazine
,28436712,plasma half-life,"2. The galunisertib plasma half-life was 8.6 h, while the 14C half-life was 10.0 h.","Disposition and metabolism of [14C]-galunisertib, a TGF-βRI kinase/ALK5 inhibitor, following oral administration in healthy subjects and mechanistic prediction of the effect of itraconazole on galunisertib pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28436712/),h,8.6,2718,DB00592,Piperazine
,28436712,half-life,"2. The galunisertib plasma half-life was 8.6 h, while the 14C half-life was 10.0 h.","Disposition and metabolism of [14C]-galunisertib, a TGF-βRI kinase/ALK5 inhibitor, following oral administration in healthy subjects and mechanistic prediction of the effect of itraconazole on galunisertib pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28436712/),h,10.0,2719,DB00592,Piperazine
,28436712,AUC ratio,"Mechanistic static modeling that incorporated small non-CYP-mediated metabolic clearance and renal clearance components predicted an AUC ratio of 4.7 for the effect of itraconazole, a strong CYP3A4 inhibitor, on galunisertib.","Disposition and metabolism of [14C]-galunisertib, a TGF-βRI kinase/ALK5 inhibitor, following oral administration in healthy subjects and mechanistic prediction of the effect of itraconazole on galunisertib pharmacokinetics. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28436712/),,4.7,2720,DB00592,Piperazine
,2848702,half-lives,"Following intravenous injection of 150 micrograms kg-1, pipecuronium disappeared from the plasma bi-exponentially with half-lives of 9.8 +/- 5.4, 77.7 +/- 9.7 min and 7.2 +/- 5.0, 100, 6 +/- 23.7 min; the Vd was 362.3 +/- 74.9 ml kg-1 and 123.7 +/- 14.6 ml kg-1 and the clearance was 5.0 +/- 0.9 ml min-1 kg-1 and 1.0 +/- 0.1 ml min-1 in the animals with and without renal function, respectively.",Pharmacokinetics and disposition of pipecuronium bromide in the cat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848702/),min,9.8,2734,DB00592,Piperazine
,2848702,half-lives,"Following intravenous injection of 150 micrograms kg-1, pipecuronium disappeared from the plasma bi-exponentially with half-lives of 9.8 +/- 5.4, 77.7 +/- 9.7 min and 7.2 +/- 5.0, 100, 6 +/- 23.7 min; the Vd was 362.3 +/- 74.9 ml kg-1 and 123.7 +/- 14.6 ml kg-1 and the clearance was 5.0 +/- 0.9 ml min-1 kg-1 and 1.0 +/- 0.1 ml min-1 in the animals with and without renal function, respectively.",Pharmacokinetics and disposition of pipecuronium bromide in the cat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848702/),min,77.7,2735,DB00592,Piperazine
,2848702,half-lives,"Following intravenous injection of 150 micrograms kg-1, pipecuronium disappeared from the plasma bi-exponentially with half-lives of 9.8 +/- 5.4, 77.7 +/- 9.7 min and 7.2 +/- 5.0, 100, 6 +/- 23.7 min; the Vd was 362.3 +/- 74.9 ml kg-1 and 123.7 +/- 14.6 ml kg-1 and the clearance was 5.0 +/- 0.9 ml min-1 kg-1 and 1.0 +/- 0.1 ml min-1 in the animals with and without renal function, respectively.",Pharmacokinetics and disposition of pipecuronium bromide in the cat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848702/),min,7.2,2736,DB00592,Piperazine
,2848702,half-lives,"Following intravenous injection of 150 micrograms kg-1, pipecuronium disappeared from the plasma bi-exponentially with half-lives of 9.8 +/- 5.4, 77.7 +/- 9.7 min and 7.2 +/- 5.0, 100, 6 +/- 23.7 min; the Vd was 362.3 +/- 74.9 ml kg-1 and 123.7 +/- 14.6 ml kg-1 and the clearance was 5.0 +/- 0.9 ml min-1 kg-1 and 1.0 +/- 0.1 ml min-1 in the animals with and without renal function, respectively.",Pharmacokinetics and disposition of pipecuronium bromide in the cat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848702/),min,"100, 6",2737,DB00592,Piperazine
,2848702,Vd,"Following intravenous injection of 150 micrograms kg-1, pipecuronium disappeared from the plasma bi-exponentially with half-lives of 9.8 +/- 5.4, 77.7 +/- 9.7 min and 7.2 +/- 5.0, 100, 6 +/- 23.7 min; the Vd was 362.3 +/- 74.9 ml kg-1 and 123.7 +/- 14.6 ml kg-1 and the clearance was 5.0 +/- 0.9 ml min-1 kg-1 and 1.0 +/- 0.1 ml min-1 in the animals with and without renal function, respectively.",Pharmacokinetics and disposition of pipecuronium bromide in the cat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848702/),[ml] / [kg],362.3,2738,DB00592,Piperazine
,2848702,Vd,"Following intravenous injection of 150 micrograms kg-1, pipecuronium disappeared from the plasma bi-exponentially with half-lives of 9.8 +/- 5.4, 77.7 +/- 9.7 min and 7.2 +/- 5.0, 100, 6 +/- 23.7 min; the Vd was 362.3 +/- 74.9 ml kg-1 and 123.7 +/- 14.6 ml kg-1 and the clearance was 5.0 +/- 0.9 ml min-1 kg-1 and 1.0 +/- 0.1 ml min-1 in the animals with and without renal function, respectively.",Pharmacokinetics and disposition of pipecuronium bromide in the cat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848702/),[ml] / [kg],123.7,2739,DB00592,Piperazine
,2848702,clearance,"Following intravenous injection of 150 micrograms kg-1, pipecuronium disappeared from the plasma bi-exponentially with half-lives of 9.8 +/- 5.4, 77.7 +/- 9.7 min and 7.2 +/- 5.0, 100, 6 +/- 23.7 min; the Vd was 362.3 +/- 74.9 ml kg-1 and 123.7 +/- 14.6 ml kg-1 and the clearance was 5.0 +/- 0.9 ml min-1 kg-1 and 1.0 +/- 0.1 ml min-1 in the animals with and without renal function, respectively.",Pharmacokinetics and disposition of pipecuronium bromide in the cat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848702/),[ml] / [kg·min],5.0,2740,DB00592,Piperazine
,2848702,clearance,"Following intravenous injection of 150 micrograms kg-1, pipecuronium disappeared from the plasma bi-exponentially with half-lives of 9.8 +/- 5.4, 77.7 +/- 9.7 min and 7.2 +/- 5.0, 100, 6 +/- 23.7 min; the Vd was 362.3 +/- 74.9 ml kg-1 and 123.7 +/- 14.6 ml kg-1 and the clearance was 5.0 +/- 0.9 ml min-1 kg-1 and 1.0 +/- 0.1 ml min-1 in the animals with and without renal function, respectively.",Pharmacokinetics and disposition of pipecuronium bromide in the cat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848702/),[ml] / [min],1.0,2741,DB00592,Piperazine
,16640453,absolute bioavailability,The absolute bioavailability ranges from 35% to 50%.,Clinical pharmacokinetics of ranolazine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),%,35,3347,DB00592,Piperazine
,16640453,absolute bioavailability,The absolute bioavailability ranges from 35% to 50%.,Clinical pharmacokinetics of ranolazine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),%,50,3348,DB00592,Piperazine
,16640453,protein binding,Ranolazine protein binding is about 61-64% over the therapeutic concentration range.,Clinical pharmacokinetics of ranolazine. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),%,61-64,3349,DB00592,Piperazine
,16640453,Volume of distribution at steady state,Volume of distribution at steady state ranges from 85 to 180 L.,Clinical pharmacokinetics of ranolazine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),l,85 to 180,3350,DB00592,Piperazine
,16640453,Elimination half-life,"Elimination half-life of ranolazine is 1.4-1.9 hours but is apparently prolonged, on average, to 7 hours for the ER formulation as a result of extended absorption (flip-flop kinetics).",Clinical pharmacokinetics of ranolazine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),h,1.4-1.9,3351,DB00592,Piperazine
,16640453,Elimination half-life,"Elimination half-life of ranolazine is 1.4-1.9 hours but is apparently prolonged, on average, to 7 hours for the ER formulation as a result of extended absorption (flip-flop kinetics).",Clinical pharmacokinetics of ranolazine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),h,7,3352,DB00592,Piperazine
,16640453,Oral plasma clearance,"Oral plasma clearance diminishes with dose from, on average, 45 L/h at 500 mg twice daily to 33 L/h at 1000 mg twice daily.",Clinical pharmacokinetics of ranolazine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),[l] / [h],45,3353,DB00592,Piperazine
,16640453,Oral plasma clearance,"Oral plasma clearance diminishes with dose from, on average, 45 L/h at 500 mg twice daily to 33 L/h at 1000 mg twice daily.",Clinical pharmacokinetics of ranolazine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),[l] / [h],33,3354,DB00592,Piperazine
,3285427,half-life,"Its main pharmacokinetic features are: complete absorption when given orally, short half-life (4 to 8 h), reduced plasma clearance in patients with hepatic cirrhosis or renal impairment and no major interaction with most of the other psychotropic drugs.",[Buspirone: pharmacological and clinical properties of the first member of a new anxiolytic drug family]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3285427/),h,4 to 8,3466,DB00592,Piperazine
,17502775,trough serum concentration,The dose of carbamazepine was titrated to produce a trough serum concentration within the range of 8 to 12 mg/L.,Pharmacokinetics of aripiprazole and concomitant carbamazepine. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502775/),[mg] / [l],8 to 12,3752,DB00592,Piperazine
,24733788,hepatic intrinsic clearance,"The hepatic intrinsic clearance values for methylation of the RS, RR, SS, and SR isomers (ml/min/kg) were 0, 0, 40.4, and 37.6, respectively, in rat liver microsomes, 0, 0, 11.6, and 2.5, respectively, in dog liver microsomes, and 0, 0, 17.3, and 17.7, respectively, in human liver microsomes, indicating that the RS and RR isomers are not methylated in vitro and that the methylation of SS and SR isomers is high with rat > human > dog.",Hepatic microsomal thiol methyltransferase is involved in stereoselective methylation of pharmacologically active metabolite of prasugrel. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24733788/),[ml] / [kg·min],0,4034,DB00592,Piperazine
,24733788,hepatic intrinsic clearance,"The hepatic intrinsic clearance values for methylation of the RS, RR, SS, and SR isomers (ml/min/kg) were 0, 0, 40.4, and 37.6, respectively, in rat liver microsomes, 0, 0, 11.6, and 2.5, respectively, in dog liver microsomes, and 0, 0, 17.3, and 17.7, respectively, in human liver microsomes, indicating that the RS and RR isomers are not methylated in vitro and that the methylation of SS and SR isomers is high with rat > human > dog.",Hepatic microsomal thiol methyltransferase is involved in stereoselective methylation of pharmacologically active metabolite of prasugrel. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24733788/),[ml] / [kg·min],40.4,4035,DB00592,Piperazine
,24733788,hepatic intrinsic clearance,"The hepatic intrinsic clearance values for methylation of the RS, RR, SS, and SR isomers (ml/min/kg) were 0, 0, 40.4, and 37.6, respectively, in rat liver microsomes, 0, 0, 11.6, and 2.5, respectively, in dog liver microsomes, and 0, 0, 17.3, and 17.7, respectively, in human liver microsomes, indicating that the RS and RR isomers are not methylated in vitro and that the methylation of SS and SR isomers is high with rat > human > dog.",Hepatic microsomal thiol methyltransferase is involved in stereoselective methylation of pharmacologically active metabolite of prasugrel. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24733788/),[ml] / [kg·min],37.6,4036,DB00592,Piperazine
,24733788,hepatic intrinsic clearance,"The hepatic intrinsic clearance values for methylation of the RS, RR, SS, and SR isomers (ml/min/kg) were 0, 0, 40.4, and 37.6, respectively, in rat liver microsomes, 0, 0, 11.6, and 2.5, respectively, in dog liver microsomes, and 0, 0, 17.3, and 17.7, respectively, in human liver microsomes, indicating that the RS and RR isomers are not methylated in vitro and that the methylation of SS and SR isomers is high with rat > human > dog.",Hepatic microsomal thiol methyltransferase is involved in stereoselective methylation of pharmacologically active metabolite of prasugrel. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24733788/),[ml] / [kg·min],11.6,4037,DB00592,Piperazine
,24733788,hepatic intrinsic clearance,"The hepatic intrinsic clearance values for methylation of the RS, RR, SS, and SR isomers (ml/min/kg) were 0, 0, 40.4, and 37.6, respectively, in rat liver microsomes, 0, 0, 11.6, and 2.5, respectively, in dog liver microsomes, and 0, 0, 17.3, and 17.7, respectively, in human liver microsomes, indicating that the RS and RR isomers are not methylated in vitro and that the methylation of SS and SR isomers is high with rat > human > dog.",Hepatic microsomal thiol methyltransferase is involved in stereoselective methylation of pharmacologically active metabolite of prasugrel. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24733788/),[ml] / [kg·min],2.5,4038,DB00592,Piperazine
,24733788,hepatic intrinsic clearance,"The hepatic intrinsic clearance values for methylation of the RS, RR, SS, and SR isomers (ml/min/kg) were 0, 0, 40.4, and 37.6, respectively, in rat liver microsomes, 0, 0, 11.6, and 2.5, respectively, in dog liver microsomes, and 0, 0, 17.3, and 17.7, respectively, in human liver microsomes, indicating that the RS and RR isomers are not methylated in vitro and that the methylation of SS and SR isomers is high with rat > human > dog.",Hepatic microsomal thiol methyltransferase is involved in stereoselective methylation of pharmacologically active metabolite of prasugrel. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24733788/),[ml] / [kg·min],17.3,4039,DB00592,Piperazine
,24733788,hepatic intrinsic clearance,"The hepatic intrinsic clearance values for methylation of the RS, RR, SS, and SR isomers (ml/min/kg) were 0, 0, 40.4, and 37.6, respectively, in rat liver microsomes, 0, 0, 11.6, and 2.5, respectively, in dog liver microsomes, and 0, 0, 17.3, and 17.7, respectively, in human liver microsomes, indicating that the RS and RR isomers are not methylated in vitro and that the methylation of SS and SR isomers is high with rat > human > dog.",Hepatic microsomal thiol methyltransferase is involved in stereoselective methylation of pharmacologically active metabolite of prasugrel. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24733788/),[ml] / [kg·min],17.7,4040,DB00592,Piperazine
,11291746,elimination half-life,"After an intraperitoneal dose of 10 mg kg(-1), the compound attained mean maximum plasma concentrations within 5 min of dosing, then declined with a mean elimination half-life of approximately 1 h.","Distribution of the methylpiperazinopyridobenzoxazepine derivative JL13, a potential antipsychotic, in rat brain. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11291746/),h,1,4133,DB00592,Piperazine
,15900286,elimination half-life (t (1/2) ),"Gemfibrozil alone raised the mean total area under the plasma concentration-time curve from time 0 to infinity [AUC(0-infinity)] of pioglitazone 3.2-fold (range, 2.3-fold to 6.5-fold; P < .001) and prolonged its elimination half-life (t (1/2) ) from 8.3 to 22.7 hours ( P < .001) but had no significant effect on its peak concentration (C max ) compared with placebo (control).","Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900286/),h,8.3 to 22.7,4948,DB00592,Piperazine
,21491144,half-life,Clearance from the lung epithelial lining fluid (ELF) of FDKP and insulin have a half-life of ~1 hour.,Insulin lung deposition and clearance following Technosphere® insulin inhalation powder administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21491144/),h,1,5020,DB00592,Piperazine
,21491144,terminal clearance half-life,"The terminal clearance half-life from the lung ELF, estimated from sequential BAL fluid measurements for both components, was ~1 hour.",Insulin lung deposition and clearance following Technosphere® insulin inhalation powder administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21491144/),h,1,5021,DB00592,Piperazine
,16791848,clearance (CL),"The clearance (CL) of levocetirizine and dextrocetirizine was 1.2 and 2.7 ml/min, respectively, and the volume of distribution at steady state (Vss) was 457 ml and 996 ml, respectively.",Stereoselective pharmacokinetics of cetirizine in the guinea pig: role of protein binding. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791848/),[ml] / [min],1.2,5406,DB00592,Piperazine
,16791848,clearance (CL),"The clearance (CL) of levocetirizine and dextrocetirizine was 1.2 and 2.7 ml/min, respectively, and the volume of distribution at steady state (Vss) was 457 ml and 996 ml, respectively.",Stereoselective pharmacokinetics of cetirizine in the guinea pig: role of protein binding. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791848/),[ml] / [min],2.7,5407,DB00592,Piperazine
,16791848,volume of distribution at steady state (Vss),"The clearance (CL) of levocetirizine and dextrocetirizine was 1.2 and 2.7 ml/min, respectively, and the volume of distribution at steady state (Vss) was 457 ml and 996 ml, respectively.",Stereoselective pharmacokinetics of cetirizine in the guinea pig: role of protein binding. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791848/),ml,457,5408,DB00592,Piperazine
,16791848,volume of distribution at steady state (Vss),"The clearance (CL) of levocetirizine and dextrocetirizine was 1.2 and 2.7 ml/min, respectively, and the volume of distribution at steady state (Vss) was 457 ml and 996 ml, respectively.",Stereoselective pharmacokinetics of cetirizine in the guinea pig: role of protein binding. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791848/),ml,996,5409,DB00592,Piperazine
,16791848,fraction unbound (fu),"The fraction unbound (fu) in guinea pig plasma for levocetirizine and dextrocetirizine was 7-10% and 16-21% while in human plasma, it was 8% and 12%, respectively.",Stereoselective pharmacokinetics of cetirizine in the guinea pig: role of protein binding. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791848/),%,7-10,5410,DB00592,Piperazine
,16791848,fraction unbound (fu),"The fraction unbound (fu) in guinea pig plasma for levocetirizine and dextrocetirizine was 7-10% and 16-21% while in human plasma, it was 8% and 12%, respectively.",Stereoselective pharmacokinetics of cetirizine in the guinea pig: role of protein binding. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791848/),%,16-21,5411,DB00592,Piperazine
,16791848,fraction unbound (fu),"The fraction unbound (fu) in guinea pig plasma for levocetirizine and dextrocetirizine was 7-10% and 16-21% while in human plasma, it was 8% and 12%, respectively.",Stereoselective pharmacokinetics of cetirizine in the guinea pig: role of protein binding. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791848/),%,8,5412,DB00592,Piperazine
,16791848,fraction unbound (fu),"The fraction unbound (fu) in guinea pig plasma for levocetirizine and dextrocetirizine was 7-10% and 16-21% while in human plasma, it was 8% and 12%, respectively.",Stereoselective pharmacokinetics of cetirizine in the guinea pig: role of protein binding. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791848/),%,12,5413,DB00592,Piperazine
,25586294,plasma concentration,"In clinical studies, when patients initiated AOM 400 with concomitant oral aripiprazole (10-15 mg/d based on stabilized dose) or continued their previous antipsychotic for ≤14 days, mean aripiprazole plasma concentration after 4 weeks (93 to 112 ng/mL) was in range of the therapeutic window established for aripiprazole (94.0-534.0 ng/mL).",Initiation of aripiprazole once-monthly in patients with schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25586294/),[ng] / [ml],93 to 112,5610,DB00592,Piperazine
,25586294,plasma concentration,"In clinical studies, when patients initiated AOM 400 with concomitant oral aripiprazole (10-15 mg/d based on stabilized dose) or continued their previous antipsychotic for ≤14 days, mean aripiprazole plasma concentration after 4 weeks (93 to 112 ng/mL) was in range of the therapeutic window established for aripiprazole (94.0-534.0 ng/mL).",Initiation of aripiprazole once-monthly in patients with schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25586294/),[ng] / [m],94.0-534.0,5611,DB00592,Piperazine
,3624392,limit of detection,The limit of detection of the method is 5 ng/ml for zopiclone in plasma and urine and 10 ng/ml for its two main metabolites (coefficient of variation less than 10%).,Simultaneous determination of zopiclone and its two major metabolites (N-oxide and N-desmethyl) in human biological fluids by reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3624392/),[ng] / [ml],5,5769,DB00592,Piperazine
,3624392,limit of detection,The limit of detection of the method is 5 ng/ml for zopiclone in plasma and urine and 10 ng/ml for its two main metabolites (coefficient of variation less than 10%).,Simultaneous determination of zopiclone and its two major metabolites (N-oxide and N-desmethyl) in human biological fluids by reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3624392/),[ng] / [ml],10,5770,DB00592,Piperazine
less,3624392,limit of detection,The limit of detection of the method is 5 ng/ml for zopiclone in plasma and urine and 10 ng/ml for its two main metabolites (coefficient of variation less than 10%).,Simultaneous determination of zopiclone and its two major metabolites (N-oxide and N-desmethyl) in human biological fluids by reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3624392/),,10,5771,DB00592,Piperazine
,2747741,unbound fractions,The unbound fractions of ketoconazole in SBF (2.3%) and CBF (1.2%) were calculated from plasma protein binding (99.0%).,Skin blister fluid levels of ketoconazole during repetitive administration in healthy man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2747741/),%,2.3,6290,DB00592,Piperazine
,2747741,unbound fractions,The unbound fractions of ketoconazole in SBF (2.3%) and CBF (1.2%) were calculated from plasma protein binding (99.0%).,Skin blister fluid levels of ketoconazole during repetitive administration in healthy man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2747741/),%,1.2,6291,DB00592,Piperazine
,2747741,unbound fractions,The unbound fractions of ketoconazole in SBF (2.3%) and CBF (1.2%) were calculated from plasma protein binding (99.0%).,Skin blister fluid levels of ketoconazole during repetitive administration in healthy man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2747741/),%,99.0,6292,DB00592,Piperazine
,2747741,unbound,"Before the ultimate dose, levels of unbound ketoconazole in SBF and CBF were 0.64 +/- 0.16 and 0.70 +/- 0.25 ng/ml and were thus in accordance with free ketoconazole serum levels (0.52 +/- 0.24 ng/ml; p greater than 0.05).",Skin blister fluid levels of ketoconazole during repetitive administration in healthy man. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2747741/),[ng] / [ml],0.64,6293,DB00592,Piperazine
,2747741,unbound,"Before the ultimate dose, levels of unbound ketoconazole in SBF and CBF were 0.64 +/- 0.16 and 0.70 +/- 0.25 ng/ml and were thus in accordance with free ketoconazole serum levels (0.52 +/- 0.24 ng/ml; p greater than 0.05).",Skin blister fluid levels of ketoconazole during repetitive administration in healthy man. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2747741/),[ng] / [ml],0.70,6294,DB00592,Piperazine
,2747741,unbound,"Before the ultimate dose, levels of unbound ketoconazole in SBF and CBF were 0.64 +/- 0.16 and 0.70 +/- 0.25 ng/ml and were thus in accordance with free ketoconazole serum levels (0.52 +/- 0.24 ng/ml; p greater than 0.05).",Skin blister fluid levels of ketoconazole during repetitive administration in healthy man. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2747741/),ng,0.52,6295,DB00592,Piperazine
,2747741,Peak concentrations,Peak concentrations of free ketoconazole were (SBF) 8.6 +/- 2.9 ng/ml and (CBF) 8.9 +/- 2.3 ng/ml.,Skin blister fluid levels of ketoconazole during repetitive administration in healthy man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2747741/),[ng] / [ml],8.6,6296,DB00592,Piperazine
,2747741,Peak concentrations,Peak concentrations of free ketoconazole were (SBF) 8.6 +/- 2.9 ng/ml and (CBF) 8.9 +/- 2.3 ng/ml.,Skin blister fluid levels of ketoconazole during repetitive administration in healthy man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2747741/),[ng] / [ml],8.9,6297,DB00592,Piperazine
,2747741,CBF,Peak concentrations of free ketoconazole were (SBF) 8.6 +/- 2.9 ng/ml and (CBF) 8.9 +/- 2.3 ng/ml.,Skin blister fluid levels of ketoconazole during repetitive administration in healthy man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2747741/),[ng] / [ml],8.9,6298,DB00592,Piperazine
,17062683,area under the curve (AUC) ratio,"A significant time-dependent decrease in CLM/fm was evidenced with a mean (+SD) CGP 74588/imatinib area under the curve (AUC) ratio of 0.25 (+/-0.07) at steady state, compared with 0.14 (+/-0.03) on day 1.",Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17062683/),,0.25,6677,DB00592,Piperazine
,17062683,area under the curve (AUC) ratio,"A significant time-dependent decrease in CLM/fm was evidenced with a mean (+SD) CGP 74588/imatinib area under the curve (AUC) ratio of 0.25 (+/-0.07) at steady state, compared with 0.14 (+/-0.03) on day 1.",Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17062683/),,0.14,6678,DB00592,Piperazine
,9578186,total area under the plasma buspirone concentration-time curve,"The total area under the plasma buspirone concentration-time curve after rifampicin was 10.4% (95% CI, 6.3-14.5%) of that after placebo (1.64+/-0.35 ng ml(-1) h vs 22.0+/-15.1 ng ml(-1) h (mean+/-s.d.); P< 0.01).",Concentrations and effects of buspirone are considerably reduced by rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578186/),[h·ng] / [ml],1.64,7058,DB00592,Piperazine
,9578186,total area under the plasma buspirone concentration-time curve,"The total area under the plasma buspirone concentration-time curve after rifampicin was 10.4% (95% CI, 6.3-14.5%) of that after placebo (1.64+/-0.35 ng ml(-1) h vs 22.0+/-15.1 ng ml(-1) h (mean+/-s.d.); P< 0.01).",Concentrations and effects of buspirone are considerably reduced by rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578186/),[h·ng] / [ml],22.0,7059,DB00592,Piperazine
,9578186,peak plasma concentration,Rifampicin decreased the peak plasma concentration of buspirone from 6.6+/-3.7 ng ml(-1) to 0.84+/-0.23 ng ml(-1) (P< 0.01) and the half-life from 2.8+/-0.7 h to 1.3+/-0.5 h (P< 0.01).,Concentrations and effects of buspirone are considerably reduced by rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578186/),[ng] / [ml],6.6,7060,DB00592,Piperazine
,9578186,peak plasma concentration,Rifampicin decreased the peak plasma concentration of buspirone from 6.6+/-3.7 ng ml(-1) to 0.84+/-0.23 ng ml(-1) (P< 0.01) and the half-life from 2.8+/-0.7 h to 1.3+/-0.5 h (P< 0.01).,Concentrations and effects of buspirone are considerably reduced by rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578186/),[ng] / [ml],0.84,7061,DB00592,Piperazine
,9578186,half-life,Rifampicin decreased the peak plasma concentration of buspirone from 6.6+/-3.7 ng ml(-1) to 0.84+/-0.23 ng ml(-1) (P< 0.01) and the half-life from 2.8+/-0.7 h to 1.3+/-0.5 h (P< 0.01).,Concentrations and effects of buspirone are considerably reduced by rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578186/),h,2.8,7062,DB00592,Piperazine
,9578186,half-life,Rifampicin decreased the peak plasma concentration of buspirone from 6.6+/-3.7 ng ml(-1) to 0.84+/-0.23 ng ml(-1) (P< 0.01) and the half-life from 2.8+/-0.7 h to 1.3+/-0.5 h (P< 0.01).,Concentrations and effects of buspirone are considerably reduced by rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578186/),h,1.3,7063,DB00592,Piperazine
<,16386397,terminal half-life,The Mz concentration declined rapidly in plasma with a terminal half-life<2 h.,Distribution and metabolism of the antipsychotic agent mazapertine succinate in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386397/),h,2,7183,DB00592,Piperazine
,16386397,terminal half-life,The total radioactive dose in plasma displayed a considerably longer terminal half-life of 9-13 h.,Distribution and metabolism of the antipsychotic agent mazapertine succinate in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386397/),h,9-13,7184,DB00592,Piperazine
,1362206,Plasma protein binding (free fraction),"Plasma protein binding (free fraction) for tandospirone was 30.4%, and for 1-PP, 87.5%.","Kinetics, brain uptake, and receptor binding of tandospirone and its metabolite 1-(2-pyrimidinyl)-piperazine. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1362206/),%,30.4,7558,DB00592,Piperazine
,1362206,Plasma protein binding (free fraction),"Plasma protein binding (free fraction) for tandospirone was 30.4%, and for 1-PP, 87.5%.","Kinetics, brain uptake, and receptor binding of tandospirone and its metabolite 1-(2-pyrimidinyl)-piperazine. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1362206/),%,87.5,7559,DB00592,Piperazine
,15537555,Protein binding,"Protein binding ranged from 97.7-90.3% (mean 94.9%), was concentration independent, and was not altered by St. John's wort.",The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15537555/),%,97.7-90.3,7713,DB00592,Piperazine
,15537555,Protein binding,"Protein binding ranged from 97.7-90.3% (mean 94.9%), was concentration independent, and was not altered by St. John's wort.",The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15537555/),%,94.9,7714,DB00592,Piperazine
,22000961,detection limits,"The detection limits were 20 ng/mL and 10 ng/mL for M1 and IM, respectively.",Method development and validation for the simultaneous determination of imatinib mesylate and N-desmethyl imatinib using rapid resolution high performance liquid chromatography coupled with UV-detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22000961/),[ng] / [ml],20,7914,DB00592,Piperazine
,22000961,detection limits,"The detection limits were 20 ng/mL and 10 ng/mL for M1 and IM, respectively.",Method development and validation for the simultaneous determination of imatinib mesylate and N-desmethyl imatinib using rapid resolution high performance liquid chromatography coupled with UV-detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22000961/),[ng] / [ml],10,7915,DB00592,Piperazine
more,22000961,percent recoveries,The intra- and inter-day precisions were less than 1% with percent recoveries of more than 90%.,Method development and validation for the simultaneous determination of imatinib mesylate and N-desmethyl imatinib using rapid resolution high performance liquid chromatography coupled with UV-detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22000961/),%,90,7916,DB00592,Piperazine
,26834462,Terminal half-lives,"Terminal half-lives of cariprazine, desmethyl-cariprazine, and didesmethyl-cariprazine ranged from 31.6 to 68.4, 29.7 to 37.5, and 314 to 446 hours, respectively.",Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26834462/),h,31.6 to 68.4,8037,DB00592,Piperazine
,26834462,Terminal half-lives,"Terminal half-lives of cariprazine, desmethyl-cariprazine, and didesmethyl-cariprazine ranged from 31.6 to 68.4, 29.7 to 37.5, and 314 to 446 hours, respectively.",Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26834462/),h,29.7 to 37.5,8038,DB00592,Piperazine
,26834462,Terminal half-lives,"Terminal half-lives of cariprazine, desmethyl-cariprazine, and didesmethyl-cariprazine ranged from 31.6 to 68.4, 29.7 to 37.5, and 314 to 446 hours, respectively.",Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26834462/),h,314 to 446,8039,DB00592,Piperazine
,26834462,half-life,Effective half-life (calculated from time to steady state) of total active moieties was ~1 week.,Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26834462/),week,1,8040,DB00592,Piperazine
,20233203,metabolic AUC ratio (AUC(last),"The metabolic AUC ratio (AUC(last) of DA-8164/AUC(last) of udenafil) was 1.71 when udenafil was administered alone, and the value decreased to 0.19 when udenafil was dosed in the presence of ketoconazole.",Effect of ketoconazole on the pharmacokinetics of udenafil in healthy Korean subjects. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233203/),,1.71,8116,DB00592,Piperazine
,20233203,metabolic AUC ratio (AUC(last),"The metabolic AUC ratio (AUC(last) of DA-8164/AUC(last) of udenafil) was 1.71 when udenafil was administered alone, and the value decreased to 0.19 when udenafil was dosed in the presence of ketoconazole.",Effect of ketoconazole on the pharmacokinetics of udenafil in healthy Korean subjects. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233203/),,0.19,8117,DB00592,Piperazine
,1321655,Cmax,"There were no significant differences between treatments in relation to Cmax (82.3 ng ml-1 in the absence and 81.4 ng ml-1 in the presence of flunarizine), AUC (368 ng ml-1 h in the absence and 360 ng ml-1 in the presence) and elimination half-life (2.2 h in the absence and 2.4 h in the presence of flunarizine) of sumatriptan.",Lack of effect of flunarizine on the pharmacokinetics and pharmacodynamics of sumatriptan in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1321655/),[ng] / [ml],82.3,8593,DB00592,Piperazine
,1321655,Cmax,"There were no significant differences between treatments in relation to Cmax (82.3 ng ml-1 in the absence and 81.4 ng ml-1 in the presence of flunarizine), AUC (368 ng ml-1 h in the absence and 360 ng ml-1 in the presence) and elimination half-life (2.2 h in the absence and 2.4 h in the presence of flunarizine) of sumatriptan.",Lack of effect of flunarizine on the pharmacokinetics and pharmacodynamics of sumatriptan in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1321655/),[ng] / [ml],81.4,8594,DB00592,Piperazine
,1321655,AUC,"There were no significant differences between treatments in relation to Cmax (82.3 ng ml-1 in the absence and 81.4 ng ml-1 in the presence of flunarizine), AUC (368 ng ml-1 h in the absence and 360 ng ml-1 in the presence) and elimination half-life (2.2 h in the absence and 2.4 h in the presence of flunarizine) of sumatriptan.",Lack of effect of flunarizine on the pharmacokinetics and pharmacodynamics of sumatriptan in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1321655/),[h·ng] / [ml],368,8595,DB00592,Piperazine
,1321655,AUC,"There were no significant differences between treatments in relation to Cmax (82.3 ng ml-1 in the absence and 81.4 ng ml-1 in the presence of flunarizine), AUC (368 ng ml-1 h in the absence and 360 ng ml-1 in the presence) and elimination half-life (2.2 h in the absence and 2.4 h in the presence of flunarizine) of sumatriptan.",Lack of effect of flunarizine on the pharmacokinetics and pharmacodynamics of sumatriptan in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1321655/),[ng] / [ml],360,8596,DB00592,Piperazine
,1321655,elimination half-life,"There were no significant differences between treatments in relation to Cmax (82.3 ng ml-1 in the absence and 81.4 ng ml-1 in the presence of flunarizine), AUC (368 ng ml-1 h in the absence and 360 ng ml-1 in the presence) and elimination half-life (2.2 h in the absence and 2.4 h in the presence of flunarizine) of sumatriptan.",Lack of effect of flunarizine on the pharmacokinetics and pharmacodynamics of sumatriptan in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1321655/),h,2.2,8597,DB00592,Piperazine
,1321655,elimination half-life,"There were no significant differences between treatments in relation to Cmax (82.3 ng ml-1 in the absence and 81.4 ng ml-1 in the presence of flunarizine), AUC (368 ng ml-1 h in the absence and 360 ng ml-1 in the presence) and elimination half-life (2.2 h in the absence and 2.4 h in the presence of flunarizine) of sumatriptan.",Lack of effect of flunarizine on the pharmacokinetics and pharmacodynamics of sumatriptan in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1321655/),h,2.4,8598,DB00592,Piperazine
,10972478,specific activity,"In an in vivo study female Sprague Dawley rats were pretreated with 100 mg/kg of dexrazoxane by intravenous injection 1 h before the injection of 14C-doxorubicin (specific activity 0.4 microCi/mg, 10 mg/kg).",Interaction of dexrazoxane with red blood cells and hemoglobin alters pharmacokinetics of doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972478/),[μci] / [mg],0.4,8782,DB00592,Piperazine
,25819132,apparent clearance,"Population estimates for apparent clearance, apparent volume of distribution, absorption rate constant and absorption lag time were 0.901 l h(-1) , 17.4 l, 2.24 h(-1) , and 0.263 h, respectively.",Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25819132/),[l] / [h],0.901,9187,DB00592,Piperazine
,25819132,apparent volume of distribution,"Population estimates for apparent clearance, apparent volume of distribution, absorption rate constant and absorption lag time were 0.901 l h(-1) , 17.4 l, 2.24 h(-1) , and 0.263 h, respectively.",Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25819132/),l,17.4,9188,DB00592,Piperazine
,25819132,apparent volume of distribution,"Population estimates for apparent clearance, apparent volume of distribution, absorption rate constant and absorption lag time were 0.901 l h(-1) , 17.4 l, 2.24 h(-1) , and 0.263 h, respectively.",Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25819132/),1/[h],2.24,9189,DB00592,Piperazine
,25819132,absorption rate constant,"Population estimates for apparent clearance, apparent volume of distribution, absorption rate constant and absorption lag time were 0.901 l h(-1) , 17.4 l, 2.24 h(-1) , and 0.263 h, respectively.",Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25819132/),l,17.4,9190,DB00592,Piperazine
,25819132,absorption rate constant,"Population estimates for apparent clearance, apparent volume of distribution, absorption rate constant and absorption lag time were 0.901 l h(-1) , 17.4 l, 2.24 h(-1) , and 0.263 h, respectively.",Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25819132/),1/[h],2.24,9191,DB00592,Piperazine
,25819132,absorption lag time,"Population estimates for apparent clearance, apparent volume of distribution, absorption rate constant and absorption lag time were 0.901 l h(-1) , 17.4 l, 2.24 h(-1) , and 0.263 h, respectively.",Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25819132/),h,0.263,9192,DB00592,Piperazine
,24492720,minimum effective dose (MED),Intravenous administration of FK886 dose-dependently inhibited cisplatin (10 mg/kg)-induced acute emesis with a minimum effective dose (MED) of 0.32 mg/kg.,"Antiemetic effect of a potent and selective neurokinin-1 receptor antagonist, FK886, on cisplatin-induced acute and delayed emesis in ferrets. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24492720/),[mg] / [kg],0.32,9527,DB00592,Piperazine
less,20484616,CL(CR),Modeling study results suggested that equivalent exposure could be achieved if dosing was halved in subjects with CL(CR) less than 40 mL/min compared with controls.,Pharmacokinetics of dexrazoxane in subjects with impaired kidney function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20484616/),[ml] / [min],40,9704,DB00592,Piperazine
,17581764,trough plasma concentration,"After three consecutive administrations of cetirizine (0.2 mg/kg body weight, bw) every 12h, the trough plasma concentration of cetirizine was 16+/-4 ng/mL (mean+/-SD) and the wheal formation was inhibited by 45+/-23%.",Cetirizine in horses: pharmacokinetics and pharmacodynamics following repeated oral administration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17581764/),[ng] / [ml],16,9715,DB00592,Piperazine
,17581764,trough plasma concentration,"After four additional administrations of cetirizine (0.4 mg/kg bw) every 12 h, the trough plasma concentration was 48+/-15 ng/mL and the wheal formation was inhibited by 68+/-11%.",Cetirizine in horses: pharmacokinetics and pharmacodynamics following repeated oral administration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17581764/),[ng] / [ml],48,9716,DB00592,Piperazine
,17581764,terminal half-life,The terminal half-life was about 5.8 h.,Cetirizine in horses: pharmacokinetics and pharmacodynamics following repeated oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17581764/),h,5.8,9717,DB00592,Piperazine
,17581764,EC(50),A pharmacokinetic/pharmacodynamic link model showed that the maximal inhibition of wheal formation was about 95% and the EC(50) about 18 ng/mL.,Cetirizine in horses: pharmacokinetics and pharmacodynamics following repeated oral administration. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17581764/),[ng] / [ml],18,9718,DB00592,Piperazine
,17310470,limit of detection,The limit of detection for each analyte was 1 ng/mL.,Simultaneous determination of docetaxel and ketoconazole in rat plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17310470/),[ng] / [ml],1,10156,DB00592,Piperazine
,17310470,overall recoveries,"The overall recoveries for docetaxel and ketoconazole were about 89.0% and 91.1%, respectively.",Simultaneous determination of docetaxel and ketoconazole in rat plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17310470/),%,89.0,10157,DB00592,Piperazine
,17310470,overall recoveries,"The overall recoveries for docetaxel and ketoconazole were about 89.0% and 91.1%, respectively.",Simultaneous determination of docetaxel and ketoconazole in rat plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17310470/),%,91.1,10158,DB00592,Piperazine
,17310470,total analysis time,The total analysis time was only 9.0 min.,Simultaneous determination of docetaxel and ketoconazole in rat plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17310470/),min,9.0,10159,DB00592,Piperazine
,29749631,half-life,Posttreatment washout of posaconazole was slow in normals (mean half-life 36 hours) and further prolonged in obese subjects (64 hours).,Persistence of a Posaconazole-Mediated Drug-Drug Interaction With Ranolazine After Cessation of Posaconazole Administration: Impact of Obesity and Implications for Patient Safety. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29749631/),h,36,10238,DB00592,Piperazine
,29749631,half-life,Posttreatment washout of posaconazole was slow in normals (mean half-life 36 hours) and further prolonged in obese subjects (64 hours).,Persistence of a Posaconazole-Mediated Drug-Drug Interaction With Ranolazine After Cessation of Posaconazole Administration: Impact of Obesity and Implications for Patient Safety. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29749631/),h,64,10239,DB00592,Piperazine
,34265164,maximum plasma concentrations,"Geometric mean maximum plasma concentrations were 5.22 μg/mL (time to maximum concentration [tmax ], 1.01 hours) for abacavir, 4.13 μg/mL (tmax , 3.50 hours) for dolutegravir, and 3.35 μg/mL (tmax , 2.98 hours) for lamivudine.","Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34265164/),[μg] / [ml],5.22,10431,DB00592,Piperazine
,34265164,maximum plasma concentrations,"Geometric mean maximum plasma concentrations were 5.22 μg/mL (time to maximum concentration [tmax ], 1.01 hours) for abacavir, 4.13 μg/mL (tmax , 3.50 hours) for dolutegravir, and 3.35 μg/mL (tmax , 2.98 hours) for lamivudine.","Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34265164/),[μg] / [ml],4.13,10432,DB00592,Piperazine
,34265164,time to maximum concentration [tmax ],"Geometric mean maximum plasma concentrations were 5.22 μg/mL (time to maximum concentration [tmax ], 1.01 hours) for abacavir, 4.13 μg/mL (tmax , 3.50 hours) for dolutegravir, and 3.35 μg/mL (tmax , 2.98 hours) for lamivudine.","Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34265164/),h,1.01,10433,DB00592,Piperazine
,34265164,tmax,"Geometric mean maximum plasma concentrations were 5.22 μg/mL (time to maximum concentration [tmax ], 1.01 hours) for abacavir, 4.13 μg/mL (tmax , 3.50 hours) for dolutegravir, and 3.35 μg/mL (tmax , 2.98 hours) for lamivudine.","Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34265164/),h,3.50,10434,DB00592,Piperazine
,34265164,tmax,"Geometric mean maximum plasma concentrations were 5.22 μg/mL (time to maximum concentration [tmax ], 1.01 hours) for abacavir, 4.13 μg/mL (tmax , 3.50 hours) for dolutegravir, and 3.35 μg/mL (tmax , 2.98 hours) for lamivudine.","Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34265164/),h,2.98,10435,DB00592,Piperazine
,34265164,area under the concentration-time curve,"Geometric mean area under the concentration-time curve values were 18.20, 71.60, and 16.60 μg • h/mL for abacavir, dolutegravir, and lamivudine, respectively.","Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34265164/),[h·μg] / [ml],18.20,10436,DB00592,Piperazine
,34265164,area under the concentration-time curve,"Geometric mean area under the concentration-time curve values were 18.20, 71.60, and 16.60 μg • h/mL for abacavir, dolutegravir, and lamivudine, respectively.","Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34265164/),[h·μg] / [ml],71.60,10437,DB00592,Piperazine
,34265164,area under the concentration-time curve,"Geometric mean area under the concentration-time curve values were 18.20, 71.60, and 16.60 μg • h/mL for abacavir, dolutegravir, and lamivudine, respectively.","Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34265164/),[h·μg] / [ml],16.60,10438,DB00592,Piperazine
,28544884,flow rate,"Chromatographic separation were carried out on a Acquity UPLC HSS Cyano column (100mm x 2.1mm, 1.8μm) using gradient mobile phase system consisting of 0.1% formic acid and acetonitrile at a flow rate of 0.4mL/min, within a run time of 6min.",A validated UHPLC-QTOF-MS method for quantification of metformin and teneligliptin in rat plasma: Application to pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28544884/),[ml] / [min],0.4,10485,DB00592,Piperazine
,28544884,run time,"Chromatographic separation were carried out on a Acquity UPLC HSS Cyano column (100mm x 2.1mm, 1.8μm) using gradient mobile phase system consisting of 0.1% formic acid and acetonitrile at a flow rate of 0.4mL/min, within a run time of 6min.",A validated UHPLC-QTOF-MS method for quantification of metformin and teneligliptin in rat plasma: Application to pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28544884/),min,6,10486,DB00592,Piperazine
,19280520,areas under the plasma concentration versus time curve (AUC),"The areas under the plasma concentration versus time curve (AUC) of the thiolactone intermediates in the portal vein plasma after an oral dose of prasugrel (1 mg kg(-1)) and clopidogrel (0.77 mg kg(-1)) were 15.8 +/- 15.9 ng h ml(-1) and 0.113 +/- 0.226 ng h ml(-1), respectively, in rats, and 454 +/- 104 ng h ml(-1) and 23.3 +/- 4.3 ng h ml(-1), respectively, in dogs, indicating efficient hydrolysis of prasugrel and little metabolism of clopidogrel to their thiolactones in the intestine.",Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19280520/),[h·ng] / [ml],15.8,10569,DB00592,Piperazine
,19280520,areas under the plasma concentration versus time curve (AUC),"The areas under the plasma concentration versus time curve (AUC) of the thiolactone intermediates in the portal vein plasma after an oral dose of prasugrel (1 mg kg(-1)) and clopidogrel (0.77 mg kg(-1)) were 15.8 +/- 15.9 ng h ml(-1) and 0.113 +/- 0.226 ng h ml(-1), respectively, in rats, and 454 +/- 104 ng h ml(-1) and 23.3 +/- 4.3 ng h ml(-1), respectively, in dogs, indicating efficient hydrolysis of prasugrel and little metabolism of clopidogrel to their thiolactones in the intestine.",Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19280520/),[h·ng] / [ml],0.113,10570,DB00592,Piperazine
,19280520,areas under the plasma concentration versus time curve (AUC),"The areas under the plasma concentration versus time curve (AUC) of the thiolactone intermediates in the portal vein plasma after an oral dose of prasugrel (1 mg kg(-1)) and clopidogrel (0.77 mg kg(-1)) were 15.8 +/- 15.9 ng h ml(-1) and 0.113 +/- 0.226 ng h ml(-1), respectively, in rats, and 454 +/- 104 ng h ml(-1) and 23.3 +/- 4.3 ng h ml(-1), respectively, in dogs, indicating efficient hydrolysis of prasugrel and little metabolism of clopidogrel to their thiolactones in the intestine.",Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19280520/),[h·ng] / [ml],454,10571,DB00592,Piperazine
,19280520,areas under the plasma concentration versus time curve (AUC),"The areas under the plasma concentration versus time curve (AUC) of the thiolactone intermediates in the portal vein plasma after an oral dose of prasugrel (1 mg kg(-1)) and clopidogrel (0.77 mg kg(-1)) were 15.8 +/- 15.9 ng h ml(-1) and 0.113 +/- 0.226 ng h ml(-1), respectively, in rats, and 454 +/- 104 ng h ml(-1) and 23.3 +/- 4.3 ng h ml(-1), respectively, in dogs, indicating efficient hydrolysis of prasugrel and little metabolism of clopidogrel to their thiolactones in the intestine.",Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19280520/),[h·ng] / [ml],23.3,10572,DB00592,Piperazine
,19280520,relative bioavailability,"The relative bioavailability of the active metabolites of prasugrel and clopidogrel calculated by the ratio of active metabolite AUC (prodrug oral administration/active metabolite intravenous administration) were 25% and 7%, respectively, in rats, and 25% and 10%, respectively, in dogs.",Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19280520/),%,25,10573,DB00592,Piperazine
,19280520,relative bioavailability,"The relative bioavailability of the active metabolites of prasugrel and clopidogrel calculated by the ratio of active metabolite AUC (prodrug oral administration/active metabolite intravenous administration) were 25% and 7%, respectively, in rats, and 25% and 10%, respectively, in dogs.",Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19280520/),%,7,10574,DB00592,Piperazine
,19280520,relative bioavailability,"The relative bioavailability of the active metabolites of prasugrel and clopidogrel calculated by the ratio of active metabolite AUC (prodrug oral administration/active metabolite intravenous administration) were 25% and 7%, respectively, in rats, and 25% and 10%, respectively, in dogs.",Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19280520/),%,10,10575,DB00592,Piperazine
,18294330,"AUC(0,24 h)","After placebo administration, mean AUC(0,24 h) of S- and R-fexofenadine was 474 ng ml(-1) h (95% CI 311, 638) and 798 ng ml(-1) h (95% CI 497, 1101), respectively.",The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294330/),[h·ng] / [ml],474,11102,DB00592,Piperazine
,18294330,"AUC(0,24 h)","After placebo administration, mean AUC(0,24 h) of S- and R-fexofenadine was 474 ng ml(-1) h (95% CI 311, 638) and 798 ng ml(-1) h (95% CI 497, 1101), respectively.",The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294330/),[h·ng] / [ml],798,11103,DB00592,Piperazine
,25047407,peak plasma concentration (C max,"Systemic exposure to ziprasidone was similar following administration alone or after pretreatment with armodafinil, as assessed by mean peak plasma concentration (C max, 52.1 vs 50.4 ng/mL) and area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞, 544.6 vs 469.1 ng·h/mL).",Evaluation of the potential for a pharmacokinetic drug-drug interaction between armodafinil and ziprasidone in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047407/),[ng] / [ml],52.1,11110,DB00592,Piperazine
,25047407,peak plasma concentration (C max,"Systemic exposure to ziprasidone was similar following administration alone or after pretreatment with armodafinil, as assessed by mean peak plasma concentration (C max, 52.1 vs 50.4 ng/mL) and area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞, 544.6 vs 469.1 ng·h/mL).",Evaluation of the potential for a pharmacokinetic drug-drug interaction between armodafinil and ziprasidone in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047407/),[ng] / [ml],50.4,11111,DB00592,Piperazine
,25047407,area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞,"Systemic exposure to ziprasidone was similar following administration alone or after pretreatment with armodafinil, as assessed by mean peak plasma concentration (C max, 52.1 vs 50.4 ng/mL) and area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞, 544.6 vs 469.1 ng·h/mL).",Evaluation of the potential for a pharmacokinetic drug-drug interaction between armodafinil and ziprasidone in healthy adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047407/),[h·ng] / [ml],544.6,11112,DB00592,Piperazine
,25047407,area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞,"Systemic exposure to ziprasidone was similar following administration alone or after pretreatment with armodafinil, as assessed by mean peak plasma concentration (C max, 52.1 vs 50.4 ng/mL) and area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞, 544.6 vs 469.1 ng·h/mL).",Evaluation of the potential for a pharmacokinetic drug-drug interaction between armodafinil and ziprasidone in healthy adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047407/),[h·ng] / [ml],469.1,11113,DB00592,Piperazine
,28770827,IC50,"Four potent analogs 17, 43, 47, and 50 (IC50=2.2-4.4 nmol/L) effectively inhibited the proliferation of Chinese hamster lung fibroblast V-C8 cells (IC50=3.2-37.6 nmol/L) in vitro, and showed specificity toward BRCA-deficient cells (SI=40-510).","Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28770827/),[nM] / [l],2.2-4.4,11253,DB00592,Piperazine
,28770827,IC50,"Four potent analogs 17, 43, 47, and 50 (IC50=2.2-4.4 nmol/L) effectively inhibited the proliferation of Chinese hamster lung fibroblast V-C8 cells (IC50=3.2-37.6 nmol/L) in vitro, and showed specificity toward BRCA-deficient cells (SI=40-510).","Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28770827/),[nM] / [l],3.2-37.6,11254,DB00592,Piperazine
,28770827,F,"Additionally, compound 56 exhibited good oral bioavailability (F=32.2%), similar to that of olaparib (F=45.4%).","Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28770827/),%,32.2,11255,DB00592,Piperazine
,28770827,F,"Additionally, compound 56 exhibited good oral bioavailability (F=32.2%), similar to that of olaparib (F=45.4%).","Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28770827/),%,45.4,11256,DB00592,Piperazine
,28770827,IC50,"Furthermore, the free base 43 of the hydrochloride salt 56 exhibited minimal hERG inhibition activity (IC50=6.64 μmol/L).","Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28770827/),[μM] / [l],6.64,11257,DB00592,Piperazine
,22226981,IC(50),"Compound 6r, in particular, showed the lowest IC(50) values, ranging from 6.1 to 17nM, in inhibition of the growth of cancer cells, which is better than compound 6k (compound 25 in the reference cited above).","Synthesis, anticancer activity and pharmacokinetic analysis of 1-[(substituted 2-alkoxyquinoxalin-3-yl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22226981/),nM,6.1 to 17,11442,DB00592,Piperazine
,22226981,oral bioavailability,"In these studies, compound 6k showed the highest oral bioavailability of 83.4%, and compounds 6j and 6q followed, with 77.8% and 57.6%, respectively.","Synthesis, anticancer activity and pharmacokinetic analysis of 1-[(substituted 2-alkoxyquinoxalin-3-yl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22226981/),%,83.4,11443,DB00592,Piperazine
,22226981,oral bioavailability,"In these studies, compound 6k showed the highest oral bioavailability of 83.4%, and compounds 6j and 6q followed, with 77.8% and 57.6%, respectively.","Synthesis, anticancer activity and pharmacokinetic analysis of 1-[(substituted 2-alkoxyquinoxalin-3-yl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22226981/),%,77.8,11444,DB00592,Piperazine
,22226981,oral bioavailability,"In these studies, compound 6k showed the highest oral bioavailability of 83.4%, and compounds 6j and 6q followed, with 77.8% and 57.6%, respectively.","Synthesis, anticancer activity and pharmacokinetic analysis of 1-[(substituted 2-alkoxyquinoxalin-3-yl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22226981/),%,57.6,11445,DB00592,Piperazine
,3576671,ED50,"The dose that produced 50% of the maximal immunosuppression (ED50) for cyclosporine alone was 89 mg/kg/day, whereas the ED50 for cyclosporine, when combined with ketoconazole, was 33 mg/kg/day.",Pharmacodynamics of cyclosporine-ketoconazole interaction in mice. Combined therapy potentiates cyclosporine immunosuppression and toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3576671/),[mg] / [d·kg],33,11465,DB00592,Piperazine
,23043539,K(d),"Optimization of the imidazo[4,5-b]pyridine-based series of Aurora kinase inhibitors led to the identification of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine (27e), a potent inhibitor of Aurora kinases (Aurora-A K(d) = 7.5 nM, Aurora-B K(d) = 48 nM), FLT3 kinase (K(d) = 6.2 nM), and FLT3 mutants including FLT3-ITD (K(d) = 38 nM) and FLT3(D835Y) (K(d) = 14 nM).","Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23043539/),nM,7.5,11697,DB00592,Piperazine
,23043539,K(d),"Optimization of the imidazo[4,5-b]pyridine-based series of Aurora kinase inhibitors led to the identification of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine (27e), a potent inhibitor of Aurora kinases (Aurora-A K(d) = 7.5 nM, Aurora-B K(d) = 48 nM), FLT3 kinase (K(d) = 6.2 nM), and FLT3 mutants including FLT3-ITD (K(d) = 38 nM) and FLT3(D835Y) (K(d) = 14 nM).","Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23043539/),nM,48,11698,DB00592,Piperazine
,23043539,K(d),"Optimization of the imidazo[4,5-b]pyridine-based series of Aurora kinase inhibitors led to the identification of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine (27e), a potent inhibitor of Aurora kinases (Aurora-A K(d) = 7.5 nM, Aurora-B K(d) = 48 nM), FLT3 kinase (K(d) = 6.2 nM), and FLT3 mutants including FLT3-ITD (K(d) = 38 nM) and FLT3(D835Y) (K(d) = 14 nM).","Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23043539/),nM,6.2,11699,DB00592,Piperazine
,23043539,K(d),"Optimization of the imidazo[4,5-b]pyridine-based series of Aurora kinase inhibitors led to the identification of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine (27e), a potent inhibitor of Aurora kinases (Aurora-A K(d) = 7.5 nM, Aurora-B K(d) = 48 nM), FLT3 kinase (K(d) = 6.2 nM), and FLT3 mutants including FLT3-ITD (K(d) = 38 nM) and FLT3(D835Y) (K(d) = 14 nM).","Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23043539/),nM,38,11700,DB00592,Piperazine
,23043539,K(d),"Optimization of the imidazo[4,5-b]pyridine-based series of Aurora kinase inhibitors led to the identification of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine (27e), a potent inhibitor of Aurora kinases (Aurora-A K(d) = 7.5 nM, Aurora-B K(d) = 48 nM), FLT3 kinase (K(d) = 6.2 nM), and FLT3 mutants including FLT3-ITD (K(d) = 38 nM) and FLT3(D835Y) (K(d) = 14 nM).","Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23043539/),nM,14,11701,DB00592,Piperazine
,24079718,bile-to-plasma AUC ratio,"High concentrations of the active form was measured in bile with a bile-to-plasma AUC ratio of approximately 75, indicating involvement of transporter-mediated excretion of the compound.",Combined in vitro-in vivo approach to assess the hepatobiliary disposition of a novel oral thrombin inhibitor. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24079718/),,75,11794,DB00592,Piperazine
,30515674,PFS,"At the February 26, 2016 cutoff, median PFS among the 46 Japanese patients was 22.2 months (95%CI, 13.6‒not estimable) with palbociclib-letrozole vs 13.8 months (5.6‒22.2) with placebo-letrozole (hazard ratio, 0.59 [95%CI, 0.26-1.34]).","Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30515674/),month,22,12011,DB00592,Piperazine
,30515674,PFS,"At the February 26, 2016 cutoff, median PFS among the 46 Japanese patients was 22.2 months (95%CI, 13.6‒not estimable) with palbociclib-letrozole vs 13.8 months (5.6‒22.2) with placebo-letrozole (hazard ratio, 0.59 [95%CI, 0.26-1.34]).","Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30515674/),month,13,12012,DB00592,Piperazine
,30515674,PFS,"At the February 26, 2016 cutoff, median PFS among the 46 Japanese patients was 22.2 months (95%CI, 13.6‒not estimable) with palbociclib-letrozole vs 13.8 months (5.6‒22.2) with placebo-letrozole (hazard ratio, 0.59 [95%CI, 0.26-1.34]).","Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30515674/),month,13.8,12013,DB00592,Piperazine
,30515674,trough concentration,"Although mean palbociclib trough concentration was higher in Japanese patients vs non-Asians (95.4 vs 61.7 ng/mL), the range of individual values of the Japanese patients was within that of non-Asians.","Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30515674/),[ng] / [ml],95.4,12014,DB00592,Piperazine
,30515674,trough concentration,"Although mean palbociclib trough concentration was higher in Japanese patients vs non-Asians (95.4 vs 61.7 ng/mL), the range of individual values of the Japanese patients was within that of non-Asians.","Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30515674/),[ng] / [ml],61.7,12015,DB00592,Piperazine
,14522602,elimination half-lives (t(1/2)),"[14C]-DW-116 was rapidly absorbed, and distributed into the maternal and fetal tissues, and it declined in a biphasic manner with elimination half-lives (t(1/2)) of 10-15 h and mean residence times (MRT(0-24 h)) of 4-9 h.",Fetal and maternal tissue distribution of the new fluoroquinolone DW-116 in pregnant rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522602/),h,10-15,12243,DB00592,Piperazine
,14522602,mean residence times (MRT(0-24 h)),"[14C]-DW-116 was rapidly absorbed, and distributed into the maternal and fetal tissues, and it declined in a biphasic manner with elimination half-lives (t(1/2)) of 10-15 h and mean residence times (MRT(0-24 h)) of 4-9 h.",Fetal and maternal tissue distribution of the new fluoroquinolone DW-116 in pregnant rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522602/),h,4-9,12244,DB00592,Piperazine
,14522602,K(p),"The tissue-to-plasma partition coefficient (K(p), AUC(0-24 h,tissue)/AUC(0-24 h,plasma)) of [14C]-DW-116 in maternal tissues was highest in the lung (K(p)=3.7), followed by the spleen (2.2), kidney (2.0), liver (1.8), heart (1.5), placenta (1.3), brain (1.3), ovary (1.1), uterus (1.1), and mammary gland (1.0).",Fetal and maternal tissue distribution of the new fluoroquinolone DW-116 in pregnant rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522602/),,3.7,12245,DB00592,Piperazine
,14522602,K(p),"The tissue-to-plasma partition coefficient (K(p), AUC(0-24 h,tissue)/AUC(0-24 h,plasma)) of [14C]-DW-116 in maternal tissues was highest in the lung (K(p)=3.7), followed by the spleen (2.2), kidney (2.0), liver (1.8), heart (1.5), placenta (1.3), brain (1.3), ovary (1.1), uterus (1.1), and mammary gland (1.0).",Fetal and maternal tissue distribution of the new fluoroquinolone DW-116 in pregnant rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522602/),,2.2,12246,DB00592,Piperazine
,14522602,K(p),"The tissue-to-plasma partition coefficient (K(p), AUC(0-24 h,tissue)/AUC(0-24 h,plasma)) of [14C]-DW-116 in maternal tissues was highest in the lung (K(p)=3.7), followed by the spleen (2.2), kidney (2.0), liver (1.8), heart (1.5), placenta (1.3), brain (1.3), ovary (1.1), uterus (1.1), and mammary gland (1.0).",Fetal and maternal tissue distribution of the new fluoroquinolone DW-116 in pregnant rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522602/),,2.0,12247,DB00592,Piperazine
,14522602,tissue-to-plasma partition coefficient,"The tissue-to-plasma partition coefficient values in fetal tissues were heart (K(p)=2.2), kidney (2.1), liver (1.9), lung (1.6) and brain (1.4).",Fetal and maternal tissue distribution of the new fluoroquinolone DW-116 in pregnant rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522602/),,2.2,12248,DB00592,Piperazine
,14522602,tissue-to-plasma partition coefficient,"The tissue-to-plasma partition coefficient values in fetal tissues were heart (K(p)=2.2), kidney (2.1), liver (1.9), lung (1.6) and brain (1.4).",Fetal and maternal tissue distribution of the new fluoroquinolone DW-116 in pregnant rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522602/),,2.1,12249,DB00592,Piperazine
,14522602,tissue-to-plasma partition coefficient,"The tissue-to-plasma partition coefficient values in fetal tissues were heart (K(p)=2.2), kidney (2.1), liver (1.9), lung (1.6) and brain (1.4).",Fetal and maternal tissue distribution of the new fluoroquinolone DW-116 in pregnant rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522602/),,1.9,12250,DB00592,Piperazine
,14522602,tissue-to-plasma partition coefficient,"The tissue-to-plasma partition coefficient values in fetal tissues were heart (K(p)=2.2), kidney (2.1), liver (1.9), lung (1.6) and brain (1.4).",Fetal and maternal tissue distribution of the new fluoroquinolone DW-116 in pregnant rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522602/),,1.6,12251,DB00592,Piperazine
,14522602,tissue-to-plasma partition coefficient,"The tissue-to-plasma partition coefficient values in fetal tissues were heart (K(p)=2.2), kidney (2.1), liver (1.9), lung (1.6) and brain (1.4).",Fetal and maternal tissue distribution of the new fluoroquinolone DW-116 in pregnant rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522602/),,1.4,12252,DB00592,Piperazine
,14522602,K(p),"The tissue-to-plasma partition coefficient values in fetal tissues were heart (K(p)=2.2), kidney (2.1), liver (1.9), lung (1.6) and brain (1.4).",Fetal and maternal tissue distribution of the new fluoroquinolone DW-116 in pregnant rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522602/),,2.2,12253,DB00592,Piperazine
,14522602,K(p),"The tissue-to-plasma partition coefficient values in fetal tissues were heart (K(p)=2.2), kidney (2.1), liver (1.9), lung (1.6) and brain (1.4).",Fetal and maternal tissue distribution of the new fluoroquinolone DW-116 in pregnant rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522602/),,2.1,12254,DB00592,Piperazine
,14522602,K(p),"The tissue-to-plasma partition coefficient values in fetal tissues were heart (K(p)=2.2), kidney (2.1), liver (1.9), lung (1.6) and brain (1.4).",Fetal and maternal tissue distribution of the new fluoroquinolone DW-116 in pregnant rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522602/),,1.9,12255,DB00592,Piperazine
,14522602,K(p),"The tissue-to-plasma partition coefficient values in fetal tissues were heart (K(p)=2.2), kidney (2.1), liver (1.9), lung (1.6) and brain (1.4).",Fetal and maternal tissue distribution of the new fluoroquinolone DW-116 in pregnant rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522602/),,1.6,12256,DB00592,Piperazine
,14522602,K(p),"The tissue-to-plasma partition coefficient values in fetal tissues were heart (K(p)=2.2), kidney (2.1), liver (1.9), lung (1.6) and brain (1.4).",Fetal and maternal tissue distribution of the new fluoroquinolone DW-116 in pregnant rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522602/),,1.4,12257,DB00592,Piperazine
,14522602,K(p),"When lactating rats were given a single oral dose of [14C]-DW-116, the radioactivity was rapidly secreted into the milk with K(p) of 1.7 at T(max) (0.5 h).",Fetal and maternal tissue distribution of the new fluoroquinolone DW-116 in pregnant rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522602/),,1.7,12258,DB00592,Piperazine
,14522602,T(max),"When lactating rats were given a single oral dose of [14C]-DW-116, the radioactivity was rapidly secreted into the milk with K(p) of 1.7 at T(max) (0.5 h).",Fetal and maternal tissue distribution of the new fluoroquinolone DW-116 in pregnant rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522602/),h,0.5,12259,DB00592,Piperazine
,15829116,detection limit,The detection limit of itraconazole was 5.0 microg/L.,Determination of itraconazole in human plasma by high-performance liquid chromatography with solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15829116/),[μg] / [l],5.0,12349,DB00592,Piperazine
,15829116,area under the plasma concentration-time curve from 0 to 24 h (AUC(0-24) ),We monitored the plasma level of itraconazole for the following 24 h and obtained the mean area under the plasma concentration-time curve from 0 to 24 h (AUC(0-24) ) value of 4358.9 +/- 1933.4 microg h/L.,Determination of itraconazole in human plasma by high-performance liquid chromatography with solid-phase extraction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15829116/),[h·μg] / [l],4358.9,12350,DB00592,Piperazine
,8712747,clearance,"Mean BU clearance was 7.653 +/- 1.871 l/hr.m2 in the itraconazole patients, 10.103 +/- 2.007 l/hr.",Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8712747/),[l] / [h·m2],7.653,12476,DB00592,Piperazine
,8712747,clearance,"Mean BU clearance was 7.653 +/- 1.871 l/hr.m2 in the itraconazole patients, 10.103 +/- 2.007 l/hr.",Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8712747/),[l] / [h],10.103,12477,DB00592,Piperazine
,12047483,tmax,"Bosentan was absorbed and eliminated with a tmax of 4.5 h (range 3.5-6.0 h) and a t(1/2) of 5.4 h (95% CI; 4.5, 6.6).",Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12047483/),h,4.5,12545,DB00592,Piperazine
,12047483,t(1/2),"Bosentan was absorbed and eliminated with a tmax of 4.5 h (range 3.5-6.0 h) and a t(1/2) of 5.4 h (95% CI; 4.5, 6.6).",Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12047483/),h,5.4,12546,DB00592,Piperazine
,33571728,flow rate,"The chromatographic separation was carried out on a BEH C18 column using a mobile phase containing deionized water and acetonitrile, both with 0.05 % (v/v) of formic acid, with a gradient elution at a flow rate of 0.5 mL/min.","Development of a simple and rapid method to determine the unbound fraction of dolutegravir, raltegravir and darunavir in human plasma using ultrafiltration and LC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33571728/),[ml] / [min],0.5,12606,DB00592,Piperazine
,33571728,run time,The run time was only 4 min.,"Development of a simple and rapid method to determine the unbound fraction of dolutegravir, raltegravir and darunavir in human plasma using ultrafiltration and LC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33571728/),min,4,12607,DB00592,Piperazine
,20027670,pK(i),"This led to the 2', 4'-difluorophenyl dimethylamide 40, a highly potent (pK(i) =9.2) and selective OT antagonist (>1,000-fold selectivity vs. the human vasopressin receptors V1a, V2, and V1b) with good oral bioavailability (>50%) in the rat and dog.","The design of orally bioavailable 2, 5-diketopiperazine oxytocin antagonists: from concept to clinical candidate for premature labor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20027670/),,9.2,12685,DB00592,Piperazine
>,20027670,oral bioavailability,"This led to the 2', 4'-difluorophenyl dimethylamide 40, a highly potent (pK(i) =9.2) and selective OT antagonist (>1,000-fold selectivity vs. the human vasopressin receptors V1a, V2, and V1b) with good oral bioavailability (>50%) in the rat and dog.","The design of orally bioavailable 2, 5-diketopiperazine oxytocin antagonists: from concept to clinical candidate for premature labor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20027670/),%,50,12686,DB00592,Piperazine
,20027670,K(i),Retosiban has sub-nanomolar affinity (K(i) =0.65 nM) for the oxytocin receptor with >1400-fold selectivity over the closely related vasopressin receptors.,"The design of orally bioavailable 2, 5-diketopiperazine oxytocin antagonists: from concept to clinical candidate for premature labor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20027670/),nM,0.65,12687,DB00592,Piperazine
>,20027670,IC(50),"It has good solubility, low protein binding and has a good Cyp450 profile with no significant inhibition IC(50) >100 µM.","The design of orally bioavailable 2, 5-diketopiperazine oxytocin antagonists: from concept to clinical candidate for premature labor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20027670/),μM,100,12688,DB00592,Piperazine
,20520639,times,"Median times from diagnosis of CP or AP to nilotinib therapy were 89 and 83 months, respectively.",Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20520639/),month,89,12771,DB00592,Piperazine
,20520639,times,"Median times from diagnosis of CP or AP to nilotinib therapy were 89 and 83 months, respectively.",Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20520639/),month,83,12772,DB00592,Piperazine
,17208404,flow rate,"The chromatographic separation was accomplished on a Xterra MS C18 Column (150 mm x 4.6 mm, 5 microm particle size) with the mobile phase consisting of methanol and water (40:60, v/v) (pH 2.0, adjusted with trifluoroacetic acid), and the flow rate was set at 0.6 mL/min.",LC/ESI-MS method for the determination of trimetazidine in human plasma: application to a bioequivalence study on Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208404/),[ml] / [min],0.6,12778,DB00592,Piperazine
,17208404,retention time,"Detection was performed on a single quadruple mass spectrometer by selected ion monitoring (SIM) mode (m/z 267.0 for trimetazidine and m/z 235.0 for lidocaine) with the retention time at about 3.47 and 5.05 min, respectively.",LC/ESI-MS method for the determination of trimetazidine in human plasma: application to a bioequivalence study on Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208404/),min,3.47,12779,DB00592,Piperazine
,17208404,retention time,"Detection was performed on a single quadruple mass spectrometer by selected ion monitoring (SIM) mode (m/z 267.0 for trimetazidine and m/z 235.0 for lidocaine) with the retention time at about 3.47 and 5.05 min, respectively.",LC/ESI-MS method for the determination of trimetazidine in human plasma: application to a bioequivalence study on Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208404/),min,5.05,12780,DB00592,Piperazine
,17208404,LOQ (,The LOQ (S/N=10) was accordingly 2.5 ng/mL.,LC/ESI-MS method for the determination of trimetazidine in human plasma: application to a bioequivalence study on Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208404/),[ng] / [ml],10,12781,DB00592,Piperazine
,17208404,LOQ (,The LOQ (S/N=10) was accordingly 2.5 ng/mL.,LC/ESI-MS method for the determination of trimetazidine in human plasma: application to a bioequivalence study on Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208404/),[ng] / [ml],2.5,12782,DB00592,Piperazine
,17208404,S/N,The LOQ (S/N=10) was accordingly 2.5 ng/mL.,LC/ESI-MS method for the determination of trimetazidine in human plasma: application to a bioequivalence study on Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208404/),[ng] / [ml],10,12783,DB00592,Piperazine
,17208404,S/N,The LOQ (S/N=10) was accordingly 2.5 ng/mL.,LC/ESI-MS method for the determination of trimetazidine in human plasma: application to a bioequivalence study on Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208404/),[ng] / [ml],2.5,12784,DB00592,Piperazine
,17208404,AUC(0-24),"After a single 20 mg dose for the test and reference product, the resulting mean of major pharmacokinetic parameters such as AUC(0-24), AUC(0-infinity), Cmax, Tmax and t(1/2) of trimetazidine were (673.1+/-117.6 ng h mL(-1) versus 652.3+/-121.9 ng h mL(-1)), (717.1+/-120.9 ng h mL(-1) versus 692+/-128.6 ng h mL(-1)), (74.85+/-12.13 ng mL(-1) versus 71.93+/-14.32 ng mL(-1)), (2.312+/-0.663 h versus 2.211+/-0.608 h) and (4.785+/-0.919 h versus 4.740+/-0.823 h), respectively, indicating that these two kinds of tablets were bioequivalent in the Chinese population.",LC/ESI-MS method for the determination of trimetazidine in human plasma: application to a bioequivalence study on Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208404/),[h·ng] / [ml],673.1,12785,DB00592,Piperazine
,17208404,t(1/2),"After a single 20 mg dose for the test and reference product, the resulting mean of major pharmacokinetic parameters such as AUC(0-24), AUC(0-infinity), Cmax, Tmax and t(1/2) of trimetazidine were (673.1+/-117.6 ng h mL(-1) versus 652.3+/-121.9 ng h mL(-1)), (717.1+/-120.9 ng h mL(-1) versus 692+/-128.6 ng h mL(-1)), (74.85+/-12.13 ng mL(-1) versus 71.93+/-14.32 ng mL(-1)), (2.312+/-0.663 h versus 2.211+/-0.608 h) and (4.785+/-0.919 h versus 4.740+/-0.823 h), respectively, indicating that these two kinds of tablets were bioequivalent in the Chinese population.",LC/ESI-MS method for the determination of trimetazidine in human plasma: application to a bioequivalence study on Chinese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208404/),h,2.312,12786,DB00592,Piperazine
,17208404,t(1/2),"After a single 20 mg dose for the test and reference product, the resulting mean of major pharmacokinetic parameters such as AUC(0-24), AUC(0-infinity), Cmax, Tmax and t(1/2) of trimetazidine were (673.1+/-117.6 ng h mL(-1) versus 652.3+/-121.9 ng h mL(-1)), (717.1+/-120.9 ng h mL(-1) versus 692+/-128.6 ng h mL(-1)), (74.85+/-12.13 ng mL(-1) versus 71.93+/-14.32 ng mL(-1)), (2.312+/-0.663 h versus 2.211+/-0.608 h) and (4.785+/-0.919 h versus 4.740+/-0.823 h), respectively, indicating that these two kinds of tablets were bioequivalent in the Chinese population.",LC/ESI-MS method for the determination of trimetazidine in human plasma: application to a bioequivalence study on Chinese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208404/),h,2.211,12787,DB00592,Piperazine
,17208404,t(1/2),"After a single 20 mg dose for the test and reference product, the resulting mean of major pharmacokinetic parameters such as AUC(0-24), AUC(0-infinity), Cmax, Tmax and t(1/2) of trimetazidine were (673.1+/-117.6 ng h mL(-1) versus 652.3+/-121.9 ng h mL(-1)), (717.1+/-120.9 ng h mL(-1) versus 692+/-128.6 ng h mL(-1)), (74.85+/-12.13 ng mL(-1) versus 71.93+/-14.32 ng mL(-1)), (2.312+/-0.663 h versus 2.211+/-0.608 h) and (4.785+/-0.919 h versus 4.740+/-0.823 h), respectively, indicating that these two kinds of tablets were bioequivalent in the Chinese population.",LC/ESI-MS method for the determination of trimetazidine in human plasma: application to a bioequivalence study on Chinese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208404/),h,4.785,12788,DB00592,Piperazine
,17208404,t(1/2),"After a single 20 mg dose for the test and reference product, the resulting mean of major pharmacokinetic parameters such as AUC(0-24), AUC(0-infinity), Cmax, Tmax and t(1/2) of trimetazidine were (673.1+/-117.6 ng h mL(-1) versus 652.3+/-121.9 ng h mL(-1)), (717.1+/-120.9 ng h mL(-1) versus 692+/-128.6 ng h mL(-1)), (74.85+/-12.13 ng mL(-1) versus 71.93+/-14.32 ng mL(-1)), (2.312+/-0.663 h versus 2.211+/-0.608 h) and (4.785+/-0.919 h versus 4.740+/-0.823 h), respectively, indicating that these two kinds of tablets were bioequivalent in the Chinese population.",LC/ESI-MS method for the determination of trimetazidine in human plasma: application to a bioequivalence study on Chinese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208404/),h,4.740,12789,DB00592,Piperazine
,12235265,C(max),Sirolimus C(max) (6.6 +/- 1.6 versus 26 +/- 7 ng/ml) and area under the concentration versus time curve from 0 to 6 h (AUC(0-6)) (22 +/- 7 versus 105 +/- 27 ng.,Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235265/),[ng] / [ml],6.6,12867,DB00592,Piperazine
,12235265,C(max),Sirolimus C(max) (6.6 +/- 1.6 versus 26 +/- 7 ng/ml) and area under the concentration versus time curve from 0 to 6 h (AUC(0-6)) (22 +/- 7 versus 105 +/- 27 ng.,Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235265/),[ng] / [ml],26,12868,DB00592,Piperazine
,12235265,area under the concentration versus time curve from 0 to 6 h (AUC(0-6)),Sirolimus C(max) (6.6 +/- 1.6 versus 26 +/- 7 ng/ml) and area under the concentration versus time curve from 0 to 6 h (AUC(0-6)) (22 +/- 7 versus 105 +/- 27 ng.,Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235265/),ng,22,12869,DB00592,Piperazine
,12235265,area under the concentration versus time curve from 0 to 6 h (AUC(0-6)),Sirolimus C(max) (6.6 +/- 1.6 versus 26 +/- 7 ng/ml) and area under the concentration versus time curve from 0 to 6 h (AUC(0-6)) (22 +/- 7 versus 105 +/- 27 ng.,Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235265/),ng,105,12870,DB00592,Piperazine
,12235265,T(max),Median T(max) (1.5-2 h) was unchanged.,Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235265/),h,1.5-2,12871,DB00592,Piperazine
,12235265,IC(50),"Consistent with published reports, sirolimus was a good inhibitor of P-glycoprotein, inhibiting polarized basolateral-to-apical flux of rhodamine 123 with an IC(50) of 0.625 to 1.25 microM (cyclosporine caused >80% inhibition at 5 microM).",Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235265/),μM,0.625 to 1.25,12872,DB00592,Piperazine
,3950868,clearance,"In the presence of ketoconazole, cyclosporine clearance decreased from 15.4 to 7.6 ml/hr; terminal half-life increased from 4.1 to 11.2 hr; and steady-state volume of distribution did not change significantly.",Ketoconazole inhibits cyclosporine metabolism in vivo in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950868/),[ml] / [h],15.4 to 7.6,13193,DB00592,Piperazine
,3950868,terminal half-life,"In the presence of ketoconazole, cyclosporine clearance decreased from 15.4 to 7.6 ml/hr; terminal half-life increased from 4.1 to 11.2 hr; and steady-state volume of distribution did not change significantly.",Ketoconazole inhibits cyclosporine metabolism in vivo in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950868/),h,4.1 to 11.2,13194,DB00592,Piperazine
,30947125,recovery,"Importantly, a simple, one-step protein precipitation and extraction method was used to extract the four compounds efficiently with a recovery in the range of 79.88 ± 5.02%-90.71 ± 5.13%, 85.72 ± 7.22%-93.17 ± 5.55%, 94.38 ± 7.35%-101.00 ± 8.88% and 94.38 ± 7.35%-99.87 ± 10.22% in plasma and organs for DOX, DEC, ABZ-OZ and ABZ-ON, respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),%,79.88,13278,DB00592,Piperazine
,30947125,recovery,"Importantly, a simple, one-step protein precipitation and extraction method was used to extract the four compounds efficiently with a recovery in the range of 79.88 ± 5.02%-90.71 ± 5.13%, 85.72 ± 7.22%-93.17 ± 5.55%, 94.38 ± 7.35%-101.00 ± 8.88% and 94.38 ± 7.35%-99.87 ± 10.22% in plasma and organs for DOX, DEC, ABZ-OZ and ABZ-ON, respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),%,90.71,13279,DB00592,Piperazine
,30947125,recovery,"Importantly, a simple, one-step protein precipitation and extraction method was used to extract the four compounds efficiently with a recovery in the range of 79.88 ± 5.02%-90.71 ± 5.13%, 85.72 ± 7.22%-93.17 ± 5.55%, 94.38 ± 7.35%-101.00 ± 8.88% and 94.38 ± 7.35%-99.87 ± 10.22% in plasma and organs for DOX, DEC, ABZ-OZ and ABZ-ON, respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),%,85.72,13280,DB00592,Piperazine
,30947125,recovery,"Importantly, a simple, one-step protein precipitation and extraction method was used to extract the four compounds efficiently with a recovery in the range of 79.88 ± 5.02%-90.71 ± 5.13%, 85.72 ± 7.22%-93.17 ± 5.55%, 94.38 ± 7.35%-101.00 ± 8.88% and 94.38 ± 7.35%-99.87 ± 10.22% in plasma and organs for DOX, DEC, ABZ-OZ and ABZ-ON, respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),%,93.17,13281,DB00592,Piperazine
,30947125,recovery,"Importantly, a simple, one-step protein precipitation and extraction method was used to extract the four compounds efficiently with a recovery in the range of 79.88 ± 5.02%-90.71 ± 5.13%, 85.72 ± 7.22%-93.17 ± 5.55%, 94.38 ± 7.35%-101.00 ± 8.88% and 94.38 ± 7.35%-99.87 ± 10.22% in plasma and organs for DOX, DEC, ABZ-OZ and ABZ-ON, respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),%,94.38,13282,DB00592,Piperazine
,30947125,recovery,"Importantly, a simple, one-step protein precipitation and extraction method was used to extract the four compounds efficiently with a recovery in the range of 79.88 ± 5.02%-90.71 ± 5.13%, 85.72 ± 7.22%-93.17 ± 5.55%, 94.38 ± 7.35%-101.00 ± 8.88% and 94.38 ± 7.35%-99.87 ± 10.22% in plasma and organs for DOX, DEC, ABZ-OZ and ABZ-ON, respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),%,101.00,13283,DB00592,Piperazine
,30947125,recovery,"Importantly, a simple, one-step protein precipitation and extraction method was used to extract the four compounds efficiently with a recovery in the range of 79.88 ± 5.02%-90.71 ± 5.13%, 85.72 ± 7.22%-93.17 ± 5.55%, 94.38 ± 7.35%-101.00 ± 8.88% and 94.38 ± 7.35%-99.87 ± 10.22% in plasma and organs for DOX, DEC, ABZ-OZ and ABZ-ON, respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),%,99.87,13284,DB00592,Piperazine
,30947125,run time,"Separation of all analytes was performed on a Xselect CSH™ C18 HPLC column (Waters, 3.0 x 150 mm, 3.5 μm particle size) with gradient elution employing a mobile phase consisting of 0.1% v/v formic acid in water and methanol with a run time of 20 min.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),min,20,13285,DB00592,Piperazine
,30947125,m/z,"Quantification was carried out employing a single, quadruple MS detector operated with single ion monitoring (SIM) mode and the ion transitions at m/z of 445.4, 200.2, 282.3 and 298.3 for DOX, DEC, ABZ-OX and ABZ-ON respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),,445.4,13286,DB00592,Piperazine
,30947125,m/z,"Quantification was carried out employing a single, quadruple MS detector operated with single ion monitoring (SIM) mode and the ion transitions at m/z of 445.4, 200.2, 282.3 and 298.3 for DOX, DEC, ABZ-OX and ABZ-ON respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),,200.2,13287,DB00592,Piperazine
,30947125,m/z,"Quantification was carried out employing a single, quadruple MS detector operated with single ion monitoring (SIM) mode and the ion transitions at m/z of 445.4, 200.2, 282.3 and 298.3 for DOX, DEC, ABZ-OX and ABZ-ON respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),,282.3,13288,DB00592,Piperazine
,30947125,m/z,"Quantification was carried out employing a single, quadruple MS detector operated with single ion monitoring (SIM) mode and the ion transitions at m/z of 445.4, 200.2, 282.3 and 298.3 for DOX, DEC, ABZ-OX and ABZ-ON respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),,298.3,13289,DB00592,Piperazine
,16928786,area under the plasma concentration-time curve (AUC(0-infinity)),"Although the elimination half-life and the renal clearance of fexofenadine remained relatively constant, a single administration of itraconazole with fexofenadine significantly increased mean area under the plasma concentration-time curve (AUC(0-infinity)) of fexofenadine (1701/3554, 4308, and 4107 ng h/ml for control; 50 mg, 100 mg, and 200 mg of itraconazole, respectively).",Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16928786/),[h·ng] / [ml],1701,13330,DB00592,Piperazine
,16928786,area under the plasma concentration-time curve (AUC(0-infinity)),"Although the elimination half-life and the renal clearance of fexofenadine remained relatively constant, a single administration of itraconazole with fexofenadine significantly increased mean area under the plasma concentration-time curve (AUC(0-infinity)) of fexofenadine (1701/3554, 4308, and 4107 ng h/ml for control; 50 mg, 100 mg, and 200 mg of itraconazole, respectively).",Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16928786/),[h·ng] / [ml],3554,13331,DB00592,Piperazine
,16928786,area under the plasma concentration-time curve (AUC(0-infinity)),"Although the elimination half-life and the renal clearance of fexofenadine remained relatively constant, a single administration of itraconazole with fexofenadine significantly increased mean area under the plasma concentration-time curve (AUC(0-infinity)) of fexofenadine (1701/3554, 4308, and 4107 ng h/ml for control; 50 mg, 100 mg, and 200 mg of itraconazole, respectively).",Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16928786/),[h·ng] / [ml],4308,13332,DB00592,Piperazine
,16928786,area under the plasma concentration-time curve (AUC(0-infinity)),"Although the elimination half-life and the renal clearance of fexofenadine remained relatively constant, a single administration of itraconazole with fexofenadine significantly increased mean area under the plasma concentration-time curve (AUC(0-infinity)) of fexofenadine (1701/3554, 4308, and 4107 ng h/ml for control; 50 mg, 100 mg, and 200 mg of itraconazole, respectively).",Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16928786/),[h·ng] / [ml],4107,13333,DB00592,Piperazine
,16928786,AUC(0-48),"Although mean itraconazole AUC(0-48) from 50 mg to 200 mg increased dose dependently from 214 to 772 ng h/ml (p = 0.003), no significant difference was noted in the three parameters, AUC (p = 0.423), C(max) (p = 0.636), and renal clearance (p = 0.495), of fexofenadine among the three doses of itraconazole.",Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16928786/),[h·ng] / [ml],214,13334,DB00592,Piperazine
,16928786,AUC(0-48),"Although mean itraconazole AUC(0-48) from 50 mg to 200 mg increased dose dependently from 214 to 772 ng h/ml (p = 0.003), no significant difference was noted in the three parameters, AUC (p = 0.423), C(max) (p = 0.636), and renal clearance (p = 0.495), of fexofenadine among the three doses of itraconazole.",Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16928786/),[h·ng] / [ml],77,13335,DB00592,Piperazine
,16928786,AUC(0-48),"Although mean itraconazole AUC(0-48) from 50 mg to 200 mg increased dose dependently from 214 to 772 ng h/ml (p = 0.003), no significant difference was noted in the three parameters, AUC (p = 0.423), C(max) (p = 0.636), and renal clearance (p = 0.495), of fexofenadine among the three doses of itraconazole.",Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16928786/),[h·ng] / [ml],2,13336,DB00592,Piperazine
,10365644,Recovery,"Recovery of buspirone and 1-PP averaged 98% and 89%, respectively, and the limit of quantification was 0.2 ng/mL for both compounds.",Determination of buspirone and 1-(2-pyrimidinyl)-piperazine (1-PP) in human plasma by capillary gas chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365644/),%,98,13512,DB00592,Piperazine
,10365644,Recovery,"Recovery of buspirone and 1-PP averaged 98% and 89%, respectively, and the limit of quantification was 0.2 ng/mL for both compounds.",Determination of buspirone and 1-(2-pyrimidinyl)-piperazine (1-PP) in human plasma by capillary gas chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365644/),%,89,13513,DB00592,Piperazine
,16842382,oral clearance,"A one-compartment model with first-order absorption appropriately described the data, giving a mean (+/-SEM) oral clearance of 14.3 l h-1 (+/-1.0) and a volume of distribution of 347 l (+/-62).",Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842382/),[l] / [h],14.3,14072,DB00592,Piperazine
,16842382,volume of distribution,"A one-compartment model with first-order absorption appropriately described the data, giving a mean (+/-SEM) oral clearance of 14.3 l h-1 (+/-1.0) and a volume of distribution of 347 l (+/-62).",Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842382/),l,347,14073,DB00592,Piperazine
,16842382,intra/extracellular ratio,"Moreover, we observed an intra/extracellular ratio of 8, suggesting substantial uptake of the drug into the target cells.",Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842382/),,8,14074,DB00592,Piperazine
,31076203,AUC0-t,"In humans, systemic exposure (AUC) was greater after inhalation of 750 versus 500 μg of nemiralisib (AUC0-t: 17,200 h∙pg/mL; 95% CI, 10,900-27,200 h∙pg/mL and 13,100; 95% CI, 8130-21,000 h∙pg/mL, respectively).","Safety, Tolerability, and Pharmacokinetics of a New Formulation of Nemiralisib Administered via a Dry Powder Inhaler to Healthy Individuals. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31076203/),[h∙pg] / [ml],"17,200",14076,DB00592,Piperazine
,31076203,AUC0-t,"In humans, systemic exposure (AUC) was greater after inhalation of 750 versus 500 μg of nemiralisib (AUC0-t: 17,200 h∙pg/mL; 95% CI, 10,900-27,200 h∙pg/mL and 13,100; 95% CI, 8130-21,000 h∙pg/mL, respectively).","Safety, Tolerability, and Pharmacokinetics of a New Formulation of Nemiralisib Administered via a Dry Powder Inhaler to Healthy Individuals. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31076203/),[h∙pg] / [ml],"13,100",14077,DB00592,Piperazine
,19237257,flow rate,It was delivered at a flow rate of 0.3 mL/min.,Determination of articaine in human plasma by liquid chromatography-mass spectrometry and its application in a preliminary pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19237257/),[ml] / [min],0.3,14611,DB00592,Piperazine
<,19237257,total run-time,"This method was fast (total run-time<3 min), accurate (bias<16%), and reproducible (intra-assay and inter-assay precision<14%) with a quantitation limit of 78.1 ng/mL.",Determination of articaine in human plasma by liquid chromatography-mass spectrometry and its application in a preliminary pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19237257/),min,3,14612,DB00592,Piperazine
,24766668,oral clearance,The population mean was 32.7 L/hr for oral clearance and 1.97∙10(3) L for the central volume of distribution.,Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24766668/),[l] / [h],32.7,15129,DB00592,Piperazine
,24766668,central volume of distribution,The population mean was 32.7 L/hr for oral clearance and 1.97∙10(3) L for the central volume of distribution.,Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24766668/),l,1.,15130,DB00592,Piperazine
,24766668,elimination half-life,The average elimination half-life was 65.8 hr.,Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24766668/),h,65.8,15131,DB00592,Piperazine
,2723000,C.V.,The inter-assay C.V. was 7.36% for a drug level of 1 ng/ml.,Determination of the antihypertensive drug 1-[2-ethoxy-2-(3'-pyridyl)ethyl]-4-(2'-methoxyphenyl) piperazine (IP/66) in rat and human plasma by high-performance liquid chromatography and isotope dilution mass spectrometry. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723000/),%,7.36,15247,DB00592,Piperazine
,19740395,C(max),"Co-administration of single-dose sotrastaurin during steady-state ketoconazole increased sotrastaurin C(max) by 2.5-fold (90% confidence interval 2.2, 2.9) from 285 +/- 128 to 678 +/- 189 ng ml(-1) and increased AUC by 4.6-fold (4.1, 5.2) from 1666 +/- 808 to 7378 +/- 3011 ng ml(-1) h.",The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740395/),[ng] / [ml],285,15301,DB00592,Piperazine
,19740395,C(max),"Co-administration of single-dose sotrastaurin during steady-state ketoconazole increased sotrastaurin C(max) by 2.5-fold (90% confidence interval 2.2, 2.9) from 285 +/- 128 to 678 +/- 189 ng ml(-1) and increased AUC by 4.6-fold (4.1, 5.2) from 1666 +/- 808 to 7378 +/- 3011 ng ml(-1) h.",The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740395/),[ng] / [ml],678,15302,DB00592,Piperazine
,19740395,AUC,"Co-administration of single-dose sotrastaurin during steady-state ketoconazole increased sotrastaurin C(max) by 2.5-fold (90% confidence interval 2.2, 2.9) from 285 +/- 128 to 678 +/- 189 ng ml(-1) and increased AUC by 4.6-fold (4.1, 5.2) from 1666 +/- 808 to 7378 +/- 3011 ng ml(-1) h.",The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740395/),[h·ng] / [ml],1666,15303,DB00592,Piperazine
,19740395,AUC,"Co-administration of single-dose sotrastaurin during steady-state ketoconazole increased sotrastaurin C(max) by 2.5-fold (90% confidence interval 2.2, 2.9) from 285 +/- 128 to 678 +/- 189 ng ml(-1) and increased AUC by 4.6-fold (4.1, 5.2) from 1666 +/- 808 to 7378 +/- 3011 ng ml(-1) h.",The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740395/),[h·ng] / [ml],7378,15304,DB00592,Piperazine
,19740395,half-life,Sotrastaurin half-life was nearly doubled from 5.9 +/- 1.7 to 10.6 +/- 2.5 h.,The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740395/),h,5.9,15305,DB00592,Piperazine
,19740395,half-life,Sotrastaurin half-life was nearly doubled from 5.9 +/- 1.7 to 10.6 +/- 2.5 h.,The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740395/),h,10.6,15306,DB00592,Piperazine
,28603935,bioavailability,Oral tramadol bioavailability was low (2.6%).,The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603935/),%,2.6,15349,DB00592,Piperazine
,28603935,bioavailability,"Ketoconazole and cimetidine significantly increased tramadol bioavailability to 18.2% and 20.3%, respectively.",The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603935/),%,18.2,15350,DB00592,Piperazine
,28603935,bioavailability,"Ketoconazole and cimetidine significantly increased tramadol bioavailability to 18.2% and 20.3%, respectively.",The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603935/),%,20.3,15351,DB00592,Piperazine
,28603935,maximum plasma concentration,"The mean maximum plasma concentration of tramadol alone was 22.9 ng/ml, and increased to 109.9 and 143.2 μg/ml with ketoconazole and cimetidine, respectively.",The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603935/),[ng] / [ml],22.9,15352,DB00592,Piperazine
,28603935,maximum plasma concentration,"The mean maximum plasma concentration of tramadol alone was 22.9 ng/ml, and increased to 109.9 and 143.2 μg/ml with ketoconazole and cimetidine, respectively.",The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603935/),[μg] / [ml],109.9,15353,DB00592,Piperazine
,28603935,maximum plasma concentration,"The mean maximum plasma concentration of tramadol alone was 22.9 ng/ml, and increased to 109.9 and 143.2 μg/ml with ketoconazole and cimetidine, respectively.",The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603935/),[μg] / [ml],143.2,15354,DB00592,Piperazine
,28603935,minimum concentration,"However, measured tramadol plasma concentrations were below the minimum concentration considered effective in humans (228 μg/ml).",The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603935/),[μg] / [ml],228,15355,DB00592,Piperazine
,26804967,maximum concentration (Cmax ),"Formulation 2 had a higher maximum concentration (Cmax ) for testosterone, 8.06 ng ml(-1) (95% confidence interval [CI] 6.84, 9.28) and higher area under the plasma concentration-time curve (AUC), 7.69 ng ml(-1) h (95% CI 6.22, 9.16) than formulation 1, 5.66 ng ml(-1) (95% CI 4.63, 6.69) and 5.12 ng ml(-1) h (95% CI 4.51, 5.73), respectively.",Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804967/),[ng] / [ml],8.06,15432,DB00592,Piperazine
,26804967,area under the plasma concentration-time curve (AUC),"Formulation 2 had a higher maximum concentration (Cmax ) for testosterone, 8.06 ng ml(-1) (95% confidence interval [CI] 6.84, 9.28) and higher area under the plasma concentration-time curve (AUC), 7.69 ng ml(-1) h (95% CI 6.22, 9.16) than formulation 1, 5.66 ng ml(-1) (95% CI 4.63, 6.69) and 5.12 ng ml(-1) h (95% CI 4.51, 5.73), respectively.",Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804967/),[h·ng] / [ml],7.69,15433,DB00592,Piperazine
,26804967,area under the plasma concentration-time curve (AUC),"Formulation 2 had a higher maximum concentration (Cmax ) for testosterone, 8.06 ng ml(-1) (95% confidence interval [CI] 6.84, 9.28) and higher area under the plasma concentration-time curve (AUC), 7.69 ng ml(-1) h (95% CI 6.22, 9.16) than formulation 1, 5.66 ng ml(-1) (95% CI 4.63, 6.69) and 5.12 ng ml(-1) h (95% CI 4.51, 5.73), respectively.",Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804967/),[ng] / [ml],5.66,15434,DB00592,Piperazine
,26804967,area under the plasma concentration-time curve (AUC),"Formulation 2 had a higher maximum concentration (Cmax ) for testosterone, 8.06 ng ml(-1) (95% confidence interval [CI] 6.84, 9.28) and higher area under the plasma concentration-time curve (AUC), 7.69 ng ml(-1) h (95% CI 6.22, 9.16) than formulation 1, 5.66 ng ml(-1) (95% CI 4.63, 6.69) and 5.12 ng ml(-1) h (95% CI 4.51, 5.73), respectively.",Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804967/),[h·ng] / [ml],5.12,15435,DB00592,Piperazine
,26804967,Cmax,"Formulation 2 had a lower Cmax for sildenafil, 173 ng ml(-1) (95% CI 126, 220) and a lower AUC, 476 ng ml(-1) h (95% CI 401, 551) than formulation 1, 268 ng ml(-1) (95% CI 188, 348) and 577 ng ml(-1) h (95% CI 462, 692), respectively.",Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804967/),[ng] / [ml],173,15436,DB00592,Piperazine
,26804967,AUC,"Formulation 2 had a lower Cmax for sildenafil, 173 ng ml(-1) (95% CI 126, 220) and a lower AUC, 476 ng ml(-1) h (95% CI 401, 551) than formulation 1, 268 ng ml(-1) (95% CI 188, 348) and 577 ng ml(-1) h (95% CI 462, 692), respectively.",Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804967/),[h·ng] / [ml],476,15437,DB00592,Piperazine
,26804967,AUC,"Formulation 2 had a lower Cmax for sildenafil, 173 ng ml(-1) (95% CI 126, 220) and a lower AUC, 476 ng ml(-1) h (95% CI 401, 551) than formulation 1, 268 ng ml(-1) (95% CI 188, 348) and 577 ng ml(-1) h (95% CI 462, 692), respectively.",Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804967/),[ng] / [ml],",",15438,DB00592,Piperazine
,26804967,AUC,"Formulation 2 had a lower Cmax for sildenafil, 173 ng ml(-1) (95% CI 126, 220) and a lower AUC, 476 ng ml(-1) h (95% CI 401, 551) than formulation 1, 268 ng ml(-1) (95% CI 188, 348) and 577 ng ml(-1) h (95% CI 462, 692), respectively.",Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804967/),[ng] / [ml],268,15439,DB00592,Piperazine
,26804967,AUC,"Formulation 2 had a lower Cmax for sildenafil, 173 ng ml(-1) (95% CI 126, 220) and a lower AUC, 476 ng ml(-1) h (95% CI 401, 551) than formulation 1, 268 ng ml(-1) (95% CI 188, 348) and 577 ng ml(-1) h (95% CI 462, 692), respectively.",Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804967/),[h·ng] / [ml],577,15440,DB00592,Piperazine
,20210560,entrapment efficiency,The size distribution of the liposomes was 264.5 nm and the entrapment efficiency of ITZ-LPs was 73.82 +/- 0.73%.,Pharmacokinetics and biodistribution of itraconazole in rats and mice following intravenous administration in a novel liposome formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20210560/),%,73.82,15711,DB00592,Piperazine
,20210560,AUC(0-->24 h),The AUC(0-->24 h) for ITZ-CD was 87.12 mg/L.h and that for ITZ-LPs was 155.47 mg/L.h (p < 0.05).,Pharmacokinetics and biodistribution of itraconazole in rats and mice following intravenous administration in a novel liposome formulation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20210560/),[mg] / [h·l],87.12,15712,DB00592,Piperazine
,20210560,AUC(0-->24 h),The AUC(0-->24 h) for ITZ-CD was 87.12 mg/L.h and that for ITZ-LPs was 155.47 mg/L.h (p < 0.05).,Pharmacokinetics and biodistribution of itraconazole in rats and mice following intravenous administration in a novel liposome formulation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20210560/),[mg] / [h·l],155.47,15713,DB00592,Piperazine
,20210560,MRT(0-->24 h),The MRT(0-->24 h) value was 1.70 h for ITZ-CD and 3.68 h for ITZ-LPs.,Pharmacokinetics and biodistribution of itraconazole in rats and mice following intravenous administration in a novel liposome formulation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20210560/),h,1.70,15714,DB00592,Piperazine
,20210560,MRT(0-->24 h),The MRT(0-->24 h) value was 1.70 h for ITZ-CD and 3.68 h for ITZ-LPs.,Pharmacokinetics and biodistribution of itraconazole in rats and mice following intravenous administration in a novel liposome formulation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20210560/),h,3.68,15715,DB00592,Piperazine
,11259329,maximum inactivation rate constant,"The maximum inactivation rate constant and the apparent inactivation constant of EM on MDZ metabolism were 0.0665 min(-1) and 81.8 microM, respectively.","Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11259329/),1/[min],0.0665,16036,DB00592,Piperazine
,11259329,apparent inactivation constant,"The maximum inactivation rate constant and the apparent inactivation constant of EM on MDZ metabolism were 0.0665 min(-1) and 81.8 microM, respectively.","Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11259329/),μM,81.8,16037,DB00592,Piperazine
,31536852,PFS,"At the cut-off date, the median PFS was 4.4 months (95% confidence interval [CI], 2.8-6.0) and 12-week progression-free rate was 73.4% (95% CI, 58.1-88.7).","Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31536852/),month,4,16206,DB00592,Piperazine
,31536852,OS,"The median OS was 11.5 months (95% CI, 7.0-not reached).","Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31536852/),month,11.5,16207,DB00592,Piperazine
,32889741,IC50,"Among them, 12r showed the most potent inhibition with an IC50 value of 5.66 ± 0.47 μM.","Design, synthesis and anti-inflammatory study of novel N-heterocyclic substituted Aloe-emodin derivatives. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32889741/),μM,5.66,16394,DB00592,Piperazine
up to,32889741,oral bioavailability,"Importantly, 12r showed oral bioavailability of up to 55.16% and attenuated the inflammatory symptoms in an ulcerative colitis mouse model in vivo.","Design, synthesis and anti-inflammatory study of novel N-heterocyclic substituted Aloe-emodin derivatives. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32889741/),%,55.16,16395,DB00592,Piperazine
,19246732,half-life (t(1/2),Some investigators suggest that a single dose of 400 mg (SD400) KTZ is sufficient given its short half-life (t(1/2) approximately 3-5 hr).,Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19246732/),h,3-5,16567,DB00592,Piperazine
,26123925,brain-to-plasma ratios,"At 4 h the brain-to-plasma ratios were 0.3 in WT and Abcg2(-/-) mice versus 5.5 and 15 in Abcb1a/b(-/-) and Abcg2; Abcb1a/b(-/-) mice, respectively.",P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26123925/),,0.3,16622,DB00592,Piperazine
,26123925,brain-to-plasma ratios,"At 4 h the brain-to-plasma ratios were 0.3 in WT and Abcg2(-/-) mice versus 5.5 and 15 in Abcb1a/b(-/-) and Abcg2; Abcb1a/b(-/-) mice, respectively.",P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26123925/),,5.5,16623,DB00592,Piperazine
,26123925,brain-to-plasma ratios,"At 4 h the brain-to-plasma ratios were 0.3 in WT and Abcg2(-/-) mice versus 5.5 and 15 in Abcb1a/b(-/-) and Abcg2; Abcb1a/b(-/-) mice, respectively.",P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26123925/),,15,16624,DB00592,Piperazine
,26123925,oral bioavailability,The oral bioavailability of palbociclib was high (63 %) in WT mice and increased only modestly and non-significantly in Abcg2; Abcb1a/b(-/-) mice.,P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26123925/),%,63,16625,DB00592,Piperazine
,9342502,oral bioavailability,Nefazodone undergoes significant first-pass metabolism resulting in an oral bioavailability of approximately 20%.,Clinical pharmacokinetics of nefazodone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342502/),%,20,16638,DB00592,Piperazine
,28578536,apparent clearance (CL/F),"The final popPK model for children with SCA provided a reasonable fit to Pras-AM plasma concentrations over time, with estimates of apparent clearance (CL/F) (172 L/h) and apparent volume of distribution (Vd/F) (51.7 L) that were comparable to previous studies in adults.",Population Pharmacokinetic and Exposure-Response Analyses of Prasugrel in Pediatric Patients with Sickle Cell Anemia. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28578536/),[l] / [h],172,16689,DB00592,Piperazine
,28578536,apparent volume of distribution (Vd/F),"The final popPK model for children with SCA provided a reasonable fit to Pras-AM plasma concentrations over time, with estimates of apparent clearance (CL/F) (172 L/h) and apparent volume of distribution (Vd/F) (51.7 L) that were comparable to previous studies in adults.",Population Pharmacokinetic and Exposure-Response Analyses of Prasugrel in Pediatric Patients with Sickle Cell Anemia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28578536/),l,51.7,16690,DB00592,Piperazine
,33185345,maximum concentration,"An earlier achievement of the maximum concentration of sildenafil was detected when taking the test drug compared with the standard form (51 and 62 minutes, respectively, Z-value=-2.25, p-value=0.0244).",[Pharmacokinetic features of sildenafil spray in healthy men depending on food intake]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33185345/),min,51,16805,DB00592,Piperazine
,33185345,maximum concentration,"An earlier achievement of the maximum concentration of sildenafil was detected when taking the test drug compared with the standard form (51 and 62 minutes, respectively, Z-value=-2.25, p-value=0.0244).",[Pharmacokinetic features of sildenafil spray in healthy men depending on food intake]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33185345/),min,62,16806,DB00592,Piperazine
,29880085,bioavailability,"The total clearance (CL/F) of oral and intravenous given IMA was increased by 1.41 and 1.32-fold, and the bioavailability was greatly decreased about 30.43% and 24.40% respectively.",Effects of aprepitant on the pharmacokinetics of imatinib and its main metabolite in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29880085/),%,30.43,17060,DB00592,Piperazine
,29880085,bioavailability,"The total clearance (CL/F) of oral and intravenous given IMA was increased by 1.41 and 1.32-fold, and the bioavailability was greatly decreased about 30.43% and 24.40% respectively.",Effects of aprepitant on the pharmacokinetics of imatinib and its main metabolite in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29880085/),%,24.40,17061,DB00592,Piperazine
,23715577,time to reach maximum concentration,"Dasatinib pediatric pharmacokinetic parameters were comparable with those in adult studies, showing rapid absorption (time to reach maximum concentration, 0.5 to 6.0 hours) and elimination (mean half-life, 3.0 to 4.4 hours).",Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23715577/),h,0.5 to 6.0,17096,DB00592,Piperazine
,23715577,half-life,"Dasatinib pediatric pharmacokinetic parameters were comparable with those in adult studies, showing rapid absorption (time to reach maximum concentration, 0.5 to 6.0 hours) and elimination (mean half-life, 3.0 to 4.4 hours).",Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23715577/),h,3.0 to 4.4,17097,DB00592,Piperazine
,23139378,inhibition constants,"The plasma concentration profiles of repaglinide were well reproduced by the PBPK model based on the above assumptions, and the optimized values for the inhibition constants (0.0676 nM for itraconazole against CYP3A4; 14.2 μM for gemfibrozil against OATP1B1; and 5.48 μM for gemfibrozil glucuronide against OATP1B1) and the fraction of repaglinide metabolized by CYP2C8 (0.801) were consistent with the reported values.",Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23139378/),nM,0.0676,17157,DB00592,Piperazine
,23139378,inhibition constants,"The plasma concentration profiles of repaglinide were well reproduced by the PBPK model based on the above assumptions, and the optimized values for the inhibition constants (0.0676 nM for itraconazole against CYP3A4; 14.2 μM for gemfibrozil against OATP1B1; and 5.48 μM for gemfibrozil glucuronide against OATP1B1) and the fraction of repaglinide metabolized by CYP2C8 (0.801) were consistent with the reported values.",Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23139378/),μM,14.2,17158,DB00592,Piperazine
,23139378,inhibition constants,"The plasma concentration profiles of repaglinide were well reproduced by the PBPK model based on the above assumptions, and the optimized values for the inhibition constants (0.0676 nM for itraconazole against CYP3A4; 14.2 μM for gemfibrozil against OATP1B1; and 5.48 μM for gemfibrozil glucuronide against OATP1B1) and the fraction of repaglinide metabolized by CYP2C8 (0.801) were consistent with the reported values.",Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23139378/),μM,5.48,17159,DB00592,Piperazine
,23139378,inhibition constants,"The plasma concentration profiles of repaglinide were well reproduced by the PBPK model based on the above assumptions, and the optimized values for the inhibition constants (0.0676 nM for itraconazole against CYP3A4; 14.2 μM for gemfibrozil against OATP1B1; and 5.48 μM for gemfibrozil glucuronide against OATP1B1) and the fraction of repaglinide metabolized by CYP2C8 (0.801) were consistent with the reported values.",Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23139378/),,0.,17160,DB00592,Piperazine
,28623772,flow rate,Elution was achieved in gradient mode on High Resolution Chromolith RP-18e column with mobile phase comprised of acetonitrile and 0.1% (v/v) formic acid in water at the flow rate of 0.4mL/min.,"Development and validation of a highly sensitive LC-ESI-MS/MS method for estimation of IIIM-MCD-211, a novel nitrofuranyl methyl piperazine derivative with potential activity against tuberculosis: Application to drug development. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28623772/),[ml] / [min],0.4,17680,DB00592,Piperazine
,28623772,m,"Precursor to product ion transitions (m/z 344.5/218.4 and m/z 237.3/194.2) were used to measure analyte and IS, respectively.","Development and validation of a highly sensitive LC-ESI-MS/MS method for estimation of IIIM-MCD-211, a novel nitrofuranyl methyl piperazine derivative with potential activity against tuberculosis: Application to drug development. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28623772/),,344.5,17681,DB00592,Piperazine
,28623772,m,"Precursor to product ion transitions (m/z 344.5/218.4 and m/z 237.3/194.2) were used to measure analyte and IS, respectively.","Development and validation of a highly sensitive LC-ESI-MS/MS method for estimation of IIIM-MCD-211, a novel nitrofuranyl methyl piperazine derivative with potential activity against tuberculosis: Application to drug development. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28623772/),,218,17682,DB00592,Piperazine
,28623772,m/z,"Precursor to product ion transitions (m/z 344.5/218.4 and m/z 237.3/194.2) were used to measure analyte and IS, respectively.","Development and validation of a highly sensitive LC-ESI-MS/MS method for estimation of IIIM-MCD-211, a novel nitrofuranyl methyl piperazine derivative with potential activity against tuberculosis: Application to drug development. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28623772/),,237,17683,DB00592,Piperazine
,9261765,half-life,Each subject was treated with each of the three dapiprazole regimens in three different study sessions separated by at least 5 days (drug half-life in the eye is 5 hours).,Dose-response study of dapiprazole HCl in the reversal of mydriasis induced by 2.5% phenylephrine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9261765/),h,5,17858,DB00592,Piperazine
,10383565,50% inhibitory concentration (IC50 ),"Ketoconazole had a 50% inhibitory concentration (IC50 ) of 0.61 microm vs formation of the M-3 metabolite of zolpidem in vitro; in a clinical study, ketoconazole coadministration reduced zolpidem oral clearance by approximately 40%, somewhat less than anticipated based on the IC50 value and total plasma ketoconazole levels, but much more than predicted based on unbound plasma ketoconazole levels.","Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383565/),μm,0.61,18082,DB00592,Piperazine
,30889695,AUC0-24h,"Furthermore, the pharmacokinetic profiles of obtained nano-formulations were assessed in rats, among which the improved adsorption of SBA-15/EPL/ITZ composites (AUC0-24h sum: 8381.7 nM·h) was identified compared with that of pure ITZ (525.1 nM·h) and the commercial drug of Sporanox (7516.6 nM·h).",Epsilon-poly-l-lysine decorated ordered mesoporous silica contributes to the synergistic antifungal effect and enhanced solubility of a lipophilic drug. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30889695/),h·nM,8381.7,18164,DB00592,Piperazine
,30889695,AUC0-24h,"Furthermore, the pharmacokinetic profiles of obtained nano-formulations were assessed in rats, among which the improved adsorption of SBA-15/EPL/ITZ composites (AUC0-24h sum: 8381.7 nM·h) was identified compared with that of pure ITZ (525.1 nM·h) and the commercial drug of Sporanox (7516.6 nM·h).",Epsilon-poly-l-lysine decorated ordered mesoporous silica contributes to the synergistic antifungal effect and enhanced solubility of a lipophilic drug. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30889695/),h·nM,525.1,18165,DB00592,Piperazine
,30889695,AUC0-24h,"Furthermore, the pharmacokinetic profiles of obtained nano-formulations were assessed in rats, among which the improved adsorption of SBA-15/EPL/ITZ composites (AUC0-24h sum: 8381.7 nM·h) was identified compared with that of pure ITZ (525.1 nM·h) and the commercial drug of Sporanox (7516.6 nM·h).",Epsilon-poly-l-lysine decorated ordered mesoporous silica contributes to the synergistic antifungal effect and enhanced solubility of a lipophilic drug. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30889695/),h·nM,7516.6,18166,DB00592,Piperazine
,7929869,wash-out t1/2,"Mean wash-out t1/2 was 18 to 20 hours for the parent compound, 22-23 hours for metabolite II, and 28-33 hours for metabolite IV; these elimination t1/2 are comparable for the two doses, and are similar to those observed in single-dose studies.","Multiple-dose pharmacokinetics and safety of a potential memory-enhancing compound, CL 275,838, in healthy male volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7929869/),h,18 to 20,18201,DB00592,Piperazine
,7929869,wash-out t1/2,"Mean wash-out t1/2 was 18 to 20 hours for the parent compound, 22-23 hours for metabolite II, and 28-33 hours for metabolite IV; these elimination t1/2 are comparable for the two doses, and are similar to those observed in single-dose studies.","Multiple-dose pharmacokinetics and safety of a potential memory-enhancing compound, CL 275,838, in healthy male volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7929869/),h,22-23,18202,DB00592,Piperazine
,7929869,wash-out t1/2,"Mean wash-out t1/2 was 18 to 20 hours for the parent compound, 22-23 hours for metabolite II, and 28-33 hours for metabolite IV; these elimination t1/2 are comparable for the two doses, and are similar to those observed in single-dose studies.","Multiple-dose pharmacokinetics and safety of a potential memory-enhancing compound, CL 275,838, in healthy male volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7929869/),h,28-33,18203,DB00592,Piperazine
,9098842,apparent elimination half-life,"After i.v. administration in rats and dogs, plasma concentrations of lesopitron decreased biphasically with an apparent elimination half-life of 100 min.","Absorption, distribution and excretion of [14C]-Lesopitron after single and repeated administration in rats and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9098842/),min,100,18223,DB00592,Piperazine
,9098842,absolute bioavailability,"The absolute bioavailability of lesopitron was about 10%, suggesting an important first-pass effect.","Absorption, distribution and excretion of [14C]-Lesopitron after single and repeated administration in rats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9098842/),%,10,18224,DB00592,Piperazine
,32430518,absolute bioavailability,The median absolute bioavailability of oral imatinib at steady state was 76% (range 44-106%).,Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32430518/),%,76,18362,DB00592,Piperazine
,32293723,Cmin,"The imatinib Cmin was 1315 ± 716 ng/mL, 2117 ± 597 ng/mL, and 3844 ± 987 ng/mL in patients who were receiving imatinib 400 mg, 600 mg, and 800 mg daily, respectively.",Correlations between imatinib plasma trough concentration and adverse reactions in Chinese patients with gastrointestinal stromal tumors. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32293723/),[ng] / [ml],1315,18580,DB00592,Piperazine
,32293723,Cmin,"The imatinib Cmin was 1315 ± 716 ng/mL, 2117 ± 597 ng/mL, and 3844 ± 987 ng/mL in patients who were receiving imatinib 400 mg, 600 mg, and 800 mg daily, respectively.",Correlations between imatinib plasma trough concentration and adverse reactions in Chinese patients with gastrointestinal stromal tumors. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32293723/),[ng] / [ml],2117,18581,DB00592,Piperazine
,32293723,Cmin,"The imatinib Cmin was 1315 ± 716 ng/mL, 2117 ± 597 ng/mL, and 3844 ± 987 ng/mL in patients who were receiving imatinib 400 mg, 600 mg, and 800 mg daily, respectively.",Correlations between imatinib plasma trough concentration and adverse reactions in Chinese patients with gastrointestinal stromal tumors. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32293723/),[ng] / [ml],3844,18582,DB00592,Piperazine
,22989976,polydispersion index (PI),The resultant APZ nanosuspensions showed a mean particle size of 350 nm with polydispersion index (PI) value of 0.20.,Enhanced dissolution and oral bioavailability of aripiprazole nanosuspensions prepared by nanoprecipitation/homogenization based on acid-base neutralization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22989976/),,0,18859,DB00592,Piperazine
,22989976,relative bioavailability,"APZ nanosuspensions got maximum absorption rate and extent comparing with APZ commercial tablet and suspensions with relative bioavailability of 123.43 ± 12.98% and 171.41 ± 14.62%, respectively.",Enhanced dissolution and oral bioavailability of aripiprazole nanosuspensions prepared by nanoprecipitation/homogenization based on acid-base neutralization. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22989976/),%,123.43,18860,DB00592,Piperazine
,22989976,relative bioavailability,"APZ nanosuspensions got maximum absorption rate and extent comparing with APZ commercial tablet and suspensions with relative bioavailability of 123.43 ± 12.98% and 171.41 ± 14.62%, respectively.",Enhanced dissolution and oral bioavailability of aripiprazole nanosuspensions prepared by nanoprecipitation/homogenization based on acid-base neutralization. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22989976/),%,171.41,18861,DB00592,Piperazine
,17620223,AUC(0-infinity),"After oral and intravenous dosing, the values of AUC(0-infinity) of total radioactivity were 36.2 and 47.1 microg eqx h ml(-1), respectively.","Absorption, distribution and excretion of the new thienopyridine agent prasugrel in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17620223/),[eq·h·μg] / [ml],36.2,18905,DB00592,Piperazine
,17620223,AUC(0-infinity),"After oral and intravenous dosing, the values of AUC(0-infinity) of total radioactivity were 36.2 and 47.1 microg eqx h ml(-1), respectively.","Absorption, distribution and excretion of the new thienopyridine agent prasugrel in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17620223/),[eq·h·μg] / [ml],47.1,18906,DB00592,Piperazine
,17620223,excretion of radioactivity,"The excretion of radioactivity in the urine and feces were 20.2% and 78.7%, respectively, after oral dosing.","Absorption, distribution and excretion of the new thienopyridine agent prasugrel in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17620223/),%,20.2,18907,DB00592,Piperazine
,17620223,excretion of radioactivity,"The excretion of radioactivity in the urine and feces were 20.2% and 78.7%, respectively, after oral dosing.","Absorption, distribution and excretion of the new thienopyridine agent prasugrel in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17620223/),%,78.7,18908,DB00592,Piperazine
,20093186,t(max),"HPbetaCD-ITZ demonstrated faster systemic absorption of ITZ across lung epithelium than URF-ITZ, with t(max) values of 1.5 and 3.0 h, and AUC(0-infinity) of 2513 and 3717 ng h/mL, respectively.",In vitro characterization and pharmacokinetics in mice following pulmonary delivery of itraconazole as cyclodextrin solubilized solution. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20093186/),h,1.5,18997,DB00592,Piperazine
,20093186,t(max),"HPbetaCD-ITZ demonstrated faster systemic absorption of ITZ across lung epithelium than URF-ITZ, with t(max) values of 1.5 and 3.0 h, and AUC(0-infinity) of 2513 and 3717 ng h/mL, respectively.",In vitro characterization and pharmacokinetics in mice following pulmonary delivery of itraconazole as cyclodextrin solubilized solution. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20093186/),h,3.0,18998,DB00592,Piperazine
,20093186,AUC(0-infinity),"HPbetaCD-ITZ demonstrated faster systemic absorption of ITZ across lung epithelium than URF-ITZ, with t(max) values of 1.5 and 3.0 h, and AUC(0-infinity) of 2513 and 3717 ng h/mL, respectively.",In vitro characterization and pharmacokinetics in mice following pulmonary delivery of itraconazole as cyclodextrin solubilized solution. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20093186/),[h·ng] / [ml],2513,18999,DB00592,Piperazine
,20093186,AUC(0-infinity),"HPbetaCD-ITZ demonstrated faster systemic absorption of ITZ across lung epithelium than URF-ITZ, with t(max) values of 1.5 and 3.0 h, and AUC(0-infinity) of 2513 and 3717 ng h/mL, respectively.",In vitro characterization and pharmacokinetics in mice following pulmonary delivery of itraconazole as cyclodextrin solubilized solution. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20093186/),[h·ng] / [ml],3717,19000,DB00592,Piperazine
,23095205,Total run time,Detection was performed by a tandem mass spectrometer coupled to LC via an atmospheric pressure chemical ionization (APCI) and quantification was performed using selected reaction monitoring (SRM) transitions Total run time was 4.5 min.,"Validation of a fast and reliable liquid chromatography-tandem mass spectrometry (LC-MS/MS) with atmospheric pressure chemical ionization method for simultaneous quantitation of voriconazole, itraconazole and its active metabolite hydroxyitraconazole in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23095205/),min,4.5,19355,DB00592,Piperazine
,17923446,m/,"The precursor to product ion transitions of m/z 535.3-->288.2 and m/z 409.1-->205.2 were used to measure the analyte and the IS, respectively.",Sensitive and rapid liquid chromatography/tandem mass spectrometric assay for the quantification of piperaquine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17923446/),,535.3,19601,DB00592,Piperazine
,17923446,m/z,"The precursor to product ion transitions of m/z 535.3-->288.2 and m/z 409.1-->205.2 were used to measure the analyte and the IS, respectively.",Sensitive and rapid liquid chromatography/tandem mass spectrometric assay for the quantification of piperaquine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17923446/),,409.1,19602,DB00592,Piperazine
,17923446,m/z,"The precursor to product ion transitions of m/z 535.3-->288.2 and m/z 409.1-->205.2 were used to measure the analyte and the IS, respectively.",Sensitive and rapid liquid chromatography/tandem mass spectrometric assay for the quantification of piperaquine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17923446/),,205.2,19603,DB00592,Piperazine
,17923446,linear dynamic,The assay exhibited a linear dynamic range of 1.0-250.2 ng/mL for piperaquine in plasma.,Sensitive and rapid liquid chromatography/tandem mass spectrometric assay for the quantification of piperaquine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17923446/),[ng] / [ml],1.0-250.2,19604,DB00592,Piperazine
,17923446,limit of detection (LOD),"The limit of detection (LOD) and lower limit of quantification (LLOQ) in plasma were 0.2 and 1.0 ng/mL, respectively.",Sensitive and rapid liquid chromatography/tandem mass spectrometric assay for the quantification of piperaquine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17923446/),[ng] / [ml],0.2,19605,DB00592,Piperazine
,17923446,limit of detection (LOD),"The limit of detection (LOD) and lower limit of quantification (LLOQ) in plasma were 0.2 and 1.0 ng/mL, respectively.",Sensitive and rapid liquid chromatography/tandem mass spectrometric assay for the quantification of piperaquine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17923446/),[ng] / [ml],1,19606,DB00592,Piperazine
,17923446,run time,A run time of 2.5 min for a sample made it possible to achieve a throughput of more than 400 plasma samples analyzed per day.,Sensitive and rapid liquid chromatography/tandem mass spectrometric assay for the quantification of piperaquine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17923446/),min,2.5,19607,DB00592,Piperazine
,17923446,observed maximum plasma concentration (Cmax),"The mean pharmacokinetic parameters of piperaquine following 1000 mg oral dose: observed maximum plasma concentration (Cmax), time to maximum plasma concentration (Tmax) and elimination half-life (T1/2) were 46.1 ng/mL, 3.8h and 13 days, respectively.",Sensitive and rapid liquid chromatography/tandem mass spectrometric assay for the quantification of piperaquine in human plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17923446/),[ng] / [ml],46.1,19608,DB00592,Piperazine
,17923446,time to maximum plasma concentration (Tmax),"The mean pharmacokinetic parameters of piperaquine following 1000 mg oral dose: observed maximum plasma concentration (Cmax), time to maximum plasma concentration (Tmax) and elimination half-life (T1/2) were 46.1 ng/mL, 3.8h and 13 days, respectively.",Sensitive and rapid liquid chromatography/tandem mass spectrometric assay for the quantification of piperaquine in human plasma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17923446/),h,3.8,19609,DB00592,Piperazine
,17923446,elimination half-life (T1/2),"The mean pharmacokinetic parameters of piperaquine following 1000 mg oral dose: observed maximum plasma concentration (Cmax), time to maximum plasma concentration (Tmax) and elimination half-life (T1/2) were 46.1 ng/mL, 3.8h and 13 days, respectively.",Sensitive and rapid liquid chromatography/tandem mass spectrometric assay for the quantification of piperaquine in human plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17923446/),d,13,19610,DB00592,Piperazine
,32199329,non-specific bindings,Ultrafiltration procedures presented non-specific bindings of (8.6 ± 1.2) % for bictegravir in plasma and (26.6 ± 3.1) % for bictegravir in cerebrospinal fluid.,Measurement of total and unbound bictegravir concentrations in plasma and cerebrospinal fluid by UHPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32199329/),%,8.6,19758,DB00592,Piperazine
,32199329,non-specific bindings,Ultrafiltration procedures presented non-specific bindings of (8.6 ± 1.2) % for bictegravir in plasma and (26.6 ± 3.1) % for bictegravir in cerebrospinal fluid.,Measurement of total and unbound bictegravir concentrations in plasma and cerebrospinal fluid by UHPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32199329/),%,26.6,19759,DB00592,Piperazine
,16142720,oral bioavailability,BMS-378806 exhibited species-dependent oral bioavailability which was 19%-24% in rats and monkeys and 77% in dogs.,Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16142720/),%,19,19987,DB00592,Piperazine
,16142720,oral bioavailability,BMS-378806 exhibited species-dependent oral bioavailability which was 19%-24% in rats and monkeys and 77% in dogs.,Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16142720/),%,24,19988,DB00592,Piperazine
,16142720,oral bioavailability,BMS-378806 exhibited species-dependent oral bioavailability which was 19%-24% in rats and monkeys and 77% in dogs.,Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16142720/),%,77,19989,DB00592,Piperazine
,16142720,apparent terminal half-life,"In rats and monkeys, absorption was prolonged, with an apparent terminal half-life of 2.1 and 6.5 h, respectively.",Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16142720/),h,2.1,19990,DB00592,Piperazine
,16142720,apparent terminal half-life,"In rats and monkeys, absorption was prolonged, with an apparent terminal half-life of 2.1 and 6.5 h, respectively.",Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16142720/),h,6.5,19991,DB00592,Piperazine
,16142720,steady-state volume of distribution,"The steady-state volume of distribution was moderate (0.4-0.6 l/kg), contributing to a short half-life (0.3-1.2 h) after i.v. dosing.",Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16142720/),[l] / [kg],0.4-0.6,19992,DB00592,Piperazine
,16142720,half-life,"The steady-state volume of distribution was moderate (0.4-0.6 l/kg), contributing to a short half-life (0.3-1.2 h) after i.v. dosing.",Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16142720/),h,0.3-1.2,19993,DB00592,Piperazine
,16142720,permeability,The Caco-2 permeability was modest (51 nm/s) and confounded by P-glycoprotein mediated efflux transport.,Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16142720/),[nm] / [s],51,19994,DB00592,Piperazine
,16142720,brain/plasma AUC ratio,Both of these may contribute to the low brain penetration observed in rats (brain/plasma AUC ratio=0.06).,Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16142720/),,0.06,19995,DB00592,Piperazine
,16142720,human oral bioavailability,"Based on in vitro and animal data, a mechanistic approach that factors in absorption and first-pass metabolism was employed to predict the human oral bioavailability of BMS-378806 (ca 20%).",Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16142720/),%,20,19996,DB00592,Piperazine
,19591710,flow rate,The eluent was monitored by UV detector at 235 nm and at a flow rate of 1.0 mL min(-1).,Development of high performance liquid chromatography method for buspirone in rabbit serum: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19591710/),[ml] / [min],1.0,20067,DB00592,Piperazine
,9159561,total area under the plasma z,The total area under the plasma zopiclone concentration-time curve after rifampicin was 18.0% (95% CI 13.5-22.5%) of that after placebo (86.1 +/- 34.5 ng ml(-1) h vs 473 +/- 114 ng ml(-1) h (mean +/- s.d.); P<0.001).,Concentrations and effects of zopiclone are greatly reduced by rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159561/),[h·ng] / [ml],86.1,20158,DB00592,Piperazine
,9159561,total area under the plasma z,The total area under the plasma zopiclone concentration-time curve after rifampicin was 18.0% (95% CI 13.5-22.5%) of that after placebo (86.1 +/- 34.5 ng ml(-1) h vs 473 +/- 114 ng ml(-1) h (mean +/- s.d.); P<0.001).,Concentrations and effects of zopiclone are greatly reduced by rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159561/),[h·ng] / [ml],473,20159,DB00592,Piperazine
,9159561,peak plasma concentration,Rifampicin decreased the peak plasma concentration of zopiclone from 76.9 +/- 27.2 ng ml(-1) to 22.5 +/- 6.0 ng ml(-1) (P<0.001) and the half-life from 3.8 +/- 0.6 h to 2.3 +/- 0.9 h (P<0.005).,Concentrations and effects of zopiclone are greatly reduced by rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159561/),[ng] / [ml],76.9,20160,DB00592,Piperazine
,9159561,peak plasma concentration,Rifampicin decreased the peak plasma concentration of zopiclone from 76.9 +/- 27.2 ng ml(-1) to 22.5 +/- 6.0 ng ml(-1) (P<0.001) and the half-life from 3.8 +/- 0.6 h to 2.3 +/- 0.9 h (P<0.005).,Concentrations and effects of zopiclone are greatly reduced by rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159561/),[ng] / [ml],22.5,20161,DB00592,Piperazine
,9159561,half-life,Rifampicin decreased the peak plasma concentration of zopiclone from 76.9 +/- 27.2 ng ml(-1) to 22.5 +/- 6.0 ng ml(-1) (P<0.001) and the half-life from 3.8 +/- 0.6 h to 2.3 +/- 0.9 h (P<0.005).,Concentrations and effects of zopiclone are greatly reduced by rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159561/),h,3.8,20162,DB00592,Piperazine
,9159561,half-life,Rifampicin decreased the peak plasma concentration of zopiclone from 76.9 +/- 27.2 ng ml(-1) to 22.5 +/- 6.0 ng ml(-1) (P<0.001) and the half-life from 3.8 +/- 0.6 h to 2.3 +/- 0.9 h (P<0.005).,Concentrations and effects of zopiclone are greatly reduced by rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159561/),h,2.3,20163,DB00592,Piperazine
,18621530,plasma t(1/2),"Finally, an optimized compound 13 (LDN-193189 or DM-3189) demonstrated moderate pharmacokinetic characteristics (e.g., plasma t(1/2)=1.6h) following intraperitoneal administration in mice.",Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18621530/),h,1.6,20534,DB00592,Piperazine
,20538720,IC(50),"An indirect response model was fitted to the inhibition of Akt and PRAS40 phosphorylation data and provided IC(50) estimates of 0.36 and 0.29 muM for pAkt and pPRAS40, respectively.",Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20538720/),muM,0.36,20568,DB00592,Piperazine
,20538720,IC(50),"An indirect response model was fitted to the inhibition of Akt and PRAS40 phosphorylation data and provided IC(50) estimates of 0.36 and 0.29 muM for pAkt and pPRAS40, respectively.",Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20538720/),muM,0.29,20569,DB00592,Piperazine
,9017465,limit of detection,Determination of manidipine was possible over the concentration range 0.5-10 ng/ml: the limit of detection was 0.3 ng/ml.,Liquid chromatographic determination of manidipine in serum with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9017465/),[ng] / [ml],0.3,20725,DB00592,Piperazine
,9017465,recovery,The recovery of manidipine added to serum was 93.1-98.4% with coefficients of variation of less than 7.1%.,Liquid chromatographic determination of manidipine in serum with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9017465/),%,93.1-98.4,20726,DB00592,Piperazine
,24847779,maximum entrapment efficiency,The size of the spherical particles was in the range of 27.25 ± 3.43 nm to 179 ± 3.08 nm and a maximum entrapment efficiency of 68.63 ± 1.53% was observed.,Solid lipid nanoparticles of diethylcarbamazine citrate for enhanced delivery to the lymphatics: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847779/),%,68.63,21234,DB00592,Piperazine
,24847779,maximum time,In vitro release studies in pH 7.4 PBS displayed a rapid release and the maximum time taken for the complete drug to release was 150 min.,Solid lipid nanoparticles of diethylcarbamazine citrate for enhanced delivery to the lymphatics: in vitro and in vivo evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847779/),min,150,21235,DB00592,Piperazine
,12949996,maximum concentration (C(max)),"Mean maximum concentration (C(max)) was 6.1 ng/mL for gepirone-IR, which was statistically significantly (p < 0.05) higher than that of two of the ER-formulations (3.7 and 3.6 ng/mL, respectively, for types 2 and 3).",Pharmacokinetic evaluation of gepirone immediate-release capsules and gepirone extended-release tablets in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12949996/),[ng] / [ml],6.1,21704,DB00592,Piperazine
,12949996,maximum concentration (C(max)),"Mean maximum concentration (C(max)) was 6.1 ng/mL for gepirone-IR, which was statistically significantly (p < 0.05) higher than that of two of the ER-formulations (3.7 and 3.6 ng/mL, respectively, for types 2 and 3).",Pharmacokinetic evaluation of gepirone immediate-release capsules and gepirone extended-release tablets in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12949996/),[ng] / [ml],3.7,21705,DB00592,Piperazine
,12949996,maximum concentration (C(max)),"Mean maximum concentration (C(max)) was 6.1 ng/mL for gepirone-IR, which was statistically significantly (p < 0.05) higher than that of two of the ER-formulations (3.7 and 3.6 ng/mL, respectively, for types 2 and 3).",Pharmacokinetic evaluation of gepirone immediate-release capsules and gepirone extended-release tablets in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12949996/),[ng] / [ml],3.6,21706,DB00592,Piperazine
,12949996,time to C(max) (,The mean time to C(max) (mean T(max)) was 1.3 h for gepirone-IR and ranged from 4.8 to 5.6 h for gepirone-ER.,Pharmacokinetic evaluation of gepirone immediate-release capsules and gepirone extended-release tablets in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12949996/),h,1.3,21707,DB00592,Piperazine
,12949996,time to C(max) (,The mean time to C(max) (mean T(max)) was 1.3 h for gepirone-IR and ranged from 4.8 to 5.6 h for gepirone-ER.,Pharmacokinetic evaluation of gepirone immediate-release capsules and gepirone extended-release tablets in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12949996/),h,4.8 to 5.6,21708,DB00592,Piperazine
,9839763,Cmax,"The concurrent administration of both drugs resulted in a 12% greater Cmax (9.5 ng ml(-1) versus 8.4 ng ml(-1); P=0.01) and a 12% greater AUC(0-24) (135.2 ng h ml(-1) versus 118.7 ng h ml(-1); P=0.001) than donepezil alone on day 1, and a 26.8% greater Cmax (37.7 ng ml(-1) versus 27.6 ng ml(-1); P < 0.0001) and a 26.4% greater AUC(0-24) (680.9 ng h ml(-1) versus 501.0 ng h ml(-1); P<0.0001) than donepezil alone on day 7.",Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839763/),[ng] / [ml],9.5,21772,DB00592,Piperazine
,9839763,Cmax,"The concurrent administration of both drugs resulted in a 12% greater Cmax (9.5 ng ml(-1) versus 8.4 ng ml(-1); P=0.01) and a 12% greater AUC(0-24) (135.2 ng h ml(-1) versus 118.7 ng h ml(-1); P=0.001) than donepezil alone on day 1, and a 26.8% greater Cmax (37.7 ng ml(-1) versus 27.6 ng ml(-1); P < 0.0001) and a 26.4% greater AUC(0-24) (680.9 ng h ml(-1) versus 501.0 ng h ml(-1); P<0.0001) than donepezil alone on day 7.",Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839763/),[ng] / [ml],8.4,21773,DB00592,Piperazine
,9839763,AUC(0-24),"The concurrent administration of both drugs resulted in a 12% greater Cmax (9.5 ng ml(-1) versus 8.4 ng ml(-1); P=0.01) and a 12% greater AUC(0-24) (135.2 ng h ml(-1) versus 118.7 ng h ml(-1); P=0.001) than donepezil alone on day 1, and a 26.8% greater Cmax (37.7 ng ml(-1) versus 27.6 ng ml(-1); P < 0.0001) and a 26.4% greater AUC(0-24) (680.9 ng h ml(-1) versus 501.0 ng h ml(-1); P<0.0001) than donepezil alone on day 7.",Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839763/),[h·ng] / [ml],135.2,21774,DB00592,Piperazine
,9839763,AUC(0-24),"The concurrent administration of both drugs resulted in a 12% greater Cmax (9.5 ng ml(-1) versus 8.4 ng ml(-1); P=0.01) and a 12% greater AUC(0-24) (135.2 ng h ml(-1) versus 118.7 ng h ml(-1); P=0.001) than donepezil alone on day 1, and a 26.8% greater Cmax (37.7 ng ml(-1) versus 27.6 ng ml(-1); P < 0.0001) and a 26.4% greater AUC(0-24) (680.9 ng h ml(-1) versus 501.0 ng h ml(-1); P<0.0001) than donepezil alone on day 7.",Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839763/),[h·ng] / [ml],118.7,21775,DB00592,Piperazine
,9839763,Cmax,"The concurrent administration of both drugs resulted in a 12% greater Cmax (9.5 ng ml(-1) versus 8.4 ng ml(-1); P=0.01) and a 12% greater AUC(0-24) (135.2 ng h ml(-1) versus 118.7 ng h ml(-1); P=0.001) than donepezil alone on day 1, and a 26.8% greater Cmax (37.7 ng ml(-1) versus 27.6 ng ml(-1); P < 0.0001) and a 26.4% greater AUC(0-24) (680.9 ng h ml(-1) versus 501.0 ng h ml(-1); P<0.0001) than donepezil alone on day 7.",Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839763/),[ng] / [ml],37.7,21776,DB00592,Piperazine
,9839763,Cmax,"The concurrent administration of both drugs resulted in a 12% greater Cmax (9.5 ng ml(-1) versus 8.4 ng ml(-1); P=0.01) and a 12% greater AUC(0-24) (135.2 ng h ml(-1) versus 118.7 ng h ml(-1); P=0.001) than donepezil alone on day 1, and a 26.8% greater Cmax (37.7 ng ml(-1) versus 27.6 ng ml(-1); P < 0.0001) and a 26.4% greater AUC(0-24) (680.9 ng h ml(-1) versus 501.0 ng h ml(-1); P<0.0001) than donepezil alone on day 7.",Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839763/),[ng] / [ml],27.6,21777,DB00592,Piperazine
,9839763,AUC(0-24),"The concurrent administration of both drugs resulted in a 12% greater Cmax (9.5 ng ml(-1) versus 8.4 ng ml(-1); P=0.01) and a 12% greater AUC(0-24) (135.2 ng h ml(-1) versus 118.7 ng h ml(-1); P=0.001) than donepezil alone on day 1, and a 26.8% greater Cmax (37.7 ng ml(-1) versus 27.6 ng ml(-1); P < 0.0001) and a 26.4% greater AUC(0-24) (680.9 ng h ml(-1) versus 501.0 ng h ml(-1); P<0.0001) than donepezil alone on day 7.",Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839763/),[h·ng] / [ml],680.9,21778,DB00592,Piperazine
,9839763,AUC(0-24),"The concurrent administration of both drugs resulted in a 12% greater Cmax (9.5 ng ml(-1) versus 8.4 ng ml(-1); P=0.01) and a 12% greater AUC(0-24) (135.2 ng h ml(-1) versus 118.7 ng h ml(-1); P=0.001) than donepezil alone on day 1, and a 26.8% greater Cmax (37.7 ng ml(-1) versus 27.6 ng ml(-1); P < 0.0001) and a 26.4% greater AUC(0-24) (680.9 ng h ml(-1) versus 501.0 ng h ml(-1); P<0.0001) than donepezil alone on day 7.",Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839763/),[h·ng] / [ml],501.0,21779,DB00592,Piperazine
<,9164416,steady,"In the rifampin group, delavirdine oral clearance increased by about 27-fold (p = 0.022), resulting in virtually negligible (< 0.09 mumol/L) steady-state through drug concentrations in all patients after 2 weeks of concurrent dosing of delavirdine mesylate and rifampin.",Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164416/),,0,21792,DB00592,Piperazine
,9164416,elimination half-life,The ratio of metabolite formation to elimination clearance for desalkyldelavirdine was significantly higher (3.9 +/- 1.2 versus 0.23 +/- 0.10) and delavirdine elimination half-life was significantly shorter (1.7 +/- 1.4 versus 4.3 +/- 1.3 hours) when delavirdine mesylate was taken with rifampin.,Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164416/),h,1.7,21793,DB00592,Piperazine
,9164416,elimination half-life,The ratio of metabolite formation to elimination clearance for desalkyldelavirdine was significantly higher (3.9 +/- 1.2 versus 0.23 +/- 0.10) and delavirdine elimination half-life was significantly shorter (1.7 +/- 1.4 versus 4.3 +/- 1.3 hours) when delavirdine mesylate was taken with rifampin.,Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164416/),h,4.3,21794,DB00592,Piperazine
,23272163,CL,"Haplotype-specific GLM estimated that the haplotypes AGT and CGC were both associated with 22% decrease in clearance compared to CAC [CL (10(-2) L/hr/mg): CAC vs AGT: 4.03 vs 3.16, p = 0.017; CAC vs CGC: 4.03 vs 3.15, p = 0.017].",SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23272163/),,10(,21909,DB00592,Piperazine
,23272163,CL,"Haplotype-specific GLM estimated that the haplotypes AGT and CGC were both associated with 22% decrease in clearance compared to CAC [CL (10(-2) L/hr/mg): CAC vs AGT: 4.03 vs 3.16, p = 0.017; CAC vs CGC: 4.03 vs 3.15, p = 0.017].",SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23272163/),,4.03,21910,DB00592,Piperazine
,23272163,CL,"Haplotype-specific GLM estimated that the haplotypes AGT and CGC were both associated with 22% decrease in clearance compared to CAC [CL (10(-2) L/hr/mg): CAC vs AGT: 4.03 vs 3.16, p = 0.017; CAC vs CGC: 4.03 vs 3.15, p = 0.017].",SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23272163/),,3,21911,DB00592,Piperazine
,23272163,CL,"Haplotype-specific GLM estimated that the haplotypes AGT and CGC were both associated with 22% decrease in clearance compared to CAC [CL (10(-2) L/hr/mg): CAC vs AGT: 4.03 vs 3.16, p = 0.017; CAC vs CGC: 4.03 vs 3.15, p = 0.017].",SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23272163/),,4,21912,DB00592,Piperazine
,23272163,CL,"Patients harboring 2 copies of AGT or CGC haplotypes had 33.4% lower clearance and 50% higher C(0h) than patients carrying 0 or 1 copy [CL (10(-2) L/hr/mg): 2.19 vs 3.29, p = 0.026; C(0h) (10(-6) 1/ml): 4.76 vs 3.17, p = 0.013, respectively].",SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23272163/),[l] / [h·mg],2.19,21913,DB00592,Piperazine
,23272163,CL,"Patients harboring 2 copies of AGT or CGC haplotypes had 33.4% lower clearance and 50% higher C(0h) than patients carrying 0 or 1 copy [CL (10(-2) L/hr/mg): 2.19 vs 3.29, p = 0.026; C(0h) (10(-6) 1/ml): 4.76 vs 3.17, p = 0.013, respectively].",SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23272163/),[l] / [h·mg],3.29,21914,DB00592,Piperazine
,23272163,C(0h),"Patients harboring 2 copies of AGT or CGC haplotypes had 33.4% lower clearance and 50% higher C(0h) than patients carrying 0 or 1 copy [CL (10(-2) L/hr/mg): 2.19 vs 3.29, p = 0.026; C(0h) (10(-6) 1/ml): 4.76 vs 3.17, p = 0.013, respectively].",SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23272163/),[1] / [(10)^6·ml],4.76,21915,DB00592,Piperazine
,23272163,C(0h),"Patients harboring 2 copies of AGT or CGC haplotypes had 33.4% lower clearance and 50% higher C(0h) than patients carrying 0 or 1 copy [CL (10(-2) L/hr/mg): 2.19 vs 3.29, p = 0.026; C(0h) (10(-6) 1/ml): 4.76 vs 3.17, p = 0.013, respectively].",SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23272163/),[1] / [(10)^6·ml],3.17,21916,DB00592,Piperazine
above,22329523,Cmax,"Our patients both experienced sildenafil Cmax above 500 ng/mL; however, they did not report any significant adverse reactions to sildenafil during the follow-up period.",Sildenafil plasma concentrations in two HIV patients with pulmonary hypertension treated with ritonavir-boosted protease inhibitors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22329523/),[ng] / [ml],500,22198,DB00592,Piperazine
,18381901,E(max) (EC(50)),The values for serum concentration predicted to provide 50% of E(max) (EC(50)) were in the range of 5-10 ng/ml in all brain regions.,Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18381901/),[ng] / [ml],5-10,22652,DB00592,Piperazine
,33627685,disease control rate,"In conclusion, olaparib in combination with lurbinectedin was well tolerated with a disease control rate of 60%.","A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33627685/),%,60,22837,DB00592,Piperazine
,34038119,human half-life,"However, 2 projected to a short human half-life (∼5 h) that could necessitate more frequent than once a day dosing.","Discovery of MK-8153, a Potent and Selective ROMK Inhibitor and Novel Diuretic/Natriuretic. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34038119/),h,∼5,23104,DB00592,Piperazine
,34038119,human half-life,"This report describes the discovery of a new ROMK inhibitor 22e (MK-8153), with a longer projected human half-life (∼14 h), which should lead to a reduced peak-to-trough ratio, potentially extrapolating to more extended and better tolerated diuretic effects.","Discovery of MK-8153, a Potent and Selective ROMK Inhibitor and Novel Diuretic/Natriuretic. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34038119/),h,∼14,23105,DB00592,Piperazine
,29325456,Tmax,"In vivo study results from six healthy male volunteers showed shorter Tmax of VH from VH/DH ODT of 0.583 ± 0.129 h and shorter Tmax of DH from VH/DH ODT of 0.625 ± 0.137 h and showed AUC0-12 of VH from VH/DH ODT of 39.234 ± 10.932 ng/ml h1 and AUC0-12 of DH from VH/DH ODT of 531.681 ± 129.544 ng/ml h1, with relative bioavailability values of 100.9 and 85%, respectively, compared to (Levitra®) and (Priligy®).","Dual-purpose vardenafil hydrochloride/dapoxetine hydrochloride orodispersible tablets: in vitro formulation/evaluation, stability study and in vivo comparative pharmacokinetic study in healthy human subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29325456/),h,0.583,23254,DB00592,Piperazine
,29325456,Tmax,"In vivo study results from six healthy male volunteers showed shorter Tmax of VH from VH/DH ODT of 0.583 ± 0.129 h and shorter Tmax of DH from VH/DH ODT of 0.625 ± 0.137 h and showed AUC0-12 of VH from VH/DH ODT of 39.234 ± 10.932 ng/ml h1 and AUC0-12 of DH from VH/DH ODT of 531.681 ± 129.544 ng/ml h1, with relative bioavailability values of 100.9 and 85%, respectively, compared to (Levitra®) and (Priligy®).","Dual-purpose vardenafil hydrochloride/dapoxetine hydrochloride orodispersible tablets: in vitro formulation/evaluation, stability study and in vivo comparative pharmacokinetic study in healthy human subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29325456/),h,0.625,23255,DB00592,Piperazine
,29325456,AUC0-12,"In vivo study results from six healthy male volunteers showed shorter Tmax of VH from VH/DH ODT of 0.583 ± 0.129 h and shorter Tmax of DH from VH/DH ODT of 0.625 ± 0.137 h and showed AUC0-12 of VH from VH/DH ODT of 39.234 ± 10.932 ng/ml h1 and AUC0-12 of DH from VH/DH ODT of 531.681 ± 129.544 ng/ml h1, with relative bioavailability values of 100.9 and 85%, respectively, compared to (Levitra®) and (Priligy®).","Dual-purpose vardenafil hydrochloride/dapoxetine hydrochloride orodispersible tablets: in vitro formulation/evaluation, stability study and in vivo comparative pharmacokinetic study in healthy human subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29325456/),[ng] / [h1·ml],39.234,23256,DB00592,Piperazine
,29325456,AUC0-12,"In vivo study results from six healthy male volunteers showed shorter Tmax of VH from VH/DH ODT of 0.583 ± 0.129 h and shorter Tmax of DH from VH/DH ODT of 0.625 ± 0.137 h and showed AUC0-12 of VH from VH/DH ODT of 39.234 ± 10.932 ng/ml h1 and AUC0-12 of DH from VH/DH ODT of 531.681 ± 129.544 ng/ml h1, with relative bioavailability values of 100.9 and 85%, respectively, compared to (Levitra®) and (Priligy®).","Dual-purpose vardenafil hydrochloride/dapoxetine hydrochloride orodispersible tablets: in vitro formulation/evaluation, stability study and in vivo comparative pharmacokinetic study in healthy human subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29325456/),[ng] / [h1·ml],531.681,23257,DB00592,Piperazine
,29325456,relative bioavailability,"In vivo study results from six healthy male volunteers showed shorter Tmax of VH from VH/DH ODT of 0.583 ± 0.129 h and shorter Tmax of DH from VH/DH ODT of 0.625 ± 0.137 h and showed AUC0-12 of VH from VH/DH ODT of 39.234 ± 10.932 ng/ml h1 and AUC0-12 of DH from VH/DH ODT of 531.681 ± 129.544 ng/ml h1, with relative bioavailability values of 100.9 and 85%, respectively, compared to (Levitra®) and (Priligy®).","Dual-purpose vardenafil hydrochloride/dapoxetine hydrochloride orodispersible tablets: in vitro formulation/evaluation, stability study and in vivo comparative pharmacokinetic study in healthy human subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29325456/),%,100.9,23258,DB00592,Piperazine
,29325456,relative bioavailability,"In vivo study results from six healthy male volunteers showed shorter Tmax of VH from VH/DH ODT of 0.583 ± 0.129 h and shorter Tmax of DH from VH/DH ODT of 0.625 ± 0.137 h and showed AUC0-12 of VH from VH/DH ODT of 39.234 ± 10.932 ng/ml h1 and AUC0-12 of DH from VH/DH ODT of 531.681 ± 129.544 ng/ml h1, with relative bioavailability values of 100.9 and 85%, respectively, compared to (Levitra®) and (Priligy®).","Dual-purpose vardenafil hydrochloride/dapoxetine hydrochloride orodispersible tablets: in vitro formulation/evaluation, stability study and in vivo comparative pharmacokinetic study in healthy human subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29325456/),%,85,23259,DB00592,Piperazine
less,1411510,oral bioavailabilities,Peptidic renin inhibitors have been poorly absorbed across the intestine or rapidly eliminated by the liver and have been reported to have oral bioavailabilities of less than 2%.,Discovery of a peptide-based renin inhibitor with oral bioavailability and efficacy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1411510/),%,2,23375,DB00592,Piperazine
,1411510,oral bioavailabilities,"A peptide-based renin inhibitor, A-72517 (molecular mass of 706 daltons), was devised that has oral bioavailabilities of 8, 24, 32, and 53% in the monkey, rat, ferret, and dog, respectively.",Discovery of a peptide-based renin inhibitor with oral bioavailability and efficacy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1411510/),%,8,23376,DB00592,Piperazine
,1411510,oral bioavailabilities,"A peptide-based renin inhibitor, A-72517 (molecular mass of 706 daltons), was devised that has oral bioavailabilities of 8, 24, 32, and 53% in the monkey, rat, ferret, and dog, respectively.",Discovery of a peptide-based renin inhibitor with oral bioavailability and efficacy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1411510/),%,24,23377,DB00592,Piperazine
,1411510,oral bioavailabilities,"A peptide-based renin inhibitor, A-72517 (molecular mass of 706 daltons), was devised that has oral bioavailabilities of 8, 24, 32, and 53% in the monkey, rat, ferret, and dog, respectively.",Discovery of a peptide-based renin inhibitor with oral bioavailability and efficacy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1411510/),%,32,23378,DB00592,Piperazine
,1411510,oral bioavailabilities,"A peptide-based renin inhibitor, A-72517 (molecular mass of 706 daltons), was devised that has oral bioavailabilities of 8, 24, 32, and 53% in the monkey, rat, ferret, and dog, respectively.",Discovery of a peptide-based renin inhibitor with oral bioavailability and efficacy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1411510/),%,53,23379,DB00592,Piperazine
,11504277,bioavailability,"The bioavailability of buspirone from the ER formulation was more than three times higher than that from the IR formulation at steady state, and that of 1-PP was about 25% less.",A comparative multidose pharmacokinetic study of buspirone extended-release tablets with a reference immediate-release product. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11504277/),%,25,23634,DB00592,Piperazine
,11504277,apparent half-life,The mean apparent half-life of buspirone from the ER formulation (9.04 hours) was considerably longer than that observed for the IR formulation (3.06 hours).,A comparative multidose pharmacokinetic study of buspirone extended-release tablets with a reference immediate-release product. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11504277/),h,9.04,23635,DB00592,Piperazine
,11504277,apparent half-life,The mean apparent half-life of buspirone from the ER formulation (9.04 hours) was considerably longer than that observed for the IR formulation (3.06 hours).,A comparative multidose pharmacokinetic study of buspirone extended-release tablets with a reference immediate-release product. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11504277/),h,3.06,23636,DB00592,Piperazine
,11504277,AUC ratio,The median 1-PP/buspirone AUC ratio was much higher for the IR formulation at steady state (24.4) than for the ER formulation (6.44).,A comparative multidose pharmacokinetic study of buspirone extended-release tablets with a reference immediate-release product. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11504277/),,24.4,23637,DB00592,Piperazine
,11504277,AUC ratio,The median 1-PP/buspirone AUC ratio was much higher for the IR formulation at steady state (24.4) than for the ER formulation (6.44).,A comparative multidose pharmacokinetic study of buspirone extended-release tablets with a reference immediate-release product. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11504277/),,6.44,23638,DB00592,Piperazine
,9010634,radiocarbon recovery,"Mean radiocarbon recovery was approximately 87%, with 30% appearing in the faces and 57% excreted in the urine.",Disposition and biotransformation of the antipsychotic agent olanzapine in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010634/),%,87,23947,DB00592,Piperazine
,9010634,radiocarbon recovery,"Mean radiocarbon recovery was approximately 87%, with 30% appearing in the faces and 57% excreted in the urine.",Disposition and biotransformation of the antipsychotic agent olanzapine in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010634/),%,30,23948,DB00592,Piperazine
,9010634,radiocarbon recovery,"Mean radiocarbon recovery was approximately 87%, with 30% appearing in the faces and 57% excreted in the urine.",Disposition and biotransformation of the antipsychotic agent olanzapine in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010634/),%,57,23949,DB00592,Piperazine
,9010634,peak plasma concentration,"Mean peak plasma concentration of OLZ was 11 ng/ml, whereas that of radioactivity was 39 ng eq/ml.",Disposition and biotransformation of the antipsychotic agent olanzapine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010634/),[ng] / [ml],11,23950,DB00592,Piperazine
,9010634,peak plasma concentration,"Mean peak plasma concentration of OLZ was 11 ng/ml, whereas that of radioactivity was 39 ng eq/ml.",Disposition and biotransformation of the antipsychotic agent olanzapine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010634/),[eq·ng] / [ml],39,23951,DB00592,Piperazine
,9010634,plasma terminal elimination half-lives,"Mean plasma terminal elimination half-lives were 27 and 59 hr, respectively, for OLZ and total radioactivity.",Disposition and biotransformation of the antipsychotic agent olanzapine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010634/),h,27,23952,DB00592,Piperazine
,9010634,plasma terminal elimination half-lives,"Mean plasma terminal elimination half-lives were 27 and 59 hr, respectively, for OLZ and total radioactivity.",Disposition and biotransformation of the antipsychotic agent olanzapine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010634/),h,59,23953,DB00592,Piperazine
,16083790,peak levocetirizine concentration,"In children aged 8.6 +/- 0.4 years (+/- SEM), the peak levocetirizine concentration was 450 +/- 37 ng/mL, and the time at which peak concentrations occurred was 1.2 +/- 0.2 hours.",Levocetirizine: pharmacokinetics and pharmacodynamics in children age 6 to 11 years. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16083790/),[ng] / [ml],450,24318,DB00592,Piperazine
,16083790,time at which peak concentrations occurred,"In children aged 8.6 +/- 0.4 years (+/- SEM), the peak levocetirizine concentration was 450 +/- 37 ng/mL, and the time at which peak concentrations occurred was 1.2 +/- 0.2 hours.",Levocetirizine: pharmacokinetics and pharmacodynamics in children age 6 to 11 years. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16083790/),h,1.2,24319,DB00592,Piperazine
,16083790,terminal elimination half-life,"The terminal elimination half-life was 5.7 +/- 0.2 hours, the oral clearance was 0.82 +/- 0.05 mL/min/kg, and the volume of distribution was 0.4 +/- 0.02 L/kg.",Levocetirizine: pharmacokinetics and pharmacodynamics in children age 6 to 11 years. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16083790/),h,5.7,24320,DB00592,Piperazine
,16083790,oral clearance,"The terminal elimination half-life was 5.7 +/- 0.2 hours, the oral clearance was 0.82 +/- 0.05 mL/min/kg, and the volume of distribution was 0.4 +/- 0.02 L/kg.",Levocetirizine: pharmacokinetics and pharmacodynamics in children age 6 to 11 years. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16083790/),[ml] / [kg·min],0.82,24321,DB00592,Piperazine
,16083790,volume of distribution,"The terminal elimination half-life was 5.7 +/- 0.2 hours, the oral clearance was 0.82 +/- 0.05 mL/min/kg, and the volume of distribution was 0.4 +/- 0.02 L/kg.",Levocetirizine: pharmacokinetics and pharmacodynamics in children age 6 to 11 years. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16083790/),[l] / [kg],0.4,24322,DB00592,Piperazine
,16083790,maximum inhibition,"Mean maximum inhibition of wheals and flares occurred from 2 to 10 hours (97% +/- 1%) and from 2 to 24 hours (93% +/- 1%), respectively.",Levocetirizine: pharmacokinetics and pharmacodynamics in children age 6 to 11 years. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16083790/),%,97,24323,DB00592,Piperazine
,16083790,maximum inhibition,"Mean maximum inhibition of wheals and flares occurred from 2 to 10 hours (97% +/- 1%) and from 2 to 24 hours (93% +/- 1%), respectively.",Levocetirizine: pharmacokinetics and pharmacodynamics in children age 6 to 11 years. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16083790/),%,93,24324,DB00592,Piperazine
,30909832,elimination phase half-lives,"Ranolazine off-hemodialysis elimination phase half-lives were 3.6 and 3.9 h for 500 mg and 1000 mg doses, respectively.",Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30909832/),h,3.6,25709,DB00592,Piperazine
,30909832,elimination phase half-lives,"Ranolazine off-hemodialysis elimination phase half-lives were 3.6 and 3.9 h for 500 mg and 1000 mg doses, respectively.",Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30909832/),h,3.9,25710,DB00592,Piperazine
,30909832,time to maximum concentration,"The time to maximum concentration ranged from 2 to 18 hours and the average maximum concentration was 0.65 ± 0.27 mcg/mL and 1.18 ± 0.48 mcg/mL for ranolazine 500 mg and 1000 mg dose, respectively.",Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30909832/),h,2 to 18,25711,DB00592,Piperazine
,30909832,maximum concentration,"The time to maximum concentration ranged from 2 to 18 hours and the average maximum concentration was 0.65 ± 0.27 mcg/mL and 1.18 ± 0.48 mcg/mL for ranolazine 500 mg and 1000 mg dose, respectively.",Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30909832/),[mcg] / [ml],0.65,25712,DB00592,Piperazine
,30909832,maximum concentration,"The time to maximum concentration ranged from 2 to 18 hours and the average maximum concentration was 0.65 ± 0.27 mcg/mL and 1.18 ± 0.48 mcg/mL for ranolazine 500 mg and 1000 mg dose, respectively.",Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30909832/),[mcg] / [ml],1.18,25713,DB00592,Piperazine
,30909832,percent reduction ratio,The mean hemodialysis percent reduction ratio for the ranolazine 500 mg dose was 52.3 ± 8.1% and for the ranolazine 1000 mg dose was 69.2 ± 37.6%.,Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30909832/),%,52.3,25714,DB00592,Piperazine
,30909832,percent reduction ratio,The mean hemodialysis percent reduction ratio for the ranolazine 500 mg dose was 52.3 ± 8.1% and for the ranolazine 1000 mg dose was 69.2 ± 37.6%.,Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30909832/),%,69.2,25715,DB00592,Piperazine
,29369162,cord blood/maternal plasma concentration ratio,The median cord blood/maternal plasma concentration ratio was 1.25 (n = 18).,Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29369162/),,1.25,25724,DB00592,Piperazine
,29369162,elimination half-life,"In 21 infants, median elimination half-life was 32.8 h after in utero exposure.",Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29369162/),h,32.8,25725,DB00592,Piperazine
,29369162,Trough concentrations,Trough concentrations in pregnancy were well above dolutegravir EC90 (0.064 μg/ml).,Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29369162/),[μg] / [ml],0.064,25726,DB00592,Piperazine
,29369162,EC90,Trough concentrations in pregnancy were well above dolutegravir EC90 (0.064 μg/ml).,Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29369162/),[μg] / [ml],0.064,25727,DB00592,Piperazine
,24944406,maximum peak plasma concentration (Cmax),"In study 1, the mean (SD) maximum peak plasma concentration (Cmax) for gepirone ER was 69.2% higher (3.25 [1.71] vs 1.92 [0.96] ng/mL) (P≤0.05) and the AUC from time 0 to 30 hours for gepirone ER was 31.9% higher (39.3 [20.6] vs 29.8 [15.3] ng/mL·h) (P≤0.05) for the 15-minute postprandial dose than for the fasting dose, respectively.",Effects of food on the bioavailability of gepirone from extended-release tablets in humans: results of two open-label crossover studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944406/),[ng] / [ml],3.25,25817,DB00592,Piperazine
,24944406,maximum peak plasma concentration (Cmax),"In study 1, the mean (SD) maximum peak plasma concentration (Cmax) for gepirone ER was 69.2% higher (3.25 [1.71] vs 1.92 [0.96] ng/mL) (P≤0.05) and the AUC from time 0 to 30 hours for gepirone ER was 31.9% higher (39.3 [20.6] vs 29.8 [15.3] ng/mL·h) (P≤0.05) for the 15-minute postprandial dose than for the fasting dose, respectively.",Effects of food on the bioavailability of gepirone from extended-release tablets in humans: results of two open-label crossover studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944406/),[ng] / [ml],1.92,25818,DB00592,Piperazine
,24944406,AUC from time 0 to 30 hours,"In study 1, the mean (SD) maximum peak plasma concentration (Cmax) for gepirone ER was 69.2% higher (3.25 [1.71] vs 1.92 [0.96] ng/mL) (P≤0.05) and the AUC from time 0 to 30 hours for gepirone ER was 31.9% higher (39.3 [20.6] vs 29.8 [15.3] ng/mL·h) (P≤0.05) for the 15-minute postprandial dose than for the fasting dose, respectively.",Effects of food on the bioavailability of gepirone from extended-release tablets in humans: results of two open-label crossover studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944406/),[ng] / [h·ml],39.3,25819,DB00592,Piperazine
,24944406,AUC from time 0 to 30 hours,"In study 1, the mean (SD) maximum peak plasma concentration (Cmax) for gepirone ER was 69.2% higher (3.25 [1.71] vs 1.92 [0.96] ng/mL) (P≤0.05) and the AUC from time 0 to 30 hours for gepirone ER was 31.9% higher (39.3 [20.6] vs 29.8 [15.3] ng/mL·h) (P≤0.05) for the 15-minute postprandial dose than for the fasting dose, respectively.",Effects of food on the bioavailability of gepirone from extended-release tablets in humans: results of two open-label crossover studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944406/),[ng] / [h·ml],29.8,25820,DB00592,Piperazine
,24944406,Cmax,"In study 2, the mean Cmax for gepirone was 62.0% higher (4.13 vs 2.55 ng/mL) and the mean AUC from time 0 to infinity for gepirone was 24% higher (38.71 vs 31.14 ng/mL·h) for the postprandial dose than for the fasting dose (P<0.05).",Effects of food on the bioavailability of gepirone from extended-release tablets in humans: results of two open-label crossover studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944406/),[ng] / [ml],4.13,25821,DB00592,Piperazine
,24944406,Cmax,"In study 2, the mean Cmax for gepirone was 62.0% higher (4.13 vs 2.55 ng/mL) and the mean AUC from time 0 to infinity for gepirone was 24% higher (38.71 vs 31.14 ng/mL·h) for the postprandial dose than for the fasting dose (P<0.05).",Effects of food on the bioavailability of gepirone from extended-release tablets in humans: results of two open-label crossover studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944406/),[ng] / [ml],2.55,25822,DB00592,Piperazine
,24944406,AUC from time 0 to infinity,"In study 2, the mean Cmax for gepirone was 62.0% higher (4.13 vs 2.55 ng/mL) and the mean AUC from time 0 to infinity for gepirone was 24% higher (38.71 vs 31.14 ng/mL·h) for the postprandial dose than for the fasting dose (P<0.05).",Effects of food on the bioavailability of gepirone from extended-release tablets in humans: results of two open-label crossover studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944406/),[ng] / [h·ml],38.71,25823,DB00592,Piperazine
,24944406,AUC from time 0 to infinity,"In study 2, the mean Cmax for gepirone was 62.0% higher (4.13 vs 2.55 ng/mL) and the mean AUC from time 0 to infinity for gepirone was 24% higher (38.71 vs 31.14 ng/mL·h) for the postprandial dose than for the fasting dose (P<0.05).",Effects of food on the bioavailability of gepirone from extended-release tablets in humans: results of two open-label crossover studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944406/),[ng] / [h·ml],31.14,25824,DB00592,Piperazine
,25336915,terminal elimination half-life,"The evogliptin plasma concentration reached its peak within 4-5 hours and decreased relatively slowly, with a terminal elimination half-life of 33-39 hours.","Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25336915/),h,33-39,25940,DB00592,Piperazine
,6688260,area under the plasma concentration/time curve,"The mean area under the plasma concentration/time curve was 10.07 micrograms h ml-1 and 10.44 micrograms h ml-1, for Molipaxin capsules and trazodone liquid, respectively.",A comparative bioavailability study of Molipaxin capsules and a trazodone liquid formulation in normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688260/),[h·μg] / [ml],10.07,25991,DB00592,Piperazine
,6688260,area under the plasma concentration/time curve,"The mean area under the plasma concentration/time curve was 10.07 micrograms h ml-1 and 10.44 micrograms h ml-1, for Molipaxin capsules and trazodone liquid, respectively.",A comparative bioavailability study of Molipaxin capsules and a trazodone liquid formulation in normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688260/),[h·μg] / [ml],10.44,25992,DB00592,Piperazine
,6688260,observed maximum plasma concentration,"There was considerable individual variation between the observed maximum plasma concentration of Molipaxin capsules and trazodone liquid but the mean values of 1.61 micrograms/ml and 1.66 micrograms/ml, respectively, were very similar.",A comparative bioavailability study of Molipaxin capsules and a trazodone liquid formulation in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688260/),[μg] / [ml],1.61,25993,DB00592,Piperazine
,6688260,observed maximum plasma concentration,"There was considerable individual variation between the observed maximum plasma concentration of Molipaxin capsules and trazodone liquid but the mean values of 1.61 micrograms/ml and 1.66 micrograms/ml, respectively, were very similar.",A comparative bioavailability study of Molipaxin capsules and a trazodone liquid formulation in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688260/),[μg] / [ml],1.66,25994,DB00592,Piperazine
,6688260,time to observed maximum plasma concentrations,"The time to observed maximum plasma concentrations varied from 15 min to 4 h, but there was no statistical difference between the two formulations.",A comparative bioavailability study of Molipaxin capsules and a trazodone liquid formulation in normal volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688260/),min,15,25995,DB00592,Piperazine
,6688260,time to observed maximum plasma concentrations,"The time to observed maximum plasma concentrations varied from 15 min to 4 h, but there was no statistical difference between the two formulations.",A comparative bioavailability study of Molipaxin capsules and a trazodone liquid formulation in normal volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688260/),h,4,25996,DB00592,Piperazine
,6688260,terminal phase half-life,The terminal phase half-life was 7.16 h for Molipaxin capsules and 6.73 h for trazodone liquid.,A comparative bioavailability study of Molipaxin capsules and a trazodone liquid formulation in normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688260/),h,7.16,25997,DB00592,Piperazine
,6688260,terminal phase half-life,The terminal phase half-life was 7.16 h for Molipaxin capsules and 6.73 h for trazodone liquid.,A comparative bioavailability study of Molipaxin capsules and a trazodone liquid formulation in normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688260/),h,6.73,25998,DB00592,Piperazine
,8907720,peak concentration (Cmax),"The mean (SD) peak concentration (Cmax) for NEF was not affected by food and was 416 (220) ng mL-1 and 446 (271) ng mL-1 after the fed and fasted treatments, respectively.",The lack effect of food on the bioavailability of nefazodone tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8907720/),[ng] / [ml],416,26100,DB00592,Piperazine
,8907720,peak concentration (Cmax),"The mean (SD) peak concentration (Cmax) for NEF was not affected by food and was 416 (220) ng mL-1 and 446 (271) ng mL-1 after the fed and fasted treatments, respectively.",The lack effect of food on the bioavailability of nefazodone tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8907720/),[ng] / [ml],446,26101,DB00592,Piperazine
,8907720,time to reach Cmax (Tmax),The median time to reach Cmax (Tmax) was also unaffected by food and was 2 h for both treatments.,The lack effect of food on the bioavailability of nefazodone tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8907720/),h,2,26102,DB00592,Piperazine
,8907720,area under the curve (AUC),"However, the mean (SD) area under the curve (AUC) was significantly reduced by food from 1815 (1017) ng h mL-1 to 1409 (695) ng h mL-1.",The lack effect of food on the bioavailability of nefazodone tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8907720/),[h·ng] / [ml],1815,26103,DB00592,Piperazine
,8907720,area under the curve (AUC),"However, the mean (SD) area under the curve (AUC) was significantly reduced by food from 1815 (1017) ng h mL-1 to 1409 (695) ng h mL-1.",The lack effect of food on the bioavailability of nefazodone tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8907720/),[h·ng] / [ml],1409,26104,DB00592,Piperazine
,14643517,flow-rate,"Analysis was run at flow-rate of 0.9 ml/min with excitation and emission wavelengths set at 260 and 365 nm, respectively.",Liquid chromatographic method for the determination of plasma itraconazole and its hydroxy metabolite in pharmacokinetic/bioavailability studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14643517/),[ml] / [min],0.9,26410,DB00592,Piperazine
,14643517,limit of quantification,The method was sensitive with limit of quantification of 3 ng/ml for itraconazole and 6 ng/ml for hydroxyitraconazole.,Liquid chromatographic method for the determination of plasma itraconazole and its hydroxy metabolite in pharmacokinetic/bioavailability studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14643517/),[ng] / [ml],3,26411,DB00592,Piperazine
,14643517,limit of quantification,The method was sensitive with limit of quantification of 3 ng/ml for itraconazole and 6 ng/ml for hydroxyitraconazole.,Liquid chromatographic method for the determination of plasma itraconazole and its hydroxy metabolite in pharmacokinetic/bioavailability studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14643517/),[ng] / [ml],6,26412,DB00592,Piperazine
,10206320,peak steady-state azimilide concentrations,"Mean peak steady-state azimilide concentrations ranged from 186 to 1030 ng mL(-1) across the 35-200 mg day(-1) dose range, while mean trough steady-state azimilide concentrations ranged from 108 to 549 ng mL(-1).",Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10206320/),[ng] / [ml],186 to 1030,26921,DB00592,Piperazine
,10206320,trough steady-state azimilide concentrations,"Mean peak steady-state azimilide concentrations ranged from 186 to 1030 ng mL(-1) across the 35-200 mg day(-1) dose range, while mean trough steady-state azimilide concentrations ranged from 108 to 549 ng mL(-1).",Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10206320/),[ng] / [ml],108 to 549,26922,DB00592,Piperazine
,10206320,maximum effect (Emax),The mean maximum effect (Emax) ranged from 24 to 28% change in QTc from baseline.,Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10206320/),%,24,26923,DB00592,Piperazine
,10206320,concentration needed to attain one half Emax,The concentration needed to attain one half Emax ranged from 432 to 542 ng mL(-1) across dose groups.,Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10206320/),[ng] / [ml],432 to 542,26924,DB00592,Piperazine
less,10206320,half-lives,"Equilibration was rapid between blood and the biophase, with equilibration half-lives of less than 1 min.",Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10206320/),min,1,26925,DB00592,Piperazine
,14709940,elimination half-life,"Nefazodone was also the only antidepressant that caused a significant change in ALPZ disposition, decreasing its area under the concentration-versus-time curve (AUC; P < 0.01), and increasing its elimination half-life (16.4 vs. 12.3 hours; P < 0.05) compared with values at baseline.","Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14709940/),h,16.4,26950,DB00592,Piperazine
,14709940,elimination half-life,"Nefazodone was also the only antidepressant that caused a significant change in ALPZ disposition, decreasing its area under the concentration-versus-time curve (AUC; P < 0.01), and increasing its elimination half-life (16.4 vs. 12.3 hours; P < 0.05) compared with values at baseline.","Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14709940/),h,12.3,26951,DB00592,Piperazine
,9158881,AUC ratios,"The AUC ratios between CSF and plasma for hydroxyzine after intranasal and intra-arterial administration were 4.0 and 0.4, respectively.",Distribution of antihistamines into the CSF following intranasal delivery. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9158881/),,4.0,27318,DB00592,Piperazine
,9158881,AUC ratios,"The AUC ratios between CSF and plasma for hydroxyzine after intranasal and intra-arterial administration were 4.0 and 0.4, respectively.",Distribution of antihistamines into the CSF following intranasal delivery. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9158881/),,0.4,27319,DB00592,Piperazine
,9158881,AUC ratios,"The AUC ratios for triprolidine, the other antihistamine with measurable CSF concentrations, were 0.5 and 0.7, respectively.",Distribution of antihistamines into the CSF following intranasal delivery. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9158881/),,0.5,27320,DB00592,Piperazine
,9158881,AUC ratios,"The AUC ratios for triprolidine, the other antihistamine with measurable CSF concentrations, were 0.5 and 0.7, respectively.",Distribution of antihistamines into the CSF following intranasal delivery. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9158881/),,0.7,27321,DB00592,Piperazine
,18500518,area under the plasma imatinib concentration versus time curve (AUC),"Antacid administration did not significantly affect the area under the plasma imatinib concentration versus time curve (AUC) [31.7 microg/(mL h) alone versus 32.6 microg/(mL h) with antacid, P = 0.37; 80% power].",Effect of antacid on imatinib absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18500518/),[μg] / [h·ml],31.7,27694,DB00592,Piperazine
,18500518,area under the plasma imatinib concentration versus time curve (AUC),"Antacid administration did not significantly affect the area under the plasma imatinib concentration versus time curve (AUC) [31.7 microg/(mL h) alone versus 32.6 microg/(mL h) with antacid, P = 0.37; 80% power].",Effect of antacid on imatinib absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18500518/),[μg] / [h·ml],32.6,27695,DB00592,Piperazine
,31134657,AUCinf,"The average AUCinf value was 659.8 ng·h/mL for CYP4F2*1/*1, 878.1 ng·h/mL for CYP4F2*1/*3, and 1125.2 ng·h/mL for CYP4F2*3/*3 (P = .010).","Effects of Ketoconazole, a CYP4F2 Inhibitor, and CYP4F2*3 Genetic Polymorphism on Pharmacokinetics of Vitamin K1. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31134657/),[h·ng] / [ml],659.8,27752,DB00592,Piperazine
,31134657,AUCinf,"The average AUCinf value was 659.8 ng·h/mL for CYP4F2*1/*1, 878.1 ng·h/mL for CYP4F2*1/*3, and 1125.2 ng·h/mL for CYP4F2*3/*3 (P = .010).","Effects of Ketoconazole, a CYP4F2 Inhibitor, and CYP4F2*3 Genetic Polymorphism on Pharmacokinetics of Vitamin K1. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31134657/),[h·ng] / [ml],878.1,27753,DB00592,Piperazine
,31134657,AUCinf,"The average AUCinf value was 659.8 ng·h/mL for CYP4F2*1/*1, 878.1 ng·h/mL for CYP4F2*1/*3, and 1125.2 ng·h/mL for CYP4F2*3/*3 (P = .010).","Effects of Ketoconazole, a CYP4F2 Inhibitor, and CYP4F2*3 Genetic Polymorphism on Pharmacokinetics of Vitamin K1. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31134657/),[h·ng] / [ml],1125.2,27754,DB00592,Piperazine
,15645510,m/z,"The multiple reaction monitoring was based on the transitions m/z 624.7 --> 84.3 and 372.1 --> 176.1 for apicidin and trazodone, respectively.","Development of a liquid chromatography/electrospray tandem mass spectrometry assay for the quantification of apicidin, a novel histone deacetylase inhibitor, in rat serum: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15645510/),,624.7,27779,DB00592,Piperazine
,15645510,m/z,"The multiple reaction monitoring was based on the transitions m/z 624.7 --> 84.3 and 372.1 --> 176.1 for apicidin and trazodone, respectively.","Development of a liquid chromatography/electrospray tandem mass spectrometry assay for the quantification of apicidin, a novel histone deacetylase inhibitor, in rat serum: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15645510/),,84.3,27780,DB00592,Piperazine
,15645510,m/z,"The multiple reaction monitoring was based on the transitions m/z 624.7 --> 84.3 and 372.1 --> 176.1 for apicidin and trazodone, respectively.","Development of a liquid chromatography/electrospray tandem mass spectrometry assay for the quantification of apicidin, a novel histone deacetylase inhibitor, in rat serum: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15645510/),,372.1,27781,DB00592,Piperazine
,15645510,m/z,"The multiple reaction monitoring was based on the transitions m/z 624.7 --> 84.3 and 372.1 --> 176.1 for apicidin and trazodone, respectively.","Development of a liquid chromatography/electrospray tandem mass spectrometry assay for the quantification of apicidin, a novel histone deacetylase inhibitor, in rat serum: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15645510/),,176.1,27782,DB00592,Piperazine
,6361228,peak serum hydroxyzine concentration,"After a single 0.7 mg/kg orally administered dose of the drug, the mean peak serum hydroxyzine concentration of 47.4 +/- 17.3 ng/ml occurred at a mean time of 2.0 +/- 0.9 hours.",Pharmacokinetics and antipruritic effects of hydroxyzine in children with atopic dermatitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6361228/),[ng] / [ml],47.4,27785,DB00592,Piperazine
,6361228,mean time,"After a single 0.7 mg/kg orally administered dose of the drug, the mean peak serum hydroxyzine concentration of 47.4 +/- 17.3 ng/ml occurred at a mean time of 2.0 +/- 0.9 hours.",Pharmacokinetics and antipruritic effects of hydroxyzine in children with atopic dermatitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6361228/),h,2.0,27786,DB00592,Piperazine
,6361228,elimination half-life,"The mean elimination half-life was 7.1 +/- 2.3 hours, the mean clearance rate was 32.08 +/- 11.05 ml/min/kg, and the mean apparent volume of distribution was 18.5 +/- 8.6 L/kg.",Pharmacokinetics and antipruritic effects of hydroxyzine in children with atopic dermatitis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6361228/),h,7.1,27787,DB00592,Piperazine
,6361228,clearance rate,"The mean elimination half-life was 7.1 +/- 2.3 hours, the mean clearance rate was 32.08 +/- 11.05 ml/min/kg, and the mean apparent volume of distribution was 18.5 +/- 8.6 L/kg.",Pharmacokinetics and antipruritic effects of hydroxyzine in children with atopic dermatitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6361228/),[ml] / [kg·min],32.08,27788,DB00592,Piperazine
,6361228,apparent volume of distribution,"The mean elimination half-life was 7.1 +/- 2.3 hours, the mean clearance rate was 32.08 +/- 11.05 ml/min/kg, and the mean apparent volume of distribution was 18.5 +/- 8.6 L/kg.",Pharmacokinetics and antipruritic effects of hydroxyzine in children with atopic dermatitis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6361228/),[l] / [kg],18.5,27789,DB00592,Piperazine
,29345736,steady-,"Results of intensive pharmacokinetics in a subset of 6 patients showed palbociclib steady-state mean area under the plasma concentration-time curve over the dosing interval [τ] and mean maximum plasma concentration were 1979 ng·h/mL and 124.7 ng/mL, respectively.",Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29345736/),[h·ng] / [ml],1979,27950,DB00592,Piperazine
,29345736,area under the plasma concentration-time curve over the dosing interval [τ],"Results of intensive pharmacokinetics in a subset of 6 patients showed palbociclib steady-state mean area under the plasma concentration-time curve over the dosing interval [τ] and mean maximum plasma concentration were 1979 ng·h/mL and 124.7 ng/mL, respectively.",Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29345736/),[h·ng] / [ml],1979,27951,DB00592,Piperazine
,29345736,maximum plasma concentration,"Results of intensive pharmacokinetics in a subset of 6 patients showed palbociclib steady-state mean area under the plasma concentration-time curve over the dosing interval [τ] and mean maximum plasma concentration were 1979 ng·h/mL and 124.7 ng/mL, respectively.",Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29345736/),[ng] / [ml],124.7,27952,DB00592,Piperazine
,29345736,trough concentration,"For day 15 plasma samples from cycles 1 and 2, geometric mean of the within-patient mean trough concentration was 90.1 ng/mL.",Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29345736/),[ng] / [ml],90.1,27953,DB00592,Piperazine
,24417786,Cmax,"The Cmax of CG100649 with CG100649 only and with concurrent administration of CG100649 + ketoconazole were similar (10.7 and 11.0 ng/mL, respectively).","Effects of ketoconazole on the pharmacokinetic properties of CG100649, a novel NSAID: a randomized, open-label crossover study in healthy Korean male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24417786/),[ng] / [ml],10.7,28111,DB00592,Piperazine
,24417786,Cmax,"The Cmax of CG100649 with CG100649 only and with concurrent administration of CG100649 + ketoconazole were similar (10.7 and 11.0 ng/mL, respectively).","Effects of ketoconazole on the pharmacokinetic properties of CG100649, a novel NSAID: a randomized, open-label crossover study in healthy Korean male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24417786/),[ng] / [ml],11.0,28112,DB00592,Piperazine
,24417786,AUClast,The CG100649 AUClast with concurrent ketoconazole was 1.29-fold greater than that with CG100649 only (2074.0 and 2685.8 ng · h/mL) and demonstrated a statistically significant difference (P < 0.05).,"Effects of ketoconazole on the pharmacokinetic properties of CG100649, a novel NSAID: a randomized, open-label crossover study in healthy Korean male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24417786/),[h·ng] / [ml],2074.0,28113,DB00592,Piperazine
,24417786,AUClast,The CG100649 AUClast with concurrent ketoconazole was 1.29-fold greater than that with CG100649 only (2074.0 and 2685.8 ng · h/mL) and demonstrated a statistically significant difference (P < 0.05).,"Effects of ketoconazole on the pharmacokinetic properties of CG100649, a novel NSAID: a randomized, open-label crossover study in healthy Korean male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24417786/),[h·ng] / [ml],2685.8,28114,DB00592,Piperazine
,15286096,CL(T),"The GFR and Vd remained unchanged, but significant reductions in CL(T) (655 vs. 486 mL/min, p < 0.001) and CL(sec) (410 vs. 311 mL/min, p = 0.001) were observed.",Renal interaction between itraconazole and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286096/),[ml] / [min],655,28392,DB00592,Piperazine
,15286096,CL(T),"The GFR and Vd remained unchanged, but significant reductions in CL(T) (655 vs. 486 mL/min, p < 0.001) and CL(sec) (410 vs. 311 mL/min, p = 0.001) were observed.",Renal interaction between itraconazole and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286096/),[ml] / [min],486,28393,DB00592,Piperazine
,15286096,CL(sec),"The GFR and Vd remained unchanged, but significant reductions in CL(T) (655 vs. 486 mL/min, p < 0.001) and CL(sec) (410 vs. 311 mL/min, p = 0.001) were observed.",Renal interaction between itraconazole and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286096/),[ml] / [min],410,28394,DB00592,Piperazine
,15286096,CL(sec),"The GFR and Vd remained unchanged, but significant reductions in CL(T) (655 vs. 486 mL/min, p < 0.001) and CL(sec) (410 vs. 311 mL/min, p = 0.001) were observed.",Renal interaction between itraconazole and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286096/),[ml] / [min],311,28395,DB00592,Piperazine
,30259403,relative bioavailability,"The obtained pharmacokinetic results showed that the relative bioavailability for orally administered ARP-loaded silicosan particles (SC-2-CTAB) was 66% higher relative to the oral suspension (AUC0-10h was 16.38 ± 3.21 and 27.23 ± 2.35 ng.h/mL for drug powder and SC-2-CTAB formulation, respectively).","Bioavailability Enhancement of Aripiprazole Via Silicosan Particles: Preparation, Characterization and In vivo Evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30259403/),,66,28773,DB00592,Piperazine
,30259403,AUC0-10h,"The obtained pharmacokinetic results showed that the relative bioavailability for orally administered ARP-loaded silicosan particles (SC-2-CTAB) was 66% higher relative to the oral suspension (AUC0-10h was 16.38 ± 3.21 and 27.23 ± 2.35 ng.h/mL for drug powder and SC-2-CTAB formulation, respectively).","Bioavailability Enhancement of Aripiprazole Via Silicosan Particles: Preparation, Characterization and In vivo Evaluation. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30259403/),[h·ng] / [ml],16.38,28774,DB00592,Piperazine
,30259403,AUC0-10h,"The obtained pharmacokinetic results showed that the relative bioavailability for orally administered ARP-loaded silicosan particles (SC-2-CTAB) was 66% higher relative to the oral suspension (AUC0-10h was 16.38 ± 3.21 and 27.23 ± 2.35 ng.h/mL for drug powder and SC-2-CTAB formulation, respectively).","Bioavailability Enhancement of Aripiprazole Via Silicosan Particles: Preparation, Characterization and In vivo Evaluation. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30259403/),[h·ng] / [ml],27.23,28775,DB00592,Piperazine
,20947617,unbound fraction,"Nutlin-3a exhibited nonlinear binding to murine plasma proteins, with the unbound fraction ranging from 0.7 to 11.8%.",Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20947617/),%,0.7 to 11.8,28783,DB00592,Piperazine
,16633141,area under the time-concentration curves (AUCs),Itraconazole pretreatment increased the mean area under the time-concentration curves (AUCs) of haloperidol by 55% compared to placebo pretreatment (21.7 +/- 11.3 vs 33.5 +/- 29.3 ng h/mL).,Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16633141/),[h·ng] / [ml],21.7,28806,DB00592,Piperazine
,16633141,area under the time-concentration curves (AUCs),Itraconazole pretreatment increased the mean area under the time-concentration curves (AUCs) of haloperidol by 55% compared to placebo pretreatment (21.7 +/- 11.3 vs 33.5 +/- 29.3 ng h/mL).,Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16633141/),[h·ng] / [ml],33.5,28807,DB00592,Piperazine
,16633141,AUC,The subjects with CYP2D6*10/*10 genotype showed 81% higher AUC compared to that of subjects with CYP2D6*1/*1 genotype (27.6 +/- 22.2 vs 50.2 +/- 47.1 ng h/mL).,Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16633141/),[h·ng] / [ml],27.6,28808,DB00592,Piperazine
,16633141,AUC,The subjects with CYP2D6*10/*10 genotype showed 81% higher AUC compared to that of subjects with CYP2D6*1/*1 genotype (27.6 +/- 22.2 vs 50.2 +/- 47.1 ng h/mL).,Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16633141/),[h·ng] / [ml],50.2,28809,DB00592,Piperazine
,16633141,AUC,"In the presence of itraconazole, subjects with CYP2D6*10/*10 showed 3-fold higher AUC of haloperidol compared to that of placebo pretreated subjects with CYP2D6*1/*1 genotype (21.7 +/- 11.3 vs 66.7 +/- 62.1 ng h/mL; P < 0.05).",Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16633141/),[h·ng] / [ml],21.7,28810,DB00592,Piperazine
,16633141,AUC,"In the presence of itraconazole, subjects with CYP2D6*10/*10 showed 3-fold higher AUC of haloperidol compared to that of placebo pretreated subjects with CYP2D6*1/*1 genotype (21.7 +/- 11.3 vs 66.7 +/- 62.1 ng h/mL; P < 0.05).",Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16633141/),[h·ng] / [ml],66.7,28811,DB00592,Piperazine
,16633141,oral clearance,"In the subjects with both CYP2D6*10 genotype and itraconazole pretreatment, however, the oral clearance was significantly decreased to 42% of subjects with wild genotype in the placebo pretreatment (4.7 +/- 3.6 vs 2.0 +/- 1.9 L/h/kg; P < 0.05).",Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16633141/),[l] / [h·kg],4.7,28812,DB00592,Piperazine
,16633141,oral clearance,"In the subjects with both CYP2D6*10 genotype and itraconazole pretreatment, however, the oral clearance was significantly decreased to 42% of subjects with wild genotype in the placebo pretreatment (4.7 +/- 3.6 vs 2.0 +/- 1.9 L/h/kg; P < 0.05).",Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16633141/),[l] / [h·kg],2.0,28813,DB00592,Piperazine
,24245252,basal spacing,"According to the powder X-ray diffraction pattern, the basal spacing of the intraconazole-layered aluminosilicate nanohybrid increased from 14.7 to 22.7 A depending on the pH of the aqueous suspension.",Heterostructured layered aluminosilicate-itraconazole nanohybrid for drug delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24245252/),a,14.7,28868,DB00592,Piperazine
,24245252,basal spacing,"According to the powder X-ray diffraction pattern, the basal spacing of the intraconazole-layered aluminosilicate nanohybrid increased from 14.7 to 22.7 A depending on the pH of the aqueous suspension.",Heterostructured layered aluminosilicate-itraconazole nanohybrid for drug delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24245252/),a,22.7,28869,DB00592,Piperazine
,24245252,area under the plasma concentration-time curve (AUC,"The pharmacokinetic data for the nanohybrid and Sporanox showed that the mean area under the plasma concentration-time curve (AUC, 2477 +/- 898 ng x hr/mL and 2630 +/- 953 ng x hr/mL, respectively) and maximum concentration (Cmax, 225.4 +/- 77.4 ng x hr/mL and 223.6 +/- 51.9 ng x hr/mL, respectively), were within the bioequivalence (BE) range.",Heterostructured layered aluminosilicate-itraconazole nanohybrid for drug delivery system. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24245252/),[h·ng] / [ml],2477,28870,DB00592,Piperazine
,24245252,area under the plasma concentration-time curve (AUC,"The pharmacokinetic data for the nanohybrid and Sporanox showed that the mean area under the plasma concentration-time curve (AUC, 2477 +/- 898 ng x hr/mL and 2630 +/- 953 ng x hr/mL, respectively) and maximum concentration (Cmax, 225.4 +/- 77.4 ng x hr/mL and 223.6 +/- 51.9 ng x hr/mL, respectively), were within the bioequivalence (BE) range.",Heterostructured layered aluminosilicate-itraconazole nanohybrid for drug delivery system. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24245252/),[h·ng] / [ml],2630,28871,DB00592,Piperazine
,24245252,maximum concentration (Cmax,"The pharmacokinetic data for the nanohybrid and Sporanox showed that the mean area under the plasma concentration-time curve (AUC, 2477 +/- 898 ng x hr/mL and 2630 +/- 953 ng x hr/mL, respectively) and maximum concentration (Cmax, 225.4 +/- 77.4 ng x hr/mL and 223.6 +/- 51.9 ng x hr/mL, respectively), were within the bioequivalence (BE) range.",Heterostructured layered aluminosilicate-itraconazole nanohybrid for drug delivery system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24245252/),[h·ng] / [ml],225.4,28872,DB00592,Piperazine
,24245252,maximum concentration (Cmax,"The pharmacokinetic data for the nanohybrid and Sporanox showed that the mean area under the plasma concentration-time curve (AUC, 2477 +/- 898 ng x hr/mL and 2630 +/- 953 ng x hr/mL, respectively) and maximum concentration (Cmax, 225.4 +/- 77.4 ng x hr/mL and 223.6 +/- 51.9 ng x hr/mL, respectively), were within the bioequivalence (BE) range.",Heterostructured layered aluminosilicate-itraconazole nanohybrid for drug delivery system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24245252/),[h·ng] / [ml],223.6,28873,DB00592,Piperazine
,26139313,biological half-life,"The serum concentration further declined to 9.2 and 2.3 µg/mL, respectively, 5 and 14 h later, revealing a biological half-life of 4.2 h.",A Non-Fatal Self-Poisoning Attempt with Sildenafil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26139313/),h,4.2,29211,DB00592,Piperazine
,23523546,maximum solubility,"F2 and F3 formulations allowed the in vitro formation of an ITZ supersaturated solution with a maximum solubility of 450±124ng/ml (F2) and 498±44ng/ml (F3), in contrast to formulation F1 (<10ng/ml).",Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523546/),[ng] / [ml],450,29220,DB00592,Piperazine
,23523546,maximum solubility,"F2 and F3 formulations allowed the in vitro formation of an ITZ supersaturated solution with a maximum solubility of 450±124ng/ml (F2) and 498±44ng/ml (F3), in contrast to formulation F1 (<10ng/ml).",Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523546/),[ng] / [ml],498,29221,DB00592,Piperazine
<,23523546,maximum solubility,"F2 and F3 formulations allowed the in vitro formation of an ITZ supersaturated solution with a maximum solubility of 450±124ng/ml (F2) and 498±44ng/ml (F3), in contrast to formulation F1 (<10ng/ml).",Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523546/),[ng] / [ml],10,29222,DB00592,Piperazine
,23523546,plasmatic AUC0-24h,"As a result of these higher solubilities, absorption into the systemic compartment after endotracheal administration was faster for formulations F2 and F3 (shorter tmax) and in larger quantities compared to the F1 formulation (plasmatic AUC0-24h of 182ngh/ml, 491.5ngh/ml and 376.8ngh/ml, and tmax of 60min, 30min and 5min for F1, F2 and F3, respectively).",Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523546/),[ngh] / [ml],182,29223,DB00592,Piperazine
,23523546,plasmatic AUC0-24h,"As a result of these higher solubilities, absorption into the systemic compartment after endotracheal administration was faster for formulations F2 and F3 (shorter tmax) and in larger quantities compared to the F1 formulation (plasmatic AUC0-24h of 182ngh/ml, 491.5ngh/ml and 376.8ngh/ml, and tmax of 60min, 30min and 5min for F1, F2 and F3, respectively).",Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523546/),[ngh] / [ml],491.5,29224,DB00592,Piperazine
,23523546,plasmatic AUC0-24h,"As a result of these higher solubilities, absorption into the systemic compartment after endotracheal administration was faster for formulations F2 and F3 (shorter tmax) and in larger quantities compared to the F1 formulation (plasmatic AUC0-24h of 182ngh/ml, 491.5ngh/ml and 376.8ngh/ml, and tmax of 60min, 30min and 5min for F1, F2 and F3, respectively).",Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523546/),[ngh] / [ml],376.8,29225,DB00592,Piperazine
,23523546,tmax,"As a result of these higher solubilities, absorption into the systemic compartment after endotracheal administration was faster for formulations F2 and F3 (shorter tmax) and in larger quantities compared to the F1 formulation (plasmatic AUC0-24h of 182ngh/ml, 491.5ngh/ml and 376.8ngh/ml, and tmax of 60min, 30min and 5min for F1, F2 and F3, respectively).",Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523546/),min,60,29226,DB00592,Piperazine
,23523546,tmax,"As a result of these higher solubilities, absorption into the systemic compartment after endotracheal administration was faster for formulations F2 and F3 (shorter tmax) and in larger quantities compared to the F1 formulation (plasmatic AUC0-24h of 182ngh/ml, 491.5ngh/ml and 376.8ngh/ml, and tmax of 60min, 30min and 5min for F1, F2 and F3, respectively).",Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523546/),min,30,29227,DB00592,Piperazine
,23523546,tmax,"As a result of these higher solubilities, absorption into the systemic compartment after endotracheal administration was faster for formulations F2 and F3 (shorter tmax) and in larger quantities compared to the F1 formulation (plasmatic AUC0-24h of 182ngh/ml, 491.5ngh/ml and 376.8ngh/ml, and tmax of 60min, 30min and 5min for F1, F2 and F3, respectively).",Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523546/),min,5,29228,DB00592,Piperazine
,23523546,minimal inhibitory concentrations,"ITZ lung concentrations after pulmonary administration remained higher than the targeted dose, based on the minimal inhibitory concentrations for Aspergillus fumigatus (2μg/glung), 24h post-administration for both F1 and F2 formulations.",Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523546/),[μg] / [glung],2,29229,DB00592,Piperazine
,23523546,elimination half-life,"However, this was not the case for formulation F3, which exhibited a faster elimination rate from the lung, with an elimination half-life of 4.1h vs. 6.5h and 14.7h for F1 and F2, respectively.",Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523546/),h,4.1,29230,DB00592,Piperazine
,23523546,elimination half-life,"However, this was not the case for formulation F3, which exhibited a faster elimination rate from the lung, with an elimination half-life of 4.1h vs. 6.5h and 14.7h for F1 and F2, respectively.",Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523546/),h,6.5,29231,DB00592,Piperazine
,23523546,elimination half-life,"However, this was not the case for formulation F3, which exhibited a faster elimination rate from the lung, with an elimination half-life of 4.1h vs. 6.5h and 14.7h for F1 and F2, respectively.",Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523546/),h,14.7,29232,DB00592,Piperazine
,9311628,elimination half life,The plasma kinetic profiles were characterized by monoexponential elimination with an elimination half life of 3-4 hr.,Metabolic disposition of the new fluoroquinolone antibacterial agent DW116 in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9311628/),h,3-4,29509,DB00592,Piperazine
,9311628,apparent mean total clearance (CL(T)),"The apparent mean total clearance (CL(T)) and the volume of distribution (V(SS)) ranged from 221 +/- 55 to 274 +/- 27 ml/hr/kg and 1.0+/-0.1 to 1.5+/-0.2 l/kg, respectively, and were independent of dose between 4 and 20 mg/kg levels.",Metabolic disposition of the new fluoroquinolone antibacterial agent DW116 in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9311628/),[ml] / [h·kg],221,29510,DB00592,Piperazine
,9311628,volume of distribution (V(SS)),"The apparent mean total clearance (CL(T)) and the volume of distribution (V(SS)) ranged from 221 +/- 55 to 274 +/- 27 ml/hr/kg and 1.0+/-0.1 to 1.5+/-0.2 l/kg, respectively, and were independent of dose between 4 and 20 mg/kg levels.",Metabolic disposition of the new fluoroquinolone antibacterial agent DW116 in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9311628/),[ml] / [h·kg],274,29511,DB00592,Piperazine
,9311628,volume of distribution (V(SS)),"The apparent mean total clearance (CL(T)) and the volume of distribution (V(SS)) ranged from 221 +/- 55 to 274 +/- 27 ml/hr/kg and 1.0+/-0.1 to 1.5+/-0.2 l/kg, respectively, and were independent of dose between 4 and 20 mg/kg levels.",Metabolic disposition of the new fluoroquinolone antibacterial agent DW116 in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9311628/),[l] / [kg],1.0,29512,DB00592,Piperazine
,9311628,volume of distribution (V(SS)),"The apparent mean total clearance (CL(T)) and the volume of distribution (V(SS)) ranged from 221 +/- 55 to 274 +/- 27 ml/hr/kg and 1.0+/-0.1 to 1.5+/-0.2 l/kg, respectively, and were independent of dose between 4 and 20 mg/kg levels.",Metabolic disposition of the new fluoroquinolone antibacterial agent DW116 in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9311628/),[l] / [kg],1.5,29513,DB00592,Piperazine
,9311628,renal (CL(R)) clearance,The renal (CL(R)) clearance was 64.5 ml/hr/kg and the biliary (CL(B)) clearance was 33.8 ml/hr/kg.,Metabolic disposition of the new fluoroquinolone antibacterial agent DW116 in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9311628/),[ml] / [h·kg],64.5,29514,DB00592,Piperazine
,9311628,biliary (CL(B)) clearance,The renal (CL(R)) clearance was 64.5 ml/hr/kg and the biliary (CL(B)) clearance was 33.8 ml/hr/kg.,Metabolic disposition of the new fluoroquinolone antibacterial agent DW116 in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9311628/),[ml] / [h·kg],33.8,29515,DB00592,Piperazine
,9311628,urinary recoveries,"The mean urinary recoveries of free and total (free plus glucuronide ester) DW116 were 28.6 +/- 2.7% and 36.4 +/- 1.8% of the administered dose and the corresponding biliary recoveries were 14.4 +/- 5.5% and 37.0 +/- 7.6%, respectively.",Metabolic disposition of the new fluoroquinolone antibacterial agent DW116 in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9311628/),%,28.6,29516,DB00592,Piperazine
,9311628,urinary recoveries,"The mean urinary recoveries of free and total (free plus glucuronide ester) DW116 were 28.6 +/- 2.7% and 36.4 +/- 1.8% of the administered dose and the corresponding biliary recoveries were 14.4 +/- 5.5% and 37.0 +/- 7.6%, respectively.",Metabolic disposition of the new fluoroquinolone antibacterial agent DW116 in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9311628/),%,36.4,29517,DB00592,Piperazine
,9311628,biliary recoveries,"The mean urinary recoveries of free and total (free plus glucuronide ester) DW116 were 28.6 +/- 2.7% and 36.4 +/- 1.8% of the administered dose and the corresponding biliary recoveries were 14.4 +/- 5.5% and 37.0 +/- 7.6%, respectively.",Metabolic disposition of the new fluoroquinolone antibacterial agent DW116 in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9311628/),%,14.4,29518,DB00592,Piperazine
,9311628,biliary recoveries,"The mean urinary recoveries of free and total (free plus glucuronide ester) DW116 were 28.6 +/- 2.7% and 36.4 +/- 1.8% of the administered dose and the corresponding biliary recoveries were 14.4 +/- 5.5% and 37.0 +/- 7.6%, respectively.",Metabolic disposition of the new fluoroquinolone antibacterial agent DW116 in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9311628/),%,37.0,29519,DB00592,Piperazine
,20499133,oral bioavailability,The oral bioavailability of PAC-1 was relatively low and highly variable (17.8 ± 9.5%).,"Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1, a preferential small molecule activator of procaspase-3, in healthy dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20499133/),%,17.8,29694,DB00592,Piperazine
,15081939,flow rate,"Assay was conducted using a C8 column (250 mm x 4.6 mm, 5 microm particle size) under isocratic elution with 0.02 M potassium dihydrogen phosphate-acetonitrile (7:3, v/v) at a flow rate of 1 ml/min and detected using photodiode array at 265 nm.",Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15081939/),[ml] / [min],1,29709,DB00592,Piperazine
,11996495,flow-rate,"HPLC separation was achieved on a C18 column with the mobile phase of acetonitrile-50 mM sodium dihydrogen phosphate (60:40, v/v) at a flow-rate of 1 ml/min.",Determination of delavirdine in very small volumes of plasma by high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996495/),[ml] / [min],1,29813,DB00592,Piperazine
,11996495,retention time,The retention time was about 5.3 min for delavirdine and 6.5 min for cisapride.,Determination of delavirdine in very small volumes of plasma by high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996495/),min,5.3,29814,DB00592,Piperazine
,11996495,retention time,The retention time was about 5.3 min for delavirdine and 6.5 min for cisapride.,Determination of delavirdine in very small volumes of plasma by high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996495/),min,6.5,29815,DB00592,Piperazine
,11879254,absolute oral bioavailability,The calculated absolute oral bioavailability of sildenafil was 41% (90% CI: 36--47).,"Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11879254/),%,41,30241,DB00592,Piperazine
,11879254,absolute bioavailability,Sildenafil had a mean absolute bioavailability of 41%.,"Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11879254/),%,41,30242,DB00592,Piperazine
,11823754,oral bioavailability,"Because of extensive first-pass metabolism, oral bioavailability of sildenafil reaches only 40%.",Effects of grapefruit juice on the pharmacokinetics of sildenafil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11823754/),%,40,30295,DB00592,Piperazine
,11823754,area under the sildenafil plasma concentration-time curve from time zero to infinity [AUC(0-infinity),"Grapefruit juice changed the area under the sildenafil plasma concentration-time curve from time zero to infinity [AUC(0-infinity) from 620 [1.53] ng/ml x h to 761 [1.58] ng/ml x h (geometric mean with geometric standard deviation), corresponding to a 23% increase (90% confidence interval, 13%-33%).",Effects of grapefruit juice on the pharmacokinetics of sildenafil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11823754/),[ng] / [h·ml],620,30296,DB00592,Piperazine
,11823754,area under the sildenafil plasma concentration-time curve from time zero to infinity [AUC(0-infinity),"Grapefruit juice changed the area under the sildenafil plasma concentration-time curve from time zero to infinity [AUC(0-infinity) from 620 [1.53] ng/ml x h to 761 [1.58] ng/ml x h (geometric mean with geometric standard deviation), corresponding to a 23% increase (90% confidence interval, 13%-33%).",Effects of grapefruit juice on the pharmacokinetics of sildenafil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11823754/),[ng] / [h·ml],761,30297,DB00592,Piperazine
,11823754,time to reach C(max),"There was a trend toward a prolonged time to reach C(max) during the grapefruit juice period (from a median of 0.75 hour to a median of 1.13 hours), corresponding to an increase by 0.25 hour (90% confidence interval, 0-0.63 hour).",Effects of grapefruit juice on the pharmacokinetics of sildenafil. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11823754/),h,0.75,30298,DB00592,Piperazine
,11823754,time to reach C(max),"There was a trend toward a prolonged time to reach C(max) during the grapefruit juice period (from a median of 0.75 hour to a median of 1.13 hours), corresponding to an increase by 0.25 hour (90% confidence interval, 0-0.63 hour).",Effects of grapefruit juice on the pharmacokinetics of sildenafil. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11823754/),h,1.13,30299,DB00592,Piperazine
,7875642,apparent elimination half-life,"In healthy volunteers, nefazodone was rapidly absorbed after which the plasma concentrations declined with an apparent elimination half-life ranging from 2.7 +/- 1.7 h to 10.2 +/- 4.4 h according to the dosage.",Influence of hepatic impairment on the pharmacokinetics of nefazodone and two of its metabolites after single and multiple oral doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875642/),h,2.7,30564,DB00592,Piperazine
,7875642,apparent elimination half-life,"In healthy volunteers, nefazodone was rapidly absorbed after which the plasma concentrations declined with an apparent elimination half-life ranging from 2.7 +/- 1.7 h to 10.2 +/- 4.4 h according to the dosage.",Influence of hepatic impairment on the pharmacokinetics of nefazodone and two of its metabolites after single and multiple oral doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875642/),h,10.2,30565,DB00592,Piperazine
,7875642,half-life,"Hydroxy-nefazodone appeared rapidly in plasma and its time-course (half-life ranging 1.4 +/- 0.9 h to 6.5 +/- 1.6 h) paralleled that of nefazodone, while mCPP showed low and variable concentrations.",Influence of hepatic impairment on the pharmacokinetics of nefazodone and two of its metabolites after single and multiple oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875642/),h,1.4,30566,DB00592,Piperazine
,7875642,half-life,"Hydroxy-nefazodone appeared rapidly in plasma and its time-course (half-life ranging 1.4 +/- 0.9 h to 6.5 +/- 1.6 h) paralleled that of nefazodone, while mCPP showed low and variable concentrations.",Influence of hepatic impairment on the pharmacokinetics of nefazodone and two of its metabolites after single and multiple oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875642/),h,6.5,30567,DB00592,Piperazine
,7875642,molar AUC0-48,The constant molar AUC0-48 hydroxy-nefazodone/nefazodone ratio (0.32 +/- 0.04) and the close correlation (r2 = 0.95) between kinetic parameters of nefazodone and hydroxy-nefazodone suggest that nefazodone hydroxylation is not a saturable process.,Influence of hepatic impairment on the pharmacokinetics of nefazodone and two of its metabolites after single and multiple oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875642/),,0.32,30568,DB00592,Piperazine
,10653208,steady-state plasma area under the concentration-time curve (AUC),"Coadministration of nefazodone increased steady-state plasma area under the concentration-time curve (AUC) of carbamazepine from 60.77 (+/-8.44) to 74.98 (+/-12.88) microg x hr/mL (p < 0.001) and decreased the active carbamazepine-10,11-epoxide metabolite AUC concentration from 7.10 (+/-1.16) to 5.71 (+/-0.52) microg x hr/mL (p < 0.005).",Carbamazepine-nefazodone interaction in healthy subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10653208/),[h·μg] / [ml],60.77,31379,DB00592,Piperazine
,10653208,steady-state plasma area under the concentration-time curve (AUC),"Coadministration of nefazodone increased steady-state plasma area under the concentration-time curve (AUC) of carbamazepine from 60.77 (+/-8.44) to 74.98 (+/-12.88) microg x hr/mL (p < 0.001) and decreased the active carbamazepine-10,11-epoxide metabolite AUC concentration from 7.10 (+/-1.16) to 5.71 (+/-0.52) microg x hr/mL (p < 0.005).",Carbamazepine-nefazodone interaction in healthy subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10653208/),[h·μg] / [ml],74.98,31380,DB00592,Piperazine
,10653208,AUC concentration,"Coadministration of nefazodone increased steady-state plasma area under the concentration-time curve (AUC) of carbamazepine from 60.77 (+/-8.44) to 74.98 (+/-12.88) microg x hr/mL (p < 0.001) and decreased the active carbamazepine-10,11-epoxide metabolite AUC concentration from 7.10 (+/-1.16) to 5.71 (+/-0.52) microg x hr/mL (p < 0.005).",Carbamazepine-nefazodone interaction in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10653208/),[h·μg] / [ml],7.10,31381,DB00592,Piperazine
,10653208,AUC concentration,"Coadministration of nefazodone increased steady-state plasma area under the concentration-time curve (AUC) of carbamazepine from 60.77 (+/-8.44) to 74.98 (+/-12.88) microg x hr/mL (p < 0.001) and decreased the active carbamazepine-10,11-epoxide metabolite AUC concentration from 7.10 (+/-1.16) to 5.71 (+/-0.52) microg x hr/mL (p < 0.005).",Carbamazepine-nefazodone interaction in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10653208/),[h·μg] / [ml],5.71,31382,DB00592,Piperazine
,10653208,steady-state AUC,"During the combination, the steady-state AUC of nefazodone decreased from 7,326 (+/-3,768) to 542 (+/-191) ng x hr/mL, and the AUCs of its metabolites (hydroxynefazodone, meta-chlorophenylpiperazine, and triazoledione) decreased significantly as well (p < 0.001).",Carbamazepine-nefazodone interaction in healthy subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10653208/),[h·ng] / [ml],"7,326",31383,DB00592,Piperazine
,10653208,steady-state AUC,"During the combination, the steady-state AUC of nefazodone decreased from 7,326 (+/-3,768) to 542 (+/-191) ng x hr/mL, and the AUCs of its metabolites (hydroxynefazodone, meta-chlorophenylpiperazine, and triazoledione) decreased significantly as well (p < 0.001).",Carbamazepine-nefazodone interaction in healthy subjects. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10653208/),[h·ng] / [ml],542,31384,DB00592,Piperazine
,26058662,half-life,"In addition, the unique pharmacokinetics of salvinorin A (half-life ~8 min in non-human primates) allowed us to study the residual impact on KOR after the drug had eliminated from the brain.","Immediate and Persistent Effects of Salvinorin A on the Kappa Opioid Receptor in Rodents, Monitored In Vivo with PET. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26058662/),min,8,31422,DB00592,Piperazine
,11673753,E(max),The mean E(max) (maximum increase in the QTc interval for the E(max) models) was a 61.7 ms increase from baseline.,A population pharmacokinetic-pharmacodynamic analysis and model validation of azimilide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673753/),ms,61.7,31488,DB00592,Piperazine
,9433650,apparent volume of distribution,The high values for the apparent volume of distribution (5 to 8 L/kg) suggested extensive distribution of grepafloxacin in the tissues.,Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433650/),[l] / [kg],5 to 8,31586,DB00592,Piperazine
,9433650,half-life,The half-life of grepafloxacin was about 12 hours after single doses and about 15 hours after repeat doses.,Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433650/),h,12,31587,DB00592,Piperazine
,9433650,half-life,The half-life of grepafloxacin was about 12 hours after single doses and about 15 hours after repeat doses.,Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433650/),h,15,31588,DB00592,Piperazine
,2536254,volume of distribution at steady state,"The pharmacokinetic parameters derived by compartmental modelling were (normal vs. renal failure, respectively): volume of distribution at steady state (309 +/- 103 vs. 442 +/- 158 ml.kg-1, mean +/- SD), plasma clearance, (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (140 +/- 63 vs. 329 +/- 198 min), and elimination half-life (137 +/- 68 vs. 263 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),[ml] / [kg],309,32109,DB00592,Piperazine
,2536254,volume of distribution at steady state,"The pharmacokinetic parameters derived by compartmental modelling were (normal vs. renal failure, respectively): volume of distribution at steady state (309 +/- 103 vs. 442 +/- 158 ml.kg-1, mean +/- SD), plasma clearance, (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (140 +/- 63 vs. 329 +/- 198 min), and elimination half-life (137 +/- 68 vs. 263 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),[ml] / [kg],442,32110,DB00592,Piperazine
,2536254,plasma clearance,"The pharmacokinetic parameters derived by compartmental modelling were (normal vs. renal failure, respectively): volume of distribution at steady state (309 +/- 103 vs. 442 +/- 158 ml.kg-1, mean +/- SD), plasma clearance, (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (140 +/- 63 vs. 329 +/- 198 min), and elimination half-life (137 +/- 68 vs. 263 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),[ml] / [kg·min],2.4,32111,DB00592,Piperazine
,2536254,plasma clearance,"The pharmacokinetic parameters derived by compartmental modelling were (normal vs. renal failure, respectively): volume of distribution at steady state (309 +/- 103 vs. 442 +/- 158 ml.kg-1, mean +/- SD), plasma clearance, (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (140 +/- 63 vs. 329 +/- 198 min), and elimination half-life (137 +/- 68 vs. 263 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),[ml] / [kg·min],1.6,32112,DB00592,Piperazine
,2536254,mean residence time,"The pharmacokinetic parameters derived by compartmental modelling were (normal vs. renal failure, respectively): volume of distribution at steady state (309 +/- 103 vs. 442 +/- 158 ml.kg-1, mean +/- SD), plasma clearance, (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (140 +/- 63 vs. 329 +/- 198 min), and elimination half-life (137 +/- 68 vs. 263 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),min,140,32113,DB00592,Piperazine
,2536254,mean residence time,"The pharmacokinetic parameters derived by compartmental modelling were (normal vs. renal failure, respectively): volume of distribution at steady state (309 +/- 103 vs. 442 +/- 158 ml.kg-1, mean +/- SD), plasma clearance, (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (140 +/- 63 vs. 329 +/- 198 min), and elimination half-life (137 +/- 68 vs. 263 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),min,329,32114,DB00592,Piperazine
,2536254,elimination half-life,"The pharmacokinetic parameters derived by compartmental modelling were (normal vs. renal failure, respectively): volume of distribution at steady state (309 +/- 103 vs. 442 +/- 158 ml.kg-1, mean +/- SD), plasma clearance, (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (140 +/- 63 vs. 329 +/- 198 min), and elimination half-life (137 +/- 68 vs. 263 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),min,137,32115,DB00592,Piperazine
,2536254,elimination half-life,"The pharmacokinetic parameters derived by compartmental modelling were (normal vs. renal failure, respectively): volume of distribution at steady state (309 +/- 103 vs. 442 +/- 158 ml.kg-1, mean +/- SD), plasma clearance, (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (140 +/- 63 vs. 329 +/- 198 min), and elimination half-life (137 +/- 68 vs. 263 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),min,263,32116,DB00592,Piperazine
,2536254,volume of distribution at steady state,"The same parameters as derived by the non-compartmental method were (normal vs. renal failure, respectively): volume of distribution at steady state (307 +/- 80 vs.",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),,307,32117,DB00592,Piperazine
,2536254,plasma clearance,"426 +/- 119 ml.kg-1, mean +/- SD), plasma clearance (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (134 +/- 41 vs. 323 +/- 228 min), and elimination half-life (118 +/- 35 vs. 247 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),[ml] / [kg·min],2.4,32118,DB00592,Piperazine
,2536254,plasma clearance,"426 +/- 119 ml.kg-1, mean +/- SD), plasma clearance (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (134 +/- 41 vs. 323 +/- 228 min), and elimination half-life (118 +/- 35 vs. 247 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),[ml] / [kg·min],1.6,32119,DB00592,Piperazine
,2536254,mean residence time,"426 +/- 119 ml.kg-1, mean +/- SD), plasma clearance (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (134 +/- 41 vs. 323 +/- 228 min), and elimination half-life (118 +/- 35 vs. 247 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),min,134,32120,DB00592,Piperazine
,2536254,mean residence time,"426 +/- 119 ml.kg-1, mean +/- SD), plasma clearance (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (134 +/- 41 vs. 323 +/- 228 min), and elimination half-life (118 +/- 35 vs. 247 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),min,323,32121,DB00592,Piperazine
,2536254,elimination half-life,"426 +/- 119 ml.kg-1, mean +/- SD), plasma clearance (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (134 +/- 41 vs. 323 +/- 228 min), and elimination half-life (118 +/- 35 vs. 247 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),min,118,32122,DB00592,Piperazine
,2536254,elimination half-life,"426 +/- 119 ml.kg-1, mean +/- SD), plasma clearance (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (134 +/- 41 vs. 323 +/- 228 min), and elimination half-life (118 +/- 35 vs. 247 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),min,247,32123,DB00592,Piperazine
,22891806,dissociation constant Kd,"Imatinib free concentrations were best predicted using a non-linear binding model to AGP, with a dissociation constant Kd of 319 ng ml(-1) , assuming a 1:1 molar binding ratio.",Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22891806/),[ng] / [ml],319,32407,DB00592,Piperazine
,10784424,plasma-saliva concentration ratio,The plasma-saliva concentration ratio was calculated as 1.53 whereas the observed ratio was 3.82.,Pharmacokinetics of diethylcarbamazine: prediction by concentration in saliva. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10784424/),,1.53,32438,DB00592,Piperazine
,8851608,maximum concentration,Concurrent administration of didanosine and atevirdine significantly reduced the maximum concentration of atevirdine in serum from 3.45 +/- 2.8 to 0.854 +/- 0.33 microM (P = 0.004).,Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851608/),μM,3.45,32617,DB00592,Piperazine
,8851608,maximum concentration,Concurrent administration of didanosine and atevirdine significantly reduced the maximum concentration of atevirdine in serum from 3.45 +/- 2.8 to 0.854 +/- 0.33 microM (P = 0.004).,Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851608/),μM,0.854,32618,DB00592,Piperazine
,8851608,area under the concentration-time curve from 0 to 24 h,"Likewise, the mean atevirdine area under the concentration-time curve from 0 to 24 h after administration of the combination was reduced to 6.47 +/- 2.2 microM.h (P = 0.004) relative to a value of 11.3 +/- 4.8 microM.h for atevirdine alone.",Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851608/),h·μM,6.47,32619,DB00592,Piperazine
,8851608,area under the concentration-time curve from 0 to 24 h,"Likewise, the mean atevirdine area under the concentration-time curve from 0 to 24 h after administration of the combination was reduced to 6.47 +/- 2.2 microM.h (P = 0.004) relative to a value of 11.3 +/- 4.8 microM.h for atevirdine alone.",Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851608/),h·μM,11.3,32620,DB00592,Piperazine
,21889427,flow rate,"The chromatography was achieved using an Agilent microbore C(18) Extend, 1.0 × 50 mm, 3.5 μm column at a flow rate of 0.150 mL/min with a total run time of 1.8 min.",Quantitative analysis of PD 0332991 in mouse plasma using automated micro-sample processing and microbore liquid chromatography coupled with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21889427/),[ml] / [min],0.150,32829,DB00592,Piperazine
,21889427,total run time,"The chromatography was achieved using an Agilent microbore C(18) Extend, 1.0 × 50 mm, 3.5 μm column at a flow rate of 0.150 mL/min with a total run time of 1.8 min.",Quantitative analysis of PD 0332991 in mouse plasma using automated micro-sample processing and microbore liquid chromatography coupled with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21889427/),min,1.8,32830,DB00592,Piperazine
,27311401,TTP,"In cetuximab-resistant HNSCC, best tumor response was PR in 1 and DC in 5 and median TTP was 112days (range: 28-168).","Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27311401/),d,112,33120,DB00592,Piperazine
,27311401,TTP,"In platin-resistant HNSCC, best tumor response: PR in 1, DC in 3 and median TTP was 112days (range: 28-112).","Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27311401/),d,112,33121,DB00592,Piperazine
,17048974,apparent clearance (CL(itraconazole)),"For itraconazole the apparent clearance (CL(itraconazole)) was 35.5 L/hour, the apparent volume of distribution (V(d(itraconazole)) was 672 L, the absorption rate constant for the capsule formulation was 0.0901 h(-)(1) and for the oral solution formulation was 0.96 h(-1).",Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048974/),[l] / [h],35.5,33603,DB00592,Piperazine
,17048974,apparent volume of distribution (V(d(itraconazole)),"For itraconazole the apparent clearance (CL(itraconazole)) was 35.5 L/hour, the apparent volume of distribution (V(d(itraconazole)) was 672 L, the absorption rate constant for the capsule formulation was 0.0901 h(-)(1) and for the oral solution formulation was 0.96 h(-1).",Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048974/),l,672,33604,DB00592,Piperazine
,17048974,absorption rate constant,"For itraconazole the apparent clearance (CL(itraconazole)) was 35.5 L/hour, the apparent volume of distribution (V(d(itraconazole)) was 672 L, the absorption rate constant for the capsule formulation was 0.0901 h(-)(1) and for the oral solution formulation was 0.96 h(-1).",Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048974/),h(-)(1),0.0901,33605,DB00592,Piperazine
,17048974,absorption rate constant,"For itraconazole the apparent clearance (CL(itraconazole)) was 35.5 L/hour, the apparent volume of distribution (V(d(itraconazole)) was 672 L, the absorption rate constant for the capsule formulation was 0.0901 h(-)(1) and for the oral solution formulation was 0.96 h(-1).",Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048974/),1/[h],0.96,33606,DB00592,Piperazine
,17048974,lag time,The lag time was estimated to be 19.1 minutes and the relative bioavailability between capsules and oral solution (F(rel)) was 0.55.,Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048974/),min,19.1,33607,DB00592,Piperazine
,17048974,relative bioavailability,The lag time was estimated to be 19.1 minutes and the relative bioavailability between capsules and oral solution (F(rel)) was 0.55.,Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048974/),,0.55,33608,DB00592,Piperazine
,17048974,volume of distribution,"For the metabolite, volume of distribution, V(m)/(F . f(m)), and clearance, CL/(F . f(m)), were 10.6L and 5.28 L/h, respectively.",Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048974/),l,10.6,33609,DB00592,Piperazine
,17048974,"clearance, CL/(F . f(m))","For the metabolite, volume of distribution, V(m)/(F . f(m)), and clearance, CL/(F . f(m)), were 10.6L and 5.28 L/h, respectively.",Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048974/),[l] / [h],5.28,33610,DB00592,Piperazine
,17048974,minimum therapeutic trough plasma concentration,More appropriate dosing schedules have been developed for the oral solution and the capsules to secure a minimum therapeutic trough plasma concentration of 0.5 mg/L for these patients.,Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048974/),[mg] / [l],0.5,33611,DB00592,Piperazine
,12445027,"AUC(0, infinity )","AUC(0, infinity ) was increased from 320 to 740 ng ml-1 h (ratio 2.4, 90% CI 2.00, 2.86) for artemether, from 331 to 501 ng ml-1 h (ratio 1.7, 90% CI 1.40, 1.98) for DHA, and from 207 to 333 micro g ml-1 h (ratio 1.7, 90% CI 1.23, 2.21) for lumefantrine in the presence of ketoconazole.",Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445027/),[h·ng] / [ml],320 to 740,33690,DB00592,Piperazine
,12445027,"AUC(0, infinity )","AUC(0, infinity ) was increased from 320 to 740 ng ml-1 h (ratio 2.4, 90% CI 2.00, 2.86) for artemether, from 331 to 501 ng ml-1 h (ratio 1.7, 90% CI 1.40, 1.98) for DHA, and from 207 to 333 micro g ml-1 h (ratio 1.7, 90% CI 1.23, 2.21) for lumefantrine in the presence of ketoconazole.",Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445027/),[h·ng] / [ml],331 to 501,33691,DB00592,Piperazine
,12445027,"AUC(0, infinity )","AUC(0, infinity ) was increased from 320 to 740 ng ml-1 h (ratio 2.4, 90% CI 2.00, 2.86) for artemether, from 331 to 501 ng ml-1 h (ratio 1.7, 90% CI 1.40, 1.98) for DHA, and from 207 to 333 micro g ml-1 h (ratio 1.7, 90% CI 1.23, 2.21) for lumefantrine in the presence of ketoconazole.",Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445027/),[h·μg] / [ml],207 to 333,33692,DB00592,Piperazine
,12445027,terminal elimination half-life,"The terminal elimination half-life was increased for artemether (2.5 vs 1.9 h, 90% CI 1.12, 1.72) and DHA (3.1 vs 2.1 h, 90% CI 0.02, 3.36), but remained unchanged for lumefantrine (88 vs 95 h, 90% CI 0.81, 1.04).",Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445027/),h,2.5,33693,DB00592,Piperazine
,12445027,terminal elimination half-life,"The terminal elimination half-life was increased for artemether (2.5 vs 1.9 h, 90% CI 1.12, 1.72) and DHA (3.1 vs 2.1 h, 90% CI 0.02, 3.36), but remained unchanged for lumefantrine (88 vs 95 h, 90% CI 0.81, 1.04).",Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445027/),h,1.9,33694,DB00592,Piperazine
,12445027,terminal elimination half-life,"The terminal elimination half-life was increased for artemether (2.5 vs 1.9 h, 90% CI 1.12, 1.72) and DHA (3.1 vs 2.1 h, 90% CI 0.02, 3.36), but remained unchanged for lumefantrine (88 vs 95 h, 90% CI 0.81, 1.04).",Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445027/),h,3.1,33695,DB00592,Piperazine
,12445027,terminal elimination half-life,"The terminal elimination half-life was increased for artemether (2.5 vs 1.9 h, 90% CI 1.12, 1.72) and DHA (3.1 vs 2.1 h, 90% CI 0.02, 3.36), but remained unchanged for lumefantrine (88 vs 95 h, 90% CI 0.81, 1.04).",Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445027/),h,2.1,33696,DB00592,Piperazine
,12445027,terminal elimination half-life,"The terminal elimination half-life was increased for artemether (2.5 vs 1.9 h, 90% CI 1.12, 1.72) and DHA (3.1 vs 2.1 h, 90% CI 0.02, 3.36), but remained unchanged for lumefantrine (88 vs 95 h, 90% CI 0.81, 1.04).",Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445027/),h,88,33697,DB00592,Piperazine
,12445027,terminal elimination half-life,"The terminal elimination half-life was increased for artemether (2.5 vs 1.9 h, 90% CI 1.12, 1.72) and DHA (3.1 vs 2.1 h, 90% CI 0.02, 3.36), but remained unchanged for lumefantrine (88 vs 95 h, 90% CI 0.81, 1.04).",Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445027/),h,95,33698,DB00592,Piperazine
,9832363,flow-rate,"The residue was reconstituted in 25% acetonitrile in 10 mM ammonium formate (pH 4.0), and an aliquot was injected onto a BDS Hypersil C18 column at a flow-rate of 0.3 ml/min.",Sensitive liquid chromatographic-mass spectrometric assay for the simultaneous quantitation of nefazodone and its metabolites hydroxynefazodone m-chlorophenylpiperazine and triazole-dione in human plasma using single-ion monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832363/),[ml] / [min],0.3,34253,DB00592,Piperazine
,9832363,extraction recovery,The extraction recovery of the various analytes ranged from 67.3 to 86.5%.,Sensitive liquid chromatographic-mass spectrometric assay for the simultaneous quantitation of nefazodone and its metabolites hydroxynefazodone m-chlorophenylpiperazine and triazole-dione in human plasma using single-ion monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832363/),%,67.3 to 86.5,34254,DB00592,Piperazine
,32897402,volumes of distribution,"The typical volumes of distribution of the conjugated CPT central and free CPT central compartments were 3.16 L (BSV CV%; 18.1%) and 21.1 L (CV%; 79.8%), respectively.",Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32897402/),l,3.16,34257,DB00592,Piperazine
,32897402,volumes of distribution,"The typical volumes of distribution of the conjugated CPT central and free CPT central compartments were 3.16 L (BSV CV%; 18.1%) and 21.1 L (CV%; 79.8%), respectively.",Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32897402/),l,21.1,34258,DB00592,Piperazine
,32897402,half-life,"CPT release from the nanoparticle formulation was characterized via an initial rapid clearance of 5.71 L/h (CV%; 62.6%), which decreased via first-order decay (estimated half-life of 0.307 h) to the steady-state value of 0.0988 L/h (CV%; 33.5%) by ~ 4 h after end of infusion.",Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32897402/),h,0.307,34259,DB00592,Piperazine
,32897402,steady-state,"CPT release from the nanoparticle formulation was characterized via an initial rapid clearance of 5.71 L/h (CV%; 62.6%), which decreased via first-order decay (estimated half-life of 0.307 h) to the steady-state value of 0.0988 L/h (CV%; 33.5%) by ~ 4 h after end of infusion.",Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32897402/),[l] / [h],0.0988,34260,DB00592,Piperazine
,32897402,Renal clearance,Renal clearance of free CPT was 0.874 L/h (CV%; 42.2%).,Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32897402/),[l] / [h],0.874,34261,DB00592,Piperazine
less,19296519,run time,The run time was less than 15 min.,Development of a method for the determination of vardenafil in human plasma by high performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19296519/),min,15,34539,DB00592,Piperazine
,10952769,Ki,"When triazolam is the P450 3A4 substrate and ketoconazole the competitive inhibitor, Ki approximately 1.2 microg/mL in humans.",Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10952769/),[μg] / [ml],1.2,34568,DB00592,Piperazine
,10952769,hepatic extraction,"For example, human terfenadine hepatic extraction goes from 95% in the absence of a competitive inhibitor to 35% in the presence of one (ketoconazole, 200 mg po Q 12 h dosed to steady-state).",Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10952769/),%,95,34569,DB00592,Piperazine
,10952769,hepatic extraction,"For example, human terfenadine hepatic extraction goes from 95% in the absence of a competitive inhibitor to 35% in the presence of one (ketoconazole, 200 mg po Q 12 h dosed to steady-state).",Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10952769/),%,35,34570,DB00592,Piperazine
≥,32688207,Cmin,The aim of this study is to evaluate whether pharmacokinetically (PK)-guided dose increases are feasible in daily clinical practice and result in an improved exposure (Cmin≥1100 ng/mL) and longer progression-free survival (PFS).,Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours - Results from daily clinical practice. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32688207/),[ng] / [ml],1100,34814,DB00592,Piperazine
below,32688207,Cmin,"In 126 patients (75%), Cmin was below the efficacy threshold of 1100 ng/mL.",Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours - Results from daily clinical practice. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32688207/),[ng] / [ml],1100,34815,DB00592,Piperazine
,28411632,limit of detection,"Under optimized conditions, this sandwich ELISA shows a linear detection range from 64 pg mL-1 to 8 ng mL-1, and a limit of detection of approximately 64 pg mL-1 for 100-μL samples.",An ultra-specific and sensitive sandwich ELISA for imatinib using two anti-imatinib antibodies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28411632/),[pg] / [ml],64,34901,DB00592,Piperazine
,10771450,"AUC(0,12 h)","The mean AUC(0,12 h) for ziprasidone was statistically significantly greater in the hepatically impaired subjects compared with the normal subjects (590 ng ml(-1) h vs. 467 ng ml(-1) h, P = 0. 042).",The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771450/),[h·ng] / [ml],590,35535,DB00592,Piperazine
,10771450,"AUC(0,12 h)","The mean AUC(0,12 h) for ziprasidone was statistically significantly greater in the hepatically impaired subjects compared with the normal subjects (590 ng ml(-1) h vs. 467 ng ml(-1) h, P = 0. 042).",The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771450/),[h·ng] / [ml],467,35536,DB00592,Piperazine
,29869515,EE%,"SIL-loaded cubosomes showed EE% ranging between 32.15 and 72.01%, particle size in the range of 150.81-446.02 nm and sustained drug release over 8 h.",Novel in situ gelling vaginal sponges of sildenafil citrate-based cubosomes for uterine targeting. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29869515/),%,32.15 and 72.01,35785,DB00592,Piperazine
,1877979,terminal half-lives,The elimination proceeded biexponentially with terminal half-lives from 14.6 to 43.4 h in volunteers and 12.5-45.0 h in patients.,Pharmacokinetics of almitrine in healthy volunteers and patients with essential hypertension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1877979/),h,14.6 to 43.4,35863,DB00592,Piperazine
,1877979,terminal half-lives,The elimination proceeded biexponentially with terminal half-lives from 14.6 to 43.4 h in volunteers and 12.5-45.0 h in patients.,Pharmacokinetics of almitrine in healthy volunteers and patients with essential hypertension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1877979/),h,12.5-45.0,35864,DB00592,Piperazine
,1877979,distribution volumes,"Further characteristics were large distribution volumes (16.1 +/- 4.5 ml/g in healthy volunteers, 13.9 +/- 4.7 ml/g in patients) and large interindividual variations of all pharmacokinetic parameters by a factor of 2 to 6.",Pharmacokinetics of almitrine in healthy volunteers and patients with essential hypertension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1877979/),[ml] / [g],16.1,35865,DB00592,Piperazine
,1877979,distribution volumes,"Further characteristics were large distribution volumes (16.1 +/- 4.5 ml/g in healthy volunteers, 13.9 +/- 4.7 ml/g in patients) and large interindividual variations of all pharmacokinetic parameters by a factor of 2 to 6.",Pharmacokinetics of almitrine in healthy volunteers and patients with essential hypertension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1877979/),[ml] / [g],13.9,35866,DB00592,Piperazine
,30354005,maximum concentration,"The results demonstrate that after a single, 3 mg/kg oral dose, the maximum concentration for the Vortioxetine hemi-hydrochloride salt is 14.63 ± 4.00 ng/mL, and is attained in 1.00∼4.00 h.",Pharmacokinetic and metabolic studies of Vortioxetine in rats using ultra high performance liquid chromatography with tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30354005/),[ng] / [ml],14.63,35940,DB00592,Piperazine
,30354005,area under the plasma concentration-time curve from time 0 to 24 h,The area under the plasma concentration-time curve from time 0 to 24 h is 67.30 ± 23.78 ng·h·mL-1 .,Pharmacokinetic and metabolic studies of Vortioxetine in rats using ultra high performance liquid chromatography with tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30354005/),[h·ng] / [ml],67.30,35941,DB00592,Piperazine
,26333939,g,Nanoemulsion with average globule size of 100.9 nm and zeta potential of -35.9 ± 1.2 mV was able to penetrate well into the intestinal membrane as confirmed by the laser confocal scanning microscopy and ex vivo intestinal permeability study.,Formulation and evaluation of Itraconazole nanoemulsion for enhanced oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26333939/),,100.9,36034,DB00592,Piperazine
,26333939,zeta potential,Nanoemulsion with average globule size of 100.9 nm and zeta potential of -35.9 ± 1.2 mV was able to penetrate well into the intestinal membrane as confirmed by the laser confocal scanning microscopy and ex vivo intestinal permeability study.,Formulation and evaluation of Itraconazole nanoemulsion for enhanced oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26333939/),mv,-,36035,DB00592,Piperazine
,26333939,zeta potential,Nanoemulsion with average globule size of 100.9 nm and zeta potential of -35.9 ± 1.2 mV was able to penetrate well into the intestinal membrane as confirmed by the laser confocal scanning microscopy and ex vivo intestinal permeability study.,Formulation and evaluation of Itraconazole nanoemulsion for enhanced oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26333939/),mv,35.9,36036,DB00592,Piperazine
,533260,elimination half-life,Mean elimination half-life was 1.26 +/- 0.1 h; the mean elimination constant was 0.95 +/- 0.08 h-1; the mean volume of distribution was 0.16 +/- 0.02 liters/kg of body weight; the mean volume of the central compartment was 0.10 +/- 0.01 liters/kg of body weight; and the mean clearance was 0.09 +/- 0.01 liters/h per kg of body weight.,Pharmacokinetics of intravenous piperacillin in patients undergoing chronic hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/533260/),h,1.26,36362,DB00592,Piperazine
,533260,elimination constant,Mean elimination half-life was 1.26 +/- 0.1 h; the mean elimination constant was 0.95 +/- 0.08 h-1; the mean volume of distribution was 0.16 +/- 0.02 liters/kg of body weight; the mean volume of the central compartment was 0.10 +/- 0.01 liters/kg of body weight; and the mean clearance was 0.09 +/- 0.01 liters/h per kg of body weight.,Pharmacokinetics of intravenous piperacillin in patients undergoing chronic hemodialysis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/533260/),1/[h],0.95,36363,DB00592,Piperazine
,533260,volume of distribution,Mean elimination half-life was 1.26 +/- 0.1 h; the mean elimination constant was 0.95 +/- 0.08 h-1; the mean volume of distribution was 0.16 +/- 0.02 liters/kg of body weight; the mean volume of the central compartment was 0.10 +/- 0.01 liters/kg of body weight; and the mean clearance was 0.09 +/- 0.01 liters/h per kg of body weight.,Pharmacokinetics of intravenous piperacillin in patients undergoing chronic hemodialysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/533260/),[l] / [kg],0.16,36364,DB00592,Piperazine
,533260,volume of the central compartment,Mean elimination half-life was 1.26 +/- 0.1 h; the mean elimination constant was 0.95 +/- 0.08 h-1; the mean volume of distribution was 0.16 +/- 0.02 liters/kg of body weight; the mean volume of the central compartment was 0.10 +/- 0.01 liters/kg of body weight; and the mean clearance was 0.09 +/- 0.01 liters/h per kg of body weight.,Pharmacokinetics of intravenous piperacillin in patients undergoing chronic hemodialysis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/533260/),[l] / [kg],0.10,36365,DB00592,Piperazine
,533260,clearance,Mean elimination half-life was 1.26 +/- 0.1 h; the mean elimination constant was 0.95 +/- 0.08 h-1; the mean volume of distribution was 0.16 +/- 0.02 liters/kg of body weight; the mean volume of the central compartment was 0.10 +/- 0.01 liters/kg of body weight; and the mean clearance was 0.09 +/- 0.01 liters/h per kg of body weight.,Pharmacokinetics of intravenous piperacillin in patients undergoing chronic hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/533260/),[l] / [h·kg],0.09,36366,DB00592,Piperazine
,533260,elimination half-life,Mean elimination half-life while off dialysis of 2.1 h.,Pharmacokinetics of intravenous piperacillin in patients undergoing chronic hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/533260/),h,2.1,36367,DB00592,Piperazine
,31649125,blood clearance,"Intravenous pharmacokinetics of nemiralisib were characterized by low blood clearance (10.0 l/h), long terminal half-life (55 hours), and high volume of distribution at steady state (728 l).",An Innovative Approach to Characterize Clinical ADME and Pharmacokinetics of the Inhaled Drug Nemiralisib Using an Intravenous Microtracer Combined with an Inhaled Dose and an Oral Radiolabel Dose in Healthy Male Subjects. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31649125/),[l] / [h],10.0,36831,DB00592,Piperazine
,31649125,terminal half-life,"Intravenous pharmacokinetics of nemiralisib were characterized by low blood clearance (10.0 l/h), long terminal half-life (55 hours), and high volume of distribution at steady state (728 l).",An Innovative Approach to Characterize Clinical ADME and Pharmacokinetics of the Inhaled Drug Nemiralisib Using an Intravenous Microtracer Combined with an Inhaled Dose and an Oral Radiolabel Dose in Healthy Male Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31649125/),h,55,36832,DB00592,Piperazine
,31649125,volume of distribution at steady state,"Intravenous pharmacokinetics of nemiralisib were characterized by low blood clearance (10.0 l/h), long terminal half-life (55 hours), and high volume of distribution at steady state (728 l).",An Innovative Approach to Characterize Clinical ADME and Pharmacokinetics of the Inhaled Drug Nemiralisib Using an Intravenous Microtracer Combined with an Inhaled Dose and an Oral Radiolabel Dose in Healthy Male Subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31649125/),l,728,36833,DB00592,Piperazine
,31649125,inhaled,Nemiralisib exhibited moderate inhaled and oral bioavailability (38% and 35%) while Flung was 29%.,An Innovative Approach to Characterize Clinical ADME and Pharmacokinetics of the Inhaled Drug Nemiralisib Using an Intravenous Microtracer Combined with an Inhaled Dose and an Oral Radiolabel Dose in Healthy Male Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31649125/),%,38,36834,DB00592,Piperazine
,31649125,oral bioavailability,Nemiralisib exhibited moderate inhaled and oral bioavailability (38% and 35%) while Flung was 29%.,An Innovative Approach to Characterize Clinical ADME and Pharmacokinetics of the Inhaled Drug Nemiralisib Using an Intravenous Microtracer Combined with an Inhaled Dose and an Oral Radiolabel Dose in Healthy Male Subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31649125/),%,38,36835,DB00592,Piperazine
,31649125,oral bioavailability,Nemiralisib exhibited moderate inhaled and oral bioavailability (38% and 35%) while Flung was 29%.,An Innovative Approach to Characterize Clinical ADME and Pharmacokinetics of the Inhaled Drug Nemiralisib Using an Intravenous Microtracer Combined with an Inhaled Dose and an Oral Radiolabel Dose in Healthy Male Subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31649125/),%,35,36836,DB00592,Piperazine
,31649125,Flung,Nemiralisib exhibited moderate inhaled and oral bioavailability (38% and 35%) while Flung was 29%.,An Innovative Approach to Characterize Clinical ADME and Pharmacokinetics of the Inhaled Drug Nemiralisib Using an Intravenous Microtracer Combined with an Inhaled Dose and an Oral Radiolabel Dose in Healthy Male Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31649125/),%,29,36837,DB00592,Piperazine
,31649125,Fabs,"Any swallowed nemiralisib was relatively well absorbed (Fabs, 0.48) with a high fraction escaping gut wall metabolism and low extraction by the liver (Fg and Eh being 0.83 and 0.10, respectively).",An Innovative Approach to Characterize Clinical ADME and Pharmacokinetics of the Inhaled Drug Nemiralisib Using an Intravenous Microtracer Combined with an Inhaled Dose and an Oral Radiolabel Dose in Healthy Male Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31649125/),,0.48,36838,DB00592,Piperazine
,2566337,"maximum almitrine plasma concentration, Cmax","The same trend was observed for the mean maximum almitrine plasma concentration, Cmax, which ranged from 38.9 +/- 11.8 to 286.2 +/- 99.1 ng ml-1 for the 25 and 200 mg dose, respectively.",Single oral dose proportionality pharmacokinetics of almitrine bismesylate in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566337/),[ng] / [ml],38.9,37052,DB00592,Piperazine
,2566337,"maximum almitrine plasma concentration, Cmax","The same trend was observed for the mean maximum almitrine plasma concentration, Cmax, which ranged from 38.9 +/- 11.8 to 286.2 +/- 99.1 ng ml-1 for the 25 and 200 mg dose, respectively.",Single oral dose proportionality pharmacokinetics of almitrine bismesylate in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566337/),[ng] / [ml],286.2,37053,DB00592,Piperazine
,2566337,time to peak,The time to peak was relatively constant regardless of the administered dose and ranged from 2.4 +/- 0.5 h to 2.8 +/- 0.8 h.,Single oral dose proportionality pharmacokinetics of almitrine bismesylate in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566337/),h,2.4,37054,DB00592,Piperazine
,2566337,time to peak,The time to peak was relatively constant regardless of the administered dose and ranged from 2.4 +/- 0.5 h to 2.8 +/- 0.8 h.,Single oral dose proportionality pharmacokinetics of almitrine bismesylate in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566337/),h,2.8,37055,DB00592,Piperazine
,2566337,total body clearance over fraction of dose absorbed,"Further kinetic analysis of the data revealed mean total body clearance over fraction of dose absorbed ranging from 268.2 +/- 132.8 to 436.4 +/- 191.4 ml min-1 for doses 50 and 200mg, respectively.",Single oral dose proportionality pharmacokinetics of almitrine bismesylate in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566337/),[ml] / [min],268.2,37056,DB00592,Piperazine
,2566337,total body clearance over fraction of dose absorbed,"Further kinetic analysis of the data revealed mean total body clearance over fraction of dose absorbed ranging from 268.2 +/- 132.8 to 436.4 +/- 191.4 ml min-1 for doses 50 and 200mg, respectively.",Single oral dose proportionality pharmacokinetics of almitrine bismesylate in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566337/),[ml] / [min],436.4,37057,DB00592,Piperazine
,8227463,elimination t1/2,The elimination t1/2 was prolonged in patients (mean +/- standard deviation; group A: 14.32 +/- 2.30 hours; group B: 13.86 +/- 3.14 hours) in comparison with the values observed in volunteers (9.42 +/- 2.4 hours).,Single-dose pharmacokinetics of cetirizine in patients with chronic liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227463/),h,14.32,37088,DB00592,Piperazine
,8227463,elimination t1/2,The elimination t1/2 was prolonged in patients (mean +/- standard deviation; group A: 14.32 +/- 2.30 hours; group B: 13.86 +/- 3.14 hours) in comparison with the values observed in volunteers (9.42 +/- 2.4 hours).,Single-dose pharmacokinetics of cetirizine in patients with chronic liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227463/),h,13.86,37089,DB00592,Piperazine
,8227463,elimination t1/2,The elimination t1/2 was prolonged in patients (mean +/- standard deviation; group A: 14.32 +/- 2.30 hours; group B: 13.86 +/- 3.14 hours) in comparison with the values observed in volunteers (9.42 +/- 2.4 hours).,Single-dose pharmacokinetics of cetirizine in patients with chronic liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227463/),h,9.42,37090,DB00592,Piperazine
,8227463,apparent oral body clearance,A reduced apparent oral body clearance also was observed in patients (group A: .48 +/- .23 mL/min/kg; group B: .41 +/- .09 mL/min/kg) in comparison with volunteers (.74 +/- .19 mL/min/kg).,Single-dose pharmacokinetics of cetirizine in patients with chronic liver disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227463/),[ml] / [kg·min],.48,37091,DB00592,Piperazine
,8227463,apparent oral body clearance,A reduced apparent oral body clearance also was observed in patients (group A: .48 +/- .23 mL/min/kg; group B: .41 +/- .09 mL/min/kg) in comparison with volunteers (.74 +/- .19 mL/min/kg).,Single-dose pharmacokinetics of cetirizine in patients with chronic liver disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227463/),[ml] / [kg·min],.41,37092,DB00592,Piperazine
,8227463,apparent oral body clearance,A reduced apparent oral body clearance also was observed in patients (group A: .48 +/- .23 mL/min/kg; group B: .41 +/- .09 mL/min/kg) in comparison with volunteers (.74 +/- .19 mL/min/kg).,Single-dose pharmacokinetics of cetirizine in patients with chronic liver disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227463/),[ml] / [kg·min],.74,37093,DB00592,Piperazine
,8227463,cumulative urinary excretion,No differences were observed in the mean cumulative urinary excretion between patients (group A: 69 +/- 15%; group B: 69 +/- 13%) and volunteers (70.7 +/- 7.8%).,Single-dose pharmacokinetics of cetirizine in patients with chronic liver disease. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227463/),%,69,37094,DB00592,Piperazine
,8227463,cumulative urinary excretion,No differences were observed in the mean cumulative urinary excretion between patients (group A: 69 +/- 15%; group B: 69 +/- 13%) and volunteers (70.7 +/- 7.8%).,Single-dose pharmacokinetics of cetirizine in patients with chronic liver disease. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227463/),%,69,37095,DB00592,Piperazine
,8227463,cumulative urinary excretion,No differences were observed in the mean cumulative urinary excretion between patients (group A: 69 +/- 15%; group B: 69 +/- 13%) and volunteers (70.7 +/- 7.8%).,Single-dose pharmacokinetics of cetirizine in patients with chronic liver disease. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227463/),%,70.7,37096,DB00592,Piperazine
,21881249,flow rate,"Chromatographic separation was performed using Pursuit XRS C₁₈ column (50 mm × 2.1 mm, i.d., 3 μm, Varian Inc., CA, U.S.A.) with an isocratic mobile phase consisting of acetonitrile and 10 mM ammonium acetate (90 : 10, v/v) at a flow rate of 0.2 ml/min over a total run time of 2.5 min.",Rapid and sensitive determination of udenafil in plasma by LC-MS/MS for intranasal pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21881249/),[ml] / [min],0.2,37191,DB00592,Piperazine
,21881249,total run time,"Chromatographic separation was performed using Pursuit XRS C₁₈ column (50 mm × 2.1 mm, i.d., 3 μm, Varian Inc., CA, U.S.A.) with an isocratic mobile phase consisting of acetonitrile and 10 mM ammonium acetate (90 : 10, v/v) at a flow rate of 0.2 ml/min over a total run time of 2.5 min.",Rapid and sensitive determination of udenafil in plasma by LC-MS/MS for intranasal pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21881249/),min,2.5,37192,DB00592,Piperazine
,31194563,entrapment efficiency,"The entrapment efficiency of the liposomal fasudil was 95.5 ± 4.5%, and the cumulative release was 93.95 ± 6.22%.","CAR, a Homing Peptide, Prolongs Pulmonary Preferential Vasodilation by Increasing Pulmonary Retention and Reducing Systemic Absorption of Liposomal Fasudil. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31194563/),%,95.5,37461,DB00592,Piperazine
,31194563,cumulative release,"The entrapment efficiency of the liposomal fasudil was 95.5 ± 4.5%, and the cumulative release was 93.95 ± 6.22%.","CAR, a Homing Peptide, Prolongs Pulmonary Preferential Vasodilation by Increasing Pulmonary Retention and Reducing Systemic Absorption of Liposomal Fasudil. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31194563/),%,93.95,37462,DB00592,Piperazine
,31119479,overall PFS6,"For phase II patients, overall PFS6 was 33% and median PFS 4.0 months (95% CI 2.1, 5.7).",Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31119479/),%,33,37646,DB00592,Piperazine
,31119479,PFS,"For phase II patients, overall PFS6 was 33% and median PFS 4.0 months (95% CI 2.1, 5.7).",Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31119479/),month,4,37647,DB00592,Piperazine
,31119479,overall survival (OS),"Median overall survival (OS) was longer in imatinib-treated patients compared with controls (16.6 vs. 8.0 months; HR = 0.64, 95% CI 0.41,1.0, p = 0.049), and longer in patients with 1p/19q-codeleted tumors (19.2 vs. 6.2 months, HR = 0.43, 95% CI 0.21,0.89, p = 0.019).",Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31119479/),month,16.6,37648,DB00592,Piperazine
,31119479,overall survival (OS),"Median overall survival (OS) was longer in imatinib-treated patients compared with controls (16.6 vs. 8.0 months; HR = 0.64, 95% CI 0.41,1.0, p = 0.049), and longer in patients with 1p/19q-codeleted tumors (19.2 vs. 6.2 months, HR = 0.43, 95% CI 0.21,0.89, p = 0.019).",Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31119479/),month,8.0,37649,DB00592,Piperazine
,31119479,overall survival (OS),"Median overall survival (OS) was longer in imatinib-treated patients compared with controls (16.6 vs. 8.0 months; HR = 0.64, 95% CI 0.41,1.0, p = 0.049), and longer in patients with 1p/19q-codeleted tumors (19.2 vs. 6.2 months, HR = 0.43, 95% CI 0.21,0.89, p = 0.019).",Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31119479/),month,19.2,37650,DB00592,Piperazine
,31119479,overall survival (OS),"Median overall survival (OS) was longer in imatinib-treated patients compared with controls (16.6 vs. 8.0 months; HR = 0.64, 95% CI 0.41,1.0, p = 0.049), and longer in patients with 1p/19q-codeleted tumors (19.2 vs. 6.2 months, HR = 0.43, 95% CI 0.21,0.89, p = 0.019).",Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31119479/),month,6.2,37651,DB00592,Piperazine
,31119479,Confirmed response rate,"Confirmed response rate was 3.9% (PR = 1; REGR = 1), with stable disease observed in 52.9%.",Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31119479/),%,3.9,37652,DB00592,Piperazine
,31119479,steady-state imatinib plasma concentration,"At 600 mg/D, mean steady-state imatinib plasma concentration was 2513 ng/ml (95% CI 1831,3195).",Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31119479/),[ng] / [ml],2513,37653,DB00592,Piperazine
,26165421,half-life,CNZ is characterized by short half-life (3-6 h).,Utilization of ionotropic gelation technique for bioavailability enhancement of cinnarizine: in-vitro optimization and in-vivo performance in human. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26165421/),h,3-6,37723,DB00592,Piperazine
,32387328,plasma concentrations,"Geometric mean etonogestrel plasma concentrations and 90% confidence intervals of the mean were 227.5(212.4-243.8), 289.6(251.8-333.0) and 76.4(63.9-91.4) pg/mL among the HIV-negative, dolutegravir- and efavirenz-based ART groups, respectively.",Etonogestrel concentrations among contraceptive implant users in Botswana using and not using dolutegravir-based antiretroviral therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32387328/),[pg] / [ml],227.5,37927,DB00592,Piperazine
,32387328,plasma concentrations,"Geometric mean etonogestrel plasma concentrations and 90% confidence intervals of the mean were 227.5(212.4-243.8), 289.6(251.8-333.0) and 76.4(63.9-91.4) pg/mL among the HIV-negative, dolutegravir- and efavirenz-based ART groups, respectively.",Etonogestrel concentrations among contraceptive implant users in Botswana using and not using dolutegravir-based antiretroviral therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32387328/),[pg] / [ml],289.6,37928,DB00592,Piperazine
,32387328,plasma concentrations,"Geometric mean etonogestrel plasma concentrations and 90% confidence intervals of the mean were 227.5(212.4-243.8), 289.6(251.8-333.0) and 76.4(63.9-91.4) pg/mL among the HIV-negative, dolutegravir- and efavirenz-based ART groups, respectively.",Etonogestrel concentrations among contraceptive implant users in Botswana using and not using dolutegravir-based antiretroviral therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32387328/),[pg] / [ml],76.4,37929,DB00592,Piperazine
,9321512,t1/2,"After iv dosing at 1, 2.5, and 10 mg/kg, the compound had a t1/2 of approximately 2 hr and plasma clearance between 23 and 36 ml/min/kg at all doses and in both species.","Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321512/),h,2,38144,DB00592,Piperazine
,9321512,plasma clearance,"After iv dosing at 1, 2.5, and 10 mg/kg, the compound had a t1/2 of approximately 2 hr and plasma clearance between 23 and 36 ml/min/kg at all doses and in both species.","Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321512/),[ml] / [kg·min],23 and 36,38145,DB00592,Piperazine
,9321512,plasma clearance,The exception was female rats at the 10 mg/kg dose where plasma clearance decreased to 18 ml/min/kg.,"Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321512/),[ml] / [kg·min],18,38146,DB00592,Piperazine
,9321512,Vdss,The Vdss was between 2.0 and 2.6 liters/kg for rats and 3.4 to 4.9 liters/kg for dogs.,"Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321512/),[l] / [kg],2.0 and 2.6,38147,DB00592,Piperazine
,9321512,Vdss,The Vdss was between 2.0 and 2.6 liters/kg for rats and 3.4 to 4.9 liters/kg for dogs.,"Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321512/),[l] / [kg],3.4 to 4.9,38148,DB00592,Piperazine
<,9321512,Cmax,Mean Cmax values were achieved at <1 hr at the low doses (25 mg/kg in rats and 5 mg/kg in dogs) and between 1 and 4 hr at the higher doses (100 mg/kg in rats and 33 mg/kg in dogs).,"Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321512/),h,1,38149,DB00592,Piperazine
,9321512,Cmax,Mean Cmax values were achieved at <1 hr at the low doses (25 mg/kg in rats and 5 mg/kg in dogs) and between 1 and 4 hr at the higher doses (100 mg/kg in rats and 33 mg/kg in dogs).,"Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321512/),h,1 and 4,38150,DB00592,Piperazine
,9321512,Oral bioavailability,"Oral bioavailability was estimated at 14% and 18% for the 5 mg/kg dose in female and male rats, respectively, 41% for the 25 mg/kg dose in male rats and 17% and 41%, respectively, for the 5 and 33 mg/kg doses in dogs.","Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321512/),%,14,38151,DB00592,Piperazine
,9321512,Oral bioavailability,"Oral bioavailability was estimated at 14% and 18% for the 5 mg/kg dose in female and male rats, respectively, 41% for the 25 mg/kg dose in male rats and 17% and 41%, respectively, for the 5 and 33 mg/kg doses in dogs.","Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321512/),%,18,38152,DB00592,Piperazine
,9321512,Oral bioavailability,"Oral bioavailability was estimated at 14% and 18% for the 5 mg/kg dose in female and male rats, respectively, 41% for the 25 mg/kg dose in male rats and 17% and 41%, respectively, for the 5 and 33 mg/kg doses in dogs.","Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321512/),%,41,38153,DB00592,Piperazine
,9321512,Oral bioavailability,"Oral bioavailability was estimated at 14% and 18% for the 5 mg/kg dose in female and male rats, respectively, 41% for the 25 mg/kg dose in male rats and 17% and 41%, respectively, for the 5 and 33 mg/kg doses in dogs.","Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9321512/),%,17,38154,DB00592,Piperazine
,26679246,plasma terminal elimination t1/2,"For dolutegravir, plasma terminal elimination t1/2 to the last measurable concentration (within 216 h) was longer than its t1/2 within the dosing interval (0-24 h): 14.3 h (12.9-15.7 h) versus 23.1 h (19.7-26.6 h); conversely, the terminal elimination t1/2 for elvitegravir was lower than its t1/2 within the dosing interval (0-24 h): 10.8 h (9.7-13.0 h) versus 5.2 h (4.7-6.1 h).",Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26679246/),h,14.3,38648,DB00592,Piperazine
,26679246,plasma terminal elimination t1/2,"For dolutegravir, plasma terminal elimination t1/2 to the last measurable concentration (within 216 h) was longer than its t1/2 within the dosing interval (0-24 h): 14.3 h (12.9-15.7 h) versus 23.1 h (19.7-26.6 h); conversely, the terminal elimination t1/2 for elvitegravir was lower than its t1/2 within the dosing interval (0-24 h): 10.8 h (9.7-13.0 h) versus 5.2 h (4.7-6.1 h).",Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26679246/),h,23.1,38649,DB00592,Piperazine
,26679246,terminal elimination t1/2,"For dolutegravir, plasma terminal elimination t1/2 to the last measurable concentration (within 216 h) was longer than its t1/2 within the dosing interval (0-24 h): 14.3 h (12.9-15.7 h) versus 23.1 h (19.7-26.6 h); conversely, the terminal elimination t1/2 for elvitegravir was lower than its t1/2 within the dosing interval (0-24 h): 10.8 h (9.7-13.0 h) versus 5.2 h (4.7-6.1 h).",Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26679246/),h,10.8,38650,DB00592,Piperazine
,26679246,terminal elimination t1/2,"For dolutegravir, plasma terminal elimination t1/2 to the last measurable concentration (within 216 h) was longer than its t1/2 within the dosing interval (0-24 h): 14.3 h (12.9-15.7 h) versus 23.1 h (19.7-26.6 h); conversely, the terminal elimination t1/2 for elvitegravir was lower than its t1/2 within the dosing interval (0-24 h): 10.8 h (9.7-13.0 h) versus 5.2 h (4.7-6.1 h).",Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26679246/),h,5.2,38651,DB00592,Piperazine
,26679246,IC90,Dolutegravir concentrations were above the protein-adjusted (PA) IC90 (64 ng/mL) in 100% of subjects after 36 and 48 h and in 94% after 60 and 72 h.,Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26679246/),[ng] / [ml],64,38652,DB00592,Piperazine
above,26679246,IC95,"Elvitegravir concentrations were above the PA IC95 (45 ng/mL) in 100% of subjects at 24 h, 65% at 36 h but 0% after 48 h.",Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26679246/),[ng] / [ml],45,38653,DB00592,Piperazine
,31860112,AUC,"Regimen 6 involved 5 mg doses with a 48 h interval from Day 1-20, increasing to 5 mg once daily on Week 3, yielding AUC and Ctrough values of 37.2 mg·h/L and 1.3 mg/L, respectively.",Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31860112/),[h·mg] / [l],37.2,38699,DB00592,Piperazine
,31860112,Ctrough,"Regimen 6 involved 5 mg doses with a 48 h interval from Day 1-20, increasing to 5 mg once daily on Week 3, yielding AUC and Ctrough values of 37.2 mg·h/L and 1.3 mg/L, respectively.",Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31860112/),[mg] / [l],1.3,38700,DB00592,Piperazine
,9757147,clearance,"For trial B versus trial A, alprazolam clearance was reduced (27 versus 86 mL/min; P < .002) and apparent elimination half-life (t1/2) prolonged (59 versus 15 hours; P < .03), whereas peak plasma concentration (Cmax) was only slightly increased (16.1 versus 14.7 ng/mL).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),[ml] / [min],27,38781,DB00592,Piperazine
,9757147,clearance,"For trial B versus trial A, alprazolam clearance was reduced (27 versus 86 mL/min; P < .002) and apparent elimination half-life (t1/2) prolonged (59 versus 15 hours; P < .03), whereas peak plasma concentration (Cmax) was only slightly increased (16.1 versus 14.7 ng/mL).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),[ml] / [min],86,38782,DB00592,Piperazine
,9757147,apparent elimination half-life (t1/2),"For trial B versus trial A, alprazolam clearance was reduced (27 versus 86 mL/min; P < .002) and apparent elimination half-life (t1/2) prolonged (59 versus 15 hours; P < .03), whereas peak plasma concentration (Cmax) was only slightly increased (16.1 versus 14.7 ng/mL).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),h,59,38783,DB00592,Piperazine
,9757147,apparent elimination half-life (t1/2),"For trial B versus trial A, alprazolam clearance was reduced (27 versus 86 mL/min; P < .002) and apparent elimination half-life (t1/2) prolonged (59 versus 15 hours; P < .03), whereas peak plasma concentration (Cmax) was only slightly increased (16.1 versus 14.7 ng/mL).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),h,15,38784,DB00592,Piperazine
,9757147,peak plasma concentration (Cmax),"For trial B versus trial A, alprazolam clearance was reduced (27 versus 86 mL/min; P < .002) and apparent elimination half-life (t1/2) prolonged (59 versus 15 hours; P < .03), whereas peak plasma concentration (Cmax) was only slightly increased (16.1 versus 14.7 ng/mL).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),[ng] / [ml],16.1,38785,DB00592,Piperazine
,9757147,peak plasma concentration (Cmax),"For trial B versus trial A, alprazolam clearance was reduced (27 versus 86 mL/min; P < .002) and apparent elimination half-life (t1/2) prolonged (59 versus 15 hours; P < .03), whereas peak plasma concentration (Cmax) was only slightly increased (16.1 versus 14.7 ng/mL).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),[ng] / [ml],14.7,38786,DB00592,Piperazine
,9757147,clearance,"For trial D versus trial C, triazolam clearance was reduced (40 versus 444 mL/min; P < .002), t1/2 was prolonged (18.3 versus 3.0 hours; P < .01), and Cmax was increased (2.6 versus 5.4 ng/mL; P < .001).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),[ml] / [min],40,38787,DB00592,Piperazine
,9757147,clearance,"For trial D versus trial C, triazolam clearance was reduced (40 versus 444 mL/min; P < .002), t1/2 was prolonged (18.3 versus 3.0 hours; P < .01), and Cmax was increased (2.6 versus 5.4 ng/mL; P < .001).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),[ml] / [min],444,38788,DB00592,Piperazine
,9757147,t1/2,"For trial D versus trial C, triazolam clearance was reduced (40 versus 444 mL/min; P < .002), t1/2 was prolonged (18.3 versus 3.0 hours; P < .01), and Cmax was increased (2.6 versus 5.4 ng/mL; P < .001).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),h,18.3,38789,DB00592,Piperazine
,9757147,t1/2,"For trial D versus trial C, triazolam clearance was reduced (40 versus 444 mL/min; P < .002), t1/2 was prolonged (18.3 versus 3.0 hours; P < .01), and Cmax was increased (2.6 versus 5.4 ng/mL; P < .001).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),h,3.0,38790,DB00592,Piperazine
,9757147,Cmax,"For trial D versus trial C, triazolam clearance was reduced (40 versus 444 mL/min; P < .002), t1/2 was prolonged (18.3 versus 3.0 hours; P < .01), and Cmax was increased (2.6 versus 5.4 ng/mL; P < .001).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),[ng] / [ml],2.6,38791,DB00592,Piperazine
,9757147,Cmax,"For trial D versus trial C, triazolam clearance was reduced (40 versus 444 mL/min; P < .002), t1/2 was prolonged (18.3 versus 3.0 hours; P < .01), and Cmax was increased (2.6 versus 5.4 ng/mL; P < .001).",Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757147/),[ng] / [ml],5.4,38792,DB00592,Piperazine
,9145377,systemic clearance,"In the three doses examined, systemic clearance and steady-state volume of distribution of DW-116, calculated by model-independent methods, were in the range 0.17 approximately 0.23 L/h/kg and 2.90 approximately 4.44 L/kg, respectively.","Pharmacokinetics of 1-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-1- piperazinyl)-1,4-dihydro-4-oxoquinolone-3-carboxylic acid hydrochloride (DW-116), a new quinolone antibiotic in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145377/),[l] / [h·kg],0.17 approximately 0.23,38861,DB00592,Piperazine
,9145377,steady-state volume of distribution,"In the three doses examined, systemic clearance and steady-state volume of distribution of DW-116, calculated by model-independent methods, were in the range 0.17 approximately 0.23 L/h/kg and 2.90 approximately 4.44 L/kg, respectively.","Pharmacokinetics of 1-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-1- piperazinyl)-1,4-dihydro-4-oxoquinolone-3-carboxylic acid hydrochloride (DW-116), a new quinolone antibiotic in rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145377/),[l] / [kg],2.90 approximately 4.44,38862,DB00592,Piperazine
,9145377,percent bioavailability,"When DW-116 was given orally at doses of 4, 20, or 200 mg/kg, the AUC values were nearly identical to those following iv administration, indicating an almost complete absorption (i.e., the percent bioavailability was 90.0 for 4 mg/kg, 99.0 for 20 mg/kg, and 98.3 for 200 mg/kg) in the dose range examined.","Pharmacokinetics of 1-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-1- piperazinyl)-1,4-dihydro-4-oxoquinolone-3-carboxylic acid hydrochloride (DW-116), a new quinolone antibiotic in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145377/),,90.0,38863,DB00592,Piperazine
,9145377,percent bioavailability,"When DW-116 was given orally at doses of 4, 20, or 200 mg/kg, the AUC values were nearly identical to those following iv administration, indicating an almost complete absorption (i.e., the percent bioavailability was 90.0 for 4 mg/kg, 99.0 for 20 mg/kg, and 98.3 for 200 mg/kg) in the dose range examined.","Pharmacokinetics of 1-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-1- piperazinyl)-1,4-dihydro-4-oxoquinolone-3-carboxylic acid hydrochloride (DW-116), a new quinolone antibiotic in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145377/),,99.0,38864,DB00592,Piperazine
,9145377,percent bioavailability,"When DW-116 was given orally at doses of 4, 20, or 200 mg/kg, the AUC values were nearly identical to those following iv administration, indicating an almost complete absorption (i.e., the percent bioavailability was 90.0 for 4 mg/kg, 99.0 for 20 mg/kg, and 98.3 for 200 mg/kg) in the dose range examined.","Pharmacokinetics of 1-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-1- piperazinyl)-1,4-dihydro-4-oxoquinolone-3-carboxylic acid hydrochloride (DW-116), a new quinolone antibiotic in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145377/),,98.3,38865,DB00592,Piperazine
,9145377,Absolute percent bioavailabilities,Absolute percent bioavailabilities of ciprofloxacin (69.9%) and rufloxacin (84.9%) were smaller than that obtained for DW-116 (99.0%).,"Pharmacokinetics of 1-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-1- piperazinyl)-1,4-dihydro-4-oxoquinolone-3-carboxylic acid hydrochloride (DW-116), a new quinolone antibiotic in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145377/),%,69.9,38866,DB00592,Piperazine
,9145377,Absolute percent bioavailabilities,Absolute percent bioavailabilities of ciprofloxacin (69.9%) and rufloxacin (84.9%) were smaller than that obtained for DW-116 (99.0%).,"Pharmacokinetics of 1-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-1- piperazinyl)-1,4-dihydro-4-oxoquinolone-3-carboxylic acid hydrochloride (DW-116), a new quinolone antibiotic in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145377/),%,84.9,38867,DB00592,Piperazine
,9145377,Absolute percent bioavailabilities,Absolute percent bioavailabilities of ciprofloxacin (69.9%) and rufloxacin (84.9%) were smaller than that obtained for DW-116 (99.0%).,"Pharmacokinetics of 1-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-1- piperazinyl)-1,4-dihydro-4-oxoquinolone-3-carboxylic acid hydrochloride (DW-116), a new quinolone antibiotic in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145377/),%,99.0,38868,DB00592,Piperazine
,21903894,onset of action,"However, the onset of action of meclizine was about 1 hour for the treatment of motion sickness and vertigo.",Meclizine metabolism and pharmacokinetics: formulation on its absorption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21903894/),h,1,38979,DB00592,Piperazine
,28219799,recovery,"The mean recovery of RPV, DTG and EVG were 101%, 87% and 112.3% respectively.","UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28219799/),%,101,38982,DB00592,Piperazine
,28219799,recovery,"The mean recovery of RPV, DTG and EVG were 101%, 87% and 112.3% respectively.","UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28219799/),%,87,38983,DB00592,Piperazine
,28219799,recovery,"The mean recovery of RPV, DTG and EVG were 101%, 87% and 112.3% respectively.","UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28219799/),%,112.3,38984,DB00592,Piperazine
,10771458,"AUC(0,infinity)","Co-administration of ziprasidone with ketoconazole was associated with a modest increase in ziprasidone exposure; mean ziprasidone AUC(0,infinity) increased by 33%, from 899 ng ml(-1) h with placebo to 1199 ng ml(-1) h with ketoconazole.",The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771458/),[h·ng] / [ml],899,39121,DB00592,Piperazine
,10771458,"AUC(0,infinity)","Co-administration of ziprasidone with ketoconazole was associated with a modest increase in ziprasidone exposure; mean ziprasidone AUC(0,infinity) increased by 33%, from 899 ng ml(-1) h with placebo to 1199 ng ml(-1) h with ketoconazole.",The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771458/),[h·ng] / [ml],1199,39122,DB00592,Piperazine
,10771458,Cmax,"Mean Cmax increased by 34%, from 89 ng ml(-1) to 119 ng ml(-1), respectively.",The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771458/),[ng] / [ml],89,39123,DB00592,Piperazine
,10771458,Cmax,"Mean Cmax increased by 34%, from 89 ng ml(-1) to 119 ng ml(-1), respectively.",The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771458/),[ng] / [ml],119,39124,DB00592,Piperazine
,6476816,Oral bioavailability,Oral bioavailability was 93.1 +/- 11% (mean +/- standard error).,Single- and multiple-dose pharmacokinetics of pipemidic acid in normal human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6476816/),%,93.1,39190,DB00592,Piperazine
,6476816,saliva/serum ratio,"Excretion of pipemidic acid in saliva was negligible, the saliva/serum ratio being about 0.32.",Single- and multiple-dose pharmacokinetics of pipemidic acid in normal human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6476816/),,0.32,39191,DB00592,Piperazine
,6476816,peak drug concentration,"At steady state after the twice-daily administration of a 500-mg tablet, which is a recommended dosage regimen, a peak drug concentration in serum of 4.3 +/- 0.5 micrograms/ml was attained in 1.2 +/- 0.1 h.",Single- and multiple-dose pharmacokinetics of pipemidic acid in normal human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6476816/),[μg] / [ml],4.3,39192,DB00592,Piperazine
,6476816,apparent volume of distribution,"The apparent volume of distribution was 1.9 +/- 0.2 liters/kg, and the elimination half-life was 3.4 +/- 0.2 h.",Single- and multiple-dose pharmacokinetics of pipemidic acid in normal human volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6476816/),[l] / [kg],1.9,39193,DB00592,Piperazine
,6476816,elimination half-life,"The apparent volume of distribution was 1.9 +/- 0.2 liters/kg, and the elimination half-life was 3.4 +/- 0.2 h.",Single- and multiple-dose pharmacokinetics of pipemidic acid in normal human volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6476816/),h,3.4,39194,DB00592,Piperazine
,6476816,renal clearance,"The renal clearance was 4.3 +/- 0.7 ml/min per kg, and the total clearance was 6.3 +/- 0.5 ml/min per kg.",Single- and multiple-dose pharmacokinetics of pipemidic acid in normal human volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6476816/),[ml] / [kg·min],4.3,39195,DB00592,Piperazine
,6476816,total clearance,"The renal clearance was 4.3 +/- 0.7 ml/min per kg, and the total clearance was 6.3 +/- 0.5 ml/min per kg.",Single- and multiple-dose pharmacokinetics of pipemidic acid in normal human volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6476816/),[ml] / [kg·min],6.3,39196,DB00592,Piperazine
,6476816,minimum concentration,"Despite a considerable water load, the minimum concentration in urine at the end of a dosing interval averaged 100 micrograms/ml, which widely exceeds the known MIC of pipemidic acid against bacteria commonly causing urinary tract infections.",Single- and multiple-dose pharmacokinetics of pipemidic acid in normal human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6476816/),[μg] / [ml],100,39197,DB00592,Piperazine
,9591931,dose-corrected,"During itraconazole treatment, or 4 days after, alpha-hydroxymetabolite the dose-corrected area under the plasma midazolam concentration time curve (AUC0-infinity) was 8- or 2.6-fold larger than that before itraconazole (i.e. 1707 or 695 versus 277 ng x h x ml(-1)), respectively.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],1707,39239,DB00592,Piperazine
,9591931,dose-corrected,"During itraconazole treatment, or 4 days after, alpha-hydroxymetabolite the dose-corrected area under the plasma midazolam concentration time curve (AUC0-infinity) was 8- or 2.6-fold larger than that before itraconazole (i.e. 1707 or 695 versus 277 ng x h x ml(-1)), respectively.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],695,39240,DB00592,Piperazine
,9591931,dose-corrected,"During itraconazole treatment, or 4 days after, alpha-hydroxymetabolite the dose-corrected area under the plasma midazolam concentration time curve (AUC0-infinity) was 8- or 2.6-fold larger than that before itraconazole (i.e. 1707 or 695 versus 277 ng x h x ml(-1)), respectively.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],277,39241,DB00592,Piperazine
,9591931,area under the plasma midazolam concentration time curve (AUC0-infinity),"During itraconazole treatment, or 4 days after, alpha-hydroxymetabolite the dose-corrected area under the plasma midazolam concentration time curve (AUC0-infinity) was 8- or 2.6-fold larger than that before itraconazole (i.e. 1707 or 695 versus 277 ng x h x ml(-1)), respectively.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],1707,39242,DB00592,Piperazine
,9591931,area under the plasma midazolam concentration time curve (AUC0-infinity),"During itraconazole treatment, or 4 days after, alpha-hydroxymetabolite the dose-corrected area under the plasma midazolam concentration time curve (AUC0-infinity) was 8- or 2.6-fold larger than that before itraconazole (i.e. 1707 or 695 versus 277 ng x h x ml(-1)), respectively.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],695,39243,DB00592,Piperazine
,9591931,area under the plasma midazolam concentration time curve (AUC0-infinity),"During itraconazole treatment, or 4 days after, alpha-hydroxymetabolite the dose-corrected area under the plasma midazolam concentration time curve (AUC0-infinity) was 8- or 2.6-fold larger than that before itraconazole (i.e. 1707 or 695 versus 277 ng x h x ml(-1)), respectively.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],277,39244,DB00592,Piperazine
,9591931,AUC0-infinity,"One day after rifampicin treatment, the AUC0-infinity of midazolam was 2.3% (i.e. 4.4 ng x h x ml(-1)) of the before-treatment value and only 0.26% of its value during itraconazole treatment; 4 days after rifampicin, the AUC0-infinity was still only 13% (i.e. 27.1 ng x h x ml(-1)) of the before-treatment value.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],4.4,39245,DB00592,Piperazine
,9591931,AUC0-infinity,"One day after rifampicin treatment, the AUC0-infinity of midazolam was 2.3% (i.e. 4.4 ng x h x ml(-1)) of the before-treatment value and only 0.26% of its value during itraconazole treatment; 4 days after rifampicin, the AUC0-infinity was still only 13% (i.e. 27.1 ng x h x ml(-1)) of the before-treatment value.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),%,13,39246,DB00592,Piperazine
,9591931,AUC0-infinity,"One day after rifampicin treatment, the AUC0-infinity of midazolam was 2.3% (i.e. 4.4 ng x h x ml(-1)) of the before-treatment value and only 0.26% of its value during itraconazole treatment; 4 days after rifampicin, the AUC0-infinity was still only 13% (i.e. 27.1 ng x h x ml(-1)) of the before-treatment value.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],27.1,39247,DB00592,Piperazine
,30273837,absolute bioavailability,"SM-1 had good absorption in the body, with 59.01% of the absolute bioavailability in rats and 55.63% of that in dogs.","Pharmacokinetics, tissue distribution and plasma protein binding study of SM-1, a novel PAC-1 derivative. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30273837/),%,59.01,39356,DB00592,Piperazine
over,31740991,target plasma concentration,We developed a pharmacokinetic model of intravenous sildenafil in newborns with congenital diaphragmatic hernia (CDH) to achieve a target plasma concentration of over 50 μg/l.,Pharmacokinetic modeling of intravenous sildenafil in newborns with congenital diaphragmatic hernia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31740991/),[μg] / [l],50,39502,DB00592,Piperazine
,7871095,elimination half-life (t 1/2),Its disappearance from brain and plasma was almost parallel with a comparable elimination half-life (t 1/2) of about 2 h.,"Brain uptake and distribution of the potential memory enhancer CL 275,838 and its main metabolites in rats: relationship between brain concentrations and in vitro potencies on neurotransmitter mechanisms. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7871095/),h,2,39743,DB00592,Piperazine
,7871095,Cmax,"Metabolite II entered the brain and equilibrated with plasma more slowly than the parent compound, achieving mean Cmax (0.2 microM) within 3 h of dosing.","Brain uptake and distribution of the potential memory enhancer CL 275,838 and its main metabolites in rats: relationship between brain concentrations and in vitro potencies on neurotransmitter mechanisms. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7871095/),μM,0.2,39744,DB00592,Piperazine
,7871095,Cmax,Metabolite IV was rapidly detected in rat brain but hardly amounted to 10% (0.1 microM) of the parent compound Cmax (1 microM).,"Brain uptake and distribution of the potential memory enhancer CL 275,838 and its main metabolites in rats: relationship between brain concentrations and in vitro potencies on neurotransmitter mechanisms. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7871095/),μM,1,39745,DB00592,Piperazine
above,19737946,total drug trough concentrations,"On the 50-mg dose across all schedules, 79% of PK-evaluable patients achieved total drug trough concentrations above the target concentration (50 ng/mL) within 14 days of dosing.","Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19737946/),[ng] / [ml],50,39980,DB00592,Piperazine
,28238945,brain/plasma ratio,"Following intravenous administration, the brain/plasma ratio for imatinib was calculated to be 2% and remained at this ratio for 30min.",Nose-to-brain transport of imatinib mesylate: A pharmacokinetic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28238945/),%,2,40263,DB00592,Piperazine
,28238945,brain/plasma ratio,"The brain/plasma ratio following intranasal administration, however, was found to be 5.3% and remained at this ratio for up to 90min.",Nose-to-brain transport of imatinib mesylate: A pharmacokinetic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28238945/),%,5.3,40264,DB00592,Piperazine
,11744613,K(i),"The K(i) values of KTZ for MDZ 1'-hydroxylation and 4-hydroxylation were 0.0237 and 0.111 microM, respectively, indicating that KTZ extensively inhibits hepatic CYP3A activity in dogs.","Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in beagle dogs. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11744613/),μM,0.0237,40339,DB00592,Piperazine
,11744613,K(i),"The K(i) values of KTZ for MDZ 1'-hydroxylation and 4-hydroxylation were 0.0237 and 0.111 microM, respectively, indicating that KTZ extensively inhibits hepatic CYP3A activity in dogs.","Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in beagle dogs. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11744613/),μM,0.111,40340,DB00592,Piperazine
,14605865,excretion,All subjects demonstrated a marked induction of hepatic microsomal CYP3A analyzed by the excretion ratio of 6beta-hydroxycortisol to cortisol from a mean baseline concentration of 5.6 U to 50.5 U.,"Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14605865/),,50,40758,DB00592,Piperazine
<,16231965,time to reach peak serum concentration [tmax],"The pharmacokinetics of intramuscular ziprasidone include rapid attainment of therapeutic drug level (time to reach peak serum concentration [tmax]<or=60 minutes postdose), a mean terminal elimination half-life ranging from 2 to 5 hours, bioavailability of approximately 100%, exposure to drug that increases in a dose-related manner and little drug accumulation even after 3 days of repeated intramuscular administration.",Pharmacokinetics and therapeutics of acute intramuscular ziprasidone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231965/),min,60,41350,DB00592,Piperazine
,16231965,terminal elimination half-life,"The pharmacokinetics of intramuscular ziprasidone include rapid attainment of therapeutic drug level (time to reach peak serum concentration [tmax]<or=60 minutes postdose), a mean terminal elimination half-life ranging from 2 to 5 hours, bioavailability of approximately 100%, exposure to drug that increases in a dose-related manner and little drug accumulation even after 3 days of repeated intramuscular administration.",Pharmacokinetics and therapeutics of acute intramuscular ziprasidone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231965/),h,2 to 5,41351,DB00592,Piperazine
,16231965,bioavailability,"The pharmacokinetics of intramuscular ziprasidone include rapid attainment of therapeutic drug level (time to reach peak serum concentration [tmax]<or=60 minutes postdose), a mean terminal elimination half-life ranging from 2 to 5 hours, bioavailability of approximately 100%, exposure to drug that increases in a dose-related manner and little drug accumulation even after 3 days of repeated intramuscular administration.",Pharmacokinetics and therapeutics of acute intramuscular ziprasidone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231965/),%,100,41352,DB00592,Piperazine
,23395659,IC50 ratio,"Compound 6m and 6q showed high selectivity over hERG channel (IC50 ratio of hERG/α1G6m=8.5, 6q=18.38) and they were subjected to measure pharmacokinetics profiles.",Synthesis and biological evaluation of 1-(2-hydroxy-3-phenyloxypropyl)piperazine derivatives as T-type calcium channel blockers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395659/),,8.5,41875,DB00592,Piperazine
,23395659,IC50 ratio,"Compound 6m and 6q showed high selectivity over hERG channel (IC50 ratio of hERG/α1G6m=8.5, 6q=18.38) and they were subjected to measure pharmacokinetics profiles.",Synthesis and biological evaluation of 1-(2-hydroxy-3-phenyloxypropyl)piperazine derivatives as T-type calcium channel blockers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395659/),,18.38,41876,DB00592,Piperazine
,1827622,clearance,"The addition of ketoconazole did not significantly change the clearance (96 +/- 11 versus 90 +/- 11 ml/hr/kg), mean residence time (4.29 +/- 0.43 versus 4.45 +/- 0.59 hours), volume of distribution (0.41 +/- 0.02 versus 0.40 +/- 0.02 L/kg), or plasma protein binding characteristics of prednisolone.",Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827622/),[ml] / [h·kg],96,42037,DB00592,Piperazine
,1827622,clearance,"The addition of ketoconazole did not significantly change the clearance (96 +/- 11 versus 90 +/- 11 ml/hr/kg), mean residence time (4.29 +/- 0.43 versus 4.45 +/- 0.59 hours), volume of distribution (0.41 +/- 0.02 versus 0.40 +/- 0.02 L/kg), or plasma protein binding characteristics of prednisolone.",Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827622/),[ml] / [h·kg],90,42038,DB00592,Piperazine
,1827622,mean residence time,"The addition of ketoconazole did not significantly change the clearance (96 +/- 11 versus 90 +/- 11 ml/hr/kg), mean residence time (4.29 +/- 0.43 versus 4.45 +/- 0.59 hours), volume of distribution (0.41 +/- 0.02 versus 0.40 +/- 0.02 L/kg), or plasma protein binding characteristics of prednisolone.",Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827622/),h,4.29,42039,DB00592,Piperazine
,1827622,mean residence time,"The addition of ketoconazole did not significantly change the clearance (96 +/- 11 versus 90 +/- 11 ml/hr/kg), mean residence time (4.29 +/- 0.43 versus 4.45 +/- 0.59 hours), volume of distribution (0.41 +/- 0.02 versus 0.40 +/- 0.02 L/kg), or plasma protein binding characteristics of prednisolone.",Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827622/),h,4.45,42040,DB00592,Piperazine
,1827622,volume of distribution,"The addition of ketoconazole did not significantly change the clearance (96 +/- 11 versus 90 +/- 11 ml/hr/kg), mean residence time (4.29 +/- 0.43 versus 4.45 +/- 0.59 hours), volume of distribution (0.41 +/- 0.02 versus 0.40 +/- 0.02 L/kg), or plasma protein binding characteristics of prednisolone.",Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827622/),[l] / [kg],0.41,42041,DB00592,Piperazine
,1827622,volume of distribution,"The addition of ketoconazole did not significantly change the clearance (96 +/- 11 versus 90 +/- 11 ml/hr/kg), mean residence time (4.29 +/- 0.43 versus 4.45 +/- 0.59 hours), volume of distribution (0.41 +/- 0.02 versus 0.40 +/- 0.02 L/kg), or plasma protein binding characteristics of prednisolone.",Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827622/),[l] / [kg],0.40,42042,DB00592,Piperazine
,33550391,clearance,"Typical population estimates for clearance, absorption rate constant, central volume, peripheral volume and mean absorption transit time were 0.713 L/h, 1.68 h-1, 13.2 L, 5.73 L and 1.18 h, respectively.",Dolutegravir pharmacokinetics during co-administration with either artemether/lumefantrine or artesunate/amodiaquine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33550391/),[l] / [h],0.713,42067,DB00592,Piperazine
,33550391,IC90,Simulations showed that simulated trough concentrations of dolutegravir alone or in combination with artemether/lumefantrine or artesunate/amodiaquine are maintained above the dolutegravir protein-adjusted IC90 of 0.064 mg/L for more than 99% of the individuals.,Dolutegravir pharmacokinetics during co-administration with either artemether/lumefantrine or artesunate/amodiaquine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33550391/),[mg] / [l],0.064,42068,DB00592,Piperazine
,12765244,T(1/2)abs,"The T(1/2)abs, T(1/2)beta, AUC, Tmax and Cmax in the maternal plasma were approximately 6 min, 13.3 h, 1620 microg h/ml, 0.5 h and 136 microg/ml, respectively.",Transplacental pharmacokinetics of the new fluoroquinolone DW-116 in pregnant rats. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12765244/),min,6,42089,DB00592,Piperazine
,12765244,T(1/2)beta,"The T(1/2)abs, T(1/2)beta, AUC, Tmax and Cmax in the maternal plasma were approximately 6 min, 13.3 h, 1620 microg h/ml, 0.5 h and 136 microg/ml, respectively.",Transplacental pharmacokinetics of the new fluoroquinolone DW-116 in pregnant rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12765244/),h,13.3,42090,DB00592,Piperazine
,12765244,T(1/2)beta,"The T(1/2)abs, T(1/2)beta, AUC, Tmax and Cmax in the maternal plasma were approximately 6 min, 13.3 h, 1620 microg h/ml, 0.5 h and 136 microg/ml, respectively.",Transplacental pharmacokinetics of the new fluoroquinolone DW-116 in pregnant rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12765244/),[h·μg] / [ml],1620,42091,DB00592,Piperazine
,12765244,T(1/2)beta,"The T(1/2)abs, T(1/2)beta, AUC, Tmax and Cmax in the maternal plasma were approximately 6 min, 13.3 h, 1620 microg h/ml, 0.5 h and 136 microg/ml, respectively.",Transplacental pharmacokinetics of the new fluoroquinolone DW-116 in pregnant rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12765244/),h,0.5,42092,DB00592,Piperazine
,12765244,Tmax,"The T(1/2)abs, T(1/2)beta, AUC, Tmax and Cmax in the maternal plasma were approximately 6 min, 13.3 h, 1620 microg h/ml, 0.5 h and 136 microg/ml, respectively.",Transplacental pharmacokinetics of the new fluoroquinolone DW-116 in pregnant rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12765244/),h,13.3,42093,DB00592,Piperazine
,12765244,Cmax,"The T(1/2)abs, T(1/2)beta, AUC, Tmax and Cmax in the maternal plasma were approximately 6 min, 13.3 h, 1620 microg h/ml, 0.5 h and 136 microg/ml, respectively.",Transplacental pharmacokinetics of the new fluoroquinolone DW-116 in pregnant rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12765244/),[μg] / [ml],136,42094,DB00592,Piperazine
,12765244,T(1/2)abs,"In the amniotic fluid of maternal uterus, the T(1/2)abs, T(1/2)beta, AUC, Tmax and Cmax were approximately 1.3 h, 9.3 h, 2508 microg h/ml, 4.4 h, and 135 microg/ ml, respectively.",Transplacental pharmacokinetics of the new fluoroquinolone DW-116 in pregnant rats. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12765244/),h,1.3,42095,DB00592,Piperazine
,12765244,T(1/2)beta,"In the amniotic fluid of maternal uterus, the T(1/2)abs, T(1/2)beta, AUC, Tmax and Cmax were approximately 1.3 h, 9.3 h, 2508 microg h/ml, 4.4 h, and 135 microg/ ml, respectively.",Transplacental pharmacokinetics of the new fluoroquinolone DW-116 in pregnant rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12765244/),h,9.3,42096,DB00592,Piperazine
,12765244,T(1/2)beta,"In the amniotic fluid of maternal uterus, the T(1/2)abs, T(1/2)beta, AUC, Tmax and Cmax were approximately 1.3 h, 9.3 h, 2508 microg h/ml, 4.4 h, and 135 microg/ ml, respectively.",Transplacental pharmacokinetics of the new fluoroquinolone DW-116 in pregnant rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12765244/),[h·μg] / [ml],2508,42097,DB00592,Piperazine
,12765244,T(1/2)beta,"In the amniotic fluid of maternal uterus, the T(1/2)abs, T(1/2)beta, AUC, Tmax and Cmax were approximately 1.3 h, 9.3 h, 2508 microg h/ml, 4.4 h, and 135 microg/ ml, respectively.",Transplacental pharmacokinetics of the new fluoroquinolone DW-116 in pregnant rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12765244/),h,4.4,42098,DB00592,Piperazine
,12765244,AUC,"In the amniotic fluid of maternal uterus, the T(1/2)abs, T(1/2)beta, AUC, Tmax and Cmax were approximately 1.3 h, 9.3 h, 2508 microg h/ml, 4.4 h, and 135 microg/ ml, respectively.",Transplacental pharmacokinetics of the new fluoroquinolone DW-116 in pregnant rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12765244/),h,9.3,42099,DB00592,Piperazine
,12765244,Tmax,"In the amniotic fluid of maternal uterus, the T(1/2)abs, T(1/2)beta, AUC, Tmax and Cmax were approximately 1.3 h, 9.3 h, 2508 microg h/ml, 4.4 h, and 135 microg/ ml, respectively.",Transplacental pharmacokinetics of the new fluoroquinolone DW-116 in pregnant rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12765244/),h,9.3,42100,DB00592,Piperazine
,12765244,Tmax,"In the amniotic fluid of maternal uterus, the T(1/2)abs, T(1/2)beta, AUC, Tmax and Cmax were approximately 1.3 h, 9.3 h, 2508 microg h/ml, 4.4 h, and 135 microg/ ml, respectively.",Transplacental pharmacokinetics of the new fluoroquinolone DW-116 in pregnant rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12765244/),[h·μg] / [ml],2508,42101,DB00592,Piperazine
,12765244,Cmax,"In the amniotic fluid of maternal uterus, the T(1/2)abs, T(1/2)beta, AUC, Tmax and Cmax were approximately 1.3 h, 9.3 h, 2508 microg h/ml, 4.4 h, and 135 microg/ ml, respectively.",Transplacental pharmacokinetics of the new fluoroquinolone DW-116 in pregnant rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12765244/),[μg] / [ml],135,42102,DB00592,Piperazine
,30477556,plasma terminal half-life,Median (range) cetirizine plasma terminal half-life was 10 h (7.9-16.5).,Cetirizine per os: exposure and antihistamine effect in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30477556/),h,10,42372,DB00592,Piperazine
,30477556,IC50,The median (range) IC50-value for reduction in wheal area was 0.33 µg/mL (0.07-0.45).,Cetirizine per os: exposure and antihistamine effect in the dog. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30477556/),[μg] / [ml],0.33,42373,DB00592,Piperazine
,8930784,half-life (t1/2),"Significant changes in the pharmacokinetic parameters of haloperidol were not found in group I; a mean increase in the half-life (t1/2) of haloperidol from 21.5 to 28.1 hours was observed, but this finding was not statistically significant.",Lack of pharmacokinetic interaction between buspirone and haloperidol in patients with schizophrenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930784/),h,21.5,42408,DB00592,Piperazine
,8930784,half-life (t1/2),"Significant changes in the pharmacokinetic parameters of haloperidol were not found in group I; a mean increase in the half-life (t1/2) of haloperidol from 21.5 to 28.1 hours was observed, but this finding was not statistically significant.",Lack of pharmacokinetic interaction between buspirone and haloperidol in patients with schizophrenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930784/),h,28.1,42409,DB00592,Piperazine
,14963065,IC(50),BB-81384 selectively inhibited PDF with an IC(50) approximately 10 nM and with MICs < 0.5 mg/L against most S. pneumoniae pathogens.,Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14963065/),nM,10,42533,DB00592,Piperazine
<,14963065,MICs,BB-81384 selectively inhibited PDF with an IC(50) approximately 10 nM and with MICs < 0.5 mg/L against most S. pneumoniae pathogens.,Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14963065/),[mg] / [l],0.5,42534,DB00592,Piperazine
,14963065,ED(50),Single-administration oral efficacy in a mouse peritonitis model was evident with an ED(50) of 30 mg/kg.,Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14963065/),[mg] / [kg],30,42535,DB00592,Piperazine
,12885135,half-life (t1/2),"At a 15-mg/kg dosage, the half-life (t1/2) was 75 hr for itraconazole and 55 hr for OH-ITRA.","Steady-state plasma concentrations of itraconazole after oral administration in Kemp's ridley sea turtles, Lepidochelys kempi. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12885135/),h,75,42942,DB00592,Piperazine
,12885135,half-life (t1/2),"At a 15-mg/kg dosage, the half-life (t1/2) was 75 hr for itraconazole and 55 hr for OH-ITRA.","Steady-state plasma concentrations of itraconazole after oral administration in Kemp's ridley sea turtles, Lepidochelys kempi. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12885135/),h,55,42943,DB00592,Piperazine
,18781906,trough levels,"Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%).",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],1404,43042,DB00592,Piperazine
,18781906,trough levels,"Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%).",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],1374,43043,DB00592,Piperazine
,18781906,trough levels,"Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%).",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],1400,43044,DB00592,Piperazine
,18781906,trough levels,"Mean trough levels of imatinib were reduced up to 2.9-fold (477 ng/ml, CV 70%) in patients treated with EIAEDs.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],477,43045,DB00592,Piperazine
,18781906,trough level,"Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%), 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],240,43046,DB00592,Piperazine
,18781906,trough level,"Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%), 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],351,43047,DB00592,Piperazine
,18781906,trough level,"Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%), 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],356,43048,DB00592,Piperazine
,19451435,TTP,"The median TTP was 11.3 months for patients in the lowest C(min) quartile (Q1, < 1,110 ng/mL) compared with more than 30 months for Q2 to Q4 (P = .0029).",Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19451435/),month,11.3,43195,DB00592,Piperazine
more,19451435,TTP,"The median TTP was 11.3 months for patients in the lowest C(min) quartile (Q1, < 1,110 ng/mL) compared with more than 30 months for Q2 to Q4 (P = .0029).",Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19451435/),month,30,43196,DB00592,Piperazine
,19451435,OOBR,"In patients with GIST with KIT exon 11 mutations (n = 39), the OOBR was 67% for Q1 patients versus 100% for all others (P = .001).",Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19451435/),%,67,43197,DB00592,Piperazine
,19451435,OOBR,"In patients with GIST with KIT exon 11 mutations (n = 39), the OOBR was 67% for Q1 patients versus 100% for all others (P = .001).",Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19451435/),%,100,43198,DB00592,Piperazine
below,19451435,C(min),"Patients with IM C(min) below 1,100 ng/mL showed a shorter TTP and lower rate of clinical benefit (OOBR).",Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19451435/),[ng] / [ml],"1,100",43199,DB00592,Piperazine
,15490489,Maximum wheal suppression,"Maximum wheal suppression by cetirizine in SUV and MLV ranged from 90.6%+/-4.9% to 89.0%+/-3.8% and 98.0%+/-1.3% to 94.0%+/-2.3%, respectively, from 6 to 8 h.",Cetirizine from topical phosphatidylcholine liposomes: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15490489/),%,90.6,43480,DB00592,Piperazine
,15490489,Maximum wheal suppression,"Maximum wheal suppression by cetirizine in SUV and MLV ranged from 90.6%+/-4.9% to 89.0%+/-3.8% and 98.0%+/-1.3% to 94.0%+/-2.3%, respectively, from 6 to 8 h.",Cetirizine from topical phosphatidylcholine liposomes: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15490489/),%,89.0,43481,DB00592,Piperazine
,15490489,Maximum wheal suppression,"Maximum wheal suppression by cetirizine in SUV and MLV ranged from 90.6%+/-4.9% to 89.0%+/-3.8% and 98.0%+/-1.3% to 94.0%+/-2.3%, respectively, from 6 to 8 h.",Cetirizine from topical phosphatidylcholine liposomes: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15490489/),%,98.0,43482,DB00592,Piperazine
,15490489,Maximum wheal suppression,"Maximum wheal suppression by cetirizine in SUV and MLV ranged from 90.6%+/-4.9% to 89.0%+/-3.8% and 98.0%+/-1.3% to 94.0%+/-2.3%, respectively, from 6 to 8 h.",Cetirizine from topical phosphatidylcholine liposomes: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15490489/),%,94.0,43483,DB00592,Piperazine
,15490489,AUC,"The plasma cetirizine AUC of 201+/-24.2 ng.h/ml from SUV was lower than from PC-MLV, 334.6+/-65.1 ng.h/ml and from GB, 248.3+/-34.6 ng.h/ml.",Cetirizine from topical phosphatidylcholine liposomes: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15490489/),[h·ng] / [ml],201,43484,DB00592,Piperazine
,15490489,AUC,"The plasma cetirizine AUC of 201+/-24.2 ng.h/ml from SUV was lower than from PC-MLV, 334.6+/-65.1 ng.h/ml and from GB, 248.3+/-34.6 ng.h/ml.",Cetirizine from topical phosphatidylcholine liposomes: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15490489/),[h·ng] / [ml],334.6,43485,DB00592,Piperazine
,15490489,AUC,"The plasma cetirizine AUC of 201+/-24.2 ng.h/ml from SUV was lower than from PC-MLV, 334.6+/-65.1 ng.h/ml and from GB, 248.3+/-34.6 ng.h/ml.",Cetirizine from topical phosphatidylcholine liposomes: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15490489/),[h·ng] / [ml],248.3,43486,DB00592,Piperazine
,34271151,D90,"D90 of DTG and DTG-Palmitate microparticles was 107.1 ± 2.7 and 94.3 ± 3.4 µm, respectively.","Ultra-long acting prodrug of dolutegravir and delivery system - Physicochemical, pharmacokinetic and formulation characterizations. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34271151/),µm,107.1,43492,DB00592,Piperazine
,34271151,D90,"D90 of DTG and DTG-Palmitate microparticles was 107.1 ± 2.7 and 94.3 ± 3.4 µm, respectively.","Ultra-long acting prodrug of dolutegravir and delivery system - Physicochemical, pharmacokinetic and formulation characterizations. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34271151/),µm,94.3,43493,DB00592,Piperazine
,2737798,elimination half-life,"The elimination half-life of theophylline before quinolone treatment was 5.7 +/- 2.0 h and did not change significantly under coadministration of lomefloxacin (6.2 +/- 2.0 h), whereas with pipemidic acid a marked prolongation (10.8 +/- 2.3 h) occurred.",Interaction of quinolones with the theophylline metabolism in man: investigations with lomefloxacin and pipemidic acid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737798/),h,5.7,43650,DB00592,Piperazine
,2737798,elimination half-life,"The elimination half-life of theophylline before quinolone treatment was 5.7 +/- 2.0 h and did not change significantly under coadministration of lomefloxacin (6.2 +/- 2.0 h), whereas with pipemidic acid a marked prolongation (10.8 +/- 2.3 h) occurred.",Interaction of quinolones with the theophylline metabolism in man: investigations with lomefloxacin and pipemidic acid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737798/),h,6.2,43651,DB00592,Piperazine
,2737798,elimination half-life,"The elimination half-life of theophylline before quinolone treatment was 5.7 +/- 2.0 h and did not change significantly under coadministration of lomefloxacin (6.2 +/- 2.0 h), whereas with pipemidic acid a marked prolongation (10.8 +/- 2.3 h) occurred.",Interaction of quinolones with the theophylline metabolism in man: investigations with lomefloxacin and pipemidic acid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737798/),h,10.8,43652,DB00592,Piperazine
,15370956,apparent K(i),"2. Midazolam metabolism was also inhibited in vitro by typical chemical inhibitors of CYP3A, such as ketoconazole, erythromycin and diltiazem, and the apparent K(i) values for ketoconazole, erythromycin and diltiazem were 0.127, 94.2 and 29.6 microM, respectively.",Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15370956/),μM,0.127,43675,DB00592,Piperazine
,15370956,apparent K(i),"2. Midazolam metabolism was also inhibited in vitro by typical chemical inhibitors of CYP3A, such as ketoconazole, erythromycin and diltiazem, and the apparent K(i) values for ketoconazole, erythromycin and diltiazem were 0.127, 94.2 and 29.6 microM, respectively.",Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15370956/),μM,94.2,43676,DB00592,Piperazine
,15370956,apparent K(i),"2. Midazolam metabolism was also inhibited in vitro by typical chemical inhibitors of CYP3A, such as ketoconazole, erythromycin and diltiazem, and the apparent K(i) values for ketoconazole, erythromycin and diltiazem were 0.127, 94.2 and 29.6 microM, respectively.",Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15370956/),μM,29.6,43677,DB00592,Piperazine
,16628140,CL,"Midazolam CL were normally distributed in both groups, and ranged from 1.7 to 51.9 and 1.4 to 8.2 L/hour in the control and ketoconazole groups, respectively, corresponding to a 7-fold reduction in dispersion between the 2 groups.",Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628140/),[l] / [h],1.7 to 51.9,43995,DB00592,Piperazine
,16628140,CL,"Midazolam CL were normally distributed in both groups, and ranged from 1.7 to 51.9 and 1.4 to 8.2 L/hour in the control and ketoconazole groups, respectively, corresponding to a 7-fold reduction in dispersion between the 2 groups.",Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628140/),[l] / [h],1.4 to 8.2,43996,DB00592,Piperazine
,16076552,free fraction,Protein binding by ultrafiltration showed free fraction of 29+/-4%.,Pharmacokinetics and tissue distribution of a new heterocyclic N-phenylpiperazine derivative (LASSBio-581) in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16076552/),%,29,44087,DB00592,Piperazine
,16076552,oral bioavailability,The oral bioavailability ( approximately 25%) was approximately half of the intra-peritoneal one ( approximately 47%).,Pharmacokinetics and tissue distribution of a new heterocyclic N-phenylpiperazine derivative (LASSBio-581) in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16076552/),%,25,44088,DB00592,Piperazine
,16076552,oral bioavailability,The oral bioavailability ( approximately 25%) was approximately half of the intra-peritoneal one ( approximately 47%).,Pharmacokinetics and tissue distribution of a new heterocyclic N-phenylpiperazine derivative (LASSBio-581) in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16076552/),%,47,44089,DB00592,Piperazine
,16076552,Vd,The Vd (0.8+/-0.4l/kg) and the t(1/2) (1.2+/-0.4h) were smaller for i.v. than for the other routes.,Pharmacokinetics and tissue distribution of a new heterocyclic N-phenylpiperazine derivative (LASSBio-581) in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16076552/),[l] / [kg],0.8,44090,DB00592,Piperazine
,16076552,t(1/2),The Vd (0.8+/-0.4l/kg) and the t(1/2) (1.2+/-0.4h) were smaller for i.v. than for the other routes.,Pharmacokinetics and tissue distribution of a new heterocyclic N-phenylpiperazine derivative (LASSBio-581) in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16076552/),h,1.2,44091,DB00592,Piperazine
,16076552,CL(tot),The CL(tot) was statistically similar for all three administration routes investigated (0.6+/-0.2l/(hkg)) (alpha=0.05).,Pharmacokinetics and tissue distribution of a new heterocyclic N-phenylpiperazine derivative (LASSBio-581) in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16076552/),[l] / [hkg],0.6,44092,DB00592,Piperazine
,16076552,half-life,"The compound distribution into different organs, evaluated in tissue homogenates after i.v. administration, showed a higher penetration in lungs (51.0%), followed by the brain (39.2%), where the half-life was three times bigger than in the other tissues (1.9h).",Pharmacokinetics and tissue distribution of a new heterocyclic N-phenylpiperazine derivative (LASSBio-581) in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16076552/),h,1.9,44093,DB00592,Piperazine
,8799514,CL,"3. For 619C89, geometric CL means ranged between 0.71 and 0.99 1 h-1 kg-1 for maintenance infusions up to 1.25 mg kg-1 over 30 min, with an overall mean of 0.85 l h-1 kg-1 (95% CI: 0.70-1.04 l h-1 kg-1).","Pharmacokinetics of 619C89, a novel neuronal sodium channel inhibitor, in acute stroke patients after loading and discrete maintenance infusions. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799514/),[1] / [h·kg],0.71 and 0.99,44323,DB00592,Piperazine
,8799514,CL,"3. For 619C89, geometric CL means ranged between 0.71 and 0.99 1 h-1 kg-1 for maintenance infusions up to 1.25 mg kg-1 over 30 min, with an overall mean of 0.85 l h-1 kg-1 (95% CI: 0.70-1.04 l h-1 kg-1).","Pharmacokinetics of 619C89, a novel neuronal sodium channel inhibitor, in acute stroke patients after loading and discrete maintenance infusions. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799514/),[l] / [h·kg],0.85,44324,DB00592,Piperazine
,8799514,Vss,"Geometric Vss means ranged between 13.2 and 27.9 l kg-1 for the same doses, with an overall mean of 22.5 l kg-1 (95% CI: 16.4-30.9 l kg-1).","Pharmacokinetics of 619C89, a novel neuronal sodium channel inhibitor, in acute stroke patients after loading and discrete maintenance infusions. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799514/),[l] / [kg],13.2 and 27.9,44325,DB00592,Piperazine
,8799514,Vss,"Geometric Vss means ranged between 13.2 and 27.9 l kg-1 for the same doses, with an overall mean of 22.5 l kg-1 (95% CI: 16.4-30.9 l kg-1).","Pharmacokinetics of 619C89, a novel neuronal sodium channel inhibitor, in acute stroke patients after loading and discrete maintenance infusions. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799514/),[l] / [kg],22.5,44326,DB00592,Piperazine
,19051591,steady-state skin permeation rate,A steady-state skin permeation rate of 134.09 +/- 2.49 microg/cm2/h was achieved from the matrix patch across mouse epidermis after an initial lag time of approximately 3.5 h.,Ex vivo and in vivo evaluation of transdermal formulation of trazodone hydrochloride. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19051591/),[μg] / [cm2·h],134.09,44570,DB00592,Piperazine
,19051591,initial lag time,A steady-state skin permeation rate of 134.09 +/- 2.49 microg/cm2/h was achieved from the matrix patch across mouse epidermis after an initial lag time of approximately 3.5 h.,Ex vivo and in vivo evaluation of transdermal formulation of trazodone hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19051591/),h,3.5,44571,DB00592,Piperazine
,19051591,steady-state transdermal TZN concentration,The steady-state transdermal TZN concentration of 2.3 microg/mL was achieved in rabbit from the matrix patch after an initial lag time of approximately 2 h.,Ex vivo and in vivo evaluation of transdermal formulation of trazodone hydrochloride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19051591/),[μg] / [ml],2.3,44572,DB00592,Piperazine
,19051591,initial lag time,The steady-state transdermal TZN concentration of 2.3 microg/mL was achieved in rabbit from the matrix patch after an initial lag time of approximately 2 h.,Ex vivo and in vivo evaluation of transdermal formulation of trazodone hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19051591/),h,2,44573,DB00592,Piperazine
,19051591,Cmax,The Cmax of peroral TZN solution was calculated to be 5.84 microg/mL at a Tmax of 2 h indicating its rapid absorption compared to the transdermal administration with a Tmax of 5 h.,Ex vivo and in vivo evaluation of transdermal formulation of trazodone hydrochloride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19051591/),[μg] / [ml],5.84,44574,DB00592,Piperazine
,19051591,Tmax,The Cmax of peroral TZN solution was calculated to be 5.84 microg/mL at a Tmax of 2 h indicating its rapid absorption compared to the transdermal administration with a Tmax of 5 h.,Ex vivo and in vivo evaluation of transdermal formulation of trazodone hydrochloride. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19051591/),h,2,44575,DB00592,Piperazine
,19051591,Tmax,The Cmax of peroral TZN solution was calculated to be 5.84 microg/mL at a Tmax of 2 h indicating its rapid absorption compared to the transdermal administration with a Tmax of 5 h.,Ex vivo and in vivo evaluation of transdermal formulation of trazodone hydrochloride. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19051591/),h,5,44576,DB00592,Piperazine
,33851349,major molecular response rate,"The major molecular response rate at 24 months favored bosutinib vs imatinib among Asian (63.6 vs 38.2%) and non-Asian (60.9 vs 52.6%) patients, as did the complete cytogenetic response rate by 24 months (86.7 vs 76.7%, 81.5 vs 76.3%).",Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33851349/),%,63.6,44834,DB00592,Piperazine
,33851349,major molecular response rate,"The major molecular response rate at 24 months favored bosutinib vs imatinib among Asian (63.6 vs 38.2%) and non-Asian (60.9 vs 52.6%) patients, as did the complete cytogenetic response rate by 24 months (86.7 vs 76.7%, 81.5 vs 76.3%).",Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33851349/),%,38.2,44835,DB00592,Piperazine
,33851349,major molecular response rate,"The major molecular response rate at 24 months favored bosutinib vs imatinib among Asian (63.6 vs 38.2%) and non-Asian (60.9 vs 52.6%) patients, as did the complete cytogenetic response rate by 24 months (86.7 vs 76.7%, 81.5 vs 76.3%).",Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33851349/),%,60.9,44836,DB00592,Piperazine
,33851349,major molecular response rate,"The major molecular response rate at 24 months favored bosutinib vs imatinib among Asian (63.6 vs 38.2%) and non-Asian (60.9 vs 52.6%) patients, as did the complete cytogenetic response rate by 24 months (86.7 vs 76.7%, 81.5 vs 76.3%).",Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33851349/),%,52.6,44837,DB00592,Piperazine
,33851349,complete cytogenetic response rate,"The major molecular response rate at 24 months favored bosutinib vs imatinib among Asian (63.6 vs 38.2%) and non-Asian (60.9 vs 52.6%) patients, as did the complete cytogenetic response rate by 24 months (86.7 vs 76.7%, 81.5 vs 76.3%).",Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33851349/),%,86.7,44838,DB00592,Piperazine
,33851349,complete cytogenetic response rate,"The major molecular response rate at 24 months favored bosutinib vs imatinib among Asian (63.6 vs 38.2%) and non-Asian (60.9 vs 52.6%) patients, as did the complete cytogenetic response rate by 24 months (86.7 vs 76.7%, 81.5 vs 76.3%).",Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33851349/),%,76.7,44839,DB00592,Piperazine
,33851349,complete cytogenetic response rate,"The major molecular response rate at 24 months favored bosutinib vs imatinib among Asian (63.6 vs 38.2%) and non-Asian (60.9 vs 52.6%) patients, as did the complete cytogenetic response rate by 24 months (86.7 vs 76.7%, 81.5 vs 76.3%).",Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33851349/),%,81.5,44840,DB00592,Piperazine
,33851349,complete cytogenetic response rate,"The major molecular response rate at 24 months favored bosutinib vs imatinib among Asian (63.6 vs 38.2%) and non-Asian (60.9 vs 52.6%) patients, as did the complete cytogenetic response rate by 24 months (86.7 vs 76.7%, 81.5 vs 76.3%).",Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33851349/),%,76.3,44841,DB00592,Piperazine
,30052328,half-life,Maximum alicapistat plasma concentrations were reached in 2 to 5 hours; half-life was 7 to 12 hours postdose.,"Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Alicapistat, a Selective Inhibitor of Human Calpains 1 and 2 for the Treatment of Alzheimer Disease: An Overview of Phase 1 Studies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30052328/),h,7 to 12,44852,DB00592,Piperazine
,12723462,apparent oral clearance,"Compared to the control condition, ritonavir significantly reduced apparent oral clearance of trazodone (155 +/- 23 vs. 75 +/- 12 ml/min, p < 0.001), prolonged elimination half-life (6.7 +/- 0.7 vs. 14.9 +/- 3.9 h, p < 0.05), and increased peak plasma concentrations (842 +/- 64 vs. 1125 +/- 111 ng/ml, p < 0.05) (mean +/- SE).",Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723462/),[ml] / [min],155,44884,DB00592,Piperazine
,12723462,apparent oral clearance,"Compared to the control condition, ritonavir significantly reduced apparent oral clearance of trazodone (155 +/- 23 vs. 75 +/- 12 ml/min, p < 0.001), prolonged elimination half-life (6.7 +/- 0.7 vs. 14.9 +/- 3.9 h, p < 0.05), and increased peak plasma concentrations (842 +/- 64 vs. 1125 +/- 111 ng/ml, p < 0.05) (mean +/- SE).",Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723462/),[ml] / [min],75,44885,DB00592,Piperazine
,12723462,elimination half-life,"Compared to the control condition, ritonavir significantly reduced apparent oral clearance of trazodone (155 +/- 23 vs. 75 +/- 12 ml/min, p < 0.001), prolonged elimination half-life (6.7 +/- 0.7 vs. 14.9 +/- 3.9 h, p < 0.05), and increased peak plasma concentrations (842 +/- 64 vs. 1125 +/- 111 ng/ml, p < 0.05) (mean +/- SE).",Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723462/),h,6.7,44886,DB00592,Piperazine
,12723462,elimination half-life,"Compared to the control condition, ritonavir significantly reduced apparent oral clearance of trazodone (155 +/- 23 vs. 75 +/- 12 ml/min, p < 0.001), prolonged elimination half-life (6.7 +/- 0.7 vs. 14.9 +/- 3.9 h, p < 0.05), and increased peak plasma concentrations (842 +/- 64 vs. 1125 +/- 111 ng/ml, p < 0.05) (mean +/- SE).",Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723462/),h,14.9,44887,DB00592,Piperazine
,12723462,peak plasma concentrations,"Compared to the control condition, ritonavir significantly reduced apparent oral clearance of trazodone (155 +/- 23 vs. 75 +/- 12 ml/min, p < 0.001), prolonged elimination half-life (6.7 +/- 0.7 vs. 14.9 +/- 3.9 h, p < 0.05), and increased peak plasma concentrations (842 +/- 64 vs. 1125 +/- 111 ng/ml, p < 0.05) (mean +/- SE).",Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723462/),[ng] / [ml],842,44888,DB00592,Piperazine
,12723462,peak plasma concentrations,"Compared to the control condition, ritonavir significantly reduced apparent oral clearance of trazodone (155 +/- 23 vs. 75 +/- 12 ml/min, p < 0.001), prolonged elimination half-life (6.7 +/- 0.7 vs. 14.9 +/- 3.9 h, p < 0.05), and increased peak plasma concentrations (842 +/- 64 vs. 1125 +/- 111 ng/ml, p < 0.05) (mean +/- SE).",Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723462/),[ng] / [ml],1125,44889,DB00592,Piperazine
,15787865,volume of distribution,"The population PK model used predicted that with increasing body weight, levocetirizine oral clearance would increase by 0.044 l/h/kg, and levocetirizine volume of distribution would increase by 0.639 l/kg.",Population pharmacokinetics of levocetirizine in very young children: the pediatricians' perspective. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15787865/),,0,45292,DB00592,Piperazine
,18339815,F(H),"During the absorption phase, the F(H) of ITZ increased from 0.2 to 1.0, reflecting the time course of hepatic CYP3A inhibition.","Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18339815/),,0.2,45475,DB00592,Piperazine
,18339815,F(H),"During the absorption phase, the F(H) of ITZ increased from 0.2 to 1.0, reflecting the time course of hepatic CYP3A inhibition.","Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18339815/),,1.0,45476,DB00592,Piperazine
,18339815,Ki,"The in vivo Ki for OH-ITZ (38 +/- 3 nM) was estimated from C(IN,OH-ITZ) versus F(H) of ITZ, and is similar to values obtained from inhibition of midazolam hydroxylation in CYP3A4 supersomes (Drug Metab Dispos 32:1121-1131, 2004).","Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18339815/),nM,38,45477,DB00592,Piperazine
,7711339,peak salivary concentration,The mean (+/- SD) peak salivary concentration for ketoconazole was 0.119 +/- 0.050 microgram/mL at 3 hours; no subject had a detectable ketoconazole salivary concentration at 24 hours.,Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711339/),[μg] / [ml],0.119,45504,DB00592,Piperazine
,7711339,plasma concentrations,"At 2 and 24 hours, mean ketoconazole plasma concentrations were 7.64 +/- 3.87 and 0.11 +/- 0.05 microgram/mL, respectively.",Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711339/),[μg] / [ml],7.64,45505,DB00592,Piperazine
,7711339,plasma concentrations,"At 2 and 24 hours, mean ketoconazole plasma concentrations were 7.64 +/- 3.87 and 0.11 +/- 0.05 microgram/mL, respectively.",Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711339/),[μg] / [ml],0.11,45506,DB00592,Piperazine
,7711339,saliva to plasma concentration ratio,The saliva to plasma concentration ratio at 2 hours was 0.01.,Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711339/),,0.01,45507,DB00592,Piperazine
,7711339,peak salivary concentration,The mean peak salivary concentration of fluconazole was 2.56 +/- 0.34 microgram/mL at 3 hours.,Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711339/),[μg] / [ml],2.56,45508,DB00592,Piperazine
,7711339,salivary concentration,"At 24 hours, the mean salivary concentration was 1.44 +/- 0.33 microgram/mL.",Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711339/),[μg] / [ml],1.44,45509,DB00592,Piperazine
,7711339,plasma concentrations,"At 2 and 24 hours, mean fluconazole plasma concentrations were 4.39 +/- 3.33 and 3.72 +/- 2.83 micrograms/mL, respectively.",Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711339/),[μg] / [ml],4.39,45510,DB00592,Piperazine
,7711339,plasma concentrations,"At 2 and 24 hours, mean fluconazole plasma concentrations were 4.39 +/- 3.33 and 3.72 +/- 2.83 micrograms/mL, respectively.",Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711339/),[μg] / [ml],3.72,45511,DB00592,Piperazine
,7711339,saliva to plasma concentration ratio,The saliva to plasma concentration ratio at 2 hours was 0.55.,Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711339/),,0.55,45512,DB00592,Piperazine
,7711339,MIC,Median MIC values were 0.0625 microgram/mL (range 0.0313-0.125) for ketoconazole and 0.25 microgram/mL (range 0.125-0.5) for fluconazole.,Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711339/),[μg] / [ml],0.0625,45513,DB00592,Piperazine
,7711339,MIC,Median MIC values were 0.0625 microgram/mL (range 0.0313-0.125) for ketoconazole and 0.25 microgram/mL (range 0.125-0.5) for fluconazole.,Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711339/),[μg] / [ml],0.25,45514,DB00592,Piperazine
,7711339,MICs,"Calculated times over which ketoconazole and fluconazole exceeded the median MICs in saliva were approximately 13 and greater than 24 hours, respectively.",Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711339/),h,13,45515,DB00592,Piperazine
greater,7711339,MICs,"Calculated times over which ketoconazole and fluconazole exceeded the median MICs in saliva were approximately 13 and greater than 24 hours, respectively.",Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711339/),h,24,45516,DB00592,Piperazine
,9654217,AUC,"When given intravenously, digoxin AUC increased from 93 +/- 22 to 486 +/- 26 microg x h/l with ketoconazole administration.",Effects of ketoconazole on digoxin absorption and disposition in rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9654217/),[h·μg] / [l],93,46037,DB00592,Piperazine
,9654217,AUC,"When given intravenously, digoxin AUC increased from 93 +/- 22 to 486 +/- 26 microg x h/l with ketoconazole administration.",Effects of ketoconazole on digoxin absorption and disposition in rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9654217/),[h·μg] / [l],486,46038,DB00592,Piperazine
,9654217,AUC,"Similarly, ketoconazole raised the AUC of orally administered digoxin from 63 +/- 17 to 411 +/- 50 microg x h/l.",Effects of ketoconazole on digoxin absorption and disposition in rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9654217/),[h·μg] / [l],63,46039,DB00592,Piperazine
,9654217,AUC,"Similarly, ketoconazole raised the AUC of orally administered digoxin from 63 +/- 17 to 411 +/- 50 microg x h/l.",Effects of ketoconazole on digoxin absorption and disposition in rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9654217/),[h·μg] / [l],411,46040,DB00592,Piperazine
,9654217,bioavailability,"Using time-averaged values, digoxin bioavailability increased from 0.68 +/- 0.18 to 0.84 +/- 0.10, while mean absorption time was reduced from 1.1 +/- 0.4 to 0.3 +/- 0.1 h.",Effects of ketoconazole on digoxin absorption and disposition in rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9654217/),,0.68,46041,DB00592,Piperazine
,9654217,bioavailability,"Using time-averaged values, digoxin bioavailability increased from 0.68 +/- 0.18 to 0.84 +/- 0.10, while mean absorption time was reduced from 1.1 +/- 0.4 to 0.3 +/- 0.1 h.",Effects of ketoconazole on digoxin absorption and disposition in rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9654217/),,0.84,46042,DB00592,Piperazine
,9654217,mean absorption time,"Using time-averaged values, digoxin bioavailability increased from 0.68 +/- 0.18 to 0.84 +/- 0.10, while mean absorption time was reduced from 1.1 +/- 0.4 to 0.3 +/- 0.1 h.",Effects of ketoconazole on digoxin absorption and disposition in rat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9654217/),h,1.1,46043,DB00592,Piperazine
,9654217,mean absorption time,"Using time-averaged values, digoxin bioavailability increased from 0.68 +/- 0.18 to 0.84 +/- 0.10, while mean absorption time was reduced from 1.1 +/- 0.4 to 0.3 +/- 0.1 h.",Effects of ketoconazole on digoxin absorption and disposition in rat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9654217/),h,0.3,46044,DB00592,Piperazine
,14577318,maximum concentration,"The pharmacokinetics revealed that the maximum concentration (1.4 micrograms/ml); time to maximum concentration (5.1 h); half-life (11.0 h); trough concentration (0.4 microgram/ml); and, area under the concentration-time curve (28.1 micrograms.h/ml) were inferior to those for adult patients in the 400 mg/day group.",[Efficacy and pharmacokinetics of imatinib mesylate in a child with chronic myeloid leukemia]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14577318/),[μg] / [ml],1.4,46080,DB00592,Piperazine
,14577318,time to maximum concentration,"The pharmacokinetics revealed that the maximum concentration (1.4 micrograms/ml); time to maximum concentration (5.1 h); half-life (11.0 h); trough concentration (0.4 microgram/ml); and, area under the concentration-time curve (28.1 micrograms.h/ml) were inferior to those for adult patients in the 400 mg/day group.",[Efficacy and pharmacokinetics of imatinib mesylate in a child with chronic myeloid leukemia]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14577318/),h,5.1,46081,DB00592,Piperazine
,14577318,half-life,"The pharmacokinetics revealed that the maximum concentration (1.4 micrograms/ml); time to maximum concentration (5.1 h); half-life (11.0 h); trough concentration (0.4 microgram/ml); and, area under the concentration-time curve (28.1 micrograms.h/ml) were inferior to those for adult patients in the 400 mg/day group.",[Efficacy and pharmacokinetics of imatinib mesylate in a child with chronic myeloid leukemia]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14577318/),h,11.0,46082,DB00592,Piperazine
,14577318,trough concentration,"The pharmacokinetics revealed that the maximum concentration (1.4 micrograms/ml); time to maximum concentration (5.1 h); half-life (11.0 h); trough concentration (0.4 microgram/ml); and, area under the concentration-time curve (28.1 micrograms.h/ml) were inferior to those for adult patients in the 400 mg/day group.",[Efficacy and pharmacokinetics of imatinib mesylate in a child with chronic myeloid leukemia]. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14577318/),[μg] / [ml],0.4,46083,DB00592,Piperazine
,14577318,area under the concentration-time curve,"The pharmacokinetics revealed that the maximum concentration (1.4 micrograms/ml); time to maximum concentration (5.1 h); half-life (11.0 h); trough concentration (0.4 microgram/ml); and, area under the concentration-time curve (28.1 micrograms.h/ml) were inferior to those for adult patients in the 400 mg/day group.",[Efficacy and pharmacokinetics of imatinib mesylate in a child with chronic myeloid leukemia]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14577318/),[h·μg] / [ml],28.1,46084,DB00592,Piperazine
,25365188,IC50,"Also, silybin showed inhibitory effect on human and rat microsomes, the IC50 of silybin were 26.42 μmol·L(-1) and 49.12 μmol·L(-1) in human and rat liver microsomes, respectively.",Inhibitory effect of silybin on pharmacokinetics of imatinib in vivo and in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25365188/),[μM] / [l],26.42,47008,DB00592,Piperazine
,25365188,IC50,"Also, silybin showed inhibitory effect on human and rat microsomes, the IC50 of silybin were 26.42 μmol·L(-1) and 49.12 μmol·L(-1) in human and rat liver microsomes, respectively.",Inhibitory effect of silybin on pharmacokinetics of imatinib in vivo and in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25365188/),[μM] / [l],49.12,47009,DB00592,Piperazine
,25851638,absolute bioavailability,"Tasimelteon is rapidly absorbed, with a mean absolute bioavailability of approximately 38%, and is extensively metabolized primarily by oxidation at multiple sites, mainly by cytochrome P450 (CYP) 1A2 and CYP3A4/5, as initially demonstrated by in vitro studies and confirmed by the results of clinical drug-drug interactions presented here.","Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25851638/),%,38,47044,DB00592,Piperazine
,24817601,Oral clearance (CL/F),"Oral clearance (CL/F) and the volume of distribution (V/F) were estimated to 10.8 L/h with 30 % IIV and 265 L with 53 % IIV, respectively.",Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24817601/),[l] / [h],10.8,47106,DB00592,Piperazine
,24817601,volume of distribution (V/F),"Oral clearance (CL/F) and the volume of distribution (V/F) were estimated to 10.8 L/h with 30 % IIV and 265 L with 53 % IIV, respectively.",Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24817601/),l,265,47107,DB00592,Piperazine
<,24817601,trough plasma levels,"Imatinib trough plasma levels <1,257 ng/mL were associated with lower rates of major molecular response.",Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24817601/),[ng] / [ml],"1,257",47108,DB00592,Piperazine
,26924243,Gastric half-emptying time,"Gastric half-emptying time decreased by -95 min (95% CI: -156.8, -34.2) after a single dose of camicinal 125 mg compared with placebo (52 vs. 147 min, P < 0.05), representing a 65% improvement.","The pharmacodynamics, safety and pharmacokinetics of single doses of the motilin agonist, camicinal, in type 1 diabetes mellitus with slow gastric emptying. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26924243/),min,52,47180,DB00592,Piperazine
,26924243,Gastric half-emptying time,"Gastric half-emptying time decreased by -95 min (95% CI: -156.8, -34.2) after a single dose of camicinal 125 mg compared with placebo (52 vs. 147 min, P < 0.05), representing a 65% improvement.","The pharmacodynamics, safety and pharmacokinetics of single doses of the motilin agonist, camicinal, in type 1 diabetes mellitus with slow gastric emptying. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26924243/),min,147,47181,DB00592,Piperazine
,26924243,gastric half-emptying time,"A decrease of the gastric half-emptying time compared with placebo (approximately 39 min) was observed with camicinal 25 and 50 mg, representing a 27% reduction for both doses (not statistically significant).","The pharmacodynamics, safety and pharmacokinetics of single doses of the motilin agonist, camicinal, in type 1 diabetes mellitus with slow gastric emptying. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26924243/),min,39,47182,DB00592,Piperazine
,34286354,Ctrough,"The palbociclib Ctrough geometric median (min-max) was significantly higher in cohort with potential DDI [106 ng/mL (66.7-113)], than cohort without potential DDI [70.1 ng/mL (54.1-89.7)], p = 0.0284.",Impact of pharmacist consultation at clinical trial inclusion: an effective way to reduce drug-drug interactions with oral targeted therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34286354/),[ng] / [ml],106,47204,DB00592,Piperazine
,34286354,Ctrough,"The palbociclib Ctrough geometric median (min-max) was significantly higher in cohort with potential DDI [106 ng/mL (66.7-113)], than cohort without potential DDI [70.1 ng/mL (54.1-89.7)], p = 0.0284.",Impact of pharmacist consultation at clinical trial inclusion: an effective way to reduce drug-drug interactions with oral targeted therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34286354/),[ng] / [ml],70.1,47205,DB00592,Piperazine
,34286354,geometric median,"The palbociclib Ctrough geometric median (min-max) was significantly higher in cohort with potential DDI [106 ng/mL (66.7-113)], than cohort without potential DDI [70.1 ng/mL (54.1-89.7)], p = 0.0284.",Impact of pharmacist consultation at clinical trial inclusion: an effective way to reduce drug-drug interactions with oral targeted therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34286354/),[ng] / [ml],106,47206,DB00592,Piperazine
,34286354,geometric median,"The palbociclib Ctrough geometric median (min-max) was significantly higher in cohort with potential DDI [106 ng/mL (66.7-113)], than cohort without potential DDI [70.1 ng/mL (54.1-89.7)], p = 0.0284.",Impact of pharmacist consultation at clinical trial inclusion: an effective way to reduce drug-drug interactions with oral targeted therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34286354/),[ng] / [ml],70.1,47207,DB00592,Piperazine
,31561043,IC50,"In particular, compound 49 containing 2,4-difluoro substitution at terminal phenyl ring considered as most potential lead with inhibition of acetylcholinesterase (hAChE, IC50 = 0.054 μM), butyrylcholinesterase (hBChE, IC50 = 0.787 μM) and beta-secretase-1 (hBACE-1, IC50 = 0.098 μM).","Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31561043/),μM,0.054,47290,DB00592,Piperazine
,31561043,IC50,"In particular, compound 49 containing 2,4-difluoro substitution at terminal phenyl ring considered as most potential lead with inhibition of acetylcholinesterase (hAChE, IC50 = 0.054 μM), butyrylcholinesterase (hBChE, IC50 = 0.787 μM) and beta-secretase-1 (hBACE-1, IC50 = 0.098 μM).","Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31561043/),μM,0.787,47291,DB00592,Piperazine
,31561043,IC50,"In particular, compound 49 containing 2,4-difluoro substitution at terminal phenyl ring considered as most potential lead with inhibition of acetylcholinesterase (hAChE, IC50 = 0.054 μM), butyrylcholinesterase (hBChE, IC50 = 0.787 μM) and beta-secretase-1 (hBACE-1, IC50 = 0.098 μM).","Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31561043/),μM,0.098,47292,DB00592,Piperazine
,31561043,Ki,The enzyme kinetics study of 49 against hAChE suggested a mixed type of inhibition (Ki = 0.030 μM).,"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31561043/),μM,0.030,47293,DB00592,Piperazine
,26022135,trough plasma concentration,"Mean trough plasma concentration of itraconazole after oral prophylaxis and intravenous induction were 577.2 and 1659.7 μg/L, respectively.",Successful empirical antifungal therapy of intravenous itraconazole with pharmacokinetic evidence in pediatric cancer patients undergoing hematopoietic stem cell transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26022135/),[μg] / [l],577.2,47306,DB00592,Piperazine
,26022135,trough plasma concentration,"Mean trough plasma concentration of itraconazole after oral prophylaxis and intravenous induction were 577.2 and 1659.7 μg/L, respectively.",Successful empirical antifungal therapy of intravenous itraconazole with pharmacokinetic evidence in pediatric cancer patients undergoing hematopoietic stem cell transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26022135/),[μg] / [l],1659.7,47307,DB00592,Piperazine
,26022135,area under the concentration-time curve,"Mean area under the concentration-time curve of itraconazole and its metabolite at steady state were 42,837 ± 24,746 μg·h/L and 63,094 ± 19,255 μg·h/L.",Successful empirical antifungal therapy of intravenous itraconazole with pharmacokinetic evidence in pediatric cancer patients undergoing hematopoietic stem cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26022135/),[h·μg] / [l],"42,837",47308,DB00592,Piperazine
,26022135,area under the concentration-time curve,"Mean area under the concentration-time curve of itraconazole and its metabolite at steady state were 42,837 ± 24,746 μg·h/L and 63,094 ± 19,255 μg·h/L.",Successful empirical antifungal therapy of intravenous itraconazole with pharmacokinetic evidence in pediatric cancer patients undergoing hematopoietic stem cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26022135/),[h·μg] / [l],"63,094",47309,DB00592,Piperazine
,9349931,dissociation constant Kd,"The population typical value for the dissociation constant Kd (%CV) was 0.648 (12) ng.ml-1 plasma, expressing the very high affinity of draflazine for the erythrocytes.",Population analysis of the non-linear red blood cell partitioning of draflazine following various infusion durations. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349931/),[ng·plasma] / [ml],0.648,47485,DB00592,Piperazine
,9349931,specific maximal binding capacity Bmax,The typical value of the specific maximal binding capacity Bmax (%CV) was 155 (2) ng.,Population analysis of the non-linear red blood cell partitioning of draflazine following various infusion durations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349931/),ng,155,47486,DB00592,Piperazine
,9349931,t1/2 beta,The t1/2 beta averaged 11.0-30.5 h and the mean CL from the plasma was 327 to 465 ml.min-1.,Population analysis of the non-linear red blood cell partitioning of draflazine following various infusion durations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349931/),h,11.0-30.5,47487,DB00592,Piperazine
,9349931,CL,The t1/2 beta averaged 11.0-30.5 h and the mean CL from the plasma was 327 to 465 ml.min-1.,Population analysis of the non-linear red blood cell partitioning of draflazine following various infusion durations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349931/),[ml] / [min],327 to 465,47488,DB00592,Piperazine
,9349931,t1/2 beta,The mean t1/2 beta was 30.2 to 42.2 h and the blood CL averaged 17.4-35.6 ml.min-1.,Population analysis of the non-linear red blood cell partitioning of draflazine following various infusion durations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349931/),h,30.2 to 42.2,47489,DB00592,Piperazine
,9349931,blood CL,The mean t1/2 beta was 30.2 to 42.2 h and the blood CL averaged 17.4-35.6 ml.min-1.,Population analysis of the non-linear red blood cell partitioning of draflazine following various infusion durations. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349931/),[ml] / [min],17.4-35.6,47490,DB00592,Piperazine
,9349931,occupancy,"During a 15-min i.v. infusion of 1 mg, followed by an infusion of 1 mg.h-1, the RBC occupancy of draflazine was 96% or more.",Population analysis of the non-linear red blood cell partitioning of draflazine following various infusion durations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349931/),%,96,47491,DB00592,Piperazine
,8951192,binding (dissociation) constant Kd,"The binding (dissociation) constant Kd was 0.87 ng ml-1 plasma and the maximal specific binding capacity (Bmax) was 164 ng ml-1 RBC, which corresponds to about 14,000 specific binding sites per erythrocyte.",The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951192/),[ng·plasma] / [ml],0.87,47926,DB00592,Piperazine
,8951192,maximal specific binding capacity (Bmax),"The binding (dissociation) constant Kd was 0.87 ng ml-1 plasma and the maximal specific binding capacity (Bmax) was 164 ng ml-1 RBC, which corresponds to about 14,000 specific binding sites per erythrocyte.",The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951192/),[ng·rbc] / [ml],164,47927,DB00592,Piperazine
,8951192,maximal specific binding capacity (Bmax),"The binding (dissociation) constant Kd was 0.87 ng ml-1 plasma and the maximal specific binding capacity (Bmax) was 164 ng ml-1 RBC, which corresponds to about 14,000 specific binding sites per erythrocyte.",The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951192/),,14,47928,DB00592,Piperazine
,8951192,clearance,"The pharmacokinetic parameters (mean +/- s.d.) were: clearance 22.0 +/- 8.0 ml mm-1, volume of distribution at steady-state 39.8 +/- 4.7 l and terminal half-life 24.0 +/- 9.4 h.",The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951192/),[ml] / [mm],22.0,47929,DB00592,Piperazine
,8951192,volume of distribution at steady-state,"The pharmacokinetic parameters (mean +/- s.d.) were: clearance 22.0 +/- 8.0 ml mm-1, volume of distribution at steady-state 39.8 +/- 4.7 l and terminal half-life 24.0 +/- 9.4 h.",The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951192/),l,39.8,47930,DB00592,Piperazine
,8951192,terminal half-life,"The pharmacokinetic parameters (mean +/- s.d.) were: clearance 22.0 +/- 8.0 ml mm-1, volume of distribution at steady-state 39.8 +/- 4.7 l and terminal half-life 24.0 +/- 9.4 h.",The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951192/),h,24.0,47931,DB00592,Piperazine
,8951192,clearance,"The pharmacokinetic parameters in pooled plasma were: clearance 551 ml min-1, volume of distribution at steady-state 349 l and terminal half-life 10.7 h.",The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951192/),[ml] / [min],551,47932,DB00592,Piperazine
,8951192,volume of distribution at steady-state,"The pharmacokinetic parameters in pooled plasma were: clearance 551 ml min-1, volume of distribution at steady-state 349 l and terminal half-life 10.7 h.",The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951192/),l,349,47933,DB00592,Piperazine
,8951192,terminal half-life,"The pharmacokinetic parameters in pooled plasma were: clearance 551 ml min-1, volume of distribution at steady-state 349 l and terminal half-life 10.7 h.",The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951192/),h,10.7,47934,DB00592,Piperazine
,8951192,Emax,"Based on concentrations in pooled plasma, values of the pharmacodynamic parameters were Emax 100%, IC50 10.5 ng ml-1 and Hill factor 0.9.",The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951192/),%,100,47935,DB00592,Piperazine
,8951192,IC50,"Based on concentrations in pooled plasma, values of the pharmacodynamic parameters were Emax 100%, IC50 10.5 ng ml-1 and Hill factor 0.9.",The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951192/),[ng] / [ml],10.5,47936,DB00592,Piperazine
,8951192,Hill factor,"Based on concentrations in pooled plasma, values of the pharmacodynamic parameters were Emax 100%, IC50 10.5 ng ml-1 and Hill factor 0.9.",The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951192/),,0.9,47937,DB00592,Piperazine
,8951192,Emax,"When using whole blood concentrations, the relationship was much steeper with values (mean +/- s.d.) Emax 92.4 +/- 5.6%, IC50 76.0 +/- 15.3 ng ml-1 and Hill factor 3.5 +/- 0.9.",The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951192/),%,92.4,47938,DB00592,Piperazine
,8951192,IC50,"When using whole blood concentrations, the relationship was much steeper with values (mean +/- s.d.) Emax 92.4 +/- 5.6%, IC50 76.0 +/- 15.3 ng ml-1 and Hill factor 3.5 +/- 0.9.",The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951192/),[ng] / [ml],76.0,47939,DB00592,Piperazine
,8951192,Hill factor,"When using whole blood concentrations, the relationship was much steeper with values (mean +/- s.d.) Emax 92.4 +/- 5.6%, IC50 76.0 +/- 15.3 ng ml-1 and Hill factor 3.5 +/- 0.9.",The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951192/),,3.5,47940,DB00592,Piperazine
,3392239,Vz,"Estimated pharmacokinetic parameters included Vz (0.80 +/- 0.20 L/kg), CL (2.53 +/- 0.99 mL/min/kg) and t1/2 (4.0 +/- 1.5 hr).",Pharmacokinetics and pharmacodynamics of urapidil in severe hypertension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392239/),[l] / [kg],0.80,48165,DB00592,Piperazine
,3392239,CL,"Estimated pharmacokinetic parameters included Vz (0.80 +/- 0.20 L/kg), CL (2.53 +/- 0.99 mL/min/kg) and t1/2 (4.0 +/- 1.5 hr).",Pharmacokinetics and pharmacodynamics of urapidil in severe hypertension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392239/),[ml] / [kg·min],2.53,48166,DB00592,Piperazine
,3392239,t1/2,"Estimated pharmacokinetic parameters included Vz (0.80 +/- 0.20 L/kg), CL (2.53 +/- 0.99 mL/min/kg) and t1/2 (4.0 +/- 1.5 hr).",Pharmacokinetics and pharmacodynamics of urapidil in severe hypertension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392239/),h,4.0,48167,DB00592,Piperazine
,28025967,tmax,"When sildenafil was given with high-fat meals, mean C<sub>max</sub> was reduced by 23%, and median tmax ranged from 0.75 to 1.50 hours (p ≤ 0.05).","A single dose, randomized, open-label, cross-over bioequivalence study of sildenafil citrate tablets in healthy Chinese volunteers . ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28025967/),h,0.75 to 1.50,48606,DB00592,Piperazine
,9256973,mean residence time (MRT),"For E1, itraconazole plasma drug concentration extrapolated to time zero (IV dose) was 5.2 +/- 1.4 micrograms/ml, and mean residence time (MRT) was 37 +/- 16 hours.",Itraconazole disposition after single oral and intravenous and multiple oral dosing in healthy cats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256973/),h,37,48639,DB00592,Piperazine
,9256973,maximal itraconazole concentration,"For oral dosing, maximal itraconazole concentration was 1.69 +/- 0.864 micrograms/ml, MRT was 48 +/- 17 hours, and bioavailability was 78.8 +/- 28%.",Itraconazole disposition after single oral and intravenous and multiple oral dosing in healthy cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256973/),[μg] / [ml],1.69,48640,DB00592,Piperazine
,9256973,MRT,"For oral dosing, maximal itraconazole concentration was 1.69 +/- 0.864 micrograms/ml, MRT was 48 +/- 17 hours, and bioavailability was 78.8 +/- 28%.",Itraconazole disposition after single oral and intravenous and multiple oral dosing in healthy cats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256973/),h,48,48641,DB00592,Piperazine
,9256973,bioavailability,"For oral dosing, maximal itraconazole concentration was 1.69 +/- 0.864 micrograms/ml, MRT was 48 +/- 17 hours, and bioavailability was 78.8 +/- 28%.",Itraconazole disposition after single oral and intravenous and multiple oral dosing in healthy cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256973/),%,78.8,48642,DB00592,Piperazine
,9256973,MRT,"For the multiple oral dosing study, MRT (at last dose: 81.1 +/- 97.4 hours for G1, and 63.1 +/- 15.1 hours for G2) was shorter (P = 0.02) at first dose, compared with last dose, for both groups but did not differ between groups.",Itraconazole disposition after single oral and intravenous and multiple oral dosing in healthy cats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256973/),h,81.1,48643,DB00592,Piperazine
,9256973,MRT,"For the multiple oral dosing study, MRT (at last dose: 81.1 +/- 97.4 hours for G1, and 63.1 +/- 15.1 hours for G2) was shorter (P = 0.02) at first dose, compared with last dose, for both groups but did not differ between groups.",Itraconazole disposition after single oral and intravenous and multiple oral dosing in healthy cats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256973/),h,63.1,48644,DB00592,Piperazine
up,9256973,steady-state concentrations,The oral itraconazole solution is preferred to capsules; a 24-hour dosing interval should be sufficient; 10 mg/kg given daily should generate therapeutic concentrations in most cats; steady-state concentrations may take up to 3 weeks to achieve; and cats appear to tolerate itraconazole well.,Itraconazole disposition after single oral and intravenous and multiple oral dosing in healthy cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9256973/),weeks,3,48645,DB00592,Piperazine
,10677817,half-life,The plasma concentration of DW116 declined monoexponentially with a half-life range of 16-22 hr.,"Pharmacokinetics and urinary excretion of DW116, a new fluoroquinolone antibacterial agent, in humans as a phase I study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677817/),h,16-22,48846,DB00592,Piperazine
,10677817,T1/2,The T1/2 and mean residence time (MRT) (28.3-30.9 hr) were independent of dose.,"Pharmacokinetics and urinary excretion of DW116, a new fluoroquinolone antibacterial agent, in humans as a phase I study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677817/),h,28.3-30.9,48847,DB00592,Piperazine
,10677817,Tmax,The Tmax appeared within 3 hr (0.9-2.7 hr) after drug administration.,"Pharmacokinetics and urinary excretion of DW116, a new fluoroquinolone antibacterial agent, in humans as a phase I study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677817/),h,3,48848,DB00592,Piperazine
,10677817,Ka,The Ka ranged from 1.3 to 4.1 (hr-1).,"Pharmacokinetics and urinary excretion of DW116, a new fluoroquinolone antibacterial agent, in humans as a phase I study. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677817/),,1.3 to 4.1,48849,DB00592,Piperazine
,33720590,solub,"The solubility assessment in biorelevant media showed that the average limit of macozinone substance dissolution in the pH 5.0 acetate buffer solution was from 6 to 9 mg/l, in FaSSIF medium (fasted) from 2.5 to 4 mg/l, and in FeSSIF medium (after meals) from 16.8 to 29 mg/l.",[Effect of physicochemical properties on the pharmacokinetic parameters of the new representative of benzothiazinones antituberculosis drug macozinonе]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33720590/),,6 to 9,48893,DB00592,Piperazine
,33720590,solub,"The solubility assessment in biorelevant media showed that the average limit of macozinone substance dissolution in the pH 5.0 acetate buffer solution was from 6 to 9 mg/l, in FaSSIF medium (fasted) from 2.5 to 4 mg/l, and in FeSSIF medium (after meals) from 16.8 to 29 mg/l.",[Effect of physicochemical properties on the pharmacokinetic parameters of the new representative of benzothiazinones antituberculosis drug macozinonе]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33720590/),mg,2.5 to 4,48894,DB00592,Piperazine
,33720590,solub,"The solubility assessment in biorelevant media showed that the average limit of macozinone substance dissolution in the pH 5.0 acetate buffer solution was from 6 to 9 mg/l, in FaSSIF medium (fasted) from 2.5 to 4 mg/l, and in FeSSIF medium (after meals) from 16.8 to 29 mg/l.",[Effect of physicochemical properties on the pharmacokinetic parameters of the new representative of benzothiazinones antituberculosis drug macozinonе]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33720590/),mg,16.8 to 29,48895,DB00592,Piperazine
,33720590,cell permeability,"It is established that the cell permeability of the pharmaceutical substance macozinone in the CACO-2 test system is on average 2.510-6cm/s in the forward direction from the apical to basolateral cell membrane, and 1.510-6cm/s in the reverse direction, which corresponds to low permeability.",[Effect of physicochemical properties on the pharmacokinetic parameters of the new representative of benzothiazinones antituberculosis drug macozinonе]. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33720590/),[cm] / [s],2.510-6,48896,DB00592,Piperazine
,33720590,cell permeability,"It is established that the cell permeability of the pharmaceutical substance macozinone in the CACO-2 test system is on average 2.510-6cm/s in the forward direction from the apical to basolateral cell membrane, and 1.510-6cm/s in the reverse direction, which corresponds to low permeability.",[Effect of physicochemical properties on the pharmacokinetic parameters of the new representative of benzothiazinones antituberculosis drug macozinonе]. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33720590/),[cm] / [s],1.510-6,48897,DB00592,Piperazine
,10417494,inlet concentration,"The inlet concentration of (R/S)-verapamil was 120 mg l-1 in both periods, and ketoconazole was added at 40 mg l-1 in period 2.",The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10417494/),[mg] / [l],120,49074,DB00592,Piperazine
,20920436,area under the curve from time 0 to 480 minutes (AUC(0-480)),"No significant pharmacokinetic differences were observed between healthy subjects and CLD subjects [geometric mean (% coefficient of variation) area under the curve from time 0 to 480 minutes (AUC(0-480)): 26,710 (34.8) and 31,477 (28.8) ng/ml·min, respectively].",Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20920436/),[ng] / [min·ml],"26,710",49155,DB00592,Piperazine
,20920436,area under the curve from time 0 to 480 minutes (AUC(0-480)),"No significant pharmacokinetic differences were observed between healthy subjects and CLD subjects [geometric mean (% coefficient of variation) area under the curve from time 0 to 480 minutes (AUC(0-480)): 26,710 (34.8) and 31,477 (28.8) ng/ml·min, respectively].",Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20920436/),[ng] / [min·ml],"31,477",49156,DB00592,Piperazine
,20920436,C(max),"Maximum observed drug concentration (C(max)) and AUC(0-480) were higher in DNP subjects than in subjects with normal renal function [C(max): 159.9 (59.4) ng/ml versus 147.0 (44.3) ng/ml; AUC(0-480): 36,869 (47.2) ng/ml·min versus 30,474 (31.8) ng/ml·min].",Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20920436/),[ng] / [ml],159.9,49157,DB00592,Piperazine
,20920436,C(max),"Maximum observed drug concentration (C(max)) and AUC(0-480) were higher in DNP subjects than in subjects with normal renal function [C(max): 159.9 (59.4) ng/ml versus 147.0 (44.3) ng/ml; AUC(0-480): 36,869 (47.2) ng/ml·min versus 30,474 (31.8) ng/ml·min].",Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20920436/),[ng] / [ml],147.0,49158,DB00592,Piperazine
,20920436,AUC(0-480),"Maximum observed drug concentration (C(max)) and AUC(0-480) were higher in DNP subjects than in subjects with normal renal function [C(max): 159.9 (59.4) ng/ml versus 147.0 (44.3) ng/ml; AUC(0-480): 36,869 (47.2) ng/ml·min versus 30,474 (31.8) ng/ml·min].",Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20920436/),[ng] / [min·ml],"36,869",49159,DB00592,Piperazine
,20920436,AUC(0-480),"Maximum observed drug concentration (C(max)) and AUC(0-480) were higher in DNP subjects than in subjects with normal renal function [C(max): 159.9 (59.4) ng/ml versus 147.0 (44.3) ng/ml; AUC(0-480): 36,869 (47.2) ng/ml·min versus 30,474 (31.8) ng/ml·min].",Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20920436/),[ng] / [min·ml],"30,474",49160,DB00592,Piperazine
,17073891,trough target concentration,Dosing schedules were simulated to assess their ability to achieve a trough target concentration of 0.5 mg ml(-1).,A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17073891/),[mg] / [ml],0.5,49595,DB00592,Piperazine
,17073891,absorption rate constants,"For itraconazole the absorption rate constants (between-subject variability) for capsule and solution were 0.0315 h(-1) (91.9%) and 0.125 h(-1) (106.3%), respectively, and the relative bioavailability of the capsule was 0.82 (62.3%) (confidence interval 0.36, 1.97), compared with the solution.",A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17073891/),1/[h],0.0315,49596,DB00592,Piperazine
,17073891,absorption rate constants,"For itraconazole the absorption rate constants (between-subject variability) for capsule and solution were 0.0315 h(-1) (91.9%) and 0.125 h(-1) (106.3%), respectively, and the relative bioavailability of the capsule was 0.82 (62.3%) (confidence interval 0.36, 1.97), compared with the solution.",A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17073891/),1/[h],0.125,49597,DB00592,Piperazine
,17073891,relative bioavailability,"For itraconazole the absorption rate constants (between-subject variability) for capsule and solution were 0.0315 h(-1) (91.9%) and 0.125 h(-1) (106.3%), respectively, and the relative bioavailability of the capsule was 0.82 (62.3%) (confidence interval 0.36, 1.97), compared with the solution.",A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17073891/),,0.82,49598,DB00592,Piperazine
,17073891,relative bioavailability,The relative bioavailability for itraconazole capsules was 82% compared with the solution.,A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17073891/),%,82,49599,DB00592,Piperazine
,25421475,peak drug concentration (Cmax),"At the highest dose level, the peak drug concentration (Cmax) and the area under the plasma concentration-time curve from zero to infinity of ACT-451840 under fasted conditions reached 11.9 ng/ml and 100.6 ng·h/ml, respectively, and these were approximately 13-fold higher under fed conditions.","First-in-humans study of the safety, tolerability, and pharmacokinetics of ACT-451840, a new chemical entity with antimalarial activity. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25421475/),[ng] / [ml],11.9,49864,DB00592,Piperazine
,25421475,area under the plasma concentration-time curve from zero to infinity,"At the highest dose level, the peak drug concentration (Cmax) and the area under the plasma concentration-time curve from zero to infinity of ACT-451840 under fasted conditions reached 11.9 ng/ml and 100.6 ng·h/ml, respectively, and these were approximately 13-fold higher under fed conditions.","First-in-humans study of the safety, tolerability, and pharmacokinetics of ACT-451840, a new chemical entity with antimalarial activity. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25421475/),[h·ng] / [ml],100.6,49865,DB00592,Piperazine
,25421475,half-life,"Food did not affect the half-life (approximately 34 h) of the drug, while the Cmax was attained 2.0 and 3.5 h postdose under fasted and fed conditions, respectively.","First-in-humans study of the safety, tolerability, and pharmacokinetics of ACT-451840, a new chemical entity with antimalarial activity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25421475/),h,34,49866,DB00592,Piperazine
,25421475,Cmax,"Food did not affect the half-life (approximately 34 h) of the drug, while the Cmax was attained 2.0 and 3.5 h postdose under fasted and fed conditions, respectively.","First-in-humans study of the safety, tolerability, and pharmacokinetics of ACT-451840, a new chemical entity with antimalarial activity. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25421475/),h,2.0,49867,DB00592,Piperazine
,25421475,Cmax,"Food did not affect the half-life (approximately 34 h) of the drug, while the Cmax was attained 2.0 and 3.5 h postdose under fasted and fed conditions, respectively.","First-in-humans study of the safety, tolerability, and pharmacokinetics of ACT-451840, a new chemical entity with antimalarial activity. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25421475/),h,3.5,49868,DB00592,Piperazine
,11865970,Cmax,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),[ng] / [ml],500,49891,DB00592,Piperazine
,11865970,Cmax,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),[ng] / [ml],637,49892,DB00592,Piperazine
,11865970,tmax,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),h,2.3,49893,DB00592,Piperazine
,11865970,tmax,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),h,2.7,49894,DB00592,Piperazine
,11865970,Ka,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),1/[h],2.23,49895,DB00592,Piperazine
,11865970,Ka,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),1/[h],1.96,49896,DB00592,Piperazine
,11865970,t1/2,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),h,14.6,49897,DB00592,Piperazine
,11865970,t1/2,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),h,11.4,49898,DB00592,Piperazine
,11865970,AUC0-t,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),[h·ng] / [ml],"5,334",49899,DB00592,Piperazine
,11865970,AUC0-t,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),[h·ng] / [ml],"6,901",49900,DB00592,Piperazine
,11865970,AUC0-infinity,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),[h·ng] / [ml],"5,840",49901,DB00592,Piperazine
,11865970,AUC0-infinity,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),[h·ng] / [ml],"7,220",49902,DB00592,Piperazine
,11865970,CL/F,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),[ml] / [h·kg],"36,058",49903,DB00592,Piperazine
,11865970,CL/F,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),[ml] / [h·kg],"32,189",49904,DB00592,Piperazine
,11865970,Vd/F,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),l,570,49905,DB00592,Piperazine
,11865970,Vd/F,"The mean +/- SD values of pharmacokinetic parameters of DEC for the treatments at 0600 versus 1800 h were as follows: Cmax, 500+/-227 versus 637+/-401 ng/ml; tmax, 2.3+/-0.7 versus 2.7+/-1 h; Ka, 2.23+/-0.72 versus 1.96+/-0.97 h(-1); t1/2, 14.6+/-6.7 versus 11.4+/-4.9 h; AUC0-t, 5,334+/-1,853 versus 6,901+/-4,203 ng x h/ml; AUC0-infinity, 5,840+/-1,922 versus 7,220+/-4,205 ng x h/ml; CL/F, 36,058+/-19,011 versus 32,189+/-25,293 ml/h/kg; Vd/F, 570+/-225 versus 533+/-447 L; and MRT 17.7+/-5.9 versus 15.3+/-5.2 h.",Pharmacokinetics of diethylcarbamazine after single oral dose at two different times of day in human subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11865970/),l,533,49906,DB00592,Piperazine
,30594035,m/z,"In positive ion mode, four analytes and IS were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 494.3→394.2 for imatinib, m/z 480.3→394.2 for N-desmethyl imatinib, m/z 350.1→281.1 for voriconazole, m/z 366.1→224.1 for N-oxide voriconazole, and m/z 285.0→154.0 for IS.","UPLC-MS/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30594035/),,350.1,49923,DB00592,Piperazine
,30594035,m/z,"In positive ion mode, four analytes and IS were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 494.3→394.2 for imatinib, m/z 480.3→394.2 for N-desmethyl imatinib, m/z 350.1→281.1 for voriconazole, m/z 366.1→224.1 for N-oxide voriconazole, and m/z 285.0→154.0 for IS.","UPLC-MS/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30594035/),,281.1,49924,DB00592,Piperazine
,30594035,m/z,"In positive ion mode, four analytes and IS were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 494.3→394.2 for imatinib, m/z 480.3→394.2 for N-desmethyl imatinib, m/z 350.1→281.1 for voriconazole, m/z 366.1→224.1 for N-oxide voriconazole, and m/z 285.0→154.0 for IS.","UPLC-MS/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30594035/),,366.1,49925,DB00592,Piperazine
,30594035,m/z,"In positive ion mode, four analytes and IS were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 494.3→394.2 for imatinib, m/z 480.3→394.2 for N-desmethyl imatinib, m/z 350.1→281.1 for voriconazole, m/z 366.1→224.1 for N-oxide voriconazole, and m/z 285.0→154.0 for IS.","UPLC-MS/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30594035/),,224.1,49926,DB00592,Piperazine
,30594035,m,"In positive ion mode, four analytes and IS were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 494.3→394.2 for imatinib, m/z 480.3→394.2 for N-desmethyl imatinib, m/z 350.1→281.1 for voriconazole, m/z 366.1→224.1 for N-oxide voriconazole, and m/z 285.0→154.0 for IS.","UPLC-MS/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30594035/),,285.0,49927,DB00592,Piperazine
,15073132,Peak plasma imatinib concentrations,Peak plasma imatinib concentrations ranged from 6.4 to 9.5 microM after i.v. dosing and 0.8 to 2.8 microM after p.o. dosing.,Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073132/),μM,6.4 to 9.5,50129,DB00592,Piperazine
,15073132,Peak plasma imatinib concentrations,Peak plasma imatinib concentrations ranged from 6.4 to 9.5 microM after i.v. dosing and 0.8 to 2.8 microM after p.o. dosing.,Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073132/),μM,0.8 to 2.8,50130,DB00592,Piperazine
,15073132,area under the plasma concentration versus time curve,"The mean +/-SD area under the plasma concentration versus time curve was 2480 +/-1340 microM.min and 1191 +/-146 microM.min after i.v. and p.o. dosing, respectively.",Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073132/),min·μM,2480,50131,DB00592,Piperazine
,15073132,area under the plasma concentration versus time curve,"The mean +/-SD area under the plasma concentration versus time curve was 2480 +/-1340 microM.min and 1191 +/-146 microM.min after i.v. and p.o. dosing, respectively.",Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073132/),min·μM,1191,50132,DB00592,Piperazine
,15073132,terminal half-life,The terminal half-life was 529 +/-167 min after i.v. dosing and 266 +/-88 min after p.o. dosing.,Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073132/),min,529,50133,DB00592,Piperazine
,15073132,terminal half-life,The terminal half-life was 529 +/-167 min after i.v. dosing and 266 +/-88 min after p.o. dosing.,Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073132/),min,266,50134,DB00592,Piperazine
,15073132,steady state volume of distribution,"After i.v. dosing the steady state volume of distribution was 5.9 +/-2.8 liter/kg, and the total body clearance was 12 +/-5 ml/min/kg.",Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073132/),[l] / [kg],5.9,50135,DB00592,Piperazine
,15073132,total body clearance,"After i.v. dosing the steady state volume of distribution was 5.9 +/-2.8 liter/kg, and the total body clearance was 12 +/-5 ml/min/kg.",Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073132/),[ml] / [kg·min],12,50136,DB00592,Piperazine
,15073132,peak CSF concentration,The mean peak CSF concentration was 0.25 +/-0.07 microM after i.v. dosing and 0.07 +/-0.04 microM after p.o. dosing.,Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073132/),μM,0.25,50137,DB00592,Piperazine
,15073132,peak CSF concentration,The mean peak CSF concentration was 0.25 +/-0.07 microM after i.v. dosing and 0.07 +/-0.04 microM after p.o. dosing.,Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073132/),μM,0.07,50138,DB00592,Piperazine
,15073132,CSF:plasma area under the plasma concentration versus time curve ratio,The mean CSF:plasma area under the plasma concentration versus time curve ratio for all of the animals was 5% +/-2%.,Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073132/),%,5,50139,DB00592,Piperazine
,25450725,fraction absorbed,"The fraction absorbed and intestinal availability of teneligliptin predicted by the model were 0.62 and 0.99, respectively.",Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25450725/),,0,50163,DB00592,Piperazine
,15058598,flow rate,"The mobile phase consisted of [0.01% triethylamine solution adjusted to pH 2.8 with orthophosphoric acid-acetonitrile (46:54)]-isopropanol (90:10, v/v) at a flow rate of 1.0 ml/min.",Simultaneous determination of itraconazole and hydroxyitraconazole in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15058598/),[ml] / [min],1.0,50409,DB00592,Piperazine
more,15058598,observed recovery,"An observed recovery was more than 70% for drug, metabolite and internal standard.",Simultaneous determination of itraconazole and hydroxyitraconazole in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15058598/),%,70,50410,DB00592,Piperazine
,7905394,AUC0-->infinity,Determination of concentrations of zopiclone enantiomers in plasma showed that zopiclone pharmacokinetics is stereoselective with AUC0-->infinity values of 691.3 and 209.5 ng.,Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905394/),ng,691.3,50776,DB00592,Piperazine
,7905394,AUC0-->infinity,Determination of concentrations of zopiclone enantiomers in plasma showed that zopiclone pharmacokinetics is stereoselective with AUC0-->infinity values of 691.3 and 209.5 ng.,Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905394/),ng,209.5,50777,DB00592,Piperazine
,7905394,Cmax,"ml-1.hr (p < 0.001), Cmax values of 87.3 and 44.0 ng.",Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905394/),ng,87.3,50778,DB00592,Piperazine
,7905394,Cmax,"ml-1.hr (p < 0.001), Cmax values of 87.3 and 44.0 ng.",Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905394/),ng,44.0,50779,DB00592,Piperazine
,7905394,oral CLtot/F,"ml-1 (p < 0.001), oral CLtot/F values of 195.5 and 659.8 ml.min-1 (p < 0.001), Vd/F values of 98.6 and 192.8 liters (p < 0.01) and elimination half-life of 399.2 and 225.6 min (p < 0.01) for (+)-zopiclone and (-)-zopiclone, respectively.",Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905394/),[ml] / [min],195.5,50780,DB00592,Piperazine
,7905394,oral CLtot/F,"ml-1 (p < 0.001), oral CLtot/F values of 195.5 and 659.8 ml.min-1 (p < 0.001), Vd/F values of 98.6 and 192.8 liters (p < 0.01) and elimination half-life of 399.2 and 225.6 min (p < 0.01) for (+)-zopiclone and (-)-zopiclone, respectively.",Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905394/),[ml] / [min],659.8,50781,DB00592,Piperazine
,7905394,Vd/F,"ml-1 (p < 0.001), oral CLtot/F values of 195.5 and 659.8 ml.min-1 (p < 0.001), Vd/F values of 98.6 and 192.8 liters (p < 0.01) and elimination half-life of 399.2 and 225.6 min (p < 0.01) for (+)-zopiclone and (-)-zopiclone, respectively.",Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905394/),l,98.6,50782,DB00592,Piperazine
,7905394,Vd/F,"ml-1 (p < 0.001), oral CLtot/F values of 195.5 and 659.8 ml.min-1 (p < 0.001), Vd/F values of 98.6 and 192.8 liters (p < 0.01) and elimination half-life of 399.2 and 225.6 min (p < 0.01) for (+)-zopiclone and (-)-zopiclone, respectively.",Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905394/),l,192.8,50783,DB00592,Piperazine
,7905394,elimination half-life,"ml-1 (p < 0.001), oral CLtot/F values of 195.5 and 659.8 ml.min-1 (p < 0.001), Vd/F values of 98.6 and 192.8 liters (p < 0.01) and elimination half-life of 399.2 and 225.6 min (p < 0.01) for (+)-zopiclone and (-)-zopiclone, respectively.",Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905394/),min,399.2,50784,DB00592,Piperazine
,7905394,elimination half-life,"ml-1 (p < 0.001), oral CLtot/F values of 195.5 and 659.8 ml.min-1 (p < 0.001), Vd/F values of 98.6 and 192.8 liters (p < 0.01) and elimination half-life of 399.2 and 225.6 min (p < 0.01) for (+)-zopiclone and (-)-zopiclone, respectively.",Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905394/),min,225.6,50785,DB00592,Piperazine
,23824675,90 % inhibitory concentration (IC90),"The in vitro, protein-adjusted 90 % inhibitory concentration (IC90) of dolutegravir for wild-type virus is 0.064 μg/ml, and it retains in vitro anti-HIV 1 activity across a broad range of viral phenotypes that are known to confer resistance to the currently marketed INSTIs, raltegravir and elvitegravir.","Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23824675/),[μg] / [ml],0.064,51136,DB00592,Piperazine
,23824675,terminal elimination half-life,"Dolutegravir has a terminal elimination half-life of 13-14 h and maintains concentrations over the in vitro, protein-adjusted IC90 for more than 30 h following a single dose.","Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23824675/),h,13-14,51137,DB00592,Piperazine
,22111976,zeta potential,CMC-ITZ-Lips had an average diameter of 349.3 ± 18 nm with a zeta potential of -35.71 ± 0.62 mV and the in vitro antifungal activity was not inhibited by the entrapment.,Preparation of itraconazole-loaded liposomes coated by carboxymethyl chitosan and its pharmacokinetics and tissue distribution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22111976/),mv,-,51352,DB00592,Piperazine
,22111976,zeta potential,CMC-ITZ-Lips had an average diameter of 349.3 ± 18 nm with a zeta potential of -35.71 ± 0.62 mV and the in vitro antifungal activity was not inhibited by the entrapment.,Preparation of itraconazole-loaded liposomes coated by carboxymethyl chitosan and its pharmacokinetics and tissue distribution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22111976/),mv,35.71,51353,DB00592,Piperazine
,29333613,maximum concentration,Trazodone was rapidly absorbed after oral administration with a maximum concentration of 2.5-4.1 μg/ml and half-life of the terminal phase of approximately 7 hr.,"Pharmacokinetics, pharmacodynamics and clinical use of trazodone and its active metabolite m-chlorophenylpiperazine in the horse. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29333613/),[μg] / [ml],2.5-4.1,52050,DB00592,Piperazine
,29333613,half-life of the terminal phase,Trazodone was rapidly absorbed after oral administration with a maximum concentration of 2.5-4.1 μg/ml and half-life of the terminal phase of approximately 7 hr.,"Pharmacokinetics, pharmacodynamics and clinical use of trazodone and its active metabolite m-chlorophenylpiperazine in the horse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29333613/),h,7,52051,DB00592,Piperazine
,24838249,apparent elimination rate constant,"The apparent elimination rate constant and corresponding half-life of unchanged (11)C-ORM-13070 in arterial plasma were 0.0117 ± 0.0056 min(-1) and 73.6 ± 35.8 min, respectively.","¹¹C-ORM-13070, a novel PET ligand for brain α₂C-adrenoceptors: radiometabolism, plasma pharmacokinetics, whole-body distribution and radiation dosimetry in healthy men. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24838249/),1/[min],0.0117,52102,DB00592,Piperazine
,24838249,half-life,"The apparent elimination rate constant and corresponding half-life of unchanged (11)C-ORM-13070 in arterial plasma were 0.0117 ± 0.0056 min(-1) and 73.6 ± 35.8 min, respectively.","¹¹C-ORM-13070, a novel PET ligand for brain α₂C-adrenoceptors: radiometabolism, plasma pharmacokinetics, whole-body distribution and radiation dosimetry in healthy men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24838249/),min,73.6,52103,DB00592,Piperazine
,24838249,effective dose,"The mean effective dose was 3.9 μSv/MBq, with a range of 3.6 - 4.2 μSv/MBq.","¹¹C-ORM-13070, a novel PET ligand for brain α₂C-adrenoceptors: radiometabolism, plasma pharmacokinetics, whole-body distribution and radiation dosimetry in healthy men. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24838249/),[μsv] / [Mbq],3.9,52104,DB00592,Piperazine
,2892447,peak mean concentration,The drug was rapidly absorbed: The peak mean concentration of radioactivity (359 ng-equivalents/mL) and of unchanged drug (341 ng/mL) were achieved within one hour.,The metabolism and pharmacokinetics of 14C-cetirizine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892447/),[ng-equivalents] / [ml],359,52260,DB00592,Piperazine
,2892447,peak mean concentration,The drug was rapidly absorbed: The peak mean concentration of radioactivity (359 ng-equivalents/mL) and of unchanged drug (341 ng/mL) were achieved within one hour.,The metabolism and pharmacokinetics of 14C-cetirizine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892447/),[ng] / [ml],341,52261,DB00592,Piperazine
,2892447,elimination half-life,Mean concentrations of cetirizine declined biexponentially and had a mean elimination half-life of 7.4 hours.,The metabolism and pharmacokinetics of 14C-cetirizine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892447/),h,7.4,52262,DB00592,Piperazine
,27861318,plasma trough concentration,"It has been suggested that a plasma trough concentration of aripiprazole plus its active metabolite, dehydroaripiprazole of 225 ng/mL is a threshold for a good therapeutic response in the treatment of acutely exacerbated patients with schizophrenia.",Prediction of an Optimal Dose of Aripiprazole in the Treatment of Schizophrenia From Plasma Concentrations of Aripiprazole Plus Its Active Metabolite Dehydroaripiprazole at Week 1. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27861318/),[ng] / [ml],225,52271,DB00592,Piperazine
,1994529,trough whole-blood,"The mean trough whole-blood cyclosporine concentrations measured by HPLC, were 130 ng/mL preketoconazole and 149 ng/mL after 1 year of combination therapy.",Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1994529/),[ng] / [ml],130,52439,DB00592,Piperazine
,1994529,trough whole-blood,"The mean trough whole-blood cyclosporine concentrations measured by HPLC, were 130 ng/mL preketoconazole and 149 ng/mL after 1 year of combination therapy.",Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1994529/),[ng] / [ml],149,52440,DB00592,Piperazine
,17517842,maximum plasma concentrations (C(max)),"The maximum plasma concentrations (C(max)) for itraconazole, hydroxyitraconazole, and HP-beta-CD averaged 1,015 +/- 692 ng/ml, 293 +/- 133 ng/ml, and 329 +/- 200 mug/ml, respectively.","Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17517842/),[ng] / [ml],"1,015",52791,DB00592,Piperazine
,17517842,maximum plasma concentrations (C(max)),"The maximum plasma concentrations (C(max)) for itraconazole, hydroxyitraconazole, and HP-beta-CD averaged 1,015 +/- 692 ng/ml, 293 +/- 133 ng/ml, and 329 +/- 200 mug/ml, respectively.","Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17517842/),[ng] / [ml],293,52792,DB00592,Piperazine
,17517842,maximum plasma concentrations (C(max)),"The maximum plasma concentrations (C(max)) for itraconazole, hydroxyitraconazole, and HP-beta-CD averaged 1,015 +/- 692 ng/ml, 293 +/- 133 ng/ml, and 329 +/- 200 mug/ml, respectively.","Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17517842/),[μg] / [ml],329,52793,DB00592,Piperazine
,17517842,area under the concentration-time curve from 0 to 24 h,"The total body exposures (area under the concentration-time curve from 0 to 24 h) for itraconazole, hydroxyitraconazole, and HP-beta-CD averaged 4,922 +/- 6,784 ng.h/ml, 3,811 +/- 2,794 ng.h/ml, and 641.5 +/- 265.0 mug.h/ml, respectively, with no significant age dependence observed among the children evaluated.","Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17517842/),[h·ng] / [ml],"4,922",52794,DB00592,Piperazine
,17517842,area under the concentration-time curve from 0 to 24 h,"The total body exposures (area under the concentration-time curve from 0 to 24 h) for itraconazole, hydroxyitraconazole, and HP-beta-CD averaged 4,922 +/- 6,784 ng.h/ml, 3,811 +/- 2,794 ng.h/ml, and 641.5 +/- 265.0 mug.h/ml, respectively, with no significant age dependence observed among the children evaluated.","Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17517842/),[h·ng] / [ml],"3,811",52795,DB00592,Piperazine
,17517842,area under the concentration-time curve from 0 to 24 h,"The total body exposures (area under the concentration-time curve from 0 to 24 h) for itraconazole, hydroxyitraconazole, and HP-beta-CD averaged 4,922 +/- 6,784 ng.h/ml, 3,811 +/- 2,794 ng.h/ml, and 641.5 +/- 265.0 mug.h/ml, respectively, with no significant age dependence observed among the children evaluated.","Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17517842/),[h·μg] / [ml],641.5,52796,DB00592,Piperazine
,17517842,total body clearance,"Similarly, there was no relationship between age and total body clearance (702.8 +/- 499.4 ml/h/kg); however, weak associations between age and the itraconazole distribution volume (r(2) = 0.18, P = 0.02), C(max) (r(2) = 0.14, P = 0.045), and terminal elimination rate (r(2) = 0.26, P < 0.01) were noted.","Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17517842/),[ml] / [h·kg],702.8,52797,DB00592,Piperazine
,18447799,half-life,Morphine was rapidly eliminated with a half-life of 1.28 hours and a plasma clearance of 32.55 mL/min/kg.,Effects of ketoconazole on the pharmacokinetics and pharmacodynamics of morphine in healthy Greyhounds. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447799/),h,1.28,52879,DB00592,Piperazine
,18447799,plasma clearance,Morphine was rapidly eliminated with a half-life of 1.28 hours and a plasma clearance of 32.55 mL/min/kg.,Effects of ketoconazole on the pharmacokinetics and pharmacodynamics of morphine in healthy Greyhounds. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447799/),[ml] / [kg·min],32.55,52880,DB00592,Piperazine
,18447799,volume of distribution,The volume of distribution was 3.6 L/kg.,Effects of ketoconazole on the pharmacokinetics and pharmacodynamics of morphine in healthy Greyhounds. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447799/),[l] / [kg],3.6,52881,DB00592,Piperazine
,7840567,maximum concentrations,"OPC-17116 showed a high degree of distribution in the lung tissues of both species, with maximum concentrations of 29.6 and 32.0 micrograms/g, respectively.",Evaluation of OPC-17116 against important pathogens that cause respiratory tract infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7840567/),[μg] / [g],29.6,53129,DB00592,Piperazine
,7840567,maximum concentrations,"OPC-17116 showed a high degree of distribution in the lung tissues of both species, with maximum concentrations of 29.6 and 32.0 micrograms/g, respectively.",Evaluation of OPC-17116 against important pathogens that cause respiratory tract infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7840567/),[μg] / [g],32.0,53130,DB00592,Piperazine
<,7840567,MICs,The MICs of this compound for 90% of these organisms except methicillin-resistant S. aureus and P. aeruginosa ranged from < or = 0.006 to 0.78 microgram/ml.,Evaluation of OPC-17116 against important pathogens that cause respiratory tract infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7840567/),[μg] / [ml],0,53131,DB00592,Piperazine
,7726523,peak concentration,The mean peak concentration in plasma of 1.5 micrograms/ml was attained at a mean time of 2.0 h postdose.,Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726523/),[μg] / [ml],1.5,53143,DB00592,Piperazine
,7726523,mean time,The mean peak concentration in plasma of 1.5 micrograms/ml was attained at a mean time of 2.0 h postdose.,Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726523/),h,2.0,53144,DB00592,Piperazine
,7726523,peak concentration in inflammatory fluid,The mean peak concentration in inflammatory fluid of 1.1 micrograms/ml was attained at a mean time of 4.8 h postdose.,Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726523/),[μg] / [ml],1.1,53145,DB00592,Piperazine
,7726523,mean time,The mean peak concentration in inflammatory fluid of 1.1 micrograms/ml was attained at a mean time of 4.8 h postdose.,Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726523/),h,4.8,53146,DB00592,Piperazine
,7726523,elimination half-life,"The mean elimination half-life in plasma was 5.2 h, and that in inflammatory fluid was 12.7 h.",Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726523/),h,5.2,53147,DB00592,Piperazine
,7726523,elimination half-life,"The mean elimination half-life in plasma was 5.2 h, and that in inflammatory fluid was 12.7 h.",Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726523/),h,12.7,53148,DB00592,Piperazine
,7726523,overall penetration into inflammatory fluid,The overall penetration into inflammatory fluid was 180.6% (or 133% if one aberrant result from one volunteer is excluded).,Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726523/),%,180.6,53149,DB00592,Piperazine
,7726523,overall penetration into inflammatory fluid,The overall penetration into inflammatory fluid was 180.6% (or 133% if one aberrant result from one volunteer is excluded).,Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7726523/),%,133,53150,DB00592,Piperazine
,32608074,IC50,"Apatinib inhibited the generations of 1-PP and 6-OH buspirone dose-dependently with IC50 of 1.76 and 2.23 μm in RLMs, and 1.51 and 1.48 μm in HLMs, respectively.",The effect of apatinib on pharmacokinetic profile of buspirone both in vivo and in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32608074/),μm,1.76,53180,DB00592,Piperazine
,32608074,IC50,"Apatinib inhibited the generations of 1-PP and 6-OH buspirone dose-dependently with IC50 of 1.76 and 2.23 μm in RLMs, and 1.51 and 1.48 μm in HLMs, respectively.",The effect of apatinib on pharmacokinetic profile of buspirone both in vivo and in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32608074/),μm,2.23,53181,DB00592,Piperazine
,32608074,IC50,"Apatinib inhibited the generations of 1-PP and 6-OH buspirone dose-dependently with IC50 of 1.76 and 2.23 μm in RLMs, and 1.51 and 1.48 μm in HLMs, respectively.",The effect of apatinib on pharmacokinetic profile of buspirone both in vivo and in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32608074/),μm,1.51,53182,DB00592,Piperazine
,32608074,IC50,"Apatinib inhibited the generations of 1-PP and 6-OH buspirone dose-dependently with IC50 of 1.76 and 2.23 μm in RLMs, and 1.51 and 1.48 μm in HLMs, respectively.",The effect of apatinib on pharmacokinetic profile of buspirone both in vivo and in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32608074/),μm,1.48,53183,DB00592,Piperazine
,15198516,maximum suppression,"Mean maximum suppression, 85% to 94%, occurred from 2 to 6 hours, with no differences among the formulations.",Hydroxyzine from topical phospholipid liposomal formulations: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198516/),%,85,53490,DB00592,Piperazine
,15198516,maximum suppression,"Mean maximum suppression, 85% to 94%, occurred from 2 to 6 hours, with no differences among the formulations.",Hydroxyzine from topical phospholipid liposomal formulations: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198516/),%,94,53491,DB00592,Piperazine
,15198516,areas of plasma hydroxyzine concentration versus time area under the curve (AUCs),"The areas of plasma hydroxyzine concentration versus time area under the curve (AUCs) from PC-SUV and PC-MLV, 80.1 +/- 20.8 and 78.4 +/- 33.9 ng/mL/h, respectively, were lower than that from GB, 492 +/- 141 ng/mL/h (P < or =.05) over 24 hours.",Hydroxyzine from topical phospholipid liposomal formulations: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198516/),[ng] / [h·ml],80.1,53492,DB00592,Piperazine
,15198516,areas of plasma hydroxyzine concentration versus time area under the curve (AUCs),"The areas of plasma hydroxyzine concentration versus time area under the curve (AUCs) from PC-SUV and PC-MLV, 80.1 +/- 20.8 and 78.4 +/- 33.9 ng/mL/h, respectively, were lower than that from GB, 492 +/- 141 ng/mL/h (P < or =.05) over 24 hours.",Hydroxyzine from topical phospholipid liposomal formulations: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198516/),[ng] / [h·ml],78.4,53493,DB00592,Piperazine
,15198516,areas of plasma hydroxyzine concentration versus time area under the curve (AUCs),"The areas of plasma hydroxyzine concentration versus time area under the curve (AUCs) from PC-SUV and PC-MLV, 80.1 +/- 20.8 and 78.4 +/- 33.9 ng/mL/h, respectively, were lower than that from GB, 492 +/- 141 ng/mL/h (P < or =.05) over 24 hours.",Hydroxyzine from topical phospholipid liposomal formulations: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198516/),[ng] / [h·ml],492,53494,DB00592,Piperazine
,15198516,AUCs,"Plasma concentrations of cetirizine arising in-vivo as the active metabolite of hydroxyzine, from PC-SUV, PC-MLV, and GB, were similar with AUCs of 765 +/- 50, 1035 +/- 202, and 957 +/- 227 ng/mL/h, respectively (P < or =.05).",Hydroxyzine from topical phospholipid liposomal formulations: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198516/),[ng] / [h·ml],765,53495,DB00592,Piperazine
,15198516,AUCs,"Plasma concentrations of cetirizine arising in-vivo as the active metabolite of hydroxyzine, from PC-SUV, PC-MLV, and GB, were similar with AUCs of 765 +/- 50, 1035 +/- 202, and 957 +/- 227 ng/mL/h, respectively (P < or =.05).",Hydroxyzine from topical phospholipid liposomal formulations: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198516/),[ng] / [h·ml],1035,53496,DB00592,Piperazine
,15198516,AUCs,"Plasma concentrations of cetirizine arising in-vivo as the active metabolite of hydroxyzine, from PC-SUV, PC-MLV, and GB, were similar with AUCs of 765 +/- 50, 1035 +/- 202, and 957 +/- 227 ng/mL/h, respectively (P < or =.05).",Hydroxyzine from topical phospholipid liposomal formulations: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198516/),[ng] / [h·ml],957,53497,DB00592,Piperazine
,22080802,flow rate,Chromatographic separation of the drugs is achieved on an RP-C(18) column at flow rate of 0.9 mL/min at 35°C; eluate is monitored at 267 nm.,A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22080802/),[ml] / [min],0.9,53637,DB00592,Piperazine
,22080802,extraction recovery,Mean intra-day and inter-day precision for all compounds are 2.5 and 13.3%; mean accuracy is 13.9%; extraction recovery ranges within 40.24 and 81.81%.,A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22080802/),%,40.24,53638,DB00592,Piperazine
,22080802,extraction recovery,Mean intra-day and inter-day precision for all compounds are 2.5 and 13.3%; mean accuracy is 13.9%; extraction recovery ranges within 40.24 and 81.81%.,A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22080802/),%,81.81,53639,DB00592,Piperazine
,22080802,Limits of detection,"Limits of detection are 10 ng/mL for imatinib and nilotinib, 50 ng/mL for dasatinib; limits of quantitation are 50 ng/mL for imatinib and nilotinib, 100 ng/mL for dasatinib.",A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22080802/),[ng] / [ml],10,53640,DB00592,Piperazine
,22080802,Limits of detection,"Limits of detection are 10 ng/mL for imatinib and nilotinib, 50 ng/mL for dasatinib; limits of quantitation are 50 ng/mL for imatinib and nilotinib, 100 ng/mL for dasatinib.",A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22080802/),[ng] / [ml],50,53641,DB00592,Piperazine
,22080802,limits of quantitation,"Limits of detection are 10 ng/mL for imatinib and nilotinib, 50 ng/mL for dasatinib; limits of quantitation are 50 ng/mL for imatinib and nilotinib, 100 ng/mL for dasatinib.",A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22080802/),[ng] / [ml],50,53642,DB00592,Piperazine
,22080802,limits of quantitation,"Limits of detection are 10 ng/mL for imatinib and nilotinib, 50 ng/mL for dasatinib; limits of quantitation are 50 ng/mL for imatinib and nilotinib, 100 ng/mL for dasatinib.",A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22080802/),[ng] / [ml],100,53643,DB00592,Piperazine
,18784280,K(m),Aliskiren stimulated in vitro P-glycoprotein ATPase activity in recombinant baculovirus-infected Sf9 cells with high affinity (K(m) 2.1 micromol/L) and was transported by organic anion-transporting peptide OATP2B1-expressing HEK293 cells with moderate affinity (K(m) 72 micromol/L).,"Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18784280/),[μM] / [l],2.1,54148,DB00592,Piperazine
,18784280,K(m),Aliskiren stimulated in vitro P-glycoprotein ATPase activity in recombinant baculovirus-infected Sf9 cells with high affinity (K(m) 2.1 micromol/L) and was transported by organic anion-transporting peptide OATP2B1-expressing HEK293 cells with moderate affinity (K(m) 72 micromol/L).,"Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18784280/),[μM] / [l],72,54149,DB00592,Piperazine
,6894697,half-lives,"After a single i.v. injection of the drug (2 mg/kg), the concentration of radioactivity in the blood decreased bi-phasically with half-lives of 1 and 8 h.","Absorption, distribution and excretion of 14C-pirenzepine in rats. Accumulation characteristics after multiple dose regimen. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6894697/),h,1,54529,DB00592,Piperazine
,6894697,half-lives,"After a single i.v. injection of the drug (2 mg/kg), the concentration of radioactivity in the blood decreased bi-phasically with half-lives of 1 and 8 h.","Absorption, distribution and excretion of 14C-pirenzepine in rats. Accumulation characteristics after multiple dose regimen. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6894697/),h,8,54530,DB00592,Piperazine
,6894697,excreted,The drug found excreted into urine was about 46% and into feces about 53% of the administered dose 96 h after i.v. injection.,"Absorption, distribution and excretion of 14C-pirenzepine in rats. Accumulation characteristics after multiple dose regimen. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6894697/),%,46,54531,DB00592,Piperazine
,6894697,urinary excretion,"After single oral administration, urinary excretion was found extremely low, i.e., 8%, while 91% was excreted via feces.","Absorption, distribution and excretion of 14C-pirenzepine in rats. Accumulation characteristics after multiple dose regimen. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6894697/),%,8,54532,DB00592,Piperazine
,6894697,urinary excretion,"After single oral administration, urinary excretion was found extremely low, i.e., 8%, while 91% was excreted via feces.","Absorption, distribution and excretion of 14C-pirenzepine in rats. Accumulation characteristics after multiple dose regimen. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6894697/),%,91,54533,DB00592,Piperazine
<,7808019,half-lives,RA is much more rapidly cleared from plasma following oral administration; their respective half-lives are < 1 h and 13 h.,Clinical pharmacology of all-trans retinoic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7808019/),h,1,54541,DB00592,Piperazine
,7808019,half-lives,RA is much more rapidly cleared from plasma following oral administration; their respective half-lives are < 1 h and 13 h.,Clinical pharmacology of all-trans retinoic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7808019/),h,13,54542,DB00592,Piperazine
,11528239,Basal levels,Basal levels of cetirizine in HD patients were confirmed to be 0 ng/ml.,Pharmacokinetics of cetirizine in chronic hemodialysis patients: multiple-dose study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11528239/),,0,54956,DB00592,Piperazine
,20515524,flow rate,"Efficient chromatographic separation has been performed on a Zorbax Extend (5 microm, 4.6 x 250 mm) double end-capped C(18) column using a mobile phase consisting of methanol and aqueous triethyl amine (pH 10.5; 1%, v/v) (60:40, v/v) in an isocratic mode at a flow rate of 1 mL/min.",Validation of an HPLC method for determination of imatinib mesylate in rat serum and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20515524/),[ml] / [min],1,55100,DB00592,Piperazine
,20515524,recoveries,Simple and effective liquid-liquid extraction technique has resulted in consistent and high recoveries (90.32-95.86%) at all concentrations studied.,Validation of an HPLC method for determination of imatinib mesylate in rat serum and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20515524/),%,90.32-95.86,55101,DB00592,Piperazine
,32763217,Ctrough,"In children weighing 20 kg to less than 25 kg taking 25 mg film-coated tablets, the geometric mean (GM) Ctrough (coefficient of variation) was 0·32 mg/L (94%), which was 61% lower than the GM Ctrough of 0·83 mg/L (26%) in fasted adults on dolutegravir 50 mg once-daily; in children weighing 25 kg to less than 30 kg taking 25 mg film-coated tablets, the GM Ctrough was 0·39 mg/L (48%), which was 54% lower than the GM Ctrough in fasted adults; and in those 30 kg to less than 40 kg taking 35 mg film-coated tablets the GM Ctrough was 0·46 mg/L (63%), which was 45% lower than the GM Ctrough in fasted adults.","Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32763217/),[mg] / [l],0·32,55122,DB00592,Piperazine
,32763217,Ctrough,"In children weighing 20 kg to less than 25 kg taking 25 mg film-coated tablets, the geometric mean (GM) Ctrough (coefficient of variation) was 0·32 mg/L (94%), which was 61% lower than the GM Ctrough of 0·83 mg/L (26%) in fasted adults on dolutegravir 50 mg once-daily; in children weighing 25 kg to less than 30 kg taking 25 mg film-coated tablets, the GM Ctrough was 0·39 mg/L (48%), which was 54% lower than the GM Ctrough in fasted adults; and in those 30 kg to less than 40 kg taking 35 mg film-coated tablets the GM Ctrough was 0·46 mg/L (63%), which was 45% lower than the GM Ctrough in fasted adults.","Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32763217/),[mg] / [l],0·83,55123,DB00592,Piperazine
,32763217,Ctrough,"In children weighing 20 kg to less than 25 kg taking 25 mg film-coated tablets, the geometric mean (GM) Ctrough (coefficient of variation) was 0·32 mg/L (94%), which was 61% lower than the GM Ctrough of 0·83 mg/L (26%) in fasted adults on dolutegravir 50 mg once-daily; in children weighing 25 kg to less than 30 kg taking 25 mg film-coated tablets, the GM Ctrough was 0·39 mg/L (48%), which was 54% lower than the GM Ctrough in fasted adults; and in those 30 kg to less than 40 kg taking 35 mg film-coated tablets the GM Ctrough was 0·46 mg/L (63%), which was 45% lower than the GM Ctrough in fasted adults.","Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32763217/),[mg] / [l],0·39,55124,DB00592,Piperazine
,32763217,Ctrough,"In children weighing 20 kg to less than 25 kg taking 25 mg film-coated tablets, the geometric mean (GM) Ctrough (coefficient of variation) was 0·32 mg/L (94%), which was 61% lower than the GM Ctrough of 0·83 mg/L (26%) in fasted adults on dolutegravir 50 mg once-daily; in children weighing 25 kg to less than 30 kg taking 25 mg film-coated tablets, the GM Ctrough was 0·39 mg/L (48%), which was 54% lower than the GM Ctrough in fasted adults; and in those 30 kg to less than 40 kg taking 35 mg film-coated tablets the GM Ctrough was 0·46 mg/L (63%), which was 45% lower than the GM Ctrough in fasted adults.","Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32763217/),[mg] / [l],0·46,55125,DB00592,Piperazine
,24412691,flow rate,"Plasma samples were separated by HPLC on an Agela Venusil XBP Phenyl column (100 mm × 2.1 mm, 5 μm) using a mobile phase consisting of methanol-2mM ammonium acetate-formic acid (70:30:0.1, v/v/v) and the flow rate was set at 0.35 mL/min.",Determination of lomerizine in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24412691/),[ml] / [min],0.35,55295,DB00592,Piperazine
,24412691,total run time,The total run time was 4.0 min and the elution of lomerizine was at 1.9 min.,Determination of lomerizine in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24412691/),min,4.0,55296,DB00592,Piperazine
,24412691,elution,The total run time was 4.0 min and the elution of lomerizine was at 1.9 min.,Determination of lomerizine in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24412691/),min,1.9,55297,DB00592,Piperazine
,1796920,absolute bioavailability,"The absolute bioavailability of the parent compound amounted to 9% in rats and indicates a high first pass effect to in part pharmacodynamically effective metabolites, as was shown in a previous paper.",Pharmacokinetic fate of the novel antihypertensive drug naftopidil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1796920/),%,9,55389,DB00592,Piperazine
,1037253,half-life,"The elimination of radioactivity occurs in a biphasic manner with a half-life of 1 h for the earlier and 13 h for the second phase, no matter what application route had been chosen.",[Pharmacokinetics and metabolism of trazodone in man (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1037253/),h,1,55504,DB00592,Piperazine
,1037253,half-life,"The elimination of radioactivity occurs in a biphasic manner with a half-life of 1 h for the earlier and 13 h for the second phase, no matter what application route had been chosen.",[Pharmacokinetics and metabolism of trazodone in man (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1037253/),h,13,55505,DB00592,Piperazine
,9469675,AUC0-infinity,"Ziprasidone had a significant effect on area under the curve (AUC0-infinity), maximum serum concentration, and half-life (analysis of variance all p<0.05), with the mean AUC0-infinity being significantly greater (627.2 +/- 206.4 vs 371.0 +/- 126.5 ng x hr/ml, ANOVA with Bonferroni's criteria p<0.016) and half-life significantly shorter (4.7 +/- 0.8 vs 6.6 +/- 1.3 hrs, ANOVA with Bonferroni's criteria p<0.016) after treatment B compared with treatment A.",The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9469675/),[h·ng] / [ml],627.2,55745,DB00592,Piperazine
,9469675,AUC0-infinity,"Ziprasidone had a significant effect on area under the curve (AUC0-infinity), maximum serum concentration, and half-life (analysis of variance all p<0.05), with the mean AUC0-infinity being significantly greater (627.2 +/- 206.4 vs 371.0 +/- 126.5 ng x hr/ml, ANOVA with Bonferroni's criteria p<0.016) and half-life significantly shorter (4.7 +/- 0.8 vs 6.6 +/- 1.3 hrs, ANOVA with Bonferroni's criteria p<0.016) after treatment B compared with treatment A.",The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9469675/),[h·ng] / [ml],371.0,55746,DB00592,Piperazine
,9469675,half-life,"Ziprasidone had a significant effect on area under the curve (AUC0-infinity), maximum serum concentration, and half-life (analysis of variance all p<0.05), with the mean AUC0-infinity being significantly greater (627.2 +/- 206.4 vs 371.0 +/- 126.5 ng x hr/ml, ANOVA with Bonferroni's criteria p<0.016) and half-life significantly shorter (4.7 +/- 0.8 vs 6.6 +/- 1.3 hrs, ANOVA with Bonferroni's criteria p<0.016) after treatment B compared with treatment A.",The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9469675/),h,4.7,55747,DB00592,Piperazine
,9469675,half-life,"Ziprasidone had a significant effect on area under the curve (AUC0-infinity), maximum serum concentration, and half-life (analysis of variance all p<0.05), with the mean AUC0-infinity being significantly greater (627.2 +/- 206.4 vs 371.0 +/- 126.5 ng x hr/ml, ANOVA with Bonferroni's criteria p<0.016) and half-life significantly shorter (4.7 +/- 0.8 vs 6.6 +/- 1.3 hrs, ANOVA with Bonferroni's criteria p<0.016) after treatment B compared with treatment A.",The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9469675/),h,6.6,55748,DB00592,Piperazine
,9661014,half-life,"The concentration of ITZ in liver tissue declined in parallel with the plasma ITZ concentration until 24 h after intravenous injection of the drug (half-life, 5 h); however, the ITZ in brain tissue rapidly disappeared (half-life, 0.4 h).",P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661014/),h,5,56069,DB00592,Piperazine
,9661014,half-life,"The concentration of ITZ in liver tissue declined in parallel with the plasma ITZ concentration until 24 h after intravenous injection of the drug (half-life, 5 h); however, the ITZ in brain tissue rapidly disappeared (half-life, 0.4 h).",P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661014/),h,0.4,56070,DB00592,Piperazine
,9246018,clearance,"Coadministration of ketoconazole did not consistently affect tacrolimus clearance (55.6 +/- 16.7 ml/hr/kg versus 42.5 +/- 7.6 ml/hr/kg), and steady-state volume of distribution was unchanged (0.99 +/- 0.26 L/kg versus 0.93 +/- 0.25 L/kg).",Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9246018/),[ml] / [h·kg],55.6,56123,DB00592,Piperazine
,9246018,clearance,"Coadministration of ketoconazole did not consistently affect tacrolimus clearance (55.6 +/- 16.7 ml/hr/kg versus 42.5 +/- 7.6 ml/hr/kg), and steady-state volume of distribution was unchanged (0.99 +/- 0.26 L/kg versus 0.93 +/- 0.25 L/kg).",Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9246018/),[ml] / [h·kg],42.5,56124,DB00592,Piperazine
,9246018,steady-state volume of distribution,"Coadministration of ketoconazole did not consistently affect tacrolimus clearance (55.6 +/- 16.7 ml/hr/kg versus 42.5 +/- 7.6 ml/hr/kg), and steady-state volume of distribution was unchanged (0.99 +/- 0.26 L/kg versus 0.93 +/- 0.25 L/kg).",Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9246018/),[l] / [kg],0.99,56125,DB00592,Piperazine
,9246018,steady-state volume of distribution,"Coadministration of ketoconazole did not consistently affect tacrolimus clearance (55.6 +/- 16.7 ml/hr/kg versus 42.5 +/- 7.6 ml/hr/kg), and steady-state volume of distribution was unchanged (0.99 +/- 0.26 L/kg versus 0.93 +/- 0.25 L/kg).",Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9246018/),[l] / [kg],0.93,56126,DB00592,Piperazine
,9246018,bioavailability,"However, a significant increase in tacrolimus bioavailability (14% +/- 5% versus 30% +/- 8%; p < 0.01) was observed with coadministered ketoconazole.",Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9246018/),%,14,56127,DB00592,Piperazine
,9246018,bioavailability,"However, a significant increase in tacrolimus bioavailability (14% +/- 5% versus 30% +/- 8%; p < 0.01) was observed with coadministered ketoconazole.",Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9246018/),%,30,56128,DB00592,Piperazine
,9246018,Hepatic bioavailability,Hepatic bioavailability was unchanged by the presence of ketoconazole (96% +/- 1% versus 97% +/- 1%).,Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9246018/),%,96,56129,DB00592,Piperazine
,9246018,Hepatic bioavailability,Hepatic bioavailability was unchanged by the presence of ketoconazole (96% +/- 1% versus 97% +/- 1%).,Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9246018/),%,97,56130,DB00592,Piperazine
,19067472,concentration ratios,"Mean prostatic tissue/plasma ulifloxacin concentration ratios after single and repeated prulifloxacin administration ranged from 3.8 to 7.1 and from 3.9 to 9.5, respectively.",Penetration of orally administered prulifloxacin into human prostate tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19067472/),,3.8 to 7.1,56672,DB00592,Piperazine
,19067472,concentration ratios,"Mean prostatic tissue/plasma ulifloxacin concentration ratios after single and repeated prulifloxacin administration ranged from 3.8 to 7.1 and from 3.9 to 9.5, respectively.",Penetration of orally administered prulifloxacin into human prostate tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19067472/),,3.9 to 9.5,56673,DB00592,Piperazine
,20740300,C(max),"For axitinib alone or with ketoconazole, C(max) occurred 1.5 and 2.0 h after dosing, respectively.",Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20740300/),h,1.5,57005,DB00592,Piperazine
,20740300,C(max),"For axitinib alone or with ketoconazole, C(max) occurred 1.5 and 2.0 h after dosing, respectively.",Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20740300/),h,2.0,57006,DB00592,Piperazine
,1662599,Onset time,"Onset time and clinical duration were 2.3 and 109 min and 2.8 and 39 min in Groups L and C, respectively.","The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),min,2.3,57479,DB00592,Piperazine
,1662599,clinical duration,"Onset time and clinical duration were 2.3 and 109 min and 2.8 and 39 min in Groups L and C, respectively.","The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),min,109,57480,DB00592,Piperazine
,1662599,clinical duration,"Onset time and clinical duration were 2.3 and 109 min and 2.8 and 39 min in Groups L and C, respectively.","The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),min,2.8,57481,DB00592,Piperazine
,1662599,clinical duration,"Onset time and clinical duration were 2.3 and 109 min and 2.8 and 39 min in Groups L and C, respectively.","The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),min,39,57482,DB00592,Piperazine
,1662599,Terminal half-lives,Terminal half-lives were 101.5 min (Group L) and 179 min (Group C) in a three-exponent decay; the distribution volumes at steady state 0.339 l kg-1 (Group L) and 0.506 l kg-1 (Group C); the plasma clearance 3.4 ml kg-1 min-1 (Group L) and 2.5 ml kg-1 min-1 (Group C).,"The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),min,101.5,57483,DB00592,Piperazine
,1662599,Terminal half-lives,Terminal half-lives were 101.5 min (Group L) and 179 min (Group C) in a three-exponent decay; the distribution volumes at steady state 0.339 l kg-1 (Group L) and 0.506 l kg-1 (Group C); the plasma clearance 3.4 ml kg-1 min-1 (Group L) and 2.5 ml kg-1 min-1 (Group C).,"The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),min,179,57484,DB00592,Piperazine
,1662599,distribution volumes at steady state,Terminal half-lives were 101.5 min (Group L) and 179 min (Group C) in a three-exponent decay; the distribution volumes at steady state 0.339 l kg-1 (Group L) and 0.506 l kg-1 (Group C); the plasma clearance 3.4 ml kg-1 min-1 (Group L) and 2.5 ml kg-1 min-1 (Group C).,"The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),[l] / [kg],0.339,57485,DB00592,Piperazine
,1662599,distribution volumes at steady state,Terminal half-lives were 101.5 min (Group L) and 179 min (Group C) in a three-exponent decay; the distribution volumes at steady state 0.339 l kg-1 (Group L) and 0.506 l kg-1 (Group C); the plasma clearance 3.4 ml kg-1 min-1 (Group L) and 2.5 ml kg-1 min-1 (Group C).,"The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),[l] / [kg],0.506,57486,DB00592,Piperazine
,1662599,plasma clearance,Terminal half-lives were 101.5 min (Group L) and 179 min (Group C) in a three-exponent decay; the distribution volumes at steady state 0.339 l kg-1 (Group L) and 0.506 l kg-1 (Group C); the plasma clearance 3.4 ml kg-1 min-1 (Group L) and 2.5 ml kg-1 min-1 (Group C).,"The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),[ml] / [kg·min],3.4,57487,DB00592,Piperazine
,1662599,plasma clearance,Terminal half-lives were 101.5 min (Group L) and 179 min (Group C) in a three-exponent decay; the distribution volumes at steady state 0.339 l kg-1 (Group L) and 0.506 l kg-1 (Group C); the plasma clearance 3.4 ml kg-1 min-1 (Group L) and 2.5 ml kg-1 min-1 (Group C).,"The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),[ml] / [kg·min],2.5,57488,DB00592,Piperazine
,8100508,total body clearance,"Mean (SD) total body clearance of NEF was 1.56 (0.34) liter/hr.kg-1, and mean (SD) steady-state volume of distribution of NEF was 3.24 (1.0) liter/kg.","Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in the dog. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100508/),[l] / [h·kg],1.56,57513,DB00592,Piperazine
,8100508,steady-state volume of distribution,"Mean (SD) total body clearance of NEF was 1.56 (0.34) liter/hr.kg-1, and mean (SD) steady-state volume of distribution of NEF was 3.24 (1.0) liter/kg.","Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in the dog. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100508/),[l] / [kg],3.24,57514,DB00592,Piperazine
,8100508,absolute bioavailability,Mean (SD) absolute bioavailability of NEF after po administration was calculated to be 14.0 (4.2)%.,"Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in the dog. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100508/),%,14.0,57515,DB00592,Piperazine
,27139217,flow rate,"After VA-DSPE, chromatographic separation was performed on an ACQUITY UPLC(®) BEH C18 column (2.1mm×100mm, 1.7μm) with a 3min gradient elution using 0.1% formic acid and methanol as mobile phase at a flow rate of 0.3mL/min.",The metal-organic framework MIL-101(Cr) as efficient adsorbent in a vortex-assisted dispersive solid-phase extraction of imatinib mesylate in rat plasma coupled with ultra-performance liquid chromatography/mass spectrometry: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27139217/),[ml] / [min],0.3,57752,DB00592,Piperazine
higher,27139217,recovery,The lower limit of quantification of 1ng/mL was achieved and the mean recovery of the analyte was higher than 81.2%.,The metal-organic framework MIL-101(Cr) as efficient adsorbent in a vortex-assisted dispersive solid-phase extraction of imatinib mesylate in rat plasma coupled with ultra-performance liquid chromatography/mass spectrometry: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27139217/),%,81.2,57753,DB00592,Piperazine
,25677784,m/,The selected reaction monitoring transitions monitored were m/z 499.3 → 341.1 for GDC-0980 and m/z 507.3 → 341.1 for IS.,"Determination of GDC-0980 (apitolisib), a small molecule dual phosphatidylinositide 3-kinase/mammalian target of rapamycin inhibitor in dog plasma by LC-MS/MS to support a GLP toxicology study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25677784/),,499.3,57772,DB00592,Piperazine
,25677784,m,The selected reaction monitoring transitions monitored were m/z 499.3 → 341.1 for GDC-0980 and m/z 507.3 → 341.1 for IS.,"Determination of GDC-0980 (apitolisib), a small molecule dual phosphatidylinositide 3-kinase/mammalian target of rapamycin inhibitor in dog plasma by LC-MS/MS to support a GLP toxicology study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25677784/),,507.3,57773,DB00592,Piperazine
,25677784,Peak concentration,Peak concentration ranged from 3.23 to 84.9 ng/mL.,"Determination of GDC-0980 (apitolisib), a small molecule dual phosphatidylinositide 3-kinase/mammalian target of rapamycin inhibitor in dog plasma by LC-MS/MS to support a GLP toxicology study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25677784/),[ng] / [ml],3.23 to 84.9,57774,DB00592,Piperazine
,25677784,time to peak concentration,GDC-0980 was rapidly absorbed with a mean time to peak concentration ranging from 1.3 to 2.4 h.,"Determination of GDC-0980 (apitolisib), a small molecule dual phosphatidylinositide 3-kinase/mammalian target of rapamycin inhibitor in dog plasma by LC-MS/MS to support a GLP toxicology study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25677784/),h,1.3 to 2.4,57775,DB00592,Piperazine
,25677784,area under the concentration-time curve from 0 to 24 hours,Mean area under the concentration-time curve from 0 to 24 hours ranged from 54.4 to 542 ng h/mL.,"Determination of GDC-0980 (apitolisib), a small molecule dual phosphatidylinositide 3-kinase/mammalian target of rapamycin inhibitor in dog plasma by LC-MS/MS to support a GLP toxicology study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25677784/),[h·ng] / [ml],54.4 to 542,57776,DB00592,Piperazine
,7616366,t1/2,Cinnarizine pharmacokinetics after iv administration as a 1.25 mg/mL SBE4-beta-CD solution followed triexponential behavior (t1/2 = 12.6 +/- 0.4 h and CI = 1.4 +/- 0.17 L/h/kg).,"beta-cyclodextrin derivatives, SBE4-beta-CD and HP-beta-CD, increase the oral bioavailability of cinnarizine in beagle dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7616366/),h,12.6,58177,DB00592,Piperazine
,7616366,CI,Cinnarizine pharmacokinetics after iv administration as a 1.25 mg/mL SBE4-beta-CD solution followed triexponential behavior (t1/2 = 12.6 +/- 0.4 h and CI = 1.4 +/- 0.17 L/h/kg).,"beta-cyclodextrin derivatives, SBE4-beta-CD and HP-beta-CD, increase the oral bioavailability of cinnarizine in beagle dogs. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7616366/),[l] / [h·kg],1.4,58178,DB00592,Piperazine
,7616366,Fabs,A very low bioavailability of cinnarizine with a wide interanimal variation was observed after oral administration as a suspension (Fabs = 8 +/- 4%) or capsule containing only cinnarizine (Fabs = 0.8 +/- 0.4%).,"beta-cyclodextrin derivatives, SBE4-beta-CD and HP-beta-CD, increase the oral bioavailability of cinnarizine in beagle dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7616366/),%,8,58179,DB00592,Piperazine
,7616366,Fabs,A very low bioavailability of cinnarizine with a wide interanimal variation was observed after oral administration as a suspension (Fabs = 8 +/- 4%) or capsule containing only cinnarizine (Fabs = 0.8 +/- 0.4%).,"beta-cyclodextrin derivatives, SBE4-beta-CD and HP-beta-CD, increase the oral bioavailability of cinnarizine in beagle dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7616366/),%,0.8,58180,DB00592,Piperazine
,7616366,Fabs,Administration of cinnarizine as a CD complex either as a solution (Fabs = 55-60%) or in a capsule (Fabs = 38 +/- 12%) significantly enhanced the bioavailability.,"beta-cyclodextrin derivatives, SBE4-beta-CD and HP-beta-CD, increase the oral bioavailability of cinnarizine in beagle dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7616366/),%,55-60,58181,DB00592,Piperazine
,7616366,Fabs,Administration of cinnarizine as a CD complex either as a solution (Fabs = 55-60%) or in a capsule (Fabs = 38 +/- 12%) significantly enhanced the bioavailability.,"beta-cyclodextrin derivatives, SBE4-beta-CD and HP-beta-CD, increase the oral bioavailability of cinnarizine in beagle dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7616366/),%,38,58182,DB00592,Piperazine
,2566338,area under,"The U.S. manufactured formulations were 85.88 and 87.85 per cent of the calculated mean area under the individual concentration-time curve for almitrine bismesylate reference solution compared to 88.40 and 88.86 per cent for the waxed and unwaxed film coated European tablets, respectively.",Relative bioavailability of almitrine bismesylate in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566338/),%,85.88,58384,DB00592,Piperazine
,2566338,area under,"The U.S. manufactured formulations were 85.88 and 87.85 per cent of the calculated mean area under the individual concentration-time curve for almitrine bismesylate reference solution compared to 88.40 and 88.86 per cent for the waxed and unwaxed film coated European tablets, respectively.",Relative bioavailability of almitrine bismesylate in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566338/),%,87.85,58385,DB00592,Piperazine
,2566338,area under,"The U.S. manufactured formulations were 85.88 and 87.85 per cent of the calculated mean area under the individual concentration-time curve for almitrine bismesylate reference solution compared to 88.40 and 88.86 per cent for the waxed and unwaxed film coated European tablets, respectively.",Relative bioavailability of almitrine bismesylate in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566338/),%,88.40,58386,DB00592,Piperazine
,2566338,area under,"The U.S. manufactured formulations were 85.88 and 87.85 per cent of the calculated mean area under the individual concentration-time curve for almitrine bismesylate reference solution compared to 88.40 and 88.86 per cent for the waxed and unwaxed film coated European tablets, respectively.",Relative bioavailability of almitrine bismesylate in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566338/),%,88.86,58387,DB00592,Piperazine
,2566338,peak plasma concentrations,"The mean peak plasma concentrations for the U.S. formulations were 176.3 ng ml-1 and 180.1 ng ml-1 compared to 196.3 and 200.1 ng ml-1 for the waxed and unwaxed European formulations, respectively.",Relative bioavailability of almitrine bismesylate in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566338/),[ng] / [ml],176.3,58388,DB00592,Piperazine
,2566338,peak plasma concentrations,"The mean peak plasma concentrations for the U.S. formulations were 176.3 ng ml-1 and 180.1 ng ml-1 compared to 196.3 and 200.1 ng ml-1 for the waxed and unwaxed European formulations, respectively.",Relative bioavailability of almitrine bismesylate in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566338/),[ng] / [ml],180.1,58389,DB00592,Piperazine
,2566338,peak plasma concentrations,"The mean peak plasma concentrations for the U.S. formulations were 176.3 ng ml-1 and 180.1 ng ml-1 compared to 196.3 and 200.1 ng ml-1 for the waxed and unwaxed European formulations, respectively.",Relative bioavailability of almitrine bismesylate in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566338/),[ng] / [ml],196.3,58390,DB00592,Piperazine
,2566338,peak plasma concentrations,"The mean peak plasma concentrations for the U.S. formulations were 176.3 ng ml-1 and 180.1 ng ml-1 compared to 196.3 and 200.1 ng ml-1 for the waxed and unwaxed European formulations, respectively.",Relative bioavailability of almitrine bismesylate in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566338/),[ng] / [ml],200.1,58391,DB00592,Piperazine
,2566338,time to peak plasma concentrations,"Mean time to peak plasma concentrations for the two U.S. formulations and the waxed and unwaxed European formulations were 3.22, 3.33, 3.06, and 3.26 h, respectively.",Relative bioavailability of almitrine bismesylate in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566338/),h,3.22,58392,DB00592,Piperazine
,2566338,time to peak plasma concentrations,"Mean time to peak plasma concentrations for the two U.S. formulations and the waxed and unwaxed European formulations were 3.22, 3.33, 3.06, and 3.26 h, respectively.",Relative bioavailability of almitrine bismesylate in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566338/),h,3.33,58393,DB00592,Piperazine
,2566338,time to peak plasma concentrations,"Mean time to peak plasma concentrations for the two U.S. formulations and the waxed and unwaxed European formulations were 3.22, 3.33, 3.06, and 3.26 h, respectively.",Relative bioavailability of almitrine bismesylate in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566338/),h,3.06,58394,DB00592,Piperazine
,2566338,time to peak plasma concentrations,"Mean time to peak plasma concentrations for the two U.S. formulations and the waxed and unwaxed European formulations were 3.22, 3.33, 3.06, and 3.26 h, respectively.",Relative bioavailability of almitrine bismesylate in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566338/),h,3.26,58395,DB00592,Piperazine
,2566338,peak plasma concentration,"In addition, the oral reference solution yielded a mean peak plasma concentration of 222.8 ng ml-1 and a mean time to peak plasma concentration of 2.68 h.",Relative bioavailability of almitrine bismesylate in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566338/),[ng] / [ml],222.8,58396,DB00592,Piperazine
,2566338,time to peak plasma concentration,"In addition, the oral reference solution yielded a mean peak plasma concentration of 222.8 ng ml-1 and a mean time to peak plasma concentration of 2.68 h.",Relative bioavailability of almitrine bismesylate in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566338/),h,2.68,58397,DB00592,Piperazine
exceed,2566338,relative bioavailability,The results of this study show that the U.S. formulated almitrine bismesylate tablets exceed 85 per cent relative bioavailability with respect to the oral reference solution and are bioequivalent compared to the marketed standard European tablet formulations.,Relative bioavailability of almitrine bismesylate in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566338/),%,85,58398,DB00592,Piperazine
,20636873,oral bioavailability,"The oral bioavailability of cinnarizine using the PHY formulation was 41%, compared to 19% for the GMO formulation and 6% for an aqueous suspension.",Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water-soluble drugs II. In-vivo evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20636873/),%,41,58438,DB00592,Piperazine
,20636873,oral bioavailability,"The oral bioavailability of cinnarizine using the PHY formulation was 41%, compared to 19% for the GMO formulation and 6% for an aqueous suspension.",Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water-soluble drugs II. In-vivo evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20636873/),%,19,58439,DB00592,Piperazine
,20636873,oral bioavailability,"The oral bioavailability of cinnarizine using the PHY formulation was 41%, compared to 19% for the GMO formulation and 6% for an aqueous suspension.",Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water-soluble drugs II. In-vivo evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20636873/),%,6,58440,DB00592,Piperazine
,20636873,T(max),"The PHY formulation provided a T(max) for cinnarizine of 33 h, with absorption apparent up to 55 h after administration.",Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water-soluble drugs II. In-vivo evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20636873/),h,33,58441,DB00592,Piperazine
,20636873,T(max),"In contrast, the T(max) for the GMO formulation was only 5 h.",Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water-soluble drugs II. In-vivo evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20636873/),h,5,58442,DB00592,Piperazine
,21635257,tissue-to-plasma AUC(0-∞) ratio,"Metronidazole increased imatinib's tissue-to-plasma AUC(0-∞) ratio in liver from 2.29 to 4.53 and in kidney from 3.04 to 7.57, suggesting higher uptake efficiency.","Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21635257/),,2.29 to 4.53,58838,DB00592,Piperazine
,21635257,tissue-to-plasma AUC(0-∞) ratio,"Metronidazole increased imatinib's tissue-to-plasma AUC(0-∞) ratio in liver from 2.29 to 4.53 and in kidney from 3.04 to 7.57, suggesting higher uptake efficiency.","Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21635257/),,3.04 to 7.57,58839,DB00592,Piperazine
,20864622,AUC ratio,"The mean simulated degree of interaction, measured by midazolam AUC ratio with and without ketoconazole (AUCR), was 10.28.",Bioavailability considerations in evaluating drug-drug interactions using the population pharmacokinetic approach. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20864622/),,10.28,59097,DB00592,Piperazine
,10546921,terminal half-life,Mean terminal half-life after administration of ketoconazole (21.5 hours and 18.9 hours) was significantly longer than after reboxetine alone (14.8 hours and 14.4 hours; P < or = .005).,Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546921/),h,21.5,59195,DB00592,Piperazine
,10546921,terminal half-life,Mean terminal half-life after administration of ketoconazole (21.5 hours and 18.9 hours) was significantly longer than after reboxetine alone (14.8 hours and 14.4 hours; P < or = .005).,Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546921/),h,18.9,59196,DB00592,Piperazine
,10546921,terminal half-life,Mean terminal half-life after administration of ketoconazole (21.5 hours and 18.9 hours) was significantly longer than after reboxetine alone (14.8 hours and 14.4 hours; P < or = .005).,Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546921/),h,14.8,59197,DB00592,Piperazine
,10546921,terminal half-life,Mean terminal half-life after administration of ketoconazole (21.5 hours and 18.9 hours) was significantly longer than after reboxetine alone (14.8 hours and 14.4 hours; P < or = .005).,Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546921/),h,14.4,59198,DB00592,Piperazine
,10546921,AUC ratio,"The AUC ratio for R,R(-)-reboxetine to S,S(+)-reboxetine was reduced by ketoconazole administration (2.76 after ketoconazole versus 2.39; P < .003).",Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546921/),,2.76,59199,DB00592,Piperazine
,10546921,AUC ratio,"The AUC ratio for R,R(-)-reboxetine to S,S(+)-reboxetine was reduced by ketoconazole administration (2.76 after ketoconazole versus 2.39; P < .003).",Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546921/),,2.39,59200,DB00592,Piperazine
,20420905,AUC,"When high enough amounts of HPMC were co-administered with itraconazole-loaded SBA-15 (itraconazole:SBA-15:HPMC 1:4:6), the extent of absorption was increased by more than 60% when compared to SBA-15 without precipitation inhibitors (AUC 14,937+/-1617 versus 8987+/-2726nMh).",Combined use of ordered mesoporous silica and precipitation inhibitors for improved oral absorption of the poorly soluble weak base itraconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20420905/),nMh,"14,937",59301,DB00592,Piperazine
,20420905,AUC,"When high enough amounts of HPMC were co-administered with itraconazole-loaded SBA-15 (itraconazole:SBA-15:HPMC 1:4:6), the extent of absorption was increased by more than 60% when compared to SBA-15 without precipitation inhibitors (AUC 14,937+/-1617 versus 8987+/-2726nMh).",Combined use of ordered mesoporous silica and precipitation inhibitors for improved oral absorption of the poorly soluble weak base itraconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20420905/),nMh,8987,59302,DB00592,Piperazine
,9832299,elimination half-life,The area under the lignocaine concentration-time curve was similar during all three phases but erythromycin significantly increased the elimination half-life of lignocaine from 2.5 to 2.9 (0.7) h compared with placebo.,Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832299/),h,2.5,59428,DB00592,Piperazine
,9832299,elimination half-life,The area under the lignocaine concentration-time curve was similar during all three phases but erythromycin significantly increased the elimination half-life of lignocaine from 2.5 to 2.9 (0.7) h compared with placebo.,Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832299/),h,2.9,59429,DB00592,Piperazine
,9832299,t1/2,"Following itraconazole administration, t1/2 was 2.6 h.",Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832299/),h,2.6,59430,DB00592,Piperazine
>,26240287,LD50,"Single bolus dose and 28-days of repeated administration of DMA in mice for toxicity studies determined an LD50 of >2000 mg/kg body weight (bw) and 225 mg/kg bw, respectively, suggesting DMA is safe.","Preclinical Evaluation of DMA, a Bisbenzimidazole, as Radioprotector: Toxicity, Pharmacokinetics, and Biodistribution Studies in Balb/c Mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26240287/),[mg] / [kg],2000,59681,DB00592,Piperazine
,26240287,LD50,"Single bolus dose and 28-days of repeated administration of DMA in mice for toxicity studies determined an LD50 of >2000 mg/kg body weight (bw) and 225 mg/kg bw, respectively, suggesting DMA is safe.","Preclinical Evaluation of DMA, a Bisbenzimidazole, as Radioprotector: Toxicity, Pharmacokinetics, and Biodistribution Studies in Balb/c Mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26240287/),[mg] / [kg],225,59682,DB00592,Piperazine
,26240287,C(max),"The pharmacokinetic study of DMA at oral and intravenous doses showed its C(max) = 1 hour, bioavailability of 8.84%, elimination half-life of 4 hours, and an enterohepatic recirculation.","Preclinical Evaluation of DMA, a Bisbenzimidazole, as Radioprotector: Toxicity, Pharmacokinetics, and Biodistribution Studies in Balb/c Mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26240287/),h,1,59683,DB00592,Piperazine
,26240287,bioavailability,"The pharmacokinetic study of DMA at oral and intravenous doses showed its C(max) = 1 hour, bioavailability of 8.84%, elimination half-life of 4 hours, and an enterohepatic recirculation.","Preclinical Evaluation of DMA, a Bisbenzimidazole, as Radioprotector: Toxicity, Pharmacokinetics, and Biodistribution Studies in Balb/c Mice. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26240287/),%,8.84,59684,DB00592,Piperazine
,26240287,elimination half-life,"The pharmacokinetic study of DMA at oral and intravenous doses showed its C(max) = 1 hour, bioavailability of 8.84%, elimination half-life of 4 hours, and an enterohepatic recirculation.","Preclinical Evaluation of DMA, a Bisbenzimidazole, as Radioprotector: Toxicity, Pharmacokinetics, and Biodistribution Studies in Balb/c Mice. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26240287/),h,4,59685,DB00592,Piperazine
,20307656,relative bioavailability,The relative bioavailability of oral administration was 46.4%.,Effect of route of administration on the pharmacokinetics and toxicokinetics of cinnarizine in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20307656/),%,46.4,59762,DB00592,Piperazine
,20608939,C(min),"The C(min) level was strongly associated with the achievement of MMR at the 12th month, and ROC analysis demonstrated C(min) levels and their discrimination potential for major molecular response (MMR) with the best sensitivity (63.2%) and specificity (68.2%) at a C(min) threshold of 974 ng/mL.",Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20608939/),[ng] / [ml],974,59787,DB00592,Piperazine
,20608939,C(min),These results collectively indicated that maintaining ∼1000 ng/mL of C(min) was clinically and biologically important for the optimal response in CML patients treated with imatinib.,Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20608939/),[ng] / [ml],∼1000,59788,DB00592,Piperazine
,24274510,brain targeting efficiency,A high brain targeting efficiency (86.6%) and a direct nose to brain transport (88%) confirmed the direct nose to brain transport of buspirone following nasal administration of the microemulsions.,Chitosan and cyclodextrin in intranasal microemulsion for improved brain buspirone hydrochloride pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24274510/),%,86.6,59810,DB00592,Piperazine
,14624194,area under the methylprednisolone concentration-time curve,"Following nefazodone administration, the mean (+/-SD) area under the methylprednisolone concentration-time curve was significantly higher (1393 +/- 343 vs. 2966 +/- 928 ug*h/L; P < 0.005), apparent clearance was lower (28.7 +/- 7.2 vs. 14.6 +/- 7.8 L/h; P < 0.02) and the terminal elimination half-life was longer (2.28 +/- 0.49 vs. 3.32 +/- 0.95 hours; P < 0.02).",Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624194/),[h·ug] / [l],1393,60429,DB00592,Piperazine
,14624194,area under the methylprednisolone concentration-time curve,"Following nefazodone administration, the mean (+/-SD) area under the methylprednisolone concentration-time curve was significantly higher (1393 +/- 343 vs. 2966 +/- 928 ug*h/L; P < 0.005), apparent clearance was lower (28.7 +/- 7.2 vs. 14.6 +/- 7.8 L/h; P < 0.02) and the terminal elimination half-life was longer (2.28 +/- 0.49 vs. 3.32 +/- 0.95 hours; P < 0.02).",Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624194/),[h·ug] / [l],2966,60430,DB00592,Piperazine
,14624194,apparent clearance,"Following nefazodone administration, the mean (+/-SD) area under the methylprednisolone concentration-time curve was significantly higher (1393 +/- 343 vs. 2966 +/- 928 ug*h/L; P < 0.005), apparent clearance was lower (28.7 +/- 7.2 vs. 14.6 +/- 7.8 L/h; P < 0.02) and the terminal elimination half-life was longer (2.28 +/- 0.49 vs. 3.32 +/- 0.95 hours; P < 0.02).",Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624194/),[l] / [h],28.7,60431,DB00592,Piperazine
,14624194,apparent clearance,"Following nefazodone administration, the mean (+/-SD) area under the methylprednisolone concentration-time curve was significantly higher (1393 +/- 343 vs. 2966 +/- 928 ug*h/L; P < 0.005), apparent clearance was lower (28.7 +/- 7.2 vs. 14.6 +/- 7.8 L/h; P < 0.02) and the terminal elimination half-life was longer (2.28 +/- 0.49 vs. 3.32 +/- 0.95 hours; P < 0.02).",Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624194/),[l] / [h],14.6,60432,DB00592,Piperazine
,14624194,terminal elimination half-life,"Following nefazodone administration, the mean (+/-SD) area under the methylprednisolone concentration-time curve was significantly higher (1393 +/- 343 vs. 2966 +/- 928 ug*h/L; P < 0.005), apparent clearance was lower (28.7 +/- 7.2 vs. 14.6 +/- 7.8 L/h; P < 0.02) and the terminal elimination half-life was longer (2.28 +/- 0.49 vs. 3.32 +/- 0.95 hours; P < 0.02).",Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624194/),h,2.28,60433,DB00592,Piperazine
,14624194,terminal elimination half-life,"Following nefazodone administration, the mean (+/-SD) area under the methylprednisolone concentration-time curve was significantly higher (1393 +/- 343 vs. 2966 +/- 928 ug*h/L; P < 0.005), apparent clearance was lower (28.7 +/- 7.2 vs. 14.6 +/- 7.8 L/h; P < 0.02) and the terminal elimination half-life was longer (2.28 +/- 0.49 vs. 3.32 +/- 0.95 hours; P < 0.02).",Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624194/),h,3.32,60434,DB00592,Piperazine
,10477901,extraction recovery,The extraction recovery of I was established as 97%.,"Sensitive triple-quadrupole mass spectrometric assay for the determination of BMS-181885, a 5-HT1 agonist, in human plasma following solid phase extraction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10477901/),%,97,60505,DB00592,Piperazine
,33141308,time to 90% of steady state,The median time to 90% of steady state was approximately 1 week for cariprazine and DCAR and 3 weeks for DDCAR.,Population Pharmacokinetics of Cariprazine and its Major Metabolites. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33141308/),week,1,60910,DB00592,Piperazine
,33141308,time to 90% of steady state,The median time to 90% of steady state was approximately 1 week for cariprazine and DCAR and 3 weeks for DDCAR.,Population Pharmacokinetics of Cariprazine and its Major Metabolites. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33141308/),weeks,3,60911,DB00592,Piperazine
,1433357,terminal half-life,Doxorubicin's estimated terminal half-life was 39.5 +/- 18.3 (mean +/- SD) hours; the area under the curve for plasma concentration of drug x time (AUC) was 1.74 +/- 0.40 (micrograms/microL) x hour.,Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433357/),h,39.5,61210,DB00592,Piperazine
,1433357,area under the curve for plasma concentration of drug x time (AUC),Doxorubicin's estimated terminal half-life was 39.5 +/- 18.3 (mean +/- SD) hours; the area under the curve for plasma concentration of drug x time (AUC) was 1.74 +/- 0.40 (micrograms/microL) x hour.,Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433357/),[μg] / [h·μl)],1.74,61211,DB00592,Piperazine
,1433357,Total-body clearance,"Total-body clearance was 598 +/- 142 microL/m2 per minute (N = 20), and it did not vary with ADR-529 dose.",Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433357/),[μl] / [m2·min],598,61212,DB00592,Piperazine
,1433357,distribution,"Estimated distribution and elimination phase half-lives for plasma ADR-529 were 0.46 +/- 0.30 hours and 4.16 +/- 2.94 hours, respectively.",Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433357/),h,0.46,61213,DB00592,Piperazine
,1433357,elimination phase half-lives,"Estimated distribution and elimination phase half-lives for plasma ADR-529 were 0.46 +/- 0.30 hours and 4.16 +/- 2.94 hours, respectively.",Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433357/),h,4.16,61214,DB00592,Piperazine
,1433357,Total-body clearance,"Total-body clearance was 111 +/- 87 microL/m2 per minute (N = 18); AUC was linear (r2 = .92), and the clearance rate was constant (r2 = .18) from 60 to 900 mg/m2.",Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433357/),[μl] / [m2·min],111,61215,DB00592,Piperazine
less,3027850,MICs,"The MICs of itraconazole for 16 strains of Aspergillus fumigatus were in the same range as those of amphotericin B: less than 0.09-0.36 microgram/ml vs. less than 0.09-0.78 microgram/ml, respectively.",Early experience with itraconazole in vitro and in patients: pharmacokinetic studies and clinical results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3027850/),[μg] / [ml],0.09-0.36,61359,DB00592,Piperazine
less,3027850,MICs,"The MICs of itraconazole for 16 strains of Aspergillus fumigatus were in the same range as those of amphotericin B: less than 0.09-0.36 microgram/ml vs. less than 0.09-0.78 microgram/ml, respectively.",Early experience with itraconazole in vitro and in patients: pharmacokinetic studies and clinical results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3027850/),[μg] / [ml],0.09-0.78,61360,DB00592,Piperazine
,8751042,distribution half-life,The median for the distribution half-life of pipecuronium was 2.54 min (interquartile range: 1.0-2.5 min) in infants and 2.04 min (0.26-2.04 min) in children; both were significantly shorter than in adults (5.75 [3.7-9.7] min).,"Pharmacokinetics of pipecuronium in infants, children and adults. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751042/),min,2.54,61380,DB00592,Piperazine
,8751042,distribution half-life,The median for the distribution half-life of pipecuronium was 2.54 min (interquartile range: 1.0-2.5 min) in infants and 2.04 min (0.26-2.04 min) in children; both were significantly shorter than in adults (5.75 [3.7-9.7] min).,"Pharmacokinetics of pipecuronium in infants, children and adults. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751042/),min,2.04,61381,DB00592,Piperazine
,8751042,distribution half-life,The median for the distribution half-life of pipecuronium was 2.54 min (interquartile range: 1.0-2.5 min) in infants and 2.04 min (0.26-2.04 min) in children; both were significantly shorter than in adults (5.75 [3.7-9.7] min).,"Pharmacokinetics of pipecuronium in infants, children and adults. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751042/),min,5.75,61382,DB00592,Piperazine
,8751042,plasma clearance,"The plasma clearance of pipecuronium was significantly decreased in infants (1.50 [0.6-1.5] ml.min-1.kg-1; P < 0.05) as compared to children and adults (2.27 [0.88-2.27] and 2.45 [1.7-3.2] ml.min-1.kg-1, respectively).","Pharmacokinetics of pipecuronium in infants, children and adults. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751042/),[ml] / [kg·min],1.50,61383,DB00592,Piperazine
,8751042,plasma clearance,"The plasma clearance of pipecuronium was significantly decreased in infants (1.50 [0.6-1.5] ml.min-1.kg-1; P < 0.05) as compared to children and adults (2.27 [0.88-2.27] and 2.45 [1.7-3.2] ml.min-1.kg-1, respectively).","Pharmacokinetics of pipecuronium in infants, children and adults. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751042/),[ml] / [kg·min],2.27,61384,DB00592,Piperazine
,8751042,plasma clearance,"The plasma clearance of pipecuronium was significantly decreased in infants (1.50 [0.6-1.5] ml.min-1.kg-1; P < 0.05) as compared to children and adults (2.27 [0.88-2.27] and 2.45 [1.7-3.2] ml.min-1.kg-1, respectively).","Pharmacokinetics of pipecuronium in infants, children and adults. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751042/),[ml] / [kg·min],2.45,61385,DB00592,Piperazine
above,30420479,trough concentrations,The significant decreases in DTG trough concentrations with artemether-lumefantrine and artesunate-amodiaquine and dolutegravir exposure with artesunate-amodiaquine are unlikely to be of clinical significance since the DTG trough concentrations were above dolutegravir target concentrations of 300 ng/ml.,Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30420479/),[ng] / [ml],300,61566,DB00592,Piperazine
,21492388,C(max),The C(max) of methadone was significantly different (p=0.016) for Phase 1 (5.5 ng mL(-1)) and Phase 2 (171.9 ng mL(-1)).,The effects of concurrent administration of cytochrome P-450 inhibitors on the pharmacokinetics of oral methadone in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492388/),[ng] / [ml],5.5,61646,DB00592,Piperazine
,21492388,C(max),The C(max) of methadone was significantly different (p=0.016) for Phase 1 (5.5 ng mL(-1)) and Phase 2 (171.9 ng mL(-1)).,The effects of concurrent administration of cytochrome P-450 inhibitors on the pharmacokinetics of oral methadone in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492388/),[ng] / [ml],171.9,61647,DB00592,Piperazine
,21492388,AUC(0-LAST),The AUC(0-LAST) was also significantly different (p=0.004) for Phase 1 (13.1 hour ng mL(-1)) and Phase 2 (3075.2 hour ng mL(-1)).,The effects of concurrent administration of cytochrome P-450 inhibitors on the pharmacokinetics of oral methadone in healthy dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492388/),[h·ng] / [ml],13.1,61648,DB00592,Piperazine
,21492388,AUC(0-LAST),The AUC(0-LAST) was also significantly different (p=0.004) for Phase 1 (13.1 hour ng mL(-1)) and Phase 2 (3075.2 hour ng mL(-1)).,The effects of concurrent administration of cytochrome P-450 inhibitors on the pharmacokinetics of oral methadone in healthy dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492388/),[h·ng] / [ml],3075.2,61649,DB00592,Piperazine
,2584318,detection limits,The detection limits of both I and II are 0.1 ng/ml using 1 ml of serum.,Determination of manidipine and its pyridine metabolite in human serum by high-performance liquid chromatography with ultraviolet detection and column switching. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2584318/),[ng] / [ml],0.1,61820,DB00592,Piperazine
,30815895,absolute bioavailability,"The results revealed satisfactory absorption of MFD in vivo, with an absolute bioavailability of MFD in rats and monkeys of approximately 77.2% and 70.0%, respectively.","Pharmacokinetics, tissue distribution, plasma protein binding, and metabolism study of mefunidone, a novel pirfenidone derivative. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30815895/),%,77.2,62049,DB00592,Piperazine
,30815895,absolute bioavailability,"The results revealed satisfactory absorption of MFD in vivo, with an absolute bioavailability of MFD in rats and monkeys of approximately 77.2% and 70.0%, respectively.","Pharmacokinetics, tissue distribution, plasma protein binding, and metabolism study of mefunidone, a novel pirfenidone derivative. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30815895/),%,70.0,62050,DB00592,Piperazine
,30815895,plasma protein binding rates,"The plasma protein binding rates in rat, monkey, and human plasma were 36.40%-41.68%, 30.88%-63.92%, and 37.75%-57.77%, respectively.","Pharmacokinetics, tissue distribution, plasma protein binding, and metabolism study of mefunidone, a novel pirfenidone derivative. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30815895/),%,36.40,62051,DB00592,Piperazine
,30815895,plasma protein binding rates,"The plasma protein binding rates in rat, monkey, and human plasma were 36.40%-41.68%, 30.88%-63.92%, and 37.75%-57.77%, respectively.","Pharmacokinetics, tissue distribution, plasma protein binding, and metabolism study of mefunidone, a novel pirfenidone derivative. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30815895/),%,41,62052,DB00592,Piperazine
,30815895,plasma protein binding rates,"The plasma protein binding rates in rat, monkey, and human plasma were 36.40%-41.68%, 30.88%-63.92%, and 37.75%-57.77%, respectively.","Pharmacokinetics, tissue distribution, plasma protein binding, and metabolism study of mefunidone, a novel pirfenidone derivative. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30815895/),%,30.88,62053,DB00592,Piperazine
,30815895,plasma protein binding rates,"The plasma protein binding rates in rat, monkey, and human plasma were 36.40%-41.68%, 30.88%-63.92%, and 37.75%-57.77%, respectively.","Pharmacokinetics, tissue distribution, plasma protein binding, and metabolism study of mefunidone, a novel pirfenidone derivative. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30815895/),%,63,62054,DB00592,Piperazine
,30815895,plasma protein binding rates,"The plasma protein binding rates in rat, monkey, and human plasma were 36.40%-41.68%, 30.88%-63.92%, and 37.75%-57.77%, respectively.","Pharmacokinetics, tissue distribution, plasma protein binding, and metabolism study of mefunidone, a novel pirfenidone derivative. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30815895/),%,37.75,62055,DB00592,Piperazine
,30815895,plasma protein binding rates,"The plasma protein binding rates in rat, monkey, and human plasma were 36.40%-41.68%, 30.88%-63.92%, and 37.75%-57.77%, respectively.","Pharmacokinetics, tissue distribution, plasma protein binding, and metabolism study of mefunidone, a novel pirfenidone derivative. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30815895/),%,57.77,62056,DB00592,Piperazine
,10771451,"AUC(0,12 h)","The mean AUC(0,12 h) was 272, 370, 250 and 297 ng ml(-1) h in groups 1, 2, 3 and 4, respectively.",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[h·ng] / [ml],272,62378,DB00592,Piperazine
,10771451,"AUC(0,12 h)","The mean AUC(0,12 h) was 272, 370, 250 and 297 ng ml(-1) h in groups 1, 2, 3 and 4, respectively.",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[h·ng] / [ml],370,62379,DB00592,Piperazine
,10771451,"AUC(0,12 h)","The mean AUC(0,12 h) was 272, 370, 250 and 297 ng ml(-1) h in groups 1, 2, 3 and 4, respectively.",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[h·ng] / [ml],250,62380,DB00592,Piperazine
,10771451,"AUC(0,12 h)","The mean AUC(0,12 h) was 272, 370, 250 and 297 ng ml(-1) h in groups 1, 2, 3 and 4, respectively.",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[h·ng] / [ml],297,62381,DB00592,Piperazine
,10771451,Cmax,"Corresponding mean Cmax values were 47, 61, 41 and 50 ng ml(-1) and corresponding mean tmax values were 5, 6, 5 and 5 h.",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[ng] / [ml],47,62382,DB00592,Piperazine
,10771451,Cmax,"Corresponding mean Cmax values were 47, 61, 41 and 50 ng ml(-1) and corresponding mean tmax values were 5, 6, 5 and 5 h.",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[ng] / [ml],61,62383,DB00592,Piperazine
,10771451,Cmax,"Corresponding mean Cmax values were 47, 61, 41 and 50 ng ml(-1) and corresponding mean tmax values were 5, 6, 5 and 5 h.",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[ng] / [ml],41,62384,DB00592,Piperazine
,10771451,Cmax,"Corresponding mean Cmax values were 47, 61, 41 and 50 ng ml(-1) and corresponding mean tmax values were 5, 6, 5 and 5 h.",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[ng] / [ml],50,62385,DB00592,Piperazine
,10771451,tmax,"Corresponding mean Cmax values were 47, 61, 41 and 50 ng ml(-1) and corresponding mean tmax values were 5, 6, 5 and 5 h.",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),h,5,62386,DB00592,Piperazine
,10771451,tmax,"Corresponding mean Cmax values were 47, 61, 41 and 50 ng ml(-1) and corresponding mean tmax values were 5, 6, 5 and 5 h.",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),h,6,62387,DB00592,Piperazine
,10771451,"AUC(0,12 h)","The mean AUC(0,12 h) were 446, 650, 389 and 427 ng ml(-1) h in groups 1, 2, 3 and 4, respectively.",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[h·ng] / [ml],446,62388,DB00592,Piperazine
,10771451,"AUC(0,12 h)","The mean AUC(0,12 h) were 446, 650, 389 and 427 ng ml(-1) h in groups 1, 2, 3 and 4, respectively.",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[h·ng] / [ml],650,62389,DB00592,Piperazine
,10771451,"AUC(0,12 h)","The mean AUC(0,12 h) were 446, 650, 389 and 427 ng ml(-1) h in groups 1, 2, 3 and 4, respectively.",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[h·ng] / [ml],389,62390,DB00592,Piperazine
,10771451,"AUC(0,12 h)","The mean AUC(0,12 h) were 446, 650, 389 and 427 ng ml(-1) h in groups 1, 2, 3 and 4, respectively.",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[h·ng] / [ml],427,62391,DB00592,Piperazine
,10771451,Cmax,"Corresponding mean Cmax values were 68, 93, 54 and 70 ng ml(-1), corresponding mean tmax values were 4, 5, 4 and 5 h and corresponding mean lambda(z) were 0.14, 0.11, 0.14 and 0.17 h(-1).",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[ng] / [ml],68,62392,DB00592,Piperazine
,10771451,Cmax,"Corresponding mean Cmax values were 68, 93, 54 and 70 ng ml(-1), corresponding mean tmax values were 4, 5, 4 and 5 h and corresponding mean lambda(z) were 0.14, 0.11, 0.14 and 0.17 h(-1).",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[ng] / [ml],93,62393,DB00592,Piperazine
,10771451,Cmax,"Corresponding mean Cmax values were 68, 93, 54 and 70 ng ml(-1), corresponding mean tmax values were 4, 5, 4 and 5 h and corresponding mean lambda(z) were 0.14, 0.11, 0.14 and 0.17 h(-1).",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[ng] / [ml],54,62394,DB00592,Piperazine
,10771451,Cmax,"Corresponding mean Cmax values were 68, 93, 54 and 70 ng ml(-1), corresponding mean tmax values were 4, 5, 4 and 5 h and corresponding mean lambda(z) were 0.14, 0.11, 0.14 and 0.17 h(-1).",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[ng] / [ml],70,62395,DB00592,Piperazine
,10771451,tmax,"Corresponding mean Cmax values were 68, 93, 54 and 70 ng ml(-1), corresponding mean tmax values were 4, 5, 4 and 5 h and corresponding mean lambda(z) were 0.14, 0.11, 0.14 and 0.17 h(-1).",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),h,4,62396,DB00592,Piperazine
,10771451,tmax,"Corresponding mean Cmax values were 68, 93, 54 and 70 ng ml(-1), corresponding mean tmax values were 4, 5, 4 and 5 h and corresponding mean lambda(z) were 0.14, 0.11, 0.14 and 0.17 h(-1).",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),h,5,62397,DB00592,Piperazine
,10771451,lambda(z),"Corresponding mean Cmax values were 68, 93, 54 and 70 ng ml(-1), corresponding mean tmax values were 4, 5, 4 and 5 h and corresponding mean lambda(z) were 0.14, 0.11, 0.14 and 0.17 h(-1).",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),1/[h],0.14,62398,DB00592,Piperazine
,10771451,lambda(z),"Corresponding mean Cmax values were 68, 93, 54 and 70 ng ml(-1), corresponding mean tmax values were 4, 5, 4 and 5 h and corresponding mean lambda(z) were 0.14, 0.11, 0.14 and 0.17 h(-1).",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),1/[h],0.11,62399,DB00592,Piperazine
,10771451,lambda(z),"Corresponding mean Cmax values were 68, 93, 54 and 70 ng ml(-1), corresponding mean tmax values were 4, 5, 4 and 5 h and corresponding mean lambda(z) were 0.14, 0.11, 0.14 and 0.17 h(-1).",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),1/[h],0.17,62400,DB00592,Piperazine
,10771451,"t(1/2),z","The mean percentage Fb was 99.84-99.88% across all groups and the mean t(1/2),z ranged from 4.2 to 6.4 h.",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),h,4.2 to 6.4,62401,DB00592,Piperazine
,28886938,Rs,"An excellent chiral separation (Rs=5.0) was achieved using a chiral stationary phase comprising cellulose tris(3,5-dichlorophenylcarbamate) and a volatile mobile phase of 10mM ammonium carbonate (pH 8.0)-acetonitrile (25:75, v/v).",Enantioselective determination of (R)-zopiclone and (S)-zopiclone (eszopiclone) in human hair by micropulverized extraction and chiral liquid chromatography/high resolution mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28886938/),,5.0,63126,DB00592,Piperazine
,7946933,Ki,"3. Among the serotonin-specific reuptake inhibitors fluoxetine (FLU) and sertraline (SERT), and their respective demethylated metabolites norfluoxetine (NOR) and desmethylsertraline (DES), NOR was the most potent inhibitor (mean Ki for 4-OH-ALP formation in humans: 11 microM), FLU the weakest (Ki = 83 microM), with SERT and DES falling in between (Ki = 24 and 20 microM).","Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),μM,11,63198,DB00592,Piperazine
,7946933,Ki,"3. Among the serotonin-specific reuptake inhibitors fluoxetine (FLU) and sertraline (SERT), and their respective demethylated metabolites norfluoxetine (NOR) and desmethylsertraline (DES), NOR was the most potent inhibitor (mean Ki for 4-OH-ALP formation in humans: 11 microM), FLU the weakest (Ki = 83 microM), with SERT and DES falling in between (Ki = 24 and 20 microM).","Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),μM,83,63199,DB00592,Piperazine
,7946933,Ki,"3. Among the serotonin-specific reuptake inhibitors fluoxetine (FLU) and sertraline (SERT), and their respective demethylated metabolites norfluoxetine (NOR) and desmethylsertraline (DES), NOR was the most potent inhibitor (mean Ki for 4-OH-ALP formation in humans: 11 microM), FLU the weakest (Ki = 83 microM), with SERT and DES falling in between (Ki = 24 and 20 microM).","Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),μM,24,63200,DB00592,Piperazine
,7946933,Ki,"3. Among the serotonin-specific reuptake inhibitors fluoxetine (FLU) and sertraline (SERT), and their respective demethylated metabolites norfluoxetine (NOR) and desmethylsertraline (DES), NOR was the most potent inhibitor (mean Ki for 4-OH-ALP formation in humans: 11 microM), FLU the weakest (Ki = 83 microM), with SERT and DES falling in between (Ki = 24 and 20 microM).","Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),μM,20,63201,DB00592,Piperazine
,7946933,liver:water partition ratios,"4. The in vitro data predict 29% inhibition of ALP clearance at mean FLU and NOR plasma concentrations of 77 ng ml-1 and 72 ng ml-1, respectively, after correction for liver:water partition ratios in the range of 12-14.","Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),,12-14,63202,DB00592,Piperazine
,7946933,Ki,"5. Ketoconazole was a potent inhibitor of ALP metabolism in vitro (Ki = 0.046 microM), suggesting that ALP hydroxylation is mediated by the cytochrome P450-3A sub-family.","Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),μM,0.046,63203,DB00592,Piperazine
,7946933,Ki,Quinidine was a weak inhibitor (Ki = 626 microM).,"Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946933/),μM,626,63204,DB00592,Piperazine
,1362656,limits of detection,The measurement of oxatomide was by means of a new sensitive and specific HPLC assay with limits of detection of 0.2 ng ml-1 in plasma and 1.0 ng ml-1 in urine.,Pharmacokinetics of oxatomide given percutaneously to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1362656/),[ng] / [ml],0.2,63298,DB00592,Piperazine
,1362656,limits of detection,The measurement of oxatomide was by means of a new sensitive and specific HPLC assay with limits of detection of 0.2 ng ml-1 in plasma and 1.0 ng ml-1 in urine.,Pharmacokinetics of oxatomide given percutaneously to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1362656/),[ng] / [ml],1.0,63299,DB00592,Piperazine
,1362656,peak plasma concentrations,Poor percutaneous absorption was confirmed by the peak plasma concentrations which were 5.03 +/- 0.79 ng ml-1 following application of the gel for 7 days and 10.08 +/- 1.29 ng ml-1 following oral administration; the corresponding amounts of unchanged oxatomide recovered from 24 h urine collections were 1.42 +/- 0.39 micrograms and 3.93 +/- 0.92 micrograms.,Pharmacokinetics of oxatomide given percutaneously to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1362656/),[ng] / [ml],5.03,63300,DB00592,Piperazine
,1362656,peak plasma concentrations,Poor percutaneous absorption was confirmed by the peak plasma concentrations which were 5.03 +/- 0.79 ng ml-1 following application of the gel for 7 days and 10.08 +/- 1.29 ng ml-1 following oral administration; the corresponding amounts of unchanged oxatomide recovered from 24 h urine collections were 1.42 +/- 0.39 micrograms and 3.93 +/- 0.92 micrograms.,Pharmacokinetics of oxatomide given percutaneously to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1362656/),[ng] / [ml],10.08,63301,DB00592,Piperazine
,1362656,peak plasma concentrations,Poor percutaneous absorption was confirmed by the peak plasma concentrations which were 5.03 +/- 0.79 ng ml-1 following application of the gel for 7 days and 10.08 +/- 1.29 ng ml-1 following oral administration; the corresponding amounts of unchanged oxatomide recovered from 24 h urine collections were 1.42 +/- 0.39 micrograms and 3.93 +/- 0.92 micrograms.,Pharmacokinetics of oxatomide given percutaneously to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1362656/),μg,1.42,63302,DB00592,Piperazine
,1362656,peak plasma concentrations,Poor percutaneous absorption was confirmed by the peak plasma concentrations which were 5.03 +/- 0.79 ng ml-1 following application of the gel for 7 days and 10.08 +/- 1.29 ng ml-1 following oral administration; the corresponding amounts of unchanged oxatomide recovered from 24 h urine collections were 1.42 +/- 0.39 micrograms and 3.93 +/- 0.92 micrograms.,Pharmacokinetics of oxatomide given percutaneously to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1362656/),μg,3.93,63303,DB00592,Piperazine
,3370902,half-life (t 1/2),"When assessed between and during haemodialysis, the anuric patients had significantly (p less than 0.05) greater pharmacokinetic median values: half-life (t 1/2) = 15.2 vs 9.8 hours; area under the concentration-time curve (AUC) = 604 vs 404 nmol/L.h; and mean residence time (MRT) = 9.28 vs 6.96 hours.",Clinical pharmacokinetics of oral buspirone in patients with impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370902/),h,15.2,63361,DB00592,Piperazine
,3370902,half-life (t 1/2),"When assessed between and during haemodialysis, the anuric patients had significantly (p less than 0.05) greater pharmacokinetic median values: half-life (t 1/2) = 15.2 vs 9.8 hours; area under the concentration-time curve (AUC) = 604 vs 404 nmol/L.h; and mean residence time (MRT) = 9.28 vs 6.96 hours.",Clinical pharmacokinetics of oral buspirone in patients with impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370902/),h,9.8,63362,DB00592,Piperazine
,3370902,area under the concentration-time curve (AUC),"When assessed between and during haemodialysis, the anuric patients had significantly (p less than 0.05) greater pharmacokinetic median values: half-life (t 1/2) = 15.2 vs 9.8 hours; area under the concentration-time curve (AUC) = 604 vs 404 nmol/L.h; and mean residence time (MRT) = 9.28 vs 6.96 hours.",Clinical pharmacokinetics of oral buspirone in patients with impaired renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370902/),[nM] / [h·l],604,63363,DB00592,Piperazine
,3370902,area under the concentration-time curve (AUC),"When assessed between and during haemodialysis, the anuric patients had significantly (p less than 0.05) greater pharmacokinetic median values: half-life (t 1/2) = 15.2 vs 9.8 hours; area under the concentration-time curve (AUC) = 604 vs 404 nmol/L.h; and mean residence time (MRT) = 9.28 vs 6.96 hours.",Clinical pharmacokinetics of oral buspirone in patients with impaired renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370902/),[nM] / [h·l],404,63364,DB00592,Piperazine
,3370902,mean residence time (MRT),"When assessed between and during haemodialysis, the anuric patients had significantly (p less than 0.05) greater pharmacokinetic median values: half-life (t 1/2) = 15.2 vs 9.8 hours; area under the concentration-time curve (AUC) = 604 vs 404 nmol/L.h; and mean residence time (MRT) = 9.28 vs 6.96 hours.",Clinical pharmacokinetics of oral buspirone in patients with impaired renal function. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370902/),h,9.28,63365,DB00592,Piperazine
,3370902,mean residence time (MRT),"When assessed between and during haemodialysis, the anuric patients had significantly (p less than 0.05) greater pharmacokinetic median values: half-life (t 1/2) = 15.2 vs 9.8 hours; area under the concentration-time curve (AUC) = 604 vs 404 nmol/L.h; and mean residence time (MRT) = 9.28 vs 6.96 hours.",Clinical pharmacokinetics of oral buspirone in patients with impaired renal function. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370902/),h,6.96,63366,DB00592,Piperazine
,20604833,maximum drug solubility,"The gelatin microcapsule at a weight ratio for itraconazole/gelatin/citric acid of 1 : 3 : 0.3 was spherical in shape with a smooth surface and inner hole, and gave a maximum drug solubility of about 700 microg/ml.",Development of an itraconazole-loaded gelatin microcapsule with enhanced oral bioavailability: physicochemical characterization and in-vivo evaluation. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20604833/),[μg] / [ml],700,63418,DB00592,Piperazine
,19088049,apparent oral clearance,"Mean +/- SD pharmacokinetic variables in smokers (n = 9) versus nonsmokers (n = 25) groups were 9.6 +/- 5.5 versus 9.2 +/- 4.6 L/h (apparent oral clearance), 216.5 +/- 114.3 versus 207.0 +/- 116.9 L (distribution volume), 16.1 +/- 6.0 versus 16.5 +/- 6.0 h (elimination half-life), and 133.6 +/- 71.0 versus 142.3 +/- 84.0 ng h/mL mg area under the concentration curve; P > 0.05.",Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19088049/),[l] / [h],9.2,63827,DB00592,Piperazine
,19088049,distribution volume,"Mean +/- SD pharmacokinetic variables in smokers (n = 9) versus nonsmokers (n = 25) groups were 9.6 +/- 5.5 versus 9.2 +/- 4.6 L/h (apparent oral clearance), 216.5 +/- 114.3 versus 207.0 +/- 116.9 L (distribution volume), 16.1 +/- 6.0 versus 16.5 +/- 6.0 h (elimination half-life), and 133.6 +/- 71.0 versus 142.3 +/- 84.0 ng h/mL mg area under the concentration curve; P > 0.05.",Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19088049/),l,207.0,63828,DB00592,Piperazine
,19088049,elimination half-life,"Mean +/- SD pharmacokinetic variables in smokers (n = 9) versus nonsmokers (n = 25) groups were 9.6 +/- 5.5 versus 9.2 +/- 4.6 L/h (apparent oral clearance), 216.5 +/- 114.3 versus 207.0 +/- 116.9 L (distribution volume), 16.1 +/- 6.0 versus 16.5 +/- 6.0 h (elimination half-life), and 133.6 +/- 71.0 versus 142.3 +/- 84.0 ng h/mL mg area under the concentration curve; P > 0.05.",Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19088049/),h,16.5,63829,DB00592,Piperazine
,19088049,elimination half-life,"Mean +/- SD pharmacokinetic variables in smokers (n = 9) versus nonsmokers (n = 25) groups were 9.6 +/- 5.5 versus 9.2 +/- 4.6 L/h (apparent oral clearance), 216.5 +/- 114.3 versus 207.0 +/- 116.9 L (distribution volume), 16.1 +/- 6.0 versus 16.5 +/- 6.0 h (elimination half-life), and 133.6 +/- 71.0 versus 142.3 +/- 84.0 ng h/mL mg area under the concentration curve; P > 0.05.",Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19088049/),[h·ng] / [mg·ml],142.3,63830,DB00592,Piperazine
,19088049,area under the concentration curve,"Mean +/- SD pharmacokinetic variables in smokers (n = 9) versus nonsmokers (n = 25) groups were 9.6 +/- 5.5 versus 9.2 +/- 4.6 L/h (apparent oral clearance), 216.5 +/- 114.3 versus 207.0 +/- 116.9 L (distribution volume), 16.1 +/- 6.0 versus 16.5 +/- 6.0 h (elimination half-life), and 133.6 +/- 71.0 versus 142.3 +/- 84.0 ng h/mL mg area under the concentration curve; P > 0.05.",Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19088049/),[h·ng] / [mg·ml],133.6,63831,DB00592,Piperazine
,19088049,area under the concentration curve,"Mean +/- SD pharmacokinetic variables in smokers (n = 9) versus nonsmokers (n = 25) groups were 9.6 +/- 5.5 versus 9.2 +/- 4.6 L/h (apparent oral clearance), 216.5 +/- 114.3 versus 207.0 +/- 116.9 L (distribution volume), 16.1 +/- 6.0 versus 16.5 +/- 6.0 h (elimination half-life), and 133.6 +/- 71.0 versus 142.3 +/- 84.0 ng h/mL mg area under the concentration curve; P > 0.05.",Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19088049/),[h·ng] / [mg·ml],142.3,63832,DB00592,Piperazine
,22422361,ΔΔQTcF,"The maximum ΔΔQTcF values for dolutegravir and moxifloxacin were observed at 4 hours: 1.99 msec (90% CI -0.55-4.53 msec) and 9.58 msec (90% CI 7.05-12.11 msec), respectively.",Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22422361/),ms,1.99,63976,DB00592,Piperazine
,22422361,ΔΔQTcF,"The maximum ΔΔQTcF values for dolutegravir and moxifloxacin were observed at 4 hours: 1.99 msec (90% CI -0.55-4.53 msec) and 9.58 msec (90% CI 7.05-12.11 msec), respectively.",Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22422361/),ms,9.58,63977,DB00592,Piperazine
,11466177,flow rate,"The internal standard and glyburide eluted at about 6.7 and 9.6 min, respectively at the flow rate of 1 mL/min.",A novel extractionless hplc fluorescence method for the determination of glyburide in the human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11466177/),[ml] / [min],1,64264,DB00592,Piperazine
,11466177,absolute recovery,The absolute recovery ranged from 94.32 to 98.12% and the relative recovery ranged from 91.12 to 97.15%.,A novel extractionless hplc fluorescence method for the determination of glyburide in the human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11466177/),%,94.32 to 98.12,64265,DB00592,Piperazine
,11466177,relative recovery,The absolute recovery ranged from 94.32 to 98.12% and the relative recovery ranged from 91.12 to 97.15%.,A novel extractionless hplc fluorescence method for the determination of glyburide in the human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11466177/),%,91.12 to 97.15,64266,DB00592,Piperazine
,22162540,C(max),"Test and reference formulations gave a mean trimetazidine C(max) of 63.26 ng/mL and 69.18 ng/mL for the fasting state and 64.19 ng/mL and 63.11 ng/mL for the fed state, respectively.",Food effect on bioavailability of modified-release trimetazidine tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162540/),[ng] / [ml],63.26,64548,DB00592,Piperazine
,22162540,C(max),"Test and reference formulations gave a mean trimetazidine C(max) of 63.26 ng/mL and 69.18 ng/mL for the fasting state and 64.19 ng/mL and 63.11 ng/mL for the fed state, respectively.",Food effect on bioavailability of modified-release trimetazidine tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162540/),[ng] / [ml],69.18,64549,DB00592,Piperazine
,22162540,C(max),"Test and reference formulations gave a mean trimetazidine C(max) of 63.26 ng/mL and 69.18 ng/mL for the fasting state and 64.19 ng/mL and 63.11 ng/mL for the fed state, respectively.",Food effect on bioavailability of modified-release trimetazidine tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162540/),[ng] / [ml],64.19,64550,DB00592,Piperazine
,22162540,C(max),"Test and reference formulations gave a mean trimetazidine C(max) of 63.26 ng/mL and 69.18 ng/mL for the fasting state and 64.19 ng/mL and 63.11 ng/mL for the fed state, respectively.",Food effect on bioavailability of modified-release trimetazidine tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162540/),[ng] / [ml],63.11,64551,DB00592,Piperazine
,22162540,AUC(0-tlast),The AUC(0-tlast) mean of trimetazidine was 726.31 ng·h/mL and 733.01 ng·h/mL for the fasting state and 706.40 ng·h/mL and 691.40 ng·h/mL for the fed state for test/reference formulations.,Food effect on bioavailability of modified-release trimetazidine tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162540/),[h·ng] / [ml],726.31,64552,DB00592,Piperazine
,22162540,AUC(0-tlast),The AUC(0-tlast) mean of trimetazidine was 726.31 ng·h/mL and 733.01 ng·h/mL for the fasting state and 706.40 ng·h/mL and 691.40 ng·h/mL for the fed state for test/reference formulations.,Food effect on bioavailability of modified-release trimetazidine tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162540/),[h·ng] / [ml],733.01,64553,DB00592,Piperazine
,22162540,AUC(0-tlast),The AUC(0-tlast) mean of trimetazidine was 726.31 ng·h/mL and 733.01 ng·h/mL for the fasting state and 706.40 ng·h/mL and 691.40 ng·h/mL for the fed state for test/reference formulations.,Food effect on bioavailability of modified-release trimetazidine tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162540/),[h·ng] / [ml],706.40,64554,DB00592,Piperazine
,22162540,AUC(0-tlast),The AUC(0-tlast) mean of trimetazidine was 726.31 ng·h/mL and 733.01 ng·h/mL for the fasting state and 706.40 ng·h/mL and 691.40 ng·h/mL for the fed state for test/reference formulations.,Food effect on bioavailability of modified-release trimetazidine tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162540/),[h·ng] / [ml],691.40,64555,DB00592,Piperazine
,8471409,tmax,The mean tmax value increased from 0.82 h after fasting to 1.44 h after a low-fat meal and to 2.46 h after a high-fat meal.,Food intake increases the relative oral bioavailability of vanoxerine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471409/),h,0.82,64745,DB00592,Piperazine
,8471409,tmax,The mean tmax value increased from 0.82 h after fasting to 1.44 h after a low-fat meal and to 2.46 h after a high-fat meal.,Food intake increases the relative oral bioavailability of vanoxerine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471409/),h,1.44,64746,DB00592,Piperazine
,8471409,tmax,The mean tmax value increased from 0.82 h after fasting to 1.44 h after a low-fat meal and to 2.46 h after a high-fat meal.,Food intake increases the relative oral bioavailability of vanoxerine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471409/),h,2.46,64747,DB00592,Piperazine
,8471409,Cmax,"Only modest food effects were seen on mean Cmax values (55 nM, 52 nM and 84 nM, after fasting, after the low-fat meal and after the high-fat meal, respectively) but values of AUC up to the last measurable concentration (AUC(0,t)) increased by 76% (from 110 to 194 nM h) after the low-fat meal and by 255% (from 110 to 391 nM h) after the high-fat meal compared with fasting.",Food intake increases the relative oral bioavailability of vanoxerine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471409/),nM,55,64748,DB00592,Piperazine
,8471409,Cmax,"Only modest food effects were seen on mean Cmax values (55 nM, 52 nM and 84 nM, after fasting, after the low-fat meal and after the high-fat meal, respectively) but values of AUC up to the last measurable concentration (AUC(0,t)) increased by 76% (from 110 to 194 nM h) after the low-fat meal and by 255% (from 110 to 391 nM h) after the high-fat meal compared with fasting.",Food intake increases the relative oral bioavailability of vanoxerine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471409/),nM,52,64749,DB00592,Piperazine
,8471409,Cmax,"Only modest food effects were seen on mean Cmax values (55 nM, 52 nM and 84 nM, after fasting, after the low-fat meal and after the high-fat meal, respectively) but values of AUC up to the last measurable concentration (AUC(0,t)) increased by 76% (from 110 to 194 nM h) after the low-fat meal and by 255% (from 110 to 391 nM h) after the high-fat meal compared with fasting.",Food intake increases the relative oral bioavailability of vanoxerine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471409/),nM,84,64750,DB00592,Piperazine
,8471409,"AUC up to the last measurable concentration (AUC(0,t))","Only modest food effects were seen on mean Cmax values (55 nM, 52 nM and 84 nM, after fasting, after the low-fat meal and after the high-fat meal, respectively) but values of AUC up to the last measurable concentration (AUC(0,t)) increased by 76% (from 110 to 194 nM h) after the low-fat meal and by 255% (from 110 to 391 nM h) after the high-fat meal compared with fasting.",Food intake increases the relative oral bioavailability of vanoxerine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471409/),h·nM,110 to 194,64751,DB00592,Piperazine
,8471409,"AUC up to the last measurable concentration (AUC(0,t))","Only modest food effects were seen on mean Cmax values (55 nM, 52 nM and 84 nM, after fasting, after the low-fat meal and after the high-fat meal, respectively) but values of AUC up to the last measurable concentration (AUC(0,t)) increased by 76% (from 110 to 194 nM h) after the low-fat meal and by 255% (from 110 to 391 nM h) after the high-fat meal compared with fasting.",Food intake increases the relative oral bioavailability of vanoxerine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471409/),h·nM,110 to 391,64752,DB00592,Piperazine
,22818206,analysis time,The analysis time was about 5.5 min.,Simultaneous determination of blonanserin and its metabolite in human plasma and urine by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22818206/),min,5.5,64874,DB00592,Piperazine
,19949232,clearance at 100% bioavailability,Interpatient and intrapatient variability for clearance at 100% bioavailability were 87% and 27% (SIL) and 62% and 26% (DMS).,Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19949232/),%,87,64975,DB00592,Piperazine
,19949232,clearance at 100% bioavailability,Interpatient and intrapatient variability for clearance at 100% bioavailability were 87% and 27% (SIL) and 62% and 26% (DMS).,Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19949232/),%,27,64976,DB00592,Piperazine
,19949232,clearance at 100% bioavailability,Interpatient and intrapatient variability for clearance at 100% bioavailability were 87% and 27% (SIL) and 62% and 26% (DMS).,Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19949232/),%,62,64977,DB00592,Piperazine
,19949232,clearance at 100% bioavailability,Interpatient and intrapatient variability for clearance at 100% bioavailability were 87% and 27% (SIL) and 62% and 26% (DMS).,Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19949232/),%,26,64978,DB00592,Piperazine
,19949232,area under the curve over 24 h (AUC(24,The exposure expressed as average plasma concentration area under the curve over 24 h (AUC(24 (SIL+DMS))) ranged from 625 to 13 579 ng/h/ml.,Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19949232/),[ng] / [h·ml],625 to 13 579,64979,DB00592,Piperazine
,19949232,AUC(24,An oral dose of 4.2 mg/kg/24 h would lead to a median AUC(24 (SIL+DMS)) of 2650 ng/h/ml equivalent to 20 mg three times a day in adults.,Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19949232/),[ng] / [h·ml],2650,64980,DB00592,Piperazine
,19949232,AUC(24,"Interpatient variability was large, with a simulated AUC(24 (SIL+DMS)) range (10th and 90th percentiles) of 1000-8000 ng/h/ml.",Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19949232/),[ng] / [h·ml],1000-8000,64981,DB00592,Piperazine
,27137713,tmax,"The parent drug's median tmax was approximately 0.5 hours, and the metabolite's median tmax ranged from 0.5 to 1.0 hours post-parent dosing.","A single- and multiple-dose study to investigate the pharmacokinetics of epelsiban and its metabolite, GSK2395448, in healthy female volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137713/),h,0.5,65011,DB00592,Piperazine
,27137713,tmax,"The parent drug's median tmax was approximately 0.5 hours, and the metabolite's median tmax ranged from 0.5 to 1.0 hours post-parent dosing.","A single- and multiple-dose study to investigate the pharmacokinetics of epelsiban and its metabolite, GSK2395448, in healthy female volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137713/),h,0.5 to 1.0,65012,DB00592,Piperazine
,27137713,elimination half-lives,"Both epelsiban and GSK2395448 had rapid elimination half-lives, ranging between 2.66 and 4.85 hours.","A single- and multiple-dose study to investigate the pharmacokinetics of epelsiban and its metabolite, GSK2395448, in healthy female volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137713/),h,2.66 and 4.85,65013,DB00592,Piperazine
,23073140,tmax,"The mean lodenafil pharmacokinetic parameters for tmax and t1/2 were 1.6 ( ± 0.4) h and 3.3 ( ± 1.1) h, respectively.","A Phase I clinical trial of lodenafil carbonate, a new phosphodiesterase Type 5 (PDE5) inhibitor, in healthy male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23073140/),h,1.6,65077,DB00592,Piperazine
,23073140,t1/2,"The mean lodenafil pharmacokinetic parameters for tmax and t1/2 were 1.6 ( ± 0.4) h and 3.3 ( ± 1.1) h, respectively.","A Phase I clinical trial of lodenafil carbonate, a new phosphodiesterase Type 5 (PDE5) inhibitor, in healthy male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23073140/),h,3.3,65078,DB00592,Piperazine
,8534279,steady-state plasma concentration,Flunarizine was given in increasing doses starting with 0.1-0.3 mg/kg/day until effect was observed or a steady-state plasma concentration of 50-60 ng/ml was reached.,Flunarizine of limited value in children with intractable epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8534279/),[ng] / [ml],50-60,65120,DB00592,Piperazine
,8534279,time of peak concentration (Tmax),Flunarizine was rapidly absorbed; mean time of peak concentration (Tmax) was 2.7 hours (range: 1-8).,Flunarizine of limited value in children with intractable epilepsy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8534279/),h,2.7,65121,DB00592,Piperazine
,8534279,terminal half-life,"The mean terminal half-life was 23.2 days (range: 7-48), the total plasma clearance of flunarizine per fraction of the dose absorbed (CLp/F) was 0.28 ml/min/kg (range: 0.07-042), and the volume of distribution of flunarizine per fraction of the dose absorbed (Vd/F) was 187 L/kg (range: 99-348).",Flunarizine of limited value in children with intractable epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8534279/),d,23.2,65122,DB00592,Piperazine
,8534279,total plasma clearance of flunarizine per fraction of the dose absorbed (CLp/F),"The mean terminal half-life was 23.2 days (range: 7-48), the total plasma clearance of flunarizine per fraction of the dose absorbed (CLp/F) was 0.28 ml/min/kg (range: 0.07-042), and the volume of distribution of flunarizine per fraction of the dose absorbed (Vd/F) was 187 L/kg (range: 99-348).",Flunarizine of limited value in children with intractable epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8534279/),[ml] / [kg·min],0.28,65123,DB00592,Piperazine
,8534279,volume of distribution of flunarizine per fraction of the dose absorbed (Vd/F),"The mean terminal half-life was 23.2 days (range: 7-48), the total plasma clearance of flunarizine per fraction of the dose absorbed (CLp/F) was 0.28 ml/min/kg (range: 0.07-042), and the volume of distribution of flunarizine per fraction of the dose absorbed (Vd/F) was 187 L/kg (range: 99-348).",Flunarizine of limited value in children with intractable epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8534279/),[l] / [kg],187,65124,DB00592,Piperazine
>,31899538,m/z,Mass spectrometric detection was carried out by selective reaction monitoring mode via positive ESI mode with precursor-to-product transitions of m/z 435.3 > 367.1 and m/z 443.1 > 375.2 for olaparib and 2 H8 -olaparib (internal standard).,Gender-dependent pharmacokinetics of olaparib in rats determined by ultra-high performance liquid chromatography/electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31899538/),,435.3,65569,DB00592,Piperazine
>,31899538,m/z,Mass spectrometric detection was carried out by selective reaction monitoring mode via positive ESI mode with precursor-to-product transitions of m/z 435.3 > 367.1 and m/z 443.1 > 375.2 for olaparib and 2 H8 -olaparib (internal standard).,Gender-dependent pharmacokinetics of olaparib in rats determined by ultra-high performance liquid chromatography/electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31899538/),,367.1,65570,DB00592,Piperazine
>,31899538,m/z,Mass spectrometric detection was carried out by selective reaction monitoring mode via positive ESI mode with precursor-to-product transitions of m/z 435.3 > 367.1 and m/z 443.1 > 375.2 for olaparib and 2 H8 -olaparib (internal standard).,Gender-dependent pharmacokinetics of olaparib in rats determined by ultra-high performance liquid chromatography/electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31899538/),,443.1,65571,DB00592,Piperazine
>,31899538,m/z,Mass spectrometric detection was carried out by selective reaction monitoring mode via positive ESI mode with precursor-to-product transitions of m/z 435.3 > 367.1 and m/z 443.1 > 375.2 for olaparib and 2 H8 -olaparib (internal standard).,Gender-dependent pharmacokinetics of olaparib in rats determined by ultra-high performance liquid chromatography/electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31899538/),,375.2,65572,DB00592,Piperazine
,2091887,volume of distribution,"After intravenous administration of 0.5 mg.kg-1, the mean volume of distribution was 5.7 +/- 1.1 l.kg-1.",Pharmacokinetics of eltoprazine in the dog. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2091887/),[l] / [kg],5.7,65920,DB00592,Piperazine
,2091887,Clearance,Clearance was 25.5 +/- 1.4 ml.min-1.kg-1.,Pharmacokinetics of eltoprazine in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2091887/),[ml] / [kg·min],25.5,65921,DB00592,Piperazine
,2091887,renal clearance,"About 25% of the doses was excreted in urine, resulting ina renal clearance of 6.1 +/- 1.4 ml.min-1.kg-1.",Pharmacokinetics of eltoprazine in the dog. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2091887/),[ml] / [kg·min],6.1,65922,DB00592,Piperazine
,2091887,elimination half-life (t1/2),The mean elimination half-life (t1/2) after intravenous dosing was about 2.6 h.,Pharmacokinetics of eltoprazine in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2091887/),h,2.6,65923,DB00592,Piperazine
,2091887,time to reach Cmax (tmax),"The mean time to reach Cmax (tmax) varied between 1.5 and 1.9 h, and t1/2 was about 2.4 h, which was not significantly different (p greater than 0.05) from the half-life obtained after intravenous dosing.",Pharmacokinetics of eltoprazine in the dog. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2091887/),h,1.5 and 1.9,65924,DB00592,Piperazine
,2091887,t1/2,"The mean time to reach Cmax (tmax) varied between 1.5 and 1.9 h, and t1/2 was about 2.4 h, which was not significantly different (p greater than 0.05) from the half-life obtained after intravenous dosing.",Pharmacokinetics of eltoprazine in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2091887/),h,2.4,65925,DB00592,Piperazine
,2091887,Absolute bioavailability,Absolute bioavailability was 67% +/- 20%.,Pharmacokinetics of eltoprazine in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2091887/),%,67,65926,DB00592,Piperazine
,27392173,flow rate,"With an octadeuterated sildenafil as the internal standard, the drugs were separated via gradient elution using a C18 column and formic acid in methanol or in water as the mobile phase with a flow rate of 0.25mL/min.",A highly sensitive LC-MS/MS method for concurrent determination of sildenafil and rosiglitazone in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27392173/),[ml] / [min],0.25,66162,DB00592,Piperazine
,10993198,Ki,"The Ki values of KCZ and FCZ for NVP 12-hydroxylation were 1.59 microm and 11.5 microM, respectively, indicating that KCZ inhibited this activity more strongly than FCZ in vitro.",Quantitative prediction of in vivo drug interactions between nevirapine and antifungal agents from in vitro data in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10993198/),μm,1.59,66283,DB00592,Piperazine
,10993198,Ki,"The Ki values of KCZ and FCZ for NVP 12-hydroxylation were 1.59 microm and 11.5 microM, respectively, indicating that KCZ inhibited this activity more strongly than FCZ in vitro.",Quantitative prediction of in vivo drug interactions between nevirapine and antifungal agents from in vitro data in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10993198/),μM,11.5,66284,DB00592,Piperazine
,10993198,unbound fraction,"Further, the unbound fraction of KCZ was decreased dramatically to around 3%, whereas more than 90% of FCZ remained in unbound form.",Quantitative prediction of in vivo drug interactions between nevirapine and antifungal agents from in vitro data in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10993198/),%,3,66285,DB00592,Piperazine
,8690825,inhibition constants (Ki),"The azole antifungal agent ketoconazole was a highly potent inhibitor of both reactions, having mean inhibition constants (Ki) of 0.037 and 0.34 microM for desalkyl- and hydroxy-terfenadine formation, respectively.",Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8690825/),μM,0.037,66325,DB00592,Piperazine
,8690825,inhibition constants (Ki),"The azole antifungal agent ketoconazole was a highly potent inhibitor of both reactions, having mean inhibition constants (Ki) of 0.037 and 0.34 microM for desalkyl- and hydroxy-terfenadine formation, respectively.",Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8690825/),μM,0.34,66326,DB00592,Piperazine
,8690825,Ki,"Itraconazole also was a potent inhibitor, with Ki values of 0.28 and 2.05 microM, respectively.",Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8690825/),μM,0.28,66327,DB00592,Piperazine
,8690825,Ki,"Itraconazole also was a potent inhibitor, with Ki values of 0.28 and 2.05 microM, respectively.",Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8690825/),μM,2.05,66328,DB00592,Piperazine
,10435475,peak values,Plasma cetirizine levels increased within 30 min to reach peak values of 315+/-10 and 786+/-45 ng/ml 90-120 min after administration of 10 and 20 mg of cetirizine.,Measurement of interstitial cetirizine concentrations in human skin: correlation of drug levels with inhibition of histamine-induced skin responses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435475/),[ng] / [ml],315,66340,DB00592,Piperazine
,10435475,peak values,Plasma cetirizine levels increased within 30 min to reach peak values of 315+/-10 and 786+/-45 ng/ml 90-120 min after administration of 10 and 20 mg of cetirizine.,Measurement of interstitial cetirizine concentrations in human skin: correlation of drug levels with inhibition of histamine-induced skin responses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435475/),[ng] / [ml],786,66341,DB00592,Piperazine
,10435475,In vivo recovery,In vivo recovery of cetirizine was 14.4+/-4.3%.,Measurement of interstitial cetirizine concentrations in human skin: correlation of drug levels with inhibition of histamine-induced skin responses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435475/),%,14.4,66342,DB00592,Piperazine
,30825803,flow rate,"In this study, a reversed-phase chromatography was performed at room temperature on a C18 column with a mobile phase composed of 10 mM Na2HPO4 solution (pH 7.5): acetonitrile (45:55, v/v) at a flow rate of 0.8 mL min-1 using caffeine (CAF) as an internal standard.",Development and validation of an HPLC-UV method for simultaneous determination of sildenafil and tramadol in biological fluids: Application to drug-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30825803/),[ml] / [min],0.8,66387,DB00592,Piperazine
,30825803,total analysis time,The total analysis time was 6 min.,Development and validation of an HPLC-UV method for simultaneous determination of sildenafil and tramadol in biological fluids: Application to drug-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30825803/),min,6,66388,DB00592,Piperazine
,30825803,detection limit,"Calibration graphs were linear in the concentration ranges of 0.1-10 and 0.05-10 μg mL-1 with a detection limit of 0.05 and 0.02 μg mL-1 for TMD and SDF, respectively.",Development and validation of an HPLC-UV method for simultaneous determination of sildenafil and tramadol in biological fluids: Application to drug-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30825803/),[μg] / [ml],0.05,66389,DB00592,Piperazine
,30825803,detection limit,"Calibration graphs were linear in the concentration ranges of 0.1-10 and 0.05-10 μg mL-1 with a detection limit of 0.05 and 0.02 μg mL-1 for TMD and SDF, respectively.",Development and validation of an HPLC-UV method for simultaneous determination of sildenafil and tramadol in biological fluids: Application to drug-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30825803/),[μg] / [ml],0.02,66390,DB00592,Piperazine
,10193676,oral bioavailability,"Lignocaine is metabolized by cytochrome P450 3A4 enzyme (CYP3A4), and has a moderate to high extraction ratio resulting in oral bioavailability of 30%.",Effect of erythromycin and itraconazole on the pharmacokinetics of oral lignocaine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10193676/),%,30,66836,DB00592,Piperazine
,20071999,area under the curve breakpoint,Similar results were seen with an area under the curve breakpoint of 1460 ng h/mL.,Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20071999/),[h·ng] / [ml],1460,66837,DB00592,Piperazine
,32857315,terminal elimination half-life (t1/2),The mean terminal elimination half-life (t1/2) for ozanimod was approximately 20-22 h while the mean t1/2 for CC112273 and CC1084037 were approximately 10 days.,"Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32857315/),h,20-22,66946,DB00592,Piperazine
,32857315,t1/2,The mean terminal elimination half-life (t1/2) for ozanimod was approximately 20-22 h while the mean t1/2 for CC112273 and CC1084037 were approximately 10 days.,"Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32857315/),d,10,66947,DB00592,Piperazine
,18359865,MTD,"The MTD of imatinib for patients concurrently receiving or not receiving EIAEDs was 1,000 mg.",Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18359865/),mg,"1,000",67011,DB00592,Piperazine
,18359865,progression-free,"Among GBM patients with stable disease at enrollment (n=28), the median progression-free and overall survival times were 41.7 and 56.1 weeks, respectively.",Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18359865/),weeks,41.7,67012,DB00592,Piperazine
,18359865,overall survival times,"Among GBM patients with stable disease at enrollment (n=28), the median progression-free and overall survival times were 41.7 and 56.1 weeks, respectively.",Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18359865/),weeks,56.1,67013,DB00592,Piperazine
,30516093,"Kp,uu,liver","3. PBPK model using each Kp,uu,liver projected the area under the curve (AUC) increase of substrates more accurately than the model assuming a Kp,uu,liver of 1 for the average fold error and root mean square error did.",Application of unbound liver-to-plasma concentration ratio to quantitative projection of cytochrome P450-mediated drug-drug interactions using physiologically based pharmacokinetic modelling approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30516093/),,1,67020,DB00592,Piperazine
,602249,Peak mean plasma concentrations,3. Peak mean plasma concentrations of radioactivity (5.5 microgram equiv./ml) occurred at 90 min after an oral dose and were higher than those at 2 min following an equivalent intravenous (3.4 microgram equiv./ml) or rectal (4.0 microgram equiv./ml) dose which gave a max.,Identification of an N-oxide as the major metabolite of the analgesic O-(diethylaminoethyl)-4-chlorobenzaldoxime hydrochloride in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/602249/),[equiv·μg] / [ml],5.5,67101,DB00592,Piperazine
,21913329,LODs,"The LODs were 1.50 and 5.00 ng/mL for SDL and DSDL, respectively, whereas the respective LOQs were 5.00 and 15.0 ng/mL.",Development and validation of a gas chromatography-mass spectrometric method for the determination of sildenafil and desmethyl-sildenafil in whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21913329/),[ng] / [ml],1.50,67607,DB00592,Piperazine
,21913329,LODs,"The LODs were 1.50 and 5.00 ng/mL for SDL and DSDL, respectively, whereas the respective LOQs were 5.00 and 15.0 ng/mL.",Development and validation of a gas chromatography-mass spectrometric method for the determination of sildenafil and desmethyl-sildenafil in whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21913329/),[ng] / [ml],5.00,67608,DB00592,Piperazine
,21913329,LOQ,"The LODs were 1.50 and 5.00 ng/mL for SDL and DSDL, respectively, whereas the respective LOQs were 5.00 and 15.0 ng/mL.",Development and validation of a gas chromatography-mass spectrometric method for the determination of sildenafil and desmethyl-sildenafil in whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21913329/),ng,5.00,67609,DB00592,Piperazine
,21913329,LOQ,"The LODs were 1.50 and 5.00 ng/mL for SDL and DSDL, respectively, whereas the respective LOQs were 5.00 and 15.0 ng/mL.",Development and validation of a gas chromatography-mass spectrometric method for the determination of sildenafil and desmethyl-sildenafil in whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21913329/),ng,15.0,67610,DB00592,Piperazine
,21913329,Absolute recovery,Absolute recovery values for both analytes ranged from 83.1 to 93.2%.,Development and validation of a gas chromatography-mass spectrometric method for the determination of sildenafil and desmethyl-sildenafil in whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21913329/),%,83.1 to 93.2,67611,DB00592,Piperazine
,22210483,IC(50),"Efonidipine inhibited CYP3A4 activity with an IC(50) value of 0.08 μM, and efonidipine significantly inhibited P-gp activity in a concentration-dependent manner.",Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210483/),μM,0.08,68078,DB00592,Piperazine
,22210483,absolute bioavailability,Efonidipine also significantly (P < 0.01 for 3 mg/kg) increased the absolute bioavailability (AB) of repaglinide by 51.5% compared to the oral control group (33.6%).,Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210483/),%,33.6,68079,DB00592,Piperazine
,18514353,Stability constants,Stability constants calculated for a 1:1 molar ratio of CD/rifampicin were 73.4 +/- 8.2 M(-1) for RAMEB and 68.5 +/- 5.2 M(-1) for HPbetaCD.,Formulation of rifampicin-cyclodextrin complexes for lung nebulization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18514353/),1/[M],73.4,68144,DB00592,Piperazine
,18514353,Stability constants,Stability constants calculated for a 1:1 molar ratio of CD/rifampicin were 73.4 +/- 8.2 M(-1) for RAMEB and 68.5 +/- 5.2 M(-1) for HPbetaCD.,Formulation of rifampicin-cyclodextrin complexes for lung nebulization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18514353/),1/[M],68.5,68145,DB00592,Piperazine
,3582469,maximum serum urapidil level,"A maximum serum urapidil level of 625 +/- 232 ng/ml was achieved at the end of the 10 mg/h infusion, when the fall in blood pressure was 37/21 mmHg.",Pharmacodynamics and pharmacokinetics of urapidil in hypertensive patients: a crossover study comparing infusion with an infusion-capsule combination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582469/),[ng] / [ml],625,68658,DB00592,Piperazine
,15897016,flow rate,"Separation was by Nova-pak phenyl column; flow rate, 1.0 ml/min; mobile phase, acetonitrile-methanol-20 mM sodium sulfate-acetic acid (27:25:48:1, v/v/v/v); UV detection at 254 nm.",High performance liquid chromatographic methods for the determination of aripiprazole with ultraviolet detection in rat plasma and brain: application to the pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15897016/),[ml] / [min],1.0,68956,DB00592,Piperazine
,27379747,flow rate,The flow rate was 0.5mL/min.,A highly sensitive LC-MS/MS method for determination of ketoconazole in human plasma: Application to a clinical study of the exposure to ketoconazole in patients after topical administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27379747/),[ml] / [min],0.5,68987,DB00592,Piperazine
,31125276,trough concentration,Geometric mean palbociclib trough concentration values were higher in Asians versus non-Asians (93.8 v 61.7 ng/mL).,"Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31125276/),[ng] / [ml],93.8,69625,DB00592,Piperazine
,31125276,trough concentration,Geometric mean palbociclib trough concentration values were higher in Asians versus non-Asians (93.8 v 61.7 ng/mL).,"Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31125276/),[ng] / [ml],61.7,69626,DB00592,Piperazine
,9768830,steady-state DEX plasma concentrations,Results of pharmacokinetic studies in support of the trial have found that steady-state DEX plasma concentrations in the range of 4 to 5 micromol/L can be achieved safely.,Antineoplastic activity of continuous exposure to dexrazoxane: potential new role as a novel topoisomerase II inhibitor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9768830/),[μM] / [l],4 to 5,69641,DB00592,Piperazine
,34426442,C max ratio,"For DXd (cycle 3/cycle 2), C max ratio was 0.99 (90% CI, 0.85-1.14) for cohort 1 and 1.04 (0.92-1.18) for cohort 2; AUC17d ratio was 1.22 (1.08-1.37) and 1.18 (1.11-1.25), respectively.","Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34426442/),,0.99,69654,DB00592,Piperazine
,34426442,C max ratio,"For DXd (cycle 3/cycle 2), C max ratio was 0.99 (90% CI, 0.85-1.14) for cohort 1 and 1.04 (0.92-1.18) for cohort 2; AUC17d ratio was 1.22 (1.08-1.37) and 1.18 (1.11-1.25), respectively.","Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34426442/),,1.04,69655,DB00592,Piperazine
,34426442,AUC17d ratio,"For DXd (cycle 3/cycle 2), C max ratio was 0.99 (90% CI, 0.85-1.14) for cohort 1 and 1.04 (0.92-1.18) for cohort 2; AUC17d ratio was 1.22 (1.08-1.37) and 1.18 (1.11-1.25), respectively.","Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34426442/),,1.22,69656,DB00592,Piperazine
,34426442,AUC17d ratio,"For DXd (cycle 3/cycle 2), C max ratio was 0.99 (90% CI, 0.85-1.14) for cohort 1 and 1.04 (0.92-1.18) for cohort 2; AUC17d ratio was 1.22 (1.08-1.37) and 1.18 (1.11-1.25), respectively.","Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34426442/),,1.18,69657,DB00592,Piperazine
,28575987,AUC(0-t),In vivo skin deposition parameters further confirmed high skin deposition of drug-loaded micelles (AUC(0-t)=396.16μg·h/cm2) over marketed ketoconazole cream (AUC(0-t)=250.03μg·h/cm2).,Y-shaped methoxy poly (ethylene glycol)-block-poly (epsilon-caprolactone)-based micelles for skin delivery of ketoconazole: in vitro study and in vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28575987/),[h·μg] / [cm2],396.16,69719,DB00592,Piperazine
,28575987,AUC(0-t),In vivo skin deposition parameters further confirmed high skin deposition of drug-loaded micelles (AUC(0-t)=396.16μg·h/cm2) over marketed ketoconazole cream (AUC(0-t)=250.03μg·h/cm2).,Y-shaped methoxy poly (ethylene glycol)-block-poly (epsilon-caprolactone)-based micelles for skin delivery of ketoconazole: in vitro study and in vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28575987/),[h·μg] / [cm2],250.03,69720,DB00592,Piperazine
,28575987,AUC(0-t),"Meanwhile, in vivo pharmacokinetic parameters proved that ketoconazole-loaded micelles reduced ketoconazole's distribution in blood in comparison with the cream (AUC(0-t)=93,028.00μg·h/L vs AUC(0-t)=151,714.00μg·h/L), meaning lower possibility of its systemic unwanted effects in the skin fungal infection treatment.",Y-shaped methoxy poly (ethylene glycol)-block-poly (epsilon-caprolactone)-based micelles for skin delivery of ketoconazole: in vitro study and in vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28575987/),[h·μg] / [l],"93,028.00",69721,DB00592,Piperazine
,28575987,AUC(0-t),"Meanwhile, in vivo pharmacokinetic parameters proved that ketoconazole-loaded micelles reduced ketoconazole's distribution in blood in comparison with the cream (AUC(0-t)=93,028.00μg·h/L vs AUC(0-t)=151,714.00μg·h/L), meaning lower possibility of its systemic unwanted effects in the skin fungal infection treatment.",Y-shaped methoxy poly (ethylene glycol)-block-poly (epsilon-caprolactone)-based micelles for skin delivery of ketoconazole: in vitro study and in vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28575987/),[h·μg] / [l],"151,714.00",69722,DB00592,Piperazine
,12635496,peak plasma concentration (Cmax),"Following the administration of oxatomide 1 mg/kg, the peak plasma concentration (Cmax), the elimination half-life (t1/2), the volume of distribution (Vd), and the area under the curve (AUC) 0-36 h were measured and the following results were obtained: 42.2 +/- 15 ng/ml at 2 h after oxatomide administration, 41.4 +/- 2.0 h, 37.4 +/- 4.2 l/kg, and 468 +/- 52 ng/ml/h, respectively.",Pharmacokinetics of oxatomide in preterm infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12635496/),[ng] / [ml],42.2,69735,DB00592,Piperazine
,12635496,elimination half-life (t1/2),"Following the administration of oxatomide 1 mg/kg, the peak plasma concentration (Cmax), the elimination half-life (t1/2), the volume of distribution (Vd), and the area under the curve (AUC) 0-36 h were measured and the following results were obtained: 42.2 +/- 15 ng/ml at 2 h after oxatomide administration, 41.4 +/- 2.0 h, 37.4 +/- 4.2 l/kg, and 468 +/- 52 ng/ml/h, respectively.",Pharmacokinetics of oxatomide in preterm infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12635496/),h,41.4,69736,DB00592,Piperazine
,12635496,volume of distribution (Vd),"Following the administration of oxatomide 1 mg/kg, the peak plasma concentration (Cmax), the elimination half-life (t1/2), the volume of distribution (Vd), and the area under the curve (AUC) 0-36 h were measured and the following results were obtained: 42.2 +/- 15 ng/ml at 2 h after oxatomide administration, 41.4 +/- 2.0 h, 37.4 +/- 4.2 l/kg, and 468 +/- 52 ng/ml/h, respectively.",Pharmacokinetics of oxatomide in preterm infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12635496/),h,41.4,69737,DB00592,Piperazine
,12635496,area under the curve (AUC) 0-36 h,"Following the administration of oxatomide 1 mg/kg, the peak plasma concentration (Cmax), the elimination half-life (t1/2), the volume of distribution (Vd), and the area under the curve (AUC) 0-36 h were measured and the following results were obtained: 42.2 +/- 15 ng/ml at 2 h after oxatomide administration, 41.4 +/- 2.0 h, 37.4 +/- 4.2 l/kg, and 468 +/- 52 ng/ml/h, respectively.",Pharmacokinetics of oxatomide in preterm infants. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12635496/),[ng] / [h·ml],468,69738,DB00592,Piperazine
,2596127,clearance,Prednisolone clearance before and after ketoconazole therapy was not significantly different (160 +/- 38 vs. 148 +/- 23 mL/h/kg).,Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),[ml] / [h·kg],160,69779,DB00592,Piperazine
,2596127,clearance,Prednisolone clearance before and after ketoconazole therapy was not significantly different (160 +/- 38 vs. 148 +/- 23 mL/h/kg).,Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),[ml] / [h·kg],148,69780,DB00592,Piperazine
,2596127,mean residence time,"In addition, no significant differences were found in mean residence time (5.03 +/- 0.69 vs. 6.18 +/- 1.77 h), terminal slope (0.23 +/- 0.03 vs. 0.19 +/- 0.05 h-1), or volume of distribution (0.79 +/- 0.11 vs. 0.84 +/- 0.12 L/kg).",Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),h,5.03,69781,DB00592,Piperazine
,2596127,mean residence time,"In addition, no significant differences were found in mean residence time (5.03 +/- 0.69 vs. 6.18 +/- 1.77 h), terminal slope (0.23 +/- 0.03 vs. 0.19 +/- 0.05 h-1), or volume of distribution (0.79 +/- 0.11 vs. 0.84 +/- 0.12 L/kg).",Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),h,6.18,69782,DB00592,Piperazine
,2596127,terminal slope,"In addition, no significant differences were found in mean residence time (5.03 +/- 0.69 vs. 6.18 +/- 1.77 h), terminal slope (0.23 +/- 0.03 vs. 0.19 +/- 0.05 h-1), or volume of distribution (0.79 +/- 0.11 vs. 0.84 +/- 0.12 L/kg).",Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),1/[h],0.23,69783,DB00592,Piperazine
,2596127,terminal slope,"In addition, no significant differences were found in mean residence time (5.03 +/- 0.69 vs. 6.18 +/- 1.77 h), terminal slope (0.23 +/- 0.03 vs. 0.19 +/- 0.05 h-1), or volume of distribution (0.79 +/- 0.11 vs. 0.84 +/- 0.12 L/kg).",Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),1/[h],0.19,69784,DB00592,Piperazine
,2596127,volume of distribution,"In addition, no significant differences were found in mean residence time (5.03 +/- 0.69 vs. 6.18 +/- 1.77 h), terminal slope (0.23 +/- 0.03 vs. 0.19 +/- 0.05 h-1), or volume of distribution (0.79 +/- 0.11 vs. 0.84 +/- 0.12 L/kg).",Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),[l] / [kg],0.79,69785,DB00592,Piperazine
,2596127,volume of distribution,"In addition, no significant differences were found in mean residence time (5.03 +/- 0.69 vs. 6.18 +/- 1.77 h), terminal slope (0.23 +/- 0.03 vs. 0.19 +/- 0.05 h-1), or volume of distribution (0.79 +/- 0.11 vs. 0.84 +/- 0.12 L/kg).",Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),[l] / [kg],0.84,69786,DB00592,Piperazine
,15150174,C12,A considerable and clinically important higher median C12 was seen with combination 3 when compared to combination 1 (835 to 3944 ng/mL) (P=0.0039).,Dose-dependent pharmacokinetics of delavirdine in combination with amprenavir in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15150174/),[ng] / [ml],835 to 3944,69937,DB00592,Piperazine
,15150174,C12,"Only small differences in the amprenavir pharmacokinetic parameters were seen between the three dose combinations, with a median C12 of 412, 434 and 536 ng/mL, respectively.",Dose-dependent pharmacokinetics of delavirdine in combination with amprenavir in healthy volunteers. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15150174/),[ng] / [ml],412,69938,DB00592,Piperazine
,15150174,C12,"Only small differences in the amprenavir pharmacokinetic parameters were seen between the three dose combinations, with a median C12 of 412, 434 and 536 ng/mL, respectively.",Dose-dependent pharmacokinetics of delavirdine in combination with amprenavir in healthy volunteers. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15150174/),[ng] / [ml],434,69939,DB00592,Piperazine
,15150174,C12,"Only small differences in the amprenavir pharmacokinetic parameters were seen between the three dose combinations, with a median C12 of 412, 434 and 536 ng/mL, respectively.",Dose-dependent pharmacokinetics of delavirdine in combination with amprenavir in healthy volunteers. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15150174/),[ng] / [ml],536,69940,DB00592,Piperazine
,9786475,maximum plasma concentrations (Cmax),The geometric means of the maximum plasma concentrations (Cmax) linearly increased with the dose administered from 1.19 mg/L to 8.73 mg/L after single dose administration.,"Safety, tolerability and pharmacokinetics of the new long-acting quinolone DW-116 after single and multiple dosing in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9786475/),,8.73,70102,DB00592,Piperazine
,9786475,minimum,"At steady state, the geometric mean minimum and maximum plasma concentrations were 2.14 and 5.65 mg/L, respectively, after the multiple 300 mg dose and 2.73 and 8.00 mg/L, respectively, for the multiple 400 mg dose.","Safety, tolerability and pharmacokinetics of the new long-acting quinolone DW-116 after single and multiple dosing in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9786475/),[mg] / [l],2.14,70103,DB00592,Piperazine
,9786475,minimum,"At steady state, the geometric mean minimum and maximum plasma concentrations were 2.14 and 5.65 mg/L, respectively, after the multiple 300 mg dose and 2.73 and 8.00 mg/L, respectively, for the multiple 400 mg dose.","Safety, tolerability and pharmacokinetics of the new long-acting quinolone DW-116 after single and multiple dosing in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9786475/),[mg] / [l],2.73,70104,DB00592,Piperazine
,9786475,maximum plasma concentrations,"At steady state, the geometric mean minimum and maximum plasma concentrations were 2.14 and 5.65 mg/L, respectively, after the multiple 300 mg dose and 2.73 and 8.00 mg/L, respectively, for the multiple 400 mg dose.","Safety, tolerability and pharmacokinetics of the new long-acting quinolone DW-116 after single and multiple dosing in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9786475/),[mg] / [l],5.65,70105,DB00592,Piperazine
,9786475,maximum plasma concentrations,"At steady state, the geometric mean minimum and maximum plasma concentrations were 2.14 and 5.65 mg/L, respectively, after the multiple 300 mg dose and 2.73 and 8.00 mg/L, respectively, for the multiple 400 mg dose.","Safety, tolerability and pharmacokinetics of the new long-acting quinolone DW-116 after single and multiple dosing in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9786475/),[mg] / [l],2.73,70106,DB00592,Piperazine
,9786475,maximum plasma concentrations,"At steady state, the geometric mean minimum and maximum plasma concentrations were 2.14 and 5.65 mg/L, respectively, after the multiple 300 mg dose and 2.73 and 8.00 mg/L, respectively, for the multiple 400 mg dose.","Safety, tolerability and pharmacokinetics of the new long-acting quinolone DW-116 after single and multiple dosing in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9786475/),[mg] / [l],8.00,70107,DB00592,Piperazine
,9786475,Tmax,Tmax varied between 1 and 5 h.,"Safety, tolerability and pharmacokinetics of the new long-acting quinolone DW-116 after single and multiple dosing in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9786475/),h,1 and 5,70108,DB00592,Piperazine
,9786475,terminal half-life,The terminal half-life ranged from 11.37 to 24.89 h.,"Safety, tolerability and pharmacokinetics of the new long-acting quinolone DW-116 after single and multiple dosing in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9786475/),h,11.37 to 24.89,70109,DB00592,Piperazine
,9786475,renal clearance,The geometric mean renal clearance was approximately 30 mL/min.,"Safety, tolerability and pharmacokinetics of the new long-acting quinolone DW-116 after single and multiple dosing in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9786475/),[ml] / [min],30,70110,DB00592,Piperazine
,9805816,AUC,"The ingestion of a high fat containing breakfast, increased the AUC of nifedipine from 259.0 +/- 101.2 ng h/ml to 326.7 +/- 122.5 ng h/ml and Cmax from 34.5 +/- 15.9 ng/ml to 74.3 +/- 23.9 ng/ml in case of nifedipine 20 mg retard tablet, in agreement with the data of literature.",[Role of food interaction pharmacokinetic studies in drug development. Food interaction studies of theophylline and nifedipine retard and buspirone tablets]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9805816/),[h·ng] / [ml],259.0,70275,DB00592,Piperazine
,9805816,AUC,"The ingestion of a high fat containing breakfast, increased the AUC of nifedipine from 259.0 +/- 101.2 ng h/ml to 326.7 +/- 122.5 ng h/ml and Cmax from 34.5 +/- 15.9 ng/ml to 74.3 +/- 23.9 ng/ml in case of nifedipine 20 mg retard tablet, in agreement with the data of literature.",[Role of food interaction pharmacokinetic studies in drug development. Food interaction studies of theophylline and nifedipine retard and buspirone tablets]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9805816/),[h·ng] / [ml],326.7,70276,DB00592,Piperazine
,9805816,Cmax,"The ingestion of a high fat containing breakfast, increased the AUC of nifedipine from 259.0 +/- 101.2 ng h/ml to 326.7 +/- 122.5 ng h/ml and Cmax from 34.5 +/- 15.9 ng/ml to 74.3 +/- 23.9 ng/ml in case of nifedipine 20 mg retard tablet, in agreement with the data of literature.",[Role of food interaction pharmacokinetic studies in drug development. Food interaction studies of theophylline and nifedipine retard and buspirone tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9805816/),[ng] / [ml],34.5,70277,DB00592,Piperazine
,9805816,Cmax,"The ingestion of a high fat containing breakfast, increased the AUC of nifedipine from 259.0 +/- 101.2 ng h/ml to 326.7 +/- 122.5 ng h/ml and Cmax from 34.5 +/- 15.9 ng/ml to 74.3 +/- 23.9 ng/ml in case of nifedipine 20 mg retard tablet, in agreement with the data of literature.",[Role of food interaction pharmacokinetic studies in drug development. Food interaction studies of theophylline and nifedipine retard and buspirone tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9805816/),[ng] / [ml],74.3,70278,DB00592,Piperazine
,26951309,progression-free survival,"After 67 events, stratified analysis revealed that median progression-free survival was significantly shorter for apitolisib than for everolimus (3.7 v 6.1 months; hazard ratio, 2.12 [95% CI, 1.23 to 3.63; P < .01]); apitolisib was not favored in any stratification subgroup.","Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26951309/),month,3.7,70597,DB00592,Piperazine
,26951309,progression-free survival,"After 67 events, stratified analysis revealed that median progression-free survival was significantly shorter for apitolisib than for everolimus (3.7 v 6.1 months; hazard ratio, 2.12 [95% CI, 1.23 to 3.63; P < .01]); apitolisib was not favored in any stratification subgroup.","Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26951309/),month,6.1,70598,DB00592,Piperazine
,26951309,overall survival,"Median overall survival was not significantly different but trended in favor of everolimus (16.5 v 22.8 months; hazard ratio, 1.77 [95% CI, 0.97 to 3.24; P = .06]).","Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26951309/),month,16.5,70599,DB00592,Piperazine
,26951309,overall survival,"Median overall survival was not significantly different but trended in favor of everolimus (16.5 v 22.8 months; hazard ratio, 1.77 [95% CI, 0.97 to 3.24; P = .06]).","Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26951309/),month,22.8,70600,DB00592,Piperazine
,26951309,objective response rate,The objective response rate was 7.1% for apitolisib and 11.6% for everolimus.,"Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26951309/),%,7.1,70601,DB00592,Piperazine
,26951309,objective response rate,The objective response rate was 7.1% for apitolisib and 11.6% for everolimus.,"Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26951309/),%,11.6,70602,DB00592,Piperazine
,9871431,apparent oral clearance,"Mean apparent oral clearance of zolpidem when given with placebo was 422 mL/min, and elimination half-life was 1.9 hours.","Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871431/),[ml] / [min],422,71084,DB00592,Piperazine
,9871431,elimination half-life,"Mean apparent oral clearance of zolpidem when given with placebo was 422 mL/min, and elimination half-life was 1.9 hours.","Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871431/),h,1.9,71085,DB00592,Piperazine
,9871431,Clearance,"Clearance was significantly reduced to 250 mL/min when zolpidem was given with ketoconazole, and half-life was prolonged to 2.4 hours.","Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871431/),[ml] / [min],250,71086,DB00592,Piperazine
,9871431,half-life,"Clearance was significantly reduced to 250 mL/min when zolpidem was given with ketoconazole, and half-life was prolonged to 2.4 hours.","Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871431/),h,2.4,71087,DB00592,Piperazine
,9871431,clearance,"Coadministration of zolpidem with itraconazole or fluconazole also reduced clearance (320 and 338 mL/min), but differences compared to the zolpidem plus placebo treatment did not reach significance.","Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871431/),[ml] / [min],320,71088,DB00592,Piperazine
,9871431,clearance,"Coadministration of zolpidem with itraconazole or fluconazole also reduced clearance (320 and 338 mL/min), but differences compared to the zolpidem plus placebo treatment did not reach significance.","Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871431/),[ml] / [min],338,71089,DB00592,Piperazine
,28615371,overall response rate,The overall response rate was 8% (1 PR).,A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28615371/),%,8,71612,DB00592,Piperazine
,28615371,overall survival,"Two of 15 patients (13.3%) were progression-free at 12 weeks, and the median overall survival was 4.9 months.",A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28615371/),month,4.9,71613,DB00592,Piperazine
,32785428,absolute bioavailability,"Since oral administration of sildenafil shows pharmacokinetic problems with mean absolute bioavailability of 41%, the goal of this work was to develop a novel sildenafil self-emulsifying drug delivery system (SEDDS) for oral absorption improvement and management of dosage.",In Silico studies of novel Sildenafil self-emulsifying drug delivery system absorption improvement for pulmonary arterial hypertension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32785428/),%,41,71815,DB00592,Piperazine
,32785428,LD50,"The safety of 2-pyrrolidone/isobutanol in oral formulations was assessed in mice and no lethality was achieved in the placebo groups with LD50 of 490 mg/Kg for SEDDS II-3.3, suggesting it as a safe excipient for humans.",In Silico studies of novel Sildenafil self-emulsifying drug delivery system absorption improvement for pulmonary arterial hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32785428/),[mg] / [kg],490,71816,DB00592,Piperazine
,14656603,flow rate,"Mobile phase consisting of sodium dihydrogen phosphate monohydrate (pH 4.5, 0.02 M) and methanol mixture (35:65, v/v) was used at a flow rate of 1.0 ml/min.","Validated HPLC method for determination of LASSBio-581, a new heterocyclic N-phenylpiperazine derivative, in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14656603/),[ml] / [min],1.0,72168,DB00592,Piperazine
,14656603,retention times,"The retention times of LASSBio-581 and the internal standard were approximately 3.8 and 5.6 min, respectively.","Validated HPLC method for determination of LASSBio-581, a new heterocyclic N-phenylpiperazine derivative, in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14656603/),min,3.8,72169,DB00592,Piperazine
,14656603,retention times,"The retention times of LASSBio-581 and the internal standard were approximately 3.8 and 5.6 min, respectively.","Validated HPLC method for determination of LASSBio-581, a new heterocyclic N-phenylpiperazine derivative, in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14656603/),min,5.6,72170,DB00592,Piperazine
,20533987,flow rate,"Compounds were resolved using a mixture of ammonium formate (pH 4.5, 0.01 M) and acetonitrile (flow rate of 1.0 mL/min) with a C18 column.",Validation of an LC-MS method for the detection and quantification of BZP and TFMPP and their hydroxylated metabolites in human plasma and its application to the pharmacokinetic study of TFMPP in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20533987/),[ml] / [min],1.0,72362,DB00592,Piperazine
,20533987,C(max),Human plasma concentrations of TFMPP were measured in blood samples taken from healthy adults (n = 6) over 24 h following a 60-mg oral dose of TFMPP: these peaked at 24.10 ng/mL (±1.8 ng/mL) (C(max) ) after 90 min (T(max)).,Validation of an LC-MS method for the detection and quantification of BZP and TFMPP and their hydroxylated metabolites in human plasma and its application to the pharmacokinetic study of TFMPP in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20533987/),[ng] / [ml],24.10,72363,DB00592,Piperazine
,20533987,T(max),Human plasma concentrations of TFMPP were measured in blood samples taken from healthy adults (n = 6) over 24 h following a 60-mg oral dose of TFMPP: these peaked at 24.10 ng/mL (±1.8 ng/mL) (C(max) ) after 90 min (T(max)).,Validation of an LC-MS method for the detection and quantification of BZP and TFMPP and their hydroxylated metabolites in human plasma and its application to the pharmacokinetic study of TFMPP in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20533987/),min,90,72364,DB00592,Piperazine
,20533987,Plasma concentrations,Plasma concentrations of 1-(3-trifluoromethyl-4-hydroxyphenyl) piperazine peaked at 20.2 ng/mL (±4.6 ng/mL) after 90 min.,Validation of an LC-MS method for the detection and quantification of BZP and TFMPP and their hydroxylated metabolites in human plasma and its application to the pharmacokinetic study of TFMPP in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20533987/),[ng] / [ml],20.2,72365,DB00592,Piperazine
,20533987,t(½),TFMPP had two disposition phases (t(½) = 2.04 h (±0.19 h) and 5.95 h (±1.63 h).,Validation of an LC-MS method for the detection and quantification of BZP and TFMPP and their hydroxylated metabolites in human plasma and its application to the pharmacokinetic study of TFMPP in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20533987/),h,2.04,72366,DB00592,Piperazine
,20533987,t(½),TFMPP had two disposition phases (t(½) = 2.04 h (±0.19 h) and 5.95 h (±1.63 h).,Validation of an LC-MS method for the detection and quantification of BZP and TFMPP and their hydroxylated metabolites in human plasma and its application to the pharmacokinetic study of TFMPP in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20533987/),h,5.95,72367,DB00592,Piperazine
,20533987,Apparent clearance (Cl/F),Apparent clearance (Cl/F) was 384 L/h (±45 L/h).,Validation of an LC-MS method for the detection and quantification of BZP and TFMPP and their hydroxylated metabolites in human plasma and its application to the pharmacokinetic study of TFMPP in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20533987/),[l] / [h],384,72368,DB00592,Piperazine
,9987703,terminal half-life,"The mean terminal half-life was approximately 45 and 44 hours, respectively.",Lack of effect of erythromycin and ketoconazole on the pharmacokinetics and pharmacodynamics of steady-state intranasal levocabastine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9987703/),h,45,72608,DB00592,Piperazine
,9987703,terminal half-life,"The mean terminal half-life was approximately 45 and 44 hours, respectively.",Lack of effect of erythromycin and ketoconazole on the pharmacokinetics and pharmacodynamics of steady-state intranasal levocabastine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9987703/),h,44,72609,DB00592,Piperazine
,2864156,apparent elimination half-life,The enanthate produces peak plasma concentrations on days 2 to 3 and declines with an apparent elimination half-life (i.e. the half-time of the apparent first-order decline of plasma concentrations) of 3.5 to 4 days after a single injection.,Clinical pharmacokinetics of the depot antipsychotics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864156/),d,3.5 to 4,72901,DB00592,Piperazine
,2864156,half-time of the apparent first-order decline of plasma concentrations,The enanthate produces peak plasma concentrations on days 2 to 3 and declines with an apparent elimination half-life (i.e. the half-time of the apparent first-order decline of plasma concentrations) of 3.5 to 4 days after a single injection.,Clinical pharmacokinetics of the depot antipsychotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864156/),d,3.5 to 4,72902,DB00592,Piperazine
,2864156,apparent half-life,The decanoate produces an early high peak which occurs during the first day and then declines with an apparent half-life ranging from 6.8 to 9.6 days following a single injection.,Clinical pharmacokinetics of the depot antipsychotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864156/),d,6.8 to 9.6,72903,DB00592,Piperazine
,2864156,apparent half-life,"After multiple injections of fluphenazine decanoate, however, the mean apparent half-life increases to 14.3 days, and the time to reach steady-state is 4 to 6 weeks.",Clinical pharmacokinetics of the depot antipsychotics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864156/),d,14.3,72904,DB00592,Piperazine
,2864156,time to reach steady-state,"After multiple injections of fluphenazine decanoate, however, the mean apparent half-life increases to 14.3 days, and the time to reach steady-state is 4 to 6 weeks.",Clinical pharmacokinetics of the depot antipsychotics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864156/),weeks,4 to 6,72905,DB00592,Piperazine
,11879255,Absorption,"Absorption of sildenafil after oral administration was rapid and approximately 92% whilst the absolute bioavailability was limited to 38%, due to first-pass metabolism.",Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11879255/),%,92,73008,DB00592,Piperazine
,11879255,absolute bioavailability,"Absorption of sildenafil after oral administration was rapid and approximately 92% whilst the absolute bioavailability was limited to 38%, due to first-pass metabolism.",Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11879255/),%,38,73009,DB00592,Piperazine
,2964551,first component half-life,"Elimination of drug from the brain was biphasic, with a first component half-life of 24.8 min and a second component half-life of 96 min.",Pharmacokinetics of buspirone as determined by ex vivo (3H)-DPAT binding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2964551/),min,24.8,73065,DB00592,Piperazine
,2964551,second component half-life,"Elimination of drug from the brain was biphasic, with a first component half-life of 24.8 min and a second component half-life of 96 min.",Pharmacokinetics of buspirone as determined by ex vivo (3H)-DPAT binding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2964551/),min,96,73066,DB00592,Piperazine
,10771448,Trough-to-peak ratios at steady state,Trough-to-peak ratios at steady state ranged from 2 to 5.,Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771448/),,2 to 5,73067,DB00592,Piperazine
,10771448,Accumulation ratios,"Accumulation ratios for the fixed-dose regimens were 1.49 and 1.48 at the 5 and 20 mg dose levels, respectively.",Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771448/),,1.49,73068,DB00592,Piperazine
,10771448,Accumulation ratios,"Accumulation ratios for the fixed-dose regimens were 1.49 and 1.48 at the 5 and 20 mg dose levels, respectively.",Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771448/),,1.48,73069,DB00592,Piperazine
,32886932,Cmax,"Following administration of 35, 70, and 105 mg TMZ-modified release; the Cmax (mean±SD) was 79.32 (±23.08), 153.17 (±23.08), and 199.67 (±23.08) ng/mL, the Tmax was 5.42 (±0.49), 4.51 (±1.27), and 4.57 (±0.96) h, t1/2 was 7.75 (±1.62), 6.40 (±1.23), and 6.50 (±1.18) h, AUC(0-inf) was 1116.89 (±378.35), 1838.39 (±284.50), and 2504.84 (±348.35) ng.h/mL, CLR was 13.70 (±2.24), 14.80 (±5.91), and 19.58 (±6.24) L·h-1 and CL/F was 33.69 (±8.51), 38.85 (±6.15), and 42.74 (±7.10) L·h-1, respectively.","Single Ascending Dose Study to Assess Pharmacokinetic Linearity, Safety, and Tolerability of Trimetazidine - Modified Release in Healthy Human Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32886932/),[ng] / [ml],79.32,73082,DB00592,Piperazine
,32886932,Cmax,"Following administration of 35, 70, and 105 mg TMZ-modified release; the Cmax (mean±SD) was 79.32 (±23.08), 153.17 (±23.08), and 199.67 (±23.08) ng/mL, the Tmax was 5.42 (±0.49), 4.51 (±1.27), and 4.57 (±0.96) h, t1/2 was 7.75 (±1.62), 6.40 (±1.23), and 6.50 (±1.18) h, AUC(0-inf) was 1116.89 (±378.35), 1838.39 (±284.50), and 2504.84 (±348.35) ng.h/mL, CLR was 13.70 (±2.24), 14.80 (±5.91), and 19.58 (±6.24) L·h-1 and CL/F was 33.69 (±8.51), 38.85 (±6.15), and 42.74 (±7.10) L·h-1, respectively.","Single Ascending Dose Study to Assess Pharmacokinetic Linearity, Safety, and Tolerability of Trimetazidine - Modified Release in Healthy Human Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32886932/),[ng] / [ml],153.17,73083,DB00592,Piperazine
,32886932,Cmax,"Following administration of 35, 70, and 105 mg TMZ-modified release; the Cmax (mean±SD) was 79.32 (±23.08), 153.17 (±23.08), and 199.67 (±23.08) ng/mL, the Tmax was 5.42 (±0.49), 4.51 (±1.27), and 4.57 (±0.96) h, t1/2 was 7.75 (±1.62), 6.40 (±1.23), and 6.50 (±1.18) h, AUC(0-inf) was 1116.89 (±378.35), 1838.39 (±284.50), and 2504.84 (±348.35) ng.h/mL, CLR was 13.70 (±2.24), 14.80 (±5.91), and 19.58 (±6.24) L·h-1 and CL/F was 33.69 (±8.51), 38.85 (±6.15), and 42.74 (±7.10) L·h-1, respectively.","Single Ascending Dose Study to Assess Pharmacokinetic Linearity, Safety, and Tolerability of Trimetazidine - Modified Release in Healthy Human Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32886932/),[ng] / [ml],199.67,73084,DB00592,Piperazine
,32886932,Tmax,"Following administration of 35, 70, and 105 mg TMZ-modified release; the Cmax (mean±SD) was 79.32 (±23.08), 153.17 (±23.08), and 199.67 (±23.08) ng/mL, the Tmax was 5.42 (±0.49), 4.51 (±1.27), and 4.57 (±0.96) h, t1/2 was 7.75 (±1.62), 6.40 (±1.23), and 6.50 (±1.18) h, AUC(0-inf) was 1116.89 (±378.35), 1838.39 (±284.50), and 2504.84 (±348.35) ng.h/mL, CLR was 13.70 (±2.24), 14.80 (±5.91), and 19.58 (±6.24) L·h-1 and CL/F was 33.69 (±8.51), 38.85 (±6.15), and 42.74 (±7.10) L·h-1, respectively.","Single Ascending Dose Study to Assess Pharmacokinetic Linearity, Safety, and Tolerability of Trimetazidine - Modified Release in Healthy Human Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32886932/),h,5.42,73085,DB00592,Piperazine
,32886932,Tmax,"Following administration of 35, 70, and 105 mg TMZ-modified release; the Cmax (mean±SD) was 79.32 (±23.08), 153.17 (±23.08), and 199.67 (±23.08) ng/mL, the Tmax was 5.42 (±0.49), 4.51 (±1.27), and 4.57 (±0.96) h, t1/2 was 7.75 (±1.62), 6.40 (±1.23), and 6.50 (±1.18) h, AUC(0-inf) was 1116.89 (±378.35), 1838.39 (±284.50), and 2504.84 (±348.35) ng.h/mL, CLR was 13.70 (±2.24), 14.80 (±5.91), and 19.58 (±6.24) L·h-1 and CL/F was 33.69 (±8.51), 38.85 (±6.15), and 42.74 (±7.10) L·h-1, respectively.","Single Ascending Dose Study to Assess Pharmacokinetic Linearity, Safety, and Tolerability of Trimetazidine - Modified Release in Healthy Human Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32886932/),h,4.51,73086,DB00592,Piperazine
,32886932,Tmax,"Following administration of 35, 70, and 105 mg TMZ-modified release; the Cmax (mean±SD) was 79.32 (±23.08), 153.17 (±23.08), and 199.67 (±23.08) ng/mL, the Tmax was 5.42 (±0.49), 4.51 (±1.27), and 4.57 (±0.96) h, t1/2 was 7.75 (±1.62), 6.40 (±1.23), and 6.50 (±1.18) h, AUC(0-inf) was 1116.89 (±378.35), 1838.39 (±284.50), and 2504.84 (±348.35) ng.h/mL, CLR was 13.70 (±2.24), 14.80 (±5.91), and 19.58 (±6.24) L·h-1 and CL/F was 33.69 (±8.51), 38.85 (±6.15), and 42.74 (±7.10) L·h-1, respectively.","Single Ascending Dose Study to Assess Pharmacokinetic Linearity, Safety, and Tolerability of Trimetazidine - Modified Release in Healthy Human Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32886932/),h,4.57,73087,DB00592,Piperazine
,32886932,t1/2,"Following administration of 35, 70, and 105 mg TMZ-modified release; the Cmax (mean±SD) was 79.32 (±23.08), 153.17 (±23.08), and 199.67 (±23.08) ng/mL, the Tmax was 5.42 (±0.49), 4.51 (±1.27), and 4.57 (±0.96) h, t1/2 was 7.75 (±1.62), 6.40 (±1.23), and 6.50 (±1.18) h, AUC(0-inf) was 1116.89 (±378.35), 1838.39 (±284.50), and 2504.84 (±348.35) ng.h/mL, CLR was 13.70 (±2.24), 14.80 (±5.91), and 19.58 (±6.24) L·h-1 and CL/F was 33.69 (±8.51), 38.85 (±6.15), and 42.74 (±7.10) L·h-1, respectively.","Single Ascending Dose Study to Assess Pharmacokinetic Linearity, Safety, and Tolerability of Trimetazidine - Modified Release in Healthy Human Subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32886932/),h,7.75,73088,DB00592,Piperazine
,32886932,t1/2,"Following administration of 35, 70, and 105 mg TMZ-modified release; the Cmax (mean±SD) was 79.32 (±23.08), 153.17 (±23.08), and 199.67 (±23.08) ng/mL, the Tmax was 5.42 (±0.49), 4.51 (±1.27), and 4.57 (±0.96) h, t1/2 was 7.75 (±1.62), 6.40 (±1.23), and 6.50 (±1.18) h, AUC(0-inf) was 1116.89 (±378.35), 1838.39 (±284.50), and 2504.84 (±348.35) ng.h/mL, CLR was 13.70 (±2.24), 14.80 (±5.91), and 19.58 (±6.24) L·h-1 and CL/F was 33.69 (±8.51), 38.85 (±6.15), and 42.74 (±7.10) L·h-1, respectively.","Single Ascending Dose Study to Assess Pharmacokinetic Linearity, Safety, and Tolerability of Trimetazidine - Modified Release in Healthy Human Subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32886932/),h,6.40,73089,DB00592,Piperazine
,32886932,t1/2,"Following administration of 35, 70, and 105 mg TMZ-modified release; the Cmax (mean±SD) was 79.32 (±23.08), 153.17 (±23.08), and 199.67 (±23.08) ng/mL, the Tmax was 5.42 (±0.49), 4.51 (±1.27), and 4.57 (±0.96) h, t1/2 was 7.75 (±1.62), 6.40 (±1.23), and 6.50 (±1.18) h, AUC(0-inf) was 1116.89 (±378.35), 1838.39 (±284.50), and 2504.84 (±348.35) ng.h/mL, CLR was 13.70 (±2.24), 14.80 (±5.91), and 19.58 (±6.24) L·h-1 and CL/F was 33.69 (±8.51), 38.85 (±6.15), and 42.74 (±7.10) L·h-1, respectively.","Single Ascending Dose Study to Assess Pharmacokinetic Linearity, Safety, and Tolerability of Trimetazidine - Modified Release in Healthy Human Subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32886932/),h,6.50,73090,DB00592,Piperazine
,32886932,AUC(0-inf),"Following administration of 35, 70, and 105 mg TMZ-modified release; the Cmax (mean±SD) was 79.32 (±23.08), 153.17 (±23.08), and 199.67 (±23.08) ng/mL, the Tmax was 5.42 (±0.49), 4.51 (±1.27), and 4.57 (±0.96) h, t1/2 was 7.75 (±1.62), 6.40 (±1.23), and 6.50 (±1.18) h, AUC(0-inf) was 1116.89 (±378.35), 1838.39 (±284.50), and 2504.84 (±348.35) ng.h/mL, CLR was 13.70 (±2.24), 14.80 (±5.91), and 19.58 (±6.24) L·h-1 and CL/F was 33.69 (±8.51), 38.85 (±6.15), and 42.74 (±7.10) L·h-1, respectively.","Single Ascending Dose Study to Assess Pharmacokinetic Linearity, Safety, and Tolerability of Trimetazidine - Modified Release in Healthy Human Subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32886932/),[h·ng] / [ml],1116.89,73091,DB00592,Piperazine
,32886932,AUC(0-inf),"Following administration of 35, 70, and 105 mg TMZ-modified release; the Cmax (mean±SD) was 79.32 (±23.08), 153.17 (±23.08), and 199.67 (±23.08) ng/mL, the Tmax was 5.42 (±0.49), 4.51 (±1.27), and 4.57 (±0.96) h, t1/2 was 7.75 (±1.62), 6.40 (±1.23), and 6.50 (±1.18) h, AUC(0-inf) was 1116.89 (±378.35), 1838.39 (±284.50), and 2504.84 (±348.35) ng.h/mL, CLR was 13.70 (±2.24), 14.80 (±5.91), and 19.58 (±6.24) L·h-1 and CL/F was 33.69 (±8.51), 38.85 (±6.15), and 42.74 (±7.10) L·h-1, respectively.","Single Ascending Dose Study to Assess Pharmacokinetic Linearity, Safety, and Tolerability of Trimetazidine - Modified Release in Healthy Human Subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32886932/),[h·ng] / [ml],1838.39,73092,DB00592,Piperazine
,32886932,AUC(0-inf),"Following administration of 35, 70, and 105 mg TMZ-modified release; the Cmax (mean±SD) was 79.32 (±23.08), 153.17 (±23.08), and 199.67 (±23.08) ng/mL, the Tmax was 5.42 (±0.49), 4.51 (±1.27), and 4.57 (±0.96) h, t1/2 was 7.75 (±1.62), 6.40 (±1.23), and 6.50 (±1.18) h, AUC(0-inf) was 1116.89 (±378.35), 1838.39 (±284.50), and 2504.84 (±348.35) ng.h/mL, CLR was 13.70 (±2.24), 14.80 (±5.91), and 19.58 (±6.24) L·h-1 and CL/F was 33.69 (±8.51), 38.85 (±6.15), and 42.74 (±7.10) L·h-1, respectively.","Single Ascending Dose Study to Assess Pharmacokinetic Linearity, Safety, and Tolerability of Trimetazidine - Modified Release in Healthy Human Subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32886932/),[h·ng] / [ml],2504.84,73093,DB00592,Piperazine
,32886932,CLR,"Following administration of 35, 70, and 105 mg TMZ-modified release; the Cmax (mean±SD) was 79.32 (±23.08), 153.17 (±23.08), and 199.67 (±23.08) ng/mL, the Tmax was 5.42 (±0.49), 4.51 (±1.27), and 4.57 (±0.96) h, t1/2 was 7.75 (±1.62), 6.40 (±1.23), and 6.50 (±1.18) h, AUC(0-inf) was 1116.89 (±378.35), 1838.39 (±284.50), and 2504.84 (±348.35) ng.h/mL, CLR was 13.70 (±2.24), 14.80 (±5.91), and 19.58 (±6.24) L·h-1 and CL/F was 33.69 (±8.51), 38.85 (±6.15), and 42.74 (±7.10) L·h-1, respectively.","Single Ascending Dose Study to Assess Pharmacokinetic Linearity, Safety, and Tolerability of Trimetazidine - Modified Release in Healthy Human Subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32886932/),[l] / [h],13.70,73094,DB00592,Piperazine
,32886932,CLR,"Following administration of 35, 70, and 105 mg TMZ-modified release; the Cmax (mean±SD) was 79.32 (±23.08), 153.17 (±23.08), and 199.67 (±23.08) ng/mL, the Tmax was 5.42 (±0.49), 4.51 (±1.27), and 4.57 (±0.96) h, t1/2 was 7.75 (±1.62), 6.40 (±1.23), and 6.50 (±1.18) h, AUC(0-inf) was 1116.89 (±378.35), 1838.39 (±284.50), and 2504.84 (±348.35) ng.h/mL, CLR was 13.70 (±2.24), 14.80 (±5.91), and 19.58 (±6.24) L·h-1 and CL/F was 33.69 (±8.51), 38.85 (±6.15), and 42.74 (±7.10) L·h-1, respectively.","Single Ascending Dose Study to Assess Pharmacokinetic Linearity, Safety, and Tolerability of Trimetazidine - Modified Release in Healthy Human Subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32886932/),[l] / [h],14.80,73095,DB00592,Piperazine
,32886932,CLR,"Following administration of 35, 70, and 105 mg TMZ-modified release; the Cmax (mean±SD) was 79.32 (±23.08), 153.17 (±23.08), and 199.67 (±23.08) ng/mL, the Tmax was 5.42 (±0.49), 4.51 (±1.27), and 4.57 (±0.96) h, t1/2 was 7.75 (±1.62), 6.40 (±1.23), and 6.50 (±1.18) h, AUC(0-inf) was 1116.89 (±378.35), 1838.39 (±284.50), and 2504.84 (±348.35) ng.h/mL, CLR was 13.70 (±2.24), 14.80 (±5.91), and 19.58 (±6.24) L·h-1 and CL/F was 33.69 (±8.51), 38.85 (±6.15), and 42.74 (±7.10) L·h-1, respectively.","Single Ascending Dose Study to Assess Pharmacokinetic Linearity, Safety, and Tolerability of Trimetazidine - Modified Release in Healthy Human Subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32886932/),[l] / [h],19.58,73096,DB00592,Piperazine
,32886932,CL/F,"Following administration of 35, 70, and 105 mg TMZ-modified release; the Cmax (mean±SD) was 79.32 (±23.08), 153.17 (±23.08), and 199.67 (±23.08) ng/mL, the Tmax was 5.42 (±0.49), 4.51 (±1.27), and 4.57 (±0.96) h, t1/2 was 7.75 (±1.62), 6.40 (±1.23), and 6.50 (±1.18) h, AUC(0-inf) was 1116.89 (±378.35), 1838.39 (±284.50), and 2504.84 (±348.35) ng.h/mL, CLR was 13.70 (±2.24), 14.80 (±5.91), and 19.58 (±6.24) L·h-1 and CL/F was 33.69 (±8.51), 38.85 (±6.15), and 42.74 (±7.10) L·h-1, respectively.","Single Ascending Dose Study to Assess Pharmacokinetic Linearity, Safety, and Tolerability of Trimetazidine - Modified Release in Healthy Human Subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32886932/),,33.69,73097,DB00592,Piperazine
,32886932,CL/F,"Following administration of 35, 70, and 105 mg TMZ-modified release; the Cmax (mean±SD) was 79.32 (±23.08), 153.17 (±23.08), and 199.67 (±23.08) ng/mL, the Tmax was 5.42 (±0.49), 4.51 (±1.27), and 4.57 (±0.96) h, t1/2 was 7.75 (±1.62), 6.40 (±1.23), and 6.50 (±1.18) h, AUC(0-inf) was 1116.89 (±378.35), 1838.39 (±284.50), and 2504.84 (±348.35) ng.h/mL, CLR was 13.70 (±2.24), 14.80 (±5.91), and 19.58 (±6.24) L·h-1 and CL/F was 33.69 (±8.51), 38.85 (±6.15), and 42.74 (±7.10) L·h-1, respectively.","Single Ascending Dose Study to Assess Pharmacokinetic Linearity, Safety, and Tolerability of Trimetazidine - Modified Release in Healthy Human Subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32886932/),,38.85,73098,DB00592,Piperazine
,32886932,CL/F,"Following administration of 35, 70, and 105 mg TMZ-modified release; the Cmax (mean±SD) was 79.32 (±23.08), 153.17 (±23.08), and 199.67 (±23.08) ng/mL, the Tmax was 5.42 (±0.49), 4.51 (±1.27), and 4.57 (±0.96) h, t1/2 was 7.75 (±1.62), 6.40 (±1.23), and 6.50 (±1.18) h, AUC(0-inf) was 1116.89 (±378.35), 1838.39 (±284.50), and 2504.84 (±348.35) ng.h/mL, CLR was 13.70 (±2.24), 14.80 (±5.91), and 19.58 (±6.24) L·h-1 and CL/F was 33.69 (±8.51), 38.85 (±6.15), and 42.74 (±7.10) L·h-1, respectively.","Single Ascending Dose Study to Assess Pharmacokinetic Linearity, Safety, and Tolerability of Trimetazidine - Modified Release in Healthy Human Subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32886932/),,42.74,73099,DB00592,Piperazine
,28204912,time to maximum concentration,Median time to maximum concentration was 8 h for all conditions.,Effect of food on the bioavailability of palbociclib. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28204912/),h,8,73134,DB00592,Piperazine
,16122278,absolute bioavailability,"Pharmacokinetic studies of imatinib in healthy volunteers and patients with CML, GIST and other cancers show that orally administered imatinib is well absorbed, and has an absolute bioavailability of 98% irrespective of oral dosage form (solution, capsule, tablet) or dosage strength (100 mg, 400 mg).",Clinical pharmacokinetics of imatinib. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122278/),%,98,73700,DB00592,Piperazine
,16122278,terminal elimination half-life,The terminal elimination half-life is approximately 18 hours.,Clinical pharmacokinetics of imatinib. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122278/),h,18,73701,DB00592,Piperazine
,16122278,plasma concentrations,"Imatinib plasma concentrations predictably increase by 2- to 3-fold when reaching steady state with 400mg once-daily administration, to 2.6 +/- 0.8 microg/mL at peak and 1.2 +/- 0.8 microg/mL at trough, exceeding the 0.5 microg/mL (1 micromol/L) concentrations needed for tyrosine kinase inhibition in vitro and leading to normalisation of haematological parameters in the large majority of patients with CML irrespective of baseline white blood cell count.",Clinical pharmacokinetics of imatinib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122278/),[μg] / [ml],2,73702,DB00592,Piperazine
,16122278,peak,"Imatinib plasma concentrations predictably increase by 2- to 3-fold when reaching steady state with 400mg once-daily administration, to 2.6 +/- 0.8 microg/mL at peak and 1.2 +/- 0.8 microg/mL at trough, exceeding the 0.5 microg/mL (1 micromol/L) concentrations needed for tyrosine kinase inhibition in vitro and leading to normalisation of haematological parameters in the large majority of patients with CML irrespective of baseline white blood cell count.",Clinical pharmacokinetics of imatinib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122278/),[μg] / [ml],2,73703,DB00592,Piperazine
,16122278,trough,"Imatinib plasma concentrations predictably increase by 2- to 3-fold when reaching steady state with 400mg once-daily administration, to 2.6 +/- 0.8 microg/mL at peak and 1.2 +/- 0.8 microg/mL at trough, exceeding the 0.5 microg/mL (1 micromol/L) concentrations needed for tyrosine kinase inhibition in vitro and leading to normalisation of haematological parameters in the large majority of patients with CML irrespective of baseline white blood cell count.",Clinical pharmacokinetics of imatinib. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122278/),[μg] / [ml],1.2,73704,DB00592,Piperazine
,16122278,faecal to urinary excretion ratio,The faecal to urinary excretion ratio is approximately 5:1.,Clinical pharmacokinetics of imatinib. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16122278/),,5:1,73705,DB00592,Piperazine
,26756977,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve of sildenafil was significantly higher in S+A treatment than in S+B treatment (165.8 ng•h/mL vs. 396.8 ng•h/mL, P = 0.018) and the oral clearance of sildenafil was significantly lower after S+A treatment than after S+B treatment (120.6 L/h/kg vs. 50.4 L/h/kg, P = 0.018).",Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil-Bosentan and Sildenafil-Ambrisentan Combination Therapies for Pulmonary Hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26756977/),[h·ng] / [ml],165.8,74000,DB00592,Piperazine
,26756977,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve of sildenafil was significantly higher in S+A treatment than in S+B treatment (165.8 ng•h/mL vs. 396.8 ng•h/mL, P = 0.018) and the oral clearance of sildenafil was significantly lower after S+A treatment than after S+B treatment (120.6 L/h/kg vs. 50.4 L/h/kg, P = 0.018).",Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil-Bosentan and Sildenafil-Ambrisentan Combination Therapies for Pulmonary Hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26756977/),[h·ng] / [ml],396.8,74001,DB00592,Piperazine
,26756977,oral clearance,"The area under the plasma concentration-time curve of sildenafil was significantly higher in S+A treatment than in S+B treatment (165.8 ng•h/mL vs. 396.8 ng•h/mL, P = 0.018) and the oral clearance of sildenafil was significantly lower after S+A treatment than after S+B treatment (120.6 L/h/kg vs. 50.4 L/h/kg, P = 0.018).",Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil-Bosentan and Sildenafil-Ambrisentan Combination Therapies for Pulmonary Hypertension. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26756977/),[l] / [h·kg],120.6,74002,DB00592,Piperazine
,26756977,oral clearance,"The area under the plasma concentration-time curve of sildenafil was significantly higher in S+A treatment than in S+B treatment (165.8 ng•h/mL vs. 396.8 ng•h/mL, P = 0.018) and the oral clearance of sildenafil was significantly lower after S+A treatment than after S+B treatment (120.6 L/h/kg vs. 50.4 L/h/kg, P = 0.018).",Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil-Bosentan and Sildenafil-Ambrisentan Combination Therapies for Pulmonary Hypertension. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26756977/),[l] / [h·kg],50.4,74003,DB00592,Piperazine
,10820141,K(i),"The resulting analog 2-MIBN (II) exhibited an inhibitory potency 70-fold weaker (K(i) = 25 microM) than that of I (K(i) = 0.3 microM) toward CYP3A, the major rat liver microsomal P450 isoform(s) for the metabolism of I and II by rat liver microsomes in the presence of NADPH.",Comparison of imidazole- and 2-methyl imidazole-containing farnesyl-protein transferase inhibitors: interaction with and metabolism by rat hepatic cytochrome P450s. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10820141/),μM,25,74039,DB00592,Piperazine
,10820141,K(i),"The resulting analog 2-MIBN (II) exhibited an inhibitory potency 70-fold weaker (K(i) = 25 microM) than that of I (K(i) = 0.3 microM) toward CYP3A, the major rat liver microsomal P450 isoform(s) for the metabolism of I and II by rat liver microsomes in the presence of NADPH.",Comparison of imidazole- and 2-methyl imidazole-containing farnesyl-protein transferase inhibitors: interaction with and metabolism by rat hepatic cytochrome P450s. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10820141/),μM,0.3,74040,DB00592,Piperazine
,10820141,apparent K(m),"Enzyme kinetic studies also demonstrated that I had a lower apparent K(m) (0.3 microM) than than II (18 microM), but an apparent V(max) 14 times lower than II.",Comparison of imidazole- and 2-methyl imidazole-containing farnesyl-protein transferase inhibitors: interaction with and metabolism by rat hepatic cytochrome P450s. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10820141/),μM,0.3,74041,DB00592,Piperazine
,10820141,apparent K(m),"Enzyme kinetic studies also demonstrated that I had a lower apparent K(m) (0.3 microM) than than II (18 microM), but an apparent V(max) 14 times lower than II.",Comparison of imidazole- and 2-methyl imidazole-containing farnesyl-protein transferase inhibitors: interaction with and metabolism by rat hepatic cytochrome P450s. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10820141/),μM,18,74042,DB00592,Piperazine
,7841951,Ki,"In vitro study of enantiomeric inhibition of the metabolism showed that (+)-HCZ was a competitive inhibitor of (-)-HCZ metabolism, with a Ki of 6.96 microM.","Effect of first-pass metabolism on enantioselective pharmacokinetics after oral administration of (+)-, (-)- and racemic homochlorcyclizine to rats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7841951/),μM,6.96,74329,DB00592,Piperazine
,7841951,Ki,"(-)-HCZ was also a competitive inhibitor of (+)-HCZ metabolism, with a Ki of 20.4 microM.(ABSTRACT TRUNCATED AT 250 WORDS)","Effect of first-pass metabolism on enantioselective pharmacokinetics after oral administration of (+)-, (-)- and racemic homochlorcyclizine to rats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7841951/),μM,20.4,74330,DB00592,Piperazine
,6487481,Cmax,"For formulation A, B and solution, the relative (trazodone/D4-trazodone) Cmax values were 0.84 +/- 0.09, 0.90 +/- 0.05 and 1.05 +/- 0.04.",Comparative bioavailability of trazodone formulations using stable isotope methodology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487481/),,0.84,74873,DB00592,Piperazine
,6487481,Cmax,"For formulation A, B and solution, the relative (trazodone/D4-trazodone) Cmax values were 0.84 +/- 0.09, 0.90 +/- 0.05 and 1.05 +/- 0.04.",Comparative bioavailability of trazodone formulations using stable isotope methodology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487481/),,0.90,74874,DB00592,Piperazine
,6487481,Cmax,"For formulation A, B and solution, the relative (trazodone/D4-trazodone) Cmax values were 0.84 +/- 0.09, 0.90 +/- 0.05 and 1.05 +/- 0.04.",Comparative bioavailability of trazodone formulations using stable isotope methodology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487481/),,1.05,74875,DB00592,Piperazine
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,47.0,75129,DB00592,Piperazine
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,5.2,75130,DB00592,Piperazine
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,15.0,75131,DB00592,Piperazine
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,3.3,75132,DB00592,Piperazine
,6464503,tmax,"The main pharmacokinetic parameters were: tmax, 2.3 h; Cmax, 3.3 micrograms/ml; t1/2, 4.6 h; Varea, 2.04 l/kg; Cltot, 5.48 ml/min per kg; Clren, 3.05 ml/min per kg; Ae(0-24), 55.7% of dose.",Pharmacokinetics of pipemidic acid in healthy middle-aged volunteers and elderly patients with renal insufficiency. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6464503/),h,2.3,75355,DB00592,Piperazine
,6464503,Cmax,"The main pharmacokinetic parameters were: tmax, 2.3 h; Cmax, 3.3 micrograms/ml; t1/2, 4.6 h; Varea, 2.04 l/kg; Cltot, 5.48 ml/min per kg; Clren, 3.05 ml/min per kg; Ae(0-24), 55.7% of dose.",Pharmacokinetics of pipemidic acid in healthy middle-aged volunteers and elderly patients with renal insufficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6464503/),[μg] / [ml],3.3,75356,DB00592,Piperazine
,6464503,t1/2,"The main pharmacokinetic parameters were: tmax, 2.3 h; Cmax, 3.3 micrograms/ml; t1/2, 4.6 h; Varea, 2.04 l/kg; Cltot, 5.48 ml/min per kg; Clren, 3.05 ml/min per kg; Ae(0-24), 55.7% of dose.",Pharmacokinetics of pipemidic acid in healthy middle-aged volunteers and elderly patients with renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6464503/),h,4.6,75357,DB00592,Piperazine
,6464503,Varea,"The main pharmacokinetic parameters were: tmax, 2.3 h; Cmax, 3.3 micrograms/ml; t1/2, 4.6 h; Varea, 2.04 l/kg; Cltot, 5.48 ml/min per kg; Clren, 3.05 ml/min per kg; Ae(0-24), 55.7% of dose.",Pharmacokinetics of pipemidic acid in healthy middle-aged volunteers and elderly patients with renal insufficiency. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6464503/),[l] / [kg],2.04,75358,DB00592,Piperazine
,6464503,Cltot,"The main pharmacokinetic parameters were: tmax, 2.3 h; Cmax, 3.3 micrograms/ml; t1/2, 4.6 h; Varea, 2.04 l/kg; Cltot, 5.48 ml/min per kg; Clren, 3.05 ml/min per kg; Ae(0-24), 55.7% of dose.",Pharmacokinetics of pipemidic acid in healthy middle-aged volunteers and elderly patients with renal insufficiency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6464503/),[ml] / [kg·min],5.48,75359,DB00592,Piperazine
,6464503,Clren,"The main pharmacokinetic parameters were: tmax, 2.3 h; Cmax, 3.3 micrograms/ml; t1/2, 4.6 h; Varea, 2.04 l/kg; Cltot, 5.48 ml/min per kg; Clren, 3.05 ml/min per kg; Ae(0-24), 55.7% of dose.",Pharmacokinetics of pipemidic acid in healthy middle-aged volunteers and elderly patients with renal insufficiency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6464503/),[ml] / [kg·min],3.05,75360,DB00592,Piperazine
,6464503,Clcreat,"In the treatment of urinary-tract infections with pipemidic acid, a mild renal insufficiency (Clcreat 30 ml/min or more) does not necessitate dose adjustments.",Pharmacokinetics of pipemidic acid in healthy middle-aged volunteers and elderly patients with renal insufficiency. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6464503/),[ml] / [min],30,75361,DB00592,Piperazine
,8665999,ClCR,"The single-dose pharmacokinetics of nefazodone (NEF) and its metabolites hydroxynefazodone (HO-NEF) and m-chlorophenylpiperazine (mCPP) were examined in 12 healthy younger subjects < or = 55 years of age (YNG), 12 elderly subjects > or = 65 years of age (ELD), 12 patients with biopsy proven hepatic cirrhosis (HEP) and 12 patients with moderate renal impairment (REN), ClCR 20-60 ml.min-1.",Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8665999/),[ml] / [min],20-60,75686,DB00592,Piperazine
,16979864,flow rate,"Analyses were performed on a Shimadzu HPLC system using a Shimadzu C18 column and isocratic elution with acetonitrile-water (80:20, v/v), containing 0.4mM ammonium hydroxide and 0.2 mM acetic acid at a flow rate of 1.0 ml/min (split ratio 1:5).",Development and validation of a LC-MS/MS method with electrospray ionization for determination of LASSBio-579 in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16979864/),[ml] / [min],1.0,75700,DB00592,Piperazine
,16979864,retention times,"The retention times of LASSBio-579 and IS were approximately 4.7 and 2.4 min, respectively.",Development and validation of a LC-MS/MS method with electrospray ionization for determination of LASSBio-579 in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16979864/),min,4.7,75701,DB00592,Piperazine
,16979864,retention times,"The retention times of LASSBio-579 and IS were approximately 4.7 and 2.4 min, respectively.",Development and validation of a LC-MS/MS method with electrospray ionization for determination of LASSBio-579 in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16979864/),min,2.4,75702,DB00592,Piperazine
,7738219,inhibition constants (Ki),"Ketoconazole inhibition constants (Ki) averaged 0.024 microM for the desalkyl terfenadine pathway, and 0.237 microM for the hydroxy terfenadine pathway.",In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738219/),μM,0.024,76336,DB00592,Piperazine
,7738219,inhibition constants (Ki),"Ketoconazole inhibition constants (Ki) averaged 0.024 microM for the desalkyl terfenadine pathway, and 0.237 microM for the hydroxy terfenadine pathway.",In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738219/),μM,0.237,76337,DB00592,Piperazine
,29803908,m,"Mass detection was carried out by electrospray ionization in the position mode, and the multiple reaction monitoring transitions were m/z 474.23 → 456.17 and m/z 494.30 → 394.20 for Enasidenib and imatinib, respectively.",Determination and pharmacokinetic study of Enasidenib in rat plasma by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29803908/),,474.23,76810,DB00592,Piperazine
,7983237,maximum concentrations,"The mean plasma concentrations of active metabolite NM394 peaked between 0.5 and 1.0 hours, and the maximum concentrations were 0.68, 1.09, and 1.88 micrograms/mL at doses of 100, 200, and 400 mg, respectively.","Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983237/),[μg] / [ml],0.68,77016,DB00592,Piperazine
,7983237,maximum concentrations,"The mean plasma concentrations of active metabolite NM394 peaked between 0.5 and 1.0 hours, and the maximum concentrations were 0.68, 1.09, and 1.88 micrograms/mL at doses of 100, 200, and 400 mg, respectively.","Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983237/),[μg] / [ml],1.09,77017,DB00592,Piperazine
,7983237,maximum concentrations,"The mean plasma concentrations of active metabolite NM394 peaked between 0.5 and 1.0 hours, and the maximum concentrations were 0.68, 1.09, and 1.88 micrograms/mL at doses of 100, 200, and 400 mg, respectively.","Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983237/),[μg] / [ml],1.88,77018,DB00592,Piperazine
,7983237,half-lives,The mean half-lives were 7.7 to 8.9 hours and were not affected by dose.,"Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983237/),h,7.7 to 8.9,77019,DB00592,Piperazine
,7983237,urinary excretion rates,"The mean urinary excretion rates of NM394 were 46.0, 38.3, and 30.6% of the doses within 48 hours, respectively, and other metabolites were excreted in urine by 7% of the doses.","Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983237/),%,46.0,77020,DB00592,Piperazine
,7983237,urinary excretion rates,"The mean urinary excretion rates of NM394 were 46.0, 38.3, and 30.6% of the doses within 48 hours, respectively, and other metabolites were excreted in urine by 7% of the doses.","Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983237/),%,38.3,77021,DB00592,Piperazine
,7983237,urinary excretion rates,"The mean urinary excretion rates of NM394 were 46.0, 38.3, and 30.6% of the doses within 48 hours, respectively, and other metabolites were excreted in urine by 7% of the doses.","Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983237/),%,30.6,77022,DB00592,Piperazine
,7983237,fecal excretion rates,"The mean fecal excretion rates of NM394 and NM441 were 52.9 and 4.2%, respectively within 72 hours after dosing of 400 mg.","Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983237/),%,52.9,77023,DB00592,Piperazine
,7983237,fecal excretion rates,"The mean fecal excretion rates of NM394 and NM441 were 52.9 and 4.2%, respectively within 72 hours after dosing of 400 mg.","Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983237/),%,4.2,77024,DB00592,Piperazine
,7983237,urinary excretion rate,The mean urinary excretion rate of NM394 was 49.0% during and 48 hours after the multiple administration.,"Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7983237/),%,49.0,77025,DB00592,Piperazine
,17089336,ratio of intrinsic formation clearances,Formation of (-)-DHF exceeded that of (+)-DHF in liver microsomes [(-):(+) ratio of intrinsic formation clearances = 1.4].,The stereoselective metabolism of halofantrine to desbutylhalofantrine in the rat: evidence of tissue-specific enantioselectivity in microsomal metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17089336/),,1.4,77047,DB00592,Piperazine
,26583764,conversion factors,"Due to poor distribution into erythrocytes, drug concentrations in DBS were always lower than in plasma, resulting in conversion factors of 1.58 for ambrisentan and sildenafil and 1.52 for bosentan and tadalafil.","Dried Blood Spot Technique for the Monitoring of Ambrisentan, Bosentan, Sildenafil, and Tadalafil in Patients with Pulmonary Arterial Hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26583764/),,1.58,77354,DB00592,Piperazine
,26583764,conversion factors,"Due to poor distribution into erythrocytes, drug concentrations in DBS were always lower than in plasma, resulting in conversion factors of 1.58 for ambrisentan and sildenafil and 1.52 for bosentan and tadalafil.","Dried Blood Spot Technique for the Monitoring of Ambrisentan, Bosentan, Sildenafil, and Tadalafil in Patients with Pulmonary Arterial Hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26583764/),,1.52,77355,DB00592,Piperazine
,11477320,limit of detection,The limit of detection was approximately 10 ng/mL for seven drugs (25 ng/mL for efavirenz).,Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography--mass spectrometry assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11477320/),[ng] / [ml],10,77637,DB00592,Piperazine
,11477320,limit of detection,The limit of detection was approximately 10 ng/mL for seven drugs (25 ng/mL for efavirenz).,Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography--mass spectrometry assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11477320/),[ng] / [ml],25,77638,DB00592,Piperazine
,11477320,recovery,The recovery of the eight drugs ranged from 88.5% to 100%.,Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography--mass spectrometry assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11477320/),%,88.5,77639,DB00592,Piperazine
,11477320,recovery,The recovery of the eight drugs ranged from 88.5% to 100%.,Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography--mass spectrometry assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11477320/),%,100,77640,DB00592,Piperazine
,11289568,tmax,"Single doses of 10 and 20 mg vardenafil led to a rapid rise in the plasma concentrations of vardenafil, with a median tmax of 0.9 h and 0.7 h and a geometric mean Cmax of 9.1 microg/l (geometric SD = 1.63) and 20.9 microg/l (geometric SD = 1.83), respectively.",Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11289568/),h,0.9,78159,DB00592,Piperazine
,11289568,tmax,"Single doses of 10 and 20 mg vardenafil led to a rapid rise in the plasma concentrations of vardenafil, with a median tmax of 0.9 h and 0.7 h and a geometric mean Cmax of 9.1 microg/l (geometric SD = 1.63) and 20.9 microg/l (geometric SD = 1.83), respectively.",Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11289568/),h,0.7,78160,DB00592,Piperazine
,11289568,Cmax,"Single doses of 10 and 20 mg vardenafil led to a rapid rise in the plasma concentrations of vardenafil, with a median tmax of 0.9 h and 0.7 h and a geometric mean Cmax of 9.1 microg/l (geometric SD = 1.63) and 20.9 microg/l (geometric SD = 1.83), respectively.",Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11289568/),[μg] / [l],9.1,78161,DB00592,Piperazine
,11289568,Cmax,"Single doses of 10 and 20 mg vardenafil led to a rapid rise in the plasma concentrations of vardenafil, with a median tmax of 0.9 h and 0.7 h and a geometric mean Cmax of 9.1 microg/l (geometric SD = 1.63) and 20.9 microg/l (geometric SD = 1.83), respectively.",Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11289568/),[μg] / [l],20.9,78162,DB00592,Piperazine
,11289568,terminal t 1/2,"In the post-absorptive phase, the concentrations declined with an average terminal t 1/2 of 4.2 h (geometric SD = 1.27) and 3.9 h (geometric SD = 1.31).",Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11289568/),h,4.2,78163,DB00592,Piperazine
,11289568,terminal t 1/2,"In the post-absorptive phase, the concentrations declined with an average terminal t 1/2 of 4.2 h (geometric SD = 1.27) and 3.9 h (geometric SD = 1.31).",Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11289568/),h,3.9,78164,DB00592,Piperazine
more,11516908,recovery,The method was sensitive with a limit of quantitation of 10 ng ml(-1) in rat serum and the recovery was more than 84%.,LC determination of the anti-ischemic and anti-hypertensive agent CDRI-93/478 in rat serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11516908/),%,84,78196,DB00592,Piperazine
,27842891,Ki,"SAR optimization resulted in identification of two novel A2BAdoR antagonists, 8-{1-[5-Oxo-1-(4-trifluoromethyl-phenyl)-pyrrolidin-3-ylmethyl]-1H-pyrazol-4-yl}-1,3-dipropyl-xanthine (31) and 8-(1-{2-Oxo-2-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-ethyl}-1H-pyrazol-4-yl)-1,3-dipropyl-xanthine (65), with high binding affinity (Ki = 1 and 1.5 nM, respectively) and selectivity for A2BAdoR with very good functional potency of 0.9 nM and 4 nM, respectively.","A2B adenosine receptor antagonists: Design, synthesis and biological evaluation of novel xanthine derivatives. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27842891/),nM,1,78418,DB00592,Piperazine
,27842891,Ki,"SAR optimization resulted in identification of two novel A2BAdoR antagonists, 8-{1-[5-Oxo-1-(4-trifluoromethyl-phenyl)-pyrrolidin-3-ylmethyl]-1H-pyrazol-4-yl}-1,3-dipropyl-xanthine (31) and 8-(1-{2-Oxo-2-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-ethyl}-1H-pyrazol-4-yl)-1,3-dipropyl-xanthine (65), with high binding affinity (Ki = 1 and 1.5 nM, respectively) and selectivity for A2BAdoR with very good functional potency of 0.9 nM and 4 nM, respectively.","A2B adenosine receptor antagonists: Design, synthesis and biological evaluation of novel xanthine derivatives. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27842891/),nM,1.5,78419,DB00592,Piperazine
,27842891,oral bioavailability,Compound 31 and 65 also displayed good pharmacokinetic properties in mice with 27% and 65% oral bioavailability respectively.,"A2B adenosine receptor antagonists: Design, synthesis and biological evaluation of novel xanthine derivatives. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27842891/),%,27,78420,DB00592,Piperazine
,27842891,oral bioavailability,Compound 31 and 65 also displayed good pharmacokinetic properties in mice with 27% and 65% oral bioavailability respectively.,"A2B adenosine receptor antagonists: Design, synthesis and biological evaluation of novel xanthine derivatives. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27842891/),%,65,78421,DB00592,Piperazine
,18021336,area under the curve from time zero to infinity (AUC(0-alpha)),"Concurrent administration of ketoconazole with praziquantel significantly increased the mean area under the curve from time zero to infinity (AUC(0-alpha)) and maximum plasma concentration (Cmax) of praziquantel by 93% (955.94 +/- 307.74 vs. 1843.10 +/- 336.39 ng h/mL; P < 0.01) and 102% (183.38 +/- 43.90 vs. 371.31 +/- 44.63 ng/mL; P < 0.01), respectively, whereas the mean total clearance (Cl/F) of praziquantel was significantly decreased by 58% (2.65 +/- 0.64 vs. 1.11 +/- 0.35 mL/h/kg; P < 0.01).",Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021336/),[h·ng] / [ml],955.94,78698,DB00592,Piperazine
,18021336,area under the curve from time zero to infinity (AUC(0-alpha)),"Concurrent administration of ketoconazole with praziquantel significantly increased the mean area under the curve from time zero to infinity (AUC(0-alpha)) and maximum plasma concentration (Cmax) of praziquantel by 93% (955.94 +/- 307.74 vs. 1843.10 +/- 336.39 ng h/mL; P < 0.01) and 102% (183.38 +/- 43.90 vs. 371.31 +/- 44.63 ng/mL; P < 0.01), respectively, whereas the mean total clearance (Cl/F) of praziquantel was significantly decreased by 58% (2.65 +/- 0.64 vs. 1.11 +/- 0.35 mL/h/kg; P < 0.01).",Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021336/),[h·ng] / [ml],1843.10,78699,DB00592,Piperazine
,18021336,area under the curve from time zero to infinity (AUC(0-alpha)),"Concurrent administration of ketoconazole with praziquantel significantly increased the mean area under the curve from time zero to infinity (AUC(0-alpha)) and maximum plasma concentration (Cmax) of praziquantel by 93% (955.94 +/- 307.74 vs. 1843.10 +/- 336.39 ng h/mL; P < 0.01) and 102% (183.38 +/- 43.90 vs. 371.31 +/- 44.63 ng/mL; P < 0.01), respectively, whereas the mean total clearance (Cl/F) of praziquantel was significantly decreased by 58% (2.65 +/- 0.64 vs. 1.11 +/- 0.35 mL/h/kg; P < 0.01).",Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021336/),[ng] / [ml],183.38,78700,DB00592,Piperazine
,18021336,maximum plasma concentration (Cmax),"Concurrent administration of ketoconazole with praziquantel significantly increased the mean area under the curve from time zero to infinity (AUC(0-alpha)) and maximum plasma concentration (Cmax) of praziquantel by 93% (955.94 +/- 307.74 vs. 1843.10 +/- 336.39 ng h/mL; P < 0.01) and 102% (183.38 +/- 43.90 vs. 371.31 +/- 44.63 ng/mL; P < 0.01), respectively, whereas the mean total clearance (Cl/F) of praziquantel was significantly decreased by 58% (2.65 +/- 0.64 vs. 1.11 +/- 0.35 mL/h/kg; P < 0.01).",Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021336/),[ng] / [ml],183.38,78701,DB00592,Piperazine
,18021336,maximum plasma concentration (Cmax),"Concurrent administration of ketoconazole with praziquantel significantly increased the mean area under the curve from time zero to infinity (AUC(0-alpha)) and maximum plasma concentration (Cmax) of praziquantel by 93% (955.94 +/- 307.74 vs. 1843.10 +/- 336.39 ng h/mL; P < 0.01) and 102% (183.38 +/- 43.90 vs. 371.31 +/- 44.63 ng/mL; P < 0.01), respectively, whereas the mean total clearance (Cl/F) of praziquantel was significantly decreased by 58% (2.65 +/- 0.64 vs. 1.11 +/- 0.35 mL/h/kg; P < 0.01).",Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021336/),[ng] / [ml],371.31,78702,DB00592,Piperazine
,18021336,total clearance (Cl/F),"Concurrent administration of ketoconazole with praziquantel significantly increased the mean area under the curve from time zero to infinity (AUC(0-alpha)) and maximum plasma concentration (Cmax) of praziquantel by 93% (955.94 +/- 307.74 vs. 1843.10 +/- 336.39 ng h/mL; P < 0.01) and 102% (183.38 +/- 43.90 vs. 371.31 +/- 44.63 ng/mL; P < 0.01), respectively, whereas the mean total clearance (Cl/F) of praziquantel was significantly decreased by 58% (2.65 +/- 0.64 vs. 1.11 +/- 0.35 mL/h/kg; P < 0.01).",Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021336/),[ml] / [h·kg],2.65,78703,DB00592,Piperazine
,18021336,total clearance (Cl/F),"Concurrent administration of ketoconazole with praziquantel significantly increased the mean area under the curve from time zero to infinity (AUC(0-alpha)) and maximum plasma concentration (Cmax) of praziquantel by 93% (955.94 +/- 307.74 vs. 1843.10 +/- 336.39 ng h/mL; P < 0.01) and 102% (183.38 +/- 43.90 vs. 371.31 +/- 44.63 ng/mL; P < 0.01), respectively, whereas the mean total clearance (Cl/F) of praziquantel was significantly decreased by 58% (2.65 +/- 0.64 vs. 1.11 +/- 0.35 mL/h/kg; P < 0.01).",Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021336/),[ml] / [h·kg],1.11,78704,DB00592,Piperazine
,1971750,binding affinity constant (Ki),"Naftopidil could be characterized by receptor binding studies as an alpha 1-adrenergic antagonist with a binding affinity constant (Ki) of 58.3 nmol/l. both enantiomers of naftopidil revealed similar values, indicating no stereoselective inhibition of 3H-prazosin-binding.",Radioreceptor assay for the determination of alpha 1-adrenoceptor-binding material in rat plasma following single oral administration of naftopidil. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971750/),[nM] / [l],58.3,78923,DB00592,Piperazine
,1971750,Terminal half-life,Terminal half-life was calculated with 16.7 h.,Radioreceptor assay for the determination of alpha 1-adrenoceptor-binding material in rat plasma following single oral administration of naftopidil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971750/),h,16.7,78924,DB00592,Piperazine
,512901,peak plasma concentrations,"Following administration of 100-mg single oral doses to normal male volunteers, peak plasma concentrations of approximately 80 ng/ml were observed; the half-life of drug removal was approximately 3 hr.",Sensitive assay for determination of hydroxyzine in plasma and its human pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/512901/),[ng] / [ml],80,78955,DB00592,Piperazine
,512901,half-life of drug removal,"Following administration of 100-mg single oral doses to normal male volunteers, peak plasma concentrations of approximately 80 ng/ml were observed; the half-life of drug removal was approximately 3 hr.",Sensitive assay for determination of hydroxyzine in plasma and its human pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/512901/),h,3,78956,DB00592,Piperazine
,15232663,total area under the plasma concentration-time curve (AUC,"Itraconazole treatment significantly increased the total area under the plasma concentration-time curve (AUC; 213+/-106 ng rectangle h/ml versus 326+/-166 ng rectangle h/ml, P<0.001) and the elimination half-life (12.0+/-5.4 h versus 17.3+/-7.4 h, P<0.01) of etizolam.",Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15232663/),[h·ng·rectangle] / [ml],213,79185,DB00592,Piperazine
,15232663,total area under the plasma concentration-time curve (AUC,"Itraconazole treatment significantly increased the total area under the plasma concentration-time curve (AUC; 213+/-106 ng rectangle h/ml versus 326+/-166 ng rectangle h/ml, P<0.001) and the elimination half-life (12.0+/-5.4 h versus 17.3+/-7.4 h, P<0.01) of etizolam.",Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15232663/),[h·ng·rectangle] / [ml],326,79186,DB00592,Piperazine
,15232663,elimination half-life,"Itraconazole treatment significantly increased the total area under the plasma concentration-time curve (AUC; 213+/-106 ng rectangle h/ml versus 326+/-166 ng rectangle h/ml, P<0.001) and the elimination half-life (12.0+/-5.4 h versus 17.3+/-7.4 h, P<0.01) of etizolam.",Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15232663/),h,12.0,79187,DB00592,Piperazine
,15232663,elimination half-life,"Itraconazole treatment significantly increased the total area under the plasma concentration-time curve (AUC; 213+/-106 ng rectangle h/ml versus 326+/-166 ng rectangle h/ml, P<0.001) and the elimination half-life (12.0+/-5.4 h versus 17.3+/-7.4 h, P<0.01) of etizolam.",Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15232663/),h,17.3,79188,DB00592,Piperazine
,16372380,oral bioavailability,"Its oral bioavailability is only 40% due to extensive presystemic elimination, mainly by CYP3A4.",The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372380/),%,40,79257,DB00592,Piperazine
,16372380,AUC,The pharmacokinetic analysis showed that ciprofloxacin coadministration with sildenafil significantly increased the AUC from 1407 +/- 380 to 2986 +/- 917 microg h/l (90% confidence interval 119%-159%) and the Cmax from 287 +/- 67 to 623 +/- 192 microg/l (90% confidence interval 127%-152%).,The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372380/),[h·μg] / [l],1407,79258,DB00592,Piperazine
,16372380,AUC,The pharmacokinetic analysis showed that ciprofloxacin coadministration with sildenafil significantly increased the AUC from 1407 +/- 380 to 2986 +/- 917 microg h/l (90% confidence interval 119%-159%) and the Cmax from 287 +/- 67 to 623 +/- 192 microg/l (90% confidence interval 127%-152%).,The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372380/),[h·μg] / [l],2986,79259,DB00592,Piperazine
,16372380,Cmax,The pharmacokinetic analysis showed that ciprofloxacin coadministration with sildenafil significantly increased the AUC from 1407 +/- 380 to 2986 +/- 917 microg h/l (90% confidence interval 119%-159%) and the Cmax from 287 +/- 67 to 623 +/- 192 microg/l (90% confidence interval 127%-152%).,The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372380/),[μg] / [l],287,79260,DB00592,Piperazine
,16372380,Cmax,The pharmacokinetic analysis showed that ciprofloxacin coadministration with sildenafil significantly increased the AUC from 1407 +/- 380 to 2986 +/- 917 microg h/l (90% confidence interval 119%-159%) and the Cmax from 287 +/- 67 to 623 +/- 192 microg/l (90% confidence interval 127%-152%).,The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372380/),[μg] / [l],623,79261,DB00592,Piperazine
,16372380,AUC,"Similarly, clarithromycin coadministration increased sildenafil AUC from 1407 +/- 380 to 3209 +/- 762 microg h/l (90% confidence interval 127%-161%) and Cmax from 287 +/- 67 to 694 +/- 259 microg/l (90% confidence interval 132%-157%).",The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372380/),[h·μg] / [l],1407,79262,DB00592,Piperazine
,16372380,AUC,"Similarly, clarithromycin coadministration increased sildenafil AUC from 1407 +/- 380 to 3209 +/- 762 microg h/l (90% confidence interval 127%-161%) and Cmax from 287 +/- 67 to 694 +/- 259 microg/l (90% confidence interval 132%-157%).",The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372380/),[h·μg] / [l],3209,79263,DB00592,Piperazine
,16372380,Cmax,"Similarly, clarithromycin coadministration increased sildenafil AUC from 1407 +/- 380 to 3209 +/- 762 microg h/l (90% confidence interval 127%-161%) and Cmax from 287 +/- 67 to 694 +/- 259 microg/l (90% confidence interval 132%-157%).",The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372380/),[μg] / [l],287,79264,DB00592,Piperazine
,16372380,Cmax,"Similarly, clarithromycin coadministration increased sildenafil AUC from 1407 +/- 380 to 3209 +/- 762 microg h/l (90% confidence interval 127%-161%) and Cmax from 287 +/- 67 to 694 +/- 259 microg/l (90% confidence interval 132%-157%).",The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372380/),[μg] / [l],694,79265,DB00592,Piperazine
,17174640,time to reach >,"For 20 micromol/L ADP, the median time to reach > or = 20% IPA was 30 minutes for prasugrel and 1.5 hours for clopidogrel (P < .001).",A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17174640/),min,30,79419,DB00592,Piperazine
,17174640,time to reach >,"For 20 micromol/L ADP, the median time to reach > or = 20% IPA was 30 minutes for prasugrel and 1.5 hours for clopidogrel (P < .001).",A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17174640/),h,1.5,79420,DB00592,Piperazine
,17174640,maximum IPA,"The maximum IPA was 84.1% +/- 9.5% with prasugrel versus 48.9% +/- 27.0% with clopidogrel for 5 micromol/L ADP and 78.8% +/- 9.2% versus 35.0% +/- 24.5%, respectively, for 20 micromol/L ADP (P < .001).",A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17174640/),%,84.1,79421,DB00592,Piperazine
,17174640,maximum IPA,"The maximum IPA was 84.1% +/- 9.5% with prasugrel versus 48.9% +/- 27.0% with clopidogrel for 5 micromol/L ADP and 78.8% +/- 9.2% versus 35.0% +/- 24.5%, respectively, for 20 micromol/L ADP (P < .001).",A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17174640/),%,48.9,79422,DB00592,Piperazine
,17174640,maximum IPA,"The maximum IPA was 84.1% +/- 9.5% with prasugrel versus 48.9% +/- 27.0% with clopidogrel for 5 micromol/L ADP and 78.8% +/- 9.2% versus 35.0% +/- 24.5%, respectively, for 20 micromol/L ADP (P < .001).",A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17174640/),%,78.8,79423,DB00592,Piperazine
,17174640,maximum IPA,"The maximum IPA was 84.1% +/- 9.5% with prasugrel versus 48.9% +/- 27.0% with clopidogrel for 5 micromol/L ADP and 78.8% +/- 9.2% versus 35.0% +/- 24.5%, respectively, for 20 micromol/L ADP (P < .001).",A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17174640/),%,35.0,79424,DB00592,Piperazine
,28975417,elimination half-life,"Co-administration of blonanserin with grapefruit juice remarkably prolonged elimination half-life of blonanserin (from 9.7 to 21.4 h) and significantly increased exposures to blonanserin and N-desethyl blonanserin by 5.82-fold (90% CI 4.57, 7.42) and 1.81-fold (90% CI 1.65, 1.98), respectively.",Effects of food and grapefruit juice on single-dose pharmacokinetics of blonanserin in healthy Chinese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28975417/),h,9.7 to 21.4,79544,DB00592,Piperazine
,19730279,k(e),"The percent deviation of C(t) at 3 hours before or after tau from C(min,std) will be 7.1%, 13.1%, and 23.4% for pts with low, typical, and high k(e) values, 0.023/hour, 0.041/hour, and 0.070/hour, respectively.",A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19730279/),1/[h],0.041,79557,DB00592,Piperazine
,19730279,k(e),"The percent deviation of C(t) at 3 hours before or after tau from C(min,std) will be 7.1%, 13.1%, and 23.4% for pts with low, typical, and high k(e) values, 0.023/hour, 0.041/hour, and 0.070/hour, respectively.",A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19730279/),1/[h],0.070,79558,DB00592,Piperazine
,19730279,k(e),"However, if a correction is made for C(t) by the algorithm using the typical k(e) value of 0.041 per hour, the percent deviation at 3 hours will be reduced to 5.3%, 0%, and 9.1% for pts with low, typical, and high k(e) values, respectively.",A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19730279/),1/[h],0.041,79559,DB00592,Piperazine
,23594968,exposure,Mean (coefficient of variation) exposure to R-138727 was 600 ng·h/mL (16%) after 60 mg prasugrel and 283 ng·h/mL (17%) after 30 mg.,Pharmacokinetic and pharmacodynamic effects of prasugrel in healthy Korean males. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23594968/),[h·ng] / [ml],600,79636,DB00592,Piperazine
,23594968,exposure,Mean (coefficient of variation) exposure to R-138727 was 600 ng·h/mL (16%) after 60 mg prasugrel and 283 ng·h/mL (17%) after 30 mg.,Pharmacokinetic and pharmacodynamic effects of prasugrel in healthy Korean males. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23594968/),[h·ng] / [ml],283,79637,DB00592,Piperazine
,23594968,exposures,"After 10, 7.5, and 5 mg, mean exposures were 78.1 (24%), 58.4 (21%), and 38.3 ng·h/mL (24%).",Pharmacokinetic and pharmacodynamic effects of prasugrel in healthy Korean males. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23594968/),,78.1,79638,DB00592,Piperazine
,23594968,exposures,"After 10, 7.5, and 5 mg, mean exposures were 78.1 (24%), 58.4 (21%), and 38.3 ng·h/mL (24%).",Pharmacokinetic and pharmacodynamic effects of prasugrel in healthy Korean males. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23594968/),,58.4,79639,DB00592,Piperazine
,23594968,exposures,"After 10, 7.5, and 5 mg, mean exposures were 78.1 (24%), 58.4 (21%), and 38.3 ng·h/mL (24%).",Pharmacokinetic and pharmacodynamic effects of prasugrel in healthy Korean males. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23594968/),[h·ng] / [ml],38.3,79640,DB00592,Piperazine
,22943970,terminal t(½),"DA-1229 reached a peak at 3.0 to 5.5 hours after a single oral dose and the concentrations declined, with a terminal t(½) from 32.5 to 39.8 hours.","Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22943970/),h,32.5 to 39.8,79772,DB00592,Piperazine
,10660641,Cmax,"Pharmacokinetic parameters of ITCZ and OH-ITCZ as follows: ITCZ: Cmax 93.2 ng/ml, T1/2 beta 11 hours, AUC0-24 999 ng.h/ml, OH-ITCZ: Cmax 159.4 ng/ml, T1/2 beta 16.",Serum itraconazole and hydroxyitraconazole concentrations and interaction with digoxin in a case of chronic hypertrophic pachymenigitis caused by Aspergillus flavus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10660641/),[ng] / [ml],93.2,79988,DB00592,Piperazine
,10660641,T1/2 beta,"Pharmacokinetic parameters of ITCZ and OH-ITCZ as follows: ITCZ: Cmax 93.2 ng/ml, T1/2 beta 11 hours, AUC0-24 999 ng.h/ml, OH-ITCZ: Cmax 159.4 ng/ml, T1/2 beta 16.",Serum itraconazole and hydroxyitraconazole concentrations and interaction with digoxin in a case of chronic hypertrophic pachymenigitis caused by Aspergillus flavus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10660641/),h,11,79989,DB00592,Piperazine
,10660641,AUC0-24,"Pharmacokinetic parameters of ITCZ and OH-ITCZ as follows: ITCZ: Cmax 93.2 ng/ml, T1/2 beta 11 hours, AUC0-24 999 ng.h/ml, OH-ITCZ: Cmax 159.4 ng/ml, T1/2 beta 16.",Serum itraconazole and hydroxyitraconazole concentrations and interaction with digoxin in a case of chronic hypertrophic pachymenigitis caused by Aspergillus flavus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10660641/),[h·ng] / [ml],999,79990,DB00592,Piperazine
,10660641,Cmax,"Pharmacokinetic parameters of ITCZ and OH-ITCZ as follows: ITCZ: Cmax 93.2 ng/ml, T1/2 beta 11 hours, AUC0-24 999 ng.h/ml, OH-ITCZ: Cmax 159.4 ng/ml, T1/2 beta 16.",Serum itraconazole and hydroxyitraconazole concentrations and interaction with digoxin in a case of chronic hypertrophic pachymenigitis caused by Aspergillus flavus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10660641/),[ng] / [ml],159.4,79991,DB00592,Piperazine
,10660641,T1/2 beta,"Pharmacokinetic parameters of ITCZ and OH-ITCZ as follows: ITCZ: Cmax 93.2 ng/ml, T1/2 beta 11 hours, AUC0-24 999 ng.h/ml, OH-ITCZ: Cmax 159.4 ng/ml, T1/2 beta 16.",Serum itraconazole and hydroxyitraconazole concentrations and interaction with digoxin in a case of chronic hypertrophic pachymenigitis caused by Aspergillus flavus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10660641/),,16,79992,DB00592,Piperazine
,10660641,AUC0-24,"2 hours, AUC0-24 of 1391 ng.h/ml.",Serum itraconazole and hydroxyitraconazole concentrations and interaction with digoxin in a case of chronic hypertrophic pachymenigitis caused by Aspergillus flavus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10660641/),[h·ng] / [ml],1391,79993,DB00592,Piperazine
,33835229,maximum plasma concentration,"After single and multiple dosing, palbociclib maximum plasma concentration was 82.14 and 139.7 ng/mL, apparent clearance was 52.40 and 49.97 L/h, AUCτ was 1217 and 2501 ng∙h/mL, and t½ was 23.46 and 27.26 h, respectively.","Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33835229/),[ng] / [ml],82.14,80001,DB00592,Piperazine
,33835229,maximum plasma concentration,"After single and multiple dosing, palbociclib maximum plasma concentration was 82.14 and 139.7 ng/mL, apparent clearance was 52.40 and 49.97 L/h, AUCτ was 1217 and 2501 ng∙h/mL, and t½ was 23.46 and 27.26 h, respectively.","Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33835229/),[ng] / [ml],139.7,80002,DB00592,Piperazine
,33835229,apparent clearance,"After single and multiple dosing, palbociclib maximum plasma concentration was 82.14 and 139.7 ng/mL, apparent clearance was 52.40 and 49.97 L/h, AUCτ was 1217 and 2501 ng∙h/mL, and t½ was 23.46 and 27.26 h, respectively.","Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33835229/),[l] / [h],52.40,80003,DB00592,Piperazine
,33835229,apparent clearance,"After single and multiple dosing, palbociclib maximum plasma concentration was 82.14 and 139.7 ng/mL, apparent clearance was 52.40 and 49.97 L/h, AUCτ was 1217 and 2501 ng∙h/mL, and t½ was 23.46 and 27.26 h, respectively.","Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33835229/),[l] / [h],49.97,80004,DB00592,Piperazine
,33835229,AUCτ,"After single and multiple dosing, palbociclib maximum plasma concentration was 82.14 and 139.7 ng/mL, apparent clearance was 52.40 and 49.97 L/h, AUCτ was 1217 and 2501 ng∙h/mL, and t½ was 23.46 and 27.26 h, respectively.","Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33835229/),[ng∙h] / [ml],1217,80005,DB00592,Piperazine
,33835229,AUCτ,"After single and multiple dosing, palbociclib maximum plasma concentration was 82.14 and 139.7 ng/mL, apparent clearance was 52.40 and 49.97 L/h, AUCτ was 1217 and 2501 ng∙h/mL, and t½ was 23.46 and 27.26 h, respectively.","Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33835229/),[ng∙h] / [ml],2501,80006,DB00592,Piperazine
,33835229,t½,"After single and multiple dosing, palbociclib maximum plasma concentration was 82.14 and 139.7 ng/mL, apparent clearance was 52.40 and 49.97 L/h, AUCτ was 1217 and 2501 ng∙h/mL, and t½ was 23.46 and 27.26 h, respectively.","Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33835229/),h,23.46,80007,DB00592,Piperazine
,33835229,t½,"After single and multiple dosing, palbociclib maximum plasma concentration was 82.14 and 139.7 ng/mL, apparent clearance was 52.40 and 49.97 L/h, AUCτ was 1217 and 2501 ng∙h/mL, and t½ was 23.46 and 27.26 h, respectively.","Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33835229/),h,27.26,80008,DB00592,Piperazine
,14747427,elimination half-life,"In Study 1, mean elimination half-life ranged from 47 to 68 hours with aripiprazole, with apparent systemic clearance (CL/F) of approximately 3.45 L/h.","Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14747427/),h,47 to 68,80081,DB00592,Piperazine
,14747427,apparent systemic clearance (CL/F),"In Study 1, mean elimination half-life ranged from 47 to 68 hours with aripiprazole, with apparent systemic clearance (CL/F) of approximately 3.45 L/h.","Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14747427/),[l] / [h],3.45,80082,DB00592,Piperazine
,14747427,elimination half-life,"In Study 2, mean elimination half-life was 59 hours (CL/F approximately 4.0 L/h).","Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14747427/),h,59,80083,DB00592,Piperazine
,14747427,CL/F,"In Study 2, mean elimination half-life was 59 hours (CL/F approximately 4.0 L/h).","Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14747427/),[l] / [h],4.0,80084,DB00592,Piperazine
,11569532,half-life,The half-life (4-6 h) was similar at all doses.,"Potential role for P-glycoprotein in the non-proportional pharmacokinetics of UK-343,664 in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11569532/),h,4-6,80287,DB00592,Piperazine
,11569532,log D7.4,"2. UK-343,664 is a lipophilic molecule (log D7.4 = 3.1) and as such is expected to be cleared mainly by metabolism.","Potential role for P-glycoprotein in the non-proportional pharmacokinetics of UK-343,664 in man. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11569532/),,3.1,80288,DB00592,Piperazine
,11569532,Km,"With a moderate Km = 76 microM for this enzyme, saturation of first-pass metabolism alone was considered unlikely to account for the non-proportional pharmacokinetics.","Potential role for P-glycoprotein in the non-proportional pharmacokinetics of UK-343,664 in man. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11569532/),μM,76,80289,DB00592,Piperazine
,11569532,Km,"3. UK-343,664 showed high affinity for P-glycoprotein in vitro, with a Km = 7.3 microM.","Potential role for P-glycoprotein in the non-proportional pharmacokinetics of UK-343,664 in man. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11569532/),μM,7.3,80290,DB00592,Piperazine
,16885720,total time for,"The peaks were monitored with an ultraviolet detector set at a wavelength of 263 nm, and total time for chromatographic separation was about 24 minutes.",Sensitive determination of itraconazole and its active metabolite in human plasma by column-switching high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16885720/),min,24,80462,DB00592,Piperazine
,16885720,recoveries,Mean recoveries were 59.7% for ITZ and 72.8% for HIT.,Sensitive determination of itraconazole and its active metabolite in human plasma by column-switching high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16885720/),%,59.7,80463,DB00592,Piperazine
,16885720,recoveries,Mean recoveries were 59.7% for ITZ and 72.8% for HIT.,Sensitive determination of itraconazole and its active metabolite in human plasma by column-switching high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16885720/),%,72.8,80464,DB00592,Piperazine
,24937809,flow rate,"An isocratic mobile phase of acetonitrile: 5mM ammonium acetate: formic acid (35:65:0.1, v/v/v) was applied at a flow rate of 0.25mL/min.",A validated LC-MS/MS method for the rapid quantification of vilazodone in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24937809/),[ml] / [min],0.25,80785,DB00592,Piperazine
,24937809,m,Detection was performed using multiple reaction-monitoring (MRM) modes at m/z 442.4→155.3 for vilazodone and m/z 325.1→109.0 for escitalopram.,A validated LC-MS/MS method for the rapid quantification of vilazodone in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24937809/),,442.4,80786,DB00592,Piperazine
,24937809,total analysis time,The total analysis time was 2.2min.,A validated LC-MS/MS method for the rapid quantification of vilazodone in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24937809/),min,2.2,80787,DB00592,Piperazine
,9821410,trough,"Mean trough and peak concentrations of ITZ without famotidine were 332 ng/ml and 476 ng/ml, respectively.",Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9821410/),[ng] / [ml],332,81035,DB00592,Piperazine
,9821410,peak concentrations,"Mean trough and peak concentrations of ITZ without famotidine were 332 ng/ml and 476 ng/ml, respectively.",Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9821410/),[ng] / [ml],476,81036,DB00592,Piperazine
,7849232,Urinary excretion,"Urinary excretion of cefoperazone showed a highly significant increase in patients, 23.95 +/- 5.06% and 37.54 +/- 13.61% for normal men and hepatitis patients respectively.",The influence of chronic lobular hepatitis on pharmacokinetics of cefoperazone--a novel galactose single-point method as a measure of residual liver function. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7849232/),%,23.95,81287,DB00592,Piperazine
,7849232,Urinary excretion,"Urinary excretion of cefoperazone showed a highly significant increase in patients, 23.95 +/- 5.06% and 37.54 +/- 13.61% for normal men and hepatitis patients respectively.",The influence of chronic lobular hepatitis on pharmacokinetics of cefoperazone--a novel galactose single-point method as a measure of residual liver function. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7849232/),%,37.54,81288,DB00592,Piperazine
,34322850,zeta potential,"The nanoemulsion characteristics included particle size range of 60-80 nm, zeta potential of -6.6 to -7.8 mV, polydispersity index < 0.3, 3-day stability at 4 °C, and limited ImM leakage from the nanoemulsion in serum.",An evaluation of a novel nanoformulation of imatinib mesylate in a mouse model of lupus nephritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34322850/),mv,6.6 to -7.8,81535,DB00592,Piperazine
<,34322850,polydispersity index,"The nanoemulsion characteristics included particle size range of 60-80 nm, zeta potential of -6.6 to -7.8 mV, polydispersity index < 0.3, 3-day stability at 4 °C, and limited ImM leakage from the nanoemulsion in serum.",An evaluation of a novel nanoformulation of imatinib mesylate in a mouse model of lupus nephritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34322850/),,0.3,81536,DB00592,Piperazine
,2240801,half-life at alpha phase,"Mean disposition variables were a half-life at alpha phase of 0.06 hours or 0.33 hours, a half-life at beta phase of 1.18 hours or 1.72 hours, a volume of distribution in the central compartment of 0.12 L/kg or 0.31 L/kg, a volume of distribution during the elimination beta phase of 1.64 L/kg or 1.05 L/kg, and a total plasma clearance of 0.97 L/h.kg or 0.41 L/h.kg, for the 10 or 30 mg/kg dose, respectively.",Pharmacokinetics of pipemidic acid in chickens after single intravenous and oral dosings. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2240801/),h,0.06,81697,DB00592,Piperazine
,2240801,half-life at alpha phase,"Mean disposition variables were a half-life at alpha phase of 0.06 hours or 0.33 hours, a half-life at beta phase of 1.18 hours or 1.72 hours, a volume of distribution in the central compartment of 0.12 L/kg or 0.31 L/kg, a volume of distribution during the elimination beta phase of 1.64 L/kg or 1.05 L/kg, and a total plasma clearance of 0.97 L/h.kg or 0.41 L/h.kg, for the 10 or 30 mg/kg dose, respectively.",Pharmacokinetics of pipemidic acid in chickens after single intravenous and oral dosings. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2240801/),h,0.33,81698,DB00592,Piperazine
,2240801,half-life at beta phase,"Mean disposition variables were a half-life at alpha phase of 0.06 hours or 0.33 hours, a half-life at beta phase of 1.18 hours or 1.72 hours, a volume of distribution in the central compartment of 0.12 L/kg or 0.31 L/kg, a volume of distribution during the elimination beta phase of 1.64 L/kg or 1.05 L/kg, and a total plasma clearance of 0.97 L/h.kg or 0.41 L/h.kg, for the 10 or 30 mg/kg dose, respectively.",Pharmacokinetics of pipemidic acid in chickens after single intravenous and oral dosings. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2240801/),h,1.18,81699,DB00592,Piperazine
,2240801,half-life at beta phase,"Mean disposition variables were a half-life at alpha phase of 0.06 hours or 0.33 hours, a half-life at beta phase of 1.18 hours or 1.72 hours, a volume of distribution in the central compartment of 0.12 L/kg or 0.31 L/kg, a volume of distribution during the elimination beta phase of 1.64 L/kg or 1.05 L/kg, and a total plasma clearance of 0.97 L/h.kg or 0.41 L/h.kg, for the 10 or 30 mg/kg dose, respectively.",Pharmacokinetics of pipemidic acid in chickens after single intravenous and oral dosings. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2240801/),h,1.72,81700,DB00592,Piperazine
,2240801,volume of distribution in the central compartment,"Mean disposition variables were a half-life at alpha phase of 0.06 hours or 0.33 hours, a half-life at beta phase of 1.18 hours or 1.72 hours, a volume of distribution in the central compartment of 0.12 L/kg or 0.31 L/kg, a volume of distribution during the elimination beta phase of 1.64 L/kg or 1.05 L/kg, and a total plasma clearance of 0.97 L/h.kg or 0.41 L/h.kg, for the 10 or 30 mg/kg dose, respectively.",Pharmacokinetics of pipemidic acid in chickens after single intravenous and oral dosings. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2240801/),[l] / [kg],0.12,81701,DB00592,Piperazine
,2240801,volume of distribution in the central compartment,"Mean disposition variables were a half-life at alpha phase of 0.06 hours or 0.33 hours, a half-life at beta phase of 1.18 hours or 1.72 hours, a volume of distribution in the central compartment of 0.12 L/kg or 0.31 L/kg, a volume of distribution during the elimination beta phase of 1.64 L/kg or 1.05 L/kg, and a total plasma clearance of 0.97 L/h.kg or 0.41 L/h.kg, for the 10 or 30 mg/kg dose, respectively.",Pharmacokinetics of pipemidic acid in chickens after single intravenous and oral dosings. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2240801/),[l] / [kg],0.31,81702,DB00592,Piperazine
,2240801,volume of distribution during the elimination beta phase,"Mean disposition variables were a half-life at alpha phase of 0.06 hours or 0.33 hours, a half-life at beta phase of 1.18 hours or 1.72 hours, a volume of distribution in the central compartment of 0.12 L/kg or 0.31 L/kg, a volume of distribution during the elimination beta phase of 1.64 L/kg or 1.05 L/kg, and a total plasma clearance of 0.97 L/h.kg or 0.41 L/h.kg, for the 10 or 30 mg/kg dose, respectively.",Pharmacokinetics of pipemidic acid in chickens after single intravenous and oral dosings. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2240801/),[l] / [kg],1.64,81703,DB00592,Piperazine
,2240801,volume of distribution during the elimination beta phase,"Mean disposition variables were a half-life at alpha phase of 0.06 hours or 0.33 hours, a half-life at beta phase of 1.18 hours or 1.72 hours, a volume of distribution in the central compartment of 0.12 L/kg or 0.31 L/kg, a volume of distribution during the elimination beta phase of 1.64 L/kg or 1.05 L/kg, and a total plasma clearance of 0.97 L/h.kg or 0.41 L/h.kg, for the 10 or 30 mg/kg dose, respectively.",Pharmacokinetics of pipemidic acid in chickens after single intravenous and oral dosings. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2240801/),[l] / [kg],1.05,81704,DB00592,Piperazine
,2240801,total plasma clearance,"Mean disposition variables were a half-life at alpha phase of 0.06 hours or 0.33 hours, a half-life at beta phase of 1.18 hours or 1.72 hours, a volume of distribution in the central compartment of 0.12 L/kg or 0.31 L/kg, a volume of distribution during the elimination beta phase of 1.64 L/kg or 1.05 L/kg, and a total plasma clearance of 0.97 L/h.kg or 0.41 L/h.kg, for the 10 or 30 mg/kg dose, respectively.",Pharmacokinetics of pipemidic acid in chickens after single intravenous and oral dosings. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2240801/),[l] / [h·kg],0.97,81705,DB00592,Piperazine
,2240801,total plasma clearance,"Mean disposition variables were a half-life at alpha phase of 0.06 hours or 0.33 hours, a half-life at beta phase of 1.18 hours or 1.72 hours, a volume of distribution in the central compartment of 0.12 L/kg or 0.31 L/kg, a volume of distribution during the elimination beta phase of 1.64 L/kg or 1.05 L/kg, and a total plasma clearance of 0.97 L/h.kg or 0.41 L/h.kg, for the 10 or 30 mg/kg dose, respectively.",Pharmacokinetics of pipemidic acid in chickens after single intravenous and oral dosings. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2240801/),[l] / [h·kg],0.41,81706,DB00592,Piperazine
,2240801,time to maximal concentration,"After the single oral doses of 10 and 30 mg of pipemidic acid/kg, pipemidic acid was absorbed rapidly (time to maximal concentration of 0.31 hours or 0.71 hours) and eliminated with a mean half-life of 0.86 hours or 0.61 hours, respectively.",Pharmacokinetics of pipemidic acid in chickens after single intravenous and oral dosings. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2240801/),h,0.31,81707,DB00592,Piperazine
,2240801,time to maximal concentration,"After the single oral doses of 10 and 30 mg of pipemidic acid/kg, pipemidic acid was absorbed rapidly (time to maximal concentration of 0.31 hours or 0.71 hours) and eliminated with a mean half-life of 0.86 hours or 0.61 hours, respectively.",Pharmacokinetics of pipemidic acid in chickens after single intravenous and oral dosings. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2240801/),h,0.71,81708,DB00592,Piperazine
,2240801,half-life,"After the single oral doses of 10 and 30 mg of pipemidic acid/kg, pipemidic acid was absorbed rapidly (time to maximal concentration of 0.31 hours or 0.71 hours) and eliminated with a mean half-life of 0.86 hours or 0.61 hours, respectively.",Pharmacokinetics of pipemidic acid in chickens after single intravenous and oral dosings. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2240801/),h,0.86,81709,DB00592,Piperazine
,2240801,half-life,"After the single oral doses of 10 and 30 mg of pipemidic acid/kg, pipemidic acid was absorbed rapidly (time to maximal concentration of 0.31 hours or 0.71 hours) and eliminated with a mean half-life of 0.86 hours or 0.61 hours, respectively.",Pharmacokinetics of pipemidic acid in chickens after single intravenous and oral dosings. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2240801/),h,0.61,81710,DB00592,Piperazine
,2240801,bioavailability,The bioavailability was 39% at 10 mg of pipemidic acid/kg and 61% at 30 mg of pipemidic acid/kg.,Pharmacokinetics of pipemidic acid in chickens after single intravenous and oral dosings. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2240801/),%,39,81711,DB00592,Piperazine
,2240801,bioavailability,The bioavailability was 39% at 10 mg of pipemidic acid/kg and 61% at 30 mg of pipemidic acid/kg.,Pharmacokinetics of pipemidic acid in chickens after single intravenous and oral dosings. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2240801/),%,61,81712,DB00592,Piperazine
,31537425,brain to plasma ratios,The pharmacokinetic analysis of active compounds done by a non-compartmental approach have shown a rapid absorption of all studied molecules from intraperitoneal cavity and good penetration the blood-brain barrier after i.p. administration with brain to plasma ratios varied from 2.8 to 31.6.,"Design, synthesis and evaluation of activity and pharmacokinetic profile of new derivatives of xanthone and piperazine in the central nervous system. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31537425/),,2.8,82655,DB00592,Piperazine
,31537425,brain to plasma ratios,The pharmacokinetic analysis of active compounds done by a non-compartmental approach have shown a rapid absorption of all studied molecules from intraperitoneal cavity and good penetration the blood-brain barrier after i.p. administration with brain to plasma ratios varied from 2.8 to 31.6.,"Design, synthesis and evaluation of activity and pharmacokinetic profile of new derivatives of xanthone and piperazine in the central nervous system. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31537425/),,31.6,82656,DB00592,Piperazine
,16273899,plasma concentrations,Itraconazole reached higher mean +/- SD plasma concentrations after administration of the solution (0.41 +/- 0.13 microg/mL) versus the capsules (0.15 +/- 0.12 microg/mL).,Pharmacokinetics and tissue distribution of itraconazole after oral and intravenous administration to horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16273899/),[μg] / [ml],0.41,83067,DB00592,Piperazine
,16273899,plasma concentrations,Itraconazole reached higher mean +/- SD plasma concentrations after administration of the solution (0.41 +/- 0.13 microg/mL) versus the capsules (0.15 +/- 0.12 microg/mL).,Pharmacokinetics and tissue distribution of itraconazole after oral and intravenous administration to horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16273899/),[μg] / [ml],0.15,83068,DB00592,Piperazine
,16273899,Bioavailability,Bioavailability after administration of capsules relative to solution was 33.83 +/- 33.08%.,Pharmacokinetics and tissue distribution of itraconazole after oral and intravenous administration to horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16273899/),%,33.83,83069,DB00592,Piperazine
,16273899,volume of distribution,"Similar to other species, itraconazole has a high volume of distribution (6.3 +/- 0.94 L/kg) and a long half-life (11.3 +/- 2.84 hours).",Pharmacokinetics and tissue distribution of itraconazole after oral and intravenous administration to horses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16273899/),[l] / [kg],6.3,83070,DB00592,Piperazine
,16273899,half-life,"Similar to other species, itraconazole has a high volume of distribution (6.3 +/- 0.94 L/kg) and a long half-life (11.3 +/- 2.84 hours).",Pharmacokinetics and tissue distribution of itraconazole after oral and intravenous administration to horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16273899/),h,11.3,83071,DB00592,Piperazine
,16273899,Plasma protein binding,Plasma protein binding was 98.81 +/- 0.17%.,Pharmacokinetics and tissue distribution of itraconazole after oral and intravenous administration to horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16273899/),%,98.81,83072,DB00592,Piperazine
,8866044,terminal half-life,The terminal half-life ranged between 1.1 and 1.3 h and the apparent steady-state distribution volume was 0.67 L kg-1.,Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866044/),h,1.1 and 1.3,83262,DB00592,Piperazine
,8866044,apparent steady-state distribution volume,The terminal half-life ranged between 1.1 and 1.3 h and the apparent steady-state distribution volume was 0.67 L kg-1.,Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866044/),[l] / [kg],0.67,83263,DB00592,Piperazine
,8866044,systemic clearance (CL),"The systemic clearance (CL) ranged from 10.3 to 11.5 mL min-1 kg-1, while estimates of renal clearance approximated the glomerular filtration rate (GFR approximately 3.2-4.9 mL min-1 kg-1).",Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866044/),[ml] / [kg·min],10.3 to 11.5,83264,DB00592,Piperazine
,8866044,blood cell to plasma partitioning ratio,The blood cell to plasma partitioning ratio was approximately 0.517 and drug was essentially unbound to plasma proteins (fu approximately 0.95).,Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866044/),,0.517,83265,DB00592,Piperazine
,8866044,fu,The blood cell to plasma partitioning ratio was approximately 0.517 and drug was essentially unbound to plasma proteins (fu approximately 0.95).,Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866044/),,0.95,83266,DB00592,Piperazine
,8866044,hepatic,"Dexrazoxane appeared to be subject to low organ extraction, since the hepatic and renal drug extraction ratios were on the order of 0.228 +/- 0.054 and 0.184 +/- 0.024, respectively.",Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866044/),,0.228,83267,DB00592,Piperazine
,8866044,renal,"Dexrazoxane appeared to be subject to low organ extraction, since the hepatic and renal drug extraction ratios were on the order of 0.228 +/- 0.054 and 0.184 +/- 0.024, respectively.",Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866044/),,0.228,83268,DB00592,Piperazine
,8866044,renal,"Dexrazoxane appeared to be subject to low organ extraction, since the hepatic and renal drug extraction ratios were on the order of 0.228 +/- 0.054 and 0.184 +/- 0.024, respectively.",Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866044/),,0.184,83269,DB00592,Piperazine
,8866044,drug extraction ratios,"Dexrazoxane appeared to be subject to low organ extraction, since the hepatic and renal drug extraction ratios were on the order of 0.228 +/- 0.054 and 0.184 +/- 0.024, respectively.",Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866044/),,0.184,83270,DB00592,Piperazine
,9219927,peak plasma levels,"Following i.p. administration of 0.5 mmol/kg of CB7645 and CB7661, peak plasma levels of 13.4 and 3.4 microM, respectively, occurred after 2-4 h, both compounds were cleared rapidly (terminal half-lives 2.7 and 3.3 h, respectively) and neither was detectable at 24 h.",Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219927/),μM,13.4,83627,DB00592,Piperazine
,9219927,peak plasma levels,"Following i.p. administration of 0.5 mmol/kg of CB7645 and CB7661, peak plasma levels of 13.4 and 3.4 microM, respectively, occurred after 2-4 h, both compounds were cleared rapidly (terminal half-lives 2.7 and 3.3 h, respectively) and neither was detectable at 24 h.",Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219927/),μM,3.4,83628,DB00592,Piperazine
,9219927,terminal half-lives,"Following i.p. administration of 0.5 mmol/kg of CB7645 and CB7661, peak plasma levels of 13.4 and 3.4 microM, respectively, occurred after 2-4 h, both compounds were cleared rapidly (terminal half-lives 2.7 and 3.3 h, respectively) and neither was detectable at 24 h.",Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219927/),h,2.7,83629,DB00592,Piperazine
,9219927,terminal half-lives,"Following i.p. administration of 0.5 mmol/kg of CB7645 and CB7661, peak plasma levels of 13.4 and 3.4 microM, respectively, occurred after 2-4 h, both compounds were cleared rapidly (terminal half-lives 2.7 and 3.3 h, respectively) and neither was detectable at 24 h.",Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219927/),h,3.3,83630,DB00592,Piperazine
,9219927,K(i),"When tested in vitro against the WHT testicular enzyme, the CB7645 and CB7661 were competitive inhibitors with K(i) values of 10 and 13 nM, respectively.",Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219927/),nM,10,83631,DB00592,Piperazine
,9219927,K(i),"When tested in vitro against the WHT testicular enzyme, the CB7645 and CB7661 were competitive inhibitors with K(i) values of 10 and 13 nM, respectively.",Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219927/),nM,13,83632,DB00592,Piperazine
,9219927,K(m),"However, the K(m) for the substrate progesterone was lower at 4.3 nM.",Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219927/),nM,4.3,83633,DB00592,Piperazine
,25466188,EC50,This compound possessed good in vitro efficacy and pharmacokinetic parameters and demonstrated an EC50 of 239 ng/mL in a mouse liver pharmacodynamic model measuring the inhibition of hepatocyte growth factor (HGF)-induced Akt Ser473 phosphorylation in CD1 nude mice 6 h post-oral dosing.,Phosphoinositide-3-kinase inhibitors: evaluation of substituted alcohols as replacements for the piperazine sulfonamide portion of AMG 511. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25466188/),[ng] / [ml],239,83708,DB00592,Piperazine
,12584863,C0-->infinity,"The C0-->infinity, Cmax and Tmax of naftopidil capsule was (3728 +/- 573) h.ng.mL-1, (697 +/- 94) ng.mL-1 and (1.2 +/- 0.5) h.",[Improving bioavailability of naftopidil by using bioadhesion in dogs]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584863/),[h·ng] / [ml],3728,84093,DB00592,Piperazine
,12584863,Cmax,"The C0-->infinity, Cmax and Tmax of naftopidil capsule was (3728 +/- 573) h.ng.mL-1, (697 +/- 94) ng.mL-1 and (1.2 +/- 0.5) h.",[Improving bioavailability of naftopidil by using bioadhesion in dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584863/),[ng] / [ml],697,84094,DB00592,Piperazine
,12584863,Tmax,"The C0-->infinity, Cmax and Tmax of naftopidil capsule was (3728 +/- 573) h.ng.mL-1, (697 +/- 94) ng.mL-1 and (1.2 +/- 0.5) h.",[Improving bioavailability of naftopidil by using bioadhesion in dogs]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584863/),h,1.2,84095,DB00592,Piperazine
,12584863,relative bioavailability,"The bioadhesive formulations and the non-bioadhesive one were not bioequivalent, the relative bioavailability of the two bioadhesive sustained-release capsules were respectively 150% +/- 14% and 154% +/- 23% when compared with the non-bioadhesive capsule.",[Improving bioavailability of naftopidil by using bioadhesion in dogs]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584863/),%,150,84096,DB00592,Piperazine
,12584863,relative bioavailability,"The bioadhesive formulations and the non-bioadhesive one were not bioequivalent, the relative bioavailability of the two bioadhesive sustained-release capsules were respectively 150% +/- 14% and 154% +/- 23% when compared with the non-bioadhesive capsule.",[Improving bioavailability of naftopidil by using bioadhesion in dogs]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584863/),%,154,84097,DB00592,Piperazine
,17236738,total analysis run time,"The total analysis run time for each sample was 2 min, which included the time needed for on-line extraction, chromatographic separation and LC-MS/MS analysis.",High-throughput quantitation of nefazodone and its metabolites in human plasma by high flow direct-injection LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17236738/),min,2,84598,DB00592,Piperazine
,9518148,limit of detection,The limit of detection is 4 ng/ml.,Specific gas chromatographic analysis of diethylcarbamazine in human plasma using solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9518148/),[ng] / [ml],4,84765,DB00592,Piperazine
,9518148,Recovery,Recovery following solid-phase extraction is 99.3% for DEC and 94.8% for the internal standard.,Specific gas chromatographic analysis of diethylcarbamazine in human plasma using solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9518148/),%,99.3,84766,DB00592,Piperazine
,9518148,Recovery,Recovery following solid-phase extraction is 99.3% for DEC and 94.8% for the internal standard.,Specific gas chromatographic analysis of diethylcarbamazine in human plasma using solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9518148/),%,94.8,84767,DB00592,Piperazine
more,30302773,half-life (T½),"We identified a long half-life (T½) of more than 75 hr and a maximum plasma concentration (CMAX ) of 1.69 µg/ml, which is above the minimal inhibitory concentrations for different aspergillus isolates.",Population pharmacokinetics of itraconazole solution after a single oral administration in captive lesser flamingos (Phoeniconaias minor). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30302773/),h,75,85146,DB00592,Piperazine
,30302773,maximum plasma concentration (CMAX ),"We identified a long half-life (T½) of more than 75 hr and a maximum plasma concentration (CMAX ) of 1.69 µg/ml, which is above the minimal inhibitory concentrations for different aspergillus isolates.",Population pharmacokinetics of itraconazole solution after a single oral administration in captive lesser flamingos (Phoeniconaias minor). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30302773/),[μg] / [ml],1.69,85147,DB00592,Piperazine
,11019654,elimination half-life,"The elimination half-life of digoxin in case 3 patient who continued itraconazole therapy was 8.4 days, which was estimated by nonlinear least squares method from the serum concentrations of digoxin versus time curve.",[Effect of itraconazole on digoxin clearance in patients with congestive heart failure]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11019654/),d,8.4,85157,DB00592,Piperazine
,18201067,IC50,"Among these, compound 34b with excellent in vitro potency (IC50 = 4.3 nM) against DPP-4, high selectivity over other enzymes, and good pharmacokinetic profiles exhibited pronounced in vivo efficacy in an oral glucose tolerance test (OGTT) in lean mice.",Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from beta-aminoamides bearing subsituted triazolopiperazines. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18201067/),nM,4.3,85960,DB00592,Piperazine
,18201067,IC50,"Further refinement of the triazolopiperazines resulted in the discovery of a series of extremely potent compounds with subnanomolar activity against DPP-4 (42b- 49b), that is, 4-fluorobenzyl-substituted compound 46b, which is notable for its superior potency (IC50 = 0.18 nM).",Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from beta-aminoamides bearing subsituted triazolopiperazines. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18201067/),nM,0.18,85961,DB00592,Piperazine
,15132131,Tmax,Median Tmax was 2.5 h for capsules and tablets.,"Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15132131/),h,2.5,86257,DB00592,Piperazine
,15132131,AUC((0-inf)),"Mean AUC((0-inf)) values were 27,094, 26,081 and 25,464 ng.h/ml for 4 x 100-mg capsules, 4 x 100-mg tablets, and 1 x 400-mg tablets, respectively.","Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15132131/),[h·ng] / [ml],"27,094",86258,DB00592,Piperazine
,15132131,AUC((0-inf)),"Mean AUC((0-inf)) values were 27,094, 26,081 and 25,464 ng.h/ml for 4 x 100-mg capsules, 4 x 100-mg tablets, and 1 x 400-mg tablets, respectively.","Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15132131/),[h·ng] / [ml],"26,081",86259,DB00592,Piperazine
,15132131,AUC((0-inf)),"Mean AUC((0-inf)) values were 27,094, 26,081 and 25,464 ng.h/ml for 4 x 100-mg capsules, 4 x 100-mg tablets, and 1 x 400-mg tablets, respectively.","Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15132131/),[h·ng] / [ml],"25,464",86260,DB00592,Piperazine
,15132131,Cmax,"Cmax values were 1748, 1638 and 1606 ng/ml, and t(1/2) values were 15.8, 15.9 and 15.7 h.","Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15132131/),[ng] / [ml],1748,86261,DB00592,Piperazine
,15132131,Cmax,"Cmax values were 1748, 1638 and 1606 ng/ml, and t(1/2) values were 15.8, 15.9 and 15.7 h.","Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15132131/),[ng] / [ml],1638,86262,DB00592,Piperazine
,15132131,Cmax,"Cmax values were 1748, 1638 and 1606 ng/ml, and t(1/2) values were 15.8, 15.9 and 15.7 h.","Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15132131/),[ng] / [ml],1606,86263,DB00592,Piperazine
,15132131,t(1/2),"Cmax values were 1748, 1638 and 1606 ng/ml, and t(1/2) values were 15.8, 15.9 and 15.7 h.","Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15132131/),h,15.8,86264,DB00592,Piperazine
,15132131,t(1/2),"Cmax values were 1748, 1638 and 1606 ng/ml, and t(1/2) values were 15.8, 15.9 and 15.7 h.","Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15132131/),h,15.9,86265,DB00592,Piperazine
,15132131,t(1/2),"Cmax values were 1748, 1638 and 1606 ng/ml, and t(1/2) values were 15.8, 15.9 and 15.7 h.","Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15132131/),h,15.7,86266,DB00592,Piperazine
,29484638,steady-state half-life,"Plasma concentrations peaked 1-3 hours after oral administration and declined thereafter, with a steady-state half-life ranging from 4.2-9.9 hours.","Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29484638/),h,4.2-9.9,86610,DB00592,Piperazine
,6151170,serum half-life,It achieves peak serum concentrations within one hour and has a serum half-life of 2 to 5 hours.,"Buspirone hydrochloride: a unique new anxiolytic agent. Pharmacokinetics, clinical pharmacology, abuse potential and clinical efficacy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6151170/),h,2 to 5,86750,DB00592,Piperazine
,24168312,elimination half-life,"Following IV administration, the mean ± SD elimination half-life, apparent volume of distribution, and plasma total body clearance were 169 ± 53 minutes, 2.53 ± 0.47 L/kg, and 11.15 ± 3.56 mL/min/kg, respectively.","Pharmacokinetics, bioavailability, and hemodynamic effects of trazodone after intravenous and oral administration of a single dose to dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24168312/),min,169,86889,DB00592,Piperazine
,24168312,apparent volume of distribution,"Following IV administration, the mean ± SD elimination half-life, apparent volume of distribution, and plasma total body clearance were 169 ± 53 minutes, 2.53 ± 0.47 L/kg, and 11.15 ± 3.56 mL/min/kg, respectively.","Pharmacokinetics, bioavailability, and hemodynamic effects of trazodone after intravenous and oral administration of a single dose to dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24168312/),[l] / [kg],2.53,86890,DB00592,Piperazine
,24168312,plasma total body clearance,"Following IV administration, the mean ± SD elimination half-life, apparent volume of distribution, and plasma total body clearance were 169 ± 53 minutes, 2.53 ± 0.47 L/kg, and 11.15 ± 3.56 mL/min/kg, respectively.","Pharmacokinetics, bioavailability, and hemodynamic effects of trazodone after intravenous and oral administration of a single dose to dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24168312/),[ml] / [kg·min],11.15,86891,DB00592,Piperazine
,24168312,elimination half-life,"Following oral administration, the mean ± SD elimination half-life and absolute bioavailability were 166 ± 47 minutes and 84.6 ± 13.2%, respectively.","Pharmacokinetics, bioavailability, and hemodynamic effects of trazodone after intravenous and oral administration of a single dose to dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24168312/),min,166,86892,DB00592,Piperazine
,24168312,absolute bioavailability,"Following oral administration, the mean ± SD elimination half-life and absolute bioavailability were 166 ± 47 minutes and 84.6 ± 13.2%, respectively.","Pharmacokinetics, bioavailability, and hemodynamic effects of trazodone after intravenous and oral administration of a single dose to dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24168312/),%,84.6,86893,DB00592,Piperazine
,24168312,Maximum plasma concentration,"Maximum plasma concentration following oral administration was 1.3 ± 0.5 μ/mL, and time to maximum plasma concentration was 445 ± 271 minutes.","Pharmacokinetics, bioavailability, and hemodynamic effects of trazodone after intravenous and oral administration of a single dose to dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24168312/),[μ] / [ml],1.3,86894,DB00592,Piperazine
,24168312,time to maximum plasma concentration,"Maximum plasma concentration following oral administration was 1.3 ± 0.5 μ/mL, and time to maximum plasma concentration was 445 ± 271 minutes.","Pharmacokinetics, bioavailability, and hemodynamic effects of trazodone after intravenous and oral administration of a single dose to dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24168312/),min,445,86895,DB00592,Piperazine
,16490405,flow rate,"After sample preparation by protein precipitation with methanol, ulifloxacin and ofloxacin (internal standard) were chromatographically separated on a C(18) column using a mobile phase consisting of methanol, water and formic acid (70:30:0.2, v/v/v) at a flow rate of 0.5 ml/min and then were detected using MS/MS by monitoring their precursor-to-product ion transitions, m/z 350-->m/z 248 for ulifloxacin and m/z 362-->m/z 261 for ofloxacin, in selected reaction monitoring (SRM) mode.",Determination of the active metabolite of prulifloxacin in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490405/),[ml] / [min],0.5,87170,DB00592,Piperazine
,16490405,recovery,"The recovery ranged from 92.1 to 98.2% at the concentrations of 0.025, 0.50 and 5.0 microg/ml.",Determination of the active metabolite of prulifloxacin in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490405/),%,92.1 to 98.2,87171,DB00592,Piperazine
<,20582493,lag time,"All tablet formulas achieved < 0.5 min of floating lag time, more than 12 h of floating duration, and extended t (1/2).",Floating tablet of trimetazidine dihydrochloride: an approach for extended release with zero-order kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20582493/),min,0.5,87359,DB00592,Piperazine
more,20582493,duration,"All tablet formulas achieved < 0.5 min of floating lag time, more than 12 h of floating duration, and extended t (1/2).",Floating tablet of trimetazidine dihydrochloride: an approach for extended release with zero-order kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20582493/),h,12,87360,DB00592,Piperazine
,26341813,AUC0-inf ratios,"The predicted AUC0-inf ratios for the interaction with ketoconazole and erythromycin were 7.7 and 1.9, respectively.",Effects of Cytochrome P450 3A4 Inhibitors-Ketoconazole and Erythromycin-on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26341813/),,7.7,87366,DB00592,Piperazine
,26341813,AUC0-inf ratios,"The predicted AUC0-inf ratios for the interaction with ketoconazole and erythromycin were 7.7 and 1.9, respectively.",Effects of Cytochrome P450 3A4 Inhibitors-Ketoconazole and Erythromycin-on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26341813/),,1.9,87367,DB00592,Piperazine
,31125491,Tmax,"Tmax was 2-3 hour, regardless of race.","A safety, pharmacokinetic, pharmacogenomic and population pharmacokinetic analysis of the third-generation EGFR TKI, olmutinib (HM61713), after single oral administration in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31125491/),h,2-3,87528,DB00592,Piperazine
,31125491,terminal half-life,"The mean terminal half-life ranged from 4.8 to 7.4 hour, with no significant differences between dose or racial groups.","A safety, pharmacokinetic, pharmacogenomic and population pharmacokinetic analysis of the third-generation EGFR TKI, olmutinib (HM61713), after single oral administration in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31125491/),h,4.8 to 7.4,87529,DB00592,Piperazine
,15883819,maximum concentration,"The pharmacokinetic values for imatinib and CGP74588, respectively, were: maximum concentration (3,340 and 781 ng/ml), time to maximum concentration (2 h), half-life (18.2 and 34.0 h), area under the curve (53.9 and 14.8 microg.h/ml), and trough concentration (1,540 and 508 ng/ml) for at least 24 h.",Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15883819/),[ng] / [ml],"3,340",87590,DB00592,Piperazine
,15883819,maximum concentration,"The pharmacokinetic values for imatinib and CGP74588, respectively, were: maximum concentration (3,340 and 781 ng/ml), time to maximum concentration (2 h), half-life (18.2 and 34.0 h), area under the curve (53.9 and 14.8 microg.h/ml), and trough concentration (1,540 and 508 ng/ml) for at least 24 h.",Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15883819/),[ng] / [ml],781,87591,DB00592,Piperazine
,15883819,time to maximum concentration,"The pharmacokinetic values for imatinib and CGP74588, respectively, were: maximum concentration (3,340 and 781 ng/ml), time to maximum concentration (2 h), half-life (18.2 and 34.0 h), area under the curve (53.9 and 14.8 microg.h/ml), and trough concentration (1,540 and 508 ng/ml) for at least 24 h.",Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15883819/),h,2,87592,DB00592,Piperazine
,15883819,half-life,"The pharmacokinetic values for imatinib and CGP74588, respectively, were: maximum concentration (3,340 and 781 ng/ml), time to maximum concentration (2 h), half-life (18.2 and 34.0 h), area under the curve (53.9 and 14.8 microg.h/ml), and trough concentration (1,540 and 508 ng/ml) for at least 24 h.",Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15883819/),h,18.2,87593,DB00592,Piperazine
,15883819,half-life,"The pharmacokinetic values for imatinib and CGP74588, respectively, were: maximum concentration (3,340 and 781 ng/ml), time to maximum concentration (2 h), half-life (18.2 and 34.0 h), area under the curve (53.9 and 14.8 microg.h/ml), and trough concentration (1,540 and 508 ng/ml) for at least 24 h.",Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15883819/),h,34.0,87594,DB00592,Piperazine
,15883819,area under the curve,"The pharmacokinetic values for imatinib and CGP74588, respectively, were: maximum concentration (3,340 and 781 ng/ml), time to maximum concentration (2 h), half-life (18.2 and 34.0 h), area under the curve (53.9 and 14.8 microg.h/ml), and trough concentration (1,540 and 508 ng/ml) for at least 24 h.",Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15883819/),[h·μg] / [ml],53.9,87595,DB00592,Piperazine
,15883819,area under the curve,"The pharmacokinetic values for imatinib and CGP74588, respectively, were: maximum concentration (3,340 and 781 ng/ml), time to maximum concentration (2 h), half-life (18.2 and 34.0 h), area under the curve (53.9 and 14.8 microg.h/ml), and trough concentration (1,540 and 508 ng/ml) for at least 24 h.",Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15883819/),[h·μg] / [ml],14.8,87596,DB00592,Piperazine
,15883819,trough concentration,"The pharmacokinetic values for imatinib and CGP74588, respectively, were: maximum concentration (3,340 and 781 ng/ml), time to maximum concentration (2 h), half-life (18.2 and 34.0 h), area under the curve (53.9 and 14.8 microg.h/ml), and trough concentration (1,540 and 508 ng/ml) for at least 24 h.",Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15883819/),[ng] / [ml],"1,540",87597,DB00592,Piperazine
,15883819,trough concentration,"The pharmacokinetic values for imatinib and CGP74588, respectively, were: maximum concentration (3,340 and 781 ng/ml), time to maximum concentration (2 h), half-life (18.2 and 34.0 h), area under the curve (53.9 and 14.8 microg.h/ml), and trough concentration (1,540 and 508 ng/ml) for at least 24 h.",Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15883819/),[ng] / [ml],508,87598,DB00592,Piperazine
,7897151,area under the curve,"When hydroxyzine was administered with cimetidine, the partial hydroxyzine area under the curve increased significantly (p < 0.05) to 303 +/- 92 ng/ml/hr from 227 +/- 77 ng/ml/hr after administration of hydroxyzine alone, and the concentration of cetirizine arising from hydroxyzine was lower.",Effect of the H2-antagonist cimetidine on the pharmacokinetics and pharmacodynamics of the H1-antagonists hydroxyzine and cetirizine in patients with chronic urticaria. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7897151/),[ng] / [h·ml],303,87715,DB00592,Piperazine
,7897151,area under the curve,"When hydroxyzine was administered with cimetidine, the partial hydroxyzine area under the curve increased significantly (p < 0.05) to 303 +/- 92 ng/ml/hr from 227 +/- 77 ng/ml/hr after administration of hydroxyzine alone, and the concentration of cetirizine arising from hydroxyzine was lower.",Effect of the H2-antagonist cimetidine on the pharmacokinetics and pharmacodynamics of the H1-antagonists hydroxyzine and cetirizine in patients with chronic urticaria. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7897151/),[ng] / [h·ml],227,87716,DB00592,Piperazine
,32935287,time to steady state,"Itraconazole 200 mg/day elevated steady-state exposure to 5 mg/day balovaptan approximately 4.5-5.5-fold (Day 15 GMR [90% CI], 4.46 [4.06-4.90] for Cmax and 5.57 [5.00-6.21] for AUC) and extended the time to steady state from ~ 5 days to ~ 13-14 days.",Open-Label Assessment of the Effects of Itraconazole and Rifampicin on Balovaptan Pharmacokinetics in Healthy Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32935287/),d,5,87831,DB00592,Piperazine
,32935287,time to steady state,"Itraconazole 200 mg/day elevated steady-state exposure to 5 mg/day balovaptan approximately 4.5-5.5-fold (Day 15 GMR [90% CI], 4.46 [4.06-4.90] for Cmax and 5.57 [5.00-6.21] for AUC) and extended the time to steady state from ~ 5 days to ~ 13-14 days.",Open-Label Assessment of the Effects of Itraconazole and Rifampicin on Balovaptan Pharmacokinetics in Healthy Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32935287/),d,13-14,87832,DB00592,Piperazine
,24309556,flow rate,The four drugs were separated by high-performance liquid chromatography using a C18 column and an isocratic mobile phase running at a flow rate of 0.2mL/min for 5min.,"Simultaneous microdetermination of bosentan, ambrisentan, sildenafil, and tadalafil in plasma using liquid chromatography/tandem mass spectrometry for pediatric patients with pulmonary arterial hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24309556/),[ml] / [min],0.2,88314,DB00592,Piperazine
,16533791,IC50,The IC50 of YM-359445 for VEGFR2 tyrosine kinase was 0.0085 micromol/L.,"YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16533791/),[μM] / [l],0.0085,88615,DB00592,Piperazine
,10211868,"liver-plasma unbound concentration ratio, K(pu)","The liver-plasma unbound concentration ratio, K(pu), of GPFX (1.7) was also higher than that of LFLX (0.7).","Differences in the hepatobiliary transport of two quinolone antibiotics, grepafloxacin and lomefloxacin, in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211868/),,1.7,88885,DB00592,Piperazine
,10211868,"liver-plasma unbound concentration ratio, K(pu)","The liver-plasma unbound concentration ratio, K(pu), of GPFX (1.7) was also higher than that of LFLX (0.7).","Differences in the hepatobiliary transport of two quinolone antibiotics, grepafloxacin and lomefloxacin, in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211868/),,0.7,88886,DB00592,Piperazine
,10211868,bile-liver unbound concentration ratio,"The bile-liver unbound concentration ratio of GPFX and LFLX was approximately 6 and 3, respectively, and the biliary clearance based on the unbound liver concentration of GPFX was 1.8 times that of LFLX.","Differences in the hepatobiliary transport of two quinolone antibiotics, grepafloxacin and lomefloxacin, in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211868/),,6,88887,DB00592,Piperazine
,10211868,bile-liver unbound concentration ratio,"The bile-liver unbound concentration ratio of GPFX and LFLX was approximately 6 and 3, respectively, and the biliary clearance based on the unbound liver concentration of GPFX was 1.8 times that of LFLX.","Differences in the hepatobiliary transport of two quinolone antibiotics, grepafloxacin and lomefloxacin, in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211868/),,3,88888,DB00592,Piperazine
less,3972759,MICs,"The isolate of Can. albicans used, and isolates obtained after treatment with the antifungals, were susceptible to all three drugs (MICs less than or equal to 0.5 mg/l).","New azole compounds: vibunazole (Bay n7133) and Bay L9139, compared with ketoconazole in the therapy of systemic candidosis and in pharmacokinetic studies, in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3972759/),[mg] / [l],0.5,89249,DB00592,Piperazine
,23463771,flow rate,"Chromatographic separation was achieved on a Phenomenex C18 (4.6 × 50 mm, 5 µm) column with 0.1% formic acid-acetonitrile (10:90, v/v) as the mobile phase with flow rate of 0.6 mL/min.",Liquid chromatography-tandem mass spectrometry method for simultaneous quantification of urapidil and aripiprazole in human plasma and its application to human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23463771/),[ml] / [min],0.6,89530,DB00592,Piperazine
,23463771,recovery,Mean recovery was in the range of 69.94-75.62% for both analytes and internal standards.,Liquid chromatography-tandem mass spectrometry method for simultaneous quantification of urapidil and aripiprazole in human plasma and its application to human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23463771/),%,69.94-75.62,89531,DB00592,Piperazine
,12733855,slowest rate,"She had significant drowsiness in the first 6 hours, associated with hypotension (systolic BP < 90 mmHg; lowest BP 70/30 mmHg) for 18 hours, and mild bradycardia (slowest rate of 56 bpm).",Nefazodone poisoning: toxicokinetics and toxicodynamics using continuous data collection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12733855/),bpm,56,90127,DB00592,Piperazine
,12733855,terminal elimination half-life,"The terminal elimination half-life for nefazodone was 8.3 hours, and its metabolite hydroxy(OH)-nefazodone was 14.6 hours.",Nefazodone poisoning: toxicokinetics and toxicodynamics using continuous data collection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12733855/),h,8.3,90128,DB00592,Piperazine
,12733855,terminal elimination half-life,"The terminal elimination half-life for nefazodone was 8.3 hours, and its metabolite hydroxy(OH)-nefazodone was 14.6 hours.",Nefazodone poisoning: toxicokinetics and toxicodynamics using continuous data collection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12733855/),h,14.6,90129,DB00592,Piperazine
,12733855,HR,HR remained between 56 and 66 bpm for 30 hours despite hypotension.,Nefazodone poisoning: toxicokinetics and toxicodynamics using continuous data collection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12733855/),,56,90130,DB00592,Piperazine
,2557762,bioavailability,The oxazine ring of ofloxacin provides excellent oral absorption with virtually 95 percent bioavailability; this modification also has prevented metabolism and has provided a long half-life of seven to eight hours.,Chemical evolution of the fluoroquinolone antimicrobial agents. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2557762/),%,95,90487,DB00592,Piperazine
,2557762,half-life,The oxazine ring of ofloxacin provides excellent oral absorption with virtually 95 percent bioavailability; this modification also has prevented metabolism and has provided a long half-life of seven to eight hours.,Chemical evolution of the fluoroquinolone antimicrobial agents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2557762/),h,seven to eight,90488,DB00592,Piperazine
,22263871,heart rate,He was found to be bradycardic with a heart rate of 42/min.,"Ranolazine, tacrolimus, and diltiazem might be a hazardous combination in a transplant patient. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22263871/),1/[min],42,90698,DB00592,Piperazine
,22263871,trough,"The tacrolimus trough was elevated at 14 ng/mL, which decreased after stopping ranolazine, reaching 7 ng/mL after 3 days, while continuing the same dose of tacrolimus.","Ranolazine, tacrolimus, and diltiazem might be a hazardous combination in a transplant patient. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22263871/),[ng] / [ml],14,90699,DB00592,Piperazine
,22263871,trough,"The tacrolimus trough was elevated at 14 ng/mL, which decreased after stopping ranolazine, reaching 7 ng/mL after 3 days, while continuing the same dose of tacrolimus.","Ranolazine, tacrolimus, and diltiazem might be a hazardous combination in a transplant patient. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22263871/),[ng] / [ml],7,90700,DB00592,Piperazine
,28535410,elimination half-life (t1/2),"In vitro studies and Phase I trials indicate that perampanel is metabolized almost exclusively by CYP3A, with an elimination half-life (t1/2) averaging approximately 105h.",Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28535410/),h,105,90742,DB00592,Piperazine
high,28535410,AUC ratio,"Simulations further suggested that an interaction effect of ketoconazole on perampanel exposure (>2-fold) of potential clinical significance could be predicted when using larger doses of ketoconazole (e.g., 200mg every 6h) coadministered for a greater time period (e.g., 30days), with AUC ratio as high as 3.36.",Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28535410/),,3.36,90743,DB00592,Piperazine
,18514457,retention time,"The retention time of mianserin and cinnarizine was 3.4 and 2.1 min, respectively.",Determination of mianserin in human plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-ESI/MS): application to a bioequivalence study in Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18514457/),min,3.4,90863,DB00592,Piperazine
,18514457,retention time,"The retention time of mianserin and cinnarizine was 3.4 and 2.1 min, respectively.",Determination of mianserin in human plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-ESI/MS): application to a bioequivalence study in Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18514457/),min,2.1,90864,DB00592,Piperazine
,18514457,recovery,"The recovery was 81.3-84.1%, intra- and inter-day precision of the assay at three concentrations were 9.6-11.4% with accuracy of 97.5-101.2% and the lower limit of quantitation (LLOQ) detection was 1.0 ng/ml for mianserin.",Determination of mianserin in human plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-ESI/MS): application to a bioequivalence study in Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18514457/),%,81.3-84.1,90865,DB00592,Piperazine
,26242220,t max,"Rate of olaparib absorption was slower in the presence of food (t max delayed by 2.5 h), resulting in a statistically significant ~21 % decrease in peak plasma exposure (C max) [ratio of geometric means (90 % CI), 0.79 (0.72, 0.86)] but only a marginal increase in olaparib absorption (AUC0-∞) [ratio of geometric means (90 % CI), 1.08 (1.01, 1.16)].",Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26242220/),h,2.5,91323,DB00592,Piperazine
,7814285,serum concentration,"The mean pre-dose itraconazole serum concentration at hour 0, day 8 was 385 ng/mL in the od group and 394 ng/mL in the bd group, rising to 762 and 845 ng/mL by day 15, respectively.",Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7814285/),[ng] / [ml],385,91455,DB00592,Piperazine
,7814285,serum concentration,"The mean pre-dose itraconazole serum concentration at hour 0, day 8 was 385 ng/mL in the od group and 394 ng/mL in the bd group, rising to 762 and 845 ng/mL by day 15, respectively.",Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7814285/),[ng] / [ml],394,91456,DB00592,Piperazine
,7814285,serum concentration,"The mean pre-dose itraconazole serum concentration at hour 0, day 8 was 385 ng/mL in the od group and 394 ng/mL in the bd group, rising to 762 and 845 ng/mL by day 15, respectively.",Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7814285/),[ng] / [ml],762,91457,DB00592,Piperazine
,7814285,serum concentration,"The mean pre-dose itraconazole serum concentration at hour 0, day 8 was 385 ng/mL in the od group and 394 ng/mL in the bd group, rising to 762 and 845 ng/mL by day 15, respectively.",Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7814285/),[ng] / [ml],845,91458,DB00592,Piperazine
,7814285,AUCs for 0-24 h,"The mean AUCs for 0-24 h on day 8, 15 and 22 were 17,310 and 13,302 ng/mL/h, 24,476 and 25,154 and 22,621 and 21,423, for the od and bd groups, respectively.",Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7814285/),[ng] / [h·ml],"17,310",91459,DB00592,Piperazine
,7814285,AUCs for 0-24 h,"The mean AUCs for 0-24 h on day 8, 15 and 22 were 17,310 and 13,302 ng/mL/h, 24,476 and 25,154 and 22,621 and 21,423, for the od and bd groups, respectively.",Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7814285/),[ng] / [h·ml],"13,302",91460,DB00592,Piperazine
,7814285,AUCs for 0-24 h,"The mean AUCs for 0-24 h on day 8, 15 and 22 were 17,310 and 13,302 ng/mL/h, 24,476 and 25,154 and 22,621 and 21,423, for the od and bd groups, respectively.",Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7814285/),,"24,476",91461,DB00592,Piperazine
,7814285,AUCs for 0-24 h,"The mean AUCs for 0-24 h on day 8, 15 and 22 were 17,310 and 13,302 ng/mL/h, 24,476 and 25,154 and 22,621 and 21,423, for the od and bd groups, respectively.",Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7814285/),[ng] / [h·ml],"25,154",91462,DB00592,Piperazine
,7814285,AUCs for 0-24 h,"The mean AUCs for 0-24 h on day 8, 15 and 22 were 17,310 and 13,302 ng/mL/h, 24,476 and 25,154 and 22,621 and 21,423, for the od and bd groups, respectively.",Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7814285/),[ng] / [h·ml],"22,621",91463,DB00592,Piperazine
,7814285,AUCs for 0-24 h,"The mean AUCs for 0-24 h on day 8, 15 and 22 were 17,310 and 13,302 ng/mL/h, 24,476 and 25,154 and 22,621 and 21,423, for the od and bd groups, respectively.",Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7814285/),[ng] / [h·ml],"21,423",91464,DB00592,Piperazine
,10866139,terminal elimination half-life,"After i.v. injection, serum itraconazole concentrations decreased biexponentially, with an average terminal elimination half-life, volume of distribution and systemic clearance of 4.9 h, 6.0 l/kg and 14.2 ml/min/kg, respectively.","Absorption, first-pass metabolism, and disposition of itraconazole in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866139/),h,4.9,91563,DB00592,Piperazine
,10866139,volume of distribution,"After i.v. injection, serum itraconazole concentrations decreased biexponentially, with an average terminal elimination half-life, volume of distribution and systemic clearance of 4.9 h, 6.0 l/kg and 14.2 ml/min/kg, respectively.","Absorption, first-pass metabolism, and disposition of itraconazole in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866139/),[l] / [kg],6.0,91564,DB00592,Piperazine
,10866139,systemic clearance,"After i.v. injection, serum itraconazole concentrations decreased biexponentially, with an average terminal elimination half-life, volume of distribution and systemic clearance of 4.9 h, 6.0 l/kg and 14.2 ml/min/kg, respectively.","Absorption, first-pass metabolism, and disposition of itraconazole in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866139/),[ml] / [kg·min],14.2,91565,DB00592,Piperazine
,10866139,absolute bioavailability,"When given orally, its absorption was low, with a mean absolute bioavailability of 16.6%.","Absorption, first-pass metabolism, and disposition of itraconazole in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866139/),%,16.6,91566,DB00592,Piperazine
,10866139,hepatic drug extraction ratio,The hepatic drug extraction ratio determined after femoral and portal vein administration averaged 18.5%.,"Absorption, first-pass metabolism, and disposition of itraconazole in rats. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866139/),%,18.5,91567,DB00592,Piperazine
,10866139,elimination half-life,"When hydroxyitraconazole was injected i.v., the elimination half-life, volume of distribution and systemic clearance of itraconazole averaged 10.0 h, 2.4 l/kg and 3.4 ml/min/kg, respectively.","Absorption, first-pass metabolism, and disposition of itraconazole in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866139/),h,10.0,91568,DB00592,Piperazine
,10866139,volume of distribution,"When hydroxyitraconazole was injected i.v., the elimination half-life, volume of distribution and systemic clearance of itraconazole averaged 10.0 h, 2.4 l/kg and 3.4 ml/min/kg, respectively.","Absorption, first-pass metabolism, and disposition of itraconazole in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866139/),[l] / [kg],2.4,91569,DB00592,Piperazine
,10866139,systemic clearance,"When hydroxyitraconazole was injected i.v., the elimination half-life, volume of distribution and systemic clearance of itraconazole averaged 10.0 h, 2.4 l/kg and 3.4 ml/min/kg, respectively.","Absorption, first-pass metabolism, and disposition of itraconazole in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866139/),[ml] / [kg·min],3.4,91570,DB00592,Piperazine
,28363155,EC50,"Five compounds 16, 19, 20, 21 and 22 significantly inhibited proliferation of androgen-sensitive LNCaP prostatic cell line with EC50 values of 12.4 μM, 15.6 μM, 11.8 μM, 10.4 μM, 12.2 μM respectively and decreased Ca2+ entry through adrenergic-receptor α1A blocking activity.",Novel aryl piperazines for alleviation of 'andropause' associated prostatic disorders and depression. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363155/),μM,12.4,91701,DB00592,Piperazine
,28363155,EC50,"Five compounds 16, 19, 20, 21 and 22 significantly inhibited proliferation of androgen-sensitive LNCaP prostatic cell line with EC50 values of 12.4 μM, 15.6 μM, 11.8 μM, 10.4 μM, 12.2 μM respectively and decreased Ca2+ entry through adrenergic-receptor α1A blocking activity.",Novel aryl piperazines for alleviation of 'andropause' associated prostatic disorders and depression. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363155/),μM,15.6,91702,DB00592,Piperazine
,28363155,EC50,"Five compounds 16, 19, 20, 21 and 22 significantly inhibited proliferation of androgen-sensitive LNCaP prostatic cell line with EC50 values of 12.4 μM, 15.6 μM, 11.8 μM, 10.4 μM, 12.2 μM respectively and decreased Ca2+ entry through adrenergic-receptor α1A blocking activity.",Novel aryl piperazines for alleviation of 'andropause' associated prostatic disorders and depression. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363155/),μM,11.8,91703,DB00592,Piperazine
,28363155,EC50,"Five compounds 16, 19, 20, 21 and 22 significantly inhibited proliferation of androgen-sensitive LNCaP prostatic cell line with EC50 values of 12.4 μM, 15.6 μM, 11.8 μM, 10.4 μM, 12.2 μM respectively and decreased Ca2+ entry through adrenergic-receptor α1A blocking activity.",Novel aryl piperazines for alleviation of 'andropause' associated prostatic disorders and depression. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363155/),μM,10.4,91704,DB00592,Piperazine
,28363155,EC50,"Five compounds 16, 19, 20, 21 and 22 significantly inhibited proliferation of androgen-sensitive LNCaP prostatic cell line with EC50 values of 12.4 μM, 15.6 μM, 11.8 μM, 10.4 μM, 12.2 μM respectively and decreased Ca2+ entry through adrenergic-receptor α1A blocking activity.",Novel aryl piperazines for alleviation of 'andropause' associated prostatic disorders and depression. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363155/),μM,12.2,91705,DB00592,Piperazine
,28363155,oral bioavailability,Pharmacokinetic and tissue uptake of 19 at 10 mg/kg demonstrated an oral bioavailability of 35.4%.,Novel aryl piperazines for alleviation of 'andropause' associated prostatic disorders and depression. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363155/),%,35.4,91706,DB00592,Piperazine
>,16250654,pK(i),Varying the functionality and substitution pattern of substituents in the 7-aryl ring and varying the chirality of this exocyclic ring have produced potent oxytocin antagonists (pK(i) > 8.5).,"2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16250654/),,8.5,91938,DB00592,Piperazine
,16250654,bioavailability,It has good bioavailability (46%) in the rat and moderate bioavailability (13-31%) in the dog and is more active in vivo in the rat than atosiban (rat DR(10) = 0.44 mg/kg iv).,"2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16250654/),%,46,91939,DB00592,Piperazine
,16250654,bioavailability,It has good bioavailability (46%) in the rat and moderate bioavailability (13-31%) in the dog and is more active in vivo in the rat than atosiban (rat DR(10) = 0.44 mg/kg iv).,"2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16250654/),%,13-31,91940,DB00592,Piperazine
,2150527,Elimination half-life,Elimination half-life was estimated at 1-2 days.,A tolerance study of single and multiple dosing of the selective dopamine uptake inhibitor GBR 12909 in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2150527/),d,1-2,92188,DB00592,Piperazine
,9010708,Cmax,Itraconazole significantly increased the Cmax of zopiclone from 49 to 63 ng.,Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010708/),ng,49,92194,DB00592,Piperazine
,9010708,Cmax,Itraconazole significantly increased the Cmax of zopiclone from 49 to 63 ng.,Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010708/),ng,63,92195,DB00592,Piperazine
,9010708,t 1/2,The t 1/2 of zopiclone was prolonged from 5.0 to 7.0 h.,Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010708/),h,5,92196,DB00592,Piperazine
,9010708,AUC(0-inifinity),The AUC(0-inifinity) of zopiclone was increased from 415 to 719 ng.,Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010708/),ng,415,92197,DB00592,Piperazine
,9010708,AUC(0-inifinity),The AUC(0-inifinity) of zopiclone was increased from 415 to 719 ng.,Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010708/),ng,719,92198,DB00592,Piperazine
,28577239,Clearance,Clearance (6.8 L/h) and volume (33 L) estimates were comparable with literature.,Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28577239/),[l] / [h],6.8,92448,DB00592,Piperazine
,28577239,volume,Clearance (6.8 L/h) and volume (33 L) estimates were comparable with literature.,Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28577239/),l,33,92449,DB00592,Piperazine
,24726088,corrected efflux ratios,"The in vitro study revealed corrected efflux ratios for teneligliptin of 6.81 and 5.27 at teneligliptin concentrations of 1 and 10 μM, respectively.",Effect of ketoconazole on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor teneligliptin: an open-label study in healthy white subjects in Germany. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24726088/),,6.81,93117,DB00592,Piperazine
,24726088,corrected efflux ratios,"The in vitro study revealed corrected efflux ratios for teneligliptin of 6.81 and 5.27 at teneligliptin concentrations of 1 and 10 μM, respectively.",Effect of ketoconazole on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor teneligliptin: an open-label study in healthy white subjects in Germany. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24726088/),,5.27,93118,DB00592,Piperazine
,7032872,elimination half-life,Trazodone is excreted primarily as metabolites by the kidneys and possesses a biphasic elimination half-life of 4.4 hours for the first 10 hours and 7.5 hours for the next 24 hours.,"Trazodone (Desyrel, Mead-Johnson Pharmaceutical Division). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7032872/),h,4.4,93210,DB00592,Piperazine
,7032872,elimination half-life,Trazodone is excreted primarily as metabolites by the kidneys and possesses a biphasic elimination half-life of 4.4 hours for the first 10 hours and 7.5 hours for the next 24 hours.,"Trazodone (Desyrel, Mead-Johnson Pharmaceutical Division). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7032872/),h,7.5,93211,DB00592,Piperazine
,20151942,C(max) (maximum concentration),"The C(max) (maximum concentration), T(max), and MRT of T(1) were 311.7 ng/mL, 5.3 h and 8.3 h, respectively.",Preparation of pH-dependent modified-release pellets of urapidil to improve its bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20151942/),[ng] / [ml],311.7,93385,DB00592,Piperazine
,20151942,T(max),"The C(max) (maximum concentration), T(max), and MRT of T(1) were 311.7 ng/mL, 5.3 h and 8.3 h, respectively.",Preparation of pH-dependent modified-release pellets of urapidil to improve its bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20151942/),h,5.3,93386,DB00592,Piperazine
,20151942,MRT,"The C(max) (maximum concentration), T(max), and MRT of T(1) were 311.7 ng/mL, 5.3 h and 8.3 h, respectively.",Preparation of pH-dependent modified-release pellets of urapidil to improve its bioavailability. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20151942/),h,8.3,93387,DB00592,Piperazine
,20151942,relative bioavailability,"T(1) was bioequivalent to R, with a relative bioavailability 110.9%.",Preparation of pH-dependent modified-release pellets of urapidil to improve its bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20151942/),%,110.9,93388,DB00592,Piperazine
,20151942,C(max),"The C(max) and T(max), of T(2) were 105.3 ng/mL and 13.3 h, respectively, and the relative bioavailability was 72.7%.",Preparation of pH-dependent modified-release pellets of urapidil to improve its bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20151942/),[ng] / [ml],105.3,93389,DB00592,Piperazine
,20151942,T(max),"The C(max) and T(max), of T(2) were 105.3 ng/mL and 13.3 h, respectively, and the relative bioavailability was 72.7%.",Preparation of pH-dependent modified-release pellets of urapidil to improve its bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20151942/),h,13.3,93390,DB00592,Piperazine
,20151942,relative bioavailability,"The C(max) and T(max), of T(2) were 105.3 ng/mL and 13.3 h, respectively, and the relative bioavailability was 72.7%.",Preparation of pH-dependent modified-release pellets of urapidil to improve its bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20151942/),%,72.7,93391,DB00592,Piperazine
,15606437,CL/F,"Population estimates in children with weights of 8 and 20 kg were 0.60 and 1.13 l h(-1) for CL/F, and 5.1 and 12.8 l for V/F, respectively, with interpatient variabilities of 24.4% and 14.7%.",Retrospective population pharmacokinetics of levocetirizine in atopic children receiving cetirizine: the ETAC study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606437/),[l] / [h],0.60,93395,DB00592,Piperazine
,15606437,CL/F,"Population estimates in children with weights of 8 and 20 kg were 0.60 and 1.13 l h(-1) for CL/F, and 5.1 and 12.8 l for V/F, respectively, with interpatient variabilities of 24.4% and 14.7%.",Retrospective population pharmacokinetics of levocetirizine in atopic children receiving cetirizine: the ETAC study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606437/),[l] / [h],1.13,93396,DB00592,Piperazine
,15606437,V/F,"Population estimates in children with weights of 8 and 20 kg were 0.60 and 1.13 l h(-1) for CL/F, and 5.1 and 12.8 l for V/F, respectively, with interpatient variabilities of 24.4% and 14.7%.",Retrospective population pharmacokinetics of levocetirizine in atopic children receiving cetirizine: the ETAC study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606437/),l,5.1,93397,DB00592,Piperazine
,15606437,V/F,"Population estimates in children with weights of 8 and 20 kg were 0.60 and 1.13 l h(-1) for CL/F, and 5.1 and 12.8 l for V/F, respectively, with interpatient variabilities of 24.4% and 14.7%.",Retrospective population pharmacokinetics of levocetirizine in atopic children receiving cetirizine: the ETAC study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606437/),l,12.8,93398,DB00592,Piperazine
,15606437,relative bioavailability,The estimated relative bioavailability was 0.28 in 12% of instances of suspected noncompliance.,Retrospective population pharmacokinetics of levocetirizine in atopic children receiving cetirizine: the ETAC study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606437/),,0.28,93399,DB00592,Piperazine
,15606437,AUC(ss),"AUC(ss), calculated in compliant subjects using posterior estimates of the final model, was 1952 (1227-3319) microg l(-1) h (mean, min-max), a value similar to that in adults after intake of 5 mg oral solution (2036 (1414-2827) microg l(-1) h.",Retrospective population pharmacokinetics of levocetirizine in atopic children receiving cetirizine: the ETAC study. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606437/),[h·μg] / [l],1952,93400,DB00592,Piperazine
,15606437,AUC(ss),"AUC(ss), calculated in compliant subjects using posterior estimates of the final model, was 1952 (1227-3319) microg l(-1) h (mean, min-max), a value similar to that in adults after intake of 5 mg oral solution (2036 (1414-2827) microg l(-1) h.",Retrospective population pharmacokinetics of levocetirizine in atopic children receiving cetirizine: the ETAC study. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606437/),[h·μg] / [l],2036,93401,DB00592,Piperazine
,3515929,systemic availability,The mean systemic availability is approximately 4 percent.,Metabolism and disposition of buspirone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3515929/),%,4,93421,DB00592,Piperazine
,3515929,Half-life,Half-life values observed in healthy volunteers ranged from two to 33 hours.,Metabolism and disposition of buspirone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3515929/),h,two to 33,93422,DB00592,Piperazine
,3515929,half-life,Mean half-life values observed in healthy volunteers in the 14 studies conducted to date ranged from 2 +/- 1 to 11 +/- 3 hours.,Metabolism and disposition of buspirone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3515929/),h,2,93423,DB00592,Piperazine
,3515929,half-life,Mean half-life values observed in healthy volunteers in the 14 studies conducted to date ranged from 2 +/- 1 to 11 +/- 3 hours.,Metabolism and disposition of buspirone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3515929/),h,11,93424,DB00592,Piperazine
,9665503,Tmax,Mean Tmax values were similar and ranged from 1.0 +/- 0.3/hour for indinavir 800 mg administered alone to 1.3 +/- 0.4/hour for indinavir 600 mg administered with delavirdine.,Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9665503/),1/[h],1.0,93557,DB00592,Piperazine
,9665503,Tmax,Mean Tmax values were similar and ranged from 1.0 +/- 0.3/hour for indinavir 800 mg administered alone to 1.3 +/- 0.4/hour for indinavir 600 mg administered with delavirdine.,Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9665503/),1/[h],1.3,93558,DB00592,Piperazine
,9665503,AUC0-infinity,"In contrast, the mean indinavir AUC0-infinity, value following the 400-mg dose administered with delavirdine was only 14% lower than the baseline value determined for the 800-mg indinavir dose (25,400 +/- 6960 nM hour versus 29,600 +/- 7920 nM hour), and the mean indinavir AUC0-infinity value for the 600-mg indinavir dose administered with delavirdine (42,700 +/- 9800 nM hour) was 44% greater than the baseline value.",Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9665503/),h·nM,"25,400",93559,DB00592,Piperazine
,9665503,AUC0-infinity,"In contrast, the mean indinavir AUC0-infinity, value following the 400-mg dose administered with delavirdine was only 14% lower than the baseline value determined for the 800-mg indinavir dose (25,400 +/- 6960 nM hour versus 29,600 +/- 7920 nM hour), and the mean indinavir AUC0-infinity value for the 600-mg indinavir dose administered with delavirdine (42,700 +/- 9800 nM hour) was 44% greater than the baseline value.",Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9665503/),h·nM,"29,600",93560,DB00592,Piperazine
,9665503,AUC0-infinity,"In contrast, the mean indinavir AUC0-infinity, value following the 400-mg dose administered with delavirdine was only 14% lower than the baseline value determined for the 800-mg indinavir dose (25,400 +/- 6960 nM hour versus 29,600 +/- 7920 nM hour), and the mean indinavir AUC0-infinity value for the 600-mg indinavir dose administered with delavirdine (42,700 +/- 9800 nM hour) was 44% greater than the baseline value.",Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9665503/),h·nM,"42,700",93561,DB00592,Piperazine
,23089073,plasma concentrations,"The mean±SD of plasma concentrations of ITZ, OH-ITZ, and keto-ITZ were 833±468, 798±454, and 3.94±2.68 μg/l, respectively.",Hydroxy-itraconazole pharmacokinetics is similar to that of itraconazole in immunocompromised patients receiving oral solution of itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23089073/),[μg] / [l],833,94141,DB00592,Piperazine
,23089073,plasma concentrations,"The mean±SD of plasma concentrations of ITZ, OH-ITZ, and keto-ITZ were 833±468, 798±454, and 3.94±2.68 μg/l, respectively.",Hydroxy-itraconazole pharmacokinetics is similar to that of itraconazole in immunocompromised patients receiving oral solution of itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23089073/),[μg] / [l],798,94142,DB00592,Piperazine
,23089073,plasma concentrations,"The mean±SD of plasma concentrations of ITZ, OH-ITZ, and keto-ITZ were 833±468, 798±454, and 3.94±2.68 μg/l, respectively.",Hydroxy-itraconazole pharmacokinetics is similar to that of itraconazole in immunocompromised patients receiving oral solution of itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23089073/),[μg] / [l],3.94,94143,DB00592,Piperazine
,27497648,total run time,The total run time for each sample was 6min.,"Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and dolutegravir in mouse biological matrices by LC-MS/MS and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27497648/),min,6,94165,DB00592,Piperazine
,22789530,apparent clearance (CL/F),"In the first study (study 1, n = 20), semagacestat increased the mean apparent clearance (CL/F) of oral midazolam (76-324 l/h) and nifedipine (63-229 l/h) as predicted from hepatocytes.","The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22789530/),[l] / [h],76-324,94436,DB00592,Piperazine
,22789530,apparent clearance (CL/F),"In the first study (study 1, n = 20), semagacestat increased the mean apparent clearance (CL/F) of oral midazolam (76-324 l/h) and nifedipine (63-229 l/h) as predicted from hepatocytes.","The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22789530/),[l] / [h],63-229,94437,DB00592,Piperazine
,22789530,CL/F,"In a second (steady-state) study (study 2, n = 20), semagacestat CL/F increased from 22 after a single dose to 31 l/h.","The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22789530/),[l] / [h],22,94438,DB00592,Piperazine
,22789530,CL/F,"In a second (steady-state) study (study 2, n = 20), semagacestat CL/F increased from 22 after a single dose to 31 l/h.","The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22789530/),[l] / [h],31,94439,DB00592,Piperazine
,16638734,peak concentration,The peak concentration of buspirone averaged 1141 +/- 748 pg/mL with a time to maximum concentration of 0.8 hours.,Pharmacokinetics of buspirone in autistic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16638734/),[pg] / [ml],1141,94450,DB00592,Piperazine
,16638734,time to maximum concentration,The peak concentration of buspirone averaged 1141 +/- 748 pg/mL with a time to maximum concentration of 0.8 hours.,Pharmacokinetics of buspirone in autistic children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16638734/),h,0.8,94451,DB00592,Piperazine
,16638734,Half-life,Half-life was 1.6 +/- 0.3 hours.,Pharmacokinetics of buspirone in autistic children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16638734/),h,1.6,94452,DB00592,Piperazine
,16638734,peak concentrations,Girls had higher peak concentrations (1876 vs 746 pg/mL) for buspirone and a lower peak 1-PP/buspirone concentration ratio.,Pharmacokinetics of buspirone in autistic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16638734/),[pg] / [ml],1876,94453,DB00592,Piperazine
,16638734,peak concentrations,Girls had higher peak concentrations (1876 vs 746 pg/mL) for buspirone and a lower peak 1-PP/buspirone concentration ratio.,Pharmacokinetics of buspirone in autistic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16638734/),[pg] / [ml],746,94454,DB00592,Piperazine
,23890595,Completion rates,"Completion rates were 36.4% (n=4/11), 50.0% (n=8/16) and 71.4% (n=10/14) for the 200mg, 300 mg and 400mg groups, respectively.","Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23890595/),%,36,94478,DB00592,Piperazine
>,10371783,Cmin,"Therapeutic through drug plasma concentration (Cmin > or = 250 ng/ml of itraconazole, or > or = 750 ng/ml of itraconazole plus hydroxyitraconazole) was not reached in 5/16 patients.",[Prevention of aspergillosis with itraconazole in neutropenic patients: importance of drug monitoring]. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10371783/),[ng] / [ml],250,94665,DB00592,Piperazine
>,10371783,Cmin,"Therapeutic through drug plasma concentration (Cmin > or = 250 ng/ml of itraconazole, or > or = 750 ng/ml of itraconazole plus hydroxyitraconazole) was not reached in 5/16 patients.",[Prevention of aspergillosis with itraconazole in neutropenic patients: importance of drug monitoring]. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10371783/),[ng] / [ml],750,94666,DB00592,Piperazine
,30357650,area under the curve (AUC),"The olaparib geometric mean area under the curve (AUC) and maximal concentration (Cmax) following a single 300 mg tablet were 42.1 μg h/mL and 5.8 μg/mL, respectively, and the steady-state geometric mean AUC and Cmax following a 300 mg tablet twice daily were 49.0 μg h/mL and 7.7 μg/mL, respectively.",Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30357650/),[h·μg] / [ml],42.1,94762,DB00592,Piperazine
,30357650,maximal concentration (Cmax),"The olaparib geometric mean area under the curve (AUC) and maximal concentration (Cmax) following a single 300 mg tablet were 42.1 μg h/mL and 5.8 μg/mL, respectively, and the steady-state geometric mean AUC and Cmax following a 300 mg tablet twice daily were 49.0 μg h/mL and 7.7 μg/mL, respectively.",Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30357650/),[μg] / [ml],5.8,94763,DB00592,Piperazine
,30357650,AUC,"The olaparib geometric mean area under the curve (AUC) and maximal concentration (Cmax) following a single 300 mg tablet were 42.1 μg h/mL and 5.8 μg/mL, respectively, and the steady-state geometric mean AUC and Cmax following a 300 mg tablet twice daily were 49.0 μg h/mL and 7.7 μg/mL, respectively.",Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30357650/),[h·μg] / [ml],49.0,94764,DB00592,Piperazine
,30357650,Cmax,"The olaparib geometric mean area under the curve (AUC) and maximal concentration (Cmax) following a single 300 mg tablet were 42.1 μg h/mL and 5.8 μg/mL, respectively, and the steady-state geometric mean AUC and Cmax following a 300 mg tablet twice daily were 49.0 μg h/mL and 7.7 μg/mL, respectively.",Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30357650/),[μg] / [ml],7.7,94765,DB00592,Piperazine
,33283304,flow rate,"AMG 510 and the IS (MRTX-1257) were extracted from mouse plasma using tert-butyl methyl ether and chromatographed using an isocratic mobile phase (0.2% formic acid:acetonitrile; 25:75, v/v) at a flow rate of 0.65 mL/min on an Atlantis dC18 column.","Validated HPLC-MS/MS method for quantitation of AMG 510, a KRAS G12C inhibitor, in mouse plasma and its application to a pharmacokinetic study in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33283304/),[ml] / [min],0.65,94827,DB00592,Piperazine
,20430905,clearance,"Ketoconazole-modulated docetaxel resulted in reduced docetaxel clearance (22.05 ± 8.29 versus 36.52 ± 13.39 l/h, P < 0.001), similar docetaxel AUC (3.93 ± 2.77 versus 3.77 ± 2.70 mg/l·h, P = 0.794) and tumor efficacy (cycle 1 responder 52% versus 55%) and less day 8 neutrophil suppression (1.24 ± 1.02 × 10⁹/l versus 0.47 ± 0.56 × 10⁹/l, P < 0.001), grade 4 neutropenia (32.3% versus 72.0%, P < 0.001) and febrile neutropenia (3.2 versus 23.5%, P = 0.015), compared with conventional-dosed docetaxel.",Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430905/),[l] / [h],22.05,94859,DB00592,Piperazine
,20430905,clearance,"Ketoconazole-modulated docetaxel resulted in reduced docetaxel clearance (22.05 ± 8.29 versus 36.52 ± 13.39 l/h, P < 0.001), similar docetaxel AUC (3.93 ± 2.77 versus 3.77 ± 2.70 mg/l·h, P = 0.794) and tumor efficacy (cycle 1 responder 52% versus 55%) and less day 8 neutrophil suppression (1.24 ± 1.02 × 10⁹/l versus 0.47 ± 0.56 × 10⁹/l, P < 0.001), grade 4 neutropenia (32.3% versus 72.0%, P < 0.001) and febrile neutropenia (3.2 versus 23.5%, P = 0.015), compared with conventional-dosed docetaxel.",Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430905/),[l] / [h],36.52,94860,DB00592,Piperazine
,20430905,AUC,"Ketoconazole-modulated docetaxel resulted in reduced docetaxel clearance (22.05 ± 8.29 versus 36.52 ± 13.39 l/h, P < 0.001), similar docetaxel AUC (3.93 ± 2.77 versus 3.77 ± 2.70 mg/l·h, P = 0.794) and tumor efficacy (cycle 1 responder 52% versus 55%) and less day 8 neutrophil suppression (1.24 ± 1.02 × 10⁹/l versus 0.47 ± 0.56 × 10⁹/l, P < 0.001), grade 4 neutropenia (32.3% versus 72.0%, P < 0.001) and febrile neutropenia (3.2 versus 23.5%, P = 0.015), compared with conventional-dosed docetaxel.",Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430905/),[mg] / [h·l],3.93,94861,DB00592,Piperazine
,20430905,AUC,"Ketoconazole-modulated docetaxel resulted in reduced docetaxel clearance (22.05 ± 8.29 versus 36.52 ± 13.39 l/h, P < 0.001), similar docetaxel AUC (3.93 ± 2.77 versus 3.77 ± 2.70 mg/l·h, P = 0.794) and tumor efficacy (cycle 1 responder 52% versus 55%) and less day 8 neutrophil suppression (1.24 ± 1.02 × 10⁹/l versus 0.47 ± 0.56 × 10⁹/l, P < 0.001), grade 4 neutropenia (32.3% versus 72.0%, P < 0.001) and febrile neutropenia (3.2 versus 23.5%, P = 0.015), compared with conventional-dosed docetaxel.",Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430905/),[mg] / [h·l],3.77,94862,DB00592,Piperazine
,27476581,BTt1/2,"Following 50 mg enteral camicinal, there was a trend to accelerated gastric emptying [adjusted geometric means: pre-treatment BTt1/2 117 minutes vs. post- treatment 76 minutes; 95 % confidence intervals (CI; 0.39, 1.08) and increased glucose absorption (AUC240min pre-treatment: 28.63 mmol.min/L vs. post-treatment: 71.63 mmol.min/L; 95 % CI (1.68, 3.72)].","The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27476581/),min,117,94864,DB00592,Piperazine
,27476581,BTt1/2,"Following 50 mg enteral camicinal, there was a trend to accelerated gastric emptying [adjusted geometric means: pre-treatment BTt1/2 117 minutes vs. post- treatment 76 minutes; 95 % confidence intervals (CI; 0.39, 1.08) and increased glucose absorption (AUC240min pre-treatment: 28.63 mmol.min/L vs. post-treatment: 71.63 mmol.min/L; 95 % CI (1.68, 3.72)].","The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27476581/),min,76,94865,DB00592,Piperazine
,27476581,AUC240min,"Following 50 mg enteral camicinal, there was a trend to accelerated gastric emptying [adjusted geometric means: pre-treatment BTt1/2 117 minutes vs. post- treatment 76 minutes; 95 % confidence intervals (CI; 0.39, 1.08) and increased glucose absorption (AUC240min pre-treatment: 28.63 mmol.min/L vs. post-treatment: 71.63 mmol.min/L; 95 % CI (1.68, 3.72)].","The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27476581/),[mM·min] / [l],28.63,94866,DB00592,Piperazine
,27476581,AUC240min,"Following 50 mg enteral camicinal, there was a trend to accelerated gastric emptying [adjusted geometric means: pre-treatment BTt1/2 117 minutes vs. post- treatment 76 minutes; 95 % confidence intervals (CI; 0.39, 1.08) and increased glucose absorption (AUC240min pre-treatment: 28.63 mmol.min/L vs. post-treatment: 71.63 mmol.min/L; 95 % CI (1.68, 3.72)].","The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27476581/),[mM·min] / [l],71.63,94867,DB00592,Piperazine
,27476581,BTt1/2,"When two patients who did not have detectable plasma concentrations of camicinal were excluded from analysis, camicinal accelerated gastric emptying (adjusted geometric means: pre-treatment BTt1/2 121 minutes vs. post-treatment 65 minutes 95 % CI (0.32, 0.91) and increased glucose absorption (AUC240min pre-treatment: 33.04 mmol.min/L vs. post-treatment: 74.59 mmol.min/L; 95 % CI (1.478, 3.449).","The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27476581/),min,121,94868,DB00592,Piperazine
,27476581,BTt1/2,"When two patients who did not have detectable plasma concentrations of camicinal were excluded from analysis, camicinal accelerated gastric emptying (adjusted geometric means: pre-treatment BTt1/2 121 minutes vs. post-treatment 65 minutes 95 % CI (0.32, 0.91) and increased glucose absorption (AUC240min pre-treatment: 33.04 mmol.min/L vs. post-treatment: 74.59 mmol.min/L; 95 % CI (1.478, 3.449).","The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27476581/),min,65,94869,DB00592,Piperazine
,27476581,AUC240min,"When two patients who did not have detectable plasma concentrations of camicinal were excluded from analysis, camicinal accelerated gastric emptying (adjusted geometric means: pre-treatment BTt1/2 121 minutes vs. post-treatment 65 minutes 95 % CI (0.32, 0.91) and increased glucose absorption (AUC240min pre-treatment: 33.04 mmol.min/L vs. post-treatment: 74.59 mmol.min/L; 95 % CI (1.478, 3.449).","The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27476581/),[mM·min] / [l],33.04,94870,DB00592,Piperazine
,27476581,AUC240min,"When two patients who did not have detectable plasma concentrations of camicinal were excluded from analysis, camicinal accelerated gastric emptying (adjusted geometric means: pre-treatment BTt1/2 121 minutes vs. post-treatment 65 minutes 95 % CI (0.32, 0.91) and increased glucose absorption (AUC240min pre-treatment: 33.04 mmol.min/L vs. post-treatment: 74.59 mmol.min/L; 95 % CI (1.478, 3.449).","The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27476581/),[mM·min] / [l],74.59,94871,DB00592,Piperazine
,21311410,clearance,"Approximately 4.6-fold variability in individual clearance was observed (range, 3.4-15.5 L/hr).",Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21311410/),[l] / [h],3.4-15.5,95761,DB00592,Piperazine
,21311410,clearance,"The individual estimated clearance was significantly increased in patients with the SLCO1B3 334GG genotype (median value ± standard deviation, 9.5 ± 3.1 L/hr; n = 19) compared with SLCO1B3 334TT and TG genotypes (7.0 ± 3.1 L/hr; n = 15) (P = 0.019).",Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21311410/),[l] / [h],9.5,95762,DB00592,Piperazine
,21311410,clearance,"The individual estimated clearance was significantly increased in patients with the SLCO1B3 334GG genotype (median value ± standard deviation, 9.5 ± 3.1 L/hr; n = 19) compared with SLCO1B3 334TT and TG genotypes (7.0 ± 3.1 L/hr; n = 15) (P = 0.019).",Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21311410/),[l] / [h],7.0,95763,DB00592,Piperazine
,21311410,clearance,Patients with the ABCB1 3435CC genotype had significantly higher imatinib clearance (12.7 ± 3.0 L/hr; n = 7) compared with patients with ABCB1 3435CT and TT genotypes (7.9 ± 2.7 L/hr; n = 27) (P = 0.035).,Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21311410/),[l] / [h],12.7,95764,DB00592,Piperazine
,21311410,clearance,Patients with the ABCB1 3435CC genotype had significantly higher imatinib clearance (12.7 ± 3.0 L/hr; n = 7) compared with patients with ABCB1 3435CT and TT genotypes (7.9 ± 2.7 L/hr; n = 27) (P = 0.035).,Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21311410/),[l] / [h],7.9,95765,DB00592,Piperazine
,18412019,ka,The compound showed negligible absorption (ka = 0.01 h(-1)) at pH 2.6.,"Absorption, protein binding, pharmacokinetics and excretion of the anti-ischemic and anti-hypertensive arylpiperazine derivative CDRI-93/478 in rats. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18412019/),1/[h],0.01,95999,DB00592,Piperazine
,18412019,rate of absorption,"However, the rate of absorption of the compound at pH 7.4 was 0.6 h(-1) and was comparable to that observed in the in vivo study (ka, >0.58 h(-1)) in rats after a single 2 mg/kg oral dose.","Absorption, protein binding, pharmacokinetics and excretion of the anti-ischemic and anti-hypertensive arylpiperazine derivative CDRI-93/478 in rats. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18412019/),1/[h],0.6,96000,DB00592,Piperazine
>,18412019,ka,"However, the rate of absorption of the compound at pH 7.4 was 0.6 h(-1) and was comparable to that observed in the in vivo study (ka, >0.58 h(-1)) in rats after a single 2 mg/kg oral dose.","Absorption, protein binding, pharmacokinetics and excretion of the anti-ischemic and anti-hypertensive arylpiperazine derivative CDRI-93/478 in rats. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18412019/),1/[h],0.58,96001,DB00592,Piperazine
,18412019,bioavailability,The absorption of CDRI-93/478 was rapid and showed a bioavailability of 69.9 +/- 5.1% (mean +/- S. D.) after 2 and 8 mg/kg oral dose.,"Absorption, protein binding, pharmacokinetics and excretion of the anti-ischemic and anti-hypertensive arylpiperazine derivative CDRI-93/478 in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18412019/),%,69.9,96002,DB00592,Piperazine
,2866055,Bioavailability,"Bioavailability has not been extensively studied, but is about 0.34 for chlorpheniramine, 0.40 to 0.60 for diphenhydramine, and about 0.25 for promethazine.",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),,0.34,96056,DB00592,Piperazine
,2866055,Bioavailability,"Bioavailability has not been extensively studied, but is about 0.34 for chlorpheniramine, 0.40 to 0.60 for diphenhydramine, and about 0.25 for promethazine.",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),,0.40 to 0.60,96057,DB00592,Piperazine
,2866055,Bioavailability,"Bioavailability has not been extensively studied, but is about 0.34 for chlorpheniramine, 0.40 to 0.60 for diphenhydramine, and about 0.25 for promethazine.",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),,0.25,96058,DB00592,Piperazine
,2866055,Total body clearance,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),[ml] / [kg·min],5 to 12,96059,DB00592,Piperazine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,3,96060,DB00592,Piperazine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),d,18,96061,DB00592,Piperazine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,4,96062,DB00592,Piperazine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,10 to 14,96063,DB00592,Piperazine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,14 to 25,96064,DB00592,Piperazine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,20,96065,DB00592,Piperazine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,25,96066,DB00592,Piperazine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),d,18 to 20,96067,DB00592,Piperazine
excess,2866055,apparent volumes of distribution,They also have relatively large apparent volumes of distribution in excess of 4 L/kg.,Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),[l] / [kg],4,96068,DB00592,Piperazine
,2866055,elimination half-life,"In patients with alcohol-related liver disease, the elimination half-life of diphenhydramine was increased from 9 to 15 hours, while in patients with chronic renal disease that of chlorpheniramine was very greatly prolonged.",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,9 to 15,96069,DB00592,Piperazine
,18237464,volume of distribution,"At nominal i.v. doses of 0.2, 1 and 3mg kg(-1), AM-36 exhibited an extremely large volume of distribution (18.2-24.6 L kg(-1)) and a long terminal elimination half-life, ranging from 25.2 to 37.7 h.","Pharmacokinetics and brain uptake of AM-36, a novel neuroprotective agent, following intravenous administration to rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18237464/),[l] / [kg],18.2-24.6,96124,DB00592,Piperazine
,18237464,terminal elimination half-life,"At nominal i.v. doses of 0.2, 1 and 3mg kg(-1), AM-36 exhibited an extremely large volume of distribution (18.2-24.6 L kg(-1)) and a long terminal elimination half-life, ranging from 25.2 to 37.7 h.","Pharmacokinetics and brain uptake of AM-36, a novel neuroprotective agent, following intravenous administration to rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18237464/),h,25.2 to 37.7,96125,DB00592,Piperazine
,18237464,brain-to-plasma ratios,"Following a single i.v. dose of AM-36 at 3mg kg(-1) to rats, brain concentrations were detected for up to 72 h, and the brain-to-plasma ratios were high at all time points (ranging from 8.2 at 5 min post-dose to 0.9 at 72 h post-dose).","Pharmacokinetics and brain uptake of AM-36, a novel neuroprotective agent, following intravenous administration to rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18237464/),,8.2,96126,DB00592,Piperazine
,18237464,brain-to-plasma ratios,"Following a single i.v. dose of AM-36 at 3mg kg(-1) to rats, brain concentrations were detected for up to 72 h, and the brain-to-plasma ratios were high at all time points (ranging from 8.2 at 5 min post-dose to 0.9 at 72 h post-dose).","Pharmacokinetics and brain uptake of AM-36, a novel neuroprotective agent, following intravenous administration to rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18237464/),,0.9,96127,DB00592,Piperazine
,33947696,progression-free survival,"The median progression-free survival was 2.8 months, and 5 (27.8%) patients showed a clinical response.",Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAF V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33947696/),month,2.8,96244,DB00592,Piperazine
,1941630,mean residence time,The mean residence time decreased from 0.60 +/- 0.15 (control) to 0.43 +/- 0.10 hr with ketoconazole (P less than .05) after 5 mg/kg of MPL (free alcohol).,Effect of ketoconazole on methylprednisolone pharmacokinetics and receptor/gene-mediated pharmacodynamics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941630/),h,0.60,96350,DB00592,Piperazine
,1941630,mean residence time,The mean residence time decreased from 0.60 +/- 0.15 (control) to 0.43 +/- 0.10 hr with ketoconazole (P less than .05) after 5 mg/kg of MPL (free alcohol).,Effect of ketoconazole on methylprednisolone pharmacokinetics and receptor/gene-mediated pharmacodynamics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941630/),h,0.43,96351,DB00592,Piperazine
,1941630,area under the curve ratio,The methylprednisone to MPL area under the curve ratio decreased from 0.19 +/- 0.04 in control to 0.14 +/- 0.03 in ketoconazole-treated rats (P less than .05) due to altered interconversion between these steroids.,Effect of ketoconazole on methylprednisolone pharmacokinetics and receptor/gene-mediated pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941630/),,0.19,96352,DB00592,Piperazine
,1941630,area under the curve ratio,The methylprednisone to MPL area under the curve ratio decreased from 0.19 +/- 0.04 in control to 0.14 +/- 0.03 in ketoconazole-treated rats (P less than .05) due to altered interconversion between these steroids.,Effect of ketoconazole on methylprednisolone pharmacokinetics and receptor/gene-mediated pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941630/),,0.14,96353,DB00592,Piperazine
,28008867,trough drug concentrations,"All patients were given dolutegravir at 50 mg once daily, with median trough drug concentrations of 1,096 (664-2,356) ng/ml (interindividual coefficient of variation: 85.3%).",Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect? ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28008867/),[ng] / [ml],"1,096",96385,DB00592,Piperazine
,28008867,drug concentrations,"Patients given dolutegravir with atazanavir had significantly higher drug concentrations compared with those given darunavir, rilpivirine or abacavir/lamivudine (2,399 [1,929-4,070] versus 738 [552-1,048], 603 [432-1,373] or 1,045 [856-1,115] ng/ml; P<0.001 for all comparisons).",Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28008867/),[ng] / [ml],"2,399",96386,DB00592,Piperazine
,28008867,drug concentrations,"Patients given dolutegravir with atazanavir had significantly higher drug concentrations compared with those given darunavir, rilpivirine or abacavir/lamivudine (2,399 [1,929-4,070] versus 738 [552-1,048], 603 [432-1,373] or 1,045 [856-1,115] ng/ml; P<0.001 for all comparisons).",Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28008867/),[ng] / [ml],738,96387,DB00592,Piperazine
,28008867,drug concentrations,"Patients given dolutegravir with atazanavir had significantly higher drug concentrations compared with those given darunavir, rilpivirine or abacavir/lamivudine (2,399 [1,929-4,070] versus 738 [552-1,048], 603 [432-1,373] or 1,045 [856-1,115] ng/ml; P<0.001 for all comparisons).",Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28008867/),[ng] / [ml],603,96388,DB00592,Piperazine
,28008867,drug concentrations,"Patients given dolutegravir with atazanavir had significantly higher drug concentrations compared with those given darunavir, rilpivirine or abacavir/lamivudine (2,399 [1,929-4,070] versus 738 [552-1,048], 603 [432-1,373] or 1,045 [856-1,115] ng/ml; P<0.001 for all comparisons).",Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28008867/),[ng] / [ml],"1,045",96389,DB00592,Piperazine
,25697420,Tmax,"Both ticagrelor and prasugrel were rapidly absorbed, with the shortest median Tmax of 2.0 and 2.25 hours for ticagrelor and AR-C124910XX, respectively, and a Tmax of 0.5 hour for both R-95913 and R-138727.",Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25697420/),h,2.0,96562,DB00592,Piperazine
,25697420,Tmax,"Both ticagrelor and prasugrel were rapidly absorbed, with the shortest median Tmax of 2.0 and 2.25 hours for ticagrelor and AR-C124910XX, respectively, and a Tmax of 0.5 hour for both R-95913 and R-138727.",Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25697420/),h,2.25,96563,DB00592,Piperazine
,25697420,Tmax,"Both ticagrelor and prasugrel were rapidly absorbed, with the shortest median Tmax of 2.0 and 2.25 hours for ticagrelor and AR-C124910XX, respectively, and a Tmax of 0.5 hour for both R-95913 and R-138727.",Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25697420/),h,0.5,96564,DB00592,Piperazine
,8634767,detection limits,"The detection limits are 1 and 2 ng/ml for zolpidem and zopiclone, respectively.",Simultaneous determination of zolpidem and zopiclone in human plasma by gas chromatography-nitrogen-phosphorus detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8634767/),[ng] / [ml],1,96810,DB00592,Piperazine
,8634767,detection limits,"The detection limits are 1 and 2 ng/ml for zolpidem and zopiclone, respectively.",Simultaneous determination of zolpidem and zopiclone in human plasma by gas chromatography-nitrogen-phosphorus detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8634767/),[ng] / [ml],2,96811,DB00592,Piperazine
,22232759,areas under the concentration versus time curve changes (AUCR,"The simulated versus observed areas under the concentration versus time curve changes (AUCR, severe RI/normal) were comparable for sildenafil (2.2 vs 2.0) and telithromycin (1.6 vs 1.9).",Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232759/),,2.2,96896,DB00592,Piperazine
,22232759,areas under the concentration versus time curve changes (AUCR,"The simulated versus observed areas under the concentration versus time curve changes (AUCR, severe RI/normal) were comparable for sildenafil (2.2 vs 2.0) and telithromycin (1.6 vs 1.9).",Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232759/),,2.0,96897,DB00592,Piperazine
,22232759,areas under the concentration versus time curve changes (AUCR,"The simulated versus observed areas under the concentration versus time curve changes (AUCR, severe RI/normal) were comparable for sildenafil (2.2 vs 2.0) and telithromycin (1.6 vs 1.9).",Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232759/),,1.6,96898,DB00592,Piperazine
,22232759,areas under the concentration versus time curve changes (AUCR,"The simulated versus observed areas under the concentration versus time curve changes (AUCR, severe RI/normal) were comparable for sildenafil (2.2 vs 2.0) and telithromycin (1.6 vs 1.9).",Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232759/),,1.9,96899,DB00592,Piperazine
,22232759,AUCR,"For repaglinide, the initial, simulated AUCR was lower than that observed (1.2 vs 3.0).",Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232759/),,1.2,96900,DB00592,Piperazine
,22232759,AUCR,"For repaglinide, the initial, simulated AUCR was lower than that observed (1.2 vs 3.0).",Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232759/),,3.0,96901,DB00592,Piperazine
,16319507,time to treatment failure,Median time to treatment failure was 1.8 months in the whole study cohort and 3.7 months in the patients with stable disease.,Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16319507/),month,1.8,97341,DB00592,Piperazine
,16319507,time to treatment failure,Median time to treatment failure was 1.8 months in the whole study cohort and 3.7 months in the patients with stable disease.,Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16319507/),month,3.7,97342,DB00592,Piperazine
,20422948,constant flow rate,The elution was performed by a constant flow rate of 1.2 mL/min and the mobile phase consisted of acetonitrile and acetic acid 0.1% (85 :15 v/v).,Bioequivalence study of two formulations of 100 mg capsule of itraconazole. Quantification by tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20422948/),[ml] / [min],1.2,97384,DB00592,Piperazine
,3413208,half-life,Pharmacokinetic properties class ZPC in the category of hypnotics with intermediate-short half-life (5-7 hours) and explain the low incidence of unwanted effects reported.,"Zopiclone, a cyclopyrrolone hypnotic: review of properties. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3413208/),h,5-7,97480,DB00592,Piperazine
,24134039,radius of gyration,"Molecular dynamics simulations showed a high degree of hydration of the core, and a radius of gyration of 2.8 ± 0.2 nm.","Design, synthesis and biological assessment of a triazine dendrimer with approximately 16 Paclitaxel groups and 8 PEG groups. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24134039/),nm,2.8,97803,DB00592,Piperazine
,24134039,hydrodynamic radius,"The hydrodynamic radius of the target was found to be 15.8 nm by dynamic light scattering, an observation indicative of aggregation.","Design, synthesis and biological assessment of a triazine dendrimer with approximately 16 Paclitaxel groups and 8 PEG groups. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24134039/),,15.8,97804,DB00592,Piperazine
,24134039,elimination,"Using a two component model, the elimination and distribution half-lives were 2.65 h and 38.2 h, respectively.","Design, synthesis and biological assessment of a triazine dendrimer with approximately 16 Paclitaxel groups and 8 PEG groups. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24134039/),h,2.65,97805,DB00592,Piperazine
,24134039,distribution half-lives,"Using a two component model, the elimination and distribution half-lives were 2.65 h and 38.2 h, respectively.","Design, synthesis and biological assessment of a triazine dendrimer with approximately 16 Paclitaxel groups and 8 PEG groups. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24134039/),h,38.2,97806,DB00592,Piperazine
,18539312,IC50,"BX 667 blocks ADP-induced platelet aggregation in human, dog and rat blood (IC50=97, 317 and 3000 nM respectively).",Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): pharmacodynamic and pharmacokinetic characterization. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18539312/),nM,"97,",97878,DB00592,Piperazine
,18539312,IC50,"BX 667 blocks ADP-induced platelet aggregation in human, dog and rat blood (IC50=97, 317 and 3000 nM respectively).",Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): pharmacodynamic and pharmacokinetic characterization. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18539312/),nM,317,97879,DB00592,Piperazine
,18539312,IC50,"BX 667 blocks ADP-induced platelet aggregation in human, dog and rat blood (IC50=97, 317 and 3000 nM respectively).",Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): pharmacodynamic and pharmacokinetic characterization. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18539312/),nM,3000,97880,DB00592,Piperazine
,18539312,IC50,"BX 667 has an active metabolite, BX 048, that also potently inhibits ADP-induced aggregation (IC50=290 nM) in human blood.",Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): pharmacodynamic and pharmacokinetic characterization. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18539312/),nM,290,97881,DB00592,Piperazine
,9626920,limit of detection,The limit of detection for itraconazole concentration was 16 ng x ml(-1).,Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626920/),[ng] / [ml],16,97908,DB00592,Piperazine
,9626920,AUC0-24,"The mean AUC0-24 was 3.28 vs 0.39 microg x h x ml(-1) in phase 1 and 2, respectively, in healthy normal volunteers.",Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626920/),[h·μg] / [ml],3.28,97909,DB00592,Piperazine
,9626920,AUC0-24,"The mean AUC0-24 was 3.28 vs 0.39 microg x h x ml(-1) in phase 1 and 2, respectively, in healthy normal volunteers.",Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626920/),[h·μg] / [ml],0.39,97910,DB00592,Piperazine
,9626920,AUC0-24,"The mean AUC0-24 was 1.07 vs 0.38 microg x h x ml(-1) in phase 1 and 2, respectively, in AIDS patients.",Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626920/),[h·μg] / [ml],1.07,97911,DB00592,Piperazine
,9626920,AUC0-24,"The mean AUC0-24 was 1.07 vs 0.38 microg x h x ml(-1) in phase 1 and 2, respectively, in AIDS patients.",Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626920/),[h·μg] / [ml],0.38,97912,DB00592,Piperazine
,18235115,dose-normalized areas under the plasma concentration-time curve from time 0 to infinity (AUC(0-infinity)),"After the first imatinib dose, the mean (+/- SD) dose-normalized areas under the plasma concentration-time curve from time 0 to infinity (AUC(0-infinity)) were 162 +/- 155, 171 +/- 72, 182 +/- 157, and 185 +/- 172 (mug/mL x h)/mg for normal, mild, moderate, and severe LD groups, respectively.",Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18235115/),[μg] / [h)·mg·ml],162,97956,DB00592,Piperazine
,18235115,dose-normalized areas under the plasma concentration-time curve from time 0 to infinity (AUC(0-infinity)),"After the first imatinib dose, the mean (+/- SD) dose-normalized areas under the plasma concentration-time curve from time 0 to infinity (AUC(0-infinity)) were 162 +/- 155, 171 +/- 72, 182 +/- 157, and 185 +/- 172 (mug/mL x h)/mg for normal, mild, moderate, and severe LD groups, respectively.",Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18235115/),[μg] / [h)·mg·ml],171,97957,DB00592,Piperazine
,18235115,dose-normalized areas under the plasma concentration-time curve from time 0 to infinity (AUC(0-infinity)),"After the first imatinib dose, the mean (+/- SD) dose-normalized areas under the plasma concentration-time curve from time 0 to infinity (AUC(0-infinity)) were 162 +/- 155, 171 +/- 72, 182 +/- 157, and 185 +/- 172 (mug/mL x h)/mg for normal, mild, moderate, and severe LD groups, respectively.",Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18235115/),[μg] / [h)·mg·ml],182,97958,DB00592,Piperazine
,18235115,dose-normalized areas under the plasma concentration-time curve from time 0 to infinity (AUC(0-infinity)),"After the first imatinib dose, the mean (+/- SD) dose-normalized areas under the plasma concentration-time curve from time 0 to infinity (AUC(0-infinity)) were 162 +/- 155, 171 +/- 72, 182 +/- 157, and 185 +/- 172 (mug/mL x h)/mg for normal, mild, moderate, and severe LD groups, respectively.",Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18235115/),[μg] / [h)·mg·ml],185,97959,DB00592,Piperazine
<,12166950,IC(50),"Systematic modifications in the A-bicyclic ring and D-rings of protype I were carried out to afford potent analogues, which display IC(50) values of <250 nM in cellular betaPDGFR phosphorylation assays.","Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12166950/),nM,250,98060,DB00592,Piperazine
,12166950,IC(50),"An optimized analogue in this series, 75 (CT53518), inhibits Flt-3, betaPDGFR, and c-Kit receptor phosphorylation with IC(50) values of 50-200 nM, whereas 15-20-fold less potent activity against CSF-1R was observed.","Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12166950/),nM,50-200,98061,DB00592,Piperazine
,12166950,IC(50),This analogue also inhibits autophosphorylation of Flt-3 ligand-stimulated wild-type Flt-3 and a constitutively activated Flt-3/internal tandem duplication (ITD) with IC(50) values of 30-100 nM.,"Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12166950/),nM,30-100,98062,DB00592,Piperazine
>,12166950,F%,"Through this optimization process, 75 was found to be metabolically stable and has desirable pharmacokinetic properties in all animal species studied (F% > 50%, T(1/2) > 8 h).","Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12166950/),%,50,98063,DB00592,Piperazine
>,12166950,T(1/2),"Through this optimization process, 75 was found to be metabolically stable and has desirable pharmacokinetic properties in all animal species studied (F% > 50%, T(1/2) > 8 h).","Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12166950/),h,8,98064,DB00592,Piperazine
,28196003,Tmax,"Median Tmax ranged from 1.0 to 1.8 hours (day 1, postdose) and 1.3-2.7 hours (day 10), with median t1/2 ranging from 15.9 to 20.9 hours.","Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1-Infected Adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28196003/),h,1.0 to 1.8,98180,DB00592,Piperazine
,28196003,Tmax,"Median Tmax ranged from 1.0 to 1.8 hours (day 1, postdose) and 1.3-2.7 hours (day 10), with median t1/2 ranging from 15.9 to 20.9 hours.","Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1-Infected Adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28196003/),h,1.3-2.7,98181,DB00592,Piperazine
,28196003,t1/2,"Median Tmax ranged from 1.0 to 1.8 hours (day 1, postdose) and 1.3-2.7 hours (day 10), with median t1/2 ranging from 15.9 to 20.9 hours.","Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1-Infected Adults. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28196003/),h,15.9 to 20.9,98182,DB00592,Piperazine
,12169045,maximum corrected QT (QT(c)) intervals,"Comparable maximum corrected QT (QT(c)) intervals were observed after coadministration of desloratadine and placebo or ketoconazole (431 and 435 msec, respectively).",Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169045/),ms,431,98418,DB00592,Piperazine
,12169045,maximum corrected QT (QT(c)) intervals,"Comparable maximum corrected QT (QT(c)) intervals were observed after coadministration of desloratadine and placebo or ketoconazole (431 and 435 msec, respectively).",Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169045/),ms,435,98419,DB00592,Piperazine
,2898533,Ki,"Several compounds demonstrated moderate to high affinity for the 5-HT1A receptor binding site; compounds 27 and 36 containing the serotonin mimetic (o-methoxyphenyl)piperazinyl moiety and compounds 42 and 50 containing the 2-pyrimidinylpiperazinyl moiety displayed the highest affinity, being equal to that of the 5-HT1A agonist 8-OH-DPAT (Ki = 1-1.3 nM).",Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898533/),nM,1-1.3,99033,DB00592,Piperazine
,2898533,AB50,"Compound 34, 2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]hexahydro-4,7-etheno-1H- cyclobut[f]isoindole-1,3(2H)-dione, demonstrated 3 times the activity of buspirone, blocking CAR in rats with an AB50 of 13 mg/kg.",Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898533/),[mg] / [kg],13,99034,DB00592,Piperazine
,2898533,Ki,"It also displayed high affinity for the 5-HT1A receptor (Ki = 16 nM), which is at least 20 times higher than its affinity for D2 (Ki = 345 nM) and 5-HT2 (Ki = 458 nM) receptors.",Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898533/),nM,16,99035,DB00592,Piperazine
,2898533,Ki,"It also displayed high affinity for the 5-HT1A receptor (Ki = 16 nM), which is at least 20 times higher than its affinity for D2 (Ki = 345 nM) and 5-HT2 (Ki = 458 nM) receptors.",Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898533/),nM,345,99036,DB00592,Piperazine
,2898533,Ki,"It also displayed high affinity for the 5-HT1A receptor (Ki = 16 nM), which is at least 20 times higher than its affinity for D2 (Ki = 345 nM) and 5-HT2 (Ki = 458 nM) receptors.",Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898533/),nM,458,99037,DB00592,Piperazine
,18540159,absolute extraction recovery,"The absolute extraction recovery of cinnarizine and clocinizine (internal standard) from plasma samples were 97% and 89%, respectively.",High-performance liquid chromatographic assay for cinnarizine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18540159/),%,97,99191,DB00592,Piperazine
,18540159,absolute extraction recovery,"The absolute extraction recovery of cinnarizine and clocinizine (internal standard) from plasma samples were 97% and 89%, respectively.",High-performance liquid chromatographic assay for cinnarizine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18540159/),%,89,99192,DB00592,Piperazine
,20803125,maximum drug solubility,The itraconazole-loaded solid dispersion at the weight ratio of itraconazole/polyvinylpyrroline/poloxamer of 10/2/0.5 gave maximum drug solubility of about 20 microg/mL.,Development of novel itraconazole-loaded solid dispersion without crystalline change with improved bioavailability. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20803125/),[μg] / [ml],20,99604,DB00592,Piperazine
,1357148,peak plasma concentrations,Mean peak plasma concentrations were 446 +/- 196 and 530 +/- 214 ng mL-1 at days 8 and 15.,The pharmacokinetics of oral itraconazole in AIDS patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357148/),[ng] / [ml],446,99605,DB00592,Piperazine
,1357148,peak plasma concentrations,Mean peak plasma concentrations were 446 +/- 196 and 530 +/- 214 ng mL-1 at days 8 and 15.,The pharmacokinetics of oral itraconazole in AIDS patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357148/),[ng] / [ml],530,99606,DB00592,Piperazine
,1357148,area under the curve over 24 h (AUC0-24),"The area under the curve over 24 h (AUC0-24) was 2105 +/- 1241, 7679 +/- 3838 and 8748 +/- 4385 ng mL-1 h for days 1, 8 and 15, respectively.",The pharmacokinetics of oral itraconazole in AIDS patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357148/),[h·ng] / [ml],2105,99607,DB00592,Piperazine
,1357148,area under the curve over 24 h (AUC0-24),"The area under the curve over 24 h (AUC0-24) was 2105 +/- 1241, 7679 +/- 3838 and 8748 +/- 4385 ng mL-1 h for days 1, 8 and 15, respectively.",The pharmacokinetics of oral itraconazole in AIDS patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357148/),[h·ng] / [ml],7679,99608,DB00592,Piperazine
,1357148,area under the curve over 24 h (AUC0-24),"The area under the curve over 24 h (AUC0-24) was 2105 +/- 1241, 7679 +/- 3838 and 8748 +/- 4385 ng mL-1 h for days 1, 8 and 15, respectively.",The pharmacokinetics of oral itraconazole in AIDS patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357148/),[h·ng] / [ml],8748,99609,DB00592,Piperazine
,24944232,concentrations,"The median DTG concentrations in CSF were 18 ng/mL (range, 4-23 ng/mL) at week 2 and 13 ng/mL (4-18 ng/mL) at week 16.","ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944232/),[ng] / [ml],18,99700,DB00592,Piperazine
,24944232,concentrations,"The median DTG concentrations in CSF were 18 ng/mL (range, 4-23 ng/mL) at week 2 and 13 ng/mL (4-18 ng/mL) at week 16.","ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944232/),[ng] / [ml],13,99701,DB00592,Piperazine
,24944232,50% inhibitory concentration,"The DTG concentrations in CSF were similar to unbound plasma concentrations and exceeded the in vitro 50% inhibitory concentration for wild-type HIV (0.2 ng/mL), suggesting that DTG achieves therapeutic concentrations in the central nervous system.","ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944232/),[ng] / [ml],0.2,99702,DB00592,Piperazine
,16971194,ch,"The method had a chromatographic run time of 12.0 min and a linear calibration curve over the concentration range of 1.0-800 ng/ml for pseudoephedrine and 1.0-400 ng/ml for cetirizine, respectively.",Development and evaluation of an efficient HPLC/MS/MS method for the simultaneous determination of pseudoephedrine and cetirizine in human plasma: application to phase-I pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16971194/),min,12.0,99830,DB00592,Piperazine
,16971194,run time,"The method had a chromatographic run time of 12.0 min and a linear calibration curve over the concentration range of 1.0-800 ng/ml for pseudoephedrine and 1.0-400 ng/ml for cetirizine, respectively.",Development and evaluation of an efficient HPLC/MS/MS method for the simultaneous determination of pseudoephedrine and cetirizine in human plasma: application to phase-I pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16971194/),min,12.0,99831,DB00592,Piperazine
,6743780,elimination half-life,The average elimination half-life was 3.8 +/- 0.2 h.,Pharmacokinetic and clinical parameters of zopiclone and trimipramine when administered simultaneously to volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6743780/),h,3.8,100733,DB00592,Piperazine
,9105546,elimination half-life,"2. After i.v. administration of 14C-NM394 (5 mg/kg), the plasma concentration of radioactivity decreased biexponentially, and the elimination half-life in rats, dogs and monkeys was 4.2, 5.8 and 7.0 h, respectively.","Pharmacokinetics of prulifloxacin. 1st communication: absorption, distribution and excretion in rats, dogs and monkeys after a single administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105546/),h,4.2,100756,DB00592,Piperazine
,9105546,elimination half-life,"2. After i.v. administration of 14C-NM394 (5 mg/kg), the plasma concentration of radioactivity decreased biexponentially, and the elimination half-life in rats, dogs and monkeys was 4.2, 5.8 and 7.0 h, respectively.","Pharmacokinetics of prulifloxacin. 1st communication: absorption, distribution and excretion in rats, dogs and monkeys after a single administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105546/),h,5.8,100757,DB00592,Piperazine
,9105546,elimination half-life,"2. After i.v. administration of 14C-NM394 (5 mg/kg), the plasma concentration of radioactivity decreased biexponentially, and the elimination half-life in rats, dogs and monkeys was 4.2, 5.8 and 7.0 h, respectively.","Pharmacokinetics of prulifloxacin. 1st communication: absorption, distribution and excretion in rats, dogs and monkeys after a single administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105546/),h,7.0,100758,DB00592,Piperazine
,2155951,binding,Itraconazole binding in suction-induced blister fluid (99.54%) and cantharides-induced blister fluid (99.77%) was calculated from plasma protein binding (99.8%).,Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155951/),%,99.54,100792,DB00592,Piperazine
,2155951,binding,Itraconazole binding in suction-induced blister fluid (99.54%) and cantharides-induced blister fluid (99.77%) was calculated from plasma protein binding (99.8%).,Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155951/),%,99.77,100793,DB00592,Piperazine
,2155951,binding,Itraconazole binding in suction-induced blister fluid (99.54%) and cantharides-induced blister fluid (99.77%) was calculated from plasma protein binding (99.8%).,Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155951/),%,99.8,100794,DB00592,Piperazine
,2155951,terminal half-life,The terminal half-life of itraconazole in serum was 22.5 +/- 3.2 hours.,Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155951/),h,22.5,100795,DB00592,Piperazine
,2155951,penetration,"After the final dose, itraconazole penetration into cantharides-induced blister fluid was only 70%.",Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155951/),%,70,100796,DB00592,Piperazine
,2155951,trough levels,"Moreover, trough levels of unbound itraconazole in suction- and cantharides-induced blister fluid were 0.239 +/- 0.115 and 0.334 +/- 0.101 ng/ml and thus were significantly lower than free itraconazole levels in serum (0.422 +/- 0.125 ng/ml).",Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155951/),[ng] / [ml],0.239,100797,DB00592,Piperazine
,2155951,trough levels,"Moreover, trough levels of unbound itraconazole in suction- and cantharides-induced blister fluid were 0.239 +/- 0.115 and 0.334 +/- 0.101 ng/ml and thus were significantly lower than free itraconazole levels in serum (0.422 +/- 0.125 ng/ml).",Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155951/),[ng] / [ml],0.334,100798,DB00592,Piperazine
,2155951,trough levels,"Moreover, trough levels of unbound itraconazole in suction- and cantharides-induced blister fluid were 0.239 +/- 0.115 and 0.334 +/- 0.101 ng/ml and thus were significantly lower than free itraconazole levels in serum (0.422 +/- 0.125 ng/ml).",Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155951/),[ng] / [ml],0.422,100799,DB00592,Piperazine
,2849968,steady-state volume of distribution (Vss),"Pipecuronium had a larger steady-state volume of distribution (Vss) (309 (SD 103) ml kg-1) and greater plasma clearance (Cl) (2.4 (0.6) ml kg-1 min-1) than pancuronium (199 (54) ml kg-1 and 1.5 (0.4) ml kg-1 min-1, respectively).",Pipecuronium and pancuronium: comparison of pharmacokinetics and duration of action. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2849968/),[ml] / [kg],309,100901,DB00592,Piperazine
,2849968,plasma clearance (Cl),"Pipecuronium had a larger steady-state volume of distribution (Vss) (309 (SD 103) ml kg-1) and greater plasma clearance (Cl) (2.4 (0.6) ml kg-1 min-1) than pancuronium (199 (54) ml kg-1 and 1.5 (0.4) ml kg-1 min-1, respectively).",Pipecuronium and pancuronium: comparison of pharmacokinetics and duration of action. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2849968/),[ml] / [kg·min],2.4,100902,DB00592,Piperazine
,2849968,plasma clearance (Cl),"Pipecuronium had a larger steady-state volume of distribution (Vss) (309 (SD 103) ml kg-1) and greater plasma clearance (Cl) (2.4 (0.6) ml kg-1 min-1) than pancuronium (199 (54) ml kg-1 and 1.5 (0.4) ml kg-1 min-1, respectively).",Pipecuronium and pancuronium: comparison of pharmacokinetics and duration of action. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2849968/),[ml] / [kg],199,100903,DB00592,Piperazine
,2849968,plasma clearance (Cl),"Pipecuronium had a larger steady-state volume of distribution (Vss) (309 (SD 103) ml kg-1) and greater plasma clearance (Cl) (2.4 (0.6) ml kg-1 min-1) than pancuronium (199 (54) ml kg-1 and 1.5 (0.4) ml kg-1 min-1, respectively).",Pipecuronium and pancuronium: comparison of pharmacokinetics and duration of action. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2849968/),[ml] / [kg·min],1.5,100904,DB00592,Piperazine
,2849968,durations of action,"The durations of action (injection to 25% recovery of twitch tension) of pipecuronium and pancuronium were similar: 98.0 (36.1) min and 117.2 (35.8) min, respectively.",Pipecuronium and pancuronium: comparison of pharmacokinetics and duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2849968/),min,98.0,100905,DB00592,Piperazine
,2849968,durations of action,"The durations of action (injection to 25% recovery of twitch tension) of pipecuronium and pancuronium were similar: 98.0 (36.1) min and 117.2 (35.8) min, respectively.",Pipecuronium and pancuronium: comparison of pharmacokinetics and duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2849968/),min,117.2,100906,DB00592,Piperazine
,25581063,apparent clearance (CL/F),"The population mean estimates of apparent clearance (CL/F) and volume (V/F) were 10.8 l h(-1) (95% CI 9.2, 12.4 l h(-1) ) and 267 l (95% CI 208, 326 l), respectively.","Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25581063/),[l] / [h],10.8,100930,DB00592,Piperazine
,25581063,volume (V/F),"The population mean estimates of apparent clearance (CL/F) and volume (V/F) were 10.8 l h(-1) (95% CI 9.2, 12.4 l h(-1) ) and 267 l (95% CI 208, 326 l), respectively.","Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25581063/),l,267,100931,DB00592,Piperazine
,22896728,recoveries,"Mean recoveries of administered radioactivity were 97.1, 92.2, and 87.2% in rats, dogs, and humans, respectively.","Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22896728/),%,97.1,100936,DB00592,Piperazine
,22896728,recoveries,"Mean recoveries of administered radioactivity were 97.1, 92.2, and 87.2% in rats, dogs, and humans, respectively.","Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22896728/),%,92.2,100937,DB00592,Piperazine
,22896728,recoveries,"Mean recoveries of administered radioactivity were 97.1, 92.2, and 87.2% in rats, dogs, and humans, respectively.","Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22896728/),%,87.2,100938,DB00592,Piperazine
,20109290,flow rate,The flow rate was 0.8 mL/min.,"Simultaneous determination of 4-methyl-piperazine-1-carbodithioc acid 3-cyano-3,3-diphenylpropyl ester hydrochloride and its major metabolite in rats by HPLC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20109290/),[ml] / [min],0.8,100957,DB00592,Piperazine
,8737972,clearance,"The median (range) values for clearance, volume of distribution and elimination half-life were 21 (15-53) L/hr, 132 (58-161) L and 3.4 (1.7-5.7) hr, respectively.",Pharmacokinetic-pharmacodynamic modelling of zopiclone effects on human central nervous system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8737972/),[l] / [h],21,101720,DB00592,Piperazine
,8737972,volume of distribution,"The median (range) values for clearance, volume of distribution and elimination half-life were 21 (15-53) L/hr, 132 (58-161) L and 3.4 (1.7-5.7) hr, respectively.",Pharmacokinetic-pharmacodynamic modelling of zopiclone effects on human central nervous system. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8737972/),l,132,101721,DB00592,Piperazine
,8737972,elimination half-life,"The median (range) values for clearance, volume of distribution and elimination half-life were 21 (15-53) L/hr, 132 (58-161) L and 3.4 (1.7-5.7) hr, respectively.",Pharmacokinetic-pharmacodynamic modelling of zopiclone effects on human central nervous system. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8737972/),h,3.4,101722,DB00592,Piperazine
,23085738,T(max),The median T(max) was 0.5 h in all groups.,Pharmacokinetics and pharmacodynamics of single and multiple doses of prasugrel in healthy native Chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23085738/),h,0.5,101742,DB00592,Piperazine
,21988334,Twenty-four hour,Twenty-four hour urine volume increased from 5.9 to 7.7 l.,"Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21988334/),l,5.9,102209,DB00592,Piperazine
,21988334,Twenty-four hour,Twenty-four hour urine volume increased from 5.9 to 7.7 l.,"Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21988334/),l,7.7,102210,DB00592,Piperazine
,21988334,urine volume,Twenty-four hour urine volume increased from 5.9 to 7.7 l.,"Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21988334/),l,5.9,102211,DB00592,Piperazine
,21988334,urine volume,Twenty-four hour urine volume increased from 5.9 to 7.7 l.,"Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21988334/),l,7.7,102212,DB00592,Piperazine
,21988334,Twenty-four hour urine volume,Twenty-four hour urine volume decreased from 12.3 to 8.8 l.,"Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21988334/),l,12.3,102213,DB00592,Piperazine
,21988334,Twenty-four hour urine volume,Twenty-four hour urine volume decreased from 12.3 to 8.8 l.,"Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21988334/),l,8.8,102214,DB00592,Piperazine
,33515583,maximum rate of permeation co-efficient,The improved in vitro release profile of the formulation was in agreement to enhanced ex vivo permeation through sheep mucous membranes with a maximum rate of permeation co-efficient (62.87 cm h-1 × 103) and flux (31.43 μg cm-2.h-1).,Antipsychotic Potential and Safety Profile of TPGS-Based Mucoadhesive Aripiprazole Nanoemulsion: Development and Optimization for Nose-To-Brain Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33515583/),[103·cm] / [h],62.87,102752,DB00592,Piperazine
,33515583,flux,The improved in vitro release profile of the formulation was in agreement to enhanced ex vivo permeation through sheep mucous membranes with a maximum rate of permeation co-efficient (62.87 cm h-1 × 103) and flux (31.43 μg cm-2.h-1).,Antipsychotic Potential and Safety Profile of TPGS-Based Mucoadhesive Aripiprazole Nanoemulsion: Development and Optimization for Nose-To-Brain Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33515583/),[μg] / [(cm)^2·h],31.43,102753,DB00592,Piperazine
,33515583,maximum concentration of drug in the brain (Cmax),"The pharmacokinetic profile following single-dose administration showed the maximum concentration of drug in the brain (Cmax) of 15.19 ± 2.51 μg mL-1 and Tmax of 1 h in animals with ARP-MNE as compared to 10.57 ± 1.88 μg mL-1 and 1 h, and 2.52 ± 0.38 μg mL-1 and 3 h upon intranasal and intravenous administration of ARP-NE, respectively.",Antipsychotic Potential and Safety Profile of TPGS-Based Mucoadhesive Aripiprazole Nanoemulsion: Development and Optimization for Nose-To-Brain Delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33515583/),[μg] / [ml],15.19,102754,DB00592,Piperazine
,33515583,Tmax,"The pharmacokinetic profile following single-dose administration showed the maximum concentration of drug in the brain (Cmax) of 15.19 ± 2.51 μg mL-1 and Tmax of 1 h in animals with ARP-MNE as compared to 10.57 ± 1.88 μg mL-1 and 1 h, and 2.52 ± 0.38 μg mL-1 and 3 h upon intranasal and intravenous administration of ARP-NE, respectively.",Antipsychotic Potential and Safety Profile of TPGS-Based Mucoadhesive Aripiprazole Nanoemulsion: Development and Optimization for Nose-To-Brain Delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33515583/),h,1,102755,DB00592,Piperazine
,33515583,Tmax,"The pharmacokinetic profile following single-dose administration showed the maximum concentration of drug in the brain (Cmax) of 15.19 ± 2.51 μg mL-1 and Tmax of 1 h in animals with ARP-MNE as compared to 10.57 ± 1.88 μg mL-1 and 1 h, and 2.52 ± 0.38 μg mL-1 and 3 h upon intranasal and intravenous administration of ARP-NE, respectively.",Antipsychotic Potential and Safety Profile of TPGS-Based Mucoadhesive Aripiprazole Nanoemulsion: Development and Optimization for Nose-To-Brain Delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33515583/),[μg] / [ml],10.57,102756,DB00592,Piperazine
,33515583,Tmax,"The pharmacokinetic profile following single-dose administration showed the maximum concentration of drug in the brain (Cmax) of 15.19 ± 2.51 μg mL-1 and Tmax of 1 h in animals with ARP-MNE as compared to 10.57 ± 1.88 μg mL-1 and 1 h, and 2.52 ± 0.38 μg mL-1 and 3 h upon intranasal and intravenous administration of ARP-NE, respectively.",Antipsychotic Potential and Safety Profile of TPGS-Based Mucoadhesive Aripiprazole Nanoemulsion: Development and Optimization for Nose-To-Brain Delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33515583/),[μg] / [ml],2.52,102757,DB00592,Piperazine
,33515583,Tmax,"The pharmacokinetic profile following single-dose administration showed the maximum concentration of drug in the brain (Cmax) of 15.19 ± 2.51 μg mL-1 and Tmax of 1 h in animals with ARP-MNE as compared to 10.57 ± 1.88 μg mL-1 and 1 h, and 2.52 ± 0.38 μg mL-1 and 3 h upon intranasal and intravenous administration of ARP-NE, respectively.",Antipsychotic Potential and Safety Profile of TPGS-Based Mucoadhesive Aripiprazole Nanoemulsion: Development and Optimization for Nose-To-Brain Delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33515583/),h,3,102758,DB00592,Piperazine
,33515583,% drug targeting efficiency,"Further, higher values of % drug targeting efficiency (96.9%) and % drug targeting potential (89.73%) of ARP-MNE through intranasal administration were investigated.",Antipsychotic Potential and Safety Profile of TPGS-Based Mucoadhesive Aripiprazole Nanoemulsion: Development and Optimization for Nose-To-Brain Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33515583/),%,96.9,102759,DB00592,Piperazine
,33515583,% drug targeting potential,"Further, higher values of % drug targeting efficiency (96.9%) and % drug targeting potential (89.73%) of ARP-MNE through intranasal administration were investigated.",Antipsychotic Potential and Safety Profile of TPGS-Based Mucoadhesive Aripiprazole Nanoemulsion: Development and Optimization for Nose-To-Brain Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33515583/),%,89.73,102760,DB00592,Piperazine
,19740393,area under the plasma concentration vs time curve (AUC),"PPI administration did not significantly affect the imatinib area under the plasma concentration vs time curve (AUC) (34.1 microg ml(-1) h alone vs 33.1 microg ml(-1) h with omeprazole, P= 0.64; 80% power), maximum plasma concentration (C(max)) (2.04 microg ml(-1) alone vs 2.02 microg ml(-1) with omeprazole, P= 0.97), or half-life (13.4 h alone vs 14.1 h with omeprazole, P= 0.13).",Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740393/),[h·μg] / [ml],34.1,102887,DB00592,Piperazine
,19740393,area under the plasma concentration vs time curve (AUC),"PPI administration did not significantly affect the imatinib area under the plasma concentration vs time curve (AUC) (34.1 microg ml(-1) h alone vs 33.1 microg ml(-1) h with omeprazole, P= 0.64; 80% power), maximum plasma concentration (C(max)) (2.04 microg ml(-1) alone vs 2.02 microg ml(-1) with omeprazole, P= 0.97), or half-life (13.4 h alone vs 14.1 h with omeprazole, P= 0.13).",Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740393/),[h·μg] / [ml],33.1,102888,DB00592,Piperazine
,19740393,maximum plasma concentration (C(max)),"PPI administration did not significantly affect the imatinib area under the plasma concentration vs time curve (AUC) (34.1 microg ml(-1) h alone vs 33.1 microg ml(-1) h with omeprazole, P= 0.64; 80% power), maximum plasma concentration (C(max)) (2.04 microg ml(-1) alone vs 2.02 microg ml(-1) with omeprazole, P= 0.97), or half-life (13.4 h alone vs 14.1 h with omeprazole, P= 0.13).",Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740393/),[μg] / [ml],2.04,102889,DB00592,Piperazine
,19740393,maximum plasma concentration (C(max)),"PPI administration did not significantly affect the imatinib area under the plasma concentration vs time curve (AUC) (34.1 microg ml(-1) h alone vs 33.1 microg ml(-1) h with omeprazole, P= 0.64; 80% power), maximum plasma concentration (C(max)) (2.04 microg ml(-1) alone vs 2.02 microg ml(-1) with omeprazole, P= 0.97), or half-life (13.4 h alone vs 14.1 h with omeprazole, P= 0.13).",Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740393/),[μg] / [ml],2.02,102890,DB00592,Piperazine
,19740393,half-life,"PPI administration did not significantly affect the imatinib area under the plasma concentration vs time curve (AUC) (34.1 microg ml(-1) h alone vs 33.1 microg ml(-1) h with omeprazole, P= 0.64; 80% power), maximum plasma concentration (C(max)) (2.04 microg ml(-1) alone vs 2.02 microg ml(-1) with omeprazole, P= 0.97), or half-life (13.4 h alone vs 14.1 h with omeprazole, P= 0.13).",Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740393/),h,13.4,102891,DB00592,Piperazine
,19740393,half-life,"PPI administration did not significantly affect the imatinib area under the plasma concentration vs time curve (AUC) (34.1 microg ml(-1) h alone vs 33.1 microg ml(-1) h with omeprazole, P= 0.64; 80% power), maximum plasma concentration (C(max)) (2.04 microg ml(-1) alone vs 2.02 microg ml(-1) with omeprazole, P= 0.97), or half-life (13.4 h alone vs 14.1 h with omeprazole, P= 0.13).",Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740393/),h,14.1,102892,DB00592,Piperazine
,21474977,plasma threshold level,"Because of the variability in imatinib exposure among patients, therapeutic drug monitoring to maintain a plasma threshold level of about 1,000 ng/ml would be beneficial during imatinib therapy.",Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21474977/),[ng] / [ml],"1,000",102952,DB00592,Piperazine
,21474977,trough level,"For CML patients who have an imatinib trough level of 1,000 ng/ml but lack a sufficient clinical response, switching to another tyrosine kinase inhibitor is recommended.",Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21474977/),[ng] / [ml],"1,000",102953,DB00592,Piperazine
,10923864,bioavailability,"In dog, the compound exhibited moderate bioavailability (55%), whereas in rat and man oral bioavailability was < 10%.","Pharmacokinetics and metabolism of a sulphamide NK2 antagonist in rat, dog and human. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10923864/),%,55,103172,DB00592,Piperazine
<,10923864,oral bioavailability,"In dog, the compound exhibited moderate bioavailability (55%), whereas in rat and man oral bioavailability was < 10%.","Pharmacokinetics and metabolism of a sulphamide NK2 antagonist in rat, dog and human. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10923864/),%,10,103173,DB00592,Piperazine
,12442638,elimination half-life (T1/2),Plasma concentration of oxatomide decreased biphasically with an elimination half-life (T1/2) of 1.59 h after intravenous administration of oxatomide (1 mg/kg) to non-fasting male rats.,High-performance liquid chromatographic determination of oxatomide and its metabolite and its application to pharmacokinetic study in rat plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12442638/),h,1.59,103199,DB00592,Piperazine
,12442638,maximum concentration,"After oral administration of oxatomide (30 mg/kg) to fasting male rats, plasma concentration of oxatomide increased rapidly, and reached the maximum concentration of 188 ng/ml (Cmax) at 1.0 h.",High-performance liquid chromatographic determination of oxatomide and its metabolite and its application to pharmacokinetic study in rat plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12442638/),[ng] / [ml],188,103200,DB00592,Piperazine
,12442638,Cmax,"After oral administration of oxatomide (30 mg/kg) to fasting male rats, plasma concentration of oxatomide increased rapidly, and reached the maximum concentration of 188 ng/ml (Cmax) at 1.0 h.",High-performance liquid chromatographic determination of oxatomide and its metabolite and its application to pharmacokinetic study in rat plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12442638/),[ng] / [ml],188,103201,DB00592,Piperazine
,12442638,T1/2,The T1/2 was 2.58 h.,High-performance liquid chromatographic determination of oxatomide and its metabolite and its application to pharmacokinetic study in rat plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12442638/),h,2.58,103202,DB00592,Piperazine
,12442638,bioavailability,The bioavailability was 6.74%.,High-performance liquid chromatographic determination of oxatomide and its metabolite and its application to pharmacokinetic study in rat plasma. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12442638/),%,6.74,103203,DB00592,Piperazine
,12442638,Cmax,"Plasma concentration of M-11 increased rapidly, and reached Cmax of 64.3 ng/ml at 0.7 h, and decreased monophasically with T1/2 of 3.79 h.",High-performance liquid chromatographic determination of oxatomide and its metabolite and its application to pharmacokinetic study in rat plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12442638/),[ng] / [ml],64.3,103204,DB00592,Piperazine
,12442638,T1/2,"Plasma concentration of M-11 increased rapidly, and reached Cmax of 64.3 ng/ml at 0.7 h, and decreased monophasically with T1/2 of 3.79 h.",High-performance liquid chromatographic determination of oxatomide and its metabolite and its application to pharmacokinetic study in rat plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12442638/),h,3.79,103205,DB00592,Piperazine
,12442638,Cmax,"After oral administration of oxatomide to non-fasting male rats, plasma concentration of oxatomide reached Cmax of 378 ng/ml at 3.3 h.",High-performance liquid chromatographic determination of oxatomide and its metabolite and its application to pharmacokinetic study in rat plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12442638/),[ng] / [ml],378,103206,DB00592,Piperazine
,12442638,T1/2,The T1/2 was 3.27 h and the bioavailability was 17.5%.,High-performance liquid chromatographic determination of oxatomide and its metabolite and its application to pharmacokinetic study in rat plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12442638/),h,3.27,103207,DB00592,Piperazine
,12442638,bioavailability,The T1/2 was 3.27 h and the bioavailability was 17.5%.,High-performance liquid chromatographic determination of oxatomide and its metabolite and its application to pharmacokinetic study in rat plasma. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12442638/),%,17.5,103208,DB00592,Piperazine
,9768822,alpha half-life,Pharmacologic studies of single agent dexrazoxane (originally studied as an antineoplastic agent) demonstrates an alpha half-life of approximately 30 minutes and a beta half-life of 2 to 4 hours.,Clinical pharmacology of dexrazoxane. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9768822/),min,30,103351,DB00592,Piperazine
,9768822,beta half-life,Pharmacologic studies of single agent dexrazoxane (originally studied as an antineoplastic agent) demonstrates an alpha half-life of approximately 30 minutes and a beta half-life of 2 to 4 hours.,Clinical pharmacology of dexrazoxane. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9768822/),h,2 to 4,103352,DB00592,Piperazine
,9725481,AUC,"Food significantly improved the absorption, with an increase in AUC from 19.1 to 27.2 ng.h/ml (geometric mean, p<0.01) but did not modify the rate of absorption (tmax unchanged, median = 1.5 h).","Food effect on the oral bioavailability of Manidipine: single dose, randomized, crossover study in healthy male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725481/),[h·ng] / [ml],19.,103479,DB00592,Piperazine
,9725481,AUC,"Food significantly improved the absorption, with an increase in AUC from 19.1 to 27.2 ng.h/ml (geometric mean, p<0.01) but did not modify the rate of absorption (tmax unchanged, median = 1.5 h).","Food effect on the oral bioavailability of Manidipine: single dose, randomized, crossover study in healthy male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725481/),[h·ng] / [ml],27,103480,DB00592,Piperazine
,9725481,tmax,"Food significantly improved the absorption, with an increase in AUC from 19.1 to 27.2 ng.h/ml (geometric mean, p<0.01) but did not modify the rate of absorption (tmax unchanged, median = 1.5 h).","Food effect on the oral bioavailability of Manidipine: single dose, randomized, crossover study in healthy male subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725481/),h,1.5,103481,DB00592,Piperazine
,9725481,Peak plasma concentration,"Peak plasma concentration was also increased (from 6.2 to 7.8 ng/ml), but the difference was not statistically significant (p=0.18).","Food effect on the oral bioavailability of Manidipine: single dose, randomized, crossover study in healthy male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725481/),[ng] / [ml],6.2,103482,DB00592,Piperazine
,9725481,Peak plasma concentration,"Peak plasma concentration was also increased (from 6.2 to 7.8 ng/ml), but the difference was not statistically significant (p=0.18).","Food effect on the oral bioavailability of Manidipine: single dose, randomized, crossover study in healthy male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725481/),[ng] / [ml],7.8,103483,DB00592,Piperazine
,9209780,MICs,The MICs of AM-1155 for 11 highly fluoroquinolone-resistant isolates with alterations in both GyrA and ParC ranged from 0.06 to 1.0 microgram/ml.,Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],0.06 to 1.0,104038,DB00592,Piperazine
,9209780,MICs inhibiting 50% (,"The MICs inhibiting 50% (MIC50) and 90% (MIC90) of these isolates were 0.125 and 1.0 microgram/ml, respectively.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],90,104039,DB00592,Piperazine
,9209780,MICs inhibiting 50% (,"The MICs inhibiting 50% (MIC50) and 90% (MIC90) of these isolates were 0.125 and 1.0 microgram/ml, respectively.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],0.125,104040,DB00592,Piperazine
,9209780,MIC50,"The MICs inhibiting 50% (MIC50) and 90% (MIC90) of these isolates were 0.125 and 1.0 microgram/ml, respectively.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],90,104041,DB00592,Piperazine
,9209780,MIC50,"The MICs inhibiting 50% (MIC50) and 90% (MIC90) of these isolates were 0.125 and 1.0 microgram/ml, respectively.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],0.125,104042,DB00592,Piperazine
,9209780,MIC90,"The MICs inhibiting 50% (MIC50) and 90% (MIC90) of these isolates were 0.125 and 1.0 microgram/ml, respectively.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],90,104043,DB00592,Piperazine
,9209780,MIC90,"The MICs inhibiting 50% (MIC50) and 90% (MIC90) of these isolates were 0.125 and 1.0 microgram/ml, respectively.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],1.0,104044,DB00592,Piperazine
,9209780,MICs,"The MICs of AM-1155 for 20 moderately fluoroquinolone-resistant isolates with alterations only in GyrA ranged from 0.03 to 0.25 microgram/ml (MIC50, 0.06 microgram/ml; MIC90m, 0.125 microgram/ml).",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],0.03 to 0.25,104045,DB00592,Piperazine
,9209780,MIC50,"The MICs of AM-1155 for 20 moderately fluoroquinolone-resistant isolates with alterations only in GyrA ranged from 0.03 to 0.25 microgram/ml (MIC50, 0.06 microgram/ml; MIC90m, 0.125 microgram/ml).",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],0.06,104046,DB00592,Piperazine
,9209780,MIC90m,"The MICs of AM-1155 for 20 moderately fluoroquinolone-resistant isolates with alterations only in GyrA ranged from 0.03 to 0.25 microgram/ml (MIC50, 0.06 microgram/ml; MIC90m, 0.125 microgram/ml).",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],0.125,104047,DB00592,Piperazine
,9209780,MICs,"The MICs of AM-1155 for 24 of the quinolone-susceptible isolates without alterations in either GyrA or ParC ranged from 0.004 to 0.03 microgram/ml (MIC50, 0.008 microgram/ml. MIC90, 0.015 microgram/ml).",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],0.004 to 0.03,104048,DB00592,Piperazine
,9209780,MIC50,"The MICs of AM-1155 for 24 of the quinolone-susceptible isolates without alterations in either GyrA or ParC ranged from 0.004 to 0.03 microgram/ml (MIC50, 0.008 microgram/ml. MIC90, 0.015 microgram/ml).",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],0.008,104049,DB00592,Piperazine
,9209780,MIC90,"The MICs of AM-1155 for 24 of the quinolone-susceptible isolates without alterations in either GyrA or ParC ranged from 0.004 to 0.03 microgram/ml (MIC50, 0.008 microgram/ml. MIC90, 0.015 microgram/ml).",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],0.015,104050,DB00592,Piperazine
,9209780,MICs,MICs for the causative organisms have ranged from 1.0 to 16.0 micrograms/ml.,Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],1.0 to 16.0,104051,DB00592,Piperazine
,9209780,MICs,"The MICs of AM-1155 for the isolates harboring quinolone resistance-associated genetic alterations, including strains exhibiting ciprofloxacin MICs of 2.0 and 8.0 micrograms/ml, still ranged from 0.03 to 1.0 microgram/mL A single-dose study in humans has demonstrated higher peak serum concentrations and longer half-lives of AM-1155, resulting in the AUC0-00 values of AM-1155, which are threefold greater than those of ciprofloxacin at the single doses of 400 and 600 mg.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],2.0,104052,DB00592,Piperazine
,9209780,MICs,"The MICs of AM-1155 for the isolates harboring quinolone resistance-associated genetic alterations, including strains exhibiting ciprofloxacin MICs of 2.0 and 8.0 micrograms/ml, still ranged from 0.03 to 1.0 microgram/mL A single-dose study in humans has demonstrated higher peak serum concentrations and longer half-lives of AM-1155, resulting in the AUC0-00 values of AM-1155, which are threefold greater than those of ciprofloxacin at the single doses of 400 and 600 mg.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],8.0,104053,DB00592,Piperazine
,9209780,MICs,"The MICs of AM-1155 for the isolates harboring quinolone resistance-associated genetic alterations, including strains exhibiting ciprofloxacin MICs of 2.0 and 8.0 micrograms/ml, still ranged from 0.03 to 1.0 microgram/mL A single-dose study in humans has demonstrated higher peak serum concentrations and longer half-lives of AM-1155, resulting in the AUC0-00 values of AM-1155, which are threefold greater than those of ciprofloxacin at the single doses of 400 and 600 mg.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],2.0,104054,DB00592,Piperazine
,9209780,MICs,"The MICs of AM-1155 for the isolates harboring quinolone resistance-associated genetic alterations, including strains exhibiting ciprofloxacin MICs of 2.0 and 8.0 micrograms/ml, still ranged from 0.03 to 1.0 microgram/mL A single-dose study in humans has demonstrated higher peak serum concentrations and longer half-lives of AM-1155, resulting in the AUC0-00 values of AM-1155, which are threefold greater than those of ciprofloxacin at the single doses of 400 and 600 mg.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],8.0,104055,DB00592,Piperazine
,9209780,MICs,"The MICs of AM-1155 for the isolates harboring quinolone resistance-associated genetic alterations, including strains exhibiting ciprofloxacin MICs of 2.0 and 8.0 micrograms/ml, still ranged from 0.03 to 1.0 microgram/mL A single-dose study in humans has demonstrated higher peak serum concentrations and longer half-lives of AM-1155, resulting in the AUC0-00 values of AM-1155, which are threefold greater than those of ciprofloxacin at the single doses of 400 and 600 mg.",Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209780/),[μg] / [ml],0.03 to 1.0,104056,DB00592,Piperazine
,20399458,overall survival,"Median overall survival was 22.8 months and was significantly greater in docetaxel naïve patients than in patients pretreated with docetaxel (36.8 vs 10.3 months, p = 0.0001).",A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399458/),month,22.8,104479,DB00592,Piperazine
,20399458,overall survival,"Median overall survival was 22.8 months and was significantly greater in docetaxel naïve patients than in patients pretreated with docetaxel (36.8 vs 10.3 months, p = 0.0001).",A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399458/),month,36.8,104480,DB00592,Piperazine
,20399458,overall survival,"Median overall survival was 22.8 months and was significantly greater in docetaxel naïve patients than in patients pretreated with docetaxel (36.8 vs 10.3 months, p = 0.0001).",A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399458/),month,10.3,104481,DB00592,Piperazine
,20399458,maximum tolerated dose,Combination regimens using 600 mg ketoconazole daily were fairly well tolerated and the maximum tolerated dose of docetaxel was 32 mg/m(2).,A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399458/),mg,32,104482,DB00592,Piperazine
>,28617978,extraction recovery,The mean extraction recovery was >80% for both enantiomers.,Enantioselective determination of R-(-)-manidipine and S-(+)-manidipine in human plasma by a sensitive and selective chiral LC-MS/MS assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28617978/),%,80,104676,DB00592,Piperazine
,15467976,absolute bioavailability,The absolute bioavailability ranged from 12% to 84%.,Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15467976/),%,12,104832,DB00592,Piperazine
,15467976,absolute bioavailability,The absolute bioavailability ranged from 12% to 84%.,Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15467976/),%,84,104833,DB00592,Piperazine
,15467976,elimination half-life,mCPP's elimination half-life ranged from 2.4 h to 6.8 h after intravenous infusion and from 2.6 h to 6.1 h after oral application.,Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15467976/),h,2.4,104834,DB00592,Piperazine
,15467976,elimination half-life,mCPP's elimination half-life ranged from 2.4 h to 6.8 h after intravenous infusion and from 2.6 h to 6.1 h after oral application.,Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15467976/),h,6.8,104835,DB00592,Piperazine
,15467976,elimination half-life,mCPP's elimination half-life ranged from 2.4 h to 6.8 h after intravenous infusion and from 2.6 h to 6.1 h after oral application.,Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15467976/),h,2.6,104836,DB00592,Piperazine
,15467976,elimination half-life,mCPP's elimination half-life ranged from 2.4 h to 6.8 h after intravenous infusion and from 2.6 h to 6.1 h after oral application.,Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15467976/),h,6.1,104837,DB00592,Piperazine
,22900583,metabolic ratio (MR),"Midazolam metabolic ratio (MR) dramatically decreased in presence of ritonavir (6.7 ± 2.6 versus 0.13 ± 0.07) reflecting an almost complete inhibition of CYP3A4, whereas omeprazole, flurbiprofen and bupropion MR were not affected.",Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22900583/),,6.7,104991,DB00592,Piperazine
,22900583,metabolic ratio (MR),"Midazolam metabolic ratio (MR) dramatically decreased in presence of ritonavir (6.7 ± 2.6 versus 0.13 ± 0.07) reflecting an almost complete inhibition of CYP3A4, whereas omeprazole, flurbiprofen and bupropion MR were not affected.",Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22900583/),,0.13,104992,DB00592,Piperazine
,11879259,apparent clearance (CL/F),"For the population average patient (age 58 years; aspartate transaminase [AST], 24 IU l(-1); weight, 87 kg; not receiving CYP3A4 potential inhibitors), typical values for sildenafil (mean +/- SE) were 58.5 +/- 1.4 l h(-1) for apparent clearance (CL/F), 310 +/- 6.92 l for volume of distribution (V/F), and 2.6 +/- 0.176 h(-1) for first-order absorption constant (ka).",A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11879259/),[l] / [h],58.5,105367,DB00592,Piperazine
,11879259,volume of distribution (V/F),"For the population average patient (age 58 years; aspartate transaminase [AST], 24 IU l(-1); weight, 87 kg; not receiving CYP3A4 potential inhibitors), typical values for sildenafil (mean +/- SE) were 58.5 +/- 1.4 l h(-1) for apparent clearance (CL/F), 310 +/- 6.92 l for volume of distribution (V/F), and 2.6 +/- 0.176 h(-1) for first-order absorption constant (ka).",A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11879259/),l,310,105368,DB00592,Piperazine
,11879259,first-order absorption constant (ka),"For the population average patient (age 58 years; aspartate transaminase [AST], 24 IU l(-1); weight, 87 kg; not receiving CYP3A4 potential inhibitors), typical values for sildenafil (mean +/- SE) were 58.5 +/- 1.4 l h(-1) for apparent clearance (CL/F), 310 +/- 6.92 l for volume of distribution (V/F), and 2.6 +/- 0.176 h(-1) for first-order absorption constant (ka).",A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11879259/),1/[h],2.6,105369,DB00592,Piperazine
,21943935,limits of detection (LOD),"The limits of detection (LOD) and quantification (LOQ) for the studied analytes were within the range of 2-4 ng mL(-1) and 7.0-13.4 ng mL(-1), respectively.","High-performance liquid chromatographic method with amperometric detection employing boron-doped diamond electrode for the determination of sildenafil, vardenafil and their main metabolites in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21943935/),[ng] / [ml],2-4,105374,DB00592,Piperazine
,21943935,quantification (LOQ),"The limits of detection (LOD) and quantification (LOQ) for the studied analytes were within the range of 2-4 ng mL(-1) and 7.0-13.4 ng mL(-1), respectively.","High-performance liquid chromatographic method with amperometric detection employing boron-doped diamond electrode for the determination of sildenafil, vardenafil and their main metabolites in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21943935/),[ng] / [ml],7.0-13.4,105375,DB00592,Piperazine
,34201372,50% effective dose (ED50),The 50% effective dose (ED50) of NPDM in a Galleria mellonella infection model was 50.53 mg/kg.,Antibacterial Activity of a Promising Antibacterial Agent: 22-(4-(2-(4-Nitrophenyl-piperazin-1-yl)-acetyl)-piperazin-1-yl)-22-deoxypleuromutilin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34201372/),[mg] / [kg],50.53,105553,DB00592,Piperazine
,25339590,Relative bioavailability,Relative bioavailability of carbamazepine after administration of nanoemulsion was 160% compared to unmodified substance.,Experimental investigation of pharmacodynamics and pharmacokinetics of carbamazepine nanoemulsion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25339590/),%,160,105602,DB00592,Piperazine
,17318927,radiocarbon recovery,"After a single oral administration, the mean radiocarbon recovery was 92.32+/-6.26%, with 91.25+/-6.25 and 1.07+/-0.21% in the feces and urine, respectively.","Metabolism and excretion of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]-pyrimidin-4-one (SK3530) in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318927/),%,92.32,105963,DB00592,Piperazine
,17318927,radiocarbon recovery,"After a single oral administration, the mean radiocarbon recovery was 92.32+/-6.26%, with 91.25+/-6.25 and 1.07+/-0.21% in the feces and urine, respectively.","Metabolism and excretion of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]-pyrimidin-4-one (SK3530) in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318927/),%,91.25,105964,DB00592,Piperazine
,17318927,radiocarbon recovery,"After a single oral administration, the mean radiocarbon recovery was 92.32+/-6.26%, with 91.25+/-6.25 and 1.07+/-0.21% in the feces and urine, respectively.","Metabolism and excretion of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]-pyrimidin-4-one (SK3530) in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318927/),%,1.07,105965,DB00592,Piperazine
,17318927,biliary excretion,"The biliary excretion of radioactivity for the first 24 h period was approximately 38.82%, suggesting that SK3530 is cleared by hepatobiliary excretion.","Metabolism and excretion of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]-pyrimidin-4-one (SK3530) in rats. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318927/),%,38.82,105966,DB00592,Piperazine
,6455787,peak serum concentrations,"In studies of the intramuscular (i.m.) administration of cefoperazone at doses of 0.25, 0.5, and 1 g, mean peak serum concentrations were 22, 33, and 67 micrograms/ml at 1 hr.","A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),[μg] / [ml],22,106110,DB00592,Piperazine
,6455787,peak serum concentrations,"In studies of the intramuscular (i.m.) administration of cefoperazone at doses of 0.25, 0.5, and 1 g, mean peak serum concentrations were 22, 33, and 67 micrograms/ml at 1 hr.","A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),[μg] / [ml],33,106111,DB00592,Piperazine
,6455787,peak serum concentrations,"In studies of the intramuscular (i.m.) administration of cefoperazone at doses of 0.25, 0.5, and 1 g, mean peak serum concentrations were 22, 33, and 67 micrograms/ml at 1 hr.","A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),[μg] / [ml],67,106112,DB00592,Piperazine
,6455787,half-life,The mean half-life after intramuscular injection was 108-154 min.,"A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),min,108-154,106113,DB00592,Piperazine
,6455787,Urinary recovery,Urinary recovery ranged from 14 to 18% of an administered dose.,"A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),%,14 to 18,106114,DB00592,Piperazine
,6455787,Concentrations,"Concentrations of cefoperazone at 8 hr were 2.4, 6.5, and 11.8 micrograms/ml after these respective doses.","A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),,2.4,106115,DB00592,Piperazine
,6455787,Concentrations,"Concentrations of cefoperazone at 8 hr were 2.4, 6.5, and 11.8 micrograms/ml after these respective doses.","A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),,6.5,106116,DB00592,Piperazine
,6455787,Concentrations,"Concentrations of cefoperazone at 8 hr were 2.4, 6.5, and 11.8 micrograms/ml after these respective doses.","A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),,11.8,106117,DB00592,Piperazine
,6455787,Serum half-life,"Serum half-life was 115-120 min and urinary recovery, 29-33%.","A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),min,115-120,106118,DB00592,Piperazine
,6455787,urinary recovery,"Serum half-life was 115-120 min and urinary recovery, 29-33%.","A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),%,29-33,106119,DB00592,Piperazine
,6455787,half-life,The half-life found in these studies ranged from 1.6 to 2.38 hr.,"A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),h,1.6 to 2.38,106120,DB00592,Piperazine
,6455787,Urinary recovery,Urinary recovery was 25-30%.,"A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),%,25-30,106121,DB00592,Piperazine
,6455787,Serum clearances,"Serum clearances have been 80-90 ml/min and renal clearances, 18-30 ml/min.","A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),[ml] / [min],80-90,106122,DB00592,Piperazine
,6455787,renal clearances,"Serum clearances have been 80-90 ml/min and renal clearances, 18-30 ml/min.","A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),[ml] / [min],18-30,106123,DB00592,Piperazine
,6455787,apparent volume of distribution,The apparent volume of distribution of the compound has ranged from 10 to 16 liters.,"A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),l,10 to 16,106124,DB00592,Piperazine
,6455787,serum half-life,"In the presence of renal failure there is a minimal increase in serum half-life; but in the presence of biliary obstruction, serum half-life may reach 11 hr, depending on the degree of biliary obstruction.","A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),h,11,106125,DB00592,Piperazine
,9527794,AUC0-24-,"The mean AUC0-24-based accumulation factors of itraconazole and hydroxyitraconazole from day 1 to 14 ranged from 3.3 to 8.6 and 2.3 to 11.4, respectively.",Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527794/),,3.3 to 8.6,106710,DB00592,Piperazine
,9527794,AUC0-24-,"The mean AUC0-24-based accumulation factors of itraconazole and hydroxyitraconazole from day 1 to 14 ranged from 3.3 to 8.6 and 2.3 to 11.4, respectively.",Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527794/),,2.3 to 11.4,106711,DB00592,Piperazine
,9527794,accumulation factors,"The mean AUC0-24-based accumulation factors of itraconazole and hydroxyitraconazole from day 1 to 14 ranged from 3.3 to 8.6 and 2.3 to 11.4, respectively.",Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527794/),,3.3 to 8.6,106712,DB00592,Piperazine
,9527794,accumulation factors,"The mean AUC0-24-based accumulation factors of itraconazole and hydroxyitraconazole from day 1 to 14 ranged from 3.3 to 8.6 and 2.3 to 11.4, respectively.",Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527794/),,2.3 to 11.4,106713,DB00592,Piperazine
,9527794,Cmax,"After 14 days of treatment, Cmax, AUC0-24, and the half-life, respectively, were (mean +/- standard deviation) 571+/-416 ng/ml, 6,930+/-5,830 ng.h/ml, and 47+/-55 h in the children aged 6 months to 2 years; 534+/-431 ng/ml, 7,330+/-5,420 ng.h/ml, and 30.6+/-25.3 h in the children aged 2 to 5 years; and 631+/-358 ng/ml, 8,770+/-5,050 ng.h/ml, and 28.3+/-9.6 h in the children aged 5 to 12 years.",Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527794/),[ng] / [ml],571,106714,DB00592,Piperazine
,9527794,AUC0-24,"After 14 days of treatment, Cmax, AUC0-24, and the half-life, respectively, were (mean +/- standard deviation) 571+/-416 ng/ml, 6,930+/-5,830 ng.h/ml, and 47+/-55 h in the children aged 6 months to 2 years; 534+/-431 ng/ml, 7,330+/-5,420 ng.h/ml, and 30.6+/-25.3 h in the children aged 2 to 5 years; and 631+/-358 ng/ml, 8,770+/-5,050 ng.h/ml, and 28.3+/-9.6 h in the children aged 5 to 12 years.",Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527794/),[h·ng] / [ml],"6,930",106715,DB00592,Piperazine
,9527794,AUC0-24,"After 14 days of treatment, Cmax, AUC0-24, and the half-life, respectively, were (mean +/- standard deviation) 571+/-416 ng/ml, 6,930+/-5,830 ng.h/ml, and 47+/-55 h in the children aged 6 months to 2 years; 534+/-431 ng/ml, 7,330+/-5,420 ng.h/ml, and 30.6+/-25.3 h in the children aged 2 to 5 years; and 631+/-358 ng/ml, 8,770+/-5,050 ng.h/ml, and 28.3+/-9.6 h in the children aged 5 to 12 years.",Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527794/),[ng] / [ml],631,106716,DB00592,Piperazine
,9527794,half-life,"After 14 days of treatment, Cmax, AUC0-24, and the half-life, respectively, were (mean +/- standard deviation) 571+/-416 ng/ml, 6,930+/-5,830 ng.h/ml, and 47+/-55 h in the children aged 6 months to 2 years; 534+/-431 ng/ml, 7,330+/-5,420 ng.h/ml, and 30.6+/-25.3 h in the children aged 2 to 5 years; and 631+/-358 ng/ml, 8,770+/-5,050 ng.h/ml, and 28.3+/-9.6 h in the children aged 5 to 12 years.",Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527794/),h,47,106717,DB00592,Piperazine
,9527794,half-life,"After 14 days of treatment, Cmax, AUC0-24, and the half-life, respectively, were (mean +/- standard deviation) 571+/-416 ng/ml, 6,930+/-5,830 ng.h/ml, and 47+/-55 h in the children aged 6 months to 2 years; 534+/-431 ng/ml, 7,330+/-5,420 ng.h/ml, and 30.6+/-25.3 h in the children aged 2 to 5 years; and 631+/-358 ng/ml, 8,770+/-5,050 ng.h/ml, and 28.3+/-9.6 h in the children aged 5 to 12 years.",Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527794/),[ng] / [ml],631,106718,DB00592,Piperazine
,9527794,half-life,"After 14 days of treatment, Cmax, AUC0-24, and the half-life, respectively, were (mean +/- standard deviation) 571+/-416 ng/ml, 6,930+/-5,830 ng.h/ml, and 47+/-55 h in the children aged 6 months to 2 years; 534+/-431 ng/ml, 7,330+/-5,420 ng.h/ml, and 30.6+/-25.3 h in the children aged 2 to 5 years; and 631+/-358 ng/ml, 8,770+/-5,050 ng.h/ml, and 28.3+/-9.6 h in the children aged 5 to 12 years.",Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527794/),[h·ng] / [ml],"8,770",106719,DB00592,Piperazine
,9527794,half-life,"After 14 days of treatment, Cmax, AUC0-24, and the half-life, respectively, were (mean +/- standard deviation) 571+/-416 ng/ml, 6,930+/-5,830 ng.h/ml, and 47+/-55 h in the children aged 6 months to 2 years; 534+/-431 ng/ml, 7,330+/-5,420 ng.h/ml, and 30.6+/-25.3 h in the children aged 2 to 5 years; and 631+/-358 ng/ml, 8,770+/-5,050 ng.h/ml, and 28.3+/-9.6 h in the children aged 5 to 12 years.",Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527794/),h,28.3,106720,DB00592,Piperazine
less,9527794,oral bioavailability,The oral bioavailability of the solubilizer hydroxypropyl-beta-cyclodextrin was less than 1% in the majority of the patients.,Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527794/),%,1,106721,DB00592,Piperazine
,2291877,AUC,Mean (+/- s.d.) AUC CGP 6140 values were 67.0 +/- 10.8 mumol l-1 h in fed and 22.0 +/- 17.2 mumol l-1 h in fasting patients.,The influence of food on the pharmacokinetics of CGP 6140 (amocarzine) after oral administration of a 1200 mg single dose to patients with onchocerciasis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291877/),[h·μM] / [l],67.0,106810,DB00592,Piperazine
,2291877,AUC,Mean (+/- s.d.) AUC CGP 6140 values were 67.0 +/- 10.8 mumol l-1 h in fed and 22.0 +/- 17.2 mumol l-1 h in fasting patients.,The influence of food on the pharmacokinetics of CGP 6140 (amocarzine) after oral administration of a 1200 mg single dose to patients with onchocerciasis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291877/),[h·μM] / [l],22.0,106811,DB00592,Piperazine
,2291877,maximum concentrations (Cmax),The mean maximum concentrations (Cmax) in plasma +/- s.d. were 12.7 +/- 2.8 mumol l-1 in fed and 4.7 +/- 4.1 mumol l-1 in fasting patients.,The influence of food on the pharmacokinetics of CGP 6140 (amocarzine) after oral administration of a 1200 mg single dose to patients with onchocerciasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291877/),[μM] / [l],12.7,106812,DB00592,Piperazine
,2291877,maximum concentrations (Cmax),The mean maximum concentrations (Cmax) in plasma +/- s.d. were 12.7 +/- 2.8 mumol l-1 in fed and 4.7 +/- 4.1 mumol l-1 in fasting patients.,The influence of food on the pharmacokinetics of CGP 6140 (amocarzine) after oral administration of a 1200 mg single dose to patients with onchocerciasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291877/),[μM] / [l],4.7,106813,DB00592,Piperazine
,2291877,time to Cmax,The median time to Cmax was 3 h in fed and 2 h in fasting patients.,The influence of food on the pharmacokinetics of CGP 6140 (amocarzine) after oral administration of a 1200 mg single dose to patients with onchocerciasis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291877/),h,3,106814,DB00592,Piperazine
,2291877,time to Cmax,The median time to Cmax was 3 h in fed and 2 h in fasting patients.,The influence of food on the pharmacokinetics of CGP 6140 (amocarzine) after oral administration of a 1200 mg single dose to patients with onchocerciasis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291877/),h,2,106815,DB00592,Piperazine
,2291877,AUC,Mean (+/- s.d.) AUC of the N-oxide metabolite was 59.9 +/- 10.7 mumol l-1 h in fed and 23.4 +/- 16.2 mumol l-1 h in fasting patients.,The influence of food on the pharmacokinetics of CGP 6140 (amocarzine) after oral administration of a 1200 mg single dose to patients with onchocerciasis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291877/),[h·μM] / [l],59.9,106816,DB00592,Piperazine
,2291877,AUC,Mean (+/- s.d.) AUC of the N-oxide metabolite was 59.9 +/- 10.7 mumol l-1 h in fed and 23.4 +/- 16.2 mumol l-1 h in fasting patients.,The influence of food on the pharmacokinetics of CGP 6140 (amocarzine) after oral administration of a 1200 mg single dose to patients with onchocerciasis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291877/),[h·μM] / [l],23.4,106817,DB00592,Piperazine
less,2291877,urinary recovery,The urinary recovery was less than 0.5% of dose for CGP 6140 in both fed and fasting conditions.,The influence of food on the pharmacokinetics of CGP 6140 (amocarzine) after oral administration of a 1200 mg single dose to patients with onchocerciasis. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291877/),%,0.5,106818,DB00592,Piperazine
,19261399,C(max),Plasma concentrations of BZP were found to peak at 262 ng/mL (C(max)) and 75min (T(max)).,Pharmacokinetics of 'party pill' drug N-benzylpiperazine (BZP) in healthy human participants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19261399/),[ng] / [ml],262,106835,DB00592,Piperazine
,19261399,T(max),Plasma concentrations of BZP were found to peak at 262 ng/mL (C(max)) and 75min (T(max)).,Pharmacokinetics of 'party pill' drug N-benzylpiperazine (BZP) in healthy human participants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19261399/),min,75,106836,DB00592,Piperazine
,19261399,elimination half-life (t(1/2)),The elimination half-life (t(1/2)) for BZP was found to be 5.5h.,Pharmacokinetics of 'party pill' drug N-benzylpiperazine (BZP) in healthy human participants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19261399/),h,5.5,106837,DB00592,Piperazine
,19261399,Clearance (Cl/F),Clearance (Cl/F) was found to be 99L/h.,Pharmacokinetics of 'party pill' drug N-benzylpiperazine (BZP) in healthy human participants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19261399/),[l] / [h],99,106838,DB00592,Piperazine
,2495983,PaO2,"Mean PaO2 increases in the sixteen patients were 0.9 kPa (7 mmHg), 1.5 kPa (11 mmHg) and 1.6 kPa (12 mmHg) 3 h after 50, 100 and 150 mg, respectively.",Dose-response and pharmacokinetic study with almitrine bismesylate after single oral administrations in COPD patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495983/),kpa,0.9,106857,DB00592,Piperazine
,2495983,PaO2,"Mean PaO2 increases in the sixteen patients were 0.9 kPa (7 mmHg), 1.5 kPa (11 mmHg) and 1.6 kPa (12 mmHg) 3 h after 50, 100 and 150 mg, respectively.",Dose-response and pharmacokinetic study with almitrine bismesylate after single oral administrations in COPD patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495983/),kpa,1.5,106858,DB00592,Piperazine
,2495983,PaO2,"Mean PaO2 increases in the sixteen patients were 0.9 kPa (7 mmHg), 1.5 kPa (11 mmHg) and 1.6 kPa (12 mmHg) 3 h after 50, 100 and 150 mg, respectively.",Dose-response and pharmacokinetic study with almitrine bismesylate after single oral administrations in COPD patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495983/),kpa,1.6,106859,DB00592,Piperazine
,2495983,plasma half-life,Almitrine plasma half-life was found to be 116-140 h.,Dose-response and pharmacokinetic study with almitrine bismesylate after single oral administrations in COPD patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495983/),h,116-140,106860,DB00592,Piperazine
,16875808,AUC ratios,"The AUC ratios of ELF/plasma and AM/plasma of HSR-903 were 3.03+/-0.54 and 97.5+/-24.2, respectively, notably higher than those of ciprofloxacin (CPFX).","Distribution characteristics of orally administered olamufloxacin, a newly synthesized fluoroquinolone antibacterial, in lung epithelial lining fluid and alveolar macrophage in rats. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16875808/),,3.03,106946,DB00592,Piperazine
,16875808,AUC ratios,"The AUC ratios of ELF/plasma and AM/plasma of HSR-903 were 3.03+/-0.54 and 97.5+/-24.2, respectively, notably higher than those of ciprofloxacin (CPFX).","Distribution characteristics of orally administered olamufloxacin, a newly synthesized fluoroquinolone antibacterial, in lung epithelial lining fluid and alveolar macrophage in rats. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16875808/),,97.5,106947,DB00592,Piperazine
,9205820,binding constant Kd,"The estimate of the population parameter typical value (%CV) of the binding constant Kd and the maximal specific binding capacity (Bmax) was 0.385 (3.5) ng ml-1 plasma and 158 (2.1) ng ml-1 RBC, respectively.",Population analysis of the non linear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion rates. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205820/),[ng·plasma] / [ml],0.385,107061,DB00592,Piperazine
,9205820,maximal specific binding capacity (Bmax),"The estimate of the population parameter typical value (%CV) of the binding constant Kd and the maximal specific binding capacity (Bmax) was 0.385 (3.5) ng ml-1 plasma and 158 (2.1) ng ml-1 RBC, respectively.",Population analysis of the non linear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion rates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205820/),[ng] / [ml],158,107062,DB00592,Piperazine
,9205820,Emax,"In plasma, typical values (%CV) of Emax, IC50 and Hill factor were 81.4 (1.9)%, 3.76 (9.3) ng ml-1 and 1.06 (3.4), respectively.",Population analysis of the non linear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion rates. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205820/),%,81.,107063,DB00592,Piperazine
,9205820,Hill factor,"In plasma, typical values (%CV) of Emax, IC50 and Hill factor were 81.4 (1.9)%, 3.76 (9.3) ng ml-1 and 1.06 (3.4), respectively.",Population analysis of the non linear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion rates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205820/),,1.06,107064,DB00592,Piperazine
,9205820,Emax,"The relationship in whole blood was much steeper with population parameter typical values (%CV) of Emax, IC50 and Hill factor of 88.2 (2.0)%, 65.7 (2.8) ng ml-1 and 4.47 (5.5), respectively.",Population analysis of the non linear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion rates. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205820/),[ng] / [ml],88,107065,DB00592,Piperazine
,9205820,Hill factor,"The relationship in whole blood was much steeper with population parameter typical values (%CV) of Emax, IC50 and Hill factor of 88.2 (2.0)%, 65.7 (2.8) ng ml-1 and 4.47 (5.5), respectively.",Population analysis of the non linear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion rates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205820/),,4.47,107066,DB00592,Piperazine
,8895072,ED50,"The calibration curve for E-4424 from 12.5 to 6400 pg per well displays an ED50 of 34.5 pg per well, a slope factor of 0.86 and a minimum detectable dose of 4.1 pg per well.","Labelling of haptenic drug with digoxigenin for competitive immunoassay: its application to lesopitron, a new anxiolytic agent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8895072/),[pg] / [well],34.5,107160,DB00592,Piperazine
,8895072,minimum detectable dose,"The calibration curve for E-4424 from 12.5 to 6400 pg per well displays an ED50 of 34.5 pg per well, a slope factor of 0.86 and a minimum detectable dose of 4.1 pg per well.","Labelling of haptenic drug with digoxigenin for competitive immunoassay: its application to lesopitron, a new anxiolytic agent. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8895072/),[pg] / [well],4.1,107161,DB00592,Piperazine
,20016370,minimum therapeutic IM concentration,"In addition to the pharmacodynamic interest of this treatment, we found that the combined treatment significantly increased the IM Cmax (P<0.05) and significantly increased the IM trough concentration (C(24 h)) (P<0.01), which was always above the minimum therapeutic IM concentration (1 mumol/l) in plasma.","Interleukin-2 treatment effect on imatinib pharmacokinetic, P-gp and BCRP expression in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20016370/),[μM] / [l],1,108176,DB00592,Piperazine
,16758263,elimination half-life (t(1/2)),"Itraconazole raised the peak plasma loperamide concentration (Cmax) 2.9-fold (range, 1.2-5.0; P < 0.001) and the total area under the plasma loperamide concentration-time curve (AUC(0-infinity)) 3.8-fold (1.4-6.6; P < 0.001) and prolonged the elimination half-life (t(1/2)) of loperamide from 11.9 to 18.7 h (P < 0.001).","Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16758263/),h,11.,108340,DB00592,Piperazine
,16758263,elimination half-life (t(1/2)),"Itraconazole raised the peak plasma loperamide concentration (Cmax) 2.9-fold (range, 1.2-5.0; P < 0.001) and the total area under the plasma loperamide concentration-time curve (AUC(0-infinity)) 3.8-fold (1.4-6.6; P < 0.001) and prolonged the elimination half-life (t(1/2)) of loperamide from 11.9 to 18.7 h (P < 0.001).","Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16758263/),h,18,108341,DB00592,Piperazine
,16758263,t(1/2),Gemfibrozil raised the Cmax of loperamide 1.6-fold (0.9-3.2; P < 0.05) and its AUC(0-infinity) 2.2-fold (1.0-3.7; P < 0.05) and prolonged its t(1/2) to 16.7 h (P < 0.01).,"Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16758263/),h,16.7,108342,DB00592,Piperazine
,16758263,t(1/2),The combination of itraconazole and gemfibrozil raised the Cmax of loperamide 4.2-fold (1.5-8.7; P < 0.001) and its AUC(0-infinity) 12.6-fold (4.3-21.8; P < 0.001) and prolonged the t(1/2) of loperamide to 36.9 h (P < 0.001).,"Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16758263/),h,36.9,108343,DB00592,Piperazine
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],482,108437,DB00592,Piperazine
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],206,108438,DB00592,Piperazine
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],167,108439,DB00592,Piperazine
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],<,108440,DB00592,Piperazine
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],100,108441,DB00592,Piperazine
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],3160,108442,DB00592,Piperazine
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],2430,108443,DB00592,Piperazine
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],937,108444,DB00592,Piperazine
,9357389,area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)],"After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and < 100 nmol/L.hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L.hr in poor metabolizers, respectively.",Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],534,108445,DB00592,Piperazine
,9357389,AUC(0-6),Mean omeprazole AUC(0-6) increased from 1660 to 2265 nmol/L.hr in extensive metabolizers and from 7715 to 15319 nmol/L.hr in poor metabolizers after intake of 200 mg ketoconazole.,Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],1660,108446,DB00592,Piperazine
,9357389,AUC(0-6),Mean omeprazole AUC(0-6) increased from 1660 to 2265 nmol/L.hr in extensive metabolizers and from 7715 to 15319 nmol/L.hr in poor metabolizers after intake of 200 mg ketoconazole.,Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357389/),[nM] / [h·l],7715 to 15319,108447,DB00592,Piperazine
,22588199,t(max),A log brain/plasma concentration ratio at a t(max) of 1.48 suggests that SYA013 readily crosses the blood brain barrier (BBB).,"Evaluation of the behavioral and pharmacokinetic profile of SYA013, a homopiperazine analog of haloperidol in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22588199/),,1.48,109056,DB00592,Piperazine
,21822913,area under curve (0-∞),"The average area under curve (0-∞) of casopitant after a single 90-mg IV dose was 8,390 ng h/mL.","Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21822913/),[h·ng] / [ml],"8,390",109312,DB00592,Piperazine
,32764164,C m i n ∞ $,"The mean imatinib and nilotinib C m i n ∞ ${C}_{min}\hat{\infty }$ were 1,065.46 ± 765.71 and 1,445 ± 1,010.35 ng/mL respectively.",Relationship between trough level of tyrosine kinase inhibitor (imatinib and nilotinib) and BCR-ABL ratios in an Indonesian chronic-phase chronic myeloid leukemia (CML) population. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32764164/),[ng] / [ml],"1,065.46",109669,DB00592,Piperazine
,32764164,C m i n ∞ $,"The mean imatinib and nilotinib C m i n ∞ ${C}_{min}\hat{\infty }$ were 1,065.46 ± 765.71 and 1,445 ± 1,010.35 ng/mL respectively.",Relationship between trough level of tyrosine kinase inhibitor (imatinib and nilotinib) and BCR-ABL ratios in an Indonesian chronic-phase chronic myeloid leukemia (CML) population. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32764164/),[ng] / [ml],"1,445",109670,DB00592,Piperazine
≥,32764164,C m i n ∞ $,"Half of the patients in each group were found to reach C m i n ∞ ${C}_{min}\hat{\infty }$ target (≥1.000 ng/mL, imatinib; ≥800 ng/mL nilotinib), but only 12 (35,29%) of them result in BCR-ABL ratio ≤0.1%.",Relationship between trough level of tyrosine kinase inhibitor (imatinib and nilotinib) and BCR-ABL ratios in an Indonesian chronic-phase chronic myeloid leukemia (CML) population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32764164/),[ng] / [ml],1.000,109671,DB00592,Piperazine
≥,32764164,C m i n ∞ $,"Half of the patients in each group were found to reach C m i n ∞ ${C}_{min}\hat{\infty }$ target (≥1.000 ng/mL, imatinib; ≥800 ng/mL nilotinib), but only 12 (35,29%) of them result in BCR-ABL ratio ≤0.1%.",Relationship between trough level of tyrosine kinase inhibitor (imatinib and nilotinib) and BCR-ABL ratios in an Indonesian chronic-phase chronic myeloid leukemia (CML) population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32764164/),[ng] / [m],800,109672,DB00592,Piperazine
,6289740,mean plasma concentrations,"The mean plasma concentrations measured after the initial dose were 1.7 +/- 1.1 microgram/ml at 2 h, 0.9 +/- 0.2 microgram/ml at 6 h, and 0.7 +/- 0.4 microgram/ml at 8 h.",Pharmacokinetics of ketoconazole in patients with neoplastic diseases. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6289740/),[μg] / [ml],1.7,109925,DB00592,Piperazine
,6289740,mean plasma concentrations,"The mean plasma concentrations measured after the initial dose were 1.7 +/- 1.1 microgram/ml at 2 h, 0.9 +/- 0.2 microgram/ml at 6 h, and 0.7 +/- 0.4 microgram/ml at 8 h.",Pharmacokinetics of ketoconazole in patients with neoplastic diseases. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6289740/),[μg] / [ml],0.9,109926,DB00592,Piperazine
,6289740,mean plasma concentrations,"The mean plasma concentrations measured after the initial dose were 1.7 +/- 1.1 microgram/ml at 2 h, 0.9 +/- 0.2 microgram/ml at 6 h, and 0.7 +/- 0.4 microgram/ml at 8 h.",Pharmacokinetics of ketoconazole in patients with neoplastic diseases. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6289740/),[μg] / [ml],0.7,109927,DB00592,Piperazine
,6289740,Half-lives,Half-lives ranged from 1.3 to 11.6 h in individual patients.,Pharmacokinetics of ketoconazole in patients with neoplastic diseases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6289740/),h,1.3 to 11.6,109928,DB00592,Piperazine
,6289740,half-life,The mean half-life for all patients studied was 3.7 +/- 0.6 h on day 1.,Pharmacokinetics of ketoconazole in patients with neoplastic diseases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6289740/),h,3.7,109929,DB00592,Piperazine
,6289740,area under the curve,"The calculated area under the curve was 12.0 +/- 4.7 micrograms-h/ml on day 1; it increased after 7 and 14 days of administration (every-6-h schedule), suggesting plasma binding or wide drug distribution or both.",Pharmacokinetics of ketoconazole in patients with neoplastic diseases. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6289740/),[μgrams-h] / [ml],12.0,109930,DB00592,Piperazine
,22677485,flow rate,The mobile phase is acetonitrile-phosphate buffer (pH 3.6) 28:72% v/v at a flow rate of 1.0 mL/min.,High-performance liquid chromatographic assay for ziprasidone in plasma samples: application to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22677485/),[ml] / [min],1.0,110028,DB00592,Piperazine
,22677485,recoveries,"The mean recoveries of ZRS and IS are 79.32 ± 1.16 and 84.10 ± 3.2%, respectively.",High-performance liquid chromatographic assay for ziprasidone in plasma samples: application to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22677485/),%,79.32,110029,DB00592,Piperazine
,22677485,recoveries,"The mean recoveries of ZRS and IS are 79.32 ± 1.16 and 84.10 ± 3.2%, respectively.",High-performance liquid chromatographic assay for ziprasidone in plasma samples: application to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22677485/),%,84.10,110030,DB00592,Piperazine
,18164930,AUC0-8,"Using OMS as a carrier, the AUC0-8 was boosted to 681+/-566 nM h.",Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18164930/),h·nM,681,110143,DB00592,Piperazine
,18164930,AUC0-24,"In rabbits, the AUC0-24 increased significantly from 521+/-159 nM h after oral administration of crystalline itraconazole (8 mg) to 1069+/-278 nM h when this dose was loaded into OMS.",Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18164930/),h·nM,521,110144,DB00592,Piperazine
,18164930,AUC0-24,"In rabbits, the AUC0-24 increased significantly from 521+/-159 nM h after oral administration of crystalline itraconazole (8 mg) to 1069+/-278 nM h when this dose was loaded into OMS.",Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18164930/),h·nM,1069,110145,DB00592,Piperazine
,18164930,Tmax,Tmax decreased from 9.8+/-1.8 to 4.2+/-1.8h.,Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18164930/),h,9.8,110146,DB00592,Piperazine
,18164930,Tmax,Tmax decreased from 9.8+/-1.8 to 4.2+/-1.8h.,Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18164930/),h,4.2,110147,DB00592,Piperazine
,15470331,clearance,"St John's wort administration increased imatinib clearance by 43% ( P < .001), from 12.5 +/- 3.6 L/h to 17.9 +/- 5.6 L/h; imatinib area under the concentration versus time curve (AUC) extrapolated to infinity was decreased by 30%, from 34.5 +/- 9.5 microg . h/mL to 24.2 +/- 7.0 microg . h/mL ( P < .001).",Effect of St John's wort on imatinib mesylate pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470331/),[l] / [h],12.5,110451,DB00592,Piperazine
,15470331,clearance,"St John's wort administration increased imatinib clearance by 43% ( P < .001), from 12.5 +/- 3.6 L/h to 17.9 +/- 5.6 L/h; imatinib area under the concentration versus time curve (AUC) extrapolated to infinity was decreased by 30%, from 34.5 +/- 9.5 microg . h/mL to 24.2 +/- 7.0 microg . h/mL ( P < .001).",Effect of St John's wort on imatinib mesylate pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470331/),[l] / [h],17.9,110452,DB00592,Piperazine
,15470331,area under the concentration versus time curve (AUC),"St John's wort administration increased imatinib clearance by 43% ( P < .001), from 12.5 +/- 3.6 L/h to 17.9 +/- 5.6 L/h; imatinib area under the concentration versus time curve (AUC) extrapolated to infinity was decreased by 30%, from 34.5 +/- 9.5 microg . h/mL to 24.2 +/- 7.0 microg . h/mL ( P < .001).",Effect of St John's wort on imatinib mesylate pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470331/),[h·μg] / [ml],34.5,110453,DB00592,Piperazine
,15470331,area under the concentration versus time curve (AUC),"St John's wort administration increased imatinib clearance by 43% ( P < .001), from 12.5 +/- 3.6 L/h to 17.9 +/- 5.6 L/h; imatinib area under the concentration versus time curve (AUC) extrapolated to infinity was decreased by 30%, from 34.5 +/- 9.5 microg . h/mL to 24.2 +/- 7.0 microg . h/mL ( P < .001).",Effect of St John's wort on imatinib mesylate pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470331/),[h·μg] / [ml],24.2,110454,DB00592,Piperazine
,15470331,half-life,Imatinib half-life (12.8 hours versus 9.0 hours) and maximum concentration (C max ) (2.2 microg/mL versus 1.8 microg/mL) were also significantly decreased ( P < .005).,Effect of St John's wort on imatinib mesylate pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470331/),h,12.8,110455,DB00592,Piperazine
,15470331,half-life,Imatinib half-life (12.8 hours versus 9.0 hours) and maximum concentration (C max ) (2.2 microg/mL versus 1.8 microg/mL) were also significantly decreased ( P < .005).,Effect of St John's wort on imatinib mesylate pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470331/),h,9.0,110456,DB00592,Piperazine
,15470331,maximum concentration (C max ),Imatinib half-life (12.8 hours versus 9.0 hours) and maximum concentration (C max ) (2.2 microg/mL versus 1.8 microg/mL) were also significantly decreased ( P < .005).,Effect of St John's wort on imatinib mesylate pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470331/),[μg] / [ml],2.2,110457,DB00592,Piperazine
,15470331,maximum concentration (C max ),Imatinib half-life (12.8 hours versus 9.0 hours) and maximum concentration (C max ) (2.2 microg/mL versus 1.8 microg/mL) were also significantly decreased ( P < .005).,Effect of St John's wort on imatinib mesylate pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470331/),[μg] / [ml],1.8,110458,DB00592,Piperazine
,15470331,C max,"N -desmethyl-imatinib C max was increased from 285 +/- 95 ng/mL to 318 +/- 95 ng/mL during St John's wort dosing, but the AUC from 0 to 72 hours was not altered.",Effect of St John's wort on imatinib mesylate pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470331/),[ng] / [ml],285,110459,DB00592,Piperazine
,15470331,C max,"N -desmethyl-imatinib C max was increased from 285 +/- 95 ng/mL to 318 +/- 95 ng/mL during St John's wort dosing, but the AUC from 0 to 72 hours was not altered.",Effect of St John's wort on imatinib mesylate pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470331/),[ng] / [ml],318,110460,DB00592,Piperazine
,29851104,flow rate,"Chromatographic separation was achieved on a Phenomenex Kinetex C18 end-capped column (250 × 4.6 mm, 5 μm), with 38:62 v/v acetonitrile and ammonium acetate buffer (pH 5.0) as mobile phase at 1.0 mL/min flow rate.",Development and validation of rapid and sensitive LC methods with PDA and fluorescence detection for determination of piribedil in rat plasma and brain tissues and their pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29851104/),[ml] / [min],1.0,110856,DB00592,Piperazine
,23884662,flow rate,Chromatographic separation was achieved on C18 column using methanol: water (85:15 v/v) as mobile phase at a flow rate of 1 ml/min and UV detection at 230 nm.,Development and validation of RP-HPLC method for simultaneous estimation of glimepiride and sildenafil citrate in rat plasma-application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23884662/),[ml] / [min],1,110935,DB00592,Piperazine
,23884662,retention time,The retention time of GLIM and SIL was found to be 2.5 and 4.0 min respectively with total run time of 7 min.,Development and validation of RP-HPLC method for simultaneous estimation of glimepiride and sildenafil citrate in rat plasma-application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23884662/),min,2.5,110936,DB00592,Piperazine
,23884662,retention time,The retention time of GLIM and SIL was found to be 2.5 and 4.0 min respectively with total run time of 7 min.,Development and validation of RP-HPLC method for simultaneous estimation of glimepiride and sildenafil citrate in rat plasma-application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23884662/),min,4.0,110937,DB00592,Piperazine
,23884662,total run time,The retention time of GLIM and SIL was found to be 2.5 and 4.0 min respectively with total run time of 7 min.,Development and validation of RP-HPLC method for simultaneous estimation of glimepiride and sildenafil citrate in rat plasma-application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23884662/),min,7,110938,DB00592,Piperazine
,23400746,K(i),"In vitro studies indicated that ketoconazole inhibited the uptake of fimasartan into cells expressing OATP1B1 with a K(i) of 107.7 µM, and rifampicin inhibited OAT1- and OATP1B1-mediated fimasartan transport with a K(i) of 212 µM and 12.2 µM, respectively.","Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23400746/),μM,107.7,111419,DB00592,Piperazine
,23400746,K(i),"In vitro studies indicated that ketoconazole inhibited the uptake of fimasartan into cells expressing OATP1B1 with a K(i) of 107.7 µM, and rifampicin inhibited OAT1- and OATP1B1-mediated fimasartan transport with a K(i) of 212 µM and 12.2 µM, respectively.","Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23400746/),μM,212,111420,DB00592,Piperazine
,23400746,K(i),"In vitro studies indicated that ketoconazole inhibited the uptake of fimasartan into cells expressing OATP1B1 with a K(i) of 107.7 µM, and rifampicin inhibited OAT1- and OATP1B1-mediated fimasartan transport with a K(i) of 212 µM and 12.2 µM, respectively.","Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23400746/),μM,12.2,111421,DB00592,Piperazine
,15634033,volume of distribution at steady state,"Mean (%CV) population pharmacokinetic parameter estimates for delavirdine were: volume of distribution at steady state 67.6 (100) L, intrinsic oral clearance 19.8 (64) L/h, concentration at half the maximum velocity of metabolism (V(max)) 6.3 (69) micromol/L and first order oral clearance 0.57 (86) L/h.",Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15634033/),l,67.6,112615,DB00592,Piperazine
,15634033,intrinsic oral clearance,"Mean (%CV) population pharmacokinetic parameter estimates for delavirdine were: volume of distribution at steady state 67.6 (100) L, intrinsic oral clearance 19.8 (64) L/h, concentration at half the maximum velocity of metabolism (V(max)) 6.3 (69) micromol/L and first order oral clearance 0.57 (86) L/h.",Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15634033/),[l] / [h],19.8,112616,DB00592,Piperazine
,15634033,concentration at half the maximum velocity of metabolism (V(max)),"Mean (%CV) population pharmacokinetic parameter estimates for delavirdine were: volume of distribution at steady state 67.6 (100) L, intrinsic oral clearance 19.8 (64) L/h, concentration at half the maximum velocity of metabolism (V(max)) 6.3 (69) micromol/L and first order oral clearance 0.57 (86) L/h.",Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15634033/),[μM] / [l],6.3,112617,DB00592,Piperazine
,15634033,first order oral clearance,"Mean (%CV) population pharmacokinetic parameter estimates for delavirdine were: volume of distribution at steady state 67.6 (100) L, intrinsic oral clearance 19.8 (64) L/h, concentration at half the maximum velocity of metabolism (V(max)) 6.3 (69) micromol/L and first order oral clearance 0.57 (86) L/h.",Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15634033/),[l] / [h],0.57,112618,DB00592,Piperazine
,15634033,apparent volume of distribution,"For N-delavirdine, the mean (%CV) apparent volume of distribution was 24.7 (75) L and apparent clearance 29.7 (42) L/h.",Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15634033/),l,24.7,112619,DB00592,Piperazine
,15634033,apparent clearance,"For N-delavirdine, the mean (%CV) apparent volume of distribution was 24.7 (75) L and apparent clearance 29.7 (42) L/h.",Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15634033/),[l] / [h],29.7,112620,DB00592,Piperazine
,15634033,V(max),The mean V(max) was 1376 (68) mg/day.,Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15634033/),[mg] / [d],1376,112621,DB00592,Piperazine
,18571772,plasma half-life,The tracer had a plasma half-life of 77+/-1.7min and was rapidly taken up by all brain areas.,"Despite irreversible binding, PET tracer [11C]-SA5845 is suitable for imaging of drug competition at sigma receptors-the cases of ketamine and haloperidol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18571772/),min,77,112939,DB00592,Piperazine
,2544431,relative systemic availability,The relative systemic availability of itraconazole capsules compared with solution averaged 39.8% in the fasting state but 102% in the post-prandial state.,The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2544431/),%,39.8,113041,DB00592,Piperazine
,2544431,relative systemic availability,The relative systemic availability of itraconazole capsules compared with solution averaged 39.8% in the fasting state but 102% in the post-prandial state.,The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2544431/),%,102,113042,DB00592,Piperazine
,31386207,flow rate,The chromatography was performed in a gradient elution mode with a 1 mL/min flow rate.,"Simultaneous bioanalysis and pharmacokinetic interaction study of acebrophylline, levocetirizine and pranlukast in Sprague-Dawley rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31386207/),[ml] / [min],1,113096,DB00592,Piperazine
,10972485,peak plasma concentration (Cmax),"The peak plasma concentration (Cmax), time to Cmax (tmax), and bioavailability (F) of oral BG were: 2.3 +/- 0.9 microg/ml, 2.3 +/- 0.6 h, and 65.5% respectively.",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),[μg] / [ml],2.3,113127,DB00592,Piperazine
,10972485,time to Cmax (tmax),"The peak plasma concentration (Cmax), time to Cmax (tmax), and bioavailability (F) of oral BG were: 2.3 +/- 0.9 microg/ml, 2.3 +/- 0.6 h, and 65.5% respectively.",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),h,2.3,113128,DB00592,Piperazine
,10972485,bioavailability (F),"The peak plasma concentration (Cmax), time to Cmax (tmax), and bioavailability (F) of oral BG were: 2.3 +/- 0.9 microg/ml, 2.3 +/- 0.6 h, and 65.5% respectively.",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),%,65.5,113129,DB00592,Piperazine
,10972485,AUCs,The AUCs of BG and 8-oxo-BG were 13.1 +/- 4.6 microg x h/ml and 1.7 +/- 0.4 microg x h/ml after oral administration of BG.,Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),[h·μg] / [ml],13.1,113130,DB00592,Piperazine
,10972485,AUCs,The AUCs of BG and 8-oxo-BG were 13.1 +/- 4.6 microg x h/ml and 1.7 +/- 0.4 microg x h/ml after oral administration of BG.,Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),[h·μg] / [ml],1.7,113131,DB00592,Piperazine
,10972485,mean absorption time,"Coadministration with ketoconazole resulted in an increase in mean absorption time from 2.0 +/- 0.3 h to 6.0 +/- 0.9 h, a shift in tmax to 5 +/- 3.3 h, a decrease in Cmax to 0.96 +/- 0.8 microg/ml, and a decrease in AUC0-inf ratio of 8-oxo-BG:BG from about 0.12 to 0.04 (P < 0.05).",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),h,2.0,113132,DB00592,Piperazine
,10972485,mean absorption time,"Coadministration with ketoconazole resulted in an increase in mean absorption time from 2.0 +/- 0.3 h to 6.0 +/- 0.9 h, a shift in tmax to 5 +/- 3.3 h, a decrease in Cmax to 0.96 +/- 0.8 microg/ml, and a decrease in AUC0-inf ratio of 8-oxo-BG:BG from about 0.12 to 0.04 (P < 0.05).",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),h,6.0,113133,DB00592,Piperazine
,10972485,tmax,"Coadministration with ketoconazole resulted in an increase in mean absorption time from 2.0 +/- 0.3 h to 6.0 +/- 0.9 h, a shift in tmax to 5 +/- 3.3 h, a decrease in Cmax to 0.96 +/- 0.8 microg/ml, and a decrease in AUC0-inf ratio of 8-oxo-BG:BG from about 0.12 to 0.04 (P < 0.05).",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),h,5,113134,DB00592,Piperazine
,10972485,Cmax,"Coadministration with ketoconazole resulted in an increase in mean absorption time from 2.0 +/- 0.3 h to 6.0 +/- 0.9 h, a shift in tmax to 5 +/- 3.3 h, a decrease in Cmax to 0.96 +/- 0.8 microg/ml, and a decrease in AUC0-inf ratio of 8-oxo-BG:BG from about 0.12 to 0.04 (P < 0.05).",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),[μg] / [ml],0.96,113135,DB00592,Piperazine
,10972485,AUC0-inf ratio,"Coadministration with ketoconazole resulted in an increase in mean absorption time from 2.0 +/- 0.3 h to 6.0 +/- 0.9 h, a shift in tmax to 5 +/- 3.3 h, a decrease in Cmax to 0.96 +/- 0.8 microg/ml, and a decrease in AUC0-inf ratio of 8-oxo-BG:BG from about 0.12 to 0.04 (P < 0.05).",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),,0.12,113136,DB00592,Piperazine
,10972485,AUC0-inf ratio,"Coadministration with ketoconazole resulted in an increase in mean absorption time from 2.0 +/- 0.3 h to 6.0 +/- 0.9 h, a shift in tmax to 5 +/- 3.3 h, a decrease in Cmax to 0.96 +/- 0.8 microg/ml, and a decrease in AUC0-inf ratio of 8-oxo-BG:BG from about 0.12 to 0.04 (P < 0.05).",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),,0.04,113137,DB00592,Piperazine
,10972485,bioavailability,"The bioavailability of BG was not changed (65.5% vs 56.9%, P= 0.78).",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),%,65.5,113138,DB00592,Piperazine
,10972485,bioavailability,"The bioavailability of BG was not changed (65.5% vs 56.9%, P= 0.78).",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),%,56.9,113139,DB00592,Piperazine
,28968675,minimum inhibitory concentrations (MICs),F901318 minimum inhibitory concentrations (MICs) ranged from 0.015 to 0.06 mg/L. F901318 induced a concentration-dependent decline in galactomannan.,Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28968675/),[mg] / [l],0.015 to 0.06,113630,DB00592,Piperazine
,28968675,minimum concentration:MIC,"In the in vitro model, a minimum concentration:MIC of 10 resulted in suppression of galactomannan; however, values of approximately 10 and 9-19 when assessed by survival of mice or the decline in galactomannan, respectively, were equivalent or exceeded the effect induced by posaconazole.",Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28968675/),,10,113631,DB00592,Piperazine
,28968675,minimum concentration:MIC,"In the in vitro model, a minimum concentration:MIC of 10 resulted in suppression of galactomannan; however, values of approximately 10 and 9-19 when assessed by survival of mice or the decline in galactomannan, respectively, were equivalent or exceeded the effect induced by posaconazole.",Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28968675/),,9-19,113632,DB00592,Piperazine
,30217958,trough forced expiratory volume in 1 second,"Spirometry demonstrated no discernible difference in trough forced expiratory volume in 1 second (FEV1) from baseline (adjusted posterior median 7 ml; 95% credible interval -83, 102 ml) between nemiralisib and placebo treatment at day 28 (primary endpoint).","A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Repeat Doses of Inhaled Nemiralisib in Adults with Persistent, Uncontrolled Asthma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30217958/),ml,7,114008,DB00592,Piperazine
,8522641,plasma half-life (t1/2),"Mean single-dose plasma half-life (t1/2) values for nefazodone increased from approximately 1 hour at a 50-mg dose to approximately 2 hours at a 200-mg dose; at steady state, t1/2 values increased from approximately 2 hours at 50 mg twice daily to approximately 3.7 hours at 200 mg twice daily.",Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8522641/),h,1,114022,DB00592,Piperazine
,8522641,plasma half-life (t1/2),"Mean single-dose plasma half-life (t1/2) values for nefazodone increased from approximately 1 hour at a 50-mg dose to approximately 2 hours at a 200-mg dose; at steady state, t1/2 values increased from approximately 2 hours at 50 mg twice daily to approximately 3.7 hours at 200 mg twice daily.",Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8522641/),h,2,114023,DB00592,Piperazine
,8522641,t1/2,"Mean single-dose plasma half-life (t1/2) values for nefazodone increased from approximately 1 hour at a 50-mg dose to approximately 2 hours at a 200-mg dose; at steady state, t1/2 values increased from approximately 2 hours at 50 mg twice daily to approximately 3.7 hours at 200 mg twice daily.",Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8522641/),h,2,114024,DB00592,Piperazine
,8522641,t1/2,"Mean single-dose plasma half-life (t1/2) values for nefazodone increased from approximately 1 hour at a 50-mg dose to approximately 2 hours at a 200-mg dose; at steady state, t1/2 values increased from approximately 2 hours at 50 mg twice daily to approximately 3.7 hours at 200 mg twice daily.",Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8522641/),h,3.7,114025,DB00592,Piperazine
,30791754,area under the curve exposure from t = 0 to t = 8 hours [AUC0-8],Oral BT-11 resulted in low systemic exposure in both rats (area under the curve exposure from t = 0 to t = 8 hours [AUC0-8] of 216 h × ng/mL) and dogs (650 h × ng/mL) and rapid clearance with an average half-life of 3 hours.,"Nonclinical Toxicology and Toxicokinetic Profile of an Oral Lanthionine Synthetase C-Like 2 (LANCL2) Agonist, BT-11. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30791754/),[h·ng] / [ml],216,114217,DB00592,Piperazine
,30791754,area under the curve exposure from t = 0 to t = 8 hours [AUC0-8],Oral BT-11 resulted in low systemic exposure in both rats (area under the curve exposure from t = 0 to t = 8 hours [AUC0-8] of 216 h × ng/mL) and dogs (650 h × ng/mL) and rapid clearance with an average half-life of 3 hours.,"Nonclinical Toxicology and Toxicokinetic Profile of an Oral Lanthionine Synthetase C-Like 2 (LANCL2) Agonist, BT-11. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30791754/),[h·ng] / [ml],650,114218,DB00592,Piperazine
,30791754,half-life,Oral BT-11 resulted in low systemic exposure in both rats (area under the curve exposure from t = 0 to t = 8 hours [AUC0-8] of 216 h × ng/mL) and dogs (650 h × ng/mL) and rapid clearance with an average half-life of 3 hours.,"Nonclinical Toxicology and Toxicokinetic Profile of an Oral Lanthionine Synthetase C-Like 2 (LANCL2) Agonist, BT-11. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30791754/),h,3,114219,DB00592,Piperazine
>,30791754,no-observed adverse effect level,"Therefore, nonclinical studies show BT-11 to be a safe and well-tolerated oral therapeutic with potential as a potent immunometabolic therapy for UC and CD with no-observed adverse effect level >1,000 mg/kg in in vivo studies.","Nonclinical Toxicology and Toxicokinetic Profile of an Oral Lanthionine Synthetase C-Like 2 (LANCL2) Agonist, BT-11. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30791754/),[mg] / [kg],1,114220,DB00592,Piperazine
,3988401,peak plasma,"The peak plasma zopiclone concentration (65 ng/ml) occurred at 1.4 h after dosing and thereafter declined by a biexponential process, with half-lives of 2.0 and 6.5 h, to 3 ng/ml by 24 h after dosing.","A repeated dose pharmacokinetic study of a new hypnotic agent, zopiclone (Imovane). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988401/),[ng] / [ml],65,114255,DB00592,Piperazine
,3988401,half-lives,"The peak plasma zopiclone concentration (65 ng/ml) occurred at 1.4 h after dosing and thereafter declined by a biexponential process, with half-lives of 2.0 and 6.5 h, to 3 ng/ml by 24 h after dosing.","A repeated dose pharmacokinetic study of a new hypnotic agent, zopiclone (Imovane). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988401/),h,2.0,114256,DB00592,Piperazine
,3988401,half-lives,"The peak plasma zopiclone concentration (65 ng/ml) occurred at 1.4 h after dosing and thereafter declined by a biexponential process, with half-lives of 2.0 and 6.5 h, to 3 ng/ml by 24 h after dosing.","A repeated dose pharmacokinetic study of a new hypnotic agent, zopiclone (Imovane). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988401/),h,6.5,114257,DB00592,Piperazine
,3988401,half-lives,"The peak plasma zopiclone concentration (65 ng/ml) occurred at 1.4 h after dosing and thereafter declined by a biexponential process, with half-lives of 2.0 and 6.5 h, to 3 ng/ml by 24 h after dosing.","A repeated dose pharmacokinetic study of a new hypnotic agent, zopiclone (Imovane). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988401/),[ng] / [ml],3,114258,DB00592,Piperazine
,26209833,MIC,"Docking studies were performed to gain an insight into the binding mode and interactions of the most promising compound 12 [oxo derivative], comprising of reverse transcriptase (RT) inhibitory (72.30%), spermicidal (MEC 0.01%), anti-Trichomonas (MIC 46.72 μM) and antifungal (MIC 9.34-74.8 μM) activities, along with its hydroxyl (17) and O-alkylated 4-trifluoromethylphenoxy (22) derivative, with similar activities.",N-Alkyl/aryl-4-(3-substituted-3-phenylpropyl)piperazine-1-carbothioamide as dual-action vaginal microbicides with reverse transcriptase inhibition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26209833/),μM,46,114421,DB00592,Piperazine
,26209833,MIC,"Docking studies were performed to gain an insight into the binding mode and interactions of the most promising compound 12 [oxo derivative], comprising of reverse transcriptase (RT) inhibitory (72.30%), spermicidal (MEC 0.01%), anti-Trichomonas (MIC 46.72 μM) and antifungal (MIC 9.34-74.8 μM) activities, along with its hydroxyl (17) and O-alkylated 4-trifluoromethylphenoxy (22) derivative, with similar activities.",N-Alkyl/aryl-4-(3-substituted-3-phenylpropyl)piperazine-1-carbothioamide as dual-action vaginal microbicides with reverse transcriptase inhibition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26209833/),μM,9.34-74.8,114422,DB00592,Piperazine
,2781141,systemic clearance,Ketoconazole decreased the systemic clearance of cyclosporine from 7.0 ml/min/kg to 2.5 ml/min/kg.,Pharmacokinetics of the cyclosporine-ketoconazole interaction in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2781141/),[ml] / [kg·min],7.0,114731,DB00592,Piperazine
,2781141,systemic clearance,Ketoconazole decreased the systemic clearance of cyclosporine from 7.0 ml/min/kg to 2.5 ml/min/kg.,Pharmacokinetics of the cyclosporine-ketoconazole interaction in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2781141/),[ml] / [kg·min],2.5,114732,DB00592,Piperazine
,2781141,terminal disposition rate constant,The terminal disposition rate constant was also decreased significantly from 0.0794 to 0.0354 hrs-1.,Pharmacokinetics of the cyclosporine-ketoconazole interaction in dogs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2781141/),1/[h],0.0794,114733,DB00592,Piperazine
,2781141,terminal disposition rate constant,The terminal disposition rate constant was also decreased significantly from 0.0794 to 0.0354 hrs-1.,Pharmacokinetics of the cyclosporine-ketoconazole interaction in dogs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2781141/),1/[h],0.0354,114734,DB00592,Piperazine
,9164415,fraction unbound,"Plasma protein binding was linear for delavirdine in the escalating-dose and control groups; on average, the fraction unbound was about 2.3% and 2.0%, respectively.",Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164415/),%,2.3,115170,DB00592,Piperazine
,9164415,fraction unbound,"Plasma protein binding was linear for delavirdine in the escalating-dose and control groups; on average, the fraction unbound was about 2.3% and 2.0%, respectively.",Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164415/),%,2.0,115171,DB00592,Piperazine
,9164415,IC50,"Delavirdine could maximally inhibit 70% to 75% of predose ERMBT values, with an IC50 of about 0.9 mumol/L.",Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164415/),[μM] / [l],0.9,115172,DB00592,Piperazine
<,15901743,Tmax,Absorption of IM ziprasidone was rapid (Tmax < 1 hour).,"Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901743/),h,1,115327,DB00592,Piperazine
,15901743,elimination t(1/2),The mean IM elimination t(1/2) was short and approximately 2.5 hours.,"Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901743/),h,2.5,115328,DB00592,Piperazine
,15901743,bioavailability,The mean bioavailability for the 5-mg IM ziprasidone dose was approximately 100%.,"Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901743/),%,100,115329,DB00592,Piperazine
,28417436,area under the plasma concentration-time curve up to the last quantifiable time,"There was no statistically significant difference in pharmacokinetic parameters between groups: area under the plasma concentration-time curve up to the last quantifiable time and maximum plasma concentration were about 174-175 ng·h/mL and 134-153 ng/mL, respectively, after the loading dose; and about 25-26 ng·h/mL and 25 ng/mL, respectively, after the maintenance dose.",Evaluation of the Pharmacokinetics and Pharmacodynamics of Prasugrel in Japanese Elderly Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28417436/),[h·ng] / [ml],174-175,115492,DB00592,Piperazine
,28417436,area under the plasma concentration-time curve up to the last quantifiable time,"There was no statistically significant difference in pharmacokinetic parameters between groups: area under the plasma concentration-time curve up to the last quantifiable time and maximum plasma concentration were about 174-175 ng·h/mL and 134-153 ng/mL, respectively, after the loading dose; and about 25-26 ng·h/mL and 25 ng/mL, respectively, after the maintenance dose.",Evaluation of the Pharmacokinetics and Pharmacodynamics of Prasugrel in Japanese Elderly Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28417436/),[h·ng] / [ml],25-26,115493,DB00592,Piperazine
,28417436,maximum plasma concentration,"There was no statistically significant difference in pharmacokinetic parameters between groups: area under the plasma concentration-time curve up to the last quantifiable time and maximum plasma concentration were about 174-175 ng·h/mL and 134-153 ng/mL, respectively, after the loading dose; and about 25-26 ng·h/mL and 25 ng/mL, respectively, after the maintenance dose.",Evaluation of the Pharmacokinetics and Pharmacodynamics of Prasugrel in Japanese Elderly Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28417436/),[ng] / [ml],134-153,115494,DB00592,Piperazine
,28417436,maximum plasma concentration,"There was no statistically significant difference in pharmacokinetic parameters between groups: area under the plasma concentration-time curve up to the last quantifiable time and maximum plasma concentration were about 174-175 ng·h/mL and 134-153 ng/mL, respectively, after the loading dose; and about 25-26 ng·h/mL and 25 ng/mL, respectively, after the maintenance dose.",Evaluation of the Pharmacokinetics and Pharmacodynamics of Prasugrel in Japanese Elderly Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28417436/),[h·ng] / [ml],25-26,115495,DB00592,Piperazine
,28417436,maximum plasma concentration,"There was no statistically significant difference in pharmacokinetic parameters between groups: area under the plasma concentration-time curve up to the last quantifiable time and maximum plasma concentration were about 174-175 ng·h/mL and 134-153 ng/mL, respectively, after the loading dose; and about 25-26 ng·h/mL and 25 ng/mL, respectively, after the maintenance dose.",Evaluation of the Pharmacokinetics and Pharmacodynamics of Prasugrel in Japanese Elderly Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28417436/),[ng] / [ml],25,115496,DB00592,Piperazine
>,32457106,blood C trough levels,"At the end of the steady-state administration study, 13 of 16 volunteers obtained higher mean ITZ blood C trough levels of >1,000 ng/ml when they were administered S-ITZ (81%) than when they were administered C-ITZ (44%).",Open-Label Crossover Oral Bioequivalence Pharmacokinetics Comparison for a 3-Day Loading Dose Regimen and 15-Day Steady-State Administration of SUBA-Itraconazole and Conventional Itraconazole Capsules in Healthy Adults. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32457106/),[ng] / [ml],"1,000",115622,DB00592,Piperazine
,25991065,solubility,Spherical crystal agglomerates (SCA) of itraconazole prepared by quasi emulsification solvent diffusion method using Soluplus and polyethylene glycol 4000 (PEG 4000) showed increased solubility (540 μg/ml) in 0.1 N hydrochloric acid as compared to pure drug (12 μg/ml).,Formulation Development of Spherical Crystal Agglomerates of Itraconazole for Preparation of Directly Compressible Tablets with Enhanced Bioavailability. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25991065/),[μg] / [ml],540,115702,DB00592,Piperazine
,25991065,solubility,Spherical crystal agglomerates (SCA) of itraconazole prepared by quasi emulsification solvent diffusion method using Soluplus and polyethylene glycol 4000 (PEG 4000) showed increased solubility (540 μg/ml) in 0.1 N hydrochloric acid as compared to pure drug (12 μg/ml).,Formulation Development of Spherical Crystal Agglomerates of Itraconazole for Preparation of Directly Compressible Tablets with Enhanced Bioavailability. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25991065/),[μg] / [ml],12,115703,DB00592,Piperazine
,25991065,disintegration time,The optimized SCA formulation could be easily compressed into tablet with desirable characteristics of hardness (5 kg/cm(2)) and disintegration time (6.3 min).,Formulation Development of Spherical Crystal Agglomerates of Itraconazole for Preparation of Directly Compressible Tablets with Enhanced Bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25991065/),min,6.3,115704,DB00592,Piperazine
,25991065,relative bioavailability,In vivo pharmacokinetic showed significant enhancement in C max and AUC0-t with relative bioavailability of 225%.,Formulation Development of Spherical Crystal Agglomerates of Itraconazole for Preparation of Directly Compressible Tablets with Enhanced Bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25991065/),%,225,115705,DB00592,Piperazine
,8591940,areas under the serum-concentration time curves,"Mean areas under the serum-concentration time curves were also markedly higher in patients receiving 5 mg/kg/day than in those receiving 2.5 mg/kg/day itraconazole and were 22,382 and 5615 micrograms.h/L on day 15 respectively.",Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8591940/),[h·μg] / [l],"22,382",115984,DB00592,Piperazine
,8591940,areas under the serum-concentration time curves,"Mean areas under the serum-concentration time curves were also markedly higher in patients receiving 5 mg/kg/day than in those receiving 2.5 mg/kg/day itraconazole and were 22,382 and 5615 micrograms.h/L on day 15 respectively.",Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8591940/),[h·μg] / [l],5615,115985,DB00592,Piperazine
,8033487,half-life,Peak plasma triazolam concentrations preceded maximum pharmacodynamic effects; the mean plasma effect site equilibration half-life was 9.4 minutes.,Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8033487/),min,9.4,116162,DB00592,Piperazine
,31911203,total running time,"The total running time was 3 min, and the retention time of JJH201501 and JJH201501-01 was 1.17 min and 1.05 min, respectively.",Simultaneous determination of deuterated vortioxetine and its major metabolite in human plasma by UPLC-MS/MS and application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31911203/),min,3,116719,DB00592,Piperazine
,31911203,retention time,"The total running time was 3 min, and the retention time of JJH201501 and JJH201501-01 was 1.17 min and 1.05 min, respectively.",Simultaneous determination of deuterated vortioxetine and its major metabolite in human plasma by UPLC-MS/MS and application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31911203/),min,1.17,116720,DB00592,Piperazine
,31911203,retention time,"The total running time was 3 min, and the retention time of JJH201501 and JJH201501-01 was 1.17 min and 1.05 min, respectively.",Simultaneous determination of deuterated vortioxetine and its major metabolite in human plasma by UPLC-MS/MS and application to a pharmacokinetic study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31911203/),min,1.05,116721,DB00592,Piperazine
,21395644,t(max),Median t(max) was 6.0 h with both regimens.,Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395644/),h,6.0,116760,DB00592,Piperazine
,21395644,apparent oral clearance,Ketoconazole decreased mean apparent oral clearance of neratinib from 346 lh(-1) to 87.1 lh(-1) and increased mean elimination half-life from 11.7 h to 18.0 h.,Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395644/),1/[lh],346,116761,DB00592,Piperazine
,21395644,apparent oral clearance,Ketoconazole decreased mean apparent oral clearance of neratinib from 346 lh(-1) to 87.1 lh(-1) and increased mean elimination half-life from 11.7 h to 18.0 h.,Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395644/),1/[lh],87.1,116762,DB00592,Piperazine
,21395644,elimination half-life,Ketoconazole decreased mean apparent oral clearance of neratinib from 346 lh(-1) to 87.1 lh(-1) and increased mean elimination half-life from 11.7 h to 18.0 h.,Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395644/),h,11.7,116763,DB00592,Piperazine
,21395644,elimination half-life,Ketoconazole decreased mean apparent oral clearance of neratinib from 346 lh(-1) to 87.1 lh(-1) and increased mean elimination half-life from 11.7 h to 18.0 h.,Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395644/),h,18.0,116764,DB00592,Piperazine
,17640490,tissue/plasma ratio of,"After the oral administration of [14C]SK-3530, the radioactivity was widely distributed in all tissues, and the tissue/plasma ratio of the radioactivity 1 h after administration was calculated as 0.5-2.6 with the exception of excretory organs.","Pharmacokinetics and tissue distribution of a novel PDE5 inhibitor, SK-3530, in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17640490/),,0.5-2.6,116958,DB00592,Piperazine
more,17640490,binding rate,In vitro and ex vivo plasma protein binding assay by ultrafiltration showed a considerably high binding rate of more than 97%.,"Pharmacokinetics and tissue distribution of a novel PDE5 inhibitor, SK-3530, in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17640490/),%,97,116959,DB00592,Piperazine
,20517714,flux,"BUSP-OPT (optimized formulation) showed a flux 104.6 microg cm(-2) h(-1), which could meet target flux.","Enhanced bioavailability of buspirone from reservoir-based transdermal therapeutic system, optimization of formulation employing Box-Behnken statistical design. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20517714/),[μg] / [(cm)^2·h],104.6,116977,DB00592,Piperazine
,10411220,accumulation factor,The accumulation factor on day 7 for buspirone was nearly 5 for Cmax and 7 for AUC when compared with day 1.,Pharmacokinetics of buspirone following oral administration to rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10411220/),,5,117022,DB00592,Piperazine
,10411220,accumulation factor,The accumulation factor on day 7 for buspirone was nearly 5 for Cmax and 7 for AUC when compared with day 1.,Pharmacokinetics of buspirone following oral administration to rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10411220/),,7,117023,DB00592,Piperazine
,28212021,Ki,"It has high affinity at human 5-HT6R (Ki = 2.04 nM) and selectivity over 100 target sites which include receptors, enzymes, peptides, growth factors, ion channels, steroids, immunological factors, second messengers, and prostaglandins.","Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT6) Receptor Antagonist for Potential Treatment of Alzheimer's Disease. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28212021/),nM,2.04,117337,DB00592,Piperazine
,24847516,recoveries,The mean recoveries of dapiprazole from DBS and urine were 93.88 and 90.29% respectively.,Development of LC-MS/MS method for the determination of dapiprazole on dried blood spots and urine: application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847516/),%,93.88,117476,DB00592,Piperazine
,24847516,recoveries,The mean recoveries of dapiprazole from DBS and urine were 93.88 and 90.29% respectively.,Development of LC-MS/MS method for the determination of dapiprazole on dried blood spots and urine: application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847516/),%,90.29,117477,DB00592,Piperazine
,24847516,limits of detection,"The limits of detection and quantification were 0.30 and 1.10 ng/mL in DBS and 0.45 and 1.50 ng/mL in urine samples, respectively.",Development of LC-MS/MS method for the determination of dapiprazole on dried blood spots and urine: application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847516/),[ng] / [ml],0.30,117478,DB00592,Piperazine
,24847516,limits of detection,"The limits of detection and quantification were 0.30 and 1.10 ng/mL in DBS and 0.45 and 1.50 ng/mL in urine samples, respectively.",Development of LC-MS/MS method for the determination of dapiprazole on dried blood spots and urine: application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847516/),[ng] / [ml],1.10,117479,DB00592,Piperazine
,24847516,limits of detection,"The limits of detection and quantification were 0.30 and 1.10 ng/mL in DBS and 0.45 and 1.50 ng/mL in urine samples, respectively.",Development of LC-MS/MS method for the determination of dapiprazole on dried blood spots and urine: application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847516/),[ng] / [ml],0.45,117480,DB00592,Piperazine
,24847516,limits of detection,"The limits of detection and quantification were 0.30 and 1.10 ng/mL in DBS and 0.45 and 1.50 ng/mL in urine samples, respectively.",Development of LC-MS/MS method for the determination of dapiprazole on dried blood spots and urine: application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847516/),[ng] / [ml],1.50,117481,DB00592,Piperazine
,3689635,AUC,The mean AUC of buspirone was 55 +/- 38 s.d. ng ml-1 h in cirrhotics and 3.5 +/- 2.4 s.d. ng ml-1 h in normals.,Buspirone pharmacokinetics in patients with cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689635/),[h·ng] / [ml],55,117589,DB00592,Piperazine
,3689635,AUC,The mean AUC of buspirone was 55 +/- 38 s.d. ng ml-1 h in cirrhotics and 3.5 +/- 2.4 s.d. ng ml-1 h in normals.,Buspirone pharmacokinetics in patients with cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689635/),[h·ng] / [ml],3.5,117590,DB00592,Piperazine
,3689635,time until maximum concentration (tmax),"The time until maximum concentration (tmax) attained was similar in the two groups (0.6 vs 0.7 h), but mean maximum concentration Cmax was higher in patients (18.8 +/- 16.3 s.d. ng ml-1) than in normals (1.2 +/- 0.8 s.d. ng ml-1).",Buspirone pharmacokinetics in patients with cirrhosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689635/),h,0.6,117591,DB00592,Piperazine
,3689635,time until maximum concentration (tmax),"The time until maximum concentration (tmax) attained was similar in the two groups (0.6 vs 0.7 h), but mean maximum concentration Cmax was higher in patients (18.8 +/- 16.3 s.d. ng ml-1) than in normals (1.2 +/- 0.8 s.d. ng ml-1).",Buspirone pharmacokinetics in patients with cirrhosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689635/),h,0.7,117592,DB00592,Piperazine
,3689635,maximum concentration Cmax,"The time until maximum concentration (tmax) attained was similar in the two groups (0.6 vs 0.7 h), but mean maximum concentration Cmax was higher in patients (18.8 +/- 16.3 s.d. ng ml-1) than in normals (1.2 +/- 0.8 s.d. ng ml-1).",Buspirone pharmacokinetics in patients with cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689635/),,18.8,117593,DB00592,Piperazine
,3689635,maximum concentration Cmax,"The time until maximum concentration (tmax) attained was similar in the two groups (0.6 vs 0.7 h), but mean maximum concentration Cmax was higher in patients (18.8 +/- 16.3 s.d. ng ml-1) than in normals (1.2 +/- 0.8 s.d. ng ml-1).",Buspirone pharmacokinetics in patients with cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689635/),[ng] / [ml],1.2,117594,DB00592,Piperazine
,3689635,elimination half-life,"Mean elimination half-life of buspirone was greater in cirrhotics, but this difference was marginally significant statistically (cirrhotics, 6.1 +/- 3.5 s.d. h, normals 3.2 +/- 1.5 s.d. h, P = 0.05).",Buspirone pharmacokinetics in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689635/),,6.1,117595,DB00592,Piperazine
,3689635,elimination half-life,"Mean elimination half-life of buspirone was greater in cirrhotics, but this difference was marginally significant statistically (cirrhotics, 6.1 +/- 3.5 s.d. h, normals 3.2 +/- 1.5 s.d. h, P = 0.05).",Buspirone pharmacokinetics in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689635/),,3.2,117596,DB00592,Piperazine
,3689635,concentration,"In patients this occurred at 10.8 +/- 7.4 s.d. h after the dose, and its mean concentration was 3.1 +/- 6.6 ng ml-1.",Buspirone pharmacokinetics in patients with cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689635/),[ng] / [ml],3.1,117597,DB00592,Piperazine
,3689635,concentration,In normal subjects the second peak occurred at 4.3 +/- 2.1 h after the dose and its mean concentration was 0.5 +/- 0.3 ng ml-1.,Buspirone pharmacokinetics in patients with cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689635/),[ng] / [ml],0.5,117598,DB00592,Piperazine
,11121732,oral bioavailability,"In P-glycoprotein knockout mice, the oral bioavailability of UK-224,671 was 22%, representing a significant increase over the P-glycoprotein expressing wild type mice (<2%).","The role of P-glycoprotein in determining the oral absorption and clearance of the NK2 antagonist, UK-224,671. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11121732/),%,22,118481,DB00592,Piperazine
<,11121732,oral bioavailability,"In P-glycoprotein knockout mice, the oral bioavailability of UK-224,671 was 22%, representing a significant increase over the P-glycoprotein expressing wild type mice (<2%).","The role of P-glycoprotein in determining the oral absorption and clearance of the NK2 antagonist, UK-224,671. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11121732/),%,2,118482,DB00592,Piperazine
,30055824,plasma Cmax,"Near-dose proportionality was observed: mean (95% CI) plasma Cmax and AUC0-24 values were 174.3 pg/mL (96.9-313.3) and 694.6 pg·h/mL (503.5-958.2) for 100 μg and 398.9 pg/mL (318.3-500.1) and 1699.6 pg·h/mL (1273.3-2268.7) for 200 μg, respectively.","Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of Nemiralisib Administered via the Ellipta Dry Powder Inhaler to Healthy Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30055824/),[pg] / [ml],174.3,118691,DB00592,Piperazine
,30055824,plasma Cmax,"Near-dose proportionality was observed: mean (95% CI) plasma Cmax and AUC0-24 values were 174.3 pg/mL (96.9-313.3) and 694.6 pg·h/mL (503.5-958.2) for 100 μg and 398.9 pg/mL (318.3-500.1) and 1699.6 pg·h/mL (1273.3-2268.7) for 200 μg, respectively.","Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of Nemiralisib Administered via the Ellipta Dry Powder Inhaler to Healthy Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30055824/),[pg] / [ml],398.9,118692,DB00592,Piperazine
,30055824,AUC0-24,"Near-dose proportionality was observed: mean (95% CI) plasma Cmax and AUC0-24 values were 174.3 pg/mL (96.9-313.3) and 694.6 pg·h/mL (503.5-958.2) for 100 μg and 398.9 pg/mL (318.3-500.1) and 1699.6 pg·h/mL (1273.3-2268.7) for 200 μg, respectively.","Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of Nemiralisib Administered via the Ellipta Dry Powder Inhaler to Healthy Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30055824/),[h·pg] / [ml],694.6,118693,DB00592,Piperazine
,30055824,AUC0-24,"Near-dose proportionality was observed: mean (95% CI) plasma Cmax and AUC0-24 values were 174.3 pg/mL (96.9-313.3) and 694.6 pg·h/mL (503.5-958.2) for 100 μg and 398.9 pg/mL (318.3-500.1) and 1699.6 pg·h/mL (1273.3-2268.7) for 200 μg, respectively.","Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of Nemiralisib Administered via the Ellipta Dry Powder Inhaler to Healthy Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30055824/),[h·pg] / [ml],1699.6,118694,DB00592,Piperazine
,30055824,AUC0-24,Mean AUC0-24 was 2193.6 pg·h/mL and 1645.3 pg·h/mL in the absence/presence of charcoal.,"Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of Nemiralisib Administered via the Ellipta Dry Powder Inhaler to Healthy Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30055824/),[h·pg] / [ml],2193.6,118695,DB00592,Piperazine
,30055824,AUC0-24,Mean AUC0-24 was 2193.6 pg·h/mL and 1645.3 pg·h/mL in the absence/presence of charcoal.,"Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of Nemiralisib Administered via the Ellipta Dry Powder Inhaler to Healthy Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30055824/),[h·pg] / [ml],1645.3,118696,DB00592,Piperazine
,29396378,Limit of detection,"Limit of detection has been obtained as 0.083μg/mL and 0.472μg/mL respectively, for HPLC and UV-Visible techniques, corresponding to assessed linearity range.","Cloud point extraction coupled with microwave-assisted back-extraction (CPE-MABE) for determination of Eszopiclone (Z-drug) using UV-Visible, HPLC and mass spectroscopic (MS) techniques: Spiked and in vivo analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29396378/),[μg] / [ml],0.083,119382,DB00592,Piperazine
,29396378,Limit of detection,"Limit of detection has been obtained as 0.083μg/mL and 0.472μg/mL respectively, for HPLC and UV-Visible techniques, corresponding to assessed linearity range.","Cloud point extraction coupled with microwave-assisted back-extraction (CPE-MABE) for determination of Eszopiclone (Z-drug) using UV-Visible, HPLC and mass spectroscopic (MS) techniques: Spiked and in vivo analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29396378/),[μg] / [ml],0.472,119383,DB00592,Piperazine
,29396378,extraction recovery,"Under optimized conditions i.e. Aqueous-Triton X-114 4% (w/v), pH4.0, NaCl 4% (w/v) and equilibrium temperature of 45°C for 20min, average extraction recovery has been obtained between 89.8 and 99.2% and 84.0-99.2% from UV-Visible and HPLC analysis, respectively.","Cloud point extraction coupled with microwave-assisted back-extraction (CPE-MABE) for determination of Eszopiclone (Z-drug) using UV-Visible, HPLC and mass spectroscopic (MS) techniques: Spiked and in vivo analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29396378/),%,89.8 and 99.2,119384,DB00592,Piperazine
,29396378,extraction recovery,"Under optimized conditions i.e. Aqueous-Triton X-114 4% (w/v), pH4.0, NaCl 4% (w/v) and equilibrium temperature of 45°C for 20min, average extraction recovery has been obtained between 89.8 and 99.2% and 84.0-99.2% from UV-Visible and HPLC analysis, respectively.","Cloud point extraction coupled with microwave-assisted back-extraction (CPE-MABE) for determination of Eszopiclone (Z-drug) using UV-Visible, HPLC and mass spectroscopic (MS) techniques: Spiked and in vivo analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29396378/),%,84.0-99.2,119385,DB00592,Piperazine
,22696419,P(app),"Studies in parental Madin-Darby canine kidney cells indicated that GDC-0980 had high permeability (P(app) = 18 × 10⁻⁶ cm/s), suggesting good absorption potential.",Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22696419/),[cm] / [s],18 × 10⁻⁶,119505,DB00592,Piperazine
,22696419,fraction unbound,"Plasma protein binding was low, with the fraction unbound ranging from 29 to 52% across species.",Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22696419/),%,29 to 52,119506,DB00592,Piperazine
,22696419,plasma CL,"The plasma CL of GDC-0980 was low in mouse (6.30 ml · min⁻¹ · kg⁻¹), rat (15.4 ml · min⁻¹ · kg⁻¹), and dog (6.37 ml · min⁻¹ · kg⁻¹) and moderate in cynomolgus monkey (18.9 ml · min⁻¹ · kg⁻¹).",Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22696419/),kg⁻¹·min⁻¹·ml,6.30,119507,DB00592,Piperazine
,22696419,plasma CL,"The plasma CL of GDC-0980 was low in mouse (6.30 ml · min⁻¹ · kg⁻¹), rat (15.4 ml · min⁻¹ · kg⁻¹), and dog (6.37 ml · min⁻¹ · kg⁻¹) and moderate in cynomolgus monkey (18.9 ml · min⁻¹ · kg⁻¹).",Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22696419/),kg⁻¹·min⁻¹·ml,15.4,119508,DB00592,Piperazine
,22696419,plasma CL,"The plasma CL of GDC-0980 was low in mouse (6.30 ml · min⁻¹ · kg⁻¹), rat (15.4 ml · min⁻¹ · kg⁻¹), and dog (6.37 ml · min⁻¹ · kg⁻¹) and moderate in cynomolgus monkey (18.9 ml · min⁻¹ · kg⁻¹).",Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22696419/),kg⁻¹·min⁻¹·ml,6.37,119509,DB00592,Piperazine
,22696419,plasma CL,"The plasma CL of GDC-0980 was low in mouse (6.30 ml · min⁻¹ · kg⁻¹), rat (15.4 ml · min⁻¹ · kg⁻¹), and dog (6.37 ml · min⁻¹ · kg⁻¹) and moderate in cynomolgus monkey (18.9 ml · min⁻¹ · kg⁻¹).",Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22696419/),kg⁻¹·min⁻¹·ml,18.9,119510,DB00592,Piperazine
,22696419,Oral bioavailability,Oral bioavailability ranged from 14.4% in monkey to 125% in dog.,Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22696419/),%,14.4,119511,DB00592,Piperazine
,22696419,Oral bioavailability,Oral bioavailability ranged from 14.4% in monkey to 125% in dog.,Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22696419/),%,125,119512,DB00592,Piperazine
,22696419,CL,"Predicted human plasma CL and volume of distribution using allometry were 5.1 ml · min⁻¹ · kg⁻¹ and 1.8 l/kg, respectively.",Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22696419/),kg⁻¹·min⁻¹·ml,5.1,119513,DB00592,Piperazine
,22696419,volume of distribution,"Predicted human plasma CL and volume of distribution using allometry were 5.1 ml · min⁻¹ · kg⁻¹ and 1.8 l/kg, respectively.",Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22696419/),[l] / [kg],1.8,119514,DB00592,Piperazine
,17701834,blood clearance,"Based on the Clint values, in vivo blood clearance of 3.35 and 2.48 L/h/kg were predicted in naive and FCA-treated rats.",Use of Freund's Complete Adjuvant (FCA) in inflammatory pain models: consequences on the metabolism and pharmacokinetics of the non-peptidic delta receptor agonist SNC80 in the rat. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17701834/),[l] / [h·kg],3.35,119797,DB00592,Piperazine
,17701834,blood clearance,"Based on the Clint values, in vivo blood clearance of 3.35 and 2.48 L/h/kg were predicted in naive and FCA-treated rats.",Use of Freund's Complete Adjuvant (FCA) in inflammatory pain models: consequences on the metabolism and pharmacokinetics of the non-peptidic delta receptor agonist SNC80 in the rat. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17701834/),[l] / [h·kg],2.48,119798,DB00592,Piperazine
,17701834,plasma clearance,"The naive animals showed high plasma clearance (3.1 L/h/kg), low renal clearance (<0.02 L/h/kg) and poor bioavailability (<4%).",Use of Freund's Complete Adjuvant (FCA) in inflammatory pain models: consequences on the metabolism and pharmacokinetics of the non-peptidic delta receptor agonist SNC80 in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17701834/),[l] / [h·kg],3.1,119799,DB00592,Piperazine
<,17701834,renal clearance,"The naive animals showed high plasma clearance (3.1 L/h/kg), low renal clearance (<0.02 L/h/kg) and poor bioavailability (<4%).",Use of Freund's Complete Adjuvant (FCA) in inflammatory pain models: consequences on the metabolism and pharmacokinetics of the non-peptidic delta receptor agonist SNC80 in the rat. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17701834/),[l] / [h·kg],0.02,119800,DB00592,Piperazine
<,17701834,bioavailability,"The naive animals showed high plasma clearance (3.1 L/h/kg), low renal clearance (<0.02 L/h/kg) and poor bioavailability (<4%).",Use of Freund's Complete Adjuvant (FCA) in inflammatory pain models: consequences on the metabolism and pharmacokinetics of the non-peptidic delta receptor agonist SNC80 in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17701834/),%,4,119801,DB00592,Piperazine
,3182112,half-life,"The drug exhibited 4.4 h of half-life, with an elimination constant of 1.65.",Pharmacokinetics of centperazine: a new antifilarial agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3182112/),h,4.4,119839,DB00592,Piperazine
,3182112,elimination constant,"The drug exhibited 4.4 h of half-life, with an elimination constant of 1.65.",Pharmacokinetics of centperazine: a new antifilarial agent. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3182112/),,1.65,119840,DB00592,Piperazine
,3182112,area under curve,Values for the area under curve and distribution volume were determined as 14.62 micrograms h/ml and 438 ml respectively.,Pharmacokinetics of centperazine: a new antifilarial agent. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3182112/),[h·μg] / [ml],14.62,119841,DB00592,Piperazine
,3182112,distribution volume,Values for the area under curve and distribution volume were determined as 14.62 micrograms h/ml and 438 ml respectively.,Pharmacokinetics of centperazine: a new antifilarial agent. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3182112/),ml,438,119842,DB00592,Piperazine
,3182112,plasma clearance,Mean plasma clearance value was found to be 72.87 ml/h/kg body weight.,Pharmacokinetics of centperazine: a new antifilarial agent. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3182112/),[ml] / [h·kg],72.87,119843,DB00592,Piperazine
,9626922,total area under the plasma zolpidem concentration-time curve (AUC0-infinity),Itraconazole had no marked effects on the pharmacokinetics of zolpidem; the total area under the plasma zolpidem concentration-time curve (AUC0-infinity) was 34% larger during the itraconazole phase (759 ng x h x ml(-1)) than during the placebo phase (567 ng x h x ml(-1)).,Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626922/),[h·ng] / [ml],759,120029,DB00592,Piperazine
,9626922,total area under the plasma zolpidem concentration-time curve (AUC0-infinity),Itraconazole had no marked effects on the pharmacokinetics of zolpidem; the total area under the plasma zolpidem concentration-time curve (AUC0-infinity) was 34% larger during the itraconazole phase (759 ng x h x ml(-1)) than during the placebo phase (567 ng x h x ml(-1)).,Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626922/),[h·ng] / [ml],567,120030,DB00592,Piperazine
,32904111,EE %,"Their EE % ranged from 64.36±1.985% to 94.09±1.74%, and their in-vitro release percentages were between 61.82±1.92% and 95.92±1.18%.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),%,64.36,120077,DB00592,Piperazine
,32904111,EE %,"Their EE % ranged from 64.36±1.985% to 94.09±1.74%, and their in-vitro release percentages were between 61.82±1.92% and 95.92±1.18%.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),%,94.09,120078,DB00592,Piperazine
,32904111,release percentages,"Their EE % ranged from 64.36±1.985% to 94.09±1.74%, and their in-vitro release percentages were between 61.82±1.92% and 95.92±1.18%.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),%,61.82,120079,DB00592,Piperazine
,32904111,release percentages,"Their EE % ranged from 64.36±1.985% to 94.09±1.74%, and their in-vitro release percentages were between 61.82±1.92% and 95.92±1.18%.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),%,95.92,120080,DB00592,Piperazine
,32904111,PS,"Also, the vesicles PS ranged from 212.3±30.05nm to 2150±35.35nm, DI from 0.238±0.134 to 1±0.00 and zeta potential from -57.5±2.54 to +4.73±1.57 mV.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),nm,212.3,120081,DB00592,Piperazine
,32904111,PS,"Also, the vesicles PS ranged from 212.3±30.05nm to 2150±35.35nm, DI from 0.238±0.134 to 1±0.00 and zeta potential from -57.5±2.54 to +4.73±1.57 mV.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),nm,2150,120082,DB00592,Piperazine
,32904111,DI,"Also, the vesicles PS ranged from 212.3±30.05nm to 2150±35.35nm, DI from 0.238±0.134 to 1±0.00 and zeta potential from -57.5±2.54 to +4.73±1.57 mV.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),,0.238,120083,DB00592,Piperazine
,32904111,DI,"Also, the vesicles PS ranged from 212.3±30.05nm to 2150±35.35nm, DI from 0.238±0.134 to 1±0.00 and zeta potential from -57.5±2.54 to +4.73±1.57 mV.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),,1,120084,DB00592,Piperazine
,32904111,zeta potential,"Also, the vesicles PS ranged from 212.3±30.05nm to 2150±35.35nm, DI from 0.238±0.134 to 1±0.00 and zeta potential from -57.5±2.54 to +4.73±1.57 mV.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),mv,-,120085,DB00592,Piperazine
,32904111,zeta potential,"Also, the vesicles PS ranged from 212.3±30.05nm to 2150±35.35nm, DI from 0.238±0.134 to 1±0.00 and zeta potential from -57.5±2.54 to +4.73±1.57 mV.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),mv,57.5,120086,DB00592,Piperazine
,32904111,zeta potential,"Also, the vesicles PS ranged from 212.3±30.05nm to 2150±35.35nm, DI from 0.238±0.134 to 1±0.00 and zeta potential from -57.5±2.54 to +4.73±1.57 mV.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),mv,+,120087,DB00592,Piperazine
,32904111,zeta potential,"Also, the vesicles PS ranged from 212.3±30.05nm to 2150±35.35nm, DI from 0.238±0.134 to 1±0.00 and zeta potential from -57.5±2.54 to +4.73±1.57 mV.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),mv,4.73,120088,DB00592,Piperazine
,32904111,mucoadhesive force,"The transfersomal gels showed pseudoplastic behavior, pH range of 5.5 to 8, a mucoadhesive force of 169.188±1.26 to 321.212±6.94 (dyne/cm2×102), spreadability of 40 ±7.03mm to 138 ±3.77mm, and in-vitro drug release of 81.63±1.128% to 97.78±0.102%.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),[dyne] / [102·cm2],169.188,120089,DB00592,Piperazine
,32904111,mucoadhesive force,"The transfersomal gels showed pseudoplastic behavior, pH range of 5.5 to 8, a mucoadhesive force of 169.188±1.26 to 321.212±6.94 (dyne/cm2×102), spreadability of 40 ±7.03mm to 138 ±3.77mm, and in-vitro drug release of 81.63±1.128% to 97.78±0.102%.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),[dyne] / [102·cm2],321.212,120090,DB00592,Piperazine
,32904111,spreadability,"The transfersomal gels showed pseudoplastic behavior, pH range of 5.5 to 8, a mucoadhesive force of 169.188±1.26 to 321.212±6.94 (dyne/cm2×102), spreadability of 40 ±7.03mm to 138 ±3.77mm, and in-vitro drug release of 81.63±1.128% to 97.78±0.102%.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),mm,40,120091,DB00592,Piperazine
,32904111,spreadability,"The transfersomal gels showed pseudoplastic behavior, pH range of 5.5 to 8, a mucoadhesive force of 169.188±1.26 to 321.212±6.94 (dyne/cm2×102), spreadability of 40 ±7.03mm to 138 ±3.77mm, and in-vitro drug release of 81.63±1.128% to 97.78±0.102%.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),mm,138,120092,DB00592,Piperazine
,32904111,drug release,"The transfersomal gels showed pseudoplastic behavior, pH range of 5.5 to 8, a mucoadhesive force of 169.188±1.26 to 321.212±6.94 (dyne/cm2×102), spreadability of 40 ±7.03mm to 138 ±3.77mm, and in-vitro drug release of 81.63±1.128% to 97.78±0.102%.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),%,81.63,120093,DB00592,Piperazine
,32904111,drug release,"The transfersomal gels showed pseudoplastic behavior, pH range of 5.5 to 8, a mucoadhesive force of 169.188±1.26 to 321.212±6.94 (dyne/cm2×102), spreadability of 40 ±7.03mm to 138 ±3.77mm, and in-vitro drug release of 81.63±1.128% to 97.78±0.102%.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),%,97.78,120094,DB00592,Piperazine
,32904111,[AUC]0-24,"The in-vivo pharmacokinetic study illustrated that [AUC]0-24 of F1A was significantly higher than that of tablets at (P< 0.05), equivalent to 703.563±26.470 and 494.256±9.621ɲg.hr/mL respectively.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),[h·ɲg] / [ml],703.563,120095,DB00592,Piperazine
,32904111,[AUC]0-24,"The in-vivo pharmacokinetic study illustrated that [AUC]0-24 of F1A was significantly higher than that of tablets at (P< 0.05), equivalent to 703.563±26.470 and 494.256±9.621ɲg.hr/mL respectively.",Formulation and Characterization of Cinnarizine Targeted Aural Transfersomal Gel for Vertigo Treatment: A Pharmacokinetic Study on Rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32904111/),[h·ɲg] / [ml],494.256,120096,DB00592,Piperazine
,30891138,MIC,"Compound 5 was identified as the most promising candidate based on its excellent antitubercular activity (MIC of 32 nM), more than 1000-fold improvement in solubility, 2-fold lower clearance in mouse and human microsomes relative to PBTZ169, and promising pharmacokinetic parameters.",Spirocyclic and Bicyclic 8-Nitrobenzothiazinones for Tuberculosis with Improved Physicochemical and Pharmacokinetic Properties. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30891138/),nM,32,120186,DB00592,Piperazine
,2874572,brain-to-plasma concentration ratios,"After oral administration of pharmacologically effective doses of BP-hydrochloride to rats (1 and 10 mg/kg), the metabolite appears in significant amounts in body fluids and tissues; it is highly concentrated in the central nervous system, the brain-to-plasma concentration ratios being approximately 5 at the time of the maximum concentrations (Cmax).",1-(2-Pyrimidinyl)-piperazine as active metabolite of buspirone in man and rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2874572/),,5,120626,DB00592,Piperazine
more,18348338,recoveries,The recoveries were more than 90%.,Determination of oxatomide in human plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18348338/),%,90,120642,DB00592,Piperazine
,22357447,half-life,"BGT226 demonstrated rapid absorption, variable systemic exposure, and a median half-life of 6-9 h.","Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22357447/),h,6-9,121218,DB00592,Piperazine
,22357447,MTD,"The MTD of BGT226 was 125 mg/day TIW, and the clinically recommended dose was 100 mg/day TIW.","Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22357447/),mg,125,121219,DB00592,Piperazine
,2933340,MICs,The MICs of enoxacin against all but one of the gram-negative isolates cultured from 265 urological patients were between 0.03 and 4 mg/l.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933340/),[mg] / [l],0.03 and 4,121285,DB00592,Piperazine
,2933340,MICs,The MICs against 134 gram-positive isolates were between 0.25 and 16 mg/l except for two strains of streptococci.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933340/),[mg] / [l],0.25 and 16,121286,DB00592,Piperazine
,2933340,peak serum concentrations,Oral administration of 400 mg of enoxacin to elderly patients resulted in peak serum concentrations between 0.7 and 6.3 mg/l (mean 3.6 mg/l) attained between 1.0 and 6.0 h following drug ingestion.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933340/),[mg] / [l],0.7 and 6.3,121287,DB00592,Piperazine
,2933340,peak serum concentrations,Oral administration of 400 mg of enoxacin to elderly patients resulted in peak serum concentrations between 0.7 and 6.3 mg/l (mean 3.6 mg/l) attained between 1.0 and 6.0 h following drug ingestion.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933340/),[mg] / [l],3.6,121288,DB00592,Piperazine
,2933340,urinary recovery,The mean urinary recovery of parent drug within 24 h was 31.2% of the administered dose.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933340/),%,31.2,121289,DB00592,Piperazine
,27995880,Cmax,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),[μg] / [l],209.01,121364,DB00592,Piperazine
,27995880,Cmax,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),[μg] / [l],223.07,121365,DB00592,Piperazine
,27995880,Tmax,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),h,1.1,121366,DB00592,Piperazine
,27995880,T1/2,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),h,5.10,121367,DB00592,Piperazine
,27995880,T1/2,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),h,4.39,121368,DB00592,Piperazine
,27995880,AUC0-τ,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),[h·μg] / [l],646.65,121369,DB00592,Piperazine
,27995880,AUC0-τ,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),[h·μg] / [l],695.84,121370,DB00592,Piperazine
,27995880,AUC0-∝,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),[h·μg] / [l],668.11,121371,DB00592,Piperazine
,27995880,AUC0-∝,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),[h·μg] / [l],712.42,121372,DB00592,Piperazine
,27995880,MRT,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),h,5.32,121373,DB00592,Piperazine
,27995880,MRT,"The major pharmacokinetic parameters were as follows: Cmax (209.01±58.69) μg/L and (223.07±79.51) μg/L, Tmax (1.1±0.8) h and (1.1±0.8) h, T1/2 (5.10±1.34) h and (4.39±0.74) h, AUC0-τ (646.65±185.67) h·μg/L and (695.84±273.40) h·μg/L (all P>0.05); AUC0-∝ (668.11±186.00) h·μg/L and (712.42±278.08) h·μg/L, MRT (5.32 ± 1.70) h and (4.68 ± 1.53) h (all P>0.05).",[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27995880/),h,4.68,121374,DB00592,Piperazine
,26197839,clearance,"Sildenafil clearance was unaffected by hepatic pressure (clearance=0.62 L/hour/kg); however, clearance of des-methyl-sildenafil (1.94×(hepatic pressure/9)(-1.33) L/hour/kg) was predicted to decrease ~7-fold as hepatic pressure increased from 4 to 18 mmHg.",Pharmacokinetics of intravenous sildenafil in children with palliated single ventricle heart defects: effect of elevated hepatic pressures. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26197839/),[l] / [h·kg],0.62,121375,DB00592,Piperazine
,26197839,clearance,"Sildenafil clearance was unaffected by hepatic pressure (clearance=0.62 L/hour/kg); however, clearance of des-methyl-sildenafil (1.94×(hepatic pressure/9)(-1.33) L/hour/kg) was predicted to decrease ~7-fold as hepatic pressure increased from 4 to 18 mmHg.",Pharmacokinetics of intravenous sildenafil in children with palliated single ventricle heart defects: effect of elevated hepatic pressures. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26197839/),[l] / [h·kg],1.94,121376,DB00592,Piperazine
,26197839,area under the curve,Predicted drug exposure was increased by ~1.5-fold in subjects with hepatic pressures ⩾10 versus <10 mmHg (median area under the curve=533 versus 792 µg*h/L).,Pharmacokinetics of intravenous sildenafil in children with palliated single ventricle heart defects: effect of elevated hepatic pressures. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26197839/),[h·μg] / [l],533,121377,DB00592,Piperazine
,26197839,area under the curve,Predicted drug exposure was increased by ~1.5-fold in subjects with hepatic pressures ⩾10 versus <10 mmHg (median area under the curve=533 versus 792 µg*h/L).,Pharmacokinetics of intravenous sildenafil in children with palliated single ventricle heart defects: effect of elevated hepatic pressures. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26197839/),[h·μg] / [l],792,121378,DB00592,Piperazine
,33387374,bioavailability,"Nadolol is a hydrophilic and nonselective β-adrenoceptor blocker with a bioavailability of 30%, relatively longer half-life, negligible metabolism, and predominant renal excretion.",Urinary Excretion of Nadolol as a Possible In Vivo Probe for Drug Interactions Involving P-Glycoprotein. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33387374/),%,30,121647,DB00592,Piperazine
,26642765,clearance,"Compared to commonly used Ko143, the new breast cancer resistance protein (BCRP) inhibitor (compound A) showed the same potency and a significantly improved PK profile in rats (lower clearance [1.54L/h/kg] and higher bioavailability [123%]).",Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26642765/),[l] / [h·kg],1.54,121765,DB00592,Piperazine
,26642765,bioavailability,"Compared to commonly used Ko143, the new breast cancer resistance protein (BCRP) inhibitor (compound A) showed the same potency and a significantly improved PK profile in rats (lower clearance [1.54L/h/kg] and higher bioavailability [123%]).",Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26642765/),%,123,121766,DB00592,Piperazine
,1147580,peak levels,"Its peak levels in plasma ranged from 4 to 12 mug/ml at an oral dose of about 50 mg/kg in mice, rats, dogs, monkeys, and men.","Pipemidic acid: absorption, distribution, and excretion. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1147580/),[μg] / [ml],4 to 12,121787,DB00592,Piperazine
,1147580,protein binding,The protein binding of pipemidic acid was about 20% in dog plasma and about 30% in human serum.,"Pipemidic acid: absorption, distribution, and excretion. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1147580/),%,20,121788,DB00592,Piperazine
,1147580,protein binding,The protein binding of pipemidic acid was about 20% in dog plasma and about 30% in human serum.,"Pipemidic acid: absorption, distribution, and excretion. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1147580/),%,30,121789,DB00592,Piperazine
,21610706,T(max),PD 0332991 was slowly absorbed (mean T(max) 4.2 h) and eliminated (mean half-life 26.7 h).,"Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21610706/),h,4.2,121935,DB00592,Piperazine
,21610706,half-life,PD 0332991 was slowly absorbed (mean T(max) 4.2 h) and eliminated (mean half-life 26.7 h).,"Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21610706/),h,26.7,121936,DB00592,Piperazine
,21610706,Volume of distribution,Volume of distribution was large (mean 3241 l) with dose-proportional exposure.,"Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21610706/),l,3241,121937,DB00592,Piperazine
,27109141,Ke,"Median (IQR) values for Ke , Vc , Vp , Kcp and Kpc were 4.9 (4.4-5.2) h(-1) , 328.4 (304.0-331.9) l, 1000.6 (912.3-1042.4) l, 10.6 (10.3-11.1) h(-1) and 3.2 (2.9-3.7) h(-1) , respectively.",Pharmacokinetics of centhaquin citrate in a dog model. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27109141/),1/[h],4.9,121966,DB00592,Piperazine
,27109141,Kpc,"Median (IQR) values for Ke , Vc , Vp , Kcp and Kpc were 4.9 (4.4-5.2) h(-1) , 328.4 (304.0-331.9) l, 1000.6 (912.3-1042.4) l, 10.6 (10.3-11.1) h(-1) and 3.2 (2.9-3.7) h(-1) , respectively.",Pharmacokinetics of centhaquin citrate in a dog model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27109141/),1/[h],10.6,121967,DB00592,Piperazine
,27109141,Kpc,"Median (IQR) values for Ke , Vc , Vp , Kcp and Kpc were 4.9 (4.4-5.2) h(-1) , 328.4 (304.0-331.9) l, 1000.6 (912.3-1042.4) l, 10.6 (10.3-11.1) h(-1) and 3.2 (2.9-3.7) h(-1) , respectively.",Pharmacokinetics of centhaquin citrate in a dog model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27109141/),1/[h],3.2,121968,DB00592,Piperazine
,21308707,maximum mean concentration in plasma (C(max),Following oral administration the maximum mean concentration in plasma (C(max); 616 ± 73 ng/mL) was achieved at 0.5 h (T(max)) and area under curve (AUC(0-24)) was 1841 ± 308 ng h/mL.,"Quantification of urapidil, α-1-adrenoreceptor antagonist, in plasma by LC-MS/MS: validation and application to pharmacokinetic studies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21308707/),[ng] / [ml],616,122198,DB00592,Piperazine
,21308707,area under curve (AUC(0-24)),Following oral administration the maximum mean concentration in plasma (C(max); 616 ± 73 ng/mL) was achieved at 0.5 h (T(max)) and area under curve (AUC(0-24)) was 1841 ± 308 ng h/mL.,"Quantification of urapidil, α-1-adrenoreceptor antagonist, in plasma by LC-MS/MS: validation and application to pharmacokinetic studies. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21308707/),[h·ng] / [ml],1841,122199,DB00592,Piperazine
,21308707,half-life (t(1/2)),"The half-life (t(1/2)) and clearance (Cl) were 2.47 ± 0.4 h and 1660 ± 276 mL/h/kg, respectively.","Quantification of urapidil, α-1-adrenoreceptor antagonist, in plasma by LC-MS/MS: validation and application to pharmacokinetic studies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21308707/),h,2.47,122200,DB00592,Piperazine
,21308707,clearance (Cl),"The half-life (t(1/2)) and clearance (Cl) were 2.47 ± 0.4 h and 1660 ± 276 mL/h/kg, respectively.","Quantification of urapidil, α-1-adrenoreceptor antagonist, in plasma by LC-MS/MS: validation and application to pharmacokinetic studies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21308707/),[ml] / [h·kg],1660,122201,DB00592,Piperazine
,21350820,steady-state im,"Mean ± standard deviation steady-state imatinib trough concentration (2.6 ± 1.2 μg/ml) was approximately 2.6-fold higher than previously observed in other cancer populations, and likely contributed to the poor tolerability of the combination in MBC.",Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21350820/),[μg] / [ml],2.6,122566,DB00592,Piperazine
,21350820,trough concentration,"Mean ± standard deviation steady-state imatinib trough concentration (2.6 ± 1.2 μg/ml) was approximately 2.6-fold higher than previously observed in other cancer populations, and likely contributed to the poor tolerability of the combination in MBC.",Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21350820/),[μg] / [ml],2.6,122567,DB00592,Piperazine
,19961912,C(max),"Pharmacokinetic data in rats following transdermal administration indicate that buspirone was present in plasma for 12 h, reaching a C(max) value of 120.07+/-86.97 ng/ml after 2 h.","Buspirone transdermal administration for menopausal syndromes, in vitro and in animal model studies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19961912/),[ng] / [ml],120.07,122591,DB00592,Piperazine
,19961912,F(rel),A F(rel) value of 0.89 was estimated for transdermal vs. oral buspirone.,"Buspirone transdermal administration for menopausal syndromes, in vitro and in animal model studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19961912/),,0.89,122592,DB00592,Piperazine
,1394799,half-lives,"The mean half-lives calculated for the fast and slow distributive and terminal elimination phases in the saline/doxorubicin group were 3.0 +/- 0.5 and 32.2 +/- 12.8 min and 30.0 +/- 4.0 h, respectively.",Influence of the cardioprotective agent dexrazoxane on doxorubicin pharmacokinetics in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1394799/),min,3.0,122833,DB00592,Piperazine
,1394799,half-lives,"The mean half-lives calculated for the fast and slow distributive and terminal elimination phases in the saline/doxorubicin group were 3.0 +/- 0.5 and 32.2 +/- 12.8 min and 30.0 +/- 4.0 h, respectively.",Influence of the cardioprotective agent dexrazoxane on doxorubicin pharmacokinetics in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1394799/),min,32.2,122834,DB00592,Piperazine
,1394799,half-lives,"The mean half-lives calculated for the fast and slow distributive and terminal elimination phases in the saline/doxorubicin group were 3.0 +/- 0.5 and 32.2 +/- 12.8 min and 30.0 +/- 4.0 h, respectively.",Influence of the cardioprotective agent dexrazoxane on doxorubicin pharmacokinetics in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1394799/),h,30.0,122835,DB00592,Piperazine
,1791629,EC50,"In the presence of ADO (1 microM), R 75,231 (EC50 = 1.9 +/- 0.3 x 10(-7) M) (n = 3) was almost as potent as dilazep (EC50 = 1.1 +/- 0.2 x 10(-7) M) (n = 3), but far more potent than dipyridamole (EC50 = 1.2 +/- 0.2 x 10(-6) M) (n = 3).",Nucleoside transport inhibition and fMLP-stimulated whole blood luminescence. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1791629/),M,1.9,122908,DB00592,Piperazine
,1791629,EC50,"In the presence of ADO (1 microM), R 75,231 (EC50 = 1.9 +/- 0.3 x 10(-7) M) (n = 3) was almost as potent as dilazep (EC50 = 1.1 +/- 0.2 x 10(-7) M) (n = 3), but far more potent than dipyridamole (EC50 = 1.2 +/- 0.2 x 10(-6) M) (n = 3).",Nucleoside transport inhibition and fMLP-stimulated whole blood luminescence. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1791629/),M,1.1,122909,DB00592,Piperazine
,1791629,EC50,"In the presence of ADO (1 microM), R 75,231 (EC50 = 1.9 +/- 0.3 x 10(-7) M) (n = 3) was almost as potent as dilazep (EC50 = 1.1 +/- 0.2 x 10(-7) M) (n = 3), but far more potent than dipyridamole (EC50 = 1.2 +/- 0.2 x 10(-6) M) (n = 3).",Nucleoside transport inhibition and fMLP-stimulated whole blood luminescence. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1791629/),M,1.2,122910,DB00592,Piperazine
,20054526,metabolic ratio,"Patients that achieved complete molecular response showed significantly (Mann-Whitney U-test, p=0.013) higher in vivo CYP3A activity (median quinine metabolic ratio = 10.1) than patients achieving partial molecular response (median = 15.9).",CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20054526/),,10.1,122997,DB00592,Piperazine
,3115912,terminal t1/2,Pharmacokinetic studies in eight patients indicate that the drug disappears from the plasma biphasically with a terminal t1/2 of 3.2 +/- 0.9 hr.,Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3115912/),h,3.2,123152,DB00592,Piperazine
,3115912,total clearance,The total clearance was 288.7 +/- 85.0 ml/hr/kg and the volume of distribution (Vda) was 1.3 +/- 0.4 l/kg.,Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3115912/),[ml] / [h·kg],288.7,123153,DB00592,Piperazine
,3115912,volume of distribution (Vda),The total clearance was 288.7 +/- 85.0 ml/hr/kg and the volume of distribution (Vda) was 1.3 +/- 0.4 l/kg.,Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3115912/),[l] / [kg],1.3,123154,DB00592,Piperazine
,27171763,concentrations,"The median (range) sildenafil and DMS concentrations were 27.4 ng ml(-1) (2.6 to 434.0) and 105.5 ng ml(-1) (3.6 to 314.0), respectively.",An opportunistic study evaluating pharmacokinetics of sildenafil for the treatment of pulmonary hypertension in infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27171763/),[ng] / [ml],105.5,123221,DB00592,Piperazine
,27171763,metabolite-to-parent ratio,The median metabolite-to-parent ratio was higher in infants receiving co-medications that can induce cytochrome P450 (CYP) enzymes (5.2 vs 0.7).,An opportunistic study evaluating pharmacokinetics of sildenafil for the treatment of pulmonary hypertension in infants. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27171763/),,5.2,123222,DB00592,Piperazine
,27171763,metabolite-to-parent ratio,The median metabolite-to-parent ratio was higher in infants receiving co-medications that can induce cytochrome P450 (CYP) enzymes (5.2 vs 0.7).,An opportunistic study evaluating pharmacokinetics of sildenafil for the treatment of pulmonary hypertension in infants. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27171763/),,0.7,123223,DB00592,Piperazine
,2576359,peak concentration,Additional theophylline administration significantly increased peak concentration of the intermediate active metabolite M2 by 23% from 7 to 8.6 ng/ml.,Study of potential kinetic interactions of picumast dihydrochloride and theophylline in vitro and after oral administration in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576359/),[ng] / [ml],7,123263,DB00592,Piperazine
,2576359,peak concentration,Additional theophylline administration significantly increased peak concentration of the intermediate active metabolite M2 by 23% from 7 to 8.6 ng/ml.,Study of potential kinetic interactions of picumast dihydrochloride and theophylline in vitro and after oral administration in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576359/),[ng] / [ml],8.6,123264,DB00592,Piperazine
,2576359,plasma protein binding,A supplementary in vitro study showed no change in plasma protein binding of picumast (100 ng/ml) in the presence of theophylline (20 micrograms/ml) and vice versa.,Study of potential kinetic interactions of picumast dihydrochloride and theophylline in vitro and after oral administration in man. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576359/),[ng] / [ml],100,123265,DB00592,Piperazine
,22767645,flow rate,"The eluted samples were chromatographed on a Grace Smart RP 18 4.6 × 100 mm, 3 µ column by using a 95:5 v/v mixture of methanol and ammonium acetate buffer (30 mM, pH 5.0 ± 0.05) as a gradient mobile phase at a flow rate of 0.6 mL/min, and analyzed by mass spectrometry in the multiple reaction monitoring mode using the [M + H](+) ions m/z 448.03 → 285.14 for aripiprazole and m/z 308.13 → 235.25 for the internal standard (zolpidem tartrate), respectively.",Development and validation of an LC-ESI-MS method for quantitative determination of aripiprazole in human plasma and an application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22767645/),[ml] / [min],0.6,123302,DB00592,Piperazine
,22767645,Extraction recovery,Extraction recovery of aripiprazole from plasma was in the range 75.56-79.57%; mean recovery was 77.35%.,Development and validation of an LC-ESI-MS method for quantitative determination of aripiprazole in human plasma and an application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22767645/),%,75.56-79.57,123303,DB00592,Piperazine
,22767645,recovery,Extraction recovery of aripiprazole from plasma was in the range 75.56-79.57%; mean recovery was 77.35%.,Development and validation of an LC-ESI-MS method for quantitative determination of aripiprazole in human plasma and an application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22767645/),%,77.35,123304,DB00592,Piperazine
,22767645,T(max),The main pharmacokinetic parameters were T(max) = (4.00 ± 2.336) C(max) = (55.16 ± 13.490) and AUC = (1846.28 ± 484.686).,Development and validation of an LC-ESI-MS method for quantitative determination of aripiprazole in human plasma and an application to pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22767645/),,4.00,123305,DB00592,Piperazine
,22767645,C(max),The main pharmacokinetic parameters were T(max) = (4.00 ± 2.336) C(max) = (55.16 ± 13.490) and AUC = (1846.28 ± 484.686).,Development and validation of an LC-ESI-MS method for quantitative determination of aripiprazole in human plasma and an application to pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22767645/),,55.16,123306,DB00592,Piperazine
,22767645,AUC,The main pharmacokinetic parameters were T(max) = (4.00 ± 2.336) C(max) = (55.16 ± 13.490) and AUC = (1846.28 ± 484.686).,Development and validation of an LC-ESI-MS method for quantitative determination of aripiprazole in human plasma and an application to pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22767645/),,1846.28,123307,DB00592,Piperazine
,28686445,oral bioavailability,"Medicinal chemistry optimization resulted in 2, which exhibits a desirable inhibitory potency of 5.6 nM with remarkable selectivity as well as excellent pharmacokinetic properties and an oral bioavailability of 63.4%.","Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28686445/),%,63.4,123336,DB00592,Piperazine
,3675693,Plasma half-life,"Plasma half-life of urapidil averaged 1.96 +/- 0.17 h in controls, 3.31 +/- 0.75 h in patients with hypertension and normal renal function and 2.52 +/- 0.46 h in patients with hypertension and chronic renal failure.",[Renal and adrenal function following acute administration of urapidil in hypertensive patients with normal and impaired renal function]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3675693/),h,1.96,123444,DB00592,Piperazine
,3675693,Plasma half-life,"Plasma half-life of urapidil averaged 1.96 +/- 0.17 h in controls, 3.31 +/- 0.75 h in patients with hypertension and normal renal function and 2.52 +/- 0.46 h in patients with hypertension and chronic renal failure.",[Renal and adrenal function following acute administration of urapidil in hypertensive patients with normal and impaired renal function]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3675693/),h,3.31,123445,DB00592,Piperazine
,3675693,Plasma half-life,"Plasma half-life of urapidil averaged 1.96 +/- 0.17 h in controls, 3.31 +/- 0.75 h in patients with hypertension and normal renal function and 2.52 +/- 0.46 h in patients with hypertension and chronic renal failure.",[Renal and adrenal function following acute administration of urapidil in hypertensive patients with normal and impaired renal function]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3675693/),h,2.52,123446,DB00592,Piperazine
,19698017,plasma half-life,"The agent, administered orally, has approximately 98% oral bioavailability, achieves maximum plasma concentration approximately 2-4 hours after ingestion, and has a plasma half-life of approximately 18 hours.",Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19698017/),h,18,123857,DB00592,Piperazine
,19698017,trough plasma concentration,"The patient's trough plasma concentration before surgery (1558 ng/ml) was consistent with those found in the literature (>/= 1000 ng/ml), whereas her trough concentrations after surgery were 46-60% lower (629-836 ng/ml) than the preoperative value.",Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19698017/),[ng] / [ml],1558,123858,DB00592,Piperazine
,19698017,trough concentrations,"The patient's trough plasma concentration before surgery (1558 ng/ml) was consistent with those found in the literature (>/= 1000 ng/ml), whereas her trough concentrations after surgery were 46-60% lower (629-836 ng/ml) than the preoperative value.",Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19698017/),[ng] / [ml],629-836,123859,DB00592,Piperazine
,20444024,mean residence time (MRT),Ketoconazole significantly inhibited its own elimination with the mean residence time (MRT) increasing from 6.24 h in Phase 1 to 12.54 h in Phase 3.,The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444024/),h,6.24,124543,DB00592,Piperazine
,20444024,mean residence time (MRT),Ketoconazole significantly inhibited its own elimination with the mean residence time (MRT) increasing from 6.24 h in Phase 1 to 12.54 h in Phase 3.,The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444024/),h,12.54,124544,DB00592,Piperazine
,20444024,MRT,"Ketoconazole significantly decreased the elimination of midazolam, as expected, with the MRT increasing from 0.81 to 1.49 h.",The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444024/),h,0.81,124545,DB00592,Piperazine
,20444024,MRT,"Ketoconazole significantly decreased the elimination of midazolam, as expected, with the MRT increasing from 0.81 to 1.49 h.",The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444024/),h,1.49,124546,DB00592,Piperazine
,20444024,MRT,The elimination of fentanyl was not significantly altered by co-administration of ketoconazole with the MRT being 3.90 and 6.35 h.,The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444024/),h,3.90,124547,DB00592,Piperazine
,20444024,MRT,The elimination of fentanyl was not significantly altered by co-administration of ketoconazole with the MRT being 3.90 and 6.35 h.,The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444024/),h,6.35,124548,DB00592,Piperazine
,12924542,area under plasma concentration-versus-time curve (AUC0-12h),"Median (+IQR) area under plasma concentration-versus-time curve (AUC0-12h) were 3.33 (1.96-7.34), 4.29 (3.14-7.67) and 4.07 (2.76-4.49) mg/l x h for SQV 1400 mg without itraconazole, SQV 1200 mg with itraconazole and SQV 800 mg with itraconazole, respectively.",Pharmacokinetics of lower doses of saquinavir soft-gel caps (800 and 1200 mg twice daily) boosted with itraconazole in HIV-1-positive patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12924542/),[mg] / [h·l],3.33,124676,DB00592,Piperazine
,12924542,area under plasma concentration-versus-time curve (AUC0-12h),"Median (+IQR) area under plasma concentration-versus-time curve (AUC0-12h) were 3.33 (1.96-7.34), 4.29 (3.14-7.67) and 4.07 (2.76-4.49) mg/l x h for SQV 1400 mg without itraconazole, SQV 1200 mg with itraconazole and SQV 800 mg with itraconazole, respectively.",Pharmacokinetics of lower doses of saquinavir soft-gel caps (800 and 1200 mg twice daily) boosted with itraconazole in HIV-1-positive patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12924542/),[mg] / [h·l],4.29,124677,DB00592,Piperazine
,12924542,area under plasma concentration-versus-time curve (AUC0-12h),"Median (+IQR) area under plasma concentration-versus-time curve (AUC0-12h) were 3.33 (1.96-7.34), 4.29 (3.14-7.67) and 4.07 (2.76-4.49) mg/l x h for SQV 1400 mg without itraconazole, SQV 1200 mg with itraconazole and SQV 800 mg with itraconazole, respectively.",Pharmacokinetics of lower doses of saquinavir soft-gel caps (800 and 1200 mg twice daily) boosted with itraconazole in HIV-1-positive patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12924542/),[mg] / [h·l],4.07,124678,DB00592,Piperazine
,12924542,minimum effective concentration,The median Cmin was above the proposed minimum effective concentration of 0.05 mg/l for all three regimens.,Pharmacokinetics of lower doses of saquinavir soft-gel caps (800 and 1200 mg twice daily) boosted with itraconazole in HIV-1-positive patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12924542/),[mg] / [l],0.05,124679,DB00592,Piperazine
,20522663,brain-to-plasma ratio,"After administrations to mice, GDC-0941 brain-to-plasma ratio ranged from 0.02 to 0.06 in the wild-type and Bcrp1(-/-) mice and was modestly higher in the Mdr1a/b(-/-) mice, ranging from 0.08 to 0.11.",Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20522663/),,0.02 to 0.06,124710,DB00592,Piperazine
,20522663,brain-to-plasma ratio,"After administrations to mice, GDC-0941 brain-to-plasma ratio ranged from 0.02 to 0.06 in the wild-type and Bcrp1(-/-) mice and was modestly higher in the Mdr1a/b(-/-) mice, ranging from 0.08 to 0.11.",Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20522663/),,0.08 to 0.11,124711,DB00592,Piperazine
,20522663,plasma clearance,"The plasma clearance of GDC-0941 was similar in wild-type and all knockout mice, ranging from 15 to 25 ml/(min . kg) in the wild-type mice and from 18 to 35 ml/(min . kg) in the knockout mice.",Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20522663/),[ml] / [kg·min],15 to 25,124712,DB00592,Piperazine
,20522663,plasma clearance,"The plasma clearance of GDC-0941 was similar in wild-type and all knockout mice, ranging from 15 to 25 ml/(min . kg) in the wild-type mice and from 18 to 35 ml/(min . kg) in the knockout mice.",Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20522663/),[ml] / [kg·min],18 to 35,124713,DB00592,Piperazine
,23355361,maximum plasma concentration (C(max)),"The main pharmacokinetic parameters [mean (SD)] for ranolazine after administration of a single oral dose of 500, 1,000, and 1,500 mg were as follows: maximum plasma concentration (C(max)) 741.5 (253.0), 1,355.0 (502.0), and 2,328.7 (890.5) ng/mL, respectively; area under the concentration-time curve from time zero to 48 h (AUC(48)) 9,071.9 (3,400.0), 16,573.5 (6,806.2), and 29,324.5 (10,857.2) ng·h/mL; AUC from time zero extrapolated to infinity (AUC(∞)) 9,826.7 (3,152.0), 16,882.4 (6,790.8), and 29,923.5 (10,706.3) ng·h/mL; time to reach C(max) (t(max)) 5.3 (1.4), 4.2 (1.2), and 5.9 (2.8) h; elimination half-life (t(½)) 6.4 (3.3), 6.4 (3.5), and 6.7 (4.3) h.","Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355361/),[ng] / [ml],741.5,124962,DB00592,Piperazine
,23355361,maximum plasma concentration (C(max)),"The main pharmacokinetic parameters [mean (SD)] for ranolazine after administration of a single oral dose of 500, 1,000, and 1,500 mg were as follows: maximum plasma concentration (C(max)) 741.5 (253.0), 1,355.0 (502.0), and 2,328.7 (890.5) ng/mL, respectively; area under the concentration-time curve from time zero to 48 h (AUC(48)) 9,071.9 (3,400.0), 16,573.5 (6,806.2), and 29,324.5 (10,857.2) ng·h/mL; AUC from time zero extrapolated to infinity (AUC(∞)) 9,826.7 (3,152.0), 16,882.4 (6,790.8), and 29,923.5 (10,706.3) ng·h/mL; time to reach C(max) (t(max)) 5.3 (1.4), 4.2 (1.2), and 5.9 (2.8) h; elimination half-life (t(½)) 6.4 (3.3), 6.4 (3.5), and 6.7 (4.3) h.","Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355361/),[ng] / [ml],"1,355.0",124963,DB00592,Piperazine
,23355361,maximum plasma concentration (C(max)),"The main pharmacokinetic parameters [mean (SD)] for ranolazine after administration of a single oral dose of 500, 1,000, and 1,500 mg were as follows: maximum plasma concentration (C(max)) 741.5 (253.0), 1,355.0 (502.0), and 2,328.7 (890.5) ng/mL, respectively; area under the concentration-time curve from time zero to 48 h (AUC(48)) 9,071.9 (3,400.0), 16,573.5 (6,806.2), and 29,324.5 (10,857.2) ng·h/mL; AUC from time zero extrapolated to infinity (AUC(∞)) 9,826.7 (3,152.0), 16,882.4 (6,790.8), and 29,923.5 (10,706.3) ng·h/mL; time to reach C(max) (t(max)) 5.3 (1.4), 4.2 (1.2), and 5.9 (2.8) h; elimination half-life (t(½)) 6.4 (3.3), 6.4 (3.5), and 6.7 (4.3) h.","Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355361/),[ng] / [ml],"2,328.7",124964,DB00592,Piperazine
,23355361,area under the concentration-time curve from time zero to 48 h (AUC(48)),"The main pharmacokinetic parameters [mean (SD)] for ranolazine after administration of a single oral dose of 500, 1,000, and 1,500 mg were as follows: maximum plasma concentration (C(max)) 741.5 (253.0), 1,355.0 (502.0), and 2,328.7 (890.5) ng/mL, respectively; area under the concentration-time curve from time zero to 48 h (AUC(48)) 9,071.9 (3,400.0), 16,573.5 (6,806.2), and 29,324.5 (10,857.2) ng·h/mL; AUC from time zero extrapolated to infinity (AUC(∞)) 9,826.7 (3,152.0), 16,882.4 (6,790.8), and 29,923.5 (10,706.3) ng·h/mL; time to reach C(max) (t(max)) 5.3 (1.4), 4.2 (1.2), and 5.9 (2.8) h; elimination half-life (t(½)) 6.4 (3.3), 6.4 (3.5), and 6.7 (4.3) h.","Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355361/),[h·ng] / [ml],"9,071.9",124965,DB00592,Piperazine
,23355361,area under the concentration-time curve from time zero to 48 h (AUC(48)),"The main pharmacokinetic parameters [mean (SD)] for ranolazine after administration of a single oral dose of 500, 1,000, and 1,500 mg were as follows: maximum plasma concentration (C(max)) 741.5 (253.0), 1,355.0 (502.0), and 2,328.7 (890.5) ng/mL, respectively; area under the concentration-time curve from time zero to 48 h (AUC(48)) 9,071.9 (3,400.0), 16,573.5 (6,806.2), and 29,324.5 (10,857.2) ng·h/mL; AUC from time zero extrapolated to infinity (AUC(∞)) 9,826.7 (3,152.0), 16,882.4 (6,790.8), and 29,923.5 (10,706.3) ng·h/mL; time to reach C(max) (t(max)) 5.3 (1.4), 4.2 (1.2), and 5.9 (2.8) h; elimination half-life (t(½)) 6.4 (3.3), 6.4 (3.5), and 6.7 (4.3) h.","Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355361/),[h·ng] / [ml],"16,573.5",124966,DB00592,Piperazine
,23355361,area under the concentration-time curve from time zero to 48 h (AUC(48)),"The main pharmacokinetic parameters [mean (SD)] for ranolazine after administration of a single oral dose of 500, 1,000, and 1,500 mg were as follows: maximum plasma concentration (C(max)) 741.5 (253.0), 1,355.0 (502.0), and 2,328.7 (890.5) ng/mL, respectively; area under the concentration-time curve from time zero to 48 h (AUC(48)) 9,071.9 (3,400.0), 16,573.5 (6,806.2), and 29,324.5 (10,857.2) ng·h/mL; AUC from time zero extrapolated to infinity (AUC(∞)) 9,826.7 (3,152.0), 16,882.4 (6,790.8), and 29,923.5 (10,706.3) ng·h/mL; time to reach C(max) (t(max)) 5.3 (1.4), 4.2 (1.2), and 5.9 (2.8) h; elimination half-life (t(½)) 6.4 (3.3), 6.4 (3.5), and 6.7 (4.3) h.","Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355361/),[h·ng] / [ml],"29,324.5",124967,DB00592,Piperazine
,23355361,AUC from time zero extrapolated to infinity (AUC(∞)),"The main pharmacokinetic parameters [mean (SD)] for ranolazine after administration of a single oral dose of 500, 1,000, and 1,500 mg were as follows: maximum plasma concentration (C(max)) 741.5 (253.0), 1,355.0 (502.0), and 2,328.7 (890.5) ng/mL, respectively; area under the concentration-time curve from time zero to 48 h (AUC(48)) 9,071.9 (3,400.0), 16,573.5 (6,806.2), and 29,324.5 (10,857.2) ng·h/mL; AUC from time zero extrapolated to infinity (AUC(∞)) 9,826.7 (3,152.0), 16,882.4 (6,790.8), and 29,923.5 (10,706.3) ng·h/mL; time to reach C(max) (t(max)) 5.3 (1.4), 4.2 (1.2), and 5.9 (2.8) h; elimination half-life (t(½)) 6.4 (3.3), 6.4 (3.5), and 6.7 (4.3) h.","Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355361/),[h·ng] / [ml],"9,826.7",124968,DB00592,Piperazine
,23355361,AUC from time zero extrapolated to infinity (AUC(∞)),"The main pharmacokinetic parameters [mean (SD)] for ranolazine after administration of a single oral dose of 500, 1,000, and 1,500 mg were as follows: maximum plasma concentration (C(max)) 741.5 (253.0), 1,355.0 (502.0), and 2,328.7 (890.5) ng/mL, respectively; area under the concentration-time curve from time zero to 48 h (AUC(48)) 9,071.9 (3,400.0), 16,573.5 (6,806.2), and 29,324.5 (10,857.2) ng·h/mL; AUC from time zero extrapolated to infinity (AUC(∞)) 9,826.7 (3,152.0), 16,882.4 (6,790.8), and 29,923.5 (10,706.3) ng·h/mL; time to reach C(max) (t(max)) 5.3 (1.4), 4.2 (1.2), and 5.9 (2.8) h; elimination half-life (t(½)) 6.4 (3.3), 6.4 (3.5), and 6.7 (4.3) h.","Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355361/),[h·ng] / [ml],"16,882.4",124969,DB00592,Piperazine
,23355361,AUC from time zero extrapolated to infinity (AUC(∞)),"The main pharmacokinetic parameters [mean (SD)] for ranolazine after administration of a single oral dose of 500, 1,000, and 1,500 mg were as follows: maximum plasma concentration (C(max)) 741.5 (253.0), 1,355.0 (502.0), and 2,328.7 (890.5) ng/mL, respectively; area under the concentration-time curve from time zero to 48 h (AUC(48)) 9,071.9 (3,400.0), 16,573.5 (6,806.2), and 29,324.5 (10,857.2) ng·h/mL; AUC from time zero extrapolated to infinity (AUC(∞)) 9,826.7 (3,152.0), 16,882.4 (6,790.8), and 29,923.5 (10,706.3) ng·h/mL; time to reach C(max) (t(max)) 5.3 (1.4), 4.2 (1.2), and 5.9 (2.8) h; elimination half-life (t(½)) 6.4 (3.3), 6.4 (3.5), and 6.7 (4.3) h.","Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355361/),[h·ng] / [ml],"29,923.5",124970,DB00592,Piperazine
,23355361,time to reach C(max) (t(max)),"The main pharmacokinetic parameters [mean (SD)] for ranolazine after administration of a single oral dose of 500, 1,000, and 1,500 mg were as follows: maximum plasma concentration (C(max)) 741.5 (253.0), 1,355.0 (502.0), and 2,328.7 (890.5) ng/mL, respectively; area under the concentration-time curve from time zero to 48 h (AUC(48)) 9,071.9 (3,400.0), 16,573.5 (6,806.2), and 29,324.5 (10,857.2) ng·h/mL; AUC from time zero extrapolated to infinity (AUC(∞)) 9,826.7 (3,152.0), 16,882.4 (6,790.8), and 29,923.5 (10,706.3) ng·h/mL; time to reach C(max) (t(max)) 5.3 (1.4), 4.2 (1.2), and 5.9 (2.8) h; elimination half-life (t(½)) 6.4 (3.3), 6.4 (3.5), and 6.7 (4.3) h.","Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355361/),,5.3,124971,DB00592,Piperazine
,23355361,"steady-state C(max) (C(max,ss))","Mean (SD) values for the main pharmacokinetic parameters for ranolazine after administration of multiple doses were as follows: steady-state C(max) (C(max,ss)) 1,732.9 (547.3) ng/mL; C(min,ss) 838.1 (429.8) ng/mL; steady-state AUC at time t (AUC(ss,(t))) 14,655.5 (5,624.2) ng·h/mL; average steady-state plasma drug concentration during multiple-dose administration (C(av,ss)) 1,221.3 (468.7) ng/mL; t(max) 3.46 (1.48) h; t(½) 6.28 (2.48) h.","Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355361/),[ng] / [ml],"1,732.9",124972,DB00592,Piperazine
,23355361,"C(min,ss)","Mean (SD) values for the main pharmacokinetic parameters for ranolazine after administration of multiple doses were as follows: steady-state C(max) (C(max,ss)) 1,732.9 (547.3) ng/mL; C(min,ss) 838.1 (429.8) ng/mL; steady-state AUC at time t (AUC(ss,(t))) 14,655.5 (5,624.2) ng·h/mL; average steady-state plasma drug concentration during multiple-dose administration (C(av,ss)) 1,221.3 (468.7) ng/mL; t(max) 3.46 (1.48) h; t(½) 6.28 (2.48) h.","Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355361/),[ng] / [ml],838.1,124973,DB00592,Piperazine
,23355361,"steady-state AUC at time t (AUC(ss,(t)))","Mean (SD) values for the main pharmacokinetic parameters for ranolazine after administration of multiple doses were as follows: steady-state C(max) (C(max,ss)) 1,732.9 (547.3) ng/mL; C(min,ss) 838.1 (429.8) ng/mL; steady-state AUC at time t (AUC(ss,(t))) 14,655.5 (5,624.2) ng·h/mL; average steady-state plasma drug concentration during multiple-dose administration (C(av,ss)) 1,221.3 (468.7) ng/mL; t(max) 3.46 (1.48) h; t(½) 6.28 (2.48) h.","Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355361/),[h·ng] / [ml],"14,655.5",124974,DB00592,Piperazine
,23355361,"steady-state plasma drug concentration during multiple-dose administration (C(av,ss))","Mean (SD) values for the main pharmacokinetic parameters for ranolazine after administration of multiple doses were as follows: steady-state C(max) (C(max,ss)) 1,732.9 (547.3) ng/mL; C(min,ss) 838.1 (429.8) ng/mL; steady-state AUC at time t (AUC(ss,(t))) 14,655.5 (5,624.2) ng·h/mL; average steady-state plasma drug concentration during multiple-dose administration (C(av,ss)) 1,221.3 (468.7) ng/mL; t(max) 3.46 (1.48) h; t(½) 6.28 (2.48) h.","Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355361/),[ng] / [ml],"1,221.3",124975,DB00592,Piperazine
,23355361,t(max),"Mean (SD) values for the main pharmacokinetic parameters for ranolazine after administration of multiple doses were as follows: steady-state C(max) (C(max,ss)) 1,732.9 (547.3) ng/mL; C(min,ss) 838.1 (429.8) ng/mL; steady-state AUC at time t (AUC(ss,(t))) 14,655.5 (5,624.2) ng·h/mL; average steady-state plasma drug concentration during multiple-dose administration (C(av,ss)) 1,221.3 (468.7) ng/mL; t(max) 3.46 (1.48) h; t(½) 6.28 (2.48) h.","Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355361/),h,3.46,124976,DB00592,Piperazine
,23355361,t(½),"Mean (SD) values for the main pharmacokinetic parameters for ranolazine after administration of multiple doses were as follows: steady-state C(max) (C(max,ss)) 1,732.9 (547.3) ng/mL; C(min,ss) 838.1 (429.8) ng/mL; steady-state AUC at time t (AUC(ss,(t))) 14,655.5 (5,624.2) ng·h/mL; average steady-state plasma drug concentration during multiple-dose administration (C(av,ss)) 1,221.3 (468.7) ng/mL; t(max) 3.46 (1.48) h; t(½) 6.28 (2.48) h.","Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355361/),h,6.28,124977,DB00592,Piperazine
,15248189,full-run time,"Plasma harvested was analysed for ketoconazole by a modified and validated HPLC method with UV detection in the range 400-14000 ng/ml, using 200 microl of plasma in a full-run time of 2.5 min.",Bioequivalence evaluation of two brands of ketoconazole tablets (Onofin-K and Nizoral) in a healthy female Mexican population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15248189/),min,2.5,125452,DB00592,Piperazine
,16377201,plasma clearance,"In addition, the representative compounds 11o and 11p with a hydroxy group in the pyrrolidine ring showed moderate plasma clearance in rats (11o, 30 ml/min/kg and 11p, 21 ml/min/kg) and in dogs (11o, 12 ml/min/kg and 11p, 9 ml/min/kg).","Synthesis, biological evaluation, and pharmacokinetic study of prolyl-1-piperazinylacetic acid and prolyl-4-piperidinylacetic acid derivatives as VLA-4 antagonists. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16377201/),[ml] / [kg·min],30,126495,DB00592,Piperazine
,16377201,plasma clearance,"In addition, the representative compounds 11o and 11p with a hydroxy group in the pyrrolidine ring showed moderate plasma clearance in rats (11o, 30 ml/min/kg and 11p, 21 ml/min/kg) and in dogs (11o, 12 ml/min/kg and 11p, 9 ml/min/kg).","Synthesis, biological evaluation, and pharmacokinetic study of prolyl-1-piperazinylacetic acid and prolyl-4-piperidinylacetic acid derivatives as VLA-4 antagonists. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16377201/),[ml] / [kg·min],21,126496,DB00592,Piperazine
,16377201,plasma clearance,"In addition, the representative compounds 11o and 11p with a hydroxy group in the pyrrolidine ring showed moderate plasma clearance in rats (11o, 30 ml/min/kg and 11p, 21 ml/min/kg) and in dogs (11o, 12 ml/min/kg and 11p, 9 ml/min/kg).","Synthesis, biological evaluation, and pharmacokinetic study of prolyl-1-piperazinylacetic acid and prolyl-4-piperidinylacetic acid derivatives as VLA-4 antagonists. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16377201/),[ml] / [kg·min],12,126497,DB00592,Piperazine
,16377201,plasma clearance,"In addition, the representative compounds 11o and 11p with a hydroxy group in the pyrrolidine ring showed moderate plasma clearance in rats (11o, 30 ml/min/kg and 11p, 21 ml/min/kg) and in dogs (11o, 12 ml/min/kg and 11p, 9 ml/min/kg).","Synthesis, biological evaluation, and pharmacokinetic study of prolyl-1-piperazinylacetic acid and prolyl-4-piperidinylacetic acid derivatives as VLA-4 antagonists. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16377201/),[ml] / [kg·min],9,126498,DB00592,Piperazine
greater,23510852,extraction recovery,"The mean extraction recovery was greater than 96% across QC levels, while intra- and inter batch accuracy and precision (% CV) values ranged from 97.4 to 101.9% and from 1.20 to 3.72% respectively.",SPE-UPLC-MS/MS method for sensitive and rapid determination of aripiprazole in human plasma to support a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23510852/),%,96,126558,DB00592,Piperazine
,23510852,extraction recovery,"The mean extraction recovery was greater than 96% across QC levels, while intra- and inter batch accuracy and precision (% CV) values ranged from 97.4 to 101.9% and from 1.20 to 3.72% respectively.",SPE-UPLC-MS/MS method for sensitive and rapid determination of aripiprazole in human plasma to support a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23510852/),%,1,126559,DB00592,Piperazine
,30605036,terminal half-life,Mean ± SD terminal half-life of trazodone was 5.65 ± 1.75 hours.,Determination of the pharmacokinetics of a single oral dose of trazodone and its effect on the activity level of domestic pigeons (Columba livia). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30605036/),h,5.65,126580,DB00592,Piperazine
,24170263,area under the plasma concentration versus time curve (AUC),"Calcium carbonate administration did not significantly affect the imatinib area under the plasma concentration versus time curve (AUC) (41.2 μg/mL h alone vs. 40.8 μg/mL h with calcium carbonate, P = 0.99), maximum plasma concentration (C(max)) (2.35 μg/mL alone vs. 2.39 μg/mL with calcium carbonate, P = 0.89).",Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24170263/),[μg] / [h·ml],41.2,127162,DB00592,Piperazine
,24170263,area under the plasma concentration versus time curve (AUC),"Calcium carbonate administration did not significantly affect the imatinib area under the plasma concentration versus time curve (AUC) (41.2 μg/mL h alone vs. 40.8 μg/mL h with calcium carbonate, P = 0.99), maximum plasma concentration (C(max)) (2.35 μg/mL alone vs. 2.39 μg/mL with calcium carbonate, P = 0.89).",Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24170263/),[μg] / [h·ml],40.8,127163,DB00592,Piperazine
,24170263,maximum plasma concentration (C(max)),"Calcium carbonate administration did not significantly affect the imatinib area under the plasma concentration versus time curve (AUC) (41.2 μg/mL h alone vs. 40.8 μg/mL h with calcium carbonate, P = 0.99), maximum plasma concentration (C(max)) (2.35 μg/mL alone vs. 2.39 μg/mL with calcium carbonate, P = 0.89).",Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24170263/),[μg] / [ml],2.35,127164,DB00592,Piperazine
,24170263,maximum plasma concentration (C(max)),"Calcium carbonate administration did not significantly affect the imatinib area under the plasma concentration versus time curve (AUC) (41.2 μg/mL h alone vs. 40.8 μg/mL h with calcium carbonate, P = 0.99), maximum plasma concentration (C(max)) (2.35 μg/mL alone vs. 2.39 μg/mL with calcium carbonate, P = 0.89).",Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24170263/),[μg] / [ml],2.39,127165,DB00592,Piperazine
,12619051,area under the plasma concentration-time curve from time zero to time infinity (AUC),"After intravenous administration of itraconazole to rats with PCM, the area under the plasma concentration-time curve from time zero to time infinity (AUC) of itraconazole was significantly greater (3580 compared with 2670 and 2980 microg min/ml) than those in control rats and rats with PCMC (the values between control rats and rats with PCMC were not significantly different).",Effects of cysteine on the pharmacokinetics of itraconazole in rats with protein-calorie malnutrition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12619051/),[min·μg] / [ml],3580,127198,DB00592,Piperazine
,12619051,area under the plasma concentration-time curve from time zero to time infinity (AUC),"After intravenous administration of itraconazole to rats with PCM, the area under the plasma concentration-time curve from time zero to time infinity (AUC) of itraconazole was significantly greater (3580 compared with 2670 and 2980 microg min/ml) than those in control rats and rats with PCMC (the values between control rats and rats with PCMC were not significantly different).",Effects of cysteine on the pharmacokinetics of itraconazole in rats with protein-calorie malnutrition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12619051/),[min·μg] / [ml],2670,127199,DB00592,Piperazine
,12619051,area under the plasma concentration-time curve from time zero to time infinity (AUC),"After intravenous administration of itraconazole to rats with PCM, the area under the plasma concentration-time curve from time zero to time infinity (AUC) of itraconazole was significantly greater (3580 compared with 2670 and 2980 microg min/ml) than those in control rats and rats with PCMC (the values between control rats and rats with PCMC were not significantly different).",Effects of cysteine on the pharmacokinetics of itraconazole in rats with protein-calorie malnutrition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12619051/),[min·μg] / [ml],2980,127200,DB00592,Piperazine
,10086837,half-life,Serum KCZ concentrations showed an apparent nonlinear pattern of decline with a short half-life (1.38 h).,Pharmacokinetics and electroencephalographic effects of ketoconazole in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10086837/),h,1.38,127287,DB00592,Piperazine
,17564318,terminal half-life,The terminal half-life of itraconazole was 524 min.,"Pharmacokinetics, blood partition, and tissue distribution of itraconazole. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17564318/),min,524,127300,DB00592,Piperazine
,17564318,total body clearance,Itraconazole was eliminated slowly in rabbits with total body clearance of 3.26 ml/min/kg.,"Pharmacokinetics, blood partition, and tissue distribution of itraconazole. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17564318/),[ml] / [kg·min],3.26,127301,DB00592,Piperazine
,17564318,equilibrium plasma/blood cells concentration ratios,"The equilibrium plasma/blood cells concentration ratios were independent of initial rabbit blood concentrations of itraconazole, 1, 5, and 10 microg/ml; the mean value was 3.25.","Pharmacokinetics, blood partition, and tissue distribution of itraconazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17564318/),,3.25,127302,DB00592,Piperazine
greater,17564318,tissue-to-plasma (T/P) ratios,The tissue-to-plasma (T/P) ratios of itraconazole were greater-than-unity in all rat tissues studied at both 1 and 24 h except in fat and stomach at 1 h.,"Pharmacokinetics, blood partition, and tissue distribution of itraconazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17564318/),,unity,127303,DB00592,Piperazine
,28421603,TS/TO ratio,"To investigate the effects of liquid lipid in lipid core on itraconazole (ITZ) dissolution and release, TS/TO ratio was varied as 100/0, 90/10 and 80/20 (mg/mg).",High payload itraconazole-incorporated lipid nanoparticles with modulated release property for oral and parenteral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28421603/),[mg] / [mg],100/0,127326,DB00592,Piperazine
,28421603,TS/TO ratio,"To investigate the effects of liquid lipid in lipid core on itraconazole (ITZ) dissolution and release, TS/TO ratio was varied as 100/0, 90/10 and 80/20 (mg/mg).",High payload itraconazole-incorporated lipid nanoparticles with modulated release property for oral and parenteral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28421603/),[mg] / [mg],90/10,127327,DB00592,Piperazine
,28421603,TS/TO ratio,"To investigate the effects of liquid lipid in lipid core on itraconazole (ITZ) dissolution and release, TS/TO ratio was varied as 100/0, 90/10 and 80/20 (mg/mg).",High payload itraconazole-incorporated lipid nanoparticles with modulated release property for oral and parenteral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28421603/),[mg] / [mg],80,127328,DB00592,Piperazine
below,28421603,polydispersity index,All HINP formulations showed particle size around 300 nm and polydispersity index below 0.3.,High payload itraconazole-incorporated lipid nanoparticles with modulated release property for oral and parenteral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28421603/),,0.3,127329,DB00592,Piperazine
,17630547,area under the curve (AUC),"The mean saquinavir area under the curve (AUC) during boosting with ritonavir was 57.93 +/- 27.96 mg/h/l, maximum observed concentration (Cmax) was 7.50 +/- 3.45 mg/l and concentration at 24 h (Cmin) was 0.35 +/- 0.30 mg/l.",Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17630547/),[mg] / [h·l],57.93,127544,DB00592,Piperazine
,17630547,maximum observed concentration (Cmax),"The mean saquinavir area under the curve (AUC) during boosting with ritonavir was 57.93 +/- 27.96 mg/h/l, maximum observed concentration (Cmax) was 7.50 +/- 3.45 mg/l and concentration at 24 h (Cmin) was 0.35 +/- 0.30 mg/l.",Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17630547/),[mg] / [l],7.50,127545,DB00592,Piperazine
,17630547,concentration at 24 h (Cmin),"The mean saquinavir area under the curve (AUC) during boosting with ritonavir was 57.93 +/- 27.96 mg/h/l, maximum observed concentration (Cmax) was 7.50 +/- 3.45 mg/l and concentration at 24 h (Cmin) was 0.35 +/- 0.30 mg/l.",Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17630547/),[mg] / [l],0.35,127546,DB00592,Piperazine
,17630547,AUC,"When ketoconazole was used, the saquinavir AUC, Cmax, and Cmin were 12.00 +/- 6.97 mg/h/l, 2.43 +/- 1.35 mg/l and 0.03 +/- 0.04 mg/l, respectively.",Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17630547/),[mg] / [h·l],12.00,127547,DB00592,Piperazine
,17630547,Cmax,"When ketoconazole was used, the saquinavir AUC, Cmax, and Cmin were 12.00 +/- 6.97 mg/h/l, 2.43 +/- 1.35 mg/l and 0.03 +/- 0.04 mg/l, respectively.",Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17630547/),[mg] / [l],2.43,127548,DB00592,Piperazine
,17630547,Cmin,"When ketoconazole was used, the saquinavir AUC, Cmax, and Cmin were 12.00 +/- 6.97 mg/h/l, 2.43 +/- 1.35 mg/l and 0.03 +/- 0.04 mg/l, respectively.",Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17630547/),[mg] / [l],0.03,127549,DB00592,Piperazine
,17630547,trough concentrations,"Although saquinavir AUC might still be adequate for treatment, concentrations at 24 h reached levels below the recommended trough concentrations of 0.1 mg/l, which may result in selection of resistant HIV-1 viral strains.",Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17630547/),[mg] / [l],0.1,127550,DB00592,Piperazine
,27663390,maximum tolerated dose,"The maximum tolerated dose was found to be 600mg twice daily, and 30 patients were treated with this dose in the phase II study.","Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27663390/),,600,127587,DB00592,Piperazine
,8546481,concentration,"In the three-pulse treatment group, the mean concentration of itraconazole in the distal ends of the toenails ranged from 67 (month 1) to 471 (month 6) ng/g, and in the distal ends of the fingernails, it ranged from 103 (month 1) to 424 (month 6) ng/g.",Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8546481/),,103,127724,DB00592,Piperazine
,8546481,Clinical cure rates,"Clinical cure rates between 76% and 84% and negative mycological examination findings between 72% and 80%, respectively, were observed in toenail onychomycosis.",Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8546481/),%,76,127725,DB00592,Piperazine
,8546481,Clinical cure rates,"Clinical cure rates between 76% and 84% and negative mycological examination findings between 72% and 80%, respectively, were observed in toenail onychomycosis.",Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8546481/),%,84,127726,DB00592,Piperazine
,15966463,peak plasma level,A peak plasma level of 286 +/- 68 ng/ml was observed after one hour.,Levocetirizine in 1-2 year old children: pharmacokinetic and pharmacodynamic profile. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966463/),[ng] / [ml],286,127772,DB00592,Piperazine
,15966463,elimination half-life,"The elimination half-life was 4.1 +/- 0.7 hours, the apparent body clearance 1.05 +/- 0.10 ml/min/kg, and the apparent volume of distribution 0.37 +/- 0.06 l/kg.",Levocetirizine in 1-2 year old children: pharmacokinetic and pharmacodynamic profile. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966463/),h,4.1,127773,DB00592,Piperazine
,15966463,apparent body clearance,"The elimination half-life was 4.1 +/- 0.7 hours, the apparent body clearance 1.05 +/- 0.10 ml/min/kg, and the apparent volume of distribution 0.37 +/- 0.06 l/kg.",Levocetirizine in 1-2 year old children: pharmacokinetic and pharmacodynamic profile. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966463/),[ml] / [kg·min],1.05,127774,DB00592,Piperazine
,15966463,apparent volume of distribution,"The elimination half-life was 4.1 +/- 0.7 hours, the apparent body clearance 1.05 +/- 0.10 ml/min/kg, and the apparent volume of distribution 0.37 +/- 0.06 l/kg.",Levocetirizine in 1-2 year old children: pharmacokinetic and pharmacodynamic profile. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966463/),[l] / [kg],0.37,127775,DB00592,Piperazine
,15966463,Morning trough,"Morning trough values at Days 3-6, and at Day 90 were respectively 78 +/- 30 ng/ml and 110 +/- 86 ng/ml.",Levocetirizine in 1-2 year old children: pharmacokinetic and pharmacodynamic profile. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966463/),[ng] / [ml],78,127776,DB00592,Piperazine
,15966463,Morning trough,"Morning trough values at Days 3-6, and at Day 90 were respectively 78 +/- 30 ng/ml and 110 +/- 86 ng/ml.",Levocetirizine in 1-2 year old children: pharmacokinetic and pharmacodynamic profile. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966463/),[ng] / [ml],110,127777,DB00592,Piperazine
,16997909,Cmax,"Cmax increased from 23 ng/ml (95% CI 19-29 ng/ml) to 55 ng/ml (95% CI 46-66 ng/ml), p < 0.0001.",Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16997909/),[ng] / [ml],23,127959,DB00592,Piperazine
,16997909,Cmax,"Cmax increased from 23 ng/ml (95% CI 19-29 ng/ml) to 55 ng/ml (95% CI 46-66 ng/ml), p < 0.0001.",Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16997909/),[ng] / [ml],55,127960,DB00592,Piperazine
,16997909,AUCs,"AUCs [median (range)] were 0.20 mg . min/ml (0.05-0.81 mg . min/ml) and 1.94 mg . min/ml (0.25-25.4 mg . min/ml) at baseline and inhibition phase, with CV% of 41 and 61%, respectively.",Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16997909/),[mg·min] / [ml],0.20,127961,DB00592,Piperazine
,16997909,AUCs,"AUCs [median (range)] were 0.20 mg . min/ml (0.05-0.81 mg . min/ml) and 1.94 mg . min/ml (0.25-25.4 mg . min/ml) at baseline and inhibition phase, with CV% of 41 and 61%, respectively.",Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16997909/),[mg·min] / [ml],1.94,127962,DB00592,Piperazine
,7693767,serum elimination half-life,"In contrast to data obtained in healthy adults with normal hepatic function reported in the medical literature, they found that the mean serum elimination half-life value of cetirizine, 13.8 +/- 1.8 hours, was longer, and the mean clearance rate, 0.44 +/- 0.10 mL/min/kg, was lower (P < .05).",Cetirizine pharmacokinetics and pharmacodynamics in primary biliary cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7693767/),h,13.8,128182,DB00592,Piperazine
,7693767,clearance rate,"In contrast to data obtained in healthy adults with normal hepatic function reported in the medical literature, they found that the mean serum elimination half-life value of cetirizine, 13.8 +/- 1.8 hours, was longer, and the mean clearance rate, 0.44 +/- 0.10 mL/min/kg, was lower (P < .05).",Cetirizine pharmacokinetics and pharmacodynamics in primary biliary cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7693767/),[ml] / [kg·min],0.44,128183,DB00592,Piperazine
,7693767,peak serum cetirizine concentration,"The mean peak serum cetirizine concentration, 498 +/- 118 ng/mL, was higher, the mean area under the curve, 6438 +/- 1621 ng/mL/hr, was larger, and the mean fraction of the dose excreted as unchanged cetirizine in the urine, .32 +/- .14, was lower (P < .05).",Cetirizine pharmacokinetics and pharmacodynamics in primary biliary cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7693767/),[ng] / [ml],498,128184,DB00592,Piperazine
,7693767,area under the curve,"The mean peak serum cetirizine concentration, 498 +/- 118 ng/mL, was higher, the mean area under the curve, 6438 +/- 1621 ng/mL/hr, was larger, and the mean fraction of the dose excreted as unchanged cetirizine in the urine, .32 +/- .14, was lower (P < .05).",Cetirizine pharmacokinetics and pharmacodynamics in primary biliary cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7693767/),[ng] / [h·ml],6438,128185,DB00592,Piperazine
,7693767,fraction of the dose excreted as,"The mean peak serum cetirizine concentration, 498 +/- 118 ng/mL, was higher, the mean area under the curve, 6438 +/- 1621 ng/mL/hr, was larger, and the mean fraction of the dose excreted as unchanged cetirizine in the urine, .32 +/- .14, was lower (P < .05).",Cetirizine pharmacokinetics and pharmacodynamics in primary biliary cirrhosis. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7693767/),,.32,128186,DB00592,Piperazine
,2566339,half-life,The effective multiple dose half-life for almitrine bismesylate in plasma is estimated to be 32 days.,One year administration of almitrine bismesylate (Vectarion) to chronic obstructive pulmonary disease patients: pharmacokinetic analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566339/),d,32,128241,DB00592,Piperazine
above,2566339,steady state peak plasma almitrine levels,About half of the patients exhibited steady state peak plasma almitrine levels above 500 ng ml-1.,One year administration of almitrine bismesylate (Vectarion) to chronic obstructive pulmonary disease patients: pharmacokinetic analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566339/),[ng] / [ml],500,128242,DB00592,Piperazine
greater,2566339,maximum apparent steady state almitrine levels,"In addition, 19 per cent of the patients achieved maximum apparent steady state almitrine levels greater than 700 ng ml-1.",One year administration of almitrine bismesylate (Vectarion) to chronic obstructive pulmonary disease patients: pharmacokinetic analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566339/),[ng] / [ml],700,128243,DB00592,Piperazine
,2566339,accumulation,Mean accumulation was estimated to be 4.21 +/- 1.98 at one year.,One year administration of almitrine bismesylate (Vectarion) to chronic obstructive pulmonary disease patients: pharmacokinetic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2566339/),,4.21,128244,DB00592,Piperazine
,16782766,EC50,"In monkey hepatocytes, rifampin markedly induced CYP3A64 mRNA (EC50 = 0.5 microM; Emax = 6-fold) and midazolam (MDZ) 1'-hydroxylase activity (EC50 = 0.2 microM; Emax = 2-fold).",In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16782766/),μM,0.5,128314,DB00592,Piperazine
,16782766,EC50,"In monkey hepatocytes, rifampin markedly induced CYP3A64 mRNA (EC50 = 0.5 microM; Emax = 6-fold) and midazolam (MDZ) 1'-hydroxylase activity (EC50 = 0.2 microM; Emax = 2-fold).",In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16782766/),μM,0.2,128315,DB00592,Piperazine
,16782766,KI,"Compound A (N-[2(R)-hydroxy-1(S)-indanyl-5-[2(S)-(1,1-dimethylethylaminocarbonyl)-4-[(furo[2,3-b]pyridin-5-yl)-methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethylpentanamide), a known potent and mechanism-based inhibitor of CYP3A4, strongly inhibited the formation of 1'-hydroxy MDZ by recombinant CYP3A64 in a concentration- and time-dependent manner (KI = 0.25 microM; k(inact) = 0.4 min(-1)).",In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16782766/),μM,0.25,128316,DB00592,Piperazine
,16782766,k(inact),"Compound A (N-[2(R)-hydroxy-1(S)-indanyl-5-[2(S)-(1,1-dimethylethylaminocarbonyl)-4-[(furo[2,3-b]pyridin-5-yl)-methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethylpentanamide), a known potent and mechanism-based inhibitor of CYP3A4, strongly inhibited the formation of 1'-hydroxy MDZ by recombinant CYP3A64 in a concentration- and time-dependent manner (KI = 0.25 microM; k(inact) = 0.4 min(-1)).",In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16782766/),1/[min],0.4,128317,DB00592,Piperazine
,16782766,hepatic availability (Fh,"In rhesus monkeys, MDZ exhibited a relatively high metabolic clearance (primarily via 1'-hydroxylation followed by glucuronidation) and a low hepatic availability (Fh = 16%).",In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16782766/),%,16,128318,DB00592,Piperazine
,2612543,clearance,"The inhibitory effect of terbinafine was more pronounced than that of ketoconazole: clearance was decreased from 1.34 ml.kg-1.min-1 in controls to 1.06 and 1.21 ml.kg-1.min-1, respectively, and the corresponding half-life was increased from 5.8 h in controls to 7.6 and 6.7 h, respectively.",Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612543/),[ml] / [kg·min],1.34,128355,DB00592,Piperazine
,2612543,clearance,"The inhibitory effect of terbinafine was more pronounced than that of ketoconazole: clearance was decreased from 1.34 ml.kg-1.min-1 in controls to 1.06 and 1.21 ml.kg-1.min-1, respectively, and the corresponding half-life was increased from 5.8 h in controls to 7.6 and 6.7 h, respectively.",Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612543/),[ml] / [kg·min],1.06,128356,DB00592,Piperazine
,2612543,clearance,"The inhibitory effect of terbinafine was more pronounced than that of ketoconazole: clearance was decreased from 1.34 ml.kg-1.min-1 in controls to 1.06 and 1.21 ml.kg-1.min-1, respectively, and the corresponding half-life was increased from 5.8 h in controls to 7.6 and 6.7 h, respectively.",Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612543/),[ml] / [kg·min],1.21,128357,DB00592,Piperazine
,2612543,half-life,"The inhibitory effect of terbinafine was more pronounced than that of ketoconazole: clearance was decreased from 1.34 ml.kg-1.min-1 in controls to 1.06 and 1.21 ml.kg-1.min-1, respectively, and the corresponding half-life was increased from 5.8 h in controls to 7.6 and 6.7 h, respectively.",Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612543/),h,5.8,128358,DB00592,Piperazine
,2612543,half-life,"The inhibitory effect of terbinafine was more pronounced than that of ketoconazole: clearance was decreased from 1.34 ml.kg-1.min-1 in controls to 1.06 and 1.21 ml.kg-1.min-1, respectively, and the corresponding half-life was increased from 5.8 h in controls to 7.6 and 6.7 h, respectively.",Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612543/),h,7.6,128359,DB00592,Piperazine
,2612543,half-life,"The inhibitory effect of terbinafine was more pronounced than that of ketoconazole: clearance was decreased from 1.34 ml.kg-1.min-1 in controls to 1.06 and 1.21 ml.kg-1.min-1, respectively, and the corresponding half-life was increased from 5.8 h in controls to 7.6 and 6.7 h, respectively.",Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612543/),h,6.7,128360,DB00592,Piperazine
,27745744,CL/F,"Mean CL/F and Vz/F were reduced (8.16 vs 3.05 L/h and 192 vs 75.1 L), although mean t½ was unchanged (15.0 vs 15.6 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),[l] / [h],8.16,128571,DB00592,Piperazine
,27745744,CL/F,"Mean CL/F and Vz/F were reduced (8.16 vs 3.05 L/h and 192 vs 75.1 L), although mean t½ was unchanged (15.0 vs 15.6 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),[l] / [h],3.05,128572,DB00592,Piperazine
,27745744,Vz/F,"Mean CL/F and Vz/F were reduced (8.16 vs 3.05 L/h and 192 vs 75.1 L), although mean t½ was unchanged (15.0 vs 15.6 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),l,192,128573,DB00592,Piperazine
,27745744,Vz/F,"Mean CL/F and Vz/F were reduced (8.16 vs 3.05 L/h and 192 vs 75.1 L), although mean t½ was unchanged (15.0 vs 15.6 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),l,75.1,128574,DB00592,Piperazine
,27745744,t½,"Mean CL/F and Vz/F were reduced (8.16 vs 3.05 L/h and 192 vs 75.1 L), although mean t½ was unchanged (15.0 vs 15.6 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),h,15.0,128575,DB00592,Piperazine
,27745744,t½,"Mean CL/F and Vz/F were reduced (8.16 vs 3.05 L/h and 192 vs 75.1 L), although mean t½ was unchanged (15.0 vs 15.6 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),h,15.6,128576,DB00592,Piperazine
,27745744,C,"Co-administration of olaparib with rifampin resulted in a statistically significant decrease in the relative bioavailability of olaparib: Cmax treatment ratio, 0.29 (90% CI, 0.24-0.33); mean AUC treatment ratio, 0.13 (90% CI, 0.11-0.16).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),,0.29,128577,DB00592,Piperazine
,27745744,AU,"Co-administration of olaparib with rifampin resulted in a statistically significant decrease in the relative bioavailability of olaparib: Cmax treatment ratio, 0.29 (90% CI, 0.24-0.33); mean AUC treatment ratio, 0.13 (90% CI, 0.11-0.16).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),,0.13,128578,DB00592,Piperazine
,27745744,CL/F,"CL/F and Vz/F were increased when olaparib and rifampin were co-administered (6.36 vs 48.3 L/h and 112 vs 1076 L); however, mean t½ was unchanged (13.0 vs 15.8 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),[l] / [h],6.36,128579,DB00592,Piperazine
,27745744,CL/F,"CL/F and Vz/F were increased when olaparib and rifampin were co-administered (6.36 vs 48.3 L/h and 112 vs 1076 L); however, mean t½ was unchanged (13.0 vs 15.8 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),[l] / [h],48.3,128580,DB00592,Piperazine
,27745744,Vz/F,"CL/F and Vz/F were increased when olaparib and rifampin were co-administered (6.36 vs 48.3 L/h and 112 vs 1076 L); however, mean t½ was unchanged (13.0 vs 15.8 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),l,112,128581,DB00592,Piperazine
,27745744,Vz/F,"CL/F and Vz/F were increased when olaparib and rifampin were co-administered (6.36 vs 48.3 L/h and 112 vs 1076 L); however, mean t½ was unchanged (13.0 vs 15.8 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),l,1076,128582,DB00592,Piperazine
,27745744,t½,"CL/F and Vz/F were increased when olaparib and rifampin were co-administered (6.36 vs 48.3 L/h and 112 vs 1076 L); however, mean t½ was unchanged (13.0 vs 15.8 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),h,13.0,128583,DB00592,Piperazine
,27745744,t½,"CL/F and Vz/F were increased when olaparib and rifampin were co-administered (6.36 vs 48.3 L/h and 112 vs 1076 L); however, mean t½ was unchanged (13.0 vs 15.8 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),h,15.8,128584,DB00592,Piperazine
<,33415753,absolute bioavailability,The results indicated that there were significant gender differences in oral absorption and the absolute bioavailability of XHL-31 in female rats were extremely low (<10%).,"Development of a sensitive UHPLC-MS/MS method for the pharmacokinetics study of a novel tyrosine kinase inhibitors, 1-[4-(4-{5-Chloro-4-[2-(propane-2-sulfonyl)-phenylamino]-pyrimidin-2-ylamino}-phenyl)-piperazin-1-yl]-propenone in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33415753/),%,10,129238,DB00592,Piperazine
,32978634,steady-state AUC0-∞,"Predicted ivosidenib geometric mean steady-state AUC0-∞ and Cmax ratios were 3.23 and 2.26 with ketoconazole, and 1.90 and 1.52 with fluconazole, respectively.",Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32978634/),,3.23,129349,DB00592,Piperazine
,32978634,steady-state AUC0-∞,"Predicted ivosidenib geometric mean steady-state AUC0-∞ and Cmax ratios were 3.23 and 2.26 with ketoconazole, and 1.90 and 1.52 with fluconazole, respectively.",Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32978634/),,1.90,129350,DB00592,Piperazine
,32978634,Cmax ratios,"Predicted ivosidenib geometric mean steady-state AUC0-∞ and Cmax ratios were 3.23 and 2.26 with ketoconazole, and 1.90 and 1.52 with fluconazole, respectively.",Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32978634/),,2.26,129351,DB00592,Piperazine
,32978634,Cmax ratios,"Predicted ivosidenib geometric mean steady-state AUC0-∞ and Cmax ratios were 3.23 and 2.26 with ketoconazole, and 1.90 and 1.52 with fluconazole, respectively.",Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32978634/),,1.90,129352,DB00592,Piperazine
,32978634,Cmax ratios,"Predicted ivosidenib geometric mean steady-state AUC0-∞ and Cmax ratios were 3.23 and 2.26 with ketoconazole, and 1.90 and 1.52 with fluconazole, respectively.",Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32978634/),,1.52,129353,DB00592,Piperazine
,15312146,time required to reach peak plasma levels (tmax),The time required to reach peak plasma levels (tmax) is shortest for levocetirizine (0.9 h) and longest for desloratadine (> or =3 h).,"Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),h,0.9,129595,DB00592,Piperazine
> or =,15312146,time required to reach peak plasma levels (tmax),The time required to reach peak plasma levels (tmax) is shortest for levocetirizine (0.9 h) and longest for desloratadine (> or =3 h).,"Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),h,3,129596,DB00592,Piperazine
,15312146,apparent volume of distribution,"The apparent volume of distribution is limited for levocetirizine (0.4 L/kg) and mizolastine (1-1.2 L/kg), larger for fexofenadine (5.4-5.8 L/kg) and particularly large for desloratadine (approximately 49 l/kg).","Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),[l] / [kg],0.4,129597,DB00592,Piperazine
,15312146,apparent volume of distribution,"The apparent volume of distribution is limited for levocetirizine (0.4 L/kg) and mizolastine (1-1.2 L/kg), larger for fexofenadine (5.4-5.8 L/kg) and particularly large for desloratadine (approximately 49 l/kg).","Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),[l] / [kg],1-1.2,129598,DB00592,Piperazine
,15312146,apparent volume of distribution,"The apparent volume of distribution is limited for levocetirizine (0.4 L/kg) and mizolastine (1-1.2 L/kg), larger for fexofenadine (5.4-5.8 L/kg) and particularly large for desloratadine (approximately 49 l/kg).","Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),[l] / [kg],5.4-5.8,129599,DB00592,Piperazine
,15312146,apparent volume of distribution,"The apparent volume of distribution is limited for levocetirizine (0.4 L/kg) and mizolastine (1-1.2 L/kg), larger for fexofenadine (5.4-5.8 L/kg) and particularly large for desloratadine (approximately 49 l/kg).","Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),[l] / [kg],49,129600,DB00592,Piperazine
,15312146,absolute bioavailability,The absolute bioavailability is 50-65% for mizolastine; it is high for levocetirizine as the percentage of the drug eliminated unchanged in the 48 h urine is 77% of the oral dose; the estimation for fexofenadine is at least 33%; no estimation was found for desloratadine.,"Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),%,50-65,129601,DB00592,Piperazine
,15312146,absolute bioavailability,The absolute bioavailability is 50-65% for mizolastine; it is high for levocetirizine as the percentage of the drug eliminated unchanged in the 48 h urine is 77% of the oral dose; the estimation for fexofenadine is at least 33%; no estimation was found for desloratadine.,"Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),%,33,129602,DB00592,Piperazine
,12496753,bioavailability,"There were no significant differences in bioavailability (0.343 +/- 0.100 versus 0.343 +/- 0.094), ER(H) (0.269 +/- 0.064 versus 0.267 +/- 0.077), and ER(G) (0.534 +/- 0.135 versus 0.531 +/- 0.124) between the traditional and semisimultaneous methods.",Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496753/),,0.343,129709,DB00592,Piperazine
,12496753,bioavailability,"There were no significant differences in bioavailability (0.343 +/- 0.100 versus 0.343 +/- 0.094), ER(H) (0.269 +/- 0.064 versus 0.267 +/- 0.077), and ER(G) (0.534 +/- 0.135 versus 0.531 +/- 0.124) between the traditional and semisimultaneous methods.",Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496753/),,0.343,129710,DB00592,Piperazine
,12496753,bioavailability,"There were no significant differences in bioavailability (0.343 +/- 0.100 versus 0.343 +/- 0.094), ER(H) (0.269 +/- 0.064 versus 0.267 +/- 0.077), and ER(G) (0.534 +/- 0.135 versus 0.531 +/- 0.124) between the traditional and semisimultaneous methods.",Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496753/),,0.269,129711,DB00592,Piperazine
,12496753,bioavailability,"There were no significant differences in bioavailability (0.343 +/- 0.100 versus 0.343 +/- 0.094), ER(H) (0.269 +/- 0.064 versus 0.267 +/- 0.077), and ER(G) (0.534 +/- 0.135 versus 0.531 +/- 0.124) between the traditional and semisimultaneous methods.",Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496753/),,0.267,129712,DB00592,Piperazine
,12496753,bioavailability,"There were no significant differences in bioavailability (0.343 +/- 0.100 versus 0.343 +/- 0.094), ER(H) (0.269 +/- 0.064 versus 0.267 +/- 0.077), and ER(G) (0.534 +/- 0.135 versus 0.531 +/- 0.124) between the traditional and semisimultaneous methods.",Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496753/),,0.534,129713,DB00592,Piperazine
,12496753,bioavailability,"There were no significant differences in bioavailability (0.343 +/- 0.100 versus 0.343 +/- 0.094), ER(H) (0.269 +/- 0.064 versus 0.267 +/- 0.077), and ER(G) (0.534 +/- 0.135 versus 0.531 +/- 0.124) between the traditional and semisimultaneous methods.",Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496753/),,0.531,129714,DB00592,Piperazine
,12496753,bioavailability,"As expected, ketoconazole markedly increased the mean bioavailability to 0.838 (2.4-fold), the mean ER(H) was decreased 3.7-fold, and the mean ER(G) was decreased 5.7-fold.",Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496753/),,0.838,129715,DB00592,Piperazine
,350611,maximum concentration,After intravenous administration of the drug in a dose of 4 mg/kg its maximum concentration (about 8 gamma/ml) was recorded in 5 minutes and the amount eliminated during 2 hours of observation comprised 1--2 per cent of the dose introduced.,"[Clinical pharmacokinetics of azabutyron, a new short-term action neuroleptic]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/350611/),[gamma] / [ml],8,129771,DB00592,Piperazine
,24100077,K(i),"Among the studied compounds, N-pyridin-3-ylmethyl-3-[4-[2-(4-methoxyphenyl)phenyl]piperazin-1-yl]ethoxy]propanamide (4b) showed high affinity for 5-HT7 receptors (K(i)=23.8 nM), selectivity over 5-HT1A receptors (>50-fold), in vitro metabolic stability (82%) and weak interaction with P-glycoprotein (BA/AB=3.3).",Novel highly potent serotonin 5-HT7 receptor ligands: structural modifications to improve pharmacokinetic properties. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24100077/),nM,23.8,129851,DB00592,Piperazine
,6637788,terminal elimination half-life,The mean (+/- SD) terminal elimination half-life of trimazosin was 2.73 (+/- 0.90) hours.,Pharmacokinetics and pharmacodynamics of trimazosin in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6637788/),h,2.73,129885,DB00592,Piperazine
,6637788,elimination half-life,This did not alter the pharmacokinetic profile of the parent drug but did allow the elimination half-life of the metabolite to be calculated as 1.47 +/- 0.65 hours.,Pharmacokinetics and pharmacodynamics of trimazosin in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6637788/),h,1.47,129886,DB00592,Piperazine
,6637788,bioavailability,The bioavailability of oral trimazosin was 61 +/- 28%.,Pharmacokinetics and pharmacodynamics of trimazosin in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6637788/),%,61,129887,DB00592,Piperazine
,22884766,C(max),"Mean (SD) values for bosutinib 100 to 600 mg ranged from 58.4 (13.3) to 426 (100) ng/mL for C(max) and 2980 (802) to 23,000 (4020) ng·h/mL for AUC(0-∞); mean AUC(0-24) and AUC(0-last) ranged from 876 (234) to 7080 (1640) ng· h/mL and from 2740 (854) to 22,200 (3630) ng · h/mL, respectively.","Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884766/),[ng] / [ml],58.4,130017,DB00592,Piperazine
,22884766,AUC(0-∞),"Mean (SD) values for bosutinib 100 to 600 mg ranged from 58.4 (13.3) to 426 (100) ng/mL for C(max) and 2980 (802) to 23,000 (4020) ng·h/mL for AUC(0-∞); mean AUC(0-24) and AUC(0-last) ranged from 876 (234) to 7080 (1640) ng· h/mL and from 2740 (854) to 22,200 (3630) ng · h/mL, respectively.","Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884766/),[h·ng] / [ml],2980,130018,DB00592,Piperazine
,22884766,AUC(0-∞),"Mean (SD) values for bosutinib 100 to 600 mg ranged from 58.4 (13.3) to 426 (100) ng/mL for C(max) and 2980 (802) to 23,000 (4020) ng·h/mL for AUC(0-∞); mean AUC(0-24) and AUC(0-last) ranged from 876 (234) to 7080 (1640) ng· h/mL and from 2740 (854) to 22,200 (3630) ng · h/mL, respectively.","Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884766/),[h·ng] / [ml],"23,000",130019,DB00592,Piperazine
,22884766,AUC(0-∞),"Mean (SD) values for bosutinib 100 to 600 mg ranged from 58.4 (13.3) to 426 (100) ng/mL for C(max) and 2980 (802) to 23,000 (4020) ng·h/mL for AUC(0-∞); mean AUC(0-24) and AUC(0-last) ranged from 876 (234) to 7080 (1640) ng· h/mL and from 2740 (854) to 22,200 (3630) ng · h/mL, respectively.","Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884766/),[h·ng] / [ml],876,130020,DB00592,Piperazine
,22884766,AUC(0-24),"Mean (SD) values for bosutinib 100 to 600 mg ranged from 58.4 (13.3) to 426 (100) ng/mL for C(max) and 2980 (802) to 23,000 (4020) ng·h/mL for AUC(0-∞); mean AUC(0-24) and AUC(0-last) ranged from 876 (234) to 7080 (1640) ng· h/mL and from 2740 (854) to 22,200 (3630) ng · h/mL, respectively.","Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884766/),[h·ng] / [ml],876,130021,DB00592,Piperazine
,22884766,AUC(0-last),"Mean (SD) values for bosutinib 100 to 600 mg ranged from 58.4 (13.3) to 426 (100) ng/mL for C(max) and 2980 (802) to 23,000 (4020) ng·h/mL for AUC(0-∞); mean AUC(0-24) and AUC(0-last) ranged from 876 (234) to 7080 (1640) ng· h/mL and from 2740 (854) to 22,200 (3630) ng · h/mL, respectively.","Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884766/),[h·ng] / [ml],7080,130022,DB00592,Piperazine
,22884766,AUC(0-last),"Mean (SD) values for bosutinib 100 to 600 mg ranged from 58.4 (13.3) to 426 (100) ng/mL for C(max) and 2980 (802) to 23,000 (4020) ng·h/mL for AUC(0-∞); mean AUC(0-24) and AUC(0-last) ranged from 876 (234) to 7080 (1640) ng· h/mL and from 2740 (854) to 22,200 (3630) ng · h/mL, respectively.","Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884766/),[h·ng] / [ml],2740,130023,DB00592,Piperazine
,22884766,AUC(0-last),"Mean (SD) values for bosutinib 100 to 600 mg ranged from 58.4 (13.3) to 426 (100) ng/mL for C(max) and 2980 (802) to 23,000 (4020) ng·h/mL for AUC(0-∞); mean AUC(0-24) and AUC(0-last) ranged from 876 (234) to 7080 (1640) ng· h/mL and from 2740 (854) to 22,200 (3630) ng · h/mL, respectively.","Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884766/),[h·ng] / [ml],"22,200",130024,DB00592,Piperazine
,11525778,bioavailability,The disposition of Z-350 was a function of linear kinetics at doses from 1 to 30 mg/kg; the bioavailability was calculated to be 65.2%.,Pharmacodynamic analysis of steroid 5alpha-reductase inhibitory actions of Z-350 in rat prostate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11525778/),%,65.2,130071,DB00592,Piperazine
,11525778,Hill constant,Analysis of the relationship between the concentration in the prostate and the inhibition seen after a single oral administration showed that the Hill constant was almost 1.0 and EC(50)(n(H)) was 47.4 ng/g of tissue; these parameters did not change after multiple administration.,Pharmacodynamic analysis of steroid 5alpha-reductase inhibitory actions of Z-350 in rat prostate. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11525778/),,1.0,130072,DB00592,Piperazine
,11525778,EC(50)(n(H)),Analysis of the relationship between the concentration in the prostate and the inhibition seen after a single oral administration showed that the Hill constant was almost 1.0 and EC(50)(n(H)) was 47.4 ng/g of tissue; these parameters did not change after multiple administration.,Pharmacodynamic analysis of steroid 5alpha-reductase inhibitory actions of Z-350 in rat prostate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11525778/),[ng] / [g],47.4,130073,DB00592,Piperazine
,21899209,flow rate,"An isocratic mobile phase consisting of acetonitrile-0.1% trifluoroacetic acid (TFA)-water (12:40:48, v/v/v), was run at a flow rate of 1.0 mL/min.",A simple and sensitive liquid chromatography method for the determination of low dihydrocodeine concentrations in human plasma: its application in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21899209/),[ml] / [min],1.0,130256,DB00592,Piperazine
,21899209,Recoveries,Recoveries were 76.10-83.81% with coefficients of variation of 1.86-6.93%.,A simple and sensitive liquid chromatography method for the determination of low dihydrocodeine concentrations in human plasma: its application in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21899209/),%,76.10-83.81,130257,DB00592,Piperazine
,21838595,systemic clearance,"After intravenous injection, systemic clearance, steady-state volumes of distribution and half-life remained unaltered as a function of dose with values in the range 22.1-27.0 mL/min/kg, 2,380-2,850 mL/kg and 229-267 min, respectively.","Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21838595/),[ml] / [kg·min],22,130368,DB00592,Piperazine
,21838595,steady-state volumes of distribution,"After intravenous injection, systemic clearance, steady-state volumes of distribution and half-life remained unaltered as a function of dose with values in the range 22.1-27.0 mL/min/kg, 2,380-2,850 mL/kg and 229-267 min, respectively.","Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21838595/),[ml] / [kg],"2,380-2,850",130369,DB00592,Piperazine
,21838595,half-life,"After intravenous injection, systemic clearance, steady-state volumes of distribution and half-life remained unaltered as a function of dose with values in the range 22.1-27.0 mL/min/kg, 2,380-2,850 mL/kg and 229-267 min, respectively.","Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21838595/),min,229-267,130370,DB00592,Piperazine
,21838595,absolute oral bioavailability,"Following oral administration, absolute oral bioavailability was not dose dependent with approximately 23%.","Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21838595/),%,23,130371,DB00592,Piperazine
,21838595,recoveries,"The recoveries of lurasidone in urine and bile were 0.286% and 0.0606%, respectively.","Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21838595/),%,0.286,130372,DB00592,Piperazine
,21838595,recoveries,"The recoveries of lurasidone in urine and bile were 0.286% and 0.0606%, respectively.","Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21838595/),%,0.0606,130373,DB00592,Piperazine
,21838595,tissue-to-plasma ratios,"Lurasidone was primarily distributed to nine tissues (brain, liver, kidneys, heart, spleen, lungs, gut, muscle and adipose) and tissue-to-plasma ratios of lurasidone were ranged from 1.06 (brain) to 9.16 (adipose).","Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21838595/),,1.06,130374,DB00592,Piperazine
,21838595,tissue-to-plasma ratios,"Lurasidone was primarily distributed to nine tissues (brain, liver, kidneys, heart, spleen, lungs, gut, muscle and adipose) and tissue-to-plasma ratios of lurasidone were ranged from 1.06 (brain) to 9.16 (adipose).","Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21838595/),,9.16,130375,DB00592,Piperazine
,12534646,C12h,"Delavirdine C12h dropped from 7,916 to 933 ng ml-1 (median decrease 5,930 ng ml-1, 95% CI 3,013, 8,955 ng ml-1).",Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534646/),[ng] / [ml],"7,916 to 933",130598,DB00592,Piperazine
,23014737,time to progression,Five patients (13.2 %) had a partial response (PR) and 13 patients (34.2 %) had SD; the average time to progression in those with clinical benefit was 17 weeks (range: 7-28 weeks).,A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23014737/),weeks,17,130633,DB00592,Piperazine
,9389342,imprecision (C.V.),"The intra-batch imprecision (C.V.) of the method at plasma analyte concentrations of 1.00, 5.00, 50.0 and 200 ng/ml was 11.2, 3.10, 1.50, and 1.30%, respectively, and the corresponding inter-batch imprecision was estimated to be 13.5, 7.09, 3.69, and 5.43%.","Development of an assay for the simultaneous determination of sildenafil (Viagra) and its metabolite (UK-103,320) using automated sequential trace enrichment of dialysates and high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9389342/),%,11.2,131003,DB00592,Piperazine
,9389342,imprecision (C.V.),"The intra-batch imprecision (C.V.) of the method at plasma analyte concentrations of 1.00, 5.00, 50.0 and 200 ng/ml was 11.2, 3.10, 1.50, and 1.30%, respectively, and the corresponding inter-batch imprecision was estimated to be 13.5, 7.09, 3.69, and 5.43%.","Development of an assay for the simultaneous determination of sildenafil (Viagra) and its metabolite (UK-103,320) using automated sequential trace enrichment of dialysates and high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9389342/),%,3.10,131004,DB00592,Piperazine
,9389342,imprecision (C.V.),"The intra-batch imprecision (C.V.) of the method at plasma analyte concentrations of 1.00, 5.00, 50.0 and 200 ng/ml was 11.2, 3.10, 1.50, and 1.30%, respectively, and the corresponding inter-batch imprecision was estimated to be 13.5, 7.09, 3.69, and 5.43%.","Development of an assay for the simultaneous determination of sildenafil (Viagra) and its metabolite (UK-103,320) using automated sequential trace enrichment of dialysates and high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9389342/),%,1.50,131005,DB00592,Piperazine
,9389342,imprecision (C.V.),"The intra-batch imprecision (C.V.) of the method at plasma analyte concentrations of 1.00, 5.00, 50.0 and 200 ng/ml was 11.2, 3.10, 1.50, and 1.30%, respectively, and the corresponding inter-batch imprecision was estimated to be 13.5, 7.09, 3.69, and 5.43%.","Development of an assay for the simultaneous determination of sildenafil (Viagra) and its metabolite (UK-103,320) using automated sequential trace enrichment of dialysates and high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9389342/),%,1.30,131006,DB00592,Piperazine
,9389342,imprecision,"The intra-batch imprecision (C.V.) of the method at plasma analyte concentrations of 1.00, 5.00, 50.0 and 200 ng/ml was 11.2, 3.10, 1.50, and 1.30%, respectively, and the corresponding inter-batch imprecision was estimated to be 13.5, 7.09, 3.69, and 5.43%.","Development of an assay for the simultaneous determination of sildenafil (Viagra) and its metabolite (UK-103,320) using automated sequential trace enrichment of dialysates and high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9389342/),%,13.5,131007,DB00592,Piperazine
,9389342,imprecision,"The intra-batch imprecision (C.V.) of the method at plasma analyte concentrations of 1.00, 5.00, 50.0 and 200 ng/ml was 11.2, 3.10, 1.50, and 1.30%, respectively, and the corresponding inter-batch imprecision was estimated to be 13.5, 7.09, 3.69, and 5.43%.","Development of an assay for the simultaneous determination of sildenafil (Viagra) and its metabolite (UK-103,320) using automated sequential trace enrichment of dialysates and high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9389342/),%,7.09,131008,DB00592,Piperazine
,9389342,imprecision,"The intra-batch imprecision (C.V.) of the method at plasma analyte concentrations of 1.00, 5.00, 50.0 and 200 ng/ml was 11.2, 3.10, 1.50, and 1.30%, respectively, and the corresponding inter-batch imprecision was estimated to be 13.5, 7.09, 3.69, and 5.43%.","Development of an assay for the simultaneous determination of sildenafil (Viagra) and its metabolite (UK-103,320) using automated sequential trace enrichment of dialysates and high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9389342/),%,3.69,131009,DB00592,Piperazine
,9389342,imprecision,"The intra-batch imprecision (C.V.) of the method at plasma analyte concentrations of 1.00, 5.00, 50.0 and 200 ng/ml was 11.2, 3.10, 1.50, and 1.30%, respectively, and the corresponding inter-batch imprecision was estimated to be 13.5, 7.09, 3.69, and 5.43%.","Development of an assay for the simultaneous determination of sildenafil (Viagra) and its metabolite (UK-103,320) using automated sequential trace enrichment of dialysates and high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9389342/),%,5.43,131010,DB00592,Piperazine
,34404206,IC50,"Among these compounds, 15l exhibited a potent PARP-1 inhibitory effect (IC50 = 14.7 nM) and possessed high selectivity to PARP-1 over PARP-2 (61.2-fold).",Discovery of Novel Apigenin-Piperazine Hybrids as Potent and Selective Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors for the Treatment of Cancer. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34404206/),nM,14.7,131075,DB00592,Piperazine
,9590466,terminal phase half-life,"The mean terminal phase half-life after the 20 mg dose was 11.1 hours and 13.7 hours after repeated and single doses, respectively.","KA 672-HCl, a neuronal activator against dementia: tolerability, safety, and preliminary pharmacokinetics after single and multiple oral doses in healthy male and female volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9590466/),h,11.1,131173,DB00592,Piperazine
,9590466,terminal phase half-life,"The mean terminal phase half-life after the 20 mg dose was 11.1 hours and 13.7 hours after repeated and single doses, respectively.","KA 672-HCl, a neuronal activator against dementia: tolerability, safety, and preliminary pharmacokinetics after single and multiple oral doses in healthy male and female volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9590466/),h,13.7,131174,DB00592,Piperazine
,10677807,area under the curve (AUC),"In the rat, there was no difference between the Asd tablets and Sporanox capsules in the mean area under the curve (AUC) (3089.5 +/- 4332.8 ng.hr/ml and 3653.9 +/- 2348.9 ng.hr/ml, respectively) and Cmax (295.0 +/- 344.5 and 390.5 +/- 169.4 ng/ml, respectively).",Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677807/),[h·ng] / [ml],3089.5,131513,DB00592,Piperazine
,10677807,area under the curve (AUC),"In the rat, there was no difference between the Asd tablets and Sporanox capsules in the mean area under the curve (AUC) (3089.5 +/- 4332.8 ng.hr/ml and 3653.9 +/- 2348.9 ng.hr/ml, respectively) and Cmax (295.0 +/- 344.5 and 390.5 +/- 169.4 ng/ml, respectively).",Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677807/),[h·ng] / [ml],3653.9,131514,DB00592,Piperazine
,10677807,Cmax,"In the rat, there was no difference between the Asd tablets and Sporanox capsules in the mean area under the curve (AUC) (3089.5 +/- 4332.8 ng.hr/ml and 3653.9 +/- 2348.9 ng.hr/ml, respectively) and Cmax (295.0 +/- 344.5 and 390.5 +/- 169.4 ng/ml, respectively).",Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677807/),[ng] / [ml],295.0,131515,DB00592,Piperazine
,10677807,Cmax,"In the rat, there was no difference between the Asd tablets and Sporanox capsules in the mean area under the curve (AUC) (3089.5 +/- 4332.8 ng.hr/ml and 3653.9 +/- 2348.9 ng.hr/ml, respectively) and Cmax (295.0 +/- 344.5 and 390.5 +/- 169.4 ng/ml, respectively).",Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677807/),[ng] / [ml],390.5,131516,DB00592,Piperazine
,10677807,AUC (AUMC,"Also, in the rabbit, no difference was found between the two products in the mean AUC (AUMC; 19357.9 +/- 5117.5 ng.hr/ml and 23382.2 +/- 6236.5 ng.hr/ml, respectively) and Cmax (766.4 +/- 276.5 and 1127.5 +/- 577.9 ng/ml, respectively).",Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677807/),[h·ng] / [ml],19357.9,131517,DB00592,Piperazine
,10677807,AUC (AUMC,"Also, in the rabbit, no difference was found between the two products in the mean AUC (AUMC; 19357.9 +/- 5117.5 ng.hr/ml and 23382.2 +/- 6236.5 ng.hr/ml, respectively) and Cmax (766.4 +/- 276.5 and 1127.5 +/- 577.9 ng/ml, respectively).",Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677807/),[h·ng] / [ml],23382.2,131518,DB00592,Piperazine
,10677807,Cmax,"Also, in the rabbit, no difference was found between the two products in the mean AUC (AUMC; 19357.9 +/- 5117.5 ng.hr/ml and 23382.2 +/- 6236.5 ng.hr/ml, respectively) and Cmax (766.4 +/- 276.5 and 1127.5 +/- 577.9 ng/ml, respectively).",Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677807/),[ng] / [ml],766.4,131519,DB00592,Piperazine
,10677807,Cmax,"Also, in the rabbit, no difference was found between the two products in the mean AUC (AUMC; 19357.9 +/- 5117.5 ng.hr/ml and 23382.2 +/- 6236.5 ng.hr/ml, respectively) and Cmax (766.4 +/- 276.5 and 1127.5 +/- 577.9 ng/ml, respectively).",Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677807/),[ng] / [ml],1127.5,131520,DB00592,Piperazine
,22749688,m/z,The mass transitions were m/z 428.3→279.3 for ranolazine and m/z 342.4→115.9 for propafenone.,Development and validation of a sensitive U-HPLC-MS/MS method with electrospray ionization for quantitation of ranolazine in human plasma: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22749688/),,428.3,131758,DB00592,Piperazine
,22749688,m/z,The mass transitions were m/z 428.3→279.3 for ranolazine and m/z 342.4→115.9 for propafenone.,Development and validation of a sensitive U-HPLC-MS/MS method with electrospray ionization for quantitation of ranolazine in human plasma: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22749688/),,279.3,131759,DB00592,Piperazine
,22749688,m/z,The mass transitions were m/z 428.3→279.3 for ranolazine and m/z 342.4→115.9 for propafenone.,Development and validation of a sensitive U-HPLC-MS/MS method with electrospray ionization for quantitation of ranolazine in human plasma: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22749688/),,342.4,131760,DB00592,Piperazine
,22749688,m/z,The mass transitions were m/z 428.3→279.3 for ranolazine and m/z 342.4→115.9 for propafenone.,Development and validation of a sensitive U-HPLC-MS/MS method with electrospray ionization for quantitation of ranolazine in human plasma: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22749688/),,115.9,131761,DB00592,Piperazine
<,22749688,run-time,"The validated method was a simple sample preparation procedure and short run-time (<2.0 min) method, which was successfully applied to a phase I pharmacokinetic study of ranolazine in Chinese healthy volunteers.",Development and validation of a sensitive U-HPLC-MS/MS method with electrospray ionization for quantitation of ranolazine in human plasma: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22749688/),min,2.0,131762,DB00592,Piperazine
,25333706,size,"The size, polydispersity index (PDI), and zeta potential of the liposomes were 206-216 nm, 0.058-0.084, and -20-42.7 mV, respectively.",Peptide-coated liposomal fasudil enhances site specific vasodilation in pulmonary arterial hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25333706/),nm,206-216,131763,DB00592,Piperazine
,25333706,zeta potential,"The size, polydispersity index (PDI), and zeta potential of the liposomes were 206-216 nm, 0.058-0.084, and -20-42.7 mV, respectively.",Peptide-coated liposomal fasudil enhances site specific vasodilation in pulmonary arterial hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25333706/),mv,-20-42.7,131764,DB00592,Piperazine
,25333706,cumulative release,Fasudil was released in a continuous fashion over 120 h with a cumulative release of 76%.,Peptide-coated liposomal fasudil enhances site specific vasodilation in pulmonary arterial hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25333706/),%,76,131765,DB00592,Piperazine
,21189331,areas under the plasma concentration-time curve up to 2 h,"The areas under the plasma concentration-time curve up to 2 h of R-95913 in the portal, hepatic, and systemic veins were 525, 32, and 17 ng · h/ml, respectively, and those of R-138727 were 564, 529, and 495 ng · h/ml, respectively.",The intestine as an important contributor to prasugrel active metabolite formation in vivo. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21189331/),[h·ng] / [ml],525,131885,DB00592,Piperazine
,21189331,areas under the plasma concentration-time curve up to 2 h,"The areas under the plasma concentration-time curve up to 2 h of R-95913 in the portal, hepatic, and systemic veins were 525, 32, and 17 ng · h/ml, respectively, and those of R-138727 were 564, 529, and 495 ng · h/ml, respectively.",The intestine as an important contributor to prasugrel active metabolite formation in vivo. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21189331/),[h·ng] / [ml],32,131886,DB00592,Piperazine
,21189331,areas under the plasma concentration-time curve up to 2 h,"The areas under the plasma concentration-time curve up to 2 h of R-95913 in the portal, hepatic, and systemic veins were 525, 32, and 17 ng · h/ml, respectively, and those of R-138727 were 564, 529, and 495 ng · h/ml, respectively.",The intestine as an important contributor to prasugrel active metabolite formation in vivo. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21189331/),[h·ng] / [ml],17,131887,DB00592,Piperazine
,21189331,areas under the plasma concentration-time curve up to 2 h,"The areas under the plasma concentration-time curve up to 2 h of R-95913 in the portal, hepatic, and systemic veins were 525, 32, and 17 ng · h/ml, respectively, and those of R-138727 were 564, 529, and 495 ng · h/ml, respectively.",The intestine as an important contributor to prasugrel active metabolite formation in vivo. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21189331/),[h·ng] / [ml],564,131888,DB00592,Piperazine
,21189331,areas under the plasma concentration-time curve up to 2 h,"The areas under the plasma concentration-time curve up to 2 h of R-95913 in the portal, hepatic, and systemic veins were 525, 32, and 17 ng · h/ml, respectively, and those of R-138727 were 564, 529, and 495 ng · h/ml, respectively.",The intestine as an important contributor to prasugrel active metabolite formation in vivo. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21189331/),[h·ng] / [ml],529,131889,DB00592,Piperazine
,21189331,areas under the plasma concentration-time curve up to 2 h,"The areas under the plasma concentration-time curve up to 2 h of R-95913 in the portal, hepatic, and systemic veins were 525, 32, and 17 ng · h/ml, respectively, and those of R-138727 were 564, 529, and 495 ng · h/ml, respectively.",The intestine as an important contributor to prasugrel active metabolite formation in vivo. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21189331/),[h·ng] / [ml],495,131890,DB00592,Piperazine
,25939551,particle size (Sz),"The optimized IMT-NLC exhibited a particle size (Sz) of 148.80 ± 1.37 nm, polydispersity index (PDI) 0.191 ± 0.017 of and ζ-potential of -23.0 ± 1.5 mV, with a drug loading (DL) of 5.48 ± 0.01% and encapsulation efficiency (EE) of 97.93 ± 0.03%.",Modulation of Pharmacokinetic and Cytotoxicity Profile of Imatinib Base by Employing Optimized Nanostructured Lipid Carriers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939551/),nm,148.80,132046,DB00592,Piperazine
,25939551,polydispersity index (PDI),"The optimized IMT-NLC exhibited a particle size (Sz) of 148.80 ± 1.37 nm, polydispersity index (PDI) 0.191 ± 0.017 of and ζ-potential of -23.0 ± 1.5 mV, with a drug loading (DL) of 5.48 ± 0.01% and encapsulation efficiency (EE) of 97.93 ± 0.03%.",Modulation of Pharmacokinetic and Cytotoxicity Profile of Imatinib Base by Employing Optimized Nanostructured Lipid Carriers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939551/),,0.191,132047,DB00592,Piperazine
,25939551,ζ-potential,"The optimized IMT-NLC exhibited a particle size (Sz) of 148.80 ± 1.37 nm, polydispersity index (PDI) 0.191 ± 0.017 of and ζ-potential of -23.0 ± 1.5 mV, with a drug loading (DL) of 5.48 ± 0.01% and encapsulation efficiency (EE) of 97.93 ± 0.03%.",Modulation of Pharmacokinetic and Cytotoxicity Profile of Imatinib Base by Employing Optimized Nanostructured Lipid Carriers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939551/),m,-,132048,DB00592,Piperazine
,25939551,ζ-potential,"The optimized IMT-NLC exhibited a particle size (Sz) of 148.80 ± 1.37 nm, polydispersity index (PDI) 0.191 ± 0.017 of and ζ-potential of -23.0 ± 1.5 mV, with a drug loading (DL) of 5.48 ± 0.01% and encapsulation efficiency (EE) of 97.93 ± 0.03%.",Modulation of Pharmacokinetic and Cytotoxicity Profile of Imatinib Base by Employing Optimized Nanostructured Lipid Carriers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939551/),m,23.0,132049,DB00592,Piperazine
,25939551,drug loading (DL),"The optimized IMT-NLC exhibited a particle size (Sz) of 148.80 ± 1.37 nm, polydispersity index (PDI) 0.191 ± 0.017 of and ζ-potential of -23.0 ± 1.5 mV, with a drug loading (DL) of 5.48 ± 0.01% and encapsulation efficiency (EE) of 97.93 ± 0.03%.",Modulation of Pharmacokinetic and Cytotoxicity Profile of Imatinib Base by Employing Optimized Nanostructured Lipid Carriers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939551/),%,5.48,132050,DB00592,Piperazine
,25939551,encapsulation efficiency (EE),"The optimized IMT-NLC exhibited a particle size (Sz) of 148.80 ± 1.37 nm, polydispersity index (PDI) 0.191 ± 0.017 of and ζ-potential of -23.0 ± 1.5 mV, with a drug loading (DL) of 5.48 ± 0.01% and encapsulation efficiency (EE) of 97.93 ± 0.03%.",Modulation of Pharmacokinetic and Cytotoxicity Profile of Imatinib Base by Employing Optimized Nanostructured Lipid Carriers. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939551/),%,97.93,132051,DB00592,Piperazine
,11516918,Gas flow rates,"Gas flow rates were: hydrogen, 35 ml/min; carrier gas (helium), 1.5 ml/min, make-up gas (helium), 25 ml/min; and air 420 ml/min.",Gas chromatographic assay of diethylcarbamazine in human plasma for application to clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11516918/),[ml] / [min],35,132227,DB00592,Piperazine
,11516918,Gas flow rates,"Gas flow rates were: hydrogen, 35 ml/min; carrier gas (helium), 1.5 ml/min, make-up gas (helium), 25 ml/min; and air 420 ml/min.",Gas chromatographic assay of diethylcarbamazine in human plasma for application to clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11516918/),[ml] / [min],1.5,132228,DB00592,Piperazine
,11516918,Gas flow rates,"Gas flow rates were: hydrogen, 35 ml/min; carrier gas (helium), 1.5 ml/min, make-up gas (helium), 25 ml/min; and air 420 ml/min.",Gas chromatographic assay of diethylcarbamazine in human plasma for application to clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11516918/),[ml] / [min],25,132229,DB00592,Piperazine
,11516918,Gas flow rates,"Gas flow rates were: hydrogen, 35 ml/min; carrier gas (helium), 1.5 ml/min, make-up gas (helium), 25 ml/min; and air 420 ml/min.",Gas chromatographic assay of diethylcarbamazine in human plasma for application to clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11516918/),[ml] / [min],420,132230,DB00592,Piperazine
,11516918,retention times,"The retention times of DEC and internal standard were approximately 5.5 and 7.28 min, respectively.",Gas chromatographic assay of diethylcarbamazine in human plasma for application to clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11516918/),min,5.5,132231,DB00592,Piperazine
,11516918,retention times,"The retention times of DEC and internal standard were approximately 5.5 and 7.28 min, respectively.",Gas chromatographic assay of diethylcarbamazine in human plasma for application to clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11516918/),min,7.28,132232,DB00592,Piperazine
,11516918,run time,The GC run time was 22 min.,Gas chromatographic assay of diethylcarbamazine in human plasma for application to clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11516918/),min,22,132233,DB00592,Piperazine
,9084458,peak plasma level,A peak plasma level of 390 +/- 135 ng/ml was observed after 2.0 +/- 1.3 hours.,Pharmacokinetics and pharmacodynamics of cetirizine in infants and toddlers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084458/),[ng] / [ml],390,132423,DB00592,Piperazine
,9084458,elimination half-life,"The elimination half-life was 3.1 +/- 1.8 hours, the apparent oral body clearance was 2.13 +/- 1.15 ml/min/kg, and the apparent volume of distribution was 0.44 +/- 0.19 L/kg.",Pharmacokinetics and pharmacodynamics of cetirizine in infants and toddlers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084458/),h,3.1,132424,DB00592,Piperazine
,9084458,apparent oral body clearance,"The elimination half-life was 3.1 +/- 1.8 hours, the apparent oral body clearance was 2.13 +/- 1.15 ml/min/kg, and the apparent volume of distribution was 0.44 +/- 0.19 L/kg.",Pharmacokinetics and pharmacodynamics of cetirizine in infants and toddlers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084458/),[ml] / [kg·min],2.13,132425,DB00592,Piperazine
,9084458,apparent volume of distribution,"The elimination half-life was 3.1 +/- 1.8 hours, the apparent oral body clearance was 2.13 +/- 1.15 ml/min/kg, and the apparent volume of distribution was 0.44 +/- 0.19 L/kg.",Pharmacokinetics and pharmacodynamics of cetirizine in infants and toddlers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084458/),[l] / [kg],0.44,132426,DB00592,Piperazine
,9084458,excretion,The excretion of unchanged cetirizine in six complete urinary collections was 62.7% +/- 13.2% of the administered dose.,Pharmacokinetics and pharmacodynamics of cetirizine in infants and toddlers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084458/),%,62.7,132427,DB00592,Piperazine
,18485840,total run time,"The total run time was 3.0 min and the elution of ITZ, OH-ITZ and IS occurred at 2.08 min, 1.85 min and 1.29 min, respectively; this was achieved with a mobile phase consisting of 0.2% (v/v) ammonia solution:acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on a HyPurity C(18) (50 mm x 4.6 mm, 5 microm) column.",Development and validation of a highly sensitive and robust LC-MS/MS with electrospray ionization method for simultaneous quantitation of itraconazole and hydroxyitraconazole in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18485840/),min,3.0,132539,DB00592,Piperazine
,18485840,total run time,"The total run time was 3.0 min and the elution of ITZ, OH-ITZ and IS occurred at 2.08 min, 1.85 min and 1.29 min, respectively; this was achieved with a mobile phase consisting of 0.2% (v/v) ammonia solution:acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on a HyPurity C(18) (50 mm x 4.6 mm, 5 microm) column.",Development and validation of a highly sensitive and robust LC-MS/MS with electrospray ionization method for simultaneous quantitation of itraconazole and hydroxyitraconazole in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18485840/),min,2.08,132540,DB00592,Piperazine
,18485840,total run time,"The total run time was 3.0 min and the elution of ITZ, OH-ITZ and IS occurred at 2.08 min, 1.85 min and 1.29 min, respectively; this was achieved with a mobile phase consisting of 0.2% (v/v) ammonia solution:acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on a HyPurity C(18) (50 mm x 4.6 mm, 5 microm) column.",Development and validation of a highly sensitive and robust LC-MS/MS with electrospray ionization method for simultaneous quantitation of itraconazole and hydroxyitraconazole in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18485840/),min,1.85,132541,DB00592,Piperazine
,18485840,total run time,"The total run time was 3.0 min and the elution of ITZ, OH-ITZ and IS occurred at 2.08 min, 1.85 min and 1.29 min, respectively; this was achieved with a mobile phase consisting of 0.2% (v/v) ammonia solution:acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on a HyPurity C(18) (50 mm x 4.6 mm, 5 microm) column.",Development and validation of a highly sensitive and robust LC-MS/MS with electrospray ionization method for simultaneous quantitation of itraconazole and hydroxyitraconazole in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18485840/),min,1.29,132542,DB00592,Piperazine
,18485840,flow rate,"The total run time was 3.0 min and the elution of ITZ, OH-ITZ and IS occurred at 2.08 min, 1.85 min and 1.29 min, respectively; this was achieved with a mobile phase consisting of 0.2% (v/v) ammonia solution:acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on a HyPurity C(18) (50 mm x 4.6 mm, 5 microm) column.",Development and validation of a highly sensitive and robust LC-MS/MS with electrospray ionization method for simultaneous quantitation of itraconazole and hydroxyitraconazole in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18485840/),[ml] / [min],0.50,132543,DB00592,Piperazine
,20644548,steady-state C(mins),"The overall mean (+/-SD, CV%) steady-state C(mins) for imatinib at 400 mg (n=36) and 600 mg (n=10) daily was 1325.61 ng/mL (+/-583.53 ng/mL; 44%) and 1550.90 ng/mL (+/-462.63 ng/mL; 30%), respectively, and no statistically significant differences were found between them (P=0.267).",Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20644548/),[ng] / [ml],1325.61,132572,DB00592,Piperazine
,20644548,steady-state C(mins),"The overall mean (+/-SD, CV%) steady-state C(mins) for imatinib at 400 mg (n=36) and 600 mg (n=10) daily was 1325.61 ng/mL (+/-583.53 ng/mL; 44%) and 1550.90 ng/mL (+/-462.63 ng/mL; 30%), respectively, and no statistically significant differences were found between them (P=0.267).",Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20644548/),[ng] / [ml],1550.90,132573,DB00592,Piperazine
,18796225,flow,"The analyte and internal standard tramadol are extracted from plasma by liquid-liquid extraction using diethyl ether-dichloromethane (60:40 v/v), and separated on a Zorbax extend C18 column using methanol-10mM ammonium acetate (60:40 v/v, pH 4.0) at a flow of 1.0 mL/min.",Determination of ranolazine in human plasma by liquid chromatographic-tandem mass spectrometric assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18796225/),[ml] / [min],1.0,132642,DB00592,Piperazine
,18448569,f,"As the f(m CYP3A4) and f(m CYP2D6) values of pactimibe estimated from in vitro studies were 0.40 and 0.33, respectively, AUC increase ratios of pactimibe were estimated to be 1.7 with ketoconazole and 1.5 with quinidine.","Effects of ketoconazole and quinidine on pharmacokinetics of pactimibe and its plasma metabolite, R-125528, in humans. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18448569/),,0.40,132812,DB00592,Piperazine
,18448569,f,"As the f(m CYP3A4) and f(m CYP2D6) values of pactimibe estimated from in vitro studies were 0.40 and 0.33, respectively, AUC increase ratios of pactimibe were estimated to be 1.7 with ketoconazole and 1.5 with quinidine.","Effects of ketoconazole and quinidine on pharmacokinetics of pactimibe and its plasma metabolite, R-125528, in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18448569/),,0.40,132813,DB00592,Piperazine
,18448569,f,"As the f(m CYP3A4) and f(m CYP2D6) values of pactimibe estimated from in vitro studies were 0.40 and 0.33, respectively, AUC increase ratios of pactimibe were estimated to be 1.7 with ketoconazole and 1.5 with quinidine.","Effects of ketoconazole and quinidine on pharmacokinetics of pactimibe and its plasma metabolite, R-125528, in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18448569/),,0.33,132814,DB00592,Piperazine
,18448569,AUC increase ratios,"As the f(m CYP3A4) and f(m CYP2D6) values of pactimibe estimated from in vitro studies were 0.40 and 0.33, respectively, AUC increase ratios of pactimibe were estimated to be 1.7 with ketoconazole and 1.5 with quinidine.","Effects of ketoconazole and quinidine on pharmacokinetics of pactimibe and its plasma metabolite, R-125528, in humans. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18448569/),,1.7,132815,DB00592,Piperazine
,18448569,AUC increase ratios,"As the f(m CYP3A4) and f(m CYP2D6) values of pactimibe estimated from in vitro studies were 0.40 and 0.33, respectively, AUC increase ratios of pactimibe were estimated to be 1.7 with ketoconazole and 1.5 with quinidine.","Effects of ketoconazole and quinidine on pharmacokinetics of pactimibe and its plasma metabolite, R-125528, in humans. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18448569/),,1.5,132816,DB00592,Piperazine
,18448569,f(m CYP2D6),"Moreover, the f(m CYP2D6) of R-125528 estimated to be almost 1 would well explain the accumulation of R-125528 observed with the quinidine treatment.","Effects of ketoconazole and quinidine on pharmacokinetics of pactimibe and its plasma metabolite, R-125528, in humans. ",fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18448569/),,1,132817,DB00592,Piperazine
,19813178,recoveries,The recoveries of the method were found to be 69.47-71.98% for ITZ and 75.68-82.52% for OH-ITZ.,Simultaneous determination of itraconazole and hydroxyitraconazole in human plasma by liquid chromatography-isotope dilution tandem mass spectrometry method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19813178/),%,69.47-71.98,133070,DB00592,Piperazine
,19813178,recoveries,The recoveries of the method were found to be 69.47-71.98% for ITZ and 75.68-82.52% for OH-ITZ.,Simultaneous determination of itraconazole and hydroxyitraconazole in human plasma by liquid chromatography-isotope dilution tandem mass spectrometry method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19813178/),%,75.68-82.52,133071,DB00592,Piperazine
,10774589,plasma trough atevirdine concentrations,ACTG 199; 12 weeks of therapy with atevirdine (dose-adjusted to achieve plasma trough atevirdine concentrations of 5-10 microM) and zidovudine (200 mg every 8 h).,Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10774589/),μM,5-10,133113,DB00592,Piperazine
,10774589,trough plasma concentration,"ACTG 187: 12 weeks of atevirdine monotherapy with atevirdine doses adjusted to achieve escalating, targeted trough plasma concentration ranges (5-13, 14-22, and 23-31 microM).",Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10774589/),μM,5-13,133114,DB00592,Piperazine
,10774589,trough plasma concentration,"ACTG 187: 12 weeks of atevirdine monotherapy with atevirdine doses adjusted to achieve escalating, targeted trough plasma concentration ranges (5-13, 14-22, and 23-31 microM).",Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10774589/),μM,14-22,133115,DB00592,Piperazine
,10774589,trough plasma concentration,"ACTG 187: 12 weeks of atevirdine monotherapy with atevirdine doses adjusted to achieve escalating, targeted trough plasma concentration ranges (5-13, 14-22, and 23-31 microM).",Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10774589/),μM,23-31,133116,DB00592,Piperazine
,10774589,trough,In ACTG 199 it was 3.2+/-5.2 weeks (95%) to achieve a 5-10 microM trough.,Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10774589/),μ,5,133117,DB00592,Piperazine
>,10774589,Cmax to Cmin ratios,"During multiple-dosing a number of patterns of atevirdine disposition were observed including; rapid absorption with Cmax at 0.5-1 h, delayed absorption with Cmax at 3-4 h; minimal Cmax to Cmin fluctuation and Cmax to Cmin ratios of > 4.",Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10774589/),,4,133118,DB00592,Piperazine
below,26599718,EC50,"Several compounds exhibited EC50 values below 10 nM against HCV infection, cytotoxicity selectivity indices above 2000, and showed improved in vivo pharmacokinetic properties.","Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26599718/),nM,10,133295,DB00592,Piperazine
above,26599718,cytotoxicity selectivity indices,"Several compounds exhibited EC50 values below 10 nM against HCV infection, cytotoxicity selectivity indices above 2000, and showed improved in vivo pharmacokinetic properties.","Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26599718/),,2000,133296,DB00592,Piperazine
,28403576,AUCτ,"The geometric mean ratios (90% confidence intervals) for AUCτ and Cmax of coadministration/monotherapy for vorapaxar (0.93 ng·h/mL[0.85-1.02 ng·h/mL] and 0.95 ng/mL [0.86-1.05 ng/mL]) and R-138727 (0.91 ng·h/mL [0.85- 0.99 ng·h/mL] and 1.02 ng/mL [0.89-1.17 ng/mL]) were within prespecified bounds, demonstrating the absence of a pharmacokinetic interaction between vorapaxar and prasugrel.",No Pharmacokinetic Drug-Drug Interaction Between Prasugrel and Vorapaxar Following Multiple-Dose Administration in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28403576/),[h·ng] / [ml],0,133330,DB00592,Piperazine
,29278046,central,"Compared to non-pregnant rabbits, the central and peripheral volume of distribution and inter-compartmental clearance of sildenafil were lower in pregnant rabbits [32.1 versus 12.2 L, 110 versus 44.4 L and 25.5 versus 12.1 L/h; all p < 0.05].",Pregnancy affects the pharmacokinetics of sildenafil and its metabolite in the rabbit. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29278046/),l,32.1,133382,DB00592,Piperazine
,29278046,central,"Compared to non-pregnant rabbits, the central and peripheral volume of distribution and inter-compartmental clearance of sildenafil were lower in pregnant rabbits [32.1 versus 12.2 L, 110 versus 44.4 L and 25.5 versus 12.1 L/h; all p < 0.05].",Pregnancy affects the pharmacokinetics of sildenafil and its metabolite in the rabbit. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29278046/),l,12.2,133383,DB00592,Piperazine
,29278046,peripheral volume of distribution,"Compared to non-pregnant rabbits, the central and peripheral volume of distribution and inter-compartmental clearance of sildenafil were lower in pregnant rabbits [32.1 versus 12.2 L, 110 versus 44.4 L and 25.5 versus 12.1 L/h; all p < 0.05].",Pregnancy affects the pharmacokinetics of sildenafil and its metabolite in the rabbit. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29278046/),l,32.1,133384,DB00592,Piperazine
,29278046,peripheral volume of distribution,"Compared to non-pregnant rabbits, the central and peripheral volume of distribution and inter-compartmental clearance of sildenafil were lower in pregnant rabbits [32.1 versus 12.2 L, 110 versus 44.4 L and 25.5 versus 12.1 L/h; all p < 0.05].",Pregnancy affects the pharmacokinetics of sildenafil and its metabolite in the rabbit. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29278046/),l,12.2,133385,DB00592,Piperazine
,29278046,peripheral volume of distribution,"Compared to non-pregnant rabbits, the central and peripheral volume of distribution and inter-compartmental clearance of sildenafil were lower in pregnant rabbits [32.1 versus 12.2 L, 110 versus 44.4 L and 25.5 versus 12.1 L/h; all p < 0.05].",Pregnancy affects the pharmacokinetics of sildenafil and its metabolite in the rabbit. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29278046/),l,110,133386,DB00592,Piperazine
,29278046,peripheral volume of distribution,"Compared to non-pregnant rabbits, the central and peripheral volume of distribution and inter-compartmental clearance of sildenafil were lower in pregnant rabbits [32.1 versus 12.2 L, 110 versus 44.4 L and 25.5 versus 12.1 L/h; all p < 0.05].",Pregnancy affects the pharmacokinetics of sildenafil and its metabolite in the rabbit. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29278046/),l,44.4,133387,DB00592,Piperazine
,29278046,inter-compartmental clearance,"Compared to non-pregnant rabbits, the central and peripheral volume of distribution and inter-compartmental clearance of sildenafil were lower in pregnant rabbits [32.1 versus 12.2 L, 110 versus 44.4 L and 25.5 versus 12.1 L/h; all p < 0.05].",Pregnancy affects the pharmacokinetics of sildenafil and its metabolite in the rabbit. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29278046/),l,44.4,133388,DB00592,Piperazine
,29278046,inter-compartmental clearance,"Compared to non-pregnant rabbits, the central and peripheral volume of distribution and inter-compartmental clearance of sildenafil were lower in pregnant rabbits [32.1 versus 12.2 L, 110 versus 44.4 L and 25.5 versus 12.1 L/h; all p < 0.05].",Pregnancy affects the pharmacokinetics of sildenafil and its metabolite in the rabbit. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29278046/),[l] / [h],25.5,133389,DB00592,Piperazine
,29278046,inter-compartmental clearance,"Compared to non-pregnant rabbits, the central and peripheral volume of distribution and inter-compartmental clearance of sildenafil were lower in pregnant rabbits [32.1 versus 12.2 L, 110 versus 44.4 L and 25.5 versus 12.1 L/h; all p < 0.05].",Pregnancy affects the pharmacokinetics of sildenafil and its metabolite in the rabbit. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29278046/),[l] / [h],12.1,133390,DB00592,Piperazine
,29278046,formation clearance,The formation clearance from sildenafil to desmethylsildenafil was also reduced during pregnancy [13.3 versus 7.8 L/h; p < 0.05].,Pregnancy affects the pharmacokinetics of sildenafil and its metabolite in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29278046/),[l] / [h],13.3,133391,DB00592,Piperazine
,29278046,formation clearance,The formation clearance from sildenafil to desmethylsildenafil was also reduced during pregnancy [13.3 versus 7.8 L/h; p < 0.05].,Pregnancy affects the pharmacokinetics of sildenafil and its metabolite in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29278046/),[l] / [h],7.8,133392,DB00592,Piperazine
,29278046,elimination clearance,"3. In contrast, the elimination clearance of desmethylsildenafil, was higher in pregnancy [73.5 versus 116. 9; p < 0.05].",Pregnancy affects the pharmacokinetics of sildenafil and its metabolite in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29278046/),,73.5,133393,DB00592,Piperazine
,29278046,elimination clearance,"3. In contrast, the elimination clearance of desmethylsildenafil, was higher in pregnancy [73.5 versus 116. 9; p < 0.05].",Pregnancy affects the pharmacokinetics of sildenafil and its metabolite in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29278046/),,116. 9,133394,DB00592,Piperazine
,14559131,half-lifes,"The decrease of saterinone plasma concentrations can be fitted to a three-compartment-model (half-lifes were 4.24 minutes for the alpha-phase, three hours for the beta-phase and 15.7 hours for the terminal phase).",Pharmacokinetics and hemodynamic effects of the phosphodiesterase III inhibitor saterinone in patients with chronic heart failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14559131/),min,4.24,133573,DB00592,Piperazine
,14559131,half-lifes,"The decrease of saterinone plasma concentrations can be fitted to a three-compartment-model (half-lifes were 4.24 minutes for the alpha-phase, three hours for the beta-phase and 15.7 hours for the terminal phase).",Pharmacokinetics and hemodynamic effects of the phosphodiesterase III inhibitor saterinone in patients with chronic heart failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14559131/),h,three,133574,DB00592,Piperazine
,14559131,half-lifes,"The decrease of saterinone plasma concentrations can be fitted to a three-compartment-model (half-lifes were 4.24 minutes for the alpha-phase, three hours for the beta-phase and 15.7 hours for the terminal phase).",Pharmacokinetics and hemodynamic effects of the phosphodiesterase III inhibitor saterinone in patients with chronic heart failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14559131/),h,15.7,133575,DB00592,Piperazine
,12499181,influx clearance,"The average influx clearance for the population was 0.0055 ml/min (interindividual variability, 17%).",Modeling of transfer kinetics at the serum-cerebrospinal fluid barrier in rabbits with experimental meningitis: application to grepafloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12499181/),[ml] / [min],0.0055,133747,DB00592,Piperazine
,12499181,Passive diffusion clearance,Passive diffusion clearance was greater in rabbits receiving grepafloxacin at 15 mg/kg than in those treated with higher doses (0.0088 versus 0.0034 ml/min).,Modeling of transfer kinetics at the serum-cerebrospinal fluid barrier in rabbits with experimental meningitis: application to grepafloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12499181/),[ml] / [min],0.0088,133748,DB00592,Piperazine
,12499181,Passive diffusion clearance,Passive diffusion clearance was greater in rabbits receiving grepafloxacin at 15 mg/kg than in those treated with higher doses (0.0088 versus 0.0034 ml/min).,Modeling of transfer kinetics at the serum-cerebrospinal fluid barrier in rabbits with experimental meningitis: application to grepafloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12499181/),[ml] / [min],0.0034,133749,DB00592,Piperazine
,12499181,CL(bulk),"Assuming a CL(bulk) of 0.01 ml/min, CL(active) was estimated to be 0.017 ml/min (11%), and clearance by total efflux was estimated to be 0.032 ml/min.",Modeling of transfer kinetics at the serum-cerebrospinal fluid barrier in rabbits with experimental meningitis: application to grepafloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12499181/),[ml] / [min],0.01,133750,DB00592,Piperazine
,12499181,CL(active),"Assuming a CL(bulk) of 0.01 ml/min, CL(active) was estimated to be 0.017 ml/min (11%), and clearance by total efflux was estimated to be 0.032 ml/min.",Modeling of transfer kinetics at the serum-cerebrospinal fluid barrier in rabbits with experimental meningitis: application to grepafloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12499181/),[ml] / [min],0.017,133751,DB00592,Piperazine
,12499181,clearance by total efflux,"Assuming a CL(bulk) of 0.01 ml/min, CL(active) was estimated to be 0.017 ml/min (11%), and clearance by total efflux was estimated to be 0.032 ml/min.",Modeling of transfer kinetics at the serum-cerebrospinal fluid barrier in rabbits with experimental meningitis: application to grepafloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12499181/),[ml] / [min],0.032,133752,DB00592,Piperazine
,21618564,total run time,"The total run time was 1.5 min and the elution of ESZ and IS occurred at 0.90 min; this was achieved with a mobile phase consisting of 0.1% formic acid-methanol (15:85, v/v) at a flow rate of 0.50 mL/min on a Discover C(18) (50 × 4.6 mm, 5 µm) column.",A rapid LC-MS/MS method for quantitation of eszopiclone in human plasma: application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21618564/),min,1.5,133948,DB00592,Piperazine
,21618564,flow rate,"The total run time was 1.5 min and the elution of ESZ and IS occurred at 0.90 min; this was achieved with a mobile phase consisting of 0.1% formic acid-methanol (15:85, v/v) at a flow rate of 0.50 mL/min on a Discover C(18) (50 × 4.6 mm, 5 µm) column.",A rapid LC-MS/MS method for quantitation of eszopiclone in human plasma: application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21618564/),[ml] / [min],0.50,133949,DB00592,Piperazine
,27133303,EC50,"Our study showed the inhibitory effects of TM208 on tumor pEGFR levels gradually reached a maximum effect, after which it became weaker over time, which was characterized by a combined tolerance/indirect response PD model with an estimated EC50 (55.9 μg/L), as well as three parameters ('a' of 27.2%, 'b' of 2730%, 'c' of 0.58 h(-1)) denoting the maximum, extent and rate of resistance, respectively.",Pharmacokinetic-pharmacodynamic modeling of the antitumor effect of TM208 and EGFR-TKI resistance in human breast cancer xenograft mice. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27133303/),[μg] / [l],55.9,134089,DB00592,Piperazine
,27133303,kng,"The relationship between the tumor pEGFR levels and tumor growth inhibition was characterized by a combined logistic tumor growth/transit compartment model with estimated parameters associated with tumor growth characteristics kng (0.282 day(-1)), drug potency kTM208 (0.0499 cm(3)/day) and the kinetics of tumor cell death k1 (0.141 day(-1)), which provided insight into drug mechanisms and behaviors.",Pharmacokinetic-pharmacodynamic modeling of the antitumor effect of TM208 and EGFR-TKI resistance in human breast cancer xenograft mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27133303/),1/[day],0.282,134090,DB00592,Piperazine
,27133303,potency,"The relationship between the tumor pEGFR levels and tumor growth inhibition was characterized by a combined logistic tumor growth/transit compartment model with estimated parameters associated with tumor growth characteristics kng (0.282 day(-1)), drug potency kTM208 (0.0499 cm(3)/day) and the kinetics of tumor cell death k1 (0.141 day(-1)), which provided insight into drug mechanisms and behaviors.",Pharmacokinetic-pharmacodynamic modeling of the antitumor effect of TM208 and EGFR-TKI resistance in human breast cancer xenograft mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27133303/),[cm(3] / [d],0.0499,134091,DB00592,Piperazine
,27133303,kTM208,"The relationship between the tumor pEGFR levels and tumor growth inhibition was characterized by a combined logistic tumor growth/transit compartment model with estimated parameters associated with tumor growth characteristics kng (0.282 day(-1)), drug potency kTM208 (0.0499 cm(3)/day) and the kinetics of tumor cell death k1 (0.141 day(-1)), which provided insight into drug mechanisms and behaviors.",Pharmacokinetic-pharmacodynamic modeling of the antitumor effect of TM208 and EGFR-TKI resistance in human breast cancer xenograft mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27133303/),[cm(3] / [d],0.0499,134092,DB00592,Piperazine
,27133303,kinetics of tumor cell death k1,"The relationship between the tumor pEGFR levels and tumor growth inhibition was characterized by a combined logistic tumor growth/transit compartment model with estimated parameters associated with tumor growth characteristics kng (0.282 day(-1)), drug potency kTM208 (0.0499 cm(3)/day) and the kinetics of tumor cell death k1 (0.141 day(-1)), which provided insight into drug mechanisms and behaviors.",Pharmacokinetic-pharmacodynamic modeling of the antitumor effect of TM208 and EGFR-TKI resistance in human breast cancer xenograft mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27133303/),1/[day],0.141,134093,DB00592,Piperazine
,21781653,C(max),"The geometric means, C(max), of the reference and the test formulations were 696.42 and 734.06 ng/ml.",Comparative bioavailability of two sildenafil tablet formulations after single-dose administration in healthy Thai male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21781653/),[ng] / [ml],696.42,134237,DB00592,Piperazine
,21781653,C(max),"The geometric means, C(max), of the reference and the test formulations were 696.42 and 734.06 ng/ml.",Comparative bioavailability of two sildenafil tablet formulations after single-dose administration in healthy Thai male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21781653/),[ng] / [ml],734.06,134238,DB00592,Piperazine
,21781653,AUC(0-t),"The mean values of the AUC(0-t) and AUC(0-inf) of the test formulation were 2,073.03 and 2,237.37 ng × h/ml, while those of the reference formulation were 1,950.26 and 2,078.06 ng × h/ml.",Comparative bioavailability of two sildenafil tablet formulations after single-dose administration in healthy Thai male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21781653/),[h·ng] / [ml],"2,073.03",134239,DB00592,Piperazine
,21781653,AUC(0-t),"The mean values of the AUC(0-t) and AUC(0-inf) of the test formulation were 2,073.03 and 2,237.37 ng × h/ml, while those of the reference formulation were 1,950.26 and 2,078.06 ng × h/ml.",Comparative bioavailability of two sildenafil tablet formulations after single-dose administration in healthy Thai male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21781653/),[h·ng] / [ml],"2,237.37",134240,DB00592,Piperazine
,21781653,AUC(0-t),"The mean values of the AUC(0-t) and AUC(0-inf) of the test formulation were 2,073.03 and 2,237.37 ng × h/ml, while those of the reference formulation were 1,950.26 and 2,078.06 ng × h/ml.",Comparative bioavailability of two sildenafil tablet formulations after single-dose administration in healthy Thai male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21781653/),[h·ng] / [ml],"1,950.26",134241,DB00592,Piperazine
,21781653,AUC(0-inf),"The mean values of the AUC(0-t) and AUC(0-inf) of the test formulation were 2,073.03 and 2,237.37 ng × h/ml, while those of the reference formulation were 1,950.26 and 2,078.06 ng × h/ml.",Comparative bioavailability of two sildenafil tablet formulations after single-dose administration in healthy Thai male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21781653/),[h·ng] / [ml],"2,237.37",134242,DB00592,Piperazine
,21781653,AUC(0-inf),"The mean values of the AUC(0-t) and AUC(0-inf) of the test formulation were 2,073.03 and 2,237.37 ng × h/ml, while those of the reference formulation were 1,950.26 and 2,078.06 ng × h/ml.",Comparative bioavailability of two sildenafil tablet formulations after single-dose administration in healthy Thai male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21781653/),[h·ng] / [ml],"2,078.06",134243,DB00592,Piperazine
,26991823,area under the plasma concentration-time curve over dosing interval [τ],"Palbociclib exposure was higher with 125 vs 100 mg (mean area under the plasma concentration-time curve over dosing interval [τ]: 1322 vs 547.5 ng·h/mL [single dose], 2838 vs 1276 ng·h/mL [multiple dose]; mean maximum plasma concentration: 104.1 vs 41.4 ng/mL [single dose], 185.5 vs 77.4 ng/mL [multiple dose]).","Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26991823/),[h·ng] / [ml],1322,134320,DB00592,Piperazine
,26991823,area under the plasma concentration-time curve over dosing interval [τ],"Palbociclib exposure was higher with 125 vs 100 mg (mean area under the plasma concentration-time curve over dosing interval [τ]: 1322 vs 547.5 ng·h/mL [single dose], 2838 vs 1276 ng·h/mL [multiple dose]; mean maximum plasma concentration: 104.1 vs 41.4 ng/mL [single dose], 185.5 vs 77.4 ng/mL [multiple dose]).","Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26991823/),[h·ng] / [ml],547.5,134321,DB00592,Piperazine
,26991823,area under the plasma concentration-time curve over dosing interval [τ],"Palbociclib exposure was higher with 125 vs 100 mg (mean area under the plasma concentration-time curve over dosing interval [τ]: 1322 vs 547.5 ng·h/mL [single dose], 2838 vs 1276 ng·h/mL [multiple dose]; mean maximum plasma concentration: 104.1 vs 41.4 ng/mL [single dose], 185.5 vs 77.4 ng/mL [multiple dose]).","Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26991823/),[h·ng] / [ml],2838,134322,DB00592,Piperazine
,26991823,area under the plasma concentration-time curve over dosing interval [τ],"Palbociclib exposure was higher with 125 vs 100 mg (mean area under the plasma concentration-time curve over dosing interval [τ]: 1322 vs 547.5 ng·h/mL [single dose], 2838 vs 1276 ng·h/mL [multiple dose]; mean maximum plasma concentration: 104.1 vs 41.4 ng/mL [single dose], 185.5 vs 77.4 ng/mL [multiple dose]).","Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26991823/),[h·ng] / [ml],1276,134323,DB00592,Piperazine
,26991823,maximum plasma concentration,"Palbociclib exposure was higher with 125 vs 100 mg (mean area under the plasma concentration-time curve over dosing interval [τ]: 1322 vs 547.5 ng·h/mL [single dose], 2838 vs 1276 ng·h/mL [multiple dose]; mean maximum plasma concentration: 104.1 vs 41.4 ng/mL [single dose], 185.5 vs 77.4 ng/mL [multiple dose]).","Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26991823/),[ng] / [ml],104.1,134324,DB00592,Piperazine
,26991823,maximum plasma concentration,"Palbociclib exposure was higher with 125 vs 100 mg (mean area under the plasma concentration-time curve over dosing interval [τ]: 1322 vs 547.5 ng·h/mL [single dose], 2838 vs 1276 ng·h/mL [multiple dose]; mean maximum plasma concentration: 104.1 vs 41.4 ng/mL [single dose], 185.5 vs 77.4 ng/mL [multiple dose]).","Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26991823/),[ng] / [ml],41.4,134325,DB00592,Piperazine
,26991823,maximum plasma concentration,"Palbociclib exposure was higher with 125 vs 100 mg (mean area under the plasma concentration-time curve over dosing interval [τ]: 1322 vs 547.5 ng·h/mL [single dose], 2838 vs 1276 ng·h/mL [multiple dose]; mean maximum plasma concentration: 104.1 vs 41.4 ng/mL [single dose], 185.5 vs 77.4 ng/mL [multiple dose]).","Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26991823/),[ng] / [ml],185.5,134326,DB00592,Piperazine
,26991823,maximum plasma concentration,"Palbociclib exposure was higher with 125 vs 100 mg (mean area under the plasma concentration-time curve over dosing interval [τ]: 1322 vs 547.5 ng·h/mL [single dose], 2838 vs 1276 ng·h/mL [multiple dose]; mean maximum plasma concentration: 104.1 vs 41.4 ng/mL [single dose], 185.5 vs 77.4 ng/mL [multiple dose]).","Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26991823/),[ng] / [ml],77.4,134327,DB00592,Piperazine
,26991823,Half-life,Half-life was 23-26 h.,"Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26991823/),h,23-26,134328,DB00592,Piperazine
,30514402,elimination half-lives,"In general, elimination half-lives of these agents in mice and guinea pigs were much shorter (1-3 h) relative to those in larger species such as prairie dogs and monkeys.",Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30514402/),h,1-3,134334,DB00592,Piperazine
,30514402,elimination half-life,"The longer nilotinib elimination half-life in prairie dogs (i.v., 6.5 h and oral, 7.5 h), facilitated multiple dosing PK and safety assessment.",Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30514402/),h,6.5,134335,DB00592,Piperazine
,30514402,elimination half-life,"The longer nilotinib elimination half-life in prairie dogs (i.v., 6.5 h and oral, 7.5 h), facilitated multiple dosing PK and safety assessment.",Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30514402/),h,7.5,134336,DB00592,Piperazine
,24399453,elimination half-life,The mean elimination half-life of blonanserin (7.7-11.9 h) was much longer than that of M2 (1.2-1.3 h) but shorter than that of M1 (26.4-31.4 h) after single fasting doses.,The pharmacokinetic and safety profiles of blonanserin in healthy Chinese volunteers after single fasting doses and single and multiple postprandial doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24399453/),h,7.7-11.9,134439,DB00592,Piperazine
,24399453,elimination half-life,The mean elimination half-life of blonanserin (7.7-11.9 h) was much longer than that of M2 (1.2-1.3 h) but shorter than that of M1 (26.4-31.4 h) after single fasting doses.,The pharmacokinetic and safety profiles of blonanserin in healthy Chinese volunteers after single fasting doses and single and multiple postprandial doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24399453/),h,1.2-1.3,134440,DB00592,Piperazine
,24399453,elimination half-life,The mean elimination half-life of blonanserin (7.7-11.9 h) was much longer than that of M2 (1.2-1.3 h) but shorter than that of M1 (26.4-31.4 h) after single fasting doses.,The pharmacokinetic and safety profiles of blonanserin in healthy Chinese volunteers after single fasting doses and single and multiple postprandial doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24399453/),h,26.4-31.4,134441,DB00592,Piperazine
,8230282,AUC,"Following continuous oral treatment, the mean day 28 AUC for all-trans RA was significantly lower than that on day 1 (213 ng/mL per hour versus 467 ng/mL per hour; P < .01), a decline significantly attenuated by ketoconazole, which increased the mean plasma all-trans RA AUC on day 29 to 375 ng/mL per hour (P < .01).","Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230282/),[ng] / [h·ml],213,134769,DB00592,Piperazine
,8230282,AUC,"Following continuous oral treatment, the mean day 28 AUC for all-trans RA was significantly lower than that on day 1 (213 ng/mL per hour versus 467 ng/mL per hour; P < .01), a decline significantly attenuated by ketoconazole, which increased the mean plasma all-trans RA AUC on day 29 to 375 ng/mL per hour (P < .01).","Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230282/),[ng] / [h·ml],467,134770,DB00592,Piperazine
,8230282,AUC,"Following continuous oral treatment, the mean day 28 AUC for all-trans RA was significantly lower than that on day 1 (213 ng/mL per hour versus 467 ng/mL per hour; P < .01), a decline significantly attenuated by ketoconazole, which increased the mean plasma all-trans RA AUC on day 29 to 375 ng/mL per hour (P < .01).","Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230282/),[ng] / [h·ml],375,134771,DB00592,Piperazine
,2551007,half-lives,"Sequential half-lives were in the order of 11-19 min and 5-7 h, and primarily reflect rates of distribution between the systemic circulation and the rapidly equilibrating tissues such as the brain.",Tolerance and pharmacokinetics of flunarizine after cardiac arrest. The Cerebral Resuscitation Study Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2551007/),min,11-19,134804,DB00592,Piperazine
,2551007,half-lives,"Sequential half-lives were in the order of 11-19 min and 5-7 h, and primarily reflect rates of distribution between the systemic circulation and the rapidly equilibrating tissues such as the brain.",Tolerance and pharmacokinetics of flunarizine after cardiac arrest. The Cerebral Resuscitation Study Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2551007/),h,5-7,134805,DB00592,Piperazine
,14747424,Absolute bioavailability,"Absolute bioavailability values (compared with i.v. infusion) for the imatinib capsule and oral solution were 98.3% and 97.2%, respectively.",Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14747424/),%,98.3,134834,DB00592,Piperazine
,14747424,Absolute bioavailability,"Absolute bioavailability values (compared with i.v. infusion) for the imatinib capsule and oral solution were 98.3% and 97.2%, respectively.",Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14747424/),%,97.2,134835,DB00592,Piperazine
>,14747424,bioavailable,"The 400-mg oral dose of imatinib, as a capsule or a solution, was completely absorbed and was almost completely bioavailable (> 97%).",Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14747424/),%,97,134836,DB00592,Piperazine
,19780144,permeability,"The Caco-2 permeability, tested at 200 microM, was quantitatively predictive of in vivo oral absorption, with complete absorption occurring at a Caco-2 permeability of 100 nm/s or higher.","Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19780144/),[nm] / [s],100,134995,DB00592,Piperazine
,19780144,permeability,"Among the >100 compounds evaluated, BMS-488043 emerged as a lead, exhibiting a Caco-2 permeability of 178 nm/s and a microsomal half-life predictive of a low clearance (4 mL/min/kg) in humans.","Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19780144/),[nm] / [s],178,134996,DB00592,Piperazine
,19780144,clearance,"Among the >100 compounds evaluated, BMS-488043 emerged as a lead, exhibiting a Caco-2 permeability of 178 nm/s and a microsomal half-life predictive of a low clearance (4 mL/min/kg) in humans.","Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19780144/),[ml] / [kg·min],4,134997,DB00592,Piperazine
,19780144,oral bioavailability,"The oral bioavailability of BMS-488043 in rats, dogs, and monkeys was 90%, 57%, and 60%, respectively.","Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19780144/),%,90,134998,DB00592,Piperazine
,19780144,oral bioavailability,"The oral bioavailability of BMS-488043 in rats, dogs, and monkeys was 90%, 57%, and 60%, respectively.","Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19780144/),%,57,134999,DB00592,Piperazine
,19780144,oral bioavailability,"The oral bioavailability of BMS-488043 in rats, dogs, and monkeys was 90%, 57%, and 60%, respectively.","Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19780144/),%,60,135000,DB00592,Piperazine
,19780144,terminal half-life,"The clearance was low in all three species tested, with a terminal half-life ranging from 2.4 to 4.7 h.","Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19780144/),h,2.4 to 4.7,135001,DB00592,Piperazine
,19780144,permeability,"Furthermore, the oral exposure of BMS-488043 was significantly improved (6- to 12-fold in rats and monkeys) compared to the prototype compound BMS-378806 that had a suboptimal Caco-2 permeability (51 nm/s) and microsomal half-life.","Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19780144/),[nm] / [s],51,135002,DB00592,Piperazine
,12580990,Peff,"Peff of fexofenadine was low according to the BCS (0.11 +/- 0.11 and 0.04 +/- 0.13 x 10(-4) cm s(-1) in periods 1 and 2, respectively), and the coadministration of ketoconazole in period 2 had no significant acute effect on Peff (95% confidence interval (CI) on the difference -0.37, 0.51).",The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12580990/),[cm] / [s],0.11,135222,DB00592,Piperazine
,12580990,Peff,"Peff of fexofenadine was low according to the BCS (0.11 +/- 0.11 and 0.04 +/- 0.13 x 10(-4) cm s(-1) in periods 1 and 2, respectively), and the coadministration of ketoconazole in period 2 had no significant acute effect on Peff (95% confidence interval (CI) on the difference -0.37, 0.51).",The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12580990/),[cm] / [s],0.04,135223,DB00592,Piperazine
,12580990,Peff,"After pretreatment with ketoconazole (T2), the jejunal Peff of fexofenadine increased to 0.29 +/- 0.47 and 0.22 +/- 0.31 x 10-4 cm s(-1) in both periods 1 and 2, respectively, but the change was not statistically significant when compared with T1 (95% CI on the difference -0.62, 0.27 for T1 0-100 min vs T2 0-100 min; -0.54, 0.34 for T1 0-100 min vs T2 100-200 min).",The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12580990/),[cm] / [s],0.29,135224,DB00592,Piperazine
,12580990,Peff,"After pretreatment with ketoconazole (T2), the jejunal Peff of fexofenadine increased to 0.29 +/- 0.47 and 0.22 +/- 0.31 x 10-4 cm s(-1) in both periods 1 and 2, respectively, but the change was not statistically significant when compared with T1 (95% CI on the difference -0.62, 0.27 for T1 0-100 min vs T2 0-100 min; -0.54, 0.34 for T1 0-100 min vs T2 100-200 min).",The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12580990/),[cm] / [s],0.22,135225,DB00592,Piperazine
,12580990,plasma AUC,"Fexofenadine plasma AUC from 0-100 mg showed no significant difference after pretreatment with ketoconazole (55 +/- 101 and 51 +/- 33 micro g ml(-1) min(-1) respectively; 95% CI on the difference -108, 115).",The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12580990/),[μg] / [min·ml],55,135226,DB00592,Piperazine
,12580990,plasma AUC,"Fexofenadine plasma AUC from 0-100 mg showed no significant difference after pretreatment with ketoconazole (55 +/- 101 and 51 +/- 33 micro g ml(-1) min(-1) respectively; 95% CI on the difference -108, 115).",The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12580990/),[μg] / [min·ml],51,135227,DB00592,Piperazine
,12580990,Total plasma AUC (0-720 min),"Total plasma AUC (0-720 min) was 318 +/- 426 and 426 +/- 232 ng ml(-1) min in T1 and T2, respectively (95% CI on the difference -622, 405).",The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12580990/),[min·ng] / [ml],318,135228,DB00592,Piperazine
,12580990,Total plasma AUC (0-720 min),"Total plasma AUC (0-720 min) was 318 +/- 426 and 426 +/- 232 ng ml(-1) min in T1 and T2, respectively (95% CI on the difference -622, 405).",The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12580990/),[min·ng] / [ml],426,135229,DB00592,Piperazine
,26604700,entrapment efficiency,The results showed that the optimized formula produced nanoethosomes with an average size of 128 nm and an entrapment efficiency of 76.23%.,"Nanoethosomal transdermal delivery of vardenafil for treatment of erectile dysfunction: optimization, characterization, and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26604700/),%,76.23,135483,DB00592,Piperazine
,15684491,clearance ratio,"Without pretreatment with CsA or KCZ, the clearance ratio of Clbile relative to the total body clearances of Rho123, NFV and EM was 10.5, 0.07 and 31.1%, respectively.",In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15684491/),%,10.5,135601,DB00592,Piperazine
,15684491,clearance ratio,"Without pretreatment with CsA or KCZ, the clearance ratio of Clbile relative to the total body clearances of Rho123, NFV and EM was 10.5, 0.07 and 31.1%, respectively.",In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15684491/),%,0.07,135602,DB00592,Piperazine
,15684491,clearance ratio,"Without pretreatment with CsA or KCZ, the clearance ratio of Clbile relative to the total body clearances of Rho123, NFV and EM was 10.5, 0.07 and 31.1%, respectively.",In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15684491/),%,31.1,135603,DB00592,Piperazine
,12438536,clearance,"Differences in the pharmacokinetics of buspirone and 1-PP were observed with values for clearance of 13.1 and 8.2 ml/min and for terminal elimination half-life of 25 and 79 min, respectively.",Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12438536/),[ml] / [min],13.1,135774,DB00592,Piperazine
,12438536,clearance,"Differences in the pharmacokinetics of buspirone and 1-PP were observed with values for clearance of 13.1 and 8.2 ml/min and for terminal elimination half-life of 25 and 79 min, respectively.",Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12438536/),[ml] / [min],8.2,135775,DB00592,Piperazine
,12438536,terminal elimination half-life,"Differences in the pharmacokinetics of buspirone and 1-PP were observed with values for clearance of 13.1 and 8.2 ml/min and for terminal elimination half-life of 25 and 79 min, respectively.",Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12438536/),min,25,135776,DB00592,Piperazine
,12438536,terminal elimination half-life,"Differences in the pharmacokinetics of buspirone and 1-PP were observed with values for clearance of 13.1 and 8.2 ml/min and for terminal elimination half-life of 25 and 79 min, respectively.",Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12438536/),min,79,135777,DB00592,Piperazine
,12438536,intrinsic activity,"Both buspirone and 1-PP behaved as partial agonists relative to R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin (R-8-OH-DPAT) with values of the intrinsic activity of 0.465 and 0.312, respectively.",Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12438536/),,0.465,135778,DB00592,Piperazine
,12438536,intrinsic activity,"Both buspirone and 1-PP behaved as partial agonists relative to R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin (R-8-OH-DPAT) with values of the intrinsic activity of 0.465 and 0.312, respectively.",Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12438536/),,0.312,135779,DB00592,Piperazine
,20033891,flow rate,"Reversed-phase chromatographic separation was affected by gradient elution with mobile phases consisting of 10 mM ammonium formate pH 7.0 (solvent A) and methanol (100%, solvent B), delivered at a flow rate of 0.4 mL/min.",Validated LC-MS/MS assay for the quantitative determination of vardenafil in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20033891/),[ml] / [min],0.4,136083,DB00592,Piperazine
,20033891,mass transitions,The mass transitions were m/z 489.3 --> 312.2 for vardenafil and m/z 309.2 --> 281.0 for alprazolam.,Validated LC-MS/MS assay for the quantitative determination of vardenafil in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20033891/),,489.3,136084,DB00592,Piperazine
,20033891,m/z,The mass transitions were m/z 489.3 --> 312.2 for vardenafil and m/z 309.2 --> 281.0 for alprazolam.,Validated LC-MS/MS assay for the quantitative determination of vardenafil in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20033891/),,489.3,136085,DB00592,Piperazine
,20033891,m/z,The mass transitions were m/z 489.3 --> 312.2 for vardenafil and m/z 309.2 --> 281.0 for alprazolam.,Validated LC-MS/MS assay for the quantitative determination of vardenafil in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20033891/),,312.2,136086,DB00592,Piperazine
,20033891,m/z,The mass transitions were m/z 489.3 --> 312.2 for vardenafil and m/z 309.2 --> 281.0 for alprazolam.,Validated LC-MS/MS assay for the quantitative determination of vardenafil in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20033891/),,309.2,136087,DB00592,Piperazine
,20033891,m/z,The mass transitions were m/z 489.3 --> 312.2 for vardenafil and m/z 309.2 --> 281.0 for alprazolam.,Validated LC-MS/MS assay for the quantitative determination of vardenafil in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20033891/),,281.0,136088,DB00592,Piperazine
,19032724,absorption rate constant,The absorption rate constant was fixed to 1.06 h(-1).,"Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19032724/),1/[h],1.06,136567,DB00592,Piperazine
,19032724,apparent distribution volume,The typical value of apparent distribution volume of aripiprazole was estimated to be 192 l.,"Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19032724/),l,192,136568,DB00592,Piperazine
,24291719,flow rate,"The HPLC separation was performed on a CAPCELL PAK SCX column (250mm×4.6mm, 5.0μm, Shiseido, Japan) with a mobile phase of acetonitrile/80mmol/L ammonium phosphate (pH adjusted to 6.0) (60:40, v/v) at a flow rate of 1.2mL/min.",Quantitative analysis of trazodone in human plasma by using HPLC-fluorescence detector coupled with strong cation exchange chromatographic column: application to a pharmacokinetic study in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24291719/),[ml] / [min],1.2,136669,DB00592,Piperazine
,24291719,extraction recovery,The extraction recovery was 72.6-88.3% and the method was over the concentration range of 5.0-2486ng/mL with a lower limit of quantitation (LLOQ) of 5.0ng/mL using 300μL of plasma.,Quantitative analysis of trazodone in human plasma by using HPLC-fluorescence detector coupled with strong cation exchange chromatographic column: application to a pharmacokinetic study in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24291719/),%,72.6-88.3,136670,DB00592,Piperazine
,31077435,extraction recovery,The mean extraction recovery obtained for flunarizine was 98.85% without compromising the sensitivity of the method.,A high-throughput LC-MS/MS method for determination of flunarizine in human plasma: Pharmacokinetic study with different doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31077435/),%,98.85,136677,DB00592,Piperazine
,31077435,m/z,"Multiple reaction monitoring was selected for quantitation using the transitions, m/z 405.2 → 203.2 for flunarizine and m/z 413.1 → 203.2 for flunarizine-d8.",A high-throughput LC-MS/MS method for determination of flunarizine in human plasma: Pharmacokinetic study with different doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31077435/),,405.2,136678,DB00592,Piperazine
,31077435,m/z,"Multiple reaction monitoring was selected for quantitation using the transitions, m/z 405.2 → 203.2 for flunarizine and m/z 413.1 → 203.2 for flunarizine-d8.",A high-throughput LC-MS/MS method for determination of flunarizine in human plasma: Pharmacokinetic study with different doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31077435/),,203.2,136679,DB00592,Piperazine
,31077435,m/z,"Multiple reaction monitoring was selected for quantitation using the transitions, m/z 405.2 → 203.2 for flunarizine and m/z 413.1 → 203.2 for flunarizine-d8.",A high-throughput LC-MS/MS method for determination of flunarizine in human plasma: Pharmacokinetic study with different doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31077435/),,413.1,136680,DB00592,Piperazine
,17891537,delta delta QTcSS,"The one-sided 95% upper limits of the largest delta delta QTcSS for levocetirizine were 5.7 ms (5 mg) and 3.9 ms (30 mg), with mean estimates of 2.9 and 1.1 ms, respectively.",Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17891537/),ms,5.7,136991,DB00592,Piperazine
,17891537,delta delta QTcSS,"The one-sided 95% upper limits of the largest delta delta QTcSS for levocetirizine were 5.7 ms (5 mg) and 3.9 ms (30 mg), with mean estimates of 2.9 and 1.1 ms, respectively.",Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17891537/),ms,3.9,136992,DB00592,Piperazine
,17891537,delta delta QTcSS,"The one-sided 95% upper limits of the largest delta delta QTcSS for levocetirizine were 5.7 ms (5 mg) and 3.9 ms (30 mg), with mean estimates of 2.9 and 1.1 ms, respectively.",Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17891537/),ms,2.9,136993,DB00592,Piperazine
,17891537,delta delta QTcSS,"The one-sided 95% upper limits of the largest delta delta QTcSS for levocetirizine were 5.7 ms (5 mg) and 3.9 ms (30 mg), with mean estimates of 2.9 and 1.1 ms, respectively.",Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17891537/),ms,1.1,136994,DB00592,Piperazine
,17891537,delta delta QTcSS,"Statistically, moxifloxacin significantly lengthened the QTcSS, with a one-sided 95% lower limit of the largest delta delta QTcSS of 10.5 ms and a mean estimate of 13.4 ms.",Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17891537/),ms,10.5,136995,DB00592,Piperazine
,17891537,delta delta QTcSS,"Statistically, moxifloxacin significantly lengthened the QTcSS, with a one-sided 95% lower limit of the largest delta delta QTcSS of 10.5 ms and a mean estimate of 13.4 ms.",Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17891537/),m,13.4,136996,DB00592,Piperazine
,29117990,area under the curve ratio,The simulated midazolam area under the curve ratio of 0.54 and an accompanying observed 1.9-fold increase in the CYP3A4 activity of biomarker 4β-hydroxycholesterol indicated a weak-to-moderate CYP3A4 induction by midostaurin and its metabolites at steady state in patients with advSM.,Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29117990/),,0.54,137187,DB00592,Piperazine
,16019953,extraction ratio,"When ketoconazole was given orally to the animals, in conjunction with midazolam, the extraction ratio in the liver decreased from 93% to 77% in the control rats, and the bioavailability of midazolam increased to 23%.",Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug-drug interaction model rats. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16019953/),%,93,137207,DB00592,Piperazine
,16019953,extraction ratio,"When ketoconazole was given orally to the animals, in conjunction with midazolam, the extraction ratio in the liver decreased from 93% to 77% in the control rats, and the bioavailability of midazolam increased to 23%.",Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug-drug interaction model rats. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16019953/),%,77,137208,DB00592,Piperazine
,16019953,bioavailability,"When ketoconazole was given orally to the animals, in conjunction with midazolam, the extraction ratio in the liver decreased from 93% to 77% in the control rats, and the bioavailability of midazolam increased to 23%.",Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug-drug interaction model rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16019953/),%,23,137209,DB00592,Piperazine
,26643541,half-life,"NSI-189 area under the curve increased in a dose-related and nearly proportional manner across the three cohorts, with a half-life of 17.4-20.5 h.","A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26643541/),h,17.4-20.5,137467,DB00592,Piperazine
,27207059,PS,"PS, zeta potential and %EE of optimized APNPs were found to be 199.2±5.65nm, -21.4±4.6mV and 69.2±2.34% respectively.",Aripiprazole loaded poly(caprolactone) nanoparticles: Optimization and in vivo pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207059/),nm,199.2,137549,DB00592,Piperazine
,27207059,zeta potential,"PS, zeta potential and %EE of optimized APNPs were found to be 199.2±5.65nm, -21.4±4.6mV and 69.2±2.34% respectively.",Aripiprazole loaded poly(caprolactone) nanoparticles: Optimization and in vivo pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207059/),m,-,137550,DB00592,Piperazine
,27207059,zeta potential,"PS, zeta potential and %EE of optimized APNPs were found to be 199.2±5.65nm, -21.4±4.6mV and 69.2±2.34% respectively.",Aripiprazole loaded poly(caprolactone) nanoparticles: Optimization and in vivo pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207059/),m,21.4,137551,DB00592,Piperazine
,27207059,%EE,"PS, zeta potential and %EE of optimized APNPs were found to be 199.2±5.65nm, -21.4±4.6mV and 69.2±2.34% respectively.",Aripiprazole loaded poly(caprolactone) nanoparticles: Optimization and in vivo pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207059/),m,21.4,137552,DB00592,Piperazine
,27207059,%EE,"PS, zeta potential and %EE of optimized APNPs were found to be 199.2±5.65nm, -21.4±4.6mV and 69.2±2.34% respectively.",Aripiprazole loaded poly(caprolactone) nanoparticles: Optimization and in vivo pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207059/),%,69.2,137553,DB00592,Piperazine
,8825195,tmax,"Over the po dose range of 50-200 mg, NEF was rapidly absorbed (tmax values for NEF, HO-NEF and total radioactivity were approximately 0.5 hr).","Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8825195/),h,0.5,137576,DB00592,Piperazine
,8825195,Recovery,Recovery of total radioactivity in the urine (approximately 50% of dose) was similar after iv and po administrations.,"Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8825195/),,50,137577,DB00592,Piperazine
,8825195,apparent absolute oral bioavailability,"The mean (SD) apparent absolute oral bioavailability of NEF was 15(7)%, 18(7)%, and 23(7)% at doses of 50, 100, and 200 mg, respectively.","Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8825195/),%,15,137578,DB00592,Piperazine
,8825195,apparent absolute oral bioavailability,"The mean (SD) apparent absolute oral bioavailability of NEF was 15(7)%, 18(7)%, and 23(7)% at doses of 50, 100, and 200 mg, respectively.","Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8825195/),%,18,137579,DB00592,Piperazine
,8825195,apparent absolute oral bioavailability,"The mean (SD) apparent absolute oral bioavailability of NEF was 15(7)%, 18(7)%, and 23(7)% at doses of 50, 100, and 200 mg, respectively.","Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8825195/),%,23,137580,DB00592,Piperazine
,8825195,apparent extent,The apparent extent of presystemic metabolism over this dosage range was estimated to be 74-87%.,"Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in humans. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8825195/),%,74-87,137581,DB00592,Piperazine
less,22010981,friability,"The sildenafil lactate-loaded orally disintegrating tablet prepared with 45 mg/tab of menthol and 1.5 mg/tab of colloidal silica gave a hardness of 3-4 KP, friability less than 0.5% and disintegration time less than 30 s, suggesting that it was a practical and commercial product with good tablet property and excellent efficacy.",Development of sildenafil-loaded orally disintegrating tablet with new lactate salt. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22010981/),%,0.5,137720,DB00592,Piperazine
less,22010981,disintegration time,"The sildenafil lactate-loaded orally disintegrating tablet prepared with 45 mg/tab of menthol and 1.5 mg/tab of colloidal silica gave a hardness of 3-4 KP, friability less than 0.5% and disintegration time less than 30 s, suggesting that it was a practical and commercial product with good tablet property and excellent efficacy.",Development of sildenafil-loaded orally disintegrating tablet with new lactate salt. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22010981/),s,30,137721,DB00592,Piperazine
,2291876,terminal elimination half-life,The absorption of CGP 6140 was rapid and its terminal elimination half-life was about 3 h.,Pharmacokinetics of CGP 6140 (amocarzine) after oral administration of single 100-1600 mg doses to patients with onchocerciasis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291876/),h,3,137866,DB00592,Piperazine
,15114429,total,"After oral administration of 75 micro g midazolam, the 30-min total (unconjugated + conjugated) 1'OH-midazolam/midazolam ratios measured in the groups without co-medication, with ketoconazole and with rifampicin were (mean+/-SD): 6.23+/-2.61, 0.79+/-0.39 and 56.1+/-12.4, respectively.",Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114429/),,6.23,137989,DB00592,Piperazine
,15114429,total,"After oral administration of 75 micro g midazolam, the 30-min total (unconjugated + conjugated) 1'OH-midazolam/midazolam ratios measured in the groups without co-medication, with ketoconazole and with rifampicin were (mean+/-SD): 6.23+/-2.61, 0.79+/-0.39 and 56.1+/-12.4, respectively.",Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114429/),,0.79,137990,DB00592,Piperazine
,15114429,total,"After oral administration of 75 micro g midazolam, the 30-min total (unconjugated + conjugated) 1'OH-midazolam/midazolam ratios measured in the groups without co-medication, with ketoconazole and with rifampicin were (mean+/-SD): 6.23+/-2.61, 0.79+/-0.39 and 56.1+/-12.4, respectively.",Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114429/),,56.1,137991,DB00592,Piperazine
,15114429,ratios,"After oral administration of 75 micro g midazolam, the 30-min total (unconjugated + conjugated) 1'OH-midazolam/midazolam ratios measured in the groups without co-medication, with ketoconazole and with rifampicin were (mean+/-SD): 6.23+/-2.61, 0.79+/-0.39 and 56.1+/-12.4, respectively.",Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114429/),,6.23,137992,DB00592,Piperazine
,15114429,ratios,"After oral administration of 75 micro g midazolam, the 30-min total (unconjugated + conjugated) 1'OH-midazolam/midazolam ratios measured in the groups without co-medication, with ketoconazole and with rifampicin were (mean+/-SD): 6.23+/-2.61, 0.79+/-0.39 and 56.1+/-12.4, respectively.",Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114429/),,0.79,137993,DB00592,Piperazine
,15114429,ratios,"After oral administration of 75 micro g midazolam, the 30-min total (unconjugated + conjugated) 1'OH-midazolam/midazolam ratios measured in the groups without co-medication, with ketoconazole and with rifampicin were (mean+/-SD): 6.23+/-2.61, 0.79+/-0.39 and 56.1+/-12.4, respectively.",Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114429/),,56.1,137994,DB00592,Piperazine
,25656737,tissue-to-plasma AUC0→∞ ratio,"Sunitinib presented high tissue-to-plasma AUC0→∞ ratio in liver (17.8 ± 1.2), kidney (14.6 ± 1.52) and brain (2.25 ± 0.18) which was modified after coadministration: AUC0→∞ ratio increased in liver (31.4 ± 4.7; p < 0.001), kidney (17.1 ± 2.2; p > 0.05) and decreased in brain (1.70 ± 0.23, p > 0.05).",Sunitinib tissue distribution changes after coadministration with ketoconazole in mice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25656737/),,17.8,138323,DB00592,Piperazine
,25656737,tissue-to-plasma AUC0→∞ ratio,"Sunitinib presented high tissue-to-plasma AUC0→∞ ratio in liver (17.8 ± 1.2), kidney (14.6 ± 1.52) and brain (2.25 ± 0.18) which was modified after coadministration: AUC0→∞ ratio increased in liver (31.4 ± 4.7; p < 0.001), kidney (17.1 ± 2.2; p > 0.05) and decreased in brain (1.70 ± 0.23, p > 0.05).",Sunitinib tissue distribution changes after coadministration with ketoconazole in mice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25656737/),,14.6,138324,DB00592,Piperazine
,25656737,tissue-to-plasma AUC0→∞ ratio,"Sunitinib presented high tissue-to-plasma AUC0→∞ ratio in liver (17.8 ± 1.2), kidney (14.6 ± 1.52) and brain (2.25 ± 0.18) which was modified after coadministration: AUC0→∞ ratio increased in liver (31.4 ± 4.7; p < 0.001), kidney (17.1 ± 2.2; p > 0.05) and decreased in brain (1.70 ± 0.23, p > 0.05).",Sunitinib tissue distribution changes after coadministration with ketoconazole in mice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25656737/),,2.25,138325,DB00592,Piperazine
,25656737,AUC0→∞ ratio,"Sunitinib presented high tissue-to-plasma AUC0→∞ ratio in liver (17.8 ± 1.2), kidney (14.6 ± 1.52) and brain (2.25 ± 0.18) which was modified after coadministration: AUC0→∞ ratio increased in liver (31.4 ± 4.7; p < 0.001), kidney (17.1 ± 2.2; p > 0.05) and decreased in brain (1.70 ± 0.23, p > 0.05).",Sunitinib tissue distribution changes after coadministration with ketoconazole in mice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25656737/),,31.4,138326,DB00592,Piperazine
,25656737,AUC0→∞ ratio,"Sunitinib presented high tissue-to-plasma AUC0→∞ ratio in liver (17.8 ± 1.2), kidney (14.6 ± 1.52) and brain (2.25 ± 0.18) which was modified after coadministration: AUC0→∞ ratio increased in liver (31.4 ± 4.7; p < 0.001), kidney (17.1 ± 2.2; p > 0.05) and decreased in brain (1.70 ± 0.23, p > 0.05).",Sunitinib tissue distribution changes after coadministration with ketoconazole in mice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25656737/),,17.1,138327,DB00592,Piperazine
,25656737,AUC0→∞ ratio,"Sunitinib presented high tissue-to-plasma AUC0→∞ ratio in liver (17.8 ± 1.2), kidney (14.6 ± 1.52) and brain (2.25 ± 0.18) which was modified after coadministration: AUC0→∞ ratio increased in liver (31.4 ± 4.7; p < 0.001), kidney (17.1 ± 2.2; p > 0.05) and decreased in brain (1.70 ± 0.23, p > 0.05).",Sunitinib tissue distribution changes after coadministration with ketoconazole in mice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25656737/),,1.70,138328,DB00592,Piperazine
,2556065,distribution half-lives,"Following an iv bolus injection of 0.1 mg/kg, pipecuronium disappeared from the plasma exponentially with distribution half-lives of 3.9 +/- 1.1 min and 12.7 +/- 9.5 min (mean +/- SD), and elimination half-lives of 44.8 +/- 2.6 min and 196.7 +/- 102.0 min in animals with and without renal pedicle ligation, respectively.",Pharmacokinetics and disposition of pipecuronium bromide in dogs with and without ligated renal pedicles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556065/),min,3.9,138380,DB00592,Piperazine
,2556065,distribution half-lives,"Following an iv bolus injection of 0.1 mg/kg, pipecuronium disappeared from the plasma exponentially with distribution half-lives of 3.9 +/- 1.1 min and 12.7 +/- 9.5 min (mean +/- SD), and elimination half-lives of 44.8 +/- 2.6 min and 196.7 +/- 102.0 min in animals with and without renal pedicle ligation, respectively.",Pharmacokinetics and disposition of pipecuronium bromide in dogs with and without ligated renal pedicles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556065/),min,12.7,138381,DB00592,Piperazine
,2556065,elimination half-lives,"Following an iv bolus injection of 0.1 mg/kg, pipecuronium disappeared from the plasma exponentially with distribution half-lives of 3.9 +/- 1.1 min and 12.7 +/- 9.5 min (mean +/- SD), and elimination half-lives of 44.8 +/- 2.6 min and 196.7 +/- 102.0 min in animals with and without renal pedicle ligation, respectively.",Pharmacokinetics and disposition of pipecuronium bromide in dogs with and without ligated renal pedicles. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556065/),min,44.8,138382,DB00592,Piperazine
,2556065,elimination half-lives,"Following an iv bolus injection of 0.1 mg/kg, pipecuronium disappeared from the plasma exponentially with distribution half-lives of 3.9 +/- 1.1 min and 12.7 +/- 9.5 min (mean +/- SD), and elimination half-lives of 44.8 +/- 2.6 min and 196.7 +/- 102.0 min in animals with and without renal pedicle ligation, respectively.",Pharmacokinetics and disposition of pipecuronium bromide in dogs with and without ligated renal pedicles. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556065/),min,196.7,138383,DB00592,Piperazine
,2556065,elimination half-life,"The elimination half-life was longer (196.7 +/- 102 (SD) vs. 44.8 +/- 2.6 min), plasma clearance slower (5.9 +/- 0.8 ml.kg-1.min-1 vs. 0.9 +/- 0.1 ml.kg-1.min-1) and mean residence time longer (221 +/- 73 vs. 51.1 +/- 1.8 min) in dogs with ligated renal pedicles.",Pharmacokinetics and disposition of pipecuronium bromide in dogs with and without ligated renal pedicles. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556065/),min,196.7,138384,DB00592,Piperazine
,2556065,elimination half-life,"The elimination half-life was longer (196.7 +/- 102 (SD) vs. 44.8 +/- 2.6 min), plasma clearance slower (5.9 +/- 0.8 ml.kg-1.min-1 vs. 0.9 +/- 0.1 ml.kg-1.min-1) and mean residence time longer (221 +/- 73 vs. 51.1 +/- 1.8 min) in dogs with ligated renal pedicles.",Pharmacokinetics and disposition of pipecuronium bromide in dogs with and without ligated renal pedicles. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556065/),min,44.8,138385,DB00592,Piperazine
,2556065,plasma clearance,"The elimination half-life was longer (196.7 +/- 102 (SD) vs. 44.8 +/- 2.6 min), plasma clearance slower (5.9 +/- 0.8 ml.kg-1.min-1 vs. 0.9 +/- 0.1 ml.kg-1.min-1) and mean residence time longer (221 +/- 73 vs. 51.1 +/- 1.8 min) in dogs with ligated renal pedicles.",Pharmacokinetics and disposition of pipecuronium bromide in dogs with and without ligated renal pedicles. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556065/),[ml] / [kg·min],5.9,138386,DB00592,Piperazine
,2556065,plasma clearance,"The elimination half-life was longer (196.7 +/- 102 (SD) vs. 44.8 +/- 2.6 min), plasma clearance slower (5.9 +/- 0.8 ml.kg-1.min-1 vs. 0.9 +/- 0.1 ml.kg-1.min-1) and mean residence time longer (221 +/- 73 vs. 51.1 +/- 1.8 min) in dogs with ligated renal pedicles.",Pharmacokinetics and disposition of pipecuronium bromide in dogs with and without ligated renal pedicles. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556065/),[ml] / [kg·min],0.9,138387,DB00592,Piperazine
,2556065,mean residence time,"The elimination half-life was longer (196.7 +/- 102 (SD) vs. 44.8 +/- 2.6 min), plasma clearance slower (5.9 +/- 0.8 ml.kg-1.min-1 vs. 0.9 +/- 0.1 ml.kg-1.min-1) and mean residence time longer (221 +/- 73 vs. 51.1 +/- 1.8 min) in dogs with ligated renal pedicles.",Pharmacokinetics and disposition of pipecuronium bromide in dogs with and without ligated renal pedicles. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556065/),min,221,138388,DB00592,Piperazine
,2556065,mean residence time,"The elimination half-life was longer (196.7 +/- 102 (SD) vs. 44.8 +/- 2.6 min), plasma clearance slower (5.9 +/- 0.8 ml.kg-1.min-1 vs. 0.9 +/- 0.1 ml.kg-1.min-1) and mean residence time longer (221 +/- 73 vs. 51.1 +/- 1.8 min) in dogs with ligated renal pedicles.",Pharmacokinetics and disposition of pipecuronium bromide in dogs with and without ligated renal pedicles. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556065/),min,51.1,138389,DB00592,Piperazine
,2556065,recovery,"Eight hours after injection, the recovery of the parent form of pipecuronium approximated 77% of the administered dose in the urine, 4.5% in the bile, and 3.3% in the liver of normal animals.",Pharmacokinetics and disposition of pipecuronium bromide in dogs with and without ligated renal pedicles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556065/),,77,138390,DB00592,Piperazine
,2556065,recovery,"Eight hours after injection, the recovery of the parent form of pipecuronium approximated 77% of the administered dose in the urine, 4.5% in the bile, and 3.3% in the liver of normal animals.",Pharmacokinetics and disposition of pipecuronium bromide in dogs with and without ligated renal pedicles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556065/),%,4.5,138391,DB00592,Piperazine
,2556065,recovery,"Eight hours after injection, the recovery of the parent form of pipecuronium approximated 77% of the administered dose in the urine, 4.5% in the bile, and 3.3% in the liver of normal animals.",Pharmacokinetics and disposition of pipecuronium bromide in dogs with and without ligated renal pedicles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556065/),%,3,138392,DB00592,Piperazine
,24374811,IC50,"Treatment of MCF-7 and MDA-MB-231 cells with TM208 dose-dependently inhibited the cell proliferation and colony formation in vitro (the IC50 values were 36.38 ± 3.77 and 18.13 ± 0.76 μmol/L, respectively).",Inhibition of EGFR autophosphorylation plays an important role in the anti-breast cancer efficacy of the dithiocarbamate derivative TM208. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24374811/),[μM] / [l],36.38,138471,DB00592,Piperazine
,24374811,IC50,"Treatment of MCF-7 and MDA-MB-231 cells with TM208 dose-dependently inhibited the cell proliferation and colony formation in vitro (the IC50 values were 36.38 ± 3.77 and 18.13 ± 0.76 μmol/L, respectively).",Inhibition of EGFR autophosphorylation plays an important role in the anti-breast cancer efficacy of the dithiocarbamate derivative TM208. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24374811/),[μM] / [l],18.13,138472,DB00592,Piperazine
,3767339,maximum concentrations,"The absorption of ketoconazole was rapid, with mean maximum concentrations of the drug in plasma of 4.2, 5.0, and 6.2 micrograms/ml attained at 1.7, 1.2, and 1.0 h, respectively, after administration of the tablet, suspension, and solution, respectively.",Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767339/),[μg] / [ml],4.2,138651,DB00592,Piperazine
,3767339,maximum concentrations,"The absorption of ketoconazole was rapid, with mean maximum concentrations of the drug in plasma of 4.2, 5.0, and 6.2 micrograms/ml attained at 1.7, 1.2, and 1.0 h, respectively, after administration of the tablet, suspension, and solution, respectively.",Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767339/),[μg] / [ml],5.0,138652,DB00592,Piperazine
,3767339,maximum concentrations,"The absorption of ketoconazole was rapid, with mean maximum concentrations of the drug in plasma of 4.2, 5.0, and 6.2 micrograms/ml attained at 1.7, 1.2, and 1.0 h, respectively, after administration of the tablet, suspension, and solution, respectively.",Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767339/),[μg] / [ml],6.2,138653,DB00592,Piperazine
,3767339,distribution,"The mean distribution and elimination half-life values were 1.5 to 1.7 and 7.5 to 7.9 h, respectively.",Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767339/),h,1.5 to 1.7,138654,DB00592,Piperazine
,3767339,elimination half-life,"The mean distribution and elimination half-life values were 1.5 to 1.7 and 7.5 to 7.9 h, respectively.",Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767339/),h,7.5 to 7.9,138655,DB00592,Piperazine
,3767339,oral clearance of the solution dose,"The mean oral clearance of the solution dose was 209 (+/- 82.9 [standard deviation]) ml/min, and the mean apparent volume of distribution was 88.31 (+/- 68.72) liters.",Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767339/),[ml] / [min],209,138656,DB00592,Piperazine
,3767339,apparent volume of distribution,"The mean oral clearance of the solution dose was 209 (+/- 82.9 [standard deviation]) ml/min, and the mean apparent volume of distribution was 88.31 (+/- 68.72) liters.",Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767339/),l,88.31,138657,DB00592,Piperazine
,3767339,relative bioavailabilities,"The relative bioavailabilities for the tablet and suspension were 81.2 (+/- 33.5) and 89.0 (+/- 23.1)%, respectively, of that of the solution.",Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767339/),%,81.2,138658,DB00592,Piperazine
,3767339,relative bioavailabilities,"The relative bioavailabilities for the tablet and suspension were 81.2 (+/- 33.5) and 89.0 (+/- 23.1)%, respectively, of that of the solution.",Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767339/),%,89.0,138659,DB00592,Piperazine
,3767339,oral clearance,"The mean oral clearance decreased from 244.9 to 123.6 and 80.0 ml/min, respectively, as the dose increased from 200 to 400 and 800 mg.",Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767339/),[ml] / [min],244.9,138660,DB00592,Piperazine
,3767339,oral clearance,"The mean oral clearance decreased from 244.9 to 123.6 and 80.0 ml/min, respectively, as the dose increased from 200 to 400 and 800 mg.",Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767339/),[ml] / [min],123.6,138661,DB00592,Piperazine
,3767339,oral clearance,"The mean oral clearance decreased from 244.9 to 123.6 and 80.0 ml/min, respectively, as the dose increased from 200 to 400 and 800 mg.",Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3767339/),[ml] / [min],80.0,138662,DB00592,Piperazine
,25400284,flow rate,"Chromatographic separation was performed on a Thermo Scientific Accucore C18 column with an isocratic mobile phase composed of 0.1% v/v formic acid in purified water-methanol (20:80, v/v), at a flow rate of 0.3 mL/min.",Simultaneous quantification of sildenafil and N-desmethyl sildenafil in human plasma by UFLC coupled with ESI-MS/MS and pharmacokinetic and bioequivalence studies in Malay population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25400284/),[ml] / [min],0.3,138803,DB00592,Piperazine
,25400284,AUC0-t,"AUC0-t , Cmax and Tmax were 2285.79 ng h/mL, 726.10 ng/mL and 0.94 h for Viagra and 2363.25 ng h/mL, 713.91 ng/mL and 0.83 hour for Edyfil.",Simultaneous quantification of sildenafil and N-desmethyl sildenafil in human plasma by UFLC coupled with ESI-MS/MS and pharmacokinetic and bioequivalence studies in Malay population. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25400284/),[h·ng] / [ml],2285.79,138804,DB00592,Piperazine
,25400284,Cmax,"AUC0-t , Cmax and Tmax were 2285.79 ng h/mL, 726.10 ng/mL and 0.94 h for Viagra and 2363.25 ng h/mL, 713.91 ng/mL and 0.83 hour for Edyfil.",Simultaneous quantification of sildenafil and N-desmethyl sildenafil in human plasma by UFLC coupled with ESI-MS/MS and pharmacokinetic and bioequivalence studies in Malay population. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25400284/),[ng] / [ml],726.10,138805,DB00592,Piperazine
,25400284,Cmax,"AUC0-t , Cmax and Tmax were 2285.79 ng h/mL, 726.10 ng/mL and 0.94 h for Viagra and 2363.25 ng h/mL, 713.91 ng/mL and 0.83 hour for Edyfil.",Simultaneous quantification of sildenafil and N-desmethyl sildenafil in human plasma by UFLC coupled with ESI-MS/MS and pharmacokinetic and bioequivalence studies in Malay population. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25400284/),[h·ng] / [ml],2363.25,138806,DB00592,Piperazine
,25400284,Cmax,"AUC0-t , Cmax and Tmax were 2285.79 ng h/mL, 726.10 ng/mL and 0.94 h for Viagra and 2363.25 ng h/mL, 713.91 ng/mL and 0.83 hour for Edyfil.",Simultaneous quantification of sildenafil and N-desmethyl sildenafil in human plasma by UFLC coupled with ESI-MS/MS and pharmacokinetic and bioequivalence studies in Malay population. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25400284/),[ng] / [ml],713.91,138807,DB00592,Piperazine
,25400284,Tmax,"AUC0-t , Cmax and Tmax were 2285.79 ng h/mL, 726.10 ng/mL and 0.94 h for Viagra and 2363.25 ng h/mL, 713.91 ng/mL and 0.83 hour for Edyfil.",Simultaneous quantification of sildenafil and N-desmethyl sildenafil in human plasma by UFLC coupled with ESI-MS/MS and pharmacokinetic and bioequivalence studies in Malay population. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25400284/),h,0.94,138808,DB00592,Piperazine
,25400284,Tmax,"AUC0-t , Cmax and Tmax were 2285.79 ng h/mL, 726.10 ng/mL and 0.94 h for Viagra and 2363.25 ng h/mL, 713.91 ng/mL and 0.83 hour for Edyfil.",Simultaneous quantification of sildenafil and N-desmethyl sildenafil in human plasma by UFLC coupled with ESI-MS/MS and pharmacokinetic and bioequivalence studies in Malay population. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25400284/),h,0.83,138809,DB00592,Piperazine
,15224134,IC50,Vardenafil potently inhibits human phosphodiesterase 5 (PDE5) with an IC50 of 0.7 nM.,"Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15224134/),nM,0.7,138838,DB00592,Piperazine
,15224134,Tmax,"Enhancement of nitric oxide (NO)-induced erections in rabbits by 0.1 mg/kg vardenafil is limited by its pharmacokinetic properties (Tmax=1 h; T1/2=1.2 h), although erectile effects have been observed after 7 h.","Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15224134/),h,1,138839,DB00592,Piperazine
,15224134,T1/2,"Enhancement of nitric oxide (NO)-induced erections in rabbits by 0.1 mg/kg vardenafil is limited by its pharmacokinetic properties (Tmax=1 h; T1/2=1.2 h), although erectile effects have been observed after 7 h.","Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15224134/),h,1.2,138840,DB00592,Piperazine
,15224134,Tmax,"In humans, vardenafil is rapidly absorbed (Tmax approximately 40 min) and more slowly metabolized (T1/2 approximately 4 h), with an absolute bioavailability of 14.5% (vs 40% for sildenafil).","Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15224134/),min,40,138841,DB00592,Piperazine
,15224134,T1/2,"In humans, vardenafil is rapidly absorbed (Tmax approximately 40 min) and more slowly metabolized (T1/2 approximately 4 h), with an absolute bioavailability of 14.5% (vs 40% for sildenafil).","Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15224134/),h,4,138842,DB00592,Piperazine
,15224134,absolute bioavailability,"In humans, vardenafil is rapidly absorbed (Tmax approximately 40 min) and more slowly metabolized (T1/2 approximately 4 h), with an absolute bioavailability of 14.5% (vs 40% for sildenafil).","Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15224134/),%,14.5,138843,DB00592,Piperazine
,15224134,absolute bioavailability,"In humans, vardenafil is rapidly absorbed (Tmax approximately 40 min) and more slowly metabolized (T1/2 approximately 4 h), with an absolute bioavailability of 14.5% (vs 40% for sildenafil).","Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15224134/),%,40,138844,DB00592,Piperazine
,32535897,binding constant,"The in vitro binding constant between fenebrutinib and hydroxypropyl-β-cyclodextrin was determined to be 2 × 105 M-1 , and the apparent permeability of fenebrutinib across a Madin-Darby canine kidney cell monolayer decreased in a cyclodextrin concentration-dependent manner.",Understanding the Effect of Hydroxypropyl-β-Cyclodextrin on Fenebrutinib Absorption in an Itraconazole-Fenebrutinib Drug-Drug Interaction Study. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32535897/),1/[M],2 × 105,139069,DB00592,Piperazine
,1665118,half-life,Flunarizine (FLN) is a potential antiepileptic drug whose pharmacokinetic properties include a long half-life (2-7 weeks) and high interpatient variability in volume of distribution and clearance.,Design of an individualized fixed-dose clinical trial to test the antiepileptic efficacy of a plasma flunarizine concentration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1665118/),weeks,2-7,139122,DB00592,Piperazine
,19695406,T(max),Median T(max) was ~2 hours after administration of single and multiple doses.,"Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695406/),h,2,139225,DB00592,Piperazine
,19695406,C(min),"At steady state, C(min) was 1025.4 ng/mL and C(max) was 2160.7 ng/mL.","Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695406/),[ng] / [ml],1025.4,139226,DB00592,Piperazine
,19695406,C(max),"At steady state, C(min) was 1025.4 ng/mL and C(max) was 2160.7 ng/mL.","Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695406/),[ng] / [ml],2160.7,139227,DB00592,Piperazine
,19695406,AUCs from time 0 to the end of the dosing interval tau (AUC(0-tau)),"Mean AUCs from time 0 to the end of the dosing interval tau (AUC(0-tau)) were 5076.3 and 17,751.3 ng .","Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695406/),ng,5076.3,139228,DB00592,Piperazine
,19695406,AUCs from time 0 to the end of the dosing interval tau (AUC(0-tau)),"Mean AUCs from time 0 to the end of the dosing interval tau (AUC(0-tau)) were 5076.3 and 17,751.3 ng .","Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695406/),ng,"17,751.3",139229,DB00592,Piperazine
,19695406,accumulation factor,"h/mL at days 1 and 15, respectively, representing an accumulation factor of 3.92.","Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695406/),,3.92,139230,DB00592,Piperazine
,19695406,Apparent oral clearance (CL/F),"Apparent oral clearance (CL/F) was 0.39 L/h/kg (range, 0.12-0.74 L/h/ kg) at steady state.","Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695406/),[l] / [h·kg],0.39,139231,DB00592,Piperazine
,8230115,oral bioavailability,"Although 2 exhibited 25% oral bioavailability in rats, pharmacokinetic studies conducted in monkeys revealed that the parent compound was less than 5% bioavailable, the result of extensive first-pass biotransformation in the liver.","Inhibitors of blood platelet cAMP phosphodiesterase. 4. Structural variation of the side-chain terminus of water-soluble 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230115/),%,25,139522,DB00592,Piperazine
,8230115,bioavailability,Tetrazole 23e exhibited 72% bioavailability following ip administration to rats compared with 35% bioavailability for 2 and 19e under the same conditions.,"Inhibitors of blood platelet cAMP phosphodiesterase. 4. Structural variation of the side-chain terminus of water-soluble 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230115/),%,72,139523,DB00592,Piperazine
,8230115,bioavailability,Tetrazole 23e exhibited 72% bioavailability following ip administration to rats compared with 35% bioavailability for 2 and 19e under the same conditions.,"Inhibitors of blood platelet cAMP phosphodiesterase. 4. Structural variation of the side-chain terminus of water-soluble 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230115/),%,35,139524,DB00592,Piperazine
,8230115,oral bioavailability,"However, the oral bioavailability of 19e and 23e in the rat was estimated to be only 3%, suggesting that 19e and 23e are less readily absorbed from the gastrointestinal tract than 2.","Inhibitors of blood platelet cAMP phosphodiesterase. 4. Structural variation of the side-chain terminus of water-soluble 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230115/),%,3,139525,DB00592,Piperazine
,30872749,half maximal effective concentration (EC50),The half maximal effective concentration (EC50) of CLZ was substantially lower (0.42 nM) than CNO (8.1 nM); Cmpd-21 was intermediate (2.95 nM).,"Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30872749/),nM,0.42,139580,DB00592,Piperazine
,30872749,half maximal effective concentration (EC50),The half maximal effective concentration (EC50) of CLZ was substantially lower (0.42 nM) than CNO (8.1 nM); Cmpd-21 was intermediate (2.95 nM).,"Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30872749/),nM,8.1,139581,DB00592,Piperazine
,30872749,half maximal effective concentration (EC50),The half maximal effective concentration (EC50) of CLZ was substantially lower (0.42 nM) than CNO (8.1 nM); Cmpd-21 was intermediate (2.95 nM).,"Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30872749/),nM,2.95,139582,DB00592,Piperazine
,24962564,"overall exposure (AUC(0,∞))","Ketoconazole increases overall exposure (AUC(0,∞)) of apremilast by ≈36% (2827 vs. 2072 ng ml(-1) h, 90% CI = 126.2, 147.5) and peak exposure (Cmax ) by 5% (247 vs. 236 ng ml(-1) ).",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),[h·ng] / [ml],2827,139737,DB00592,Piperazine
,24962564,"overall exposure (AUC(0,∞))","Ketoconazole increases overall exposure (AUC(0,∞)) of apremilast by ≈36% (2827 vs. 2072 ng ml(-1) h, 90% CI = 126.2, 147.5) and peak exposure (Cmax ) by 5% (247 vs. 236 ng ml(-1) ).",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),[h·ng] / [ml],2072,139738,DB00592,Piperazine
,24962564,peak exposure (Cmax ),"Ketoconazole increases overall exposure (AUC(0,∞)) of apremilast by ≈36% (2827 vs. 2072 ng ml(-1) h, 90% CI = 126.2, 147.5) and peak exposure (Cmax ) by 5% (247 vs. 236 ng ml(-1) ).",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),[ng] / [ml],247,139739,DB00592,Piperazine
,24962564,peak exposure (Cmax ),"Ketoconazole increases overall exposure (AUC(0,∞)) of apremilast by ≈36% (2827 vs. 2072 ng ml(-1) h, 90% CI = 126.2, 147.5) and peak exposure (Cmax ) by 5% (247 vs. 236 ng ml(-1) ).",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),[ng] / [ml],236,139740,DB00592,Piperazine
,24962564,"AUC(0,∞)","Multiple doses of rifampicin increase apremilast clearance ≈3.6-fold and decrease apremilast mean AUC(0,∞) by ≈72% (3120 vs. 869 ng ml(-1) h, 90% CI = 25.7, 30.4) and Cmax (from 290 vs.",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),[h·ng] / [ml],869,139741,DB00592,Piperazine
,24962564,Cmax,"Multiple doses of rifampicin increase apremilast clearance ≈3.6-fold and decrease apremilast mean AUC(0,∞) by ≈72% (3120 vs. 869 ng ml(-1) h, 90% CI = 25.7, 30.4) and Cmax (from 290 vs.",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),,290,139742,DB00592,Piperazine
,24962564,"AUC(0,∞))","A 30 min intravenous infusion of rifampicin 600 mg had negligible effects on the overall exposure (AUC(0,∞)) of apremilast (2980 vs. 3120 ng ml(-1) h, 90% CI = 88.0, 104.1).",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),[h·ng] / [ml],2980,139743,DB00592,Piperazine
,24962564,"AUC(0,∞))","A 30 min intravenous infusion of rifampicin 600 mg had negligible effects on the overall exposure (AUC(0,∞)) of apremilast (2980 vs. 3120 ng ml(-1) h, 90% CI = 88.0, 104.1).",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),[h·ng] / [ml],3120,139744,DB00592,Piperazine
,3191893,apparent clearance,"Following a single dose, mean values (and ranges) for apparent clearance, volume distribution, and elimination half-life (t1/2) were 0.504 L/h/kg (0.086-1.119), 12,431 L (1,959-20,920), and 308 h (61-506), respectively.",Pharmacokinetic profile of flunarizine after single and multiple dosing in epileptic patients receiving comedication. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3191893/),[l] / [h·kg],0.504,140423,DB00592,Piperazine
,3191893,elimination half-life (t1/2),"Following a single dose, mean values (and ranges) for apparent clearance, volume distribution, and elimination half-life (t1/2) were 0.504 L/h/kg (0.086-1.119), 12,431 L (1,959-20,920), and 308 h (61-506), respectively.",Pharmacokinetic profile of flunarizine after single and multiple dosing in epileptic patients receiving comedication. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3191893/),h,308,140424,DB00592,Piperazine
,20108303,corrected QT (QTc),"Coadministration of ketoconazole led to a marked increase in dasatinib exposure, which was correlated with an increase in corrected QT (QTc) values of approximately 6 msec.",Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108303/),,6,140551,DB00592,Piperazine
,21317368,bioavailability,Ketoconazole increased the bioavailability of finasteride from 0.36 ± 0.23 to 0.91 ± 0.1 (p < 0.05) and the terminal half-life from 1.6 ± 0.4 to 4.0 ± 1.1 h (p < 0.05).,"In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21317368/),,0.36,140582,DB00592,Piperazine
,21317368,bioavailability,Ketoconazole increased the bioavailability of finasteride from 0.36 ± 0.23 to 0.91 ± 0.1 (p < 0.05) and the terminal half-life from 1.6 ± 0.4 to 4.0 ± 1.1 h (p < 0.05).,"In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21317368/),,0.91,140583,DB00592,Piperazine
,21317368,terminal half-life,Ketoconazole increased the bioavailability of finasteride from 0.36 ± 0.23 to 0.91 ± 0.1 (p < 0.05) and the terminal half-life from 1.6 ± 0.4 to 4.0 ± 1.1 h (p < 0.05).,"In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21317368/),h,1.6,140584,DB00592,Piperazine
,21317368,terminal half-life,Ketoconazole increased the bioavailability of finasteride from 0.36 ± 0.23 to 0.91 ± 0.1 (p < 0.05) and the terminal half-life from 1.6 ± 0.4 to 4.0 ± 1.1 h (p < 0.05).,"In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21317368/),h,4.0,140585,DB00592,Piperazine
∼,21317368,f(a) · F(G),"From deconvolution, it was found that the absorption rate from the intestine to the portal vein was rapid, and the product of the fraction absorbed and the fraction that escaped gut wall metabolism was high (f(a) · F(G) ∼ 1).","In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21317368/),,1,140586,DB00592,Piperazine
,21317368,liver extraction ratio,"After intrajejunal administration, from 1 to 6 h, the liver extraction ratio was significantly (p < 0.05) reduced by ketoconazole treatment from intermediate (0.41 ± 0.21) to low (0.21 ± 0.10).","In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21317368/),,0.41,140587,DB00592,Piperazine
,21317368,liver extraction ratio,"After intrajejunal administration, from 1 to 6 h, the liver extraction ratio was significantly (p < 0.05) reduced by ketoconazole treatment from intermediate (0.41 ± 0.21) to low (0.21 ± 0.10).","In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21317368/),,0.21,140588,DB00592,Piperazine
,30198595,minimum plasma concentration,"However, all scenarios suggest that a dose of 62.5 mg weekly achieves or exceeds the exposure in adults following a 250 mg weekly dose and results in a minimum plasma concentration of 620 ng ml-1 , which is considered necessary to achieve 95% prophylactic efficacy.",Development of a physiologically based pharmacokinetic model for mefloquine and its application alongside a clinical effectiveness model to select an optimal dose for prevention of malaria in young Caucasian children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30198595/),[ng] / [ml],620,140651,DB00592,Piperazine
≥,30602435,apparent permeability (Papp ),ET and 4-ME showed good permeability in both Caco-2 monolayers [apparent permeability (Papp ) ≥ 0.59 × 10-5 cm/s] and duodenum (Papp ≥ 1.81).,Breast Cancer Resistance Protein and Multidrug Resistance Protein 2 Determine the Disposition of Esculetin-7-O-Glucuronide and 4-Methylesculetin-7-O-Glucuronide. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30602435/),[cm] / [s],0.59 × 10-5,141150,DB00592,Piperazine
≥,30602435,Papp,ET and 4-ME showed good permeability in both Caco-2 monolayers [apparent permeability (Papp ) ≥ 0.59 × 10-5 cm/s] and duodenum (Papp ≥ 1.81).,Breast Cancer Resistance Protein and Multidrug Resistance Protein 2 Determine the Disposition of Esculetin-7-O-Glucuronide and 4-Methylesculetin-7-O-Glucuronide. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30602435/),,1.81,141151,DB00592,Piperazine
,2848442,peak itraconazole concentrations,"Absorption appeared to be slow, with day 1 mean peak itraconazole concentrations in plasma of 110 ng/ml at 2.8 h (regimen A), 272 ng/ml at 3.0 h (regimen B), and 553 ng/ml at 3.4 h (regimen C).",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),[ng] / [ml],110,141167,DB00592,Piperazine
,2848442,peak itraconazole concentrations,"Absorption appeared to be slow, with day 1 mean peak itraconazole concentrations in plasma of 110 ng/ml at 2.8 h (regimen A), 272 ng/ml at 3.0 h (regimen B), and 553 ng/ml at 3.4 h (regimen C).",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),[ng] / [ml],272,141168,DB00592,Piperazine
,2848442,peak itraconazole concentrations,"Absorption appeared to be slow, with day 1 mean peak itraconazole concentrations in plasma of 110 ng/ml at 2.8 h (regimen A), 272 ng/ml at 3.0 h (regimen B), and 553 ng/ml at 3.4 h (regimen C).",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),[ng] / [ml],553,141169,DB00592,Piperazine
,2848442,peak itraconazole concentrations,"Mean peak itraconazole concentrations in plasma on day 15 were 412 ng/ml at 3.0 h (regimen A), 1,070 ng/ml at 4.4 h (regimen B), and 1,980 ng/ml at 6.0 h (regimen C).",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),[ng] / [ml],412,141170,DB00592,Piperazine
,2848442,peak itraconazole concentrations,"Mean peak itraconazole concentrations in plasma on day 15 were 412 ng/ml at 3.0 h (regimen A), 1,070 ng/ml at 4.4 h (regimen B), and 1,980 ng/ml at 6.0 h (regimen C).",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),[ng] / [ml],"1,070",141171,DB00592,Piperazine
,2848442,peak itraconazole concentrations,"Mean peak itraconazole concentrations in plasma on day 15 were 412 ng/ml at 3.0 h (regimen A), 1,070 ng/ml at 4.4 h (regimen B), and 1,980 ng/ml at 6.0 h (regimen C).",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),[ng] / [ml],"1,980",141172,DB00592,Piperazine
,2848442,elimination half-lives,"Respective elimination half-lives on days 1 and 15 were 15 and 34 h (regimen A), 20.7, and 36.5 h (regimen B), and 25 and 41.7 h (regimen C), respectively.",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),h,15,141173,DB00592,Piperazine
,2848442,elimination half-lives,"Respective elimination half-lives on days 1 and 15 were 15 and 34 h (regimen A), 20.7, and 36.5 h (regimen B), and 25 and 41.7 h (regimen C), respectively.",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),h,34,141174,DB00592,Piperazine
,2848442,elimination half-lives,"Respective elimination half-lives on days 1 and 15 were 15 and 34 h (regimen A), 20.7, and 36.5 h (regimen B), and 25 and 41.7 h (regimen C), respectively.",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),h,20.7,141175,DB00592,Piperazine
,2848442,elimination half-lives,"Respective elimination half-lives on days 1 and 15 were 15 and 34 h (regimen A), 20.7, and 36.5 h (regimen B), and 25 and 41.7 h (regimen C), respectively.",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),h,36.5,141176,DB00592,Piperazine
,2848442,elimination half-lives,"Respective elimination half-lives on days 1 and 15 were 15 and 34 h (regimen A), 20.7, and 36.5 h (regimen B), and 25 and 41.7 h (regimen C), respectively.",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),h,25,141177,DB00592,Piperazine
,2848442,elimination half-lives,"Respective elimination half-lives on days 1 and 15 were 15 and 34 h (regimen A), 20.7, and 36.5 h (regimen B), and 25 and 41.7 h (regimen C), respectively.",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),h,41.7,141178,DB00592,Piperazine
,2848442,areas under the plasma concentration versus time curves (0 to infinity),"The areas under the plasma concentration versus time curves (0 to infinity) on day 1 were 1,320 (regimen A), 4,160 (regimen B), and 12,600 ng.h/ml (regimen C).",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),[h·ng] / [ml],"1,320",141179,DB00592,Piperazine
,2848442,areas under the plasma concentration versus time curves (0 to infinity),"The areas under the plasma concentration versus time curves (0 to infinity) on day 1 were 1,320 (regimen A), 4,160 (regimen B), and 12,600 ng.h/ml (regimen C).",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),[h·ng] / [ml],"4,160",141180,DB00592,Piperazine
,2848442,areas under the plasma concentration versus time curves (0 to infinity),"The areas under the plasma concentration versus time curves (0 to infinity) on day 1 were 1,320 (regimen A), 4,160 (regimen B), and 12,600 ng.h/ml (regimen C).",Pharmacokinetics of itraconazole following oral administration to normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2848442/),[h·ng] / [ml],"12,600",141181,DB00592,Piperazine
,6668546,terminal elimination half-life,The mean terminal elimination half-life for trimazosin was 186 +/- 80 min and the mean elimination half-life of its alkyl hydroxylated metabolite (CP 23445) was 93 +/- 29 min.,Pharmacokinetic and pharmacodynamic modelling of trimazosin and its major metabolite. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668546/),min,186,141359,DB00592,Piperazine
,6668546,elimination half-life,The mean terminal elimination half-life for trimazosin was 186 +/- 80 min and the mean elimination half-life of its alkyl hydroxylated metabolite (CP 23445) was 93 +/- 29 min.,Pharmacokinetic and pharmacodynamic modelling of trimazosin and its major metabolite. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668546/),min,93,141360,DB00592,Piperazine
,25165011,Extraction recovery,Extraction recovery of GDC-0980 was between 72.4% and 75.5%.,"A supported liquid extraction-LC-MS/MS method for determination of GDC-0980 (Apitolisib), a dual small-molecule inhibitor of class 1A phosphoinositide 3-kinase and mammalian target of rapamycin, in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25165011/),%,72.4,141898,DB00592,Piperazine
,25165011,Extraction recovery,Extraction recovery of GDC-0980 was between 72.4% and 75.5%.,"A supported liquid extraction-LC-MS/MS method for determination of GDC-0980 (Apitolisib), a dual small-molecule inhibitor of class 1A phosphoinositide 3-kinase and mammalian target of rapamycin, in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25165011/),%,75.5,141899,DB00592,Piperazine
,25165011,Cmax,"Mean pharmacokinetic parameters determined using this method for the day 1 control group in a phase I trial were: Cmax=11.1ng/mL, AUC0-inf=108ngh/mL, and T1/2=13.1h.","A supported liquid extraction-LC-MS/MS method for determination of GDC-0980 (Apitolisib), a dual small-molecule inhibitor of class 1A phosphoinositide 3-kinase and mammalian target of rapamycin, in human plasma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25165011/),[ng] / [ml],11.1,141900,DB00592,Piperazine
,25165011,AUC0-inf,"Mean pharmacokinetic parameters determined using this method for the day 1 control group in a phase I trial were: Cmax=11.1ng/mL, AUC0-inf=108ngh/mL, and T1/2=13.1h.","A supported liquid extraction-LC-MS/MS method for determination of GDC-0980 (Apitolisib), a dual small-molecule inhibitor of class 1A phosphoinositide 3-kinase and mammalian target of rapamycin, in human plasma. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25165011/),[ngh] / [ml],108,141901,DB00592,Piperazine
,25165011,T1/2,"Mean pharmacokinetic parameters determined using this method for the day 1 control group in a phase I trial were: Cmax=11.1ng/mL, AUC0-inf=108ngh/mL, and T1/2=13.1h.","A supported liquid extraction-LC-MS/MS method for determination of GDC-0980 (Apitolisib), a dual small-molecule inhibitor of class 1A phosphoinositide 3-kinase and mammalian target of rapamycin, in human plasma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25165011/),h,13.1,141902,DB00592,Piperazine
,22517643,run cycle time,"The run cycle time is 6.0 min for each sample, and the calibration curve over the range of 0.03 to 25.00 μg/mL has a good linear relationship (r > 0.9998).","Determination of 4-methylpiperaine-1-carbodithioc acid 3-cyano-3,3-diphenylpropyl ester hydrochloride in rats' plasma by online-SPE-HPLC-DAD: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22517643/),min,6.0,141955,DB00592,Piperazine
greater,22517643,recoveries,The recoveries of the quality control samples were all greater than 90%.,"Determination of 4-methylpiperaine-1-carbodithioc acid 3-cyano-3,3-diphenylpropyl ester hydrochloride in rats' plasma by online-SPE-HPLC-DAD: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22517643/),%,90,141956,DB00592,Piperazine
,22517643,limit of detection,"The limit of detection and the lowest limit of quantification were 0.01 and 0.03 μg/mL, respectively.","Determination of 4-methylpiperaine-1-carbodithioc acid 3-cyano-3,3-diphenylpropyl ester hydrochloride in rats' plasma by online-SPE-HPLC-DAD: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22517643/),[μg] / [ml],0.01,141957,DB00592,Piperazine
,10379984,Recoveries,"Recoveries of total radioactivity in urine and faeces were 26.9 and 62.0% of the dose, respectively.","Biotransformation of the antipsychotic agent, mazapertine, in dog--mass spectral characterization and identification of metabolites. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379984/),%,26.9,142499,DB00592,Piperazine
,10379984,Recoveries,"Recoveries of total radioactivity in urine and faeces were 26.9 and 62.0% of the dose, respectively.","Biotransformation of the antipsychotic agent, mazapertine, in dog--mass spectral characterization and identification of metabolites. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379984/),%,62.0,142500,DB00592,Piperazine
,11585437,K(i),"Structure-activity studies on piperidino-piperidine 3 led to the discovery of SCH 351125 (1), a selective CCR5 antagonist with potent activity against RANTES binding (K(i) = 2 nM), which possesses subnanomolar activity in blocking viral entry and has excellent antiviral potency versus a panel of primary HIV-1 viral isolates.","Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11585437/),nM,2,142617,DB00592,Piperazine
,15896236,Tmax,Tmax for treatment A was 3.0 +/- 0.4 and 5.1 +/- 2.7 h for treatment B.,Reduced oral itraconazole bioavailability by antacid suspension. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15896236/),h,3.0,142622,DB00592,Piperazine
,15896236,Tmax,Tmax for treatment A was 3.0 +/- 0.4 and 5.1 +/- 2.7 h for treatment B.,Reduced oral itraconazole bioavailability by antacid suspension. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15896236/),h,5.1,142623,DB00592,Piperazine
,15896236,Cmax,Cmax and AUC0-infinity of treatments A and B were 146.3 +/- 70.5 vs.,Reduced oral itraconazole bioavailability by antacid suspension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15896236/),,146.3,142624,DB00592,Piperazine
>,10543317,peak plasma concentration,The peak plasma concentration (>500 ng/ml) was rapidly reached in 1 h and the maximal effects were observed later at approximately 6 h.,A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543317/),[ng] / [ml],500,142625,DB00592,Piperazine
,10543317,Ka,"Cetirizine was characterized by two-compartmental kinetics with a rapid absorption phase (Ka = 1.0-1.4 h(-1)), a rapid distribution phase (alpha = 0.33-0.69 h(-1)) and a slower terminal half-life, 13.2-13.6 h (beta = 0.051-0.052 h(-1)).",A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543317/),1/[h],1.0-1.4,142626,DB00592,Piperazine
,10543317,alpha,"Cetirizine was characterized by two-compartmental kinetics with a rapid absorption phase (Ka = 1.0-1.4 h(-1)), a rapid distribution phase (alpha = 0.33-0.69 h(-1)) and a slower terminal half-life, 13.2-13.6 h (beta = 0.051-0.052 h(-1)).",A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543317/),1/[h],0.33-0.69,142627,DB00592,Piperazine
,10543317,terminal half-life,"Cetirizine was characterized by two-compartmental kinetics with a rapid absorption phase (Ka = 1.0-1.4 h(-1)), a rapid distribution phase (alpha = 0.33-0.69 h(-1)) and a slower terminal half-life, 13.2-13.6 h (beta = 0.051-0.052 h(-1)).",A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543317/),h,13.2-13.6,142628,DB00592,Piperazine
,10543317,beta,"Cetirizine was characterized by two-compartmental kinetics with a rapid absorption phase (Ka = 1.0-1.4 h(-1)), a rapid distribution phase (alpha = 0.33-0.69 h(-1)) and a slower terminal half-life, 13.2-13.6 h (beta = 0.051-0.052 h(-1)).",A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543317/),1/[h],0.051-0.052,142629,DB00592,Piperazine
,10543317,total clearance,The total clearance was 1.4-1.5 l/h.,A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543317/),[l] / [h],1.4-1.5,142630,DB00592,Piperazine
,10543317,concentrations,"Cetirizine effects on flare and wheal were characterized by the inhibition of the input factor (k(in)), the concentrations producing 50% of maximal effect (EC50) were 13 and 40 ng/ml and k(in) were 0.99 and 0.96 h(-1), respectively.",A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543317/),[ng] / [ml],13,142631,DB00592,Piperazine
,10543317,concentrations,"Cetirizine effects on flare and wheal were characterized by the inhibition of the input factor (k(in)), the concentrations producing 50% of maximal effect (EC50) were 13 and 40 ng/ml and k(in) were 0.99 and 0.96 h(-1), respectively.",A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543317/),[ng] / [ml],40,142632,DB00592,Piperazine
,10543317,50% of maximal effect (EC50),"Cetirizine effects on flare and wheal were characterized by the inhibition of the input factor (k(in)), the concentrations producing 50% of maximal effect (EC50) were 13 and 40 ng/ml and k(in) were 0.99 and 0.96 h(-1), respectively.",A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543317/),[ng] / [ml],13,142633,DB00592,Piperazine
,10543317,50% of maximal effect (EC50),"Cetirizine effects on flare and wheal were characterized by the inhibition of the input factor (k(in)), the concentrations producing 50% of maximal effect (EC50) were 13 and 40 ng/ml and k(in) were 0.99 and 0.96 h(-1), respectively.",A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543317/),[ng] / [ml],40,142634,DB00592,Piperazine
,10543317,k(in),"Cetirizine effects on flare and wheal were characterized by the inhibition of the input factor (k(in)), the concentrations producing 50% of maximal effect (EC50) were 13 and 40 ng/ml and k(in) were 0.99 and 0.96 h(-1), respectively.",A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543317/),1/[h],0.99,142635,DB00592,Piperazine
,10543317,k(in),"Cetirizine effects on flare and wheal were characterized by the inhibition of the input factor (k(in)), the concentrations producing 50% of maximal effect (EC50) were 13 and 40 ng/ml and k(in) were 0.99 and 0.96 h(-1), respectively.",A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543317/),1/[h],0.96,142636,DB00592,Piperazine
,10091630,concentrations,"Plasma piribedil concentrations at the end of treatment were 6.74+/-1.10 and 9.31+/-3.33 ng/mL in the 1 PP and 2 PP groups, respectively.","A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10091630/),[ng] / [ml],6.74,142639,DB00592,Piperazine
,10091630,concentrations,"Plasma piribedil concentrations at the end of treatment were 6.74+/-1.10 and 9.31+/-3.33 ng/mL in the 1 PP and 2 PP groups, respectively.","A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10091630/),[ng] / [ml],9.31,142640,DB00592,Piperazine
,28954786,response rate,"Across all doses, in patients with EGFR T790M, the response rate was 30.7% (n = 27/88; 95% CI, 19.5%-44.5%), and median progression-free survival was 6.8 months (95% CI, 5.5-10.1 months).","A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28954786/),%,30.7,142656,DB00592,Piperazine
,28954786,progression-free survival,"Across all doses, in patients with EGFR T790M, the response rate was 30.7% (n = 27/88; 95% CI, 19.5%-44.5%), and median progression-free survival was 6.8 months (95% CI, 5.5-10.1 months).","A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28954786/),month,6.8,142657,DB00592,Piperazine
,17386756,gamma(2),"Under the optimized conditions, a linear response for trazodone over the range of 20-2000 ng mL(-1) was achieved with a gamma(2) value of 0.9996.",The investigation of electrospun polymer nanofibers as a solid-phase extraction sorbent for the determination of trazodone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17386756/),,0.9996,142766,DB00592,Piperazine
,17386756,extraction recoveries,The extraction recoveries of 58.3-75.2% and the relative recoveries of 94.6-105.5% were obtained.,The investigation of electrospun polymer nanofibers as a solid-phase extraction sorbent for the determination of trazodone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17386756/),%,58.3-75.2,142767,DB00592,Piperazine
,17386756,relative recoveries,The extraction recoveries of 58.3-75.2% and the relative recoveries of 94.6-105.5% were obtained.,The investigation of electrospun polymer nanofibers as a solid-phase extraction sorbent for the determination of trazodone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17386756/),%,94.6-105.5,142768,DB00592,Piperazine
,17386756,limit of detection (LOD),The limit of detection (LOD) was determined to be 8 ng mL(-1).,The investigation of electrospun polymer nanofibers as a solid-phase extraction sorbent for the determination of trazodone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17386756/),[ng] / [ml],8,142769,DB00592,Piperazine
,9545149,bioavailabilities,"Mean bioavailabilities of ITR and OH-ITR were 43% and 38% higher, respectively, when ITR solution was taken as a single dose under fasted conditions.",Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545149/),%,43,142938,DB00592,Piperazine
,9545149,bioavailabilities,"Mean bioavailabilities of ITR and OH-ITR were 43% and 38% higher, respectively, when ITR solution was taken as a single dose under fasted conditions.",Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545149/),%,38,142939,DB00592,Piperazine
,9545149,bioavailabilities,"At steady state, mean bioavailabilities were 29% and 17% higher, respectively, in the fasted state; terminal half-life was similar under fasted and fed conditions (mean 39.8 and 37.5 hrs for ITR, respectively; 27.3 and 26.2 hrs for OH-ITR, respectively).",Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545149/),%,29,142940,DB00592,Piperazine
,9545149,bioavailabilities,"At steady state, mean bioavailabilities were 29% and 17% higher, respectively, in the fasted state; terminal half-life was similar under fasted and fed conditions (mean 39.8 and 37.5 hrs for ITR, respectively; 27.3 and 26.2 hrs for OH-ITR, respectively).",Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545149/),%,17,142941,DB00592,Piperazine
,9545149,terminal half-life,"At steady state, mean bioavailabilities were 29% and 17% higher, respectively, in the fasted state; terminal half-life was similar under fasted and fed conditions (mean 39.8 and 37.5 hrs for ITR, respectively; 27.3 and 26.2 hrs for OH-ITR, respectively).",Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545149/),h,39.8,142942,DB00592,Piperazine
,9545149,terminal half-life,"At steady state, mean bioavailabilities were 29% and 17% higher, respectively, in the fasted state; terminal half-life was similar under fasted and fed conditions (mean 39.8 and 37.5 hrs for ITR, respectively; 27.3 and 26.2 hrs for OH-ITR, respectively).",Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545149/),h,37.5,142943,DB00592,Piperazine
,9545149,terminal half-life,"At steady state, mean bioavailabilities were 29% and 17% higher, respectively, in the fasted state; terminal half-life was similar under fasted and fed conditions (mean 39.8 and 37.5 hrs for ITR, respectively; 27.3 and 26.2 hrs for OH-ITR, respectively).",Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545149/),h,27.3,142944,DB00592,Piperazine
,9545149,terminal half-life,"At steady state, mean bioavailabilities were 29% and 17% higher, respectively, in the fasted state; terminal half-life was similar under fasted and fed conditions (mean 39.8 and 37.5 hrs for ITR, respectively; 27.3 and 26.2 hrs for OH-ITR, respectively).",Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9545149/),h,26.2,142945,DB00592,Piperazine
,7696071,clearance,"After i.v. administration of [3H]CPP, clearance was mean 122 (SEM 16) ml min-1 and the CSF: serum radioactivity gradient was approximately 1:4.","CSF and plasma pharmacokinetics of the NMDA receptor antagonist CPP after intrathecal, extradural and i.v. administration in anaesthetized pigs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7696071/),[ml] / [min],122,143337,DB00592,Piperazine
,7696071,half-life,The half-life of [3H]CPP varied little (mean range 94-191 min) irrespective of the route of administration or the level of sampling.,"CSF and plasma pharmacokinetics of the NMDA receptor antagonist CPP after intrathecal, extradural and i.v. administration in anaesthetized pigs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7696071/),min,94-191,143338,DB00592,Piperazine
,1517288,detection limits,"The proposed stereoselective method offered high sensitivity: detection limits for both isomers were 0.2 ng/ml in human serum, both at a signal-to-noise ratio of 3.",Determination of manidipine enantiomers in human serum using chiral chromatography and column-switching liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1517288/),[ng] / [ml],0.2,143399,DB00592,Piperazine
,1517288,signal-to-noise ratio,"The proposed stereoselective method offered high sensitivity: detection limits for both isomers were 0.2 ng/ml in human serum, both at a signal-to-noise ratio of 3.",Determination of manidipine enantiomers in human serum using chiral chromatography and column-switching liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1517288/),,3,143400,DB00592,Piperazine
,25493452,inhibition,Platelet inhibition was significantly higher at 0.12 mg/kg (56.3%±7.4%; least squares mean±SE) compared with 0.06 mg/kg (33.8%±7.4%) or 0.08 mg/kg (37.9%±5.6%).,"Prasugrel in children with sickle cell disease: pharmacokinetic and pharmacodynamic data from an open-label, adaptive-design, dose-ranging study. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25493452/),%,56.3,143560,DB00592,Piperazine
,25493452,inhibition,Platelet inhibition was significantly higher at 0.12 mg/kg (56.3%±7.4%; least squares mean±SE) compared with 0.06 mg/kg (33.8%±7.4%) or 0.08 mg/kg (37.9%±5.6%).,"Prasugrel in children with sickle cell disease: pharmacokinetic and pharmacodynamic data from an open-label, adaptive-design, dose-ranging study. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25493452/),%,33.8,143561,DB00592,Piperazine
,25493452,inhibition,Platelet inhibition was significantly higher at 0.12 mg/kg (56.3%±7.4%; least squares mean±SE) compared with 0.06 mg/kg (33.8%±7.4%) or 0.08 mg/kg (37.9%±5.6%).,"Prasugrel in children with sickle cell disease: pharmacokinetic and pharmacodynamic data from an open-label, adaptive-design, dose-ranging study. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25493452/),%,37.9,143562,DB00592,Piperazine
,22209223,half-life,"SC dosing group: The median (interquartile range) cyclizine half-life, volume of distribution, and clearance were 13 (7-48) hours, 23 (12-30)L/kg, and 15 (11-26)mL/min/kg, respectively.",The pharmacokinetics and pharmacogenetics of the antiemetic cyclizine in palliative care patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22209223/),h,13,143604,DB00592,Piperazine
,22209223,volume of distribution,"SC dosing group: The median (interquartile range) cyclizine half-life, volume of distribution, and clearance were 13 (7-48) hours, 23 (12-30)L/kg, and 15 (11-26)mL/min/kg, respectively.",The pharmacokinetics and pharmacogenetics of the antiemetic cyclizine in palliative care patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22209223/),[l] / [kg],23,143605,DB00592,Piperazine
,22209223,clearance,"SC dosing group: The median (interquartile range) cyclizine half-life, volume of distribution, and clearance were 13 (7-48) hours, 23 (12-30)L/kg, and 15 (11-26)mL/min/kg, respectively.",The pharmacokinetics and pharmacogenetics of the antiemetic cyclizine in palliative care patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22209223/),[ml] / [kg·min],15,143606,DB00592,Piperazine
,22209223,Nausea,"Nausea and sedation scores were 3.0 (1.2-5.7) and 5.0 (2.6-8.1), respectively, overall and did not vary with genotype (P=0.76 and 0.11, respectively).",The pharmacokinetics and pharmacogenetics of the antiemetic cyclizine in palliative care patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22209223/),,3.0,143607,DB00592,Piperazine
,22209223,sedation scores,"Nausea and sedation scores were 3.0 (1.2-5.7) and 5.0 (2.6-8.1), respectively, overall and did not vary with genotype (P=0.76 and 0.11, respectively).",The pharmacokinetics and pharmacogenetics of the antiemetic cyclizine in palliative care patients. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22209223/),,5.0,143608,DB00592,Piperazine
,22209223,overall metabolic ratio at steady state,The median overall metabolic ratio at steady state was 4.9 (3.8-9.2) and did vary with CYP2D6 genotype (P=0.02).,The pharmacokinetics and pharmacogenetics of the antiemetic cyclizine in palliative care patients. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22209223/),,4.9,143609,DB00592,Piperazine
,22209223,metabolic ratio,Oral dosing group: The median metabolic ratio was 2.1 (1.5-2.9) and did not vary with CYP2D6 genotype (P=0.37).,The pharmacokinetics and pharmacogenetics of the antiemetic cyclizine in palliative care patients. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22209223/),,2.1,143610,DB00592,Piperazine
,15795639,absorption rate constants,The absorption rate constants were fixed at 0.25 L/h for Sandimmune and 1.35 L/h for Neoral formulations.,Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795639/),[l] / [h],0.25,143668,DB00592,Piperazine
,15795639,absorption rate constants,The absorption rate constants were fixed at 0.25 L/h for Sandimmune and 1.35 L/h for Neoral formulations.,Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795639/),[l] / [h],1.35,143669,DB00592,Piperazine
,15795639,Oral clearance (CL/F),Oral clearance (CL/F) was estimated to be 22.1 L/h (95% confidence intervals [CI] 19.5-24.7 L/h).,Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795639/),[l] / [h],22.1,143670,DB00592,Piperazine
,15795639,relative oral bioavailability,The relative oral bioavailability of Sandimmune to Neoral was 0.82.,Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795639/),,0.82,143671,DB00592,Piperazine
,14603504,absolute oral bioavailability (F),The extent of absolute oral bioavailability (F) of DA-8159 was 38.0% at a dose of 30 mg/kg.,"Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14603504/),%,38.0,143731,DB00592,Piperazine
,14603504,AUCs,"The AUCs were not significantly different between intragastric and intraduodenal administration of DA-8159 at a dose of 30 mg/kg (131 and 127 microg x min/mL), suggesting that gastric first-pass effect of DA-8159 was almost negligible in rats.","Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14603504/),[min·μg] / [ml],131,143732,DB00592,Piperazine
,14603504,AUCs,"The AUCs were not significantly different between intragastric and intraduodenal administration of DA-8159 at a dose of 30 mg/kg (131 and 127 microg x min/mL), suggesting that gastric first-pass effect of DA-8159 was almost negligible in rats.","Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14603504/),[min·μg] / [ml],127,143733,DB00592,Piperazine
,3758142,maximum levels,"The 32.5 and 65 mg doses resulted in similar serum urapidil concentrations, with maximum levels in the 100 to 200 ng/ml range, and the 130 mg dose caused a maximum level approximately four times that achieved with the 32.5 mg dose.",Pharmacodynamics and pharmacokinetics of three different doses of urapidil infused in hypertensive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3758142/),[ng] / [ml],100,143743,DB00592,Piperazine
,22448783,absolute bioavailability,The absolute bioavailability was 75%.,The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22448783/),%,75,143776,DB00592,Piperazine
,22448783,elimination half-life,"After oral administration, Lu AA21004 showed an extended absorption phase, a medium clearance and a large volume of distribution resulting in late t(max) values and a mean elimination half-life of 57 hr.",The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22448783/),h,57,143777,DB00592,Piperazine
,11861816,apparent oral clearance,"The apparent oral clearance of grepafloxacin was decreased to 33% of the control, and the bioavailability of grepafloxacin was increased to 95% by cyclosporin A from 53% in the controls.",Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11861816/),,33,144031,DB00592,Piperazine
,11861816,bioavailability,"The apparent oral clearance of grepafloxacin was decreased to 33% of the control, and the bioavailability of grepafloxacin was increased to 95% by cyclosporin A from 53% in the controls.",Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11861816/),,95,144032,DB00592,Piperazine
,11861816,bioavailability,"The apparent oral clearance of grepafloxacin was decreased to 33% of the control, and the bioavailability of grepafloxacin was increased to 95% by cyclosporin A from 53% in the controls.",Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11861816/),%,53,144033,DB00592,Piperazine
,30239425,relative bioavailability,"Following administration of dispersible abacavir/dolutegravir/lamivudine, the relative bioavailability of dolutegravir was approximately 50% higher.",Effects of Low- and High-Mineral Content Water on the Relative Bioavailability of a Coformulated Abacavir/Dolutegravir/Lamivudine Dispersible Tablet in Healthy Adults. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30239425/),%,50,144181,DB00592,Piperazine
,18520601,trough whole blood level,This was repeated during the period that CsA was administered and a steady-state concentration of CsA was achieved (trough whole blood level 200-400 ng/mL).,Effects of cyclosporine a on single-dose pharmacokinetics of intravenous itraconazole in patients with hematologic malignancies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520601/),[ng] / [ml],200-400,145051,DB00592,Piperazine
,26084706,flow rate,"Chromatographic separation was performed on a reverse phase column with an isocratic mobile phase of acetonitrile and 10 mM ammonium formate pH 3.5 (80:20, v/v) at a flow rate of 1.0 mL/min.",Determination of levocetirizine in human plasma by LC-MS-MS: validation and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26084706/),[ml] / [min],1.0,145052,DB00592,Piperazine
,26084706,run time,The run time was 3.5 min.,Determination of levocetirizine in human plasma by LC-MS-MS: validation and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26084706/),min,3.5,145053,DB00592,Piperazine
,26084706,m/z,Mass parameters were optimized to monitor transitions at m/z [M+H](+) 389.0→201.0 for levocetirizine and m/z [M+H](+) 375.3→201.0 for hydroxyzine as internal standard.,Determination of levocetirizine in human plasma by LC-MS-MS: validation and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26084706/),,389.0,145054,DB00592,Piperazine
,26084706,m/z,Mass parameters were optimized to monitor transitions at m/z [M+H](+) 389.0→201.0 for levocetirizine and m/z [M+H](+) 375.3→201.0 for hydroxyzine as internal standard.,Determination of levocetirizine in human plasma by LC-MS-MS: validation and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26084706/),,201.0,145055,DB00592,Piperazine
,26084706,m/z [M+H,Mass parameters were optimized to monitor transitions at m/z [M+H](+) 389.0→201.0 for levocetirizine and m/z [M+H](+) 375.3→201.0 for hydroxyzine as internal standard.,Determination of levocetirizine in human plasma by LC-MS-MS: validation and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26084706/),,375.3,145056,DB00592,Piperazine
,26084706,m/z [M+H,Mass parameters were optimized to monitor transitions at m/z [M+H](+) 389.0→201.0 for levocetirizine and m/z [M+H](+) 375.3→201.0 for hydroxyzine as internal standard.,Determination of levocetirizine in human plasma by LC-MS-MS: validation and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26084706/),,201.0,145057,DB00592,Piperazine
,26084706,recoveries,"The mean recoveries were 59 and 69% for levocetirizine and hydroxyzine, respectively.",Determination of levocetirizine in human plasma by LC-MS-MS: validation and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26084706/),%,59,145058,DB00592,Piperazine
,26084706,recoveries,"The mean recoveries were 59 and 69% for levocetirizine and hydroxyzine, respectively.",Determination of levocetirizine in human plasma by LC-MS-MS: validation and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26084706/),%,69,145059,DB00592,Piperazine
,24447534,Tmax,"Mean Cmax was reduced by 59%, and median Tmax was delayed from 0.625 hour (fasting) to 4 hours (high-fat meal).",Pharmacokinetics of a novel orodispersible tablet of sildenafil in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24447534/),h,0.625,145915,DB00592,Piperazine
,24447534,Tmax,"Mean Cmax was reduced by 59%, and median Tmax was delayed from 0.625 hour (fasting) to 4 hours (high-fat meal).",Pharmacokinetics of a novel orodispersible tablet of sildenafil in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24447534/),h,4,145916,DB00592,Piperazine
,10211867,percentage cumulative excretion,The percentage cumulative excretion (6.9%) of DGX in bile of the ITZ-treated group up to 6 h after administration of DGX was significantly reduced (p < 0.05) compared with 10.5% in the control.,Effect of itraconazole on the pharmacokinetics of digoxin in guinea pigs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211867/),%,6.9,146173,DB00592,Piperazine
,10211867,percentage cumulative excretion,The percentage cumulative excretion (6.9%) of DGX in bile of the ITZ-treated group up to 6 h after administration of DGX was significantly reduced (p < 0.05) compared with 10.5% in the control.,Effect of itraconazole on the pharmacokinetics of digoxin in guinea pigs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211867/),%,10.5,146174,DB00592,Piperazine
,10211867,percentage cumulative excretion,The percentage cumulative excretion (3.1%) of DGX in urine of the ITZ-treated group up to 6 h after administration was also one third that in the controls.,Effect of itraconazole on the pharmacokinetics of digoxin in guinea pigs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211867/),%,3.1,146175,DB00592,Piperazine
,10211867,plasma unbound fraction,The plasma unbound fraction of DGX (ranged 47-58%) in the ITZ-treated group was generally similar to that in the controls (50-57%).,Effect of itraconazole on the pharmacokinetics of digoxin in guinea pigs. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211867/),%,47-58,146176,DB00592,Piperazine
,10211867,plasma unbound fraction,The plasma unbound fraction of DGX (ranged 47-58%) in the ITZ-treated group was generally similar to that in the controls (50-57%).,Effect of itraconazole on the pharmacokinetics of digoxin in guinea pigs. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211867/),%,50-57,146177,DB00592,Piperazine
,10211867,blood-to-plasma concentration ratio,The blood-to-plasma concentration ratio of DGX (range 1.28-1.42) in the absence of ITZ did not change in the presence of ITZ.,Effect of itraconazole on the pharmacokinetics of digoxin in guinea pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211867/),,1.28-1.42,146178,DB00592,Piperazine
,16153010,"Peak theophylline plasma concentration, Cmax","Peak theophylline plasma concentration, Cmax, (mean +/- S.D) was 21.5 +/- 2.10 microg/mL & 14 +/- 0.90 microg/mL; AUC(0-t), values were 80.9 and 67.",Pharmacokinetics of theophylline after administration of suppositories formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16153010/),[μg] / [ml],21.5,146184,DB00592,Piperazine
,16153010,"Peak theophylline plasma concentration, Cmax","Peak theophylline plasma concentration, Cmax, (mean +/- S.D) was 21.5 +/- 2.10 microg/mL & 14 +/- 0.90 microg/mL; AUC(0-t), values were 80.9 and 67.",Pharmacokinetics of theophylline after administration of suppositories formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16153010/),[μg] / [ml],14,146185,DB00592,Piperazine
,16153010,AUC(0-t),"Peak theophylline plasma concentration, Cmax, (mean +/- S.D) was 21.5 +/- 2.10 microg/mL & 14 +/- 0.90 microg/mL; AUC(0-t), values were 80.9 and 67.",Pharmacokinetics of theophylline after administration of suppositories formulation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16153010/),,80.9,146186,DB00592,Piperazine
,16153010,AUC(0-t),"Peak theophylline plasma concentration, Cmax, (mean +/- S.D) was 21.5 +/- 2.10 microg/mL & 14 +/- 0.90 microg/mL; AUC(0-t), values were 80.9 and 67.",Pharmacokinetics of theophylline after administration of suppositories formulation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16153010/),,67,146187,DB00592,Piperazine
,16153010,"peak time, Tmax","The median peak time, Tmax, was 0.5 hr for theophylline rectal administration.",Pharmacokinetics of theophylline after administration of suppositories formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16153010/),h,0.5,146188,DB00592,Piperazine
above,27601197,recoveries,The recoveries were above 90% with low matrix effects.,Rapid and sensitive liquid chromatography with tandem mass spectrometry method for the simultaneous quantification of yonkenafil and its major metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27601197/),%,90,146361,DB00592,Piperazine
,30101387,progression free survival,Median progression free survival was 12.1 weeks (95% CI 4.7-19.5 weeks).,"A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30101387/),weeks,12.1,146575,DB00592,Piperazine
below,31539371,Ctrough,"Although DTG Ctrough was below the target 324ng/mL (clinical EC90) in 9/28 (32%) mothers in the third trimester, transfer across the placenta (121% of plasma concentrations) and into breastmilk (3% of plasma concentrations), coupled with slower elimination, led to significant infant plasma exposures (3-8% of maternal exposures).",Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study). ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31539371/),[ng] / [ml],324,146590,DB00592,Piperazine
,31539371,time to <50 copies,"DTG resulted in significantly faster viral suppression (P = 0.02) at the 2wPP visit, with median time to <50 copies/mL of 32 vs 72 days.",Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31539371/),d,32,146591,DB00592,Piperazine
,31539371,time to <50 copies,"DTG resulted in significantly faster viral suppression (P = 0.02) at the 2wPP visit, with median time to <50 copies/mL of 32 vs 72 days.",Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31539371/),d,72,146592,DB00592,Piperazine
<,17851638,solubility,"We found that BA and the derivatives had poor aqueous solubility (<0.1 microg/ml), low to moderate permeability (log Pe<-5.0) and high plasma protein binding (>70%).",Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17851638/),[μg] / [ml],0.1,146683,DB00592,Piperazine
<,17851638,log Pe,"We found that BA and the derivatives had poor aqueous solubility (<0.1 microg/ml), low to moderate permeability (log Pe<-5.0) and high plasma protein binding (>70%).",Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17851638/),,5.0,146684,DB00592,Piperazine
>,17851638,plasma protein binding,"We found that BA and the derivatives had poor aqueous solubility (<0.1 microg/ml), low to moderate permeability (log Pe<-5.0) and high plasma protein binding (>70%).",Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17851638/),%,70,146685,DB00592,Piperazine
,24855354,IC50,Cytotoxicity assays demonstrated that the FR-targeted imatinib liposomes promoted a six-fold IC50 reduction on the non-targeted imatinib liposomes from 910 to 150 μM.,Folate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targeting. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24855354/),μM,910,146990,DB00592,Piperazine
,24855354,IC50,Cytotoxicity assays demonstrated that the FR-targeted imatinib liposomes promoted a six-fold IC50 reduction on the non-targeted imatinib liposomes from 910 to 150 μM.,Folate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targeting. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24855354/),μM,150,146991,DB00592,Piperazine
,15039292,clearance,"Using an alternative method, based on normalization of in vitro human data with the ratio of in vivo to in vitro animal data, the in vivo clearance in humans was predicted to be 0.39 l/h/kg.","Comparison of prediction methods for in vivo clearance of (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, a dopamine D2 receptor antagonist, in humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15039292/),[l] / [h·kg],0.39,147080,DB00592,Piperazine
,23777012,C(max),"Geometric means (CV%) of single dose DTG PK parameters in Japanese subjects for C(max), AUC(inf), t1/2 and C24 were 2.14microg/mL (47%), 43.4 microg x hr/mL (46%), 14.6 hours (10%) and 0.67 microg/mL (45%).",[Pharmacokinetics and safety of dolutegravir in healthy Japanese subjects]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777012/),[μg] / [ml],2.14,147124,DB00592,Piperazine
,23777012,AUC(inf),"Geometric means (CV%) of single dose DTG PK parameters in Japanese subjects for C(max), AUC(inf), t1/2 and C24 were 2.14microg/mL (47%), 43.4 microg x hr/mL (46%), 14.6 hours (10%) and 0.67 microg/mL (45%).",[Pharmacokinetics and safety of dolutegravir in healthy Japanese subjects]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777012/),h,14.6,147125,DB00592,Piperazine
,23777012,t1/2,"Geometric means (CV%) of single dose DTG PK parameters in Japanese subjects for C(max), AUC(inf), t1/2 and C24 were 2.14microg/mL (47%), 43.4 microg x hr/mL (46%), 14.6 hours (10%) and 0.67 microg/mL (45%).",[Pharmacokinetics and safety of dolutegravir in healthy Japanese subjects]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777012/),h,14.6,147126,DB00592,Piperazine
,23777012,C24,"Geometric means (CV%) of single dose DTG PK parameters in Japanese subjects for C(max), AUC(inf), t1/2 and C24 were 2.14microg/mL (47%), 43.4 microg x hr/mL (46%), 14.6 hours (10%) and 0.67 microg/mL (45%).",[Pharmacokinetics and safety of dolutegravir in healthy Japanese subjects]. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777012/),[μg] / [ml],0.67,147127,DB00592,Piperazine
,3723361,minimum effective dose,It was found from these results that DL-phenylalanine acted as a competing agent in the GI tract and the minimum effective dose required of DL-phenylalanine might be 1 g for 50 mg of cinnarizine in the cinnarizine-beta-cyclodextrin complex.,Enhancement of bioavailability of cinnarizine from its beta-cyclodextrin complex on oral administration with DL-phenylalanine as a competing agent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3723361/),g,1,147149,DB00592,Piperazine
,3438645,Tmax,"In 45 healthy young volunteers, zopiclone had a Tmax of 0.5.",Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438645/),,0.5,147614,DB00592,Piperazine
,3438645,"absolute bioavailability, F","A first-pass effect of 20% resulted in an absolute bioavailability, F, of 77%.",Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438645/),%,77,147615,DB00592,Piperazine
,3438645,volume of distribution ratio Vdc/Vdt,The volume of distribution ratio Vdc/Vdt was 3.2.,Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438645/),,3.2,147616,DB00592,Piperazine
,3438645,plasma half-life (t1/2),The plasma half-life (t1/2) was 5.1 h.,Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438645/),h,5.1,147617,DB00592,Piperazine
,3438645,metabolic ratio,"A metabolic ratio of 3.7 and 4.6 was found for the two main urinary metabolites, N-oxide and N-desmethyl derivatives.",Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438645/),,3,147618,DB00592,Piperazine
,3438645,Tmax,"In eight patients with liver insufficiency, the main changes (delayed Tmax, 3.5 h, higher plasma concentrations with an increased F of 97%, prolonged t1/2 of 8.4 h) were essentially due to a reduced hepatic metabolic clearance, as shown by a decreased metabolic ratio for the two main metabolites.",Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438645/),h,3.5,147619,DB00592,Piperazine
,3438645,t1/2,"In eight patients with liver insufficiency, the main changes (delayed Tmax, 3.5 h, higher plasma concentrations with an increased F of 97%, prolonged t1/2 of 8.4 h) were essentially due to a reduced hepatic metabolic clearance, as shown by a decreased metabolic ratio for the two main metabolites.",Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438645/),h,8.4,147620,DB00592,Piperazine
,3438645,bioavailability (F,"In 18 patients with renal insufficiency, the only major modification was an increased bioavailability (F of 115%) probably due to a relative decrease of the Vdc.",Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438645/),%,115,147621,DB00592,Piperazine
,3438645,plasma t1/2,The increase in F (168%) and the age-dependent increase in plasma t1/2 (8.1 h) in the oldest subjects (over 74 years of age) can be explained by this double mechanism.,Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438645/),h,8.1,147622,DB00592,Piperazine
,15196585,V1,"Typical estimates of V1 were significantly (P <0.01) lower in healthy volunteers (7.16 versus 9.95 L), and typical estimates of CL were significantly lower in subjects receiving oral contraceptives (11.4 versus 17.1 L/h), although the absolute reduction in the unexplained inter-subject variability was negligible (4%).","Population pharmacokinetic modelling of BIBN 4096 BS, the first compound of the new class of calcitonin gene-related peptide receptor antagonists. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15196585/),l,7.16,147920,DB00592,Piperazine
,15196585,V1,"Typical estimates of V1 were significantly (P <0.01) lower in healthy volunteers (7.16 versus 9.95 L), and typical estimates of CL were significantly lower in subjects receiving oral contraceptives (11.4 versus 17.1 L/h), although the absolute reduction in the unexplained inter-subject variability was negligible (4%).","Population pharmacokinetic modelling of BIBN 4096 BS, the first compound of the new class of calcitonin gene-related peptide receptor antagonists. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15196585/),l,9.95,147921,DB00592,Piperazine
,15196585,CL,"Typical estimates of V1 were significantly (P <0.01) lower in healthy volunteers (7.16 versus 9.95 L), and typical estimates of CL were significantly lower in subjects receiving oral contraceptives (11.4 versus 17.1 L/h), although the absolute reduction in the unexplained inter-subject variability was negligible (4%).","Population pharmacokinetic modelling of BIBN 4096 BS, the first compound of the new class of calcitonin gene-related peptide receptor antagonists. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15196585/),[l] / [h],11.4,147922,DB00592,Piperazine
,15196585,CL,"Typical estimates of V1 were significantly (P <0.01) lower in healthy volunteers (7.16 versus 9.95 L), and typical estimates of CL were significantly lower in subjects receiving oral contraceptives (11.4 versus 17.1 L/h), although the absolute reduction in the unexplained inter-subject variability was negligible (4%).","Population pharmacokinetic modelling of BIBN 4096 BS, the first compound of the new class of calcitonin gene-related peptide receptor antagonists. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15196585/),[l] / [h],17.1,147923,DB00592,Piperazine
,15200445,extent of drug bound to plasma protein,The average extent of drug bound to plasma protein was approximately 96% in hemodialysis patients.,The pharmacokinetics and hemodynamics of sildenafil citrate in male hemodialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15200445/),%,96,148157,DB00592,Piperazine
,28597226,"C avg,ss","The mean C avg,ss values were 125.8 ng/ml, 131.1 ng/ml, and 140.7 ng/ml for the 441 mg q4wk, 882 mg q6wk, and 1064 mg q8wk doses, respectively.",Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597226/),[ng] / [ml],125.8,148220,DB00592,Piperazine
,28597226,"C avg,ss","The mean C avg,ss values were 125.8 ng/ml, 131.1 ng/ml, and 140.7 ng/ml for the 441 mg q4wk, 882 mg q6wk, and 1064 mg q8wk doses, respectively.",Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597226/),[ng] / [ml],131.1,148221,DB00592,Piperazine
,28597226,"C avg,ss","The mean C avg,ss values were 125.8 ng/ml, 131.1 ng/ml, and 140.7 ng/ml for the 441 mg q4wk, 882 mg q6wk, and 1064 mg q8wk doses, respectively.",Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597226/),[ng] / [ml],140.7,148222,DB00592,Piperazine
,28597226,elimination half-life,"The mean elimination half-life of aripiprazole following the last dose was 53.9 days for the 1064 mg dose, 55.1 days for the 882 mg dose, and 57.2 days for the 441 mg dose.",Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597226/),d,53.9,148223,DB00592,Piperazine
,28597226,elimination half-life,"The mean elimination half-life of aripiprazole following the last dose was 53.9 days for the 1064 mg dose, 55.1 days for the 882 mg dose, and 57.2 days for the 441 mg dose.",Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597226/),d,55.1,148224,DB00592,Piperazine
,28597226,elimination half-life,"The mean elimination half-life of aripiprazole following the last dose was 53.9 days for the 1064 mg dose, 55.1 days for the 882 mg dose, and 57.2 days for the 441 mg dose.",Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597226/),d,57.2,148225,DB00592,Piperazine
,28597226,duration of absorption,"The duration of absorption of aripiprazole was estimated as 43 days (95% confidence interval [CI] 42-45 days), which was preceded by a 3.2-day lag time (95% CI 3.0-3.5 days) for a total duration of input into the systemic circulation of 46 days following intramuscular administration of AL.",Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597226/),d,43,148226,DB00592,Piperazine
,96617,half-life,"The concn. declined thereafter with a half-life estimated at 1, 3-4 and 18-24 h for rat, dog, and baboon and man respectively.","The physiological disposition of the anti-tussive agent, 1,2,3,4a,9b-hexahydro-8,9b-dimethyl-4-[3-(4-methylpiperazin-1-yl)propionamido]dibenzofuran-3-one dihydrochloride Azipranone, in man, rat, dog and baboon. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/96617/),h,1,148373,DB00592,Piperazine
,96617,half-life,"The concn. declined thereafter with a half-life estimated at 1, 3-4 and 18-24 h for rat, dog, and baboon and man respectively.","The physiological disposition of the anti-tussive agent, 1,2,3,4a,9b-hexahydro-8,9b-dimethyl-4-[3-(4-methylpiperazin-1-yl)propionamido]dibenzofuran-3-one dihydrochloride Azipranone, in man, rat, dog and baboon. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/96617/),h,3-4,148374,DB00592,Piperazine
,96617,half-life,"The concn. declined thereafter with a half-life estimated at 1, 3-4 and 18-24 h for rat, dog, and baboon and man respectively.","The physiological disposition of the anti-tussive agent, 1,2,3,4a,9b-hexahydro-8,9b-dimethyl-4-[3-(4-methylpiperazin-1-yl)propionamido]dibenzofuran-3-one dihydrochloride Azipranone, in man, rat, dog and baboon. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/96617/),h,18-24,148375,DB00592,Piperazine
,10815716,detection limit,The assay is linear from 10 to 500 ng ml(-1) with a detection limit of 5 ng ml(-1) and a mean recovery of 96.5%.,RP-LC method for the determination of cetirizine in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10815716/),[ng] / [ml],5,148383,DB00592,Piperazine
,10815716,recovery,The assay is linear from 10 to 500 ng ml(-1) with a detection limit of 5 ng ml(-1) and a mean recovery of 96.5%.,RP-LC method for the determination of cetirizine in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10815716/),%,96.5,148384,DB00592,Piperazine
,24589908,CL/F,"Interestingly, 25 patients carrying at least one polymorphic c.480 G allele had a significant lower CL/F value with respect to the 35 c.480CC individuals (mean±s.d., 9.6±1.6 vs 12.1±2.3 l h(-1), respectively; P<0.001).",The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24589908/),[l] / [h],9.6,148856,DB00592,Piperazine
,24589908,CL/F,"Interestingly, 25 patients carrying at least one polymorphic c.480 G allele had a significant lower CL/F value with respect to the 35 c.480CC individuals (mean±s.d., 9.6±1.6 vs 12.1±2.3 l h(-1), respectively; P<0.001).",The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24589908/),[l] / [h],12.1,148857,DB00592,Piperazine
,3790194,terminal elimination half-life,"Following i.v. administration, the terminal elimination half-life, t 1/2, the volume of distribution, V1, and the total plasma clearance Cl were determined to be 7.7 +/- 1.4 h, 0.255 +/- 0.057 l/kg and 263.4 +/- 56.8 ml/min, respectively.",Pharmacokinetics and bioequivalence of different formulations of pirenzepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790194/),h,7.7,148990,DB00592,Piperazine
,3790194,t 1/2,"Following i.v. administration, the terminal elimination half-life, t 1/2, the volume of distribution, V1, and the total plasma clearance Cl were determined to be 7.7 +/- 1.4 h, 0.255 +/- 0.057 l/kg and 263.4 +/- 56.8 ml/min, respectively.",Pharmacokinetics and bioequivalence of different formulations of pirenzepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790194/),[l] / [kg],0.255,148991,DB00592,Piperazine
,3790194,"volume of distribution, V1","Following i.v. administration, the terminal elimination half-life, t 1/2, the volume of distribution, V1, and the total plasma clearance Cl were determined to be 7.7 +/- 1.4 h, 0.255 +/- 0.057 l/kg and 263.4 +/- 56.8 ml/min, respectively.",Pharmacokinetics and bioequivalence of different formulations of pirenzepine. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790194/),[l] / [kg],0.255,148992,DB00592,Piperazine
,3790194,total plasma clearance Cl,"Following i.v. administration, the terminal elimination half-life, t 1/2, the volume of distribution, V1, and the total plasma clearance Cl were determined to be 7.7 +/- 1.4 h, 0.255 +/- 0.057 l/kg and 263.4 +/- 56.8 ml/min, respectively.",Pharmacokinetics and bioequivalence of different formulations of pirenzepine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790194/),[ml] / [min],263.4,148993,DB00592,Piperazine
,3790194,systemic availabilities,"From the tablet and suspension formulation the systemic availabilities were calculated to be 33.5% and 20.3%, respectively.",Pharmacokinetics and bioequivalence of different formulations of pirenzepine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790194/),%,33.5,148994,DB00592,Piperazine
,3790194,systemic availabilities,"From the tablet and suspension formulation the systemic availabilities were calculated to be 33.5% and 20.3%, respectively.",Pharmacokinetics and bioequivalence of different formulations of pirenzepine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790194/),%,20.3,148995,DB00592,Piperazine
,9357392,area under the plasma concentration-time curve over the dosing interval tau (AUC tau,The mean values for area under the plasma concentration-time curve over the dosing interval tau (AUC tau; 58.8 to 102.4 ng.hr/ml) and elimination half-life t1/2; 5.7 to 10.4 hours) for the elderly subjects were significantly greater than those for the young subjects (39.0 to 64.3 ng.hr/ml and 3.2 to 4.5 hours).,"Effects of age, gender, and diurnal variation on the steady-state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357392/),[h·ng] / [ml],58.8 to 102.4,149057,DB00592,Piperazine
,9357392,elimination half-life t1/2,The mean values for area under the plasma concentration-time curve over the dosing interval tau (AUC tau; 58.8 to 102.4 ng.hr/ml) and elimination half-life t1/2; 5.7 to 10.4 hours) for the elderly subjects were significantly greater than those for the young subjects (39.0 to 64.3 ng.hr/ml and 3.2 to 4.5 hours).,"Effects of age, gender, and diurnal variation on the steady-state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357392/),h,5.7 to 10.4,149058,DB00592,Piperazine
,9357392,elimination half-life t1/2,The mean values for area under the plasma concentration-time curve over the dosing interval tau (AUC tau; 58.8 to 102.4 ng.hr/ml) and elimination half-life t1/2; 5.7 to 10.4 hours) for the elderly subjects were significantly greater than those for the young subjects (39.0 to 64.3 ng.hr/ml and 3.2 to 4.5 hours).,"Effects of age, gender, and diurnal variation on the steady-state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357392/),[h·ng] / [ml],39.0 to 64.3,149059,DB00592,Piperazine
,9357392,elimination half-life t1/2,The mean values for area under the plasma concentration-time curve over the dosing interval tau (AUC tau; 58.8 to 102.4 ng.hr/ml) and elimination half-life t1/2; 5.7 to 10.4 hours) for the elderly subjects were significantly greater than those for the young subjects (39.0 to 64.3 ng.hr/ml and 3.2 to 4.5 hours).,"Effects of age, gender, and diurnal variation on the steady-state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357392/),h,3.2 to 4.5,149060,DB00592,Piperazine
,9357392,peak plasma concentration (Cmax,The mean values for peak plasma concentration (Cmax; 14.7 to 25.2 ng/ml) and AUC tau (52.4 to 102.4 ng.hr/ml) for the women were significantly greater than those for the men (9.08 to 15.3 ng/ml and 39.0 to 73.6 ng.hr/ml).,"Effects of age, gender, and diurnal variation on the steady-state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357392/),[ng] / [ml],14.7 to 25.2,149061,DB00592,Piperazine
,9357392,peak plasma concentration (Cmax,The mean values for peak plasma concentration (Cmax; 14.7 to 25.2 ng/ml) and AUC tau (52.4 to 102.4 ng.hr/ml) for the women were significantly greater than those for the men (9.08 to 15.3 ng/ml and 39.0 to 73.6 ng.hr/ml).,"Effects of age, gender, and diurnal variation on the steady-state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357392/),[ng] / [ml],9.08 to 15.3,149062,DB00592,Piperazine
,9357392,AUC tau,The mean values for peak plasma concentration (Cmax; 14.7 to 25.2 ng/ml) and AUC tau (52.4 to 102.4 ng.hr/ml) for the women were significantly greater than those for the men (9.08 to 15.3 ng/ml and 39.0 to 73.6 ng.hr/ml).,"Effects of age, gender, and diurnal variation on the steady-state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357392/),[h·ng] / [ml],52.4 to 102.4,149063,DB00592,Piperazine
,9357392,AUC tau,The mean values for peak plasma concentration (Cmax; 14.7 to 25.2 ng/ml) and AUC tau (52.4 to 102.4 ng.hr/ml) for the women were significantly greater than those for the men (9.08 to 15.3 ng/ml and 39.0 to 73.6 ng.hr/ml).,"Effects of age, gender, and diurnal variation on the steady-state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357392/),[ng] / [ml],9.08 to 15.3,149064,DB00592,Piperazine
,9357392,AUC tau,The mean values for peak plasma concentration (Cmax; 14.7 to 25.2 ng/ml) and AUC tau (52.4 to 102.4 ng.hr/ml) for the women were significantly greater than those for the men (9.08 to 15.3 ng/ml and 39.0 to 73.6 ng.hr/ml).,"Effects of age, gender, and diurnal variation on the steady-state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357392/),[h·ng] / [ml],39.0 to 73.6,149065,DB00592,Piperazine
,9357392,Cmax,The mean values for Cmax (14.7 to 25.2 ng/ml) and AUC tau (54.8 to 102.4 ng.hr/ml) on the morning of day 7 were significantly greater than those after the evening dose on day 6 (9.08 to 17.3 ng/ml; 39.0 to 83.4 ng.hr/ml).,"Effects of age, gender, and diurnal variation on the steady-state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357392/),[ng] / [ml],14.7 to 25.2,149066,DB00592,Piperazine
,9357392,AUC tau,The mean values for Cmax (14.7 to 25.2 ng/ml) and AUC tau (54.8 to 102.4 ng.hr/ml) on the morning of day 7 were significantly greater than those after the evening dose on day 6 (9.08 to 17.3 ng/ml; 39.0 to 83.4 ng.hr/ml).,"Effects of age, gender, and diurnal variation on the steady-state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357392/),[h·ng] / [ml],54.8 to 102.4,149067,DB00592,Piperazine
,9357392,AUC tau,The mean values for Cmax (14.7 to 25.2 ng/ml) and AUC tau (54.8 to 102.4 ng.hr/ml) on the morning of day 7 were significantly greater than those after the evening dose on day 6 (9.08 to 17.3 ng/ml; 39.0 to 83.4 ng.hr/ml).,"Effects of age, gender, and diurnal variation on the steady-state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357392/),[ng] / [ml],9.08 to 17.3,149068,DB00592,Piperazine
,9357392,AUC tau,The mean values for Cmax (14.7 to 25.2 ng/ml) and AUC tau (54.8 to 102.4 ng.hr/ml) on the morning of day 7 were significantly greater than those after the evening dose on day 6 (9.08 to 17.3 ng/ml; 39.0 to 83.4 ng.hr/ml).,"Effects of age, gender, and diurnal variation on the steady-state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357392/),[h·ng] / [ml],39.0 to 83.4,149069,DB00592,Piperazine
,3902377,peak concentrations,Mean peak concentrations were obtained of 4.75 +/- 0.74 mg/ml at 1.75 hours with the new suppositories and of 4.6 +/- 0.67 mg/ml at 2.0 hours with the old suppositories.,"The relative bioavailability of paracetamol after rectal administration of suppositories containing a mixture of paracetamol, codeine phosphate and buclizine hydrochloride in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3902377/),[mg] / [ml],4.75,149218,DB00592,Piperazine
,3902377,peak concentrations,Mean peak concentrations were obtained of 4.75 +/- 0.74 mg/ml at 1.75 hours with the new suppositories and of 4.6 +/- 0.67 mg/ml at 2.0 hours with the old suppositories.,"The relative bioavailability of paracetamol after rectal administration of suppositories containing a mixture of paracetamol, codeine phosphate and buclizine hydrochloride in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3902377/),[mg] / [ml],4.6,149219,DB00592,Piperazine
,3902377,elimination half-life,"Mean elimination half-life was 4.4 +/- 0.42 hours and 3.73 +/- 0.28 hours, respectively.","The relative bioavailability of paracetamol after rectal administration of suppositories containing a mixture of paracetamol, codeine phosphate and buclizine hydrochloride in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3902377/),h,4.4,149220,DB00592,Piperazine
,3902377,elimination half-life,"Mean elimination half-life was 4.4 +/- 0.42 hours and 3.73 +/- 0.28 hours, respectively.","The relative bioavailability of paracetamol after rectal administration of suppositories containing a mixture of paracetamol, codeine phosphate and buclizine hydrochloride in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3902377/),h,3.73,149221,DB00592,Piperazine
,2872802,volume of distribution,"Approximately 90 to 94 percent of the drug is bound to plasma proteins, with the volume of distribution estimated to be 25 to 30 liters.",Pharmacokinetics of terazosin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2872802/),l,25 to 30,149425,DB00592,Piperazine
,2872802,Plasma,"Plasma and renal clearances are 80 and 10 ml per minute, respectively.",Pharmacokinetics of terazosin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2872802/),[ml] / [min],80,149426,DB00592,Piperazine
,2872802,renal clearances,"Plasma and renal clearances are 80 and 10 ml per minute, respectively.",Pharmacokinetics of terazosin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2872802/),[ml] / [min],10,149427,DB00592,Piperazine
,2872802,beta-phase half-life,The mean beta-phase half-life is approximately 12 hours.,Pharmacokinetics of terazosin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2872802/),h,12,149428,DB00592,Piperazine
>,32103260,"Cmin, unbound levels","Dolutegravir exposure in the third trimester was considered adequate if geometric mean unbound, pharmacologically active, minimal plasma concentrations (Cmin, unbound) and ≥90% of individual Cmin, unbound levels were >0.85 µg/L, the proposed 90% inhibitory concentration for unbound dolutegravir.",The Effect of Pregnancy on the Pharmacokinetics of Total and Unbound Dolutegravir and Its Main Metabolite in Women Living With Human Immunodeficiency Virus. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32103260/),[μg] / [l],0.85,149555,DB00592,Piperazine
,32103260,"Cmin, unbound","In the third trimester, geometric mean (coefficient of variation, %) Cmin, unbound was 2.87 (87) µg/L and 93% of individual Cmin, unbound levels were >0.85 µg/L.",The Effect of Pregnancy on the Pharmacokinetics of Total and Unbound Dolutegravir and Its Main Metabolite in Women Living With Human Immunodeficiency Virus. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32103260/),[μg] / [l],2.87,149556,DB00592,Piperazine
>,32103260,"Cmin, unbound levels","In the third trimester, geometric mean (coefficient of variation, %) Cmin, unbound was 2.87 (87) µg/L and 93% of individual Cmin, unbound levels were >0.85 µg/L.",The Effect of Pregnancy on the Pharmacokinetics of Total and Unbound Dolutegravir and Its Main Metabolite in Women Living With Human Immunodeficiency Virus. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32103260/),[μg] / [l],0.85,149557,DB00592,Piperazine
,9454812,Ki,"Both glucuronides inhibited the ATP-dependent uptake of DNP-SG, a typical substrate for the bile canalicular multispecific organic anion transport system in a concentration-dependent manner, with a Ki of 21.5 microM and 8.8 microM for R-GPFX-Glu and S-GPFX-Glu, respectively.",Stereoselective hepatobiliary transport of the quinolone antibiotic grepafloxacin and its glucuronide in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9454812/),μM,21.5,149574,DB00592,Piperazine
,9454812,Ki,"Both glucuronides inhibited the ATP-dependent uptake of DNP-SG, a typical substrate for the bile canalicular multispecific organic anion transport system in a concentration-dependent manner, with a Ki of 21.5 microM and 8.8 microM for R-GPFX-Glu and S-GPFX-Glu, respectively.",Stereoselective hepatobiliary transport of the quinolone antibiotic grepafloxacin and its glucuronide in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9454812/),μM,8.8,149575,DB00592,Piperazine
,9454812,Ki,"These Ki values were comparable with the corresponding Michaelis-Menten constant values for their uptake (17.3 microM and 10.1 microM, respectively).",Stereoselective hepatobiliary transport of the quinolone antibiotic grepafloxacin and its glucuronide in the rat. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9454812/),μM,17.3,149576,DB00592,Piperazine
,9454812,Michaelis-Menten constant,"These Ki values were comparable with the corresponding Michaelis-Menten constant values for their uptake (17.3 microM and 10.1 microM, respectively).",Stereoselective hepatobiliary transport of the quinolone antibiotic grepafloxacin and its glucuronide in the rat. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9454812/),μM,17.3,149577,DB00592,Piperazine
,9454812,Michaelis-Menten constant,"These Ki values were comparable with the corresponding Michaelis-Menten constant values for their uptake (17.3 microM and 10.1 microM, respectively).",Stereoselective hepatobiliary transport of the quinolone antibiotic grepafloxacin and its glucuronide in the rat. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9454812/),μM,10.1,149578,DB00592,Piperazine
,19843000,time,"There was no difference in time from randomisation to delivery in the two treatment groups, with a median time of 4 days (range 1-15) in the sildenafil group and 4.5 days (range 1-30) in the placebo group.","A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19843000/),d,4,150023,DB00592,Piperazine
,19843000,time,"There was no difference in time from randomisation to delivery in the two treatment groups, with a median time of 4 days (range 1-15) in the sildenafil group and 4.5 days (range 1-30) in the placebo group.","A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19843000/),d,4.5,150024,DB00592,Piperazine
,19843000,maximum drug concentrations,"Sildenafil achieved maximum drug concentrations of 48 ng/ml, 88 ng/ml, and 271 ng/ml after 3 days of 20 mg, 40 mg and 80 mg tid, respectively.","A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19843000/),[ng] / [ml],48,150025,DB00592,Piperazine
,19843000,maximum drug concentrations,"Sildenafil achieved maximum drug concentrations of 48 ng/ml, 88 ng/ml, and 271 ng/ml after 3 days of 20 mg, 40 mg and 80 mg tid, respectively.","A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19843000/),[ng] / [ml],88,150026,DB00592,Piperazine
,19843000,maximum drug concentrations,"Sildenafil achieved maximum drug concentrations of 48 ng/ml, 88 ng/ml, and 271 ng/ml after 3 days of 20 mg, 40 mg and 80 mg tid, respectively.","A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19843000/),[ng] / [ml],271,150027,DB00592,Piperazine
,10426160,elimination half-life,The mean elimination half-life of methylprednisolone was increased from 2.1+/-0.3 hr to 4.8+/-0.8 hr (P<0.001) by itraconazole.,Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426160/),h,2.1,150097,DB00592,Piperazine
,10426160,elimination half-life,The mean elimination half-life of methylprednisolone was increased from 2.1+/-0.3 hr to 4.8+/-0.8 hr (P<0.001) by itraconazole.,Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426160/),h,4.8,150098,DB00592,Piperazine
,10426160,plasma cortisol concentration,"The mean morning plasma cortisol concentration during the itraconazole phase, measured 24 hr after the administration of methylprednisolone, was only about 9% of that during the placebo phase (11.0+/-9.0 ng/ml versus 117+/-49.2 ng/ml; P<0.001).",Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426160/),[ng] / [ml],11.0,150099,DB00592,Piperazine
,10426160,plasma cortisol concentration,"The mean morning plasma cortisol concentration during the itraconazole phase, measured 24 hr after the administration of methylprednisolone, was only about 9% of that during the placebo phase (11.0+/-9.0 ng/ml versus 117+/-49.2 ng/ml; P<0.001).",Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426160/),[ng] / [ml],117,150100,DB00592,Piperazine
,8227460,maximum peak plasma concentration (Cmax),"The average DDI maximum peak plasma concentration (Cmax) value at steady state was significantly less when DDI was administered with KET (1836 ng/mL) than when DDI was administered alone (2094 ng/mL), although the magnitude of the decrease was only 12%.",Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227460/),[ng] / [ml],1836,150299,DB00592,Piperazine
,8227460,maximum peak plasma concentration (Cmax),"The average DDI maximum peak plasma concentration (Cmax) value at steady state was significantly less when DDI was administered with KET (1836 ng/mL) than when DDI was administered alone (2094 ng/mL), although the magnitude of the decrease was only 12%.",Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227460/),[ng] / [ml],2094,150300,DB00592,Piperazine
,8227460,area under the curve (AUC(0-tau)),Didanosine area under the curve (AUC(0-tau)) for the combination (2872 hr.ng/mL) was 8% less than when DDI was given alone (3107 hr.ng/mL); the difference was not significant.,Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227460/),[h·ng] / [ml],2872,150301,DB00592,Piperazine
,8227460,area under the curve (AUC(0-tau)),Didanosine area under the curve (AUC(0-tau)) for the combination (2872 hr.ng/mL) was 8% less than when DDI was given alone (3107 hr.ng/mL); the difference was not significant.,Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227460/),[h·ng] / [ml],3107,150302,DB00592,Piperazine
,2288834,t1/2,"After intravenous administration, the mean t1/2 ranged from 7 to 9 h, the MRT was 11 h, CL was 487 +/- 148 (3 mg dose) and 471 +/- 56 (8 mg dose) ml kg-1 h-1, while CLR was 226 +/- 124 (3 mg dose) and 189 +/- 38 (8 mg dose) ml kg-1 h-1.",Pharmacokinetics of eltoprazine in healthy male subjects after single dose oral and intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2288834/),h,7 to 9,150374,DB00592,Piperazine
,2288834,MRT,"After intravenous administration, the mean t1/2 ranged from 7 to 9 h, the MRT was 11 h, CL was 487 +/- 148 (3 mg dose) and 471 +/- 56 (8 mg dose) ml kg-1 h-1, while CLR was 226 +/- 124 (3 mg dose) and 189 +/- 38 (8 mg dose) ml kg-1 h-1.",Pharmacokinetics of eltoprazine in healthy male subjects after single dose oral and intravenous administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2288834/),h,11,150375,DB00592,Piperazine
,2288834,CL,"After intravenous administration, the mean t1/2 ranged from 7 to 9 h, the MRT was 11 h, CL was 487 +/- 148 (3 mg dose) and 471 +/- 56 (8 mg dose) ml kg-1 h-1, while CLR was 226 +/- 124 (3 mg dose) and 189 +/- 38 (8 mg dose) ml kg-1 h-1.",Pharmacokinetics of eltoprazine in healthy male subjects after single dose oral and intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2288834/),[ml] / [h·kg],487,150376,DB00592,Piperazine
,2288834,CL,"After intravenous administration, the mean t1/2 ranged from 7 to 9 h, the MRT was 11 h, CL was 487 +/- 148 (3 mg dose) and 471 +/- 56 (8 mg dose) ml kg-1 h-1, while CLR was 226 +/- 124 (3 mg dose) and 189 +/- 38 (8 mg dose) ml kg-1 h-1.",Pharmacokinetics of eltoprazine in healthy male subjects after single dose oral and intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2288834/),[ml] / [h·kg],471,150377,DB00592,Piperazine
,2288834,CLR,"After intravenous administration, the mean t1/2 ranged from 7 to 9 h, the MRT was 11 h, CL was 487 +/- 148 (3 mg dose) and 471 +/- 56 (8 mg dose) ml kg-1 h-1, while CLR was 226 +/- 124 (3 mg dose) and 189 +/- 38 (8 mg dose) ml kg-1 h-1.",Pharmacokinetics of eltoprazine in healthy male subjects after single dose oral and intravenous administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2288834/),[ml] / [h·kg],226,150378,DB00592,Piperazine
,2288834,CLR,"After intravenous administration, the mean t1/2 ranged from 7 to 9 h, the MRT was 11 h, CL was 487 +/- 148 (3 mg dose) and 471 +/- 56 (8 mg dose) ml kg-1 h-1, while CLR was 226 +/- 124 (3 mg dose) and 189 +/- 38 (8 mg dose) ml kg-1 h-1.",Pharmacokinetics of eltoprazine in healthy male subjects after single dose oral and intravenous administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2288834/),[ml] / [h·kg],189,150379,DB00592,Piperazine
,2288834,Vss,The Vss was 3.3 +/- 0.7 (3 mg dose) and 3.8 +/- 0.5 (8 mg dose) 1 kg-1.,Pharmacokinetics of eltoprazine in healthy male subjects after single dose oral and intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2288834/),[1] / [kg],3.3,150380,DB00592,Piperazine
,2288834,Vss,The Vss was 3.3 +/- 0.7 (3 mg dose) and 3.8 +/- 0.5 (8 mg dose) 1 kg-1.,Pharmacokinetics of eltoprazine in healthy male subjects after single dose oral and intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2288834/),[1] / [kg],3.8,150381,DB00592,Piperazine
,2288834,Cumulative renal excretion,Cumulative renal excretion was 40%.,Pharmacokinetics of eltoprazine in healthy male subjects after single dose oral and intravenous administration. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2288834/),%,40,150382,DB00592,Piperazine
,2288834,tmax,Values of tmax varied from 1 to 4 h after oral administration.,Pharmacokinetics of eltoprazine in healthy male subjects after single dose oral and intravenous administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2288834/),h,1 to 4,150383,DB00592,Piperazine
,2288834,Cmax,The mean Cmax value was 24 ng ml-1 after an oral dose of 8 mg.,Pharmacokinetics of eltoprazine in healthy male subjects after single dose oral and intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2288834/),[ng] / [ml],24,150384,DB00592,Piperazine
,2288834,plasma elimination half-life,The plasma elimination half-life after oral administration was 9.8 +/- 3.9 h.,Pharmacokinetics of eltoprazine in healthy male subjects after single dose oral and intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2288834/),h,9.8,150385,DB00592,Piperazine
,2288834,Absolute oral bioavailability,Absolute oral bioavailability was 110 +/- 32%.,Pharmacokinetics of eltoprazine in healthy male subjects after single dose oral and intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2288834/),%,110,150386,DB00592,Piperazine
,21899207,Cmax,"After administering a single dose of 35 mg of each trimetazidine formulation, the obtained mean (SD) values for the test and reference products were 104.78 (29.3) and 98.57 (28.7) ng/ml for Cmax; 4.00 (1.1) and 3.54 (1.32) h for t(max); 423.81 (173.9) and 410.01 (195.87) ng x h/ml for AUC0-12; and 472.51 (195.2) and 462.78 (225.13) ng x h/ml for AUC0-infinity respectively.",Relative bioavailability and pharmacokinetic study of two trimetazidine modified release formulations in healthy Bangladeshi male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21899207/),[ng] / [ml],104.78,150498,DB00592,Piperazine
,21899207,Cmax,"After administering a single dose of 35 mg of each trimetazidine formulation, the obtained mean (SD) values for the test and reference products were 104.78 (29.3) and 98.57 (28.7) ng/ml for Cmax; 4.00 (1.1) and 3.54 (1.32) h for t(max); 423.81 (173.9) and 410.01 (195.87) ng x h/ml for AUC0-12; and 472.51 (195.2) and 462.78 (225.13) ng x h/ml for AUC0-infinity respectively.",Relative bioavailability and pharmacokinetic study of two trimetazidine modified release formulations in healthy Bangladeshi male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21899207/),[ng] / [ml],98.57,150499,DB00592,Piperazine
,21899207,t(max),"After administering a single dose of 35 mg of each trimetazidine formulation, the obtained mean (SD) values for the test and reference products were 104.78 (29.3) and 98.57 (28.7) ng/ml for Cmax; 4.00 (1.1) and 3.54 (1.32) h for t(max); 423.81 (173.9) and 410.01 (195.87) ng x h/ml for AUC0-12; and 472.51 (195.2) and 462.78 (225.13) ng x h/ml for AUC0-infinity respectively.",Relative bioavailability and pharmacokinetic study of two trimetazidine modified release formulations in healthy Bangladeshi male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21899207/),h,4.00,150500,DB00592,Piperazine
,21899207,t(max),"After administering a single dose of 35 mg of each trimetazidine formulation, the obtained mean (SD) values for the test and reference products were 104.78 (29.3) and 98.57 (28.7) ng/ml for Cmax; 4.00 (1.1) and 3.54 (1.32) h for t(max); 423.81 (173.9) and 410.01 (195.87) ng x h/ml for AUC0-12; and 472.51 (195.2) and 462.78 (225.13) ng x h/ml for AUC0-infinity respectively.",Relative bioavailability and pharmacokinetic study of two trimetazidine modified release formulations in healthy Bangladeshi male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21899207/),h,3.54,150501,DB00592,Piperazine
,21899207,AUC0-12,"After administering a single dose of 35 mg of each trimetazidine formulation, the obtained mean (SD) values for the test and reference products were 104.78 (29.3) and 98.57 (28.7) ng/ml for Cmax; 4.00 (1.1) and 3.54 (1.32) h for t(max); 423.81 (173.9) and 410.01 (195.87) ng x h/ml for AUC0-12; and 472.51 (195.2) and 462.78 (225.13) ng x h/ml for AUC0-infinity respectively.",Relative bioavailability and pharmacokinetic study of two trimetazidine modified release formulations in healthy Bangladeshi male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21899207/),[h·ng] / [ml],423.81,150502,DB00592,Piperazine
,21899207,AUC0-12,"After administering a single dose of 35 mg of each trimetazidine formulation, the obtained mean (SD) values for the test and reference products were 104.78 (29.3) and 98.57 (28.7) ng/ml for Cmax; 4.00 (1.1) and 3.54 (1.32) h for t(max); 423.81 (173.9) and 410.01 (195.87) ng x h/ml for AUC0-12; and 472.51 (195.2) and 462.78 (225.13) ng x h/ml for AUC0-infinity respectively.",Relative bioavailability and pharmacokinetic study of two trimetazidine modified release formulations in healthy Bangladeshi male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21899207/),[h·ng] / [ml],410.01,150503,DB00592,Piperazine
,21899207,AUC0-infinity,"After administering a single dose of 35 mg of each trimetazidine formulation, the obtained mean (SD) values for the test and reference products were 104.78 (29.3) and 98.57 (28.7) ng/ml for Cmax; 4.00 (1.1) and 3.54 (1.32) h for t(max); 423.81 (173.9) and 410.01 (195.87) ng x h/ml for AUC0-12; and 472.51 (195.2) and 462.78 (225.13) ng x h/ml for AUC0-infinity respectively.",Relative bioavailability and pharmacokinetic study of two trimetazidine modified release formulations in healthy Bangladeshi male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21899207/),[h·ng] / [ml],472.51,150504,DB00592,Piperazine
,21899207,AUC0-infinity,"After administering a single dose of 35 mg of each trimetazidine formulation, the obtained mean (SD) values for the test and reference products were 104.78 (29.3) and 98.57 (28.7) ng/ml for Cmax; 4.00 (1.1) and 3.54 (1.32) h for t(max); 423.81 (173.9) and 410.01 (195.87) ng x h/ml for AUC0-12; and 472.51 (195.2) and 462.78 (225.13) ng x h/ml for AUC0-infinity respectively.",Relative bioavailability and pharmacokinetic study of two trimetazidine modified release formulations in healthy Bangladeshi male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21899207/),[h·ng] / [ml],462.78,150505,DB00592,Piperazine
,21899207,t1/2,The mean t1/2 was found 3.69 (1.1) h and 3.45 (0.72) h for test and reference products respectively.,Relative bioavailability and pharmacokinetic study of two trimetazidine modified release formulations in healthy Bangladeshi male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21899207/),h,3.69,150506,DB00592,Piperazine
,21899207,t1/2,The mean t1/2 was found 3.69 (1.1) h and 3.45 (0.72) h for test and reference products respectively.,Relative bioavailability and pharmacokinetic study of two trimetazidine modified release formulations in healthy Bangladeshi male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21899207/),h,3.45,150507,DB00592,Piperazine
,24710899,IC50,"In the in vitro cytochrome P450 inhibition study, the rate of disappearance of testosterone was significantly reduced in the presence of 10 µM PU, while that of other cytochrome P450 substrates was not significantly affected in both human and rat liver microsomes, suggesting that puerarin inhibits the in vitro hepatic CYP3A-mediated metabolism in the human and rat systems (IC50 = 15.5 ± 3.9 µM).",In vitro and in vivo evaluation of the effect of puerarin on hepatic cytochrome p450-mediated drug metabolism. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24710899/),μM,15.5,150775,DB00592,Piperazine
,10579473,Total bioavailability,Total bioavailability increased from 25% to 80% (P < .001).,Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579473/),%,25,150793,DB00592,Piperazine
,10579473,Total bioavailability,Total bioavailability increased from 25% to 80% (P < .001).,Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579473/),%,80,150794,DB00592,Piperazine
,8464816,volume of distribution,"The volume of distribution decreases from 3 to less than 1 L/kg, while the plasma clearance decreases 10-fold from 25 mL/min/kg as the dose is escalated.",Disposition of azole antifungal agents. I. Nonlinearities in ketoconazole clearance and binding in rat liver. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8464816/),[l] / [kg],3,150827,DB00592,Piperazine
,8464816,volume of distribution,"The volume of distribution decreases from 3 to less than 1 L/kg, while the plasma clearance decreases 10-fold from 25 mL/min/kg as the dose is escalated.",Disposition of azole antifungal agents. I. Nonlinearities in ketoconazole clearance and binding in rat liver. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8464816/),[l] / [kg],less,150828,DB00592,Piperazine
,8464816,volume of distribution,"The volume of distribution decreases from 3 to less than 1 L/kg, while the plasma clearance decreases 10-fold from 25 mL/min/kg as the dose is escalated.",Disposition of azole antifungal agents. I. Nonlinearities in ketoconazole clearance and binding in rat liver. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8464816/),[l] / [kg],1,150829,DB00592,Piperazine
,8464816,plasma clearance,"The volume of distribution decreases from 3 to less than 1 L/kg, while the plasma clearance decreases 10-fold from 25 mL/min/kg as the dose is escalated.",Disposition of azole antifungal agents. I. Nonlinearities in ketoconazole clearance and binding in rat liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8464816/),[ml] / [kg·min],25,150830,DB00592,Piperazine
,8464816,Vmax,A Vmax of 3.2 mg/hr/kg and Km of 2.1 mg/L were obtained by nonlinear regression analysis.,Disposition of azole antifungal agents. I. Nonlinearities in ketoconazole clearance and binding in rat liver. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8464816/),[mg] / [h·kg],3.2,150831,DB00592,Piperazine
,8464816,Km,A Vmax of 3.2 mg/hr/kg and Km of 2.1 mg/L were obtained by nonlinear regression analysis.,Disposition of azole antifungal agents. I. Nonlinearities in ketoconazole clearance and binding in rat liver. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8464816/),[mg] / [l],2.1,150832,DB00592,Piperazine
,8464816,kidney:plasma partition coefficient,"In contrast, the kidney:plasma partition coefficient (1.8), blood:plasma concentration ratio (0.6), and plasma binding (96%) of ketoconazole did not show a concentration dependence over the range studied.",Disposition of azole antifungal agents. I. Nonlinearities in ketoconazole clearance and binding in rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8464816/),,1.8,150833,DB00592,Piperazine
,8464816,blood:plasma concentration ratio,"In contrast, the kidney:plasma partition coefficient (1.8), blood:plasma concentration ratio (0.6), and plasma binding (96%) of ketoconazole did not show a concentration dependence over the range studied.",Disposition of azole antifungal agents. I. Nonlinearities in ketoconazole clearance and binding in rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8464816/),,0.6,150834,DB00592,Piperazine
,8464816,plasma binding,"In contrast, the kidney:plasma partition coefficient (1.8), blood:plasma concentration ratio (0.6), and plasma binding (96%) of ketoconazole did not show a concentration dependence over the range studied.",Disposition of azole antifungal agents. I. Nonlinearities in ketoconazole clearance and binding in rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8464816/),%,96,150835,DB00592,Piperazine
,31471313,progression-free survival,"Stable disease was the best response in 4 patients, and median progression-free survival was 1.9 months.",Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31471313/),month,1.9,151029,DB00592,Piperazine
,2387982,elimination half-life,Zopiclone is a new hypnotic cyclopyrrolone with a short elimination half-life (5.3 h).,Steady state pharmacokinetics of zopiclone during multiple oral dosing (7.5 mg nocte) in patients with severe chronic renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387982/),h,5.3,151270,DB00592,Piperazine
,2387982,C max,C max and T max were not significantly different between the two groups but the C min of unchanged zopiclone (at 24 h) post-dosing was significantly (p less than 0.001) higher in CRF patients (8.16 +/- 5.34 ng/ml) than in healthy volunteers (1.90 +/- 0.82 ng/ml).,Steady state pharmacokinetics of zopiclone during multiple oral dosing (7.5 mg nocte) in patients with severe chronic renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387982/),[ng] / [ml],8.16,151271,DB00592,Piperazine
,2387982,T max,C max and T max were not significantly different between the two groups but the C min of unchanged zopiclone (at 24 h) post-dosing was significantly (p less than 0.001) higher in CRF patients (8.16 +/- 5.34 ng/ml) than in healthy volunteers (1.90 +/- 0.82 ng/ml).,Steady state pharmacokinetics of zopiclone during multiple oral dosing (7.5 mg nocte) in patients with severe chronic renal failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387982/),[ng] / [ml],8.16,151272,DB00592,Piperazine
,2387982,C min,C max and T max were not significantly different between the two groups but the C min of unchanged zopiclone (at 24 h) post-dosing was significantly (p less than 0.001) higher in CRF patients (8.16 +/- 5.34 ng/ml) than in healthy volunteers (1.90 +/- 0.82 ng/ml).,Steady state pharmacokinetics of zopiclone during multiple oral dosing (7.5 mg nocte) in patients with severe chronic renal failure. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387982/),[ng] / [ml],8.16,151273,DB00592,Piperazine
,2387982,C min,C max and T max were not significantly different between the two groups but the C min of unchanged zopiclone (at 24 h) post-dosing was significantly (p less than 0.001) higher in CRF patients (8.16 +/- 5.34 ng/ml) than in healthy volunteers (1.90 +/- 0.82 ng/ml).,Steady state pharmacokinetics of zopiclone during multiple oral dosing (7.5 mg nocte) in patients with severe chronic renal failure. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387982/),[ng] / [ml],1.90,151274,DB00592,Piperazine
,2387982,AUC,The AUC values in CRF patients were also significantly increased during the seventh day (742 +/- 212 h ng/ml) compared to healthy subjects (408 +/- 66.5 h ng/ml) and the elimination half-life of zopiclone was also longer in CRF patients (about 8 h) than in the reference group (about 5 h).,Steady state pharmacokinetics of zopiclone during multiple oral dosing (7.5 mg nocte) in patients with severe chronic renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387982/),[h·ng] / [ml],742,151275,DB00592,Piperazine
,2387982,AUC,The AUC values in CRF patients were also significantly increased during the seventh day (742 +/- 212 h ng/ml) compared to healthy subjects (408 +/- 66.5 h ng/ml) and the elimination half-life of zopiclone was also longer in CRF patients (about 8 h) than in the reference group (about 5 h).,Steady state pharmacokinetics of zopiclone during multiple oral dosing (7.5 mg nocte) in patients with severe chronic renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387982/),[h·ng] / [ml],408,151276,DB00592,Piperazine
,2387982,elimination half-life,The AUC values in CRF patients were also significantly increased during the seventh day (742 +/- 212 h ng/ml) compared to healthy subjects (408 +/- 66.5 h ng/ml) and the elimination half-life of zopiclone was also longer in CRF patients (about 8 h) than in the reference group (about 5 h).,Steady state pharmacokinetics of zopiclone during multiple oral dosing (7.5 mg nocte) in patients with severe chronic renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387982/),h,8,151277,DB00592,Piperazine
,2387982,elimination half-life,The AUC values in CRF patients were also significantly increased during the seventh day (742 +/- 212 h ng/ml) compared to healthy subjects (408 +/- 66.5 h ng/ml) and the elimination half-life of zopiclone was also longer in CRF patients (about 8 h) than in the reference group (about 5 h).,Steady state pharmacokinetics of zopiclone during multiple oral dosing (7.5 mg nocte) in patients with severe chronic renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387982/),h,5,151278,DB00592,Piperazine
,2387982,accumulation ratios,"Nevertheless, the accumulation ratios remained similar in the two groups (1.09 +/- 0.18 in CRF patients and 1.02 +/- 0.2 in healthy subjects).",Steady state pharmacokinetics of zopiclone during multiple oral dosing (7.5 mg nocte) in patients with severe chronic renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387982/),,1.09,151279,DB00592,Piperazine
,2387982,accumulation ratios,"Nevertheless, the accumulation ratios remained similar in the two groups (1.09 +/- 0.18 in CRF patients and 1.02 +/- 0.2 in healthy subjects).",Steady state pharmacokinetics of zopiclone during multiple oral dosing (7.5 mg nocte) in patients with severe chronic renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2387982/),,1.02,151280,DB00592,Piperazine
,24245857,solubility,The solubility of ITR was enhanced around 200 times (from 1.54 to 248.38 µg/mL) by preparing solid dispersion (SD) with hydroxypropylmethyl cellulose.,Preparation and evaluation of dual-mode floating gastroretentive tablets containing itraconazole. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24245857/),[μg] / [ml],1,151775,DB00592,Piperazine
,24245857,solubility,The solubility of ITR was enhanced around 200 times (from 1.54 to 248.38 µg/mL) by preparing solid dispersion (SD) with hydroxypropylmethyl cellulose.,Preparation and evaluation of dual-mode floating gastroretentive tablets containing itraconazole. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24245857/),[μg] / [ml],248,151776,DB00592,Piperazine
<,24245857,Residual camphor,Residual camphor was <0.5 wt% after sublimation.,Preparation and evaluation of dual-mode floating gastroretentive tablets containing itraconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24245857/),wt%,0.5,151777,DB00592,Piperazine
,24245857,AUC ratio,Mean AUC ratio of GRT/IRT was 1.36 but there was no statistical difference between AUC values.,Preparation and evaluation of dual-mode floating gastroretentive tablets containing itraconazole. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24245857/),,1.36,151778,DB00592,Piperazine
,28034694,clearance,"When compared to the single cannulation approach, clearance, volume of distribution and bioavailability determined by dual cannulation were 39%, 60% and 38% higher for itraconazole, and 46%, 34% and 42% higher for amiodarone, respectively.",Single jugular vein cannulated rats may not be suitable for intravenous pharmacokinetic screening of high logP compounds. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28034694/),%,39,151866,DB00592,Piperazine
,28034694,volume of distribution,"When compared to the single cannulation approach, clearance, volume of distribution and bioavailability determined by dual cannulation were 39%, 60% and 38% higher for itraconazole, and 46%, 34% and 42% higher for amiodarone, respectively.",Single jugular vein cannulated rats may not be suitable for intravenous pharmacokinetic screening of high logP compounds. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28034694/),%,60,151867,DB00592,Piperazine
,28034694,volume of distribution,"When compared to the single cannulation approach, clearance, volume of distribution and bioavailability determined by dual cannulation were 39%, 60% and 38% higher for itraconazole, and 46%, 34% and 42% higher for amiodarone, respectively.",Single jugular vein cannulated rats may not be suitable for intravenous pharmacokinetic screening of high logP compounds. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28034694/),%,46,151868,DB00592,Piperazine
,28034694,bioavailability,"When compared to the single cannulation approach, clearance, volume of distribution and bioavailability determined by dual cannulation were 39%, 60% and 38% higher for itraconazole, and 46%, 34% and 42% higher for amiodarone, respectively.",Single jugular vein cannulated rats may not be suitable for intravenous pharmacokinetic screening of high logP compounds. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28034694/),%,38,151869,DB00592,Piperazine
<,12608888,half-life,"According to their pharmacokinetic profile, benzodiazepines can be classified into three groups: short half-life (<3 hours), medium half-life (8-24 hours) and long half-life (>24 hours).","New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12608888/),h,3,152307,DB00592,Piperazine
,12608888,half-life,"According to their pharmacokinetic profile, benzodiazepines can be classified into three groups: short half-life (<3 hours), medium half-life (8-24 hours) and long half-life (>24 hours).","New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12608888/),h,8-24,152308,DB00592,Piperazine
>,12608888,half-life,"According to their pharmacokinetic profile, benzodiazepines can be classified into three groups: short half-life (<3 hours), medium half-life (8-24 hours) and long half-life (>24 hours).","New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12608888/),h,24,152309,DB00592,Piperazine
,12608888,half-life,Zaleplon is characterised by an ultrashort half-life (approximately 1 hour).,"New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12608888/),h,1,152310,DB00592,Piperazine
,12608888,half-lives,"Zolpidem and zopiclone have longer half-lives (approximately 2.4 and 5 hours, respectively).","New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12608888/),h,2.4,152311,DB00592,Piperazine
,12608888,half-lives,"Zolpidem and zopiclone have longer half-lives (approximately 2.4 and 5 hours, respectively).","New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12608888/),h,5,152312,DB00592,Piperazine
,28906001,extraction recovery,The mean extraction recovery of trimetazidine (98.66%) and trimetazidine-d8 (97.63%) from spiked plasma was consistent and reproducible.,Overcoming interference of plasma phospholipids using HybridSPE for the determination of trimetazidine by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28906001/),%,98.66,152321,DB00592,Piperazine
,28906001,extraction recovery,The mean extraction recovery of trimetazidine (98.66%) and trimetazidine-d8 (97.63%) from spiked plasma was consistent and reproducible.,Overcoming interference of plasma phospholipids using HybridSPE for the determination of trimetazidine by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28906001/),%,97.63,152322,DB00592,Piperazine
,28871716,Cmax,"Pre-administration of Eruca sativa has increased Sildenafil Cmax from 226.72 to 345.25 ng/ml, (p<0.05).",The influence of Eruca sativa (Arugula) on pharmacokinetics of Sildenafil in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28871716/),[ng] / [ml],226.72,152396,DB00592,Piperazine
,28871716,Cmax,"Pre-administration of Eruca sativa has increased Sildenafil Cmax from 226.72 to 345.25 ng/ml, (p<0.05).",The influence of Eruca sativa (Arugula) on pharmacokinetics of Sildenafil in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28871716/),[ng] / [ml],345.25,152397,DB00592,Piperazine
,28871716,AUC,"In addition, the AUC of Sildenafil has significantly increased when it was pre-administered with Eruca sativa (550.59 vs. 916.48 ng/ml*hr).",The influence of Eruca sativa (Arugula) on pharmacokinetics of Sildenafil in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28871716/),[ng] / [h·ml],550.59,152398,DB00592,Piperazine
,28871716,AUC,"In addition, the AUC of Sildenafil has significantly increased when it was pre-administered with Eruca sativa (550.59 vs. 916.48 ng/ml*hr).",The influence of Eruca sativa (Arugula) on pharmacokinetics of Sildenafil in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28871716/),[ng] / [h·ml],916.48,152399,DB00592,Piperazine
,32814084,particle,The optimized KZ-SLN formulation showed particle size and entrapment efficiency of 210.9 ± 3.4 nm and 84.8 ± 1.5 % compared to 167.8 ± 5.8 nm and 95.3 ± 2.0 % for optimized KZ-NLC formulation.,Amelioration of ketoconazole in lipid nanoparticles for enhanced antifungal activity and bioavailability through oral administration for management of fungal infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32814084/),nm,210.9,152498,DB00592,Piperazine
,32814084,particle,The optimized KZ-SLN formulation showed particle size and entrapment efficiency of 210.9 ± 3.4 nm and 84.8 ± 1.5 % compared to 167.8 ± 5.8 nm and 95.3 ± 2.0 % for optimized KZ-NLC formulation.,Amelioration of ketoconazole in lipid nanoparticles for enhanced antifungal activity and bioavailability through oral administration for management of fungal infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32814084/),nm,167.8,152499,DB00592,Piperazine
,32814084,entrapment efficiency,The optimized KZ-SLN formulation showed particle size and entrapment efficiency of 210.9 ± 3.4 nm and 84.8 ± 1.5 % compared to 167.8 ± 5.8 nm and 95.3 ± 2.0 % for optimized KZ-NLC formulation.,Amelioration of ketoconazole in lipid nanoparticles for enhanced antifungal activity and bioavailability through oral administration for management of fungal infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32814084/),%,84.8,152500,DB00592,Piperazine
,32814084,entrapment efficiency,The optimized KZ-SLN formulation showed particle size and entrapment efficiency of 210.9 ± 3.4 nm and 84.8 ± 1.5 % compared to 167.8 ± 5.8 nm and 95.3 ± 2.0 % for optimized KZ-NLC formulation.,Amelioration of ketoconazole in lipid nanoparticles for enhanced antifungal activity and bioavailability through oral administration for management of fungal infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32814084/),%,95.3,152501,DB00592,Piperazine
,24827126,overall objective response rate,"The overall objective response rate was 41% for patients with measurable disease, and 43% and 71% among patients with a BRCA1/2 mutation who had ovarian and breast cancer, respectively.","Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24827126/),%,41,152504,DB00592,Piperazine
,24827126,overall objective response rate,"The overall objective response rate was 41% for patients with measurable disease, and 43% and 71% among patients with a BRCA1/2 mutation who had ovarian and breast cancer, respectively.","Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24827126/),%,43,152505,DB00592,Piperazine
,24827126,overall objective response rate,"The overall objective response rate was 41% for patients with measurable disease, and 43% and 71% among patients with a BRCA1/2 mutation who had ovarian and breast cancer, respectively.","Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24827126/),%,71,152506,DB00592,Piperazine
,7883389,Cmax ratio,The corresponding Cmax ratio was 1.04 (range 0.91-1.17).,Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in Japanese subjects. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7883389/),,1.04,152653,DB00592,Piperazine
,7883389,Cmax ratios,The Cmax ratios postprandial vs fasting ranged between 0.27 and 5.71 (median = 1.04).,Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in Japanese subjects. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7883389/),,1.04,152654,DB00592,Piperazine
,26551206,detection limit,"Under the optimized experimental conditions, the ECL intensity was linear with the concentration of urapidil hydrochloride in the range from 0.050 to 50.0ng/mL and the detection limit was 0.014ng/mL (S/N=3).",Capillary electrophoresis with end-column electrochemiluminescence for ultrasensitive determination of urapidil hydrochloride in rat plasma and its application to pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26551206/),[ng] / [ml],0.014,152899,DB00592,Piperazine
,26551206,S/N,"Under the optimized experimental conditions, the ECL intensity was linear with the concentration of urapidil hydrochloride in the range from 0.050 to 50.0ng/mL and the detection limit was 0.014ng/mL (S/N=3).",Capillary electrophoresis with end-column electrochemiluminescence for ultrasensitive determination of urapidil hydrochloride in rat plasma and its application to pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26551206/),,3,152900,DB00592,Piperazine
,26551206,peak concentration (Cmax),"The proposed method was used for studying pharmacokinetics of urapidil hydrochloride in rat plasma and the main pharmacokinetic parameters of the peak concentration (Cmax), half life time (T1/2) and peak concentration time (Tmax) were 240.45±21.15ng/mL, 0.58±0.16h and 1.08±0.13h, respectively.",Capillary electrophoresis with end-column electrochemiluminescence for ultrasensitive determination of urapidil hydrochloride in rat plasma and its application to pharmacokinetics study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26551206/),[ng] / [ml],240.45,152901,DB00592,Piperazine
,26551206,half life time (T1/2),"The proposed method was used for studying pharmacokinetics of urapidil hydrochloride in rat plasma and the main pharmacokinetic parameters of the peak concentration (Cmax), half life time (T1/2) and peak concentration time (Tmax) were 240.45±21.15ng/mL, 0.58±0.16h and 1.08±0.13h, respectively.",Capillary electrophoresis with end-column electrochemiluminescence for ultrasensitive determination of urapidil hydrochloride in rat plasma and its application to pharmacokinetics study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26551206/),h,0.58,152902,DB00592,Piperazine
,26551206,peak concentration time (Tmax),"The proposed method was used for studying pharmacokinetics of urapidil hydrochloride in rat plasma and the main pharmacokinetic parameters of the peak concentration (Cmax), half life time (T1/2) and peak concentration time (Tmax) were 240.45±21.15ng/mL, 0.58±0.16h and 1.08±0.13h, respectively.",Capillary electrophoresis with end-column electrochemiluminescence for ultrasensitive determination of urapidil hydrochloride in rat plasma and its application to pharmacokinetics study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26551206/),h,1.08,152903,DB00592,Piperazine
,26551206,recoveries,The recoveries of urapidil hydrochloride in the diluted extracts of rat plasma samples ranged from 96.68 to 98.82%.,Capillary electrophoresis with end-column electrochemiluminescence for ultrasensitive determination of urapidil hydrochloride in rat plasma and its application to pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26551206/),%,96.68 to 98.82,152904,DB00592,Piperazine
,12016999,Tp,Tp was in the range of 0.42 h to 0.90 h.,[Pharmacokinetic profile of naftopidil in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016999/),h,0.42,152952,DB00592,Piperazine
,12016999,Tp,Tp was in the range of 0.42 h to 0.90 h.,[Pharmacokinetic profile of naftopidil in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016999/),h,0.90,152953,DB00592,Piperazine
,12016999,T1/2 beta,T1/2 beta was 7.08 h after the 10 mg.,[Pharmacokinetic profile of naftopidil in rats]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016999/),h,7.08,152954,DB00592,Piperazine
,21138873,tumor blood flow (Ktrans),"A dose of 30 mg/m² was selected as the RP2D based on the adverse events of nausea, vomiting, fatigue, fever, tumor pain, and transient blood pressure elevations, with DCE-MRI indicating decreases in tumor blood flow (Ktrans) from 13.5 mg/m² (defining a biologically effective dose) with a 16% to 82% decrease in patients evaluated at 30 mg/m².",Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21138873/),[mg] / [m²],13.5,153114,DB00592,Piperazine
,21138873,Half-life,"Half-life was 6.06 ± 3.03 hours, clearance was 30.50 ± 22.88 L/h, and distributive volume was 211 ± 67.9 L.",Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21138873/),h,6.06,153115,DB00592,Piperazine
,21138873,clearance,"Half-life was 6.06 ± 3.03 hours, clearance was 30.50 ± 22.88 L/h, and distributive volume was 211 ± 67.9 L.",Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21138873/),[l] / [h],30.50,153116,DB00592,Piperazine
,26189007,zero-order kinetic (Fr),"Typical population estimates (% IIV) were fraction of the drug absorbed with a zero-order kinetic (Fr) of 0.153 (47.9 %) in period (Tk0) of 0.714 h (47.4 %), first-order absorption rate constant (k a) of 0.94 h(-1)(31.2 %), oral clearance of 19 L/h (27.9 %), central volume of distribution (V c/F) of 139 L (21.5 %), apparent peripheral volume of distribution (V p/F) of 130 L (29.7 %) and the apparent inter-compartment clearance (Q/F) of 29.6 L/h (41.8 %).",Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26189007/),,0.153,153324,DB00592,Piperazine
,26189007,Tk0),"Typical population estimates (% IIV) were fraction of the drug absorbed with a zero-order kinetic (Fr) of 0.153 (47.9 %) in period (Tk0) of 0.714 h (47.4 %), first-order absorption rate constant (k a) of 0.94 h(-1)(31.2 %), oral clearance of 19 L/h (27.9 %), central volume of distribution (V c/F) of 139 L (21.5 %), apparent peripheral volume of distribution (V p/F) of 130 L (29.7 %) and the apparent inter-compartment clearance (Q/F) of 29.6 L/h (41.8 %).",Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26189007/),h,0.714,153325,DB00592,Piperazine
,26189007,first-order absorption rate constant (k a),"Typical population estimates (% IIV) were fraction of the drug absorbed with a zero-order kinetic (Fr) of 0.153 (47.9 %) in period (Tk0) of 0.714 h (47.4 %), first-order absorption rate constant (k a) of 0.94 h(-1)(31.2 %), oral clearance of 19 L/h (27.9 %), central volume of distribution (V c/F) of 139 L (21.5 %), apparent peripheral volume of distribution (V p/F) of 130 L (29.7 %) and the apparent inter-compartment clearance (Q/F) of 29.6 L/h (41.8 %).",Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26189007/),1/[h],0.94,153326,DB00592,Piperazine
,26189007,oral clearance,"Typical population estimates (% IIV) were fraction of the drug absorbed with a zero-order kinetic (Fr) of 0.153 (47.9 %) in period (Tk0) of 0.714 h (47.4 %), first-order absorption rate constant (k a) of 0.94 h(-1)(31.2 %), oral clearance of 19 L/h (27.9 %), central volume of distribution (V c/F) of 139 L (21.5 %), apparent peripheral volume of distribution (V p/F) of 130 L (29.7 %) and the apparent inter-compartment clearance (Q/F) of 29.6 L/h (41.8 %).",Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26189007/),[l] / [h],19,153327,DB00592,Piperazine
,26189007,central volume of distribution (V c/F),"Typical population estimates (% IIV) were fraction of the drug absorbed with a zero-order kinetic (Fr) of 0.153 (47.9 %) in period (Tk0) of 0.714 h (47.4 %), first-order absorption rate constant (k a) of 0.94 h(-1)(31.2 %), oral clearance of 19 L/h (27.9 %), central volume of distribution (V c/F) of 139 L (21.5 %), apparent peripheral volume of distribution (V p/F) of 130 L (29.7 %) and the apparent inter-compartment clearance (Q/F) of 29.6 L/h (41.8 %).",Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26189007/),l,139,153328,DB00592,Piperazine
,26189007,apparent peripheral volume of distribution (V p/F),"Typical population estimates (% IIV) were fraction of the drug absorbed with a zero-order kinetic (Fr) of 0.153 (47.9 %) in period (Tk0) of 0.714 h (47.4 %), first-order absorption rate constant (k a) of 0.94 h(-1)(31.2 %), oral clearance of 19 L/h (27.9 %), central volume of distribution (V c/F) of 139 L (21.5 %), apparent peripheral volume of distribution (V p/F) of 130 L (29.7 %) and the apparent inter-compartment clearance (Q/F) of 29.6 L/h (41.8 %).",Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26189007/),l,130,153329,DB00592,Piperazine
,26189007,apparent inter-compartment clearance (Q/F),"Typical population estimates (% IIV) were fraction of the drug absorbed with a zero-order kinetic (Fr) of 0.153 (47.9 %) in period (Tk0) of 0.714 h (47.4 %), first-order absorption rate constant (k a) of 0.94 h(-1)(31.2 %), oral clearance of 19 L/h (27.9 %), central volume of distribution (V c/F) of 139 L (21.5 %), apparent peripheral volume of distribution (V p/F) of 130 L (29.7 %) and the apparent inter-compartment clearance (Q/F) of 29.6 L/h (41.8 %).",Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26189007/),[l] / [h],29.6,153330,DB00592,Piperazine
,17294808,flow rate,"The chromatographic separation was achieved within 3.5 min using the mobile phase consisting of methanol/0.05% formic acid (80:20, v/v) and the flow rate was 1.0 ml/min.",Quantification of trimetazidine in human plasma by liquid chromatography-electrospray ionization mass spectrometry and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17294808/),[ml] / [min],1.0,153366,DB00592,Piperazine
,17294808,m/z,"Ion signals m/z 181.0 and 148.0 were measured in the positive mode for trimetazidine and pseudoephedrine, respectively.",Quantification of trimetazidine in human plasma by liquid chromatography-electrospray ionization mass spectrometry and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17294808/),,181.0,153367,DB00592,Piperazine
,17294808,m/z,"Ion signals m/z 181.0 and 148.0 were measured in the positive mode for trimetazidine and pseudoephedrine, respectively.",Quantification of trimetazidine in human plasma by liquid chromatography-electrospray ionization mass spectrometry and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17294808/),,148.0,153368,DB00592,Piperazine
,29563138,response rate (RR),"Among the ALK-positive efficacy evaluable patients treated at ≥200 mg, the response rate (RR) was 60%, and median progression-free survival (PFS) was 9.2 months.","Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29563138/),%,60,153533,DB00592,Piperazine
,29563138,progression-free survival (PFS),"Among the ALK-positive efficacy evaluable patients treated at ≥200 mg, the response rate (RR) was 60%, and median progression-free survival (PFS) was 9.2 months.","Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29563138/),month,9.2,153534,DB00592,Piperazine
,29563138,PFS,"RR in ALK TKI-naïve patients was 80%, and median PFS was 26.2 months.","Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29563138/),month,26.2,153535,DB00592,Piperazine
,29563138,PFS,"In patients with prior crizotinib only, the RR was 69% and median PFS was 9.0 months.","Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29563138/),month,9,153536,DB00592,Piperazine
,2892445,serum elimination half-life,"The serum elimination half-life values of these agents are variable: a few hours for terfenadine and triprolidine; about 9 hours for cetirizine, azatadine, and loratadine; from 20 to 25 hours for hydroxyzine, chlorpheniramine, and brompheniramine; and from 5 to 14 days for astemizole.",The comparative pharmacokinetics of H1-receptor antagonists. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892445/),h,few,153583,DB00592,Piperazine
,2892445,serum elimination half-life,"The serum elimination half-life values of these agents are variable: a few hours for terfenadine and triprolidine; about 9 hours for cetirizine, azatadine, and loratadine; from 20 to 25 hours for hydroxyzine, chlorpheniramine, and brompheniramine; and from 5 to 14 days for astemizole.",The comparative pharmacokinetics of H1-receptor antagonists. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892445/),h,9,153584,DB00592,Piperazine
,2892445,serum elimination half-life,"The serum elimination half-life values of these agents are variable: a few hours for terfenadine and triprolidine; about 9 hours for cetirizine, azatadine, and loratadine; from 20 to 25 hours for hydroxyzine, chlorpheniramine, and brompheniramine; and from 5 to 14 days for astemizole.",The comparative pharmacokinetics of H1-receptor antagonists. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892445/),h,20 to 25,153585,DB00592,Piperazine
,2892445,serum elimination half-life,"The serum elimination half-life values of these agents are variable: a few hours for terfenadine and triprolidine; about 9 hours for cetirizine, azatadine, and loratadine; from 20 to 25 hours for hydroxyzine, chlorpheniramine, and brompheniramine; and from 5 to 14 days for astemizole.",The comparative pharmacokinetics of H1-receptor antagonists. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892445/),d,5 to 14,153586,DB00592,Piperazine
,2892445,apparent volumes of distribution,"Regardless of the age of patients, for most of the H1-receptor antagonists the apparent volumes of distribution and total body clearances appear to be large (3.4 to 18.5 L/kg and 4.4 to 32.1 mL/min/kg, respectively).",The comparative pharmacokinetics of H1-receptor antagonists. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892445/),[l] / [kg],3.4 to 18.5,153587,DB00592,Piperazine
,2892445,total body clearances,"Regardless of the age of patients, for most of the H1-receptor antagonists the apparent volumes of distribution and total body clearances appear to be large (3.4 to 18.5 L/kg and 4.4 to 32.1 mL/min/kg, respectively).",The comparative pharmacokinetics of H1-receptor antagonists. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892445/),[ml] / [kg·min],4.4 to 32.1,153588,DB00592,Piperazine
,11597545,elimination half-life,The elimination half-life was prolonged (4.7 hours compared with 3 hours in healthy volunteers).,Interactions of sildenafil and tacrolimus in men with erectile dysfunction after kidney transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11597545/),h,4.7,153703,DB00592,Piperazine
,11597545,elimination half-life,The elimination half-life was prolonged (4.7 hours compared with 3 hours in healthy volunteers).,Interactions of sildenafil and tacrolimus in men with erectile dysfunction after kidney transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11597545/),h,3,153704,DB00592,Piperazine
,11597545,half-life,"The area under the concentration-time data for UK was about threefold larger than in healthy volunteers, and the half-life was prolonged from 3.8 hours to 11.4 hours.",Interactions of sildenafil and tacrolimus in men with erectile dysfunction after kidney transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11597545/),h,3.8,153705,DB00592,Piperazine
,11597545,half-life,"The area under the concentration-time data for UK was about threefold larger than in healthy volunteers, and the half-life was prolonged from 3.8 hours to 11.4 hours.",Interactions of sildenafil and tacrolimus in men with erectile dysfunction after kidney transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11597545/),h,11.4,153706,DB00592,Piperazine
,15881813,retention time,The retention time of I.S and sildenafil were 5.5 minutes and 7.2 minutes respectively.,Bioequivalence study of sildenafil citrate tablets in healthy human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15881813/),min,5.5,153718,DB00592,Piperazine
,15881813,retention time,The retention time of I.S and sildenafil were 5.5 minutes and 7.2 minutes respectively.,Bioequivalence study of sildenafil citrate tablets in healthy human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15881813/),min,7.2,153719,DB00592,Piperazine
,15881813,extraction efficiency,The extraction efficiency from plasma varied from 79.69% to 81.13 %.,Bioequivalence study of sildenafil citrate tablets in healthy human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15881813/),%,79.69,153720,DB00592,Piperazine
,15881813,extraction efficiency,The extraction efficiency from plasma varied from 79.69% to 81.13 %.,Bioequivalence study of sildenafil citrate tablets in healthy human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15881813/),%,81.13,153721,DB00592,Piperazine
,15881813,minimum quantifiable concentration,The minimum quantifiable concentration was set at 10 ng/ml.,Bioequivalence study of sildenafil citrate tablets in healthy human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15881813/),[ng] / [ml],10,153722,DB00592,Piperazine
>,8474102,bioavailability,"Both 25 and 32 showed excellent bioavailability in the rat and ferret (> 25%) and, while subject to hepatic elimination in the monkey, were efficacious in this species.","Studies directed toward the design of orally active renin inhibitors. 2. Development of the efficacious, bioavailable renin inhibitor (2S)-2-benzyl-3- [[(1-methylpiperazin-4-yl)sulfonyl]propionyl]-3-thiazol-4-yl-L-alanine amide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane (A-72517). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8474102/),%,25,154225,DB00592,Piperazine
,25136017,time to maximum concentration (Tmax),KAF156 time to maximum concentration (Tmax) was between 1.0 and 6.0 h.,"A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25136017/),h,1.0 and 6.0,154478,DB00592,Piperazine
,25136017,terminal half-life,"Both the area under the concentration-time curve (AUC) and maximum concentration (Cmax) increased more than dose-proportionally in both single- and multiple-ascending-dose cohorts (terminal half-life, 42.5 to 70.7 h).","A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25136017/),h,42.5 to 70.7,154479,DB00592,Piperazine
,25136017,Cmax,"The extent of absorption was not significantly affected by food at a single dose of 400 mg, while mean Cmax decreased from 778 ng/ml to 627 ng/ml and Tmax was delayed from a median of 3.0 h under fasting conditions to 6.0 h under fed conditions.","A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25136017/),[ng] / [ml],778,154480,DB00592,Piperazine
,25136017,Cmax,"The extent of absorption was not significantly affected by food at a single dose of 400 mg, while mean Cmax decreased from 778 ng/ml to 627 ng/ml and Tmax was delayed from a median of 3.0 h under fasting conditions to 6.0 h under fed conditions.","A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25136017/),[ng] / [ml],627,154481,DB00592,Piperazine
,25136017,Tmax,"The extent of absorption was not significantly affected by food at a single dose of 400 mg, while mean Cmax decreased from 778 ng/ml to 627 ng/ml and Tmax was delayed from a median of 3.0 h under fasting conditions to 6.0 h under fed conditions.","A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25136017/),h,3.0,154482,DB00592,Piperazine
,25136017,Tmax,"The extent of absorption was not significantly affected by food at a single dose of 400 mg, while mean Cmax decreased from 778 ng/ml to 627 ng/ml and Tmax was delayed from a median of 3.0 h under fasting conditions to 6.0 h under fed conditions.","A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25136017/),h,6.0,154483,DB00592,Piperazine
,12698499,CL(creat),"Methods- Study 1: Twelve healthy elderly subjects (CL(creat) 72+/-8 ml/min, 72+/-4 years mean+/-SD) and eight young volunteers (CL(creat) 134+/-18 ml/min, 25+/-8 years) received TMZ MR 35 mg b.i.d. (eight doses).",Pharmacokinetic profile of a modified release formulation of trimetazidine (TMZ MR 35 mg) in the elderly and patients with renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12698499/),[ml] / [min],72,155164,DB00592,Piperazine
,12698499,CL(creat),"Methods- Study 1: Twelve healthy elderly subjects (CL(creat) 72+/-8 ml/min, 72+/-4 years mean+/-SD) and eight young volunteers (CL(creat) 134+/-18 ml/min, 25+/-8 years) received TMZ MR 35 mg b.i.d. (eight doses).",Pharmacokinetic profile of a modified release formulation of trimetazidine (TMZ MR 35 mg) in the elderly and patients with renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12698499/),[ml] / [min],134,155165,DB00592,Piperazine
,12698499,CL(c,"Study 2: eight patients with severe renal failure (CL(creat.) 17+/-5 ml/min, 54+/-10 years), five patients with moderate renal failure (CL(creat.) 39+/-6 ml/min, 54+/-15 years) and eight volunteers (CL(creat.) 104+/-17 ml/min, 53+/-9 years) received TMZ MR 35 mg b.i.d. (patients: ten doses, volunteers: eight doses).",Pharmacokinetic profile of a modified release formulation of trimetazidine (TMZ MR 35 mg) in the elderly and patients with renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12698499/),[ml] / [min],17,155166,DB00592,Piperazine
,12698499,CL(,"Study 2: eight patients with severe renal failure (CL(creat.) 17+/-5 ml/min, 54+/-10 years), five patients with moderate renal failure (CL(creat.) 39+/-6 ml/min, 54+/-15 years) and eight volunteers (CL(creat.) 104+/-17 ml/min, 53+/-9 years) received TMZ MR 35 mg b.i.d. (patients: ten doses, volunteers: eight doses).",Pharmacokinetic profile of a modified release formulation of trimetazidine (TMZ MR 35 mg) in the elderly and patients with renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12698499/),m,39,155167,DB00592,Piperazine
,12698499,CL(creat.,"Study 2: eight patients with severe renal failure (CL(creat.) 17+/-5 ml/min, 54+/-10 years), five patients with moderate renal failure (CL(creat.) 39+/-6 ml/min, 54+/-15 years) and eight volunteers (CL(creat.) 104+/-17 ml/min, 53+/-9 years) received TMZ MR 35 mg b.i.d. (patients: ten doses, volunteers: eight doses).",Pharmacokinetic profile of a modified release formulation of trimetazidine (TMZ MR 35 mg) in the elderly and patients with renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12698499/),[ml] / [min],104,155168,DB00592,Piperazine
,10215775,maximum,"The mean concentration of itraconazole in fingernail tips increased steadily from week 4, reached a maximum value at week 24 (213 ng/g), declined sharply between weeks 24 and 36 and returned to baseline by week 48; the mean concentration profile was similar for toenail tips (maximum value 305 ng/g at week 24) but decreased at a slower rate.",Continuous and intermittent itraconazole dosing schedules for the treatment of onychomycosis: a pharmacokinetic comparison. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10215775/),[ng] / [g],305,155257,DB00592,Piperazine
,10215775,maximum mean concentration,"The mean concentration of itraconazole in fingernail tips reached a maximum value at week 12 (524 ng/g) and returned towards baseline by week 48; in contrast, the maximum mean concentration of itraconazole in toenail tips was 698 ng/g at week 36 and did not return to baseline by week 48.",Continuous and intermittent itraconazole dosing schedules for the treatment of onychomycosis: a pharmacokinetic comparison. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10215775/),[ng] / [g],698,155258,DB00592,Piperazine
,32558944,m/z,"Positive ion electrospray was used, and multiple reaction monitoring transitions were m/z 458.2 > 387.2 for ipatasertib and m/z 433.1 > 262.1 for the internal standard.",Pharmacokinetics and bioavailability of ipatasertib in dog plasma using LC/MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32558944/),,458.2,155268,DB00592,Piperazine
,32558944,m/z,"Positive ion electrospray was used, and multiple reaction monitoring transitions were m/z 458.2 > 387.2 for ipatasertib and m/z 433.1 > 262.1 for the internal standard.",Pharmacokinetics and bioavailability of ipatasertib in dog plasma using LC/MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32558944/),,387.2,155269,DB00592,Piperazine
>,32558944,m/z,"Positive ion electrospray was used, and multiple reaction monitoring transitions were m/z 458.2 > 387.2 for ipatasertib and m/z 433.1 > 262.1 for the internal standard.",Pharmacokinetics and bioavailability of ipatasertib in dog plasma using LC/MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32558944/),,433.1,155270,DB00592,Piperazine
>,32558944,m/z,"Positive ion electrospray was used, and multiple reaction monitoring transitions were m/z 458.2 > 387.2 for ipatasertib and m/z 433.1 > 262.1 for the internal standard.",Pharmacokinetics and bioavailability of ipatasertib in dog plasma using LC/MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32558944/),,262.1,155271,DB00592,Piperazine
greater,32558944,extraction recovery,The extraction recovery was demonstrated to be greater than 85.43%.,Pharmacokinetics and bioavailability of ipatasertib in dog plasma using LC/MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32558944/),%,85.43,155272,DB00592,Piperazine
,32558944,bioavailability,The bioavailability of ipatasertib was determined to be 19.3%.,Pharmacokinetics and bioavailability of ipatasertib in dog plasma using LC/MS/MS. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32558944/),%,19.3,155273,DB00592,Piperazine
,8404751,plasma FNR concentration,"After an 8-week baseline period, a single-dose pharmacokinetic study was performed for each patient to calculate a loading dose and maintenance dosage necessary to achieve a target plasma FNR concentration of 30 ng/ml.",Increasing plasma concentration tolerability study of flunarizine in comedicated epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8404751/),[ng] / [ml],30,155293,DB00592,Piperazine
,8328998,Cmax,"Cmax was 275 +/- 36 ng/ml, tmax 3.0 +/- 0.5 h, AUC extrapolated to infinity 4437 +/- 948 ng.h/ml and terminal half-life 23.6 +/- 3.2 h.",Pharmacokinetics of cinnarizine after single and multiple dosing in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8328998/),[ng] / [ml],275,155297,DB00592,Piperazine
,8328998,tmax,"Cmax was 275 +/- 36 ng/ml, tmax 3.0 +/- 0.5 h, AUC extrapolated to infinity 4437 +/- 948 ng.h/ml and terminal half-life 23.6 +/- 3.2 h.",Pharmacokinetics of cinnarizine after single and multiple dosing in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8328998/),h,3.0,155298,DB00592,Piperazine
,8328998,AUC extrapolated to infinity,"Cmax was 275 +/- 36 ng/ml, tmax 3.0 +/- 0.5 h, AUC extrapolated to infinity 4437 +/- 948 ng.h/ml and terminal half-life 23.6 +/- 3.2 h.",Pharmacokinetics of cinnarizine after single and multiple dosing in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8328998/),[h·ng] / [ml],4437,155299,DB00592,Piperazine
,8328998,terminal half-life,"Cmax was 275 +/- 36 ng/ml, tmax 3.0 +/- 0.5 h, AUC extrapolated to infinity 4437 +/- 948 ng.h/ml and terminal half-life 23.6 +/- 3.2 h.",Pharmacokinetics of cinnarizine after single and multiple dosing in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8328998/),h,23.6,155300,DB00592,Piperazine
,8328998,accumulation factor,"At steady state (dose 29), the observed accumulation factor was 2.79 +/- 0.23, being not significantly different from that predicted with the terminal half-life obtained from single dose data, which was 3.37 +/- 0.37.",Pharmacokinetics of cinnarizine after single and multiple dosing in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8328998/),,2.79,155301,DB00592,Piperazine
,8328998,terminal half-life,"At steady state (dose 29), the observed accumulation factor was 2.79 +/- 0.23, being not significantly different from that predicted with the terminal half-life obtained from single dose data, which was 3.37 +/- 0.37.",Pharmacokinetics of cinnarizine after single and multiple dosing in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8328998/),,3.37,155302,DB00592,Piperazine
,8328998,AUC0-12,"AUC0-12 for dose 29 was 5074 +/- 1021 ng.h/ml, being not significantly different from the AUC extrapolated to infinity obtained with the single dose.",Pharmacokinetics of cinnarizine after single and multiple dosing in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8328998/),[h·ng] / [ml],5074,155303,DB00592,Piperazine
,24726707,serum concentration,The mean serum concentration of LPP1 measured 30 min following i.p. administration was 7904.6 ± 1066.1 ng/ml.,Antiallodynic and antihyperalgesic activity of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one compared to pregabalin in chemotherapy-induced neuropathic pain in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24726707/),[ng] / [ml],7904.6,155372,DB00592,Piperazine
,28900995,Concentration,Concentration of IM (CIM) was (1 501.1±646.8) μg/L and concentration of NDI (CNDI) was (221.7±92.5) μg/L.,[Association between genetic polymorphisms and variation of imatinib pharmacokinetics in gastrointestinal stromal tumors]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28900995/),[μg] / [l],1 501.1,155446,DB00592,Piperazine
,28900995,CIM,"The concentration of IM and NDI in patients with TC heterozygote was significantly lower than those with wildtype TT [CIM: (695.4±202.9) μg/L vs. (1 518.9±716.8) μg/L, P=0.002; CNDI:(133.3±59.8) μg/L vs. (244.5±99.1) μg/L, P=0.028].",[Association between genetic polymorphisms and variation of imatinib pharmacokinetics in gastrointestinal stromal tumors]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28900995/),[μg] / [l],695.4,155447,DB00592,Piperazine
,28900995,CIM,"The concentration of IM and NDI in patients with TC heterozygote was significantly lower than those with wildtype TT [CIM: (695.4±202.9) μg/L vs. (1 518.9±716.8) μg/L, P=0.002; CNDI:(133.3±59.8) μg/L vs. (244.5±99.1) μg/L, P=0.028].",[Association between genetic polymorphisms and variation of imatinib pharmacokinetics in gastrointestinal stromal tumors]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28900995/),[μg] / [l],1 518.9,155448,DB00592,Piperazine
,28900995,CNDI,"The concentration of IM and NDI in patients with TC heterozygote was significantly lower than those with wildtype TT [CIM: (695.4±202.9) μg/L vs. (1 518.9±716.8) μg/L, P=0.002; CNDI:(133.3±59.8) μg/L vs. (244.5±99.1) μg/L, P=0.028].",[Association between genetic polymorphisms and variation of imatinib pharmacokinetics in gastrointestinal stromal tumors]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28900995/),[μg] / [l],133.3,155449,DB00592,Piperazine
,28900995,CNDI,"The concentration of IM and NDI in patients with TC heterozygote was significantly lower than those with wildtype TT [CIM: (695.4±202.9) μg/L vs. (1 518.9±716.8) μg/L, P=0.002; CNDI:(133.3±59.8) μg/L vs. (244.5±99.1) μg/L, P=0.028].",[Association between genetic polymorphisms and variation of imatinib pharmacokinetics in gastrointestinal stromal tumors]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28900995/),[μg] / [l],244.5,155450,DB00592,Piperazine
,9303409,areas under the concentration-time curve (AUC),"The mean areas under the concentration-time curve (AUC) were 152.2 microg x h/ml (standard deviation [SD], 22.5) and 129.2 microg x h/ml (SD, 41.2) and the terminal half-lives were 1.1 h (SD, 0.3) and 0.9 h (SD, 0.2) when ceftriaxone was given alone and combined with itraconazole, respectively.",Pharmacokinetic interaction between itraconazole and ceftriaxone in Yucatan miniature pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9303409/),[h·μg] / [ml],152.2,155451,DB00592,Piperazine
,9303409,areas under the concentration-time curve (AUC),"The mean areas under the concentration-time curve (AUC) were 152.2 microg x h/ml (standard deviation [SD], 22.5) and 129.2 microg x h/ml (SD, 41.2) and the terminal half-lives were 1.1 h (SD, 0.3) and 0.9 h (SD, 0.2) when ceftriaxone was given alone and combined with itraconazole, respectively.",Pharmacokinetic interaction between itraconazole and ceftriaxone in Yucatan miniature pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9303409/),[h·μg] / [ml],129.2,155452,DB00592,Piperazine
,9303409,terminal half-lives,"The mean areas under the concentration-time curve (AUC) were 152.2 microg x h/ml (standard deviation [SD], 22.5) and 129.2 microg x h/ml (SD, 41.2) and the terminal half-lives were 1.1 h (SD, 0.3) and 0.9 h (SD, 0.2) when ceftriaxone was given alone and combined with itraconazole, respectively.",Pharmacokinetic interaction between itraconazole and ceftriaxone in Yucatan miniature pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9303409/),h,1.1,155453,DB00592,Piperazine
,9303409,terminal half-lives,"The mean areas under the concentration-time curve (AUC) were 152.2 microg x h/ml (standard deviation [SD], 22.5) and 129.2 microg x h/ml (SD, 41.2) and the terminal half-lives were 1.1 h (SD, 0.3) and 0.9 h (SD, 0.2) when ceftriaxone was given alone and combined with itraconazole, respectively.",Pharmacokinetic interaction between itraconazole and ceftriaxone in Yucatan miniature pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9303409/),h,0.9,155454,DB00592,Piperazine
,9303409,AUC (from 0 to 8 h),"Contrary to what was expected, the AUC (from 0 to 8 h) decreased from 139.3 ng h/ml with itraconazole alone to 122.7 ng h/ml with itraconazole and ceftriaxone combined in pig 1, from 398.5 to 315.7 ng x h/ml in pig 2, and from 979.6 to 716.6 ng x h/ml in pig 3 (P of <0.01 by analysis of variance).",Pharmacokinetic interaction between itraconazole and ceftriaxone in Yucatan miniature pigs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9303409/),[h·ng] / [ml],139.3,155455,DB00592,Piperazine
,9303409,AUC (from 0 to 8 h),"Contrary to what was expected, the AUC (from 0 to 8 h) decreased from 139.3 ng h/ml with itraconazole alone to 122.7 ng h/ml with itraconazole and ceftriaxone combined in pig 1, from 398.5 to 315.7 ng x h/ml in pig 2, and from 979.6 to 716.6 ng x h/ml in pig 3 (P of <0.01 by analysis of variance).",Pharmacokinetic interaction between itraconazole and ceftriaxone in Yucatan miniature pigs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9303409/),[h·ng] / [ml],122.7,155456,DB00592,Piperazine
,9303409,AUC (from 0 to 8 h),"Contrary to what was expected, the AUC (from 0 to 8 h) decreased from 139.3 ng h/ml with itraconazole alone to 122.7 ng h/ml with itraconazole and ceftriaxone combined in pig 1, from 398.5 to 315.7 ng x h/ml in pig 2, and from 979.6 to 716.6 ng x h/ml in pig 3 (P of <0.01 by analysis of variance).",Pharmacokinetic interaction between itraconazole and ceftriaxone in Yucatan miniature pigs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9303409/),[h·ng] / [ml],398.5 to 315.7,155457,DB00592,Piperazine
,9303409,AUC (from 0 to 8 h),"Contrary to what was expected, the AUC (from 0 to 8 h) decreased from 139.3 ng h/ml with itraconazole alone to 122.7 ng h/ml with itraconazole and ceftriaxone combined in pig 1, from 398.5 to 315.7 ng x h/ml in pig 2, and from 979.6 to 716.6 ng x h/ml in pig 3 (P of <0.01 by analysis of variance).",Pharmacokinetic interaction between itraconazole and ceftriaxone in Yucatan miniature pigs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9303409/),[h·ng] / [ml],979.6 to 716.6,155458,DB00592,Piperazine
,11762559,trough plasma concentrations,"After intravenous dosing, mean trough plasma concentrations of itraconazole and hydroxyitraconazole were 906 ng/ml and 1,690 ng/ml, respectively.",Pharmacokinetics of intravenous itraconazole followed by itraconazole oral solution in patients with human immunodeficiency virus infection. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11762559/),[ng] / [ml],906,155520,DB00592,Piperazine
,11762559,trough plasma concentrations,"After intravenous dosing, mean trough plasma concentrations of itraconazole and hydroxyitraconazole were 906 ng/ml and 1,690 ng/ml, respectively.",Pharmacokinetics of intravenous itraconazole followed by itraconazole oral solution in patients with human immunodeficiency virus infection. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11762559/),[ng] / [ml],"1,690",155521,DB00592,Piperazine
over,11762559,steady-state trough concentration,"In conclusion, itraconazole 200 mg given intravenously twice daily for 2 days, then once daily for 5 days, rapidly achieves amean steady-state trough concentration of itraconazole of over 250 ng/ml, which is associated with clinic outcome and is effectively maintained with itraconazole oral solution 200 mg twice daily in patients with advanced HIV infection.",Pharmacokinetics of intravenous itraconazole followed by itraconazole oral solution in patients with human immunodeficiency virus infection. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11762559/),[ng] / [ml],250,155522,DB00592,Piperazine
,22985658,AFT,"Before drug administration, LCx coronary artery stenosis lowered AFT from 25.2 ± 1.7 mA control (mean ± SEM) to 4.9 ± 1.0 mA baseline (P<.01).",Low doses of ranolazine and dronedarone in combination exert potent protection against atrial fibrillation and vulnerability to ventricular arrhythmias during acute myocardial ischemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22985658/),m,25.2,155719,DB00592,Piperazine
,22985658,AFT,"Before drug administration, LCx coronary artery stenosis lowered AFT from 25.2 ± 1.7 mA control (mean ± SEM) to 4.9 ± 1.0 mA baseline (P<.01).",Low doses of ranolazine and dronedarone in combination exert potent protection against atrial fibrillation and vulnerability to ventricular arrhythmias during acute myocardial ischemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22985658/),m,4.,155720,DB00592,Piperazine
,6141198,maximum serum hydroxyzine concentration,"After a single oral dose of hydroxyzine, 0.7 mg/kg (mean dose 39.0 +/- 5.4 mg), the mean maximum serum hydroxyzine concentration of 72.5 +/- 11.1 ng/ml occurred at a mean time of 2.1 +/- 0.4 hr.",The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6141198/),[ng] / [ml],72.5,156167,DB00592,Piperazine
,6141198,mean time,"After a single oral dose of hydroxyzine, 0.7 mg/kg (mean dose 39.0 +/- 5.4 mg), the mean maximum serum hydroxyzine concentration of 72.5 +/- 11.1 ng/ml occurred at a mean time of 2.1 +/- 0.4 hr.",The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6141198/),h,2.1,156168,DB00592,Piperazine
,6141198,elimination half-life,The mean elimination half-life calculated from the terminal linear portion of the serum hydroxyzine concentration vs. time curve was 20.0 +/- 4.1 hr.,The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6141198/),h,20.0,156169,DB00592,Piperazine
,6141198,clearance rate,The mean clearance rate was 9.78 +/- 3.25 ml/min/kg and the mean volume of distribution was 16.0 +/- 3.0 L/kg.,The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6141198/),[ml] / [kg·min],9.78,156170,DB00592,Piperazine
,6141198,volume of distribution,The mean clearance rate was 9.78 +/- 3.25 ml/min/kg and the mean volume of distribution was 16.0 +/- 3.0 L/kg.,The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6141198/),[l] / [kg],16.0,156171,DB00592,Piperazine
,2043170,terminal half-life,The terminal half-life is 7.3 +/- 3.3 days.,"[Pharmacokinetics and pharmacodynamics of flunarizine in multimorbid, geriatric patients with vertigo]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2043170/),d,7.3,156196,DB00592,Piperazine
,34240467,concentration ratios,Median tissue- and fluid-to-plasma cabotegravir concentration ratios across all visits were 0.32 for rectal fluid and 0.08-0.16 for other tissues and fluids.,Multicompartmental pharmacokinetic evaluation of long-acting cabotegravir in healthy adults for HIV preexposure prophylaxis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34240467/),,0.32,156731,DB00592,Piperazine
,34240467,concentration ratios,Median tissue- and fluid-to-plasma cabotegravir concentration ratios across all visits were 0.32 for rectal fluid and 0.08-0.16 for other tissues and fluids.,Multicompartmental pharmacokinetic evaluation of long-acting cabotegravir in healthy adults for HIV preexposure prophylaxis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34240467/),,0.08-0.16,156732,DB00592,Piperazine
,29560718,limits of detection,"The limits of detection were 0.025 and 0.020 ng/mL for oleanolic acid and ursolic acid, respectively.",Simultaneous Determination of Oleanolic Acid and Ursolic Acid by in Vivo Microdialysis via UHPLC-MS/MS Using Magnetic Dispersive Solid Phase Extraction Coupling with Microwave-Assisted Derivatization and Its Application to a Pharmacokinetic Study of Arctiumlappa L. Root Extract in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29560718/),[ng] / [ml],0.025,156859,DB00592,Piperazine
,29560718,limits of detection,"The limits of detection were 0.025 and 0.020 ng/mL for oleanolic acid and ursolic acid, respectively.",Simultaneous Determination of Oleanolic Acid and Ursolic Acid by in Vivo Microdialysis via UHPLC-MS/MS Using Magnetic Dispersive Solid Phase Extraction Coupling with Microwave-Assisted Derivatization and Its Application to a Pharmacokinetic Study of Arctiumlappa L. Root Extract in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29560718/),[ng] / [ml],0.020,156860,DB00592,Piperazine
,21507153,K(i-High),"In vitro receptor binding assays suggest that YQA14 has two binding sites on human cloned D3 receptors with K(i-High) (0.68 × 10(-4) nM) and K(i-Low) (2.11 nM), and displays > 150-fold selectivity for D3 over D2 receptors and > 1000-fold selectivity for D3 over other DA receptors.","YQA14: a novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor-knockout mice. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21507153/),nM,0.68 × 10(-4),157373,DB00592,Piperazine
,21507153,K(i-Low),"In vitro receptor binding assays suggest that YQA14 has two binding sites on human cloned D3 receptors with K(i-High) (0.68 × 10(-4) nM) and K(i-Low) (2.11 nM), and displays > 150-fold selectivity for D3 over D2 receptors and > 1000-fold selectivity for D3 over other DA receptors.","YQA14: a novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor-knockout mice. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21507153/),nM,2.11,157374,DB00592,Piperazine
,3689626,terminal elimination half-life,4. Peak plasma levels were attained at 1-2 h and the terminal elimination half-life was approximately 15 h.,"The effect of a new inotropic agent, DPI 201-106, on systolic time intervals and the electrocardiogram in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689626/),h,15,157479,DB00592,Piperazine
,26525043,oral clearance (CL/F),Mean estimates for oral clearance (CL/F) and volume of distribution for the central compartment of vortioxetine were 42 L/hr and 2920 L.,A Population Pharmacokinetic-Pharmacodynamic Meta-Analysis of Vortioxetine in Patients with Major Depressive Disorder. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26525043/),[l] / [h],42,157502,DB00592,Piperazine
,26525043,volume of distribution,Mean estimates for oral clearance (CL/F) and volume of distribution for the central compartment of vortioxetine were 42 L/hr and 2920 L.,A Population Pharmacokinetic-Pharmacodynamic Meta-Analysis of Vortioxetine in Patients with Major Depressive Disorder. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26525043/),[l] / [h],42,157503,DB00592,Piperazine
,26525043,volume of distribution,Mean estimates for oral clearance (CL/F) and volume of distribution for the central compartment of vortioxetine were 42 L/hr and 2920 L.,A Population Pharmacokinetic-Pharmacodynamic Meta-Analysis of Vortioxetine in Patients with Major Depressive Disorder. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26525043/),l,2920,157504,DB00592,Piperazine
,26525043,Half-maximal effective concentration (EC50),An Emax model best described the relationship between ΔMADRS and Cav. Half-maximal effective concentration (EC50) and Emax estimates were 24.9 ng/mL and 7.0.,A Population Pharmacokinetic-Pharmacodynamic Meta-Analysis of Vortioxetine in Patients with Major Depressive Disorder. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26525043/),[ng] / [ml],24.9,157505,DB00592,Piperazine
,26525043,Emax,An Emax model best described the relationship between ΔMADRS and Cav. Half-maximal effective concentration (EC50) and Emax estimates were 24.9 ng/mL and 7.0.,A Population Pharmacokinetic-Pharmacodynamic Meta-Analysis of Vortioxetine in Patients with Major Depressive Disorder. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26525043/),,7.0,157506,DB00592,Piperazine
,3608351,volume of distribution (Varea),"Among men, trazodone volume of distribution (Varea) was increased in elderly vs. young subjects (1.15 vs. 0.89 L/kg; P less than 0.05), and clearance decreased (1.65 vs. 2.31 ml/min/kg; P less than 0.05), thereby increasing elimination half-life (t1/2) in elderly men (8.2 vs. 4.7 hours; P less than 0.001).","Trazodone kinetics: effect of age, gender, and obesity. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),[l] / [kg],1.15,157633,DB00592,Piperazine
,3608351,volume of distribution (Varea),"Among men, trazodone volume of distribution (Varea) was increased in elderly vs. young subjects (1.15 vs. 0.89 L/kg; P less than 0.05), and clearance decreased (1.65 vs. 2.31 ml/min/kg; P less than 0.05), thereby increasing elimination half-life (t1/2) in elderly men (8.2 vs. 4.7 hours; P less than 0.001).","Trazodone kinetics: effect of age, gender, and obesity. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),[l] / [kg],0.89,157634,DB00592,Piperazine
,3608351,clearance,"Among men, trazodone volume of distribution (Varea) was increased in elderly vs. young subjects (1.15 vs. 0.89 L/kg; P less than 0.05), and clearance decreased (1.65 vs. 2.31 ml/min/kg; P less than 0.05), thereby increasing elimination half-life (t1/2) in elderly men (8.2 vs. 4.7 hours; P less than 0.001).","Trazodone kinetics: effect of age, gender, and obesity. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),[ml] / [kg·min],1.65,157635,DB00592,Piperazine
,3608351,clearance,"Among men, trazodone volume of distribution (Varea) was increased in elderly vs. young subjects (1.15 vs. 0.89 L/kg; P less than 0.05), and clearance decreased (1.65 vs. 2.31 ml/min/kg; P less than 0.05), thereby increasing elimination half-life (t1/2) in elderly men (8.2 vs. 4.7 hours; P less than 0.001).","Trazodone kinetics: effect of age, gender, and obesity. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),[ml] / [kg·min],2.31,157636,DB00592,Piperazine
,3608351,elimination half-life (t1/2),"Among men, trazodone volume of distribution (Varea) was increased in elderly vs. young subjects (1.15 vs. 0.89 L/kg; P less than 0.05), and clearance decreased (1.65 vs. 2.31 ml/min/kg; P less than 0.05), thereby increasing elimination half-life (t1/2) in elderly men (8.2 vs. 4.7 hours; P less than 0.001).","Trazodone kinetics: effect of age, gender, and obesity. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),h,8.2,157637,DB00592,Piperazine
,3608351,elimination half-life (t1/2),"Among men, trazodone volume of distribution (Varea) was increased in elderly vs. young subjects (1.15 vs. 0.89 L/kg; P less than 0.05), and clearance decreased (1.65 vs. 2.31 ml/min/kg; P less than 0.05), thereby increasing elimination half-life (t1/2) in elderly men (8.2 vs. 4.7 hours; P less than 0.001).","Trazodone kinetics: effect of age, gender, and obesity. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),h,4.7,157638,DB00592,Piperazine
,3608351,Varea,"Varea in women was also increased in the elderly (1.5 vs. 1.27 L/kg; P less than 0.02), causing increased t1/2 (7.6 vs. 5.9 hours; P less than 0.05), but clearance was unrelated to age.","Trazodone kinetics: effect of age, gender, and obesity. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),[l] / [kg],1.5,157639,DB00592,Piperazine
,3608351,Varea,"Varea in women was also increased in the elderly (1.5 vs. 1.27 L/kg; P less than 0.02), causing increased t1/2 (7.6 vs. 5.9 hours; P less than 0.05), but clearance was unrelated to age.","Trazodone kinetics: effect of age, gender, and obesity. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),[l] / [kg],1.27,157640,DB00592,Piperazine
,3608351,t1/2,"Varea in women was also increased in the elderly (1.5 vs. 1.27 L/kg; P less than 0.02), causing increased t1/2 (7.6 vs. 5.9 hours; P less than 0.05), but clearance was unrelated to age.","Trazodone kinetics: effect of age, gender, and obesity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),h,7.6,157641,DB00592,Piperazine
,3608351,t1/2,"Varea in women was also increased in the elderly (1.5 vs. 1.27 L/kg; P less than 0.02), causing increased t1/2 (7.6 vs. 5.9 hours; P less than 0.05), but clearance was unrelated to age.","Trazodone kinetics: effect of age, gender, and obesity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),h,5.9,157642,DB00592,Piperazine
,3608351,Absolute bioavailability,Absolute bioavailability of oral trazodone averaged 70% to 90% and was unrelated to age or sex.,"Trazodone kinetics: effect of age, gender, and obesity. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),%,70,157643,DB00592,Piperazine
,3608351,Absolute bioavailability,Absolute bioavailability of oral trazodone averaged 70% to 90% and was unrelated to age or sex.,"Trazodone kinetics: effect of age, gender, and obesity. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),%,90,157644,DB00592,Piperazine
,3608351,Varea,"In 23 obese subjects (mean weight 112 kg) vs. 23 matched control subjects of normal weight (mean 65 kg), Varea was greatly increased (162 vs. 67 L; 1.43 vs. 1.04 L/kg; P less than 0.001) and was highly correlated with body weight (r = 0.91).","Trazodone kinetics: effect of age, gender, and obesity. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),l,162,157645,DB00592,Piperazine
,3608351,Varea,"In 23 obese subjects (mean weight 112 kg) vs. 23 matched control subjects of normal weight (mean 65 kg), Varea was greatly increased (162 vs. 67 L; 1.43 vs. 1.04 L/kg; P less than 0.001) and was highly correlated with body weight (r = 0.91).","Trazodone kinetics: effect of age, gender, and obesity. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),l,67,157646,DB00592,Piperazine
,3608351,Varea,"In 23 obese subjects (mean weight 112 kg) vs. 23 matched control subjects of normal weight (mean 65 kg), Varea was greatly increased (162 vs. 67 L; 1.43 vs. 1.04 L/kg; P less than 0.001) and was highly correlated with body weight (r = 0.91).","Trazodone kinetics: effect of age, gender, and obesity. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),[l] / [kg],1.43,157647,DB00592,Piperazine
,3608351,Varea,"In 23 obese subjects (mean weight 112 kg) vs. 23 matched control subjects of normal weight (mean 65 kg), Varea was greatly increased (162 vs. 67 L; 1.43 vs. 1.04 L/kg; P less than 0.001) and was highly correlated with body weight (r = 0.91).","Trazodone kinetics: effect of age, gender, and obesity. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),[l] / [kg],1.04,157648,DB00592,Piperazine
,3608351,Clearance,"Clearance was unchanged between groups (146 vs. 136 ml/min), but the increased Varea caused prolonged t1/2 in obese subjects (13.3 vs. 5.9 hours; P less than 0.001).","Trazodone kinetics: effect of age, gender, and obesity. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),[ml] / [min],146,157649,DB00592,Piperazine
,3608351,Clearance,"Clearance was unchanged between groups (146 vs. 136 ml/min), but the increased Varea caused prolonged t1/2 in obese subjects (13.3 vs. 5.9 hours; P less than 0.001).","Trazodone kinetics: effect of age, gender, and obesity. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),[ml] / [min],136,157650,DB00592,Piperazine
,3608351,t1/2,"Clearance was unchanged between groups (146 vs. 136 ml/min), but the increased Varea caused prolonged t1/2 in obese subjects (13.3 vs. 5.9 hours; P less than 0.001).","Trazodone kinetics: effect of age, gender, and obesity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),h,13.3,157651,DB00592,Piperazine
,3608351,t1/2,"Clearance was unchanged between groups (146 vs. 136 ml/min), but the increased Varea caused prolonged t1/2 in obese subjects (13.3 vs. 5.9 hours; P less than 0.001).","Trazodone kinetics: effect of age, gender, and obesity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),h,5.9,157652,DB00592,Piperazine
,27226351,total radioactivity recovery,"At 84 days postdose, mean total radioactivity recovery was 14.2% and 67.8% of the dose in urine and feces.","Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27226351/),%,14.2,158091,DB00592,Piperazine
,27226351,total radioactivity recovery,"At 84 days postdose, mean total radioactivity recovery was 14.2% and 67.8% of the dose in urine and feces.","Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27226351/),%,67.8,158092,DB00592,Piperazine
,17522570,maximum tolerated,"The median maximum tolerated NTG dose (range) was 80 (0-160) microg/min for sildenafil vs. 160 (20-160) microg/min for placebo (adjusted mean +/- se, 77 +/- 7 vs. 127 +/- 7; p < .0001; analysis of variance), and NTG 160 microg/min was tolerated by eight (25%) and 19 (59%) men, respectively (p = .0008).","Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17522570/),[μg] / [min],80,158142,DB00592,Piperazine
,17522570,maximum tolerated,"The median maximum tolerated NTG dose (range) was 80 (0-160) microg/min for sildenafil vs. 160 (20-160) microg/min for placebo (adjusted mean +/- se, 77 +/- 7 vs. 127 +/- 7; p < .0001; analysis of variance), and NTG 160 microg/min was tolerated by eight (25%) and 19 (59%) men, respectively (p = .0008).","Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17522570/),[μg] / [min],160,158143,DB00592,Piperazine
,17522570,maximum tolerated,"The median maximum tolerated NTG dose (range) was 80 (0-160) microg/min for sildenafil vs. 160 (20-160) microg/min for placebo (adjusted mean +/- se, 77 +/- 7 vs. 127 +/- 7; p < .0001; analysis of variance), and NTG 160 microg/min was tolerated by eight (25%) and 19 (59%) men, respectively (p = .0008).","Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17522570/),,77,158144,DB00592,Piperazine
,17522570,maximum tolerated,"The median maximum tolerated NTG dose (range) was 80 (0-160) microg/min for sildenafil vs. 160 (20-160) microg/min for placebo (adjusted mean +/- se, 77 +/- 7 vs. 127 +/- 7; p < .0001; analysis of variance), and NTG 160 microg/min was tolerated by eight (25%) and 19 (59%) men, respectively (p = .0008).","Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17522570/),,127,158145,DB00592,Piperazine
,1725018,concentrations,"The highest concentrations in bile were found for diketopiperazine acid (3,080 ng/ml) and ramipril glucuronide (2,414 ng/ml).",Preliminary results of biliary excretion of ramipril after T-drainage in cholecystectomy patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1725018/),[ng] / [ml],"3,080",158198,DB00592,Piperazine
,1725018,concentrations,"The highest concentrations in bile were found for diketopiperazine acid (3,080 ng/ml) and ramipril glucuronide (2,414 ng/ml).",Preliminary results of biliary excretion of ramipril after T-drainage in cholecystectomy patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1725018/),[ng] / [ml],"2,414",158199,DB00592,Piperazine
greater,20595406,steady-state trough plasma itraconazole concentration,A steady-state trough plasma itraconazole concentration greater than 500 ng/mL is a therapeutic target for itraconazole.,"A simple, sensitive high-performance liquid chromatography -ultraviolet method for the quantification of concentration and steady-state pharmacokinetics of itraconazole and hydroxyitraconazole. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595406/),[ng] / [ml],500,158252,DB00592,Piperazine
,20595406,flow rate,"Itraconazole and hydroxyitraconazole were separated using a mobile phase of 0.5% KH2PO4 (pH 6.0)-acetonitrile (30:70, v/v) on a CAPCELLPAK C18 MGII column at a flow rate of 0.5 mL/min and ultraviolet absorbance at 260 nm.","A simple, sensitive high-performance liquid chromatography -ultraviolet method for the quantification of concentration and steady-state pharmacokinetics of itraconazole and hydroxyitraconazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595406/),[ml] / [min],0.5,158253,DB00592,Piperazine
,20595406,recoveries,"The analysis required 200 microL of plasma and involved a rapid, simple solid-phase extraction with an Oasis HLB cartridge, which resulted in recoveries of 87-92% for itraconazole and 91-94% for hydroxyitraconazole.","A simple, sensitive high-performance liquid chromatography -ultraviolet method for the quantification of concentration and steady-state pharmacokinetics of itraconazole and hydroxyitraconazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595406/),%,87-92,158254,DB00592,Piperazine
,20595406,recoveries,"The analysis required 200 microL of plasma and involved a rapid, simple solid-phase extraction with an Oasis HLB cartridge, which resulted in recoveries of 87-92% for itraconazole and 91-94% for hydroxyitraconazole.","A simple, sensitive high-performance liquid chromatography -ultraviolet method for the quantification of concentration and steady-state pharmacokinetics of itraconazole and hydroxyitraconazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595406/),%,91-94,158255,DB00592,Piperazine
,20595406,steady-state plasma concentrations,"Although the steady-state plasma concentrations of itraconazole and hydroxyitraconazole ranged from 506 to 2482 ng/mL and from 766 to 2444 ng/mL, respectively, after a two-day loading dose of 400 mg/day intravenous itraconazole followed by the administration of 200 mg/day itraconazole oral solution, calibration curves of itraconazole and hydroxyitraconazole showed positive linearity in a concentration range of 5-2500 and 50-2500 ng/mL, respectively.","A simple, sensitive high-performance liquid chromatography -ultraviolet method for the quantification of concentration and steady-state pharmacokinetics of itraconazole and hydroxyitraconazole. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595406/),[ng] / [ml],506 to 2482,158256,DB00592,Piperazine
,20595406,steady-state plasma concentrations,"Although the steady-state plasma concentrations of itraconazole and hydroxyitraconazole ranged from 506 to 2482 ng/mL and from 766 to 2444 ng/mL, respectively, after a two-day loading dose of 400 mg/day intravenous itraconazole followed by the administration of 200 mg/day itraconazole oral solution, calibration curves of itraconazole and hydroxyitraconazole showed positive linearity in a concentration range of 5-2500 and 50-2500 ng/mL, respectively.","A simple, sensitive high-performance liquid chromatography -ultraviolet method for the quantification of concentration and steady-state pharmacokinetics of itraconazole and hydroxyitraconazole. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595406/),[ng] / [ml],766 to 2444,158257,DB00592,Piperazine
,32463593,Relative bioavailability,"Relative bioavailability of sildenafil citrate ODT administered with water to the sildenafil citrate tablet (50 mg) administered with water was 97.10%, 91.43%, and 97.09% with respect to sildenafil AUClast , Cmax , and AUCinf , respectively (90%CI, 91.43%-03.12%, 82.25%-101.65%, and 90.90%-103.71%, respectively).",Bioequivalence and Bioavailability of an Orodispersible Tablet of Sildenafil Citrate in Healthy Chinese Male Subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463593/),%,97.10,158516,DB00592,Piperazine
,32463593,Relative bioavailability,"Relative bioavailability of sildenafil citrate ODT administered with water to the sildenafil citrate tablet (50 mg) administered with water was 97.10%, 91.43%, and 97.09% with respect to sildenafil AUClast , Cmax , and AUCinf , respectively (90%CI, 91.43%-03.12%, 82.25%-101.65%, and 90.90%-103.71%, respectively).",Bioequivalence and Bioavailability of an Orodispersible Tablet of Sildenafil Citrate in Healthy Chinese Male Subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463593/),%,91.43,158517,DB00592,Piperazine
,32463593,Relative bioavailability,"Relative bioavailability of sildenafil citrate ODT administered with water to the sildenafil citrate tablet (50 mg) administered with water was 97.10%, 91.43%, and 97.09% with respect to sildenafil AUClast , Cmax , and AUCinf , respectively (90%CI, 91.43%-03.12%, 82.25%-101.65%, and 90.90%-103.71%, respectively).",Bioequivalence and Bioavailability of an Orodispersible Tablet of Sildenafil Citrate in Healthy Chinese Male Subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463593/),%,97.09,158518,DB00592,Piperazine
,32463593,Relative bioavailability,"Relative bioavailability of sildenafil citrate ODT administered with water to the sildenafil citrate tablet (50 mg) administered with water was 97.10%, 91.43%, and 97.09% with respect to sildenafil AUClast , Cmax , and AUCinf , respectively (90%CI, 91.43%-03.12%, 82.25%-101.65%, and 90.90%-103.71%, respectively).",Bioequivalence and Bioavailability of an Orodispersible Tablet of Sildenafil Citrate in Healthy Chinese Male Subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463593/),%,91.43,158519,DB00592,Piperazine
,32463593,Relative bioavailability,"Relative bioavailability of sildenafil citrate ODT administered with water to the sildenafil citrate tablet (50 mg) administered with water was 97.10%, 91.43%, and 97.09% with respect to sildenafil AUClast , Cmax , and AUCinf , respectively (90%CI, 91.43%-03.12%, 82.25%-101.65%, and 90.90%-103.71%, respectively).",Bioequivalence and Bioavailability of an Orodispersible Tablet of Sildenafil Citrate in Healthy Chinese Male Subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463593/),%,03,158520,DB00592,Piperazine
,32463593,Relative bioavailability,"Relative bioavailability of sildenafil citrate ODT administered with water to the sildenafil citrate tablet (50 mg) administered with water was 97.10%, 91.43%, and 97.09% with respect to sildenafil AUClast , Cmax , and AUCinf , respectively (90%CI, 91.43%-03.12%, 82.25%-101.65%, and 90.90%-103.71%, respectively).",Bioequivalence and Bioavailability of an Orodispersible Tablet of Sildenafil Citrate in Healthy Chinese Male Subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463593/),%,82.25,158521,DB00592,Piperazine
,32463593,Relative bioavailability,"Relative bioavailability of sildenafil citrate ODT administered with water to the sildenafil citrate tablet (50 mg) administered with water was 97.10%, 91.43%, and 97.09% with respect to sildenafil AUClast , Cmax , and AUCinf , respectively (90%CI, 91.43%-03.12%, 82.25%-101.65%, and 90.90%-103.71%, respectively).",Bioequivalence and Bioavailability of an Orodispersible Tablet of Sildenafil Citrate in Healthy Chinese Male Subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463593/),%,101,158522,DB00592,Piperazine
,32463593,Relative bioavailability,"Relative bioavailability of sildenafil citrate ODT administered with water to the sildenafil citrate tablet (50 mg) administered with water was 97.10%, 91.43%, and 97.09% with respect to sildenafil AUClast , Cmax , and AUCinf , respectively (90%CI, 91.43%-03.12%, 82.25%-101.65%, and 90.90%-103.71%, respectively).",Bioequivalence and Bioavailability of an Orodispersible Tablet of Sildenafil Citrate in Healthy Chinese Male Subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463593/),%,90.90,158523,DB00592,Piperazine
,32463593,Relative bioavailability,"Relative bioavailability of sildenafil citrate ODT administered with water to the sildenafil citrate tablet (50 mg) administered with water was 97.10%, 91.43%, and 97.09% with respect to sildenafil AUClast , Cmax , and AUCinf , respectively (90%CI, 91.43%-03.12%, 82.25%-101.65%, and 90.90%-103.71%, respectively).",Bioequivalence and Bioavailability of an Orodispersible Tablet of Sildenafil Citrate in Healthy Chinese Male Subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463593/),%,103.71,158524,DB00592,Piperazine
,14520518,wheal area,"Following placebo administration, the mean (+/- SEM) wheal area at 10 min was 79.3 +/- 6.9 mm(2), mean flare area for the first 5 min following challenge 26.6 +/- 2.7 cm(2), and itch score for the same period 48.5 +/- 7.6%.","Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520518/),mm(2),79.3,158644,DB00592,Piperazine
,14520518,flare area,"Following placebo administration, the mean (+/- SEM) wheal area at 10 min was 79.3 +/- 6.9 mm(2), mean flare area for the first 5 min following challenge 26.6 +/- 2.7 cm(2), and itch score for the same period 48.5 +/- 7.6%.","Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520518/),cm(2),26.6,158645,DB00592,Piperazine
,31002950,C24h,"Median C24h of DTG 50 mg + RIF and DTG 100 mg + RIF were 251 (range 129-706) ng/mL and 140 (range 73-426) ng/mL, respectively.",Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31002950/),[ng] / [ml],251,158702,DB00592,Piperazine
,31002950,C24h,"Median C24h of DTG 50 mg + RIF and DTG 100 mg + RIF were 251 (range 129-706) ng/mL and 140 (range 73-426) ng/mL, respectively.",Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31002950/),[ng] / [ml],140,158703,DB00592,Piperazine
,31002950,IC90,"Although there were substantial reductions in DTG C24h when co-administered with RIF, concentrations of both DTG 50 mg and 100 mg once daily with RIF were still above the protein-binding-adjusted IC90 (drug concentration required to inhibit 90% of in-vitro viral replication) of 64 ng/mL.",Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31002950/),[ng] / [ml],64,158704,DB00592,Piperazine
,1976829,T1/2 alpha,"With pipecuronium, following pharmacokinetic parameters were obtained; distribution half-life; T1/2 alpha = 3.9 +/- 0.7 min (mean +/- SEM), elimination half-life; T1/2 beta = 102 +/- 12 min, volume of the central compartment; V1 = 95 +/- 13 ml.kg-1, volume of distribution at steady state; Vdss = 264 +/- 41 ml.kg-1, clearance; Cl = 1.8 +/- 0.2 ml.min-1.kg-1.","[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),min,3.9,158846,DB00592,Piperazine
,1976829,T1/2 beta,"With pipecuronium, following pharmacokinetic parameters were obtained; distribution half-life; T1/2 alpha = 3.9 +/- 0.7 min (mean +/- SEM), elimination half-life; T1/2 beta = 102 +/- 12 min, volume of the central compartment; V1 = 95 +/- 13 ml.kg-1, volume of distribution at steady state; Vdss = 264 +/- 41 ml.kg-1, clearance; Cl = 1.8 +/- 0.2 ml.min-1.kg-1.","[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),min,102,158847,DB00592,Piperazine
,1976829,V1,"With pipecuronium, following pharmacokinetic parameters were obtained; distribution half-life; T1/2 alpha = 3.9 +/- 0.7 min (mean +/- SEM), elimination half-life; T1/2 beta = 102 +/- 12 min, volume of the central compartment; V1 = 95 +/- 13 ml.kg-1, volume of distribution at steady state; Vdss = 264 +/- 41 ml.kg-1, clearance; Cl = 1.8 +/- 0.2 ml.min-1.kg-1.","[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),[ml] / [kg],95,158848,DB00592,Piperazine
,1976829,Vdss,"With pipecuronium, following pharmacokinetic parameters were obtained; distribution half-life; T1/2 alpha = 3.9 +/- 0.7 min (mean +/- SEM), elimination half-life; T1/2 beta = 102 +/- 12 min, volume of the central compartment; V1 = 95 +/- 13 ml.kg-1, volume of distribution at steady state; Vdss = 264 +/- 41 ml.kg-1, clearance; Cl = 1.8 +/- 0.2 ml.min-1.kg-1.","[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),[ml] / [kg],264,158849,DB00592,Piperazine
,1976829,Cl,"With pipecuronium, following pharmacokinetic parameters were obtained; distribution half-life; T1/2 alpha = 3.9 +/- 0.7 min (mean +/- SEM), elimination half-life; T1/2 beta = 102 +/- 12 min, volume of the central compartment; V1 = 95 +/- 13 ml.kg-1, volume of distribution at steady state; Vdss = 264 +/- 41 ml.kg-1, clearance; Cl = 1.8 +/- 0.2 ml.min-1.kg-1.","[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),[ml] / [kg·min],1.8,158850,DB00592,Piperazine
,1976829,V1,V1 and Vdss of pipecuronium were significantly larger than those of pancuronium (V1; 38 +/- 12 ml.kg-1 and Vdss; 120 +/- 4 ml.kg-1) (both P less than 0.10).,"[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),[ml] / [kg],38,158851,DB00592,Piperazine
,1976829,Vdss,V1 and Vdss of pipecuronium were significantly larger than those of pancuronium (V1; 38 +/- 12 ml.kg-1 and Vdss; 120 +/- 4 ml.kg-1) (both P less than 0.10).,"[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),[ml] / [kg],120,158852,DB00592,Piperazine
,1976829,Cl,"Reflecting the larger central volume of pipecuronium, pipecuronium tended to have a larger clearance than that of pancuroniumu (Cl; 1.1 +/- 0.2 ml.min-1.kg-1).","[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),[ml] / [kg·min],1.1,158853,DB00592,Piperazine
,19132712,maximum plasma concentration,Geometric mean (GM) values for lamotrigine maximum plasma concentration were similar for lamotrigine alone (26 ng/mL) and with co-administered aripiprazole (23 ng/mL).,A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19132712/),[ng] / [ml],26,159154,DB00592,Piperazine
,19132712,maximum plasma concentration,Geometric mean (GM) values for lamotrigine maximum plasma concentration were similar for lamotrigine alone (26 ng/mL) and with co-administered aripiprazole (23 ng/mL).,A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19132712/),[ng] / [ml],23,159155,DB00592,Piperazine
,19132712,area under the concentration-time curve (AUCtau),GM values for plasma lamotrigine area under the concentration-time curve (AUCtau) were comparable for lamotrigine alone (434 ng/h/mL) and with co-administered aripiprazole (394 ng/h/mL).,A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19132712/),[ng] / [h·ml],434,159156,DB00592,Piperazine
,19132712,area under the concentration-time curve (AUCtau),GM values for plasma lamotrigine area under the concentration-time curve (AUCtau) were comparable for lamotrigine alone (434 ng/h/mL) and with co-administered aripiprazole (394 ng/h/mL).,A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19132712/),[ng] / [h·ml],394,159157,DB00592,Piperazine
,19132712,T(max),"Median T(max) of lamotrigine alone and combined with aripiprazole was 1.98 and 0.77 h, respectively.",A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19132712/),h,1.98,159158,DB00592,Piperazine
,19132712,T(max),"Median T(max) of lamotrigine alone and combined with aripiprazole was 1.98 and 0.77 h, respectively.",A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19132712/),h,0.77,159159,DB00592,Piperazine
,9099448,AUC,"The mean predicted AUC of flunarizine was 1230 +/- 717 ng h mL-1, whereas the observed AUC was 1203 +/- 900 ng h mL-1.",A limited sampling method for the estimation of flunarizine area under the curve (AUC) and maximum plasma concentration (Cmax). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099448/),[h·ng] / [ml],1230,159481,DB00592,Piperazine
,9099448,AUC,"The mean predicted AUC of flunarizine was 1230 +/- 717 ng h mL-1, whereas the observed AUC was 1203 +/- 900 ng h mL-1.",A limited sampling method for the estimation of flunarizine area under the curve (AUC) and maximum plasma concentration (Cmax). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099448/),[h·ng] / [ml],1203,159482,DB00592,Piperazine
,9099448,Cmax,The mean predicted Cmax of flunarizine was 86 +/- 32 ng mL-1 as compared to an observed mean Cmax of 90 +/- 42 ng mL-1.,A limited sampling method for the estimation of flunarizine area under the curve (AUC) and maximum plasma concentration (Cmax). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099448/),[ng] / [ml],86,159483,DB00592,Piperazine
,9099448,Cmax,The mean predicted Cmax of flunarizine was 86 +/- 32 ng mL-1 as compared to an observed mean Cmax of 90 +/- 42 ng mL-1.,A limited sampling method for the estimation of flunarizine area under the curve (AUC) and maximum plasma concentration (Cmax). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099448/),[ng] / [ml],90,159484,DB00592,Piperazine
,12445022,renal clearance,"Azimilide renal clearance decreased in subjects with renal impairment (mean 14 vs 4.8 ml h-1 kg-1, 95% confidence interval on the ratio 0.23, 0.50).",Effect of severe renal impairment on the pharmacokinetics of azimilide following single dose oral administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445022/),[ml] / [h·kg],14,159804,DB00592,Piperazine
,12445022,renal clearance,"Azimilide renal clearance decreased in subjects with renal impairment (mean 14 vs 4.8 ml h-1 kg-1, 95% confidence interval on the ratio 0.23, 0.50).",Effect of severe renal impairment on the pharmacokinetics of azimilide following single dose oral administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445022/),[ml] / [h·kg],4.8,159805,DB00592,Piperazine
,12445022,oral clearance,"However, no change in any other pharmacokinetic parameter including oral clearance (mean 109 vs 104 ml h-1 kg-1, 95% confidence interval on the ratio 0.67, 1.36) was observed.",Effect of severe renal impairment on the pharmacokinetics of azimilide following single dose oral administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445022/),[ml] / [h·kg],109,159806,DB00592,Piperazine
,12445022,oral clearance,"However, no change in any other pharmacokinetic parameter including oral clearance (mean 109 vs 104 ml h-1 kg-1, 95% confidence interval on the ratio 0.67, 1.36) was observed.",Effect of severe renal impairment on the pharmacokinetics of azimilide following single dose oral administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445022/),[ml] / [h·kg],104,159807,DB00592,Piperazine
,16006570,t(max),Absorption was rapid (t(max) 1-2 h) and complete with imatinib as the major radioactive compound in plasma.,Metabolism and disposition of imatinib mesylate in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006570/),h,1-2,160062,DB00592,Piperazine
,16006570,Maximum plasma concentrations,"Maximum plasma concentrations were 0.921 +/- 0.095 mug/ml (mean +/- S.D., n = 4) for imatinib and 0.115 +/- 0.026 mug/ml for the pharmacologically active N-desmethyl metabolite (CGP74588).",Metabolism and disposition of imatinib mesylate in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006570/),[μg] / [ml],0.921,160063,DB00592,Piperazine
,16006570,Maximum plasma concentrations,"Maximum plasma concentrations were 0.921 +/- 0.095 mug/ml (mean +/- S.D., n = 4) for imatinib and 0.115 +/- 0.026 mug/ml for the pharmacologically active N-desmethyl metabolite (CGP74588).",Metabolism and disposition of imatinib mesylate in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006570/),[μg] / [ml],0.115,160064,DB00592,Piperazine
,16006570,plasma terminal elimination half-lives,"Mean plasma terminal elimination half-lives were 13.5 +/- 0.9 h for imatinib, 20.6 +/- 1.7 h for CGP74588, and 57.3 +/- 12.5 h for (14)C radioactivity.",Metabolism and disposition of imatinib mesylate in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006570/),h,13.5,160065,DB00592,Piperazine
,16006570,plasma terminal elimination half-lives,"Mean plasma terminal elimination half-lives were 13.5 +/- 0.9 h for imatinib, 20.6 +/- 1.7 h for CGP74588, and 57.3 +/- 12.5 h for (14)C radioactivity.",Metabolism and disposition of imatinib mesylate in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006570/),h,20.6,160066,DB00592,Piperazine
,16006570,plasma terminal elimination half-lives,"Mean plasma terminal elimination half-lives were 13.5 +/- 0.9 h for imatinib, 20.6 +/- 1.7 h for CGP74588, and 57.3 +/- 12.5 h for (14)C radioactivity.",Metabolism and disposition of imatinib mesylate in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006570/),h,57.3,160067,DB00592,Piperazine
,16006570,radiocarbon recovery,"Excretion of radioactivity was slow with a mean radiocarbon recovery of 80% within 7 days (67% in feces, 13% in urine).",Metabolism and disposition of imatinib mesylate in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006570/),%,80,160068,DB00592,Piperazine
,16006570,radiocarbon recovery,"Excretion of radioactivity was slow with a mean radiocarbon recovery of 80% within 7 days (67% in feces, 13% in urine).",Metabolism and disposition of imatinib mesylate in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006570/),%,67,160069,DB00592,Piperazine
,16006570,radiocarbon recovery,"Excretion of radioactivity was slow with a mean radiocarbon recovery of 80% within 7 days (67% in feces, 13% in urine).",Metabolism and disposition of imatinib mesylate in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006570/),%,13,160070,DB00592,Piperazine
,20668248,Total recovery,"Total recovery of the administered dose was 79% with approximately 58 and 21% of the administered radioactive dose excreted in feces and urine, respectively.","Metabolism, pharmacokinetics, and excretion of the 5-hydroxytryptamine1b receptor antagonist elzasonan in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20668248/),%,79,160077,DB00592,Piperazine
,20668248,Total recovery,"Total recovery of the administered dose was 79% with approximately 58 and 21% of the administered radioactive dose excreted in feces and urine, respectively.","Metabolism, pharmacokinetics, and excretion of the 5-hydroxytryptamine1b receptor antagonist elzasonan in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20668248/),%,58,160078,DB00592,Piperazine
,20668248,Total recovery,"Total recovery of the administered dose was 79% with approximately 58 and 21% of the administered radioactive dose excreted in feces and urine, respectively.","Metabolism, pharmacokinetics, and excretion of the 5-hydroxytryptamine1b receptor antagonist elzasonan in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20668248/),%,21,160079,DB00592,Piperazine
,20668248,t(1/2),The average t(1/2) for elzasonan was 31.5 h.,"Metabolism, pharmacokinetics, and excretion of the 5-hydroxytryptamine1b receptor antagonist elzasonan in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20668248/),h,31.5,160080,DB00592,Piperazine
>,18676693,time to 50% CCR5 receptor occupancy,"Longitudinal analysis in the drug washout period revealed the time to 50% CCR5 receptor occupancy averaged >100 hours, in both human immunodeficiency virus-positive and human immunodeficiency virus-negative subjects, substantially longer than the plasma pharmacokinetic half-life of 3 hours.",In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of Aplaviroc. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18676693/),h,100,160082,DB00592,Piperazine
,18676693,half-life,"Longitudinal analysis in the drug washout period revealed the time to 50% CCR5 receptor occupancy averaged >100 hours, in both human immunodeficiency virus-positive and human immunodeficiency virus-negative subjects, substantially longer than the plasma pharmacokinetic half-life of 3 hours.",In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of Aplaviroc. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18676693/),h,3,160083,DB00592,Piperazine
,7616407,apparent terminal half-life,"The apparent terminal half-life of L-754,394 in rats increased from 20 min at 0.5 mg/kg i.v. to 118 min at 10 mg/kg i.v.","Time- and dose-dependent pharmacokinetics of L-754,394, an HIV protease inhibitor, in rats, dogs and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7616407/),min,20,160709,DB00592,Piperazine
,7616407,apparent terminal half-life,"The apparent terminal half-life of L-754,394 in rats increased from 20 min at 0.5 mg/kg i.v. to 118 min at 10 mg/kg i.v.","Time- and dose-dependent pharmacokinetics of L-754,394, an HIV protease inhibitor, in rats, dogs and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7616407/),min,118,160710,DB00592,Piperazine
,7616407,apparent clearance,"After chronic i.v. doses for 7 days (1 mg/kg/dose/day), the apparent clearance of L-754,394 in rats decreased from 87 ml/min/kg after the first dose to 25 ml/min/kg after the last dose.","Time- and dose-dependent pharmacokinetics of L-754,394, an HIV protease inhibitor, in rats, dogs and monkeys. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7616407/),[ml] / [kg·min],87,160711,DB00592,Piperazine
,7616407,apparent clearance,"After chronic i.v. doses for 7 days (1 mg/kg/dose/day), the apparent clearance of L-754,394 in rats decreased from 87 ml/min/kg after the first dose to 25 ml/min/kg after the last dose.","Time- and dose-dependent pharmacokinetics of L-754,394, an HIV protease inhibitor, in rats, dogs and monkeys. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7616407/),[ml] / [kg·min],25,160712,DB00592,Piperazine
,8103528,Cmax,"The mean gepirone Cmax was 16.98 +/- 8.12 ng/mL (fed) and 18.73 +/- 10.30 ng/mL (fasted), with mean t1/2 of 3.32 +/- 1.84 hours (fed) and 2.94 +/- 0.90 hours (fasted).",Effect of food on the bioavailability of gepirone in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103528/),[ng] / [ml],16.98,160766,DB00592,Piperazine
,8103528,Cmax,"The mean gepirone Cmax was 16.98 +/- 8.12 ng/mL (fed) and 18.73 +/- 10.30 ng/mL (fasted), with mean t1/2 of 3.32 +/- 1.84 hours (fed) and 2.94 +/- 0.90 hours (fasted).",Effect of food on the bioavailability of gepirone in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103528/),[ng] / [ml],18.73,160767,DB00592,Piperazine
,8103528,t1/2,"The mean gepirone Cmax was 16.98 +/- 8.12 ng/mL (fed) and 18.73 +/- 10.30 ng/mL (fasted), with mean t1/2 of 3.32 +/- 1.84 hours (fed) and 2.94 +/- 0.90 hours (fasted).",Effect of food on the bioavailability of gepirone in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103528/),h,3.32,160768,DB00592,Piperazine
,8103528,t1/2,"The mean gepirone Cmax was 16.98 +/- 8.12 ng/mL (fed) and 18.73 +/- 10.30 ng/mL (fasted), with mean t1/2 of 3.32 +/- 1.84 hours (fed) and 2.94 +/- 0.90 hours (fasted).",Effect of food on the bioavailability of gepirone in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103528/),h,2.94,160769,DB00592,Piperazine
,8103528,area under the curveinf (AUCinf),"Food significantly increased the mean area under the curveinf (AUCinf) from 55.26 +/- 35.74 ng.hour/mL (fasted) to 75.69 +/- 42.79 ng.hour/mL (fed), and the mean residence timeinf (MRTinf) from 4.31 +/- 0.78 hours (fasted) to 5.37 +/- 1.21 hours (fed).",Effect of food on the bioavailability of gepirone in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103528/),[h·ng] / [ml],55.26,160770,DB00592,Piperazine
,8103528,area under the curveinf (AUCinf),"Food significantly increased the mean area under the curveinf (AUCinf) from 55.26 +/- 35.74 ng.hour/mL (fasted) to 75.69 +/- 42.79 ng.hour/mL (fed), and the mean residence timeinf (MRTinf) from 4.31 +/- 0.78 hours (fasted) to 5.37 +/- 1.21 hours (fed).",Effect of food on the bioavailability of gepirone in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103528/),[h·ng] / [ml],75.69,160771,DB00592,Piperazine
,8103528,mean residence timeinf (MRTinf),"Food significantly increased the mean area under the curveinf (AUCinf) from 55.26 +/- 35.74 ng.hour/mL (fasted) to 75.69 +/- 42.79 ng.hour/mL (fed), and the mean residence timeinf (MRTinf) from 4.31 +/- 0.78 hours (fasted) to 5.37 +/- 1.21 hours (fed).",Effect of food on the bioavailability of gepirone in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103528/),h,4.31,160772,DB00592,Piperazine
,8103528,mean residence timeinf (MRTinf),"Food significantly increased the mean area under the curveinf (AUCinf) from 55.26 +/- 35.74 ng.hour/mL (fasted) to 75.69 +/- 42.79 ng.hour/mL (fed), and the mean residence timeinf (MRTinf) from 4.31 +/- 0.78 hours (fasted) to 5.37 +/- 1.21 hours (fed).",Effect of food on the bioavailability of gepirone in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103528/),h,5.37,160773,DB00592,Piperazine
,8103528,time to maximum plasma concentration (tmax),"The median time to maximum plasma concentration (tmax) for gepirone was also significantly increased in the presence of food, 2.0 hours, versus 0.75 hours in the absence of food.",Effect of food on the bioavailability of gepirone in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103528/),h,2.0,160774,DB00592,Piperazine
,8103528,time to maximum plasma concentration (tmax),"The median time to maximum plasma concentration (tmax) for gepirone was also significantly increased in the presence of food, 2.0 hours, versus 0.75 hours in the absence of food.",Effect of food on the bioavailability of gepirone in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103528/),h,0.75,160775,DB00592,Piperazine
,8103528,t1/2,"Mean t1/2 for 1-PP in the presence and absence of food was 6.06 +/- 1.75 and 5.76 +/- 1.75 hours, respectively.",Effect of food on the bioavailability of gepirone in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103528/),h,6.06,160776,DB00592,Piperazine
,8103528,t1/2,"Mean t1/2 for 1-PP in the presence and absence of food was 6.06 +/- 1.75 and 5.76 +/- 1.75 hours, respectively.",Effect of food on the bioavailability of gepirone in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103528/),h,5.76,160777,DB00592,Piperazine
,8103528,MRTinf,"MRTinf, however, was increased significantly from 9.32 +/- 2.68 hours (fasted) to 10.53 +/- 2.89 hours (fed).",Effect of food on the bioavailability of gepirone in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103528/),h,9.32,160778,DB00592,Piperazine
,8103528,MRTinf,"MRTinf, however, was increased significantly from 9.32 +/- 2.68 hours (fasted) to 10.53 +/- 2.89 hours (fed).",Effect of food on the bioavailability of gepirone in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103528/),h,10.53,160779,DB00592,Piperazine
≈,28964952,oral bioavailability,Vardenafil (VDF) is a relatively new phosphodiesterase-5 inhibitor that exhibits a limited oral bioavailability (≈15%) due to extensive first-pass metabolism.,Preparation and characterization of intravaginal vardenafil suppositories targeting a complementary treatment to boost in vitro fertilization process. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28964952/),%,15,160949,DB00592,Piperazine
,23417352,t½,"Mean t½ (35.7 and 34.8 h mild and moderate vs. 37.0 and 34.8 h matched controls), total drug clearance (19.9 and 25.1 L/h vs. 26.4 and 26.9 L/h), and mean vilazodone recovery in urine (1.21 % and 0.58 % vs. 0.95 % and 0.81 %) were similar for mild and moderate renally impaired subjects and matched controls with normal renal function.",Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417352/),h,35.7,161029,DB00592,Piperazine
,23417352,t½,"Mean t½ (35.7 and 34.8 h mild and moderate vs. 37.0 and 34.8 h matched controls), total drug clearance (19.9 and 25.1 L/h vs. 26.4 and 26.9 L/h), and mean vilazodone recovery in urine (1.21 % and 0.58 % vs. 0.95 % and 0.81 %) were similar for mild and moderate renally impaired subjects and matched controls with normal renal function.",Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417352/),h,34.8,161030,DB00592,Piperazine
,23417352,t½,"Mean t½ (35.7 and 34.8 h mild and moderate vs. 37.0 and 34.8 h matched controls), total drug clearance (19.9 and 25.1 L/h vs. 26.4 and 26.9 L/h), and mean vilazodone recovery in urine (1.21 % and 0.58 % vs. 0.95 % and 0.81 %) were similar for mild and moderate renally impaired subjects and matched controls with normal renal function.",Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417352/),h,37.0,161031,DB00592,Piperazine
,23417352,total drug clearance,"Mean t½ (35.7 and 34.8 h mild and moderate vs. 37.0 and 34.8 h matched controls), total drug clearance (19.9 and 25.1 L/h vs. 26.4 and 26.9 L/h), and mean vilazodone recovery in urine (1.21 % and 0.58 % vs. 0.95 % and 0.81 %) were similar for mild and moderate renally impaired subjects and matched controls with normal renal function.",Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417352/),[l] / [h],19.9,161032,DB00592,Piperazine
,23417352,total drug clearance,"Mean t½ (35.7 and 34.8 h mild and moderate vs. 37.0 and 34.8 h matched controls), total drug clearance (19.9 and 25.1 L/h vs. 26.4 and 26.9 L/h), and mean vilazodone recovery in urine (1.21 % and 0.58 % vs. 0.95 % and 0.81 %) were similar for mild and moderate renally impaired subjects and matched controls with normal renal function.",Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417352/),[l] / [h],25.1,161033,DB00592,Piperazine
,23417352,total drug clearance,"Mean t½ (35.7 and 34.8 h mild and moderate vs. 37.0 and 34.8 h matched controls), total drug clearance (19.9 and 25.1 L/h vs. 26.4 and 26.9 L/h), and mean vilazodone recovery in urine (1.21 % and 0.58 % vs. 0.95 % and 0.81 %) were similar for mild and moderate renally impaired subjects and matched controls with normal renal function.",Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417352/),[l] / [h],26.4,161034,DB00592,Piperazine
,23417352,total drug clearance,"Mean t½ (35.7 and 34.8 h mild and moderate vs. 37.0 and 34.8 h matched controls), total drug clearance (19.9 and 25.1 L/h vs. 26.4 and 26.9 L/h), and mean vilazodone recovery in urine (1.21 % and 0.58 % vs. 0.95 % and 0.81 %) were similar for mild and moderate renally impaired subjects and matched controls with normal renal function.",Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417352/),[l] / [h],26.9,161035,DB00592,Piperazine
,23417352,recovery in urine,"Mean t½ (35.7 and 34.8 h mild and moderate vs. 37.0 and 34.8 h matched controls), total drug clearance (19.9 and 25.1 L/h vs. 26.4 and 26.9 L/h), and mean vilazodone recovery in urine (1.21 % and 0.58 % vs. 0.95 % and 0.81 %) were similar for mild and moderate renally impaired subjects and matched controls with normal renal function.",Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417352/),%,1.21,161036,DB00592,Piperazine
,23417352,recovery in urine,"Mean t½ (35.7 and 34.8 h mild and moderate vs. 37.0 and 34.8 h matched controls), total drug clearance (19.9 and 25.1 L/h vs. 26.4 and 26.9 L/h), and mean vilazodone recovery in urine (1.21 % and 0.58 % vs. 0.95 % and 0.81 %) were similar for mild and moderate renally impaired subjects and matched controls with normal renal function.",Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417352/),%,0.58,161037,DB00592,Piperazine
,23417352,recovery in urine,"Mean t½ (35.7 and 34.8 h mild and moderate vs. 37.0 and 34.8 h matched controls), total drug clearance (19.9 and 25.1 L/h vs. 26.4 and 26.9 L/h), and mean vilazodone recovery in urine (1.21 % and 0.58 % vs. 0.95 % and 0.81 %) were similar for mild and moderate renally impaired subjects and matched controls with normal renal function.",Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417352/),%,0.95,161038,DB00592,Piperazine
,23417352,recovery in urine,"Mean t½ (35.7 and 34.8 h mild and moderate vs. 37.0 and 34.8 h matched controls), total drug clearance (19.9 and 25.1 L/h vs. 26.4 and 26.9 L/h), and mean vilazodone recovery in urine (1.21 % and 0.58 % vs. 0.95 % and 0.81 %) were similar for mild and moderate renally impaired subjects and matched controls with normal renal function.",Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417352/),%,0.81,161039,DB00592,Piperazine
,2908109,Cmax,"Cmax (362 ng/ml), Tmax (1.30 h), terminal half-life (11.8 h) and AUC infinity (4316 ng.h/ml) in the elderly subjects were somewhat higher than in the young subjects (Cmax: 337 ng/ml, Tmax: 1.12 h, terminal half-life: 10.6 h, AUC: 3721 ng.h/ml), but the difference was not significant.",Single dose pharmacokinetics of cetirizine in young and elderly volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908109/),[ng] / [ml],362,161366,DB00592,Piperazine
,2908109,Tmax,"Cmax (362 ng/ml), Tmax (1.30 h), terminal half-life (11.8 h) and AUC infinity (4316 ng.h/ml) in the elderly subjects were somewhat higher than in the young subjects (Cmax: 337 ng/ml, Tmax: 1.12 h, terminal half-life: 10.6 h, AUC: 3721 ng.h/ml), but the difference was not significant.",Single dose pharmacokinetics of cetirizine in young and elderly volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908109/),h,1.30,161367,DB00592,Piperazine
,2908109,terminal half-life,"Cmax (362 ng/ml), Tmax (1.30 h), terminal half-life (11.8 h) and AUC infinity (4316 ng.h/ml) in the elderly subjects were somewhat higher than in the young subjects (Cmax: 337 ng/ml, Tmax: 1.12 h, terminal half-life: 10.6 h, AUC: 3721 ng.h/ml), but the difference was not significant.",Single dose pharmacokinetics of cetirizine in young and elderly volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908109/),h,11.8,161368,DB00592,Piperazine
,2908109,AUC infinity,"Cmax (362 ng/ml), Tmax (1.30 h), terminal half-life (11.8 h) and AUC infinity (4316 ng.h/ml) in the elderly subjects were somewhat higher than in the young subjects (Cmax: 337 ng/ml, Tmax: 1.12 h, terminal half-life: 10.6 h, AUC: 3721 ng.h/ml), but the difference was not significant.",Single dose pharmacokinetics of cetirizine in young and elderly volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908109/),[h·ng] / [ml],4316,161369,DB00592,Piperazine
,2908109,Cmax,"Cmax (362 ng/ml), Tmax (1.30 h), terminal half-life (11.8 h) and AUC infinity (4316 ng.h/ml) in the elderly subjects were somewhat higher than in the young subjects (Cmax: 337 ng/ml, Tmax: 1.12 h, terminal half-life: 10.6 h, AUC: 3721 ng.h/ml), but the difference was not significant.",Single dose pharmacokinetics of cetirizine in young and elderly volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908109/),[ng] / [ml],337,161370,DB00592,Piperazine
,2908109,Tmax,"Cmax (362 ng/ml), Tmax (1.30 h), terminal half-life (11.8 h) and AUC infinity (4316 ng.h/ml) in the elderly subjects were somewhat higher than in the young subjects (Cmax: 337 ng/ml, Tmax: 1.12 h, terminal half-life: 10.6 h, AUC: 3721 ng.h/ml), but the difference was not significant.",Single dose pharmacokinetics of cetirizine in young and elderly volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908109/),h,1.12,161371,DB00592,Piperazine
,2908109,terminal half-life,"Cmax (362 ng/ml), Tmax (1.30 h), terminal half-life (11.8 h) and AUC infinity (4316 ng.h/ml) in the elderly subjects were somewhat higher than in the young subjects (Cmax: 337 ng/ml, Tmax: 1.12 h, terminal half-life: 10.6 h, AUC: 3721 ng.h/ml), but the difference was not significant.",Single dose pharmacokinetics of cetirizine in young and elderly volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908109/),h,10.6,161372,DB00592,Piperazine
,2908109,AUC,"Cmax (362 ng/ml), Tmax (1.30 h), terminal half-life (11.8 h) and AUC infinity (4316 ng.h/ml) in the elderly subjects were somewhat higher than in the young subjects (Cmax: 337 ng/ml, Tmax: 1.12 h, terminal half-life: 10.6 h, AUC: 3721 ng.h/ml), but the difference was not significant.",Single dose pharmacokinetics of cetirizine in young and elderly volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908109/),[h·ng] / [ml],3721,161373,DB00592,Piperazine
,23417765,system apparent clearance (CL/F),"The population-predicted system apparent clearance (CL/F), volume of apparent distribution in center (V(1)/F), and the first-order absorption rate constant (Ka) of blonanserin under fasting was 1230 L/h, 9500 L, and 3.02 h(-1), respectively.",Population pharmacokinetics of blonanserin in Chinese healthy volunteers and the effect of the food intake. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417765/),[l] / [h],1230,161374,DB00592,Piperazine
,23417765,volume of apparent distribution in center (V(1)/F),"The population-predicted system apparent clearance (CL/F), volume of apparent distribution in center (V(1)/F), and the first-order absorption rate constant (Ka) of blonanserin under fasting was 1230 L/h, 9500 L, and 3.02 h(-1), respectively.",Population pharmacokinetics of blonanserin in Chinese healthy volunteers and the effect of the food intake. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417765/),l,9500,161375,DB00592,Piperazine
,23417765,first-order absorption rate constant (Ka),"The population-predicted system apparent clearance (CL/F), volume of apparent distribution in center (V(1)/F), and the first-order absorption rate constant (Ka) of blonanserin under fasting was 1230 L/h, 9500 L, and 3.02 h(-1), respectively.",Population pharmacokinetics of blonanserin in Chinese healthy volunteers and the effect of the food intake. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417765/),1/[h],3.02,161376,DB00592,Piperazine
,23417765,Ka,Food intake decreased Ka of blonanserin to 0.78 h(-1).,Population pharmacokinetics of blonanserin in Chinese healthy volunteers and the effect of the food intake. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417765/),1/[h],0.78,161377,DB00592,Piperazine
,23417765,relative bioavailability,The relative bioavailability between fasting and food intake estimated by the final model was 55%.,Population pharmacokinetics of blonanserin in Chinese healthy volunteers and the effect of the food intake. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417765/),%,55,161378,DB00592,Piperazine
,26725913,elimination coefficient (Ke),"Median (IQR) values for elimination coefficient (Ke), volume of distribution (V) and intercompartmental transfer rates (Kcp, Kpc) were 8.8 (5.2-12.8) h(-1), 6.4 (2.8-10.4) l, 11.9 (4.6-15.0) h(-1) and 3.7 (2.3-9.1) h(-1), respectively.",Pharmacokinetics of centhaquin citrate in a rat model. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26725913/),1/[h],8.8,161413,DB00592,Piperazine
,26725913,volume of distribution (V),"Median (IQR) values for elimination coefficient (Ke), volume of distribution (V) and intercompartmental transfer rates (Kcp, Kpc) were 8.8 (5.2-12.8) h(-1), 6.4 (2.8-10.4) l, 11.9 (4.6-15.0) h(-1) and 3.7 (2.3-9.1) h(-1), respectively.",Pharmacokinetics of centhaquin citrate in a rat model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26725913/),l,6.4,161414,DB00592,Piperazine
,26725913,"intercompartmental transfer rates (Kcp, Kpc)","Median (IQR) values for elimination coefficient (Ke), volume of distribution (V) and intercompartmental transfer rates (Kcp, Kpc) were 8.8 (5.2-12.8) h(-1), 6.4 (2.8-10.4) l, 11.9 (4.6-15.0) h(-1) and 3.7 (2.3-9.1) h(-1), respectively.",Pharmacokinetics of centhaquin citrate in a rat model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26725913/),1/[h],3.7,161415,DB00592,Piperazine
,19434851,AUC,"In vivo testing conducted in Sprague-Dawley rats (n = 6) demonstrated a significant improvement in oral bioavailability from the 1:2 ITZ:CAP (AUC = 4,516 +/- 1,949 ng x h/mL) compared to the Sporanox pellets (AUC = 2,132 +/- 1,273 ng x h/mL) (p < or = 0.05).",Amorphous compositions using concentration enhancing polymers for improved bioavailability of itraconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19434851/),[h·ng] / [ml],"4,516",161489,DB00592,Piperazine
,19434851,AUC,"In vivo testing conducted in Sprague-Dawley rats (n = 6) demonstrated a significant improvement in oral bioavailability from the 1:2 ITZ:CAP (AUC = 4,516 +/- 1,949 ng x h/mL) compared to the Sporanox pellets (AUC = 2,132 +/- 1,273 ng x h/mL) (p < or = 0.05).",Amorphous compositions using concentration enhancing polymers for improved bioavailability of itraconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19434851/),[h·ng] / [ml],"2,132",161490,DB00592,Piperazine
,22406103,elution at flow rate,"The analysis was carried out on an ACQUITY UPLC™ BEH HILIC column (1.7 μm, 2.1 mm×50 mm) with isocratic elution at flow rate of 0.2 mL/min using 10mM ammonium formate in 0.1% formic acid and acetonitrile (10:90) as the mobile phase.","Determination of a highly selective mixed-affinity sigma receptor ligand, in rat plasma by ultra performance liquid chromatography mass spectrometry and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22406103/),[ml] / [min],0.2,161605,DB00592,Piperazine
,22406103,run time,"The validated analytical method resulted in a run time of 4 min and the retention times observed were 2.6±0.1 and 2.1±0.1 min for CM156 and the IS, respectively.","Determination of a highly selective mixed-affinity sigma receptor ligand, in rat plasma by ultra performance liquid chromatography mass spectrometry and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22406103/),min,4,161606,DB00592,Piperazine
,22406103,retention times,"The validated analytical method resulted in a run time of 4 min and the retention times observed were 2.6±0.1 and 2.1±0.1 min for CM156 and the IS, respectively.","Determination of a highly selective mixed-affinity sigma receptor ligand, in rat plasma by ultra performance liquid chromatography mass spectrometry and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22406103/),min,2.6,161607,DB00592,Piperazine
,22406103,retention times,"The validated analytical method resulted in a run time of 4 min and the retention times observed were 2.6±0.1 and 2.1±0.1 min for CM156 and the IS, respectively.","Determination of a highly selective mixed-affinity sigma receptor ligand, in rat plasma by ultra performance liquid chromatography mass spectrometry and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22406103/),min,2.1,161608,DB00592,Piperazine
,22406103,recovery,The mean recovery of CM156 from plasma was 96.8%.,"Determination of a highly selective mixed-affinity sigma receptor ligand, in rat plasma by ultra performance liquid chromatography mass spectrometry and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22406103/),%,96.8,161609,DB00592,Piperazine
,18256322,steady-state C(min),"The overall mean (+/- SD, CV%) steady-state C(min) for imatinib and CGP74588 were 979 ng/mL (+/- 530 ng/mL, 54.1%) and 242 ng/mL (+/- 106 ng/mL, 43.6%), respectively.",Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18256322/),[ng] / [ml],979,161733,DB00592,Piperazine
,18256322,steady-state C(min),"The overall mean (+/- SD, CV%) steady-state C(min) for imatinib and CGP74588 were 979 ng/mL (+/- 530 ng/mL, 54.1%) and 242 ng/mL (+/- 106 ng/mL, 43.6%), respectively.",Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18256322/),[ng] / [ml],242,161734,DB00592,Piperazine
,18256322,C(min),"C(min) of imatinib was significantly higher in patients who achieved CCyR (1009 +/- 544 ng/mL vs 812 +/- 409 ng/mL, P = .01).",Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18256322/),[ng] / [ml],1009,161735,DB00592,Piperazine
,18256322,C(min),"C(min) of imatinib was significantly higher in patients who achieved CCyR (1009 +/- 544 ng/mL vs 812 +/- 409 ng/mL, P = .01).",Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18256322/),[ng] / [ml],812,161736,DB00592,Piperazine
,25034010,Plasma clearance,"Plasma clearance of dolutegravir, an unboosted HIV-1 integrase inhibitor, was low in rat and monkey (0.23 and 2.12 mL/min/kg, respectively) as was the volume of distribution (0.1 and 0.28 L/kg, respectively) with terminal elimination half-life approximately 6 h.","The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25034010/),[ml] / [kg·min],0.23,161778,DB00592,Piperazine
,25034010,Plasma clearance,"Plasma clearance of dolutegravir, an unboosted HIV-1 integrase inhibitor, was low in rat and monkey (0.23 and 2.12 mL/min/kg, respectively) as was the volume of distribution (0.1 and 0.28 L/kg, respectively) with terminal elimination half-life approximately 6 h.","The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25034010/),[ml] / [kg·min],2.12,161779,DB00592,Piperazine
,25034010,volume of distribution,"Plasma clearance of dolutegravir, an unboosted HIV-1 integrase inhibitor, was low in rat and monkey (0.23 and 2.12 mL/min/kg, respectively) as was the volume of distribution (0.1 and 0.28 L/kg, respectively) with terminal elimination half-life approximately 6 h.","The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25034010/),[l] / [kg],0.1,161780,DB00592,Piperazine
,25034010,volume of distribution,"Plasma clearance of dolutegravir, an unboosted HIV-1 integrase inhibitor, was low in rat and monkey (0.23 and 2.12 mL/min/kg, respectively) as was the volume of distribution (0.1 and 0.28 L/kg, respectively) with terminal elimination half-life approximately 6 h.","The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25034010/),[l] / [kg],0.28,161781,DB00592,Piperazine
,25034010,terminal elimination half-life,"Plasma clearance of dolutegravir, an unboosted HIV-1 integrase inhibitor, was low in rat and monkey (0.23 and 2.12 mL/min/kg, respectively) as was the volume of distribution (0.1 and 0.28 L/kg, respectively) with terminal elimination half-life approximately 6 h.","The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25034010/),h,6,161782,DB00592,Piperazine
,25034010,bioavailability,"Dolutegravir was rapidly absorbed from oral solution with a high bioavailability in rat and monkey (75.6 and 87.0% respectively), but solubility or dissolution rate limited when administered as suspension.","The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25034010/),%,75.6,161783,DB00592,Piperazine
,25034010,bioavailability,"Dolutegravir was rapidly absorbed from oral solution with a high bioavailability in rat and monkey (75.6 and 87.0% respectively), but solubility or dissolution rate limited when administered as suspension.","The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25034010/),%,87.0,161784,DB00592,Piperazine
,10071279,MTD,"The MTD of paclitaxel was 150 mg/m2, and adjunctive therapy with G-CSF was required to prevent febrile neutropenia.",Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071279/),[mg] / [m2],150,161889,DB00592,Piperazine
,19320276,m/z,"The ionization was optimized using electrospray ionization (ESI) with positive ion mode and selectivity was achieved by MS/MS analysis, m/z 705.3 --> 392.4 and m/z 374.3 --> 141.0 for itraconazole and internal standard (IS), respectively.",A sensitive validated LC-MS/MS method for quantification of itraconazole in human plasma for pharmacokinetic and bioequivalence study in 24 Korean volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19320276/),,705.3,161919,DB00592,Piperazine
,19320276,m/z,"The ionization was optimized using electrospray ionization (ESI) with positive ion mode and selectivity was achieved by MS/MS analysis, m/z 705.3 --> 392.4 and m/z 374.3 --> 141.0 for itraconazole and internal standard (IS), respectively.",A sensitive validated LC-MS/MS method for quantification of itraconazole in human plasma for pharmacokinetic and bioequivalence study in 24 Korean volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19320276/),,392.4,161920,DB00592,Piperazine
,19320276,m/z,"The ionization was optimized using electrospray ionization (ESI) with positive ion mode and selectivity was achieved by MS/MS analysis, m/z 705.3 --> 392.4 and m/z 374.3 --> 141.0 for itraconazole and internal standard (IS), respectively.",A sensitive validated LC-MS/MS method for quantification of itraconazole in human plasma for pharmacokinetic and bioequivalence study in 24 Korean volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19320276/),,374.3,161921,DB00592,Piperazine
,19320276,m/z,"The ionization was optimized using electrospray ionization (ESI) with positive ion mode and selectivity was achieved by MS/MS analysis, m/z 705.3 --> 392.4 and m/z 374.3 --> 141.0 for itraconazole and internal standard (IS), respectively.",A sensitive validated LC-MS/MS method for quantification of itraconazole in human plasma for pharmacokinetic and bioequivalence study in 24 Korean volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19320276/),,141.0,161922,DB00592,Piperazine
,19320276,retention times,The retention times of itraconazole (0.9 min) and IS (0.84 min) suggest the high throughput of the proposed method.,A sensitive validated LC-MS/MS method for quantification of itraconazole in human plasma for pharmacokinetic and bioequivalence study in 24 Korean volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19320276/),min,0.9,161923,DB00592,Piperazine
,19320276,retention times,The retention times of itraconazole (0.9 min) and IS (0.84 min) suggest the high throughput of the proposed method.,A sensitive validated LC-MS/MS method for quantification of itraconazole in human plasma for pharmacokinetic and bioequivalence study in 24 Korean volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19320276/),min,0.84,161924,DB00592,Piperazine
,22943745,T(max),"Furthermore, the addition of aripiprazole did not change the median T(max) of lithium or valproate (4 h).",Lack of a pharmacokinetic drug-drug interaction between lithium and valproate when co-administered with aripiprazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22943745/),h,4,162135,DB00592,Piperazine
,9536021,IC50,Triazolam alone inhibited [3H]flunitrazepam binding with an IC50 value of 0.85 nM and a Ki value of 0.50 nM.,"Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536021/),nM,0.85,162462,DB00592,Piperazine
,9536021,Ki,Triazolam alone inhibited [3H]flunitrazepam binding with an IC50 value of 0.85 nM and a Ki value of 0.50 nM.,"Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536021/),nM,0.50,162463,DB00592,Piperazine
,9536021,IC50,Ketoconazole alone also competitively antagonized [3H]flunitrazepam binding in a concentration-dependent manner with an IC50 value of 1.56 microM and a Ki value of 1.17 microM.,"Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536021/),μM,1.56,162464,DB00592,Piperazine
,9536021,Ki,Ketoconazole alone also competitively antagonized [3H]flunitrazepam binding in a concentration-dependent manner with an IC50 value of 1.56 microM and a Ki value of 1.17 microM.,"Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536021/),μM,1.17,162465,DB00592,Piperazine
,9536021,IC50,"In the presence of 1, 3 or 9 microM ketoconazole, the IC50 value of triazolam was increased to 1.11, 1. 58 and 5.73 nM, respectively, whereas maximal binding was reduced by 36%, 69% and 89%.","Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536021/),nM,1.11,162466,DB00592,Piperazine
,9536021,IC50,"In the presence of 1, 3 or 9 microM ketoconazole, the IC50 value of triazolam was increased to 1.11, 1. 58 and 5.73 nM, respectively, whereas maximal binding was reduced by 36%, 69% and 89%.","Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536021/),nM,1. 58,162467,DB00592,Piperazine
,9536021,IC50,"In the presence of 1, 3 or 9 microM ketoconazole, the IC50 value of triazolam was increased to 1.11, 1. 58 and 5.73 nM, respectively, whereas maximal binding was reduced by 36%, 69% and 89%.","Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536021/),nM,5.73,162468,DB00592,Piperazine
,17585751,IC50,"Optimization of in vitro potency and physicochemical and pharmacokinetic properties led to the discovery of (R)-N-(4-(6-(4-(1-(4-fluorophenyl)ethyl)piperazin-1-yl)pyrimidin-4-yloxy)benzo[d]thiazol-2-yl)acetamide (16p), a potent TRPV1 antagonist [rTRPV1(CAP) IC50 = 3.7 nM] with excellent aqueous solubility (>or=200 microg/mL in 0.01 N HCl) and a reduced half-life (rat t1/2 = 3.8 h, dog t1/2 = 2.7 h, monkey t1/2 = 3.2 h) as compared to AMG 517.",Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17585751/),nM,3.7,162529,DB00592,Piperazine
,17585751,t1/2,"Optimization of in vitro potency and physicochemical and pharmacokinetic properties led to the discovery of (R)-N-(4-(6-(4-(1-(4-fluorophenyl)ethyl)piperazin-1-yl)pyrimidin-4-yloxy)benzo[d]thiazol-2-yl)acetamide (16p), a potent TRPV1 antagonist [rTRPV1(CAP) IC50 = 3.7 nM] with excellent aqueous solubility (>or=200 microg/mL in 0.01 N HCl) and a reduced half-life (rat t1/2 = 3.8 h, dog t1/2 = 2.7 h, monkey t1/2 = 3.2 h) as compared to AMG 517.",Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17585751/),h,3.8,162530,DB00592,Piperazine
,17585751,t1/2,"Optimization of in vitro potency and physicochemical and pharmacokinetic properties led to the discovery of (R)-N-(4-(6-(4-(1-(4-fluorophenyl)ethyl)piperazin-1-yl)pyrimidin-4-yloxy)benzo[d]thiazol-2-yl)acetamide (16p), a potent TRPV1 antagonist [rTRPV1(CAP) IC50 = 3.7 nM] with excellent aqueous solubility (>or=200 microg/mL in 0.01 N HCl) and a reduced half-life (rat t1/2 = 3.8 h, dog t1/2 = 2.7 h, monkey t1/2 = 3.2 h) as compared to AMG 517.",Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17585751/),h,2.7,162531,DB00592,Piperazine
,17585751,t1/2,"Optimization of in vitro potency and physicochemical and pharmacokinetic properties led to the discovery of (R)-N-(4-(6-(4-(1-(4-fluorophenyl)ethyl)piperazin-1-yl)pyrimidin-4-yloxy)benzo[d]thiazol-2-yl)acetamide (16p), a potent TRPV1 antagonist [rTRPV1(CAP) IC50 = 3.7 nM] with excellent aqueous solubility (>or=200 microg/mL in 0.01 N HCl) and a reduced half-life (rat t1/2 = 3.8 h, dog t1/2 = 2.7 h, monkey t1/2 = 3.2 h) as compared to AMG 517.",Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17585751/),h,3.2,162532,DB00592,Piperazine
,17585751,ED50,"In addition, compound 16p was shown to be efficacious at blocking a TRPV1-mediated physiological response in vivo (ED50 = 1.9 mg/kg, p.o. in the capsaicin-induced flinch model in rats) and was also effective at reducing thermal hyperalgesia induced by complete Freund's adjuvant in rats (MED = 1 mg/kg, p.o).",Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17585751/),[mg] / [kg],1.9,162533,DB00592,Piperazine
,33044566,total recovery,"The mean total recovery was 101.21% of the radiolabeled dose with 91.00% and 10.21% excreted in feces and urine, respectively.","Mass balance, metabolic disposition, and pharmacokinetics of [14C]ensartinib, a novel potent anaplastic lymphoma kinase (ALK) inhibitor, in healthy subjects following oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33044566/),%,101.21,162536,DB00592,Piperazine
,33044566,total recovery,"The mean total recovery was 101.21% of the radiolabeled dose with 91.00% and 10.21% excreted in feces and urine, respectively.","Mass balance, metabolic disposition, and pharmacokinetics of [14C]ensartinib, a novel potent anaplastic lymphoma kinase (ALK) inhibitor, in healthy subjects following oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33044566/),%,91.00,162537,DB00592,Piperazine
,33044566,total recovery,"The mean total recovery was 101.21% of the radiolabeled dose with 91.00% and 10.21% excreted in feces and urine, respectively.","Mass balance, metabolic disposition, and pharmacokinetics of [14C]ensartinib, a novel potent anaplastic lymphoma kinase (ALK) inhibitor, in healthy subjects following oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33044566/),%,10.21,162538,DB00592,Piperazine
,33044566,Cmax,"Mean Cmax, AUC0-∞, T1/2 and Tmax values for ensartinib in plasma were 185 ng/mL, 3827 h ng/mL, 18.3 h and 3.25 h, respectively.","Mass balance, metabolic disposition, and pharmacokinetics of [14C]ensartinib, a novel potent anaplastic lymphoma kinase (ALK) inhibitor, in healthy subjects following oral administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33044566/),[ng] / [ml],185,162539,DB00592,Piperazine
,33044566,AUC0-∞,"Mean Cmax, AUC0-∞, T1/2 and Tmax values for ensartinib in plasma were 185 ng/mL, 3827 h ng/mL, 18.3 h and 3.25 h, respectively.","Mass balance, metabolic disposition, and pharmacokinetics of [14C]ensartinib, a novel potent anaplastic lymphoma kinase (ALK) inhibitor, in healthy subjects following oral administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33044566/),[h·ng] / [ml],3827,162540,DB00592,Piperazine
,33044566,AUC0-∞,"Mean Cmax, AUC0-∞, T1/2 and Tmax values for ensartinib in plasma were 185 ng/mL, 3827 h ng/mL, 18.3 h and 3.25 h, respectively.","Mass balance, metabolic disposition, and pharmacokinetics of [14C]ensartinib, a novel potent anaplastic lymphoma kinase (ALK) inhibitor, in healthy subjects following oral administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33044566/),h,18.3,162541,DB00592,Piperazine
,33044566,T1/2,"Mean Cmax, AUC0-∞, T1/2 and Tmax values for ensartinib in plasma were 185 ng/mL, 3827 h ng/mL, 18.3 h and 3.25 h, respectively.","Mass balance, metabolic disposition, and pharmacokinetics of [14C]ensartinib, a novel potent anaplastic lymphoma kinase (ALK) inhibitor, in healthy subjects following oral administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33044566/),[h·ng] / [ml],3827,162542,DB00592,Piperazine
,33044566,T1/2,"Mean Cmax, AUC0-∞, T1/2 and Tmax values for ensartinib in plasma were 185 ng/mL, 3827 h ng/mL, 18.3 h and 3.25 h, respectively.","Mass balance, metabolic disposition, and pharmacokinetics of [14C]ensartinib, a novel potent anaplastic lymphoma kinase (ALK) inhibitor, in healthy subjects following oral administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33044566/),h,18.3,162543,DB00592,Piperazine
,33044566,Tmax,"Mean Cmax, AUC0-∞, T1/2 and Tmax values for ensartinib in plasma were 185 ng/mL, 3827 h ng/mL, 18.3 h and 3.25 h, respectively.","Mass balance, metabolic disposition, and pharmacokinetics of [14C]ensartinib, a novel potent anaplastic lymphoma kinase (ALK) inhibitor, in healthy subjects following oral administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33044566/),h,3.25,162544,DB00592,Piperazine
,33044566,terminal half-life,The total radioactivity in plasma was cleared with terminal half-life of 27.2 h.,"Mass balance, metabolic disposition, and pharmacokinetics of [14C]ensartinib, a novel potent anaplastic lymphoma kinase (ALK) inhibitor, in healthy subjects following oral administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33044566/),h,27.2,162545,DB00592,Piperazine
more,20497744,elimination half-life,Itraconazole is a potent inhibitor of cytochrome P450 (CYP) 3A with an elimination half-life of more than 30 hours.,Pharmacokinetic modeling of the dosing interval dependency for the interaction between itraconazole and triazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20497744/),h,30,162644,DB00592,Piperazine
,3042359,Oral bioavailability,"Oral bioavailability is 78% (range 72 to 84%) and distribution half-life and terminal half-life are about 35 minutes and 3 hours, respectively.",Human pharmacology of urapidil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3042359/),%,78,162663,DB00592,Piperazine
,3042359,distribution half-life,"Oral bioavailability is 78% (range 72 to 84%) and distribution half-life and terminal half-life are about 35 minutes and 3 hours, respectively.",Human pharmacology of urapidil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3042359/),min,35,162664,DB00592,Piperazine
,3042359,terminal half-life,"Oral bioavailability is 78% (range 72 to 84%) and distribution half-life and terminal half-life are about 35 minutes and 3 hours, respectively.",Human pharmacology of urapidil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3042359/),h,3,162665,DB00592,Piperazine
,3042359,Plasma clearance,Plasma clearance is 12 L/h and renal clearance 1.8 L/h.,Human pharmacology of urapidil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3042359/),[l] / [h],12,162666,DB00592,Piperazine
,3042359,renal clearance,Plasma clearance is 12 L/h and renal clearance 1.8 L/h.,Human pharmacology of urapidil. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3042359/),[l] / [h],1.8,162667,DB00592,Piperazine
,11782899,maximum concentration (C(max)),Peppermint oil (100 mg/kg) tripled the mean cyclosporine maximum concentration (C(max)) from 0.60 to 1.6 microg/mL and increased the area under the concentration versus time curve (AUC(0-infinity)) from 8.3 to 24.3 microg x h/mL.,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),[μg] / [ml],0.60 to 1.6,162836,DB00592,Piperazine
,11782899,area under the concentration versus time curve (AUC(0-infinity)),Peppermint oil (100 mg/kg) tripled the mean cyclosporine maximum concentration (C(max)) from 0.60 to 1.6 microg/mL and increased the area under the concentration versus time curve (AUC(0-infinity)) from 8.3 to 24.3 microg x h/mL.,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),[h·μg] / [ml],8,162837,DB00592,Piperazine
,11782899,area under the concentration versus time curve (AUC(0-infinity)),Peppermint oil (100 mg/kg) tripled the mean cyclosporine maximum concentration (C(max)) from 0.60 to 1.6 microg/mL and increased the area under the concentration versus time curve (AUC(0-infinity)) from 8.3 to 24.3 microg x h/mL.,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),[h·μg] / [ml],24,162838,DB00592,Piperazine
,11782899,time to reach C(max) (t(max)),The median time to reach C(max) (t(max)) was increased from 2 to 6 h.,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),h,2,162839,DB00592,Piperazine
,11782899,time to reach C(max) (t(max)),The median time to reach C(max) (t(max)) was increased from 2 to 6 h.,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),h,6,162840,DB00592,Piperazine
,11782899,Terminal half-life,Terminal half-life (10 h) and mean residence time (MRT; 15 h) were unaffected.,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),h,10,162841,DB00592,Piperazine
,11782899,mean residence time (MRT,Terminal half-life (10 h) and mean residence time (MRT; 15 h) were unaffected.,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),h,15,162842,DB00592,Piperazine
,11782899,C(max),Coadministration of TPGS (50 mg/kg) with cyclosporine in a saline vehicle doubled cyclosporine C(max) from 1.3 to 2.9 microg/mL and increased AUC(0-infinity) from 28.5 to 59.7 microg x h/mL.,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),[μg] / [ml],1.3,162843,DB00592,Piperazine
,11782899,C(max),Coadministration of TPGS (50 mg/kg) with cyclosporine in a saline vehicle doubled cyclosporine C(max) from 1.3 to 2.9 microg/mL and increased AUC(0-infinity) from 28.5 to 59.7 microg x h/mL.,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),[μg] / [ml],2,162844,DB00592,Piperazine
,11782899,AUC(0-infinity),Coadministration of TPGS (50 mg/kg) with cyclosporine in a saline vehicle doubled cyclosporine C(max) from 1.3 to 2.9 microg/mL and increased AUC(0-infinity) from 28.5 to 59.7 microg x h/mL.,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),[h·μg] / [ml],28,162845,DB00592,Piperazine
,11782899,t(max),The t(max) was unchanged (3 h).,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),h,3,162846,DB00592,Piperazine
,11782899,Terminal half-life,"Terminal half-life and MRT were increased by 44% (15.4 versus 10.7 h) and 24% (19.9 versus 16.0 h), respectively.",Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),h,15.4,162847,DB00592,Piperazine
,11782899,Terminal half-life,"Terminal half-life and MRT were increased by 44% (15.4 versus 10.7 h) and 24% (19.9 versus 16.0 h), respectively.",Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),h,10.7,162848,DB00592,Piperazine
,11782899,MRT,"Terminal half-life and MRT were increased by 44% (15.4 versus 10.7 h) and 24% (19.9 versus 16.0 h), respectively.",Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),h,10.7,162849,DB00592,Piperazine
,11782899,MRT,"Terminal half-life and MRT were increased by 44% (15.4 versus 10.7 h) and 24% (19.9 versus 16.0 h), respectively.",Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),h,19.9,162850,DB00592,Piperazine
,11782899,MRT,"Terminal half-life and MRT were increased by 44% (15.4 versus 10.7 h) and 24% (19.9 versus 16.0 h), respectively.",Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),h,16.0,162851,DB00592,Piperazine
,23470352,bioavailability,"Moreover, the in vivo study showed that the AUC₀₋₁₂ of lyophilized tablets was significantly higher than that of directly compressed tablets, with bioavailability values of 159.81 and 140.85%, respectively, compared to the commercial oral product.",An in vitro and in vivo comparative study of directly compressed solid dispersions and freeze dried sildenafil citrate sublingual tablets for management of pulmonary arterial hypertension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23470352/),%,159.81,163190,DB00592,Piperazine
,23470352,bioavailability,"Moreover, the in vivo study showed that the AUC₀₋₁₂ of lyophilized tablets was significantly higher than that of directly compressed tablets, with bioavailability values of 159.81 and 140.85%, respectively, compared to the commercial oral product.",An in vitro and in vivo comparative study of directly compressed solid dispersions and freeze dried sildenafil citrate sublingual tablets for management of pulmonary arterial hypertension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23470352/),%,140.85,163191,DB00592,Piperazine
,26207899,IC50,We demonstrated that these inhibitors decreased cell viability in several human cancer cell lines with an IC50 in the 9.7 to 60.3 μM range and induced intrinsic apoptosis at concentrations of 50 μM.,Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26207899/),μM,9.7 to 60.3,163426,DB00592,Piperazine
,26207899,peak plasma concentration,Pharmacokinetics studies indicated an average peak plasma concentration of 11.4 μM one hour after oral administration and undetectable levels 23 hours after administration.,Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26207899/),μM,11.4,163427,DB00592,Piperazine
,33628019,zeta potential,"The IM-LPs showed an average size of 101.6 ± 50.80 nm with a zeta potential value of 19.66 ± 0.55 mV, a PDI of 0.250 and 81.96% ± 0.98% drug entrapment efficiency, meanwhile displayed a sustained release profile.",In vivo Pharmacokinetics and in vitro Release of Imatinib Mesylate-Loaded Liposomes for Pulmonary Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33628019/),mv,19.66,163863,DB00592,Piperazine
,33628019,PDI,"The IM-LPs showed an average size of 101.6 ± 50.80 nm with a zeta potential value of 19.66 ± 0.55 mV, a PDI of 0.250 and 81.96% ± 0.98% drug entrapment efficiency, meanwhile displayed a sustained release profile.",In vivo Pharmacokinetics and in vitro Release of Imatinib Mesylate-Loaded Liposomes for Pulmonary Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33628019/),,0.250,163864,DB00592,Piperazine
>,19333762,solubility,"The targeted solubility (>20 mg/ml) of sildenafil citrate was achieved with cosolvent systems S1, S3, and S5 and with microemulsion systems ME3-ME6.",Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19333762/),[mg] / [ml],20,163937,DB00592,Piperazine
,19333762,saturated solubility,"The saturated solubility of sildenafil citrate in cosolvent system S3 and microemulsion system ME6 were 22.98 +/- 1.26 and 23.79 +/- 1.16 mg/ml, respectively.",Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19333762/),[mg] / [ml],22.98,163938,DB00592,Piperazine
,19333762,saturated solubility,"The saturated solubility of sildenafil citrate in cosolvent system S3 and microemulsion system ME6 were 22.98 +/- 1.26 and 23.79 +/- 1.16 mg/ml, respectively.",Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19333762/),[mg] / [ml],23.79,163939,DB00592,Piperazine
,19333762,t (max),"Microemulsion formulation ME6 showed shorter t (max) (0.75 h) and higher AUC((0-infinity)) (1,412.42 ng h/ml) compared to the oral tablets which showed t (max) equals 1.25 h and AUC((0-infinity)) of 1,251.14 ng h/ml after administration to rabbits at dose level of 5 mg/kg.",Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19333762/),h,0.75,163940,DB00592,Piperazine
,19333762,AUC((0-infinity)),"Microemulsion formulation ME6 showed shorter t (max) (0.75 h) and higher AUC((0-infinity)) (1,412.42 ng h/ml) compared to the oral tablets which showed t (max) equals 1.25 h and AUC((0-infinity)) of 1,251.14 ng h/ml after administration to rabbits at dose level of 5 mg/kg.",Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19333762/),[h·ng] / [ml],"1,412.42",163941,DB00592,Piperazine
,19333762,t (max),"Microemulsion formulation ME6 showed shorter t (max) (0.75 h) and higher AUC((0-infinity)) (1,412.42 ng h/ml) compared to the oral tablets which showed t (max) equals 1.25 h and AUC((0-infinity)) of 1,251.14 ng h/ml after administration to rabbits at dose level of 5 mg/kg.",Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19333762/),h,1.25,163942,DB00592,Piperazine
,19333762,AUC((0-infinity)),"Microemulsion formulation ME6 showed shorter t (max) (0.75 h) and higher AUC((0-infinity)) (1,412.42 ng h/ml) compared to the oral tablets which showed t (max) equals 1.25 h and AUC((0-infinity)) of 1,251.14 ng h/ml after administration to rabbits at dose level of 5 mg/kg.",Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19333762/),[h·ng] / [ml],"1,251.14",163943,DB00592,Piperazine
,19333762,relative bioavailability,The relative bioavailability was 112.89%.,Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19333762/),%,112.89,163944,DB00592,Piperazine
,21142269,elimination half-life,"The combination of paroxetine and itraconazole prolonged the mean elimination half-life of oxycodone from 3.8 to 6.6 hours (p < 0.001), and increased the exposure to oxycodone 2-fold (p < 0.001).","Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21142269/),h,3.8,164029,DB00592,Piperazine
,21142269,elimination half-life,"The combination of paroxetine and itraconazole prolonged the mean elimination half-life of oxycodone from 3.8 to 6.6 hours (p < 0.001), and increased the exposure to oxycodone 2-fold (p < 0.001).","Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21142269/),h,6,164030,DB00592,Piperazine
,16791583,log10,The mean log10(omeprazole/omeprazole sulfone) ratio was 0.18 3 h after intake of omeprazole alone.,Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16791583/),,0.18,164111,DB00592,Piperazine
,16769598,bleeding time,"With prasugrel 75 mg at 4 h postdose, there was a significant increase in the mean bleeding time compared to placebo (682 vs. 161 s; P < 0.05).",Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16769598/),s,682,164135,DB00592,Piperazine
,16769598,bleeding time,"With prasugrel 75 mg at 4 h postdose, there was a significant increase in the mean bleeding time compared to placebo (682 vs. 161 s; P < 0.05).",Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16769598/),s,161,164136,DB00592,Piperazine
,18980116,flow rate,"Separations were performed in the isocratic mode on a Nucleosil CN column with the mobile phase acetonitrile-10 mM sodium acetate buffer (pH 3.5)-methanol (47 + 47 + 6, v/v/v) at a flow rate of 1.0 mL/min.","Nonextractive procedure and precolumn derivatization with 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole for trace determination of trimetazidine in plasma by high-performance liquid chromatography with fluorescence detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18980116/),[ml] / [min],1.0,164601,DB00592,Piperazine
,18980116,recoveries,The accuracy of the method was demonstrated; the recoveries of TMZ from spiked human plasma were 98.13-102.83 +/- 0.2-4.04%.,"Nonextractive procedure and precolumn derivatization with 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole for trace determination of trimetazidine in plasma by high-performance liquid chromatography with fluorescence detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18980116/),%,98.13-102.83,164602,DB00592,Piperazine
,32913337,Cmax,The Cmax of IR pellets (98.051 ng/ml) was higher than the ER pellets (84.052 ng/ml) and the Tmax of ER pellets (5.116 h) was higher than the IR pellets (3.029 h).,"QbD based Eudragit coated Meclizine HCl immediate and extended release multiparticulates: formulation, characterization and pharmacokinetic evaluation using HPLC-Fluorescence detection method. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32913337/),[ng] / [ml],98.051,164609,DB00592,Piperazine
,32913337,Cmax,The Cmax of IR pellets (98.051 ng/ml) was higher than the ER pellets (84.052 ng/ml) and the Tmax of ER pellets (5.116 h) was higher than the IR pellets (3.029 h).,"QbD based Eudragit coated Meclizine HCl immediate and extended release multiparticulates: formulation, characterization and pharmacokinetic evaluation using HPLC-Fluorescence detection method. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32913337/),[ng] / [ml],84.052,164610,DB00592,Piperazine
,32913337,Tmax,The Cmax of IR pellets (98.051 ng/ml) was higher than the ER pellets (84.052 ng/ml) and the Tmax of ER pellets (5.116 h) was higher than the IR pellets (3.029 h).,"QbD based Eudragit coated Meclizine HCl immediate and extended release multiparticulates: formulation, characterization and pharmacokinetic evaluation using HPLC-Fluorescence detection method. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32913337/),h,5.116,164611,DB00592,Piperazine
,32913337,Tmax,The Cmax of IR pellets (98.051 ng/ml) was higher than the ER pellets (84.052 ng/ml) and the Tmax of ER pellets (5.116 h) was higher than the IR pellets (3.029 h).,"QbD based Eudragit coated Meclizine HCl immediate and extended release multiparticulates: formulation, characterization and pharmacokinetic evaluation using HPLC-Fluorescence detection method. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32913337/),h,3.029,164612,DB00592,Piperazine
,9690694,clearance,mCPP showed a large variability in clearance (11-92 mL/hr) and bioavailability (14-108%).,Pharmacokinetic and pharmacodynamic profile of oral and intravenous meta-chlorophenylpiperazine in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690694/),[ml] / [h],11-92,164678,DB00592,Piperazine
,9690694,bioavailability,mCPP showed a large variability in clearance (11-92 mL/hr) and bioavailability (14-108%).,Pharmacokinetic and pharmacodynamic profile of oral and intravenous meta-chlorophenylpiperazine in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690694/),%,14-108,164679,DB00592,Piperazine
,19646080,CL,"Mean population CL and V of IV-ITZ were 10 L/h and 1050 L, respectively.",Population pharmacokinetics of intravenous itraconazole in patients with persistent neutropenic fever. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646080/),[l] / [h],10,164760,DB00592,Piperazine
,19646080,V,"Mean population CL and V of IV-ITZ were 10 L/h and 1050 L, respectively.",Population pharmacokinetics of intravenous itraconazole in patients with persistent neutropenic fever. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646080/),l,1050,164761,DB00592,Piperazine
,19646080,trough concentration,The median simulated trough concentration of ITZ after 10 days was predicted to be about 700 ng/mL.,Population pharmacokinetics of intravenous itraconazole in patients with persistent neutropenic fever. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646080/),[ng] / [ml],700,164762,DB00592,Piperazine
,20097587,maximum plasma concentration (C(max)),"The estimated maximum plasma concentration (C(max)) and trough plasma concentration of cetirizine were 135 ng/mL and 18 ng/mL, respectively.",Pharmacokinetics and effects of cetirizine in horses with insect bite hypersensitivity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20097587/),[ng] / [ml],135,165163,DB00592,Piperazine
,20097587,trough plasma concentration,"The estimated maximum plasma concentration (C(max)) and trough plasma concentration of cetirizine were 135 ng/mL and 18 ng/mL, respectively.",Pharmacokinetics and effects of cetirizine in horses with insect bite hypersensitivity. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20097587/),[ng] / [ml],18,165164,DB00592,Piperazine
,34370587,area under the concentration-time curve over 24 hours (AUC24),"Itraconazole and hydroxyitraconazole pharmacokinetic variability was considerable, with area under the concentration-time curve over 24 hours (AUC24) mean ± standard deviation 3.34 ± 4.31 mg*h/litre and 3.57 ± 4.46 mg*h/litre, respectively.",Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34370587/),[h·mg] / [l],3.34,165172,DB00592,Piperazine
,34370587,area under the concentration-time curve over 24 hours (AUC24),"Itraconazole and hydroxyitraconazole pharmacokinetic variability was considerable, with area under the concentration-time curve over 24 hours (AUC24) mean ± standard deviation 3.34 ± 4.31 mg*h/litre and 3.57 ± 4.46 mg*h/litre, respectively.",Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34370587/),[h·mg] / [l],3.57,165173,DB00592,Piperazine
,34370587,minimum concentration (Cmin),Levels of both analytes were low; itraconazole minimum concentration (Cmin) 0.11 ± 0.16 mg/liter; hydroxyitraconazole Cmin 0.13 ± 0.17 mg/litre.,Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34370587/),[mg] / [l],0.11,165174,DB00592,Piperazine
,34370587,Cmin,Levels of both analytes were low; itraconazole minimum concentration (Cmin) 0.11 ± 0.16 mg/liter; hydroxyitraconazole Cmin 0.13 ± 0.17 mg/litre.,Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34370587/),[mg] / [l],0.13,165175,DB00592,Piperazine
,34370587,maximal rates of drug-induced killing,"The mean maximal rates of drug-induced killing were 0.206 and 0.208 log10 CFU/mL/h, respectively.",Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34370587/),[cfu·log10] / [h·ml],0.206,165176,DB00592,Piperazine
,34370587,maximal rates of drug-induced killing,"The mean maximal rates of drug-induced killing were 0.206 and 0.208 log10 CFU/mL/h, respectively.",Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34370587/),[cfu·log10] / [h·ml],0.208,165177,DB00592,Piperazine
,11902799,ratios,"Conversely, after administration of (-)-zopiclone, both enantiomers were found in plasma and brain with (+)-zopiclone/(-)-zopiclone ratios of 1 and 8.4 in plasma and brain, respectively.",Stereoselective distribution and stereoconversion of zopiclone enantiomers in plasma and brain tissues in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11902799/),,1,165726,DB00592,Piperazine
,11902799,ratios,"Conversely, after administration of (-)-zopiclone, both enantiomers were found in plasma and brain with (+)-zopiclone/(-)-zopiclone ratios of 1 and 8.4 in plasma and brain, respectively.",Stereoselective distribution and stereoconversion of zopiclone enantiomers in plasma and brain tissues in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11902799/),,8,165727,DB00592,Piperazine
,27744175,bioavailability,It was previously shown that bioavailability of S(-)-NAF (14.5%) was twice that of R(+)-NAF (6.8%).,Poor and enantioselective bioavailability of naftopidil enantiomers is due to extensive and stereoselective metabolism in rat liver. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27744175/),%,14.5,165848,DB00592,Piperazine
,27744175,bioavailability,It was previously shown that bioavailability of S(-)-NAF (14.5%) was twice that of R(+)-NAF (6.8%).,Poor and enantioselective bioavailability of naftopidil enantiomers is due to extensive and stereoselective metabolism in rat liver. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27744175/),%,6.8,165849,DB00592,Piperazine
,8529326,area under the concentration-time curve (AUC),"Phenytoin decreased the area under the concentration-time curve (AUC) of itraconazole by more than 90%, from 3203 to 224 ng.hr/ml, accompanied by a decrease in half-life from 22.3 to 3.8 hours.",Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529326/),[h·ng] / [ml],3203,166050,DB00592,Piperazine
,8529326,area under the concentration-time curve (AUC),"Phenytoin decreased the area under the concentration-time curve (AUC) of itraconazole by more than 90%, from 3203 to 224 ng.hr/ml, accompanied by a decrease in half-life from 22.3 to 3.8 hours.",Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529326/),[h·ng] / [ml],224,166051,DB00592,Piperazine
,8529326,half-life,"Phenytoin decreased the area under the concentration-time curve (AUC) of itraconazole by more than 90%, from 3203 to 224 ng.hr/ml, accompanied by a decrease in half-life from 22.3 to 3.8 hours.",Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529326/),h,22.3,166052,DB00592,Piperazine
,8529326,half-life,"Phenytoin decreased the area under the concentration-time curve (AUC) of itraconazole by more than 90%, from 3203 to 224 ng.hr/ml, accompanied by a decrease in half-life from 22.3 to 3.8 hours.",Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529326/),h,3.8,166053,DB00592,Piperazine
,8529326,AUC,Similar changes were observed for hydroxyitraconazole AUC (decreased from 6224 to 315 ng.hr/ml) and half-life (11.3 versus 2.9 hours).,Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529326/),[h·ng] / [ml],6224,166054,DB00592,Piperazine
,8529326,AUC,Similar changes were observed for hydroxyitraconazole AUC (decreased from 6224 to 315 ng.hr/ml) and half-life (11.3 versus 2.9 hours).,Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529326/),[h·ng] / [ml],315,166055,DB00592,Piperazine
,8529326,half-life,Similar changes were observed for hydroxyitraconazole AUC (decreased from 6224 to 315 ng.hr/ml) and half-life (11.3 versus 2.9 hours).,Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529326/),h,11.3,166056,DB00592,Piperazine
,8529326,half-life,Similar changes were observed for hydroxyitraconazole AUC (decreased from 6224 to 315 ng.hr/ml) and half-life (11.3 versus 2.9 hours).,Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529326/),h,2.9,166057,DB00592,Piperazine
,16372826,overall,"Following administration of prulifloxacin 600mg, the overall mean corrected lung/plasma ratio over the 24-hour period was 6.9 (range 1.2-14.1).",Penetration of orally administered prulifloxacin into human lung tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372826/),,6.9,166351,DB00592,Piperazine
,16372826,corrected lung/plasma ratio,"Following administration of prulifloxacin 600mg, the overall mean corrected lung/plasma ratio over the 24-hour period was 6.9 (range 1.2-14.1).",Penetration of orally administered prulifloxacin into human lung tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372826/),,6.9,166352,DB00592,Piperazine
,16372826,corrected lung/plasma ratios,"When sampling intervals were assessed, the corrected lung/plasma ratios were 7.5 (2 hours after dosing), 6.3 (4 hours), 4.3 (6 hours), 7.0 (12 hours) and 9.2 (24 hours).",Penetration of orally administered prulifloxacin into human lung tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372826/),,7.5,166353,DB00592,Piperazine
,16372826,corrected lung/plasma ratios,"When sampling intervals were assessed, the corrected lung/plasma ratios were 7.5 (2 hours after dosing), 6.3 (4 hours), 4.3 (6 hours), 7.0 (12 hours) and 9.2 (24 hours).",Penetration of orally administered prulifloxacin into human lung tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372826/),,6.3,166354,DB00592,Piperazine
,16372826,corrected lung/plasma ratios,"When sampling intervals were assessed, the corrected lung/plasma ratios were 7.5 (2 hours after dosing), 6.3 (4 hours), 4.3 (6 hours), 7.0 (12 hours) and 9.2 (24 hours).",Penetration of orally administered prulifloxacin into human lung tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372826/),,4.3,166355,DB00592,Piperazine
,16372826,corrected lung/plasma ratios,"When sampling intervals were assessed, the corrected lung/plasma ratios were 7.5 (2 hours after dosing), 6.3 (4 hours), 4.3 (6 hours), 7.0 (12 hours) and 9.2 (24 hours).",Penetration of orally administered prulifloxacin into human lung tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372826/),,7.0,166356,DB00592,Piperazine
,16372826,corrected lung/plasma ratios,"When sampling intervals were assessed, the corrected lung/plasma ratios were 7.5 (2 hours after dosing), 6.3 (4 hours), 4.3 (6 hours), 7.0 (12 hours) and 9.2 (24 hours).",Penetration of orally administered prulifloxacin into human lung tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372826/),,9.2,166357,DB00592,Piperazine
,16372826,area under the concentration-time curve ratio,"The mean corrected lung/plasma area under the concentration-time curve ratio was 6.3, demonstrating the ability of the drug to penetrate lung tissue and confirming the high exposure of this target tissue to ulifloxacin.",Penetration of orally administered prulifloxacin into human lung tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372826/),,6.3,166358,DB00592,Piperazine
,6141018,oral bioavailability,"Kinetic analysis showed oral bioavailability of 63%, a clearance rate of 66 ml/min, and a terminal elimination t1/2 of approximately 3 hr.",Trimazosin in normotensive subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6141018/),%,63,166596,DB00592,Piperazine
,6141018,clearance rate,"Kinetic analysis showed oral bioavailability of 63%, a clearance rate of 66 ml/min, and a terminal elimination t1/2 of approximately 3 hr.",Trimazosin in normotensive subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6141018/),[ml] / [min],66,166597,DB00592,Piperazine
,6141018,terminal elimination t1/2,"Kinetic analysis showed oral bioavailability of 63%, a clearance rate of 66 ml/min, and a terminal elimination t1/2 of approximately 3 hr.",Trimazosin in normotensive subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6141018/),h,3,166598,DB00592,Piperazine
,22114028,inhibitory concentration (IC)(50),"In rat liver microsomes, inhibitory concentration (IC)(50) of BBR inhibiting KTZ depletion was determined to be 103 µm.",Drug-drug interactions between ketoconazole and berberine in rats: pharmacokinetic effects benefit pharmacodynamic synergism. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22114028/),µm,103,166686,DB00592,Piperazine
,30779479,effective half-life (t1/2(eff) ),"In the SAD study (400-1600 mg, SBF), mean effective half-life (t1/2(eff) ) of JTK-853 was 8.3 to 10.9 hours, and 20.3 to 27.3 hours in the MAD study (twice daily dosing, fed condition), with 2- to 3-fold accumulation in exposure (AUCtau ).","Pharmacokinetics, Food Effect, Ketoconazole Interaction, and Safety of JTK-853, a Novel Nonnucleoside HCV Polymerase Inhibitor, After Ascending Single and Multiple Doses in Healthy Subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30779479/),h,8.3 to 10.9,167112,DB00592,Piperazine
,30779479,effective half-life (t1/2(eff) ),"In the SAD study (400-1600 mg, SBF), mean effective half-life (t1/2(eff) ) of JTK-853 was 8.3 to 10.9 hours, and 20.3 to 27.3 hours in the MAD study (twice daily dosing, fed condition), with 2- to 3-fold accumulation in exposure (AUCtau ).","Pharmacokinetics, Food Effect, Ketoconazole Interaction, and Safety of JTK-853, a Novel Nonnucleoside HCV Polymerase Inhibitor, After Ascending Single and Multiple Doses in Healthy Subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30779479/),h,20.3 to 27.3,167113,DB00592,Piperazine
,8878578,maximum concentration,"Coadministration of rifampin resulted in an 18-fold decrease in the maximum concentration of itraconazole in serum, from 113.0 (standard deviation [SD] 17.2) to 6.2 (SD, 3.9) ng/ml and a 22-fold decrease in the area under the concentration-time curve, from 1,652.7 (SD, 297.7) to 75.6 (SD, 30.0) ng.h/ml.",Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878578/),[ng] / [ml],113.0,167478,DB00592,Piperazine
,8878578,maximum concentration,"Coadministration of rifampin resulted in an 18-fold decrease in the maximum concentration of itraconazole in serum, from 113.0 (standard deviation [SD] 17.2) to 6.2 (SD, 3.9) ng/ml and a 22-fold decrease in the area under the concentration-time curve, from 1,652.7 (SD, 297.7) to 75.6 (SD, 30.0) ng.h/ml.",Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878578/),[ng] / [ml],6.2,167479,DB00592,Piperazine
,8878578,area under the concentration-time curve,"Coadministration of rifampin resulted in an 18-fold decrease in the maximum concentration of itraconazole in serum, from 113.0 (standard deviation [SD] 17.2) to 6.2 (SD, 3.9) ng/ml and a 22-fold decrease in the area under the concentration-time curve, from 1,652.7 (SD, 297.7) to 75.6 (SD, 30.0) ng.h/ml.",Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878578/),[h·ng] / [ml],"1,652.7",167480,DB00592,Piperazine
,8878578,area under the concentration-time curve,"Coadministration of rifampin resulted in an 18-fold decrease in the maximum concentration of itraconazole in serum, from 113.0 (standard deviation [SD] 17.2) to 6.2 (SD, 3.9) ng/ml and a 22-fold decrease in the area under the concentration-time curve, from 1,652.7 (SD, 297.7) to 75.6 (SD, 30.0) ng.h/ml.",Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878578/),[h·ng] / [ml],75.6,167481,DB00592,Piperazine
,26987948,onset of action,"At a 0.5-mg dose, the mean onset of action was 1.3 ± 0.6 min and lasted for about 1.5 h according to the pharmacokinetic studies.",Rapid-Onset Sildenafil Sublingual Drug Delivery Systems: In Vitro Evaluation and In Vivo Pharmacokinetic Studies in Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26987948/),min,1.3,167772,DB00592,Piperazine
,22805325,prostatic serum antigen,The median age was 73 (57-89); median prostatic serum antigen was 284 ng ml(-1) (11.7-9027).,Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22805325/),[ng] / [ml],284,167818,DB00592,Piperazine
,22805325,time to progression,Median time to progression was 2 months (1-5).,Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22805325/),month,2,167819,DB00592,Piperazine
,27999010,C trough,"The geometric mean (95% CI) of C trough of rilpivirine and dolutegravir did not change between baseline and week 4 ( P = 0.654 and P = 0.268, respectively), with corresponding overall values of 135 (102-177) and 1357 (970-1897) ng/mL.",Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27999010/),[ng] / [ml],135,167953,DB00592,Piperazine
,27999010,C trough,"The geometric mean (95% CI) of C trough of rilpivirine and dolutegravir did not change between baseline and week 4 ( P = 0.654 and P = 0.268, respectively), with corresponding overall values of 135 (102-177) and 1357 (970-1897) ng/mL.",Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27999010/),[ng] / [ml],1357,167954,DB00592,Piperazine
,27999010,C trough,"The overall geometric mean (95% CI) of GS-331007 and simeprevir C trough was 370 (268-512) and 2537 (1569-4101) ng/mL, respectively, without significant variation between weeks 2 and 4 ( P = 0.643 and P = 0.179, respectively).",Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27999010/),[ng] / [ml],370,167955,DB00592,Piperazine
,27999010,C trough,"The overall geometric mean (95% CI) of GS-331007 and simeprevir C trough was 370 (268-512) and 2537 (1569-4101) ng/mL, respectively, without significant variation between weeks 2 and 4 ( P = 0.643 and P = 0.179, respectively).",Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27999010/),[ng] / [ml],2537,167956,DB00592,Piperazine
,18313371,ch,The method had a chromatographic run time of 4.5 min and linear calibration curves over the concentration range of 0.5-150 ng/mL for both zopiclone and N-desmethyl zopiclone and 1-150 ng/mL for zopiclone-N-oxide.,"HPLC-ESI-MS/MS validated method for simultaneous quantification of zopiclone and its metabolites, N-desmethyl zopiclone and zopiclone-N-oxide in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18313371/),min,4.5,168041,DB00592,Piperazine
,18313371,run time,The method had a chromatographic run time of 4.5 min and linear calibration curves over the concentration range of 0.5-150 ng/mL for both zopiclone and N-desmethyl zopiclone and 1-150 ng/mL for zopiclone-N-oxide.,"HPLC-ESI-MS/MS validated method for simultaneous quantification of zopiclone and its metabolites, N-desmethyl zopiclone and zopiclone-N-oxide in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18313371/),min,4.5,168042,DB00592,Piperazine
> or =,18313371,recoveries,The recoveries calculated for the analytes and internal standard were > or = 90% from spiked plasma samples.,"HPLC-ESI-MS/MS validated method for simultaneous quantification of zopiclone and its metabolites, N-desmethyl zopiclone and zopiclone-N-oxide in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18313371/),%,90,168043,DB00592,Piperazine
,25916686,terminal elimination half-life (T1/2λz ),"After IV administration, the major pharmacokinetic parameters were as follows (mean ± SD): terminal elimination half-life (T1/2λz ) 15.8 ± 1.88 h; area under the curve from time zero to infinity (AUC0-∞ ) 13.9 ± 3.17 h·μg/ml; total body clearance 0.37 ± 0.08 l/h/kg; apparent volume of distribution 8.51 ± 1.92 l/kg; mean residence time 20.6 ± 3.95 h.",Pharmacokinetics and bioavailability of itraconazole oral solution in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25916686/),h,15.8,168333,DB00592,Piperazine
,25916686,area under the curve from time zero to infinity (AUC0-∞ ),"After IV administration, the major pharmacokinetic parameters were as follows (mean ± SD): terminal elimination half-life (T1/2λz ) 15.8 ± 1.88 h; area under the curve from time zero to infinity (AUC0-∞ ) 13.9 ± 3.17 h·μg/ml; total body clearance 0.37 ± 0.08 l/h/kg; apparent volume of distribution 8.51 ± 1.92 l/kg; mean residence time 20.6 ± 3.95 h.",Pharmacokinetics and bioavailability of itraconazole oral solution in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25916686/),[h·μg] / [ml],13.9,168334,DB00592,Piperazine
,25916686,total body clearance,"After IV administration, the major pharmacokinetic parameters were as follows (mean ± SD): terminal elimination half-life (T1/2λz ) 15.8 ± 1.88 h; area under the curve from time zero to infinity (AUC0-∞ ) 13.9 ± 3.17 h·μg/ml; total body clearance 0.37 ± 0.08 l/h/kg; apparent volume of distribution 8.51 ± 1.92 l/kg; mean residence time 20.6 ± 3.95 h.",Pharmacokinetics and bioavailability of itraconazole oral solution in cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25916686/),[l] / [h·kg],0.37,168335,DB00592,Piperazine
,25916686,apparent volume of distribution,"After IV administration, the major pharmacokinetic parameters were as follows (mean ± SD): terminal elimination half-life (T1/2λz ) 15.8 ± 1.88 h; area under the curve from time zero to infinity (AUC0-∞ ) 13.9 ± 3.17 h·μg/ml; total body clearance 0.37 ± 0.08 l/h/kg; apparent volume of distribution 8.51 ± 1.92 l/kg; mean residence time 20.6 ± 3.95 h.",Pharmacokinetics and bioavailability of itraconazole oral solution in cats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25916686/),[l] / [kg],8.51,168336,DB00592,Piperazine
,25916686,mean residence time,"After IV administration, the major pharmacokinetic parameters were as follows (mean ± SD): terminal elimination half-life (T1/2λz ) 15.8 ± 1.88 h; area under the curve from time zero to infinity (AUC0-∞ ) 13.9 ± 3.17 h·μg/ml; total body clearance 0.37 ± 0.08 l/h/kg; apparent volume of distribution 8.51 ± 1.92 l/kg; mean residence time 20.6 ± 3.95 h.",Pharmacokinetics and bioavailability of itraconazole oral solution in cats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25916686/),h,20.6,168337,DB00592,Piperazine
,25916686,T1/2λz,"After PO administration, the principal pharmacokinetic parameters were as follows (mean ± SD): T1/2λz 15.6 ± 3.20 h; AUC0-∞ 7.94 ± 2.83 h·μg/ml; peak concentration 0.70 ± 0.14 μg/ml; time of peak 1.43 ± 0.53 h.",Pharmacokinetics and bioavailability of itraconazole oral solution in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25916686/),h,15.6,168338,DB00592,Piperazine
,25916686,AUC0-∞,"After PO administration, the principal pharmacokinetic parameters were as follows (mean ± SD): T1/2λz 15.6 ± 3.20 h; AUC0-∞ 7.94 ± 2.83 h·μg/ml; peak concentration 0.70 ± 0.14 μg/ml; time of peak 1.43 ± 0.53 h.",Pharmacokinetics and bioavailability of itraconazole oral solution in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25916686/),[h·μg] / [ml],7.94,168339,DB00592,Piperazine
,25916686,peak concentration,"After PO administration, the principal pharmacokinetic parameters were as follows (mean ± SD): T1/2λz 15.6 ± 3.20 h; AUC0-∞ 7.94 ± 2.83 h·μg/ml; peak concentration 0.70 ± 0.14 μg/ml; time of peak 1.43 ± 0.53 h.",Pharmacokinetics and bioavailability of itraconazole oral solution in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25916686/),[μg] / [ml],0.70,168340,DB00592,Piperazine
,25916686,time of peak,"After PO administration, the principal pharmacokinetic parameters were as follows (mean ± SD): T1/2λz 15.6 ± 3.20 h; AUC0-∞ 7.94 ± 2.83 h·μg/ml; peak concentration 0.70 ± 0.14 μg/ml; time of peak 1.43 ± 0.53 h.",Pharmacokinetics and bioavailability of itraconazole oral solution in cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25916686/),h,1.43,168341,DB00592,Piperazine
,25916686,absolute bioavailability,The absolute bioavailability of ITR oral solution after oral administration was 52.1 ± 11.6%.,Pharmacokinetics and bioavailability of itraconazole oral solution in cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25916686/),%,52.1,168342,DB00592,Piperazine
,33771716,AUC0-t,"For AST2818, the Cmax, AUC0-t, and AUC0-∞ in period II (coadministration of itraconazole) increased by 6.5 ng/mL, 1263.0 h*ng/mL, and 1067.0 h*ng/mL, respectively.","Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33771716/),[h·ng] / [ml],1263.0,168606,DB00592,Piperazine
,33771716,AUC0-∞,"For AST2818, the Cmax, AUC0-t, and AUC0-∞ in period II (coadministration of itraconazole) increased by 6.5 ng/mL, 1263.0 h*ng/mL, and 1067.0 h*ng/mL, respectively.","Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33771716/),[h·ng] / [ml],1067.0,168607,DB00592,Piperazine
,33771716,Cmax,"The Cmax, AUC0-t, and AUC0-∞ of AST5902 in period II decreased by 4.849 ng/mL, 415.60 h*ng/mL, and 391.4 h*ng/mL, respectively.","Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33771716/),ng,4.,168608,DB00592,Piperazine
,33771716,AUC0-t,"The Cmax, AUC0-t, and AUC0-∞ of AST5902 in period II decreased by 4.849 ng/mL, 415.60 h*ng/mL, and 391.4 h*ng/mL, respectively.","Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33771716/),[h·ng] / [ml],415.60,168609,DB00592,Piperazine
,33771716,AUC0-∞,"The Cmax, AUC0-t, and AUC0-∞ of AST5902 in period II decreased by 4.849 ng/mL, 415.60 h*ng/mL, and 391.4 h*ng/mL, respectively.","Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33771716/),[h·ng] / [ml],391.4,168610,DB00592,Piperazine
,19248046,MTD,The MTD of vatalanib for all patients was 1000 mg twice-a-day.,Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19248046/),mg,1000,168805,DB00592,Piperazine
,20980997,IM-C(min),"Among 254 CML patients, the mean IM-C(min) was 1,010.5 ng/ml.",Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20980997/),[ng] / [ml],"1,010.5",169050,DB00592,Piperazine
>,20980997,C(min),"Given that patients with IM-C(min) values >1,002 ng/ml had a higher probability of achieving an MMR in our large cohort (P = 0.0120), the data suggest that monitoring of IM levels in plasma may improve the efficacy of IM therapy for CML patients.",Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20980997/),[ng] / [ml],"1,002",169051,DB00592,Piperazine
,9420044,trough concentrations,"At the end of i.v. treatment, mean (+/- standard deviation) itraconazole and hydroxy-itraconazole trough concentrations in plasma were 0.344 +/- 0.140 and 0.605 +/- 0.205 microg/ml, respectively.",Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420044/),[μg] / [ml],0.344,169188,DB00592,Piperazine
,9420044,trough concentrations,"At the end of i.v. treatment, mean (+/- standard deviation) itraconazole and hydroxy-itraconazole trough concentrations in plasma were 0.344 +/- 0.140 and 0.605 +/- 0.205 microg/ml, respectively.",Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420044/),[μg] / [ml],0.605,169189,DB00592,Piperazine
,9420044,trough concentration,"After the 2-week oral follow-up of 200 mg once daily the mean trough concentration had decreased to 0.245 microg/ml, whereas after 200 mg b.i.d. it increased to 0.369 microg/ml.",Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420044/),[μg] / [ml],0.245,169190,DB00592,Piperazine
,9420044,trough concentration,"After the 2-week oral follow-up of 200 mg once daily the mean trough concentration had decreased to 0.245 microg/ml, whereas after 200 mg b.i.d. it increased to 0.369 microg/ml.",Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420044/),[μg] / [ml],0.369,169191,DB00592,Piperazine
,21425954,solubility,"Sildenafil displayed a high solubility of 124 mg/mL in the microemulsion consisting of 40% oleic acid, 10% H(2)O, and 50% Tween 80:ethanol (EA) (at a 1:4 weight ratio).",Rapid-onset sildenafil nasal spray carried by microemulsion systems: in vitro evaluation and in vivo pharmacokinetic studies in rabbits. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21425954/),[mg] / [ml],124,169246,DB00592,Piperazine
,16488611,half-life,"All four compounds were characterized and radiolabeled with fluorine-18, a 109.7 min half-life radionuclide used in positron emission tomography.","Synthesis and in vivo biodistribution of F-18 labeled 3-cis-, 3-trans-, 4-cis-, and 4-trans-fluorocyclohexane derivatives of WAY 100635. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16488611/),min,109.7,169259,DB00592,Piperazine
,29189941,terminal half-life,"The pharmacokinetics of vortioxetine are linear and dose proportional, with a mean terminal half-life of approximately 66 h and steady-state plasma concentrations generally achieved within 2 weeks of dosing.",Vortioxetine: Clinical Pharmacokinetics and Drug Interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29189941/),h,66,169321,DB00592,Piperazine
,29189941,absolute oral bioavailability,The mean absolute oral bioavailability of vortioxetine is 75%.,Vortioxetine: Clinical Pharmacokinetics and Drug Interactions. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29189941/),%,75,169322,DB00592,Piperazine
,2211561,half-life,The 3- to 9-hour half-life of trazodone and its pharmacokinetics favors a dose weighted at bedtime.,Trazodone dosing regimen: experience with single daily administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2211561/),h,3- to 9-,169340,DB00592,Piperazine
,18647303,K(m),Maraviroc was metabolized to its N-dealkylated product via a single CYP enzyme characterized by a K(m) of 21 microM and V(max) of 0.45 pmol pmol(-1) min(-1) in human liver microsomes and was inhibited by ketoconazole (CYP3A4 inhibitor).,Maraviroc: in vitro assessment of drug-drug interaction potential. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18647303/),μM,21,169385,DB00592,Piperazine
,18647303,V(max),Maraviroc was metabolized to its N-dealkylated product via a single CYP enzyme characterized by a K(m) of 21 microM and V(max) of 0.45 pmol pmol(-1) min(-1) in human liver microsomes and was inhibited by ketoconazole (CYP3A4 inhibitor).,Maraviroc: in vitro assessment of drug-drug interaction potential. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18647303/),[pM] / [min·pmol],0.45,169386,DB00592,Piperazine
,18647303,K(m),"Using recombinant CYP3A4, N-dealkylation was characterized by a K(m) of 13 microM and a V(max) of 3 pmol pmol(-1) CYP min(-1).",Maraviroc: in vitro assessment of drug-drug interaction potential. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18647303/),μM,13,169387,DB00592,Piperazine
,18647303,V(max),"Using recombinant CYP3A4, N-dealkylation was characterized by a K(m) of 13 microM and a V(max) of 3 pmol pmol(-1) CYP min(-1).",Maraviroc: in vitro assessment of drug-drug interaction potential. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18647303/),[cyp·pM] / [min·pmol],3,169388,DB00592,Piperazine
,10473237,MIC,"UR-9825 was more potent against Candida spp. than both fluconazole and itraconazole, even against some Candida albicans and Candida krusei isolates with decreased susceptibility to fluconazole (MIC 16 mg/L).","In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10473237/),[mg] / [l],16,169442,DB00592,Piperazine
,2888611,FiO2,"The infants did not require assisted ventilation, but needed oxygen therapy with an FiO2 of 25-30% in stable condition.",Study of the pharmacokinetics and pharmacodynamic activity of almitrine bismesylate in infants during the recovery phase following bronchopulmonary dysplasia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888611/),%,25-30,169606,DB00592,Piperazine
,2888611,maximum almitrine concentration,The maximum almitrine concentration was 173 +/- 44 ng/ml; plasma clearance was 21.9 +/- 6.6 ml/min and the volume of distribution was 18.7 +/- 2.1 liters/kg.,Study of the pharmacokinetics and pharmacodynamic activity of almitrine bismesylate in infants during the recovery phase following bronchopulmonary dysplasia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888611/),[ng] / [ml],173,169607,DB00592,Piperazine
,2888611,plasma clearance,The maximum almitrine concentration was 173 +/- 44 ng/ml; plasma clearance was 21.9 +/- 6.6 ml/min and the volume of distribution was 18.7 +/- 2.1 liters/kg.,Study of the pharmacokinetics and pharmacodynamic activity of almitrine bismesylate in infants during the recovery phase following bronchopulmonary dysplasia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888611/),[ml] / [min],21.9,169608,DB00592,Piperazine
,2888611,volume of distribution,The maximum almitrine concentration was 173 +/- 44 ng/ml; plasma clearance was 21.9 +/- 6.6 ml/min and the volume of distribution was 18.7 +/- 2.1 liters/kg.,Study of the pharmacokinetics and pharmacodynamic activity of almitrine bismesylate in infants during the recovery phase following bronchopulmonary dysplasia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888611/),[l] / [kg],18.7,169609,DB00592,Piperazine
,19275964,IC(50),"(3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone (5) emerged as a potent (IC(50) = 13 nM) and selective compound, with high oral bioavailability in preclinical species and low plasma protein binding.","(3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19275964/),nM,13,169872,DB00592,Piperazine
greater,6669634,oral bioavailability,"ZD is rapidly and efficiently absorbed: its oral bioavailability was greater than 75% in all species except rats, where a first-pass effect of about 65% was recorded.",Pharmacokinetics and metabolism of zopiclone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6669634/),%,75,171136,DB00592,Piperazine
,6669634,Plasma protein binding,Plasma protein binding is about 45%.,Pharmacokinetics and metabolism of zopiclone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6669634/),%,45,171137,DB00592,Piperazine
,6669634,terminal half-life,"Plasma kinetics of ZD are generally well described by a two-compartment open model; in man, terminal half-life is 4-5 h; total body clearance is large (300 ml/mn), renal clearance very low (10 ml/min).",Pharmacokinetics and metabolism of zopiclone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6669634/),h,4-5,171138,DB00592,Piperazine
,6669634,total body clearance,"Plasma kinetics of ZD are generally well described by a two-compartment open model; in man, terminal half-life is 4-5 h; total body clearance is large (300 ml/mn), renal clearance very low (10 ml/min).",Pharmacokinetics and metabolism of zopiclone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6669634/),[ml] / [mn],300,171139,DB00592,Piperazine
,6669634,renal clearance,"Plasma kinetics of ZD are generally well described by a two-compartment open model; in man, terminal half-life is 4-5 h; total body clearance is large (300 ml/mn), renal clearance very low (10 ml/min).",Pharmacokinetics and metabolism of zopiclone. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6669634/),[ml] / [min],10,171140,DB00592,Piperazine
,6669634,milk/plasma ratio,"In nursing mothers, milk and plasma kinetics of ZD are similar with a milk/plasma ratio around 0.80.",Pharmacokinetics and metabolism of zopiclone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6669634/),,0.80,171141,DB00592,Piperazine
,15671557,survival,Median survival was 14.6 months.,"A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15671557/),month,14.6,171334,DB00592,Piperazine
,33112166,maximum plasma trazodone concentration,"Median (interquartile [25th to 75th percentile] range [IQR]) maximum plasma trazodone concentration and volume of distribution and clearance corrected for bioavailability were 1.00 μg/mL (0.66 to 1.40 μg/mL), 10.3 L/kg (7.37 to 14.4 L/kg), and 639 mL/kg/h (594 to 719 mL/kg/h), respectively.",Pharmacokinetics and efficacy of trazodone following rectal administration of a single dose to healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33112166/),[μg] / [ml],1.00,171411,DB00592,Piperazine
,33112166,volume of distribution,"Median (interquartile [25th to 75th percentile] range [IQR]) maximum plasma trazodone concentration and volume of distribution and clearance corrected for bioavailability were 1.00 μg/mL (0.66 to 1.40 μg/mL), 10.3 L/kg (7.37 to 14.4 L/kg), and 639 mL/kg/h (594 to 719 mL/kg/h), respectively.",Pharmacokinetics and efficacy of trazodone following rectal administration of a single dose to healthy dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33112166/),[l] / [kg],10.3,171412,DB00592,Piperazine
,33112166,clearance corrected for bioavailability,"Median (interquartile [25th to 75th percentile] range [IQR]) maximum plasma trazodone concentration and volume of distribution and clearance corrected for bioavailability were 1.00 μg/mL (0.66 to 1.40 μg/mL), 10.3 L/kg (7.37 to 14.4 L/kg), and 639 mL/kg/h (594 to 719 mL/kg/h), respectively.",Pharmacokinetics and efficacy of trazodone following rectal administration of a single dose to healthy dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33112166/),[ml] / [h·kg],639,171413,DB00592,Piperazine
,33112166,time to maximum plasma trazodone concentration,"Median time to maximum plasma trazodone concentration and elimination half-life were 15 minutes (range, 15 to 30 minutes) and 12 hours (IQR, 7.99 to 12.7 hours), respectively.",Pharmacokinetics and efficacy of trazodone following rectal administration of a single dose to healthy dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33112166/),min,15,171414,DB00592,Piperazine
,33112166,elimination half-life,"Median time to maximum plasma trazodone concentration and elimination half-life were 15 minutes (range, 15 to 30 minutes) and 12 hours (IQR, 7.99 to 12.7 hours), respectively.",Pharmacokinetics and efficacy of trazodone following rectal administration of a single dose to healthy dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33112166/),h,12,171415,DB00592,Piperazine
,8627582,absolute bioavailability,The absolute bioavailability of oral tirilazad was 8.7 +/- 4.8%; ketoconazole increased the bioavailability to 20.9 +/- 6.5%.,Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8627582/),%,8.7,172768,DB00592,Piperazine
,8627582,bioavailability,The absolute bioavailability of oral tirilazad was 8.7 +/- 4.8%; ketoconazole increased the bioavailability to 20.9 +/- 6.5%.,Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8627582/),%,20.9,172769,DB00592,Piperazine
,20565112,IC(50),"Subsequent physicochemical property refinement by the incorporation of solubilizing groups led to the identification of 3-((4-(6-bromo-2-(4-(4-methylpiperazin-1-yl)phenyl)-3H-imidazo[4,5-b]pyridin-7-yl)piperazin-1-yl)methyl)-5-methylisoxazole (51, CCT137690) which is a potent inhibitor of Aurora kinases (Aurora-A IC(50) = 0.015 +/- 0.003 muM, Aurora-B IC(50) = 0.025 muM, Aurora-C IC(50) = 0.019 muM).","Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20565112/),muM,0.015,172941,DB00592,Piperazine
,20565112,IC(50),"Subsequent physicochemical property refinement by the incorporation of solubilizing groups led to the identification of 3-((4-(6-bromo-2-(4-(4-methylpiperazin-1-yl)phenyl)-3H-imidazo[4,5-b]pyridin-7-yl)piperazin-1-yl)methyl)-5-methylisoxazole (51, CCT137690) which is a potent inhibitor of Aurora kinases (Aurora-A IC(50) = 0.015 +/- 0.003 muM, Aurora-B IC(50) = 0.025 muM, Aurora-C IC(50) = 0.019 muM).","Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20565112/),muM,0.025,172942,DB00592,Piperazine
,20565112,IC(50),"Subsequent physicochemical property refinement by the incorporation of solubilizing groups led to the identification of 3-((4-(6-bromo-2-(4-(4-methylpiperazin-1-yl)phenyl)-3H-imidazo[4,5-b]pyridin-7-yl)piperazin-1-yl)methyl)-5-methylisoxazole (51, CCT137690) which is a potent inhibitor of Aurora kinases (Aurora-A IC(50) = 0.015 +/- 0.003 muM, Aurora-B IC(50) = 0.025 muM, Aurora-C IC(50) = 0.019 muM).","Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20565112/),muM,0.019,172943,DB00592,Piperazine
,8592675,bioavailability,"The bioavailability of NEF, based on AUC(INF), from proximal and distal regions relative to that from oral administration was 97% and 106%, respectively.",Absorption and presystemic metabolism of nefazodone administered at different regions in the gastrointestinal tract of humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592675/),%,97,173361,DB00592,Piperazine
,8592675,bioavailability,"The bioavailability of NEF, based on AUC(INF), from proximal and distal regions relative to that from oral administration was 97% and 106%, respectively.",Absorption and presystemic metabolism of nefazodone administered at different regions in the gastrointestinal tract of humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592675/),%,106,173362,DB00592,Piperazine
,8592675,Tmax,NEF was absorbed equally well from all three treatments with median Tmax of 5.0 hours which coincided with the duration of infusion.,Absorption and presystemic metabolism of nefazodone administered at different regions in the gastrointestinal tract of humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592675/),h,5.0,173363,DB00592,Piperazine
,2874974,half-life,"Minimal impairment of psychomotor skills and mental acuity occurs in the morning after a bedtime dose of zopiclone, which has a short half-life of about 5 hours and no long acting metabolites.",Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2874974/),h,5,173477,DB00592,Piperazine
,10719007,T(erad),Grepafloxacin eliminated potential bacterial pathogens more quickly than clarithromycin (median T(erad) 4 h versus 76 h).,Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10719007/),h,4,173983,DB00592,Piperazine
,10719007,T(erad),Grepafloxacin eliminated potential bacterial pathogens more quickly than clarithromycin (median T(erad) 4 h versus 76 h).,Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10719007/),h,76,173984,DB00592,Piperazine
,10719007,AUIC(24),"The greater efficacy of grepafloxacin, compared with that of clarithromycin, in terms of the incidence and speed of eradication of the Haemophilus spp. isolates, was associated with higher median values of AUIC(24) (169 SIT(-1)*h versus 8.1 SIT(-1)*h), C(max):MIC ratio (23.6 versus 0.7) and %tau >MIC (100% versus 0%).",Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10719007/),[h] / [sit],169,173985,DB00592,Piperazine
,10719007,AUIC(24),"The greater efficacy of grepafloxacin, compared with that of clarithromycin, in terms of the incidence and speed of eradication of the Haemophilus spp. isolates, was associated with higher median values of AUIC(24) (169 SIT(-1)*h versus 8.1 SIT(-1)*h), C(max):MIC ratio (23.6 versus 0.7) and %tau >MIC (100% versus 0%).",Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10719007/),[h] / [sit],8.1,173986,DB00592,Piperazine
,10719007,C(max):MIC ratio,"The greater efficacy of grepafloxacin, compared with that of clarithromycin, in terms of the incidence and speed of eradication of the Haemophilus spp. isolates, was associated with higher median values of AUIC(24) (169 SIT(-1)*h versus 8.1 SIT(-1)*h), C(max):MIC ratio (23.6 versus 0.7) and %tau >MIC (100% versus 0%).",Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10719007/),,23.6,173987,DB00592,Piperazine
,10719007,C(max):MIC ratio,"The greater efficacy of grepafloxacin, compared with that of clarithromycin, in terms of the incidence and speed of eradication of the Haemophilus spp. isolates, was associated with higher median values of AUIC(24) (169 SIT(-1)*h versus 8.1 SIT(-1)*h), C(max):MIC ratio (23.6 versus 0.7) and %tau >MIC (100% versus 0%).",Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10719007/),,0.7,173988,DB00592,Piperazine
,12784318,Cl,"The mean Cl, V(ss) and t(1/2) were 0.3 l/h, 0.1 l and 63.2 min in mice, 1.5 l/h, 1.6 l and 247.7 min in rats, 13.8 l/h, 39.6 l and 245.9 min in rabbits, and 29.2 l/h, 44.6 l and 117.4 min in dogs, respectively.","Pharmacokinetic scaling of SJ-8029, a novel anticancer agent possessing microtubule and topoisomerase inhibiting activities, by species-invariant time methods. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784318/),[l] / [h],0.3,174130,DB00592,Piperazine
,12784318,V(ss),"The mean Cl, V(ss) and t(1/2) were 0.3 l/h, 0.1 l and 63.2 min in mice, 1.5 l/h, 1.6 l and 247.7 min in rats, 13.8 l/h, 39.6 l and 245.9 min in rabbits, and 29.2 l/h, 44.6 l and 117.4 min in dogs, respectively.","Pharmacokinetic scaling of SJ-8029, a novel anticancer agent possessing microtubule and topoisomerase inhibiting activities, by species-invariant time methods. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784318/),l,0.1,174131,DB00592,Piperazine
,12784318,V(ss),"The mean Cl, V(ss) and t(1/2) were 0.3 l/h, 0.1 l and 63.2 min in mice, 1.5 l/h, 1.6 l and 247.7 min in rats, 13.8 l/h, 39.6 l and 245.9 min in rabbits, and 29.2 l/h, 44.6 l and 117.4 min in dogs, respectively.","Pharmacokinetic scaling of SJ-8029, a novel anticancer agent possessing microtubule and topoisomerase inhibiting activities, by species-invariant time methods. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784318/),min,63.2,174132,DB00592,Piperazine
,12784318,V(ss),"The mean Cl, V(ss) and t(1/2) were 0.3 l/h, 0.1 l and 63.2 min in mice, 1.5 l/h, 1.6 l and 247.7 min in rats, 13.8 l/h, 39.6 l and 245.9 min in rabbits, and 29.2 l/h, 44.6 l and 117.4 min in dogs, respectively.","Pharmacokinetic scaling of SJ-8029, a novel anticancer agent possessing microtubule and topoisomerase inhibiting activities, by species-invariant time methods. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784318/),[l] / [h],1.5,174133,DB00592,Piperazine
,12784318,V(ss),"The mean Cl, V(ss) and t(1/2) were 0.3 l/h, 0.1 l and 63.2 min in mice, 1.5 l/h, 1.6 l and 247.7 min in rats, 13.8 l/h, 39.6 l and 245.9 min in rabbits, and 29.2 l/h, 44.6 l and 117.4 min in dogs, respectively.","Pharmacokinetic scaling of SJ-8029, a novel anticancer agent possessing microtubule and topoisomerase inhibiting activities, by species-invariant time methods. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784318/),[l] / [h],13.8,174134,DB00592,Piperazine
,12784318,V(ss),"The mean Cl, V(ss) and t(1/2) were 0.3 l/h, 0.1 l and 63.2 min in mice, 1.5 l/h, 1.6 l and 247.7 min in rats, 13.8 l/h, 39.6 l and 245.9 min in rabbits, and 29.2 l/h, 44.6 l and 117.4 min in dogs, respectively.","Pharmacokinetic scaling of SJ-8029, a novel anticancer agent possessing microtubule and topoisomerase inhibiting activities, by species-invariant time methods. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784318/),l,39.6,174135,DB00592,Piperazine
,12784318,V(ss),"The mean Cl, V(ss) and t(1/2) were 0.3 l/h, 0.1 l and 63.2 min in mice, 1.5 l/h, 1.6 l and 247.7 min in rats, 13.8 l/h, 39.6 l and 245.9 min in rabbits, and 29.2 l/h, 44.6 l and 117.4 min in dogs, respectively.","Pharmacokinetic scaling of SJ-8029, a novel anticancer agent possessing microtubule and topoisomerase inhibiting activities, by species-invariant time methods. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784318/),[l] / [h],29.2,174136,DB00592,Piperazine
,12784318,V(ss),"The mean Cl, V(ss) and t(1/2) were 0.3 l/h, 0.1 l and 63.2 min in mice, 1.5 l/h, 1.6 l and 247.7 min in rats, 13.8 l/h, 39.6 l and 245.9 min in rabbits, and 29.2 l/h, 44.6 l and 117.4 min in dogs, respectively.","Pharmacokinetic scaling of SJ-8029, a novel anticancer agent possessing microtubule and topoisomerase inhibiting activities, by species-invariant time methods. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784318/),l,44.6,174137,DB00592,Piperazine
,12784318,V(ss),"The mean Cl, V(ss) and t(1/2) were 0.3 l/h, 0.1 l and 63.2 min in mice, 1.5 l/h, 1.6 l and 247.7 min in rats, 13.8 l/h, 39.6 l and 245.9 min in rabbits, and 29.2 l/h, 44.6 l and 117.4 min in dogs, respectively.","Pharmacokinetic scaling of SJ-8029, a novel anticancer agent possessing microtubule and topoisomerase inhibiting activities, by species-invariant time methods. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784318/),min,117.4,174138,DB00592,Piperazine
,12784318,t(1/2),"The mean Cl, V(ss) and t(1/2) were 0.3 l/h, 0.1 l and 63.2 min in mice, 1.5 l/h, 1.6 l and 247.7 min in rats, 13.8 l/h, 39.6 l and 245.9 min in rabbits, and 29.2 l/h, 44.6 l and 117.4 min in dogs, respectively.","Pharmacokinetic scaling of SJ-8029, a novel anticancer agent possessing microtubule and topoisomerase inhibiting activities, by species-invariant time methods. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784318/),min,63.2,174139,DB00592,Piperazine
,12784318,t(1/2),"The mean Cl, V(ss) and t(1/2) were 0.3 l/h, 0.1 l and 63.2 min in mice, 1.5 l/h, 1.6 l and 247.7 min in rats, 13.8 l/h, 39.6 l and 245.9 min in rabbits, and 29.2 l/h, 44.6 l and 117.4 min in dogs, respectively.","Pharmacokinetic scaling of SJ-8029, a novel anticancer agent possessing microtubule and topoisomerase inhibiting activities, by species-invariant time methods. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784318/),min,245.9,174140,DB00592,Piperazine
,12784318,t(1/2),"The mean Cl, V(ss) and t(1/2) were 0.3 l/h, 0.1 l and 63.2 min in mice, 1.5 l/h, 1.6 l and 247.7 min in rats, 13.8 l/h, 39.6 l and 245.9 min in rabbits, and 29.2 l/h, 44.6 l and 117.4 min in dogs, respectively.","Pharmacokinetic scaling of SJ-8029, a novel anticancer agent possessing microtubule and topoisomerase inhibiting activities, by species-invariant time methods. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784318/),[l] / [h],29.2,174141,DB00592,Piperazine
,12784318,t(1/2),"The mean Cl, V(ss) and t(1/2) were 0.3 l/h, 0.1 l and 63.2 min in mice, 1.5 l/h, 1.6 l and 247.7 min in rats, 13.8 l/h, 39.6 l and 245.9 min in rabbits, and 29.2 l/h, 44.6 l and 117.4 min in dogs, respectively.","Pharmacokinetic scaling of SJ-8029, a novel anticancer agent possessing microtubule and topoisomerase inhibiting activities, by species-invariant time methods. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784318/),l,44.6,174142,DB00592,Piperazine
,12784318,t(1/2),"The mean Cl, V(ss) and t(1/2) were 0.3 l/h, 0.1 l and 63.2 min in mice, 1.5 l/h, 1.6 l and 247.7 min in rats, 13.8 l/h, 39.6 l and 245.9 min in rabbits, and 29.2 l/h, 44.6 l and 117.4 min in dogs, respectively.","Pharmacokinetic scaling of SJ-8029, a novel anticancer agent possessing microtubule and topoisomerase inhibiting activities, by species-invariant time methods. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784318/),min,117.4,174143,DB00592,Piperazine
,12784318,Cl,"The human pharmacokinetic parameters of Cl, V(ss) and t(1/2) predicted by the simple allometry and various species-invariant time methods were 50.4-145.0 l/h, 369.0-579.8 l and 242.0-1448.3 min, respectively.","Pharmacokinetic scaling of SJ-8029, a novel anticancer agent possessing microtubule and topoisomerase inhibiting activities, by species-invariant time methods. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784318/),[l] / [h],50.4-145.0,174144,DB00592,Piperazine
,12784318,V(ss),"The human pharmacokinetic parameters of Cl, V(ss) and t(1/2) predicted by the simple allometry and various species-invariant time methods were 50.4-145.0 l/h, 369.0-579.8 l and 242.0-1448.3 min, respectively.","Pharmacokinetic scaling of SJ-8029, a novel anticancer agent possessing microtubule and topoisomerase inhibiting activities, by species-invariant time methods. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784318/),l,369.0-579.8,174145,DB00592,Piperazine
,12784318,t(1/2),"The human pharmacokinetic parameters of Cl, V(ss) and t(1/2) predicted by the simple allometry and various species-invariant time methods were 50.4-145.0 l/h, 369.0-579.8 l and 242.0-1448.3 min, respectively.","Pharmacokinetic scaling of SJ-8029, a novel anticancer agent possessing microtubule and topoisomerase inhibiting activities, by species-invariant time methods. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12784318/),min,242.0-1448.3,174146,DB00592,Piperazine
,6637789,Maximum plasma concentration (Cmax),"Maximum plasma concentration (Cmax) after SRT (8.1 +/- 3.0 mg/L) was significantly lower than that observed after ST (13.5 +/- 2.3 mg/L), time to peak was strongly delayed by a factor 7, and the time when plasma concentrations were higher than half of Cmax (t Cmax/2) was longer (10.4 +/- 3.2 vs 2.3 +/- 0.6 hours, p less than 0.001).",Pharmacokinetics of a sustained-release trimazosin tablet formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6637789/),[mg] / [l],8.1,174271,DB00592,Piperazine
,6637789,Maximum plasma concentration (Cmax),"Maximum plasma concentration (Cmax) after SRT (8.1 +/- 3.0 mg/L) was significantly lower than that observed after ST (13.5 +/- 2.3 mg/L), time to peak was strongly delayed by a factor 7, and the time when plasma concentrations were higher than half of Cmax (t Cmax/2) was longer (10.4 +/- 3.2 vs 2.3 +/- 0.6 hours, p less than 0.001).",Pharmacokinetics of a sustained-release trimazosin tablet formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6637789/),[mg] / [l],13.5,174272,DB00592,Piperazine
,6637789,time when plasma concentrations,"Maximum plasma concentration (Cmax) after SRT (8.1 +/- 3.0 mg/L) was significantly lower than that observed after ST (13.5 +/- 2.3 mg/L), time to peak was strongly delayed by a factor 7, and the time when plasma concentrations were higher than half of Cmax (t Cmax/2) was longer (10.4 +/- 3.2 vs 2.3 +/- 0.6 hours, p less than 0.001).",Pharmacokinetics of a sustained-release trimazosin tablet formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6637789/),h,10.4,174273,DB00592,Piperazine
,6637789,time when plasma concentrations,"Maximum plasma concentration (Cmax) after SRT (8.1 +/- 3.0 mg/L) was significantly lower than that observed after ST (13.5 +/- 2.3 mg/L), time to peak was strongly delayed by a factor 7, and the time when plasma concentrations were higher than half of Cmax (t Cmax/2) was longer (10.4 +/- 3.2 vs 2.3 +/- 0.6 hours, p less than 0.001).",Pharmacokinetics of a sustained-release trimazosin tablet formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6637789/),h,2.3,174274,DB00592,Piperazine
,6637789,Bioavailability,Bioavailability of the SRT (300 mg) as measured by the area under the curve (AUC00) was about 65% of the ST.,Pharmacokinetics of a sustained-release trimazosin tablet formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6637789/),%,65,174275,DB00592,Piperazine
,6637789,Cmax,"At the seventh dose, after single daily doses of the SRT in 12 subjects, the mean Cmax values were not significantly higher than after the first dose (8.6 +/- 3.2 mg/L vs 7.7 +/- 2.2 mg/L), t Cmax/2 values were the same (10.4 hours), and the AUC0-24 hr was comparable to AUC00 calculated after the first dose.",Pharmacokinetics of a sustained-release trimazosin tablet formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6637789/),[mg] / [l],8.6,174276,DB00592,Piperazine
,6637789,Cmax,"At the seventh dose, after single daily doses of the SRT in 12 subjects, the mean Cmax values were not significantly higher than after the first dose (8.6 +/- 3.2 mg/L vs 7.7 +/- 2.2 mg/L), t Cmax/2 values were the same (10.4 hours), and the AUC0-24 hr was comparable to AUC00 calculated after the first dose.",Pharmacokinetics of a sustained-release trimazosin tablet formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6637789/),[mg] / [l],7.7,174277,DB00592,Piperazine
,6637789,Cmax/2,"At the seventh dose, after single daily doses of the SRT in 12 subjects, the mean Cmax values were not significantly higher than after the first dose (8.6 +/- 3.2 mg/L vs 7.7 +/- 2.2 mg/L), t Cmax/2 values were the same (10.4 hours), and the AUC0-24 hr was comparable to AUC00 calculated after the first dose.",Pharmacokinetics of a sustained-release trimazosin tablet formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6637789/),h,10.4,174278,DB00592,Piperazine
,23064325,maximum lung tissue concentration,A single dose inhalation at a predicted dose of 22.5mg/kg resulted in maximum lung tissue concentration of 21.4μg/g tissue with a terminal half-life of 25.4h.,Inhalable highly concentrated itraconazole nanosuspension for the treatment of bronchopulmonary aspergillosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23064325/),[μg] / [g·tissue],21.4,174304,DB00592,Piperazine
,23064325,terminal half-life,A single dose inhalation at a predicted dose of 22.5mg/kg resulted in maximum lung tissue concentration of 21.4μg/g tissue with a terminal half-life of 25.4h.,Inhalable highly concentrated itraconazole nanosuspension for the treatment of bronchopulmonary aspergillosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23064325/),h,25.4,174305,DB00592,Piperazine
,23064325,maximum concentration,"Serum concentrations were lower, with a maximum concentration of 104ng/ml at 4h after dosing and a terminal half-life of 10.5h.",Inhalable highly concentrated itraconazole nanosuspension for the treatment of bronchopulmonary aspergillosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23064325/),[ng] / [ml],104,174306,DB00592,Piperazine
,23064325,terminal half-life,"Serum concentrations were lower, with a maximum concentration of 104ng/ml at 4h after dosing and a terminal half-life of 10.5h.",Inhalable highly concentrated itraconazole nanosuspension for the treatment of bronchopulmonary aspergillosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23064325/),h,10.5,174307,DB00592,Piperazine
,15025737,intercept,The intercept of the relationship was slightly lower for female children (0.59 vs. 0.77 l h(-1) in male).,Retrospective population pharmacokinetic analysis of cetirizine in children aged 6 months to 12 years. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025737/),[l] / [h],0.59,174785,DB00592,Piperazine
,15025737,intercept,The intercept of the relationship was slightly lower for female children (0.59 vs. 0.77 l h(-1) in male).,Retrospective population pharmacokinetic analysis of cetirizine in children aged 6 months to 12 years. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025737/),[l] / [h],0.77,174786,DB00592,Piperazine
,15025737,CL/F,"The population estimate of CL/F for an average age of 7 years was 1.61 and 1.43 l h(-1) for male and female children, respectively.",Retrospective population pharmacokinetic analysis of cetirizine in children aged 6 months to 12 years. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025737/),[l] / [h],1.61,174787,DB00592,Piperazine
,15025737,CL/F,"The population estimate of CL/F for an average age of 7 years was 1.61 and 1.43 l h(-1) for male and female children, respectively.",Retrospective population pharmacokinetic analysis of cetirizine in children aged 6 months to 12 years. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025737/),[l] / [h],1.43,174788,DB00592,Piperazine
,15025737,V/F,The population estimate of V/F for an average age of 7 years was 13.9 l.,Retrospective population pharmacokinetic analysis of cetirizine in children aged 6 months to 12 years. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025737/),l,13.9,174789,DB00592,Piperazine
<,15025737,half-life,"Since V/F increased more rapidly with age than CL/F, a nonlinear increase in half-life was seen, from < 4 h in infants to near the adult value at 12 years of age.",Retrospective population pharmacokinetic analysis of cetirizine in children aged 6 months to 12 years. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025737/),h,4,174790,DB00592,Piperazine
,11334355,extraction recoveries,"The extraction recoveries for ketoconazole and clotrimazole in human plasma were 93+/-9.7% and 83+/-10.0%, respectively.","Liquid chromatographic determination of ketoconazole, a potent inhibitor of CYP3A4-mediated metabolism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11334355/),%,93,174868,DB00592,Piperazine
,11334355,extraction recoveries,"The extraction recoveries for ketoconazole and clotrimazole in human plasma were 93+/-9.7% and 83+/-10.0%, respectively.","Liquid chromatographic determination of ketoconazole, a potent inhibitor of CYP3A4-mediated metabolism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11334355/),%,83,174869,DB00592,Piperazine
,32821096,Q12h,"The optimized invasomal system (ETH9-INV8) was characterized with spherical vesicles (159.9 nm) possessing negative zeta potential (-20.3 mV), promising EE% (81.3%), low Q0.5h (25.4%), high Q12h (85.3%) and the largest steady-state flux (6.4 µg.cm-2h-1).","Ethosome-Derived Invasomes as a Potential Transdermal Delivery System for Vardenafil Hydrochloride: Development, Optimization and Application of Physiologically Based Pharmacokinetic Modeling in Adults and Geriatrics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32821096/),%,85.3,174989,DB00592,Piperazine
,32821096,steady-state flux,"The optimized invasomal system (ETH9-INV8) was characterized with spherical vesicles (159.9 nm) possessing negative zeta potential (-20.3 mV), promising EE% (81.3%), low Q0.5h (25.4%), high Q12h (85.3%) and the largest steady-state flux (6.4 µg.cm-2h-1).","Ethosome-Derived Invasomes as a Potential Transdermal Delivery System for Vardenafil Hydrochloride: Development, Optimization and Application of Physiologically Based Pharmacokinetic Modeling in Adults and Geriatrics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32821096/),[μg] / [(cm)^2],6.4,174990,DB00592,Piperazine
,32821096,AUC0-24h,"Lower Cmax values, delayed Tmax estimates and greater AUC0-24h folds in adults and geriatrics (≈ 2.18 and 1.69, respectively) were estimated following the transdermal application of ETH9-INV8 system.","Ethosome-Derived Invasomes as a Potential Transdermal Delivery System for Vardenafil Hydrochloride: Development, Optimization and Application of Physiologically Based Pharmacokinetic Modeling in Adults and Geriatrics. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32821096/),,2,174991,DB00592,Piperazine
,10771456,renal clearance,Mean renal clearance of lithium decreased by 0.09 l h(-1) (5%) in the ziprasidone group and by 0.14 l h(-1) (9%) in the placebo group.,The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771456/),h(-·l,0,174992,DB00592,Piperazine
,10771456,renal clearance,Mean renal clearance of lithium decreased by 0.09 l h(-1) (5%) in the ziprasidone group and by 0.14 l h(-1) (9%) in the placebo group.,The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771456/),,0,174993,DB00592,Piperazine
,7910724,area under the concentration-time curve,"Simultaneous administration of ketoconazole and sucralfate led to a significant reduction in the area under the concentration-time curve and maximal concentration of ketoconazole in serum (78.12 +/- 12.20 versus 59.32 +/- 13.61 micrograms.h/ml and 12.34 +/- 3.07 versus 8.92 +/- 2.57 micrograms/ml, respectively; P < 0.05).",In vivo interaction of ketoconazole and sucralfate in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910724/),[h·μg] / [ml],78.12,175099,DB00592,Piperazine
,7910724,area under the concentration-time curve,"Simultaneous administration of ketoconazole and sucralfate led to a significant reduction in the area under the concentration-time curve and maximal concentration of ketoconazole in serum (78.12 +/- 12.20 versus 59.32 +/- 13.61 micrograms.h/ml and 12.34 +/- 3.07 versus 8.92 +/- 2.57 micrograms/ml, respectively; P < 0.05).",In vivo interaction of ketoconazole and sucralfate in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910724/),[h·μg] / [ml],59.32,175100,DB00592,Piperazine
,7910724,maximal concentration,"Simultaneous administration of ketoconazole and sucralfate led to a significant reduction in the area under the concentration-time curve and maximal concentration of ketoconazole in serum (78.12 +/- 12.20 versus 59.32 +/- 13.61 micrograms.h/ml and 12.34 +/- 3.07 versus 8.92 +/- 2.57 micrograms/ml, respectively; P < 0.05).",In vivo interaction of ketoconazole and sucralfate in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910724/),[μg] / [ml],12.34,175101,DB00592,Piperazine
,7910724,maximal concentration,"Simultaneous administration of ketoconazole and sucralfate led to a significant reduction in the area under the concentration-time curve and maximal concentration of ketoconazole in serum (78.12 +/- 12.20 versus 59.32 +/- 13.61 micrograms.h/ml and 12.34 +/- 3.07 versus 8.92 +/- 2.57 micrograms/ml, respectively; P < 0.05).",In vivo interaction of ketoconazole and sucralfate in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910724/),[μg] / [ml],8.92,175102,DB00592,Piperazine
,31951849,Ka,"Thus, association constant was determined as Ka = 873.36 M-1.",Study of the binding affinity between imatinib and α-1 glycoprotein using nuclear spin relaxation and isothermal titration calorimetry. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31951849/),1/[M],873.36,175364,DB00592,Piperazine
,31951849,association constant Ka,"The ITC data revealed that the binding was an entropy driven process and the association constant Ka = 3.22 × 103 M-1, with a 1:1 stoichiometry.",Study of the binding affinity between imatinib and α-1 glycoprotein using nuclear spin relaxation and isothermal titration calorimetry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31951849/),1/[M],3.22 × 103,175365,DB00592,Piperazine
,29723110,elimination half-life,VAR has a short elimination half-life (4-5 h) and suffers low oral bioavailability (15%).,Polyamidoamine (PAMAM) dendrimers as potential release modulators and oral bioavailability enhancers of vardenafil hydrochloride. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29723110/),h,4-5,175371,DB00592,Piperazine
,29723110,oral bioavailability,VAR has a short elimination half-life (4-5 h) and suffers low oral bioavailability (15%).,Polyamidoamine (PAMAM) dendrimers as potential release modulators and oral bioavailability enhancers of vardenafil hydrochloride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29723110/),%,15,175372,DB00592,Piperazine
,29723110,desirability,The highest desirability (0.82) was achieved with D10 system comprising VAR (10 mg) and G6 (190 nM).,Polyamidoamine (PAMAM) dendrimers as potential release modulators and oral bioavailability enhancers of vardenafil hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29723110/),,0.82,175373,DB00592,Piperazine
,29723110,desirability,The highest desirability (0.82) was achieved with D10 system comprising VAR (10 mg) and G6 (190 nM).,Polyamidoamine (PAMAM) dendrimers as potential release modulators and oral bioavailability enhancers of vardenafil hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29723110/),,190,175374,DB00592,Piperazine
,25345429,maximum plasma concentration (Cmax),"The maximum plasma concentration (Cmax) of thioctic acid after administration of the reference tablet was 4.08 ± 2.35 μg/mL (means ± SD), and the Cmax of PDT-1 and PDT-2 was 3.53 ± 2.87 μg/mL and 4.15 ± 1.62 μg/mL, respectively.",Pharmacokinetic evaluation of a newly developed piperazine dithioctate formulation in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25345429/),[μg] / [ml],4.08,175658,DB00592,Piperazine
,25345429,Cmax,"The maximum plasma concentration (Cmax) of thioctic acid after administration of the reference tablet was 4.08 ± 2.35 μg/mL (means ± SD), and the Cmax of PDT-1 and PDT-2 was 3.53 ± 2.87 μg/mL and 4.15 ± 1.62 μg/mL, respectively.",Pharmacokinetic evaluation of a newly developed piperazine dithioctate formulation in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25345429/),[μg] / [ml],3.53,175659,DB00592,Piperazine
,25345429,Cmax,"The maximum plasma concentration (Cmax) of thioctic acid after administration of the reference tablet was 4.08 ± 2.35 μg/mL (means ± SD), and the Cmax of PDT-1 and PDT-2 was 3.53 ± 2.87 μg/mL and 4.15 ± 1.62 μg/mL, respectively.",Pharmacokinetic evaluation of a newly developed piperazine dithioctate formulation in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25345429/),[μg] / [ml],4.15,175660,DB00592,Piperazine
,25345429,AUClast,"The AUClast value was 2.96 ± 1.13 μg x h/mL for the reference, 2.84 ± 1.12 μg x h/mL for PDT-1, and 3.30 ± 1.32 μg x h/mL for PDT-2.",Pharmacokinetic evaluation of a newly developed piperazine dithioctate formulation in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25345429/),[h·μg] / [ml],2.96,175661,DB00592,Piperazine
,25345429,AUClast,"The AUClast value was 2.96 ± 1.13 μg x h/mL for the reference, 2.84 ± 1.12 μg x h/mL for PDT-1, and 3.30 ± 1.32 μg x h/mL for PDT-2.",Pharmacokinetic evaluation of a newly developed piperazine dithioctate formulation in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25345429/),[h·μg] / [ml],2.84,175662,DB00592,Piperazine
,25345429,AUClast,"The AUClast value was 2.96 ± 1.13 μg x h/mL for the reference, 2.84 ± 1.12 μg x h/mL for PDT-1, and 3.30 ± 1.32 μg x h/mL for PDT-2.",Pharmacokinetic evaluation of a newly developed piperazine dithioctate formulation in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25345429/),[h·μg] / [ml],3.30,175663,DB00592,Piperazine
,25345429,Cmax,"The Cmax of reference and PDT-2 was 5.59 ± 3.07 μg/mL and 5.14 ± 3.18 μg/mL, respectively.",Pharmacokinetic evaluation of a newly developed piperazine dithioctate formulation in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25345429/),[μg] / [ml],5.59,175664,DB00592,Piperazine
,25345429,Cmax,"The Cmax of reference and PDT-2 was 5.59 ± 3.07 μg/mL and 5.14 ± 3.18 μg/mL, respectively.",Pharmacokinetic evaluation of a newly developed piperazine dithioctate formulation in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25345429/),[μg] / [ml],5.14,175665,DB00592,Piperazine
,25345429,AUClast,The AUClast value was 4.01 ± 1.65 μg x h/mL for the reference and 3.96 ± 1.47 μg x h/mL for PDT-2.,Pharmacokinetic evaluation of a newly developed piperazine dithioctate formulation in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25345429/),[h·μg] / [ml],4.01,175666,DB00592,Piperazine
,25345429,AUClast,The AUClast value was 4.01 ± 1.65 μg x h/mL for the reference and 3.96 ± 1.47 μg x h/mL for PDT-2.,Pharmacokinetic evaluation of a newly developed piperazine dithioctate formulation in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25345429/),[h·μg] / [ml],3.96,175667,DB00592,Piperazine
,27506082,AUC(28d),"After the fifth AOM 400 injection, mean aripiprazole AUC(28d), C(max) and C(min) were 165 μg x h/ml, 331 ng/ml and 201 ng/ml, respectively, which were similar to previously published pharmacokinetic parameters after the fifth gluteal injection of AOM 400.","[Pharmacokinetics and safety of aripiprazole long-acting injection, following multiple deltoid administrations in schizophrenia patients in Japan]. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27506082/),[h·μg] / [ml],165,175867,DB00592,Piperazine
,27506082,C(max),"After the fifth AOM 400 injection, mean aripiprazole AUC(28d), C(max) and C(min) were 165 μg x h/ml, 331 ng/ml and 201 ng/ml, respectively, which were similar to previously published pharmacokinetic parameters after the fifth gluteal injection of AOM 400.","[Pharmacokinetics and safety of aripiprazole long-acting injection, following multiple deltoid administrations in schizophrenia patients in Japan]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27506082/),[ng] / [ml],331,175868,DB00592,Piperazine
,27506082,C(min),"After the fifth AOM 400 injection, mean aripiprazole AUC(28d), C(max) and C(min) were 165 μg x h/ml, 331 ng/ml and 201 ng/ml, respectively, which were similar to previously published pharmacokinetic parameters after the fifth gluteal injection of AOM 400.","[Pharmacokinetics and safety of aripiprazole long-acting injection, following multiple deltoid administrations in schizophrenia patients in Japan]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27506082/),[ng] / [ml],201,175869,DB00592,Piperazine
,30767712,Ka (1/,The final PPK model is: Ka (1/h) = 0.329; CL/F (l/h) = 9.25 × (actual bodyweight/70)0.228; V/F(l) = 222.,Population pharmacokinetic and pharmacogenetics of imatinib in Chinese patients with chronic myeloid leukemia. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30767712/),,0,176251,DB00592,Piperazine
,30767712,V/F,The final PPK model is: Ka (1/h) = 0.329; CL/F (l/h) = 9.25 × (actual bodyweight/70)0.228; V/F(l) = 222.,Population pharmacokinetic and pharmacogenetics of imatinib in Chinese patients with chronic myeloid leukemia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30767712/),l,222,176252,DB00592,Piperazine
,18972873,flow rate,"The separation was achieved on a monolithic silica column using acetonitrile-potassium dihydrogen phosphate buffer (25:75,v/v), pH 3.0, as the mobile phase at a flow rate of 1.5 ml min(-1).",A rapid high-performance liquid chromatographic method for the determination of pantoprazole in plasma using UV detection. Application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18972873/),[ml] / [min],1.5,176276,DB00592,Piperazine
,10745059,K(m),Formation of mCPP from trazodone in liver microsomes had a mean (+/- SE) K(m) value of 163 (+/- 21) micromol/L.,In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10745059/),[μM] / [l],163,176334,DB00592,Piperazine
,10745059,inhibition constant (K(i)),"Ketoconazole, a relatively specific CYP3A inhibitor, impaired mCPP formation consistent with a competitive mechanism, having an inhibition constant (K(i)) of 0.12 (+/- 0.01) micromol/L.",In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10745059/),[μM] / [l],0.12,176335,DB00592,Piperazine
,10745059,K(m),"Among heterologously expressed human cytochromes, only CYP3A4 mediated formation of mCPP from trazodone; the K(m) was 180 micromol/L, consistent with the value in microsomes.",In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10745059/),[μM] / [l],180,176336,DB00592,Piperazine
,10745059,K(i),The HIVPI ritonavir was a potent inhibitor of mCPP formation in liver microsomes (K(i) = 0.14 +/- 0.04 micromol/L).,In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10745059/),[μM] / [l],0.14,176337,DB00592,Piperazine
,11583471,apparent oral clearance,The mean apparent oral clearance of amitriptyline in 8 human volunteers was decreased from 2791 ml/min in the control condition to 2069 ml/min with ketoconazole.,Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583471/),[ml] / [min],2791,176461,DB00592,Piperazine
,11583471,apparent oral clearance,The mean apparent oral clearance of amitriptyline in 8 human volunteers was decreased from 2791 ml/min in the control condition to 2069 ml/min with ketoconazole.,Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583471/),[ml] / [min],2069,176462,DB00592,Piperazine
,29679708,Mean dissolution time (MDT),"Mean dissolution time (MDT) from tablets made of HPMC, carbomer or a mixture of HPMC and sodium alginate (2:1) was ca. 100 min, which was more than twelve times longer as compared to matrices prepared of silicified microcrystalline cellulose (MDT = 8 min).",The impact of polymers on 3D microstructure and controlled release of sildenafil citrate from hydrophilic matrices. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29679708/),min,100,176515,DB00592,Piperazine
,29679708,MDT,"Mean dissolution time (MDT) from tablets made of HPMC, carbomer or a mixture of HPMC and sodium alginate (2:1) was ca. 100 min, which was more than twelve times longer as compared to matrices prepared of silicified microcrystalline cellulose (MDT = 8 min).",The impact of polymers on 3D microstructure and controlled release of sildenafil citrate from hydrophilic matrices. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29679708/),min,8,176516,DB00592,Piperazine
,29679708,tmax,Sustained release of sildenafil from ground carbomer tablets reflected in the slow absorption of the drug (tmax = 5.0 ± 1.2 h) in vivo and the relative bioavailability of 151%.,The impact of polymers on 3D microstructure and controlled release of sildenafil citrate from hydrophilic matrices. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29679708/),h,5.0,176517,DB00592,Piperazine
,29679708,relative bioavailability,Sustained release of sildenafil from ground carbomer tablets reflected in the slow absorption of the drug (tmax = 5.0 ± 1.2 h) in vivo and the relative bioavailability of 151%.,The impact of polymers on 3D microstructure and controlled release of sildenafil citrate from hydrophilic matrices. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29679708/),%,151,176518,DB00592,Piperazine
,17545705,half-life,"Vicriviroc was rapidly absorbed with a half-life of 28-33 h, supporting once-daily dosing.","Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17545705/),h,28-33,176622,DB00592,Piperazine
,30297369,area under the concentration-time curve,"In the fed and fasted states, SUBA itraconazole demonstrated similar concentrations at the end of the dosing interval, with modestly lower total and peak ITZ exposure being shown when it was administered under fed conditions than when it was administered in the fasted state, with fed state/fasted state ratios of 78.09% (90% confidence interval [CI], 74.49 to 81.86%) for the area under the concentration-time curve over the dosing interval (14,183.2 versus 18,479.8 ng · h/ml), 73.05% (90% CI, 69.01 to 77.33%) for the maximum concentration at steady state (1,519.1 versus 2,085.2 ng/ml), and 91.53% (90% CI, 86.41 to 96.96%) for the trough concentration (1,071.5 versus 1,218.5 ng/ml) being found.",Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30297369/),[h·ng] / [ml],"14,183.2",176680,DB00592,Piperazine
,30297369,area under the concentration-time curve,"In the fed and fasted states, SUBA itraconazole demonstrated similar concentrations at the end of the dosing interval, with modestly lower total and peak ITZ exposure being shown when it was administered under fed conditions than when it was administered in the fasted state, with fed state/fasted state ratios of 78.09% (90% confidence interval [CI], 74.49 to 81.86%) for the area under the concentration-time curve over the dosing interval (14,183.2 versus 18,479.8 ng · h/ml), 73.05% (90% CI, 69.01 to 77.33%) for the maximum concentration at steady state (1,519.1 versus 2,085.2 ng/ml), and 91.53% (90% CI, 86.41 to 96.96%) for the trough concentration (1,071.5 versus 1,218.5 ng/ml) being found.",Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30297369/),[h·ng] / [ml],"18,479.8",176681,DB00592,Piperazine
,30297369,maximum concentration at steady state,"In the fed and fasted states, SUBA itraconazole demonstrated similar concentrations at the end of the dosing interval, with modestly lower total and peak ITZ exposure being shown when it was administered under fed conditions than when it was administered in the fasted state, with fed state/fasted state ratios of 78.09% (90% confidence interval [CI], 74.49 to 81.86%) for the area under the concentration-time curve over the dosing interval (14,183.2 versus 18,479.8 ng · h/ml), 73.05% (90% CI, 69.01 to 77.33%) for the maximum concentration at steady state (1,519.1 versus 2,085.2 ng/ml), and 91.53% (90% CI, 86.41 to 96.96%) for the trough concentration (1,071.5 versus 1,218.5 ng/ml) being found.",Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30297369/),ng,"1,519.1",176682,DB00592,Piperazine
,30297369,maximum concentration at steady state,"In the fed and fasted states, SUBA itraconazole demonstrated similar concentrations at the end of the dosing interval, with modestly lower total and peak ITZ exposure being shown when it was administered under fed conditions than when it was administered in the fasted state, with fed state/fasted state ratios of 78.09% (90% confidence interval [CI], 74.49 to 81.86%) for the area under the concentration-time curve over the dosing interval (14,183.2 versus 18,479.8 ng · h/ml), 73.05% (90% CI, 69.01 to 77.33%) for the maximum concentration at steady state (1,519.1 versus 2,085.2 ng/ml), and 91.53% (90% CI, 86.41 to 96.96%) for the trough concentration (1,071.5 versus 1,218.5 ng/ml) being found.",Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30297369/),ng,"2,085.2",176683,DB00592,Piperazine
,30297369,trough concentration,"In the fed and fasted states, SUBA itraconazole demonstrated similar concentrations at the end of the dosing interval, with modestly lower total and peak ITZ exposure being shown when it was administered under fed conditions than when it was administered in the fasted state, with fed state/fasted state ratios of 78.09% (90% confidence interval [CI], 74.49 to 81.86%) for the area under the concentration-time curve over the dosing interval (14,183.2 versus 18,479.8 ng · h/ml), 73.05% (90% CI, 69.01 to 77.33%) for the maximum concentration at steady state (1,519.1 versus 2,085.2 ng/ml), and 91.53% (90% CI, 86.41 to 96.96%) for the trough concentration (1,071.5 versus 1,218.5 ng/ml) being found.",Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30297369/),[ng] / [ml],"1,071.5",176684,DB00592,Piperazine
,30297369,trough concentration,"In the fed and fasted states, SUBA itraconazole demonstrated similar concentrations at the end of the dosing interval, with modestly lower total and peak ITZ exposure being shown when it was administered under fed conditions than when it was administered in the fasted state, with fed state/fasted state ratios of 78.09% (90% confidence interval [CI], 74.49 to 81.86%) for the area under the concentration-time curve over the dosing interval (14,183.2 versus 18,479.8 ng · h/ml), 73.05% (90% CI, 69.01 to 77.33%) for the maximum concentration at steady state (1,519.1 versus 2,085.2 ng/ml), and 91.53% (90% CI, 86.41 to 96.96%) for the trough concentration (1,071.5 versus 1,218.5 ng/ml) being found.",Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30297369/),[ng] / [ml],"1,218.5",176685,DB00592,Piperazine
,12642963,peak concentrations,The peak concentrations of opipramol were 13-15 ng ml-1 (study I) and 28 ng ml-1 (study II).,"Bioavailability of opipramol from a film-coated tablet, a sugar-coated tablet and an aqueous solution in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12642963/),[ng] / [ml],13-15,176755,DB00592,Piperazine
,12642963,peak concentrations,The peak concentrations of opipramol were 13-15 ng ml-1 (study I) and 28 ng ml-1 (study II).,"Bioavailability of opipramol from a film-coated tablet, a sugar-coated tablet and an aqueous solution in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12642963/),[ng] / [ml],28,176756,DB00592,Piperazine
,12642963,area under the plasma concentration-time curve,The area under the plasma concentration-time curve was about 170 ng ml-1 h (study I) and about 320 ng ml-1 h (study II).,"Bioavailability of opipramol from a film-coated tablet, a sugar-coated tablet and an aqueous solution in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12642963/),[h·ng] / [ml],170,176757,DB00592,Piperazine
,12642963,area under the plasma concentration-time curve,The area under the plasma concentration-time curve was about 170 ng ml-1 h (study I) and about 320 ng ml-1 h (study II).,"Bioavailability of opipramol from a film-coated tablet, a sugar-coated tablet and an aqueous solution in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12642963/),[h·ng] / [ml],320,176758,DB00592,Piperazine
,12642963,terminal plasma half-life,The terminal plasma half-life was 11 h.,"Bioavailability of opipramol from a film-coated tablet, a sugar-coated tablet and an aqueous solution in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12642963/),h,11,176759,DB00592,Piperazine
,26902828,half-life,"Distribution was extensive and clearance low to moderate, resulting in a mean half-life of 48.3 h.","Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902828/),h,48.3,176776,DB00592,Piperazine
,26902828,peak-to-trough ratio,"Steady state was achieved by 15 days of dosing, consistent with single-dose PK, with a peak-to-trough ratio of 1.6.","Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902828/),,1.6,176777,DB00592,Piperazine
,1596283,IC50,"Ketoconazole caused marked inhibition of carboxymefloquine formation with IC50 and Ki values of 7.5 and 11.2 microM, respectively.",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,7.5,176859,DB00592,Piperazine
,1596283,Ki,"Ketoconazole caused marked inhibition of carboxymefloquine formation with IC50 and Ki values of 7.5 and 11.2 microM, respectively.",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,11.2,176860,DB00592,Piperazine
,1596283,IC50,"Of compounds actually or likely to be coadministered with mefloquine to malaria patients only primaquine and quinine produced marked inhibition (IC50, 17.5 and 122 microM; Ki, 8.6 and 28.5 microM, respectively).",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,17.5,176861,DB00592,Piperazine
,1596283,IC50,"Of compounds actually or likely to be coadministered with mefloquine to malaria patients only primaquine and quinine produced marked inhibition (IC50, 17.5 and 122 microM; Ki, 8.6 and 28.5 microM, respectively).",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,122,176862,DB00592,Piperazine
,1596283,Ki,"Of compounds actually or likely to be coadministered with mefloquine to malaria patients only primaquine and quinine produced marked inhibition (IC50, 17.5 and 122 microM; Ki, 8.6 and 28.5 microM, respectively).",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,8.6,176863,DB00592,Piperazine
,1596283,Ki,"Of compounds actually or likely to be coadministered with mefloquine to malaria patients only primaquine and quinine produced marked inhibition (IC50, 17.5 and 122 microM; Ki, 8.6 and 28.5 microM, respectively).",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,28.5,176864,DB00592,Piperazine
,19931997,retention times,The retention times of nutlin-3a and ketoconazole were 1.14 and 1.45min.,Determination of nutlin-3a in murine plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19931997/),min,1.14,176926,DB00592,Piperazine
,19931997,retention times,The retention times of nutlin-3a and ketoconazole were 1.14 and 1.45min.,Determination of nutlin-3a in murine plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19931997/),min,1.45,176927,DB00592,Piperazine
,19931997,recoveries,"The mean recoveries for PP and LLE were 24% and 78%, respectively.",Determination of nutlin-3a in murine plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19931997/),%,24,176928,DB00592,Piperazine
,19931997,recoveries,"The mean recoveries for PP and LLE were 24% and 78%, respectively.",Determination of nutlin-3a in murine plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19931997/),%,78,176929,DB00592,Piperazine
,29338933,Ki,The estimated in vivo Ki of ketoconazole for hepatic CYP3A4 (6.64 ng/mL) was consistent with the reported values.,Physiological based pharmacokinetic modeling to estimate in vivo Ki of ketoconazole on renal P-gp using human drug-drug interaction study result of fesoterodine and ketoconazole. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29338933/),[ng] / [ml],6.64,177393,DB00592,Piperazine
,29338933,Ki,"The in vivo Ki of ketoconazole for renal P-gp was successfully estimated as 2.27 ng/mL, which was notably lower than reported in vitro 50% inhibitory concentration (IC50) values ranged 223-2440 ng/mL due to different condition between in vitro and in vivo.",Physiological based pharmacokinetic modeling to estimate in vivo Ki of ketoconazole on renal P-gp using human drug-drug interaction study result of fesoterodine and ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29338933/),[ng] / [ml],2.27,177394,DB00592,Piperazine
,29338933,50% inhibitory concentration (IC50),"The in vivo Ki of ketoconazole for renal P-gp was successfully estimated as 2.27 ng/mL, which was notably lower than reported in vitro 50% inhibitory concentration (IC50) values ranged 223-2440 ng/mL due to different condition between in vitro and in vivo.",Physiological based pharmacokinetic modeling to estimate in vivo Ki of ketoconazole on renal P-gp using human drug-drug interaction study result of fesoterodine and ketoconazole. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29338933/),[ng] / [ml],223-2440,177395,DB00592,Piperazine
,24674989,flow rate,"Chromatographic separation was achieved on a reversed phase C18 column with a mobile phase consisted of a water mixture of 10mM potassium dihydrogen phosphate (pH=4.5):methanol (40:60, v/v), pumped at flow rate of 1.0mL/min, and detected at 303nm.",High performance liquid chromatographic method for the determination of cinepazide maleate and its application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24674989/),[ml] / [min],1.0,177442,DB00592,Piperazine
,21496064,terminal half-life (t(1/2) ),"Co-administration of multiple oral doses of 20 mg paroxetine once daily with a single oral dose of the 0.4 mg tamsulosin HCl capsule increased the adjusted geometric mean (gMean) values of C(max) and AUC(0,∞) of tamsulosin by factors of 1.34 (90% CI 1.21, 1.49) and 1.64 (90% CI 1.44, 1.85), respectively, and increased the terminal half-life (t(1/2) ) of tamsulosin HCl from 11.4 h to 15.3 h.","Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21496064/),h,11.4,177627,DB00592,Piperazine
,21496064,terminal half-life (t(1/2) ),"Co-administration of multiple oral doses of 20 mg paroxetine once daily with a single oral dose of the 0.4 mg tamsulosin HCl capsule increased the adjusted geometric mean (gMean) values of C(max) and AUC(0,∞) of tamsulosin by factors of 1.34 (90% CI 1.21, 1.49) and 1.64 (90% CI 1.44, 1.85), respectively, and increased the terminal half-life (t(1/2) ) of tamsulosin HCl from 11.4 h to 15.3 h.","Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21496064/),h,15.3,177628,DB00592,Piperazine
,21496064,terminal half-life,The terminal half-life was slightly increased from 10.5 h to 11.8 h.,"Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21496064/),h,10.5,177629,DB00592,Piperazine
,21496064,terminal half-life,The terminal half-life was slightly increased from 10.5 h to 11.8 h.,"Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21496064/),h,11.8,177630,DB00592,Piperazine
,25136019,AUCs from time zero to infinity,"In the animals receiving a microdose and the therapeutically dosed animals, the AUCs from time zero to infinity were 2.6 ng · h/ml and 1,336 ng · h/ml, respectively, and the terminal half-lives were 5.6 h and 1.4 h, respectively.",Use of microdosing and accelerator mass spectrometry to evaluate the pharmacokinetic linearity of a novel tricyclic GyrB/ParE inhibitor in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25136019/),[h·ng] / [ml],2.6,177681,DB00592,Piperazine
,25136019,AUCs from time zero to infinity,"In the animals receiving a microdose and the therapeutically dosed animals, the AUCs from time zero to infinity were 2.6 ng · h/ml and 1,336 ng · h/ml, respectively, and the terminal half-lives were 5.6 h and 1.4 h, respectively.",Use of microdosing and accelerator mass spectrometry to evaluate the pharmacokinetic linearity of a novel tricyclic GyrB/ParE inhibitor in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25136019/),[h·ng] / [ml],"1,336",177682,DB00592,Piperazine
,25136019,terminal half-lives,"In the animals receiving a microdose and the therapeutically dosed animals, the AUCs from time zero to infinity were 2.6 ng · h/ml and 1,336 ng · h/ml, respectively, and the terminal half-lives were 5.6 h and 1.4 h, respectively.",Use of microdosing and accelerator mass spectrometry to evaluate the pharmacokinetic linearity of a novel tricyclic GyrB/ParE inhibitor in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25136019/),h,5.6,177683,DB00592,Piperazine
,25136019,terminal half-lives,"In the animals receiving a microdose and the therapeutically dosed animals, the AUCs from time zero to infinity were 2.6 ng · h/ml and 1,336 ng · h/ml, respectively, and the terminal half-lives were 5.6 h and 1.4 h, respectively.",Use of microdosing and accelerator mass spectrometry to evaluate the pharmacokinetic linearity of a novel tricyclic GyrB/ParE inhibitor in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25136019/),h,1.4,177684,DB00592,Piperazine
,25136019,AUC,"When the AUC values were normalized to a dose of 1.0 mg/kg, the AUC values were 277.5 ng · h/ml for the microdose and 418.2 ng · h/ml for the pharmacological dose.",Use of microdosing and accelerator mass spectrometry to evaluate the pharmacokinetic linearity of a novel tricyclic GyrB/ParE inhibitor in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25136019/),[h·ng] / [ml],277.5,177685,DB00592,Piperazine
,25136019,AUC,"When the AUC values were normalized to a dose of 1.0 mg/kg, the AUC values were 277.5 ng · h/ml for the microdose and 418.2 ng · h/ml for the pharmacological dose.",Use of microdosing and accelerator mass spectrometry to evaluate the pharmacokinetic linearity of a novel tricyclic GyrB/ParE inhibitor in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25136019/),[h·ng] / [ml],418.2,177686,DB00592,Piperazine
,16316651,K(i),"In vitro, M55551 and M55165 competitively inhibited factor Xa with K(i) values of 3.2 nM and 2.3 nM, respectively, and prolonged clotting time in human and rat plasma.",Pharmacological characterization of the active synthetic factor Xa inhibitors M55551 and M55165. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16316651/),nM,3.2,178029,DB00592,Piperazine
,16316651,K(i),"In vitro, M55551 and M55165 competitively inhibited factor Xa with K(i) values of 3.2 nM and 2.3 nM, respectively, and prolonged clotting time in human and rat plasma.",Pharmacological characterization of the active synthetic factor Xa inhibitors M55551 and M55165. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16316651/),nM,2.3,178030,DB00592,Piperazine
,16316651,half-life,Pharmacokinetic analysis of these compounds revealed that M55551 was intravenously active with a short half-life (0.2 h) and that M55165 exhibited good bioavailability (31%) with a long half-life (3.9 h).,Pharmacological characterization of the active synthetic factor Xa inhibitors M55551 and M55165. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16316651/),h,0.2,178031,DB00592,Piperazine
,16316651,bioavailability,Pharmacokinetic analysis of these compounds revealed that M55551 was intravenously active with a short half-life (0.2 h) and that M55165 exhibited good bioavailability (31%) with a long half-life (3.9 h).,Pharmacological characterization of the active synthetic factor Xa inhibitors M55551 and M55165. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16316651/),%,31,178032,DB00592,Piperazine
,16316651,half-life,Pharmacokinetic analysis of these compounds revealed that M55551 was intravenously active with a short half-life (0.2 h) and that M55165 exhibited good bioavailability (31%) with a long half-life (3.9 h).,Pharmacological characterization of the active synthetic factor Xa inhibitors M55551 and M55165. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16316651/),h,3.9,178033,DB00592,Piperazine
,25142820,relative bioavailability,Faster rate of absorption of flupentixol could be obtained from the oral film formulation and the relative bioavailability was found to be 151.06% compared to the marketed product.,Pharmaceutical and pharmacokinetic evaluation of a novel fast dissolving film formulation of flupentixol dihydrochloride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25142820/),%,151.06,178124,DB00592,Piperazine
,31094010,"steady-state Cmax,ss","The steady-state Cmax,ss values of teneligliptin without and with glimepiride were 207.01 ng/mL and 202.15 ng/mL, respectively.",Effect of glimepiride on the pharmacokinetics of teneligliptin in healthy Korean subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094010/),[ng] / [ml],207.01,178351,DB00592,Piperazine
,31094010,"steady-state Cmax,ss","The steady-state Cmax,ss values of teneligliptin without and with glimepiride were 207.01 ng/mL and 202.15 ng/mL, respectively.",Effect of glimepiride on the pharmacokinetics of teneligliptin in healthy Korean subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094010/),[ng] / [ml],202.15,178352,DB00592,Piperazine
,31094010,AUCτ,"Its AUCτ values at steady-state without and with glimepiride were 1527.8 ng · h/mL and 1578.6 ng · h/mL, respectively.",Effect of glimepiride on the pharmacokinetics of teneligliptin in healthy Korean subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094010/),[h·ng] / [ml],1527.8,178353,DB00592,Piperazine
,31094010,AUCτ,"Its AUCτ values at steady-state without and with glimepiride were 1527.8 ng · h/mL and 1578.6 ng · h/mL, respectively.",Effect of glimepiride on the pharmacokinetics of teneligliptin in healthy Korean subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094010/),[h·ng] / [ml],1578.6,178354,DB00592,Piperazine
,21070033,T1/2,"The 1-(4-(4-(4-acetylpiperazin-1-yl)butoxy)phenyl)-3-adamantan-1-yl urea (29c) demonstrated excellent in vivo pharmacokinetic properties in mice: T1/2 =14 h, Cmax = 84 nM, AUC = 40 200 nM·min, and IC50 = 7.0 nM against human sEH enzyme.","Incorporation of piperazino functionality into 1,3-disubstituted urea as the tertiary pharmacophore affording potent inhibitors of soluble epoxide hydrolase with improved pharmacokinetic properties. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21070033/),h,14,178406,DB00592,Piperazine
,21070033,Cmax,"The 1-(4-(4-(4-acetylpiperazin-1-yl)butoxy)phenyl)-3-adamantan-1-yl urea (29c) demonstrated excellent in vivo pharmacokinetic properties in mice: T1/2 =14 h, Cmax = 84 nM, AUC = 40 200 nM·min, and IC50 = 7.0 nM against human sEH enzyme.","Incorporation of piperazino functionality into 1,3-disubstituted urea as the tertiary pharmacophore affording potent inhibitors of soluble epoxide hydrolase with improved pharmacokinetic properties. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21070033/),nM,84,178407,DB00592,Piperazine
,21070033,AUC,"The 1-(4-(4-(4-acetylpiperazin-1-yl)butoxy)phenyl)-3-adamantan-1-yl urea (29c) demonstrated excellent in vivo pharmacokinetic properties in mice: T1/2 =14 h, Cmax = 84 nM, AUC = 40 200 nM·min, and IC50 = 7.0 nM against human sEH enzyme.","Incorporation of piperazino functionality into 1,3-disubstituted urea as the tertiary pharmacophore affording potent inhibitors of soluble epoxide hydrolase with improved pharmacokinetic properties. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21070033/),min·nM,40 200,178408,DB00592,Piperazine
,21070033,IC50,"The 1-(4-(4-(4-acetylpiperazin-1-yl)butoxy)phenyl)-3-adamantan-1-yl urea (29c) demonstrated excellent in vivo pharmacokinetic properties in mice: T1/2 =14 h, Cmax = 84 nM, AUC = 40 200 nM·min, and IC50 = 7.0 nM against human sEH enzyme.","Incorporation of piperazino functionality into 1,3-disubstituted urea as the tertiary pharmacophore affording potent inhibitors of soluble epoxide hydrolase with improved pharmacokinetic properties. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21070033/),nM,7.0,178409,DB00592,Piperazine
,2698437,half-life,Mean half-life of Isoniazid was 3.9 +/- 1.4 hs in 7 slow acetylators and 1.1 hs in one fast acetylator when given one at a time and 4.4 +/- 1.5 hs when given simultaneously.,"[Pharmacokinetic interaction of ketoconazole, isoniazid and rifampicin]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2698437/),hs,3.9,178571,DB00592,Piperazine
,2698437,half-life,Mean half-life of Isoniazid was 3.9 +/- 1.4 hs in 7 slow acetylators and 1.1 hs in one fast acetylator when given one at a time and 4.4 +/- 1.5 hs when given simultaneously.,"[Pharmacokinetic interaction of ketoconazole, isoniazid and rifampicin]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2698437/),hs,1.1,178572,DB00592,Piperazine
,2698437,half-life,Mean half-life of Isoniazid was 3.9 +/- 1.4 hs in 7 slow acetylators and 1.1 hs in one fast acetylator when given one at a time and 4.4 +/- 1.5 hs when given simultaneously.,"[Pharmacokinetic interaction of ketoconazole, isoniazid and rifampicin]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2698437/),hs,4.4,178573,DB00592,Piperazine
,2698437,half-life,"Mean half-life of Rifampicin was 3.5 +/- 0.8 and 4.2 +/- 1.1 hs, respectively, when it was given alone and concurrently.","[Pharmacokinetic interaction of ketoconazole, isoniazid and rifampicin]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2698437/),hs,3.5,178574,DB00592,Piperazine
,2698437,half-life,"Mean half-life of Rifampicin was 3.5 +/- 0.8 and 4.2 +/- 1.1 hs, respectively, when it was given alone and concurrently.","[Pharmacokinetic interaction of ketoconazole, isoniazid and rifampicin]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2698437/),hs,4.2,178575,DB00592,Piperazine
,25985066,maximum concentration (C(max)),"After intragastric administration, S(-)-NAF in plasma [maximum concentration (C(max)) = 186.4 ng/mL, area under the curve from 0 h to 24h (AUC(0-24 h)) = 877.9 ng h/mL] was significantly higher than that of R(+)-NAF (C(max) = 133.2 ng/mL, AUC(0-24 h) = 602.1 ng h/mL).",Enantiospecific determination of naftopidil by RRLC-MS/MS reveals stereoselective pharmacokinetics and tissue distributions in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25985066/),[ng] / [ml],186.4,178598,DB00592,Piperazine
,25985066,area under the curve from 0 h to 24h (AUC(0-24 h)),"After intragastric administration, S(-)-NAF in plasma [maximum concentration (C(max)) = 186.4 ng/mL, area under the curve from 0 h to 24h (AUC(0-24 h)) = 877.9 ng h/mL] was significantly higher than that of R(+)-NAF (C(max) = 133.2 ng/mL, AUC(0-24 h) = 602.1 ng h/mL).",Enantiospecific determination of naftopidil by RRLC-MS/MS reveals stereoselective pharmacokinetics and tissue distributions in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25985066/),[h·ng] / [ml],877.9,178599,DB00592,Piperazine
,25985066,C(max),"After intragastric administration, S(-)-NAF in plasma [maximum concentration (C(max)) = 186.4 ng/mL, area under the curve from 0 h to 24h (AUC(0-24 h)) = 877.9 ng h/mL] was significantly higher than that of R(+)-NAF (C(max) = 133.2 ng/mL, AUC(0-24 h) = 602.1 ng h/mL).",Enantiospecific determination of naftopidil by RRLC-MS/MS reveals stereoselective pharmacokinetics and tissue distributions in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25985066/),[ng] / [ml],133.2,178600,DB00592,Piperazine
,25985066,AUC(0-24 h),"After intragastric administration, S(-)-NAF in plasma [maximum concentration (C(max)) = 186.4 ng/mL, area under the curve from 0 h to 24h (AUC(0-24 h)) = 877.9 ng h/mL] was significantly higher than that of R(+)-NAF (C(max) = 133.2 ng/mL, AUC(0-24 h) = 602.1 ng h/mL).",Enantiospecific determination of naftopidil by RRLC-MS/MS reveals stereoselective pharmacokinetics and tissue distributions in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25985066/),[h·ng] / [ml],602.1,178601,DB00592,Piperazine
,25985066,R/S ratios,"R(+)-NAF distributions in the prostate, liver, and kidney were significantly higher than S(-)-NAF distributions (R/S ratios of 3.16, 1.33, and 2.90, respectively).",Enantiospecific determination of naftopidil by RRLC-MS/MS reveals stereoselective pharmacokinetics and tissue distributions in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25985066/),,3.16,178602,DB00592,Piperazine
,25985066,R/S ratios,"R(+)-NAF distributions in the prostate, liver, and kidney were significantly higher than S(-)-NAF distributions (R/S ratios of 3.16, 1.33, and 2.90, respectively).",Enantiospecific determination of naftopidil by RRLC-MS/MS reveals stereoselective pharmacokinetics and tissue distributions in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25985066/),,1.33,178603,DB00592,Piperazine
,25985066,R/S ratios,"R(+)-NAF distributions in the prostate, liver, and kidney were significantly higher than S(-)-NAF distributions (R/S ratios of 3.16, 1.33, and 2.90, respectively).",Enantiospecific determination of naftopidil by RRLC-MS/MS reveals stereoselective pharmacokinetics and tissue distributions in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25985066/),,2,178604,DB00592,Piperazine
,24798283,-to-unbound plasma drug concentration ratios,"ELF drug concentrations were systematically higher than corresponding plasma drug concentrations, whatever the route of administration, and average ELF-to-unbound plasma drug concentration ratios post-distribution equilibrium did not change significantly between the ways of administration and were equal: 4.0 ± 5.3 for CIP, 12.6 ± 7.3 for MXF, and 19.1 ± 10.5 for GRX (means ± standard deviations).","Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. Ciprofloxacin, moxifloxacin, and grepafloxacin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24798283/),,4.0,179003,DB00592,Piperazine
,24798283,-to-unbound plasma drug concentration ratios,"ELF drug concentrations were systematically higher than corresponding plasma drug concentrations, whatever the route of administration, and average ELF-to-unbound plasma drug concentration ratios post-distribution equilibrium did not change significantly between the ways of administration and were equal: 4.0 ± 5.3 for CIP, 12.6 ± 7.3 for MXF, and 19.1 ± 10.5 for GRX (means ± standard deviations).","Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. Ciprofloxacin, moxifloxacin, and grepafloxacin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24798283/),,12.6,179004,DB00592,Piperazine
,24798283,-to-unbound plasma drug concentration ratios,"ELF drug concentrations were systematically higher than corresponding plasma drug concentrations, whatever the route of administration, and average ELF-to-unbound plasma drug concentration ratios post-distribution equilibrium did not change significantly between the ways of administration and were equal: 4.0 ± 5.3 for CIP, 12.6 ± 7.3 for MXF, and 19.1 ± 10.5 for GRX (means ± standard deviations).","Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. Ciprofloxacin, moxifloxacin, and grepafloxacin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24798283/),,19.1,179005,DB00592,Piperazine
,29239002,objective response rate,"Investigator-assessed objective response rate was 47% (7 of 15; 95%CI, 21.3-73.4) in the 40-mg cohort and 75% (12 of 16; 95%CI, 47.6-92.7) in the 80-mg cohort.",Pharmacokinetics of Osimertinib in Chinese Patients With Advanced NSCLC: A Phase 1 Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29239002/),%,47,179431,DB00592,Piperazine
,29239002,objective response rate,"Investigator-assessed objective response rate was 47% (7 of 15; 95%CI, 21.3-73.4) in the 40-mg cohort and 75% (12 of 16; 95%CI, 47.6-92.7) in the 80-mg cohort.",Pharmacokinetics of Osimertinib in Chinese Patients With Advanced NSCLC: A Phase 1 Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29239002/),%,75,179432,DB00592,Piperazine
,33835317,Cmax,"Finally, the rapid drug release from the solid dispersion formulation revealed increased Cmax (14.56 μg/mL) when compared to the physical mixture (4.12 μg/mL) and pure drug (3.45 μg/mL).",Enhanced Solubility and Bioavailability of Dolutegravir by Solid Dispersion Method: In Vitro and In Vivo Evaluation-a Potential Approach for HIV Therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33835317/),[μg] / [ml],14.56,179588,DB00592,Piperazine
,33835317,Cmax,"Finally, the rapid drug release from the solid dispersion formulation revealed increased Cmax (14.56 μg/mL) when compared to the physical mixture (4.12 μg/mL) and pure drug (3.45 μg/mL).",Enhanced Solubility and Bioavailability of Dolutegravir by Solid Dispersion Method: In Vitro and In Vivo Evaluation-a Potential Approach for HIV Therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33835317/),[μg] / [ml],4.12,179589,DB00592,Piperazine
,33835317,Cmax,"Finally, the rapid drug release from the solid dispersion formulation revealed increased Cmax (14.56 μg/mL) when compared to the physical mixture (4.12 μg/mL) and pure drug (3.45 μg/mL).",Enhanced Solubility and Bioavailability of Dolutegravir by Solid Dispersion Method: In Vitro and In Vivo Evaluation-a Potential Approach for HIV Therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33835317/),[μg] / [ml],3.45,179590,DB00592,Piperazine
,33835317,AUC,This was further reflected by improved bioavailability of DTG (AUC: 105.99±10.07 μg/h/mL) in the experimental Wistar rats when compared to the AUC of animals administered with physical mixture (54.45±6.58 μg/h/mL) and pure drug (49.27±6.16 μg/h/mL).,Enhanced Solubility and Bioavailability of Dolutegravir by Solid Dispersion Method: In Vitro and In Vivo Evaluation-a Potential Approach for HIV Therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33835317/),[μg] / [h·ml],105.99,179591,DB00592,Piperazine
,33835317,AUC,This was further reflected by improved bioavailability of DTG (AUC: 105.99±10.07 μg/h/mL) in the experimental Wistar rats when compared to the AUC of animals administered with physical mixture (54.45±6.58 μg/h/mL) and pure drug (49.27±6.16 μg/h/mL).,Enhanced Solubility and Bioavailability of Dolutegravir by Solid Dispersion Method: In Vitro and In Vivo Evaluation-a Potential Approach for HIV Therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33835317/),[μg] / [h·ml],54.45,179592,DB00592,Piperazine
,33835317,AUC,This was further reflected by improved bioavailability of DTG (AUC: 105.99±10.07 μg/h/mL) in the experimental Wistar rats when compared to the AUC of animals administered with physical mixture (54.45±6.58 μg/h/mL) and pure drug (49.27±6.16 μg/h/mL).,Enhanced Solubility and Bioavailability of Dolutegravir by Solid Dispersion Method: In Vitro and In Vivo Evaluation-a Potential Approach for HIV Therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33835317/),[μg] / [h·ml],49.27,179593,DB00592,Piperazine
,33349869,AUC0-12,"Geometric mean (95% CI) of itraconazole and hydroxyitraconazole AUC0-12 without efavirenz were 9097 (6761-12 239) and 11 705 (8586-15 959) ng·h/mL, respectively, with a median metabolic ratio of OH-ITC : ITC of 1.3 (95% CI 0.9-1.9).",Drug-drug interaction between itraconazole capsule and efavirenz in adults with HIV for talaromycosis treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33349869/),[h·ng] / [ml],9097,179801,DB00592,Piperazine
,33349869,AUC0-12,"Geometric mean (95% CI) of itraconazole and hydroxyitraconazole AUC0-12 without efavirenz were 9097 (6761-12 239) and 11 705 (8586-15 959) ng·h/mL, respectively, with a median metabolic ratio of OH-ITC : ITC of 1.3 (95% CI 0.9-1.9).",Drug-drug interaction between itraconazole capsule and efavirenz in adults with HIV for talaromycosis treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33349869/),[h·ng] / [ml],11 705,179802,DB00592,Piperazine
,33349869,metabolic ratio,"Geometric mean (95% CI) of itraconazole and hydroxyitraconazole AUC0-12 without efavirenz were 9097 (6761-12 239) and 11 705 (8586-15 959) ng·h/mL, respectively, with a median metabolic ratio of OH-ITC : ITC of 1.3 (95% CI 0.9-1.9).",Drug-drug interaction between itraconazole capsule and efavirenz in adults with HIV for talaromycosis treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33349869/),,1.3,179803,DB00592,Piperazine
below,33349869,trough concentrations,"With efavirenz, itraconazole trough concentrations were also below the recommended therapeutic level (0.5 μg/mL).",Drug-drug interaction between itraconazole capsule and efavirenz in adults with HIV for talaromycosis treatment. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33349869/),[μg] / [ml],0.5,179804,DB00592,Piperazine
,11410492,plasma CL(ss),"Dexrazoxane plasma CL(ss) and elimination t(1/2) were 7.2 +/- 1.6 l/h/m(2) and 2.0 +/- 0.8 h, respectively.",Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11410492/),[h·l] / [m(2],7.2,179963,DB00592,Piperazine
,11410492,elimination t(1/2),"Dexrazoxane plasma CL(ss) and elimination t(1/2) were 7.2 +/- 1.6 l/h/m(2) and 2.0 +/- 0.8 h, respectively.",Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11410492/),h,2.0,179964,DB00592,Piperazine
up to,17097755,solubility,The ITZ-PM formulation remarkably increased the itraconazole solubility up to 15 mg/mL in aqueous media and provided stable solutions at a wide range of concentrations and pH's.,"A mixed polymeric micellar formulation of itraconazole: Characteristics, toxicity and pharmacokinetics. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17097755/),[mg] / [ml],15,179977,DB00592,Piperazine
,17304149,peak plasma concentration (Cmax),"Compared with placebo, itraconazole treatment significantly increased the peak plasma concentration (Cmax) of paroxetine by 1.3 fold (6.7 +/- 2.5 versus 9.0 +/- 3.3 ng/mL, P < 0.05) and the area under the plasma concentration-time curve from zero to 48 hours [AUC (0-48)] of paroxetine by 1.5 fold (137 +/- 73 versus 199 +/- 91 ng*h/mL, P < 0.01).",Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17304149/),[ng] / [ml],6.7,180180,DB00592,Piperazine
,17304149,peak plasma concentration (Cmax),"Compared with placebo, itraconazole treatment significantly increased the peak plasma concentration (Cmax) of paroxetine by 1.3 fold (6.7 +/- 2.5 versus 9.0 +/- 3.3 ng/mL, P < 0.05) and the area under the plasma concentration-time curve from zero to 48 hours [AUC (0-48)] of paroxetine by 1.5 fold (137 +/- 73 versus 199 +/- 91 ng*h/mL, P < 0.01).",Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17304149/),[ng] / [ml],9.0,180181,DB00592,Piperazine
,17304149,area under the plasma concentration-time curve from zero to 48 hours [AUC (0-48)],"Compared with placebo, itraconazole treatment significantly increased the peak plasma concentration (Cmax) of paroxetine by 1.3 fold (6.7 +/- 2.5 versus 9.0 +/- 3.3 ng/mL, P < 0.05) and the area under the plasma concentration-time curve from zero to 48 hours [AUC (0-48)] of paroxetine by 1.5 fold (137 +/- 73 versus 199 +/- 91 ng*h/mL, P < 0.01).",Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17304149/),[h·ng] / [ml],137,180182,DB00592,Piperazine
,17304149,area under the plasma concentration-time curve from zero to 48 hours [AUC (0-48)],"Compared with placebo, itraconazole treatment significantly increased the peak plasma concentration (Cmax) of paroxetine by 1.3 fold (6.7 +/- 2.5 versus 9.0 +/- 3.3 ng/mL, P < 0.05) and the area under the plasma concentration-time curve from zero to 48 hours [AUC (0-48)] of paroxetine by 1.5 fold (137 +/- 73 versus 199 +/- 91 ng*h/mL, P < 0.01).",Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17304149/),[h·ng] / [ml],199,180183,DB00592,Piperazine
,17304149,elimination half-life,"Although elimination half-life differed significantly (16.1 +/- 3.4 versus 18.8 +/- 5.9 hours, P < 0.05), the alteration was small (1.1 fold).",Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17304149/),h,16.1,180184,DB00592,Piperazine
,17304149,elimination half-life,"Although elimination half-life differed significantly (16.1 +/- 3.4 versus 18.8 +/- 5.9 hours, P < 0.05), the alteration was small (1.1 fold).",Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17304149/),h,18.8,180185,DB00592,Piperazine
,21049519,total time,"Peaks were detected with an UV detector set at a wavelength of 254 nm, and the total time for chromatographic separation was ∼20 min.",A sensitive column-switching HPLC method for aripiprazole and dehydroaripiprazole and its application to human pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21049519/),min,∼20,180267,DB00592,Piperazine
,21049519,absolute recoveries,"Mean absolute recoveries were 74.0 and 74.7% for aripiprazole and dehydroaripiprazole, respectively.",A sensitive column-switching HPLC method for aripiprazole and dehydroaripiprazole and its application to human pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21049519/),%,74.0,180268,DB00592,Piperazine
,21049519,absolute recoveries,"Mean absolute recoveries were 74.0 and 74.7% for aripiprazole and dehydroaripiprazole, respectively.",A sensitive column-switching HPLC method for aripiprazole and dehydroaripiprazole and its application to human pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21049519/),%,74.7,180269,DB00592,Piperazine
,21049519,limits of detection,The validated concentration ranges for this method were 1-500 ng/mL and the limits of detection were 0.5 ng/mL for both aripiprazole and dehydroaripiprazole.,A sensitive column-switching HPLC method for aripiprazole and dehydroaripiprazole and its application to human pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21049519/),[ng] / [ml],0.5,180270,DB00592,Piperazine
,9088587,apparent oral clearance,"Ketoconazole administration was associated with a decrease in imipramine apparent oral clearance (from 1.16 +/- 0.21 to 0.96 +/- 0.20 l h-1 kg-1, mean +/- s.d.; P < 0.02), a prolongation in imipramine half-life (from 16.7 +/- 3.3 to 19.2 +/- 5.4 h, P < 0.05) and a decrease in area under the curve of metabolically derived desipramine (from 3507 +/- 1707 to 3180 +/- 1505 nmol l-1 h, P < 0.05), whereas concentrations of 2-hydroxy-imipramine were unaffected.",Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088587/),[l] / [h·kg],1.16,180537,DB00592,Piperazine
,9088587,apparent oral clearance,"Ketoconazole administration was associated with a decrease in imipramine apparent oral clearance (from 1.16 +/- 0.21 to 0.96 +/- 0.20 l h-1 kg-1, mean +/- s.d.; P < 0.02), a prolongation in imipramine half-life (from 16.7 +/- 3.3 to 19.2 +/- 5.4 h, P < 0.05) and a decrease in area under the curve of metabolically derived desipramine (from 3507 +/- 1707 to 3180 +/- 1505 nmol l-1 h, P < 0.05), whereas concentrations of 2-hydroxy-imipramine were unaffected.",Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088587/),[l] / [h·kg],0.96,180538,DB00592,Piperazine
,9088587,half-life,"Ketoconazole administration was associated with a decrease in imipramine apparent oral clearance (from 1.16 +/- 0.21 to 0.96 +/- 0.20 l h-1 kg-1, mean +/- s.d.; P < 0.02), a prolongation in imipramine half-life (from 16.7 +/- 3.3 to 19.2 +/- 5.4 h, P < 0.05) and a decrease in area under the curve of metabolically derived desipramine (from 3507 +/- 1707 to 3180 +/- 1505 nmol l-1 h, P < 0.05), whereas concentrations of 2-hydroxy-imipramine were unaffected.",Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088587/),h,16.7,180539,DB00592,Piperazine
,9088587,half-life,"Ketoconazole administration was associated with a decrease in imipramine apparent oral clearance (from 1.16 +/- 0.21 to 0.96 +/- 0.20 l h-1 kg-1, mean +/- s.d.; P < 0.02), a prolongation in imipramine half-life (from 16.7 +/- 3.3 to 19.2 +/- 5.4 h, P < 0.05) and a decrease in area under the curve of metabolically derived desipramine (from 3507 +/- 1707 to 3180 +/- 1505 nmol l-1 h, P < 0.05), whereas concentrations of 2-hydroxy-imipramine were unaffected.",Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088587/),h,19.2,180540,DB00592,Piperazine
,9088587,area under the curve,"Ketoconazole administration was associated with a decrease in imipramine apparent oral clearance (from 1.16 +/- 0.21 to 0.96 +/- 0.20 l h-1 kg-1, mean +/- s.d.; P < 0.02), a prolongation in imipramine half-life (from 16.7 +/- 3.3 to 19.2 +/- 5.4 h, P < 0.05) and a decrease in area under the curve of metabolically derived desipramine (from 3507 +/- 1707 to 3180 +/- 1505 nmol l-1 h, P < 0.05), whereas concentrations of 2-hydroxy-imipramine were unaffected.",Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088587/),[h·nM] / [l],3507,180541,DB00592,Piperazine
,9088587,area under the curve,"Ketoconazole administration was associated with a decrease in imipramine apparent oral clearance (from 1.16 +/- 0.21 to 0.96 +/- 0.20 l h-1 kg-1, mean +/- s.d.; P < 0.02), a prolongation in imipramine half-life (from 16.7 +/- 3.3 to 19.2 +/- 5.4 h, P < 0.05) and a decrease in area under the curve of metabolically derived desipramine (from 3507 +/- 1707 to 3180 +/- 1505 nmol l-1 h, P < 0.05), whereas concentrations of 2-hydroxy-imipramine were unaffected.",Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088587/),[h·nM] / [l],3180,180542,DB00592,Piperazine
,29193123,AUC(0-24) ratios,"Predicted and observed metoprolol geometric least-squares mean AUC(0-24) ratios in UM vs EM were also similar (0.46 and 0.55, respectively), suggesting that system components related to CYP2D6 in the PBPK model were properly established.",Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29193123/),,0.46,180852,DB00592,Piperazine
,29193123,AUC(0-24) ratios,"Predicted and observed metoprolol geometric least-squares mean AUC(0-24) ratios in UM vs EM were also similar (0.46 and 0.55, respectively), suggesting that system components related to CYP2D6 in the PBPK model were properly established.",Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29193123/),,0.55,180853,DB00592,Piperazine
,24975211,retention time,The retention time was approximately 4.8min.,Liquid chromatography-mass spectrometry analysis of diethylcarbamazine in human plasma for clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24975211/),min,4.8,180933,DB00592,Piperazine
,24975211,Recovery,Recovery of DEC from plasma ranged from 84.2% to 90.1%.,Liquid chromatography-mass spectrometry analysis of diethylcarbamazine in human plasma for clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24975211/),%,84.2,180934,DB00592,Piperazine
,24975211,Recovery,Recovery of DEC from plasma ranged from 84.2% to 90.1%.,Liquid chromatography-mass spectrometry analysis of diethylcarbamazine in human plasma for clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24975211/),%,90.1,180935,DB00592,Piperazine
,27209054,total run time,The total run time was 1.5 min.,UPLC-MS-MS Method for the Determination of Vilazodone in Human Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27209054/),min,1.5,181804,DB00592,Piperazine
over,33480570,plasma concentrations,"All animals achieved plasma concentrations over 130 ng/ml, a level considered therapeutic in humans and dogs, for a mean of 6.4 ± 5.0 hr.",PHARMACOKINETICS AND CLINICAL EFFECTS OF A SINGLE ORAL DOSE OF TRAZODONE IN THE DOMESTIC GOAT (CAPRA HIRCUS) AS A MODEL FOR WILD RUMINANTS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33480570/),[ng] / [ml],130,182014,DB00592,Piperazine
,33480570,terminal half-life,Mean terminal half-life was 10.55 ± 6.80 hr.,PHARMACOKINETICS AND CLINICAL EFFECTS OF A SINGLE ORAL DOSE OF TRAZODONE IN THE DOMESTIC GOAT (CAPRA HIRCUS) AS A MODEL FOR WILD RUMINANTS. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33480570/),h,10.55,182015,DB00592,Piperazine
,27779776,AUC∞,"For a dose of 10 mg administered as a bolus followed by 2.5 mg administered over 2 h the results were AUC∞ 537 ng h ml-1 , Cmax 189.4 ng ml-1 and t1/2 10.5 h.","A Phase I study to determine the pharmacokinetic profile, safety and tolerability of sildenafil (Revatio® ) in cardiac surgery: the REVAKI-1 study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27779776/),[h·ng] / [ml],537,182986,DB00592,Piperazine
,27779776,Cmax,"For a dose of 10 mg administered as a bolus followed by 2.5 mg administered over 2 h the results were AUC∞ 537 ng h ml-1 , Cmax 189.4 ng ml-1 and t1/2 10.5 h.","A Phase I study to determine the pharmacokinetic profile, safety and tolerability of sildenafil (Revatio® ) in cardiac surgery: the REVAKI-1 study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27779776/),[ng] / [ml],189.4,182987,DB00592,Piperazine
,27779776,t1/2,"For a dose of 10 mg administered as a bolus followed by 2.5 mg administered over 2 h the results were AUC∞ 537 ng h ml-1 , Cmax 189.4 ng ml-1 and t1/2 10.5 h.","A Phase I study to determine the pharmacokinetic profile, safety and tolerability of sildenafil (Revatio® ) in cardiac surgery: the REVAKI-1 study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27779776/),h,10.5,182988,DB00592,Piperazine
,9371367,Cmin,"At day 14, Cmin values of itraconazole were 643 +/- 304 and 592 +/- 401 ng/ml for groups A and B, respectively, and Cmin values of hydroxyitraconazole were 1,411 +/- 594 and 1,389 +/- 804 ng/ml for groups A and B, respectively.",Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus-infected adults with oral candidiasis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9371367/),[ng] / [ml],643,183167,DB00592,Piperazine
,9371367,Cmin,"At day 14, Cmin values of itraconazole were 643 +/- 304 and 592 +/- 401 ng/ml for groups A and B, respectively, and Cmin values of hydroxyitraconazole were 1,411 +/- 594 and 1,389 +/- 804 ng/ml for groups A and B, respectively.",Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus-infected adults with oral candidiasis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9371367/),[ng] / [ml],592,183168,DB00592,Piperazine
,9371367,Cmin,"At day 14, Cmin values of itraconazole were 643 +/- 304 and 592 +/- 401 ng/ml for groups A and B, respectively, and Cmin values of hydroxyitraconazole were 1,411 +/- 594 and 1,389 +/- 804 ng/ml for groups A and B, respectively.",Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus-infected adults with oral candidiasis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9371367/),[ng] / [ml],"1,411",183169,DB00592,Piperazine
,9371367,Cmin,"At day 14, Cmin values of itraconazole were 643 +/- 304 and 592 +/- 401 ng/ml for groups A and B, respectively, and Cmin values of hydroxyitraconazole were 1,411 +/- 594 and 1,389 +/- 804 ng/ml for groups A and B, respectively.",Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus-infected adults with oral candidiasis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9371367/),[ng] / [ml],"1,389",183170,DB00592,Piperazine
,10582742,systemic,KC significantly decreased the mean systemic CsA clearance from 2.73 mL/min/kg to 1.22 mL/min/kg resulting in an increase in the terminal phase half-life from 10.7 to 22.2 hours.,The effects of ketoconazole on the pharmacokinetics of cyclosporine A in cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582742/),[ml] / [kg·min],2.73,183205,DB00592,Piperazine
,10582742,systemic,KC significantly decreased the mean systemic CsA clearance from 2.73 mL/min/kg to 1.22 mL/min/kg resulting in an increase in the terminal phase half-life from 10.7 to 22.2 hours.,The effects of ketoconazole on the pharmacokinetics of cyclosporine A in cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582742/),[ml] / [kg·min],1.22,183206,DB00592,Piperazine
,10582742,terminal phase half-life,KC significantly decreased the mean systemic CsA clearance from 2.73 mL/min/kg to 1.22 mL/min/kg resulting in an increase in the terminal phase half-life from 10.7 to 22.2 hours.,The effects of ketoconazole on the pharmacokinetics of cyclosporine A in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582742/),h,10.7,183207,DB00592,Piperazine
,10582742,terminal phase half-life,KC significantly decreased the mean systemic CsA clearance from 2.73 mL/min/kg to 1.22 mL/min/kg resulting in an increase in the terminal phase half-life from 10.7 to 22.2 hours.,The effects of ketoconazole on the pharmacokinetics of cyclosporine A in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582742/),h,22.2,183208,DB00592,Piperazine
,1428196,peak plasma concentration (Cmax),"This occurred when the drug concentrations in cauda epididymal fluid and seminal plasma were at their peak (18.0 +/- 7.3 and 13.5 +/- 3.0 micrograms ml-1, respectively), and which was preceded by a peak plasma concentration (Cmax) of 64.82 +/- 2.47 micrograms ml-1 at 5.15 +/- 0.68 h (Tmax).",Pharmacokinetic and pharmacodynamic studies of the effect of ketoconazole on reproductive function in male rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1428196/),[μg] / [ml],64.82,183380,DB00592,Piperazine
,1428196,Tmax,"This occurred when the drug concentrations in cauda epididymal fluid and seminal plasma were at their peak (18.0 +/- 7.3 and 13.5 +/- 3.0 micrograms ml-1, respectively), and which was preceded by a peak plasma concentration (Cmax) of 64.82 +/- 2.47 micrograms ml-1 at 5.15 +/- 0.68 h (Tmax).",Pharmacokinetic and pharmacodynamic studies of the effect of ketoconazole on reproductive function in male rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1428196/),h,5.15,183381,DB00592,Piperazine
,23363721,C(max),"The main pharmacokinetic parameters of domestic and imported formulation of trimetazidine were similar: C(max) (70.9 ± 15.3), (66.4 ± 13.8) µg/ml; t(max) (1.70 ± 0.72), (1.85 ± 0.55) h; t(1/2z) (4.70 ± 1.75), (4.77 ± 1.96) h; AUC(0-24 h) (481 ± 176), (469 ± 171) µg×h×ml(-1); AUC(0-∞) (511 ± 189), (500 ± 188) µg×h×ml(-1).",[Pharmacokinetics and bioequivalence of domestic trimetazidine formulations]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23363721/),[μg] / [ml],70.9,183382,DB00592,Piperazine
,23363721,C(max),"The main pharmacokinetic parameters of domestic and imported formulation of trimetazidine were similar: C(max) (70.9 ± 15.3), (66.4 ± 13.8) µg/ml; t(max) (1.70 ± 0.72), (1.85 ± 0.55) h; t(1/2z) (4.70 ± 1.75), (4.77 ± 1.96) h; AUC(0-24 h) (481 ± 176), (469 ± 171) µg×h×ml(-1); AUC(0-∞) (511 ± 189), (500 ± 188) µg×h×ml(-1).",[Pharmacokinetics and bioequivalence of domestic trimetazidine formulations]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23363721/),[μg] / [ml],66.4,183383,DB00592,Piperazine
,23363721,t(max),"The main pharmacokinetic parameters of domestic and imported formulation of trimetazidine were similar: C(max) (70.9 ± 15.3), (66.4 ± 13.8) µg/ml; t(max) (1.70 ± 0.72), (1.85 ± 0.55) h; t(1/2z) (4.70 ± 1.75), (4.77 ± 1.96) h; AUC(0-24 h) (481 ± 176), (469 ± 171) µg×h×ml(-1); AUC(0-∞) (511 ± 189), (500 ± 188) µg×h×ml(-1).",[Pharmacokinetics and bioequivalence of domestic trimetazidine formulations]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23363721/),h,1.70,183384,DB00592,Piperazine
,23363721,t(max),"The main pharmacokinetic parameters of domestic and imported formulation of trimetazidine were similar: C(max) (70.9 ± 15.3), (66.4 ± 13.8) µg/ml; t(max) (1.70 ± 0.72), (1.85 ± 0.55) h; t(1/2z) (4.70 ± 1.75), (4.77 ± 1.96) h; AUC(0-24 h) (481 ± 176), (469 ± 171) µg×h×ml(-1); AUC(0-∞) (511 ± 189), (500 ± 188) µg×h×ml(-1).",[Pharmacokinetics and bioequivalence of domestic trimetazidine formulations]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23363721/),h,1.85,183385,DB00592,Piperazine
,23363721,t(1/2z),"The main pharmacokinetic parameters of domestic and imported formulation of trimetazidine were similar: C(max) (70.9 ± 15.3), (66.4 ± 13.8) µg/ml; t(max) (1.70 ± 0.72), (1.85 ± 0.55) h; t(1/2z) (4.70 ± 1.75), (4.77 ± 1.96) h; AUC(0-24 h) (481 ± 176), (469 ± 171) µg×h×ml(-1); AUC(0-∞) (511 ± 189), (500 ± 188) µg×h×ml(-1).",[Pharmacokinetics and bioequivalence of domestic trimetazidine formulations]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23363721/),h,4.70,183386,DB00592,Piperazine
,23363721,t(1/2z),"The main pharmacokinetic parameters of domestic and imported formulation of trimetazidine were similar: C(max) (70.9 ± 15.3), (66.4 ± 13.8) µg/ml; t(max) (1.70 ± 0.72), (1.85 ± 0.55) h; t(1/2z) (4.70 ± 1.75), (4.77 ± 1.96) h; AUC(0-24 h) (481 ± 176), (469 ± 171) µg×h×ml(-1); AUC(0-∞) (511 ± 189), (500 ± 188) µg×h×ml(-1).",[Pharmacokinetics and bioequivalence of domestic trimetazidine formulations]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23363721/),h,4.77,183387,DB00592,Piperazine
,23363721,AUC(0-24 h),"The main pharmacokinetic parameters of domestic and imported formulation of trimetazidine were similar: C(max) (70.9 ± 15.3), (66.4 ± 13.8) µg/ml; t(max) (1.70 ± 0.72), (1.85 ± 0.55) h; t(1/2z) (4.70 ± 1.75), (4.77 ± 1.96) h; AUC(0-24 h) (481 ± 176), (469 ± 171) µg×h×ml(-1); AUC(0-∞) (511 ± 189), (500 ± 188) µg×h×ml(-1).",[Pharmacokinetics and bioequivalence of domestic trimetazidine formulations]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23363721/),[h·μg] / [ml],481,183388,DB00592,Piperazine
,23363721,AUC(0-24 h),"The main pharmacokinetic parameters of domestic and imported formulation of trimetazidine were similar: C(max) (70.9 ± 15.3), (66.4 ± 13.8) µg/ml; t(max) (1.70 ± 0.72), (1.85 ± 0.55) h; t(1/2z) (4.70 ± 1.75), (4.77 ± 1.96) h; AUC(0-24 h) (481 ± 176), (469 ± 171) µg×h×ml(-1); AUC(0-∞) (511 ± 189), (500 ± 188) µg×h×ml(-1).",[Pharmacokinetics and bioequivalence of domestic trimetazidine formulations]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23363721/),[h·μg] / [ml],469,183389,DB00592,Piperazine
,23363721,AUC(0-∞),"The main pharmacokinetic parameters of domestic and imported formulation of trimetazidine were similar: C(max) (70.9 ± 15.3), (66.4 ± 13.8) µg/ml; t(max) (1.70 ± 0.72), (1.85 ± 0.55) h; t(1/2z) (4.70 ± 1.75), (4.77 ± 1.96) h; AUC(0-24 h) (481 ± 176), (469 ± 171) µg×h×ml(-1); AUC(0-∞) (511 ± 189), (500 ± 188) µg×h×ml(-1).",[Pharmacokinetics and bioequivalence of domestic trimetazidine formulations]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23363721/),[h·μg] / [ml],511,183390,DB00592,Piperazine
,23363721,AUC(0-∞),"The main pharmacokinetic parameters of domestic and imported formulation of trimetazidine were similar: C(max) (70.9 ± 15.3), (66.4 ± 13.8) µg/ml; t(max) (1.70 ± 0.72), (1.85 ± 0.55) h; t(1/2z) (4.70 ± 1.75), (4.77 ± 1.96) h; AUC(0-24 h) (481 ± 176), (469 ± 171) µg×h×ml(-1); AUC(0-∞) (511 ± 189), (500 ± 188) µg×h×ml(-1).",[Pharmacokinetics and bioequivalence of domestic trimetazidine formulations]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23363721/),[h·μg] / [ml],500,183391,DB00592,Piperazine
,23363721,relative bioavailability,The relative bioavailability of domestic formulation was (102.2 ± 8.3)%.,[Pharmacokinetics and bioequivalence of domestic trimetazidine formulations]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23363721/),%,102.2,183392,DB00592,Piperazine
,25448073,half life,"It is also characterized by a short half life of 3-6h, which requires frequent daily administration resulting in poor patient compliance.",Floating lipid beads for the improvement of bioavailability of poorly soluble basic drugs: in-vitro optimization and in-vivo performance in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25448073/),h,3-6,183393,DB00592,Piperazine
,10320950,peak plasma concentration (Cmax),"The mean peak plasma concentration (Cmax) is approximately 2.5 micrograms/L, and the time to reach the peak is under 1 hour.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),[μg] / [l],2.5,183615,DB00592,Piperazine
under,10320950,time to reach the peak,"The mean peak plasma concentration (Cmax) is approximately 2.5 micrograms/L, and the time to reach the peak is under 1 hour.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),h,1,183616,DB00592,Piperazine
,10320950,absolute bioavailability,The absolute bioavailability of buspirone is approximately 4%.,"Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),%,4,183617,DB00592,Piperazine
,10320950,volume of distribution,"Buspirone has a volume of distribution of 5.3 L/kg, a systemic clearance of about 1.7 L/h/kg, an elimination half-life of about 2.5 hours and the pharmacokinetics are linear over the dose range 10 to 40 mg.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),[l] / [kg],5.3,183618,DB00592,Piperazine
,10320950,systemic clearance,"Buspirone has a volume of distribution of 5.3 L/kg, a systemic clearance of about 1.7 L/h/kg, an elimination half-life of about 2.5 hours and the pharmacokinetics are linear over the dose range 10 to 40 mg.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),[l] / [h·kg],1.7,183619,DB00592,Piperazine
,10320950,elimination half-life,"Buspirone has a volume of distribution of 5.3 L/kg, a systemic clearance of about 1.7 L/h/kg, an elimination half-life of about 2.5 hours and the pharmacokinetics are linear over the dose range 10 to 40 mg.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),h,2.5,183620,DB00592,Piperazine
,8477559,plasma elimination half-life,"The plasma elimination half-life of cetirizine was significantly shorter in children (p < 0.001; 4.91 +/- 0.6 hours) than in adults (8.6 +/- 2.1 hours), and the clearance rate was significantly higher in children (p < 0.001; 1.48 +/- 0.41 ml/min/kg) than in adults (0.80 +/- 0.17 ml/min/kg).",A pharmacokinetic evaluation of the second-generation H1-receptor antagonist cetirizine in very young children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477559/),h,4.91,183625,DB00592,Piperazine
,8477559,plasma elimination half-life,"The plasma elimination half-life of cetirizine was significantly shorter in children (p < 0.001; 4.91 +/- 0.6 hours) than in adults (8.6 +/- 2.1 hours), and the clearance rate was significantly higher in children (p < 0.001; 1.48 +/- 0.41 ml/min/kg) than in adults (0.80 +/- 0.17 ml/min/kg).",A pharmacokinetic evaluation of the second-generation H1-receptor antagonist cetirizine in very young children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477559/),h,8.6,183626,DB00592,Piperazine
,8477559,clearance rate,"The plasma elimination half-life of cetirizine was significantly shorter in children (p < 0.001; 4.91 +/- 0.6 hours) than in adults (8.6 +/- 2.1 hours), and the clearance rate was significantly higher in children (p < 0.001; 1.48 +/- 0.41 ml/min/kg) than in adults (0.80 +/- 0.17 ml/min/kg).",A pharmacokinetic evaluation of the second-generation H1-receptor antagonist cetirizine in very young children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477559/),[ml] / [kg·min],1.48,183627,DB00592,Piperazine
,8477559,clearance rate,"The plasma elimination half-life of cetirizine was significantly shorter in children (p < 0.001; 4.91 +/- 0.6 hours) than in adults (8.6 +/- 2.1 hours), and the clearance rate was significantly higher in children (p < 0.001; 1.48 +/- 0.41 ml/min/kg) than in adults (0.80 +/- 0.17 ml/min/kg).",A pharmacokinetic evaluation of the second-generation H1-receptor antagonist cetirizine in very young children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477559/),[ml] / [kg·min],0.80,183628,DB00592,Piperazine
,8477559,Urinary excretion,Urinary excretion of unchanged cetirizine was significantly lower in children (p < 0.001; 37.8% +/- 5.2%; n = 5) than in adults (57.7% +/- 11.8%).,A pharmacokinetic evaluation of the second-generation H1-receptor antagonist cetirizine in very young children. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477559/),%,37.8,183629,DB00592,Piperazine
,8477559,Urinary excretion,Urinary excretion of unchanged cetirizine was significantly lower in children (p < 0.001; 37.8% +/- 5.2%; n = 5) than in adults (57.7% +/- 11.8%).,A pharmacokinetic evaluation of the second-generation H1-receptor antagonist cetirizine in very young children. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477559/),%,57.7,183630,DB00592,Piperazine
,7793859,times to peak values,"The times to peak values were relatively short (0.5 to 1.0 h), suggesting a rapid absorption.","Safety, tolerance, and pharmacokinetics of atevirdine mesylate (U-87201E) in asymptomatic human immunodeficiency virus-infected patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793859/),h,0.5 to 1.0,183765,DB00592,Piperazine
,7793859,maximum concentrations,"The maximum concentrations of drug in serum were 1.4 microM (400 mg), 4.2 microM (800 mg), 7.3 microM (1,200 mg), and 5.8 microM (1,600 mg).","Safety, tolerance, and pharmacokinetics of atevirdine mesylate (U-87201E) in asymptomatic human immunodeficiency virus-infected patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793859/),μM,1.4,183766,DB00592,Piperazine
,7793859,maximum concentrations,"The maximum concentrations of drug in serum were 1.4 microM (400 mg), 4.2 microM (800 mg), 7.3 microM (1,200 mg), and 5.8 microM (1,600 mg).","Safety, tolerance, and pharmacokinetics of atevirdine mesylate (U-87201E) in asymptomatic human immunodeficiency virus-infected patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793859/),μM,4.2,183767,DB00592,Piperazine
,7793859,maximum concentrations,"The maximum concentrations of drug in serum were 1.4 microM (400 mg), 4.2 microM (800 mg), 7.3 microM (1,200 mg), and 5.8 microM (1,600 mg).","Safety, tolerance, and pharmacokinetics of atevirdine mesylate (U-87201E) in asymptomatic human immunodeficiency virus-infected patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793859/),μM,7.3,183768,DB00592,Piperazine
,7793859,maximum concentrations,"The maximum concentrations of drug in serum were 1.4 microM (400 mg), 4.2 microM (800 mg), 7.3 microM (1,200 mg), and 5.8 microM (1,600 mg).","Safety, tolerance, and pharmacokinetics of atevirdine mesylate (U-87201E) in asymptomatic human immunodeficiency virus-infected patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793859/),μM,5.8,183769,DB00592,Piperazine
,20102737,C(max),"In systemic circulation, Wet-milled ITZ and URF-ITZ achieved C(max) of 50 and 180ng/mL at 2.7 and 4.0h, and AUC(0-24) of 662 and 2543ngh/mL, respectively, based on a one-compartmental analysis.",Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20102737/),[ng] / [ml],50,183775,DB00592,Piperazine
,20102737,C(max),"In systemic circulation, Wet-milled ITZ and URF-ITZ achieved C(max) of 50 and 180ng/mL at 2.7 and 4.0h, and AUC(0-24) of 662 and 2543ngh/mL, respectively, based on a one-compartmental analysis.",Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20102737/),[ng] / [ml],180,183776,DB00592,Piperazine
,20102737,AUC(0-24),"In systemic circulation, Wet-milled ITZ and URF-ITZ achieved C(max) of 50 and 180ng/mL at 2.7 and 4.0h, and AUC(0-24) of 662 and 2543ngh/mL, respectively, based on a one-compartmental analysis.",Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20102737/),[ngh] / [ml],662,183777,DB00592,Piperazine
,20102737,AUC(0-24),"In systemic circulation, Wet-milled ITZ and URF-ITZ achieved C(max) of 50 and 180ng/mL at 2.7 and 4.0h, and AUC(0-24) of 662 and 2543ngh/mL, respectively, based on a one-compartmental analysis.",Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20102737/),[ngh] / [ml],2543,183778,DB00592,Piperazine
<,16846725,oral bioavailability (F,"In rat, the low oral bioavailability (F < 10%) is largely due to poor absorption.","Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16846725/),%,10,183820,DB00592,Piperazine
,1358923,time to reach peak concentration (tmax),"Mean gepirone time to reach peak concentration (tmax) after treatments 1, 2, and 3 ranged between 0.57 and 1.07 hours.",The site of gastrointestinal absorption of gepirone in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1358923/),h,0.57 and 1.07,184176,DB00592,Piperazine
,1358923,t1/2,"There were no significant differences between sites and treatments for gepirone t1/2, which ranged between 2.8 and 3.3 hours.",The site of gastrointestinal absorption of gepirone in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1358923/),h,2.8,184177,DB00592,Piperazine
,1358923,t1/2,"There were no significant differences between sites and treatments for gepirone t1/2, which ranged between 2.8 and 3.3 hours.",The site of gastrointestinal absorption of gepirone in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1358923/),h,3,184178,DB00592,Piperazine
,1358923,maximum peak plasma concentration (Cmax),The mean gepirone maximum peak plasma concentration (Cmax) was significantly higher (P less than .05) after treatment 2 (12.92 +/- 7.24 ng/mL) compared with treatment 1 (6.79 +/- 3.54 ng/mL) or treatment 3 (6.33 +/- 2.26 ng/mL).,The site of gastrointestinal absorption of gepirone in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1358923/),[ng] / [ml],12.92,184179,DB00592,Piperazine
,1358923,maximum peak plasma concentration (Cmax),The mean gepirone maximum peak plasma concentration (Cmax) was significantly higher (P less than .05) after treatment 2 (12.92 +/- 7.24 ng/mL) compared with treatment 1 (6.79 +/- 3.54 ng/mL) or treatment 3 (6.33 +/- 2.26 ng/mL).,The site of gastrointestinal absorption of gepirone in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1358923/),[ng] / [ml],6.79,184180,DB00592,Piperazine
,1358923,maximum peak plasma concentration (Cmax),The mean gepirone maximum peak plasma concentration (Cmax) was significantly higher (P less than .05) after treatment 2 (12.92 +/- 7.24 ng/mL) compared with treatment 1 (6.79 +/- 3.54 ng/mL) or treatment 3 (6.33 +/- 2.26 ng/mL).,The site of gastrointestinal absorption of gepirone in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1358923/),[ng] / [ml],6.33,184181,DB00592,Piperazine
,1358923,area under the curve (AUCinf),Gepirone area under the curve (AUCinf) was also significantly higher (P less than .05) after treatment 2 (29.83 +/- 17.42 ng.h/mL) compared with treatment 1 (18.07 +/- 6.10 ng.h/mL) or treatment 3 (17.74 +/- 7.69 ng.h/mL).,The site of gastrointestinal absorption of gepirone in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1358923/),[h·ng] / [ml],29.83,184182,DB00592,Piperazine
,1358923,area under the curve (AUCinf),Gepirone area under the curve (AUCinf) was also significantly higher (P less than .05) after treatment 2 (29.83 +/- 17.42 ng.h/mL) compared with treatment 1 (18.07 +/- 6.10 ng.h/mL) or treatment 3 (17.74 +/- 7.69 ng.h/mL).,The site of gastrointestinal absorption of gepirone in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1358923/),[h·ng] / [ml],18.07,184183,DB00592,Piperazine
,1358923,area under the curve (AUCinf),Gepirone area under the curve (AUCinf) was also significantly higher (P less than .05) after treatment 2 (29.83 +/- 17.42 ng.h/mL) compared with treatment 1 (18.07 +/- 6.10 ng.h/mL) or treatment 3 (17.74 +/- 7.69 ng.h/mL).,The site of gastrointestinal absorption of gepirone in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1358923/),[h·ng] / [ml],17.74,184184,DB00592,Piperazine
,9600718,extraction ratios,"The gut had a high intrinsic capacity for metabolizing BMS-181101-extraction ratios were 93% and 10% for the gut and liver, respectively.","Pharmacokinetic assessment of the sites of first-pass metabolism of BMS-181101, an antidepressant agent, in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9600718/),%,93,184563,DB00592,Piperazine
,9600718,extraction ratios,"The gut had a high intrinsic capacity for metabolizing BMS-181101-extraction ratios were 93% and 10% for the gut and liver, respectively.","Pharmacokinetic assessment of the sites of first-pass metabolism of BMS-181101, an antidepressant agent, in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9600718/),%,10,184564,DB00592,Piperazine
,9600718,total first-pass effect,The estimated total first-pass effect of 94% for BMS-181101 in rats is in excellent agreement with the observed absolute oral bioavailability of 6%.,"Pharmacokinetic assessment of the sites of first-pass metabolism of BMS-181101, an antidepressant agent, in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9600718/),%,94,184565,DB00592,Piperazine
,9600718,absolute oral bioavailability,The estimated total first-pass effect of 94% for BMS-181101 in rats is in excellent agreement with the observed absolute oral bioavailability of 6%.,"Pharmacokinetic assessment of the sites of first-pass metabolism of BMS-181101, an antidepressant agent, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9600718/),%,6,184566,DB00592,Piperazine
,2572611,peak hydroxyzine levels,Mean peak hydroxyzine levels of 116.5 +/- 60.6 ng/mL occurred at 2.3 +/- 0.7 hours and mean peak cetirizine levels of 500.4 +/- 302.0 ng/mL occurred at 4.8 +/- 2.8 hours.,The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2572611/),[ng] / [ml],116.5,184584,DB00592,Piperazine
,2572611,peak cetirizine levels,Mean peak hydroxyzine levels of 116.5 +/- 60.6 ng/mL occurred at 2.3 +/- 0.7 hours and mean peak cetirizine levels of 500.4 +/- 302.0 ng/mL occurred at 4.8 +/- 2.8 hours.,The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2572611/),[ng] / [ml],500.4,184585,DB00592,Piperazine
,2572611,serum elimination half-life,"The mean serum elimination half-life of hydroxyzine was 36.6 +/- 13.1 hours, and the mean serum elimination half-life of cetirizine was 25.0 +/- 8.2 hours.",The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2572611/),h,36.6,184586,DB00592,Piperazine
,2572611,serum elimination half-life,"The mean serum elimination half-life of hydroxyzine was 36.6 +/- 13.1 hours, and the mean serum elimination half-life of cetirizine was 25.0 +/- 8.2 hours.",The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2572611/),h,25.0,184587,DB00592,Piperazine
,2572611,clearance rate,"The mean hydroxyzine clearance rate was 8.65 +/- 7.46 mL/min/kg, and the mean volume of distribution was 22.7 +/- 13.3 L/kg.",The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2572611/),[ml] / [kg·min],8.65,184588,DB00592,Piperazine
,2572611,volume of distribution,"The mean hydroxyzine clearance rate was 8.65 +/- 7.46 mL/min/kg, and the mean volume of distribution was 22.7 +/- 13.3 L/kg.",The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2572611/),[l] / [kg],22.7,184589,DB00592,Piperazine
,9505985,time to maximum plasma concentration (tmax),The drug was rapidly absorbed with a median time to maximum plasma concentration (tmax) between 0.5 and 1.5 hours.,The effects of age and gender on the single dose pharmacokinetics of avitriptan administered to healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9505985/),h,0.5 and 1.5,184766,DB00592,Piperazine
,2091888,absolute bioavailability,"It was shown that the absorption of eltoprazine from the gastro-intestinal tract was complete, and that absolute bioavailability was 100%.",Pharmacokinetics of eltoprazine in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2091888/),%,100,184796,DB00592,Piperazine
,2091888,elimination half-life,The mean elimination half-life of eltoprazine in plasma was about 8 hours.,Pharmacokinetics of eltoprazine in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2091888/),h,8,184797,DB00592,Piperazine
,16369998,oral bioavailability,Its oral bioavailability is about 40%.,Intestinal absorption and presystemic disposition of sildenafil citrate in the rabbit: evidence for site-dependent absorptive clearance. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369998/),%,40,184914,DB00592,Piperazine
,16369998,permeability area,"The values of the permeability area product normalized to segment length (ml/min.cm) were 0.0101, 0.0063, 0.0059 and 0.0023 and those of the percentage absorbed were 68.0, 32.3, 23.0 and 5.0 in jejunoileum, duodenum, ascending colon and rectum, respectively.",Intestinal absorption and presystemic disposition of sildenafil citrate in the rabbit: evidence for site-dependent absorptive clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369998/),[ml] / [cm·min],0.0101,184915,DB00592,Piperazine
,16369998,permeability area,"The values of the permeability area product normalized to segment length (ml/min.cm) were 0.0101, 0.0063, 0.0059 and 0.0023 and those of the percentage absorbed were 68.0, 32.3, 23.0 and 5.0 in jejunoileum, duodenum, ascending colon and rectum, respectively.",Intestinal absorption and presystemic disposition of sildenafil citrate in the rabbit: evidence for site-dependent absorptive clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369998/),[ml] / [cm·min],0.,184916,DB00592,Piperazine
,16369998,permeability area,"The values of the permeability area product normalized to segment length (ml/min.cm) were 0.0101, 0.0063, 0.0059 and 0.0023 and those of the percentage absorbed were 68.0, 32.3, 23.0 and 5.0 in jejunoileum, duodenum, ascending colon and rectum, respectively.",Intestinal absorption and presystemic disposition of sildenafil citrate in the rabbit: evidence for site-dependent absorptive clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369998/),[ml] / [cm·min],0,184917,DB00592,Piperazine
,16369998,percentage absorbed,"The values of the permeability area product normalized to segment length (ml/min.cm) were 0.0101, 0.0063, 0.0059 and 0.0023 and those of the percentage absorbed were 68.0, 32.3, 23.0 and 5.0 in jejunoileum, duodenum, ascending colon and rectum, respectively.",Intestinal absorption and presystemic disposition of sildenafil citrate in the rabbit: evidence for site-dependent absorptive clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369998/),[ml] / [cm·min],68.0,184918,DB00592,Piperazine
,16369998,percentage absorbed,"The values of the permeability area product normalized to segment length (ml/min.cm) were 0.0101, 0.0063, 0.0059 and 0.0023 and those of the percentage absorbed were 68.0, 32.3, 23.0 and 5.0 in jejunoileum, duodenum, ascending colon and rectum, respectively.",Intestinal absorption and presystemic disposition of sildenafil citrate in the rabbit: evidence for site-dependent absorptive clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369998/),,32.3,184919,DB00592,Piperazine
,16369998,percentage absorbed,"The values of the permeability area product normalized to segment length (ml/min.cm) were 0.0101, 0.0063, 0.0059 and 0.0023 and those of the percentage absorbed were 68.0, 32.3, 23.0 and 5.0 in jejunoileum, duodenum, ascending colon and rectum, respectively.",Intestinal absorption and presystemic disposition of sildenafil citrate in the rabbit: evidence for site-dependent absorptive clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369998/),,23.0,184920,DB00592,Piperazine
,16369998,percentage absorbed,"The values of the permeability area product normalized to segment length (ml/min.cm) were 0.0101, 0.0063, 0.0059 and 0.0023 and those of the percentage absorbed were 68.0, 32.3, 23.0 and 5.0 in jejunoileum, duodenum, ascending colon and rectum, respectively.",Intestinal absorption and presystemic disposition of sildenafil citrate in the rabbit: evidence for site-dependent absorptive clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369998/),,5.0,184921,DB00592,Piperazine
,32286696,maximum concentration,An average maximum concentration of 0.22 µg/ml ± 0.11 was detected 4 hr after administration.,Plasma concentrations of itraconazole following a single oral dose in juvenile California sea lions (Zalophus californianus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32286696/),[μg] / [ml],0.22,185040,DB00592,Piperazine
,32286696,concentration,The average concentration fell to 0.12 µg/ml ± 0.11 by 6 hr and 0.02 µg/ml ± 0.02 at 12 hr.,Plasma concentrations of itraconazole following a single oral dose in juvenile California sea lions (Zalophus californianus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32286696/),[μg] / [ml],0.12,185041,DB00592,Piperazine
,32286696,concentration,The average concentration fell to 0.12 µg/ml ± 0.11 by 6 hr and 0.02 µg/ml ± 0.02 at 12 hr.,Plasma concentrations of itraconazole following a single oral dose in juvenile California sea lions (Zalophus californianus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32286696/),[μg] / [ml],0.02,185042,DB00592,Piperazine
,22402637,peak concentrations,"Pharmacokinetic data collected at time intervals following a 60 mg/kg oral dose of acridine 1 and 2 showed both compounds penetrate the blood-brain barrier yielding peak concentrations of 0.25 μM and 0.6 μM, respectively.","9-Amino acridine pharmacokinetics, brain distribution, and in vitro/in vivo efficacy against malignant glioma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22402637/),μM,0.25,185100,DB00592,Piperazine
,22402637,peak concentrations,"Pharmacokinetic data collected at time intervals following a 60 mg/kg oral dose of acridine 1 and 2 showed both compounds penetrate the blood-brain barrier yielding peak concentrations of 0.25 μM and 0.6 μM, respectively.","9-Amino acridine pharmacokinetics, brain distribution, and in vitro/in vivo efficacy against malignant glioma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22402637/),μM,0.6,185101,DB00592,Piperazine
,22402637,Peak plasma concentrations,Peak plasma concentrations were determined to be 2.25 μM (1) and 20.38 μM (2).,"9-Amino acridine pharmacokinetics, brain distribution, and in vitro/in vivo efficacy against malignant glioma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22402637/),μM,2.25,185102,DB00592,Piperazine
,22402637,Peak plasma concentrations,Peak plasma concentrations were determined to be 2.25 μM (1) and 20.38 μM (2).,"9-Amino acridine pharmacokinetics, brain distribution, and in vitro/in vivo efficacy against malignant glioma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22402637/),μM,20.38,185103,DB00592,Piperazine
,22402637,peak concentration,The results were further compared with data collected using a 15 mg/kg intravenous dose of 2 which yielded a peak concentration in the brain of 1.7 μM at 2.0 h relative to a 2.04 μM peak plasma concentration.,"9-Amino acridine pharmacokinetics, brain distribution, and in vitro/in vivo efficacy against malignant glioma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22402637/),μM,1.7,185104,DB00592,Piperazine
,22402637,peak plasma concentration,The results were further compared with data collected using a 15 mg/kg intravenous dose of 2 which yielded a peak concentration in the brain of 1.7 μM at 2.0 h relative to a 2.04 μM peak plasma concentration.,"9-Amino acridine pharmacokinetics, brain distribution, and in vitro/in vivo efficacy against malignant glioma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22402637/),μM,2.04,185105,DB00592,Piperazine
,22402637,bioavailability,The bioavailability was calculated to be 83.8%.,"9-Amino acridine pharmacokinetics, brain distribution, and in vitro/in vivo efficacy against malignant glioma. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22402637/),%,83.8,185106,DB00592,Piperazine
,21840269,flow rate,"An aliquot of 150 μl of plasma sample was introduced into the pretreatment column via the auto sampler using mobile phase 1 at a flow rate of 0.5 ml/min, column switching valve being positioned at A.",High performance liquid chromatographic method for the determination of cetirizine and ambroxol in human plasma and urine--a boxcar approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21840269/),[ml] / [min],0.5,185335,DB00592,Piperazine
,21840269,flow rate,"Finally, cetirizine, ambroxol and IS were introduced to the separation column by switching valve using mobile phase 2 at a flow rate of 0.4 ml/min.",High performance liquid chromatographic method for the determination of cetirizine and ambroxol in human plasma and urine--a boxcar approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21840269/),[ml] / [min],0.4,185336,DB00592,Piperazine
,21840269,total run time,The total run time was 25 min for a sample.,High performance liquid chromatographic method for the determination of cetirizine and ambroxol in human plasma and urine--a boxcar approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21840269/),min,25,185337,DB00592,Piperazine
,14517708,area under the plasma concentration-time curve,"The mean (+/-SD) values of area under the plasma concentration-time curve and elimination half-life for placebo versus itraconazole were 1328+/-330 ng h/ml versus 1445+/-419 ng h/ml and 32.1+/-9.3 h versus 31.1+/-8.4 h, respectively.",The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14517708/),[h·ng] / [ml],1328,185458,DB00592,Piperazine
,14517708,area under the plasma concentration-time curve,"The mean (+/-SD) values of area under the plasma concentration-time curve and elimination half-life for placebo versus itraconazole were 1328+/-330 ng h/ml versus 1445+/-419 ng h/ml and 32.1+/-9.3 h versus 31.1+/-8.4 h, respectively.",The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14517708/),[h·ng] / [ml],1445,185459,DB00592,Piperazine
,14517708,elimination half-life,"The mean (+/-SD) values of area under the plasma concentration-time curve and elimination half-life for placebo versus itraconazole were 1328+/-330 ng h/ml versus 1445+/-419 ng h/ml and 32.1+/-9.3 h versus 31.1+/-8.4 h, respectively.",The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14517708/),h,32.1,185460,DB00592,Piperazine
,14517708,elimination half-life,"The mean (+/-SD) values of area under the plasma concentration-time curve and elimination half-life for placebo versus itraconazole were 1328+/-330 ng h/ml versus 1445+/-419 ng h/ml and 32.1+/-9.3 h versus 31.1+/-8.4 h, respectively.",The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14517708/),h,31.1,185461,DB00592,Piperazine
,7997384,peak serum itraconazole concentration,"A mean +/- SD peak serum itraconazole concentration of 0.90 +/- 0.30 micrograms/ml was observed at 3.0 +/- 0.7 hours when itraconazole was administered alone, compared with undetectable levels in all patients during therapy with ddI.",Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7997384/),[μg] / [ml],0.90,185520,DB00592,Piperazine
,26094207,extraction recovery,"The extraction recovery was in the range of 78.3-88.4% for vortioxetine and 80.3% for carbamazepine (internal standard, IS).",An UPLC-MS/MS method for the quantitation of vortioxetine in rat plasma: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26094207/),%,78.3-88.4,185572,DB00592,Piperazine
,26094207,extraction recovery,"The extraction recovery was in the range of 78.3-88.4% for vortioxetine and 80.3% for carbamazepine (internal standard, IS).",An UPLC-MS/MS method for the quantitation of vortioxetine in rat plasma: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26094207/),%,80.3,185573,DB00592,Piperazine
,16914578,maximum tolerated dose,The maximum tolerated dose for non-EIAED patients was 800 mg/d.,Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16914578/),mg,800,185829,DB00592,Piperazine
,16914578,progression-free survival,Six-month progression-free survival was 3% for glioblastoma multiforme and 10% for anaplastic glioma patients.,Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16914578/),%,3,185830,DB00592,Piperazine
,16914578,progression-free survival,Six-month progression-free survival was 3% for glioblastoma multiforme and 10% for anaplastic glioma patients.,Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16914578/),%,10,185831,DB00592,Piperazine
,29510329,flow rate,"Chromatographic separation was performed on an Agilent Eclipse XDB-CN column (100 × 2.1 mm i.d., 3.5 μm) using the mobile phase of water and acetonitrile (25:75, v/v) containing 0.1% formic acid with a flow rate of 0.5 mL/min.",LC-MS/MS method for the determination of the prodrug aripiprazole lauroxil and its three metabolites in plasma and its application to in vitro biotransformation and animal pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29510329/),[ml] / [min],0.5,186314,DB00592,Piperazine
,20957481,progression-free survival (PFS),"Median progression-free survival (PFS) and overall survival (OS) were 23.6 weeks (95% confidence interval [CI] 0.0-50.6 weeks) and 74.0 weeks (95% CI 27.4-120.6 weeks), respectively.",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),weeks,23.6,186383,DB00592,Piperazine
,20957481,overall survival (OS),"Median progression-free survival (PFS) and overall survival (OS) were 23.6 weeks (95% confidence interval [CI] 0.0-50.6 weeks) and 74.0 weeks (95% CI 27.4-120.6 weeks), respectively.",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),weeks,74.0,186384,DB00592,Piperazine
,20957481,C (max),"Pharmacokinetic parameters of nilotinib were as follows: C (max) of 1,754 ± 970 μg/L, T(1/2) of 13.4 ± 8.94 h and AUC (0-12 h) of 14,190 ± 6,853 h μg/L.",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),[μg] / [l],"1,754",186385,DB00592,Piperazine
,20957481,T(1/2),"Pharmacokinetic parameters of nilotinib were as follows: C (max) of 1,754 ± 970 μg/L, T(1/2) of 13.4 ± 8.94 h and AUC (0-12 h) of 14,190 ± 6,853 h μg/L.",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),h,13.4,186386,DB00592,Piperazine
,20957481,AUC (0-12 h),"Pharmacokinetic parameters of nilotinib were as follows: C (max) of 1,754 ± 970 μg/L, T(1/2) of 13.4 ± 8.94 h and AUC (0-12 h) of 14,190 ± 6,853 h μg/L.",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),[h·μg] / [l],"14,190",186387,DB00592,Piperazine
,20957481,AUC (0-12 h),"The AUC (0-12 h) of nilotinib was significantly lower in the 4 patients with prior major (total or subtotal) gastrectomy than in the other 13 patients (8,526 ± 7,869 h μg/L vs. 15,930 ± 5,759 h μg/L, P = 0.014).",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),[h·μg] / [l],"8,526",186388,DB00592,Piperazine
,20957481,AUC (0-12 h),"The AUC (0-12 h) of nilotinib was significantly lower in the 4 patients with prior major (total or subtotal) gastrectomy than in the other 13 patients (8,526 ± 7,869 h μg/L vs. 15,930 ± 5,759 h μg/L, P = 0.014).",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),[h·μg] / [l],"15,930",186389,DB00592,Piperazine
,20957481,AUC (0-12 h),"Of the 4 gastrectomized patients, two (50%) showed markedly decreased nilotinib exposure (AUC (0-12 h) of 1,914 and 3,194 h μg/L) and rapid disease progression (PFS of 4.6 and 7.1 weeks).",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),[h·μg] / [l],"1,914",186390,DB00592,Piperazine
,20957481,AUC (0-12 h),"Of the 4 gastrectomized patients, two (50%) showed markedly decreased nilotinib exposure (AUC (0-12 h) of 1,914 and 3,194 h μg/L) and rapid disease progression (PFS of 4.6 and 7.1 weeks).",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),[h·μg] / [l],"3,194",186391,DB00592,Piperazine
,2576356,terminal half-lives,The terminal half-lives of the active compounds varied between 11 h in rats and 26 h in monkeys.,"Pharmacokinetics of picumast after administration of 14C-picumast dihydrochloride in dogs, rats, rabbits and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576356/),h,11,186756,DB00592,Piperazine
,2576356,terminal half-lives,The terminal half-lives of the active compounds varied between 11 h in rats and 26 h in monkeys.,"Pharmacokinetics of picumast after administration of 14C-picumast dihydrochloride in dogs, rats, rabbits and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576356/),h,26,186757,DB00592,Piperazine
,2576356,bioavailability,"In dogs the bioavailability of the parent compound was 14%, the absorption of radioactivity 68%.","Pharmacokinetics of picumast after administration of 14C-picumast dihydrochloride in dogs, rats, rabbits and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576356/),%,14,186758,DB00592,Piperazine
,2576356,absorption,"In dogs the bioavailability of the parent compound was 14%, the absorption of radioactivity 68%.","Pharmacokinetics of picumast after administration of 14C-picumast dihydrochloride in dogs, rats, rabbits and monkeys. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576356/),%,68,186759,DB00592,Piperazine
,15289787,systemic clearance,"However, during the inhibited metabolic state, the CYP3A5*3/*3 group showed a greater decrease in systemic clearance than was seen in the CYP3A5*1/*1 group (8.5 +/- 3.8 L. h(-1). 70 kg(-1) versus 13.5 +/- 2.7 L. h(-1). 70 kg(-1), P =.027).",Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289787/),[l] / [70·h·kg],8.5,187223,DB00592,Piperazine
,15289787,systemic clearance,"However, during the inhibited metabolic state, the CYP3A5*3/*3 group showed a greater decrease in systemic clearance than was seen in the CYP3A5*1/*1 group (8.5 +/- 3.8 L. h(-1). 70 kg(-1) versus 13.5 +/- 2.7 L. h(-1). 70 kg(-1), P =.027).",Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289787/),[l] / [70·h·kg],13.5,187224,DB00592,Piperazine
,15289787,area under the plasma concentration-time curve ratio,"The 1'-hydroxymidazolam-to-midazolam area under the plasma concentration-time curve ratio was also significantly lower in the CYP3A5*3/*3 group (0.58 +/- 0.35 versus 1.09 +/- 0.37 for the homozygous wild-type group, P =.026).",Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289787/),,0.58,187225,DB00592,Piperazine
,15289787,area under the plasma concentration-time curve ratio,"The 1'-hydroxymidazolam-to-midazolam area under the plasma concentration-time curve ratio was also significantly lower in the CYP3A5*3/*3 group (0.58 +/- 0.35 versus 1.09 +/- 0.37 for the homozygous wild-type group, P =.026).",Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289787/),,1.09,187226,DB00592,Piperazine
,18162446,m/,The selected reaction monitoring (SRM) was set using precursor ion and product ion combinations of m/z 389>201 for I and m/z 502>467 for II.,Determination of levocetirizine in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18162446/),,38,187392,DB00592,Piperazine
,18162446,m/,The selected reaction monitoring (SRM) was set using precursor ion and product ion combinations of m/z 389>201 for I and m/z 502>467 for II.,Determination of levocetirizine in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18162446/),,201,187393,DB00592,Piperazine
>,18162446,m/,The selected reaction monitoring (SRM) was set using precursor ion and product ion combinations of m/z 389>201 for I and m/z 502>467 for II.,Determination of levocetirizine in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18162446/),,467,187394,DB00592,Piperazine
,20228156,elimination half-lives,"All compounds exhibited moderate elimination half-lives, ranging from 1.49 to 3.27 h, and large volumes of distribution (5.95-14.19 l/kg).","Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20228156/),h,1.49 to 3.27,187646,DB00592,Piperazine
,20228156,volumes of distribution,"All compounds exhibited moderate elimination half-lives, ranging from 1.49 to 3.27 h, and large volumes of distribution (5.95-14.19 l/kg).","Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20228156/),[l] / [kg],5.95-14.19,187647,DB00592,Piperazine
,20228156,brain-to-plasma ratios,The brain-to-plasma ratios ranged from 2.93 to 11.81 and were higher than those previously reported for cocaine.,"Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20228156/),,2.93 to 11.81,187648,DB00592,Piperazine
,24869944,flow rate,"The mobile phase was a mixture of acetonitrile and 10mM ammonium acetate buffer (36:64, v/v), adjusted to pH 9.4 with 20% ammonium solution at a flow rate of 1.0mL/min.",Determination of domperidone in human plasma using high performance liquid chromatography with fluorescence detection for clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24869944/),[ml] / [min],1.0,187970,DB00592,Piperazine
,24869944,Retention times,"Retention times for domperidone and internal standard (propranolol) were 8.3min and 11.2min, respectively.",Determination of domperidone in human plasma using high performance liquid chromatography with fluorescence detection for clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24869944/),min,8.3,187971,DB00592,Piperazine
,24869944,Retention times,"Retention times for domperidone and internal standard (propranolol) were 8.3min and 11.2min, respectively.",Determination of domperidone in human plasma using high performance liquid chromatography with fluorescence detection for clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24869944/),min,11.2,187972,DB00592,Piperazine
,9784084,area under the concentration-time curves from 0 h to infinity,"Itraconazole significantly (P < 0.01) increased the area under the concentration-time curves from 0 h to infinity (252 +/- 47 versus 671 +/- 205 ng h/ml), decreased the apparent oral clearance (0.89 +/- 0.21 versus 0.35+/-0.10 ml/min per kg) and prolonged the elimination half-life (15.7 +/- 4.1 versus 40.3 +/- 13.5 h) of alprazolam.",Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9784084/),[h·ng] / [ml],252,188054,DB00592,Piperazine
,9784084,area under the concentration-time curves from 0 h to infinity,"Itraconazole significantly (P < 0.01) increased the area under the concentration-time curves from 0 h to infinity (252 +/- 47 versus 671 +/- 205 ng h/ml), decreased the apparent oral clearance (0.89 +/- 0.21 versus 0.35+/-0.10 ml/min per kg) and prolonged the elimination half-life (15.7 +/- 4.1 versus 40.3 +/- 13.5 h) of alprazolam.",Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9784084/),[h·ng] / [ml],671,188055,DB00592,Piperazine
,9784084,apparent oral clearance,"Itraconazole significantly (P < 0.01) increased the area under the concentration-time curves from 0 h to infinity (252 +/- 47 versus 671 +/- 205 ng h/ml), decreased the apparent oral clearance (0.89 +/- 0.21 versus 0.35+/-0.10 ml/min per kg) and prolonged the elimination half-life (15.7 +/- 4.1 versus 40.3 +/- 13.5 h) of alprazolam.",Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9784084/),[ml] / [kg·min],0.89,188056,DB00592,Piperazine
,9784084,apparent oral clearance,"Itraconazole significantly (P < 0.01) increased the area under the concentration-time curves from 0 h to infinity (252 +/- 47 versus 671 +/- 205 ng h/ml), decreased the apparent oral clearance (0.89 +/- 0.21 versus 0.35+/-0.10 ml/min per kg) and prolonged the elimination half-life (15.7 +/- 4.1 versus 40.3 +/- 13.5 h) of alprazolam.",Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9784084/),[ml] / [kg·min],0.35,188057,DB00592,Piperazine
,9784084,elimination half-life,"Itraconazole significantly (P < 0.01) increased the area under the concentration-time curves from 0 h to infinity (252 +/- 47 versus 671 +/- 205 ng h/ml), decreased the apparent oral clearance (0.89 +/- 0.21 versus 0.35+/-0.10 ml/min per kg) and prolonged the elimination half-life (15.7 +/- 4.1 versus 40.3 +/- 13.5 h) of alprazolam.",Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9784084/),h,15.7,188058,DB00592,Piperazine
,9784084,elimination half-life,"Itraconazole significantly (P < 0.01) increased the area under the concentration-time curves from 0 h to infinity (252 +/- 47 versus 671 +/- 205 ng h/ml), decreased the apparent oral clearance (0.89 +/- 0.21 versus 0.35+/-0.10 ml/min per kg) and prolonged the elimination half-life (15.7 +/- 4.1 versus 40.3 +/- 13.5 h) of alprazolam.",Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9784084/),h,40.3,188059,DB00592,Piperazine
,15792396,"maximal telithromycin concentration at steady state (C(max),ss)","In subjects with CL(CR) 30 - 80 ml/min, the mean maximal telithromycin concentration at steady state (C(max),ss) was 3.6 mg/l and the steady state area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24 h) ss) was 33.4 mg x h/l.",Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15792396/),[mg] / [l],3.6,188152,DB00592,Piperazine
,15792396,steady state area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24 h) ss),"In subjects with CL(CR) 30 - 80 ml/min, the mean maximal telithromycin concentration at steady state (C(max),ss) was 3.6 mg/l and the steady state area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24 h) ss) was 33.4 mg x h/l.",Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15792396/),[h·mg] / [l],33.4,188153,DB00592,Piperazine
,15792396,"C(max), ss","The mean C(max), ss and AUC(0-12 h)ss for clarithromycin were 6.2 mg/l and 56.1 mg x h/l, respectively.",Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15792396/),[mg] / [l],6.2,188154,DB00592,Piperazine
,15792396,AUC(0-12 h)ss,"The mean C(max), ss and AUC(0-12 h)ss for clarithromycin were 6.2 mg/l and 56.1 mg x h/l, respectively.",Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15792396/),[h·mg] / [l],56.1,188155,DB00592,Piperazine
<,15792396,deltaQTc,In the telithromycin plus ketoconazole group deltaQTc values were equal or < 60 ms.,Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15792396/),ms,60,188156,DB00592,Piperazine
<,15792396,QTc,All QTc values were equal or < 450 ms in males and equal or < 470 ms in females.,Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15792396/),ms,450,188157,DB00592,Piperazine
<,15792396,QTc,All QTc values were equal or < 450 ms in males and equal or < 470 ms in females.,Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15792396/),ms,470,188158,DB00592,Piperazine
,7619663,critical flicker fusion threshold,"4. Only buspirone reduced total reaction time and increased critical flicker fusion threshold measured 12 h after the evening dose and these effects were correlated with the residual plasma 1PP concentration which was higher on buspirone than on ipsapirone (2.76 micrograms l-1, 95% CI:1.3-4.22 vs 0.65 microgram l-1, 95% CI: 0.32-0.98, P = 0.006).",Evaluation of the alpha 2-adrenoceptor blocking properties of buspirone and ipsapirone in healthy subjects. Relationship with the plasma concentration of the common metabolite 1-(2-pyrimidinyl)-piperazine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619663/),[μg] / [l],2.76,188197,DB00592,Piperazine
,7619663,AUC ipsapirone/AUC 1PP ratio,The AUC ipsapirone/AUC 1PP ratio was 6.45 and the AUC buspirone/AUC 1PP ratio was 0.076.,Evaluation of the alpha 2-adrenoceptor blocking properties of buspirone and ipsapirone in healthy subjects. Relationship with the plasma concentration of the common metabolite 1-(2-pyrimidinyl)-piperazine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619663/),,6.45,188198,DB00592,Piperazine
,7619663,AUC buspirone/AUC 1PP ratio,The AUC ipsapirone/AUC 1PP ratio was 6.45 and the AUC buspirone/AUC 1PP ratio was 0.076.,Evaluation of the alpha 2-adrenoceptor blocking properties of buspirone and ipsapirone in healthy subjects. Relationship with the plasma concentration of the common metabolite 1-(2-pyrimidinyl)-piperazine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619663/),,0.076,188199,DB00592,Piperazine
,32935235,Tmax,"The times at which maximum delamanid levels in plasma were observed (Tmax) after oral administration of the phytantriol, selachyl alcohol and reconstituted milk powder formulations of delamanid to rats were 27 ± 3, 20 ± 4 and 6.5 ± 1.0 h, respectively, compared with the aqueous suspension formulation with a Tmax of 3.4 ± 1 h, which confirms the hypothesis of an extended duration of absorption after administration in non-digestible self-assembling lipids.",Sustained absorption of delamanid from lipid-based formulations as a path to reduced frequency of administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32935235/),h,27,188304,DB00592,Piperazine
,32935235,Tmax,"The times at which maximum delamanid levels in plasma were observed (Tmax) after oral administration of the phytantriol, selachyl alcohol and reconstituted milk powder formulations of delamanid to rats were 27 ± 3, 20 ± 4 and 6.5 ± 1.0 h, respectively, compared with the aqueous suspension formulation with a Tmax of 3.4 ± 1 h, which confirms the hypothesis of an extended duration of absorption after administration in non-digestible self-assembling lipids.",Sustained absorption of delamanid from lipid-based formulations as a path to reduced frequency of administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32935235/),h,20,188305,DB00592,Piperazine
,32935235,Tmax,"The times at which maximum delamanid levels in plasma were observed (Tmax) after oral administration of the phytantriol, selachyl alcohol and reconstituted milk powder formulations of delamanid to rats were 27 ± 3, 20 ± 4 and 6.5 ± 1.0 h, respectively, compared with the aqueous suspension formulation with a Tmax of 3.4 ± 1 h, which confirms the hypothesis of an extended duration of absorption after administration in non-digestible self-assembling lipids.",Sustained absorption of delamanid from lipid-based formulations as a path to reduced frequency of administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32935235/),h,6.5,188306,DB00592,Piperazine
,32935235,Tmax,"The times at which maximum delamanid levels in plasma were observed (Tmax) after oral administration of the phytantriol, selachyl alcohol and reconstituted milk powder formulations of delamanid to rats were 27 ± 3, 20 ± 4 and 6.5 ± 1.0 h, respectively, compared with the aqueous suspension formulation with a Tmax of 3.4 ± 1 h, which confirms the hypothesis of an extended duration of absorption after administration in non-digestible self-assembling lipids.",Sustained absorption of delamanid from lipid-based formulations as a path to reduced frequency of administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32935235/),h,3.4,188307,DB00592,Piperazine
,10801241,50% inhibitory concentration,The 50% inhibitory concentration was 0.11 micromol/L (0.08 microg/mL); this is below the usual therapeutic plasma concentration range (generally exceeding 2 microg/mL).,Alprazolam-ritonavir interaction: implications for product labeling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10801241/),[μM] / [l],0.11,188544,DB00592,Piperazine
,10801241,elimination half-life,"In the clinical study, ritonavir reduced alprazolam clearance to 41% of control values (P < .001), prolonged elimination half-life (mean values, 30 versus 13 hours; P < .005), and magnified benzodiazepine agonist effects such as sedation and performance impairment.",Alprazolam-ritonavir interaction: implications for product labeling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10801241/),h,30,188545,DB00592,Piperazine
,10801241,elimination half-life,"In the clinical study, ritonavir reduced alprazolam clearance to 41% of control values (P < .001), prolonged elimination half-life (mean values, 30 versus 13 hours; P < .005), and magnified benzodiazepine agonist effects such as sedation and performance impairment.",Alprazolam-ritonavir interaction: implications for product labeling. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10801241/),h,13,188546,DB00592,Piperazine
,33400035,Tmax,Oral bioavailability studies in Sprague-Dawley rats confirmed quicker and greater extent of absorption with solid SMEDDS as evident from the significant reduction in Tmax in case of solid SMEDDS (0.83 ± 0.12 h) as compared with commercial tablet (3.33 ± 0.94 h).,pH-Independent Dissolution and Enhanced Oral Bioavailability of Aripiprazole-Loaded Solid Self-microemulsifying Drug Delivery System. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33400035/),h,0.83,188631,DB00592,Piperazine
,33400035,Tmax,Oral bioavailability studies in Sprague-Dawley rats confirmed quicker and greater extent of absorption with solid SMEDDS as evident from the significant reduction in Tmax in case of solid SMEDDS (0.83 ± 0.12 h) as compared with commercial tablet (3.33 ± 0.94 h).,pH-Independent Dissolution and Enhanced Oral Bioavailability of Aripiprazole-Loaded Solid Self-microemulsifying Drug Delivery System. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33400035/),h,3.33,188632,DB00592,Piperazine
,8096848,flow-rate,"A mobile phase of methanol-0.02 M acetate buffer (pH 4.7) (25:75,v/v) at a flow-rate of 1.0 ml/min was used for the urine assays.",Enantioselective pharmacokinetics of homochlorcyclizine. Simultaneous determination of (+)- and (-)- homochlorcyclizine in human urine by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8096848/),[ml] / [min],1.0,188915,DB00592,Piperazine
,8096848,retention times,"(+)-HCZ, (-)-HCZ and the internal standard were eluted at retention times of 15, 25 and 8 min, respectively.",Enantioselective pharmacokinetics of homochlorcyclizine. Simultaneous determination of (+)- and (-)- homochlorcyclizine in human urine by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8096848/),min,15,188916,DB00592,Piperazine
,8096848,retention times,"(+)-HCZ, (-)-HCZ and the internal standard were eluted at retention times of 15, 25 and 8 min, respectively.",Enantioselective pharmacokinetics of homochlorcyclizine. Simultaneous determination of (+)- and (-)- homochlorcyclizine in human urine by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8096848/),min,25,188917,DB00592,Piperazine
,8096848,retention times,"(+)-HCZ, (-)-HCZ and the internal standard were eluted at retention times of 15, 25 and 8 min, respectively.",Enantioselective pharmacokinetics of homochlorcyclizine. Simultaneous determination of (+)- and (-)- homochlorcyclizine in human urine by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8096848/),min,8,188918,DB00592,Piperazine
,32415468,AUC0-72,"Volunteers (n = 26; aged 24 ± 3 years; 69% male) presented regular pharmacokinetic imatinib data (concentration at 24 h, 436 ± 140 ng/mL and at 72 h, 40 ± 26 ng/mL; AUC0-72 32,868 ± 10,713 ng/mL⋅h; and Cmax 2074 ± 604 ng/mL).",Effect of Cytochrome P450 and ABCB1 Polymorphisms on Imatinib Pharmacokinetics After Single-Dose Administration to Healthy Subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32415468/),[ng] / [h·ml],"32,868",188967,DB00592,Piperazine
,32415468,Cmax,"Volunteers (n = 26; aged 24 ± 3 years; 69% male) presented regular pharmacokinetic imatinib data (concentration at 24 h, 436 ± 140 ng/mL and at 72 h, 40 ± 26 ng/mL; AUC0-72 32,868 ± 10,713 ng/mL⋅h; and Cmax 2074 ± 604 ng/mL).",Effect of Cytochrome P450 and ABCB1 Polymorphisms on Imatinib Pharmacokinetics After Single-Dose Administration to Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32415468/),[ng] / [ml],2074,188968,DB00592,Piperazine
,32415468,elimination half-life,"CYP2B6 516GT carriers showed a significant reduction of imatinib concentration at 24 h (23%, 391 ng/dL vs 511 ng/dL in 516GG carriers, p = 0.005) and elimination half-life (11%, 12.6 h vs 14.1 h in 516GG carriers, p = 0.041).",Effect of Cytochrome P450 and ABCB1 Polymorphisms on Imatinib Pharmacokinetics After Single-Dose Administration to Healthy Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32415468/),%,11,188969,DB00592,Piperazine
,32415468,elimination half-life,"CYP2B6 516GT carriers showed a significant reduction of imatinib concentration at 24 h (23%, 391 ng/dL vs 511 ng/dL in 516GG carriers, p = 0.005) and elimination half-life (11%, 12.6 h vs 14.1 h in 516GG carriers, p = 0.041).",Effect of Cytochrome P450 and ABCB1 Polymorphisms on Imatinib Pharmacokinetics After Single-Dose Administration to Healthy Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32415468/),h,12.6,188970,DB00592,Piperazine
,32415468,elimination half-life,"CYP2B6 516GT carriers showed a significant reduction of imatinib concentration at 24 h (23%, 391 ng/dL vs 511 ng/dL in 516GG carriers, p = 0.005) and elimination half-life (11%, 12.6 h vs 14.1 h in 516GG carriers, p = 0.041).",Effect of Cytochrome P450 and ABCB1 Polymorphisms on Imatinib Pharmacokinetics After Single-Dose Administration to Healthy Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32415468/),h,14.1,188971,DB00592,Piperazine
,14686220,oral availability,The oral availability is 87%.,Aripiprazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14686220/),%,87,189040,DB00592,Piperazine
,14686220,elimination half-life,The mean elimination half-life is about 75 hours for aripiprazole and 94 hours for its active metabolite.,Aripiprazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14686220/),h,75,189041,DB00592,Piperazine
,14686220,elimination half-life,The mean elimination half-life is about 75 hours for aripiprazole and 94 hours for its active metabolite.,Aripiprazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14686220/),h,94,189042,DB00592,Piperazine
,24099858,flow rate,The mobile phase consisted of acetonitrile-water containing 5mM ammonium formate and 0.1% formic acid at a flow rate of 0.5mL/min.,Simultaneous determination of blonanserin and its four metabolites in human plasma using ultra-performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24099858/),[ml] / [min],0.5,189066,DB00592,Piperazine
,24099858,analysis time,The analysis time was about 3.5min.,Simultaneous determination of blonanserin and its four metabolites in human plasma using ultra-performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24099858/),min,3.5,189067,DB00592,Piperazine
,21154639,flow rate,"The analyte was separated on a Peerless basic C(18) column (33 × 4.6 mm, 3 µm) with an isocratic mobile phase of methanol-water containing formic acid (0.5%, v/v; 9:1, v/v) at a flow rate of 0.5 mL/min.","Development and validation of a liquid chromatography-tandem mass spectrometry method to determine ulifloxacin, the active metabolite of prulifloxacin in rat and rabbit plasma: application to toxicokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21154639/),[ml] / [min],0.5,189506,DB00592,Piperazine
,9542119,absolute recovery,The compounds were isolated from plasma on a Bakerbond C18 solid-phase extraction cartridge and the mean absolute recovery was 92.9%.,"Validated liquid chromatographic method for the determination of N-3-(2,2,5,5-tetramethyl-3-pirrolin-3-carboxamidopropylphthalimide hydrochloride), a novel antiarrhythmic agent in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542119/),%,92.9,189723,DB00592,Piperazine
,9280401,plasma clearance,"The mean values for its plasma clearance, terminal half-life, and volume of distribution at steady state were 27 ml/min/kg, 1.8 hr, and 4.0 liters/kg in rats and 34 ml/min/kg, 2.3 hr, and 5 liters/kg in rhesus monkeys.","Orally active inhibitors of human leukocyte elastase. Disposition of L-694,458 in rats and rhesus monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280401/),[ml] / [kg·min],27,189830,DB00592,Piperazine
,9280401,terminal half-life,"The mean values for its plasma clearance, terminal half-life, and volume of distribution at steady state were 27 ml/min/kg, 1.8 hr, and 4.0 liters/kg in rats and 34 ml/min/kg, 2.3 hr, and 5 liters/kg in rhesus monkeys.","Orally active inhibitors of human leukocyte elastase. Disposition of L-694,458 in rats and rhesus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280401/),[ml] / [kg·min],34,189831,DB00592,Piperazine
,9280401,terminal half-life,"The mean values for its plasma clearance, terminal half-life, and volume of distribution at steady state were 27 ml/min/kg, 1.8 hr, and 4.0 liters/kg in rats and 34 ml/min/kg, 2.3 hr, and 5 liters/kg in rhesus monkeys.","Orally active inhibitors of human leukocyte elastase. Disposition of L-694,458 in rats and rhesus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280401/),h,2.3,189832,DB00592,Piperazine
,9280401,volume of distribution at steady state,"The mean values for its plasma clearance, terminal half-life, and volume of distribution at steady state were 27 ml/min/kg, 1.8 hr, and 4.0 liters/kg in rats and 34 ml/min/kg, 2.3 hr, and 5 liters/kg in rhesus monkeys.","Orally active inhibitors of human leukocyte elastase. Disposition of L-694,458 in rats and rhesus monkeys. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280401/),[l] / [kg],4.0,189833,DB00592,Piperazine
,9280401,volume of distribution at steady state,"The mean values for its plasma clearance, terminal half-life, and volume of distribution at steady state were 27 ml/min/kg, 1.8 hr, and 4.0 liters/kg in rats and 34 ml/min/kg, 2.3 hr, and 5 liters/kg in rhesus monkeys.","Orally active inhibitors of human leukocyte elastase. Disposition of L-694,458 in rats and rhesus monkeys. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280401/),[l] / [kg],5,189834,DB00592,Piperazine
,9280401,bioavailability,The bioavailability of a 10 mg/kg oral dose was higher in rats (65%) than in rhesus monkeys (39%).,"Orally active inhibitors of human leukocyte elastase. Disposition of L-694,458 in rats and rhesus monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280401/),%,65,189835,DB00592,Piperazine
,9280401,bioavailability,The bioavailability of a 10 mg/kg oral dose was higher in rats (65%) than in rhesus monkeys (39%).,"Orally active inhibitors of human leukocyte elastase. Disposition of L-694,458 in rats and rhesus monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280401/),%,39,189836,DB00592,Piperazine
,9280401,T(max),"In monkeys a protracted plasma concentration-time profile was observed at 40 mg/kg, characterized by a delayed T(max) (8-24 hr) and a long terminal half-life (6 hr).","Orally active inhibitors of human leukocyte elastase. Disposition of L-694,458 in rats and rhesus monkeys. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280401/),h,8-24,189837,DB00592,Piperazine
,9280401,terminal half-life,"In monkeys a protracted plasma concentration-time profile was observed at 40 mg/kg, characterized by a delayed T(max) (8-24 hr) and a long terminal half-life (6 hr).","Orally active inhibitors of human leukocyte elastase. Disposition of L-694,458 in rats and rhesus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280401/),h,6,189838,DB00592,Piperazine
,9280401,recovery of,"[3H]L-694,458 was well absorbed after oral dosing to rats at 10 mg/kg, as indicated by the high recovery of radioactivity in bile (83%) and urine (6%) of bile duct-cannulated rats.","Orally active inhibitors of human leukocyte elastase. Disposition of L-694,458 in rats and rhesus monkeys. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280401/),%,83,189839,DB00592,Piperazine
,9280401,recovery of,"[3H]L-694,458 was well absorbed after oral dosing to rats at 10 mg/kg, as indicated by the high recovery of radioactivity in bile (83%) and urine (6%) of bile duct-cannulated rats.","Orally active inhibitors of human leukocyte elastase. Disposition of L-694,458 in rats and rhesus monkeys. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280401/),%,6,189840,DB00592,Piperazine
,18005357,unbound fraction,The unbound fraction was 0.074 for levocetirizine and 0.141 for dextrocetirizine.,"Stereoselective renal tubular secretion of levocetirizine and dextrocetirizine, the two enantiomers of the H1-antihistamine cetirizine. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18005357/),,0.074,190413,DB00592,Piperazine
,18005357,unbound fraction,The unbound fraction was 0.074 for levocetirizine and 0.141 for dextrocetirizine.,"Stereoselective renal tubular secretion of levocetirizine and dextrocetirizine, the two enantiomers of the H1-antihistamine cetirizine. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18005357/),,0.141,190414,DB00592,Piperazine
,18005357,tubular secretion,"The tubular secretion of dextrocetirizine (44.5 mL/min) is higher than that of levocetirizine (23.1 mL/min), which may have consequences for drug interactions at the renal level.","Stereoselective renal tubular secretion of levocetirizine and dextrocetirizine, the two enantiomers of the H1-antihistamine cetirizine. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18005357/),[ml] / [min],44.5,190415,DB00592,Piperazine
,18005357,tubular secretion,"The tubular secretion of dextrocetirizine (44.5 mL/min) is higher than that of levocetirizine (23.1 mL/min), which may have consequences for drug interactions at the renal level.","Stereoselective renal tubular secretion of levocetirizine and dextrocetirizine, the two enantiomers of the H1-antihistamine cetirizine. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18005357/),[ml] / [min],23.1,190416,DB00592,Piperazine
,11884487,first-order rate constant K(1),"The brain uptake was more than 2-fold higher for (11)C-DWAY than for (11)C-WAY, in part because of higher delivery (first-order rate constant K(1), 0.38 vs. 0.16).",The PET radioligand [carbonyl-(11)C]desmethyl-WAY-100635 binds to 5-HT(1A) receptors and provides a higher radioactive signal than [carbonyl-(11)C]WAY-100635 in the human brain. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11884487/),,0.38,190875,DB00592,Piperazine
,11884487,first-order rate constant K(1),"The brain uptake was more than 2-fold higher for (11)C-DWAY than for (11)C-WAY, in part because of higher delivery (first-order rate constant K(1), 0.38 vs. 0.16).",The PET radioligand [carbonyl-(11)C]desmethyl-WAY-100635 binds to 5-HT(1A) receptors and provides a higher radioactive signal than [carbonyl-(11)C]WAY-100635 in the human brain. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11884487/),,0.16,190876,DB00592,Piperazine
,18950992,serum concentrations,"In patients who were at least much improved and defined as ""responders"" mean serum concentrations of ziprasidone were 80 ng/ml and 78 ng/ml in patients who did not reach this improvement score.",The use of ziprasidone in clinical practice: analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18950992/),[ng] / [ml],80,190877,DB00592,Piperazine
,18950992,serum concentrations,"In patients who were at least much improved and defined as ""responders"" mean serum concentrations of ziprasidone were 80 ng/ml and 78 ng/ml in patients who did not reach this improvement score.",The use of ziprasidone in clinical practice: analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18950992/),[ng] / [ml],78,190878,DB00592,Piperazine
,32852618,LOD,"Under the optimized conditions, the anodic oxidation currents were linearly proportional to VORT concentration at the working range 1.8-90 nM with a LOD of 0.55 nM.",Synthesis of three-dimensional nickel ferrite nanospheres decorated activated graphite nanoplatelets for electrochemical detection of vortioxetine with pharmacokinetic insights in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32852618/),nM,0.55,190990,DB00592,Piperazine
,32852618,recoveries,"Satisfactory recoveries and RSD percentages were obtained in the range 103.8-107.7% (RSD% = 2.7-3.1%) and 101.4-105.3% (RSD % = 2.8-3.4%) for tablets and plasma samples, respectively.",Synthesis of three-dimensional nickel ferrite nanospheres decorated activated graphite nanoplatelets for electrochemical detection of vortioxetine with pharmacokinetic insights in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32852618/),%,103.8-107.7,190991,DB00592,Piperazine
,20739919,half maximal inhibitory concentration (IC(50)),The in vivo half maximal inhibitory concentration (IC(50)) for ITZ ranged from 5 to 132 nmol/l in the six subjects.,Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20739919/),[nM] / [l],5 to 132,191471,DB00592,Piperazine
,9765344,area under the curve,Ketoconazole markedly raised the area under the curve of orally administered K02 from 9.4 +/- 4.4 to 102 +/- 24 mg . min/liter and decreased K02 oral plasma clearance from 3810 +/- 1620 to 306 +/- 60 ml/min/kg.,"Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765344/),[mg·min] / [l],9.4,191639,DB00592,Piperazine
,9765344,area under the curve,Ketoconazole markedly raised the area under the curve of orally administered K02 from 9.4 +/- 4.4 to 102 +/- 24 mg . min/liter and decreased K02 oral plasma clearance from 3810 +/- 1620 to 306 +/- 60 ml/min/kg.,"Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765344/),[mg·min] / [l],102,191640,DB00592,Piperazine
,9765344,oral plasma clearance,Ketoconazole markedly raised the area under the curve of orally administered K02 from 9.4 +/- 4.4 to 102 +/- 24 mg . min/liter and decreased K02 oral plasma clearance from 3810 +/- 1620 to 306 +/- 60 ml/min/kg.,"Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765344/),[ml] / [kg·min],3810,191641,DB00592,Piperazine
,9765344,oral plasma clearance,Ketoconazole markedly raised the area under the curve of orally administered K02 from 9.4 +/- 4.4 to 102 +/- 24 mg . min/liter and decreased K02 oral plasma clearance from 3810 +/- 1620 to 306 +/- 60 ml/min/kg.,"Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765344/),[ml] / [kg·min],306,191642,DB00592,Piperazine
,9765344,AUC,"With concomitant ketoconazole dosing, the changes of AUC of i.v. administered K02 (from 94 +/- 17 to 107 +/- 14 mg . min/liter) and clearance (from 110 +/- 22 to 95 +/- 13 ml/min/kg) were not significant, although K02 oral bioavailability increased from 2.9 +/- 1.4 to 31.0 +/- 7.5% (P < .001).","Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765344/),[mg·min] / [l],94,191643,DB00592,Piperazine
,9765344,AUC,"With concomitant ketoconazole dosing, the changes of AUC of i.v. administered K02 (from 94 +/- 17 to 107 +/- 14 mg . min/liter) and clearance (from 110 +/- 22 to 95 +/- 13 ml/min/kg) were not significant, although K02 oral bioavailability increased from 2.9 +/- 1.4 to 31.0 +/- 7.5% (P < .001).","Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765344/),[mg·min] / [l],107,191644,DB00592,Piperazine
,9765344,clearance,"With concomitant ketoconazole dosing, the changes of AUC of i.v. administered K02 (from 94 +/- 17 to 107 +/- 14 mg . min/liter) and clearance (from 110 +/- 22 to 95 +/- 13 ml/min/kg) were not significant, although K02 oral bioavailability increased from 2.9 +/- 1.4 to 31.0 +/- 7.5% (P < .001).","Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765344/),[ml] / [kg·min],110,191645,DB00592,Piperazine
,9765344,clearance,"With concomitant ketoconazole dosing, the changes of AUC of i.v. administered K02 (from 94 +/- 17 to 107 +/- 14 mg . min/liter) and clearance (from 110 +/- 22 to 95 +/- 13 ml/min/kg) were not significant, although K02 oral bioavailability increased from 2.9 +/- 1.4 to 31.0 +/- 7.5% (P < .001).","Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765344/),[ml] / [kg·min],95,191646,DB00592,Piperazine
,9765344,oral bioavailability,"With concomitant ketoconazole dosing, the changes of AUC of i.v. administered K02 (from 94 +/- 17 to 107 +/- 14 mg . min/liter) and clearance (from 110 +/- 22 to 95 +/- 13 ml/min/kg) were not significant, although K02 oral bioavailability increased from 2.9 +/- 1.4 to 31.0 +/- 7.5% (P < .001).","Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765344/),%,2.9,191647,DB00592,Piperazine
,9765344,oral bioavailability,"With concomitant ketoconazole dosing, the changes of AUC of i.v. administered K02 (from 94 +/- 17 to 107 +/- 14 mg . min/liter) and clearance (from 110 +/- 22 to 95 +/- 13 ml/min/kg) were not significant, although K02 oral bioavailability increased from 2.9 +/- 1.4 to 31.0 +/- 7.5% (P < .001).","Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765344/),%,31.0,191648,DB00592,Piperazine
,28945130,total clearance,"RESULTS After IV administration, total clearance of trazodone was 6.85 ± 2.80 mL/min/kg, volume of distribution at steady state was 1.06 ± 0.07 L/kg, and elimination half-life was 8.58 ± 1.88 hours.",Pharmacokinetics and selected pharmacodynamics of trazodone following intravenous and oral administration to horses undergoing fitness training. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28945130/),[ml] / [kg·min],6.85,191737,DB00592,Piperazine
,28945130,volume of distribution at steady state,"RESULTS After IV administration, total clearance of trazodone was 6.85 ± 2.80 mL/min/kg, volume of distribution at steady state was 1.06 ± 0.07 L/kg, and elimination half-life was 8.58 ± 1.88 hours.",Pharmacokinetics and selected pharmacodynamics of trazodone following intravenous and oral administration to horses undergoing fitness training. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28945130/),[l] / [kg],1.06,191738,DB00592,Piperazine
,28945130,elimination half-life,"RESULTS After IV administration, total clearance of trazodone was 6.85 ± 2.80 mL/min/kg, volume of distribution at steady state was 1.06 ± 0.07 L/kg, and elimination half-life was 8.58 ± 1.88 hours.",Pharmacokinetics and selected pharmacodynamics of trazodone following intravenous and oral administration to horses undergoing fitness training. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28945130/),h,8.58,191739,DB00592,Piperazine
,28945130,Terminal phase half-life,Terminal phase half-life was 7.11 ± 1.70 hours after oral administration.,Pharmacokinetics and selected pharmacodynamics of trazodone following intravenous and oral administration to horses undergoing fitness training. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28945130/),h,7.11,191740,DB00592,Piperazine
,10365649,recoveries,"The recoveries averaged 94.5% for theophylline, 93% for ciprofloxacin, 93.7% for grepafloxacin, and 95.1% for the internal standard (IS).","Simultaneous determination of grepafloxacin, ciprofloxacin, and theophylline in human plasma and urine by HPLC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365649/),%,94.5,191903,DB00592,Piperazine
,10365649,recoveries,"The recoveries averaged 94.5% for theophylline, 93% for ciprofloxacin, 93.7% for grepafloxacin, and 95.1% for the internal standard (IS).","Simultaneous determination of grepafloxacin, ciprofloxacin, and theophylline in human plasma and urine by HPLC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365649/),%,93,191904,DB00592,Piperazine
,10365649,recoveries,"The recoveries averaged 94.5% for theophylline, 93% for ciprofloxacin, 93.7% for grepafloxacin, and 95.1% for the internal standard (IS).","Simultaneous determination of grepafloxacin, ciprofloxacin, and theophylline in human plasma and urine by HPLC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365649/),%,93.7,191905,DB00592,Piperazine
,10365649,recoveries,"The recoveries averaged 94.5% for theophylline, 93% for ciprofloxacin, 93.7% for grepafloxacin, and 95.1% for the internal standard (IS).","Simultaneous determination of grepafloxacin, ciprofloxacin, and theophylline in human plasma and urine by HPLC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365649/),%,95.1,191906,DB00592,Piperazine
,6282204,half life,The half life ranged from 2.0 to 3.3 h.,"Disposition of ketoconazole, an oral antifungal, in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6282204/),h,2.0 to 3.3,192001,DB00592,Piperazine
up to,6282204,Peak serum concentrations,"Peak serum concentrations up to 50 micrograms/ml were detected in this study, and potentially therapeutic concentrations were detectable up to 26 h after high doses.","Disposition of ketoconazole, an oral antifungal, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6282204/),[μg] / [ml],50,192002,DB00592,Piperazine
,25864807,flow rate,"Chromatographic separation was achieved on a cyanopropyl bonded-phase column with a mobile phase composed of 50 m m potassium dihydrogen phosphate buffer (pH 4.5) and acetonitrile (75:25, v/v), pumped at the flow rate of 1 mL/min.",Sensitive and precise HPLC method with back-extraction clean-up step for the determination of sildenafil in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25864807/),[ml] / [min],1,192029,DB00592,Piperazine
,25864807,limit of detection,The limit of detection was 5 ng/mL.,Sensitive and precise HPLC method with back-extraction clean-up step for the determination of sildenafil in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25864807/),[ng] / [ml],5,192030,DB00592,Piperazine
,25864807,recovery,The recovery of sildenafil was 85.22 ± 4.54%.,Sensitive and precise HPLC method with back-extraction clean-up step for the determination of sildenafil in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25864807/),%,85.22,192031,DB00592,Piperazine
,18574328,trough,"The average trough value (8-hour value) of the fasudil active metabolite, hydroxyfasudil, was 50 nM.",Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18574328/),nM,8,192357,DB00592,Piperazine
,18574328,trough,"The average trough value (8-hour value) of the fasudil active metabolite, hydroxyfasudil, was 50 nM.",Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18574328/),nM,50,192358,DB00592,Piperazine
,8181324,art,"Acute effects of AB were as follows: a significant increase in arterial oxygen tension (PaO2) from 61 +/- 7 mm Hg to 74 +/- 8 mm Hg (p < 0.001), a decrease in arterial carbon dioxide tension (PaCO2) from 41 +/- 8 mm Hg to 38 +/- 7 mm Hg (p < 0.01), a rise of pH from 7.45 +/- 0.04 to 7.48 +/- 0.04 (p < 0.01), and a transient increase in mean pulmonary artery pressure from 26 +/- 7 to 29 +/- 6 mm Hg (not significant).",Low-dose almitrine bismesylate in the treatment of hypoxemia due to chronic obstructive pulmonary disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181324/),mm,61,192629,DB00592,Piperazine
,8181324,arterial carbon dioxide tension (PaCO2),"Acute effects of AB were as follows: a significant increase in arterial oxygen tension (PaO2) from 61 +/- 7 mm Hg to 74 +/- 8 mm Hg (p < 0.001), a decrease in arterial carbon dioxide tension (PaCO2) from 41 +/- 8 mm Hg to 38 +/- 7 mm Hg (p < 0.01), a rise of pH from 7.45 +/- 0.04 to 7.48 +/- 0.04 (p < 0.01), and a transient increase in mean pulmonary artery pressure from 26 +/- 7 to 29 +/- 6 mm Hg (not significant).",Low-dose almitrine bismesylate in the treatment of hypoxemia due to chronic obstructive pulmonary disease. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181324/),hg·mm,41,192630,DB00592,Piperazine
,8181324,arterial carbon dioxide tension (PaCO2),"Acute effects of AB were as follows: a significant increase in arterial oxygen tension (PaO2) from 61 +/- 7 mm Hg to 74 +/- 8 mm Hg (p < 0.001), a decrease in arterial carbon dioxide tension (PaCO2) from 41 +/- 8 mm Hg to 38 +/- 7 mm Hg (p < 0.01), a rise of pH from 7.45 +/- 0.04 to 7.48 +/- 0.04 (p < 0.01), and a transient increase in mean pulmonary artery pressure from 26 +/- 7 to 29 +/- 6 mm Hg (not significant).",Low-dose almitrine bismesylate in the treatment of hypoxemia due to chronic obstructive pulmonary disease. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181324/),hg·mm,38,192631,DB00592,Piperazine
,8181324,PaO2,"After long-term treatment, once tissues were saturated with almitrine, improvement in gas exchange persisted with a PaO2 of 70 +/- 10 mm Hg (p < 0.001) and a PaCO2 of 39 +/- 6 mm Hg (not significant) without elevation of pH (7.45 +/- 0.04) or of pulmonary artery pressure (26 +/- 8 mm Hg).",Low-dose almitrine bismesylate in the treatment of hypoxemia due to chronic obstructive pulmonary disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181324/),hg·mm,70,192632,DB00592,Piperazine
,8181324,PaCO2,"After long-term treatment, once tissues were saturated with almitrine, improvement in gas exchange persisted with a PaO2 of 70 +/- 10 mm Hg (p < 0.001) and a PaCO2 of 39 +/- 6 mm Hg (not significant) without elevation of pH (7.45 +/- 0.04) or of pulmonary artery pressure (26 +/- 8 mm Hg).",Low-dose almitrine bismesylate in the treatment of hypoxemia due to chronic obstructive pulmonary disease. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181324/),hg·mm,39,192633,DB00592,Piperazine
,8181324,terminal half-life,"The terminal half-life of AB was 56 +/- 45 days after a single intravenous administration, and 55 +/- 16 days after long-term oral dosing.",Low-dose almitrine bismesylate in the treatment of hypoxemia due to chronic obstructive pulmonary disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181324/),d,56,192634,DB00592,Piperazine
,8181324,terminal half-life,"The terminal half-life of AB was 56 +/- 45 days after a single intravenous administration, and 55 +/- 16 days after long-term oral dosing.",Low-dose almitrine bismesylate in the treatment of hypoxemia due to chronic obstructive pulmonary disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181324/),d,55,192635,DB00592,Piperazine
,7839313,t1/2,"dl-threo-Methylphenidate (Ritalin) was labeled with carbon-11 (t1/2:20.4 minutes) in order to measure its pharmacokinetics, to evaluate it as a radiotracer for the presynaptic dopaminergic neuron, and to examine its sensitivity to the loss of dopaminergic neurons.",Pharmacokinetics and in vivo specificity of [11C]dl-threo-methylphenidate for the presynaptic dopaminergic neuron. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7839313/),min,20.4,192690,DB00592,Piperazine
,7839313,Peak uptake,Peak uptake (0.04%/cc) occurred at 5-15 minutes post-injection.,Pharmacokinetics and in vivo specificity of [11C]dl-threo-methylphenidate for the presynaptic dopaminergic neuron. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7839313/),[%] / [cc],0.04,192691,DB00592,Piperazine
,7839313,half-time for clearance from peak uptake,The half-time for clearance from peak uptake for [11C]MP was 60 minutes and the ratio between the radioactivity in the striatum and that in the cerebellum (ST/CB) ranged from 2.2 to 2.6 at 40 minutes.,Pharmacokinetics and in vivo specificity of [11C]dl-threo-methylphenidate for the presynaptic dopaminergic neuron. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7839313/),min,60,192692,DB00592,Piperazine
,20828970,flow rate,"After extraction with ethyl acetate, the chromatographic separation was carried out on an ACQUITY UPLC™ BEH C(18) column, with acetonitrile and water (39:61 (v/v) both containing 0.1% formic acid) as mobile phase at a flow rate of 0.20 mL/min.",A liquid chromatography-tandem mass spectrometry method for the quantification of PAC-1 in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20828970/),[ml] / [min],0.20,193047,DB00592,Piperazine
,20828970,LOQ,The LOQ was evaluated to be 0.3 ng/mL.,A liquid chromatography-tandem mass spectrometry method for the quantification of PAC-1 in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20828970/),[ng] / [ml],0.3,193048,DB00592,Piperazine
,9690949,Cmax,Itraconazole had no significant effect on the Cmax (190 +/- 124 ng ml(-1) vs 197 +/- 189 ng ml(-1) (mean +/- s.d.)) or total AUC (368 +/- 153 ng ml(-1) h vs 324 +/- 155 ng ml(-1) h) of fluvastatin compared with placebo.,Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),[ng] / [ml],190,193159,DB00592,Piperazine
,9690949,Cmax,Itraconazole had no significant effect on the Cmax (190 +/- 124 ng ml(-1) vs 197 +/- 189 ng ml(-1) (mean +/- s.d.)) or total AUC (368 +/- 153 ng ml(-1) h vs 324 +/- 155 ng ml(-1) h) of fluvastatin compared with placebo.,Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),[ng] / [ml],197,193160,DB00592,Piperazine
,9690949,total AUC,Itraconazole had no significant effect on the Cmax (190 +/- 124 ng ml(-1) vs 197 +/- 189 ng ml(-1) (mean +/- s.d.)) or total AUC (368 +/- 153 ng ml(-1) h vs 324 +/- 155 ng ml(-1) h) of fluvastatin compared with placebo.,Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),[h·ng] / [ml],368,193161,DB00592,Piperazine
,9690949,total AUC,Itraconazole had no significant effect on the Cmax (190 +/- 124 ng ml(-1) vs 197 +/- 189 ng ml(-1) (mean +/- s.d.)) or total AUC (368 +/- 153 ng ml(-1) h vs 324 +/- 155 ng ml(-1) h) of fluvastatin compared with placebo.,Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),[h·ng] / [ml],324,193162,DB00592,Piperazine
,9690949,"t1/2,z","However, the t1/2,z of fluvastatin was slightly prolonged by itraconazole (2.8 +/- 0.49 h vs 2.4 +/- 0.51 h; P < 0.05).",Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),h,2.8,193163,DB00592,Piperazine
,9690949,"t1/2,z","However, the t1/2,z of fluvastatin was slightly prolonged by itraconazole (2.8 +/- 0.49 h vs 2.4 +/- 0.51 h; P < 0.05).",Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),h,2.4,193164,DB00592,Piperazine
,9690949,"t1/2,z","The t1/2,z of lovastatin averaged 3.7 +/- 3.8 h and that of lovastatin acid 4.7 +/- 4.0 h during the itraconazole phase; these variables could not be determined in all subjects during the placebo phase.",Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),h,3.7,193165,DB00592,Piperazine
,9690949,"t1/2,z","The t1/2,z of lovastatin averaged 3.7 +/- 3.8 h and that of lovastatin acid 4.7 +/- 4.0 h during the itraconazole phase; these variables could not be determined in all subjects during the placebo phase.",Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690949/),h,4.7,193166,DB00592,Piperazine
,1323914,elimination half-life,"The elimination half-life in animals was found to be around 40 min, in humans between 44-137 min.",[Pharmacokinetics and metabolism of pipecuronium bromide (Arduan)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1323914/),min,40,193557,DB00592,Piperazine
,1323914,elimination half-life,"The elimination half-life in animals was found to be around 40 min, in humans between 44-137 min.",[Pharmacokinetics and metabolism of pipecuronium bromide (Arduan)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1323914/),min,44-137,193558,DB00592,Piperazine
,17558437,"partition coefficient, K(p)","The concentration-time profile of levocetirizine indicated lower levels (partition coefficient, K(p)=0.06-0.08), higher t(max) (2-4 h vs 1-1.5 h) and longer terminal half-life (4-5.6 h vs 2.1-2.8 h) in brain than plasma.","Peripheral and central H1 histamine receptor occupancy by levocetirizine, a non-sedating antihistamine; a time course study in the guinea pig. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17558437/),,0.06-0.08,193565,DB00592,Piperazine
,17558437,t(max),"The concentration-time profile of levocetirizine indicated lower levels (partition coefficient, K(p)=0.06-0.08), higher t(max) (2-4 h vs 1-1.5 h) and longer terminal half-life (4-5.6 h vs 2.1-2.8 h) in brain than plasma.","Peripheral and central H1 histamine receptor occupancy by levocetirizine, a non-sedating antihistamine; a time course study in the guinea pig. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17558437/),h,2-4,193566,DB00592,Piperazine
,17558437,t(max),"The concentration-time profile of levocetirizine indicated lower levels (partition coefficient, K(p)=0.06-0.08), higher t(max) (2-4 h vs 1-1.5 h) and longer terminal half-life (4-5.6 h vs 2.1-2.8 h) in brain than plasma.","Peripheral and central H1 histamine receptor occupancy by levocetirizine, a non-sedating antihistamine; a time course study in the guinea pig. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17558437/),h,1-1.5,193567,DB00592,Piperazine
,17558437,terminal half-life,"The concentration-time profile of levocetirizine indicated lower levels (partition coefficient, K(p)=0.06-0.08), higher t(max) (2-4 h vs 1-1.5 h) and longer terminal half-life (4-5.6 h vs 2.1-2.8 h) in brain than plasma.","Peripheral and central H1 histamine receptor occupancy by levocetirizine, a non-sedating antihistamine; a time course study in the guinea pig. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17558437/),h,4-5.6,193568,DB00592,Piperazine
,17558437,terminal half-life,"The concentration-time profile of levocetirizine indicated lower levels (partition coefficient, K(p)=0.06-0.08), higher t(max) (2-4 h vs 1-1.5 h) and longer terminal half-life (4-5.6 h vs 2.1-2.8 h) in brain than plasma.","Peripheral and central H1 histamine receptor occupancy by levocetirizine, a non-sedating antihistamine; a time course study in the guinea pig. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17558437/),h,2.1-2.8,193569,DB00592,Piperazine
,8681493,elimination half-life,The elimination half-life was about 5 to 10 hours.,Incremental dosage of the new antipsychotic mazapertine induces tolerance to cardiovascular and cognitive effects in healthy men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8681493/),h,5 to 10,193667,DB00592,Piperazine
,12705176,terminal half-life,"Very high urinary concentrations and the relatively long terminal half-life (10-12 h) suggest that a once-daily application would show adequate clinical efficacy, especially in urinary infections.",Pharmacokinetics and tolerability of prulifloxacin after single oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12705176/),h,10-12,193807,DB00592,Piperazine
,2369134,days to na,Median days to nadir and recovery were both about 2 weeks.,[Phase I study of MST-16]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369134/),,2,193872,DB00592,Piperazine
,21209240,kdeg,"In addition, the authors believe that a hepatic CYP3A kdeg of 0.03 h(-1) should be considered for future Simcyp studies.",Effect of different durations and formulations of diltiazem on the single-dose pharmacokinetics of midazolam: how long do we go? ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21209240/),1/[h],0.03,193945,DB00592,Piperazine
,16084853,area under the curve from time 0 to infinity (AUC(0-infinity)),"In the placebo phase, pharmacokinetic parameters of fexofenadine showed no statistically significant difference between 2 MDR1 haplotypes; the area under the curve from time 0 to infinity (AUC(0-infinity)) of fexofenadine in the T/T and G/C groups was 5194.0 +/- 1910.8 and 4040.4 +/- 1832.2 ng.mL(-1).",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084853/),[ng] / [ml],5194.0,194084,DB00592,Piperazine
,16084853,area under the curve from time 0 to infinity (AUC(0-infinity)),"In the placebo phase, pharmacokinetic parameters of fexofenadine showed no statistically significant difference between 2 MDR1 haplotypes; the area under the curve from time 0 to infinity (AUC(0-infinity)) of fexofenadine in the T/T and G/C groups was 5194.0 +/- 1910.8 and 4040.4 +/- 1832.2 ng.mL(-1).",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084853/),[ng] / [ml],4040.4,194085,DB00592,Piperazine
,16084853,oral clearance (CL/F),"h(-1), respectively (P = .271), and the oral clearance (CL/F) was 530.9 +/- 191.1 and 806.0 +/- 355.3 mL.h(-1).kg(-1), respectively (P = .096).",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084853/),[ml] / [h·kg],530.9,194086,DB00592,Piperazine
,16084853,oral clearance (CL/F),"h(-1), respectively (P = .271), and the oral clearance (CL/F) was 530.9 +/- 191.1 and 806.0 +/- 355.3 mL.h(-1).kg(-1), respectively (P = .096).",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084853/),[ml] / [h·kg],806.0,194087,DB00592,Piperazine
,16084853,AUC(0-infinity),"After itraconazole pretreatment, however, the differences in fexofenadine pharmacokinetics became statistically significant; the mean fexofenadine AUC(0-infinity) in the T/T group was significantly higher than that in the G/C group (15,630.6 +/- 5070.0 and 9252.9 +/- 2044.1 ng/mL.h, respectively; P = .007), and CL/F of the T/T subjects was lower than that of the G/C subjects (167.0 +/- 33.3 and 292.3 +/- 42.2 mL.h(-1).kg(-1), respectively; P < .001).",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084853/),[ng] / [h·ml],"15,630.6",194088,DB00592,Piperazine
,16084853,AUC(0-infinity),"After itraconazole pretreatment, however, the differences in fexofenadine pharmacokinetics became statistically significant; the mean fexofenadine AUC(0-infinity) in the T/T group was significantly higher than that in the G/C group (15,630.6 +/- 5070.0 and 9252.9 +/- 2044.1 ng/mL.h, respectively; P = .007), and CL/F of the T/T subjects was lower than that of the G/C subjects (167.0 +/- 33.3 and 292.3 +/- 42.2 mL.h(-1).kg(-1), respectively; P < .001).",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084853/),[ng] / [h·ml],9252.9,194089,DB00592,Piperazine
,16084853,CL/F,"After itraconazole pretreatment, however, the differences in fexofenadine pharmacokinetics became statistically significant; the mean fexofenadine AUC(0-infinity) in the T/T group was significantly higher than that in the G/C group (15,630.6 +/- 5070.0 and 9252.9 +/- 2044.1 ng/mL.h, respectively; P = .007), and CL/F of the T/T subjects was lower than that of the G/C subjects (167.0 +/- 33.3 and 292.3 +/- 42.2 mL.h(-1).kg(-1), respectively; P < .001).",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084853/),[ml] / [h·kg],167.0,194090,DB00592,Piperazine
,16084853,CL/F,"After itraconazole pretreatment, however, the differences in fexofenadine pharmacokinetics became statistically significant; the mean fexofenadine AUC(0-infinity) in the T/T group was significantly higher than that in the G/C group (15,630.6 +/- 5070.0 and 9252.9 +/- 2044.1 ng/mL.h, respectively; P = .007), and CL/F of the T/T subjects was lower than that of the G/C subjects (167.0 +/- 33.3 and 292.3 +/- 42.2 mL.h(-1).kg(-1), respectively; P < .001).",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16084853/),[ml] / [h·kg],292.3,194091,DB00592,Piperazine
<,24096683,Renal elimination,Renal elimination of unchanged DTG is very low (< 1 %).,Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24096683/),%,1,194172,DB00592,Piperazine
,26356245,intestinal availability,"The simulated intestinal availability, hepatic availability and the fraction absorbed were 0.45 ± 0.14, 0.31 ± 0.10 and 0.89 ± 0.11, respectively, and comparable to observed in vivo values.",A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions between domperidone and inhibitors of CYP3A4. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356245/),,0.45,194246,DB00592,Piperazine
,26356245,hepatic availability,"The simulated intestinal availability, hepatic availability and the fraction absorbed were 0.45 ± 0.14, 0.31 ± 0.10 and 0.89 ± 0.11, respectively, and comparable to observed in vivo values.",A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions between domperidone and inhibitors of CYP3A4. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356245/),,0.31,194247,DB00592,Piperazine
,26356245,fraction absorbed,"The simulated intestinal availability, hepatic availability and the fraction absorbed were 0.45 ± 0.14, 0.31 ± 0.10 and 0.89 ± 0.11, respectively, and comparable to observed in vivo values.",A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions between domperidone and inhibitors of CYP3A4. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356245/),,0.89,194248,DB00592,Piperazine
,24549963,Cmax,"The Cmax value was 922.8±318.8 μg/L at 3.15 h for 200-mg imatinib tablet, and 986.3±266.0 μg/L at 2.91 h for the 2×100-mg imatinib tablet.",Bioequivalence study of two imatinib formulations after single-dose administration in healthy Korean male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24549963/),[μg] / [l],922.8,194378,DB00592,Piperazine
,24549963,Cmax,"The Cmax value was 922.8±318.8 μg/L at 3.15 h for 200-mg imatinib tablet, and 986.3±266.0 μg/L at 2.91 h for the 2×100-mg imatinib tablet.",Bioequivalence study of two imatinib formulations after single-dose administration in healthy Korean male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24549963/),[μg] / [l],986.3,194379,DB00592,Piperazine
,24549963,AUClast,"The AUClast of 200-mg and 2×100-mg tablets were 13 084.3±39.1 and 14 131.7±3 826.2 h · μg/L, respectively.",Bioequivalence study of two imatinib formulations after single-dose administration in healthy Korean male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24549963/),[h·μg] / [l],13 084.3,194380,DB00592,Piperazine
,24549963,AUClast,"The AUClast of 200-mg and 2×100-mg tablets were 13 084.3±39.1 and 14 131.7±3 826.2 h · μg/L, respectively.",Bioequivalence study of two imatinib formulations after single-dose administration in healthy Korean male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24549963/),[h·μg] / [l],14 131.7,194381,DB00592,Piperazine
,17220241,plasma clearance,"The plasma clearance and volume of distribution of sitagliptin were higher in rats (40-48 ml/min/kg, 7-9 l/kg) than in dogs ( approximately 9 ml/min/kg, approximately 3 l/kg), and its half-life was shorter in rats, approximately 2 h compared with approximately 4 h in dogs.",Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220241/),[ml] / [kg·min],40-48,195152,DB00592,Piperazine
,17220241,plasma clearance,"The plasma clearance and volume of distribution of sitagliptin were higher in rats (40-48 ml/min/kg, 7-9 l/kg) than in dogs ( approximately 9 ml/min/kg, approximately 3 l/kg), and its half-life was shorter in rats, approximately 2 h compared with approximately 4 h in dogs.",Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220241/),[ml] / [kg·min],9,195153,DB00592,Piperazine
,17220241,volume of distribution,"The plasma clearance and volume of distribution of sitagliptin were higher in rats (40-48 ml/min/kg, 7-9 l/kg) than in dogs ( approximately 9 ml/min/kg, approximately 3 l/kg), and its half-life was shorter in rats, approximately 2 h compared with approximately 4 h in dogs.",Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220241/),[l] / [kg],7-9,195154,DB00592,Piperazine
,17220241,volume of distribution,"The plasma clearance and volume of distribution of sitagliptin were higher in rats (40-48 ml/min/kg, 7-9 l/kg) than in dogs ( approximately 9 ml/min/kg, approximately 3 l/kg), and its half-life was shorter in rats, approximately 2 h compared with approximately 4 h in dogs.",Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220241/),[ml] / [kg·min],9,195155,DB00592,Piperazine
,17220241,volume of distribution,"The plasma clearance and volume of distribution of sitagliptin were higher in rats (40-48 ml/min/kg, 7-9 l/kg) than in dogs ( approximately 9 ml/min/kg, approximately 3 l/kg), and its half-life was shorter in rats, approximately 2 h compared with approximately 4 h in dogs.",Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220241/),[l] / [kg],3,195156,DB00592,Piperazine
,17220241,half-life,"The plasma clearance and volume of distribution of sitagliptin were higher in rats (40-48 ml/min/kg, 7-9 l/kg) than in dogs ( approximately 9 ml/min/kg, approximately 3 l/kg), and its half-life was shorter in rats, approximately 2 h compared with approximately 4 h in dogs.",Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220241/),h,2,195157,DB00592,Piperazine
,17220241,half-life,"The plasma clearance and volume of distribution of sitagliptin were higher in rats (40-48 ml/min/kg, 7-9 l/kg) than in dogs ( approximately 9 ml/min/kg, approximately 3 l/kg), and its half-life was shorter in rats, approximately 2 h compared with approximately 4 h in dogs.",Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220241/),h,4,195158,DB00592,Piperazine
,17220241,renal clearance of unbound drug,"The renal clearance of unbound drug in rats, 32 to 39 ml/min/kg, far exceeded the glomerular filtration rate, indicative of active renal elimination of parent drug.",Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220241/),[ml] / [kg·min],32 to 39,195159,DB00592,Piperazine
,32879225,activation energy (Ea),The degradation was a pseudo first-order reaction; activation energy (Ea) was 88.70 kJ/mol and activation entropy (ΔS) was -80.73 J/K·mol.,Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),[kj] / [mol],88.70,195214,DB00592,Piperazine
,32879225,activation entropy (ΔS),The degradation was a pseudo first-order reaction; activation energy (Ea) was 88.70 kJ/mol and activation entropy (ΔS) was -80.73 J/K·mol.,Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),[j] / [k·mol],-,195215,DB00592,Piperazine
,32879225,activation entropy (ΔS),The degradation was a pseudo first-order reaction; activation energy (Ea) was 88.70 kJ/mol and activation entropy (ΔS) was -80.73 J/K·mol.,Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),[j] / [k·mol],80.73,195216,DB00592,Piperazine
,32879225,retention times,"In the AMX degradation experiment, peaks considered to be degradation products A (I) and B (II) were detected at retention times of around 3 min and 30 min in LC/UV measurements, respectively.",Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),min,3,195217,DB00592,Piperazine
,32879225,retention times,"In the AMX degradation experiment, peaks considered to be degradation products A (I) and B (II) were detected at retention times of around 3 min and 30 min in LC/UV measurements, respectively.",Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),min,30,195218,DB00592,Piperazine
,7607739,oral bioavailability,The oral bioavailability of SC-56525 in conscious dogs at doses of 5 mg/kg IV and 30 mg/kg PO was 66.1 +/- 16.4%.,"Effects of SC-56525, a potent, orally active renin inhibitor, in salt-depleted and renal hypertensive dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7607739/),%,66.1,195461,DB00592,Piperazine
,9218932,AUC,"The mean AUC was 1.12 vs 2.02 micrograms.h.m1-1, the mean Cmax was 0.14 vs 0.31 micrograms.",Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9218932/),[h·μg] / [m1],1.12,195642,DB00592,Piperazine
,9218932,AUC,"The mean AUC was 1.12 vs 2.02 micrograms.h.m1-1, the mean Cmax was 0.14 vs 0.31 micrograms.",Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9218932/),[h·μg] / [m1],2.02,195643,DB00592,Piperazine
,9218932,Cmax,"The mean AUC was 1.12 vs 2.02 micrograms.h.m1-1, the mean Cmax was 0.14 vs 0.31 micrograms.",Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9218932/),μg,0.14,195644,DB00592,Piperazine
,9218932,Cmax,"The mean AUC was 1.12 vs 2.02 micrograms.h.m1-1, the mean Cmax was 0.14 vs 0.31 micrograms.",Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9218932/),μg,0.31,195645,DB00592,Piperazine
,9218932,tmax,"m1-1 and the mean tmax was 2.56 vs 3.38 h in treatments I and II, respectively.",Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9218932/),h,2.56,195646,DB00592,Piperazine
,9218932,tmax,"m1-1 and the mean tmax was 2.56 vs 3.38 h in treatments I and II, respectively.",Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9218932/),h,3.38,195647,DB00592,Piperazine
,1317685,Onset time,"Onset time in the elderly was prolonged (6.9 +/- 2.6 vs 4.3 +/- 1.5 min, P less than 0.02).",Pharmacokinetics and pharmacodynamics of pipecuronium bromide (Arduan) in elderly surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1317685/),min,6.9,195672,DB00592,Piperazine
,1317685,Onset time,"Onset time in the elderly was prolonged (6.9 +/- 2.6 vs 4.3 +/- 1.5 min, P less than 0.02).",Pharmacokinetics and pharmacodynamics of pipecuronium bromide (Arduan) in elderly surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1317685/),min,4.3,195673,DB00592,Piperazine
,21184398,Limits of detection,"Limits of detection and quantification for VDN were 0.70 and 2.00 µg/l, respectively.",A fully validated method for the determination of vardenafil in blood using gas chromatography/mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21184398/),[μg] / [l],0.70,195688,DB00592,Piperazine
,21184398,Limits of detection,"Limits of detection and quantification for VDN were 0.70 and 2.00 µg/l, respectively.",A fully validated method for the determination of vardenafil in blood using gas chromatography/mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21184398/),[μg] / [l],2.00,195689,DB00592,Piperazine
,21184398,Absolute recovery,Absolute recovery ranged from 88.6% to 95.7% for the analyte of interest at three quality control levels.,A fully validated method for the determination of vardenafil in blood using gas chromatography/mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21184398/),%,88.6,195690,DB00592,Piperazine
,21184398,Absolute recovery,Absolute recovery ranged from 88.6% to 95.7% for the analyte of interest at three quality control levels.,A fully validated method for the determination of vardenafil in blood using gas chromatography/mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21184398/),%,95.7,195691,DB00592,Piperazine
,8289134,elimination half-lives,"The mean elimination half-lives were 53.5 and 66.0 h at 75 and 125 mg/day, respectively, in accordance with the observed time to reach near steady-state conditions.",Nonlinear multiple-dose pharmacokinetics of the dopamine reuptake inhibitor vanoxerine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8289134/),h,53.5,195858,DB00592,Piperazine
,8289134,elimination half-lives,"The mean elimination half-lives were 53.5 and 66.0 h at 75 and 125 mg/day, respectively, in accordance with the observed time to reach near steady-state conditions.",Nonlinear multiple-dose pharmacokinetics of the dopamine reuptake inhibitor vanoxerine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8289134/),h,66.0,195859,DB00592,Piperazine
,33517421,V:V,"The protein precipitation was used for extraction and the gradient elution of the mobile phase A of water (containing 0.01% formic acid) and the mobile phase B of acetonitrile, and methanol (V:V = 1:1, containing 0.01% formic acid) was used for chromatographic separation on a C18 column.",UPLC-MS/MS for the Simultaneous Determination of Sildenafil and N-Desmethyl Sildenafil. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33517421/),,1:1,196209,DB00592,Piperazine
,19042162,flow rate,"Chromatographic separation was carried on a Luna C(18) column (50 mm x 2.0 mm, 3 microm) at 40 degrees C, with an isocratic mobile phase consisting of 10 mM ammonium acetate (pH 5.0) and acetonitrile (10:90, v/v), a flow rate of 0.2 mL/min, and a total run time of 2 min.","Liquid chromatography/tandem mass spectrometry method for the simultaneous determination of vardenafil and its major metabolite, N-desethylvardenafil, in human plasma: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19042162/),[ml] / [min],0.2,196427,DB00592,Piperazine
,19042162,total run time,"Chromatographic separation was carried on a Luna C(18) column (50 mm x 2.0 mm, 3 microm) at 40 degrees C, with an isocratic mobile phase consisting of 10 mM ammonium acetate (pH 5.0) and acetonitrile (10:90, v/v), a flow rate of 0.2 mL/min, and a total run time of 2 min.","Liquid chromatography/tandem mass spectrometry method for the simultaneous determination of vardenafil and its major metabolite, N-desethylvardenafil, in human plasma: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19042162/),min,2,196428,DB00592,Piperazine
,19042162,m,"Detection and quantification were performed using a mass spectrometer in the selected reaction-monitoring mode with positive electrospray ionization at m/z 489.1-->151.2 for vardenafil, m/z 460.9-->151.2 for N-desethylvardenafil, and m/z 475.3-->100.1 for the internal standard (IS), respectively.","Liquid chromatography/tandem mass spectrometry method for the simultaneous determination of vardenafil and its major metabolite, N-desethylvardenafil, in human plasma: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19042162/),,489.1,196429,DB00592,Piperazine
,19042162,m/z,"Detection and quantification were performed using a mass spectrometer in the selected reaction-monitoring mode with positive electrospray ionization at m/z 489.1-->151.2 for vardenafil, m/z 460.9-->151.2 for N-desethylvardenafil, and m/z 475.3-->100.1 for the internal standard (IS), respectively.","Liquid chromatography/tandem mass spectrometry method for the simultaneous determination of vardenafil and its major metabolite, N-desethylvardenafil, in human plasma: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19042162/),,460.9,196430,DB00592,Piperazine
,19042162,m/z,"Detection and quantification were performed using a mass spectrometer in the selected reaction-monitoring mode with positive electrospray ionization at m/z 489.1-->151.2 for vardenafil, m/z 460.9-->151.2 for N-desethylvardenafil, and m/z 475.3-->100.1 for the internal standard (IS), respectively.","Liquid chromatography/tandem mass spectrometry method for the simultaneous determination of vardenafil and its major metabolite, N-desethylvardenafil, in human plasma: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19042162/),,151.2,196431,DB00592,Piperazine
,19042162,m/z,"Detection and quantification were performed using a mass spectrometer in the selected reaction-monitoring mode with positive electrospray ionization at m/z 489.1-->151.2 for vardenafil, m/z 460.9-->151.2 for N-desethylvardenafil, and m/z 475.3-->100.1 for the internal standard (IS), respectively.","Liquid chromatography/tandem mass spectrometry method for the simultaneous determination of vardenafil and its major metabolite, N-desethylvardenafil, in human plasma: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19042162/),,475.3,196432,DB00592,Piperazine
,19042162,m/z,"Detection and quantification were performed using a mass spectrometer in the selected reaction-monitoring mode with positive electrospray ionization at m/z 489.1-->151.2 for vardenafil, m/z 460.9-->151.2 for N-desethylvardenafil, and m/z 475.3-->100.1 for the internal standard (IS), respectively.","Liquid chromatography/tandem mass spectrometry method for the simultaneous determination of vardenafil and its major metabolite, N-desethylvardenafil, in human plasma: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19042162/),,100.1,196433,DB00592,Piperazine
,6285814,peak concentrations,"The peak concentrations of ketoconazole attained with brand 1 were 4.1 +/- 0.3 micrograms/ml (mean +/- standard error of the mean) after fasting, 2.3 +/- 0.3 micrograms/ml after the standardized meal (P less than 0.01), and 3.6 +/- 0.2 micrograms/ml with orange juice.",Impairing effect of food on ketoconazole absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285814/),[μg] / [ml],4.1,196797,DB00592,Piperazine
,6285814,peak concentrations,"The peak concentrations of ketoconazole attained with brand 1 were 4.1 +/- 0.3 micrograms/ml (mean +/- standard error of the mean) after fasting, 2.3 +/- 0.3 micrograms/ml after the standardized meal (P less than 0.01), and 3.6 +/- 0.2 micrograms/ml with orange juice.",Impairing effect of food on ketoconazole absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285814/),[μg] / [ml],2.3,196798,DB00592,Piperazine
,6285814,peak concentrations,"The peak concentrations of ketoconazole attained with brand 1 were 4.1 +/- 0.3 micrograms/ml (mean +/- standard error of the mean) after fasting, 2.3 +/- 0.3 micrograms/ml after the standardized meal (P less than 0.01), and 3.6 +/- 0.2 micrograms/ml with orange juice.",Impairing effect of food on ketoconazole absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285814/),[μg] / [ml],3.6,196799,DB00592,Piperazine
,6285814,areas under the serum concentration-time curves,"The peak concentrations were reached in 1.4, 2.3 (P less than 0.05), and 1.8 h, respectively, whereas the areas under the serum concentration-time curves were 14.4 +/- 2.21, 8.6 +/- 1.33 (P less than 0.05), and 13.4 +/- 1.30 micrograms.h/ml, respectively.",Impairing effect of food on ketoconazole absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285814/),[h·μg] / [ml],14.4,196800,DB00592,Piperazine
,6285814,areas under the serum concentration-time curves,"The peak concentrations were reached in 1.4, 2.3 (P less than 0.05), and 1.8 h, respectively, whereas the areas under the serum concentration-time curves were 14.4 +/- 2.21, 8.6 +/- 1.33 (P less than 0.05), and 13.4 +/- 1.30 micrograms.h/ml, respectively.",Impairing effect of food on ketoconazole absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285814/),[h·μg] / [ml],8.6,196801,DB00592,Piperazine
,6285814,areas under the serum concentration-time curves,"The peak concentrations were reached in 1.4, 2.3 (P less than 0.05), and 1.8 h, respectively, whereas the areas under the serum concentration-time curves were 14.4 +/- 2.21, 8.6 +/- 1.33 (P less than 0.05), and 13.4 +/- 1.30 micrograms.h/ml, respectively.",Impairing effect of food on ketoconazole absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285814/),[h·μg] / [ml],13.4,196802,DB00592,Piperazine
,6285814,half-lives,The half-lives (1.7 to 2 h) did not vary significantly among the different regimens.,Impairing effect of food on ketoconazole absorption. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285814/),h,1.7 to 2,196803,DB00592,Piperazine
,6285814,peak concentration,"Compared with ketoconazole, oral absorption of miconazole was poor (peak concentration, 0.47 +/- 0.7 micrograms/ml; time to reach the peak concentration, 2.6 h; area under the serum concentration-time curve, 1.10 +/- 0.20 micrograms.h/ml).",Impairing effect of food on ketoconazole absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285814/),[μg] / [ml],0.47,196804,DB00592,Piperazine
,6285814,time to reach the peak concentration,"Compared with ketoconazole, oral absorption of miconazole was poor (peak concentration, 0.47 +/- 0.7 micrograms/ml; time to reach the peak concentration, 2.6 h; area under the serum concentration-time curve, 1.10 +/- 0.20 micrograms.h/ml).",Impairing effect of food on ketoconazole absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285814/),h,2.6,196805,DB00592,Piperazine
,6285814,area under the serum concentration-time curve,"Compared with ketoconazole, oral absorption of miconazole was poor (peak concentration, 0.47 +/- 0.7 micrograms/ml; time to reach the peak concentration, 2.6 h; area under the serum concentration-time curve, 1.10 +/- 0.20 micrograms.h/ml).",Impairing effect of food on ketoconazole absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285814/),[h·μg] / [ml],1.10,196806,DB00592,Piperazine
,26253809,recovery,The mean recovery was 83.2 % for sildenafil and 84.5% for N-desmethyl sildenafil.,Development and validation of an ultra performance liquid chromatography tandem mass method for sildenafil and N-desmethyl sildenafil plasma determination and quantification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26253809/),%,83.2,197172,DB00592,Piperazine
,26253809,recovery,The mean recovery was 83.2 % for sildenafil and 84.5% for N-desmethyl sildenafil.,Development and validation of an ultra performance liquid chromatography tandem mass method for sildenafil and N-desmethyl sildenafil plasma determination and quantification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26253809/),%,84.5,197173,DB00592,Piperazine
,15078426,total sum,It then gradually decreased to a total sum of 10.3 ng g(-1) on average at 8 weeks following the completion of administration.,Pharmacokinetic investigation of oral itraconazole in stratum corneum level of tinea pedis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15078426/),[ng] / [g],10.3,197309,DB00592,Piperazine
,15078426,minimum inhibitory concentration (MIC),"When compared with the geometric mean minimum inhibitory concentration (MIC) of ITCZ against fresh clinical isolates of dermatophytes (Trichophyton rubrum) (0.06 microg ml(-1)), the stratum corneum ITCZ concentration in this study was 2.1-fold of the geometric mean MIC at 2 weeks following the completion of administration, and 2.4-fold at 4 weeks.",Pharmacokinetic investigation of oral itraconazole in stratum corneum level of tinea pedis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15078426/),[μg] / [ml],0.06,197310,DB00592,Piperazine
,8372048,t 1/2,"The following main parameters were calculated at steady state for psychiatric patients (mean +/- S.D.): t 1/2 = 7.0 +/- 1.2, V beta/F = 0.50 +/- 0.13 l/kg and Clt/F = 3.2 +/- 0.5 l/hr.",Pharmacokinetics of trazodone during multiple dosing to psychiatric patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8372048/),,7.0,197318,DB00592,Piperazine
,8372048,V beta/F,"The following main parameters were calculated at steady state for psychiatric patients (mean +/- S.D.): t 1/2 = 7.0 +/- 1.2, V beta/F = 0.50 +/- 0.13 l/kg and Clt/F = 3.2 +/- 0.5 l/hr.",Pharmacokinetics of trazodone during multiple dosing to psychiatric patients. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8372048/),[l] / [kg],0.50,197319,DB00592,Piperazine
,8372048,Clt/F,"The following main parameters were calculated at steady state for psychiatric patients (mean +/- S.D.): t 1/2 = 7.0 +/- 1.2, V beta/F = 0.50 +/- 0.13 l/kg and Clt/F = 3.2 +/- 0.5 l/hr.",Pharmacokinetics of trazodone during multiple dosing to psychiatric patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8372048/),[l] / [h],3.2,197320,DB00592,Piperazine
,8372048,oral availability,These pharmacokinetic parameters did not differ significantly from those earlier reported in healthy subjects after a single dose administration of 100 mg when based on an oral availability of trazodone of 65%.,Pharmacokinetics of trazodone during multiple dosing to psychiatric patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8372048/),%,65,197321,DB00592,Piperazine
,11240972,area under the plasma concentration-time curve,"Concomitant nefazodone treatment markedly increased the dose interval area under the plasma concentration-time curve of both terfenadine (mean value, 17.3 +/- 8.5 ng.",Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240972/),ng,17.3,197542,DB00592,Piperazine
,11240972,area under the plasma concentration-time curve,"h/mL; P <.001) and moderately increased the dose interval area under the plasma concentration-time curve of both loratadine (mean value, 31.5 +/- 27.9 ng.",Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240972/),ng,31.5,197543,DB00592,Piperazine
,11240972,QTc,"Similarly, the mean QTc was unchanged with loratadine alone; however, it was prolonged with concomitant nefazodone and loratadine (21.6 ms [13.7, 29.4 ms]; P <.05).",Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240972/),ms,21.6,197544,DB00592,Piperazine
,15980352,time to maximum concentration,Plasma 873140 concentrations increased rapidly; the median time to maximum concentration of drug in serum was 1.75 to 5 h.,"Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15980352/),h,1.75 to 5,197662,DB00592,Piperazine
,15980352,area under the plasma concentration-time profile (AUC),"The median area under the plasma concentration-time profile (AUC) and the maximum concentration of drug in serum (C(max)) ranged from 127 ng.h/ml and 24 ng/ml at 200 mg BID to 329 ng.h/ml and 100 ng/ml at 800 mg BID, respectively.","Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15980352/),[h·ng] / [ml],127,197663,DB00592,Piperazine
,15980352,area under the plasma concentration-time profile (AUC),"The median area under the plasma concentration-time profile (AUC) and the maximum concentration of drug in serum (C(max)) ranged from 127 ng.h/ml and 24 ng/ml at 200 mg BID to 329 ng.h/ml and 100 ng/ml at 800 mg BID, respectively.","Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15980352/),[h·ng] / [ml],329,197664,DB00592,Piperazine
,15980352,maximum concentration of drug in serum (C(max)),"The median area under the plasma concentration-time profile (AUC) and the maximum concentration of drug in serum (C(max)) ranged from 127 ng.h/ml and 24 ng/ml at 200 mg BID to 329 ng.h/ml and 100 ng/ml at 800 mg BID, respectively.","Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15980352/),[ng] / [ml],24,197665,DB00592,Piperazine
,15980352,maximum concentration of drug in serum (C(max)),"The median area under the plasma concentration-time profile (AUC) and the maximum concentration of drug in serum (C(max)) ranged from 127 ng.h/ml and 24 ng/ml at 200 mg BID to 329 ng.h/ml and 100 ng/ml at 800 mg BID, respectively.","Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15980352/),[ng] / [ml],100,197666,DB00592,Piperazine
greater,7188377,oral bioavailability,"ZD is rapidly and efficiently absorbed: its oral bioavailability was greater than 75% in all species except rats, where a first-pass effect of about 65% was recorded.",Pharmacokinetics and metabolism of zopiclone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7188377/),%,75,197667,DB00592,Piperazine
,7188377,Plasma protein binding,Plasma protein binding is about 45%.,Pharmacokinetics and metabolism of zopiclone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7188377/),%,45,197668,DB00592,Piperazine
,7188377,terminal half-life,"Plasma kinetics of ZD are generally well described by a two-compartment open model; in man, terminal half-life is 4-5 h; total body clearance is large (300 ml/mn), renal clearance very low (10 ml/min).",Pharmacokinetics and metabolism of zopiclone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7188377/),h,4-5,197669,DB00592,Piperazine
,7188377,total body clearance,"Plasma kinetics of ZD are generally well described by a two-compartment open model; in man, terminal half-life is 4-5 h; total body clearance is large (300 ml/mn), renal clearance very low (10 ml/min).",Pharmacokinetics and metabolism of zopiclone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7188377/),[ml] / [mn],300,197670,DB00592,Piperazine
,7188377,renal clearance,"Plasma kinetics of ZD are generally well described by a two-compartment open model; in man, terminal half-life is 4-5 h; total body clearance is large (300 ml/mn), renal clearance very low (10 ml/min).",Pharmacokinetics and metabolism of zopiclone. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7188377/),[ml] / [min],10,197671,DB00592,Piperazine
,7188377,milk/plasma ratio,"In nursing mothers, milk and plasma kinetics of ZD are similar with a milk/plasma ratio around 0.80.",Pharmacokinetics and metabolism of zopiclone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7188377/),,0.80,197672,DB00592,Piperazine
,30299299,Cmax,"Sildenafil Cmax (156.8 ± 124.5 ng/ml) was elevated in 66% of patients, with a two to fivefold increase over the upper limit of the reference range in 25% of patients.",Pharmacokinetics of Sildenafil in Patients with a Left Ventricular Assist Device: A Word of Caution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30299299/),[ng] / [ml],156.8,197772,DB00592,Piperazine
,30299299,Cmax,"Metabolite Cmax (133.3 ± 102.0 ng/ml) was elevated in 75% of patients, with a three to sevenfold increase over the upper limit of the reference range in 40% of patients.",Pharmacokinetics of Sildenafil in Patients with a Left Ventricular Assist Device: A Word of Caution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30299299/),[ng] / [ml],133.3,197773,DB00592,Piperazine
,10546851,area under the concentration curve for 0-8 h (AUC0-8h),"The geometric mean area under the concentration curve for 0-8 h (AUC0-8h) and maximum plasma concentration (Cmax) for indinavir were 19.69 microg/ml h (range, 9.19-31.99 microg/ml h) and 7.02 microg/ml (range, 2.33-16.17 microg/ml), respectively, on the first study day.",Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546851/),[μg] / [h·ml],19.69,197867,DB00592,Piperazine
,10546851,maximum plasma concentration (Cmax),"The geometric mean area under the concentration curve for 0-8 h (AUC0-8h) and maximum plasma concentration (Cmax) for indinavir were 19.69 microg/ml h (range, 9.19-31.99 microg/ml h) and 7.02 microg/ml (range, 2.33-16.17 microg/ml), respectively, on the first study day.",Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546851/),[μg] / [ml],7.02,197868,DB00592,Piperazine
,10546851,AUC0-8h,"In the presence of sildenafil, the mean AUC0-8h and Cmax of indinavir were 22.37 microg/ml h [range, 10.08-37.25 microg/ml h; 95% confidence interval (CI) for difference between means, -15 to 13.25) and 9.11 microg/ml (range, 3.41-22.78 microg/ml; 95% CI, -13 to 6.37), respectively.",Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546851/),[μg] / [h·ml],22.37,197869,DB00592,Piperazine
,10546851,Cmax,"In the presence of sildenafil, the mean AUC0-8h and Cmax of indinavir were 22.37 microg/ml h [range, 10.08-37.25 microg/ml h; 95% confidence interval (CI) for difference between means, -15 to 13.25) and 9.11 microg/ml (range, 3.41-22.78 microg/ml; 95% CI, -13 to 6.37), respectively.",Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546851/),[μg] / [ml],9.11,197870,DB00592,Piperazine
,10546851,AUC0-8h,"The geometric mean AUC0-8h and Cmax for sildenafil were 1631 ng/ml h (range, 643-2970 ng/ml h) and 384 ng/ml (range, 209-766 ng/ml) respectively.",Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546851/),[ng] / [h·ml],1631,197871,DB00592,Piperazine
,10546851,Cmax,"The geometric mean AUC0-8h and Cmax for sildenafil were 1631 ng/ml h (range, 643-2970 ng/ml h) and 384 ng/ml (range, 209-766 ng/ml) respectively.",Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546851/),[ng] / [ml],384,197872,DB00592,Piperazine
,10546851,concentration producing 50% inhibition of control enzyme activity (IC50),"Indinavir was a potent inhibitor of sildenafil hepatic metabolism in vitro [concentration producing 50% inhibition of control enzyme activity (IC50) = 0.39 +/- 0.17 microM, mean +/- SD].",Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546851/),μM,0.39,197873,DB00592,Piperazine
,21383523,CL/F,"The final population mean values of CL/F and k were estimated to be 0.409 · (1 - 0.0377 · (AGE - 3.81)) · WT L/h and 0.175 h(-1), respectively.",Pharmacokinetics of bosentan in routinely treated Japanese pediatric patients with pulmonary arterial hypertension. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21383523/),,0.409,197956,DB00592,Piperazine
,21383523,k,"The final population mean values of CL/F and k were estimated to be 0.409 · (1 - 0.0377 · (AGE - 3.81)) · WT L/h and 0.175 h(-1), respectively.",Pharmacokinetics of bosentan in routinely treated Japanese pediatric patients with pulmonary arterial hypertension. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21383523/),1/[h],0.175,197957,DB00592,Piperazine
,27578849,half-life,"Viral decay was faster in BP than in SP in the first decay phase (half-life, 4.5 vs 8.6 days; P = .001) with no statistically significant differences in the second phase.",HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27578849/),d,4.5,198164,DB00592,Piperazine
,27578849,half-life,"Viral decay was faster in BP than in SP in the first decay phase (half-life, 4.5 vs 8.6 days; P = .001) with no statistically significant differences in the second phase.",HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27578849/),d,8.6,198165,DB00592,Piperazine
,27578849,total DTG,"The median total DTG 24 hours after the dose in SP was 119.1 ng/mL (range, 27.2-377 ng/mL), which represents 7.8% of BP exposure.",HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27578849/),[ng] / [ml],119.1,198166,DB00592,Piperazine
,27578849,free-fraction,The median DTG free-fraction in SP was 48% of the total drug.,HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27578849/),%,48,198167,DB00592,Piperazine
,27578849,50% inhibitory concentration,Seminal protein-unbound DTG concentrations exceeded the in vitro 50% inhibitory concentration (0.21 ng/mL) by a median of 214-fold.,HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27578849/),[ng] / [ml],0.21,198168,DB00592,Piperazine
,1362384,elimination half-lives,"There were significant differences between (+)-, (-)- and racemic HCZ in AUC (0-14 h) and plasma protein binding, but all HCZ enantiomers were slowly absorbed and eliminated (elimination half-lives about 11 h).","Enantioselective pharmacokinetics of homochlorcyclizine. II: Disposition and metabolism of (+)-, (-)- and racemic homochlorcyclizine after oral administration to man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1362384/),h,11,198458,DB00592,Piperazine
,23899439,90% inhibitory concentration (IC90),BP areas under the concentration-time curve (AUCs) were similar to previous reports and concentrations remained greater than the protein-adjusted (PA) 90% inhibitory concentration (IC90) for wild-type HIV (64 ng/ml).,Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23899439/),[ng] / [ml],64,198524,DB00592,Piperazine
,15265053,total plasma clearance (CL),"Based on the results from the two high dose levels (5 and 10 mg) with sufficient individual subject data, BIBN 4096 BS exhibited a total plasma clearance (CL) of approximately 12 l/h and an apparent volume of distribution at steady state (Vss) of approximately 20 l, resulting in a terminal half-life (t1/2) of approximately 2.5 h.","Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15265053/),[l] / [h],12,198571,DB00592,Piperazine
,15265053,apparent volume of distribution at steady state (Vss),"Based on the results from the two high dose levels (5 and 10 mg) with sufficient individual subject data, BIBN 4096 BS exhibited a total plasma clearance (CL) of approximately 12 l/h and an apparent volume of distribution at steady state (Vss) of approximately 20 l, resulting in a terminal half-life (t1/2) of approximately 2.5 h.","Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15265053/),l,20,198572,DB00592,Piperazine
,15265053,terminal half-life (t1/2),"Based on the results from the two high dose levels (5 and 10 mg) with sufficient individual subject data, BIBN 4096 BS exhibited a total plasma clearance (CL) of approximately 12 l/h and an apparent volume of distribution at steady state (Vss) of approximately 20 l, resulting in a terminal half-life (t1/2) of approximately 2.5 h.","Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15265053/),h,2.5,198573,DB00592,Piperazine
,15265053,renal clearance (CLR),"The mean renal clearance (CLR) was approximately 2 l/h, suggesting that renal excretion plays only a minor role in the elimination of unchanged BIBN 4096 BS.","Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15265053/),[l] / [h],2,198574,DB00592,Piperazine
,20953055,detection limit,The detection limit was as low as 1 pg/mL.,"Sensitive analysis of blonanserin, a novel antipsychotic agent, in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20953055/),[pg] / [ml],1,198841,DB00592,Piperazine
,2155718,t1/2,Plasma and urine concentrations of pipecuronium were also measured and the pharmacokinetic variables obtained indicated rapid initial decrease in plasma concentration (t1/2 = 7.6 minutes) followed by a longer terminal phase (t1/2 = 161 minutes).,Pharmacokinetics and cardiovascular dynamics of pipecuronium bromide during coronary artery surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155718/),min,7.6,199052,DB00592,Piperazine
,2155718,terminal phase (t1/2,Plasma and urine concentrations of pipecuronium were also measured and the pharmacokinetic variables obtained indicated rapid initial decrease in plasma concentration (t1/2 = 7.6 minutes) followed by a longer terminal phase (t1/2 = 161 minutes).,Pharmacokinetics and cardiovascular dynamics of pipecuronium bromide during coronary artery surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155718/),min,161,199053,DB00592,Piperazine
,2155718,central compartment volume,The central compartment volume was 102 +/- 24 ml.kg-1 and plasma clearance was 1.8 +/- 0.4 ml.kg-1 min-1.,Pharmacokinetics and cardiovascular dynamics of pipecuronium bromide during coronary artery surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155718/),[ml] / [kg],102,199054,DB00592,Piperazine
,2155718,plasma clearance,The central compartment volume was 102 +/- 24 ml.kg-1 and plasma clearance was 1.8 +/- 0.4 ml.kg-1 min-1.,Pharmacokinetics and cardiovascular dynamics of pipecuronium bromide during coronary artery surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155718/),[ml] / [kg·min],1.8,199055,DB00592,Piperazine
,2576358,peak concentration,After intravenous administration of 10 mg picumast dihydrochloride a peak concentration of 182 ng/ml was achieved at the end of the 1 h infusion.,Pharmacokinetics of picumast dihydrochloride and its active metabolites M1 and M2 in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576358/),[ng] / [ml],182,199206,DB00592,Piperazine
,2576358,Vz,"Picumast dihydrochloride was extensively distributed to the tissues (Vz = 130 l) and almost exclusively eliminated by hepatic metabolism (total clearance 95 ml/min, amount of unchanged compound excreted in urine below detection limit).",Pharmacokinetics of picumast dihydrochloride and its active metabolites M1 and M2 in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576358/),l,130,199207,DB00592,Piperazine
,2576358,total clearance,"Picumast dihydrochloride was extensively distributed to the tissues (Vz = 130 l) and almost exclusively eliminated by hepatic metabolism (total clearance 95 ml/min, amount of unchanged compound excreted in urine below detection limit).",Pharmacokinetics of picumast dihydrochloride and its active metabolites M1 and M2 in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576358/),[ml] / [min],95,199208,DB00592,Piperazine
,2576358,elimination half-life,Median elimination half-life was 16.5 h.,Pharmacokinetics of picumast dihydrochloride and its active metabolites M1 and M2 in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576358/),h,16.5,199209,DB00592,Piperazine
,2576358,absolute bioavailability,The absolute bioavailability reached 57%.,Pharmacokinetics of picumast dihydrochloride and its active metabolites M1 and M2 in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576358/),%,57,199210,DB00592,Piperazine
,2576358,relative bioavailability,The relative bioavailability of picumast dihydrochloride was 20% higher after a meal.,Pharmacokinetics of picumast dihydrochloride and its active metabolites M1 and M2 in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576358/),%,20,199211,DB00592,Piperazine
,2576358,maximum concentrations,After a 20 mg oral dose maximum concentrations between 129 and 284 ng/ml were achieved within 1.3 h.,Pharmacokinetics of picumast dihydrochloride and its active metabolites M1 and M2 in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576358/),[ng] / [ml],129 and 284,199212,DB00592,Piperazine
,2576358,elimination half-life,The elimination half-life ranged from 10-26 h.,Pharmacokinetics of picumast dihydrochloride and its active metabolites M1 and M2 in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576358/),h,10-26,199213,DB00592,Piperazine
,2576358,renal clearance,"The renal clearance was determined as 28 and 0.5 ml/min for M1 and M2, resp.",Pharmacokinetics of picumast dihydrochloride and its active metabolites M1 and M2 in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576358/),[ml] / [min],28,199214,DB00592,Piperazine
,2576358,renal clearance,"The renal clearance was determined as 28 and 0.5 ml/min for M1 and M2, resp.",Pharmacokinetics of picumast dihydrochloride and its active metabolites M1 and M2 in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576358/),[ml] / [min],0.5,199215,DB00592,Piperazine
,25987616,MICs,"Here, we report the synthesis and characterization of the pyrrole-benzothiazinones PyrBTZ01 and PyrBTZ02, non-nitro-benzothiazinones that retain significant antimycobacterial activity, with MICs of 0.16 μg/ml against M. tuberculosis.",The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosis. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987616/),[μg] / [ml],0.16,199259,DB00592,Piperazine
<,25987616,50% inhibitory concentration (IC50),These compounds inhibit DprE1 with 50% inhibitory concentration (IC50) values of <8 μM and present favorable in vitro absorption-distribution-metabolism-excretion/toxicity (ADME/T) and in vivo pharmacokinetic profiles.,The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosis. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987616/),μM,8,199260,DB00592,Piperazine
,32334935,clearance,The in vitro metabolic study exhibited a high clearance value (720 μL/min/mg protein) of 1 using human liver microsomes.,"Syntheses and pharmacokinetic evaluations of four metabolites of 2-(4-(2-((1H-benzo[d]imidazol-2-yl)thio)ethyl)piperazin-1-yl)-N-(6-methyl-2,4-bis-(methylthio)pyridin-3-yl)acetamide hydrochloride [K-604], an acyl-CoA:cholesterol O-acyltransferase-1 inhibitor. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32334935/),[μl] / [mg·min],720,199653,DB00592,Piperazine
,17963428,mean concentrations,"Ulifloxacin mean concentrations were always higher in group C than in group B patients, both in plasma (0.76 vs 0.53 microg/mL) and in gynaecological tissues, namely fallopian tube (1.38 vs 0.81 microg/g), posterior fornix (1.48 vs 1.05 microg/g), portio vaginalis (1.46 vs 1.45 microg/g) and endometrium (2.20 vs 1.39 microg/g), as expected after repeated drug administrations.",Penetration of prulifloxacin into gynaecological tissues after single and repeated oral administrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17963428/),[μg] / [ml],0.76,199654,DB00592,Piperazine
,17963428,mean concentrations,"Ulifloxacin mean concentrations were always higher in group C than in group B patients, both in plasma (0.76 vs 0.53 microg/mL) and in gynaecological tissues, namely fallopian tube (1.38 vs 0.81 microg/g), posterior fornix (1.48 vs 1.05 microg/g), portio vaginalis (1.46 vs 1.45 microg/g) and endometrium (2.20 vs 1.39 microg/g), as expected after repeated drug administrations.",Penetration of prulifloxacin into gynaecological tissues after single and repeated oral administrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17963428/),[μg] / [ml],0.53,199655,DB00592,Piperazine
,17963428,mean concentrations,"Ulifloxacin mean concentrations were always higher in group C than in group B patients, both in plasma (0.76 vs 0.53 microg/mL) and in gynaecological tissues, namely fallopian tube (1.38 vs 0.81 microg/g), posterior fornix (1.48 vs 1.05 microg/g), portio vaginalis (1.46 vs 1.45 microg/g) and endometrium (2.20 vs 1.39 microg/g), as expected after repeated drug administrations.",Penetration of prulifloxacin into gynaecological tissues after single and repeated oral administrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17963428/),μg,1.38,199656,DB00592,Piperazine
,17963428,mean concentrations,"Ulifloxacin mean concentrations were always higher in group C than in group B patients, both in plasma (0.76 vs 0.53 microg/mL) and in gynaecological tissues, namely fallopian tube (1.38 vs 0.81 microg/g), posterior fornix (1.48 vs 1.05 microg/g), portio vaginalis (1.46 vs 1.45 microg/g) and endometrium (2.20 vs 1.39 microg/g), as expected after repeated drug administrations.",Penetration of prulifloxacin into gynaecological tissues after single and repeated oral administrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17963428/),μg,0.81,199657,DB00592,Piperazine
,17963428,mean concentrations,"Ulifloxacin mean concentrations were always higher in group C than in group B patients, both in plasma (0.76 vs 0.53 microg/mL) and in gynaecological tissues, namely fallopian tube (1.38 vs 0.81 microg/g), posterior fornix (1.48 vs 1.05 microg/g), portio vaginalis (1.46 vs 1.45 microg/g) and endometrium (2.20 vs 1.39 microg/g), as expected after repeated drug administrations.",Penetration of prulifloxacin into gynaecological tissues after single and repeated oral administrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17963428/),μ,1.48,199658,DB00592,Piperazine
,17963428,mean concentrations,"Ulifloxacin mean concentrations were always higher in group C than in group B patients, both in plasma (0.76 vs 0.53 microg/mL) and in gynaecological tissues, namely fallopian tube (1.38 vs 0.81 microg/g), posterior fornix (1.48 vs 1.05 microg/g), portio vaginalis (1.46 vs 1.45 microg/g) and endometrium (2.20 vs 1.39 microg/g), as expected after repeated drug administrations.",Penetration of prulifloxacin into gynaecological tissues after single and repeated oral administrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17963428/),μ,1.05,199659,DB00592,Piperazine
,17963428,mean concentrations,"Ulifloxacin mean concentrations were always higher in group C than in group B patients, both in plasma (0.76 vs 0.53 microg/mL) and in gynaecological tissues, namely fallopian tube (1.38 vs 0.81 microg/g), posterior fornix (1.48 vs 1.05 microg/g), portio vaginalis (1.46 vs 1.45 microg/g) and endometrium (2.20 vs 1.39 microg/g), as expected after repeated drug administrations.",Penetration of prulifloxacin into gynaecological tissues after single and repeated oral administrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17963428/),[μg] / [g],1.46,199660,DB00592,Piperazine
,17963428,mean concentrations,"Ulifloxacin mean concentrations were always higher in group C than in group B patients, both in plasma (0.76 vs 0.53 microg/mL) and in gynaecological tissues, namely fallopian tube (1.38 vs 0.81 microg/g), posterior fornix (1.48 vs 1.05 microg/g), portio vaginalis (1.46 vs 1.45 microg/g) and endometrium (2.20 vs 1.39 microg/g), as expected after repeated drug administrations.",Penetration of prulifloxacin into gynaecological tissues after single and repeated oral administrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17963428/),[μg] / [g],1.45,199661,DB00592,Piperazine
,17963428,mean concentrations,"Ulifloxacin mean concentrations were always higher in group C than in group B patients, both in plasma (0.76 vs 0.53 microg/mL) and in gynaecological tissues, namely fallopian tube (1.38 vs 0.81 microg/g), posterior fornix (1.48 vs 1.05 microg/g), portio vaginalis (1.46 vs 1.45 microg/g) and endometrium (2.20 vs 1.39 microg/g), as expected after repeated drug administrations.",Penetration of prulifloxacin into gynaecological tissues after single and repeated oral administrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17963428/),[μg] / [g],2.20,199662,DB00592,Piperazine
,17963428,mean concentrations,"Ulifloxacin mean concentrations were always higher in group C than in group B patients, both in plasma (0.76 vs 0.53 microg/mL) and in gynaecological tissues, namely fallopian tube (1.38 vs 0.81 microg/g), posterior fornix (1.48 vs 1.05 microg/g), portio vaginalis (1.46 vs 1.45 microg/g) and endometrium (2.20 vs 1.39 microg/g), as expected after repeated drug administrations.",Penetration of prulifloxacin into gynaecological tissues after single and repeated oral administrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17963428/),[μg] / [g],1.39,199663,DB00592,Piperazine
,17963428,tissue/plasma ratios,The mean tissue/plasma ratios ranged between 1.5 and almost 3.,Penetration of prulifloxacin into gynaecological tissues after single and repeated oral administrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17963428/),,1.5,199664,DB00592,Piperazine
,17963428,tissue/plasma ratios,The mean tissue/plasma ratios ranged between 1.5 and almost 3.,Penetration of prulifloxacin into gynaecological tissues after single and repeated oral administrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17963428/),,3,199665,DB00592,Piperazine
,18553235,progression-free survival time,The median progression-free survival time was 96 weeks.,Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18553235/),weeks,96,200082,DB00592,Piperazine
,25271258,brain-to-plasma ratio,"In this study, we characterized JNJ-42253432 [2-methyl-N-([1-(4-phenylpiperazin-1-yl)cyclohexyl]methyl)-1,2,3,4-tetrahydroisoquinoline-5-carboxamide] as a centrally permeable (brain-to-plasma ratio of 1), high-affinity P2X7 antagonist with desirable pharmacokinetic and pharmacodynamic properties for in vivo testing in rodents.",Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25271258/),,1,200086,DB00592,Piperazine
,25271258,p,JNJ-42253432 is a high-affinity antagonist for the rat (pKi 9.1 ± 0.07) and human (pKi 7.9 ± 0.08) P2X7 channel.,Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25271258/),,9.1,200087,DB00592,Piperazine
,25271258,p,JNJ-42253432 is a high-affinity antagonist for the rat (pKi 9.1 ± 0.07) and human (pKi 7.9 ± 0.08) P2X7 channel.,Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25271258/),,7.9,200088,DB00592,Piperazine
,25271258,ED50,"When dosed in rats, JNJ-42253432 occupied the brain P2X7 channel with an ED50 of 0.3 mg/kg, corresponding to a mean plasma concentration of 42 ng/ml.",Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25271258/),[mg] / [kg],0.3,200089,DB00592,Piperazine
,25271258,ED50,"At higher doses/exposure, JNJ-42253432 also increased serotonin levels in the rat brain, which is due to antagonism of the serotonin transporter (SERT) resulting in an ED50 of 10 mg/kg for SERT occupancy.",Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25271258/),[mg] / [kg],10,200090,DB00592,Piperazine
,11932959,C(max),"Comparing a 15 mg/kg dose, cyclosporine C(max) (mean+/-SD 1.12+/-0.16 microg/ml) and AUC(0-6) (5.34+/-0.71 microg h/ml) were 50% lower when propylene glycol was used as gavage vehicle instead of saline (2.19+/-0.94 microg/ml and 9.52+/-2.52 microg h/ml, respectively).",Minimal effect of ketoconazole on cyclosporine (SangCyA) oral absorption and first-pass metabolism in rats: evidence of a significant vehicle effect on SangCyA absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11932959/),[μg] / [ml],1.12,200255,DB00592,Piperazine
,11932959,AUC(0-6),"Comparing a 15 mg/kg dose, cyclosporine C(max) (mean+/-SD 1.12+/-0.16 microg/ml) and AUC(0-6) (5.34+/-0.71 microg h/ml) were 50% lower when propylene glycol was used as gavage vehicle instead of saline (2.19+/-0.94 microg/ml and 9.52+/-2.52 microg h/ml, respectively).",Minimal effect of ketoconazole on cyclosporine (SangCyA) oral absorption and first-pass metabolism in rats: evidence of a significant vehicle effect on SangCyA absorption. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11932959/),[h·μg] / [ml],5.34,200256,DB00592,Piperazine
,11932959,AUC(0-6),"Comparing a 15 mg/kg dose, cyclosporine C(max) (mean+/-SD 1.12+/-0.16 microg/ml) and AUC(0-6) (5.34+/-0.71 microg h/ml) were 50% lower when propylene glycol was used as gavage vehicle instead of saline (2.19+/-0.94 microg/ml and 9.52+/-2.52 microg h/ml, respectively).",Minimal effect of ketoconazole on cyclosporine (SangCyA) oral absorption and first-pass metabolism in rats: evidence of a significant vehicle effect on SangCyA absorption. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11932959/),[μg] / [ml],2.19,200257,DB00592,Piperazine
,11932959,AUC(0-6),"Comparing a 15 mg/kg dose, cyclosporine C(max) (mean+/-SD 1.12+/-0.16 microg/ml) and AUC(0-6) (5.34+/-0.71 microg h/ml) were 50% lower when propylene glycol was used as gavage vehicle instead of saline (2.19+/-0.94 microg/ml and 9.52+/-2.52 microg h/ml, respectively).",Minimal effect of ketoconazole on cyclosporine (SangCyA) oral absorption and first-pass metabolism in rats: evidence of a significant vehicle effect on SangCyA absorption. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11932959/),[h·μg] / [ml],9.52,200258,DB00592,Piperazine
,11932959,T(max),"Ketoconazole increased cyclosporine C(max) and AUC(0-6) by 50-60%, regardless of the vehicle or the cyclosporine dose, without altering T(max) (2-3 h).",Minimal effect of ketoconazole on cyclosporine (SangCyA) oral absorption and first-pass metabolism in rats: evidence of a significant vehicle effect on SangCyA absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11932959/),h,2-3,200259,DB00592,Piperazine
,23340005,PFS times,"The median PFS times were 11.9 weeks and 35.9 weeks, respectively.",Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23340005/),weeks,11.9,200375,DB00592,Piperazine
,23340005,PFS times,"The median PFS times were 11.9 weeks and 35.9 weeks, respectively.",Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23340005/),weeks,35.9,200376,DB00592,Piperazine
,23340005,response rates,"PSA response rates were 0% and 14.3%, respectively.",Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23340005/),%,0,200377,DB00592,Piperazine
,23340005,response rates,"PSA response rates were 0% and 14.3%, respectively.",Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23340005/),%,14.3,200378,DB00592,Piperazine
,27810562,absolute bioavailability (BA),"Although the oral absorption of crystalline ITZ was negligible, SMSD/ITZ showed an improved pharmacokinetic profile in normal rats, with an absolute bioavailability (BA) of 2.9%, and even 6.3% in the hypochlorhydric model.",Improved oral absorption profile of itraconazole in hypochlorhydria by self-micellizing solid dispersion approach. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27810562/),%,2.9,200449,DB00592,Piperazine
,27810562,absolute bioavailability (BA),"Although the oral absorption of crystalline ITZ was negligible, SMSD/ITZ showed an improved pharmacokinetic profile in normal rats, with an absolute bioavailability (BA) of 2.9%, and even 6.3% in the hypochlorhydric model.",Improved oral absorption profile of itraconazole in hypochlorhydria by self-micellizing solid dispersion approach. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27810562/),%,6.3,200450,DB00592,Piperazine
,38121,rate of biliary elimination,For the rat the rate of biliary elimination was 16.6% of the administered dose/hour; for the rabbit this rate was 5.6%/hour.,"Studies on the absorption, distribution and elimination of 6-o-chlorophenyl-2,4-dihydro-2(N-methyl-piperazin-1-yl)-methylene-8-nitro-1H-imidazo[1,2-a] [1,4]benzodiazepin-1-one methanesulphonate in the male rat and rabbit. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/38121/),[%] / [h],5.6,200532,DB00592,Piperazine
,38121,rate,For the rat the rate of biliary elimination was 16.6% of the administered dose/hour; for the rabbit this rate was 5.6%/hour.,"Studies on the absorption, distribution and elimination of 6-o-chlorophenyl-2,4-dihydro-2(N-methyl-piperazin-1-yl)-methylene-8-nitro-1H-imidazo[1,2-a] [1,4]benzodiazepin-1-one methanesulphonate in the male rat and rabbit. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/38121/),[%] / [h],5.6,200533,DB00592,Piperazine
,38121,Recovery,Recovery of administered radioactivity during 0-24 hours for urine and faeces respectively was 4.8% and 69% for the rat and 23.2% and 10.9% for the rabbit.,"Studies on the absorption, distribution and elimination of 6-o-chlorophenyl-2,4-dihydro-2(N-methyl-piperazin-1-yl)-methylene-8-nitro-1H-imidazo[1,2-a] [1,4]benzodiazepin-1-one methanesulphonate in the male rat and rabbit. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/38121/),%,4.8,200534,DB00592,Piperazine
,38121,Recovery,Recovery of administered radioactivity during 0-24 hours for urine and faeces respectively was 4.8% and 69% for the rat and 23.2% and 10.9% for the rabbit.,"Studies on the absorption, distribution and elimination of 6-o-chlorophenyl-2,4-dihydro-2(N-methyl-piperazin-1-yl)-methylene-8-nitro-1H-imidazo[1,2-a] [1,4]benzodiazepin-1-one methanesulphonate in the male rat and rabbit. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/38121/),%,69,200535,DB00592,Piperazine
,38121,Recovery,Recovery of administered radioactivity during 0-24 hours for urine and faeces respectively was 4.8% and 69% for the rat and 23.2% and 10.9% for the rabbit.,"Studies on the absorption, distribution and elimination of 6-o-chlorophenyl-2,4-dihydro-2(N-methyl-piperazin-1-yl)-methylene-8-nitro-1H-imidazo[1,2-a] [1,4]benzodiazepin-1-one methanesulphonate in the male rat and rabbit. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/38121/),%,23.2,200536,DB00592,Piperazine
,38121,Recovery,Recovery of administered radioactivity during 0-24 hours for urine and faeces respectively was 4.8% and 69% for the rat and 23.2% and 10.9% for the rabbit.,"Studies on the absorption, distribution and elimination of 6-o-chlorophenyl-2,4-dihydro-2(N-methyl-piperazin-1-yl)-methylene-8-nitro-1H-imidazo[1,2-a] [1,4]benzodiazepin-1-one methanesulphonate in the male rat and rabbit. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/38121/),%,10.9,200537,DB00592,Piperazine
,12709342,maximum concentration in serum (C(max)),"The mean values (+/- standard deviations) for the maximum concentration in serum (C(max)) of ritonavir, the area under the concentration-time curve from 0 to 12 h (AUC(0-12)), and the minimum concentration in serum (C(min)) of ritonavir before the addition of delavirdine were 14.8 +/- 6.7 micro M, 94 +/- 36 micro M. h, and 3.6 +/- 2.1 micro M, respectively.",Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709342/),μM,14.8,200714,DB00592,Piperazine
,12709342,area under the concentration-time curve from 0 to 12 h (AUC(0-12)),"The mean values (+/- standard deviations) for the maximum concentration in serum (C(max)) of ritonavir, the area under the concentration-time curve from 0 to 12 h (AUC(0-12)), and the minimum concentration in serum (C(min)) of ritonavir before the addition of delavirdine were 14.8 +/- 6.7 micro M, 94 +/- 36 micro M. h, and 3.6 +/- 2.1 micro M, respectively.",Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709342/),h·μM,94,200715,DB00592,Piperazine
,12709342,minimum concentration in serum (C(min)),"The mean values (+/- standard deviations) for the maximum concentration in serum (C(max)) of ritonavir, the area under the concentration-time curve from 0 to 12 h (AUC(0-12)), and the minimum concentration in serum (C(min)) of ritonavir before the addition of delavirdine were 14.8 +/- 6.7 micro M, 94 +/- 36 micro M. h, and 3.6 +/- 2.1 micro M, respectively.",Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709342/),μM,3.6,200716,DB00592,Piperazine
,12709342,C(max),"Delavirdine pharmacokinetic parameters in the presence of ritonavir included a C(max) of 23 +/- 16 micro M, an AUC(0-8) of 114 +/- 75 micro M. h, and a C(min) of 9.1 +/- 7.5 micro M.",Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709342/),μM,23,200717,DB00592,Piperazine
,12709342,AUC(0-8),"Delavirdine pharmacokinetic parameters in the presence of ritonavir included a C(max) of 23 +/- 16 micro M, an AUC(0-8) of 114 +/- 75 micro M. h, and a C(min) of 9.1 +/- 7.5 micro M.",Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709342/),h·μM,114,200718,DB00592,Piperazine
,12709342,C(min),"Delavirdine pharmacokinetic parameters in the presence of ritonavir included a C(max) of 23 +/- 16 micro M, an AUC(0-8) of 114 +/- 75 micro M. h, and a C(min) of 9.1 +/- 7.5 micro M.",Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709342/),μM,9.1,200719,DB00592,Piperazine
,14697925,peak,Mean peak and trough itraconazole levels were 1.64 +/- 0.82 and 1.23 +/- 0.90 microg/mL respectively.,Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14697925/),[μg] / [ml],1.64,200851,DB00592,Piperazine
,14697925,trough itraconazole levels,Mean peak and trough itraconazole levels were 1.64 +/- 0.82 and 1.23 +/- 0.90 microg/mL respectively.,Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14697925/),[μg] / [ml],1.23,200852,DB00592,Piperazine
,14697925,peak,"Mean peak and trough hydroxy-itraconazole levels were 2.37 +/- 1.55 and 2.20 +/- 1.48 microg/mL, respectively.",Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14697925/),[μg] / [ml],2.37,200853,DB00592,Piperazine
,14697925,trough hydroxy,"Mean peak and trough hydroxy-itraconazole levels were 2.37 +/- 1.55 and 2.20 +/- 1.48 microg/mL, respectively.",Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14697925/),[μg] / [ml],2.20,200854,DB00592,Piperazine
,29067789,bioavailability,Absorption after i.m. application was relatively fast; the bioavailability expressed as AUCtotal was 28179 ± 4691 min.ng/mL for PC-37 and 23374 ± 4045 min.ng/mL for PC-48.,"The New Acetylcholinesterase Inhibitors PC-37 and PC-48 (7-Methoxytacrine-Donepezil-Like Compounds): Characterization of Their Metabolites in Human Liver Microsomes, Pharmacokinetics and In Vivo Formation of the Major Metabolites in Rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29067789/),[min·ng] / [ml],28179,201245,DB00592,Piperazine
,29067789,bioavailability,Absorption after i.m. application was relatively fast; the bioavailability expressed as AUCtotal was 28179 ± 4691 min.ng/mL for PC-37 and 23374 ± 4045 min.ng/mL for PC-48.,"The New Acetylcholinesterase Inhibitors PC-37 and PC-48 (7-Methoxytacrine-Donepezil-Like Compounds): Characterization of Their Metabolites in Human Liver Microsomes, Pharmacokinetics and In Vivo Formation of the Major Metabolites in Rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29067789/),[min·ng] / [ml],23374,201246,DB00592,Piperazine
,29067789,AUCtotal,Absorption after i.m. application was relatively fast; the bioavailability expressed as AUCtotal was 28179 ± 4691 min.ng/mL for PC-37 and 23374 ± 4045 min.ng/mL for PC-48.,"The New Acetylcholinesterase Inhibitors PC-37 and PC-48 (7-Methoxytacrine-Donepezil-Like Compounds): Characterization of Their Metabolites in Human Liver Microsomes, Pharmacokinetics and In Vivo Formation of the Major Metabolites in Rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29067789/),[min·ng] / [ml],28179,201247,DB00592,Piperazine
,29067789,AUCtotal,Absorption after i.m. application was relatively fast; the bioavailability expressed as AUCtotal was 28179 ± 4691 min.ng/mL for PC-37 and 23374 ± 4045 min.ng/mL for PC-48.,"The New Acetylcholinesterase Inhibitors PC-37 and PC-48 (7-Methoxytacrine-Donepezil-Like Compounds): Characterization of Their Metabolites in Human Liver Microsomes, Pharmacokinetics and In Vivo Formation of the Major Metabolites in Rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29067789/),[min·ng] / [ml],23374,201248,DB00592,Piperazine
,33356314,zeta potential,"Results displayed that IMS-LF-LCNPs presented an optimum particle size of 120.40 ± 2.75 nm, a zeta potential of +12.5 ± 0.23 mV, and 73.94 ± 2.69% release.",Fabrication of Imatinib Mesylate-Loaded Lactoferrin-Modified PEGylated Liquid Crystalline Nanoparticles for Mitochondrial-Dependent Apoptosis in Hepatocellular Carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33356314/),m,12.5,201257,DB00592,Piperazine
,26010440,IC50,"Moreover, GLY inhibited CYP3A activity with an IC50 of 20.1 ± 10.7 μM via a mixed inhibition mechanism.",Modulation of Cytochrome P450 Activity by 18β-Glycyrrhetic Acid and its Consequence on Buspirone Pharmacokinetics in Rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26010440/),μM,20.1,201440,DB00592,Piperazine
,19726292,C(max),"For the test and reference preparation, the pharmacokinetics parameter C(max) was 170.7-/+71.3 and 174.4-/+81.6 ng/ml, t(max) 3.73-/+1.87 and 3.69-/+1.84 h, t((1/2)) 5.57-/+1.62 and 5.61-/+1.73 h, AUC(0-t) 1273-/+252.3 and 1296-/+266.9 ng.h.ml(-1), and AUC(0-infinity)1396-/+276.9 and 1407-/+281.5 ng.h.ml(-1), respectively, with the relative bioavailability of (98.3-/+12.6)%.",[Pharmacokinetics and relative bioavailability of ziprasidone tablets in Chinese healthy volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726292/),[ng] / [ml],170.7,201651,DB00592,Piperazine
,19726292,C(max),"For the test and reference preparation, the pharmacokinetics parameter C(max) was 170.7-/+71.3 and 174.4-/+81.6 ng/ml, t(max) 3.73-/+1.87 and 3.69-/+1.84 h, t((1/2)) 5.57-/+1.62 and 5.61-/+1.73 h, AUC(0-t) 1273-/+252.3 and 1296-/+266.9 ng.h.ml(-1), and AUC(0-infinity)1396-/+276.9 and 1407-/+281.5 ng.h.ml(-1), respectively, with the relative bioavailability of (98.3-/+12.6)%.",[Pharmacokinetics and relative bioavailability of ziprasidone tablets in Chinese healthy volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726292/),[ng] / [ml],174.4,201652,DB00592,Piperazine
,19726292,t(max),"For the test and reference preparation, the pharmacokinetics parameter C(max) was 170.7-/+71.3 and 174.4-/+81.6 ng/ml, t(max) 3.73-/+1.87 and 3.69-/+1.84 h, t((1/2)) 5.57-/+1.62 and 5.61-/+1.73 h, AUC(0-t) 1273-/+252.3 and 1296-/+266.9 ng.h.ml(-1), and AUC(0-infinity)1396-/+276.9 and 1407-/+281.5 ng.h.ml(-1), respectively, with the relative bioavailability of (98.3-/+12.6)%.",[Pharmacokinetics and relative bioavailability of ziprasidone tablets in Chinese healthy volunteers]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726292/),h,3.73,201653,DB00592,Piperazine
,19726292,t(max),"For the test and reference preparation, the pharmacokinetics parameter C(max) was 170.7-/+71.3 and 174.4-/+81.6 ng/ml, t(max) 3.73-/+1.87 and 3.69-/+1.84 h, t((1/2)) 5.57-/+1.62 and 5.61-/+1.73 h, AUC(0-t) 1273-/+252.3 and 1296-/+266.9 ng.h.ml(-1), and AUC(0-infinity)1396-/+276.9 and 1407-/+281.5 ng.h.ml(-1), respectively, with the relative bioavailability of (98.3-/+12.6)%.",[Pharmacokinetics and relative bioavailability of ziprasidone tablets in Chinese healthy volunteers]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726292/),h,3.69,201654,DB00592,Piperazine
,19726292,t((1/2)),"For the test and reference preparation, the pharmacokinetics parameter C(max) was 170.7-/+71.3 and 174.4-/+81.6 ng/ml, t(max) 3.73-/+1.87 and 3.69-/+1.84 h, t((1/2)) 5.57-/+1.62 and 5.61-/+1.73 h, AUC(0-t) 1273-/+252.3 and 1296-/+266.9 ng.h.ml(-1), and AUC(0-infinity)1396-/+276.9 and 1407-/+281.5 ng.h.ml(-1), respectively, with the relative bioavailability of (98.3-/+12.6)%.",[Pharmacokinetics and relative bioavailability of ziprasidone tablets in Chinese healthy volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726292/),h,5.57,201655,DB00592,Piperazine
,19726292,t((1/2)),"For the test and reference preparation, the pharmacokinetics parameter C(max) was 170.7-/+71.3 and 174.4-/+81.6 ng/ml, t(max) 3.73-/+1.87 and 3.69-/+1.84 h, t((1/2)) 5.57-/+1.62 and 5.61-/+1.73 h, AUC(0-t) 1273-/+252.3 and 1296-/+266.9 ng.h.ml(-1), and AUC(0-infinity)1396-/+276.9 and 1407-/+281.5 ng.h.ml(-1), respectively, with the relative bioavailability of (98.3-/+12.6)%.",[Pharmacokinetics and relative bioavailability of ziprasidone tablets in Chinese healthy volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726292/),h,5.61,201656,DB00592,Piperazine
,19726292,AUC(0-t),"For the test and reference preparation, the pharmacokinetics parameter C(max) was 170.7-/+71.3 and 174.4-/+81.6 ng/ml, t(max) 3.73-/+1.87 and 3.69-/+1.84 h, t((1/2)) 5.57-/+1.62 and 5.61-/+1.73 h, AUC(0-t) 1273-/+252.3 and 1296-/+266.9 ng.h.ml(-1), and AUC(0-infinity)1396-/+276.9 and 1407-/+281.5 ng.h.ml(-1), respectively, with the relative bioavailability of (98.3-/+12.6)%.",[Pharmacokinetics and relative bioavailability of ziprasidone tablets in Chinese healthy volunteers]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726292/),[h·ng] / [ml],1273,201657,DB00592,Piperazine
,19726292,AUC(0-t),"For the test and reference preparation, the pharmacokinetics parameter C(max) was 170.7-/+71.3 and 174.4-/+81.6 ng/ml, t(max) 3.73-/+1.87 and 3.69-/+1.84 h, t((1/2)) 5.57-/+1.62 and 5.61-/+1.73 h, AUC(0-t) 1273-/+252.3 and 1296-/+266.9 ng.h.ml(-1), and AUC(0-infinity)1396-/+276.9 and 1407-/+281.5 ng.h.ml(-1), respectively, with the relative bioavailability of (98.3-/+12.6)%.",[Pharmacokinetics and relative bioavailability of ziprasidone tablets in Chinese healthy volunteers]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726292/),[h·ng] / [ml],1296,201658,DB00592,Piperazine
,19726292,AUC(0-infinity),"For the test and reference preparation, the pharmacokinetics parameter C(max) was 170.7-/+71.3 and 174.4-/+81.6 ng/ml, t(max) 3.73-/+1.87 and 3.69-/+1.84 h, t((1/2)) 5.57-/+1.62 and 5.61-/+1.73 h, AUC(0-t) 1273-/+252.3 and 1296-/+266.9 ng.h.ml(-1), and AUC(0-infinity)1396-/+276.9 and 1407-/+281.5 ng.h.ml(-1), respectively, with the relative bioavailability of (98.3-/+12.6)%.",[Pharmacokinetics and relative bioavailability of ziprasidone tablets in Chinese healthy volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726292/),[h·ng] / [ml],1396,201659,DB00592,Piperazine
,19726292,AUC(0-infinity),"For the test and reference preparation, the pharmacokinetics parameter C(max) was 170.7-/+71.3 and 174.4-/+81.6 ng/ml, t(max) 3.73-/+1.87 and 3.69-/+1.84 h, t((1/2)) 5.57-/+1.62 and 5.61-/+1.73 h, AUC(0-t) 1273-/+252.3 and 1296-/+266.9 ng.h.ml(-1), and AUC(0-infinity)1396-/+276.9 and 1407-/+281.5 ng.h.ml(-1), respectively, with the relative bioavailability of (98.3-/+12.6)%.",[Pharmacokinetics and relative bioavailability of ziprasidone tablets in Chinese healthy volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726292/),[h·ng] / [ml],1407,201660,DB00592,Piperazine
,19726292,relative bioavailability,"For the test and reference preparation, the pharmacokinetics parameter C(max) was 170.7-/+71.3 and 174.4-/+81.6 ng/ml, t(max) 3.73-/+1.87 and 3.69-/+1.84 h, t((1/2)) 5.57-/+1.62 and 5.61-/+1.73 h, AUC(0-t) 1273-/+252.3 and 1296-/+266.9 ng.h.ml(-1), and AUC(0-infinity)1396-/+276.9 and 1407-/+281.5 ng.h.ml(-1), respectively, with the relative bioavailability of (98.3-/+12.6)%.",[Pharmacokinetics and relative bioavailability of ziprasidone tablets in Chinese healthy volunteers]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726292/),%,98.3,201661,DB00592,Piperazine
,2893696,Biliary excretion,Biliary excretion of radioactivity averaged 54.3 +/- 18.0% of the dose over a 7.5-8-hr period in pentobarbital-anesthesized rats.,The disposition and pharmacokinetics of ketoconazole in the rat. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2893696/),%,54.3,202272,DB00592,Piperazine
,2893696,VD,"In eight male rats, the plasma pharmacokinetics of ketoconazole, as determined by an HPLC assay with fluorescence detection, were as follows: VD = 655 +/- 91 ml/kg, Cl = 14.4 +/- 5.1 ml/min/kg, and t 1/2 = 35.0 +/- 12.3 min.",The disposition and pharmacokinetics of ketoconazole in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2893696/),[ml] / [kg],655,202273,DB00592,Piperazine
,2893696,Cl,"In eight male rats, the plasma pharmacokinetics of ketoconazole, as determined by an HPLC assay with fluorescence detection, were as follows: VD = 655 +/- 91 ml/kg, Cl = 14.4 +/- 5.1 ml/min/kg, and t 1/2 = 35.0 +/- 12.3 min.",The disposition and pharmacokinetics of ketoconazole in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2893696/),[ml] / [kg·min],14.4,202274,DB00592,Piperazine
,2893696,t 1/2,"In eight male rats, the plasma pharmacokinetics of ketoconazole, as determined by an HPLC assay with fluorescence detection, were as follows: VD = 655 +/- 91 ml/kg, Cl = 14.4 +/- 5.1 ml/min/kg, and t 1/2 = 35.0 +/- 12.3 min.",The disposition and pharmacokinetics of ketoconazole in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2893696/),min,35.0,202275,DB00592,Piperazine
,2893696,time to peak,"The time to peak was 30-60 min, and the bioavailability was 35.8 +/- 3.55%.",The disposition and pharmacokinetics of ketoconazole in the rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2893696/),min,30-60,202276,DB00592,Piperazine
,2893696,bioavailability,"The time to peak was 30-60 min, and the bioavailability was 35.8 +/- 3.55%.",The disposition and pharmacokinetics of ketoconazole in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2893696/),%,35.8,202277,DB00592,Piperazine
,8094094,specific activity,"Radiochemical yields of 15% at the end of bombardment (EOB) for the racemic mixture, and 5% for each enantiomer with a specific activity of 2-5 Ci/mumol at EOB were obtained.",Synthesis and PET studies of fluorine-18-BMY 14802: a potential antipsychotic drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8094094/),c,2-5,202286,DB00592,Piperazine
,23301703,K(d),"It tightly bound to Bcr-Abl(WT) and Bcr-Abl(T315I) with K(d) values of 0.32 and 0.71 nM, respectively, and strongly inhibited the kinase functions with nanomolar IC(50) values.",Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23301703/),nM,0.32,202317,DB00592,Piperazine
,23301703,K(d),"It tightly bound to Bcr-Abl(WT) and Bcr-Abl(T315I) with K(d) values of 0.32 and 0.71 nM, respectively, and strongly inhibited the kinase functions with nanomolar IC(50) values.",Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23301703/),nM,0.71,202318,DB00592,Piperazine
,23301703,IC(50),"The compound potently suppressed proliferation of Bcr-Abl-positive K562 and Ku812 human CML cells with IC(50) values of 0.2 and 0.13 nM, respectively.",Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23301703/),nM,0.2,202319,DB00592,Piperazine
,23301703,IC(50),"The compound potently suppressed proliferation of Bcr-Abl-positive K562 and Ku812 human CML cells with IC(50) values of 0.2 and 0.13 nM, respectively.",Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23301703/),nM,0.13,202320,DB00592,Piperazine
,23301703,oral bioavailability,"It also displayed good oral bioavailability (48.7%), a reasonable half-life (10.6 h), and promising in vivo antitumor efficacy.",Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23301703/),%,48.7,202321,DB00592,Piperazine
,23301703,half-life,"It also displayed good oral bioavailability (48.7%), a reasonable half-life (10.6 h), and promising in vivo antitumor efficacy.",Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23301703/),h,10.6,202322,DB00592,Piperazine
,8830062,peak concentration,"Mean triazolam peak concentration values increased (p = 0.003) from 2.33 to 3.88 ng/ml when triazolam was administered alone and in combination with nefazodone, respectively.",Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830062/),[ng] / [ml],2.33,202464,DB00592,Piperazine
,8830062,peak concentration,"Mean triazolam peak concentration values increased (p = 0.003) from 2.33 to 3.88 ng/ml when triazolam was administered alone and in combination with nefazodone, respectively.",Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830062/),[ng] / [ml],3.88,202465,DB00592,Piperazine
,8830062,area under the curve,Corresponding mean triazolam area under the curve values increased (p < 0.001) from 8.14 to 31.74 ng.h/ml.,Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830062/),[h·ng] / [ml],8.14,202466,DB00592,Piperazine
,8830062,area under the curve,Corresponding mean triazolam area under the curve values increased (p < 0.001) from 8.14 to 31.74 ng.h/ml.,Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830062/),[h·ng] / [ml],31.74,202467,DB00592,Piperazine
,8830062,plasma protein binding,The plasma protein binding of triazolam was approximately 85% when triazolam was given alone and when given concurrently with nefazodone.,Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830062/),%,85,202468,DB00592,Piperazine
,30828771,AUC ratios,"Ketoconazole significantly increased exposure, with geometric mean AUC ratios of 1.90 (apixaban), 2.35 (edoxaban) and 2.27 (rivaroxaban).",Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30828771/),,1.90,202533,DB00592,Piperazine
,30828771,AUC ratios,"Ketoconazole significantly increased exposure, with geometric mean AUC ratios of 1.90 (apixaban), 2.35 (edoxaban) and 2.27 (rivaroxaban).",Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30828771/),,2.35,202534,DB00592,Piperazine
,30828771,AUC ratios,"Ketoconazole significantly increased exposure, with geometric mean AUC ratios of 1.90 (apixaban), 2.35 (edoxaban) and 2.27 (rivaroxaban).",Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30828771/),,2.27,202535,DB00592,Piperazine
,12454950,binding potential (BP),[(11)C]-DASB binding potential (BP) values ranged from about 0.2 in the neocortex to 2.2 in the midbrain.,"[11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12454950/),,0.2,202649,DB00592,Piperazine
,12454950,binding potential (BP),[(11)C]-DASB binding potential (BP) values ranged from about 0.2 in the neocortex to 2.2 in the midbrain.,"[11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12454950/),,2.2,202650,DB00592,Piperazine
,1027565,maximum level,The maximum level of azabutyron in the plasma (27 gamma/ml) was recorded 5 minutes after introduction of the drug.,"[Pharmacokinetic study of the neuroleptic, azabutyrone]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1027565/),[gamma] / [ml],27,202729,DB00592,Piperazine
,31996053,tmax,Pharmacokinetic results showed shorter tmax (0.585 vs. 1.375 h) and higher Cmax (0.113 vs. 0.0765 μg/mL) for MCGs than conventional tablets.,Development of medicated chewing gum of taste masked levocetirizine dihydrochloride using different gum bases: in vitro and in vivo evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31996053/),h,0.585,202759,DB00592,Piperazine
,31996053,tmax,Pharmacokinetic results showed shorter tmax (0.585 vs. 1.375 h) and higher Cmax (0.113 vs. 0.0765 μg/mL) for MCGs than conventional tablets.,Development of medicated chewing gum of taste masked levocetirizine dihydrochloride using different gum bases: in vitro and in vivo evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31996053/),h,1.375,202760,DB00592,Piperazine
,31996053,Cmax,Pharmacokinetic results showed shorter tmax (0.585 vs. 1.375 h) and higher Cmax (0.113 vs. 0.0765 μg/mL) for MCGs than conventional tablets.,Development of medicated chewing gum of taste masked levocetirizine dihydrochloride using different gum bases: in vitro and in vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31996053/),[μg] / [ml],0.113,202761,DB00592,Piperazine
,31996053,Cmax,Pharmacokinetic results showed shorter tmax (0.585 vs. 1.375 h) and higher Cmax (0.113 vs. 0.0765 μg/mL) for MCGs than conventional tablets.,Development of medicated chewing gum of taste masked levocetirizine dihydrochloride using different gum bases: in vitro and in vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31996053/),[μg] / [ml],0.0765,202762,DB00592,Piperazine
,16035131,AUC,"After oral administration of DA-8159 to 16-week-old SHRs, the AUC values of both DA-8159 (157 versus 103 microg min/ml) and DA-8164 (215 versus 141 microg min/ml) were significantly greater, but the values of DA-8159 were reversed in 16-week-old DOCA-salt rats (125 versus 200 microg min/ml).","Pharmacokinetic changes of DA-8159, a new erectogenic, and one of its metabolites, DA-8164 after intravenous and oral administration of DA-8159 to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16035131/),[min·μg] / [ml],157,203031,DB00592,Piperazine
,16035131,AUC,"After oral administration of DA-8159 to 16-week-old SHRs, the AUC values of both DA-8159 (157 versus 103 microg min/ml) and DA-8164 (215 versus 141 microg min/ml) were significantly greater, but the values of DA-8159 were reversed in 16-week-old DOCA-salt rats (125 versus 200 microg min/ml).","Pharmacokinetic changes of DA-8159, a new erectogenic, and one of its metabolites, DA-8164 after intravenous and oral administration of DA-8159 to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16035131/),[min·μg] / [ml],103,203032,DB00592,Piperazine
,16035131,AUC,"After oral administration of DA-8159 to 16-week-old SHRs, the AUC values of both DA-8159 (157 versus 103 microg min/ml) and DA-8164 (215 versus 141 microg min/ml) were significantly greater, but the values of DA-8159 were reversed in 16-week-old DOCA-salt rats (125 versus 200 microg min/ml).","Pharmacokinetic changes of DA-8159, a new erectogenic, and one of its metabolites, DA-8164 after intravenous and oral administration of DA-8159 to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16035131/),[min·μg] / [ml],215,203033,DB00592,Piperazine
,16035131,AUC,"After oral administration of DA-8159 to 16-week-old SHRs, the AUC values of both DA-8159 (157 versus 103 microg min/ml) and DA-8164 (215 versus 141 microg min/ml) were significantly greater, but the values of DA-8159 were reversed in 16-week-old DOCA-salt rats (125 versus 200 microg min/ml).","Pharmacokinetic changes of DA-8159, a new erectogenic, and one of its metabolites, DA-8164 after intravenous and oral administration of DA-8159 to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16035131/),[min·μg] / [ml],141,203034,DB00592,Piperazine
,16035131,AUC,"After oral administration of DA-8159 to 16-week-old SHRs, the AUC values of both DA-8159 (157 versus 103 microg min/ml) and DA-8164 (215 versus 141 microg min/ml) were significantly greater, but the values of DA-8159 were reversed in 16-week-old DOCA-salt rats (125 versus 200 microg min/ml).","Pharmacokinetic changes of DA-8159, a new erectogenic, and one of its metabolites, DA-8164 after intravenous and oral administration of DA-8159 to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16035131/),[min·μg] / [ml],125,203035,DB00592,Piperazine
,16035131,AUC,"After oral administration of DA-8159 to 16-week-old SHRs, the AUC values of both DA-8159 (157 versus 103 microg min/ml) and DA-8164 (215 versus 141 microg min/ml) were significantly greater, but the values of DA-8159 were reversed in 16-week-old DOCA-salt rats (125 versus 200 microg min/ml).","Pharmacokinetic changes of DA-8159, a new erectogenic, and one of its metabolites, DA-8164 after intravenous and oral administration of DA-8159 to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16035131/),[min·μg] / [ml],200,203036,DB00592,Piperazine
,28191803,clearance,"A one-compartment model with first-order absorption appropriately described the data, giving a mean (±SEM) clearance of 14.3l (±1.0) and a volume of distribution of 347 l (±62).",Population Pharmacokinetics of Imatinib and its application to the therapeutic drug monitoring: Middle East CML population. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28191803/),l,14.3,203064,DB00592,Piperazine
,28191803,volume of distribution,"A one-compartment model with first-order absorption appropriately described the data, giving a mean (±SEM) clearance of 14.3l (±1.0) and a volume of distribution of 347 l (±62).",Population Pharmacokinetics of Imatinib and its application to the therapeutic drug monitoring: Middle East CML population. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28191803/),l,347,203065,DB00592,Piperazine
,29424805,AUC0-24h,"In treatment A, average values of AUC0-24h, AUC0-∞, and Cmax were 3178 ng/h/L, 3879 ng/h/L, and 492 ng/L for blonanserin, and 1932 ng/h/L, 4208 ng/h/L, and 137 ng/L for N-deethylated blonanserin, respectively.",Effects of Alcohol on the Pharmacokinetics of Blonanserin and N-Deethylated Blonanserin in Healthy Chinese Subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29424805/),[ng] / [h·l],3178,203142,DB00592,Piperazine
,29424805,AUC0-∞,"In treatment A, average values of AUC0-24h, AUC0-∞, and Cmax were 3178 ng/h/L, 3879 ng/h/L, and 492 ng/L for blonanserin, and 1932 ng/h/L, 4208 ng/h/L, and 137 ng/L for N-deethylated blonanserin, respectively.",Effects of Alcohol on the Pharmacokinetics of Blonanserin and N-Deethylated Blonanserin in Healthy Chinese Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29424805/),[ng] / [h·l],3879,203143,DB00592,Piperazine
,29424805,AUC0-∞,"In treatment A, average values of AUC0-24h, AUC0-∞, and Cmax were 3178 ng/h/L, 3879 ng/h/L, and 492 ng/L for blonanserin, and 1932 ng/h/L, 4208 ng/h/L, and 137 ng/L for N-deethylated blonanserin, respectively.",Effects of Alcohol on the Pharmacokinetics of Blonanserin and N-Deethylated Blonanserin in Healthy Chinese Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29424805/),[ng] / [h·l],1932,203144,DB00592,Piperazine
,29424805,AUC0-∞,"In treatment A, average values of AUC0-24h, AUC0-∞, and Cmax were 3178 ng/h/L, 3879 ng/h/L, and 492 ng/L for blonanserin, and 1932 ng/h/L, 4208 ng/h/L, and 137 ng/L for N-deethylated blonanserin, respectively.",Effects of Alcohol on the Pharmacokinetics of Blonanserin and N-Deethylated Blonanserin in Healthy Chinese Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29424805/),[ng] / [h·l],4208,203145,DB00592,Piperazine
,29424805,Cmax,"In treatment A, average values of AUC0-24h, AUC0-∞, and Cmax were 3178 ng/h/L, 3879 ng/h/L, and 492 ng/L for blonanserin, and 1932 ng/h/L, 4208 ng/h/L, and 137 ng/L for N-deethylated blonanserin, respectively.",Effects of Alcohol on the Pharmacokinetics of Blonanserin and N-Deethylated Blonanserin in Healthy Chinese Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29424805/),[ng] / [l],492,203146,DB00592,Piperazine
,29424805,Cmax,"In treatment A, average values of AUC0-24h, AUC0-∞, and Cmax were 3178 ng/h/L, 3879 ng/h/L, and 492 ng/L for blonanserin, and 1932 ng/h/L, 4208 ng/h/L, and 137 ng/L for N-deethylated blonanserin, respectively.",Effects of Alcohol on the Pharmacokinetics of Blonanserin and N-Deethylated Blonanserin in Healthy Chinese Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29424805/),[ng] / [l],137,203147,DB00592,Piperazine
,16580907,renal clearance,"A pharmacokinetic study in 6 healthy male volunteers after a single dose of either cetirizine (20 mg) or pilsicainide (50 mg), or both, found that the renal clearance of each drug was significantly decreased by the coadministration of the drugs (from 475 +/- 101 mL/min to 279 +/- 117 mL/min for pilsicainide and from 189 +/- 37 mL/min to 118 +/- 28 mL/min for cetirizine; P = .008 and .009, respectively).",Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580907/),[ml] / [min],475,203570,DB00592,Piperazine
,16580907,renal clearance,"A pharmacokinetic study in 6 healthy male volunteers after a single dose of either cetirizine (20 mg) or pilsicainide (50 mg), or both, found that the renal clearance of each drug was significantly decreased by the coadministration of the drugs (from 475 +/- 101 mL/min to 279 +/- 117 mL/min for pilsicainide and from 189 +/- 37 mL/min to 118 +/- 28 mL/min for cetirizine; P = .008 and .009, respectively).",Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580907/),[ml] / [min],279,203571,DB00592,Piperazine
,16580907,renal clearance,"A pharmacokinetic study in 6 healthy male volunteers after a single dose of either cetirizine (20 mg) or pilsicainide (50 mg), or both, found that the renal clearance of each drug was significantly decreased by the coadministration of the drugs (from 475 +/- 101 mL/min to 279 +/- 117 mL/min for pilsicainide and from 189 +/- 37 mL/min to 118 +/- 28 mL/min for cetirizine; P = .008 and .009, respectively).",Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580907/),[ml] / [min],189,203572,DB00592,Piperazine
,16580907,renal clearance,"A pharmacokinetic study in 6 healthy male volunteers after a single dose of either cetirizine (20 mg) or pilsicainide (50 mg), or both, found that the renal clearance of each drug was significantly decreased by the coadministration of the drugs (from 475 +/- 101 mL/min to 279 +/- 117 mL/min for pilsicainide and from 189 +/- 37 mL/min to 118 +/- 28 mL/min for cetirizine; P = .008 and .009, respectively).",Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580907/),[ml] / [min],118,203573,DB00592,Piperazine
,17634544,area under plasma concentration time curve,"Comparison of plasma concentrations determined by AMS with those derived by LCMS analysis gave similar average estimates of area under plasma concentration time curve (26 +/- 3 versus 27 +/- 11 microg/mL.h), but with some variation within each individual.",Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17634544/),[μg] / [h·ml],26,203622,DB00592,Piperazine
,17634544,area under plasma concentration time curve,"Comparison of plasma concentrations determined by AMS with those derived by LCMS analysis gave similar average estimates of area under plasma concentration time curve (26 +/- 3 versus 27 +/- 11 microg/mL.h), but with some variation within each individual.",Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17634544/),[μg] / [h·ml],27,203623,DB00592,Piperazine
,15889300,"AUC(0-tau,ss)","With RTV, a 42% increase in the CTZ AUC(0-tau,ss) (3406 versus 4840 microgh/l, 90% CI of 128-158%), a 53% increase in the CTZ elimination half-life (7.8 h versus 11.9 h, P = 0.001), a slight increase (15%) in the CTZ apparent volume of distribution (V(d,ss)/f) (34.7 l versus 39.8 l, P = 0.035), a 29% decrease in the CTZ apparent total body clearance (49.9 ml/min versus 35.3 ml/min, P < 0.001) and bioequivalent C(max,ss) (374 microg/l versus 408 microg/l) were observed.","Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15889300/),[μgh] / [l],3406,203659,DB00592,Piperazine
,15889300,"AUC(0-tau,ss)","With RTV, a 42% increase in the CTZ AUC(0-tau,ss) (3406 versus 4840 microgh/l, 90% CI of 128-158%), a 53% increase in the CTZ elimination half-life (7.8 h versus 11.9 h, P = 0.001), a slight increase (15%) in the CTZ apparent volume of distribution (V(d,ss)/f) (34.7 l versus 39.8 l, P = 0.035), a 29% decrease in the CTZ apparent total body clearance (49.9 ml/min versus 35.3 ml/min, P < 0.001) and bioequivalent C(max,ss) (374 microg/l versus 408 microg/l) were observed.","Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15889300/),[μgh] / [l],4840,203660,DB00592,Piperazine
,15889300,elimination half-life,"With RTV, a 42% increase in the CTZ AUC(0-tau,ss) (3406 versus 4840 microgh/l, 90% CI of 128-158%), a 53% increase in the CTZ elimination half-life (7.8 h versus 11.9 h, P = 0.001), a slight increase (15%) in the CTZ apparent volume of distribution (V(d,ss)/f) (34.7 l versus 39.8 l, P = 0.035), a 29% decrease in the CTZ apparent total body clearance (49.9 ml/min versus 35.3 ml/min, P < 0.001) and bioequivalent C(max,ss) (374 microg/l versus 408 microg/l) were observed.","Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15889300/),h,7.8,203661,DB00592,Piperazine
,15889300,elimination half-life,"With RTV, a 42% increase in the CTZ AUC(0-tau,ss) (3406 versus 4840 microgh/l, 90% CI of 128-158%), a 53% increase in the CTZ elimination half-life (7.8 h versus 11.9 h, P = 0.001), a slight increase (15%) in the CTZ apparent volume of distribution (V(d,ss)/f) (34.7 l versus 39.8 l, P = 0.035), a 29% decrease in the CTZ apparent total body clearance (49.9 ml/min versus 35.3 ml/min, P < 0.001) and bioequivalent C(max,ss) (374 microg/l versus 408 microg/l) were observed.","Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15889300/),h,11.9,203662,DB00592,Piperazine
,15889300,"apparent volume of distribution (V(d,ss)/f)","With RTV, a 42% increase in the CTZ AUC(0-tau,ss) (3406 versus 4840 microgh/l, 90% CI of 128-158%), a 53% increase in the CTZ elimination half-life (7.8 h versus 11.9 h, P = 0.001), a slight increase (15%) in the CTZ apparent volume of distribution (V(d,ss)/f) (34.7 l versus 39.8 l, P = 0.035), a 29% decrease in the CTZ apparent total body clearance (49.9 ml/min versus 35.3 ml/min, P < 0.001) and bioequivalent C(max,ss) (374 microg/l versus 408 microg/l) were observed.","Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15889300/),l,34.7,203663,DB00592,Piperazine
,15889300,"apparent volume of distribution (V(d,ss)/f)","With RTV, a 42% increase in the CTZ AUC(0-tau,ss) (3406 versus 4840 microgh/l, 90% CI of 128-158%), a 53% increase in the CTZ elimination half-life (7.8 h versus 11.9 h, P = 0.001), a slight increase (15%) in the CTZ apparent volume of distribution (V(d,ss)/f) (34.7 l versus 39.8 l, P = 0.035), a 29% decrease in the CTZ apparent total body clearance (49.9 ml/min versus 35.3 ml/min, P < 0.001) and bioequivalent C(max,ss) (374 microg/l versus 408 microg/l) were observed.","Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15889300/),l,39.8,203664,DB00592,Piperazine
,15889300,apparent total body clearance,"With RTV, a 42% increase in the CTZ AUC(0-tau,ss) (3406 versus 4840 microgh/l, 90% CI of 128-158%), a 53% increase in the CTZ elimination half-life (7.8 h versus 11.9 h, P = 0.001), a slight increase (15%) in the CTZ apparent volume of distribution (V(d,ss)/f) (34.7 l versus 39.8 l, P = 0.035), a 29% decrease in the CTZ apparent total body clearance (49.9 ml/min versus 35.3 ml/min, P < 0.001) and bioequivalent C(max,ss) (374 microg/l versus 408 microg/l) were observed.","Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15889300/),[ml] / [min],49.9,203665,DB00592,Piperazine
,15889300,apparent total body clearance,"With RTV, a 42% increase in the CTZ AUC(0-tau,ss) (3406 versus 4840 microgh/l, 90% CI of 128-158%), a 53% increase in the CTZ elimination half-life (7.8 h versus 11.9 h, P = 0.001), a slight increase (15%) in the CTZ apparent volume of distribution (V(d,ss)/f) (34.7 l versus 39.8 l, P = 0.035), a 29% decrease in the CTZ apparent total body clearance (49.9 ml/min versus 35.3 ml/min, P < 0.001) and bioequivalent C(max,ss) (374 microg/l versus 408 microg/l) were observed.","Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15889300/),[ml] / [min],35.3,203666,DB00592,Piperazine
,15889300,"C(max,ss)","With RTV, a 42% increase in the CTZ AUC(0-tau,ss) (3406 versus 4840 microgh/l, 90% CI of 128-158%), a 53% increase in the CTZ elimination half-life (7.8 h versus 11.9 h, P = 0.001), a slight increase (15%) in the CTZ apparent volume of distribution (V(d,ss)/f) (34.7 l versus 39.8 l, P = 0.035), a 29% decrease in the CTZ apparent total body clearance (49.9 ml/min versus 35.3 ml/min, P < 0.001) and bioequivalent C(max,ss) (374 microg/l versus 408 microg/l) were observed.","Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15889300/),[μg] / [l],374,203667,DB00592,Piperazine
,15889300,"C(max,ss)","With RTV, a 42% increase in the CTZ AUC(0-tau,ss) (3406 versus 4840 microgh/l, 90% CI of 128-158%), a 53% increase in the CTZ elimination half-life (7.8 h versus 11.9 h, P = 0.001), a slight increase (15%) in the CTZ apparent volume of distribution (V(d,ss)/f) (34.7 l versus 39.8 l, P = 0.035), a 29% decrease in the CTZ apparent total body clearance (49.9 ml/min versus 35.3 ml/min, P < 0.001) and bioequivalent C(max,ss) (374 microg/l versus 408 microg/l) were observed.","Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15889300/),[μg] / [l],408,203668,DB00592,Piperazine
,19801894,inhibitory constants (Ki),"The inhibitory constants (Ki) of KTZ were 2.80 +/- 0.70 and 115 +/- 28 microM for MDZ1'H and MDZ4H, respectively.","Inhibitory effects of ketoconazole, cimetidine and erythromycin on hepatic CYP3A activities in cats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19801894/),μM,2.80,203765,DB00592,Piperazine
,19801894,inhibitory constants (Ki),"The inhibitory constants (Ki) of KTZ were 2.80 +/- 0.70 and 115 +/- 28 microM for MDZ1'H and MDZ4H, respectively.","Inhibitory effects of ketoconazole, cimetidine and erythromycin on hepatic CYP3A activities in cats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19801894/),μM,115,203766,DB00592,Piperazine
,25070100,50% inhibitory concentration [IC50],"In human hepatocytes, ketoconazole dose dependently inhibited the formation of N(+)-glucuronides (50% inhibitory concentration [IC50], 1.5 μM), while rifampin induced the mRNA level of UGT1A9 by 28% and the activity of UGT1A9 by 53%.",Effects of rifampin and ketoconazole on pharmacokinetics of morinidazole in healthy chinese subjects. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25070100/),μM,1.5,203796,DB00592,Piperazine
,16520026,biologic half-life,"Moreover, in vivo administration of Ro 28-2653 solutions highlighted some information about the pharmacokinetic behavior of Ro 28-2653: a long biologic half-life (about 15.5h) and a small overall volume of distribution (8l).",Pharmacokinetic study of a new synthetic MMP inhibitor (Ro 28-2653) after IV and oral administration of cyclodextrin solutions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16520026/),h,15.5,204704,DB00592,Piperazine
,16520026,overall volume of distribution,"Moreover, in vivo administration of Ro 28-2653 solutions highlighted some information about the pharmacokinetic behavior of Ro 28-2653: a long biologic half-life (about 15.5h) and a small overall volume of distribution (8l).",Pharmacokinetic study of a new synthetic MMP inhibitor (Ro 28-2653) after IV and oral administration of cyclodextrin solutions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16520026/),l,8,204705,DB00592,Piperazine
,20206794,ma,"In Chinese subjects, mean maximal IPA (87%) occurred 1 hour after prasugrel dosing; in white subjects, mean maximal IPA (78%) occurred 2 hours after prasugrel dosing.",Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206794/),%,87,205173,DB00592,Piperazine
,20206794,maximal IPA,"After administration of Clopidogrel 300 mg in Chinese subjects, mean maximal IPA (58%) occurred at 4 hours.",Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206794/),%,58,205174,DB00592,Piperazine
,19011672,AUCS/R ratio,The kinetic disposition of CITA was enantioselective in rats (AUCS/R ratio = 0.4).,"Influence of quinidine, fluvoxamine, and ketoconazole on the enantioselective pharmacokinetics of citalopram in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19011672/),,0.4,205323,DB00592,Piperazine
,31317804,kobs,These findings were supported by the result that the kobs (0.00000118 min-1) of bergamottin for CYP3A was lower than the kdeg (0.0005 min-1) for CYP3A.,Bergamottin can be used to assess CYP3A-mediated intestinal first-pass metabolism without affecting P-glycoprotein-mediated efflux in rats. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31317804/),1/[min],0.00000118,205759,DB00592,Piperazine
,31317804,kdeg,These findings were supported by the result that the kobs (0.00000118 min-1) of bergamottin for CYP3A was lower than the kdeg (0.0005 min-1) for CYP3A.,Bergamottin can be used to assess CYP3A-mediated intestinal first-pass metabolism without affecting P-glycoprotein-mediated efflux in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31317804/),1/[min],0.0005,205760,DB00592,Piperazine
,23591629,progression-free survival (PFS),The median progression-free survival (PFS) was 5.1 months.,"Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23591629/),month,5.1,205761,DB00592,Piperazine
,23591629,PFS,"There was a strong tendency for better PFS in patients with KIT exon 9 mutations compared to patients with other genotypes (median PFS 11 vs 4 months, p=0.051).","Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23591629/),month,11,205762,DB00592,Piperazine
,23591629,PFS,"There was a strong tendency for better PFS in patients with KIT exon 9 mutations compared to patients with other genotypes (median PFS 11 vs 4 months, p=0.051).","Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23591629/),month,4,205763,DB00592,Piperazine
,23591629,Cmin,"Mean ± standard deviation imatinib Cmin at 800 mg/day and percent Cmin change was 3,552 ± 1,540 ng/mL and 160 ± 101 %, respectively.","Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23591629/),[ng] / [ml],"3,552",205764,DB00592,Piperazine
,23591629,percent Cmin change,"Mean ± standard deviation imatinib Cmin at 800 mg/day and percent Cmin change was 3,552 ± 1,540 ng/mL and 160 ± 101 %, respectively.","Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23591629/),[ng] / [ml],"3,552",205765,DB00592,Piperazine
,23591629,percent Cmin change,"Mean ± standard deviation imatinib Cmin at 800 mg/day and percent Cmin change was 3,552 ± 1,540 ng/mL and 160 ± 101 %, respectively.","Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23591629/),%,160,205766,DB00592,Piperazine
,9351906,Total recovery of administered dose,Total recovery of administered dose was 97.4 +/- 3.3% from male rats and 85.3 +/- 9.6% from female rats.,"Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long Evans rats. Differentiation of regioisomeric glucuronides by LC/MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9351906/),%,97.4,205941,DB00592,Piperazine
,9351906,Total recovery of administered dose,Total recovery of administered dose was 97.4 +/- 3.3% from male rats and 85.3 +/- 9.6% from female rats.,"Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long Evans rats. Differentiation of regioisomeric glucuronides by LC/MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9351906/),%,85.3,205942,DB00592,Piperazine
,9351906,biliary recoveries,"In contrast, biliary recoveries of the radioactivity were higher for male rats (approximately 77% for males and 53% for females).","Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long Evans rats. Differentiation of regioisomeric glucuronides by LC/MS/MS. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9351906/),%,77,205943,DB00592,Piperazine
,9351906,biliary recoveries,"In contrast, biliary recoveries of the radioactivity were higher for male rats (approximately 77% for males and 53% for females).","Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long Evans rats. Differentiation of regioisomeric glucuronides by LC/MS/MS. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9351906/),%,53,205944,DB00592,Piperazine
,28791664,maximal concentration (Cmax),"The following pharmacokinetic parameters were obtained: maximal concentration (Cmax): 366±179 ng/mL, time to maximal concentration: 0.92±0.30 hours, elimination half-life (t1/2): 2.41±1.18 hours, total clearance (CLtot/F): 5.85±2.81 L/hour, volume of distribution (Vd/F): 20.13±14.5 L, absorption rate constants (Ka): 0.343 hour-1, elimination rate (Ke): 0.35 hour-1, area under curve from zero to infinity: 2061±618 ng/mL/hour.",Pharmacokinetics of sildenafil in children with pulmonary arterial hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28791664/),[ng] / [ml],366,205953,DB00592,Piperazine
,28791664,time to maximal concentration,"The following pharmacokinetic parameters were obtained: maximal concentration (Cmax): 366±179 ng/mL, time to maximal concentration: 0.92±0.30 hours, elimination half-life (t1/2): 2.41±1.18 hours, total clearance (CLtot/F): 5.85±2.81 L/hour, volume of distribution (Vd/F): 20.13±14.5 L, absorption rate constants (Ka): 0.343 hour-1, elimination rate (Ke): 0.35 hour-1, area under curve from zero to infinity: 2061±618 ng/mL/hour.",Pharmacokinetics of sildenafil in children with pulmonary arterial hypertension. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28791664/),h,0.92,205954,DB00592,Piperazine
,28791664,elimination half-life (t1/2),"The following pharmacokinetic parameters were obtained: maximal concentration (Cmax): 366±179 ng/mL, time to maximal concentration: 0.92±0.30 hours, elimination half-life (t1/2): 2.41±1.18 hours, total clearance (CLtot/F): 5.85±2.81 L/hour, volume of distribution (Vd/F): 20.13±14.5 L, absorption rate constants (Ka): 0.343 hour-1, elimination rate (Ke): 0.35 hour-1, area under curve from zero to infinity: 2061±618 ng/mL/hour.",Pharmacokinetics of sildenafil in children with pulmonary arterial hypertension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28791664/),h,2.41,205955,DB00592,Piperazine
,28791664,total clearance (CLtot/F),"The following pharmacokinetic parameters were obtained: maximal concentration (Cmax): 366±179 ng/mL, time to maximal concentration: 0.92±0.30 hours, elimination half-life (t1/2): 2.41±1.18 hours, total clearance (CLtot/F): 5.85±2.81 L/hour, volume of distribution (Vd/F): 20.13±14.5 L, absorption rate constants (Ka): 0.343 hour-1, elimination rate (Ke): 0.35 hour-1, area under curve from zero to infinity: 2061±618 ng/mL/hour.",Pharmacokinetics of sildenafil in children with pulmonary arterial hypertension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28791664/),[l] / [h],5.85,205956,DB00592,Piperazine
,28791664,volume of distribution (Vd/F),"The following pharmacokinetic parameters were obtained: maximal concentration (Cmax): 366±179 ng/mL, time to maximal concentration: 0.92±0.30 hours, elimination half-life (t1/2): 2.41±1.18 hours, total clearance (CLtot/F): 5.85±2.81 L/hour, volume of distribution (Vd/F): 20.13±14.5 L, absorption rate constants (Ka): 0.343 hour-1, elimination rate (Ke): 0.35 hour-1, area under curve from zero to infinity: 2061±618 ng/mL/hour.",Pharmacokinetics of sildenafil in children with pulmonary arterial hypertension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28791664/),l,20.13,205957,DB00592,Piperazine
,28791664,absorption rate constants (Ka),"The following pharmacokinetic parameters were obtained: maximal concentration (Cmax): 366±179 ng/mL, time to maximal concentration: 0.92±0.30 hours, elimination half-life (t1/2): 2.41±1.18 hours, total clearance (CLtot/F): 5.85±2.81 L/hour, volume of distribution (Vd/F): 20.13±14.5 L, absorption rate constants (Ka): 0.343 hour-1, elimination rate (Ke): 0.35 hour-1, area under curve from zero to infinity: 2061±618 ng/mL/hour.",Pharmacokinetics of sildenafil in children with pulmonary arterial hypertension. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28791664/),1/[h],0.343,205958,DB00592,Piperazine
,28791664,elimination rate (Ke),"The following pharmacokinetic parameters were obtained: maximal concentration (Cmax): 366±179 ng/mL, time to maximal concentration: 0.92±0.30 hours, elimination half-life (t1/2): 2.41±1.18 hours, total clearance (CLtot/F): 5.85±2.81 L/hour, volume of distribution (Vd/F): 20.13±14.5 L, absorption rate constants (Ka): 0.343 hour-1, elimination rate (Ke): 0.35 hour-1, area under curve from zero to infinity: 2061±618 ng/mL/hour.",Pharmacokinetics of sildenafil in children with pulmonary arterial hypertension. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28791664/),1/[h],0.35,205959,DB00592,Piperazine
,28791664,area under curve from zero to infinity,"The following pharmacokinetic parameters were obtained: maximal concentration (Cmax): 366±179 ng/mL, time to maximal concentration: 0.92±0.30 hours, elimination half-life (t1/2): 2.41±1.18 hours, total clearance (CLtot/F): 5.85±2.81 L/hour, volume of distribution (Vd/F): 20.13±14.5 L, absorption rate constants (Ka): 0.343 hour-1, elimination rate (Ke): 0.35 hour-1, area under curve from zero to infinity: 2061±618 ng/mL/hour.",Pharmacokinetics of sildenafil in children with pulmonary arterial hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28791664/),[ng] / [h·ml],2061,205960,DB00592,Piperazine
,20931790,AUC(0-->infinity),"The AUC(0-->infinity) was 11.24 microg x h x mL(-1), the elimination rate constant (k(el)) was 0.348 h(-1) and the elimination half life (t(1/2)) was 2.0 h.",Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931790/),[h·μg] / [ml],11.24,206020,DB00592,Piperazine
,20931790,elimination rate constant (k(el)),"The AUC(0-->infinity) was 11.24 microg x h x mL(-1), the elimination rate constant (k(el)) was 0.348 h(-1) and the elimination half life (t(1/2)) was 2.0 h.",Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931790/),1/[h],0.348,206021,DB00592,Piperazine
,20931790,elimination half life (t(1/2)),"The AUC(0-->infinity) was 11.24 microg x h x mL(-1), the elimination rate constant (k(el)) was 0.348 h(-1) and the elimination half life (t(1/2)) was 2.0 h.",Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931790/),h,2.0,206022,DB00592,Piperazine
,20931790,mean residence time (MRT),"The mean residence time (MRT) was 2.59 h, V(SS) was 1.44 L x kg(-1) and clearance was 0.56 L x h x kg(-1).",Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931790/),h,2.59,206023,DB00592,Piperazine
,20931790,V(SS),"The mean residence time (MRT) was 2.59 h, V(SS) was 1.44 L x kg(-1) and clearance was 0.56 L x h x kg(-1).",Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931790/),[l] / [kg],1.44,206024,DB00592,Piperazine
,20931790,clearance,"The mean residence time (MRT) was 2.59 h, V(SS) was 1.44 L x kg(-1) and clearance was 0.56 L x h x kg(-1).",Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931790/),[h·l] / [kg],0.56,206025,DB00592,Piperazine
,20931790,CMAX,Liver achieved the highest tissue exposure: CMAX = 18.72 microg x mL(-1); AUC(0-->infinity)= 58.18 microg x h x mL(-1) and longest t(1/2) (4.29 h) and MRT (5.31 h).,Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931790/),[μg] / [ml],18.72,206026,DB00592,Piperazine
,20931790,AUC(0-->infinity),Liver achieved the highest tissue exposure: CMAX = 18.72 microg x mL(-1); AUC(0-->infinity)= 58.18 microg x h x mL(-1) and longest t(1/2) (4.29 h) and MRT (5.31 h).,Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931790/),[h·μg] / [ml],58.18,206027,DB00592,Piperazine
,20931790,t(1/2),Liver achieved the highest tissue exposure: CMAX = 18.72 microg x mL(-1); AUC(0-->infinity)= 58.18 microg x h x mL(-1) and longest t(1/2) (4.29 h) and MRT (5.31 h).,Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931790/),h,4.29,206028,DB00592,Piperazine
,20931790,MRT,Liver achieved the highest tissue exposure: CMAX = 18.72 microg x mL(-1); AUC(0-->infinity)= 58.18 microg x h x mL(-1) and longest t(1/2) (4.29 h) and MRT (5.31 h).,Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931790/),h,5.31,206029,DB00592,Piperazine
,20931790,AUC(0-->infinity),"Kidney and spleen AUC(0-->infinity) were 47.98 microg x h x mL(-1) and 23.46 microg x h x mL(-1), respectively.",Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931790/),[h·μg] / [ml],47.98,206030,DB00592,Piperazine
,20931790,AUC(0-->infinity),"Kidney and spleen AUC(0-->infinity) were 47.98 microg x h x mL(-1) and 23.46 microg x h x mL(-1), respectively.",Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931790/),[h·μg] / [ml],23.46,206031,DB00592,Piperazine
,20931790,Half-life,Half-life was 1.83 h for the kidney and 3.37 h for the spleen.,Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931790/),h,1.83,206032,DB00592,Piperazine
,20931790,Half-life,Half-life was 1.83 h for the kidney and 3.37 h for the spleen.,Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20931790/),h,3.37,206033,DB00592,Piperazine
,9521570,flow-rate,The eluate was then evaporated to dryness (gentle stream of nitrogen at 40 degrees C) and the residue was dissolved in the mobile phase and injected on to a YMC basic column (15 cm x 4.6 mm; 5 microm particle size) at a flow-rate of 1 ml/min.,High-performance liquid chromatographic-electrochemical assay for the quantitation of BMS-181885 in monkey plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9521570/),[ml] / [min],1,206050,DB00592,Piperazine
,9521570,extraction recovery,The extraction recovery of I from monkey plasma was about 82%.,High-performance liquid chromatographic-electrochemical assay for the quantitation of BMS-181885 in monkey plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9521570/),%,82,206051,DB00592,Piperazine
,28648684,tmax,"The pharmacokinetic analysis demonstrated a rapid absorption of HBK-15 after i.p. administration (tmax=5min), a short half-life (t0.5=74min), large volume of distribution (Vss=3.7L/kg) and bioavailability after i.p. administration equal 25%.","HBK-15 protects mice from stress-induced behavioral disturbances and changes in corticosterone, BDNF, and NGF levels. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28648684/),min,5,206121,DB00592,Piperazine
,28648684,half-life (t0.5,"The pharmacokinetic analysis demonstrated a rapid absorption of HBK-15 after i.p. administration (tmax=5min), a short half-life (t0.5=74min), large volume of distribution (Vss=3.7L/kg) and bioavailability after i.p. administration equal 25%.","HBK-15 protects mice from stress-induced behavioral disturbances and changes in corticosterone, BDNF, and NGF levels. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28648684/),min,74,206122,DB00592,Piperazine
,28648684,volume of distribution (Vss,"The pharmacokinetic analysis demonstrated a rapid absorption of HBK-15 after i.p. administration (tmax=5min), a short half-life (t0.5=74min), large volume of distribution (Vss=3.7L/kg) and bioavailability after i.p. administration equal 25%.","HBK-15 protects mice from stress-induced behavioral disturbances and changes in corticosterone, BDNF, and NGF levels. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28648684/),[l] / [kg],3.7,206123,DB00592,Piperazine
,28648684,bioavailability,"The pharmacokinetic analysis demonstrated a rapid absorption of HBK-15 after i.p. administration (tmax=5min), a short half-life (t0.5=74min), large volume of distribution (Vss=3.7L/kg) and bioavailability after i.p. administration equal 25%.","HBK-15 protects mice from stress-induced behavioral disturbances and changes in corticosterone, BDNF, and NGF levels. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28648684/),%,25,206124,DB00592,Piperazine
,10722490,maximum concentrations (C(max)s),"SYN-2836, SYN-2869, SYN-2903, and SYN-2921 were rapidly absorbed into the systemic circulation and reached maximum concentrations (C(max)s) of 7.31 +/- 2.53, 6.29 +/- 0.85, 6.16 +/- 0.39, and 3.41 +/- 0.34 microg/ml, respectively, in BALB/c mice after administration of an oral dose of 50 mg/kg of body weight, with bioavailability being greater than 45% in all mice.",Interspecies comparison of pharmacokinetics of the novel triazole antifungal agent SYN-2869 and its derivatives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722490/),[μg] / [ml],7.31,206494,DB00592,Piperazine
,10722490,maximum concentrations (C(max)s),"SYN-2836, SYN-2869, SYN-2903, and SYN-2921 were rapidly absorbed into the systemic circulation and reached maximum concentrations (C(max)s) of 7.31 +/- 2.53, 6.29 +/- 0.85, 6.16 +/- 0.39, and 3.41 +/- 0.34 microg/ml, respectively, in BALB/c mice after administration of an oral dose of 50 mg/kg of body weight, with bioavailability being greater than 45% in all mice.",Interspecies comparison of pharmacokinetics of the novel triazole antifungal agent SYN-2869 and its derivatives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722490/),[μg] / [ml],6.29,206495,DB00592,Piperazine
,10722490,maximum concentrations (C(max)s),"SYN-2836, SYN-2869, SYN-2903, and SYN-2921 were rapidly absorbed into the systemic circulation and reached maximum concentrations (C(max)s) of 7.31 +/- 2.53, 6.29 +/- 0.85, 6.16 +/- 0.39, and 3.41 +/- 0.34 microg/ml, respectively, in BALB/c mice after administration of an oral dose of 50 mg/kg of body weight, with bioavailability being greater than 45% in all mice.",Interspecies comparison of pharmacokinetics of the novel triazole antifungal agent SYN-2869 and its derivatives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722490/),[μg] / [ml],6.16,206496,DB00592,Piperazine
,10722490,maximum concentrations (C(max)s),"SYN-2836, SYN-2869, SYN-2903, and SYN-2921 were rapidly absorbed into the systemic circulation and reached maximum concentrations (C(max)s) of 7.31 +/- 2.53, 6.29 +/- 0.85, 6.16 +/- 0.39, and 3.41 +/- 0.34 microg/ml, respectively, in BALB/c mice after administration of an oral dose of 50 mg/kg of body weight, with bioavailability being greater than 45% in all mice.",Interspecies comparison of pharmacokinetics of the novel triazole antifungal agent SYN-2869 and its derivatives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722490/),[μg] / [ml],3.41,206497,DB00592,Piperazine
greater,10722490,bioavailability,"SYN-2836, SYN-2869, SYN-2903, and SYN-2921 were rapidly absorbed into the systemic circulation and reached maximum concentrations (C(max)s) of 7.31 +/- 2.53, 6.29 +/- 0.85, 6.16 +/- 0.39, and 3.41 +/- 0.34 microg/ml, respectively, in BALB/c mice after administration of an oral dose of 50 mg/kg of body weight, with bioavailability being greater than 45% in all mice.",Interspecies comparison of pharmacokinetics of the novel triazole antifungal agent SYN-2869 and its derivatives. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722490/),%,45,206498,DB00592,Piperazine
,10722490,areas under the concentration-time curve from time zero to infinity (AUC(0-infinity)s),The areas under the concentration-time curve from time zero to infinity (AUC(0-infinity)s) after administration of a single intravenous dose of 20 mg/kg to mice varied between 25.0 and 63.6 microg.,Interspecies comparison of pharmacokinetics of the novel triazole antifungal agent SYN-2869 and its derivatives. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722490/),μg,25.0 and 63.6,206499,DB00592,Piperazine
,10722490,half-life,The half-life was in the range of 4.5 to 6 h.,Interspecies comparison of pharmacokinetics of the novel triazole antifungal agent SYN-2869 and its derivatives. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722490/),h,4.5 to 6,206500,DB00592,Piperazine
,10722490,bioavailability,"In Sprague-Dawley rats there was no significant difference in AUC(0-infinity) after administration of a single intravenous dose of 20 mg/kg, but on oral administration, the bioavailability of SYN-2836 was extremely low, while that of SYN-2869 was only 14.7%.",Interspecies comparison of pharmacokinetics of the novel triazole antifungal agent SYN-2869 and its derivatives. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722490/),%,14.7,206501,DB00592,Piperazine
,10722490,C(max),"On the other hand, in beagle dogs the C(max) and AUC(0-infinity) of SYN-2836 after administration of a single oral dose of 30 mg/kg were 4.82 +/- 1.54 microg/ml and 41.8 +/- 15.7 microg.",Interspecies comparison of pharmacokinetics of the novel triazole antifungal agent SYN-2869 and its derivatives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722490/),[μg] / [ml],4.82,206502,DB00592,Piperazine
,10722490,AUC(0-infinity),"On the other hand, in beagle dogs the C(max) and AUC(0-infinity) of SYN-2836 after administration of a single oral dose of 30 mg/kg were 4.82 +/- 1.54 microg/ml and 41.8 +/- 15.7 microg.",Interspecies comparison of pharmacokinetics of the novel triazole antifungal agent SYN-2869 and its derivatives. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722490/),μg,41.8,206503,DB00592,Piperazine
,19830413,maximum plasma concentration (C(max)),"Study results showed that pummelo juice reduced the rate and extent of sildenafil bioavailability to around 60% [maximum plasma concentration (C(max)); from 212.44 ng/ml to 134.07 ng/ml, 90% confidence interval (90% CI) 44.70-89.11, and area under the plasma concentration time curve from zero to infinity (AUC(infinity)); from 564.51 ng.hr/ml to 336.87 ng.hr/ml, 90% CI 39.17-90.92].",The effects of pummelo juice on pharmacokinetics of sildenafil in healthy adult male Jordanian volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19830413/),[ng] / [ml],212.44,206686,DB00592,Piperazine
,19830413,maximum plasma concentration (C(max)),"Study results showed that pummelo juice reduced the rate and extent of sildenafil bioavailability to around 60% [maximum plasma concentration (C(max)); from 212.44 ng/ml to 134.07 ng/ml, 90% confidence interval (90% CI) 44.70-89.11, and area under the plasma concentration time curve from zero to infinity (AUC(infinity)); from 564.51 ng.hr/ml to 336.87 ng.hr/ml, 90% CI 39.17-90.92].",The effects of pummelo juice on pharmacokinetics of sildenafil in healthy adult male Jordanian volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19830413/),[ng] / [ml],134.07,206687,DB00592,Piperazine
,19830413,area under the plasma concentration time curve from zero to infinity (AUC(infinity)),"Study results showed that pummelo juice reduced the rate and extent of sildenafil bioavailability to around 60% [maximum plasma concentration (C(max)); from 212.44 ng/ml to 134.07 ng/ml, 90% confidence interval (90% CI) 44.70-89.11, and area under the plasma concentration time curve from zero to infinity (AUC(infinity)); from 564.51 ng.hr/ml to 336.87 ng.hr/ml, 90% CI 39.17-90.92].",The effects of pummelo juice on pharmacokinetics of sildenafil in healthy adult male Jordanian volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19830413/),[h·ng] / [ml],564.51,206688,DB00592,Piperazine
,19830413,area under the plasma concentration time curve from zero to infinity (AUC(infinity)),"Study results showed that pummelo juice reduced the rate and extent of sildenafil bioavailability to around 60% [maximum plasma concentration (C(max)); from 212.44 ng/ml to 134.07 ng/ml, 90% confidence interval (90% CI) 44.70-89.11, and area under the plasma concentration time curve from zero to infinity (AUC(infinity)); from 564.51 ng.hr/ml to 336.87 ng.hr/ml, 90% CI 39.17-90.92].",The effects of pummelo juice on pharmacokinetics of sildenafil in healthy adult male Jordanian volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19830413/),[h·ng] / [ml],336.87,206689,DB00592,Piperazine
<,24065588,Δ r G,"The complex constant, K, was evaluated to be 10(9) orders of magnitude with Δ r G < 0.","Preparation, characterization, and evaluation of dipfluzine-benzoic acid co-crystals with improved physicochemical properties. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24065588/),,0,206692,DB00592,Piperazine
,23873286,IC50,"Prior to in vivo studies, ketoconazole and ritonavir were shown to inhibit midazolam hydroxylation with IC50 values of 350 ± 60 nm and 11 ± 3 nm, respectively, in rat liver microsomes (RLM).",Assessment of CYP3A-mediated drug-drug interaction potential for victim drugs using an in vivo rat model. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23873286/),nm,350,206834,DB00592,Piperazine
,23873286,IC50,"Prior to in vivo studies, ketoconazole and ritonavir were shown to inhibit midazolam hydroxylation with IC50 values of 350 ± 60 nm and 11 ± 3 nm, respectively, in rat liver microsomes (RLM).",Assessment of CYP3A-mediated drug-drug interaction potential for victim drugs using an in vivo rat model. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23873286/),nm,11,206835,DB00592,Piperazine
,15592836,apparent CL,"For a patient with 77% of the median body weight or with 1.87 times the median granulocyte count, the apparent CL is 6.53 l/h, about 70% of the typical apparent CL of 9.33 l/h; for a patient of 84% of the typical haemoglobin level, the volume of distribution is about 70%.",Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592836/),[l] / [h],6.53,207031,DB00592,Piperazine
,15592836,apparent CL,"For a patient with 77% of the median body weight or with 1.87 times the median granulocyte count, the apparent CL is 6.53 l/h, about 70% of the typical apparent CL of 9.33 l/h; for a patient of 84% of the typical haemoglobin level, the volume of distribution is about 70%.",Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592836/),[l] / [h],9.33,207032,DB00592,Piperazine
,30660839,Flow rate,Flow rate of 0. 45 mL/min with a run time of 5 min was used for separation.,Pharmacokinetic interaction study of novel combination of palbociclib and sorafenib for hepatocellular carcinoma in SD rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30660839/),[ml] / [min],0. 45,207053,DB00592,Piperazine
,30660839,run time,Flow rate of 0. 45 mL/min with a run time of 5 min was used for separation.,Pharmacokinetic interaction study of novel combination of palbociclib and sorafenib for hepatocellular carcinoma in SD rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30660839/),min,5,207054,DB00592,Piperazine
,29856004,time to maximum concentration,AZD5069 was rapidly absorbed (time to maximum concentration ~ 2 h) under fasting conditions.,Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29856004/),h,2,207364,DB00592,Piperazine
,29856004,initial half-life,The plasma concentration of AZD5069 declined with an initial half-life of 4 h and terminal half-life of 11 h.,Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29856004/),h,4,207365,DB00592,Piperazine
,29856004,terminal half-life,The plasma concentration of AZD5069 declined with an initial half-life of 4 h and terminal half-life of 11 h.,Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29856004/),h,11,207366,DB00592,Piperazine
,8787948,bioavailability,"After oral administration, zopiclone is rapidly absorbed, with a bioavailability of approximately 80%.",Clinical pharmacokinetics of zopiclone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787948/),%,80,207436,DB00592,Piperazine
,8787948,plasma protein binding,The plasma protein binding of zopiclone has been reported to be between 45 and 80%.,Clinical pharmacokinetics of zopiclone. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787948/),%,45 and 80,207437,DB00592,Piperazine
,8787948,terminal elimination half-life (t1/2z),The terminal elimination half-life (t1/2z) of zopiclone ranges from 3.5 to 6.5 hours.,Clinical pharmacokinetics of zopiclone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787948/),h,3.5 to 6.5,207438,DB00592,Piperazine
,28618035,apparent steady-state clearance,"The mean population-derived apparent steady-state clearance, elimination half-life, area under the concentration-time curve over 24 hours, and volume of distribution were 17.2 ± 1.8 L/h., 12.05 ± 2.1 hours, 23.26 ± 0.6 μg·h/mL, and 299 ± 20.4 L, respectively.",Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28618035/),[l] / [h],17.2,207500,DB00592,Piperazine
,28618035,elimination half-life,"The mean population-derived apparent steady-state clearance, elimination half-life, area under the concentration-time curve over 24 hours, and volume of distribution were 17.2 ± 1.8 L/h., 12.05 ± 2.1 hours, 23.26 ± 0.6 μg·h/mL, and 299 ± 20.4 L, respectively.",Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28618035/),h,12.05,207501,DB00592,Piperazine
,28618035,elimination half-life,"The mean population-derived apparent steady-state clearance, elimination half-life, area under the concentration-time curve over 24 hours, and volume of distribution were 17.2 ± 1.8 L/h., 12.05 ± 2.1 hours, 23.26 ± 0.6 μg·h/mL, and 299 ± 20.4 L, respectively.",Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28618035/),[h·μg] / [ml],23.26,207502,DB00592,Piperazine
,28618035,area under the concentration-time curve over 24 hours,"The mean population-derived apparent steady-state clearance, elimination half-life, area under the concentration-time curve over 24 hours, and volume of distribution were 17.2 ± 1.8 L/h., 12.05 ± 2.1 hours, 23.26 ± 0.6 μg·h/mL, and 299 ± 20.4 L, respectively.",Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28618035/),h,12.05,207503,DB00592,Piperazine
,28618035,volume of distribution,"The mean population-derived apparent steady-state clearance, elimination half-life, area under the concentration-time curve over 24 hours, and volume of distribution were 17.2 ± 1.8 L/h., 12.05 ± 2.1 hours, 23.26 ± 0.6 μg·h/mL, and 299 ± 20.4 L, respectively.",Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28618035/),l,299,207504,DB00592,Piperazine
,28618035,clearance,"Whole blood count, ethnicity, CYP3A5*3, and ABCB1 C3435T were found to have significant influence on the apparent clearance, while the interindividual variability in clearance and interoccasion variability in bioavailability were 17.4% and 20.4%, respectively.",Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28618035/),%,17.4,207505,DB00592,Piperazine
,28618035,bioavailability,"Whole blood count, ethnicity, CYP3A5*3, and ABCB1 C3435T were found to have significant influence on the apparent clearance, while the interindividual variability in clearance and interoccasion variability in bioavailability were 17.4% and 20.4%, respectively.",Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28618035/),%,20.4,207506,DB00592,Piperazine
,23625188,t ½,Ketoconazole decreased mirabegron t ½ from 50.9 to 37.6 h suggesting that volume of distribution as well as first-pass effect decreased.,"Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23625188/),h,50.9,207683,DB00592,Piperazine
,23625188,t ½,Ketoconazole decreased mirabegron t ½ from 50.9 to 37.6 h suggesting that volume of distribution as well as first-pass effect decreased.,"Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23625188/),h,37.6,207684,DB00592,Piperazine
,32149389,half [IC50 ],"GBP has low apparent affinity for OCT2 (concentration of an inhibitor where the response [or binding] is reduced by half [IC50 ] 237 µmol/L) and a high apparent affinity for hMATE1 (IC50 1.1 nmol/L), hMATE2-K (IC50 39 nmol/L), and hOCTN1 (IC50 2.1 nmol/L) in HEK cells.",Cetirizine Reduces Gabapentin Plasma Concentrations and Effect: Role of Renal Drug Transporters for Organic Cations. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32149389/),[μM] / [l],237,207864,DB00592,Piperazine
,32149389,IC50,"GBP has low apparent affinity for OCT2 (concentration of an inhibitor where the response [or binding] is reduced by half [IC50 ] 237 µmol/L) and a high apparent affinity for hMATE1 (IC50 1.1 nmol/L), hMATE2-K (IC50 39 nmol/L), and hOCTN1 (IC50 2.1 nmol/L) in HEK cells.",Cetirizine Reduces Gabapentin Plasma Concentrations and Effect: Role of Renal Drug Transporters for Organic Cations. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32149389/),[nM] / [l],1.1,207865,DB00592,Piperazine
,32149389,IC50,"GBP has low apparent affinity for OCT2 (concentration of an inhibitor where the response [or binding] is reduced by half [IC50 ] 237 µmol/L) and a high apparent affinity for hMATE1 (IC50 1.1 nmol/L), hMATE2-K (IC50 39 nmol/L), and hOCTN1 (IC50 2.1 nmol/L) in HEK cells.",Cetirizine Reduces Gabapentin Plasma Concentrations and Effect: Role of Renal Drug Transporters for Organic Cations. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32149389/),[nM] / [l],39,207866,DB00592,Piperazine
,32149389,IC50,"GBP has low apparent affinity for OCT2 (concentration of an inhibitor where the response [or binding] is reduced by half [IC50 ] 237 µmol/L) and a high apparent affinity for hMATE1 (IC50 1.1 nmol/L), hMATE2-K (IC50 39 nmol/L), and hOCTN1 (IC50 2.1 nmol/L) in HEK cells.",Cetirizine Reduces Gabapentin Plasma Concentrations and Effect: Role of Renal Drug Transporters for Organic Cations. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32149389/),[nM] / [l],2.1,207867,DB00592,Piperazine
,17523053,time of the peak concentration (T(max)),Imatinib was administered orally or intravenously to dogs and the time of the peak concentration (T(max)) of imatinib was 4-9 h.,Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523053/),h,4-9,207990,DB00592,Piperazine
,17523053,half-life,"The mean half-life was 622 +/- 368 min, and the AUC was 1256 +/- 809 microM * min after oral administration.",Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523053/),min,622,207991,DB00592,Piperazine
,17523053,AUC,"The mean half-life was 622 +/- 368 min, and the AUC was 1256 +/- 809 microM * min after oral administration.",Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523053/),min·μM,1256,207992,DB00592,Piperazine
,17523053,C0,The range of C0 of intravenously injected dogs was 12-24 microM.,Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523053/),μM,12-24,207993,DB00592,Piperazine
,17523053,half-life,"The half-life and AUC after intravenous injection were 206 +/- 112 min and 1026 +/- 371 microM * min, respectively.",Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523053/),min,206,207994,DB00592,Piperazine
,17523053,AUC,"The half-life and AUC after intravenous injection were 206 +/- 112 min and 1026 +/- 371 microM * min, respectively.",Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523053/),min·μM,1026,207995,DB00592,Piperazine
,15373932,elimination half-life,"Ketoconazole increased the mean area under the plasma concentration-time curve for rosiglitazone by 47%[P = 0.0003; 95% confidence interval (CI) 23, 70] and the mean elimination half-life from 3.55 to 5.50 h (P = 0.0003; 95% CI in difference 1.1, 2.4).",Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15373932/),h,3.55,208115,DB00592,Piperazine
,15373932,elimination half-life,"Ketoconazole increased the mean area under the plasma concentration-time curve for rosiglitazone by 47%[P = 0.0003; 95% confidence interval (CI) 23, 70] and the mean elimination half-life from 3.55 to 5.50 h (P = 0.0003; 95% CI in difference 1.1, 2.4).",Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15373932/),h,5.50,208116,DB00592,Piperazine
,28204607,time to maximum plasma concentration,"After single-dose administration, aripiprazole exposure (area under the concentration-time curve) was similar between deltoid and gluteal administrations, whereas median time to maximum plasma concentration was shorter (7.1 [deltoid] vs 24.1 days [gluteal]) and maximum concentration was 31% higher after deltoid administration.","Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28204607/),d,7.1,208352,DB00592,Piperazine
,28204607,time to maximum plasma concentration,"After single-dose administration, aripiprazole exposure (area under the concentration-time curve) was similar between deltoid and gluteal administrations, whereas median time to maximum plasma concentration was shorter (7.1 [deltoid] vs 24.1 days [gluteal]) and maximum concentration was 31% higher after deltoid administration.","Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28204607/),d,24.1,208353,DB00592,Piperazine
,28204607,time to maximum plasma concentration,"In the multiple-dose study, median time to maximum plasma concentration for deltoid administration was shorter (3.95 vs 7.1 days), whereas aripiprazole mean trough concentrations, maximum concentration, and area under the concentration-time curve were comparable between deltoid and gluteal muscles (historical data comparison).","Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28204607/),d,3.95,208354,DB00592,Piperazine
,28204607,time to maximum plasma concentration,"In the multiple-dose study, median time to maximum plasma concentration for deltoid administration was shorter (3.95 vs 7.1 days), whereas aripiprazole mean trough concentrations, maximum concentration, and area under the concentration-time curve were comparable between deltoid and gluteal muscles (historical data comparison).","Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28204607/),d,7.1,208355,DB00592,Piperazine
,25266547,Tmax,"The PK of aripiprazole following aripiprazole lauroxil was characterized by a steady rise in plasma concentrations (Tmax 44-50 days), a broad peak, and prolonged exposure attributable to the dissolution of aripiprazole lauroxil and formation rate-limited elimination of aripiprazole (t1/2=15.4-19.2 days).","Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25266547/),d,44-50,208506,DB00592,Piperazine
,25266547,t1/2,"The PK of aripiprazole following aripiprazole lauroxil was characterized by a steady rise in plasma concentrations (Tmax 44-50 days), a broad peak, and prolonged exposure attributable to the dissolution of aripiprazole lauroxil and formation rate-limited elimination of aripiprazole (t1/2=15.4-19.2 days).","Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25266547/),d,15.4-19.2,208507,DB00592,Piperazine
,6613160,t1/2 (beta),"After i.v. injection (10 mg/kg) to rats, buspirone is rapidly cleared from blood with a t1/2 (beta) or 30 min.",Disposition and metabolism of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6613160/),min,30,208745,DB00592,Piperazine
,24786013,Cmax,"The geometric mean (CV%) for Cmax in the OSF and FCT formulations were 267.21 (4.68%) ng/mL and 285.97 (5.32%) ng/mL, respectively.",Pharmacokinetics of a new orally soluble film formulation of sildenafil administered without water. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786013/),[ng] / [ml],267.21,208882,DB00592,Piperazine
,24786013,Cmax,"The geometric mean (CV%) for Cmax in the OSF and FCT formulations were 267.21 (4.68%) ng/mL and 285.97 (5.32%) ng/mL, respectively.",Pharmacokinetics of a new orally soluble film formulation of sildenafil administered without water. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786013/),[ng] / [ml],285.97,208883,DB00592,Piperazine
,24786013,AUClast,"The geometric mean for AUClast in the OSF and FCT formulations were 664.48 (4.40%) ng x h/mL and 647.96 (4.63%) ng x h/mL, respectively.",Pharmacokinetics of a new orally soluble film formulation of sildenafil administered without water. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786013/),[h·ng] / [ml],664.48,208884,DB00592,Piperazine
,24786013,AUClast,"The geometric mean for AUClast in the OSF and FCT formulations were 664.48 (4.40%) ng x h/mL and 647.96 (4.63%) ng x h/mL, respectively.",Pharmacokinetics of a new orally soluble film formulation of sildenafil administered without water. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786013/),[h·ng] / [ml],647.96,208885,DB00592,Piperazine
,24786013,AUCinf,"The geometric mean for AUCinf in the OSF and FCT formulations were 685.65 (4.37%) ng x h/mL and 666.28 (4.60%) ng x h/ mL, respectively.",Pharmacokinetics of a new orally soluble film formulation of sildenafil administered without water. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786013/),[h·ng] / [ml],685.65,208886,DB00592,Piperazine
,24786013,AUCinf,"The geometric mean for AUCinf in the OSF and FCT formulations were 685.65 (4.37%) ng x h/mL and 666.28 (4.60%) ng x h/ mL, respectively.",Pharmacokinetics of a new orally soluble film formulation of sildenafil administered without water. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786013/),[h·ng] / [ml],666.28,208887,DB00592,Piperazine
,3465533,area under the serum concentration time curve (AUC),The area under the serum concentration time curve (AUC) reached 12.3 +/- 7.7 mg/l.h (mean +/- S.D.) on the 200 mg dose and increased to 23.0 +/- 18.2 mg/l.h on the 400 mg dose (p less than 0.05).,Ketoconazole pharmacokinetics during chronic dosing in adults with haematological malignancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3465533/),[mg] / [h·l],12.3,209074,DB00592,Piperazine
,3465533,area under the serum concentration time curve (AUC),The area under the serum concentration time curve (AUC) reached 12.3 +/- 7.7 mg/l.h (mean +/- S.D.) on the 200 mg dose and increased to 23.0 +/- 18.2 mg/l.h on the 400 mg dose (p less than 0.05).,Ketoconazole pharmacokinetics during chronic dosing in adults with haematological malignancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3465533/),[mg] / [h·l],23.0,209075,DB00592,Piperazine
,3465533,half-life,The half-life of ketoconazole was 3.1 +/- 1.9 h on the 200 mg dose and 3.5 +/- 1.7 h on the 400 mg dose.,Ketoconazole pharmacokinetics during chronic dosing in adults with haematological malignancy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3465533/),h,3.1,209076,DB00592,Piperazine
,3465533,half-life,The half-life of ketoconazole was 3.1 +/- 1.9 h on the 200 mg dose and 3.5 +/- 1.7 h on the 400 mg dose.,Ketoconazole pharmacokinetics during chronic dosing in adults with haematological malignancy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3465533/),h,3.5,209077,DB00592,Piperazine
,3465533,Peak concentrations,"Peak concentrations were 3.2 +/- 1.8 mg/l and 4.6 +/- 3.2 mg/l on the 200 mg and 400 mg doses, respectively.",Ketoconazole pharmacokinetics during chronic dosing in adults with haematological malignancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3465533/),[mg] / [l],3.2,209078,DB00592,Piperazine
,3465533,Peak concentrations,"Peak concentrations were 3.2 +/- 1.8 mg/l and 4.6 +/- 3.2 mg/l on the 200 mg and 400 mg doses, respectively.",Ketoconazole pharmacokinetics during chronic dosing in adults with haematological malignancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3465533/),[mg] / [l],4.6,209079,DB00592,Piperazine
,16920325,limit of quantitation (LOQ),Sampling lasted for 24h after dosing; consequently a limit of quantitation (LOQ) of 7.858 ng/mL was achieved for sildenafil whereas a LOQ of 8.675 ng/mL was obtained for N-desmethyl sildenafil.,Simultaneous determination of sildenafil and N-desmethyl sildenafil in human plasma by high-performance liquid chromatography method using electrochemical detection with application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16920325/),[ng] / [ml],7.858,209282,DB00592,Piperazine
,16920325,LOQ,Sampling lasted for 24h after dosing; consequently a limit of quantitation (LOQ) of 7.858 ng/mL was achieved for sildenafil whereas a LOQ of 8.675 ng/mL was obtained for N-desmethyl sildenafil.,Simultaneous determination of sildenafil and N-desmethyl sildenafil in human plasma by high-performance liquid chromatography method using electrochemical detection with application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16920325/),[ng] / [ml],8.675,209283,DB00592,Piperazine
,19856790,Cmax,"After oral administration the values of Cmax, tmax, t1/2, MRT, AUC(0-t), AUC(0-infinity) for test and reference formulations were 0.80 +/- 0.14 and 0.80 +/- 0.23 microg/ml, 0.8 +/- 0.4 and 1.1 +/- 0.7 h, 7.59 +/- 0.68 and 7.63 +/- 0.93 h, 10.59 +/- 0.94 and 10.92 +/- 1.26 h, 6.00 +/- 1.04 and 5.98 +/- 1.39 microg x h/ml, respectively.",Pharmacokinetics and bioequivalence study of two cetirizine hydrochloride formulations in healthy Chinese male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19856790/),[μg] / [ml],0.80,209495,DB00592,Piperazine
,19856790,AUC(0-t),"After oral administration the values of Cmax, tmax, t1/2, MRT, AUC(0-t), AUC(0-infinity) for test and reference formulations were 0.80 +/- 0.14 and 0.80 +/- 0.23 microg/ml, 0.8 +/- 0.4 and 1.1 +/- 0.7 h, 7.59 +/- 0.68 and 7.63 +/- 0.93 h, 10.59 +/- 0.94 and 10.92 +/- 1.26 h, 6.00 +/- 1.04 and 5.98 +/- 1.39 microg x h/ml, respectively.",Pharmacokinetics and bioequivalence study of two cetirizine hydrochloride formulations in healthy Chinese male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19856790/),[μg] / [ml],0.80,209496,DB00592,Piperazine
,19856790,AUC(0-infinity),"After oral administration the values of Cmax, tmax, t1/2, MRT, AUC(0-t), AUC(0-infinity) for test and reference formulations were 0.80 +/- 0.14 and 0.80 +/- 0.23 microg/ml, 0.8 +/- 0.4 and 1.1 +/- 0.7 h, 7.59 +/- 0.68 and 7.63 +/- 0.93 h, 10.59 +/- 0.94 and 10.92 +/- 1.26 h, 6.00 +/- 1.04 and 5.98 +/- 1.39 microg x h/ml, respectively.",Pharmacokinetics and bioequivalence study of two cetirizine hydrochloride formulations in healthy Chinese male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19856790/),h,10.92,209497,DB00592,Piperazine
,19856790,AUC(0-infinity),"After oral administration the values of Cmax, tmax, t1/2, MRT, AUC(0-t), AUC(0-infinity) for test and reference formulations were 0.80 +/- 0.14 and 0.80 +/- 0.23 microg/ml, 0.8 +/- 0.4 and 1.1 +/- 0.7 h, 7.59 +/- 0.68 and 7.63 +/- 0.93 h, 10.59 +/- 0.94 and 10.92 +/- 1.26 h, 6.00 +/- 1.04 and 5.98 +/- 1.39 microg x h/ml, respectively.",Pharmacokinetics and bioequivalence study of two cetirizine hydrochloride formulations in healthy Chinese male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19856790/),[h·μg] / [ml],6.00,209498,DB00592,Piperazine
,19856790,AUC(0-infinity),"After oral administration the values of Cmax, tmax, t1/2, MRT, AUC(0-t), AUC(0-infinity) for test and reference formulations were 0.80 +/- 0.14 and 0.80 +/- 0.23 microg/ml, 0.8 +/- 0.4 and 1.1 +/- 0.7 h, 7.59 +/- 0.68 and 7.63 +/- 0.93 h, 10.59 +/- 0.94 and 10.92 +/- 1.26 h, 6.00 +/- 1.04 and 5.98 +/- 1.39 microg x h/ml, respectively.",Pharmacokinetics and bioequivalence study of two cetirizine hydrochloride formulations in healthy Chinese male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19856790/),[h·μg] / [ml],5.98,209499,DB00592,Piperazine
,19856790,bioavailability,"When the AUC(0-t) values for both formulations for natural log-transformed data were compared, the test formulation showed a bioavailability of 100.9 +/- 7.7%, as compared to the reference formulation.",Pharmacokinetics and bioequivalence study of two cetirizine hydrochloride formulations in healthy Chinese male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19856790/),%,100.9,209500,DB00592,Piperazine
,8016009,half life,The pharmacokinetic parameters obtained for the i.v. administration were comparable in both groups (half life 3.6 +/- 3.4 hours in liver-impaired subjects versus 3.3 +/- 2.1 hours in controls; clearance 11.9 +/- 4.7 ml/minute/kg versus 11.0 +/- 1.6 ml/minute/kg).,"Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunction. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8016009/),h,3.6,209680,DB00592,Piperazine
,8016009,half life,The pharmacokinetic parameters obtained for the i.v. administration were comparable in both groups (half life 3.6 +/- 3.4 hours in liver-impaired subjects versus 3.3 +/- 2.1 hours in controls; clearance 11.9 +/- 4.7 ml/minute/kg versus 11.0 +/- 1.6 ml/minute/kg).,"Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunction. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8016009/),h,3.3,209681,DB00592,Piperazine
,8016009,clearance,The pharmacokinetic parameters obtained for the i.v. administration were comparable in both groups (half life 3.6 +/- 3.4 hours in liver-impaired subjects versus 3.3 +/- 2.1 hours in controls; clearance 11.9 +/- 4.7 ml/minute/kg versus 11.0 +/- 1.6 ml/minute/kg).,"Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunction. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8016009/),[ml] / [kg·min],11.9,209682,DB00592,Piperazine
,8016009,clearance,The pharmacokinetic parameters obtained for the i.v. administration were comparable in both groups (half life 3.6 +/- 3.4 hours in liver-impaired subjects versus 3.3 +/- 2.1 hours in controls; clearance 11.9 +/- 4.7 ml/minute/kg versus 11.0 +/- 1.6 ml/minute/kg).,"Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunction. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8016009/),[ml] / [kg·min],11.0,209683,DB00592,Piperazine
,8016009,t1/2,Following oral administration the plasma levels and half-life times of naftopidil were significantly increased in liver impairment (t1/2 16.6 +/- 19.3 hours versus 5.4 +/- 3.2 hours in controls; P = 0.012).,"Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunction. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8016009/),h,16.6,209684,DB00592,Piperazine
,8016009,t1/2,Following oral administration the plasma levels and half-life times of naftopidil were significantly increased in liver impairment (t1/2 16.6 +/- 19.3 hours versus 5.4 +/- 3.2 hours in controls; P = 0.012).,"Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunction. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8016009/),h,5.4,209685,DB00592,Piperazine
,8016009,absolute bioavailability,"Mean values for the absolute bioavailability in patients with hepatic dysfunction were significantly higher (mean 75%, median 53%, range 13.4-211.0%) compared to healthy subjects (mean 17%, median 16%, range 6.7-29.6%, P = 0.001).","Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunction. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8016009/),%,75,209686,DB00592,Piperazine
,8016009,absolute bioavailability,"Mean values for the absolute bioavailability in patients with hepatic dysfunction were significantly higher (mean 75%, median 53%, range 13.4-211.0%) compared to healthy subjects (mean 17%, median 16%, range 6.7-29.6%, P = 0.001).","Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunction. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8016009/),%,53,209687,DB00592,Piperazine
,8016009,absolute bioavailability,"Mean values for the absolute bioavailability in patients with hepatic dysfunction were significantly higher (mean 75%, median 53%, range 13.4-211.0%) compared to healthy subjects (mean 17%, median 16%, range 6.7-29.6%, P = 0.001).","Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunction. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8016009/),%,17,209688,DB00592,Piperazine
,8016009,absolute bioavailability,"Mean values for the absolute bioavailability in patients with hepatic dysfunction were significantly higher (mean 75%, median 53%, range 13.4-211.0%) compared to healthy subjects (mean 17%, median 16%, range 6.7-29.6%, P = 0.001).","Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunction. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8016009/),%,16,209689,DB00592,Piperazine
,18359202,Clearance,"Clearance, volume of distribution and the absorption rate constant were 12.7 L/h, 333 L and 1.72 h(-1), respectively.",Population pharmacokinetics of itraconazole solution used as prophylaxis for febrile neutropenia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18359202/),[l] / [h],12.7,209792,DB00592,Piperazine
,18359202,volume of distribution,"Clearance, volume of distribution and the absorption rate constant were 12.7 L/h, 333 L and 1.72 h(-1), respectively.",Population pharmacokinetics of itraconazole solution used as prophylaxis for febrile neutropenia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18359202/),l,333,209793,DB00592,Piperazine
,18359202,absorption rate constant,"Clearance, volume of distribution and the absorption rate constant were 12.7 L/h, 333 L and 1.72 h(-1), respectively.",Population pharmacokinetics of itraconazole solution used as prophylaxis for febrile neutropenia. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18359202/),1/[h],1.72,209794,DB00592,Piperazine
>,18359202,trough concentrations,"Assuming a normal distribution, we predicted the trough concentrations of 94.5% of the patients receiving 200 mg/day ITC solution to be >250 ng/mL, indicating that administration of 200mg/day might be suitable for prophylaxis.",Population pharmacokinetics of itraconazole solution used as prophylaxis for febrile neutropenia. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18359202/),[ng] / [ml],250,209795,DB00592,Piperazine
,25733012,AUC,"The AUC (6 hours ng mL(-1)) and CMAX (6 ng mL(-1)) of methadone significantly increased to 541 hours ng mL(-1) and 47.8 ng mL(-1), respectively, when methadone was administered with chloramphenicol as a sole inhibitor.",Chloramphenicol significantly affects the pharmacokinetics of oral methadone in Greyhound dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25733012/),[h·ng] / [ml],6,209817,DB00592,Piperazine
,25733012,CMAX,"The AUC (6 hours ng mL(-1)) and CMAX (6 ng mL(-1)) of methadone significantly increased to 541 hours ng mL(-1) and 47.8 ng mL(-1), respectively, when methadone was administered with chloramphenicol as a sole inhibitor.",Chloramphenicol significantly affects the pharmacokinetics of oral methadone in Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25733012/),[ng] / [ml],6,209818,DB00592,Piperazine
,25733012,CMAX,"The AUC (6 hours ng mL(-1)) and CMAX (6 ng mL(-1)) of methadone significantly increased to 541 hours ng mL(-1) and 47.8 ng mL(-1), respectively, when methadone was administered with chloramphenicol as a sole inhibitor.",Chloramphenicol significantly affects the pharmacokinetics of oral methadone in Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25733012/),[h·ng] / [ml],541,209819,DB00592,Piperazine
,25733012,CMAX,"The AUC (6 hours ng mL(-1)) and CMAX (6 ng mL(-1)) of methadone significantly increased to 541 hours ng mL(-1) and 47.8 ng mL(-1), respectively, when methadone was administered with chloramphenicol as a sole inhibitor.",Chloramphenicol significantly affects the pharmacokinetics of oral methadone in Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25733012/),[ng] / [ml],47.8,209820,DB00592,Piperazine
,6812119,bioavailability,The bioavailability of orally administered cis(Z)-flupentixol was calculated to be about 40% with IV injection as reference.,Serum concentrations of cis(Z)-flupentixol and prolactin in chronic schizophrenic patients treated with flupentixol and cis(Z)-flupentixol decanoate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6812119/),%,40,210208,DB00592,Piperazine
,31637669,Overall objective response rate,Overall objective response rate was 46%.,Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31637669/),%,46,210290,DB00592,Piperazine
,18611062,CL(R),The mean CL(R) of aripiprazole was negligible (0.04 mL/h/kg in controls and 0.19 mL/h/kg in patients with severe hepatic impairment).,Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611062/),[ml] / [h·kg],0.04,210387,DB00592,Piperazine
,18611062,CL(R),The mean CL(R) of aripiprazole was negligible (0.04 mL/h/kg in controls and 0.19 mL/h/kg in patients with severe hepatic impairment).,Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611062/),[ml] / [h·kg],0.19,210388,DB00592,Piperazine
,28092984,systemic clearance,"ViperaTAb®'s systemic clearance, distribution and elimination half-lives were 4.3-13.4 mL/h/kg, 1.2-3.2 h and 14.1-55.4 h, respectively.",Vipera ammodytes bites treated with antivenom ViperaTAb: a case series with pharmacokinetic evaluation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28092984/),[ml] / [h·kg],4.3-13.4,210456,DB00592,Piperazine
,28092984,distribution,"ViperaTAb®'s systemic clearance, distribution and elimination half-lives were 4.3-13.4 mL/h/kg, 1.2-3.2 h and 14.1-55.4 h, respectively.",Vipera ammodytes bites treated with antivenom ViperaTAb: a case series with pharmacokinetic evaluation. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28092984/),h,1.2-3.2,210457,DB00592,Piperazine
,28092984,elimination half-lives,"ViperaTAb®'s systemic clearance, distribution and elimination half-lives were 4.3-13.4 mL/h/kg, 1.2-3.2 h and 14.1-55.4 h, respectively.",Vipera ammodytes bites treated with antivenom ViperaTAb: a case series with pharmacokinetic evaluation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28092984/),h,14.1-55.4,210458,DB00592,Piperazine
,29557727,total amounts of radio,"The total amounts of radioactivity excreted in urine, feces, and expired air up to 168 h after administration of [14C]evogliptin tartrate to rats (30 mg evogliptin/kg) and dogs (10 mg evogliptin/kg) were 96.7% and 96.8% of initial doses administered, respectively.","Absorption, metabolism, and excretion of [14C]evogliptin tartrate in male rats and dogs. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29557727/),%,96.7,210848,DB00592,Piperazine
,29557727,total amounts of radio,"The total amounts of radioactivity excreted in urine, feces, and expired air up to 168 h after administration of [14C]evogliptin tartrate to rats (30 mg evogliptin/kg) and dogs (10 mg evogliptin/kg) were 96.7% and 96.8% of initial doses administered, respectively.","Absorption, metabolism, and excretion of [14C]evogliptin tartrate in male rats and dogs. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29557727/),%,96.8,210849,DB00592,Piperazine
,12687332,half-life (t(1/2)),Gemfibrozil raised the area under the plasma concentration-time curve (AUC) of repaglinide 8.1-fold (range 5.5- to 15.0-fold; p<0.001) and prolonged its half-life (t(1/2)) from 1.3 to 3.7 h (p<0.001).,"Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12687332/),h,1.3,210928,DB00592,Piperazine
,12687332,half-life (t(1/2)),Gemfibrozil raised the area under the plasma concentration-time curve (AUC) of repaglinide 8.1-fold (range 5.5- to 15.0-fold; p<0.001) and prolonged its half-life (t(1/2)) from 1.3 to 3.7 h (p<0.001).,"Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12687332/),h,3.7,210929,DB00592,Piperazine
,12687332,t(1/2),"Although itraconazole alone raised repaglinide AUC only 1.4-fold (1.1- to 1.9-fold; p<0.001), the gemfibrozil-itraconazole combination raised it 19.4-fold (12.9- to 24.7-fold) and prolonged the t(1/2) of repaglinide to 6.1 h (p<0.001).","Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12687332/),h,6.1,210930,DB00592,Piperazine
,18770050,n,Formulations exhibited drug release fitting Peppas model with value of n ranging from 0.61 to 1.18.,Studies on formulation development of mucoadhesive sustained release itraconazole tablet using response surface methodology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18770050/),,0.61 to 1.18,210979,DB00592,Piperazine
,18770050,C (max),"The formulation showed C (max) 1898 +/- 75.23 ng/ml, t (max) of the formulation was 2 h and AUC was observed to be 28604.9 ng h/ml.",Studies on formulation development of mucoadhesive sustained release itraconazole tablet using response surface methodology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18770050/),[ng] / [ml],1898,210980,DB00592,Piperazine
,18770050,t (max),"The formulation showed C (max) 1898 +/- 75.23 ng/ml, t (max) of the formulation was 2 h and AUC was observed to be 28604.9 ng h/ml.",Studies on formulation development of mucoadhesive sustained release itraconazole tablet using response surface methodology. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18770050/),h,2,210981,DB00592,Piperazine
,18770050,AUC,"The formulation showed C (max) 1898 +/- 75.23 ng/ml, t (max) of the formulation was 2 h and AUC was observed to be 28604.9 ng h/ml.",Studies on formulation development of mucoadhesive sustained release itraconazole tablet using response surface methodology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18770050/),[h·ng] / [ml],28604.9,210982,DB00592,Piperazine
,3243657,peak values,"In the single-dose study, ketoconazole SL concentrations determined between 80 and 390 min showed mean peak values of 0.74 +/- 0.53 micrograms/ml at intermediate sampling times of about 180 min.",Dermo-epidermal distribution of ketoconazole in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243657/),[μg] / [ml],0.74,211434,DB00592,Piperazine
,3243657,maximum mean plasma concentration,The maximum mean plasma concentration of 2.37 +/- 1.26 micrograms/ml occurred at an intermediate sampling time (141 min) as well.,Dermo-epidermal distribution of ketoconazole in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243657/),[μg] / [ml],2.37,211435,DB00592,Piperazine
,3243657,plasma,"In those patients receiving chronic treatment from 1 to 7 days, the mean plasma and SL concentrations were 1.07 +/- 1.17 micrograms/ml and 0.08 +/- 0.2 micrograms/ml, respectively, while chronic treatment from 15 to 64 days resulted in higher values of 2.22 +/- 1.91 micrograms/ml and 0.56 +/- 0.57 micrograms/ml, respectively.",Dermo-epidermal distribution of ketoconazole in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243657/),[μg] / [ml],1.07,211436,DB00592,Piperazine
,3243657,plasma,"In those patients receiving chronic treatment from 1 to 7 days, the mean plasma and SL concentrations were 1.07 +/- 1.17 micrograms/ml and 0.08 +/- 0.2 micrograms/ml, respectively, while chronic treatment from 15 to 64 days resulted in higher values of 2.22 +/- 1.91 micrograms/ml and 0.56 +/- 0.57 micrograms/ml, respectively.",Dermo-epidermal distribution of ketoconazole in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243657/),[μg] / [ml],2.,211437,DB00592,Piperazine
,3243657,plasma,"In those patients receiving chronic treatment from 1 to 7 days, the mean plasma and SL concentrations were 1.07 +/- 1.17 micrograms/ml and 0.08 +/- 0.2 micrograms/ml, respectively, while chronic treatment from 15 to 64 days resulted in higher values of 2.22 +/- 1.91 micrograms/ml and 0.56 +/- 0.57 micrograms/ml, respectively.",Dermo-epidermal distribution of ketoconazole in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243657/),[μg] / [ml],0.56,211438,DB00592,Piperazine
,26440285,flow rate,"The chromatographic separation was performed using a Chiralpak IE column (2.1 mm×150 mm, 5 μm) with an isocratic elution of CO2/organic modifier (55/45, v/v) at a flow rate of 0.85 mL/min.",Rapid chiral separation of racemic cetirizine in human plasma using subcritical fluid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26440285/),[ml] / [min],0.85,211717,DB00592,Piperazine
,30302786,terminal half-life,Risdiplam exhibited linear PK over the dose range with a multi-phasic decline with a mean terminal half-life of 40-69 h.,"A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30302786/),h,40-69,211840,DB00592,Piperazine
<,27435281,C min,"The analyses included the occurrence of a low imatinib C min (<1000 µg/L), the change in the C min over time and the correlation between exposure and response.",Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27435281/),[μg] / [l],1000,211848,DB00592,Piperazine
<,27435281,C min,"In the first steady-state sample, 44.4 % of patients presented with C min values <1000 µg/L; 32.4 % of patients had values <1000 µg/L in >75 % of their samples.",Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27435281/),[μg] / [l],1000,211849,DB00592,Piperazine
≥,27435281,C min,Only 33.3 % of patients had C min values ≥1000 µg/L in all measured samples.,Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27435281/),[μg] / [l],1000,211850,DB00592,Piperazine
,27435281,C min,Fifty-seven (91.9 %) of 62 palliative-treated patients had a tumour response (median C min 1271 µg/L).,Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27435281/),[μg] / [l],1271,211851,DB00592,Piperazine
,27435281,C min,Five palliative patients (8.1 %) did not respond (median C min 920 µg/L).,Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27435281/),[μg] / [l],920,211852,DB00592,Piperazine
,14990650,plasma trough concentration,"Mean plasma trough concentration was 0.57 microg/mL (approximately 1 micromol/L) 24 hours after administration of 350 mg of imatinib at steady-state, which exceeds the 50% inhibitory concentration required to inhibit proliferation of Bcr-Abl-positive leukemic cells.",Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14990650/),[μg] / [ml],0.57,211888,DB00592,Piperazine
,9379783,terminal elimination half-life,The terminal elimination half-life of dotarizine and its metabolite appeared to be between 7 and 12 h.,Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9379783/),h,7 and 12,211959,DB00592,Piperazine
greater,26688342,recovery,The recovery of sildenafil was greater than 78.4%.,Sensitive and rapid HPLC-UV method with back-extraction step for the determination of sildenafil in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26688342/),%,78.4,212098,DB00592,Piperazine
,21234641,C(min),"Mean inter- and intra-subject variability values were 47.7% and 20.9%, respectively, at initial measurements, and 45.2% and 19.4%, respectively, at FU. Mean FU imatinib C(min) (1,370 ± 661 ng/mL) was significantly higher than mean initial C(min) (1,171 ± 573 ng/mL; p = 0.003).",Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21234641/),[ng] / [ml],"1,370",212128,DB00592,Piperazine
,21234641,C(min),"Mean inter- and intra-subject variability values were 47.7% and 20.9%, respectively, at initial measurements, and 45.2% and 19.4%, respectively, at FU. Mean FU imatinib C(min) (1,370 ± 661 ng/mL) was significantly higher than mean initial C(min) (1,171 ± 573 ng/mL; p = 0.003).",Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21234641/),[ng] / [ml],"1,171",212129,DB00592,Piperazine
,18384443,K(i),"Imatinib, a tyrosine kinase inhibitor, exhibits a competitive inhibition on the CYP450 2D6 isozyme with a K(i) value of 7.5 microm.","Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18384443/),μm,7.5,212302,DB00592,Piperazine
,18384443,AUC,"In the presence of 400 mg twice daily imatinib, the mean metoprolol AUC was increased by 17% in IMs (from 1190 to 1390 ng ml(-1) h), and 24% in EMs (from 660 to 818 ng ml(-1) h).","Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18384443/),[h·ng] / [ml],1190 to 1390,212303,DB00592,Piperazine
,18384443,AUC,"In the presence of 400 mg twice daily imatinib, the mean metoprolol AUC was increased by 17% in IMs (from 1190 to 1390 ng ml(-1) h), and 24% in EMs (from 660 to 818 ng ml(-1) h).","Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18384443/),[h·ng] / [ml],660 to 818,212304,DB00592,Piperazine
,18384443,oral clearance,"The oral clearance of imatinib was 11.0 +/- 2.0 l h(-1) and 11.8 +/- 4.1 l h(-1) for CYP2D6 IMs and EMs, respectively.","Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18384443/),[l] / [h],11.0,212305,DB00592,Piperazine
,18384443,oral clearance,"The oral clearance of imatinib was 11.0 +/- 2.0 l h(-1) and 11.8 +/- 4.1 l h(-1) for CYP2D6 IMs and EMs, respectively.","Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18384443/),[l] / [h],11.8,212306,DB00592,Piperazine
,23781859,content uniformity,"The mean weight variation, content uniformity, hardness and disintegration time of the prepared SVS were 1.127 ± 0.020 g, 98.25 ± 2.50%, 2.5 ± 0.08 kg and 9 ± 1.0 min, respectively.","Sildenafil vaginal suppositories: preparation, characterization, in vitro and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23781859/),kg,2.5,212437,DB00592,Piperazine
,23781859,disintegration time,"The mean weight variation, content uniformity, hardness and disintegration time of the prepared SVS were 1.127 ± 0.020 g, 98.25 ± 2.50%, 2.5 ± 0.08 kg and 9 ± 1.0 min, respectively.","Sildenafil vaginal suppositories: preparation, characterization, in vitro and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23781859/),min,9,212438,DB00592,Piperazine
,1970299,maximum serum cetirizine concentration,"The maximum serum cetirizine concentration and the time to reach that maximum were 285 micrograms.l-1 and 2.0 h, respectively.",Effect of haemodialysis on the pharmacokinetics of cetirizine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970299/),[μg] / [l],285,212623,DB00592,Piperazine
,1970299,time to reach that maximum,"The maximum serum cetirizine concentration and the time to reach that maximum were 285 micrograms.l-1 and 2.0 h, respectively.",Effect of haemodialysis on the pharmacokinetics of cetirizine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970299/),h,2.0,212624,DB00592,Piperazine
,1970299,terminal disposition half-life,The terminal disposition half-life of cetirizine in these patients was 19.3 h.,Effect of haemodialysis on the pharmacokinetics of cetirizine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970299/),h,19.3,212625,DB00592,Piperazine
,1970299,clearance,The haemodialysis clearance of cetirizine was 14.0 ml. min-1.,Effect of haemodialysis on the pharmacokinetics of cetirizine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970299/),[ml] / [min],14.0,212626,DB00592,Piperazine
,32101384,IC50,"PKM-833 showed potent inhibitory activities against human and rat FAAH with IC50 values of 8.8 and 10 nmol/L, respectively, 200-fold more selectivity against other 137 molecular targets, and irreversible mode of action.","Pharmacological characterization of a novel, potent, selective, and orally active fatty acid amide hydrolase inhibitor, PKM-833 [(R)-N-(pyridazin-3-yl)-4-(7-(trifluoromethyl)chroman-4-yl)piperazine-1-carboxamide] in rats: Potential for the treatment of inflammatory pain. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32101384/),[nM] / [l],8.8,212693,DB00592,Piperazine
,32101384,IC50,"PKM-833 showed potent inhibitory activities against human and rat FAAH with IC50 values of 8.8 and 10 nmol/L, respectively, 200-fold more selectivity against other 137 molecular targets, and irreversible mode of action.","Pharmacological characterization of a novel, potent, selective, and orally active fatty acid amide hydrolase inhibitor, PKM-833 [(R)-N-(pyridazin-3-yl)-4-(7-(trifluoromethyl)chroman-4-yl)piperazine-1-carboxamide] in rats: Potential for the treatment of inflammatory pain. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32101384/),[nM] / [l],10,212694,DB00592,Piperazine
,11765144,terminal half-life,The terminal half-life of the total radioactivity from plasma was 21.7 +/- 2.8h with an apparent clearance of 1.01 +/- 0.08 ml min(-1).,"Evaluation of the absorption, excretion and metabolism of [14C] etoperidone in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765144/),h,21.7,212856,DB00592,Piperazine
,11765144,apparent clearance,The terminal half-life of the total radioactivity from plasma was 21.7 +/- 2.8h with an apparent clearance of 1.01 +/- 0.08 ml min(-1).,"Evaluation of the absorption, excretion and metabolism of [14C] etoperidone in man. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765144/),[ml] / [min],1.01,212857,DB00592,Piperazine
,11765144,Recoveries,"Recoveries of total radioactivity in urine and faeces were 78.8 +/- 3.6% and 9.6 +/- 4.1% of the dose, respectively.","Evaluation of the absorption, excretion and metabolism of [14C] etoperidone in man. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765144/),%,78.8,212858,DB00592,Piperazine
,11765144,Recoveries,"Recoveries of total radioactivity in urine and faeces were 78.8 +/- 3.6% and 9.6 +/- 4.1% of the dose, respectively.","Evaluation of the absorption, excretion and metabolism of [14C] etoperidone in man. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765144/),%,9.6,212859,DB00592,Piperazine
,11879256,t1/2,"In the elderly, AUC values were approximately twice as high and Cmax values 60--70% higher than those for young men, while t1/2 values were approximately 1 h longer for sildenafil and 2 h longer for UK-103,320.",The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11879256/),h,1,212965,DB00592,Piperazine
,11879256,t1/2,"In the elderly, AUC values were approximately twice as high and Cmax values 60--70% higher than those for young men, while t1/2 values were approximately 1 h longer for sildenafil and 2 h longer for UK-103,320.",The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11879256/),h,2,212966,DB00592,Piperazine
,6149534,overall bioavailability,"In healthy subjects, almitrine bismesylate taken orally as tablets is rapidly absorbed from the digestive tract, with an overall bioavailability of about 70%.",[Clinical pharmacokinetics of almitrine dimesylate]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149534/),%,70,213078,DB00592,Piperazine
,6149534,Protein binding,"Protein binding is approximately 99%, irrespective of plasma concentrations.",[Clinical pharmacokinetics of almitrine dimesylate]. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149534/),%,99,213079,DB00592,Piperazine
,6149534,apparent volume of distribution,Wide diffusion through body tissues is reflected in the apparent volume of distribution approaching 15 l/kg.,[Clinical pharmacokinetics of almitrine dimesylate]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149534/),[l] / [kg],15,213080,DB00592,Piperazine
,6149534,Plasma elimination half-life,Plasma elimination half-life varies from 45 to 50 hours.,[Clinical pharmacokinetics of almitrine dimesylate]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149534/),h,45 to 50,213081,DB00592,Piperazine
,6149534,Plasma clearance,Plasma clearance (4 ml/min/kg) is about the same as hepatic clearance.,[Clinical pharmacokinetics of almitrine dimesylate]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149534/),[ml] / [kg·min],4,213082,DB00592,Piperazine
,32697563,trough imatinib concentration,"Achieving a major molecular response early in treatment, as indicated by a BCR-ABL1 major international scale result of ≤0.1% within 6 months, is associated with better patient outcomes and is statistically associated with a trough imatinib concentration of approximately 1000 ng/mL.",Evaluation of Imatinib Concentrations in Samples Submitted for BCR-ABL1 or Imatinib Testing-Evidence to Support Therapeutic Drug Monitoring for Dose Optimization? ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32697563/),[ng] / [ml],1000,213755,DB00592,Piperazine
,23404347,half-life,Their pharmacokinetics approach those of the ideal hypnotic with rapid onset within 30 min and short half-life (1-7 h).,The clinical and forensic toxicology of Z-drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23404347/),h,1-7,214122,DB00592,Piperazine
,30822365,total flow rate,"These analytes and the internal standards were extracted from plasma using protein precipitation with acetonitrile, then separated on a CAPCELL PAK ADME C18 column using a mobile phase of acetonitrile and 5 mm ammonium formate acidified with formic acid (0.1%, v/v) at a total flow rate of 0.4 mL/min.","Simultaneous determination of tandospirone and its active metabolite, 1-[2-pyrimidyl]-piperazine in rat plasma by LC-MS/MS and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30822365/),[ml] / [min],0.4,214288,DB00592,Piperazine
,30822365,Total time,Total time for each chromatograph was 3.0 min.,"Simultaneous determination of tandospirone and its active metabolite, 1-[2-pyrimidyl]-piperazine in rat plasma by LC-MS/MS and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30822365/),min,3.0,214289,DB00592,Piperazine
,16890580,apparent oral clearance,"The apparent oral clearance of imatinib was potentially reduced in individuals with at least 1 CYP2D6*4 allele (median, 7.78 versus 10.6 L/h; P = .0695).",Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16890580/),[l] / [h],7.78,214333,DB00592,Piperazine
,16890580,apparent oral clearance,"The apparent oral clearance of imatinib was potentially reduced in individuals with at least 1 CYP2D6*4 allele (median, 7.78 versus 10.6 L/h; P = .0695).",Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16890580/),[l] / [h],10.6,214334,DB00592,Piperazine
,7660794,recoveries,The mean recoveries were 79.35% to 95.72%.,[Methodological study on the determination of naftopidil concentration in biological samples by HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7660794/),%,79.35,214447,DB00592,Piperazine
,7660794,recoveries,The mean recoveries were 79.35% to 95.72%.,[Methodological study on the determination of naftopidil concentration in biological samples by HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7660794/),%,95.72,214448,DB00592,Piperazine
,6274362,T 1/2 alpha,The average half-lives were T 1/2 alpha = 4.1 +/- 1.4 (n = 8) and T 1/2 beta = 44 +/- 7 (n = 8) min.,"Pharmacokinetics of pipecurium bromide, a new non-depolarizing neuromuscular blocking agent, in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6274362/),min,4.1,215002,DB00592,Piperazine
,6274362,T 1/2 beta,The average half-lives were T 1/2 alpha = 4.1 +/- 1.4 (n = 8) and T 1/2 beta = 44 +/- 7 (n = 8) min.,"Pharmacokinetics of pipecurium bromide, a new non-depolarizing neuromuscular blocking agent, in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6274362/),min,44,215003,DB00592,Piperazine
,6274362,apparent distribution volume V beta,"The pharmacokinetic parameters of pipecurium bromide were found as follows: apparent distribution volume V beta = 261 +/- 28 (n = 8) ml/kg, plasma clearance Cl = 320 +/- 55 (n = 8) ml/min.","Pharmacokinetics of pipecurium bromide, a new non-depolarizing neuromuscular blocking agent, in humans. ",Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6274362/),[ml] / [kg],261,215004,DB00592,Piperazine
,6274362,plasma clearance Cl,"The pharmacokinetic parameters of pipecurium bromide were found as follows: apparent distribution volume V beta = 261 +/- 28 (n = 8) ml/kg, plasma clearance Cl = 320 +/- 55 (n = 8) ml/min.","Pharmacokinetics of pipecurium bromide, a new non-depolarizing neuromuscular blocking agent, in humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6274362/),[ml] / [min],320,215005,DB00592,Piperazine
,18447800,terminal half-life,"Mean +/- SD terminal half-life was 10.06 +/- 4.05 hours, and mean peak plasma concentration was 3.30 +/- 1.55 microg/mL.",Pharmacokinetics of cetirizine in healthy cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447800/),h,10.06,215041,DB00592,Piperazine
,18447800,peak plasma concentration,"Mean +/- SD terminal half-life was 10.06 +/- 4.05 hours, and mean peak plasma concentration was 3.30 +/- 1.55 microg/mL.",Pharmacokinetics of cetirizine in healthy cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447800/),[μg] / [ml],3.30,215042,DB00592,Piperazine
,18447800,volume of distribution,"Mean volume of distribution and clearance (per fraction absorbed) were 0.24 +/- 0.09 L/kg and 0.30 +/- 0.09 mL/kg/min, respectively.",Pharmacokinetics of cetirizine in healthy cats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447800/),[l] / [kg],0.24,215043,DB00592,Piperazine
,18447800,clearance (per fraction absorbed),"Mean volume of distribution and clearance (per fraction absorbed) were 0.24 +/- 0.09 L/kg and 0.30 +/- 0.09 mL/kg/min, respectively.",Pharmacokinetics of cetirizine in healthy cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447800/),[ml] / [kg·min],0.30,215044,DB00592,Piperazine
,18447800,Protein binding,Protein binding was approximately 88%.,Pharmacokinetics of cetirizine in healthy cats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447800/),%,88,215045,DB00592,Piperazine
,9140760,flow-rate,"The chromatographic conditions used for the analysis were a Keystone Scientific C18 BDS 150 x 4.6 mm, 5 microns column with a mobile phase consisting of a 40:60 (v/v) mixture of acetonitrile and water containing 10 mM ammonium acetate and 0.1% formic acid pumped at a flow-rate of 1.2 ml/min, yielding retention times of 3.4 and 5.0 min for I and II, respectively.",Picogram determination of a novel dopamine D4 receptor antagonist in human plasma and urine by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9140760/),[ml] / [min],1.2,215617,DB00592,Piperazine
,9140760,retention times,"The chromatographic conditions used for the analysis were a Keystone Scientific C18 BDS 150 x 4.6 mm, 5 microns column with a mobile phase consisting of a 40:60 (v/v) mixture of acetonitrile and water containing 10 mM ammonium acetate and 0.1% formic acid pumped at a flow-rate of 1.2 ml/min, yielding retention times of 3.4 and 5.0 min for I and II, respectively.",Picogram determination of a novel dopamine D4 receptor antagonist in human plasma and urine by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9140760/),min,3.4,215618,DB00592,Piperazine
,9140760,retention times,"The chromatographic conditions used for the analysis were a Keystone Scientific C18 BDS 150 x 4.6 mm, 5 microns column with a mobile phase consisting of a 40:60 (v/v) mixture of acetonitrile and water containing 10 mM ammonium acetate and 0.1% formic acid pumped at a flow-rate of 1.2 ml/min, yielding retention times of 3.4 and 5.0 min for I and II, respectively.",Picogram determination of a novel dopamine D4 receptor antagonist in human plasma and urine by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9140760/),min,5.0,215619,DB00592,Piperazine
,8250313,Total plasma clearance,"Total plasma clearance did not differ between controls (2.96 +/- 1.05 mL.min-1.kg-1, mean +/- SD) and cirrhotics (2.61 +/- 1.16 mL.min-1.kg-1).",Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),[ml] / [kg·min],2.96,215622,DB00592,Piperazine
,8250313,Total plasma clearance,"Total plasma clearance did not differ between controls (2.96 +/- 1.05 mL.min-1.kg-1, mean +/- SD) and cirrhotics (2.61 +/- 1.16 mL.min-1.kg-1).",Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),[ml] / [kg·min],2.61,215623,DB00592,Piperazine
,8250313,Terminal elimination half-life,Terminal elimination half-life was 111 +/- 46 min in controls and 143 +/- 25 min in cirrhotics.,Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),min,111,215624,DB00592,Piperazine
,8250313,Terminal elimination half-life,Terminal elimination half-life was 111 +/- 46 min in controls and 143 +/- 25 min in cirrhotics.,Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),min,143,215625,DB00592,Piperazine
,8250313,total apparent volume of distribution at steady state,The total apparent volume of distribution at steady state did not differ between controls (350 +/- 81 mL/kg) and cirrhotics (452 +/- 222 mL/kg).,Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),[ml] / [kg],350,215626,DB00592,Piperazine
,8250313,total apparent volume of distribution at steady state,The total apparent volume of distribution at steady state did not differ between controls (350 +/- 81 mL/kg) and cirrhotics (452 +/- 222 mL/kg).,Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),[ml] / [kg],452,215627,DB00592,Piperazine
,8250313,onset of neuromuscular blocking effect,The onset of neuromuscular blocking effect was longer in cirrhotics (233 +/- 112 s) (P < 0.05) than in controls (170 +/- 33 s).,Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),s,233,215628,DB00592,Piperazine
,8250313,onset of neuromuscular blocking effect,The onset of neuromuscular blocking effect was longer in cirrhotics (233 +/- 112 s) (P < 0.05) than in controls (170 +/- 33 s).,Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),s,170,215629,DB00592,Piperazine
,17494642,plasma clearance,"The plasma clearance (47.3 +/- 3.5 ml/min/kg), volume of distribution (2.6 +/- 0.3 l/kg), and half-life (1.2 +/- 0.2 h) of 6-OH-buspirone in rats were similar to those for buspirone.",6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17494642/),[ml] / [kg·min],47.3,215700,DB00592,Piperazine
,17494642,volume of distribution,"The plasma clearance (47.3 +/- 3.5 ml/min/kg), volume of distribution (2.6 +/- 0.3 l/kg), and half-life (1.2 +/- 0.2 h) of 6-OH-buspirone in rats were similar to those for buspirone.",6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17494642/),[l] / [kg],2.6,215701,DB00592,Piperazine
,17494642,half-life,"The plasma clearance (47.3 +/- 3.5 ml/min/kg), volume of distribution (2.6 +/- 0.3 l/kg), and half-life (1.2 +/- 0.2 h) of 6-OH-buspirone in rats were similar to those for buspirone.",6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17494642/),h,1.2,215702,DB00592,Piperazine
,17494642,Bioavailability,Bioavailability was higher for 6-OH-buspirone (19%) compared with that for buspirone (1.4%).,6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17494642/),%,19,215703,DB00592,Piperazine
,17494642,Bioavailability,Bioavailability was higher for 6-OH-buspirone (19%) compared with that for buspirone (1.4%).,6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17494642/),%,1.4,215704,DB00592,Piperazine
,17494642,EC(50),"After intravenous infusions to steady-state levels in plasma, 6-OH-buspirone and buspirone increased 5-hydroxytryptamine (HT)(1A) receptor occupancy in a concentration-dependent manner with EC(50) values of 1.0 +/- 0.3 and 0.38 +/- 0.06 microM in the dorsal raphe and 4.0 +/- 0.6 and 1.5 +/- 0.3 microM in the hippocampus, respectively.",6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17494642/),μM,1.0,215705,DB00592,Piperazine
,17494642,EC(50),"After intravenous infusions to steady-state levels in plasma, 6-OH-buspirone and buspirone increased 5-hydroxytryptamine (HT)(1A) receptor occupancy in a concentration-dependent manner with EC(50) values of 1.0 +/- 0.3 and 0.38 +/- 0.06 microM in the dorsal raphe and 4.0 +/- 0.6 and 1.5 +/- 0.3 microM in the hippocampus, respectively.",6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17494642/),μM,0.38,215706,DB00592,Piperazine
,17494642,EC(50),"After intravenous infusions to steady-state levels in plasma, 6-OH-buspirone and buspirone increased 5-hydroxytryptamine (HT)(1A) receptor occupancy in a concentration-dependent manner with EC(50) values of 1.0 +/- 0.3 and 0.38 +/- 0.06 microM in the dorsal raphe and 4.0 +/- 0.6 and 1.5 +/- 0.3 microM in the hippocampus, respectively.",6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17494642/),μM,4.0,215707,DB00592,Piperazine
,17494642,EC(50),"After intravenous infusions to steady-state levels in plasma, 6-OH-buspirone and buspirone increased 5-hydroxytryptamine (HT)(1A) receptor occupancy in a concentration-dependent manner with EC(50) values of 1.0 +/- 0.3 and 0.38 +/- 0.06 microM in the dorsal raphe and 4.0 +/- 0.6 and 1.5 +/- 0.3 microM in the hippocampus, respectively.",6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17494642/),μM,1.5,215708,DB00592,Piperazine
,25404657,flow rate,"An isocratic mobile phase of acetonitrile:10 mM ammonium acetate (80:20, v/v) was used at the 0.3 mL/min flow rate.",A simple and fast UHPLC-MS-MS assay for rapid determination of vilazodone in plasma sample. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25404657/),[ml] / [min],0.3,215774,DB00592,Piperazine
,25404657,run time,"Both vilazodone and IS were eluted at 0.44 and 0.47 min, respectively, having a run time of 1.0 min.",A simple and fast UHPLC-MS-MS assay for rapid determination of vilazodone in plasma sample. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25404657/),min,1.0,215775,DB00592,Piperazine
,25404657,m/z,"The precursor to product ion transitions were monitored at m/z 442.19 > 154.99 for vilazodone and m/z 411.18 > 191.07 for IS, respectively.",A simple and fast UHPLC-MS-MS assay for rapid determination of vilazodone in plasma sample. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25404657/),,44,215776,DB00592,Piperazine
,25404657,m/z,"The precursor to product ion transitions were monitored at m/z 442.19 > 154.99 for vilazodone and m/z 411.18 > 191.07 for IS, respectively.",A simple and fast UHPLC-MS-MS assay for rapid determination of vilazodone in plasma sample. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25404657/),,154.99,215777,DB00592,Piperazine
,25404657,m/z,"The precursor to product ion transitions were monitored at m/z 442.19 > 154.99 for vilazodone and m/z 411.18 > 191.07 for IS, respectively.",A simple and fast UHPLC-MS-MS assay for rapid determination of vilazodone in plasma sample. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25404657/),,41,215778,DB00592,Piperazine
,25404657,m/z,"The precursor to product ion transitions were monitored at m/z 442.19 > 154.99 for vilazodone and m/z 411.18 > 191.07 for IS, respectively.",A simple and fast UHPLC-MS-MS assay for rapid determination of vilazodone in plasma sample. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25404657/),,191.07,215779,DB00592,Piperazine
,18956271,IC(50),"The apparent K(m) and V(max) of beauvericin in HLM were determined by substrate depletion approach and its inhibitory effects on cytochromes P450 (CYP) activities were evaluated using probe substrates, with IC(50) and the (K(i)) values were 1.2 microM (0.5 microM) and 1.3 microM (1.9 microM), respectively for CYP3A4/5 (midazolam) and CYP2C19 (mephenytoin).",An inhibition study of beauvericin on human and rat cytochrome P450 enzymes and its pharmacokinetics in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956271/),μM,1.2,215833,DB00592,Piperazine
,18956271,(K(i)),"The apparent K(m) and V(max) of beauvericin in HLM were determined by substrate depletion approach and its inhibitory effects on cytochromes P450 (CYP) activities were evaluated using probe substrates, with IC(50) and the (K(i)) values were 1.2 microM (0.5 microM) and 1.3 microM (1.9 microM), respectively for CYP3A4/5 (midazolam) and CYP2C19 (mephenytoin).",An inhibition study of beauvericin on human and rat cytochrome P450 enzymes and its pharmacokinetics in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956271/),μM,0.5,215834,DB00592,Piperazine
,18956271,(K(i)),"The apparent K(m) and V(max) of beauvericin in HLM were determined by substrate depletion approach and its inhibitory effects on cytochromes P450 (CYP) activities were evaluated using probe substrates, with IC(50) and the (K(i)) values were 1.2 microM (0.5 microM) and 1.3 microM (1.9 microM), respectively for CYP3A4/5 (midazolam) and CYP2C19 (mephenytoin).",An inhibition study of beauvericin on human and rat cytochrome P450 enzymes and its pharmacokinetics in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956271/),μM,1.3,215835,DB00592,Piperazine
,18956271,(K(i)),"The apparent K(m) and V(max) of beauvericin in HLM were determined by substrate depletion approach and its inhibitory effects on cytochromes P450 (CYP) activities were evaluated using probe substrates, with IC(50) and the (K(i)) values were 1.2 microM (0.5 microM) and 1.3 microM (1.9 microM), respectively for CYP3A4/5 (midazolam) and CYP2C19 (mephenytoin).",An inhibition study of beauvericin on human and rat cytochrome P450 enzymes and its pharmacokinetics in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956271/),μM,1.9,215836,DB00592,Piperazine
,18956271,IC(50),"Similarly, beauvericin was also a potent inhibitor for CYP3A1/2 (IC(50): 1.3 microM) in RLM.",An inhibition study of beauvericin on human and rat cytochrome P450 enzymes and its pharmacokinetics in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956271/),μM,1.3,215837,DB00592,Piperazine
lower,28550529,brain/plasma ratio,HBK-14 (2.5 mg/kg) and HBK-15 (1.25 mg/kg) after intravenous (i.v.) and intraperitoneal (i.p.) administration permeated the blood-brain barrier with brain/plasma ratio lower than 1.,"Single Administration of HBK-15-a Triple 5-HT1A, 5-HT7, and 5-HT3 Receptor Antagonist-Reverses Depressive-Like Behaviors in Mouse Model of Depression Induced by Corticosterone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28550529/),,1,216164,DB00592,Piperazine
,28550529,bioavailability,The bioavailability of studied compounds after i.p. administration was 15% for HBK-14 and 54% for HBK-15.,"Single Administration of HBK-15-a Triple 5-HT1A, 5-HT7, and 5-HT3 Receptor Antagonist-Reverses Depressive-Like Behaviors in Mouse Model of Depression Induced by Corticosterone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28550529/),%,15,216165,DB00592,Piperazine
,28550529,bioavailability,The bioavailability of studied compounds after i.p. administration was 15% for HBK-14 and 54% for HBK-15.,"Single Administration of HBK-15-a Triple 5-HT1A, 5-HT7, and 5-HT3 Receptor Antagonist-Reverses Depressive-Like Behaviors in Mouse Model of Depression Induced by Corticosterone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28550529/),%,54,216166,DB00592,Piperazine
,3735080,AUC,In humans the AUC value for Ksol (62.21 +/- 21.2 microgram X h/ml; mean +/- SD) was significantly greater than for Ktab (50.0 +/- 15.2 micrograms X h/ml; p less than 0.05).,Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735080/),[h·μg] / [ml],62.21,216184,DB00592,Piperazine
,3735080,AUC,In humans the AUC value for Ksol (62.21 +/- 21.2 microgram X h/ml; mean +/- SD) was significantly greater than for Ktab (50.0 +/- 15.2 micrograms X h/ml; p less than 0.05).,Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735080/),[h·μg] / [ml],50.0,216185,DB00592,Piperazine
,3735080,systemic clearance (CLs),"The mean systemic clearance (CLs) of Kiv in dogs was 2.74 +/- 1.10 mL/min/kg, the volume of distribution at steady state (Vdss) was 0.72 +/- 0.28 L/kg, and the half-life was 2.7 +/- 1.6 h.",Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735080/),[ml] / [kg·min],2.74,216186,DB00592,Piperazine
,3735080,volume of distribution at steady state (Vdss),"The mean systemic clearance (CLs) of Kiv in dogs was 2.74 +/- 1.10 mL/min/kg, the volume of distribution at steady state (Vdss) was 0.72 +/- 0.28 L/kg, and the half-life was 2.7 +/- 1.6 h.",Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735080/),[l] / [kg],0.72,216187,DB00592,Piperazine
,3735080,half-life,"The mean systemic clearance (CLs) of Kiv in dogs was 2.74 +/- 1.10 mL/min/kg, the volume of distribution at steady state (Vdss) was 0.72 +/- 0.28 L/kg, and the half-life was 2.7 +/- 1.6 h.",Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735080/),h,2.7,216188,DB00592,Piperazine
,3735080,absolute bioavailability,"The absolute bioavailability of Ktab was 0.50 +/- 0.38, which did not differ statistically from that of Ksol, 0.56 +/- 0.23.",Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735080/),,0.50,216189,DB00592,Piperazine
,3735080,absolute bioavailability,"The absolute bioavailability of Ktab was 0.50 +/- 0.38, which did not differ statistically from that of Ksol, 0.56 +/- 0.23.",Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735080/),,0.56,216190,DB00592,Piperazine
,29324280,flow rate,"A combination of ammonium formate (5 mM)-acetonitrile (pH 4.0; 65:35, v/v) was used as mobile phase and the chromatogram was run under gradient conditions at a flow rate of 0.6 ml/min.",Effective phospholipids removing microelution-solid phase extraction LC-MS/MS method for simultaneous plasma quantification of aripiprazole and dehydro-aripiprazole: Application to human pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29324280/),[ml] / [min],0.6,216339,DB00592,Piperazine
,29324280,total run time,"Run time lasted 5 min, followed by a re-equilibration time of 3 min, to give a total run time of 8 min.",Effective phospholipids removing microelution-solid phase extraction LC-MS/MS method for simultaneous plasma quantification of aripiprazole and dehydro-aripiprazole: Application to human pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29324280/),min,8,216340,DB00592,Piperazine
,31408460,clearance index,"After 3h of recirculating perfusion, the mean (± SD) DTG concentrations in the maternal and in the fetal compartments were respectively 2450 ± 286 ng/mL and 715 ± 369 ng/mL, with a fetal-to-maternal ratio of 34% ± 18% and a clearance index (in comparison with antipyrine transfer) of 79% ± 23%.",Placental transfer and tissue accumulation of dolutegravir in the ex vivo human cotyledon perfusion model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31408460/),%,79,216708,DB00592,Piperazine
,31408460,accumulation index,The mean cotyledon accumulation index was 153% ± 25%.,Placental transfer and tissue accumulation of dolutegravir in the ex vivo human cotyledon perfusion model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31408460/),%,153,216709,DB00592,Piperazine
,10463320,Plasma concentrations,Plasma concentrations of bromperidol during itraconazole coadministration (16.7+/-4.9 ng/ml) were significantly higher (P<0.01) than before itraconazole coadministration (8.9+/-4.4 ng/ml) and 1 week after its discontinuation (9.9+/-4.3 ng/ml).,Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10463320/),[ng] / [ml],16.7,216921,DB00592,Piperazine
,10463320,Plasma concentrations,Plasma concentrations of bromperidol during itraconazole coadministration (16.7+/-4.9 ng/ml) were significantly higher (P<0.01) than before itraconazole coadministration (8.9+/-4.4 ng/ml) and 1 week after its discontinuation (9.9+/-4.3 ng/ml).,Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10463320/),[ng] / [ml],8.9,216922,DB00592,Piperazine
,10463320,Plasma concentrations,Plasma concentrations of bromperidol during itraconazole coadministration (16.7+/-4.9 ng/ml) were significantly higher (P<0.01) than before itraconazole coadministration (8.9+/-4.4 ng/ml) and 1 week after its discontinuation (9.9+/-4.3 ng/ml).,Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10463320/),[ng] / [ml],9.9,216923,DB00592,Piperazine
,10463320,Plasma concentrations,Plasma concentrations of reduced bromperidol during itraconazole coadministration (3.6+/-2.9 ng/ml) were significantly higher (P<0.01) than before itraconazole coadministration (1.8+/-1.3 ng/ml).,Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10463320/),[ng] / [ml],3.6,216924,DB00592,Piperazine
,10463320,Plasma concentrations,Plasma concentrations of reduced bromperidol during itraconazole coadministration (3.6+/-2.9 ng/ml) were significantly higher (P<0.01) than before itraconazole coadministration (1.8+/-1.3 ng/ml).,Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10463320/),[ng] / [ml],1.8,216925,DB00592,Piperazine
,10701961,recovery,"The recovery of centpropazine at 5, 80, 625, 1280 and 2500 ng ml(-1) ranged between 92 and 105%.","Development and validation of a new high-performance liquid chromatographic assay of centpropazine, a new antidepressant compound, in serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701961/),[ng] / [ml],625,217085,DB00592,Piperazine
,10701961,recovery,"The recovery of centpropazine at 5, 80, 625, 1280 and 2500 ng ml(-1) ranged between 92 and 105%.","Development and validation of a new high-performance liquid chromatographic assay of centpropazine, a new antidepressant compound, in serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701961/),[ng] / [ml],1280,217086,DB00592,Piperazine
,10701961,recovery,"The recovery of centpropazine at 5, 80, 625, 1280 and 2500 ng ml(-1) ranged between 92 and 105%.","Development and validation of a new high-performance liquid chromatographic assay of centpropazine, a new antidepressant compound, in serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701961/),[ng] / [ml],2500,217087,DB00592,Piperazine
,10701961,recovery,"The recovery of centpropazine at 5, 80, 625, 1280 and 2500 ng ml(-1) ranged between 92 and 105%.","Development and validation of a new high-performance liquid chromatographic assay of centpropazine, a new antidepressant compound, in serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701961/),%,92 and 105,217088,DB00592,Piperazine
,23106955,retention times,"The retention times of pseudoephedrine, dextrocetirizine, levocetirizine and diazepam (internal standard) were 5.2, 8.3, 9.6 and 11.6 min, respectively, and the total run time was less than 15 min.",Simultaneous determination of levocetirizine and pseudoephedrine in dog plasma by liquid chromatography-mass spectrometry in the presence of dextrocetirizine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23106955/),min,5.2,217311,DB00592,Piperazine
,23106955,retention times,"The retention times of pseudoephedrine, dextrocetirizine, levocetirizine and diazepam (internal standard) were 5.2, 8.3, 9.6 and 11.6 min, respectively, and the total run time was less than 15 min.",Simultaneous determination of levocetirizine and pseudoephedrine in dog plasma by liquid chromatography-mass spectrometry in the presence of dextrocetirizine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23106955/),min,8.3,217312,DB00592,Piperazine
,23106955,retention times,"The retention times of pseudoephedrine, dextrocetirizine, levocetirizine and diazepam (internal standard) were 5.2, 8.3, 9.6 and 11.6 min, respectively, and the total run time was less than 15 min.",Simultaneous determination of levocetirizine and pseudoephedrine in dog plasma by liquid chromatography-mass spectrometry in the presence of dextrocetirizine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23106955/),min,9.6,217313,DB00592,Piperazine
,23106955,retention times,"The retention times of pseudoephedrine, dextrocetirizine, levocetirizine and diazepam (internal standard) were 5.2, 8.3, 9.6 and 11.6 min, respectively, and the total run time was less than 15 min.",Simultaneous determination of levocetirizine and pseudoephedrine in dog plasma by liquid chromatography-mass spectrometry in the presence of dextrocetirizine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23106955/),min,11.6,217314,DB00592,Piperazine
less,23106955,total run time,"The retention times of pseudoephedrine, dextrocetirizine, levocetirizine and diazepam (internal standard) were 5.2, 8.3, 9.6 and 11.6 min, respectively, and the total run time was less than 15 min.",Simultaneous determination of levocetirizine and pseudoephedrine in dog plasma by liquid chromatography-mass spectrometry in the presence of dextrocetirizine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23106955/),min,15,217315,DB00592,Piperazine
,6311786,serum half life,"The serum half life of ketoconazole was 74.8 +/- 13.9 min (mean +/- S.D.) on day 1, and 155.9 +/- 32.7 min on day 5.",Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6311786/),min,74.8,217367,DB00592,Piperazine
,6311786,serum half life,"The serum half life of ketoconazole was 74.8 +/- 13.9 min (mean +/- S.D.) on day 1, and 155.9 +/- 32.7 min on day 5.",Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6311786/),min,155.9,217368,DB00592,Piperazine
,6311786,area under the serum concentration time curve,"On day 1 the area under the serum concentration time curve was 626.9 +/- 230.1 mg/l.min, and 1441 +/- 897.3 mg/l.min on day 5.",Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6311786/),[mg] / [l·min],626.9,217369,DB00592,Piperazine
,6311786,area under the serum concentration time curve,"On day 1 the area under the serum concentration time curve was 626.9 +/- 230.1 mg/l.min, and 1441 +/- 897.3 mg/l.min on day 5.",Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6311786/),[mg] / [l·min],1441,217370,DB00592,Piperazine
,15823634,plasma levels,"Sildenafil plasma levels 1 h after a 0.5, 1.0 and 2 mg/kg dose of Sildenafil were 109+/-87, 150+/-62 and 368+/-200 ng/ml, respectively.",Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823634/),[ng] / [ml],109,217515,DB00592,Piperazine
,15823634,plasma levels,"Sildenafil plasma levels 1 h after a 0.5, 1.0 and 2 mg/kg dose of Sildenafil were 109+/-87, 150+/-62 and 368+/-200 ng/ml, respectively.",Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823634/),[ng] / [ml],150,217516,DB00592,Piperazine
,15823634,plasma levels,"Sildenafil plasma levels 1 h after a 0.5, 1.0 and 2 mg/kg dose of Sildenafil were 109+/-87, 150+/-62 and 368+/-200 ng/ml, respectively.",Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823634/),[ng] / [ml],368,217517,DB00592,Piperazine
,20428608,bioavailability,Lodenafil carbonate bioavailability was increased in 74% when drug intake was associated with alcohol.,"[Cardiovascular repercussion of lodenafil carbonate, a new PDE5 inhibitor, with and without alcohol consumption]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20428608/),%,74,217917,DB00592,Piperazine
,19698014,time to peak plasma concentration,"Absorption is complete and rapid, with mean time to peak plasma concentration of approximately 30 minutes for R-138727.","Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19698014/),min,30,217918,DB00592,Piperazine
,19698014,plasma half-life,"Median plasma half-life of the active metabolite is approximately 4 hours, and excretion is mainly urinary.","Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19698014/),h,4,217919,DB00592,Piperazine
,19884365,area under the concentration-time curve over a dosing interval (AUC(0-tau)),"The steady-state geometric mean area under the concentration-time curve over a dosing interval (AUC(0-tau)) and maximum concentration of the drug in plasma (C(max)) ranged from 16.7 microg.h/ml (coefficient of variation [CV], 15%) and 1.5 microg/ml (CV, 24%) at a 10-mg dose to 76.8 microg.h/ml (CV, 19%) and 6.2 microg/ml (CV, 15%) at a 50-mg dose, respectively.","Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19884365/),[h·μg] / [ml],16.7,217960,DB00592,Piperazine
,19884365,area under the concentration-time curve over a dosing interval (AUC(0-tau)),"The steady-state geometric mean area under the concentration-time curve over a dosing interval (AUC(0-tau)) and maximum concentration of the drug in plasma (C(max)) ranged from 16.7 microg.h/ml (coefficient of variation [CV], 15%) and 1.5 microg/ml (CV, 24%) at a 10-mg dose to 76.8 microg.h/ml (CV, 19%) and 6.2 microg/ml (CV, 15%) at a 50-mg dose, respectively.","Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19884365/),[h·μg] / [ml],76.8,217961,DB00592,Piperazine
,19884365,maximum concentration of the drug in plasma (C(max)),"The steady-state geometric mean area under the concentration-time curve over a dosing interval (AUC(0-tau)) and maximum concentration of the drug in plasma (C(max)) ranged from 16.7 microg.h/ml (coefficient of variation [CV], 15%) and 1.5 microg/ml (CV, 24%) at a 10-mg dose to 76.8 microg.h/ml (CV, 19%) and 6.2 microg/ml (CV, 15%) at a 50-mg dose, respectively.","Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19884365/),[μg] / [ml],1.5,217962,DB00592,Piperazine
,19884365,maximum concentration of the drug in plasma (C(max)),"The steady-state geometric mean area under the concentration-time curve over a dosing interval (AUC(0-tau)) and maximum concentration of the drug in plasma (C(max)) ranged from 16.7 microg.h/ml (coefficient of variation [CV], 15%) and 1.5 microg/ml (CV, 24%) at a 10-mg dose to 76.8 microg.h/ml (CV, 19%) and 6.2 microg/ml (CV, 15%) at a 50-mg dose, respectively.","Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19884365/),[μg] / [ml],6.2,217963,DB00592,Piperazine
,19884365,steady-state concentration at the end of the dosing interval (C(tau)),"The geometric mean steady-state concentration at the end of the dosing interval (C(tau)) with a 50-mg dose was 1.6 microg/ml, approximately 25-fold higher than the protein-adjusted 90% inhibitory concentration (0.064 microg/ml).","Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19884365/),[μg] / [ml],1.6,217964,DB00592,Piperazine
,19884365,90% inhibitory concentration,"The geometric mean steady-state concentration at the end of the dosing interval (C(tau)) with a 50-mg dose was 1.6 microg/ml, approximately 25-fold higher than the protein-adjusted 90% inhibitory concentration (0.064 microg/ml).","Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19884365/),[μg] / [ml],0.064,217965,DB00592,Piperazine
,19884365,half-life,The half-life was approximately 15 h.,"Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19884365/),h,15,217966,DB00592,Piperazine
,1662191,maximum concentrations (Cmax),At day 7 for ITRA-PEL (n = 8) the mean +/- one standard deviation and median maximum concentrations (Cmax) were 307 +/- 155 ng/mL and 275 ng/mL respectively and for ITRA-PEG (n = 6) 272 +/- 212 ng/mL and 193 ng/mL.,Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662191/),[ng] / [ml],275,218705,DB00592,Piperazine
,1662191,maximum concentrations (Cmax),At day 7 for ITRA-PEL (n = 8) the mean +/- one standard deviation and median maximum concentrations (Cmax) were 307 +/- 155 ng/mL and 275 ng/mL respectively and for ITRA-PEG (n = 6) 272 +/- 212 ng/mL and 193 ng/mL.,Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662191/),[ng] / [ml],193,218706,DB00592,Piperazine
,1662191,Cmax,"At day 14 for ITRA-PEL (n = 8) the mean +/- S.D. and median Cmax were 412 +/- 227 ng/mL and 375 ng/mL respectively and for ITRA-PEG (n = 5), 315 +/- 177 ng/mL and 327 ng/mL.",Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662191/),[ng] / [ml],375,218707,DB00592,Piperazine
,1662191,Cmax,"At day 14 for ITRA-PEL (n = 8) the mean +/- S.D. and median Cmax were 412 +/- 227 ng/mL and 375 ng/mL respectively and for ITRA-PEG (n = 5), 315 +/- 177 ng/mL and 327 ng/mL.",Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662191/),[ng] / [ml],327,218708,DB00592,Piperazine
,10836747,retention times,"(+)-Cetirizine, (-)-cetirizine and the internal standard were eluted at retention times of 12, 16, and 32 mins, respectively.",Enantioselective determination of cetirizine in human urine by HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10836747/),min,12,218722,DB00592,Piperazine
,10836747,retention times,"(+)-Cetirizine, (-)-cetirizine and the internal standard were eluted at retention times of 12, 16, and 32 mins, respectively.",Enantioselective determination of cetirizine in human urine by HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10836747/),min,16,218723,DB00592,Piperazine
,10836747,retention times,"(+)-Cetirizine, (-)-cetirizine and the internal standard were eluted at retention times of 12, 16, and 32 mins, respectively.",Enantioselective determination of cetirizine in human urine by HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10836747/),min,32,218724,DB00592,Piperazine
,10836747,detection limit,The detection limit for cetirizine enantiomers was 400 ng/ml of urine.,Enantioselective determination of cetirizine in human urine by HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10836747/),[ng] / [ml],400,218725,DB00592,Piperazine
,6322829,area under the plasma concentration time curve (AUC),The area under the plasma concentration time curve (AUC) after the oral dose was 51.41 +/- 10.99 mg l-1 h (mean +/- s.d.) and the half-life of ketoconazole was 2.98 +/- 1.41 h.,Systemic absorption of ketoconazole from vaginal pessaries. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6322829/),[h·mg] / [l],51.41,218791,DB00592,Piperazine
,6322829,half-life,The area under the plasma concentration time curve (AUC) after the oral dose was 51.41 +/- 10.99 mg l-1 h (mean +/- s.d.) and the half-life of ketoconazole was 2.98 +/- 1.41 h.,Systemic absorption of ketoconazole from vaginal pessaries. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6322829/),h,2.98,218792,DB00592,Piperazine
,6322829,AUCs,"The AUCs after vaginal administration were 0.27 +/- 0.14, 0.52 +/- 0.25, and 0.43 +/- 0.22 mg-1 l h following the 400, 800 and 1200 mg pessaries respectively.",Systemic absorption of ketoconazole from vaginal pessaries. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6322829/),[h·l] / [mg],0.27,218793,DB00592,Piperazine
,6322829,AUCs,"The AUCs after vaginal administration were 0.27 +/- 0.14, 0.52 +/- 0.25, and 0.43 +/- 0.22 mg-1 l h following the 400, 800 and 1200 mg pessaries respectively.",Systemic absorption of ketoconazole from vaginal pessaries. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6322829/),[h·l] / [mg],0.52,218794,DB00592,Piperazine
,6322829,AUCs,"The AUCs after vaginal administration were 0.27 +/- 0.14, 0.52 +/- 0.25, and 0.43 +/- 0.22 mg-1 l h following the 400, 800 and 1200 mg pessaries respectively.",Systemic absorption of ketoconazole from vaginal pessaries. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6322829/),[h·l] / [mg],0.43,218795,DB00592,Piperazine
,31145690,fm,"The fractions metabolized in the liver via oxidation by CYP enzymes (fm,CYP3A4 = 0.75, fm,CYP2C9 = 0.19, and fm,CYPothers = 0.06) for an initial ruxolitinib model based on in vitro data were optimized (0.43, 0.56, and 0.01, respectively) using the observed exposure changes of ruxolitinib (10 mg) with co-administered ketoconazole (200 mg).","Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions. ",fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31145690/),,0.,218802,DB00592,Piperazine
,31145690,fm,"The fractions metabolized in the liver via oxidation by CYP enzymes (fm,CYP3A4 = 0.75, fm,CYP2C9 = 0.19, and fm,CYPothers = 0.06) for an initial ruxolitinib model based on in vitro data were optimized (0.43, 0.56, and 0.01, respectively) using the observed exposure changes of ruxolitinib (10 mg) with co-administered ketoconazole (200 mg).","Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions. ",fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31145690/),,0.19,218803,DB00592,Piperazine
,31145690,fm,"The fractions metabolized in the liver via oxidation by CYP enzymes (fm,CYP3A4 = 0.75, fm,CYP2C9 = 0.19, and fm,CYPothers = 0.06) for an initial ruxolitinib model based on in vitro data were optimized (0.43, 0.56, and 0.01, respectively) using the observed exposure changes of ruxolitinib (10 mg) with co-administered ketoconazole (200 mg).","Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions. ",fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31145690/),,0.06,218804,DB00592,Piperazine
,31145690,fm,"The fractions metabolized in the liver via oxidation by CYP enzymes (fm,CYP3A4 = 0.75, fm,CYP2C9 = 0.19, and fm,CYPothers = 0.06) for an initial ruxolitinib model based on in vitro data were optimized (0.43, 0.56, and 0.01, respectively) using the observed exposure changes of ruxolitinib (10 mg) with co-administered ketoconazole (200 mg).","Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions. ",fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31145690/),,0,218805,DB00592,Piperazine
,31145690,AUC ratio,"With the optimized fm values, the predicted AUC ratio was 1.82.","Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31145690/),,1.82,218806,DB00592,Piperazine
,9834040,total plasma clearance,"Coadministration with fluvoxamine decreased the mean total plasma clearance of ropivacaine from 354 to 112 mL/min (68%), whereas ketoconazole decreased plasma clearance to 302 mL/min (15%).",Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834040/),[ml] / [min],354,219053,DB00592,Piperazine
,9834040,total plasma clearance,"Coadministration with fluvoxamine decreased the mean total plasma clearance of ropivacaine from 354 to 112 mL/min (68%), whereas ketoconazole decreased plasma clearance to 302 mL/min (15%).",Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834040/),[ml] / [min],112,219054,DB00592,Piperazine
,9834040,plasma clearance,"Coadministration with fluvoxamine decreased the mean total plasma clearance of ropivacaine from 354 to 112 mL/min (68%), whereas ketoconazole decreased plasma clearance to 302 mL/min (15%).",Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834040/),[ml] / [min],302,219055,DB00592,Piperazine
,9834040,half-life (t1/2),"The ropivacaine half-life (t1/2) of 1.9 hours was almost doubled during fluvoxamine administration and the plasma concentration at the end of infusion increased slightly, whereas the corresponding parameters after ketoconazole administration remained unchanged.",Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834040/),h,1.9,219056,DB00592,Piperazine
,2884246,serum half-life,"The mean serum half-life value on day 30, 60, and 120 was significantly longer (p less than 0.05) than that of 2.4 +/- 0.3 hours obtained on day 1.",The effect of chronic administration of hydroxyzine on hydroxyzine pharmacokinetics in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2884246/),h,2.4,219069,DB00592,Piperazine
,2884246,clearance,"The mean clearance values obtained on days 30, 60, 90, 120, and 150 were significantly slower (p less than 0.05) than the value of 25.12 +/- 4.13 ml/min/kg obtained on day 1 but were not significantly different from each other.",The effect of chronic administration of hydroxyzine on hydroxyzine pharmacokinetics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2884246/),[ml] / [kg·min],25.12,219070,DB00592,Piperazine
,2884246,apparent volume of distribution,"The mean apparent volume of distribution values obtained on days 30, 60, 90, 120, and 150 did not differ significantly from the value of 5.0 +/- 1.5 L/kg obtained on day 1.",The effect of chronic administration of hydroxyzine on hydroxyzine pharmacokinetics in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2884246/),[l] / [kg],5.0,219071,DB00592,Piperazine
,15388441,maximum concentrations of drug (C(max)),"ITRA and OH-IT maximum concentrations of drug (C(max)) (mean +/- standard deviation) in plasma, ELF, and AC were 2.1 +/- 0.8 and 3.3 +/- 1.0, 0.5 +/- 0.7 and 1.0 +/- 0.9, and 5.5 +/- 2.9 and 6.6 +/- 3.1 microg/ml, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),[μg] / [ml],2.1,219182,DB00592,Piperazine
,15388441,maximum concentrations of drug (C(max)),"ITRA and OH-IT maximum concentrations of drug (C(max)) (mean +/- standard deviation) in plasma, ELF, and AC were 2.1 +/- 0.8 and 3.3 +/- 1.0, 0.5 +/- 0.7 and 1.0 +/- 0.9, and 5.5 +/- 2.9 and 6.6 +/- 3.1 microg/ml, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),[μg] / [ml],3.3,219183,DB00592,Piperazine
,15388441,maximum concentrations of drug (C(max)),"ITRA and OH-IT maximum concentrations of drug (C(max)) (mean +/- standard deviation) in plasma, ELF, and AC were 2.1 +/- 0.8 and 3.3 +/- 1.0, 0.5 +/- 0.7 and 1.0 +/- 0.9, and 5.5 +/- 2.9 and 6.6 +/- 3.1 microg/ml, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),[μg] / [ml],0.5,219184,DB00592,Piperazine
,15388441,maximum concentrations of drug (C(max)),"ITRA and OH-IT maximum concentrations of drug (C(max)) (mean +/- standard deviation) in plasma, ELF, and AC were 2.1 +/- 0.8 and 3.3 +/- 1.0, 0.5 +/- 0.7 and 1.0 +/- 0.9, and 5.5 +/- 2.9 and 6.6 +/- 3.1 microg/ml, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),[μg] / [ml],1.0,219185,DB00592,Piperazine
,15388441,maximum concentrations of drug (C(max)),"ITRA and OH-IT maximum concentrations of drug (C(max)) (mean +/- standard deviation) in plasma, ELF, and AC were 2.1 +/- 0.8 and 3.3 +/- 1.0, 0.5 +/- 0.7 and 1.0 +/- 0.9, and 5.5 +/- 2.9 and 6.6 +/- 3.1 microg/ml, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),[μg] / [ml],5.5,219186,DB00592,Piperazine
,15388441,maximum concentrations of drug (C(max)),"ITRA and OH-IT maximum concentrations of drug (C(max)) (mean +/- standard deviation) in plasma, ELF, and AC were 2.1 +/- 0.8 and 3.3 +/- 1.0, 0.5 +/- 0.7 and 1.0 +/- 0.9, and 5.5 +/- 2.9 and 6.6 +/- 3.1 microg/ml, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),[μg] / [ml],6.6,219187,DB00592,Piperazine
,15388441,AUC,"The ITRA and OH-IT AUC for plasma, ELF, and AC were 34.4 and 60.2, 7.4 and 18.9, and 101 and 134 microg.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),μg,34.4,219188,DB00592,Piperazine
,15388441,AUC,"The ITRA and OH-IT AUC for plasma, ELF, and AC were 34.4 and 60.2, 7.4 and 18.9, and 101 and 134 microg.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),μg,60.2,219189,DB00592,Piperazine
,15388441,AUC,"The ITRA and OH-IT AUC for plasma, ELF, and AC were 34.4 and 60.2, 7.4 and 18.9, and 101 and 134 microg.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),μg,7.4,219190,DB00592,Piperazine
,15388441,AUC,"The ITRA and OH-IT AUC for plasma, ELF, and AC were 34.4 and 60.2, 7.4 and 18.9, and 101 and 134 microg.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),μg,18.9,219191,DB00592,Piperazine
,15388441,AUC,"The ITRA and OH-IT AUC for plasma, ELF, and AC were 34.4 and 60.2, 7.4 and 18.9, and 101 and 134 microg.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),μg,101,219192,DB00592,Piperazine
,15388441,AUC,"The ITRA and OH-IT AUC for plasma, ELF, and AC were 34.4 and 60.2, 7.4 and 18.9, and 101 and 134 microg.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),μg,134,219193,DB00592,Piperazine
,15388441,half-lives,"Plasma, ELF, and AC concentrations of ITRA and OH-IT declined monoexponentially with half-lives of 23.1 and 37.2, 33.2 and 48.3, and 15.7 and 45.6 h, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),h,23.1,219194,DB00592,Piperazine
,15388441,half-lives,"Plasma, ELF, and AC concentrations of ITRA and OH-IT declined monoexponentially with half-lives of 23.1 and 37.2, 33.2 and 48.3, and 15.7 and 45.6 h, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),h,37.2,219195,DB00592,Piperazine
,15388441,half-lives,"Plasma, ELF, and AC concentrations of ITRA and OH-IT declined monoexponentially with half-lives of 23.1 and 37.2, 33.2 and 48.3, and 15.7 and 45.6 h, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),h,33.2,219196,DB00592,Piperazine
,15388441,half-lives,"Plasma, ELF, and AC concentrations of ITRA and OH-IT declined monoexponentially with half-lives of 23.1 and 37.2, 33.2 and 48.3, and 15.7 and 45.6 h, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),h,48.3,219197,DB00592,Piperazine
,15388441,half-lives,"Plasma, ELF, and AC concentrations of ITRA and OH-IT declined monoexponentially with half-lives of 23.1 and 37.2, 33.2 and 48.3, and 15.7 and 45.6 h, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),h,15.7,219198,DB00592,Piperazine
,15388441,half-lives,"Plasma, ELF, and AC concentrations of ITRA and OH-IT declined monoexponentially with half-lives of 23.1 and 37.2, 33.2 and 48.3, and 15.7 and 45.6 h, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15388441/),h,45.6,219199,DB00592,Piperazine
,27128835,total clearance,"The lower mean total clearance in subjects with mild (9.79 L/h) or moderate (8.57 L/h) hepatic impairment resulted in longer mean half-lives (27.9 and 30.9 hours, respectively) than in healthy subjects (clearance: 13.11 L/h, half life: 24.8 hours).",Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128835/),[l] / [h],9.79,219372,DB00592,Piperazine
,27128835,total clearance,"The lower mean total clearance in subjects with mild (9.79 L/h) or moderate (8.57 L/h) hepatic impairment resulted in longer mean half-lives (27.9 and 30.9 hours, respectively) than in healthy subjects (clearance: 13.11 L/h, half life: 24.8 hours).",Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128835/),[l] / [h],8.57,219373,DB00592,Piperazine
,27128835,half-lives,"The lower mean total clearance in subjects with mild (9.79 L/h) or moderate (8.57 L/h) hepatic impairment resulted in longer mean half-lives (27.9 and 30.9 hours, respectively) than in healthy subjects (clearance: 13.11 L/h, half life: 24.8 hours).",Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128835/),h,27.9,219374,DB00592,Piperazine
,27128835,half-lives,"The lower mean total clearance in subjects with mild (9.79 L/h) or moderate (8.57 L/h) hepatic impairment resulted in longer mean half-lives (27.9 and 30.9 hours, respectively) than in healthy subjects (clearance: 13.11 L/h, half life: 24.8 hours).",Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128835/),h,30.9,219375,DB00592,Piperazine
,27128835,clearance,"The lower mean total clearance in subjects with mild (9.79 L/h) or moderate (8.57 L/h) hepatic impairment resulted in longer mean half-lives (27.9 and 30.9 hours, respectively) than in healthy subjects (clearance: 13.11 L/h, half life: 24.8 hours).",Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128835/),[l] / [h],13.11,219376,DB00592,Piperazine
,27128835,half life,"The lower mean total clearance in subjects with mild (9.79 L/h) or moderate (8.57 L/h) hepatic impairment resulted in longer mean half-lives (27.9 and 30.9 hours, respectively) than in healthy subjects (clearance: 13.11 L/h, half life: 24.8 hours).",Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128835/),h,24.8,219377,DB00592,Piperazine
,27128835,Protein binding,Protein binding ranged between 36.9% and 47.5% in subjects with hepatic impairment and between 32.5% and 34.5% in healthy subjects.,Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128835/),%,36.9,219378,DB00592,Piperazine
,27128835,Protein binding,Protein binding ranged between 36.9% and 47.5% in subjects with hepatic impairment and between 32.5% and 34.5% in healthy subjects.,Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128835/),%,47.5,219379,DB00592,Piperazine
,27128835,Protein binding,Protein binding ranged between 36.9% and 47.5% in subjects with hepatic impairment and between 32.5% and 34.5% in healthy subjects.,Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128835/),%,32.5,219380,DB00592,Piperazine
,27128835,Protein binding,Protein binding ranged between 36.9% and 47.5% in subjects with hepatic impairment and between 32.5% and 34.5% in healthy subjects.,Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128835/),%,34.5,219381,DB00592,Piperazine
,9152596,absolute bioavailability,"After oral administration, OLZ was well absorbed in dogs (absolute bioavailability of 73%) and to the extent of at least 55% in monkeys and 32% in mice.","Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9152596/),%,73,219858,DB00592,Piperazine
,9152596,absolute bioavailability,"After oral administration, OLZ was well absorbed in dogs (absolute bioavailability of 73%) and to the extent of at least 55% in monkeys and 32% in mice.","Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9152596/),%,55,219859,DB00592,Piperazine
,9152596,absolute bioavailability,"After oral administration, OLZ was well absorbed in dogs (absolute bioavailability of 73%) and to the extent of at least 55% in monkeys and 32% in mice.","Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9152596/),%,32,219860,DB00592,Piperazine
,9152596,terminal elimination half-life,The terminal elimination half-life of OLZ was relatively short in mice and monkeys (approximately 3 hr) and long in dogs (approximately 9 hr).,"Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9152596/),h,3,219861,DB00592,Piperazine
,9152596,terminal elimination half-life,The terminal elimination half-life of OLZ was relatively short in mice and monkeys (approximately 3 hr) and long in dogs (approximately 9 hr).,"Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9152596/),h,9,219862,DB00592,Piperazine
,22014654,flow rate,"Atractylenolide I and I.S. were separated on a Phenomenex Gemini C(18) column (50 mm × 2.0 mm, 5 μm) with gradient mobile phase at the flow rate of 0.4 ml/min.",Quantitative analysis of atractylenolide I in rat plasma by LC-MS/MS method and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22014654/),[ml] / [min],0.4,220143,DB00592,Piperazine
,22014654,limit of detection (LOD),"The limit of detection (LOD) and the limit of quantification (LOQ) were 0.6 ng/ml and 2.0 ng/ml, respectively.",Quantitative analysis of atractylenolide I in rat plasma by LC-MS/MS method and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22014654/),[ng] / [ml],0.6,220144,DB00592,Piperazine
,22014654,limit of quantification (LOQ),"The limit of detection (LOD) and the limit of quantification (LOQ) were 0.6 ng/ml and 2.0 ng/ml, respectively.",Quantitative analysis of atractylenolide I in rat plasma by LC-MS/MS method and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22014654/),[ng] / [ml],2.0,220145,DB00592,Piperazine
,22014654,recoveries,"The recoveries of atractylenolide I and I.S. were 91.4% and 87.8%, respectively.",Quantitative analysis of atractylenolide I in rat plasma by LC-MS/MS method and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22014654/),%,91.4,220146,DB00592,Piperazine
,22014654,recoveries,"The recoveries of atractylenolide I and I.S. were 91.4% and 87.8%, respectively.",Quantitative analysis of atractylenolide I in rat plasma by LC-MS/MS method and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22014654/),%,87.8,220147,DB00592,Piperazine
,22014654,T(max),"The main pharmacokinetic parameters T(max) (the time to peak), C(max) (the concentration to peak), T(0.5) (the biological half time), and K(e) (the elimination rate constant) were 0.81 ± 0.11h, 7.99 ± 1.2 ng/ml, 1.94 ± 0.27 h, 0.365 ± 0.06/h, respectively.",Quantitative analysis of atractylenolide I in rat plasma by LC-MS/MS method and its application to pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22014654/),h,0.81,220148,DB00592,Piperazine
,22014654,C(max),"The main pharmacokinetic parameters T(max) (the time to peak), C(max) (the concentration to peak), T(0.5) (the biological half time), and K(e) (the elimination rate constant) were 0.81 ± 0.11h, 7.99 ± 1.2 ng/ml, 1.94 ± 0.27 h, 0.365 ± 0.06/h, respectively.",Quantitative analysis of atractylenolide I in rat plasma by LC-MS/MS method and its application to pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22014654/),[ng] / [ml],7.99,220149,DB00592,Piperazine
,22014654,C(max),"The main pharmacokinetic parameters T(max) (the time to peak), C(max) (the concentration to peak), T(0.5) (the biological half time), and K(e) (the elimination rate constant) were 0.81 ± 0.11h, 7.99 ± 1.2 ng/ml, 1.94 ± 0.27 h, 0.365 ± 0.06/h, respectively.",Quantitative analysis of atractylenolide I in rat plasma by LC-MS/MS method and its application to pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22014654/),h,1.94,220150,DB00592,Piperazine
,22014654,T(0.5),"The main pharmacokinetic parameters T(max) (the time to peak), C(max) (the concentration to peak), T(0.5) (the biological half time), and K(e) (the elimination rate constant) were 0.81 ± 0.11h, 7.99 ± 1.2 ng/ml, 1.94 ± 0.27 h, 0.365 ± 0.06/h, respectively.",Quantitative analysis of atractylenolide I in rat plasma by LC-MS/MS method and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22014654/),[ng] / [ml],7.99,220151,DB00592,Piperazine
,22014654,biological half time,"The main pharmacokinetic parameters T(max) (the time to peak), C(max) (the concentration to peak), T(0.5) (the biological half time), and K(e) (the elimination rate constant) were 0.81 ± 0.11h, 7.99 ± 1.2 ng/ml, 1.94 ± 0.27 h, 0.365 ± 0.06/h, respectively.",Quantitative analysis of atractylenolide I in rat plasma by LC-MS/MS method and its application to pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22014654/),[ng] / [ml],7.99,220152,DB00592,Piperazine
,22014654,K(e),"The main pharmacokinetic parameters T(max) (the time to peak), C(max) (the concentration to peak), T(0.5) (the biological half time), and K(e) (the elimination rate constant) were 0.81 ± 0.11h, 7.99 ± 1.2 ng/ml, 1.94 ± 0.27 h, 0.365 ± 0.06/h, respectively.",Quantitative analysis of atractylenolide I in rat plasma by LC-MS/MS method and its application to pharmacokinetic study. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22014654/),[ng] / [ml],7.99,220153,DB00592,Piperazine
,22014654,K(e),"The main pharmacokinetic parameters T(max) (the time to peak), C(max) (the concentration to peak), T(0.5) (the biological half time), and K(e) (the elimination rate constant) were 0.81 ± 0.11h, 7.99 ± 1.2 ng/ml, 1.94 ± 0.27 h, 0.365 ± 0.06/h, respectively.",Quantitative analysis of atractylenolide I in rat plasma by LC-MS/MS method and its application to pharmacokinetic study. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22014654/),h,1.94,220154,DB00592,Piperazine
,26456247,tensile strength,"The thickness of MH OTF obtained was 0.116±0.004mm, the tensile strength was 17.37±1.54Nmm(-2) and the drug dissolution at 5min was more than 80% both in distilled water and 0.1mol/L HCL.",Preparation of an oral thin film containing meclizine hydrochloride: In vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26456247/),1/[(nmm)^2],17.37,220235,DB00592,Piperazine
,26456247,Cmax,"The Cmax of Zentrip® and MH OTF were 1.46±0.44μg/mL and 1.91±0.51μg/mL, and the AUC were 10.38±2.93μgh/mL and 13.74±3.23μgh/mL, respectively.",Preparation of an oral thin film containing meclizine hydrochloride: In vitro and in vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26456247/),[μg] / [ml],1.46,220236,DB00592,Piperazine
,26456247,Cmax,"The Cmax of Zentrip® and MH OTF were 1.46±0.44μg/mL and 1.91±0.51μg/mL, and the AUC were 10.38±2.93μgh/mL and 13.74±3.23μgh/mL, respectively.",Preparation of an oral thin film containing meclizine hydrochloride: In vitro and in vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26456247/),[μg] / [ml],1.91,220237,DB00592,Piperazine
,26456247,AUC,"The Cmax of Zentrip® and MH OTF were 1.46±0.44μg/mL and 1.91±0.51μg/mL, and the AUC were 10.38±2.93μgh/mL and 13.74±3.23μgh/mL, respectively.",Preparation of an oral thin film containing meclizine hydrochloride: In vitro and in vivo evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26456247/),[μgh] / [ml],10.38,220238,DB00592,Piperazine
,26456247,AUC,"The Cmax of Zentrip® and MH OTF were 1.46±0.44μg/mL and 1.91±0.51μg/mL, and the AUC were 10.38±2.93μgh/mL and 13.74±3.23μgh/mL, respectively.",Preparation of an oral thin film containing meclizine hydrochloride: In vitro and in vivo evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26456247/),[μgh] / [ml],13.74,220239,DB00592,Piperazine
,11999755,flow-rate,"Analysis was performed using a Symmetry C18 column (150x4.6 mm, 5 microm) and isocratic elution with 25 mM KH2PO4 (pH 4.5)-acetonitrile (50:50) with a flow-rate of 1 ml/min.",Simple high-performance liquid chromatography method for the simultaneous determination of ketoconazole and piperine in rat plasma and hepatocyte culture. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999755/),[ml] / [min],1,220360,DB00592,Piperazine
,11999755,detection limits,"The detection limits for piperine and ketoconazole are 2 and 4 ng, respectively, and the limits of quantitation are 10 and 12 ng, respectively.",Simple high-performance liquid chromatography method for the simultaneous determination of ketoconazole and piperine in rat plasma and hepatocyte culture. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999755/),ng,2,220361,DB00592,Piperazine
,11999755,detection limits,"The detection limits for piperine and ketoconazole are 2 and 4 ng, respectively, and the limits of quantitation are 10 and 12 ng, respectively.",Simple high-performance liquid chromatography method for the simultaneous determination of ketoconazole and piperine in rat plasma and hepatocyte culture. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999755/),ng,4,220362,DB00592,Piperazine
,24292055,trough plasma levels,Therapeutic drug monitoring targeting trough plasma levels of about 1000 ng/mL may help to optimize imantinib's therapeutic effect.,Development of a specific and sensitive enzyme-linked immunosorbent assay for the quantification of imatinib. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24292055/),[ng] / [ml],1000,220453,DB00592,Piperazine
,23291288,recovery,Sample pretreatment by liquid-liquid extraction in diethyl ether yielded a recovery of 50% from human and mouse plasma.,Sensitive method for plasma and tumor Ko143 quantification using reversed-phase high-performance liquid chromatography and fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23291288/),%,50,220599,DB00592,Piperazine
,23291288,flow rate,"The mobile phase consisted of methanol:10mM ammonium acetate pH 5.0 (62:38, v/v), delivered at a flow rate of 0.2mL/min.",Sensitive method for plasma and tumor Ko143 quantification using reversed-phase high-performance liquid chromatography and fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23291288/),[ml] / [min],0.2,220600,DB00592,Piperazine
,15963092,apparent clearance (CL),"Population mean estimates (95% confidence interval) at day 1 for apparent clearance (CL) and apparent volume of distribution (V) of imatinib were 14 (13-15) l h(-1) and 252 (237-267) l, respectively.",Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15963092/),[l] / [h],14,221371,DB00592,Piperazine
,15963092,apparent volume of distribution (V),"Population mean estimates (95% confidence interval) at day 1 for apparent clearance (CL) and apparent volume of distribution (V) of imatinib were 14 (13-15) l h(-1) and 252 (237-267) l, respectively.",Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15963092/),l,252,221372,DB00592,Piperazine
,10219969,Tmax,"With the exception of male rat, Tmax occurred at approximately 1 h or less.","Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219969/),h,1,221877,DB00592,Piperazine
,10219969,volume of distribution,"3. The volume of distribution was similar in rodents and humans (1-2 l/kg) but was greater in dog (5.2 l/kg), due to lower plasma protein binding (84 versus 94-96% respectively).","Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219969/),[l] / [kg],1-2,221878,DB00592,Piperazine
,10219969,volume of distribution,"3. The volume of distribution was similar in rodents and humans (1-2 l/kg) but was greater in dog (5.2 l/kg), due to lower plasma protein binding (84 versus 94-96% respectively).","Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219969/),[l] / [kg],5.2,221879,DB00592,Piperazine
,10219969,plasma protein binding,"3. The volume of distribution was similar in rodents and humans (1-2 l/kg) but was greater in dog (5.2 l/kg), due to lower plasma protein binding (84 versus 94-96% respectively).","Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219969/),%,84,221880,DB00592,Piperazine
,10219969,plasma protein binding,"3. The volume of distribution was similar in rodents and humans (1-2 l/kg) but was greater in dog (5.2 l/kg), due to lower plasma protein binding (84 versus 94-96% respectively).","Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219969/),%,94-96,221881,DB00592,Piperazine
,10219969,elimination half-lives,"4. High clearance was the principal determinant of short elimination half-lives in rodents (0.4-1.3 h), whereas moderate clearance in dog and man resulted in longer half-lives (6.1 and 3.7 h respectively).","Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219969/),h,0.4-1.3,221882,DB00592,Piperazine
,10219969,half-lives,"4. High clearance was the principal determinant of short elimination half-lives in rodents (0.4-1.3 h), whereas moderate clearance in dog and man resulted in longer half-lives (6.1 and 3.7 h respectively).","Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219969/),h,6.1,221883,DB00592,Piperazine
,10219969,half-lives,"4. High clearance was the principal determinant of short elimination half-lives in rodents (0.4-1.3 h), whereas moderate clearance in dog and man resulted in longer half-lives (6.1 and 3.7 h respectively).","Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219969/),h,3.7,221884,DB00592,Piperazine
,10219969,AUC(infinity),"Following oral doses, AUC(infinity) for the piperazine N-desmethyl and piperazine N,N'-desethyl metabolites were 55 and 27% that of parent compound respectively.","Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219969/),,55,221885,DB00592,Piperazine
,10219969,AUC(infinity),"Following oral doses, AUC(infinity) for the piperazine N-desmethyl and piperazine N,N'-desethyl metabolites were 55 and 27% that of parent compound respectively.","Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219969/),,27,221886,DB00592,Piperazine
,10586392,Emax,"Mean Emax ranged from 23 to 28% delta QTc, with mean EC50 of 509 to 566 ng/mL.",Pharmacokinetics and pharmacodynamics following intravenous doses of azimilide dihydrochloride. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10586392/),%,23 to 28,221898,DB00592,Piperazine
,10586392,EC50,"Mean Emax ranged from 23 to 28% delta QTc, with mean EC50 of 509 to 566 ng/mL.",Pharmacokinetics and pharmacodynamics following intravenous doses of azimilide dihydrochloride. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10586392/),[ng] / [ml],509 to 566,221899,DB00592,Piperazine
,27803469,flow rate,Chromatographic separation was performed using Kinetex® C8 column with an isocratic mobile phase consisting of acetonitrile and 10-mM potassium phosphate buffer (pH 6.0) at a flow rate of 1.0 mL/min.,Development of HPLC Method for the Determination of Buspirone in Rat Plasma Using Fluorescence Detection and Its Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27803469/),[ml] / [min],1.0,222616,DB00592,Piperazine
,27803469,limit of detection,"The linearity was established at 20.0-5000 ng/mL, and the limit of detection was 6.51 ng/mL.",Development of HPLC Method for the Determination of Buspirone in Rat Plasma Using Fluorescence Detection and Its Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27803469/),[ng] / [ml],6.51,222617,DB00592,Piperazine
,11717177,terminal t(1/2),"Following i.v. administration, compound I was cleared rapidly in rats in a polyphasic manner with a terminal t(1/2) of 41 min.",Pharmacokinetics and metabolism of a RAS farnesyl transferase inhibitor in rats and dogs: in vitro-in vivo correlation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11717177/),min,41,222695,DB00592,Piperazine
,11717177,plasma clearance (CL(p)),"The plasma clearance (CL(p)) and volume of distribution (V(dss)) were 41.2 ml/min/kg and 1.2 l/kg, respectively.",Pharmacokinetics and metabolism of a RAS farnesyl transferase inhibitor in rats and dogs: in vitro-in vivo correlation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11717177/),[ml] / [kg·min],41.2,222696,DB00592,Piperazine
,11717177,volume of distribution (V(dss)),"The plasma clearance (CL(p)) and volume of distribution (V(dss)) were 41.2 ml/min/kg and 1.2 l/kg, respectively.",Pharmacokinetics and metabolism of a RAS farnesyl transferase inhibitor in rats and dogs: in vitro-in vivo correlation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11717177/),[l] / [kg],1.2,222697,DB00592,Piperazine
,23420017,Tmax,"The main pharmacokinetic parameters Tmax, Cmax, T1/2, and Ke were 1.88±0.22h, 18.0±3.1ng/ml, 6.89±1.0h and 0.103±0.01l/h, respectively.",Determination of diosbulbin B in rat plasma and urine by LC-MS/MS and its application in pharmacokinetic and urinary excretion studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23420017/),h,1.88,222768,DB00592,Piperazine
,23420017,Ke,"The main pharmacokinetic parameters Tmax, Cmax, T1/2, and Ke were 1.88±0.22h, 18.0±3.1ng/ml, 6.89±1.0h and 0.103±0.01l/h, respectively.",Determination of diosbulbin B in rat plasma and urine by LC-MS/MS and its application in pharmacokinetic and urinary excretion studies. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23420017/),[l] / [h],0.103,222769,DB00592,Piperazine
,23420017,cumulative excretion,"A cumulative excretion of disobulbin B in rat urine was 2.69±0.43μg at 60h after dosing, accounting for 0.89% of the total dose.",Determination of diosbulbin B in rat plasma and urine by LC-MS/MS and its application in pharmacokinetic and urinary excretion studies. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23420017/),μg,2.69,222770,DB00592,Piperazine
,6941374,terminal half-life of disposition,The mean terminal half-life of disposition was 11 hours.,An international pharmacokinetic study on pirenzepine following a single oral dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6941374/),h,11,222824,DB00592,Piperazine
,28627123,relative bioavailability,"The mean relative bioavailability of the capsule was 85% that of the solution, but drug absorption was variable, and overall drug concentrations were similar between formulations.",Pharmacokinetics and Relative Bioavailability of Orally Administered Innovator-Formulated Itraconazole Capsules and Solution in Healthy Dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28627123/),%,85,223030,DB00592,Piperazine
,28627123,elimination half-lives,Mean elimination half-lives of both formulations were nearly identical at approximately 33 hours.,Pharmacokinetics and Relative Bioavailability of Orally Administered Innovator-Formulated Itraconazole Capsules and Solution in Healthy Dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28627123/),h,33,223031,DB00592,Piperazine
,19790241,hepatic blood flow,"Using a value for hepatic blood flow from the literature (50 ml/min/kg), the apparent intestinal and hepatic extraction of everolimus without itraconazole was calculated as about 80% and 13%, respectively.",Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19790241/),[ml] / [kg·min],50,223122,DB00592,Piperazine
,19790241,hepatic blood flow,"Using a value for hepatic blood flow from the literature (50 ml/min/kg), the apparent intestinal and hepatic extraction of everolimus without itraconazole was calculated as about 80% and 13%, respectively.",Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19790241/),%,80,223123,DB00592,Piperazine
,19790241,apparent intestinal,"Using a value for hepatic blood flow from the literature (50 ml/min/kg), the apparent intestinal and hepatic extraction of everolimus without itraconazole was calculated as about 80% and 13%, respectively.",Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19790241/),%,80,223124,DB00592,Piperazine
,19790241,hepatic extraction,"Using a value for hepatic blood flow from the literature (50 ml/min/kg), the apparent intestinal and hepatic extraction of everolimus without itraconazole was calculated as about 80% and 13%, respectively.",Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19790241/),%,13,223125,DB00592,Piperazine
,19790241,apparent intestinal extraction,"Intraintestinally administered itraconazole (20 mg/kg) changed the apparent intestinal extraction by 0.26-fold from 0.829 to 0.215, but the hepatic availability of everolimus was almost unchanged after the intravenous or intraintestinal administration of itraconazole even at a dose of 50 mg/kg from 0.871 to 0.923 or 0.867, respectively.",Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19790241/),,0.829,223126,DB00592,Piperazine
,19790241,apparent intestinal extraction,"Intraintestinally administered itraconazole (20 mg/kg) changed the apparent intestinal extraction by 0.26-fold from 0.829 to 0.215, but the hepatic availability of everolimus was almost unchanged after the intravenous or intraintestinal administration of itraconazole even at a dose of 50 mg/kg from 0.871 to 0.923 or 0.867, respectively.",Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19790241/),,0.215,223127,DB00592,Piperazine
,30817698,apparent clearance (CL/F),"For a typical 70-kg PLWH, the apparent clearance (CL/F) and apparent volume of distribution (V/F) were 0.748 L/h and 14.6 L, respectively.",Dolutegravir Population Pharmacokinetics in a Real-Life Cohort of People Living With HIV Infection: A Covariate Analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30817698/),[l] / [h],0.748,223164,DB00592,Piperazine
,30817698,apparent volume of distribution (V/F),"For a typical 70-kg PLWH, the apparent clearance (CL/F) and apparent volume of distribution (V/F) were 0.748 L/h and 14.6 L, respectively.",Dolutegravir Population Pharmacokinetics in a Real-Life Cohort of People Living With HIV Infection: A Covariate Analysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30817698/),l,14.6,223165,DB00592,Piperazine
,15105131,area under the plasma concentration-time curve from time zero to infinity (AUC(0- infinity )),"After intravenous administration at a dose of 30 mg/kg, the area under the plasma concentration-time curve from time zero to infinity (AUC(0- infinity )) was significantly greater than those at 10 and 20 mg/kg (1,090, 1,270, and 1,760 micro g. min/ml for 10, 20, and 30 mg/kg, dose-normalized at 10 mg/kg).",Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15105131/),[min·μg] / [ml],"1,090",223184,DB00592,Piperazine
,15105131,area under the plasma concentration-time curve from time zero to infinity (AUC(0- infinity )),"After intravenous administration at a dose of 30 mg/kg, the area under the plasma concentration-time curve from time zero to infinity (AUC(0- infinity )) was significantly greater than those at 10 and 20 mg/kg (1,090, 1,270, and 1,760 micro g. min/ml for 10, 20, and 30 mg/kg, dose-normalized at 10 mg/kg).",Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15105131/),[min·μg] / [ml],"1,270",223185,DB00592,Piperazine
,15105131,area under the plasma concentration-time curve from time zero to infinity (AUC(0- infinity )),"After intravenous administration at a dose of 30 mg/kg, the area under the plasma concentration-time curve from time zero to infinity (AUC(0- infinity )) was significantly greater than those at 10 and 20 mg/kg (1,090, 1,270, and 1,760 micro g. min/ml for 10, 20, and 30 mg/kg, dose-normalized at 10 mg/kg).",Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15105131/),[min·μg] / [ml],"1,760",223186,DB00592,Piperazine
,15105131,AUC(0- infinity ),"After oral administration, the AUC(0- infinity ) was significantly different for three oral doses (380, 687, and 934 micro g. min/ml for 10, 30, and 50 mg/kg, respectively, dose-normalized at 10 mg/kg).",Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15105131/),[min·μg] / [ml],380,223187,DB00592,Piperazine
,15105131,AUC(0- infinity ),"After oral administration, the AUC(0- infinity ) was significantly different for three oral doses (380, 687, and 934 micro g. min/ml for 10, 30, and 50 mg/kg, respectively, dose-normalized at 10 mg/kg).",Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15105131/),[min·μg] / [ml],687,223188,DB00592,Piperazine
,15105131,AUC(0- infinity ),"After oral administration, the AUC(0- infinity ) was significantly different for three oral doses (380, 687, and 934 micro g. min/ml for 10, 30, and 50 mg/kg, respectively, dose-normalized at 10 mg/kg).",Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15105131/),[min·μg] / [ml],934,223189,DB00592,Piperazine
,15105131,absolute oral bioavailability (F),The extent of absolute oral bioavailability (F) was 34.9% after an oral dose at 10 mg/kg.,Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15105131/),%,34.9,223190,DB00592,Piperazine
,18498705,plasma protein binding,LASSBio-579 plasma protein binding was 93 +/- 4%.,Pharmacokinetic evaluation of LASSBio-579: an N-phenylpiperazine antipsychotic prototype. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498705/),%,93,223318,DB00592,Piperazine
,18498705,Vd(ss),"After intravenous administration of 10 mg kg(-1), the Vd(ss) (0.6 +/- 0.2 L kg -1) and the t(1/2) (5.2 +/- 1.1 h) determined were smaller than those obtained after extravascular routes, but the CL(tot) (0.23 +/- 0.05 Lh(-1)kg(-1)) was statistically similar (alpha = 0.05).",Pharmacokinetic evaluation of LASSBio-579: an N-phenylpiperazine antipsychotic prototype. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498705/),-1·kg·l,0.6,223319,DB00592,Piperazine
,18498705,t(1/2),"After intravenous administration of 10 mg kg(-1), the Vd(ss) (0.6 +/- 0.2 L kg -1) and the t(1/2) (5.2 +/- 1.1 h) determined were smaller than those obtained after extravascular routes, but the CL(tot) (0.23 +/- 0.05 Lh(-1)kg(-1)) was statistically similar (alpha = 0.05).",Pharmacokinetic evaluation of LASSBio-579: an N-phenylpiperazine antipsychotic prototype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498705/),h,5.2,223320,DB00592,Piperazine
,18498705,CL(tot),"After intravenous administration of 10 mg kg(-1), the Vd(ss) (0.6 +/- 0.2 L kg -1) and the t(1/2) (5.2 +/- 1.1 h) determined were smaller than those obtained after extravascular routes, but the CL(tot) (0.23 +/- 0.05 Lh(-1)kg(-1)) was statistically similar (alpha = 0.05).",Pharmacokinetic evaluation of LASSBio-579: an N-phenylpiperazine antipsychotic prototype. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498705/),1/[lh],0.23,223321,DB00592,Piperazine
,18498705,oral bioavailability,"The intraperitoneal and oral bioavailability was around 1.7% and 0.6%, respectively.",Pharmacokinetic evaluation of LASSBio-579: an N-phenylpiperazine antipsychotic prototype. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498705/),%,0.6,223322,DB00592,Piperazine
,18498705,penetration,Brain tissue showed low penetration (6.3%) and t(1/2) of 1.1 h.,Pharmacokinetic evaluation of LASSBio-579: an N-phenylpiperazine antipsychotic prototype. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498705/),%,6.3,223323,DB00592,Piperazine
,18498705,t(1/2),Brain tissue showed low penetration (6.3%) and t(1/2) of 1.1 h.,Pharmacokinetic evaluation of LASSBio-579: an N-phenylpiperazine antipsychotic prototype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18498705/),h,1.1,223324,DB00592,Piperazine
,12083980,maximum concentration,"Concentration-time profiles for cetirizine in serum and tear fluid were similar, although the mean maximum concentration in tear fluid was reached later than in serum (90 and 30 min, respectively).",Pharmacokinetics of cetirizine in tear fluid after a single oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083980/),min,90,223450,DB00592,Piperazine
,12083980,maximum concentration,"Concentration-time profiles for cetirizine in serum and tear fluid were similar, although the mean maximum concentration in tear fluid was reached later than in serum (90 and 30 min, respectively).",Pharmacokinetics of cetirizine in tear fluid after a single oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083980/),min,30,223451,DB00592,Piperazine
,19100319,solubility,BMS-488043 is classified as a Biopharmaceutics Classification System (BCS) Class-II compound with a poor aqueous solubility of 0.04mg/mL and an acceptable permeability of 178nm/s in the Caco2 cell-line model.,Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19100319/),[mg] / [ml],0.04,223683,DB00592,Piperazine
,19100319,permeability,BMS-488043 is classified as a Biopharmaceutics Classification System (BCS) Class-II compound with a poor aqueous solubility of 0.04mg/mL and an acceptable permeability of 178nm/s in the Caco2 cell-line model.,Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19100319/),[nm] / [s],178,223684,DB00592,Piperazine
,32282831,Cmax,"The mean Cmax, Tmax, AUC0-24h, t1/2 during 24 hours in the fasted condition were 130 ng/mL, 1.7 hours, 761 ng·h/mL, and 8.5 hours respectively.",Pharmacokinetics and safety after once and twice a day doses of meclizine hydrochloride administered to children with achondroplasia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32282831/),[ng] / [ml],130,223966,DB00592,Piperazine
,32282831,Tmax,"The mean Cmax, Tmax, AUC0-24h, t1/2 during 24 hours in the fasted condition were 130 ng/mL, 1.7 hours, 761 ng·h/mL, and 8.5 hours respectively.",Pharmacokinetics and safety after once and twice a day doses of meclizine hydrochloride administered to children with achondroplasia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32282831/),h,1.7,223967,DB00592,Piperazine
,32282831,Tmax,"The mean Cmax, Tmax, AUC0-24h, t1/2 during 24 hours in the fasted condition were 130 ng/mL, 1.7 hours, 761 ng·h/mL, and 8.5 hours respectively.",Pharmacokinetics and safety after once and twice a day doses of meclizine hydrochloride administered to children with achondroplasia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32282831/),[h·ng] / [ml],761,223968,DB00592,Piperazine
,32282831,AUC0-24h,"The mean Cmax, Tmax, AUC0-24h, t1/2 during 24 hours in the fasted condition were 130 ng/mL, 1.7 hours, 761 ng·h/mL, and 8.5 hours respectively.",Pharmacokinetics and safety after once and twice a day doses of meclizine hydrochloride administered to children with achondroplasia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32282831/),h,1.7,223969,DB00592,Piperazine
,32282831,AUC0-24h,"The mean Cmax, Tmax, AUC0-24h, t1/2 during 24 hours in the fasted condition were 130 ng/mL, 1.7 hours, 761 ng·h/mL, and 8.5 hours respectively.",Pharmacokinetics and safety after once and twice a day doses of meclizine hydrochloride administered to children with achondroplasia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32282831/),[h·ng] / [ml],761,223970,DB00592,Piperazine
,32282831,t1/2,"The mean Cmax, Tmax, AUC0-24h, t1/2 during 24 hours in the fasted condition were 130 ng/mL, 1.7 hours, 761 ng·h/mL, and 8.5 hours respectively.",Pharmacokinetics and safety after once and twice a day doses of meclizine hydrochloride administered to children with achondroplasia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32282831/),h,8.5,223971,DB00592,Piperazine
,32282831,AUC0-10h,"The AUC0-10h of the fasting and fed condition were 504 ng·h/mL and 813 ng·h/mL, respectively, indicating exposure of meclizine increased with the diet.",Pharmacokinetics and safety after once and twice a day doses of meclizine hydrochloride administered to children with achondroplasia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32282831/),[h·ng] / [ml],504,223972,DB00592,Piperazine
,32282831,AUC0-10h,"The AUC0-10h of the fasting and fed condition were 504 ng·h/mL and 813 ng·h/mL, respectively, indicating exposure of meclizine increased with the diet.",Pharmacokinetics and safety after once and twice a day doses of meclizine hydrochloride administered to children with achondroplasia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32282831/),[h·ng] / [ml],813,223973,DB00592,Piperazine
,22369181,IC(50),"This led to the design of derivative 37, (Z)-2-(2-bromophenyl)-3-{[4-(1-methyl-piperazine)amino]phenyl}acrylonitrile (DG172), a novel PPARβ/δ-selective ligand showing high binding affinity (IC(50) = 27 nM) and potent inverse agonistic properties.",(Z)-2-(2-bromophenyl)-3-{[4-(1-methyl-piperazine)amino]phenyl}acrylonitrile (DG172): an orally bioavailable PPARβ/δ-selective ligand with inverse agonistic properties. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22369181/),nM,27,224418,DB00592,Piperazine
,22369181,IC(50),"37 selectively inhibited the agonist-induced activity of PPARβ/δ, enhanced transcriptional corepressor recruitment, and down-regulated transcription of the PPARβ/δ target gene Angptl4 in mouse myoblasts (IC(50) = 9.5 nM).",(Z)-2-(2-bromophenyl)-3-{[4-(1-methyl-piperazine)amino]phenyl}acrylonitrile (DG172): an orally bioavailable PPARβ/δ-selective ligand with inverse agonistic properties. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22369181/),nM,9.5,224419,DB00592,Piperazine
,2206788,milk/plasma AUC ratio,2. The milk/plasma AUC ratio of zopiclone was 0.51 +/- 0.09 (mean +/- s.d.).,The excretion of zopiclone into breast milk. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206788/),,0.51,224423,DB00592,Piperazine
,8388198,maximum concentration,The mean maximum concentration in plasma of unmetabolized itraconazole after fasting (140 ng/ml) was about 59% that after the standard meal (239 ng/ml).,Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388198/),[ng] / [ml],140,224495,DB00592,Piperazine
,8388198,maximum concentration,The mean maximum concentration in plasma of unmetabolized itraconazole after fasting (140 ng/ml) was about 59% that after the standard meal (239 ng/ml).,Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388198/),[ng] / [ml],239,224496,DB00592,Piperazine
,8388198,terminal half-life,"The rate of elimination was not affected (terminal half-life, approximately 21 h).",Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388198/),h,21,224497,DB00592,Piperazine
,8388198,maximum concentration,"The mean maximum concentration in plasma of hydroxyitraconazole after fasting was about 72% the postmeal concentration (287 and 397 ng/ml, respectively).",Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388198/),[ng] / [ml],287,224498,DB00592,Piperazine
,8388198,maximum concentration,"The mean maximum concentration in plasma of hydroxyitraconazole after fasting was about 72% the postmeal concentration (287 and 397 ng/ml, respectively).",Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388198/),[ng] / [ml],397,224499,DB00592,Piperazine
,8388198,terminal half-life,The terminal half-life of hydroxyitraconazole was approximately 12 h.,Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388198/),h,12,224500,DB00592,Piperazine
,8388198,steady-state concentrations,"The average steady-state concentrations were approximately 1,900 ng/ml for itraconazole and 3,200 ng/ml for hydroxyitraconazole.",Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388198/),[ng] / [ml],"1,900",224501,DB00592,Piperazine
,8388198,steady-state concentrations,"The average steady-state concentrations were approximately 1,900 ng/ml for itraconazole and 3,200 ng/ml for hydroxyitraconazole.",Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8388198/),[ng] / [ml],"3,200",224502,DB00592,Piperazine
,12061540,Ki,"The mean Ki values of KTZ were 10.6+/-6.0, 170+/-2.5, and 0.180+/-0.131 microM for 7-ethoxyresorufin O-deethylation, tolbutamide methylhydroxylation, and midazolam 4-hydroxylation, respectively.",In vitro characterization of the inhibitory effects of ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12061540/),μM,10.6,224594,DB00592,Piperazine
,12061540,Ki,"The mean Ki values of KTZ were 10.6+/-6.0, 170+/-2.5, and 0.180+/-0.131 microM for 7-ethoxyresorufin O-deethylation, tolbutamide methylhydroxylation, and midazolam 4-hydroxylation, respectively.",In vitro characterization of the inhibitory effects of ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12061540/),μM,170,224595,DB00592,Piperazine
,12061540,Ki,"The mean Ki values of KTZ were 10.6+/-6.0, 170+/-2.5, and 0.180+/-0.131 microM for 7-ethoxyresorufin O-deethylation, tolbutamide methylhydroxylation, and midazolam 4-hydroxylation, respectively.",In vitro characterization of the inhibitory effects of ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12061540/),μM,0.180,224596,DB00592,Piperazine
,31550823,plasma concentrations,"The IM plasma concentrations were significantly different between the doses of 300 mg/d and 400 mg/d [(942.4±433.5) μg/L vs. (1340.0±500.1) μg/L, t=6.317, P<0.001], and between 400 mg/d and 600 mg/d [(1340.0±500.1) μg/L vs. (2188.0±875.5) μg/L, t=3.557, P=0.004].",[Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31550823/),[μg] / [l],942.4,224788,DB00592,Piperazine
,31550823,plasma concentrations,"The IM plasma concentrations were significantly different between the doses of 300 mg/d and 400 mg/d [(942.4±433.5) μg/L vs. (1340.0±500.1) μg/L, t=6.317, P<0.001], and between 400 mg/d and 600 mg/d [(1340.0±500.1) μg/L vs. (2188.0±875.5) μg/L, t=3.557, P=0.004].",[Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31550823/),[μg] / [l],1340.0,224789,DB00592,Piperazine
,31550823,plasma concentrations,"The IM plasma concentrations were significantly different between the doses of 300 mg/d and 400 mg/d [(942.4±433.5) μg/L vs. (1340.0±500.1) μg/L, t=6.317, P<0.001], and between 400 mg/d and 600 mg/d [(1340.0±500.1) μg/L vs. (2188.0±875.5) μg/L, t=3.557, P=0.004].",[Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31550823/),[μg] / [l],2188.0,224790,DB00592,Piperazine
,31550823,plasma concentration,"Among the blood samples of 57 patients receiving IM 300 mg/d, the IM plasma concentration of the advanced patients was significantly lower than that of the non-advanced patients [(795.6±225.8) μg/L vs. (992.2±484.4) μg/L, t=2.088, P=0.042].",[Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31550823/),[μg] / [l],795.6,224791,DB00592,Piperazine
,31550823,plasma concentration,"Among the blood samples of 57 patients receiving IM 300 mg/d, the IM plasma concentration of the advanced patients was significantly lower than that of the non-advanced patients [(795.6±225.8) μg/L vs. (992.2±484.4) μg/L, t=2.088, P=0.042].",[Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31550823/),[μg] / [l],992.2,224792,DB00592,Piperazine
,31550823,plasma concentration,"Among the 137 blood samples of patients receiving IM 400 mg/d, the IM plasma concentration was higher in patients aged >60 years than those aged ≤60 years [(1461.0±595.3) μg/L vs. (1240.0±380.9) μg/L, t=2.528, P=0.013] and the IM plasma concentration of cases with diarrhea was significantly lower than that of those without diarrhea [(745.8±249.6) μg/L vs. (1382.0±486.9) μg/L, t=6.794, P<0.001].",[Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31550823/),[μg] / [l],1461.0,224793,DB00592,Piperazine
,31550823,plasma concentration,"Among the 137 blood samples of patients receiving IM 400 mg/d, the IM plasma concentration was higher in patients aged >60 years than those aged ≤60 years [(1461.0±595.3) μg/L vs. (1240.0±380.9) μg/L, t=2.528, P=0.013] and the IM plasma concentration of cases with diarrhea was significantly lower than that of those without diarrhea [(745.8±249.6) μg/L vs. (1382.0±486.9) μg/L, t=6.794, P<0.001].",[Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31550823/),[μg] / [l],1240.0,224794,DB00592,Piperazine
,31550823,plasma concentration,"Among the 137 blood samples of patients receiving IM 400 mg/d, the IM plasma concentration was higher in patients aged >60 years than those aged ≤60 years [(1461.0±595.3) μg/L vs. (1240.0±380.9) μg/L, t=2.528, P=0.013] and the IM plasma concentration of cases with diarrhea was significantly lower than that of those without diarrhea [(745.8±249.6) μg/L vs. (1382.0±486.9) μg/L, t=6.794, P<0.001].",[Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31550823/),[μg] / [l],745.8,224795,DB00592,Piperazine
,31550823,plasma concentration,"Among the 137 blood samples of patients receiving IM 400 mg/d, the IM plasma concentration was higher in patients aged >60 years than those aged ≤60 years [(1461.0±595.3) μg/L vs. (1240.0±380.9) μg/L, t=2.528, P=0.013] and the IM plasma concentration of cases with diarrhea was significantly lower than that of those without diarrhea [(745.8±249.6) μg/L vs. (1382.0±486.9) μg/L, t=6.794, P<0.001].",[Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31550823/),[μg] / [l],1382.0,224796,DB00592,Piperazine
> or =,11550120,trough plasma levels,"After receiving iv itraconazole, concentrations increased rapidly, with trough plasma levels > or =250 ng/mL in 91% of patients and in all patients by day 7.","Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11550120/),[ng] / [ml],250,224830,DB00592,Piperazine
,11550120,trough concentrations,"Mean trough concentrations after 2 and 14 days were 670 and 850 ng/mL, respectively.","Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11550120/),[ng] / [ml],670,224831,DB00592,Piperazine
,11550120,trough concentrations,"Mean trough concentrations after 2 and 14 days were 670 and 850 ng/mL, respectively.","Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11550120/),[ng] / [ml],850,224832,DB00592,Piperazine
,15121646,occup,"The mean 5-HT(2) receptor occupancy was significantly higher than the mean D(2) receptor occupancy (mean=76%, SD=15%, and mean=56%, SD=18%, respectively).",A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15121646/),%,76,224901,DB00592,Piperazine
,15121646,occup,"The mean 5-HT(2) receptor occupancy was significantly higher than the mean D(2) receptor occupancy (mean=76%, SD=15%, and mean=56%, SD=18%, respectively).",A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15121646/),%,56,224902,DB00592,Piperazine
,9179989,elimination half-life,"After i.v. administration of SC-52151 to the female beagle dog (2.5 mg/kg), SC-52151 was rapidly eliminated in plasma with an elimination half-life of about 1 h, a plasma clearance of 44 ml/min/kg and an apparent steady-state volume distribution of 2.2 litre/kg.","Improvement of bioavailability of the HIV protease inhibitor SC-52151 in the beagle dog by coadministration of the CYP3A4 inhibitor, ketoconazole. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9179989/),h,1,225348,DB00592,Piperazine
,9179989,plasma clearance,"After i.v. administration of SC-52151 to the female beagle dog (2.5 mg/kg), SC-52151 was rapidly eliminated in plasma with an elimination half-life of about 1 h, a plasma clearance of 44 ml/min/kg and an apparent steady-state volume distribution of 2.2 litre/kg.","Improvement of bioavailability of the HIV protease inhibitor SC-52151 in the beagle dog by coadministration of the CYP3A4 inhibitor, ketoconazole. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9179989/),[ml] / [kg·min],44,225349,DB00592,Piperazine
,9179989,apparent steady-state volume distribution,"After i.v. administration of SC-52151 to the female beagle dog (2.5 mg/kg), SC-52151 was rapidly eliminated in plasma with an elimination half-life of about 1 h, a plasma clearance of 44 ml/min/kg and an apparent steady-state volume distribution of 2.2 litre/kg.","Improvement of bioavailability of the HIV protease inhibitor SC-52151 in the beagle dog by coadministration of the CYP3A4 inhibitor, ketoconazole. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9179989/),[l] / [kg],2.2,225350,DB00592,Piperazine
,9179989,bioavailability,Coadministration of ketoconazole improved the bioavailability of SC-52151 from 4.1 to 9.6% and also improved the Cmax of SC-52151 from 0.41 to 0.83 microgram/ml.,"Improvement of bioavailability of the HIV protease inhibitor SC-52151 in the beagle dog by coadministration of the CYP3A4 inhibitor, ketoconazole. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9179989/),%,4.1,225351,DB00592,Piperazine
,9179989,bioavailability,Coadministration of ketoconazole improved the bioavailability of SC-52151 from 4.1 to 9.6% and also improved the Cmax of SC-52151 from 0.41 to 0.83 microgram/ml.,"Improvement of bioavailability of the HIV protease inhibitor SC-52151 in the beagle dog by coadministration of the CYP3A4 inhibitor, ketoconazole. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9179989/),%,9.6,225352,DB00592,Piperazine
,9179989,Cmax,Coadministration of ketoconazole improved the bioavailability of SC-52151 from 4.1 to 9.6% and also improved the Cmax of SC-52151 from 0.41 to 0.83 microgram/ml.,"Improvement of bioavailability of the HIV protease inhibitor SC-52151 in the beagle dog by coadministration of the CYP3A4 inhibitor, ketoconazole. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9179989/),[μg] / [ml],0.41,225353,DB00592,Piperazine
,9179989,Cmax,Coadministration of ketoconazole improved the bioavailability of SC-52151 from 4.1 to 9.6% and also improved the Cmax of SC-52151 from 0.41 to 0.83 microgram/ml.,"Improvement of bioavailability of the HIV protease inhibitor SC-52151 in the beagle dog by coadministration of the CYP3A4 inhibitor, ketoconazole. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9179989/),[μg] / [ml],0.83,225354,DB00592,Piperazine
,9179989,absolute bioavailability,"4. Although the absolute bioavailability of SC-52151 was still low (approximately 10%), the Cmax and AUC achieved in this study were satisfactory for conducting chronic toxicology studies.","Improvement of bioavailability of the HIV protease inhibitor SC-52151 in the beagle dog by coadministration of the CYP3A4 inhibitor, ketoconazole. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9179989/),%,10,225355,DB00592,Piperazine
,17472650,terminal half-life,"After oral administration of cetirizine at 0.2 mg/kg bw, the mean terminal half-life was 3.4 h (range 2.9-3.7 h) and the maximal plasma concentration 132 ng/mL (101-196 ng/mL).",Cetirizine in horses: pharmacokinetics and effect of ivermectin pretreatment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472650/),h,3.4,226145,DB00592,Piperazine
,17472650,maximal plasma concentration,"After oral administration of cetirizine at 0.2 mg/kg bw, the mean terminal half-life was 3.4 h (range 2.9-3.7 h) and the maximal plasma concentration 132 ng/mL (101-196 ng/mL).",Cetirizine in horses: pharmacokinetics and effect of ivermectin pretreatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472650/),[ng] / [ml],132,226146,DB00592,Piperazine
,17472650,time to reach maximal plasma concentration,The time to reach maximal plasma concentration was 0.7 h (0.5-0.8 h).,Cetirizine in horses: pharmacokinetics and effect of ivermectin pretreatment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472650/),h,0.7,226147,DB00592,Piperazine
,25624751,bioavailability,"Second, the drug undergoes extensive first-pass metabolism, resulting in a low (40%) bioavailability.","Soy polysaccharide as a novel superdisintegrant in sildenafil citrate sublingual tablets: preparation, characterization, and in vivo evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25624751/),%,40,226392,DB00592,Piperazine
,25624751,wetting time,"The tablet contained 8% soy polysaccharide as a superdisintegrant and provided a wetting time of 25 seconds, and in vitro dispersion times of 55 seconds.","Soy polysaccharide as a novel superdisintegrant in sildenafil citrate sublingual tablets: preparation, characterization, and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25624751/),seconds,25,226393,DB00592,Piperazine
,25624751,dispersion times,"The tablet contained 8% soy polysaccharide as a superdisintegrant and provided a wetting time of 25 seconds, and in vitro dispersion times of 55 seconds.","Soy polysaccharide as a novel superdisintegrant in sildenafil citrate sublingual tablets: preparation, characterization, and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25624751/),seconds,55,226394,DB00592,Piperazine
,25624751,drug release,The drug release was found to be 95.6%.,"Soy polysaccharide as a novel superdisintegrant in sildenafil citrate sublingual tablets: preparation, characterization, and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25624751/),%,95.6,226395,DB00592,Piperazine
,27262994,flow rate,"The analytes and the internal standard (diazepam) were separated on an Acquity UPLC BEH C18 chromatography column (2.1mm×50mm, 1.7μm) using gradient elution with a mobile phase of acetonitrile and 0.1% formic acid in water at a flow rate of 0.4mL/min.","Simultaneous quantification of vortioxetine, carvedilol and its active metabolite 4-hydroxyphenyl carvedilol in rat plasma by UPLC-MS/MS: Application to their pharmacokinetic interaction study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27262994/),[ml] / [min],0.4,226496,DB00592,Piperazine
,27262994,m,"The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring (MRM) mode to monitor the precursor-to-product ion transitions of m/z 299.2→150.1 for vortioxetine, m/z 407.2→100.3 for carvedilol, m/z 423.2→100.1 for 4-hydroxyphenyl carvedilol and m/z 285.2→193.1 for diazepam (IS) using a positive electrospray ionization interface.","Simultaneous quantification of vortioxetine, carvedilol and its active metabolite 4-hydroxyphenyl carvedilol in rat plasma by UPLC-MS/MS: Application to their pharmacokinetic interaction study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27262994/),,423.2,226497,DB00592,Piperazine
,27262994,Total time,Total time for each chromatograph was 3.0min.,"Simultaneous quantification of vortioxetine, carvedilol and its active metabolite 4-hydroxyphenyl carvedilol in rat plasma by UPLC-MS/MS: Application to their pharmacokinetic interaction study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27262994/),min,3.0,226498,DB00592,Piperazine
,26966353,relative bioavailability,"In addition, the relative bioavailability of the optimized formulation was 165.5% with respect to the marketed CTZ tablets indicating a significant enhancement of CTZ bioavailability.",Maximizing the encapsulation efficiency and the bioavailability of controlled-release cetirizine microspheres using Draper-Lin small composite design. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26966353/),%,165.5,226548,DB00592,Piperazine
,30559132,volume of distribution,"The volume of distribution (217 liters) was greater than that of extracellular fluid, which suggests distribution beyond the central compartment.",Mass Balance and Drug Interaction Potential of Intravenous Eravacycline Administered to Healthy Subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30559132/),l,217,226567,DB00592,Piperazine
,18972871,flow rate,"The chromatographic separation was performed on a C18 column with a mobile phase of 3 mmol/L ammonium acetate solution-methanol (15:85, v/v) at a flow rate of 0.3 mL/min.",Liquid chromatography-tandem mass spectrometry method for the determination of trimetazidine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18972871/),[ml] / [min],0.3,226638,DB00592,Piperazine
,22831883,flow rate,Elution was achieved with a gradient mobile phase consisting of water and acetonitrile both containing 0.1% formic acid at a flow rate of 0.40 mL/min.,Application of a sensitive and specific LC-MS/MS method for determination of chinensinaphthol methyl ether in rat plasma for a bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22831883/),[ml] / [min],0.40,226775,DB00592,Piperazine
,22831883,precursor/product transitions (m/z),"The precursor/product transitions (m/z) in the positive ion mode were 394.5→346.0 and 386.1→122.0 for CME and IS, respectively.",Application of a sensitive and specific LC-MS/MS method for determination of chinensinaphthol methyl ether in rat plasma for a bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22831883/),,394.5,226776,DB00592,Piperazine
,22831883,precursor/product transitions (m/z),"The precursor/product transitions (m/z) in the positive ion mode were 394.5→346.0 and 386.1→122.0 for CME and IS, respectively.",Application of a sensitive and specific LC-MS/MS method for determination of chinensinaphthol methyl ether in rat plasma for a bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22831883/),,346.0,226777,DB00592,Piperazine
,22831883,precursor/product transitions (m/z),"The precursor/product transitions (m/z) in the positive ion mode were 394.5→346.0 and 386.1→122.0 for CME and IS, respectively.",Application of a sensitive and specific LC-MS/MS method for determination of chinensinaphthol methyl ether in rat plasma for a bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22831883/),,386.1,226778,DB00592,Piperazine
,22831883,precursor/product transitions (m/z),"The precursor/product transitions (m/z) in the positive ion mode were 394.5→346.0 and 386.1→122.0 for CME and IS, respectively.",Application of a sensitive and specific LC-MS/MS method for determination of chinensinaphthol methyl ether in rat plasma for a bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22831883/),,122.0,226779,DB00592,Piperazine
,22831883,oral absolute bioavailability (F),"The oral absolute bioavailability (F) of CME was estimated to be 3.2±0.2% with an elimination half-life (t½) value of 2.4±0.8h, suggesting its poor absorption and/or strong metabolism in vivo.",Application of a sensitive and specific LC-MS/MS method for determination of chinensinaphthol methyl ether in rat plasma for a bioavailability study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22831883/),%,3.2,226780,DB00592,Piperazine
,22831883,elimination half-life (t½),"The oral absolute bioavailability (F) of CME was estimated to be 3.2±0.2% with an elimination half-life (t½) value of 2.4±0.8h, suggesting its poor absorption and/or strong metabolism in vivo.",Application of a sensitive and specific LC-MS/MS method for determination of chinensinaphthol methyl ether in rat plasma for a bioavailability study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22831883/),h,2.4,226781,DB00592,Piperazine
,17690251,pK(i),The pK(i) of JNJ17203212 for recombinant guinea pig TRPV1 was 7.14 +/- 0.06.,"Pharmacology and antitussive efficacy of 4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic acid (5-trifluoromethyl-pyridin-2-yl)-amide (JNJ17203212), a transient receptor potential vanilloid 1 antagonist in guinea pigs. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17690251/),,7.14,227172,DB00592,Piperazine
,17690251,pIC(50),JNJ17203212 inhibited both pH (pIC(50) of 7.23 +/- 0.05) and capsaicin (pIC(50) of 6.32 +/- 0.06)-induced channel activation.,"Pharmacology and antitussive efficacy of 4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic acid (5-trifluoromethyl-pyridin-2-yl)-amide (JNJ17203212), a transient receptor potential vanilloid 1 antagonist in guinea pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17690251/),,7.23,227173,DB00592,Piperazine
,17690251,pIC(50),JNJ17203212 inhibited both pH (pIC(50) of 7.23 +/- 0.05) and capsaicin (pIC(50) of 6.32 +/- 0.06)-induced channel activation.,"Pharmacology and antitussive efficacy of 4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic acid (5-trifluoromethyl-pyridin-2-yl)-amide (JNJ17203212), a transient receptor potential vanilloid 1 antagonist in guinea pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17690251/),,6.32,227174,DB00592,Piperazine
,17690251,pIC(50),"In whole-cell patch clamp, the pIC(50) for inhibition of guinea pig TRPV1 was 7.3 +/- 0.01.","Pharmacology and antitussive efficacy of 4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic acid (5-trifluoromethyl-pyridin-2-yl)-amide (JNJ17203212), a transient receptor potential vanilloid 1 antagonist in guinea pigs. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17690251/),,7.3,227175,DB00592,Piperazine
,17690251,pK(B),"JNJ17203212 demonstrated surmountable antagonism in isolated trachea, with a pK(B) value of 6.2 +/- 0.1.","Pharmacology and antitussive efficacy of 4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic acid (5-trifluoromethyl-pyridin-2-yl)-amide (JNJ17203212), a transient receptor potential vanilloid 1 antagonist in guinea pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17690251/),,6.2,227176,DB00592,Piperazine
,17690251,maximal plasma exposure,"Intraperitoneal administration of 20 mg/kg JNJ17203212 achieved a maximal plasma exposure of 8.0 +/- 0.4 microM, and it attenuated capsaicin evoked coughs with similar efficacy to codeine (25 mg/kg).","Pharmacology and antitussive efficacy of 4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic acid (5-trifluoromethyl-pyridin-2-yl)-amide (JNJ17203212), a transient receptor potential vanilloid 1 antagonist in guinea pigs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17690251/),μM,8.0,227177,DB00592,Piperazine
<,7625808,MICs,"SCH 51048 inhibited C. immitis in vitro; MICs for 13 isolates ranged from < or = 0.39 to 0.78 micrograms/ml, and minimum fungicidal concentrations ranged from < or = 0.39 to 1.6 micrograms/ml.",Activities of the triazole SCH 51048 against Coccidioides immitis in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625808/),[μg] / [ml],0.39 to 0.78,227469,DB00592,Piperazine
<,7625808,minimum fungicidal concentrations,"SCH 51048 inhibited C. immitis in vitro; MICs for 13 isolates ranged from < or = 0.39 to 0.78 micrograms/ml, and minimum fungicidal concentrations ranged from < or = 0.39 to 1.6 micrograms/ml.",Activities of the triazole SCH 51048 against Coccidioides immitis in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625808/),[μg] / [ml],0.39 to 1.6,227470,DB00592,Piperazine
>,7625808,peak levels,"Pharmacokinetic studies showed peak levels in serum of > 14 micrograms/ml, with an estimated half-life of > 12 h.",Activities of the triazole SCH 51048 against Coccidioides immitis in vitro and in vivo. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625808/),[μg] / [ml],14,227471,DB00592,Piperazine
>,7625808,half-life,"Pharmacokinetic studies showed peak levels in serum of > 14 micrograms/ml, with an estimated half-life of > 12 h.",Activities of the triazole SCH 51048 against Coccidioides immitis in vitro and in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625808/),h,12,227472,DB00592,Piperazine
,8164261,IC50,"2-Guanidino-4,5-bis(4-methoxyphenyl)thiazole (3), designed from two parent compounds (itazigrel and timegadine), showed inhibitory activity of malondialdehyde (MDA, IC50 = 31 microM) production which is formed from the cyclooxygenase (CO)-catalyzed oxygenation of arachidonic acid in the synthesis of prostanoids in platelets, with vasodilatory activity (ED50 = 2.0 microM).","Antiplatelet agents based on cyclooxygenase inhibition without ulcerogenesis. Evaluation and synthesis of 4,5-bis(4-methoxyphenyl)-2-substituted-thiazoles. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8164261/),μM,31,227473,DB00592,Piperazine
,8164261,ED50,"2-Guanidino-4,5-bis(4-methoxyphenyl)thiazole (3), designed from two parent compounds (itazigrel and timegadine), showed inhibitory activity of malondialdehyde (MDA, IC50 = 31 microM) production which is formed from the cyclooxygenase (CO)-catalyzed oxygenation of arachidonic acid in the synthesis of prostanoids in platelets, with vasodilatory activity (ED50 = 2.0 microM).","Antiplatelet agents based on cyclooxygenase inhibition without ulcerogenesis. Evaluation and synthesis of 4,5-bis(4-methoxyphenyl)-2-substituted-thiazoles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8164261/),μM,2.0,227474,DB00592,Piperazine
,8164261,IC50,"Further structure-activity relationship studies on 3 culminated in the preparation of 4,5-bis(4-methoxyphenyl)-2-[(1-methylpiperazin-4-yl)carbonyl]thiaz ole (10a, FR122047) which exhibited potent inhibitory activity on MDA synthesis in vitro (IC50 = 0.088 microM) and platelet aggregation in guinea pigs ex vivo (100% inhibition even 6 h after 1.0 mg/kg administration) with vasodilatory activity in vitro (ED50 = 6.2 microM).","Antiplatelet agents based on cyclooxygenase inhibition without ulcerogenesis. Evaluation and synthesis of 4,5-bis(4-methoxyphenyl)-2-substituted-thiazoles. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8164261/),μM,0.088,227475,DB00592,Piperazine
,8164261,ED50,"Further structure-activity relationship studies on 3 culminated in the preparation of 4,5-bis(4-methoxyphenyl)-2-[(1-methylpiperazin-4-yl)carbonyl]thiaz ole (10a, FR122047) which exhibited potent inhibitory activity on MDA synthesis in vitro (IC50 = 0.088 microM) and platelet aggregation in guinea pigs ex vivo (100% inhibition even 6 h after 1.0 mg/kg administration) with vasodilatory activity in vitro (ED50 = 6.2 microM).","Antiplatelet agents based on cyclooxygenase inhibition without ulcerogenesis. Evaluation and synthesis of 4,5-bis(4-methoxyphenyl)-2-substituted-thiazoles. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8164261/),μM,6.2,227476,DB00592,Piperazine
,8164261,IC50,"Moreover, 10a demonstrated no ulcerogenesis effect in rats even at 100 mg/kg dosage (safety margin in rats is more than 70 while that of aspirin is only 1.2) in spite of its potent CO inhibition (IC50 = 0.43 microM14), while the use of aspirin, a CO inhibitor and the most popular thromboembolic drug, is restricted by the side effect.","Antiplatelet agents based on cyclooxygenase inhibition without ulcerogenesis. Evaluation and synthesis of 4,5-bis(4-methoxyphenyl)-2-substituted-thiazoles. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8164261/),μM14,0.43,227477,DB00592,Piperazine
,12386638,terminal half-life,"The mean terminal half-life of budesonide was prolonged from 1.6 to 6.2 hours (ie, 3.7-fold; range, 1.5-fold to 9.3-fold; P <.001) by itraconazole.",Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386638/),h,1.6 to 6.2,227770,DB00592,Piperazine
,33012742,maximum plasma concentrations,The maximum plasma concentrations of SIL after administration varied in range from 7.8 to 101.0 ng/mL.,The Pharmacokinetics of Sildenafil May Be Affected by Intestinal Absorption Rate in Children Admitted to the Intensive Care Unit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33012742/),[ng] / [ml],7.8 to 101.0,227800,DB00592,Piperazine
,33012742,Cmax,"When SIL was administered for 10 min, the Cmax and bioavailability were 3.46 ± 1.65 µg/mL and 23.2 ± 11.1%, respectively.",The Pharmacokinetics of Sildenafil May Be Affected by Intestinal Absorption Rate in Children Admitted to the Intensive Care Unit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33012742/),[μg] / [ml],3.46,227801,DB00592,Piperazine
,33012742,bioavailability,"When SIL was administered for 10 min, the Cmax and bioavailability were 3.46 ± 1.65 µg/mL and 23.2 ± 11.1%, respectively.",The Pharmacokinetics of Sildenafil May Be Affected by Intestinal Absorption Rate in Children Admitted to the Intensive Care Unit. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33012742/),%,23.2,227802,DB00592,Piperazine
,33012742,Cmax,"When SIL was administered for 60 min, the Cmax and bioavailability were 0.990 ± 0.352 µg/mL and 9.91 ± 3.79%, respectively.",The Pharmacokinetics of Sildenafil May Be Affected by Intestinal Absorption Rate in Children Admitted to the Intensive Care Unit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33012742/),[μg] / [ml],0.990,227803,DB00592,Piperazine
,33012742,bioavailability,"When SIL was administered for 60 min, the Cmax and bioavailability were 0.990 ± 0.352 µg/mL and 9.91 ± 3.79%, respectively.",The Pharmacokinetics of Sildenafil May Be Affected by Intestinal Absorption Rate in Children Admitted to the Intensive Care Unit. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33012742/),%,9.91,227804,DB00592,Piperazine
,2885172,T 1/2,"Mean value of T 1/2 of clopenthixol decanoate and haloperidol decanoate are 19 and 21 days, respectively, they thereby justify monthly administration.",[Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2885172/),d,19,227924,DB00592,Piperazine
,2885172,T 1/2,"Mean value of T 1/2 of clopenthixol decanoate and haloperidol decanoate are 19 and 21 days, respectively, they thereby justify monthly administration.",[Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2885172/),d,21,227925,DB00592,Piperazine
,2885172,half-lives,"Flupenthixol decanoate and fluphenazine enanthate should be injected with dosing intervals of 3 and 1 weeks, respectively in respect with their half-lives: 17 and 4 days.",[Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2885172/),d,17,227926,DB00592,Piperazine
,2885172,half-lives,"Flupenthixol decanoate and fluphenazine enanthate should be injected with dosing intervals of 3 and 1 weeks, respectively in respect with their half-lives: 17 and 4 days.",[Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2885172/),d,4,227927,DB00592,Piperazine
,2885172,half-life,"Fluphenazine decanoate have a half-life of 14 days, however, the longer time the treatment, the longer the apparent half-life, suggesting to reduce the dose or to enlarge the dosing interval.",[Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2885172/),d,14,227928,DB00592,Piperazine
,28692105,effective plasma levels,"Low effective plasma levels of prasugrel active metabolite were measured at trough [0.5 (quartiles 0.5-1.1) ng/ml at baseline], and 2 hours after intake [5.7 (3.8-9.8) ng/ml], but showed coefficients of variation of ~70 %.",Prasugrel in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28692105/),[ng] / [ml],0.5,228162,DB00592,Piperazine
,28692105,effective plasma levels,"Low effective plasma levels of prasugrel active metabolite were measured at trough [0.5 (quartiles 0.5-1.1) ng/ml at baseline], and 2 hours after intake [5.7 (3.8-9.8) ng/ml], but showed coefficients of variation of ~70 %.",Prasugrel in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28692105/),[ng] / [ml],5.7,228163,DB00592,Piperazine
,7628178,clearance,Administration of ketoconazole caused a significant decrease in intravenous cyclosporine clearance (0.18 +/- 0.05 L/kg/hr versus 0.32 +/- 0.09 L/hr/kg) and a significant increase in cyclosporine oral bioavailability (56.4% +/- 11.7% versus 22.4% +/- 4.8%) compared with values before ketoconazole administration.,The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628178/),[l] / [h·kg],0.18,228240,DB00592,Piperazine
,7628178,clearance,Administration of ketoconazole caused a significant decrease in intravenous cyclosporine clearance (0.18 +/- 0.05 L/kg/hr versus 0.32 +/- 0.09 L/hr/kg) and a significant increase in cyclosporine oral bioavailability (56.4% +/- 11.7% versus 22.4% +/- 4.8%) compared with values before ketoconazole administration.,The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628178/),[l] / [h·kg],0.32,228241,DB00592,Piperazine
,7628178,oral bioavailability,Administration of ketoconazole caused a significant decrease in intravenous cyclosporine clearance (0.18 +/- 0.05 L/kg/hr versus 0.32 +/- 0.09 L/hr/kg) and a significant increase in cyclosporine oral bioavailability (56.4% +/- 11.7% versus 22.4% +/- 4.8%) compared with values before ketoconazole administration.,The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628178/),%,56.4,228242,DB00592,Piperazine
,7628178,oral bioavailability,Administration of ketoconazole caused a significant decrease in intravenous cyclosporine clearance (0.18 +/- 0.05 L/kg/hr versus 0.32 +/- 0.09 L/hr/kg) and a significant increase in cyclosporine oral bioavailability (56.4% +/- 11.7% versus 22.4% +/- 4.8%) compared with values before ketoconazole administration.,The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628178/),%,22.4,228243,DB00592,Piperazine
,7628178,Steady-state volume of distribution,Steady-state volume of distribution for intravenously administered cyclosporine was unchanged (1.26 +/- 0.44 L/kg versus 1.10 +/- 0.27 L/kg).,The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628178/),[l] / [kg],1.26,228244,DB00592,Piperazine
,7628178,Steady-state volume of distribution,Steady-state volume of distribution for intravenously administered cyclosporine was unchanged (1.26 +/- 0.44 L/kg versus 1.10 +/- 0.27 L/kg).,The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628178/),[l] / [kg],1.10,228245,DB00592,Piperazine
,7628178,Hepatic bioavailability (1 - hepatic extraction ratio),"Hepatic bioavailability (1 - hepatic extraction ratio) calculated for intravenous cyclosporine increased by 11% in the presence of ketoconazole (86.3% +/- 3.7% versus 75.2% +/- 6.6% without ketoconazole), which accounts for only one third of the observed increase in cyclosporine oral bioavailability.",The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628178/),%,86.3,228246,DB00592,Piperazine
,7628178,Hepatic bioavailability (1 - hepatic extraction ratio),"Hepatic bioavailability (1 - hepatic extraction ratio) calculated for intravenous cyclosporine increased by 11% in the presence of ketoconazole (86.3% +/- 3.7% versus 75.2% +/- 6.6% without ketoconazole), which accounts for only one third of the observed increase in cyclosporine oral bioavailability.",The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628178/),%,75.2,228247,DB00592,Piperazine
,10728489,binding (dissociation) constant Kd,The estimated binding (dissociation) constant Kd was 0.57 ng/ml plasma and the maximal specific erythrocyte binding capacity (BmaxRBC) was 163 ng/ml RBC.,A combined specific target site binding and pharmacokinetic model to explore the non-linear disposition of draflazine. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10728489/),[ng] / [ml·plasma],0.57,228550,DB00592,Piperazine
,10728489,maximal specific erythrocyte binding capacity (BmaxRBC),The estimated binding (dissociation) constant Kd was 0.57 ng/ml plasma and the maximal specific erythrocyte binding capacity (BmaxRBC) was 163 ng/ml RBC.,A combined specific target site binding and pharmacokinetic model to explore the non-linear disposition of draflazine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10728489/),[ng] / [ml·rbc],163,228551,DB00592,Piperazine
,10728489,maximal specific binding capacity to the tissues (Bmaxtissue),The maximal specific binding capacity to the tissues (Bmaxtissue) was estimated to be about 1 mg.,A combined specific target site binding and pharmacokinetic model to explore the non-linear disposition of draflazine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10728489/),mg,1,228552,DB00592,Piperazine
,10728489,volume of the central compartment (Vplasma + tissue fluids),The estimated volume of the central compartment (Vplasma + tissue fluids) was 12.9 L and the total intrinsic CL was 645 ml/min.,A combined specific target site binding and pharmacokinetic model to explore the non-linear disposition of draflazine. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10728489/),l,12.9,228553,DB00592,Piperazine
,10728489,total intrinsic CL,The estimated volume of the central compartment (Vplasma + tissue fluids) was 12.9 L and the total intrinsic CL was 645 ml/min.,A combined specific target site binding and pharmacokinetic model to explore the non-linear disposition of draflazine. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10728489/),[ml] / [min],645,228554,DB00592,Piperazine
,26391142,IC50,"On the other hand, resveratrol showed inhibitory effect on CYP3A4*1, CYP2D6*1, human and rat microsomes, the IC50 of resveratrol was 6.771, 87.87, 45.11 and 35.59 μmol l(-1), respectively.",The effect of resveratrol on pharmacokinetics of aripiprazole in vivo and in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26391142/),[μM] / [l],6.771,228606,DB00592,Piperazine
,26391142,IC50,"On the other hand, resveratrol showed inhibitory effect on CYP3A4*1, CYP2D6*1, human and rat microsomes, the IC50 of resveratrol was 6.771, 87.87, 45.11 and 35.59 μmol l(-1), respectively.",The effect of resveratrol on pharmacokinetics of aripiprazole in vivo and in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26391142/),[μM] / [l],87.87,228607,DB00592,Piperazine
,26391142,IC50,"On the other hand, resveratrol showed inhibitory effect on CYP3A4*1, CYP2D6*1, human and rat microsomes, the IC50 of resveratrol was 6.771, 87.87, 45.11 and 35.59 μmol l(-1), respectively.",The effect of resveratrol on pharmacokinetics of aripiprazole in vivo and in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26391142/),[μM] / [l],45.11,228608,DB00592,Piperazine
,26391142,IC50,"On the other hand, resveratrol showed inhibitory effect on CYP3A4*1, CYP2D6*1, human and rat microsomes, the IC50 of resveratrol was 6.771, 87.87, 45.11 and 35.59 μmol l(-1), respectively.",The effect of resveratrol on pharmacokinetics of aripiprazole in vivo and in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26391142/),[μM] / [l],35.59,228609,DB00592,Piperazine
less,24970349,D50,An exploration of the sensitivity to the presence of larger particles within a polydisperse distribution showed that simulated Cmax is again more affected than AUC but is less than 20% reduced as long as D50 is less than 8 μm and D90 is smaller than 56 μm.,Physiologically based absorption modelling to predict the impact of drug properties on pharmacokinetics of bitopertin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24970349/),μ,8,228649,DB00592,Piperazine
smaller,24970349,D90,An exploration of the sensitivity to the presence of larger particles within a polydisperse distribution showed that simulated Cmax is again more affected than AUC but is less than 20% reduced as long as D50 is less than 8 μm and D90 is smaller than 56 μm.,Physiologically based absorption modelling to predict the impact of drug properties on pharmacokinetics of bitopertin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24970349/),μ,56,228650,DB00592,Piperazine
,9884817,absolute availability,The absolute availability of capsules in healthy volunteers under fasting conditions is about 55% and is increased after a meal.,Optimisation of itraconazole therapy using target drug concentrations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884817/),%,55,228688,DB00592,Piperazine
,9884817,apparent volume of distribution,Itraconazole is 99.8% bound to human plasma proteins and its apparent volume of distribution is about 11 L/kg.,Optimisation of itraconazole therapy using target drug concentrations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884817/),[l] / [kg],11,228689,DB00592,Piperazine
,9884817,blood clearance,Mean total itraconazole blood clearance determined in healthy volunteers following a single intravenous infusion was 39.6 L/h.,Optimisation of itraconazole therapy using target drug concentrations. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884817/),[l] / [h],39.6,228690,DB00592,Piperazine
,9884817,terminal elimination half-life,"After a single oral dose, the terminal elimination half-life of itraconazole is about 24 hours.",Optimisation of itraconazole therapy using target drug concentrations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884817/),h,24,228691,DB00592,Piperazine
,22090362,T(max),"PD 0332991 was slowly absorbed (median T(max), 5.5 hours), and slowly eliminated (mean half-life was 25.9 hours) with a large volume of distribution (mean, 2,793 L).","Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22090362/),h,5.5,229391,DB00592,Piperazine
,22090362,half-life,"PD 0332991 was slowly absorbed (median T(max), 5.5 hours), and slowly eliminated (mean half-life was 25.9 hours) with a large volume of distribution (mean, 2,793 L).","Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22090362/),h,25.9,229392,DB00592,Piperazine
,22090362,volume of distribution,"PD 0332991 was slowly absorbed (median T(max), 5.5 hours), and slowly eliminated (mean half-life was 25.9 hours) with a large volume of distribution (mean, 2,793 L).","Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22090362/),l,"2,793",229393,DB00592,Piperazine
,11181397,trough plasma itraconazole concentration,The mean trough plasma itraconazole concentration at the end of the intravenous treatment was 0.54 +/- 0.20 microg/ml.,Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11181397/),[μg] / [ml],0.54,229543,DB00592,Piperazine
,11181397,trough itraconazole concentration,"This concentration was not maintained during once-daily oral treatment but increased further in the twice-daily treatment group, with a trough itraconazole concentration of 1.12 +/- 0.73 microg/ml at the end of oral treatment.",Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11181397/),[μg] / [ml],1.12,229544,DB00592,Piperazine
,3311551,AUC ratio,"This cortisol AUC ratio was reduced from 0.45 (methylprednisolone) to 0.39 (methylprednisolone plus ketoconazole), suggesting that ketoconazole modestly enhanced (P less than 0.01) cortisol suppression.",Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311551/),,0.45,229623,DB00592,Piperazine
,3311551,AUC ratio,"This cortisol AUC ratio was reduced from 0.45 (methylprednisolone) to 0.39 (methylprednisolone plus ketoconazole), suggesting that ketoconazole modestly enhanced (P less than 0.01) cortisol suppression.",Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311551/),,0.39,229624,DB00592,Piperazine
,11498244,clearance,The clearance of CsA decreased from a mean (95% CI) of 9.47 (6.2-12.7)ml/min/kg after a single (first) dose (3mg/kg i.v.) to 1.62 (1.38-1.86)ml/min/kg after 18 days of CsA (3mg/kg i.v. twice daily) co-administration with ketoconazole.,Cyclosporin immunosuppression of sheep: pharmacokinetics and allograft survival. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11498244/),[ml] / [kg·min],9.47,229794,DB00592,Piperazine
,11498244,clearance,The clearance of CsA decreased from a mean (95% CI) of 9.47 (6.2-12.7)ml/min/kg after a single (first) dose (3mg/kg i.v.) to 1.62 (1.38-1.86)ml/min/kg after 18 days of CsA (3mg/kg i.v. twice daily) co-administration with ketoconazole.,Cyclosporin immunosuppression of sheep: pharmacokinetics and allograft survival. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11498244/),[ml] / [kg·min],1.62,229795,DB00592,Piperazine
,11498244,trough concentration,"Provided that the trough concentration of blood CsA was maintained between 1500-2500 mg/l, long-term healthy skin allografts were maintained on the sheep without significant adverse effects on haematological or biochemical parameters.",Cyclosporin immunosuppression of sheep: pharmacokinetics and allograft survival. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11498244/),[mg] / [l],1500-2500,229796,DB00592,Piperazine
,27245313,IPC,"The median IPC achieved with branded imatinib was 1454 μmol/L (range, 485-2707 μmol/L) with 18 patients (75%) having IPC ≥ 1000 μmol/L.",Comparison of Branded and Generic Imatinib Plasma Concentrations in Patients With Chronic Myelogenous Leukemia: Unicentric Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27245313/),[μM] / [l],1454,229977,DB00592,Piperazine
,27245313,IPCs,"For Neopax and Imakrebin, median IPCs were 1717 μmol/L (range, 1249-3630 μmol/L) and 1458 μmol/L (range, 707-880 μmol/L), respectively, with 11 of 11 (100%) and 16 of 18 (89%) patients having IPC ≥ 1000 μmol/L.",Comparison of Branded and Generic Imatinib Plasma Concentrations in Patients With Chronic Myelogenous Leukemia: Unicentric Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27245313/),[μM] / [l],1717,229978,DB00592,Piperazine
,27245313,IPCs,"For Neopax and Imakrebin, median IPCs were 1717 μmol/L (range, 1249-3630 μmol/L) and 1458 μmol/L (range, 707-880 μmol/L), respectively, with 11 of 11 (100%) and 16 of 18 (89%) patients having IPC ≥ 1000 μmol/L.",Comparison of Branded and Generic Imatinib Plasma Concentrations in Patients With Chronic Myelogenous Leukemia: Unicentric Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27245313/),[μM] / [l],1458,229979,DB00592,Piperazine
>,16207309,oral bioavailability,"Methadone is an opioid, which has a high oral bioavailability (>70%) and a long elimination half-life (>20 h) in human beings.","The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207309/),%,70,230489,DB00592,Piperazine
>,16207309,elimination half-life,"Methadone is an opioid, which has a high oral bioavailability (>70%) and a long elimination half-life (>20 h) in human beings.","The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207309/),h,20,230490,DB00592,Piperazine
,16207309,elimination half-life,"The mean +/- SD for the elimination half-life, volume of distribution, and clearance were 1.75 +/- 0.25 h, 3.46 +/- 1.09 L/kg, and 25.14 +/- 9.79 mL/min.","The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207309/),h,1.75,230491,DB00592,Piperazine
,16207309,volume of distribution,"The mean +/- SD for the elimination half-life, volume of distribution, and clearance were 1.75 +/- 0.25 h, 3.46 +/- 1.09 L/kg, and 25.14 +/- 9.79 mL/min.","The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207309/),[l] / [kg],3.46,230492,DB00592,Piperazine
,16207309,clearance,"The mean +/- SD for the elimination half-life, volume of distribution, and clearance were 1.75 +/- 0.25 h, 3.46 +/- 1.09 L/kg, and 25.14 +/- 9.79 mL/min.","The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207309/),[ml] / [min],25.14,230493,DB00592,Piperazine
,16207309,bioavailability,"Following administration with ketoconazole, detectable concentrations of methadone were present in one dog with a 29% bioavailability.","The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207309/),%,29,230494,DB00592,Piperazine
,16775418,clearance,"Docetaxel clearance was reduced by 50% (P = .018) from 32.8 +/- 13.7 L/hr to 16.5 +/- 8.15 L/hr upon ketoconazole coadministration, albeit with large inter-individual variability (fractional change in clearance, range 0.31 - 0.66).",Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16775418/),[l] / [h],32.8,230542,DB00592,Piperazine
,16775418,clearance,"Docetaxel clearance was reduced by 50% (P = .018) from 32.8 +/- 13.7 L/hr to 16.5 +/- 8.15 L/hr upon ketoconazole coadministration, albeit with large inter-individual variability (fractional change in clearance, range 0.31 - 0.66).",Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16775418/),[l] / [h],16.5,230543,DB00592,Piperazine
,25047497,Cmax,"The mean (SD) Cmax values of lobeglitazone with and without ketoconazole were 49 (7) ng/mL and 48 (6) ng/mL at 1.5 and 1.0 hours after dosing, respectively.",Effect of ketoconazole on lobeglitazone pharmacokinetics in Korean volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047497/),[ng] / [ml],49,230724,DB00592,Piperazine
,25047497,Cmax,"The mean (SD) Cmax values of lobeglitazone with and without ketoconazole were 49 (7) ng/mL and 48 (6) ng/mL at 1.5 and 1.0 hours after dosing, respectively.",Effect of ketoconazole on lobeglitazone pharmacokinetics in Korean volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047497/),[ng] / [ml],48,230725,DB00592,Piperazine
,25047497,AUC∞,"The mean (SD) AUC∞ values were 532 (117) ng·h/mL and 405 (110) ng·h/mL, respectively.",Effect of ketoconazole on lobeglitazone pharmacokinetics in Korean volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047497/),[h·ng] / [ml],532,230726,DB00592,Piperazine
,25047497,AUC∞,"The mean (SD) AUC∞ values were 532 (117) ng·h/mL and 405 (110) ng·h/mL, respectively.",Effect of ketoconazole on lobeglitazone pharmacokinetics in Korean volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047497/),[h·ng] / [ml],405,230727,DB00592,Piperazine
,26244832,area under the plasma concentration-time curve from time of administration to 24 hours after dosing (AUC0-24),"Dolutegravir geometric mean of the area under the plasma concentration-time curve from time of administration to 24 hours after dosing (AUC0-24) and 24 hour postdose concentration (C24) were 46.0 μg hours/mL and 0.90 μg/mL, respectively, which were within the study targets based on adult PK ranges.","Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26244832/),[h·μg] / [ml],46.0,230784,DB00592,Piperazine
,26244832,24 hour postdose concentration (C24),"Dolutegravir geometric mean of the area under the plasma concentration-time curve from time of administration to 24 hours after dosing (AUC0-24) and 24 hour postdose concentration (C24) were 46.0 μg hours/mL and 0.90 μg/mL, respectively, which were within the study targets based on adult PK ranges.","Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26244832/),[μg] / [ml],0.90,230785,DB00592,Piperazine
,16373464,relative bioavailability,The relative bioavailability of oral racemic zopiclone is about 80%.,Eszopiclone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16373464/),%,80,230893,DB00592,Piperazine
,16373464,peak serum concentrations,"Eszopiclone is rapidly absorbed after oral administration, with peak serum concentrations ranging from 1 to 1.3 hours.",Eszopiclone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16373464/),h,1 to 1.3,230894,DB00592,Piperazine
,8859010,final,"Thirty minutes after acquiring the final image, each subject was coinjected with a second dose, 10 mCi of [11C]BMS-181101 plus 3 mg of unlabeled drug (final specific activity approximately 1.5 mCi/mumol), and imaging/blood collection was repeated.","Evaluation of cerebral pharmacokinetics of the novel antidepressant drug, BMS-181101, by positron emission tomography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8859010/),[mci] / [μM],1.5,231292,DB00592,Piperazine
,8859010,specific activity,"Thirty minutes after acquiring the final image, each subject was coinjected with a second dose, 10 mCi of [11C]BMS-181101 plus 3 mg of unlabeled drug (final specific activity approximately 1.5 mCi/mumol), and imaging/blood collection was repeated.","Evaluation of cerebral pharmacokinetics of the novel antidepressant drug, BMS-181101, by positron emission tomography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8859010/),[mci] / [μM],1.5,231293,DB00592,Piperazine
,18563956,absolute bioavailability,"In study 1, the geometric mean values for the absolute bioavailability of aripiprazole following oral and intramuscular administration were 0.85 and 0.98, respectively.","Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18563956/),,0.85,231304,DB00592,Piperazine
,18563956,absolute bioavailability,"In study 1, the geometric mean values for the absolute bioavailability of aripiprazole following oral and intramuscular administration were 0.85 and 0.98, respectively.","Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18563956/),,0.98,231305,DB00592,Piperazine
,29319446,half-life,Mean half-life of itraconazole in reference formulations was 18 to 26 hours.,Comparison of absorption characteristics of oral reference and compounded itraconazole formulations in healthy cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29319446/),h,18 to 26,231382,DB00592,Piperazine
,29319446,Relative absorption,Relative absorption of compounded formulations was only 2% to 8% of reference formulation values.,Comparison of absorption characteristics of oral reference and compounded itraconazole formulations in healthy cats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29319446/),%,2,231383,DB00592,Piperazine
,29319446,Relative absorption,Relative absorption of compounded formulations was only 2% to 8% of reference formulation values.,Comparison of absorption characteristics of oral reference and compounded itraconazole formulations in healthy cats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29319446/),%,8,231384,DB00592,Piperazine
,22877221,turnaround time,"The approach allows for the investigation of a set of six compounds simultaneously, with a turnaround time of 1 week or less.",A semi-automated method for the integrated evaluation of half-life and metabolic soft spots of discovery compounds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22877221/),week,1,231407,DB00592,Piperazine
,24167844,clearance (CL,"The population mean clearance (CL; liter/h) was estimated as 5.15-0.0673 x(Age-62) L/h, the population mean volume of distribution (V; liter) was determined as 878L and the bioavailability (F) was determined as 0.665.",Population pharmacokinetics of itraconazole in Japanese patients with invasive fungal peritonitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24167844/),[l] / [h],5.15-0.0673,231413,DB00592,Piperazine
,24167844,volume of distribution (V;,"The population mean clearance (CL; liter/h) was estimated as 5.15-0.0673 x(Age-62) L/h, the population mean volume of distribution (V; liter) was determined as 878L and the bioavailability (F) was determined as 0.665.",Population pharmacokinetics of itraconazole in Japanese patients with invasive fungal peritonitis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24167844/),l,878,231414,DB00592,Piperazine
,24167844,bioavailability (F),"The population mean clearance (CL; liter/h) was estimated as 5.15-0.0673 x(Age-62) L/h, the population mean volume of distribution (V; liter) was determined as 878L and the bioavailability (F) was determined as 0.665.",Population pharmacokinetics of itraconazole in Japanese patients with invasive fungal peritonitis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24167844/),,0.665,231415,DB00592,Piperazine
,8703669,peak,"Mean peak and trough plasma concentrations of theophylline ranged from 13.1 to 14.5 micrograms ml-1 and 11.6 to 14.2 micrograms ml-1, respectively, at steady-state when theophylline was administered with or without concurrent dosing of nefazodone.",Lack of an effect of nefazodone on the pharmacokinetics and pharmacodynamics of theophylline during concurrent administration in patients with chronic obstructive pulmonary disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703669/),[μg] / [ml],13.1 to 14.5,231581,DB00592,Piperazine
,8703669,trough plasma concentrations,"Mean peak and trough plasma concentrations of theophylline ranged from 13.1 to 14.5 micrograms ml-1 and 11.6 to 14.2 micrograms ml-1, respectively, at steady-state when theophylline was administered with or without concurrent dosing of nefazodone.",Lack of an effect of nefazodone on the pharmacokinetics and pharmacodynamics of theophylline during concurrent administration in patients with chronic obstructive pulmonary disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703669/),[μg] / [ml],11.6 to 14.2,231582,DB00592,Piperazine
,8703669,area under the curve,"Similarly, the mean area under the curve for theophylline ranged from 93.5 to 103 micrograms ml-1 h.",Lack of an effect of nefazodone on the pharmacokinetics and pharmacodynamics of theophylline during concurrent administration in patients with chronic obstructive pulmonary disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703669/),[h·μg] / [ml],93.5 to 103,231583,DB00592,Piperazine
up to,7936231,half-life,"Because of FNR's long half-life (up to 7 weeks), a parallel rather than crossover design was used.",Flunarizine for treatment of partial seizures: results of a concentration-controlled trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7936231/),weeks,7,232227,DB00592,Piperazine
,18556158,absorption half-life,"The predicted absorption half-life for 230 nm amorphous ITZ particles was only 15 min, as a result of the small particle size and high supersaturation, in general agreement with the in vivo results.",High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18556158/),min,15,232388,DB00592,Piperazine
,9098985,flow-rate,"pH 3.0, adjusted with orthophosphoric acids at a flow-rate of 0.06 ml/min.",Measurement and pharmacokinetic analysis of buspirone by means of brain microdialysis coupled to high-performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9098985/),[ml] / [min],0.06,232949,DB00592,Piperazine
,19192440,half-life,"Its unique pharmacokinetic profile as an oral drug with long half-life (2-7 weeks), low cost, and low induction of extrapyramidal symptoms warrants further investigation, particularly in psychiatric patients with low adherence to treatment.",Is flunarizine a long-acting oral atypical antipsychotic? A randomized clinical trial versus haloperidol for the treatment of schizophrenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19192440/),weeks,2-7,233080,DB00592,Piperazine
,23855261,cumulative excretion,"By 216 h after administration, ≥90% of the administered radioactivity was excreted, and the cumulative excretion in the urine and faeces was 45.4% and 46.5%, respectively.",Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23855261/),%,45.4,233122,DB00592,Piperazine
,23855261,cumulative excretion,"By 216 h after administration, ≥90% of the administered radioactivity was excreted, and the cumulative excretion in the urine and faeces was 45.4% and 46.5%, respectively.",Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23855261/),%,46.5,233123,DB00592,Piperazine
better,19070586,recoveries,The average recoveries in plasma samples both were better than 85%.,Development of an LC-MS/MS method for the simultaneous quantification of aripiprazole and dehydroaripiprazole in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19070586/),%,85,233288,DB00592,Piperazine
,15044430,peak plasma concentrations,"On day 14 average peak plasma concentrations were 404 +/- 268 ng/mL (<16 years, n = 5) and 779 +/- 470 ng/mL (>/=16 years, n = 11 excluding one patient concurrently receiving oral clarithromycin).",Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15044430/),[ng] / [ml],404,233315,DB00592,Piperazine
,15044430,peak plasma concentrations,"On day 14 average peak plasma concentrations were 404 +/- 268 ng/mL (<16 years, n = 5) and 779 +/- 470 ng/mL (>/=16 years, n = 11 excluding one patient concurrently receiving oral clarithromycin).",Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15044430/),[ng] / [ml],779,233316,DB00592,Piperazine
>,15044430,plasma steady-state trough concentration,All the younger patients and 50% of the older patients failed to achieve a plasma steady-state trough concentration of >250 ng/mL.,Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15044430/),[ng] / [ml],250,233317,DB00592,Piperazine
>,15044430,Plasma concentrations,Plasma concentrations of >250 ng/mL were not reached in the paediatric cohort or in 50% of the adult cohort.,Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15044430/),ng,250,233318,DB00592,Piperazine
,17689219,m/z,"The multiple reaction monitoring was based on the transition of m/z=532.5-->99.1 for SK3530, 488.6-->295.5 for SK3541, and 520.3-->99.1 for SK3304 (internal standard).","Development of LC/MS/MS assay for the determination of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one (SK3530) in human plasma: application to a clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17689219/),,532.5,233537,DB00592,Piperazine
,17689219,m/z,"The multiple reaction monitoring was based on the transition of m/z=532.5-->99.1 for SK3530, 488.6-->295.5 for SK3541, and 520.3-->99.1 for SK3304 (internal standard).","Development of LC/MS/MS assay for the determination of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one (SK3530) in human plasma: application to a clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17689219/),,99.1,233538,DB00592,Piperazine
,17689219,m/z,"The multiple reaction monitoring was based on the transition of m/z=532.5-->99.1 for SK3530, 488.6-->295.5 for SK3541, and 520.3-->99.1 for SK3304 (internal standard).","Development of LC/MS/MS assay for the determination of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one (SK3530) in human plasma: application to a clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17689219/),,488.6,233539,DB00592,Piperazine
,17689219,m/z,"The multiple reaction monitoring was based on the transition of m/z=532.5-->99.1 for SK3530, 488.6-->295.5 for SK3541, and 520.3-->99.1 for SK3304 (internal standard).","Development of LC/MS/MS assay for the determination of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one (SK3530) in human plasma: application to a clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17689219/),,295.5,233540,DB00592,Piperazine
,17689219,m/z,"The multiple reaction monitoring was based on the transition of m/z=532.5-->99.1 for SK3530, 488.6-->295.5 for SK3541, and 520.3-->99.1 for SK3304 (internal standard).","Development of LC/MS/MS assay for the determination of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one (SK3530) in human plasma: application to a clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17689219/),,520.3,233541,DB00592,Piperazine
,17689219,m/z,"The multiple reaction monitoring was based on the transition of m/z=532.5-->99.1 for SK3530, 488.6-->295.5 for SK3541, and 520.3-->99.1 for SK3304 (internal standard).","Development of LC/MS/MS assay for the determination of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one (SK3530) in human plasma: application to a clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17689219/),,99.1,233542,DB00592,Piperazine
,9674858,Cmin ITRA,"The mean values of Cmin ITRA and OH-ITRA, respectively, were 287 +/- 109 ng/ml and 629 +/- 227 ng/ml at day -1 and 378 +/- 147 ng/ml and 725 +/- 242 ng/ml at day +1.",Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9674858/),[ng] / [ml],287,233553,DB00592,Piperazine
,9674858,Cmin ITRA,"The mean values of Cmin ITRA and OH-ITRA, respectively, were 287 +/- 109 ng/ml and 629 +/- 227 ng/ml at day -1 and 378 +/- 147 ng/ml and 725 +/- 242 ng/ml at day +1.",Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9674858/),[ng] / [ml],629,233554,DB00592,Piperazine
,9674858,Cmin ITRA,"The mean values of Cmin ITRA and OH-ITRA, respectively, were 287 +/- 109 ng/ml and 629 +/- 227 ng/ml at day -1 and 378 +/- 147 ng/ml and 725 +/- 242 ng/ml at day +1.",Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9674858/),[ng] / [ml],378,233555,DB00592,Piperazine
,9674858,OH-ITRA,"The mean values of Cmin ITRA and OH-ITRA, respectively, were 287 +/- 109 ng/ml and 629 +/- 227 ng/ml at day -1 and 378 +/- 147 ng/ml and 725 +/- 242 ng/ml at day +1.",Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9674858/),[ng] / [ml],629,233556,DB00592,Piperazine
,9674858,OH-ITRA,"The mean values of Cmin ITRA and OH-ITRA, respectively, were 287 +/- 109 ng/ml and 629 +/- 227 ng/ml at day -1 and 378 +/- 147 ng/ml and 725 +/- 242 ng/ml at day +1.",Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9674858/),[ng] / [ml],725,233557,DB00592,Piperazine
at least,9674858,residual plasma concentrations,Six patients at day -1 (54%) and 8 at day +1 (72%) had satisfactory residual plasma concentrations of at least 250 ng/ml of unchanged ITRA.,Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9674858/),[ng] / [ml],250,233558,DB00592,Piperazine
,20080374,m/,"Multiple reaction monitoring (MRM) using the precursor to product ion was m/z 292.2/99.2 for fasudil, m/z 308.2/99.2 for M3 and m/z for 315.3/176.2 for IS.",Simultaneous quantitative analysis of fasudil and its active metabolite in human plasma by liquid chromatography electro-spray tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20080374/),,292.2,233631,DB00592,Piperazine
,20080374,m/z,"Multiple reaction monitoring (MRM) using the precursor to product ion was m/z 292.2/99.2 for fasudil, m/z 308.2/99.2 for M3 and m/z for 315.3/176.2 for IS.",Simultaneous quantitative analysis of fasudil and its active metabolite in human plasma by liquid chromatography electro-spray tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20080374/),,308.2,233632,DB00592,Piperazine
,20080374,m/z,"Multiple reaction monitoring (MRM) using the precursor to product ion was m/z 292.2/99.2 for fasudil, m/z 308.2/99.2 for M3 and m/z for 315.3/176.2 for IS.",Simultaneous quantitative analysis of fasudil and its active metabolite in human plasma by liquid chromatography electro-spray tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20080374/),,315.3,233633,DB00592,Piperazine
,20080374,m/z,"Multiple reaction monitoring (MRM) using the precursor to product ion was m/z 292.2/99.2 for fasudil, m/z 308.2/99.2 for M3 and m/z for 315.3/176.2 for IS.",Simultaneous quantitative analysis of fasudil and its active metabolite in human plasma by liquid chromatography electro-spray tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20080374/),,176.2,233634,DB00592,Piperazine
,8592993,peak concentrations,"In the single-dose study, the concentrations in serum reached a peak between 1 and 2 h, and the peak concentrations were 0.873, 1.71, 3.35, and 5.41 micrograms/ml at the doses of 100, 200, 400, and 600 mg, respectively.","Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592993/),[μg] / [ml],0.873,233694,DB00592,Piperazine
,8592993,peak concentrations,"In the single-dose study, the concentrations in serum reached a peak between 1 and 2 h, and the peak concentrations were 0.873, 1.71, 3.35, and 5.41 micrograms/ml at the doses of 100, 200, 400, and 600 mg, respectively.","Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592993/),[μg] / [ml],1.71,233695,DB00592,Piperazine
,8592993,peak concentrations,"In the single-dose study, the concentrations in serum reached a peak between 1 and 2 h, and the peak concentrations were 0.873, 1.71, 3.35, and 5.41 micrograms/ml at the doses of 100, 200, 400, and 600 mg, respectively.","Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592993/),[μg] / [ml],3.35,233696,DB00592,Piperazine
,8592993,peak concentrations,"In the single-dose study, the concentrations in serum reached a peak between 1 and 2 h, and the peak concentrations were 0.873, 1.71, 3.35, and 5.41 micrograms/ml at the doses of 100, 200, 400, and 600 mg, respectively.","Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592993/),[μg] / [ml],5.41,233697,DB00592,Piperazine
,8592993,elimination half-life,"The elimination half-life was 7 to 8 h, independently of the doses.","Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592993/),h,7 to 8,233698,DB00592,Piperazine
,8592993,fecal recovery,The fecal recovery of the unchanged drug amounted to 5.7% for 72 h after a single oral administration of a 400-mg dose.,"Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592993/),%,5.7,233699,DB00592,Piperazine
,8592993,serum protein binding,"The serum protein binding was 20%, independently of the concentrations in serum.","Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592993/),%,20,233700,DB00592,Piperazine
,10634135,AUC,"Ketoconazole and rifampin pretreatment significantly changed AUC values of ALP (mean AUC values in microg/l h: ALP = 242.2, ALP + ketoconazole = 426.2, ALP + rifampin = 28.4, ANOVA F = 17.7, P < 0.001).",Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10634135/),[μg] / [h·l],242,233774,DB00592,Piperazine
,10634135,AUC,"Ketoconazole and rifampin pretreatment significantly changed AUC values of ALP (mean AUC values in microg/l h: ALP = 242.2, ALP + ketoconazole = 426.2, ALP + rifampin = 28.4, ANOVA F = 17.7, P < 0.001).",Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10634135/),[μg] / [h·l],42,233775,DB00592,Piperazine
,11293269,absolute extraction recovery,The absolute extraction recovery from plasma samples was 76%.,High-performance liquid chromatographic analysis for the determination of buspirone analogue--mesmar in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11293269/),%,76,233875,DB00592,Piperazine
,24856961,AUC0-∞,"The pharmacokinetic data of optimized CTZ microspheres showed prolonged tmax, decreased Cmax and AUC0-∞ value of 3309 ± 211 ng h/ml indicating improved relative bioavailability by 169.4% compared with marketed tablets.",Statistical optimization of controlled release microspheres containing cetirizine hydrochloride as a model for water soluble drugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24856961/),[h·ng] / [ml],3309,234171,DB00592,Piperazine
,24856961,relative bioavailability,"The pharmacokinetic data of optimized CTZ microspheres showed prolonged tmax, decreased Cmax and AUC0-∞ value of 3309 ± 211 ng h/ml indicating improved relative bioavailability by 169.4% compared with marketed tablets.",Statistical optimization of controlled release microspheres containing cetirizine hydrochloride as a model for water soluble drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24856961/),%,169.4,234172,DB00592,Piperazine
,29429832,IC50,"Compound 10d, which exhibits approximate potency on CDK4/6 (IC50 = 7.4/0.9 nM), has both good pharmacokinetic characters and high selectivity on CDK1 compared with LY2835219.","Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29429832/),nM,7.4,234414,DB00592,Piperazine
,29429832,IC50,"Compound 10d, which exhibits approximate potency on CDK4/6 (IC50 = 7.4/0.9 nM), has both good pharmacokinetic characters and high selectivity on CDK1 compared with LY2835219.","Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29429832/),nM,0.9,234415,DB00592,Piperazine
,12183684,clearance,"Ketoconazole (total dose of 15 mg/kg intraperitoneally) reduced clearance of intravenous midazolam (5 mg/kg) from 79 to 55 ml/min/kg (p < 0.05) and clearance of intragastric midazolam (15 mg/kg) from 1051 to 237 ml/min/kg (p < 0.05), increasing absolute bioavailability from 0.11 to 0.36 (p < 0.05).","In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12183684/),[ml] / [kg·min],79 to 55,234910,DB00592,Piperazine
,12183684,clearance,"Ketoconazole (total dose of 15 mg/kg intraperitoneally) reduced clearance of intravenous midazolam (5 mg/kg) from 79 to 55 ml/min/kg (p < 0.05) and clearance of intragastric midazolam (15 mg/kg) from 1051 to 237 ml/min/kg (p < 0.05), increasing absolute bioavailability from 0.11 to 0.36 (p < 0.05).","In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12183684/),[ml] / [kg·min],1051 to 237,234911,DB00592,Piperazine
,12183684,absolute bioavailability,"Ketoconazole (total dose of 15 mg/kg intraperitoneally) reduced clearance of intravenous midazolam (5 mg/kg) from 79 to 55 ml/min/kg (p < 0.05) and clearance of intragastric midazolam (15 mg/kg) from 1051 to 237 ml/min/kg (p < 0.05), increasing absolute bioavailability from 0.11 to 0.36 (p < 0.05).","In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12183684/),,0.11,234912,DB00592,Piperazine
,12183684,absolute bioavailability,"Ketoconazole (total dose of 15 mg/kg intraperitoneally) reduced clearance of intravenous midazolam (5 mg/kg) from 79 to 55 ml/min/kg (p < 0.05) and clearance of intragastric midazolam (15 mg/kg) from 1051 to 237 ml/min/kg (p < 0.05), increasing absolute bioavailability from 0.11 to 0.36 (p < 0.05).","In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12183684/),,0.36,234913,DB00592,Piperazine
,1667252,peak concentration,"After oral administration of NM441 at a dose of 20 mg/kg to dogs, the peak concentration of NM394 in plasma was 2.39 micrograms/ml, whereas it was 0.63 micrograms/ml for NM394 administered alone.","In vivo evaluation of NM441, a new thiazeto-quinoline derivative. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1667252/),[μg] / [ml],2.39,235216,DB00592,Piperazine
,1667252,peak concentration,"After oral administration of NM441 at a dose of 20 mg/kg to dogs, the peak concentration of NM394 in plasma was 2.39 micrograms/ml, whereas it was 0.63 micrograms/ml for NM394 administered alone.","In vivo evaluation of NM441, a new thiazeto-quinoline derivative. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1667252/),[μg] / [ml],0.63,235217,DB00592,Piperazine
,15951467,K(i),"Digoxin coadministration increased the apparent EC(50) with no effect on E(max), consistent with competitive inhibition (K(i) = 0.899 ng/mL).",Influence of coadministration on the pharmacokinetics of azimilide dihydrochloride and digoxin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15951467/),[ng] / [ml],0.899,235874,DB00592,Piperazine
,12515883,Maximal concentrations,"Maximal concentrations in the brain and plasma were 1.11 +/- 0.30 x 10(-7) mol/L (at 3.0 +/- 0.6 h after administration) and 4.04 +/- 1.29 x 10(-7) mol/L (at 2.0 +/- 1.1 h after administration), respectively.",Measurement of brain concentration of FK960 for development of a novel antidementia drug: a PET study in conscious rhesus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12515883/),[mol] / [l],1.11,235918,DB00592,Piperazine
,12515883,Maximal concentrations,"Maximal concentrations in the brain and plasma were 1.11 +/- 0.30 x 10(-7) mol/L (at 3.0 +/- 0.6 h after administration) and 4.04 +/- 1.29 x 10(-7) mol/L (at 2.0 +/- 1.1 h after administration), respectively.",Measurement of brain concentration of FK960 for development of a novel antidementia drug: a PET study in conscious rhesus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12515883/),[mol] / [l],4.04,235919,DB00592,Piperazine
,33599975,maximum/minimum ratio of plasma concentration,"The maximum/minimum ratio of plasma concentration was estimated as 1.10 at steady state, indicating minimal fluctuation.",Pharmacokinetic Evaluation of Blonanserin Transdermal Patch: Population Analysis and Simulation of Plasma Concentration and Dopamine D2 Receptor Occupancy in Clinical Settings. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33599975/),,1.10,236128,DB00592,Piperazine
,15005637,bioavailability,"Although zaleplon has a much lower bioavailability (30%), the treatment dose is similar to zolpidem and zopiclone (bioavilaibility of 70%) because of the increased potency of zaleplon.","Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005637/),%,30,236145,DB00592,Piperazine
,15005637,bioavilaibility,"Although zaleplon has a much lower bioavailability (30%), the treatment dose is similar to zolpidem and zopiclone (bioavilaibility of 70%) because of the increased potency of zaleplon.","Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005637/),%,70,236146,DB00592,Piperazine
,25424014,AUC0.5 - 4h,"Mean AUC0.5 - 4h increased post-meal, on combination therapy, from 9.6 to 12.5 pmol·h/l (active GLP-1) and from 21.5 to 32.3 pmol·h/l (total GLP-1).",Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25424014/),[h·pM] / [l],9.6 to 12.5,236155,DB00592,Piperazine
,25424014,AUC0.5 - 4h,"Mean AUC0.5 - 4h increased post-meal, on combination therapy, from 9.6 to 12.5 pmol·h/l (active GLP-1) and from 21.5 to 32.3 pmol·h/l (total GLP-1).",Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25424014/),[h·pM] / [l],21.5 to 32.3,236156,DB00592,Piperazine
,3663880,elimination half-life,"The elimination half-life of 14C was 105 h in the dog and 83 h in the rat, while that of 3H was approximately 32 h in both species.","Disposition of a silicon-containing amide, an inhibitor of acyl-CoA: cholesterol acyltransferase, in dog and rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3663880/),h,105,236304,DB00592,Piperazine
,3663880,elimination half-life,"The elimination half-life of 14C was 105 h in the dog and 83 h in the rat, while that of 3H was approximately 32 h in both species.","Disposition of a silicon-containing amide, an inhibitor of acyl-CoA: cholesterol acyltransferase, in dog and rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3663880/),h,83,236305,DB00592,Piperazine
,3663880,elimination half-life,"The elimination half-life of 14C was 105 h in the dog and 83 h in the rat, while that of 3H was approximately 32 h in both species.","Disposition of a silicon-containing amide, an inhibitor of acyl-CoA: cholesterol acyltransferase, in dog and rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3663880/),h,32,236306,DB00592,Piperazine
,15521894,apparent oral clearance (CL/F),"Itraconazole significantly (P < 0.001) decreased the apparent oral clearance (CL/F) (16.47 +/- 4.3 vs 3.91 +/- 2.1), increased the area under the concentration-time curves (AUC) from 0 h to 24 h (28.37 +/- 10.8 vs 68.71 +/- 24.1 ng ml h(-1)), and prolonged the elimination half-life (4.56 +/- 1.4 vs 23.27 +/- 10.3 h) of brotizolam.",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15521894/),,16.47,237083,DB00592,Piperazine
,15521894,apparent oral clearance (CL/F),"Itraconazole significantly (P < 0.001) decreased the apparent oral clearance (CL/F) (16.47 +/- 4.3 vs 3.91 +/- 2.1), increased the area under the concentration-time curves (AUC) from 0 h to 24 h (28.37 +/- 10.8 vs 68.71 +/- 24.1 ng ml h(-1)), and prolonged the elimination half-life (4.56 +/- 1.4 vs 23.27 +/- 10.3 h) of brotizolam.",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15521894/),,3.91,237084,DB00592,Piperazine
,15521894,area under the concentration-time curves (AUC) from 0 h to 24 h,"Itraconazole significantly (P < 0.001) decreased the apparent oral clearance (CL/F) (16.47 +/- 4.3 vs 3.91 +/- 2.1), increased the area under the concentration-time curves (AUC) from 0 h to 24 h (28.37 +/- 10.8 vs 68.71 +/- 24.1 ng ml h(-1)), and prolonged the elimination half-life (4.56 +/- 1.4 vs 23.27 +/- 10.3 h) of brotizolam.",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15521894/),[ml·ng] / [h],28.37,237085,DB00592,Piperazine
,15521894,area under the concentration-time curves (AUC) from 0 h to 24 h,"Itraconazole significantly (P < 0.001) decreased the apparent oral clearance (CL/F) (16.47 +/- 4.3 vs 3.91 +/- 2.1), increased the area under the concentration-time curves (AUC) from 0 h to 24 h (28.37 +/- 10.8 vs 68.71 +/- 24.1 ng ml h(-1)), and prolonged the elimination half-life (4.56 +/- 1.4 vs 23.27 +/- 10.3 h) of brotizolam.",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15521894/),[ml·ng] / [h],68.71,237086,DB00592,Piperazine
,15521894,elimination half-life,"Itraconazole significantly (P < 0.001) decreased the apparent oral clearance (CL/F) (16.47 +/- 4.3 vs 3.91 +/- 2.1), increased the area under the concentration-time curves (AUC) from 0 h to 24 h (28.37 +/- 10.8 vs 68.71 +/- 24.1 ng ml h(-1)), and prolonged the elimination half-life (4.56 +/- 1.4 vs 23.27 +/- 10.3 h) of brotizolam.",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15521894/),h,4.56,237087,DB00592,Piperazine
,15521894,elimination half-life,"Itraconazole significantly (P < 0.001) decreased the apparent oral clearance (CL/F) (16.47 +/- 4.3 vs 3.91 +/- 2.1), increased the area under the concentration-time curves (AUC) from 0 h to 24 h (28.37 +/- 10.8 vs 68.71 +/- 24.1 ng ml h(-1)), and prolonged the elimination half-life (4.56 +/- 1.4 vs 23.27 +/- 10.3 h) of brotizolam.",Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15521894/),h,23.27,237088,DB00592,Piperazine
<,23396605,Cure rate,Cure rate for subjects with refractory or relapsing metastatic neuroblastoma is <5%.,Two-stage phase II study of imatinib mesylate in subjects with refractory or relapsing neuroblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23396605/),%,5,237399,DB00592,Piperazine
,23396605,exposure,"At steady-state, PK exposure (69.7 µg h/ml) was similar to that of adults receiving 1000 mg/die.",Two-stage phase II study of imatinib mesylate in subjects with refractory or relapsing neuroblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23396605/),[h·μg] / [ml],69.7,237400,DB00592,Piperazine
,24746063,bioavailability,"These limitations include poor solubility and extensive first-pass metabolism, resulting in low (40%) bioavailability and short elimination half-life (4 h).",Sildenafil citrate as oral solid lipid nanoparticles: a novel formula with higher bioavailability and sustained action for treatment of erectile dysfunction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24746063/),%,40,238012,DB00592,Piperazine
,24746063,elimination half-life,"These limitations include poor solubility and extensive first-pass metabolism, resulting in low (40%) bioavailability and short elimination half-life (4 h).",Sildenafil citrate as oral solid lipid nanoparticles: a novel formula with higher bioavailability and sustained action for treatment of erectile dysfunction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24746063/),h,4,238013,DB00592,Piperazine
,28749305,minimum inhibitory concentration (MIC),"Itraconazole concentrations were measured using high performance liquid chromatography, and the minimum inhibitory concentration (MIC) of itraconazole (0.032 μg/ml) for B. dendrobatidis was used to determine whether therapeutic concentrations were attained.",THE PHARMACOKINETICS OF TOPICAL ITRACONAZOLE IN PANAMANIAN GOLDEN FROGS (ATELOPUS ZETEKI). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28749305/),[μg] / [ml],0.032,238075,DB00592,Piperazine
,28749305,disappearance half-life,"With the 0.001% bath, itraconazole exceeded the MIC and declined with a disappearance half-life that markedly varied (14.1-1,244 min).",THE PHARMACOKINETICS OF TOPICAL ITRACONAZOLE IN PANAMANIAN GOLDEN FROGS (ATELOPUS ZETEKI). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28749305/),min,"14.1-1,244",238076,DB00592,Piperazine
,12536488,recovery rate,"ml-1, and the correlation coefficient was 0.9992, the recovery rate of HPLC was (100.23 +/- 3.00)%, within day RSD and between day RSD were no more than 5.56% and 3.30% respectively.",[Pharmacokinetics of high-dosage naftopidil capsules in dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12536488/),%,100.23,238182,DB00592,Piperazine
no,12536488,recovery rate,"ml-1, and the correlation coefficient was 0.9992, the recovery rate of HPLC was (100.23 +/- 3.00)%, within day RSD and between day RSD were no more than 5.56% and 3.30% respectively.",[Pharmacokinetics of high-dosage naftopidil capsules in dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12536488/),%,5.56,238183,DB00592,Piperazine
,12536488,recovery rate,"ml-1, and the correlation coefficient was 0.9992, the recovery rate of HPLC was (100.23 +/- 3.00)%, within day RSD and between day RSD were no more than 5.56% and 3.30% respectively.",[Pharmacokinetics of high-dosage naftopidil capsules in dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12536488/),%,3.30,238184,DB00592,Piperazine
,12536488,T1/2Ke,"T1/2Ke value was (1.91-4.99) h, Tmax was (1.87-3.21) h, Cmax was (338.79-414.04) ng.ml-1.",[Pharmacokinetics of high-dosage naftopidil capsules in dogs]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12536488/),h,1.91-4.99,238185,DB00592,Piperazine
,12536488,Tmax,"T1/2Ke value was (1.91-4.99) h, Tmax was (1.87-3.21) h, Cmax was (338.79-414.04) ng.ml-1.",[Pharmacokinetics of high-dosage naftopidil capsules in dogs]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12536488/),h,1.87-3.21,238186,DB00592,Piperazine
,12536488,Cmax,"T1/2Ke value was (1.91-4.99) h, Tmax was (1.87-3.21) h, Cmax was (338.79-414.04) ng.ml-1.",[Pharmacokinetics of high-dosage naftopidil capsules in dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12536488/),[ng] / [ml],338.79-414.04,238187,DB00592,Piperazine
,24405707,Ki,"In an effort to identify novel CGRP receptor antagonists for the treatment of migraine, we have discovered thiazolidinone 49, a potent (Ki=30 pM, IC50=1 nM), orally bioavailable, CNS-penetrant CGRP antagonist with good pharmacokinetic properties.",Identification of potent CNS-penetrant thiazolidinones as novel CGRP receptor antagonists. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24405707/),pM,30,238547,DB00592,Piperazine
,24405707,IC50,"In an effort to identify novel CGRP receptor antagonists for the treatment of migraine, we have discovered thiazolidinone 49, a potent (Ki=30 pM, IC50=1 nM), orally bioavailable, CNS-penetrant CGRP antagonist with good pharmacokinetic properties.",Identification of potent CNS-penetrant thiazolidinones as novel CGRP receptor antagonists. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24405707/),nM,1,238548,DB00592,Piperazine
,12723463,AUC,"Ketoconazole coadministration increased mean almotriptan AUC and Cmax from 312 to 490 ng h/mL and 52.6 to 84.5 ng/mL, respectively.",Interaction between ketoconazole and almotriptan in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723463/),[h·ng] / [ml],312 to 490,238911,DB00592,Piperazine
,12723463,Cmax,"Ketoconazole coadministration increased mean almotriptan AUC and Cmax from 312 to 490 ng h/mL and 52.6 to 84.5 ng/mL, respectively.",Interaction between ketoconazole and almotriptan in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723463/),[ng] / [ml],52.6 to 84.5,238912,DB00592,Piperazine
,12723463,oral clearance,"Mean oral clearance was decreased from 40.7 to 26.2 L/h by ketoconazole, with an accompanying increase in the fraction of almotriptan excreted unchanged in the urine (40.6% to 53.3%) and a decrease in renal clearance (16.4 to 13.8 L/h).",Interaction between ketoconazole and almotriptan in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723463/),[l] / [h],40,238913,DB00592,Piperazine
,12723463,oral clearance,"Mean oral clearance was decreased from 40.7 to 26.2 L/h by ketoconazole, with an accompanying increase in the fraction of almotriptan excreted unchanged in the urine (40.6% to 53.3%) and a decrease in renal clearance (16.4 to 13.8 L/h).",Interaction between ketoconazole and almotriptan in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723463/),[l] / [h],26,238914,DB00592,Piperazine
,12723463,renal clearance,"Mean oral clearance was decreased from 40.7 to 26.2 L/h by ketoconazole, with an accompanying increase in the fraction of almotriptan excreted unchanged in the urine (40.6% to 53.3%) and a decrease in renal clearance (16.4 to 13.8 L/h).",Interaction between ketoconazole and almotriptan in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723463/),[l] / [h],16.4 to 13.8,238915,DB00592,Piperazine
,2731510,peak serum ketoconazole concentration,Mean peak serum ketoconazole concentration was 3.76 micrograms/ml at 1.5 to 2 h after intragastric administration.,Body fluid and endometrial concentrations of ketoconazole in mares after intravenous injection or repeated gavage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731510/),[μg] / [ml],3.76,238921,DB00592,Piperazine
,2731510,peak synovial concentration,Mean peak synovial concentration was 0.87 micrograms/ml 3 h after the fifth dose.,Body fluid and endometrial concentrations of ketoconazole in mares after intravenous injection or repeated gavage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731510/),[μg] / [ml],0.87,238922,DB00592,Piperazine
,2731510,peritoneal concentration,"Similarly, mean peritoneal concentration peaked 3 h after the fifth dose at 1.62 micrograms/ml.",Body fluid and endometrial concentrations of ketoconazole in mares after intravenous injection or repeated gavage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731510/),[μg] / [ml],1.62,238923,DB00592,Piperazine
,2731510,endometrial,Mean endometrial concentrations peaked at 2.73 micrograms/ml 2 h after the fifth dose.,Body fluid and endometrial concentrations of ketoconazole in mares after intravenous injection or repeated gavage. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731510/),[μg] / [ml],2.73,238924,DB00592,Piperazine
,2731510,concentrations,Mean endometrial concentrations peaked at 2.73 micrograms/ml 2 h after the fifth dose.,Body fluid and endometrial concentrations of ketoconazole in mares after intravenous injection or repeated gavage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731510/),[μg] / [ml],2.73,238925,DB00592,Piperazine
,2731510,overall elimination rate constant,A single intravenous injection of ketoconazole (10 mg/kg bwt) was given to one of the six mares; the overall elimination rate constant was estimated at 0.22/h and bioavailability after oral administration was 23 per cent.,Body fluid and endometrial concentrations of ketoconazole in mares after intravenous injection or repeated gavage. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731510/),1/[h],0.22,238926,DB00592,Piperazine
,2731510,bioavailability,A single intravenous injection of ketoconazole (10 mg/kg bwt) was given to one of the six mares; the overall elimination rate constant was estimated at 0.22/h and bioavailability after oral administration was 23 per cent.,Body fluid and endometrial concentrations of ketoconazole in mares after intravenous injection or repeated gavage. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731510/),%,23,238927,DB00592,Piperazine
,16769599,bleeding time,"The mean bleeding time was prolonged by day 5 at 4 h postdose in all subjects in the prasugrel 10 mg dose group (prasugrel 10 mg, 1058 +/- 412 s vs. placebo, 196 +/- 74 s; P < 0.001).",Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16769599/),s,1058,238941,DB00592,Piperazine
,16769599,bleeding time,"The mean bleeding time was prolonged by day 5 at 4 h postdose in all subjects in the prasugrel 10 mg dose group (prasugrel 10 mg, 1058 +/- 412 s vs. placebo, 196 +/- 74 s; P < 0.001).",Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16769599/),s,196,238942,DB00592,Piperazine
,11528196,t(max),"The plasma concentrations of vardenafil increased rapidly, with a median t(max) of about 40 min and a mean t1/2 of 4.4-4.8 h.",Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11528196/),min,40,238968,DB00592,Piperazine
,11528196,t1/2,"The plasma concentrations of vardenafil increased rapidly, with a median t(max) of about 40 min and a mean t1/2 of 4.4-4.8 h.",Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11528196/),h,4.4-4.8,238969,DB00592,Piperazine
,10805062,area under the concentration-time curve (AUC)0-24,"Following the administration of 4 mg emedastine q.d., mean area under the concentration-time curve (AUC)0-24 values of 34.49 +/- 24.07 ng h ml(-1) and 47.05 +/- 36.12 ng h ml(-1) were attained on day 1 and day 5, respectively.",Pharmacokinetics and pharmacodynamics of the novel H1-receptor antagonist emedastine in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10805062/),[h·ng] / [ml],34.49,239295,DB00592,Piperazine
,10805062,area under the concentration-time curve (AUC)0-24,"Following the administration of 4 mg emedastine q.d., mean area under the concentration-time curve (AUC)0-24 values of 34.49 +/- 24.07 ng h ml(-1) and 47.05 +/- 36.12 ng h ml(-1) were attained on day 1 and day 5, respectively.",Pharmacokinetics and pharmacodynamics of the novel H1-receptor antagonist emedastine in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10805062/),[h·ng] / [ml],47.05,239296,DB00592,Piperazine
,10805062,AUC0-24,"Following the administration of emedastine (2 mg b.i.d.) mean AUC0-24 values were 29.75 +/- 19.92 ng h ml(-1) and 46.13 +/- 38.50 ng h ml(-1) on day 1 and day 5, respectively.",Pharmacokinetics and pharmacodynamics of the novel H1-receptor antagonist emedastine in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10805062/),[h·ng] / [ml],29.75,239297,DB00592,Piperazine
,10805062,AUC0-24,"Following the administration of emedastine (2 mg b.i.d.) mean AUC0-24 values were 29.75 +/- 19.92 ng h ml(-1) and 46.13 +/- 38.50 ng h ml(-1) on day 1 and day 5, respectively.",Pharmacokinetics and pharmacodynamics of the novel H1-receptor antagonist emedastine in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10805062/),[h·ng] / [ml],46.13,239298,DB00592,Piperazine
,16669847,peak plasma concentration (Cmax),"Itraconazole pretreatment significantly increased mean (+/-SD) peak plasma concentration (Cmax) of fexofenadine from 699 (+/-366) ng ml-1 to 1346 (+/-561) ng ml-1 (95% CI of differences 253, 1040; P<0.005) and the area under the plasma concentration-time curve [AUC0,infinity] from 4133 (+/-1776) ng ml-1 h to 11287 (+/-4552) ng ml-1 h (95% CI 3731, 10575; P<0.0001).","Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669847/),[ng] / [ml],699,239417,DB00592,Piperazine
,16669847,peak plasma concentration (Cmax),"Itraconazole pretreatment significantly increased mean (+/-SD) peak plasma concentration (Cmax) of fexofenadine from 699 (+/-366) ng ml-1 to 1346 (+/-561) ng ml-1 (95% CI of differences 253, 1040; P<0.005) and the area under the plasma concentration-time curve [AUC0,infinity] from 4133 (+/-1776) ng ml-1 h to 11287 (+/-4552) ng ml-1 h (95% CI 3731, 10575; P<0.0001).","Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669847/),[ng] / [ml],1346,239418,DB00592,Piperazine
,16669847,"area under the plasma concentration-time curve [AUC0,infinity]","Itraconazole pretreatment significantly increased mean (+/-SD) peak plasma concentration (Cmax) of fexofenadine from 699 (+/-366) ng ml-1 to 1346 (+/-561) ng ml-1 (95% CI of differences 253, 1040; P<0.005) and the area under the plasma concentration-time curve [AUC0,infinity] from 4133 (+/-1776) ng ml-1 h to 11287 (+/-4552) ng ml-1 h (95% CI 3731, 10575; P<0.0001).","Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669847/),[h·ng] / [ml],4133,239419,DB00592,Piperazine
,16669847,"area under the plasma concentration-time curve [AUC0,infinity]","Itraconazole pretreatment significantly increased mean (+/-SD) peak plasma concentration (Cmax) of fexofenadine from 699 (+/-366) ng ml-1 to 1346 (+/-561) ng ml-1 (95% CI of differences 253, 1040; P<0.005) and the area under the plasma concentration-time curve [AUC0,infinity] from 4133 (+/-1776) ng ml-1 h to 11287 (+/-4552) ng ml-1 h (95% CI 3731, 10575; P<0.0001).","Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669847/),[h·ng] / [ml],11287,239420,DB00592,Piperazine
,16669847,Cmax,"In contrast, diltiazem pretreatment did not affect Cmax (704+/-316 ng ml-1, 95% CI -145, 155), AUC0, infinity (4433+/-1565 ng ml-1 h, 95% CI -1353, 754), or other pharmacokinetic parameters of fexofenadine.","Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669847/),[ng] / [ml],704,239421,DB00592,Piperazine
,16669847,"AUC0, infinity","In contrast, diltiazem pretreatment did not affect Cmax (704+/-316 ng ml-1, 95% CI -145, 155), AUC0, infinity (4433+/-1565 ng ml-1 h, 95% CI -1353, 754), or other pharmacokinetic parameters of fexofenadine.","Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16669847/),[h·ng] / [ml],4433,239422,DB00592,Piperazine
,32945851,concentrations,"The median total bictegravir concentrations in SP, RT, and CVF were 65.5 (20.1-923) ng/mL, 74.1 (6.0-478.5) ng/g, and 61.6 (14.4-1760.2) ng/mL, representing 2.7%, 2.6%, and 28% of the BP concentration, while protein-unbound fractions were 51.1%, 44.6%, and 42.6%, respectively.","Dynamics of the decay of HIV RNA and distribution of bictegravir in the genital tract and rectum in antiretroviral-naïve HIV-1-infected adults treated with bictegravir/emtricitabine/tenofovir alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32945851/),[ng] / [ml],65,239666,DB00592,Piperazine
,32945851,concentrations,"The median total bictegravir concentrations in SP, RT, and CVF were 65.5 (20.1-923) ng/mL, 74.1 (6.0-478.5) ng/g, and 61.6 (14.4-1760.2) ng/mL, representing 2.7%, 2.6%, and 28% of the BP concentration, while protein-unbound fractions were 51.1%, 44.6%, and 42.6%, respectively.","Dynamics of the decay of HIV RNA and distribution of bictegravir in the genital tract and rectum in antiretroviral-naïve HIV-1-infected adults treated with bictegravir/emtricitabine/tenofovir alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32945851/),[ng] / [g],74.1,239667,DB00592,Piperazine
,32945851,concentrations,"The median total bictegravir concentrations in SP, RT, and CVF were 65.5 (20.1-923) ng/mL, 74.1 (6.0-478.5) ng/g, and 61.6 (14.4-1760.2) ng/mL, representing 2.7%, 2.6%, and 28% of the BP concentration, while protein-unbound fractions were 51.1%, 44.6%, and 42.6%, respectively.","Dynamics of the decay of HIV RNA and distribution of bictegravir in the genital tract and rectum in antiretroviral-naïve HIV-1-infected adults treated with bictegravir/emtricitabine/tenofovir alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32945851/),[ng] / [ml],61.6,239668,DB00592,Piperazine
,32945851,concentrations,"The median total bictegravir concentrations in SP, RT, and CVF were 65.5 (20.1-923) ng/mL, 74.1 (6.0-478.5) ng/g, and 61.6 (14.4-1760.2) ng/mL, representing 2.7%, 2.6%, and 28% of the BP concentration, while protein-unbound fractions were 51.1%, 44.6%, and 42.6%, respectively.","Dynamics of the decay of HIV RNA and distribution of bictegravir in the genital tract and rectum in antiretroviral-naïve HIV-1-infected adults treated with bictegravir/emtricitabine/tenofovir alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32945851/),,2,239669,DB00592,Piperazine
,32945851,protein-unbound fractions,"The median total bictegravir concentrations in SP, RT, and CVF were 65.5 (20.1-923) ng/mL, 74.1 (6.0-478.5) ng/g, and 61.6 (14.4-1760.2) ng/mL, representing 2.7%, 2.6%, and 28% of the BP concentration, while protein-unbound fractions were 51.1%, 44.6%, and 42.6%, respectively.","Dynamics of the decay of HIV RNA and distribution of bictegravir in the genital tract and rectum in antiretroviral-naïve HIV-1-infected adults treated with bictegravir/emtricitabine/tenofovir alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32945851/),%,51.1,239670,DB00592,Piperazine
,32945851,protein-unbound fractions,"The median total bictegravir concentrations in SP, RT, and CVF were 65.5 (20.1-923) ng/mL, 74.1 (6.0-478.5) ng/g, and 61.6 (14.4-1760.2) ng/mL, representing 2.7%, 2.6%, and 28% of the BP concentration, while protein-unbound fractions were 51.1%, 44.6%, and 42.6%, respectively.","Dynamics of the decay of HIV RNA and distribution of bictegravir in the genital tract and rectum in antiretroviral-naïve HIV-1-infected adults treated with bictegravir/emtricitabine/tenofovir alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32945851/),%,44.6,239671,DB00592,Piperazine
,32945851,protein-unbound fractions,"The median total bictegravir concentrations in SP, RT, and CVF were 65.5 (20.1-923) ng/mL, 74.1 (6.0-478.5) ng/g, and 61.6 (14.4-1760.2) ng/mL, representing 2.7%, 2.6%, and 28% of the BP concentration, while protein-unbound fractions were 51.1%, 44.6%, and 42.6%, respectively.","Dynamics of the decay of HIV RNA and distribution of bictegravir in the genital tract and rectum in antiretroviral-naïve HIV-1-infected adults treated with bictegravir/emtricitabine/tenofovir alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32945851/),%,42.6,239672,DB00592,Piperazine
,32945851,EC50,"Protein-unbound bictegravir concentrations in SP, RT, and CVF highly exceeded the EC50 value (1.1 ng/mL).","Dynamics of the decay of HIV RNA and distribution of bictegravir in the genital tract and rectum in antiretroviral-naïve HIV-1-infected adults treated with bictegravir/emtricitabine/tenofovir alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58). ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32945851/),[ng] / [ml],1.1,239673,DB00592,Piperazine
,29596146,accumulation ratio,"Vortioxetine accumulated extensively over the 29 days; the accumulation ratio was not significantly different between obese and control groups (means: 5.24 and 4.46, respectively).",Vortioxetine Disposition in Obesity: Potential Implications for Patient Safety. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29596146/),,5.24,239777,DB00592,Piperazine
,29596146,accumulation ratio,"Vortioxetine accumulated extensively over the 29 days; the accumulation ratio was not significantly different between obese and control groups (means: 5.24 and 4.46, respectively).",Vortioxetine Disposition in Obesity: Potential Implications for Patient Safety. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29596146/),,4.46,239778,DB00592,Piperazine
,29596146,washout half-life (T1/2),"However mean washout half-life (T1/2) was significantly prolonged in obese vs. control subjects (3.26 days vs. 2.21 days, P < 0.01).",Vortioxetine Disposition in Obesity: Potential Implications for Patient Safety. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29596146/),d,3.26,239779,DB00592,Piperazine
,29596146,washout half-life (T1/2),"However mean washout half-life (T1/2) was significantly prolonged in obese vs. control subjects (3.26 days vs. 2.21 days, P < 0.01).",Vortioxetine Disposition in Obesity: Potential Implications for Patient Safety. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29596146/),d,2.21,239780,DB00592,Piperazine
,21438161,recovery,"The mean recovery for R-138727 ranged from 90.1 to 104.1%, with the lower limit of quantification set at 1 ng/ml.",Electrospray ionization LC-MS/MS validated method for the determination of the active metabolite (R-138727) of prasugrel in human plasma and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21438161/),%,90.1 to 104.1,240119,DB00592,Piperazine
,21438161,run time,"This method increased the sensitivity and selectivity, resulting in high-throughput analysis of R-138727 using trandolapril as the IS in pharmacokinetic and bioequivalence studies, with a chromatographic run time of 3.7 min.",Electrospray ionization LC-MS/MS validated method for the determination of the active metabolite (R-138727) of prasugrel in human plasma and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21438161/),min,3.7,240120,DB00592,Piperazine
,6653617,"absorption half-life, ta 1/2cin","Comparison of results shows that Cinoxacin was absorbed faster (absorption half-life, ta 1/2cin = 0.25 h) than pipemidic acid (ta 1/2pip = 0.37 h) and distributed in a smaller apparent volume (AVDcin = 23.5 1/1.73 m2; AVDpip = 60.1 1/1.73 m2).",Comparative pharmacokinetic profiles of cinoxacin and pipemidic acid in humans. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653617/),h,0.25,240333,DB00592,Piperazine
,6653617,ta 1/2pip,"Comparison of results shows that Cinoxacin was absorbed faster (absorption half-life, ta 1/2cin = 0.25 h) than pipemidic acid (ta 1/2pip = 0.37 h) and distributed in a smaller apparent volume (AVDcin = 23.5 1/1.73 m2; AVDpip = 60.1 1/1.73 m2).",Comparative pharmacokinetic profiles of cinoxacin and pipemidic acid in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653617/),h,0.37,240334,DB00592,Piperazine
,6653617,tb 1/2cin,Biological half-lives were identical (tb 1/2cin = 2.10 h; tb 1/2pip = 2.15 h).,Comparative pharmacokinetic profiles of cinoxacin and pipemidic acid in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653617/),h,2.10,240335,DB00592,Piperazine
,6653617,tb 1/2pip,Biological half-lives were identical (tb 1/2cin = 2.10 h; tb 1/2pip = 2.15 h).,Comparative pharmacokinetic profiles of cinoxacin and pipemidic acid in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653617/),h,2.15,240336,DB00592,Piperazine
,6653617,Urinary excretion,Urinary excretion of the two derivatives during the 12 hours following their administration was similar (Ucin0-12h = 86%; Upip0-12h = 83%).,Comparative pharmacokinetic profiles of cinoxacin and pipemidic acid in humans. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653617/),%,86,240337,DB00592,Piperazine
,6653617,Ucin0-12h,Urinary excretion of the two derivatives during the 12 hours following their administration was similar (Ucin0-12h = 86%; Upip0-12h = 83%).,Comparative pharmacokinetic profiles of cinoxacin and pipemidic acid in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653617/),%,86,240338,DB00592,Piperazine
,6653617,Upip0-12h,Urinary excretion of the two derivatives during the 12 hours following their administration was similar (Ucin0-12h = 86%; Upip0-12h = 83%).,Comparative pharmacokinetic profiles of cinoxacin and pipemidic acid in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653617/),%,83,240339,DB00592,Piperazine
,10223167,clearance,It has a low clearance (0.16 L/h/kg) and long elimination half-life (120 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.16,240354,DB00592,Piperazine
,10223167,elimination half-life,It has a low clearance (0.16 L/h/kg) and long elimination half-life (120 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,120,240355,DB00592,Piperazine
,10223167,clearance,"Its clearance (0.27 L/h/kg) is intermediate between those of pipecuronium and rapacuronium, but its elimination half-life is long (83 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.27,240356,DB00592,Piperazine
,10223167,elimination half-life,"Its clearance (0.27 L/h/kg) is intermediate between those of pipecuronium and rapacuronium, but its elimination half-life is long (83 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,83,240357,DB00592,Piperazine
,10223167,clearance,It has a high clearance (0.59 L/h/kg) but a long elimination half-life (112 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.59,240358,DB00592,Piperazine
,10223167,elimination half-life,It has a high clearance (0.59 L/h/kg) but a long elimination half-life (112 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,112,240359,DB00592,Piperazine
,10223167,clearance,"In adults, it has a low clearance (0.15 L/h/kg) and long elimination half-life (87 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.15,240360,DB00592,Piperazine
,10223167,elimination half-life,"In adults, it has a low clearance (0.15 L/h/kg) and long elimination half-life (87 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,87,240361,DB00592,Piperazine
,10223167,clearance,The 2 active isomers (cis-trans and trans-trans) have a high clearance (4.74 L/h/kg) and very short elimination half-lives (approximately 2 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],4.74,240362,DB00592,Piperazine
,10223167,elimination half-lives,The 2 active isomers (cis-trans and trans-trans) have a high clearance (4.74 L/h/kg) and very short elimination half-lives (approximately 2 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,2,240363,DB00592,Piperazine
,10223167,clearance,Cisatracurium has an intermediate clearance (0.3 L/h/kg) and short elimination half-life (26 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.3,240364,DB00592,Piperazine
,10223167,elimination half-life,Cisatracurium has an intermediate clearance (0.3 L/h/kg) and short elimination half-life (26 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,26,240365,DB00592,Piperazine
under,24844604,initial trough concentrations,"First, individual initial trough concentrations under 400mg/day imatinib starting dose were estimated.",Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24844604/),[mg] / [d],400,240493,DB00592,Piperazine
,24844604,Cmin,Time-point independent multivariate regression confirmed a correlation of individual Cmin(400mg) with response and adverse events.,Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24844604/),,400,240494,DB00592,Piperazine
,2890241,times to peak plasma concentration,3. Mean times to peak plasma concentration of loprazolam did not differ significantly between young and elderly subjects and ranged from 1.6-2.7 h.,Pharmacokinetics of loprazolam and its principal metabolite in young subjects and elderly hospital patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890241/),h,1.6-2.7,240598,DB00592,Piperazine
,2890241,time to peak concentration,"There was, however, a longer mean time to peak concentration of the N-oxide metabolite in the elderly but this was only statistically different after the 0.5 mg dose (4.5 mg young, 6.4 h elderly).",Pharmacokinetics of loprazolam and its principal metabolite in young subjects and elderly hospital patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890241/),,4,240599,DB00592,Piperazine
,2890241,time to peak concentration,"There was, however, a longer mean time to peak concentration of the N-oxide metabolite in the elderly but this was only statistically different after the 0.5 mg dose (4.5 mg young, 6.4 h elderly).",Pharmacokinetics of loprazolam and its principal metabolite in young subjects and elderly hospital patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890241/),,6.4,240600,DB00592,Piperazine
,2890241,elimination half-life,5. Although the mean elimination half-life of loprazolam was not statistically significantly different between young and elderly subjects (range 10.9-16.0 h) there was a trend towards somewhat longer half-lives in the elderly.,Pharmacokinetics of loprazolam and its principal metabolite in young subjects and elderly hospital patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890241/),h,10.9-16.0,240601,DB00592,Piperazine
,2890241,half-life,"Furthermore, there was a small but significant increase in the half-life of the N-oxide metabolite in the elderly after the 1 mg dose from 11.7 h to 16.7 h.",Pharmacokinetics of loprazolam and its principal metabolite in young subjects and elderly hospital patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890241/),h,11.7,240602,DB00592,Piperazine
,2890241,half-life,"Furthermore, there was a small but significant increase in the half-life of the N-oxide metabolite in the elderly after the 1 mg dose from 11.7 h to 16.7 h.",Pharmacokinetics of loprazolam and its principal metabolite in young subjects and elderly hospital patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890241/),h,16.7,240603,DB00592,Piperazine
,2890241,areas under the plasma concentration time curves,6. The areas under the plasma concentration time curves for both loprazolam and its N-oxide were greater in the elderly being some 50-68% (mean 132.0 and 111.5 ng/ml h) above those found in young subjects (mean 89.8 and 66.0 ng/ml h).,Pharmacokinetics of loprazolam and its principal metabolite in young subjects and elderly hospital patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890241/),[ng] / [h·ml],132.0,240604,DB00592,Piperazine
,2890241,areas under the plasma concentration time curves,6. The areas under the plasma concentration time curves for both loprazolam and its N-oxide were greater in the elderly being some 50-68% (mean 132.0 and 111.5 ng/ml h) above those found in young subjects (mean 89.8 and 66.0 ng/ml h).,Pharmacokinetics of loprazolam and its principal metabolite in young subjects and elderly hospital patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890241/),[ng] / [h·ml],111.5,240605,DB00592,Piperazine
,2890241,areas under the plasma concentration time curves,6. The areas under the plasma concentration time curves for both loprazolam and its N-oxide were greater in the elderly being some 50-68% (mean 132.0 and 111.5 ng/ml h) above those found in young subjects (mean 89.8 and 66.0 ng/ml h).,Pharmacokinetics of loprazolam and its principal metabolite in young subjects and elderly hospital patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890241/),[ng] / [h·ml],89.8,240606,DB00592,Piperazine
,2890241,areas under the plasma concentration time curves,6. The areas under the plasma concentration time curves for both loprazolam and its N-oxide were greater in the elderly being some 50-68% (mean 132.0 and 111.5 ng/ml h) above those found in young subjects (mean 89.8 and 66.0 ng/ml h).,Pharmacokinetics of loprazolam and its principal metabolite in young subjects and elderly hospital patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890241/),[ng] / [h·ml],66.0,240607,DB00592,Piperazine
,8632299,Vmax,"Mean values of Vmax (10.3 nM/min/mg of protein) and Km (304 microM) for the 4-OH pathway exceeded values for the alpha-OH pathway (2.4 and 74, respectively).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),[nM] / [mg·min],10.3,240628,DB00592,Piperazine
,8632299,Km,"Mean values of Vmax (10.3 nM/min/mg of protein) and Km (304 microM) for the 4-OH pathway exceeded values for the alpha-OH pathway (2.4 and 74, respectively).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,304,240629,DB00592,Piperazine
,8632299,Km,"Mean values of Vmax (10.3 nM/min/mg of protein) and Km (304 microM) for the 4-OH pathway exceeded values for the alpha-OH pathway (2.4 and 74, respectively).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),,2.4,240630,DB00592,Piperazine
,8632299,Km,"Mean values of Vmax (10.3 nM/min/mg of protein) and Km (304 microM) for the 4-OH pathway exceeded values for the alpha-OH pathway (2.4 and 74, respectively).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),,74,240631,DB00592,Piperazine
,8632299,competitive Ki,"Ketoconazole was a powerful inhibitor of triazolam biotransformation, having mean competitive Ki values of 0.006 and 0.023 microM for the alpha-OH and 4-OH pathways.",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,0.006,240632,DB00592,Piperazine
,8632299,competitive Ki,"Ketoconazole was a powerful inhibitor of triazolam biotransformation, having mean competitive Ki values of 0.006 and 0.023 microM for the alpha-OH and 4-OH pathways.",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,0.023,240633,DB00592,Piperazine
,8632299,Ki,"The serotonin2 antagonist antidepressant nefazodone inhibited the alpha-OH and 4-OH pathways (Ki = 0.6 and 1.7 microM, respectively), but with considerably less activity than ketoconazole.",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,0.6,240634,DB00592,Piperazine
,8632299,Ki,"The serotonin2 antagonist antidepressant nefazodone inhibited the alpha-OH and 4-OH pathways (Ki = 0.6 and 1.7 microM, respectively), but with considerably less activity than ketoconazole.",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,1.7,240635,DB00592,Piperazine
,8632299,Ki,"Among six selective serotonin reuptake-inhibitor antidepressants, norfluoxetine was the most potent inhibitor (Ki = 2.7 and 8.0 microM) and fluoxetine itself was the weakest (Ki = 7.0 and 44.3 microM).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,2.7,240636,DB00592,Piperazine
,8632299,Ki,"Among six selective serotonin reuptake-inhibitor antidepressants, norfluoxetine was the most potent inhibitor (Ki = 2.7 and 8.0 microM) and fluoxetine itself was the weakest (Ki = 7.0 and 44.3 microM).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,8.0,240637,DB00592,Piperazine
,8632299,Ki,"Among six selective serotonin reuptake-inhibitor antidepressants, norfluoxetine was the most potent inhibitor (Ki = 2.7 and 8.0 microM) and fluoxetine itself was the weakest (Ki = 7.0 and 44.3 microM).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,7.0,240638,DB00592,Piperazine
,8632299,Ki,"Among six selective serotonin reuptake-inhibitor antidepressants, norfluoxetine was the most potent inhibitor (Ki = 2.7 and 8.0 microM) and fluoxetine itself was the weakest (Ki = 7.0 and 44.3 microM).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),μM,44.3,240639,DB00592,Piperazine
,8632299,apparent oral clearance,"In a double-blind clinical pharmacokinetic-pharmacodynamic study, administration of triazolam (0.125 mg) preceded by ketoconazole, compared to triazolam preceded by placebo, produced a nearly 9-fold reduction in apparent oral clearance of triazolam (41 vs. 337 ml/min) and a 4-fold prolongation of half-life (13.5 vs. 3.4 hr).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),[ml] / [min],41,240640,DB00592,Piperazine
,8632299,apparent oral clearance,"In a double-blind clinical pharmacokinetic-pharmacodynamic study, administration of triazolam (0.125 mg) preceded by ketoconazole, compared to triazolam preceded by placebo, produced a nearly 9-fold reduction in apparent oral clearance of triazolam (41 vs. 337 ml/min) and a 4-fold prolongation of half-life (13.5 vs. 3.4 hr).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),[ml] / [min],337,240641,DB00592,Piperazine
,8632299,half-life,"In a double-blind clinical pharmacokinetic-pharmacodynamic study, administration of triazolam (0.125 mg) preceded by ketoconazole, compared to triazolam preceded by placebo, produced a nearly 9-fold reduction in apparent oral clearance of triazolam (41 vs. 337 ml/min) and a 4-fold prolongation of half-life (13.5 vs. 3.4 hr).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),h,13.5,240642,DB00592,Piperazine
,8632299,half-life,"In a double-blind clinical pharmacokinetic-pharmacodynamic study, administration of triazolam (0.125 mg) preceded by ketoconazole, compared to triazolam preceded by placebo, produced a nearly 9-fold reduction in apparent oral clearance of triazolam (41 vs. 337 ml/min) and a 4-fold prolongation of half-life (13.5 vs. 3.4 hr).",Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632299/),h,3.4,240643,DB00592,Piperazine
,24647883,Tmax,"The study data showed that YQA-14 is a basic lipophilic compound, with rapid absorption (Tmax ~ 1 h) in both rats and dogs.","Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24647883/),h,1,241017,DB00592,Piperazine
,24647883,clearance,"The PBPK model refined with human data predicted that YQA-14 would have a clearance of 8.0 ml/min/kg, a volume distribution of 1.7 l/kg and a bioavailability of 16.9%.","Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24647883/),[ml] / [kg·min],8.0,241018,DB00592,Piperazine
,24647883,volume distribution,"The PBPK model refined with human data predicted that YQA-14 would have a clearance of 8.0 ml/min/kg, a volume distribution of 1.7 l/kg and a bioavailability of 16.9%.","Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24647883/),[l] / [kg],1.7,241019,DB00592,Piperazine
,24647883,bioavailability,"The PBPK model refined with human data predicted that YQA-14 would have a clearance of 8.0 ml/min/kg, a volume distribution of 1.7 l/kg and a bioavailability of 16.9%.","Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24647883/),%,16.9,241020,DB00592,Piperazine
,15151172,time to peak,Multiple dose simulations in dogs revealed a delayed time to peak (3.0 vs.,Assessment of the sustained release properties of a new oral formulation of trimetazidine in pigs and dogs and confirmation in healthy human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15151172/),,3.0,241130,DB00592,Piperazine
,15151172,peak plasma concentration,"1.0 h), a decrease in peak plasma concentration (544 vs. 659 microg/L), an increase in trough concentrations (115 vs.",Assessment of the sustained release properties of a new oral formulation of trimetazidine in pigs and dogs and confirmation in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15151172/),[μg] / [l],544,241131,DB00592,Piperazine
,15151172,peak plasma concentration,"1.0 h), a decrease in peak plasma concentration (544 vs. 659 microg/L), an increase in trough concentrations (115 vs.",Assessment of the sustained release properties of a new oral formulation of trimetazidine in pigs and dogs and confirmation in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15151172/),[μg] / [l],659,241132,DB00592,Piperazine
,15151172,trough concentrations,"1.0 h), a decrease in peak plasma concentration (544 vs. 659 microg/L), an increase in trough concentrations (115 vs.",Assessment of the sustained release properties of a new oral formulation of trimetazidine in pigs and dogs and confirmation in healthy human volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15151172/),,115,241133,DB00592,Piperazine
,15151172,plateau time,"63 microg/L), a decrease in peak-trough fluctuation (141 vs. 193%), and an increase in plateau time (5.5 vs. 4.9 h).",Assessment of the sustained release properties of a new oral formulation of trimetazidine in pigs and dogs and confirmation in healthy human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15151172/),h,5.5,241134,DB00592,Piperazine
,15151172,plateau time,"63 microg/L), a decrease in peak-trough fluctuation (141 vs. 193%), and an increase in plateau time (5.5 vs. 4.9 h).",Assessment of the sustained release properties of a new oral formulation of trimetazidine in pigs and dogs and confirmation in healthy human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15151172/),h,4.9,241135,DB00592,Piperazine
,15151172,plateau time,"These properties have then been verified in humans where a TMZ MR 35 mg b.i.d regimen did provide similar total exposure, increased plateau time (11 vs. 4 h), decreased peak-trough fluctuation (86 vs. 121%), a 31% increase in trough concentrations, and no increase in inter-individual variability as compared to a TMZ IR 20 mg t.i.d. regimen.",Assessment of the sustained release properties of a new oral formulation of trimetazidine in pigs and dogs and confirmation in healthy human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15151172/),h,11,241136,DB00592,Piperazine
,15151172,plateau time,"These properties have then been verified in humans where a TMZ MR 35 mg b.i.d regimen did provide similar total exposure, increased plateau time (11 vs. 4 h), decreased peak-trough fluctuation (86 vs. 121%), a 31% increase in trough concentrations, and no increase in inter-individual variability as compared to a TMZ IR 20 mg t.i.d. regimen.",Assessment of the sustained release properties of a new oral formulation of trimetazidine in pigs and dogs and confirmation in healthy human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15151172/),h,4,241137,DB00592,Piperazine
,25100135,clearance,This correlated with an increased clearance with rifampin (39.6-59.8 L/h) and a decreased clearance with ketoconazole (20.3-12.0 L/h).,"Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25100135/),[l] / [h],39.6-59.8,241286,DB00592,Piperazine
,25100135,clearance,This correlated with an increased clearance with rifampin (39.6-59.8 L/h) and a decreased clearance with ketoconazole (20.3-12.0 L/h).,"Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25100135/),[l] / [h],20.3-12.0,241287,DB00592,Piperazine
,16713697,flow-rate,"Chromatographic separation was performed on a Hypurity C18 column (Thermo Hypersil-Keystone 2.1 mm x 150 mm, 5 microm, USA), The mobile phase was composed of 65% methanol and 35% water (contained 0.1% formic acid, 10 mM ammonium formate), which was run with a flow-rate of 0.2 ml/min at 40 degrees C.",Sensitive bioassay for the simultaneous determination of pseudoephedrine and cetirizine in human plasma by liquid-chromatography-ion trap spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16713697/),[ml] / [min],0.2,241323,DB00592,Piperazine
,16713697,limit of detection,The limit of detection for pseudoephedrine and cetirizine each was 5 ng/ml.,Sensitive bioassay for the simultaneous determination of pseudoephedrine and cetirizine in human plasma by liquid-chromatography-ion trap spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16713697/),[ng] / [ml],5,241324,DB00592,Piperazine
,34285156,AUC0-tau,"The median (interquartile range; IQR) BIC AUC0-tau,exp and Cmax were 128.9 µg*h/mL (78.1-159.5) and 6.9 µg/mL (5.1-9.8), respectively.",Pharmacokinetics of bictegravir and tenofovir in combination with darunavir/cobicistat in treatment-experienced persons with HIV. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34285156/),[h·μg] / [ml],128.9,241370,DB00592,Piperazine
,34285156,Cmax,"The median (interquartile range; IQR) BIC AUC0-tau,exp and Cmax were 128.9 µg*h/mL (78.1-159.5) and 6.9 µg/mL (5.1-9.8), respectively.",Pharmacokinetics of bictegravir and tenofovir in combination with darunavir/cobicistat in treatment-experienced persons with HIV. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34285156/),[μg] / [ml],6.9,241371,DB00592,Piperazine
,34285156,AUC0-tau,"The median (IQR) TAF AUC0-tau,exp and Cmax were 0.376 µg*h/mL (0.199 - 0.430) and 0.276 µg/mL (0.149 - 0.543), respectively.",Pharmacokinetics of bictegravir and tenofovir in combination with darunavir/cobicistat in treatment-experienced persons with HIV. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34285156/),[h·μg] / [ml],0.376,241372,DB00592,Piperazine
,34285156,Cmax,"The median (IQR) TAF AUC0-tau,exp and Cmax were 0.376 µg*h/mL (0.199 - 0.430) and 0.276 µg/mL (0.149 - 0.543), respectively.",Pharmacokinetics of bictegravir and tenofovir in combination with darunavir/cobicistat in treatment-experienced persons with HIV. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34285156/),[μg] / [ml],0.276,241373,DB00592,Piperazine
,21351575,Tmax,"To compare with RH-CT, RH-ST in vivo has a steady and slow release behavior, Tmax was obviously delayed (3.00 +/- 0.50) h and the relative bioavailability was over 80 percentage.",[Optimization of the formulation of ranolazine hydrochloride sustained-release tablet and its pharmacokinetics in dogs]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351575/),h,3.00,241425,DB00592,Piperazine
over,21351575,relative bioavailability,"To compare with RH-CT, RH-ST in vivo has a steady and slow release behavior, Tmax was obviously delayed (3.00 +/- 0.50) h and the relative bioavailability was over 80 percentage.",[Optimization of the formulation of ranolazine hydrochloride sustained-release tablet and its pharmacokinetics in dogs]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351575/),%,80,241426,DB00592,Piperazine
,33583377,lag time,The optimal core (F8) was found to have 1.76 min disintegration time and 61.45% Q5min PO showed a lag time of 6.17 h with 94.80% Q7h and retained good stability over three months.,"Trimetazidine Dihydrochloride Pulsatile-Release Tablets for the Treatment of Morning Anginal Symptoms: Dual Optimization, Characterization and Pharmacokinetic Evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33583377/),h,6.17,241488,DB00592,Piperazine
,33583377,Cmax,"The pharmacokinetic study confirmed the pulsatile-release pattern with Cmax of 206.19 ng/ml at 5.33 h (Tmax), as well as 95.85% relative bioavailability compared to TMZ solution.","Trimetazidine Dihydrochloride Pulsatile-Release Tablets for the Treatment of Morning Anginal Symptoms: Dual Optimization, Characterization and Pharmacokinetic Evaluation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33583377/),[ng] / [ml],206.19,241489,DB00592,Piperazine
,33583377,Tmax,"The pharmacokinetic study confirmed the pulsatile-release pattern with Cmax of 206.19 ng/ml at 5.33 h (Tmax), as well as 95.85% relative bioavailability compared to TMZ solution.","Trimetazidine Dihydrochloride Pulsatile-Release Tablets for the Treatment of Morning Anginal Symptoms: Dual Optimization, Characterization and Pharmacokinetic Evaluation. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33583377/),h,5.33,241490,DB00592,Piperazine
,33583377,relative bioavailability,"The pharmacokinetic study confirmed the pulsatile-release pattern with Cmax of 206.19 ng/ml at 5.33 h (Tmax), as well as 95.85% relative bioavailability compared to TMZ solution.","Trimetazidine Dihydrochloride Pulsatile-Release Tablets for the Treatment of Morning Anginal Symptoms: Dual Optimization, Characterization and Pharmacokinetic Evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33583377/),%,95.85,241491,DB00592,Piperazine
,16014572,EC50,Concanavalin A-stimulated IL-2 production in whole blood is inhibited by A-770041 with an EC50 of approximately 80 nM.,"A-770041, a novel and selective small-molecule inhibitor of Lck, prevents heart allograft rejection. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16014572/),nM,80,241682,DB00592,Piperazine
,16014572,F,A-770041 is orally bioavailable (F = 34.1 +/- 7.2% at 10 mg/kg) and has a t(1/2) of 4.1 +/- 0.1 h.,"A-770041, a novel and selective small-molecule inhibitor of Lck, prevents heart allograft rejection. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16014572/),%,34.1,241683,DB00592,Piperazine
,16014572,t(1/2),A-770041 is orally bioavailable (F = 34.1 +/- 7.2% at 10 mg/kg) and has a t(1/2) of 4.1 +/- 0.1 h.,"A-770041, a novel and selective small-molecule inhibitor of Lck, prevents heart allograft rejection. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16014572/),h,4.1,241684,DB00592,Piperazine
,16014572,EC50,Concanavalin A-induced IL-2 production in vivo is inhibited by oral administration of A-770041 (in vivo EC50 = 78 +/- 28 nM).,"A-770041, a novel and selective small-molecule inhibitor of Lck, prevents heart allograft rejection. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16014572/),nM,78,241685,DB00592,Piperazine
,24071566,t(max),"LY2456302 exhibits canonical pharmacokinetic properties that are favorable for clinical development, with rapid absorption (t(max): 1-2 h) and good oral bioavailability (F = 25%).","LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24071566/),h,1-2,241686,DB00592,Piperazine
,24071566,oral bioavailability (F,"LY2456302 exhibits canonical pharmacokinetic properties that are favorable for clinical development, with rapid absorption (t(max): 1-2 h) and good oral bioavailability (F = 25%).","LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24071566/),%,25,241687,DB00592,Piperazine
,24071566,ED₅₀,"Oral LY2456302 administration selectively and potently occupied central kappa opioid receptors in vivo (ED₅₀ = 0.33 mg/kg), without evidence of mu or delta receptor occupancy at doses up to 30 mg/kg.","LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24071566/),[mg] / [kg],0.33,241688,DB00592,Piperazine
,31351201,t1/2λz,"The values for t1/2λz were statistically different between the groups (fed, 4.6 ± 1.1 h vs fasted, 1.7 ± 0.2 h).",Effect of feeding on the pharmacokinetics of vilazodone in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31351201/),h,4.6,241807,DB00592,Piperazine
,31351201,t1/2λz,"The values for t1/2λz were statistically different between the groups (fed, 4.6 ± 1.1 h vs fasted, 1.7 ± 0.2 h).",Effect of feeding on the pharmacokinetics of vilazodone in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31351201/),h,1.7,241808,DB00592,Piperazine
,31351201,Tmax,"Tmax drastically changed between the groups (fed, 10 h vs fasted, 1.5 h), while Cmax did not significantly vary (fed, 39.4 ± 5.6 ng/mL vs fasted, 38.7 ± 4.8 ng/mL).",Effect of feeding on the pharmacokinetics of vilazodone in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31351201/),h,10,241809,DB00592,Piperazine
,31351201,Tmax,"Tmax drastically changed between the groups (fed, 10 h vs fasted, 1.5 h), while Cmax did not significantly vary (fed, 39.4 ± 5.6 ng/mL vs fasted, 38.7 ± 4.8 ng/mL).",Effect of feeding on the pharmacokinetics of vilazodone in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31351201/),h,1.5,241810,DB00592,Piperazine
,31351201,Cmax,"Tmax drastically changed between the groups (fed, 10 h vs fasted, 1.5 h), while Cmax did not significantly vary (fed, 39.4 ± 5.6 ng/mL vs fasted, 38.7 ± 4.8 ng/mL).",Effect of feeding on the pharmacokinetics of vilazodone in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31351201/),[ng] / [ml],39.4,241811,DB00592,Piperazine
,31351201,Cmax,"Tmax drastically changed between the groups (fed, 10 h vs fasted, 1.5 h), while Cmax did not significantly vary (fed, 39.4 ± 5.6 ng/mL vs fasted, 38.7 ± 4.8 ng/mL).",Effect of feeding on the pharmacokinetics of vilazodone in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31351201/),[ng] / [ml],38.7,241812,DB00592,Piperazine
,31351201,relative oral fasted bioavailability,"As a result, the average relative oral fasted bioavailability of VLZ was low, 28.8 ± 6.1%.",Effect of feeding on the pharmacokinetics of vilazodone in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31351201/),%,28.8,241813,DB00592,Piperazine
,30361675,particle size,"Results revealed VRD formulations showed particle size of 836.7 ± 191.3, 179.8 ± 18.4 and 147.3 ± 18.1 nm and encapsulation efficiency of 55.72 ± 4.36, 65.33 ± 7.82 and 69.38 ± 6.83% for F1, F2 and F3, respectively.",Development and single dose clinical pharmacokinetics investigation of novel zein assisted- alpha lipoic acid nanoencapsulation of vardenafil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30361675/),nm,836.7,242180,DB00592,Piperazine
,30361675,particle size,"Results revealed VRD formulations showed particle size of 836.7 ± 191.3, 179.8 ± 18.4 and 147.3 ± 18.1 nm and encapsulation efficiency of 55.72 ± 4.36, 65.33 ± 7.82 and 69.38 ± 6.83% for F1, F2 and F3, respectively.",Development and single dose clinical pharmacokinetics investigation of novel zein assisted- alpha lipoic acid nanoencapsulation of vardenafil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30361675/),nm,179.8,242181,DB00592,Piperazine
,30361675,particle size,"Results revealed VRD formulations showed particle size of 836.7 ± 191.3, 179.8 ± 18.4 and 147.3 ± 18.1 nm and encapsulation efficiency of 55.72 ± 4.36, 65.33 ± 7.82 and 69.38 ± 6.83% for F1, F2 and F3, respectively.",Development and single dose clinical pharmacokinetics investigation of novel zein assisted- alpha lipoic acid nanoencapsulation of vardenafil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30361675/),nm,147.3,242182,DB00592,Piperazine
,30361675,encapsulation efficiency,"Results revealed VRD formulations showed particle size of 836.7 ± 191.3, 179.8 ± 18.4 and 147.3 ± 18.1 nm and encapsulation efficiency of 55.72 ± 4.36, 65.33 ± 7.82 and 69.38 ± 6.83% for F1, F2 and F3, respectively.",Development and single dose clinical pharmacokinetics investigation of novel zein assisted- alpha lipoic acid nanoencapsulation of vardenafil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30361675/),%,55.72,242183,DB00592,Piperazine
,30361675,encapsulation efficiency,"Results revealed VRD formulations showed particle size of 836.7 ± 191.3, 179.8 ± 18.4 and 147.3 ± 18.1 nm and encapsulation efficiency of 55.72 ± 4.36, 65.33 ± 7.82 and 69.38 ± 6.83% for F1, F2 and F3, respectively.",Development and single dose clinical pharmacokinetics investigation of novel zein assisted- alpha lipoic acid nanoencapsulation of vardenafil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30361675/),%,65.33,242184,DB00592,Piperazine
,30361675,encapsulation efficiency,"Results revealed VRD formulations showed particle size of 836.7 ± 191.3, 179.8 ± 18.4 and 147.3 ± 18.1 nm and encapsulation efficiency of 55.72 ± 4.36, 65.33 ± 7.82 and 69.38 ± 6.83% for F1, F2 and F3, respectively.",Development and single dose clinical pharmacokinetics investigation of novel zein assisted- alpha lipoic acid nanoencapsulation of vardenafil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30361675/),%,69.38,242185,DB00592,Piperazine
,23574742,flow rate,"High-performance liquid chromatographic separation was performed on a Thermo BDS Hypersil C18 column (4.6 × 100 mm, 2.4 µm) with methanol-water (55:45, v/v) containing 0.1% formic acid and 0.2% ammonium acetate as the mobile phase, using isocratic elution at a flow rate of 0.7 mL/min.",LC-MS-MS determination of imatinib and N-desmethyl imatinib in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23574742/),[ml] / [min],0.7,242450,DB00592,Piperazine
,8227482,time to reach maximum plasma concentrations (Cmax),"In all age groups absorption of CL 275,838 was rapid as assessed by the mean time to reach maximum plasma concentrations (Cmax) which averaged 1-2 hr, regardless of the dose administered.","Single-dose safety and pharmacokinetics of a potential cognition-enhancing compound, CL 275,838, in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227482/),h,1-2,242497,DB00592,Piperazine
,8227482,elimination half-lives (t1/2),Mean elimination half-lives (t1/2) of the parent compound (18-21 hr) and of its circulating metabolites II (20-22 hr) and IV (27-30 hr) were well comparable for the doses tested (50 and 100 mg).,"Single-dose safety and pharmacokinetics of a potential cognition-enhancing compound, CL 275,838, in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227482/),h,18-21,242498,DB00592,Piperazine
,8227482,elimination half-lives (t1/2),Mean elimination half-lives (t1/2) of the parent compound (18-21 hr) and of its circulating metabolites II (20-22 hr) and IV (27-30 hr) were well comparable for the doses tested (50 and 100 mg).,"Single-dose safety and pharmacokinetics of a potential cognition-enhancing compound, CL 275,838, in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227482/),h,20-22,242499,DB00592,Piperazine
,8227482,elimination half-lives (t1/2),Mean elimination half-lives (t1/2) of the parent compound (18-21 hr) and of its circulating metabolites II (20-22 hr) and IV (27-30 hr) were well comparable for the doses tested (50 and 100 mg).,"Single-dose safety and pharmacokinetics of a potential cognition-enhancing compound, CL 275,838, in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227482/),h,27-30,242500,DB00592,Piperazine
,8227482,elimination t1/2,"The mean elimination t1/2 (+/- SD) was longer in the elderly (38.8 +/- 19.6, 50.5 +/- 24.5 and 41.7 +/- 12.1 hr, respectively, for the parent compound and its metabolites II and IV) than in the young subjects.","Single-dose safety and pharmacokinetics of a potential cognition-enhancing compound, CL 275,838, in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227482/),h,38.8,242501,DB00592,Piperazine
,8227482,elimination t1/2,"The mean elimination t1/2 (+/- SD) was longer in the elderly (38.8 +/- 19.6, 50.5 +/- 24.5 and 41.7 +/- 12.1 hr, respectively, for the parent compound and its metabolites II and IV) than in the young subjects.","Single-dose safety and pharmacokinetics of a potential cognition-enhancing compound, CL 275,838, in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227482/),h,50.5,242502,DB00592,Piperazine
,8227482,elimination t1/2,"The mean elimination t1/2 (+/- SD) was longer in the elderly (38.8 +/- 19.6, 50.5 +/- 24.5 and 41.7 +/- 12.1 hr, respectively, for the parent compound and its metabolites II and IV) than in the young subjects.","Single-dose safety and pharmacokinetics of a potential cognition-enhancing compound, CL 275,838, in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227482/),h,41.7,242503,DB00592,Piperazine
,31006038,progression-free survival,Median progression-free survival was 5.8 months (95% CI 2.3-not reached).,Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31006038/),month,5.8,242507,DB00592,Piperazine
,22817837,peak concentration (Cmax),"Quercetin increased the peak concentration (Cmax) of ranolazine from 254 ± 8.45 to 324 ± 10.21 and 331 ± 9.65 ng/mL in SDS and MDS, respectively.",Influence of quercetin on the pharmacokinetics of ranolazine in rats and in vitro models. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22817837/),[ng] / [ml],254,242516,DB00592,Piperazine
,22817837,peak concentration (Cmax),"Quercetin increased the peak concentration (Cmax) of ranolazine from 254 ± 8.45 to 324 ± 10.21 and 331 ± 9.65 ng/mL in SDS and MDS, respectively.",Influence of quercetin on the pharmacokinetics of ranolazine in rats and in vitro models. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22817837/),[ng] / [ml],324,242517,DB00592,Piperazine
,22817837,peak concentration (Cmax),"Quercetin increased the peak concentration (Cmax) of ranolazine from 254 ± 8.45 to 324 ± 10.21 and 331 ± 9.65 ng/mL in SDS and MDS, respectively.",Influence of quercetin on the pharmacokinetics of ranolazine in rats and in vitro models. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22817837/),[ng] / [ml],331,242518,DB00592,Piperazine
,22817837,area under the curve (AUC),"Quercetin also increased area under the curve (AUC) of ranolazine from 1565.12 ± 52.24 to 2016.98 ± 142.65 and 2070.85 ± 271.60 ng/mL/h in SDS and MDS, respectively.",Influence of quercetin on the pharmacokinetics of ranolazine in rats and in vitro models. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22817837/),[ng] / [h·ml],1565.12,242519,DB00592,Piperazine
,22817837,area under the curve (AUC),"Quercetin also increased area under the curve (AUC) of ranolazine from 1565.12 ± 52.24 to 2016.98 ± 142.65 and 2070.85 ± 271.60 ng/mL/h in SDS and MDS, respectively.",Influence of quercetin on the pharmacokinetics of ranolazine in rats and in vitro models. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22817837/),[ng] / [h·ml],2016.98,242520,DB00592,Piperazine
,22817837,area under the curve (AUC),"Quercetin also increased area under the curve (AUC) of ranolazine from 1565.12 ± 52.24 to 2016.98 ± 142.65 and 2070.85 ± 271.60 ng/mL/h in SDS and MDS, respectively.",Influence of quercetin on the pharmacokinetics of ranolazine in rats and in vitro models. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22817837/),[ng] / [h·ml],2070.85,242521,DB00592,Piperazine
,16542202,peak plasma concentrations,Administration of 250 mg SLV317 as an oral solution was well tolerated and resulted in mean peak plasma concentrations (+/- SEM) of 77 +/- 9 ng ml(-1) within 47 +/- 3 min; the mean half-life was 9.9 +/- 1.6 h.,Kinetics and dynamics of the peripheral neurokinin-1 receptor antagonist SLV317 in healthy individuals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16542202/),[ng] / [ml],77,242563,DB00592,Piperazine
,16542202,half-life,Administration of 250 mg SLV317 as an oral solution was well tolerated and resulted in mean peak plasma concentrations (+/- SEM) of 77 +/- 9 ng ml(-1) within 47 +/- 3 min; the mean half-life was 9.9 +/- 1.6 h.,Kinetics and dynamics of the peripheral neurokinin-1 receptor antagonist SLV317 in healthy individuals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16542202/),h,9.9,242564,DB00592,Piperazine
,16542202,maximum antagonizing effect,The maximum antagonizing effect of SLV317 averaged 95 +/- 8% and was observed after 1.47 +/- 00.24 h.,Kinetics and dynamics of the peripheral neurokinin-1 receptor antagonist SLV317 in healthy individuals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16542202/),%,95,242565,DB00592,Piperazine
,16542202,area under the effect curve,"Correspondingly, the mean area under the effect curve after administration of SLV317 [278 +/- 67% h(-1); 95% confidence interval (CI) 198, 358] was significantly higher compared with placebo (49 +/- 12% h(-1); 95% CI -24, 122; P < 0.001).",Kinetics and dynamics of the peripheral neurokinin-1 receptor antagonist SLV317 in healthy individuals. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16542202/),[%] / [h],278,242566,DB00592,Piperazine
,16542202,area under the effect curve,"Correspondingly, the mean area under the effect curve after administration of SLV317 [278 +/- 67% h(-1); 95% confidence interval (CI) 198, 358] was significantly higher compared with placebo (49 +/- 12% h(-1); 95% CI -24, 122; P < 0.001).",Kinetics and dynamics of the peripheral neurokinin-1 receptor antagonist SLV317 in healthy individuals. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16542202/),[%] / [h],49,242567,DB00592,Piperazine
,10479356,half-life,Plasma levels of the prodrugs fell below the limit of detection 5 min after iv infusion with an approximate half-life of 1 min.,A novel prodrug approach for tertiary amines. 3. In vivo evaluation of two N-phosphonooxymethyl prodrugs in rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10479356/),min,1,242594,DB00592,Piperazine
,16415110,K(s),"Despite these differences in metabolism, all four ITZ stereoisomers induced a type II binding spectrum with CYP3A4, characteristic of coordination of the triazole nitrogen to the heme iron (K(s) 2.2-10.6 nM).",Stereochemical aspects of itraconazole metabolism in vitro and in vivo. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415110/),nM,2.2-10.6,242694,DB00592,Piperazine
,16415110,IC(50),All four stereoisomers of ITZ inhibited the CYP3A4-catalyzed hydroxylation of midazolam with high affinity (IC(50) 3.7-14.8 nM).,Stereochemical aspects of itraconazole metabolism in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415110/),nM,3.7-14.8,242695,DB00592,Piperazine
,8792865,flow-rate,"The eluate mixture was evaporated to dryness, the residue was reconstituted in the mobile phase and injected onto a Zorbax Phenyl column (4.6 x 250 mm; 5 microns) at a flow-rate of 1.2 mL/min.",High-performance liquid chromatographic-ultraviolet assay for the simultaneous quantitation of BMS-181101 and its putative hydroxy metabolites in rat and monkey plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8792865/),[ml] / [min],1.2,242765,DB00592,Piperazine
,8792865,retention times,"The nominal retention times were 5, 8, 15, and 18 min for II, III, I, and IS, respectively.",High-performance liquid chromatographic-ultraviolet assay for the simultaneous quantitation of BMS-181101 and its putative hydroxy metabolites in rat and monkey plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8792865/),min,5,242766,DB00592,Piperazine
,8792865,retention times,"The nominal retention times were 5, 8, 15, and 18 min for II, III, I, and IS, respectively.",High-performance liquid chromatographic-ultraviolet assay for the simultaneous quantitation of BMS-181101 and its putative hydroxy metabolites in rat and monkey plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8792865/),min,8,242767,DB00592,Piperazine
,8792865,retention times,"The nominal retention times were 5, 8, 15, and 18 min for II, III, I, and IS, respectively.",High-performance liquid chromatographic-ultraviolet assay for the simultaneous quantitation of BMS-181101 and its putative hydroxy metabolites in rat and monkey plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8792865/),min,15,242768,DB00592,Piperazine
,8792865,retention times,"The nominal retention times were 5, 8, 15, and 18 min for II, III, I, and IS, respectively.",High-performance liquid chromatographic-ultraviolet assay for the simultaneous quantitation of BMS-181101 and its putative hydroxy metabolites in rat and monkey plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8792865/),min,18,242769,DB00592,Piperazine
,31873806,clearance (CL),"The population estimate of the clearance (CL) was 30.4 L/h, the volume of distribution (V) was 874.0 L and the bioavailability (F) was 81.1%.",Multicenter-Based Population Pharmacokinetic Analysis of Ciclosporin in Hematopoietic Stem Cell Transplantation Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31873806/),[l] / [h],30.4,242781,DB00592,Piperazine
,31873806,volume of distribution (V),"The population estimate of the clearance (CL) was 30.4 L/h, the volume of distribution (V) was 874.0 L and the bioavailability (F) was 81.1%.",Multicenter-Based Population Pharmacokinetic Analysis of Ciclosporin in Hematopoietic Stem Cell Transplantation Patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31873806/),l,874.0,242782,DB00592,Piperazine
,31873806,bioavailability (F),"The population estimate of the clearance (CL) was 30.4 L/h, the volume of distribution (V) was 874.0 L and the bioavailability (F) was 81.1%.",Multicenter-Based Population Pharmacokinetic Analysis of Ciclosporin in Hematopoietic Stem Cell Transplantation Patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31873806/),%,81.1,242783,DB00592,Piperazine
,29174840,minimum inhibitory concentration (MIC),"We have identified a potential nitrofuranyl methyl piperazine derivative, IIIM-MCD-211 as new antitubercular agent with minimum inhibitory concentration (MIC) value of 0.0072 μM against H37Rv strain.","Physicochemical, pharmacokinetic, efficacy and toxicity profiling of a potential nitrofuranyl methyl piperazine derivative IIIM-MCD-211 for oral tuberculosis therapy via in-silico-in-vitro-in-vivo approach. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29174840/),μM,0.0072,243441,DB00592,Piperazine
,18800037,terminal half-life,"Volume of distribution of sildenafil in neonates was fourfold higher than in adults, resulting in a longer terminal half-life in neonates (48-56 h) compared to adults.",Population pharmacokinetics of sildenafil in term neonates: evidence of rapid maturation of metabolic clearance in the early postnatal period. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18800037/),h,48-56,243442,DB00592,Piperazine
,27230993,maximal concentration,"One hour after oral administration of a single dose of 80 mg/kg, BT-11 had a maximal concentration of 21 ng/mL; the half-life was 3 hours.",Exploratory Studies With BT-11: A Proposed Orally Active Therapeutic for Crohn's Disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27230993/),[ng] / [ml],21,243721,DB00592,Piperazine
,27230993,half-life,"One hour after oral administration of a single dose of 80 mg/kg, BT-11 had a maximal concentration of 21 ng/mL; the half-life was 3 hours.",Exploratory Studies With BT-11: A Proposed Orally Active Therapeutic for Crohn's Disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27230993/),h,3,243722,DB00592,Piperazine
,19347334,maximum concentration in plasma (C(max),"Compared with fesoterodine alone, coadministration of fesoterodine with ketoconazole resulted in increases in mean 5-HMT maximum concentration in plasma (C(max); from 3.0 to 6.0 ng/mL in EMs and from 6.4 to 13.4 ng/mL in PMs) and mean area under the plasma concentration time curve (AUC; from 38.2 to 88.3 ng h/mL in EMs and 88.3 to 217.2 ng h/mL in PMs).",Evaluation of drug-drug interactions with fesoterodine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[ng] / [ml],3.0 to 6.0,244163,DB00592,Piperazine
,19347334,maximum concentration in plasma (C(max),"Compared with fesoterodine alone, coadministration of fesoterodine with ketoconazole resulted in increases in mean 5-HMT maximum concentration in plasma (C(max); from 3.0 to 6.0 ng/mL in EMs and from 6.4 to 13.4 ng/mL in PMs) and mean area under the plasma concentration time curve (AUC; from 38.2 to 88.3 ng h/mL in EMs and 88.3 to 217.2 ng h/mL in PMs).",Evaluation of drug-drug interactions with fesoterodine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[ng] / [ml],6.4 to 13.4,244164,DB00592,Piperazine
,19347334,area under the plasma concentration time curve (AUC,"Compared with fesoterodine alone, coadministration of fesoterodine with ketoconazole resulted in increases in mean 5-HMT maximum concentration in plasma (C(max); from 3.0 to 6.0 ng/mL in EMs and from 6.4 to 13.4 ng/mL in PMs) and mean area under the plasma concentration time curve (AUC; from 38.2 to 88.3 ng h/mL in EMs and 88.3 to 217.2 ng h/mL in PMs).",Evaluation of drug-drug interactions with fesoterodine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[h·ng] / [ml],38.2 to 88.3,244165,DB00592,Piperazine
,19347334,area under the plasma concentration time curve (AUC,"Compared with fesoterodine alone, coadministration of fesoterodine with ketoconazole resulted in increases in mean 5-HMT maximum concentration in plasma (C(max); from 3.0 to 6.0 ng/mL in EMs and from 6.4 to 13.4 ng/mL in PMs) and mean area under the plasma concentration time curve (AUC; from 38.2 to 88.3 ng h/mL in EMs and 88.3 to 217.2 ng h/mL in PMs).",Evaluation of drug-drug interactions with fesoterodine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[h·ng] / [ml],88.3 to 217.2,244166,DB00592,Piperazine
,19347334,C(max),Coadministration of festerodine with rifampicin resulted in decreases in mean 5-HMT C(max) (from 5.2 to 1.5 ng/mL in EMs and from 6.8 to 1.9 ng/mL in PMs) and mean AUC (from 62.4 to 14.4 ng h/mL in EMs and from 87.8 to 19.6 ng h/mL in PMs).,Evaluation of drug-drug interactions with fesoterodine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[ng] / [ml],5.2 to 1.5,244167,DB00592,Piperazine
,19347334,C(max),Coadministration of festerodine with rifampicin resulted in decreases in mean 5-HMT C(max) (from 5.2 to 1.5 ng/mL in EMs and from 6.8 to 1.9 ng/mL in PMs) and mean AUC (from 62.4 to 14.4 ng h/mL in EMs and from 87.8 to 19.6 ng h/mL in PMs).,Evaluation of drug-drug interactions with fesoterodine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[ng] / [ml],6.8 to 1.9,244168,DB00592,Piperazine
,19347334,AUC,Coadministration of festerodine with rifampicin resulted in decreases in mean 5-HMT C(max) (from 5.2 to 1.5 ng/mL in EMs and from 6.8 to 1.9 ng/mL in PMs) and mean AUC (from 62.4 to 14.4 ng h/mL in EMs and from 87.8 to 19.6 ng h/mL in PMs).,Evaluation of drug-drug interactions with fesoterodine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[h·ng] / [ml],62.4 to 14.4,244169,DB00592,Piperazine
,19347334,AUC,Coadministration of festerodine with rifampicin resulted in decreases in mean 5-HMT C(max) (from 5.2 to 1.5 ng/mL in EMs and from 6.8 to 1.9 ng/mL in PMs) and mean AUC (from 62.4 to 14.4 ng h/mL in EMs and from 87.8 to 19.6 ng h/mL in PMs).,Evaluation of drug-drug interactions with fesoterodine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[h·ng] / [ml],87.8 to 19.6,244170,DB00592,Piperazine
,26340762,flow rate,A gradient mobile phase consisting of 10mM ammonium formate and acetonitrile was applied at a flow rate of 0.45mL/min.,Pharmacokinetic and protein binding profile of peptidomimetic DPP-4 inhibitor - Teneligliptin in rats using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26340762/),[ml] / [min],0.45,244202,DB00592,Piperazine
,26340762,matrix effect,The matrix effect was 88.7-94.5% for teneligliptin.,Pharmacokinetic and protein binding profile of peptidomimetic DPP-4 inhibitor - Teneligliptin in rats using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26340762/),%,88.7-94.5,244203,DB00592,Piperazine
,26340762,protein binding,Results showed linear dose proportionality of pharmacokinetics at 0.1 and 1mg/kg and relatively high protein binding of teneligliptin (85.46 ± 0.24 %) compared with other DPP-4 inhibitors.,Pharmacokinetic and protein binding profile of peptidomimetic DPP-4 inhibitor - Teneligliptin in rats using liquid chromatography-tandem mass spectrometry. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26340762/),%,85.46,244204,DB00592,Piperazine
,24424300,m,"After a single liquid-liquid extraction, the assay was performed by using a C18 column and positive electrospray ionisation mode (ESI) in the multiple reaction monitoring (MRM) mode with transitions of m/z 417.3→167.3, 251.2→165.2, 199.1→121.3, and 183.2→105.1 for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),,417.3,244252,DB00592,Piperazine
,24424300,m,"After a single liquid-liquid extraction, the assay was performed by using a C18 column and positive electrospray ionisation mode (ESI) in the multiple reaction monitoring (MRM) mode with transitions of m/z 417.3→167.3, 251.2→165.2, 199.1→121.3, and 183.2→105.1 for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),,251.2,244253,DB00592,Piperazine
,24424300,m,"After a single liquid-liquid extraction, the assay was performed by using a C18 column and positive electrospray ionisation mode (ESI) in the multiple reaction monitoring (MRM) mode with transitions of m/z 417.3→167.3, 251.2→165.2, 199.1→121.3, and 183.2→105.1 for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),,199.1,244254,DB00592,Piperazine
,24424300,m,"After a single liquid-liquid extraction, the assay was performed by using a C18 column and positive electrospray ionisation mode (ESI) in the multiple reaction monitoring (MRM) mode with transitions of m/z 417.3→167.3, 251.2→165.2, 199.1→121.3, and 183.2→105.1 for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),,183.2,244255,DB00592,Piperazine
higher,24424300,extraction recoveries,The extraction recoveries of their three concentrations for Dip and its three metabolites were all higher than 71.9%.,Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),%,71.9,244256,DB00592,Piperazine
,24424300,maximum plasma concentrations (Cmax),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),[ng] / [ml],59,244257,DB00592,Piperazine
,24424300,maximum plasma concentrations (Cmax),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),[ng] / [ml],37,244258,DB00592,Piperazine
,24424300,maximum plasma concentrations (Cmax),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),[ng] / [ml],3,244259,DB00592,Piperazine
,24424300,maximum plasma concentrations (Cmax),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),[ng] / [ml],55,244260,DB00592,Piperazine
,24424300,time to maximum plasma concentration (Tmax),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),min,65,244261,DB00592,Piperazine
,24424300,time to maximum plasma concentration (Tmax),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),min,95,244262,DB00592,Piperazine
,24424300,time to maximum plasma concentration (Tmax),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),min,190,244263,DB00592,Piperazine
,24424300,time to maximum plasma concentration (Tmax),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),min,90,244264,DB00592,Piperazine
,24424300,areas under the concentration-time curves (AUC0→∞),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),[min·ng] / [ml],17573,244265,DB00592,Piperazine
,24424300,areas under the concentration-time curves (AUC0→∞),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),[min·ng] / [ml],8328,244266,DB00592,Piperazine
,24424300,areas under the concentration-time curves (AUC0→∞),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),[min·ng] / [ml],5602,244267,DB00592,Piperazine
,24424300,areas under the concentration-time curves (AUC0→∞),"The maximum plasma concentrations (Cmax) were 59±7, 37±4, 3±0.2, and 55±5 ng/ml; the time to maximum plasma concentration (Tmax) were 65±12, 95±12, 190±25, and 90±0 min and the areas under the concentration-time curves (AUC0→∞) were 17573±704, 8328±355, 5602±753, and 16101±429 ng min/ml for Dip, M1, M2, and M5, respectively.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),[min·ng] / [ml],16101,244268,DB00592,Piperazine
,24424300,half-life (t1/2),"The half-life (t1/2) of Dip, M1, M2, and M5 were 329±15, 767±75, 2364±434, and 378±36 min, respectively, which indicated that Dip and M5 were eliminated quickly.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),min,329,244269,DB00592,Piperazine
,24424300,half-life (t1/2),"The half-life (t1/2) of Dip, M1, M2, and M5 were 329±15, 767±75, 2364±434, and 378±36 min, respectively, which indicated that Dip and M5 were eliminated quickly.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),min,767,244270,DB00592,Piperazine
,24424300,half-life (t1/2),"The half-life (t1/2) of Dip, M1, M2, and M5 were 329±15, 767±75, 2364±434, and 378±36 min, respectively, which indicated that Dip and M5 were eliminated quickly.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),min,2364,244271,DB00592,Piperazine
,24424300,half-life (t1/2),"The half-life (t1/2) of Dip, M1, M2, and M5 were 329±15, 767±75, 2364±434, and 378±36 min, respectively, which indicated that Dip and M5 were eliminated quickly.",Pharmacokinetic evaluation of dipfluzine and its three metabolites in rat plasma using liquid chromatography-mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424300/),min,378,244272,DB00592,Piperazine
,11206038,Cmax,"In a single elderly male patient, grapefruit juice increased the Cmax of sildenafil by 42% (1067.7 ng/mL to 1517.0 ng/mL) although AUC was not significantly altered (4082.9 ng x h/mL to 4171.9 ng x h/mL) by grapefruit juice.",Determination of sildenafil citrate in plasma by high-performance liquid chromatography and a case for the potential interaction of grapefruit juice with sildenafil citrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11206038/),[ng] / [ml],1067.7,244434,DB00592,Piperazine
,11206038,Cmax,"In a single elderly male patient, grapefruit juice increased the Cmax of sildenafil by 42% (1067.7 ng/mL to 1517.0 ng/mL) although AUC was not significantly altered (4082.9 ng x h/mL to 4171.9 ng x h/mL) by grapefruit juice.",Determination of sildenafil citrate in plasma by high-performance liquid chromatography and a case for the potential interaction of grapefruit juice with sildenafil citrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11206038/),[ng] / [ml],1517.0,244435,DB00592,Piperazine
,11206038,AUC,"In a single elderly male patient, grapefruit juice increased the Cmax of sildenafil by 42% (1067.7 ng/mL to 1517.0 ng/mL) although AUC was not significantly altered (4082.9 ng x h/mL to 4171.9 ng x h/mL) by grapefruit juice.",Determination of sildenafil citrate in plasma by high-performance liquid chromatography and a case for the potential interaction of grapefruit juice with sildenafil citrate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11206038/),[h·ng] / [ml],4082.9,244436,DB00592,Piperazine
,11206038,AUC,"In a single elderly male patient, grapefruit juice increased the Cmax of sildenafil by 42% (1067.7 ng/mL to 1517.0 ng/mL) although AUC was not significantly altered (4082.9 ng x h/mL to 4171.9 ng x h/mL) by grapefruit juice.",Determination of sildenafil citrate in plasma by high-performance liquid chromatography and a case for the potential interaction of grapefruit juice with sildenafil citrate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11206038/),[h·ng] / [ml],4171.9,244437,DB00592,Piperazine
,2571627,peak cetirizine concentrations,"Cetirizine was rapidly absorbed with mean peak cetirizine concentrations of 427.6 +/- SD, 144.2 ng/ml, 1.4 +/- 1.1 hours after the 5 mg dose, and 978.4 +/- 340.6 ng/ml, 0.8 +/- 0.4 hours after the 10 mg dose.",Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571627/),[ng] / [ml],427.6,244555,DB00592,Piperazine
,2571627,peak cetirizine concentrations,"Cetirizine was rapidly absorbed with mean peak cetirizine concentrations of 427.6 +/- SD, 144.2 ng/ml, 1.4 +/- 1.1 hours after the 5 mg dose, and 978.4 +/- 340.6 ng/ml, 0.8 +/- 0.4 hours after the 10 mg dose.",Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571627/),[ng] / [ml],144.2,244556,DB00592,Piperazine
,2571627,peak cetirizine concentrations,"Cetirizine was rapidly absorbed with mean peak cetirizine concentrations of 427.6 +/- SD, 144.2 ng/ml, 1.4 +/- 1.1 hours after the 5 mg dose, and 978.4 +/- 340.6 ng/ml, 0.8 +/- 0.4 hours after the 10 mg dose.",Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571627/),h,1.4,244557,DB00592,Piperazine
,2571627,peak cetirizine concentrations,"Cetirizine was rapidly absorbed with mean peak cetirizine concentrations of 427.6 +/- SD, 144.2 ng/ml, 1.4 +/- 1.1 hours after the 5 mg dose, and 978.4 +/- 340.6 ng/ml, 0.8 +/- 0.4 hours after the 10 mg dose.",Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571627/),[ng] / [ml],978.4,244558,DB00592,Piperazine
,2571627,peak cetirizine concentrations,"Cetirizine was rapidly absorbed with mean peak cetirizine concentrations of 427.6 +/- SD, 144.2 ng/ml, 1.4 +/- 1.1 hours after the 5 mg dose, and 978.4 +/- 340.6 ng/ml, 0.8 +/- 0.4 hours after the 10 mg dose.",Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571627/),h,0.8,244559,DB00592,Piperazine
,2571627,serum-elimination half-life,"The dose-independent serum-elimination half-life of cetirizine was 7.1 +/- 1.6 hours after cetirizine, 5 mg, and 6.9 +/- 1.6 hours after cetirizine, 10 mg.",Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571627/),h,7.1,244560,DB00592,Piperazine
,2571627,serum-elimination half-life,"The dose-independent serum-elimination half-life of cetirizine was 7.1 +/- 1.6 hours after cetirizine, 5 mg, and 6.9 +/- 1.6 hours after cetirizine, 10 mg.",Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571627/),h,6.9,244561,DB00592,Piperazine
,2571627,Urinary excretion,"Urinary excretion of unchanged cetirizine during 24 hours after the initial dose of cetirizine, 5 mg, was 40 +/- 15%, and after cetirizine, 10 mg, it was 39 +/- 14%.",Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571627/),%,40,244562,DB00592,Piperazine
,2571627,Urinary excretion,"Urinary excretion of unchanged cetirizine during 24 hours after the initial dose of cetirizine, 5 mg, was 40 +/- 15%, and after cetirizine, 10 mg, it was 39 +/- 14%.",Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571627/),%,39,244563,DB00592,Piperazine
,17416379,flow rate,"At a flow rate of 1 ml/min, the total run time was 18 min.",Development and validation of a high-performance liquid chromatographic method using fluorescence detection for the determination of vardenafil in small volumes of rat plasma and bile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17416379/),[ml] / [min],1,244568,DB00592,Piperazine
,17416379,total run time,"At a flow rate of 1 ml/min, the total run time was 18 min.",Development and validation of a high-performance liquid chromatographic method using fluorescence detection for the determination of vardenafil in small volumes of rat plasma and bile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17416379/),min,18,244569,DB00592,Piperazine
,32800640,half-life,PK analysis showed an ES-072 half-life of 24.5 hours and a Tmax of approximately 4 hours.,"First-in-Human Phase 1 Study of ES-072, an Oral Mutant-Selective EGFR T790M Inhibitor, in Non-Small-Cell Lung Cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32800640/),h,24.5,244604,DB00592,Piperazine
,32800640,Tmax,PK analysis showed an ES-072 half-life of 24.5 hours and a Tmax of approximately 4 hours.,"First-in-Human Phase 1 Study of ES-072, an Oral Mutant-Selective EGFR T790M Inhibitor, in Non-Small-Cell Lung Cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32800640/),h,4,244605,DB00592,Piperazine
,32800640,total objective response rate,"The total objective response rate and disease control rate were 46.2% and 76.9%, respectively.","First-in-Human Phase 1 Study of ES-072, an Oral Mutant-Selective EGFR T790M Inhibitor, in Non-Small-Cell Lung Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32800640/),%,46.2,244606,DB00592,Piperazine
,32800640,disease control rate,"The total objective response rate and disease control rate were 46.2% and 76.9%, respectively.","First-in-Human Phase 1 Study of ES-072, an Oral Mutant-Selective EGFR T790M Inhibitor, in Non-Small-Cell Lung Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32800640/),%,76.9,244607,DB00592,Piperazine
,23126273,half-life,"The mean half-life in healthy nonelderly individuals (6.1 h) is prolonged in the elderly, in patients with hepatic insufficiency, and by coadministration of CYP3A inhibitors.",Pharmacokinetic evaluation of eszopiclone: clinical and therapeutic implications. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23126273/),h,6.1,244675,DB00592,Piperazine
,1438031,maximum serum concentrations,"Food intake significantly decreased the maximum serum concentrations of trazodone from 1.88 +/- 0.42 to 1.47 +/- 0.16 micrograms/ml, and increased the time for reaching maximum concentration from 1.3 +/- 0.8 hr to 2.0 +/- 1.5 hr.",Single dose pharmacokinetics of trazodone in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1438031/),[μg] / [ml],1.88,244681,DB00592,Piperazine
,1438031,maximum serum concentrations,"Food intake significantly decreased the maximum serum concentrations of trazodone from 1.88 +/- 0.42 to 1.47 +/- 0.16 micrograms/ml, and increased the time for reaching maximum concentration from 1.3 +/- 0.8 hr to 2.0 +/- 1.5 hr.",Single dose pharmacokinetics of trazodone in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1438031/),[μg] / [ml],1.47,244682,DB00592,Piperazine
,1438031,time for reaching maximum concentration,"Food intake significantly decreased the maximum serum concentrations of trazodone from 1.88 +/- 0.42 to 1.47 +/- 0.16 micrograms/ml, and increased the time for reaching maximum concentration from 1.3 +/- 0.8 hr to 2.0 +/- 1.5 hr.",Single dose pharmacokinetics of trazodone in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1438031/),h,1.3,244683,DB00592,Piperazine
,1438031,time for reaching maximum concentration,"Food intake significantly decreased the maximum serum concentrations of trazodone from 1.88 +/- 0.42 to 1.47 +/- 0.16 micrograms/ml, and increased the time for reaching maximum concentration from 1.3 +/- 0.8 hr to 2.0 +/- 1.5 hr.",Single dose pharmacokinetics of trazodone in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1438031/),h,2.0,244684,DB00592,Piperazine
,1438031,bioavailability,"No differences were observed in the total amount of trazodone absorbed with or without food with bioavailability values of 65 +/- 6 and 63 +/- 4 per cent, respectively.",Single dose pharmacokinetics of trazodone in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1438031/),%,65,244685,DB00592,Piperazine
,1438031,bioavailability,"No differences were observed in the total amount of trazodone absorbed with or without food with bioavailability values of 65 +/- 6 and 63 +/- 4 per cent, respectively.",Single dose pharmacokinetics of trazodone in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1438031/),%,63,244686,DB00592,Piperazine
,1438031,apparent volume of distribution,"The apparent volume of distribution and total body clearance for trazodone were estimated to 0.84 +/- 0.16 l/kg and 5.3 +/- 0.9 l/hr, respectively.",Single dose pharmacokinetics of trazodone in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1438031/),[l] / [kg],0.84,244687,DB00592,Piperazine
,1438031,total body clearance,"The apparent volume of distribution and total body clearance for trazodone were estimated to 0.84 +/- 0.16 l/kg and 5.3 +/- 0.9 l/hr, respectively.",Single dose pharmacokinetics of trazodone in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1438031/),[l] / [h],5.3,244688,DB00592,Piperazine
,1438031,terminal elimination half-life,The terminal elimination half-life of 7.3 +/- 0.8 hr showed no significant differences between the different ways of administration.,Single dose pharmacokinetics of trazodone in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1438031/),h,7.3,244689,DB00592,Piperazine
less,1438031,Urinary excretion,"Urinary excretion of unchanged trazodone during 26 hr was less than 0.13 per cent of the administered dose, suggesting a high degree of trazodone metabolism.",Single dose pharmacokinetics of trazodone in healthy subjects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1438031/),%,0.13,244690,DB00592,Piperazine
,8758480,Cmax,"The coadministration of rifampin resulted in a 18 fold decrease of the Cmax of itraconazole [from 113.0 (SD: 17.2) to 6.2 ng/ml (SD: 3.9)], and in a 22 fold decrease of the AUC [from 1652.7 (SD: 297.7) to 75.6 ng.h/ml (SD: 30.01)].",[Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8758480/),[ng] / [ml],113.0,244925,DB00592,Piperazine
,8758480,Cmax,"The coadministration of rifampin resulted in a 18 fold decrease of the Cmax of itraconazole [from 113.0 (SD: 17.2) to 6.2 ng/ml (SD: 3.9)], and in a 22 fold decrease of the AUC [from 1652.7 (SD: 297.7) to 75.6 ng.h/ml (SD: 30.01)].",[Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8758480/),[ng] / [ml],6.2,244926,DB00592,Piperazine
,8758480,AUC,"The coadministration of rifampin resulted in a 18 fold decrease of the Cmax of itraconazole [from 113.0 (SD: 17.2) to 6.2 ng/ml (SD: 3.9)], and in a 22 fold decrease of the AUC [from 1652.7 (SD: 297.7) to 75.6 ng.h/ml (SD: 30.01)].",[Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8758480/),[h·ng] / [ml],1652.7,244927,DB00592,Piperazine
,8758480,AUC,"The coadministration of rifampin resulted in a 18 fold decrease of the Cmax of itraconazole [from 113.0 (SD: 17.2) to 6.2 ng/ml (SD: 3.9)], and in a 22 fold decrease of the AUC [from 1652.7 (SD: 297.7) to 75.6 ng.h/ml (SD: 30.01)].",[Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8758480/),[h·ng] / [ml],75.6,244928,DB00592,Piperazine
,17331337,entrapment efficacy,"The particle size distribution, zeta-potential and entrapment efficacy were found to be 198.7+/-54.0 nm, -26.4 mV and 96.2%, respectively.","Formulation, preparation and evaluation of flunarizine-loaded lipid microspheres. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17331337/),,96,245264,DB00592,Piperazine
,17331337,AUC(0-t),"The pharmacokinetic parameters were as follows: AUC(0-t) 6.13 mug.h mL(-1), t(1/2) 5.32 h and Ke 0.16 L h(-1).","Formulation, preparation and evaluation of flunarizine-loaded lipid microspheres. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17331337/),[h·μg] / [ml],6.13,245265,DB00592,Piperazine
,17331337,t(1/2),"The pharmacokinetic parameters were as follows: AUC(0-t) 6.13 mug.h mL(-1), t(1/2) 5.32 h and Ke 0.16 L h(-1).","Formulation, preparation and evaluation of flunarizine-loaded lipid microspheres. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17331337/),h,5.32,245266,DB00592,Piperazine
,17331337,Ke,"The pharmacokinetic parameters were as follows: AUC(0-t) 6.13 mug.h mL(-1), t(1/2) 5.32 h and Ke 0.16 L h(-1).","Formulation, preparation and evaluation of flunarizine-loaded lipid microspheres. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17331337/),[l] / [h],0.16,245267,DB00592,Piperazine
,27653565,parasite clearance times,"Median parasite clearance times were 45 hours (interquartile range, 42 to 48) in 10 patients with falciparum malaria and 24 hours (interquartile range, 20 to 30) in 10 patients with vivax malaria after treatment with the multiple-dose regimen and 49 hours (interquartile range, 42 to 54) in 21 patients with falciparum malaria after treatment with the single dose.",Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27653565/),h,45,245323,DB00592,Piperazine
,27653565,parasite clearance times,"Median parasite clearance times were 45 hours (interquartile range, 42 to 48) in 10 patients with falciparum malaria and 24 hours (interquartile range, 20 to 30) in 10 patients with vivax malaria after treatment with the multiple-dose regimen and 49 hours (interquartile range, 42 to 54) in 21 patients with falciparum malaria after treatment with the single dose.",Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27653565/),h,24,245324,DB00592,Piperazine
,27653565,parasite clearance times,"Median parasite clearance times were 45 hours (interquartile range, 42 to 48) in 10 patients with falciparum malaria and 24 hours (interquartile range, 20 to 30) in 10 patients with vivax malaria after treatment with the multiple-dose regimen and 49 hours (interquartile range, 42 to 54) in 21 patients with falciparum malaria after treatment with the single dose.",Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27653565/),h,49,245325,DB00592,Piperazine
,27653565,cure rate,"Among the 21 patients who received the single dose and were followed for 28 days, 1 had reinfection and 7 had recrudescent infections (cure rate, 67%; 95% credible interval, 46 to 84).",Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27653565/),%,67,245326,DB00592,Piperazine
,27653565,terminal elimination half-life,The mean (±SD) KAF156 terminal elimination half-life was 44.1±8.9 hours.,Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27653565/),h,44.1,245327,DB00592,Piperazine
,8118163,peak plasma level,It possesses an excellent digestive adsorption and its peak plasma level after oral administration of 100 mg is 0.16 microgram/ml at 3 or 4 h after drug intake.,Itraconazole: pharmacokinetics and indications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8118163/),[μg] / [ml],0.16,245831,DB00592,Piperazine
,8118163,Half-life,"Half-life of itraconazole ranges between 17 to 21 h and 99.8% binds to plasmatic proteins, especially albumin.",Itraconazole: pharmacokinetics and indications. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8118163/),h,17 to 21,245832,DB00592,Piperazine
,14872554,elimination half-life,"CNPZ was characterized by a short elimination half-life (39.5 min), a high clearance (118 ml/min/kg) and a relatively large volume of distribution (1945 ml/kg) after intravenous administration.","Evaluation of pharmacokinetics, brain levels and protein binding of centpropazine in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14872554/),min,39.5,246694,DB00592,Piperazine
,14872554,clearance,"CNPZ was characterized by a short elimination half-life (39.5 min), a high clearance (118 ml/min/kg) and a relatively large volume of distribution (1945 ml/kg) after intravenous administration.","Evaluation of pharmacokinetics, brain levels and protein binding of centpropazine in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14872554/),[ml] / [kg·min],118,246695,DB00592,Piperazine
,14872554,volume of distribution,"CNPZ was characterized by a short elimination half-life (39.5 min), a high clearance (118 ml/min/kg) and a relatively large volume of distribution (1945 ml/kg) after intravenous administration.","Evaluation of pharmacokinetics, brain levels and protein binding of centpropazine in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14872554/),[ml] / [kg],1945,246696,DB00592,Piperazine
,14872554,oral bioavailability,After oral administration CNPZ exhibited a very low oral bioavailability ( approximately 0.2%).,"Evaluation of pharmacokinetics, brain levels and protein binding of centpropazine in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14872554/),%,0.2,246697,DB00592,Piperazine
,14872554,total first pass effect (Egit+liver),The total first pass effect (Egit+liver) was calculated as 98.7%.,"Evaluation of pharmacokinetics, brain levels and protein binding of centpropazine in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14872554/),%,98.7,246698,DB00592,Piperazine
,3623338,total urinary D,Mean (+/- SD) total urinary DKP excreted during the first 24-hr period after dosing was 6.68 +/- 1.30 mg (4.83 +/- 0.23% of the ingested DKP dose).,Plasma and urine diketopiperazine concentrations in normal adults ingesting large quantities of aspartame. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3623338/),mg,6.68,247025,DB00592,Piperazine
,3623338,excreted,Mean (+/- SD) total urinary DKP excreted during the first 24-hr period after dosing was 6.68 +/- 1.30 mg (4.83 +/- 0.23% of the ingested DKP dose).,Plasma and urine diketopiperazine concentrations in normal adults ingesting large quantities of aspartame. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3623338/),mg,6.68,247026,DB00592,Piperazine
,3623338,excreted,Mean (+/- SD) total urinary DKP excreted during the first 24-hr period after dosing was 6.68 +/- 1.30 mg (4.83 +/- 0.23% of the ingested DKP dose).,Plasma and urine diketopiperazine concentrations in normal adults ingesting large quantities of aspartame. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3623338/),%,4.83,247027,DB00592,Piperazine
,10579472,apparent oral clearance,"Coadministration with ketoconazole (which inhibits CYP3A4) decreased the mean apparent oral clearance of quinine significantly (P < .001) by 31% (from 8.7 to 6.0 L/h), whereas coadministration with fluvoxamine (which inhibits CYP1A2 and to some extent CYP2C19) had no significant effect (P > .05) on the mean apparent oral clearance of quinine.",The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579472/),[l] / [h],8.7,247154,DB00592,Piperazine
,10579472,apparent oral clearance,"Coadministration with ketoconazole (which inhibits CYP3A4) decreased the mean apparent oral clearance of quinine significantly (P < .001) by 31% (from 8.7 to 6.0 L/h), whereas coadministration with fluvoxamine (which inhibits CYP1A2 and to some extent CYP2C19) had no significant effect (P > .05) on the mean apparent oral clearance of quinine.",The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579472/),[l] / [h],6.0,247155,DB00592,Piperazine
,10579472,area under the plasma concentration versus time curve (AUC),"Coadministration with ketoconazole also decreased the mean area under the plasma concentration versus time curve (AUC) of 3-hydroxyquinine (from 28.4 to 19.7 micromol x h x L(-1); P < .001), whereas coadministration with fluvoxamine increased 3-hydroxyquinine AUC significantly (from 28.4 to 30.2 micromol x h x L(-1); P < .05).",The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579472/),[h·μM] / [l],28.4,247156,DB00592,Piperazine
,10579472,area under the plasma concentration versus time curve (AUC),"Coadministration with ketoconazole also decreased the mean area under the plasma concentration versus time curve (AUC) of 3-hydroxyquinine (from 28.4 to 19.7 micromol x h x L(-1); P < .001), whereas coadministration with fluvoxamine increased 3-hydroxyquinine AUC significantly (from 28.4 to 30.2 micromol x h x L(-1); P < .05).",The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579472/),[h·μM] / [l],19,247157,DB00592,Piperazine
,10579472,AUC,"Coadministration with ketoconazole also decreased the mean area under the plasma concentration versus time curve (AUC) of 3-hydroxyquinine (from 28.4 to 19.7 micromol x h x L(-1); P < .001), whereas coadministration with fluvoxamine increased 3-hydroxyquinine AUC significantly (from 28.4 to 30.2 micromol x h x L(-1); P < .05).",The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579472/),[h·μM] / [l],28.4,247158,DB00592,Piperazine
,10579472,AUC,"Coadministration with ketoconazole also decreased the mean area under the plasma concentration versus time curve (AUC) of 3-hydroxyquinine (from 28.4 to 19.7 micromol x h x L(-1); P < .001), whereas coadministration with fluvoxamine increased 3-hydroxyquinine AUC significantly (from 28.4 to 30.2 micromol x h x L(-1); P < .05).",The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579472/),[h·μM] / [l],30,247159,DB00592,Piperazine
,9602386,limit of detection,The intra- and inter-assay coefficient of variation was < 10% in the range of 1.0-30 ng ml-1 and the limit of detection was 0.3 ng ml-1.,"A direct competitive ELISA for the simple, sensitive and accurate determination of diethylcarbamazine concentration in serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9602386/),[ng] / [ml],0.3,247310,DB00592,Piperazine
<,9602386,cross reactivities,The cross reactivities of anti-diethylcarbamazine antibodies with diethylcarbamazine metabolites and ivermectin were < 0.09%.,"A direct competitive ELISA for the simple, sensitive and accurate determination of diethylcarbamazine concentration in serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9602386/),%,0.09,247311,DB00592,Piperazine
,16730145,F,"After oral administration (30 mg/kg), approximately 0.626% was not absorbed and F was 14.6%.",Pharmacokinetics of sildenafil after intravenous and oral administration in rats: hepatic and intestinal first-pass effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16730145/),%,14.6,247501,DB00592,Piperazine
,10771449,Cmax,Assessment of gender effects by analysis of variance revealed statistically significant differences in Cmax (85 vs.,Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771449/),,85,248009,DB00592,Piperazine
,10771449,tmax,"69 ng ml(-1) and tmax (3.19 vs. 4.81 h) but no differences in AUC(0,12 h) or lambda(z).",Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771449/),h,3.19,248010,DB00592,Piperazine
,10771449,tmax,"69 ng ml(-1) and tmax (3.19 vs. 4.81 h) but no differences in AUC(0,12 h) or lambda(z).",Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771449/),h,4.81,248011,DB00592,Piperazine
,10771449,"AUC(0,12 h)","Assessment of age effects by analysis of variance revealed statistically significant differences in AUC(0,12 h) (560 vs.",Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771449/),,560,248012,DB00592,Piperazine
,10771449,Cmax,"465 ng ml(-1) h), Cmax (85 vs.",Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771449/),,85,248013,DB00592,Piperazine
,10771449,lambda(z),69 ng ml(-1) and lambda(z) (0.126 vs. 0.197 l h(-1) but no difference in tmax.,Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771449/),[l] / [h],0.126,248014,DB00592,Piperazine
,10771449,lambda(z),69 ng ml(-1) and lambda(z) (0.126 vs. 0.197 l h(-1) but no difference in tmax.,Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771449/),[l] / [h],0.197,248015,DB00592,Piperazine
,10771449,"t(1/2), z","The mean t(1/2), z in the young men, young women, elderly men and elderly women were 3.1, 4.1, 5.7 and 5.3 h, respectively.",Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771449/),h,3.1,248016,DB00592,Piperazine
,10771449,"t(1/2), z","The mean t(1/2), z in the young men, young women, elderly men and elderly women were 3.1, 4.1, 5.7 and 5.3 h, respectively.",Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771449/),h,4.1,248017,DB00592,Piperazine
,10771449,"t(1/2), z","The mean t(1/2), z in the young men, young women, elderly men and elderly women were 3.1, 4.1, 5.7 and 5.3 h, respectively.",Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771449/),h,5.7,248018,DB00592,Piperazine
,10771449,"t(1/2), z","The mean t(1/2), z in the young men, young women, elderly men and elderly women were 3.1, 4.1, 5.7 and 5.3 h, respectively.",Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771449/),h,5.3,248019,DB00592,Piperazine
,17368019,IC(50),"SR-1459 has IC(50)=13nM versus ROCK-II while the IC(50)s for SR-715 and SR-899 are 80nM and 100nM, respectively.","Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17368019/),nM,13,248231,DB00592,Piperazine
,17368019,IC(50)s,"SR-1459 has IC(50)=13nM versus ROCK-II while the IC(50)s for SR-715 and SR-899 are 80nM and 100nM, respectively.","Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17368019/),nM,80,248232,DB00592,Piperazine
,17368019,IC(50)s,"SR-1459 has IC(50)=13nM versus ROCK-II while the IC(50)s for SR-715 and SR-899 are 80nM and 100nM, respectively.","Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17368019/),nM,100,248233,DB00592,Piperazine
,15752381,QTc,"Mean QTc was statistically significantly increased during both ebastine/ketoconazole administration (12.21 ms; 7.39-17.03 ms) and loratadine/ketoconazole administration (10.68 ms; 6.15-15.21 ms) but these changes were not statistically significantly different from the increases seen with placebo/ketoconazole (6.96 ms; 3.31-10.62 ms), P = 0.08 ebastine study, (7.52 ms; 4.15-10.89 ms), P = 0.26 loratadine study).",Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752381/),ms,12.21,248271,DB00592,Piperazine
,15752381,QTc,"Mean QTc was statistically significantly increased during both ebastine/ketoconazole administration (12.21 ms; 7.39-17.03 ms) and loratadine/ketoconazole administration (10.68 ms; 6.15-15.21 ms) but these changes were not statistically significantly different from the increases seen with placebo/ketoconazole (6.96 ms; 3.31-10.62 ms), P = 0.08 ebastine study, (7.52 ms; 4.15-10.89 ms), P = 0.26 loratadine study).",Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752381/),ms,7.39-17.03,248272,DB00592,Piperazine
,15752381,QTc,"Mean QTc was statistically significantly increased during both ebastine/ketoconazole administration (12.21 ms; 7.39-17.03 ms) and loratadine/ketoconazole administration (10.68 ms; 6.15-15.21 ms) but these changes were not statistically significantly different from the increases seen with placebo/ketoconazole (6.96 ms; 3.31-10.62 ms), P = 0.08 ebastine study, (7.52 ms; 4.15-10.89 ms), P = 0.26 loratadine study).",Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752381/),ms,10.68,248273,DB00592,Piperazine
,15752381,QTc,"Mean QTc was statistically significantly increased during both ebastine/ketoconazole administration (12.21 ms; 7.39-17.03 ms) and loratadine/ketoconazole administration (10.68 ms; 6.15-15.21 ms) but these changes were not statistically significantly different from the increases seen with placebo/ketoconazole (6.96 ms; 3.31-10.62 ms), P = 0.08 ebastine study, (7.52 ms; 4.15-10.89 ms), P = 0.26 loratadine study).",Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752381/),ms,6.96,248274,DB00592,Piperazine
,15752381,QTc,"Mean QTc was statistically significantly increased during both ebastine/ketoconazole administration (12.21 ms; 7.39-17.03 ms) and loratadine/ketoconazole administration (10.68 ms; 6.15-15.21 ms) but these changes were not statistically significantly different from the increases seen with placebo/ketoconazole (6.96 ms; 3.31-10.62 ms), P = 0.08 ebastine study, (7.52 ms; 4.15-10.89 ms), P = 0.26 loratadine study).",Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752381/),ms,7.52,248275,DB00592,Piperazine
,2139724,half-life,Myocardial accumulation of GBR 12909 showed monophasic exponential kinetics with a half-life of 93 min.,"Myocardial accumulation kinetics and pharmacodynamics in the isolated rabbit heart of a new inhibitor of dopamine reuptake, GBR 12909. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139724/),min,93,248645,DB00592,Piperazine
,2139724,half-lives,"The disposition followed a three-phasic exponential time-course with half-lives of 1.1, 17 and 98 min., respectively, which was interpreted as three-compartment kinetics.","Myocardial accumulation kinetics and pharmacodynamics in the isolated rabbit heart of a new inhibitor of dopamine reuptake, GBR 12909. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139724/),min,1.1,248646,DB00592,Piperazine
,2139724,half-lives,"The disposition followed a three-phasic exponential time-course with half-lives of 1.1, 17 and 98 min., respectively, which was interpreted as three-compartment kinetics.","Myocardial accumulation kinetics and pharmacodynamics in the isolated rabbit heart of a new inhibitor of dopamine reuptake, GBR 12909. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139724/),min,17,248647,DB00592,Piperazine
,2139724,half-lives,"The disposition followed a three-phasic exponential time-course with half-lives of 1.1, 17 and 98 min., respectively, which was interpreted as three-compartment kinetics.","Myocardial accumulation kinetics and pharmacodynamics in the isolated rabbit heart of a new inhibitor of dopamine reuptake, GBR 12909. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139724/),min,98,248648,DB00592,Piperazine
,2139724,EC50,"The inhibitory Em-values with regard to contraction velocity were 42 and 105% with corresponding EC50-values of 29 and 688 nM and the related Hill-exponents were 0.6 and 1.1, respectively.","Myocardial accumulation kinetics and pharmacodynamics in the isolated rabbit heart of a new inhibitor of dopamine reuptake, GBR 12909. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139724/),nM,29,248649,DB00592,Piperazine
,2139724,EC50,"The inhibitory Em-values with regard to contraction velocity were 42 and 105% with corresponding EC50-values of 29 and 688 nM and the related Hill-exponents were 0.6 and 1.1, respectively.","Myocardial accumulation kinetics and pharmacodynamics in the isolated rabbit heart of a new inhibitor of dopamine reuptake, GBR 12909. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139724/),nM,688,248650,DB00592,Piperazine
,2139724,Hill-exponents,"The inhibitory Em-values with regard to contraction velocity were 42 and 105% with corresponding EC50-values of 29 and 688 nM and the related Hill-exponents were 0.6 and 1.1, respectively.","Myocardial accumulation kinetics and pharmacodynamics in the isolated rabbit heart of a new inhibitor of dopamine reuptake, GBR 12909. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139724/),,0.6,248651,DB00592,Piperazine
,2139724,Hill-exponents,"The inhibitory Em-values with regard to contraction velocity were 42 and 105% with corresponding EC50-values of 29 and 688 nM and the related Hill-exponents were 0.6 and 1.1, respectively.","Myocardial accumulation kinetics and pharmacodynamics in the isolated rabbit heart of a new inhibitor of dopamine reuptake, GBR 12909. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139724/),,1.1,248652,DB00592,Piperazine
,31089768,AUC,The AUC of PZQ was increased by 75% with KTZ co-administration (3516 vs 6172 ng h/ml) (p < 0.01).,The effect of ketoconazole on praziquantel pharmacokinetics and the role of CYP3A4 in the formation of X-OH-praziquantel and not 4-OH-praziquantel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31089768/),[h·ng] / [ml],3516,249328,DB00592,Piperazine
,31089768,AUC,The AUC of PZQ was increased by 75% with KTZ co-administration (3516 vs 6172 ng h/ml) (p < 0.01).,The effect of ketoconazole on praziquantel pharmacokinetics and the role of CYP3A4 in the formation of X-OH-praziquantel and not 4-OH-praziquantel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31089768/),[h·ng] / [ml],6172,249329,DB00592,Piperazine
,31089768,AUC,"Meanwhile, the mean AUC of trans-4-OH-PZQ increased by 67% (61,749 ng h/ml vs 103,105 ng h/ml) (p < 0.01).",The effect of ketoconazole on praziquantel pharmacokinetics and the role of CYP3A4 in the formation of X-OH-praziquantel and not 4-OH-praziquantel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31089768/),[h·ng] / [ml],"61,749",249330,DB00592,Piperazine
,31089768,AUC,"Meanwhile, the mean AUC of trans-4-OH-PZQ increased by 67% (61,749 ng h/ml vs 103,105 ng h/ml) (p < 0.01).",The effect of ketoconazole on praziquantel pharmacokinetics and the role of CYP3A4 in the formation of X-OH-praziquantel and not 4-OH-praziquantel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31089768/),[h·ng] / [ml],"103,105",249331,DB00592,Piperazine
,22851617,Elimination half-lives,"Elimination half-lives of total radioactivity, remogliflozin etabonate, and remogliflozin were 6.57, 0.39, and 1.57 h, respectively.","Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22851617/),h,6.57,249659,DB00592,Piperazine
,22851617,Elimination half-lives,"Elimination half-lives of total radioactivity, remogliflozin etabonate, and remogliflozin were 6.57, 0.39, and 1.57 h, respectively.","Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22851617/),h,0.39,249660,DB00592,Piperazine
,22851617,Elimination half-lives,"Elimination half-lives of total radioactivity, remogliflozin etabonate, and remogliflozin were 6.57, 0.39, and 1.57 h, respectively.","Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22851617/),h,1.57,249661,DB00592,Piperazine
,21204634,time to reach maximum plasma concentrations,BIBF 1120 was well-tolerated and rapidly absorbed; median time to reach maximum plasma concentrations was 1.3 h and gMean terminal half-life was 13.7 h.,Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21204634/),h,1.3,249814,DB00592,Piperazine
,21204634,terminal half-life,BIBF 1120 was well-tolerated and rapidly absorbed; median time to reach maximum plasma concentrations was 1.3 h and gMean terminal half-life was 13.7 h.,Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21204634/),h,13.7,249815,DB00592,Piperazine
,21204634,Total recovery in excreta,Total recovery in excreta was 94.7% 1 week post-dose; mass balance was considered complete after 96 h.,Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21204634/),%,94.7,249816,DB00592,Piperazine
,25001129,IC50,"Compound 51 was potent in both biochemical and cellular assays (IC50=0.005 μM and EC50=0.205 μM, respectively) and exhibited acceptable pharmacokinetic properties for in vivo evaluation.",Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 4. Exploration of a novel binding pocket. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25001129/),μM,0.005,249849,DB00592,Piperazine
,25001129,EC50,"Compound 51 was potent in both biochemical and cellular assays (IC50=0.005 μM and EC50=0.205 μM, respectively) and exhibited acceptable pharmacokinetic properties for in vivo evaluation.",Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 4. Exploration of a novel binding pocket. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25001129/),μM,0.205,249850,DB00592,Piperazine
,18803444,Cmax,"The highest levels of KET in aqueous humor (Cmax, 2.67 microg/mL) were obtained after a 20-min application of KET-CD, 6.1 times greater than that corresponding to the KET-SP at 30 min.",Ocular pharmacokinetics of topically-applied ketoconazole solution containing hydroxypropyl beta-cyclodextrin to rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18803444/),[μg] / [ml],2.67,249978,DB00592,Piperazine
,18803444,Peak KET concentration,"Peak KET concentration in the cornea (118.24 microg/g) was achieved within 5 min after the instillation of KET-CD, 18.4 times higher than that of KET-SP at the same time point, whereas the highest KET level in cornea was only 8.57 microg/g after a 10-min application of KET-SP.",Ocular pharmacokinetics of topically-applied ketoconazole solution containing hydroxypropyl beta-cyclodextrin to rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18803444/),[μg] / [g],118.24,249979,DB00592,Piperazine
>,22239250,pK(i),SAR studies involving mono- and disubstitution in the 3'-pyridyl ring and variation of the 3-isobutyl group gave potent compounds (pK(i) > 9.0) with good aqueous solubility.,"Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22239250/),,9.0,250128,DB00592,Piperazine
,22239250,pK(i),"Evaluation of the pharmacokinetic profile in the rat, dog, and cynomolgus monkey of those derivatives with low cynomolgus monkey and human intrinsic clearance gave 2',6'-dimethyl-3'-pyridyl R-sec-butyl morpholine amide Epelsiban (69), a highly potent oxytocin antagonist (pK(i) = 9.9) with >31000-fold selectivity over all three human vasopressin receptors hV1aR, hV2R, and hV1bR, with no significant P450 inhibition.","Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22239250/),,9.9,250129,DB00592,Piperazine
,22239250,bioavailability,"Epelsiban has low levels of intrinsic clearance against the microsomes of four species, good bioavailability (55%) and comparable potency to atosiban in the rat, but is 100-fold more potent than the latter in vitro and was negative in the genotoxicity screens with a satisfactory oral safety profile in female rats.","Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22239250/),%,55,250130,DB00592,Piperazine
,21494909,half-life,"Oral administration of SN79 reached peak in vivo concentrations after 1.5 h and exhibited a half-life of just over 7.5 h in male, Sprague-Dawley rats.","Synthesis and pharmacological evaluation of 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a cocaine antagonist, in rodents. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21494909/),h,7.5,250164,DB00592,Piperazine
,2892446,elimination half-life,"We found that the elimination half-life of cetirizine was prolonged in patients with mild and moderate renal insufficiency, compared with age-matched individuals with normal renal function (19.0 +/- 3.3 and 20.9 +/- 4.4 hours, vs 7.4 +/- 3.0 hours, respectively).",Pharmacokinetics of cetirizine in the elderly and patients with renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892446/),h,19.0,250441,DB00592,Piperazine
,2892446,elimination half-life,"We found that the elimination half-life of cetirizine was prolonged in patients with mild and moderate renal insufficiency, compared with age-matched individuals with normal renal function (19.0 +/- 3.3 and 20.9 +/- 4.4 hours, vs 7.4 +/- 3.0 hours, respectively).",Pharmacokinetics of cetirizine in the elderly and patients with renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892446/),h,20.9,250442,DB00592,Piperazine
,2892446,elimination half-life,"We found that the elimination half-life of cetirizine was prolonged in patients with mild and moderate renal insufficiency, compared with age-matched individuals with normal renal function (19.0 +/- 3.3 and 20.9 +/- 4.4 hours, vs 7.4 +/- 3.0 hours, respectively).",Pharmacokinetics of cetirizine in the elderly and patients with renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892446/),h,7.4,250443,DB00592,Piperazine
,2892446,apparent steady-state volume of distribution,"However, the mean apparent steady-state volume of distribution did not differ significantly between these subject groups (range 0.41 to 0.47 L/kg).",Pharmacokinetics of cetirizine in the elderly and patients with renal insufficiency. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892446/),[l] / [kg],0.41 to 0.47,250444,DB00592,Piperazine
,15497717,absolute oral bioavailability,The absolute oral bioavailability is about 15%.,[Pharmacodynamics and pharmacokinetics of vardenafil in patients with erectile dysfunction]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497717/),%,15,250835,DB00592,Piperazine
,15497717,tmax,Vardenafil is rapidly absorbed with a median tmax of 0.7 h and a terminal half-life (t1/2) of more than 4 h.,[Pharmacodynamics and pharmacokinetics of vardenafil in patients with erectile dysfunction]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497717/),h,0.7,250836,DB00592,Piperazine
more,15497717,terminal half-life (t1/2),Vardenafil is rapidly absorbed with a median tmax of 0.7 h and a terminal half-life (t1/2) of more than 4 h.,[Pharmacodynamics and pharmacokinetics of vardenafil in patients with erectile dysfunction]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497717/),h,4,250837,DB00592,Piperazine
,18371719,accumulation time,"The optimized procedural conditions were: frequency=120Hz, scan increment=10mV, pulse-amplitude=25mV, accumulation potential=-0.3V, accumulation time=90-300s and a Britton-Robinson universal buffer of pH 4 as a supporting electrolyte.",Development of a voltammetric procedure for assay of the antihistamine drug hydroxyzine at a glassy carbon electrode: Quantification and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18371719/),s,90-300,250920,DB00592,Piperazine
,18371719,recoveries,"Mean recoveries of 100.5+/-0.71 and 98.6+/-1.12% (n=5) were achieved for assay of hydroxyzine in Atarax 10 and 25mg dosage forms, respectively.",Development of a voltammetric procedure for assay of the antihistamine drug hydroxyzine at a glassy carbon electrode: Quantification and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18371719/),%,100.5,250921,DB00592,Piperazine
,18371719,recoveries,"Mean recoveries of 100.5+/-0.71 and 98.6+/-1.12% (n=5) were achieved for assay of hydroxyzine in Atarax 10 and 25mg dosage forms, respectively.",Development of a voltammetric procedure for assay of the antihistamine drug hydroxyzine at a glassy carbon electrode: Quantification and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18371719/),%,98.6,250922,DB00592,Piperazine
,18371719,Limit of detection,"Limit of detection of 1.5x10(-8)molL(-1) (5.624ngmL(-1)) and limit of quantitation of 5.0x10(-8)molL(-1) (18.746ngmL(-1)) were achieved in human serum with a mean recovery of 98.4+/-1.22%, without prior extraction of the drug.",Development of a voltammetric procedure for assay of the antihistamine drug hydroxyzine at a glassy carbon electrode: Quantification and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18371719/),1/[moll],1.5x10(-8),250923,DB00592,Piperazine
,18371719,Limit of detection,"Limit of detection of 1.5x10(-8)molL(-1) (5.624ngmL(-1)) and limit of quantitation of 5.0x10(-8)molL(-1) (18.746ngmL(-1)) were achieved in human serum with a mean recovery of 98.4+/-1.22%, without prior extraction of the drug.",Development of a voltammetric procedure for assay of the antihistamine drug hydroxyzine at a glassy carbon electrode: Quantification and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18371719/),1/[ngml],5.624,250924,DB00592,Piperazine
,18371719,limit of quantitation,"Limit of detection of 1.5x10(-8)molL(-1) (5.624ngmL(-1)) and limit of quantitation of 5.0x10(-8)molL(-1) (18.746ngmL(-1)) were achieved in human serum with a mean recovery of 98.4+/-1.22%, without prior extraction of the drug.",Development of a voltammetric procedure for assay of the antihistamine drug hydroxyzine at a glassy carbon electrode: Quantification and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18371719/),1/[moll],5.0x10(-8),250925,DB00592,Piperazine
,18371719,limit of quantitation,"Limit of detection of 1.5x10(-8)molL(-1) (5.624ngmL(-1)) and limit of quantitation of 5.0x10(-8)molL(-1) (18.746ngmL(-1)) were achieved in human serum with a mean recovery of 98.4+/-1.22%, without prior extraction of the drug.",Development of a voltammetric procedure for assay of the antihistamine drug hydroxyzine at a glassy carbon electrode: Quantification and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18371719/),1/[ngml],18.746,250926,DB00592,Piperazine
,18371719,recovery,"Limit of detection of 1.5x10(-8)molL(-1) (5.624ngmL(-1)) and limit of quantitation of 5.0x10(-8)molL(-1) (18.746ngmL(-1)) were achieved in human serum with a mean recovery of 98.4+/-1.22%, without prior extraction of the drug.",Development of a voltammetric procedure for assay of the antihistamine drug hydroxyzine at a glassy carbon electrode: Quantification and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18371719/),%,98.4,250927,DB00592,Piperazine
,27121892,serum elimination half-life,The serum elimination half-life was 5.83 ± 0.841 h.,Elimination of cetirizine following administration of multiple doses to exercised thoroughbred horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121892/),h,5.83,251351,DB00592,Piperazine
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],179,251609,DB00592,Piperazine
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],167,251610,DB00592,Piperazine
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],171,251611,DB00592,Piperazine
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],147,251612,DB00592,Piperazine
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],189,251613,DB00592,Piperazine
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],194,251614,DB00592,Piperazine
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],181,251615,DB00592,Piperazine
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],201,251616,DB00592,Piperazine
,11295581,bioavailability,"The faster absorption and improved bioavailability of cyclosporine (around 40%) with Neoral compared with Sandimmune was not seen in patients receiving ketoconazole, where in fact cyclosporine bioavailability was already maximal.",Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),%,40,251617,DB00592,Piperazine
<,7967726,half-lives,RA is much more rapidly cleared from plasma following oral administration; their respective half-lives are < 1 h and 13 h.,Clinical pharmacology of all-trans retinoic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7967726/),h,1,251638,DB00592,Piperazine
,7967726,half-lives,RA is much more rapidly cleared from plasma following oral administration; their respective half-lives are < 1 h and 13 h.,Clinical pharmacology of all-trans retinoic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7967726/),h,13,251639,DB00592,Piperazine
,34302760,AUCtau,The mean bictegravir AUCtau was 89 100 ng × h/mL (coefficient of variation 31·0%) in adolescents (cohort 1) and 128 000 ng × h/mL (27·8%) in children (cohort 2).,"Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34302760/),[h·ng] / [ml],89 100,251671,DB00592,Piperazine
,34302760,AUCtau,The mean bictegravir AUCtau was 89 100 ng × h/mL (coefficient of variation 31·0%) in adolescents (cohort 1) and 128 000 ng × h/mL (27·8%) in children (cohort 2).,"Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34302760/),[h·ng] / [ml],128 000,251672,DB00592,Piperazine
,3089595,maximum tolerated dose,The maximum tolerated dose was 3500 mg/m2/day X 3 based on changes in hepatic function and coagulation abnormalities encountered when larger dosages were administered.,Phase I study of ICRF-187 in pediatric cancer patients and comparison of its pharmacokinetics in children and adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3089595/),,350,251820,DB00592,Piperazine
,16052551,AUC ratio,"4), while other plasma metabolites, azimilide N-oxide (metabolite/parent AUC ratio 0.001), and a cleaved hydantoin metabolite (metabolite/parent AUC ratio = 0.3) were present at lower concentrations than azimilide.",The metabolic profile of azimilide in man: in vivo and in vitro evaluations. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16052551/),,0.001,251959,DB00592,Piperazine
,16052551,AUC ratio,"4), while other plasma metabolites, azimilide N-oxide (metabolite/parent AUC ratio 0.001), and a cleaved hydantoin metabolite (metabolite/parent AUC ratio = 0.3) were present at lower concentrations than azimilide.",The metabolic profile of azimilide in man: in vivo and in vitro evaluations. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16052551/),,0.3,251960,DB00592,Piperazine
,17965519,C(max),"Following a single oral 6 mg dose, the mean C(max), t(max), and t(1/2, z) (terminal phase half life) of aripiprazole were 31.0 ng/mL, 3.6 hr, and 61.0 hr, respectively.","Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17965519/),[ng] / [ml],31.0,252106,DB00592,Piperazine
,17965519,t(max),"Following a single oral 6 mg dose, the mean C(max), t(max), and t(1/2, z) (terminal phase half life) of aripiprazole were 31.0 ng/mL, 3.6 hr, and 61.0 hr, respectively.","Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17965519/),h,3.6,252107,DB00592,Piperazine
,17965519,"t(1/2, z) (terminal phase half life)","Following a single oral 6 mg dose, the mean C(max), t(max), and t(1/2, z) (terminal phase half life) of aripiprazole were 31.0 ng/mL, 3.6 hr, and 61.0 hr, respectively.","Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17965519/),h,61.0,252108,DB00592,Piperazine
,17965519,"t(1/2, z)","The t(1/2, z) in CYP2D6 IM subjects (75.2 hr) was significantly (p<0.01) longer than that in CYP2D6 EM subjects (45.8 hr), and the systemic clearance of IM subjects was approximately 60% that of EM subjects.","Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17965519/),h,75.2,252109,DB00592,Piperazine
,17965519,"t(1/2, z)","The t(1/2, z) in CYP2D6 IM subjects (75.2 hr) was significantly (p<0.01) longer than that in CYP2D6 EM subjects (45.8 hr), and the systemic clearance of IM subjects was approximately 60% that of EM subjects.","Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17965519/),h,45.8,252110,DB00592,Piperazine
,16390352,plasma C(max),"In the clinical studies, ketoconazole increased mean quetiapine plasma C(max) by 3.35-fold, from 45 to 150 ng ml(-1) (mean C(max) ratio 90% CI 2.51, 4.47) and decreased its clearance (Cl/F) by 84%, from 138 to 22 l h(-1) (mean ratio 90% CI 0.13, 0.20).",Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390352/),[ng] / [ml],45 to 150,252117,DB00592,Piperazine
,16390352,clearance (Cl/F),"In the clinical studies, ketoconazole increased mean quetiapine plasma C(max) by 3.35-fold, from 45 to 150 ng ml(-1) (mean C(max) ratio 90% CI 2.51, 4.47) and decreased its clearance (Cl/F) by 84%, from 138 to 22 l h(-1) (mean ratio 90% CI 0.13, 0.20).",Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390352/),[l] / [h],138 to 22,252118,DB00592,Piperazine
,16390352,plasma C(max),"Carbamazepine decreased quetiapine plasma C(max) by 80%, from 1042 to 205 ng ml(-1) (mean C(max) ratio 90% CI 0.14, 0.28) and increased its clearance 7.5-fold, from 65 to 483 l h(-1) (mean ratio 90% CI 6.04, 9.28).",Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390352/),[ng] / [ml],1042 to 205,252119,DB00592,Piperazine
,16390352,clearance,"Carbamazepine decreased quetiapine plasma C(max) by 80%, from 1042 to 205 ng ml(-1) (mean C(max) ratio 90% CI 0.14, 0.28) and increased its clearance 7.5-fold, from 65 to 483 l h(-1) (mean ratio 90% CI 6.04, 9.28).",Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390352/),[l] / [h],65 to 483,252120,DB00592,Piperazine
,20563581,plasma area under the curve (AUC),"Following a one-time oral dose of 300 mg, the MP470 plasma area under the curve (AUC) was 1,690 ± 821 nM h (mean ± SD).",Plasma and cerebrospinal fluid pharmacokinetics of MP470 in non-human primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20563581/),h·nM,"1,690",252172,DB00592,Piperazine
,20563581,half-life,The half-life of MP470 in the plasma was 11.0 ± 3.4 h.,Plasma and cerebrospinal fluid pharmacokinetics of MP470 in non-human primates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20563581/),h,11.0,252173,DB00592,Piperazine
more,16803422,bioavailability,"Although the bioavailability of imatinib mesylate is more than 97%, the exact gastrointestinal site of its absorption is unknown.",Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16803422/),%,97,252277,DB00592,Piperazine
>,19523013,maximum tolerated dose,The maximum tolerated dose after multiple doses was >10 mg (5 mg q12).,"Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19523013/),,10,252350,DB00592,Piperazine
,19523013,maximum tolerated dose,"In the single-dose study, the maximum tolerated dose was 10 mg.","Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19523013/),mg,10,252351,DB00592,Piperazine
,18030066,area under the concentration-time curve (AUC0-tlast),Active metabolite area under the concentration-time curve (AUC0-tlast) after prasugrel 60-mg (594 ng.hr/mL) was 2.2 times that after clopidogrel 600-mg.,Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18030066/),[h·ng] / [ml],594,252650,DB00592,Piperazine
<,26852005,Ki,"Among total 30 compounds synthesized, four compounds 27-30 showed good binding affinities with Ki values of <100 nM.",Novel N-acyl-carbazole derivatives as 5-HT7R antagonists. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26852005/),nM,100,252723,DB00592,Piperazine
,26852005,oral bioavailability,The compound 28 exhibited a good pharmacokinetic profile with 67.8% oral bioavailability and good penetration to the brain.,Novel N-acyl-carbazole derivatives as 5-HT7R antagonists. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26852005/),%,67.8,252724,DB00592,Piperazine
,11422002,area under the methylprednisolone concentration-time curve,Itraconazole increased the mean area under the methylprednisolone concentration-time curve from 2773 ng ml-1 h to 7011 ng ml-1 h (P < 0.001) and the elimination half-life from 3.2 h to 5.5 h (P < 0.001).,Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422002/),[h·ng] / [ml],2773,252860,DB00592,Piperazine
,11422002,area under the methylprednisolone concentration-time curve,Itraconazole increased the mean area under the methylprednisolone concentration-time curve from 2773 ng ml-1 h to 7011 ng ml-1 h (P < 0.001) and the elimination half-life from 3.2 h to 5.5 h (P < 0.001).,Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422002/),[h·ng] / [ml],7011,252861,DB00592,Piperazine
,11422002,elimination half-life,Itraconazole increased the mean area under the methylprednisolone concentration-time curve from 2773 ng ml-1 h to 7011 ng ml-1 h (P < 0.001) and the elimination half-life from 3.2 h to 5.5 h (P < 0.001).,Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422002/),h,3.2,252862,DB00592,Piperazine
,11422002,elimination half-life,Itraconazole increased the mean area under the methylprednisolone concentration-time curve from 2773 ng ml-1 h to 7011 ng ml-1 h (P < 0.001) and the elimination half-life from 3.2 h to 5.5 h (P < 0.001).,Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422002/),h,5.5,252863,DB00592,Piperazine
,10483517,half-lives,The plasma profile of radioactivity was characterized by two decreasing phases with respective half-lives of 3.71 +/- 0.66 h and 24.67 +/- 25.01 h.,"Pharmacokinetics, metabolism and bioavailability of the new anti-allergic drug BM 113. Part III: Pharmacokinetics, metabolism, dose dependency and gender effect after single or repeated administration to human healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10483517/),h,3.71,252911,DB00592,Piperazine
,10483517,half-lives,The plasma profile of radioactivity was characterized by two decreasing phases with respective half-lives of 3.71 +/- 0.66 h and 24.67 +/- 25.01 h.,"Pharmacokinetics, metabolism and bioavailability of the new anti-allergic drug BM 113. Part III: Pharmacokinetics, metabolism, dose dependency and gender effect after single or repeated administration to human healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10483517/),h,24.67,252912,DB00592,Piperazine
,18094422,area under the curve,"In 11 evaluable patients, the geometric mean (95% confidence interval) area under the curve of imatinib on days 1 and 4 were 42.6 (33.0-54.9) microg.h/mL and 41.2 (32.1-53.1) microg.h/mL, respectively (P = 0.65).",Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18094422/),[h·μg] / [ml],42.6,252966,DB00592,Piperazine
,18094422,area under the curve,"In 11 evaluable patients, the geometric mean (95% confidence interval) area under the curve of imatinib on days 1 and 4 were 42.6 (33.0-54.9) microg.h/mL and 41.2 (32.1-53.1) microg.h/mL, respectively (P = 0.65).",Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18094422/),[h·μg] / [ml],41.2,252967,DB00592,Piperazine
,2410686,terminal elimination half-life,"The mean terminal elimination half-life (+/- SD) for prazosin was 2.0 +/- 0.4 h, and that for trimazosin was comparable at 3.1 +/- 0.3 h, whilst the mean terminal elimination half-life for doxazosin was significantly longer at 9.4 +/- 1.5 h.",Application of pharmacokinetic-pharmacodynamic modelling for the comparison of quinazoline alpha-adrenoceptor agonists in normotensive volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410686/),h,2.0,253180,DB00592,Piperazine
,2410686,terminal elimination half-life,"The mean terminal elimination half-life (+/- SD) for prazosin was 2.0 +/- 0.4 h, and that for trimazosin was comparable at 3.1 +/- 0.3 h, whilst the mean terminal elimination half-life for doxazosin was significantly longer at 9.4 +/- 1.5 h.",Application of pharmacokinetic-pharmacodynamic modelling for the comparison of quinazoline alpha-adrenoceptor agonists in normotensive volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410686/),h,3.1,253181,DB00592,Piperazine
,2410686,terminal elimination half-life,"The mean terminal elimination half-life (+/- SD) for prazosin was 2.0 +/- 0.4 h, and that for trimazosin was comparable at 3.1 +/- 0.3 h, whilst the mean terminal elimination half-life for doxazosin was significantly longer at 9.4 +/- 1.5 h.",Application of pharmacokinetic-pharmacodynamic modelling for the comparison of quinazoline alpha-adrenoceptor agonists in normotensive volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410686/),h,9.4,253182,DB00592,Piperazine
,2410686,clearance,"The clearance of prazosin (mean, 327 +/- 78 ml/min) was greater than that of both doxazosin (139 +/- 30 ml/min) and trimazosin (67 +/- 29 ml/min).",Application of pharmacokinetic-pharmacodynamic modelling for the comparison of quinazoline alpha-adrenoceptor agonists in normotensive volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410686/),[ml] / [min],327,253183,DB00592,Piperazine
,2410686,clearance,"The clearance of prazosin (mean, 327 +/- 78 ml/min) was greater than that of both doxazosin (139 +/- 30 ml/min) and trimazosin (67 +/- 29 ml/min).",Application of pharmacokinetic-pharmacodynamic modelling for the comparison of quinazoline alpha-adrenoceptor agonists in normotensive volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410686/),[ml] / [min],139,253184,DB00592,Piperazine
,2410686,clearance,"The clearance of prazosin (mean, 327 +/- 78 ml/min) was greater than that of both doxazosin (139 +/- 30 ml/min) and trimazosin (67 +/- 29 ml/min).",Application of pharmacokinetic-pharmacodynamic modelling for the comparison of quinazoline alpha-adrenoceptor agonists in normotensive volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410686/),[ml] / [min],67,253185,DB00592,Piperazine
,6260830,recovery,The average recovery of ketoconazole over a concentration range of 0.1-20.0 microgram/ml was 88.2 +/- 4.07% S.D.,"Determination of the antifungal agent, ketoconazole, in human plasma by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6260830/),%,88.2,253194,DB00592,Piperazine
less,6260830,maximum sensitivity,The maximum sensitivity of the assay is less than 0.1 microgram/ml.,"Determination of the antifungal agent, ketoconazole, in human plasma by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6260830/),[μg] / [ml],0.1,253195,DB00592,Piperazine
,19406007,absolute bioavailability,The nasal Bus-chitosan formulation improved the absolute bioavailability to 61% and the plasma concentration peaked at 30 min whereas the peak for nasal Bus-plain formulation was 60 min.,Brain targeting studies on buspirone hydrochloride after intranasal administration of mucoadhesive formulation in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406007/),%,61,253422,DB00592,Piperazine
,19406007,AUC0-480,The AUC0-480 in brain after nasal administration of Bus-chitosan formulation was 2.5 times that obtained by intravenous administration (711+/-252 ng/g vs 282+/-110 ng/g); this was also considerably higher than that obtained with the intranasal Bus-plain formulation (354+/-80 ng/g).,Brain targeting studies on buspirone hydrochloride after intranasal administration of mucoadhesive formulation in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406007/),[ng] / [g],711,253423,DB00592,Piperazine
,19406007,AUC0-480,The AUC0-480 in brain after nasal administration of Bus-chitosan formulation was 2.5 times that obtained by intravenous administration (711+/-252 ng/g vs 282+/-110 ng/g); this was also considerably higher than that obtained with the intranasal Bus-plain formulation (354+/-80 ng/g).,Brain targeting studies on buspirone hydrochloride after intranasal administration of mucoadhesive formulation in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406007/),[ng] / [g],282,253424,DB00592,Piperazine
,19406007,AUC0-480,The AUC0-480 in brain after nasal administration of Bus-chitosan formulation was 2.5 times that obtained by intravenous administration (711+/-252 ng/g vs 282+/-110 ng/g); this was also considerably higher than that obtained with the intranasal Bus-plain formulation (354+/-80 ng/g).,Brain targeting studies on buspirone hydrochloride after intranasal administration of mucoadhesive formulation in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406007/),[ng] / [g],354,253425,DB00592,Piperazine
>,19406007,drug targeting index,The high percentage of direct drug transport to the brain (75.77%) and high drug targeting index (>1) confirmed the direct nose to brain transport of buspirone following nasal administration of Bus-chitosan formulation.,Brain targeting studies on buspirone hydrochloride after intranasal administration of mucoadhesive formulation in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406007/),,1,253426,DB00592,Piperazine
,29341245,terminal elimination phase half-life,"Coadministration of a single 20-mg dose of avatrombopag with fluconazole at steady-state resulted in 2.16-fold increase of AUC of avatrombopag, prolonged terminal elimination phase half-life (from 19.7 h to 39.9 h) and led to a clinically significant increase in maximum platelet count (1.66-fold).",Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29341245/),h,19.7,253568,DB00592,Piperazine
,29341245,terminal elimination phase half-life,"Coadministration of a single 20-mg dose of avatrombopag with fluconazole at steady-state resulted in 2.16-fold increase of AUC of avatrombopag, prolonged terminal elimination phase half-life (from 19.7 h to 39.9 h) and led to a clinically significant increase in maximum platelet count (1.66-fold).",Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29341245/),h,39.9,253569,DB00592,Piperazine
,29341245,terminal elimination phase half-life,"Coadministration of rifampicin caused a 0.5-fold decrease in AUC and shortened terminal elimination phase half-life (from 20.3 h to 9.84 h), but has no impact on maximum platelet count.",Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29341245/),h,20.3,253570,DB00592,Piperazine
,29341245,terminal elimination phase half-life,"Coadministration of rifampicin caused a 0.5-fold decrease in AUC and shortened terminal elimination phase half-life (from 20.3 h to 9.84 h), but has no impact on maximum platelet count.",Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29341245/),h,9.84,253571,DB00592,Piperazine
>,25865750,therapeutic trough concentrations,The dosage regimen achieved average therapeutic trough concentrations (>0.5 μg/mL) within 3 weeks.,Alternate-day dosing of itraconazole in healthy adult cats. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25865750/),[μg] / [ml],0.5,253572,DB00592,Piperazine
,25865750,peak concentration,"At 8 weeks, an average peak concentration of 1.79 ± 0.952 μg/mL (95% CI: 0.996-2.588) and an average trough concentration of 0.761 ± 0.540 μg/mL (95% CI: 0.314-1.216) were achieved.",Alternate-day dosing of itraconazole in healthy adult cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25865750/),[μg] / [ml],1.79,253573,DB00592,Piperazine
,25865750,trough concentration,"At 8 weeks, an average peak concentration of 1.79 ± 0.952 μg/mL (95% CI: 0.996-2.588) and an average trough concentration of 0.761 ± 0.540 μg/mL (95% CI: 0.314-1.216) were achieved.",Alternate-day dosing of itraconazole in healthy adult cats. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25865750/),[μg] / [ml],0.761,253574,DB00592,Piperazine
,9224781,C(max),"The absorption of ziprasidone was rapid, and the C(max) for ziprasidone and metabolites occurred at 2 to 6 hr postdose.","Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9224781/),h,2 to 6,253708,DB00592,Piperazine
,9224781,peak serum concentration,Mean peak serum concentration of unchanged drug was 45 ng/ml and a mean AUC(0-t) of 335.7 ng x hr/ml.,"Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9224781/),[ng] / [ml],45,253709,DB00592,Piperazine
,9224781,AUC(0-t),Mean peak serum concentration of unchanged drug was 45 ng/ml and a mean AUC(0-t) of 335.7 ng x hr/ml.,"Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9224781/),[h·ng] / [ml],335.7,253710,DB00592,Piperazine
,9224781,peak serum concentration,Mean peak serum concentration of total radioactivity (average of 3H and 14C) was 91 ng-eq/ml and a mean AUC(0-t) of 724.6 ng-eq x hr/ml.,"Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9224781/),[ng-eq] / [ml],91,253711,DB00592,Piperazine
,9224781,AUC(0-t),Mean peak serum concentration of total radioactivity (average of 3H and 14C) was 91 ng-eq/ml and a mean AUC(0-t) of 724.6 ng-eq x hr/ml.,"Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9224781/),[h·ng-eq] / [ml],724.6,253712,DB00592,Piperazine
,11180198,AUC,"In rats pretreated with dexamethasone (CYP3A23 inducer), the AUC was significantly smaller (41.5 compared with 52.5 microg min/mL), Cl was significantly faster (72.2 compared with 57.1 mL/min/kg), and the amounts and/or tissue-to-plasma ratios of parathion was significantly (or tended to be) smaller than those in control rats.",Effects of enzyme inducers or inhibitors on the pharmacokinetics of intravenous parathion in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180198/),[min·μg] / [ml],41.5,253908,DB00592,Piperazine
,11180198,AUC,"In rats pretreated with dexamethasone (CYP3A23 inducer), the AUC was significantly smaller (41.5 compared with 52.5 microg min/mL), Cl was significantly faster (72.2 compared with 57.1 mL/min/kg), and the amounts and/or tissue-to-plasma ratios of parathion was significantly (or tended to be) smaller than those in control rats.",Effects of enzyme inducers or inhibitors on the pharmacokinetics of intravenous parathion in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180198/),[min·μg] / [ml],52.5,253909,DB00592,Piperazine
,11180198,Cl,"In rats pretreated with dexamethasone (CYP3A23 inducer), the AUC was significantly smaller (41.5 compared with 52.5 microg min/mL), Cl was significantly faster (72.2 compared with 57.1 mL/min/kg), and the amounts and/or tissue-to-plasma ratios of parathion was significantly (or tended to be) smaller than those in control rats.",Effects of enzyme inducers or inhibitors on the pharmacokinetics of intravenous parathion in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180198/),[ml] / [kg·min],72.2,253910,DB00592,Piperazine
,11180198,Cl,"In rats pretreated with dexamethasone (CYP3A23 inducer), the AUC was significantly smaller (41.5 compared with 52.5 microg min/mL), Cl was significantly faster (72.2 compared with 57.1 mL/min/kg), and the amounts and/or tissue-to-plasma ratios of parathion was significantly (or tended to be) smaller than those in control rats.",Effects of enzyme inducers or inhibitors on the pharmacokinetics of intravenous parathion in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180198/),[ml] / [kg·min],57.1,253911,DB00592,Piperazine
,11180198,Cl(int),This was supported by in vitro intrinsic clearance (Cl(int)) of parathion to form paraoxon in hepatic microsomal fraction; the Cl(int) in rats pretreated with dexamethasone was significantly faster (0.0900 compared with 0.0290 mL/min/mg protein) than that in control rats.,Effects of enzyme inducers or inhibitors on the pharmacokinetics of intravenous parathion in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180198/),[ml] / [mg·min],0.0900,253912,DB00592,Piperazine
,11180198,Cl(int),This was supported by in vitro intrinsic clearance (Cl(int)) of parathion to form paraoxon in hepatic microsomal fraction; the Cl(int) in rats pretreated with dexamethasone was significantly faster (0.0900 compared with 0.0290 mL/min/mg protein) than that in control rats.,Effects of enzyme inducers or inhibitors on the pharmacokinetics of intravenous parathion in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180198/),[ml] / [mg·min],0.0290,253913,DB00592,Piperazine
,9712463,dose-rate-Css(trough) ratio,"The mean (and 95% confidence interval) dose-rate-Css(trough) ratio for cyclosporine generated from concentrations measured using EMIT was 94 (82.5-105.5) Lh(-1) for patients administered cyclosporine alone, 66.7 (58.1-75.3) Lh(-1) for patients administered concomitant diltiazem, 47.9 (15.4 -80.4) Lh(-1) for patients administered concomitant itraconazole, 21.7 (14.8-28.5) Lh(-1) for patients administered concomitant ketoconazole, and 14.9 (11.8-18.1) Lh(-1) for patients concomitantly administered diltiazem and ketoconazole.",Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712463/),1/[lh],94,253963,DB00592,Piperazine
,9712463,dose-rate-Css(trough) ratio,"The mean (and 95% confidence interval) dose-rate-Css(trough) ratio for cyclosporine generated from concentrations measured using EMIT was 94 (82.5-105.5) Lh(-1) for patients administered cyclosporine alone, 66.7 (58.1-75.3) Lh(-1) for patients administered concomitant diltiazem, 47.9 (15.4 -80.4) Lh(-1) for patients administered concomitant itraconazole, 21.7 (14.8-28.5) Lh(-1) for patients administered concomitant ketoconazole, and 14.9 (11.8-18.1) Lh(-1) for patients concomitantly administered diltiazem and ketoconazole.",Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712463/),1/[lh],66.7,253964,DB00592,Piperazine
,9712463,dose-rate-Css(trough) ratio,"The mean (and 95% confidence interval) dose-rate-Css(trough) ratio for cyclosporine generated from concentrations measured using EMIT was 94 (82.5-105.5) Lh(-1) for patients administered cyclosporine alone, 66.7 (58.1-75.3) Lh(-1) for patients administered concomitant diltiazem, 47.9 (15.4 -80.4) Lh(-1) for patients administered concomitant itraconazole, 21.7 (14.8-28.5) Lh(-1) for patients administered concomitant ketoconazole, and 14.9 (11.8-18.1) Lh(-1) for patients concomitantly administered diltiazem and ketoconazole.",Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712463/),1/[lh],47.9,253965,DB00592,Piperazine
,9712463,dose-rate-Css(trough) ratio,"The mean (and 95% confidence interval) dose-rate-Css(trough) ratio for cyclosporine generated from concentrations measured using EMIT was 94 (82.5-105.5) Lh(-1) for patients administered cyclosporine alone, 66.7 (58.1-75.3) Lh(-1) for patients administered concomitant diltiazem, 47.9 (15.4 -80.4) Lh(-1) for patients administered concomitant itraconazole, 21.7 (14.8-28.5) Lh(-1) for patients administered concomitant ketoconazole, and 14.9 (11.8-18.1) Lh(-1) for patients concomitantly administered diltiazem and ketoconazole.",Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712463/),1/[lh],21.7,253966,DB00592,Piperazine
,9712463,dose-rate-Css(trough) ratio,"The mean (and 95% confidence interval) dose-rate-Css(trough) ratio for cyclosporine generated from concentrations measured using EMIT was 94 (82.5-105.5) Lh(-1) for patients administered cyclosporine alone, 66.7 (58.1-75.3) Lh(-1) for patients administered concomitant diltiazem, 47.9 (15.4 -80.4) Lh(-1) for patients administered concomitant itraconazole, 21.7 (14.8-28.5) Lh(-1) for patients administered concomitant ketoconazole, and 14.9 (11.8-18.1) Lh(-1) for patients concomitantly administered diltiazem and ketoconazole.",Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712463/),1/[lh],14.9,253967,DB00592,Piperazine
,2576360,terminal half-life,"After intravenous administration, the terminal half-life of 65 h was about 4 times longer than in healthy subjects although the total body clearance of 87 ml/min was only 7.4% lower.",Pharmacokinetics of picumast dihydrochloride in patients with liver cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576360/),h,65,254211,DB00592,Piperazine
,2576360,total body clearance,"After intravenous administration, the terminal half-life of 65 h was about 4 times longer than in healthy subjects although the total body clearance of 87 ml/min was only 7.4% lower.",Pharmacokinetics of picumast dihydrochloride in patients with liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576360/),[ml] / [min],87,254212,DB00592,Piperazine
,2576360,steady-state volume of distribution,The 3.6-fold increase in the steady-state volume of distribution (351 l) may be due to a higher uptake by the liver and other tissues and/or to a slower re-diffusion from these tissues into the circulation.,Pharmacokinetics of picumast dihydrochloride in patients with liver cirrhosis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576360/),l,351,254213,DB00592,Piperazine
,2576360,plasma elimination half-life,"After oral administration peak concentrations were reached at 1.4 h; plasma elimination half-life was considerably longer (107 h), however, without being significantly different from i.v. administration.",Pharmacokinetics of picumast dihydrochloride in patients with liver cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576360/),h,107,254214,DB00592,Piperazine
,3667740,detection limits,The detection limits were about 25 ng for each compound at a signal-to-noise ratio of 3.,"High-performance liquid chromatographic determination of ampicillin and its metabolites in rat plasma, bile and urine by post-column degradation with sodium hypochlorite. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3667740/),ng,25,254338,DB00592,Piperazine
,3667740,signal-to-noise ratio,The detection limits were about 25 ng for each compound at a signal-to-noise ratio of 3.,"High-performance liquid chromatographic determination of ampicillin and its metabolites in rat plasma, bile and urine by post-column degradation with sodium hypochlorite. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3667740/),,3,254339,DB00592,Piperazine
,30291543,elimination half-life,"VAR suffers certain limitations: (i) short elimination half-life (4-5 h), (ii) low aqueous solubility (0.11 mg/mL), (iii) susceptibility to extensive first-pass metabolism and drug efflux transporters (P-glycoprotein), and (iv) limited (15%) oral bioavailability.",Lipomers (Lipid-polymer Hybrid Particles) of Vardenafil Hydrochloride: a Promising Dual Platform for Modifying the Drug Release Rate and Enhancing Its Oral Bioavailability. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30291543/),h,4-5,254639,DB00592,Piperazine
,30291543,solubility,"VAR suffers certain limitations: (i) short elimination half-life (4-5 h), (ii) low aqueous solubility (0.11 mg/mL), (iii) susceptibility to extensive first-pass metabolism and drug efflux transporters (P-glycoprotein), and (iv) limited (15%) oral bioavailability.",Lipomers (Lipid-polymer Hybrid Particles) of Vardenafil Hydrochloride: a Promising Dual Platform for Modifying the Drug Release Rate and Enhancing Its Oral Bioavailability. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30291543/),[mg] / [ml],0.11,254640,DB00592,Piperazine
,30291543,oral bioavailability,"VAR suffers certain limitations: (i) short elimination half-life (4-5 h), (ii) low aqueous solubility (0.11 mg/mL), (iii) susceptibility to extensive first-pass metabolism and drug efflux transporters (P-glycoprotein), and (iv) limited (15%) oral bioavailability.",Lipomers (Lipid-polymer Hybrid Particles) of Vardenafil Hydrochloride: a Promising Dual Platform for Modifying the Drug Release Rate and Enhancing Its Oral Bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30291543/),%,15,254641,DB00592,Piperazine
,30291543,EE%,"Statistical analysis of data revealed that L9 system (PGDS, VAR, and Gantrez®; 3:1:1, respectively) had the highest desirability (0.85) with respect to spherical particle size (622.15 nm), PDI (0.11), zeta-potential (-27.90 mV), EE% (62.80%), Q2h (43.45%), and Q8h (77.40%).",Lipomers (Lipid-polymer Hybrid Particles) of Vardenafil Hydrochloride: a Promising Dual Platform for Modifying the Drug Release Rate and Enhancing Its Oral Bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30291543/),%,62.80,254642,DB00592,Piperazine
,30291543,relative bioavailability,"With respect to Levitra® tablets, the significantly higher relative bioavailability (170%), delayed Tmax, and extended MRT(0-∞) clarified the dual ability of L9 system.",Lipomers (Lipid-polymer Hybrid Particles) of Vardenafil Hydrochloride: a Promising Dual Platform for Modifying the Drug Release Rate and Enhancing Its Oral Bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30291543/),%,170,254643,DB00592,Piperazine
,11758635,blood-to-plasma ratio,"Levocetirizine and/or its metabolites were not, or only very poorly, associated with blood cells, as the blood-to-plasma ratio was 0.51 to 0.68.","Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11758635/),,0.51 to 0.68,254748,DB00592,Piperazine
,11758635,apparent volume of distribution (Vz/F),The mean apparent volume of distribution (Vz/F) was 26.9 1 (0.3 l/kg) indicating that the distribution of levocetirizine is restrictive.,"Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11758635/),1,26.9,254749,DB00592,Piperazine
,11758635,protein binding,The protein binding of radiolabelled levocetirizine was 96.1% l h after administration.,"Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11758635/),%·h·l,96.1,254750,DB00592,Piperazine
,11758635,protein binding,"In vitro, at concentrations ranging from 0.2 microg/ml to 1 microg/ml, the protein binding was 94.8% to 95.0%.","Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11758635/),%,94.8,254751,DB00592,Piperazine
,11758635,protein binding,"In vitro, at concentrations ranging from 0.2 microg/ml to 1 microg/ml, the protein binding was 94.8% to 95.0%.","Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11758635/),%,95.0,254752,DB00592,Piperazine
,30370647,inhibition ratios,"The inhibition ratios of isavuconazole, ketoconazole, and voriconazole in rat liver microsome were 97.87%, 96.74% and 78.9%, respectively (p < 0.01), while in human liver microsome, inhibition ratios were 86.97%, 96.46%, and 53.11%, respectively.","Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30370647/),%,97.87,254797,DB00592,Piperazine
,30370647,inhibition ratios,"The inhibition ratios of isavuconazole, ketoconazole, and voriconazole in rat liver microsome were 97.87%, 96.74% and 78.9%, respectively (p < 0.01), while in human liver microsome, inhibition ratios were 86.97%, 96.46%, and 53.11%, respectively.","Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30370647/),%,96.74,254798,DB00592,Piperazine
,30370647,inhibition ratios,"The inhibition ratios of isavuconazole, ketoconazole, and voriconazole in rat liver microsome were 97.87%, 96.74% and 78.9%, respectively (p < 0.01), while in human liver microsome, inhibition ratios were 86.97%, 96.46%, and 53.11%, respectively.","Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30370647/),%,78.9,254799,DB00592,Piperazine
,30370647,inhibition ratios,"The inhibition ratios of isavuconazole, ketoconazole, and voriconazole in rat liver microsome were 97.87%, 96.74% and 78.9%, respectively (p < 0.01), while in human liver microsome, inhibition ratios were 86.97%, 96.46%, and 53.11%, respectively.","Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30370647/),%,86.97,254800,DB00592,Piperazine
,30370647,inhibition ratios,"The inhibition ratios of isavuconazole, ketoconazole, and voriconazole in rat liver microsome were 97.87%, 96.74% and 78.9%, respectively (p < 0.01), while in human liver microsome, inhibition ratios were 86.97%, 96.46%, and 53.11%, respectively.","Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30370647/),%,96.46,254801,DB00592,Piperazine
,30370647,inhibition ratios,"The inhibition ratios of isavuconazole, ketoconazole, and voriconazole in rat liver microsome were 97.87%, 96.74% and 78.9%, respectively (p < 0.01), while in human liver microsome, inhibition ratios were 86.97%, 96.46%, and 53.11%, respectively.","Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30370647/),%,53.11,254802,DB00592,Piperazine
,30370647,IC50,"And the IC50 for inhibition activity of isavuconazole, ketoconazole, and voriconazole in rat microsomes were 7.76 μM, 8.33 μM, and 4.45 μM, respectively.","Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30370647/),μM,7.76,254803,DB00592,Piperazine
,30370647,IC50,"And the IC50 for inhibition activity of isavuconazole, ketoconazole, and voriconazole in rat microsomes were 7.76 μM, 8.33 μM, and 4.45 μM, respectively.","Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30370647/),μM,8.33,254804,DB00592,Piperazine
,30370647,IC50,"And the IC50 for inhibition activity of isavuconazole, ketoconazole, and voriconazole in rat microsomes were 7.76 μM, 8.33 μM, and 4.45 μM, respectively.","Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30370647/),μM,4.45,254805,DB00592,Piperazine
,2872815,plasma half-life,"The plasma half-life of terazosin in patients with normal renal function was 10.0 hours, compared with 8.4 hours in patients with moderate renal insufficiency and 9.8 hours in the group with severe renal insufficiency.",Influence of renal insufficiency on the pharmacokinetics and pharmacodynamics of terazosin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2872815/),h,10.0,254924,DB00592,Piperazine
,2872815,plasma half-life,"The plasma half-life of terazosin in patients with normal renal function was 10.0 hours, compared with 8.4 hours in patients with moderate renal insufficiency and 9.8 hours in the group with severe renal insufficiency.",Influence of renal insufficiency on the pharmacokinetics and pharmacodynamics of terazosin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2872815/),h,8.4,254925,DB00592,Piperazine
,2872815,plasma half-life,"The plasma half-life of terazosin in patients with normal renal function was 10.0 hours, compared with 8.4 hours in patients with moderate renal insufficiency and 9.8 hours in the group with severe renal insufficiency.",Influence of renal insufficiency on the pharmacokinetics and pharmacodynamics of terazosin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2872815/),h,9.8,254926,DB00592,Piperazine
,24060561,Cmax,"The observed mean (SD) Cmax, AUC0-last, and AUC0-∞ values for the reference formulation were 1792 (357) ng/mL, 28,485 (6274) ng · h/mL, and 29,079 (6371) ng · h/mL, respectively.","Single-dose, randomized crossover comparisons of different-strength imatinib mesylate formulations in healthy Korean male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24060561/),[ng] / [ml],1792,255050,DB00592,Piperazine
,24060561,AUC0-last,"The observed mean (SD) Cmax, AUC0-last, and AUC0-∞ values for the reference formulation were 1792 (357) ng/mL, 28,485 (6274) ng · h/mL, and 29,079 (6371) ng · h/mL, respectively.","Single-dose, randomized crossover comparisons of different-strength imatinib mesylate formulations in healthy Korean male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24060561/),[h·ng] / [ml],"28,485",255051,DB00592,Piperazine
,24060561,AUC0-∞,"The observed mean (SD) Cmax, AUC0-last, and AUC0-∞ values for the reference formulation were 1792 (357) ng/mL, 28,485 (6274) ng · h/mL, and 29,079 (6371) ng · h/mL, respectively.","Single-dose, randomized crossover comparisons of different-strength imatinib mesylate formulations in healthy Korean male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24060561/),[h·ng] / [ml],"29,079",255052,DB00592,Piperazine
,32534260,flow rate,"Plasma protein precipitation was performed on 5 µL samples, and separation of the analytes was accomplished on an Accucore aQ column using gradient elution at a flow rate of 0.4 mL/min.","Development and validation of a sensitive UHPLC-MS/MS analytical method for venetoclax in mouse plasma, and its application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32534260/),[ml] / [min],0.4,255061,DB00592,Piperazine
<,34273426,oral bioavailability,"But its clinical use is severely limited by drug delivery issues like high dosing frequency (up to 5 tablets/day), low oral bioavailability (<10%), severe GI side-effects, etc.","Design, optimization and pharmacokinetic evaluation of Piribedil loaded solid lipid nanoparticles dispersed in nasal in situ gelling system for effective management of Parkinson's disease. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34273426/),%,10,255104,DB00592,Piperazine
less,34273426,direct transport percentage (DTP),"Further, PBD-Susp showed limited direct nose to brain uptake with direct transport percentage (DTP) values less than 0, while the optimized PBD-SLN-ISG showed DTP value of 27% indicating efficient direct nose to brain uptake.","Design, optimization and pharmacokinetic evaluation of Piribedil loaded solid lipid nanoparticles dispersed in nasal in situ gelling system for effective management of Parkinson's disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34273426/),,0,255105,DB00592,Piperazine
,27993930,recovery,"After a single oral dose of [14C]venetoclax to healthy volunteers, the recovery of total radioactive dose was 100%, with feces being the major route of elimination of the administered dose, whereas urinary excretion was minimal (<0.1%).",Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27993930/),%,100,255174,DB00592,Piperazine
,16982783,half-life,"The results of both the SAD and the MAD studies indicated that there was a dose dependency in the half-life of itraconazole from the novel formulation, increasing from 44 h (100 mg) to more than 150 h (300 mg) once steady state was achieved.",Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16982783/),h,44,255340,DB00592,Piperazine
more,16982783,half-life,"The results of both the SAD and the MAD studies indicated that there was a dose dependency in the half-life of itraconazole from the novel formulation, increasing from 44 h (100 mg) to more than 150 h (300 mg) once steady state was achieved.",Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16982783/),h,150,255341,DB00592,Piperazine
,9484872,half-life,"It reaches peak plasma levels around 2 h after administration, then declines bi-exponentially, with an extended half-life of around 12 h.",Pharmacokinetics of grepafloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9484872/),h,12,255441,DB00592,Piperazine
,1761079,half-life,The mean half-life was calculated to be about 6.5 h.,Dose-proportionality of eltoprazine. Pharmacokinetics of single oral doses in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761079/),h,6.5,255679,DB00592,Piperazine
,9871430,time of the peak concentration (tmax),"The time of the peak concentration (tmax) of buspirone increased from 0.75 to 3 hours (P < .01), and the elimination half-life (t1/2) was slightly increased (P < .01) by grapefruit juice.",Grapefruit juice substantially increases plasma concentrations of buspirone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871430/),h,0.75,255681,DB00592,Piperazine
,9871430,time of the peak concentration (tmax),"The time of the peak concentration (tmax) of buspirone increased from 0.75 to 3 hours (P < .01), and the elimination half-life (t1/2) was slightly increased (P < .01) by grapefruit juice.",Grapefruit juice substantially increases plasma concentrations of buspirone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871430/),h,3,255682,DB00592,Piperazine
,22546721,tissue/plasma ratios,"The mean tissue/plasma ratios were 2.5 and 3.0 for ethmoid and turbinate, respectively.",Penetration of prulifloxacin into sinus mucosa of patients undergoing paranasal sinus elective endoscopic surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22546721/),,2.5,256154,DB00592,Piperazine
,22546721,tissue/plasma ratios,"The mean tissue/plasma ratios were 2.5 and 3.0 for ethmoid and turbinate, respectively.",Penetration of prulifloxacin into sinus mucosa of patients undergoing paranasal sinus elective endoscopic surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22546721/),,3.0,256155,DB00592,Piperazine
,22546721,Area Under the Curves (AUC,"Data expressed as Area Under the Curves (AUC±SD) showed that ulifloxacin concentrations in the ethmoid were slightly higher (18.68±6.48 μg/g*h) than in turbinate (15.00±2.89 μg/g*h), and definitely higher than in plasma (6.32±1.14 μg/ml*h).",Penetration of prulifloxacin into sinus mucosa of patients undergoing paranasal sinus elective endoscopic surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22546721/),μ,18.68,256156,DB00592,Piperazine
,22546721,Area Under the Curves (AUC,"Data expressed as Area Under the Curves (AUC±SD) showed that ulifloxacin concentrations in the ethmoid were slightly higher (18.68±6.48 μg/g*h) than in turbinate (15.00±2.89 μg/g*h), and definitely higher than in plasma (6.32±1.14 μg/ml*h).",Penetration of prulifloxacin into sinus mucosa of patients undergoing paranasal sinus elective endoscopic surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22546721/),[μg] / [g·h],15.00,256157,DB00592,Piperazine
,22546721,Area Under the Curves (AUC,"Data expressed as Area Under the Curves (AUC±SD) showed that ulifloxacin concentrations in the ethmoid were slightly higher (18.68±6.48 μg/g*h) than in turbinate (15.00±2.89 μg/g*h), and definitely higher than in plasma (6.32±1.14 μg/ml*h).",Penetration of prulifloxacin into sinus mucosa of patients undergoing paranasal sinus elective endoscopic surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22546721/),[μg] / [h·ml],6.32,256158,DB00592,Piperazine
,22546721,AUC ratios,The AUC ratios between tissues and plasma were 3.0 for ethmoides and 2.4 for turbinates.,Penetration of prulifloxacin into sinus mucosa of patients undergoing paranasal sinus elective endoscopic surgery. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22546721/),,3.0,256159,DB00592,Piperazine
,22546721,AUC ratios,The AUC ratios between tissues and plasma were 3.0 for ethmoides and 2.4 for turbinates.,Penetration of prulifloxacin into sinus mucosa of patients undergoing paranasal sinus elective endoscopic surgery. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22546721/),,2.4,256160,DB00592,Piperazine
,22980315,terminal elimination t(½),The terminal elimination t(½) was ∼53 hours.,Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22980315/),h,∼53,256609,DB00592,Piperazine
,26487909,MIC,Ten compounds demonstrated potent MIC in the range of 0.17-0.0072 μM against H37Rv Mycobacterium tuberculosis (MTB) and were further investigated against nonreplicating and resistant (Rif(R) and MDR) strains of MTB.,"Nitrofuranyl Methyl Piperazines as New Anti-TB Agents: Identification, Validation, Medicinal Chemistry, and PK Studies. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26487909/),μM,0.17-0.0072,256909,DB00592,Piperazine
,12638394,Cmax,"When administered after an overnight fast and after a high-fat breakfast, vardenafil geometric mean Cmax was 17.14 and 14.0 micrograms/L, respectively, and AUC was 66.78 and 67.09 micrograms./h/L, respectively; the median tmax was 1 hour under fasting conditions and 2 hours with consumption of high-fat breakfast.","Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12638394/),[μg] / [l],17.14,256963,DB00592,Piperazine
,12638394,Cmax,"When administered after an overnight fast and after a high-fat breakfast, vardenafil geometric mean Cmax was 17.14 and 14.0 micrograms/L, respectively, and AUC was 66.78 and 67.09 micrograms./h/L, respectively; the median tmax was 1 hour under fasting conditions and 2 hours with consumption of high-fat breakfast.","Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12638394/),[μg] / [l],14.0,256964,DB00592,Piperazine
,12638394,AUC,"When administered after an overnight fast and after a high-fat breakfast, vardenafil geometric mean Cmax was 17.14 and 14.0 micrograms/L, respectively, and AUC was 66.78 and 67.09 micrograms./h/L, respectively; the median tmax was 1 hour under fasting conditions and 2 hours with consumption of high-fat breakfast.","Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12638394/),[μg] / [h·l],66.78,256965,DB00592,Piperazine
,12638394,AUC,"When administered after an overnight fast and after a high-fat breakfast, vardenafil geometric mean Cmax was 17.14 and 14.0 micrograms/L, respectively, and AUC was 66.78 and 67.09 micrograms./h/L, respectively; the median tmax was 1 hour under fasting conditions and 2 hours with consumption of high-fat breakfast.","Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12638394/),[μg] / [h·l],67.09,256966,DB00592,Piperazine
,12638394,tmax,"When administered after an overnight fast and after a high-fat breakfast, vardenafil geometric mean Cmax was 17.14 and 14.0 micrograms/L, respectively, and AUC was 66.78 and 67.09 micrograms./h/L, respectively; the median tmax was 1 hour under fasting conditions and 2 hours with consumption of high-fat breakfast.","Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12638394/),h,1,256967,DB00592,Piperazine
,12638394,tmax,"When administered after an overnight fast and after a high-fat breakfast, vardenafil geometric mean Cmax was 17.14 and 14.0 micrograms/L, respectively, and AUC was 66.78 and 67.09 micrograms./h/L, respectively; the median tmax was 1 hour under fasting conditions and 2 hours with consumption of high-fat breakfast.","Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12638394/),h,2,256968,DB00592,Piperazine
,12638394,Cmax,"When administered in the evening on an empty stomach and after a moderate-fat meal, vardenafil geometric mean Cmax was 14.22 and 13.04 micrograms/L, respectively, and AUC was 51.97 and 59.12 micrograms.h/L, respectively.","Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12638394/),[μg] / [l],14.22,256969,DB00592,Piperazine
,12638394,Cmax,"When administered in the evening on an empty stomach and after a moderate-fat meal, vardenafil geometric mean Cmax was 14.22 and 13.04 micrograms/L, respectively, and AUC was 51.97 and 59.12 micrograms.h/L, respectively.","Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12638394/),[μg] / [l],13.04,256970,DB00592,Piperazine
,12638394,AUC,"When administered in the evening on an empty stomach and after a moderate-fat meal, vardenafil geometric mean Cmax was 14.22 and 13.04 micrograms/L, respectively, and AUC was 51.97 and 59.12 micrograms.h/L, respectively.","Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12638394/),[h·μg] / [l],51.97,256971,DB00592,Piperazine
,12638394,AUC,"When administered in the evening on an empty stomach and after a moderate-fat meal, vardenafil geometric mean Cmax was 14.22 and 13.04 micrograms/L, respectively, and AUC was 51.97 and 59.12 micrograms.h/L, respectively.","Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12638394/),[h·μg] / [l],59.12,256972,DB00592,Piperazine
,12638394,tmax,The median tmax was 1 hour after fasting or a moderate-fat meal in the evening.,"Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12638394/),h,1,256973,DB00592,Piperazine
,9661037,bioavailabilities,"The bioavailabilities of the solutions itraconazole and hydroxyitraconazole were 30 to 33% and 35 to 37% greater, respectively, than those of either capsule.",Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661037/),%,30 to 33,257266,DB00592,Piperazine
,9661037,bioavailabilities,"The bioavailabilities of the solutions itraconazole and hydroxyitraconazole were 30 to 33% and 35 to 37% greater, respectively, than those of either capsule.",Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661037/),%,35 to 37,257267,DB00592,Piperazine
,9226621,area under the curve,Values from an elimination graph of the concentrations of area under the curve (377.21 micrograms.hr/ml) and terminal elimination half-life (48.3 hr) were obtained for itraconazole in spiny lizard plasma.,Itraconazole plasma and tissue concentrations in the spiny lizard (Sceloporus sp.) following once-daily dosing. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9226621/),[h·μg] / [ml],377.21,257632,DB00592,Piperazine
,9226621,terminal elimination half-life,Values from an elimination graph of the concentrations of area under the curve (377.21 micrograms.hr/ml) and terminal elimination half-life (48.3 hr) were obtained for itraconazole in spiny lizard plasma.,Itraconazole plasma and tissue concentrations in the spiny lizard (Sceloporus sp.) following once-daily dosing. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9226621/),h,48.3,257633,DB00592,Piperazine
,9226621,Peak itraconazole concentration,Peak itraconazole concentration of 2.48 micrograms/ml was obtained in two half-lives and would be expected to achieve steady state at approximately 3.1 micrograms/ml plasma concentration in 10 days.,Itraconazole plasma and tissue concentrations in the spiny lizard (Sceloporus sp.) following once-daily dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9226621/),[μg] / [ml],2.48,257634,DB00592,Piperazine
,9226621,Peak liver concentration,Peak liver concentration of 4.27 micrograms/ml was attained in 89.95 hr.,Itraconazole plasma and tissue concentrations in the spiny lizard (Sceloporus sp.) following once-daily dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9226621/),[μg] / [ml],4.27,257635,DB00592,Piperazine
,22706921,flow rate,"Chromatographic separation was successfully achieved on an Agilent Zorbax-C(18) column (2.1 × 50 mm, 3.5 µm) with a flow rate of 0.40 mL/min.",Quantification and pharmacokinetics of Taiwanin E methyl ether in rats by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22706921/),[ml] / [min],0.40,257743,DB00592,Piperazine
,22706921,m/z,The multiple reaction monitoring was based on the transitions of m/z = 379.1 → 320.1 for TEME and 386.1 → 122.0 for buspirone (internal standard).,Quantification and pharmacokinetics of Taiwanin E methyl ether in rats by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22706921/),,379.1,257744,DB00592,Piperazine
,22706921,m/z,The multiple reaction monitoring was based on the transitions of m/z = 379.1 → 320.1 for TEME and 386.1 → 122.0 for buspirone (internal standard).,Quantification and pharmacokinetics of Taiwanin E methyl ether in rats by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22706921/),,320.1,257745,DB00592,Piperazine
,22706921,m/z,The multiple reaction monitoring was based on the transitions of m/z = 379.1 → 320.1 for TEME and 386.1 → 122.0 for buspirone (internal standard).,Quantification and pharmacokinetics of Taiwanin E methyl ether in rats by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22706921/),,386.1,257746,DB00592,Piperazine
,22706921,m/z,The multiple reaction monitoring was based on the transitions of m/z = 379.1 → 320.1 for TEME and 386.1 → 122.0 for buspirone (internal standard).,Quantification and pharmacokinetics of Taiwanin E methyl ether in rats by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22706921/),,122.0,257747,DB00592,Piperazine
,22706921,oral absolute bioavailability,"The oral absolute bioavailability of TEME was estimated to be 5.85 ± 1.41% with an elimination half-life value of 2.61 ± 0.55 h, suggesting its poor absorption and/or strong metabolism in vivo.",Quantification and pharmacokinetics of Taiwanin E methyl ether in rats by liquid chromatography-tandem mass spectrometry. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22706921/),%,5.85,257748,DB00592,Piperazine
,22706921,elimination half-life,"The oral absolute bioavailability of TEME was estimated to be 5.85 ± 1.41% with an elimination half-life value of 2.61 ± 0.55 h, suggesting its poor absorption and/or strong metabolism in vivo.",Quantification and pharmacokinetics of Taiwanin E methyl ether in rats by liquid chromatography-tandem mass spectrometry. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22706921/),h,2.61,257749,DB00592,Piperazine
,26149987,relative bioavailability,The relative bioavailability of SUBA-itraconazole compared to that of Sporanox was 173% and was 21% less variable between subjects.,Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26149987/),%,173,257874,DB00592,Piperazine
,26149987,relative bioavailability,The relative bioavailability of SUBA-itraconazole compared to that of Sporanox was 173% and was 21% less variable between subjects.,Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26149987/),%,21,257875,DB00592,Piperazine
,9797792,total area under the plasma methylprednisolone concentration-time curve,Itraconazole increased the total area under the plasma methylprednisolone concentration-time curve 3.9-fold compared with placebo (1968 +/- 470 ng.hr/mL versus 520 +/- 125 ng.hr/mL [mean +/- SD]; P < .001).,Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),[h·ng] / [ml],1968,258033,DB00592,Piperazine
,9797792,total area under the plasma methylprednisolone concentration-time curve,Itraconazole increased the total area under the plasma methylprednisolone concentration-time curve 3.9-fold compared with placebo (1968 +/- 470 ng.hr/mL versus 520 +/- 125 ng.hr/mL [mean +/- SD]; P < .001).,Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),[h·ng] / [ml],520,258034,DB00592,Piperazine
,9797792,peak plasma concentration,"The peak plasma concentration of methylprednisolone was increased 1.9-fold (221 +/- 49 ng/mL versus 118 +/- 25 ng/mL; P < .001), and its elimination half-life was increased 2.4-fold (4.4 +/- 0.7 hours versus 1.9 +/- 0.3 hours; P < .001) by itraconazole.",Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),[ng] / [ml],221,258035,DB00592,Piperazine
,9797792,peak plasma concentration,"The peak plasma concentration of methylprednisolone was increased 1.9-fold (221 +/- 49 ng/mL versus 118 +/- 25 ng/mL; P < .001), and its elimination half-life was increased 2.4-fold (4.4 +/- 0.7 hours versus 1.9 +/- 0.3 hours; P < .001) by itraconazole.",Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),[ng] / [ml],118,258036,DB00592,Piperazine
,9797792,elimination half-life,"The peak plasma concentration of methylprednisolone was increased 1.9-fold (221 +/- 49 ng/mL versus 118 +/- 25 ng/mL; P < .001), and its elimination half-life was increased 2.4-fold (4.4 +/- 0.7 hours versus 1.9 +/- 0.3 hours; P < .001) by itraconazole.",Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),h,4.4,258037,DB00592,Piperazine
,9797792,elimination half-life,"The peak plasma concentration of methylprednisolone was increased 1.9-fold (221 +/- 49 ng/mL versus 118 +/- 25 ng/mL; P < .001), and its elimination half-life was increased 2.4-fold (4.4 +/- 0.7 hours versus 1.9 +/- 0.3 hours; P < .001) by itraconazole.",Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),h,1.9,258038,DB00592,Piperazine
,9797792,plasma cortisol concentration,"The mean plasma cortisol concentration during the itraconazole phase, measured 24 hours after ingestion of methylprednisolone, was only about 13% of that during the placebo phase (18 +/- 23 ng/mL versus 139 +/- 60 ng/mL; P < .001).",Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),[ng] / [ml],18,258039,DB00592,Piperazine
,9797792,plasma cortisol concentration,"The mean plasma cortisol concentration during the itraconazole phase, measured 24 hours after ingestion of methylprednisolone, was only about 13% of that during the placebo phase (18 +/- 23 ng/mL versus 139 +/- 60 ng/mL; P < .001).",Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),[ng] / [ml],139,258040,DB00592,Piperazine
,23523258,Ki,The results indicated that Sch B significantly dose-dependently inhibited rat hepatic microsomal CYP3A activity with Ki value of 16.64 mg/kg and showed the characteristic of a noncompetitive inhibitor.,In vivo effect of Schisandrin B on cytochrome P450 enzyme activity. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523258/),[mg] / [kg],16.64,258262,DB00592,Piperazine
,33405376,MTD,The MTD for both strata was 75 mg/m2 .,A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC-042). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33405376/),[mg] / [m2],75,258447,DB00592,Piperazine
,33405376,Tmax,Palbociclib absorption (mean Tmax between 4.9 and 6.6 h) and elimination (mean half-life between 11.3 and 19.5 h) were assessed.,A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC-042). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33405376/),h,4.9 and 6.6,258448,DB00592,Piperazine
,33405376,half-life,Palbociclib absorption (mean Tmax between 4.9 and 6.6 h) and elimination (mean half-life between 11.3 and 19.5 h) were assessed.,A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC-042). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33405376/),h,11.3 and 19.5,258449,DB00592,Piperazine
,8799876,recovery,The proposed method had a recovery of 98% and the lowest amount of cetirizine that could be detected was 50 ng.,High-performance thin-layer chromatography for the determination of cetirizine in human plasma and its use in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799876/),%,98,258560,DB00592,Piperazine
,28556962,half-life,"Retosiban was rapidly absorbed after oral administration, with an observed half-life of 1.45 h.",Treatment of spontaneous preterm labour with retosiban: a phase II pilot dose-ranging study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28556962/),h,1.45,258652,DB00592,Piperazine
,23539428,Cmax,"The Cmax, Tmax, t1/2, AUC0-8, AUC0-∞, MRT0-8, MRT0-∞, CL/F and V/F of CXC195 after-single dose intraperitoneal injection of 10 mg · kg-1 CXC195 were 12.37±5.35 μg · mL-1, 0.5±0.21 h,4.24±2.43 h, 24.89±8.32 μg · mL-1 · h, 28.57±9.66 μg · mL-1 · h, 2.00±0.53 h, 2.93±0.75 h, 1.4±0.73 L · h-1 and 1.16±0.68 L.",Pharmacokinetics of a new tetramethylpyrazine analogue CXC195 in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23539428/),[μg] / [ml],12.37,258721,DB00592,Piperazine
,23539428,V/F,"The Cmax, Tmax, t1/2, AUC0-8, AUC0-∞, MRT0-8, MRT0-∞, CL/F and V/F of CXC195 after-single dose intraperitoneal injection of 10 mg · kg-1 CXC195 were 12.37±5.35 μg · mL-1, 0.5±0.21 h,4.24±2.43 h, 24.89±8.32 μg · mL-1 · h, 28.57±9.66 μg · mL-1 · h, 2.00±0.53 h, 2.93±0.75 h, 1.4±0.73 L · h-1 and 1.16±0.68 L.",Pharmacokinetics of a new tetramethylpyrazine analogue CXC195 in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23539428/),[l] / [h],1.4,258722,DB00592,Piperazine
,23539428,V/F,"The Cmax, Tmax, t1/2, AUC0-8, AUC0-∞, MRT0-8, MRT0-∞, CL/F and V/F of CXC195 after-single dose intraperitoneal injection of 10 mg · kg-1 CXC195 were 12.37±5.35 μg · mL-1, 0.5±0.21 h,4.24±2.43 h, 24.89±8.32 μg · mL-1 · h, 28.57±9.66 μg · mL-1 · h, 2.00±0.53 h, 2.93±0.75 h, 1.4±0.73 L · h-1 and 1.16±0.68 L.",Pharmacokinetics of a new tetramethylpyrazine analogue CXC195 in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23539428/),l,1.16,258723,DB00592,Piperazine
,23539428,lag time,The procedure of CXC195 in rat was fit to double-compartmental model with lag time of 0.13 h.,Pharmacokinetics of a new tetramethylpyrazine analogue CXC195 in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23539428/),h,0.13,258724,DB00592,Piperazine
,15116057,clearance,"The mean (+/-SD) clearance values were 35.0 +/- 11.8 L/h (95% confidence interval, 24.1-45.9 L/h) for docetaxel alone and 18.2 L/h (95% confidence interval, 9.22-27.1 L/h) in the presence of ketoconazole, respectively.",Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15116057/),[l] / [h],35.0,258728,DB00592,Piperazine
,15116057,clearance,"The mean (+/-SD) clearance values were 35.0 +/- 11.8 L/h (95% confidence interval, 24.1-45.9 L/h) for docetaxel alone and 18.2 L/h (95% confidence interval, 9.22-27.1 L/h) in the presence of ketoconazole, respectively.",Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15116057/),[l] / [h],18.2,258729,DB00592,Piperazine
,30869197,extraction recoveries,"A negligible matrix effect and good recovery were obtained using this assay, with average extraction recoveries of MFD and the internal standard (IS) in the range of 85.5%-124.8% and 84.1%-94.0%, respectively.",LC-MS/MS assay for the determination of a novel anti-fibrotic candidate mefunidone in monkey plasma and its application to a pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30869197/),%,85.5,259264,DB00592,Piperazine
,30869197,extraction recoveries,"A negligible matrix effect and good recovery were obtained using this assay, with average extraction recoveries of MFD and the internal standard (IS) in the range of 85.5%-124.8% and 84.1%-94.0%, respectively.",LC-MS/MS assay for the determination of a novel anti-fibrotic candidate mefunidone in monkey plasma and its application to a pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30869197/),%,124,259265,DB00592,Piperazine
,30869197,extraction recoveries,"A negligible matrix effect and good recovery were obtained using this assay, with average extraction recoveries of MFD and the internal standard (IS) in the range of 85.5%-124.8% and 84.1%-94.0%, respectively.",LC-MS/MS assay for the determination of a novel anti-fibrotic candidate mefunidone in monkey plasma and its application to a pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30869197/),%,84.1,259266,DB00592,Piperazine
,30869197,extraction recoveries,"A negligible matrix effect and good recovery were obtained using this assay, with average extraction recoveries of MFD and the internal standard (IS) in the range of 85.5%-124.8% and 84.1%-94.0%, respectively.",LC-MS/MS assay for the determination of a novel anti-fibrotic candidate mefunidone in monkey plasma and its application to a pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30869197/),%,94,259267,DB00592,Piperazine
,30869197,t1/2,"Moderate elimination of MFD from the body was observed, with t1/2 of 5-7 h, and the elimination rate of MFD was stable during multiple dosing.",LC-MS/MS assay for the determination of a novel anti-fibrotic candidate mefunidone in monkey plasma and its application to a pharmacokinetics study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30869197/),h,5-7,259268,DB00592,Piperazine
,28070720,terminal half-life,"Following single and multiple dosing, absorption rate appeared moderate; peak plasma concentrations generally occurred 3-4 h post-dose, then declined biphasically with terminal half-life ~30 h.","Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28070720/),h,30,259466,DB00592,Piperazine
,21387353,signal-to-noise ratio,"The lower detection limits of BZP and TFMPP at a signal-to-noise ratio of 3 were 0.9 and 4.6 ng/mL, respectively.",Simultaneous determination of N-benzylpiperazine and 1-(3-trifluoromethylphenyl)piperazine in rat plasma by HPLC-fluorescence detection and its application to monitoring of these drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21387353/),[ng] / [ml],3,259513,DB00592,Piperazine
,21387353,signal-to-noise ratio,"The lower detection limits of BZP and TFMPP at a signal-to-noise ratio of 3 were 0.9 and 4.6 ng/mL, respectively.",Simultaneous determination of N-benzylpiperazine and 1-(3-trifluoromethylphenyl)piperazine in rat plasma by HPLC-fluorescence detection and its application to monitoring of these drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21387353/),[ng] / [ml],0.9,259514,DB00592,Piperazine
,21387353,signal-to-noise ratio,"The lower detection limits of BZP and TFMPP at a signal-to-noise ratio of 3 were 0.9 and 4.6 ng/mL, respectively.",Simultaneous determination of N-benzylpiperazine and 1-(3-trifluoromethylphenyl)piperazine in rat plasma by HPLC-fluorescence detection and its application to monitoring of these drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21387353/),[ng] / [ml],4.6,259515,DB00592,Piperazine
,7285488,peak plasma concentration,"DEC appeared to be rapidly absorbed, with a peak plasma concentration of 150 to 250 ng/ml reached in 2 to 3 hr.",Diethylcarbamazine disposition in patients with onchocerciasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7285488/),[ng] / [ml],150 to 250,259853,DB00592,Piperazine
,33210997,tmax,"The tmax of sildenafil and N-desmethyl sildenafil was ~ 0.9 hours and 1 hour, and the T1/2 was 2.4 hours and 3.7 hours, respectively.",A UPLC-MS/MS method for simultaneous quantification of sildenafil and N-desmethyl sildenafil applied in pharmacokinetic and bioequivalence studies in a Chinese population. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210997/),h,0.9,260169,DB00592,Piperazine
,33210997,tmax,"The tmax of sildenafil and N-desmethyl sildenafil was ~ 0.9 hours and 1 hour, and the T1/2 was 2.4 hours and 3.7 hours, respectively.",A UPLC-MS/MS method for simultaneous quantification of sildenafil and N-desmethyl sildenafil applied in pharmacokinetic and bioequivalence studies in a Chinese population. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210997/),h,1,260170,DB00592,Piperazine
,33210997,T1/2,"The tmax of sildenafil and N-desmethyl sildenafil was ~ 0.9 hours and 1 hour, and the T1/2 was 2.4 hours and 3.7 hours, respectively.",A UPLC-MS/MS method for simultaneous quantification of sildenafil and N-desmethyl sildenafil applied in pharmacokinetic and bioequivalence studies in a Chinese population. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210997/),h,2.4,260171,DB00592,Piperazine
,33210997,T1/2,"The tmax of sildenafil and N-desmethyl sildenafil was ~ 0.9 hours and 1 hour, and the T1/2 was 2.4 hours and 3.7 hours, respectively.",A UPLC-MS/MS method for simultaneous quantification of sildenafil and N-desmethyl sildenafil applied in pharmacokinetic and bioequivalence studies in a Chinese population. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210997/),h,3.7,260172,DB00592,Piperazine
,33210997,relative bioavailability,The relative bioavailability of sildenafil and N-desmethyl sildenafil was 99.28 ± 3.30% and 99.20 ± 3.39%.,A UPLC-MS/MS method for simultaneous quantification of sildenafil and N-desmethyl sildenafil applied in pharmacokinetic and bioequivalence studies in a Chinese population. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210997/),%,99.28,260173,DB00592,Piperazine
,33210997,relative bioavailability,The relative bioavailability of sildenafil and N-desmethyl sildenafil was 99.28 ± 3.30% and 99.20 ± 3.39%.,A UPLC-MS/MS method for simultaneous quantification of sildenafil and N-desmethyl sildenafil applied in pharmacokinetic and bioequivalence studies in a Chinese population. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210997/),%,99.20,260174,DB00592,Piperazine
,30303626,terminal elimination half-life (T1/2 ),"Plasma Tmax was achieved rapidly at approximately 0.08 hours, and the terminal elimination half-life (T1/2 ) was approximately 40 hours.","Evaluation of the Safety, Tolerability, and Pharmacokinetics of GSK2269557 (Nemiralisib) Administered Via Dry Powder Inhaler to Healthy Japanese Subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30303626/),h,40,260234,DB00592,Piperazine
,32799335,TERs,"Following the standard dosing regimens, the predicted CDK4/6 TERs were 26/5.2 for abemaciclib, 2.4/0.62 for ribociclib, and 0.36/0.27 for palbociclib.",Physiologically Based Pharmacokinetic Modeling of Central Nervous System Pharmacokinetics of CDK4/6 Inhibitors to Guide Selection of Drug and Dosing Regimen for Brain Cancer Treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32799335/),,26/,260533,DB00592,Piperazine
,32799335,TERs,"Following the standard dosing regimens, the predicted CDK4/6 TERs were 26/5.2 for abemaciclib, 2.4/0.62 for ribociclib, and 0.36/0.27 for palbociclib.",Physiologically Based Pharmacokinetic Modeling of Central Nervous System Pharmacokinetics of CDK4/6 Inhibitors to Guide Selection of Drug and Dosing Regimen for Brain Cancer Treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32799335/),,5.2,260534,DB00592,Piperazine
,32799335,TERs,"Following the standard dosing regimens, the predicted CDK4/6 TERs were 26/5.2 for abemaciclib, 2.4/0.62 for ribociclib, and 0.36/0.27 for palbociclib.",Physiologically Based Pharmacokinetic Modeling of Central Nervous System Pharmacokinetics of CDK4/6 Inhibitors to Guide Selection of Drug and Dosing Regimen for Brain Cancer Treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32799335/),-1,2.4,260535,DB00592,Piperazine
,32799335,TERs,"Following the standard dosing regimens, the predicted CDK4/6 TERs were 26/5.2 for abemaciclib, 2.4/0.62 for ribociclib, and 0.36/0.27 for palbociclib.",Physiologically Based Pharmacokinetic Modeling of Central Nervous System Pharmacokinetics of CDK4/6 Inhibitors to Guide Selection of Drug and Dosing Regimen for Brain Cancer Treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32799335/),-1,0.62,260536,DB00592,Piperazine
,32799335,TERs,"Following the standard dosing regimens, the predicted CDK4/6 TERs were 26/5.2 for abemaciclib, 2.4/0.62 for ribociclib, and 0.36/0.27 for palbociclib.",Physiologically Based Pharmacokinetic Modeling of Central Nervous System Pharmacokinetics of CDK4/6 Inhibitors to Guide Selection of Drug and Dosing Regimen for Brain Cancer Treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32799335/),-1,0.36,260537,DB00592,Piperazine
,32799335,TERs,"Following the standard dosing regimens, the predicted CDK4/6 TERs were 26/5.2 for abemaciclib, 2.4/0.62 for ribociclib, and 0.36/0.27 for palbociclib.",Physiologically Based Pharmacokinetic Modeling of Central Nervous System Pharmacokinetics of CDK4/6 Inhibitors to Guide Selection of Drug and Dosing Regimen for Brain Cancer Treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32799335/),-1,0.27,260538,DB00592,Piperazine
<,32799335,TERs,"Simulations suggested that abemaciclib achieved comparable TERs following twice daily or daily dosing; ribociclib may sufficiently inhibit both CDK4 and CDK6 at the maximum tolerated dose; whereas, palbociclib achieved TERs < 0.5 even at a dose 50% higher than the standard dose.",Physiologically Based Pharmacokinetic Modeling of Central Nervous System Pharmacokinetics of CDK4/6 Inhibitors to Guide Selection of Drug and Dosing Regimen for Brain Cancer Treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32799335/),,0.5,260539,DB00592,Piperazine
,7582385,peak plasma level (Cmax),"The mean +/- SD kinetic parameters were: peak plasma level (Cmax) 607 +/- 231 micrograms.l-1 reached in 1.93 +/- 1.39 h (tmax), elimination half-life (t1/2) 5.55 +/- 0.98 h, area under the plasma concentration time curve (AUC0-infinity) 4,772.1 +/- 1,318.4 micrograms.",Pharmacokinetics of cetirizine in 2- to 6-year-old children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582385/),[μg] / [l],607,261207,DB00592,Piperazine
,7582385,tmax,"The mean +/- SD kinetic parameters were: peak plasma level (Cmax) 607 +/- 231 micrograms.l-1 reached in 1.93 +/- 1.39 h (tmax), elimination half-life (t1/2) 5.55 +/- 0.98 h, area under the plasma concentration time curve (AUC0-infinity) 4,772.1 +/- 1,318.4 micrograms.",Pharmacokinetics of cetirizine in 2- to 6-year-old children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582385/),h,1.93,261208,DB00592,Piperazine
,7582385,elimination half-life (t1/2),"The mean +/- SD kinetic parameters were: peak plasma level (Cmax) 607 +/- 231 micrograms.l-1 reached in 1.93 +/- 1.39 h (tmax), elimination half-life (t1/2) 5.55 +/- 0.98 h, area under the plasma concentration time curve (AUC0-infinity) 4,772.1 +/- 1,318.4 micrograms.",Pharmacokinetics of cetirizine in 2- to 6-year-old children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582385/),h,5.55,261209,DB00592,Piperazine
,7582385,area under the plasma concentration time curve (AUC0-infinity),"The mean +/- SD kinetic parameters were: peak plasma level (Cmax) 607 +/- 231 micrograms.l-1 reached in 1.93 +/- 1.39 h (tmax), elimination half-life (t1/2) 5.55 +/- 0.98 h, area under the plasma concentration time curve (AUC0-infinity) 4,772.1 +/- 1,318.4 micrograms.",Pharmacokinetics of cetirizine in 2- to 6-year-old children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582385/),μg,"4,772.1",261210,DB00592,Piperazine
,7582385,mean residence time (MRT),"l-1.h, mean residence time (MRT) 8.13 +/- 1.31 h, apparent plasma clearance (Cl/f) 1.27 +/- 0.80 ml.min-1.kg-1, apparent volume of distribution (Vz/f) 0.60 +/- 0.38 l.kg-1.",Pharmacokinetics of cetirizine in 2- to 6-year-old children. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582385/),h,8.13,261211,DB00592,Piperazine
,7582385,apparent plasma clearance (Cl/f),"l-1.h, mean residence time (MRT) 8.13 +/- 1.31 h, apparent plasma clearance (Cl/f) 1.27 +/- 0.80 ml.min-1.kg-1, apparent volume of distribution (Vz/f) 0.60 +/- 0.38 l.kg-1.",Pharmacokinetics of cetirizine in 2- to 6-year-old children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582385/),[ml] / [kg·min],1.27,261212,DB00592,Piperazine
,7582385,apparent volume of distribution (Vz/f),"l-1.h, mean residence time (MRT) 8.13 +/- 1.31 h, apparent plasma clearance (Cl/f) 1.27 +/- 0.80 ml.min-1.kg-1, apparent volume of distribution (Vz/f) 0.60 +/- 0.38 l.kg-1.",Pharmacokinetics of cetirizine in 2- to 6-year-old children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582385/),[l] / [kg],0.60,261213,DB00592,Piperazine
,7582385,Urinary recovery,Urinary recovery was 38.4 +/- 9.9% (n = 4) of the dose.,Pharmacokinetics of cetirizine in 2- to 6-year-old children. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582385/),%,38.4,261214,DB00592,Piperazine
,7582385,Renal clearance,Renal clearance was 0.42 +/- 0.10 ml.min-1.kg-1 (n = 6).,Pharmacokinetics of cetirizine in 2- to 6-year-old children. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582385/),[ml] / [kg·min],0.42,261215,DB00592,Piperazine
,21547677,T(max),"Furthermore, the plasma concentration at 0.25 h in sildenafil lactate was similar to the C(max) value at T(max) (0.5 h) in sildenafil citrate.",Comparison of the solubility and pharmacokinetics of sildenafil salts. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21547677/),h,0.5,261292,DB00592,Piperazine
,23315029,maximal extent,"The mean maximal extent of PARP inhibition in PBMCs and tumour tissue was 50.6 % and 70.0 %, respectively, and was similar to inhibitory levels reported previously.",Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23315029/),%,50.6,261484,DB00592,Piperazine
,23315029,maximal extent,"The mean maximal extent of PARP inhibition in PBMCs and tumour tissue was 50.6 % and 70.0 %, respectively, and was similar to inhibitory levels reported previously.",Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23315029/),%,70.0,261485,DB00592,Piperazine
,11564134,apparent volume of distribution,"When comparing the pharmacokinetic characteristics of levocetirizine and the distomer, the apparent volume of distribution of the eutomer is significantly smaller than that of the distomer (0.41 and 0.60 L/kg, respectively).","Absorption and disposition of levocetirizine, the eutomer of cetirizine, administered alone or as cetirizine to healthy volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11564134/),[l] / [kg],0.41,261882,DB00592,Piperazine
,11564134,apparent volume of distribution,"When comparing the pharmacokinetic characteristics of levocetirizine and the distomer, the apparent volume of distribution of the eutomer is significantly smaller than that of the distomer (0.41 and 0.60 L/kg, respectively).","Absorption and disposition of levocetirizine, the eutomer of cetirizine, administered alone or as cetirizine to healthy volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11564134/),[l] / [kg],0.60,261883,DB00592,Piperazine
,11564134,non-renal clearance,"Moreover the non-renal clearance of levocetirizine is also significantly lower than that of the distomer (9.70 and 28.70 mL/min, respectively), which constitutes an additional positive aspect particularly as far as metabolism-based drug interactions are concerned.","Absorption and disposition of levocetirizine, the eutomer of cetirizine, administered alone or as cetirizine to healthy volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11564134/),[ml] / [min],9.70,261884,DB00592,Piperazine
,11564134,non-renal clearance,"Moreover the non-renal clearance of levocetirizine is also significantly lower than that of the distomer (9.70 and 28.70 mL/min, respectively), which constitutes an additional positive aspect particularly as far as metabolism-based drug interactions are concerned.","Absorption and disposition of levocetirizine, the eutomer of cetirizine, administered alone or as cetirizine to healthy volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11564134/),[ml] / [min],28.70,261885,DB00592,Piperazine
,8039534,bioavailability,"The bioavailability (90% confidence intervals) of itraconazole relative to that after the full meal, was 54% (41-77%) on an empty stomach and 86% (65-102%) after a light meal.","Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8039534/),%,54,262509,DB00592,Piperazine
,8039534,bioavailability,"The bioavailability (90% confidence intervals) of itraconazole relative to that after the full meal, was 54% (41-77%) on an empty stomach and 86% (65-102%) after a light meal.","Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8039534/),%,86,262510,DB00592,Piperazine
,8039534,bioavailability,"In contrast, the bioavailability (90% CI) of fluconazole relative to the full meal was 110% pre-prandially (100-115%) and 102% after the light meal (88-103%), and the criteria for bioequivalence were attained.","Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8039534/),%,110,262511,DB00592,Piperazine
,8039534,bioavailability,"In contrast, the bioavailability (90% CI) of fluconazole relative to the full meal was 110% pre-prandially (100-115%) and 102% after the light meal (88-103%), and the criteria for bioequivalence were attained.","Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8039534/),%,102,262512,DB00592,Piperazine
,24050112,Ki,"Analogue 19 [2-(4-{[2-(2-ethoxyphenoxy)ethyl]amino}butyl)tetrahydro-1H-pyrrolo[1,2-c]imidazole-1,3(2H)-dione] has been characterized as a high-affinity and potent 5-HT1AR agonist (Ki = 2.3 nM; EC50 = 19 nM).",New serotonin 5-HT1A receptor agonists endowed with antinociceptive activity in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24050112/),nM,2.3,262609,DB00592,Piperazine
,24050112,EC50,"Analogue 19 [2-(4-{[2-(2-ethoxyphenoxy)ethyl]amino}butyl)tetrahydro-1H-pyrrolo[1,2-c]imidazole-1,3(2H)-dione] has been characterized as a high-affinity and potent 5-HT1AR agonist (Ki = 2.3 nM; EC50 = 19 nM).",New serotonin 5-HT1A receptor agonists endowed with antinociceptive activity in vivo. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24050112/),nM,19,262610,DB00592,Piperazine
,24050112,t1/2,"Pharmacokinetic studies indicated that compound 19 displays a good metabolic stability in human liver microsomes (t1/2 ∼ 3 h and CLint = 3.5 mL/min/kg, at 5 μM), and a low level of protein binding (25%, at 5 μM).",New serotonin 5-HT1A receptor agonists endowed with antinociceptive activity in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24050112/),h,3,262611,DB00592,Piperazine
,24050112,CLint,"Pharmacokinetic studies indicated that compound 19 displays a good metabolic stability in human liver microsomes (t1/2 ∼ 3 h and CLint = 3.5 mL/min/kg, at 5 μM), and a low level of protein binding (25%, at 5 μM).",New serotonin 5-HT1A receptor agonists endowed with antinociceptive activity in vivo. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24050112/),[ml] / [kg·min],3.5,262612,DB00592,Piperazine
,24050112,protein binding,"Pharmacokinetic studies indicated that compound 19 displays a good metabolic stability in human liver microsomes (t1/2 ∼ 3 h and CLint = 3.5 mL/min/kg, at 5 μM), and a low level of protein binding (25%, at 5 μM).",New serotonin 5-HT1A receptor agonists endowed with antinociceptive activity in vivo. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24050112/),%,25,262613,DB00592,Piperazine
,8138912,half-life,"ICRF-187 is lost from the reaction mixture with a half-life of 9.3 h, whereas the final hydrolysis product ADR-925 is produced with a half-life of 23.0 h.","Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8138912/),h,9.3,262694,DB00592,Piperazine
,8138912,half-life,"ICRF-187 is lost from the reaction mixture with a half-life of 9.3 h, whereas the final hydrolysis product ADR-925 is produced with a half-life of 23.0 h.","Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8138912/),h,23.0,262695,DB00592,Piperazine
,7198452,maximum,The results obtained revealed maximum values ranging between 1.8 and 7.2 micrograms/ml with a biological half-life of 5.7--16 h.,[Studies on the pharmacokinetics of pipemidic acid in renal insufficiency (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7198452/),[μg] / [ml],1.8 and 7.2,262723,DB00592,Piperazine
,7198452,biological half-life,The results obtained revealed maximum values ranging between 1.8 and 7.2 micrograms/ml with a biological half-life of 5.7--16 h.,[Studies on the pharmacokinetics of pipemidic acid in renal insufficiency (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7198452/),h,5.7,262724,DB00592,Piperazine
,7198452,maximum concentrations,Under maintenance therapy maximum concentrations of microbiologically active substance in urine were found to range between 177 and 580 micrograms/ml.,[Studies on the pharmacokinetics of pipemidic acid in renal insufficiency (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7198452/),[μg] / [ml],177 and 580,262725,DB00592,Piperazine
,15370957,apparent K(m),"2. Midazolam was mainly metabolized by CYP3A in DEX-treated female rat liver microsomes from an immuno-inhibition study, and the apparent K(m) was 1.8 microM, similar to that in human microsomes.",Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15370957/),μM,1.8,262842,DB00592,Piperazine
,15370957,apparent K(i),"3. Ketoconazole and erythromycin, typical CYP3A inhibitors, demonstrated extensive inhibition of midazolam metabolism in DEX-treated female rat liver microsomes, and the apparent K(i) values were 0.088 and 91.2 microM, respectively.",Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15370957/),μM,0.088,262843,DB00592,Piperazine
,15370957,apparent K(i),"3. Ketoconazole and erythromycin, typical CYP3A inhibitors, demonstrated extensive inhibition of midazolam metabolism in DEX-treated female rat liver microsomes, and the apparent K(i) values were 0.088 and 91.2 microM, respectively.",Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15370957/),μM,91.2,262844,DB00592,Piperazine
,22872575,area under the concentration curve (AUC),"The target sirolimus area under the concentration curve (AUC) of 3,810 ng-h/mL was achieved at sirolimus doses of 90, 16, and 25 mg in the sirolimus alone, sirolimus plus ketoconazole, and sirolimus plus grapefruit juice studies, respectively.",Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22872575/),[ng-h] / [ml],"3,810",262847,DB00592,Piperazine
,10583027,apparent oral clearance,"A decrease (P<0.01) in apparent oral clearance of tolterodine, from 10- 12 l h-1 to 4.3-4.7 l h-1, was obtained during concomitant administration of ketoconazole, yielding at least a two-fold increase in the area under the serum concentration-time curve after single as well as after multiple doses following single dose administration of tolterodine.",Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583027/),[l] / [h],10- 12,263027,DB00592,Piperazine
,10583027,apparent oral clearance,"A decrease (P<0.01) in apparent oral clearance of tolterodine, from 10- 12 l h-1 to 4.3-4.7 l h-1, was obtained during concomitant administration of ketoconazole, yielding at least a two-fold increase in the area under the serum concentration-time curve after single as well as after multiple doses following single dose administration of tolterodine.",Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583027/),[l] / [h],4.3-4.7,263028,DB00592,Piperazine
,10583027,terminal half-life,The mean (+/-s.d.) terminal half-life increased by 50% from 9.7+/-2.7 h to 15+/-5.4 h in the presence of ketoconazole.,Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583027/),h,9.7,263029,DB00592,Piperazine
,10583027,terminal half-life,The mean (+/-s.d.) terminal half-life increased by 50% from 9.7+/-2.7 h to 15+/-5.4 h in the presence of ketoconazole.,Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583027/),h,15,263030,DB00592,Piperazine
,6248080,Binding,Binding to rat plasma protein is of about 30%.,Disposition of pipecurium bromide in rats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6248080/),%,30,263038,DB00592,Piperazine
,6248080,excreted amount,"The compound seems to be eliminated with urine, the excreted amount being 37.55 +/- 11.91% and 45.44 +/- 17.29% during 24 and 48 h, respectively.",Disposition of pipecurium bromide in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6248080/),%,37.55,263039,DB00592,Piperazine
,6248080,excreted amount,"The compound seems to be eliminated with urine, the excreted amount being 37.55 +/- 11.91% and 45.44 +/- 17.29% during 24 and 48 h, respectively.",Disposition of pipecurium bromide in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6248080/),%,45.44,263040,DB00592,Piperazine
,21981714,IC(50)s,"This compound, is potent across PI3K class I isoforms with IC(50)s of 5, 27, 7, and 14 nM for PI3Kα, β, δ, and γ, respectively, inhibits mTOR with a K(i) of 17 nM yet is highly selective versus a large panel of kinases including others in the PIKK family.","Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21981714/),nM,5,263151,DB00592,Piperazine
,21981714,IC(50)s,"This compound, is potent across PI3K class I isoforms with IC(50)s of 5, 27, 7, and 14 nM for PI3Kα, β, δ, and γ, respectively, inhibits mTOR with a K(i) of 17 nM yet is highly selective versus a large panel of kinases including others in the PIKK family.","Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21981714/),nM,27,263152,DB00592,Piperazine
,21981714,IC(50)s,"This compound, is potent across PI3K class I isoforms with IC(50)s of 5, 27, 7, and 14 nM for PI3Kα, β, δ, and γ, respectively, inhibits mTOR with a K(i) of 17 nM yet is highly selective versus a large panel of kinases including others in the PIKK family.","Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21981714/),nM,7,263153,DB00592,Piperazine
,21981714,IC(50)s,"This compound, is potent across PI3K class I isoforms with IC(50)s of 5, 27, 7, and 14 nM for PI3Kα, β, δ, and γ, respectively, inhibits mTOR with a K(i) of 17 nM yet is highly selective versus a large panel of kinases including others in the PIKK family.","Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21981714/),nM,14,263154,DB00592,Piperazine
,21981714,K(i),"This compound, is potent across PI3K class I isoforms with IC(50)s of 5, 27, 7, and 14 nM for PI3Kα, β, δ, and γ, respectively, inhibits mTOR with a K(i) of 17 nM yet is highly selective versus a large panel of kinases including others in the PIKK family.","Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21981714/),nM,17,263155,DB00592,Piperazine
,34011155,IC50,"As the privileged (S)-isomer compared to its (R)-isomer 3a-P2, 3a-P1 exhibited potent antiproliferative activities against K562 and Ku812 CML cells and BCR-ABL and BCR-ABLT315I BaF3 cells, with IC50 values of 0.4, 0.1, 2.1, and 4.7 nM, respectively.","Discovery of a Candidate Containing an (S)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34011155/),nM,0.4,263570,DB00592,Piperazine
,34011155,IC50,"As the privileged (S)-isomer compared to its (R)-isomer 3a-P2, 3a-P1 exhibited potent antiproliferative activities against K562 and Ku812 CML cells and BCR-ABL and BCR-ABLT315I BaF3 cells, with IC50 values of 0.4, 0.1, 2.1, and 4.7 nM, respectively.","Discovery of a Candidate Containing an (S)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34011155/),nM,0.1,263571,DB00592,Piperazine
,34011155,IC50,"As the privileged (S)-isomer compared to its (R)-isomer 3a-P2, 3a-P1 exhibited potent antiproliferative activities against K562 and Ku812 CML cells and BCR-ABL and BCR-ABLT315I BaF3 cells, with IC50 values of 0.4, 0.1, 2.1, and 4.7 nM, respectively.","Discovery of a Candidate Containing an (S)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34011155/),nM,2.1,263572,DB00592,Piperazine
,34011155,IC50,"As the privileged (S)-isomer compared to its (R)-isomer 3a-P2, 3a-P1 exhibited potent antiproliferative activities against K562 and Ku812 CML cells and BCR-ABL and BCR-ABLT315I BaF3 cells, with IC50 values of 0.4, 0.1, 2.1, and 4.7 nM, respectively.","Discovery of a Candidate Containing an (S)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34011155/),nM,4.7,263573,DB00592,Piperazine
,34011155,oral bioavailability,"It also showed favorable mice pharmacokinetic properties with a good oral bioavailability (32%), a reasonable half-life (4.61 h), and a high exposure (1386 h·ng/mL).","Discovery of a Candidate Containing an (S)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34011155/),%,32,263574,DB00592,Piperazine
,34011155,half-life,"It also showed favorable mice pharmacokinetic properties with a good oral bioavailability (32%), a reasonable half-life (4.61 h), and a high exposure (1386 h·ng/mL).","Discovery of a Candidate Containing an (S)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34011155/),h,4.61,263575,DB00592,Piperazine
,34011155,exposure,"It also showed favorable mice pharmacokinetic properties with a good oral bioavailability (32%), a reasonable half-life (4.61 h), and a high exposure (1386 h·ng/mL).","Discovery of a Candidate Containing an (S)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34011155/),[h·ng] / [ml],1386,263576,DB00592,Piperazine
,20386909,MTD,The MTD was identified as 64 mg/m(2)/h.,"Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20386909/),[mg] / [h·m(2)],64,264048,DB00592,Piperazine
,20386909,terminal half-life,Pharmacokinetic analyses revealed that CIV infusion MK-0457 had an estimated mean terminal half-life of approximately 6.6-10.2 h and that end-of-infusion concentrations and mean AUCs were approximately dose proportional.,"Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20386909/),h,6.6-10.2,264049,DB00592,Piperazine
,20386909,oral bioavailability,The estimated mean oral bioavailability of MK-0457 was 7.9%.,"Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20386909/),%,7.9,264050,DB00592,Piperazine
,7268191,volume of distribution,"Analysis of data from dogs that received a dual infusion of bucainide indicated that bucainide has an extensive volume of distribution, with an average value of approximately 26 l/kg.",The pharmacodynamics of bucainide (RHC G233): pharmacokinetic parameters and relationship between plasma levels and the effect on the electrocardiogram in the dog. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7268191/),[l] / [kg],26,264100,DB00592,Piperazine
,7268191,terminal half-life,An average terminal half-life of 89 minutes was observed.,The pharmacodynamics of bucainide (RHC G233): pharmacokinetic parameters and relationship between plasma levels and the effect on the electrocardiogram in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7268191/),min,89,264101,DB00592,Piperazine
,32488885,ΔΔQTcF,"ΔΔQTcF values of 4.5, 12.3, and 19.8 ms for the 20-, 60-, and 140-mg doses were observed at the corresponding trazodone peak plasma concentrations.",Effect of 3 Single Doses of Trazodone on QTc Interval in Healthy Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32488885/),ms,4.5,264164,DB00592,Piperazine
,32488885,ΔΔQTcF,"ΔΔQTcF values of 4.5, 12.3, and 19.8 ms for the 20-, 60-, and 140-mg doses were observed at the corresponding trazodone peak plasma concentrations.",Effect of 3 Single Doses of Trazodone on QTc Interval in Healthy Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32488885/),ms,12.3,264165,DB00592,Piperazine
,32488885,ΔΔQTcF,"ΔΔQTcF values of 4.5, 12.3, and 19.8 ms for the 20-, 60-, and 140-mg doses were observed at the corresponding trazodone peak plasma concentrations.",Effect of 3 Single Doses of Trazodone on QTc Interval in Healthy Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32488885/),ms,19.8,264166,DB00592,Piperazine
,31119275,apparent clearance (CL/F),"Typical dolutegravir apparent clearance (CL/F) was 0.93 L/h with 32% between-subject variability, the apparent volume of distribution was 20.2 L and the absorption rate constant was fixed to 2.24 h-1.",Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31119275/),[l] / [h],0.93,264437,DB00592,Piperazine
,31119275,apparent volume of distribution,"Typical dolutegravir apparent clearance (CL/F) was 0.93 L/h with 32% between-subject variability, the apparent volume of distribution was 20.2 L and the absorption rate constant was fixed to 2.24 h-1.",Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31119275/),l,20.2,264438,DB00592,Piperazine
,31119275,absorption rate constant,"Typical dolutegravir apparent clearance (CL/F) was 0.93 L/h with 32% between-subject variability, the apparent volume of distribution was 20.2 L and the absorption rate constant was fixed to 2.24 h-1.",Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31119275/),1/[h],2.24,264439,DB00592,Piperazine
,15760103,area under the curve [AUC],Plasma cetirizine concentrations from MLV (area under the curve [AUC] of 221.2 +/- 42.3 ng x hr/mL) were lower than from GB (AUC of 248.3 +/- 34.6 ng.hr/mL).,Cetirizine from topical phosphatidylcholine-hydrogenated liposomes: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15760103/),[h·ng] / [ml],221.2,264517,DB00592,Piperazine
,15760103,AUC,Plasma cetirizine concentrations from MLV (area under the curve [AUC] of 221.2 +/- 42.3 ng x hr/mL) were lower than from GB (AUC of 248.3 +/- 34.6 ng.hr/mL).,Cetirizine from topical phosphatidylcholine-hydrogenated liposomes: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15760103/),[h·ng] / [ml],248.3,264518,DB00592,Piperazine
,26048134,time to maximal plasma concentration [t max],The presence of food slowed the rate of absorption (time to maximal plasma concentration [t max] was delayed by ~2 h).,Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26048134/),h,2,264528,DB00592,Piperazine
,25278451,MTD,The MTD was determined as 400 mg once daily.,"A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25278451/),mg,400,264610,DB00592,Piperazine
,23584886,AUC ratio,"For midazolam, model 2 predicted a maximal midazolam AUC ratio of 8 and a hepatic fraction metabolized by CYP3A (f(m)) of 0.97, whereas model 1 predicted 17 and 0.90, respectively, which are more consistent with observed data.",Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23584886/),,8,264678,DB00592,Piperazine
,23584886,f(m)),"For midazolam, model 2 predicted a maximal midazolam AUC ratio of 8 and a hepatic fraction metabolized by CYP3A (f(m)) of 0.97, whereas model 1 predicted 17 and 0.90, respectively, which are more consistent with observed data.",Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23584886/),,0.97,264679,DB00592,Piperazine
,23584886,f(m)),"For midazolam, model 2 predicted a maximal midazolam AUC ratio of 8 and a hepatic fraction metabolized by CYP3A (f(m)) of 0.97, whereas model 1 predicted 17 and 0.90, respectively, which are more consistent with observed data.",Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23584886/),,17,264680,DB00592,Piperazine
,23584886,f(m)),"For midazolam, model 2 predicted a maximal midazolam AUC ratio of 8 and a hepatic fraction metabolized by CYP3A (f(m)) of 0.97, whereas model 1 predicted 17 and 0.90, respectively, which are more consistent with observed data.",Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23584886/),,0.90,264681,DB00592,Piperazine
,17495280,tmax,"PRX-00023 was absorbed relatively rapidly, with a tmax of 0.5 to 2 hours, and eliminated with a half-life of approximately 12 hours.","Tolerability, pharmacokinetics, and neuroendocrine effects of PRX-00023, a novel 5-HT1A agonist, in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17495280/),h,0.5 to 2,264752,DB00592,Piperazine
,17495280,half-life,"PRX-00023 was absorbed relatively rapidly, with a tmax of 0.5 to 2 hours, and eliminated with a half-life of approximately 12 hours.","Tolerability, pharmacokinetics, and neuroendocrine effects of PRX-00023, a novel 5-HT1A agonist, in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17495280/),h,12,264753,DB00592,Piperazine
,14658008,AUC,"We present here pharmacokinetic data obtained with a newly designed HPLC approach in 97 patients with chronic myeloid leukemia or acute lymphatic leukemia (ALL) under treatment with imatinib that allowed us to calculate the AUC (39.5 microg.h/ml for an oral dose of 400 mg daily), the t(1/2) (18.2 h) and the peak concentration (1.92 micro/ml for an oral dose of 400 mg daily) of imatinib in plasma.",Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14658008/),[h·μg] / [ml],39.5,264939,DB00592,Piperazine
,14658008,t(1/2),"We present here pharmacokinetic data obtained with a newly designed HPLC approach in 97 patients with chronic myeloid leukemia or acute lymphatic leukemia (ALL) under treatment with imatinib that allowed us to calculate the AUC (39.5 microg.h/ml for an oral dose of 400 mg daily), the t(1/2) (18.2 h) and the peak concentration (1.92 micro/ml for an oral dose of 400 mg daily) of imatinib in plasma.",Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14658008/),h,18.2,264940,DB00592,Piperazine
,14658008,peak concentration,"We present here pharmacokinetic data obtained with a newly designed HPLC approach in 97 patients with chronic myeloid leukemia or acute lymphatic leukemia (ALL) under treatment with imatinib that allowed us to calculate the AUC (39.5 microg.h/ml for an oral dose of 400 mg daily), the t(1/2) (18.2 h) and the peak concentration (1.92 micro/ml for an oral dose of 400 mg daily) of imatinib in plasma.",Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14658008/),[μ] / [ml],1.92,264941,DB00592,Piperazine
,15831774,maximum concentration,"During ketoconazole coadministration, everolimus maximum concentration increased 3.9-fold (90% confidence interval, 3.4-4.6) from 15 +/- 4 ng/mL to 59 +/- 13 ng/mL.",Blood concentrations of everolimus are markedly increased by ketoconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831774/),[ng] / [ml],15,265254,DB00592,Piperazine
,15831774,maximum concentration,"During ketoconazole coadministration, everolimus maximum concentration increased 3.9-fold (90% confidence interval, 3.4-4.6) from 15 +/- 4 ng/mL to 59 +/- 13 ng/mL.",Blood concentrations of everolimus are markedly increased by ketoconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831774/),[ng] / [ml],59,265255,DB00592,Piperazine
,15831774,area under the curve,"Everolimus area under the curve increased 15.0-fold (90% confidence interval, 13.6-16.6) from 90 +/- 23 ng*h/mL to 1324 +/- 232 ng*h/mL.",Blood concentrations of everolimus are markedly increased by ketoconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831774/),[h·ng] / [ml],90,265256,DB00592,Piperazine
,15831774,area under the curve,"Everolimus area under the curve increased 15.0-fold (90% confidence interval, 13.6-16.6) from 90 +/- 23 ng*h/mL to 1324 +/- 232 ng*h/mL.",Blood concentrations of everolimus are markedly increased by ketoconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831774/),[h·ng] / [ml],1324,265257,DB00592,Piperazine
,15831774,half-life,Everolimus half-life was prolonged by 1.9-fold from 30 +/- 4 hours to 56 +/- 5 hours.,Blood concentrations of everolimus are markedly increased by ketoconazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831774/),h,30,265258,DB00592,Piperazine
,15831774,half-life,Everolimus half-life was prolonged by 1.9-fold from 30 +/- 4 hours to 56 +/- 5 hours.,Blood concentrations of everolimus are markedly increased by ketoconazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831774/),h,56,265259,DB00592,Piperazine
,17076696,bleeding time,"On day 10 at 4 h postdose, bleeding time was prolonged with prasugrel 10 mg (prasugrel 10 mg, 706 +/- 252 s vs. placebo, 221 +/- 38 s, P = 0.05) but not with clopidogrel (283 +/- 56 s, P = 0.98).","A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17076696/),s,706,265349,DB00592,Piperazine
,17076696,bleeding time,"On day 10 at 4 h postdose, bleeding time was prolonged with prasugrel 10 mg (prasugrel 10 mg, 706 +/- 252 s vs. placebo, 221 +/- 38 s, P = 0.05) but not with clopidogrel (283 +/- 56 s, P = 0.98).","A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17076696/),s,221,265350,DB00592,Piperazine
,17076696,bleeding time,"On day 10 at 4 h postdose, bleeding time was prolonged with prasugrel 10 mg (prasugrel 10 mg, 706 +/- 252 s vs. placebo, 221 +/- 38 s, P = 0.05) but not with clopidogrel (283 +/- 56 s, P = 0.98).","A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17076696/),s,283,265351,DB00592,Piperazine
,14756383,relative bioavailability,"No interaction with itraconazole was observed for moxifloxacin (relative bioavailability: 111.6% (90% CI 106.5 to 117.0%), C(max) ratio: 103.7% (84.8-126.9%) and its sulfometabolite (Ml) (AUC ratio: 107.7% (95.6, 121.4%), C(max) ratio: 105.8% (89.9-124.5%)).",Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200 mg oral itraconazole given once a day in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756383/),%,111.6,265643,DB00592,Piperazine
,14756383,C(max) ratio,"No interaction with itraconazole was observed for moxifloxacin (relative bioavailability: 111.6% (90% CI 106.5 to 117.0%), C(max) ratio: 103.7% (84.8-126.9%) and its sulfometabolite (Ml) (AUC ratio: 107.7% (95.6, 121.4%), C(max) ratio: 105.8% (89.9-124.5%)).",Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200 mg oral itraconazole given once a day in healthy subjects. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756383/),%,103.7,265644,DB00592,Piperazine
,14756383,AUC ratio,"No interaction with itraconazole was observed for moxifloxacin (relative bioavailability: 111.6% (90% CI 106.5 to 117.0%), C(max) ratio: 103.7% (84.8-126.9%) and its sulfometabolite (Ml) (AUC ratio: 107.7% (95.6, 121.4%), C(max) ratio: 105.8% (89.9-124.5%)).",Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200 mg oral itraconazole given once a day in healthy subjects. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756383/),%,107.7,265645,DB00592,Piperazine
,14756383,C(max) ratio,"No interaction with itraconazole was observed for moxifloxacin (relative bioavailability: 111.6% (90% CI 106.5 to 117.0%), C(max) ratio: 103.7% (84.8-126.9%) and its sulfometabolite (Ml) (AUC ratio: 107.7% (95.6, 121.4%), C(max) ratio: 105.8% (89.9-124.5%)).",Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200 mg oral itraconazole given once a day in healthy subjects. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756383/),%,105.8,265646,DB00592,Piperazine
,30940497,dose recovery percent,"The aerodynamic properties included fine particle fraction ranging between 24 and 30%, dose recovery percent of 68-8 5%, and average mass median aerodynamic diameter of 4.6-4.8 μm.",Design and evaluation of novel inhalable sildenafil citrate spray-dried microparticles for pulmonary arterial hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30940497/),%,68-8 5,265754,DB00592,Piperazine
,30940497,mass median aerodynamic diameter,"The aerodynamic properties included fine particle fraction ranging between 24 and 30%, dose recovery percent of 68-8 5%, and average mass median aerodynamic diameter of 4.6-4.8 μm.",Design and evaluation of novel inhalable sildenafil citrate spray-dried microparticles for pulmonary arterial hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30940497/),μm,4.6-4.8,265755,DB00592,Piperazine
,17467935,Tmax,"A second study in which CIN was again administered in OG, and plasma samples taken for 120 h, revealed a Tmax for CIN in rats of 36 h and a relative oral bioavailability of 344% when compared to the GMO formulation (117%) and the aqueous suspension formulation (assigned a nominal bioavailability of 100%).",A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17467935/),h,36,265937,DB00592,Piperazine
,17467935,relative oral bioavailability,"A second study in which CIN was again administered in OG, and plasma samples taken for 120 h, revealed a Tmax for CIN in rats of 36 h and a relative oral bioavailability of 344% when compared to the GMO formulation (117%) and the aqueous suspension formulation (assigned a nominal bioavailability of 100%).",A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17467935/),%,344,265938,DB00592,Piperazine
,17467935,relative oral bioavailability,"A second study in which CIN was again administered in OG, and plasma samples taken for 120 h, revealed a Tmax for CIN in rats of 36 h and a relative oral bioavailability of 344% when compared to the GMO formulation (117%) and the aqueous suspension formulation (assigned a nominal bioavailability of 100%).",A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17467935/),%,117,265939,DB00592,Piperazine
,17467935,bioavailability,"A second study in which CIN was again administered in OG, and plasma samples taken for 120 h, revealed a Tmax for CIN in rats of 36 h and a relative oral bioavailability of 344% when compared to the GMO formulation (117%) and the aqueous suspension formulation (assigned a nominal bioavailability of 100%).",A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17467935/),%,100,265940,DB00592,Piperazine
≤,25605358,MIC,"We report here that the investigational agent VT-1161 displays potent in vitro antifungal activity against dermatophytes, with MIC values in the range of ≤0.016 to 0.5 μg/ml.",VT-1161 dosed once daily or once weekly exhibits potent efficacy in treatment of dermatophytosis in a guinea pig model. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25605358/),[μg] / [ml],0,265941,DB00592,Piperazine
,25605358,MIC,"VT-1161 was distributed into skin and hair, with plasma and tissue concentrations in all treatment and regimen groups ranging from 0.8 to 40 μg/ml (or μg/g), at or above the MIC against the isolate used in the model (0.5 μg/ml).",VT-1161 dosed once daily or once weekly exhibits potent efficacy in treatment of dermatophytosis in a guinea pig model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25605358/),[μg] / [ml],0.5,265942,DB00592,Piperazine
,19723647,CL/F,"Oral clearance (CL/F) of nilotinib was similar across the combination groups (mean CL/F, 19.1-25.6 L/h), and lower than in the single-agent cohort (mean CL/F, 35.6 L/h).",A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19723647/),[l] / [h],19.1-25.6,266108,DB00592,Piperazine
,19723647,CL/F,"Oral clearance (CL/F) of nilotinib was similar across the combination groups (mean CL/F, 19.1-25.6 L/h), and lower than in the single-agent cohort (mean CL/F, 35.6 L/h).",A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19723647/),[l] / [h],35.6,266109,DB00592,Piperazine
,19723647,progression-free survival,Thirty-eight patients had stable disease and two patients achieved partial response with a median progression-free survival of 134 days for the entire group.,A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19723647/),d,134,266110,DB00592,Piperazine
,8951188,Cmax,"However, for mCPP, Cmax was 89 ng ml-1 in the PM subjects compared with 44 ng ml-1 in the EM subjects, AUC was higher in the PM than EM subjects (1642 ng ml-1 h and 412 ng ml-1 h, respectively), and mCPP elimination half-life increased from 6.1 h in the EM subjects to 16.4 h in the PM subjects.",Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951188/),[ng] / [ml],89,266260,DB00592,Piperazine
,8951188,Cmax,"However, for mCPP, Cmax was 89 ng ml-1 in the PM subjects compared with 44 ng ml-1 in the EM subjects, AUC was higher in the PM than EM subjects (1642 ng ml-1 h and 412 ng ml-1 h, respectively), and mCPP elimination half-life increased from 6.1 h in the EM subjects to 16.4 h in the PM subjects.",Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951188/),[ng] / [ml],44,266261,DB00592,Piperazine
,8951188,AUC,"However, for mCPP, Cmax was 89 ng ml-1 in the PM subjects compared with 44 ng ml-1 in the EM subjects, AUC was higher in the PM than EM subjects (1642 ng ml-1 h and 412 ng ml-1 h, respectively), and mCPP elimination half-life increased from 6.1 h in the EM subjects to 16.4 h in the PM subjects.",Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951188/),[h·ng] / [ml],1642,266262,DB00592,Piperazine
,8951188,AUC,"However, for mCPP, Cmax was 89 ng ml-1 in the PM subjects compared with 44 ng ml-1 in the EM subjects, AUC was higher in the PM than EM subjects (1642 ng ml-1 h and 412 ng ml-1 h, respectively), and mCPP elimination half-life increased from 6.1 h in the EM subjects to 16.4 h in the PM subjects.",Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951188/),[h·ng] / [ml],412,266263,DB00592,Piperazine
,8951188,elimination half-life,"However, for mCPP, Cmax was 89 ng ml-1 in the PM subjects compared with 44 ng ml-1 in the EM subjects, AUC was higher in the PM than EM subjects (1642 ng ml-1 h and 412 ng ml-1 h, respectively), and mCPP elimination half-life increased from 6.1 h in the EM subjects to 16.4 h in the PM subjects.",Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951188/),h,6.1,266264,DB00592,Piperazine
,8951188,elimination half-life,"However, for mCPP, Cmax was 89 ng ml-1 in the PM subjects compared with 44 ng ml-1 in the EM subjects, AUC was higher in the PM than EM subjects (1642 ng ml-1 h and 412 ng ml-1 h, respectively), and mCPP elimination half-life increased from 6.1 h in the EM subjects to 16.4 h in the PM subjects.",Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951188/),h,16.4,266265,DB00592,Piperazine
,8951188,steady state Cmax,"The steady state Cmax and AUC values for mCPP in the PM subjects were 182 ng ml-1 and 1706 ng ml-1 h, respectively, compared with 49.6 ng ml-1 and 182 ng ml-1 h in the EM subjects.",Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951188/),[ng] / [ml],182,266266,DB00592,Piperazine
,8951188,steady state Cmax,"The steady state Cmax and AUC values for mCPP in the PM subjects were 182 ng ml-1 and 1706 ng ml-1 h, respectively, compared with 49.6 ng ml-1 and 182 ng ml-1 h in the EM subjects.",Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951188/),[h·ng] / [ml],1706,266267,DB00592,Piperazine
,8951188,steady state Cmax,"The steady state Cmax and AUC values for mCPP in the PM subjects were 182 ng ml-1 and 1706 ng ml-1 h, respectively, compared with 49.6 ng ml-1 and 182 ng ml-1 h in the EM subjects.",Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951188/),[ng] / [ml],49.6,266268,DB00592,Piperazine
,8951188,AUC,"The steady state Cmax and AUC values for mCPP in the PM subjects were 182 ng ml-1 and 1706 ng ml-1 h, respectively, compared with 49.6 ng ml-1 and 182 ng ml-1 h in the EM subjects.",Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951188/),[h·ng] / [ml],1706,266269,DB00592,Piperazine
,8951188,AUC,"The steady state Cmax and AUC values for mCPP in the PM subjects were 182 ng ml-1 and 1706 ng ml-1 h, respectively, compared with 49.6 ng ml-1 and 182 ng ml-1 h in the EM subjects.",Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951188/),[h·ng] / [ml],182,266270,DB00592,Piperazine
,8980774,maximum drug concentration in serum (Cmax),"The maximum drug concentration in serum (Cmax) was reduced from 7.22 +/- 4.0 to 3.51 +/- 1.9 microM, and the area under the concentration-time curve from 0 h to infinity (AUC0-->infinity) was reduced from 22.5 +/- 14 to 14 +/- 5.7 microM.h.",Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980774/),μM,7.22,266504,DB00592,Piperazine
,8980774,maximum drug concentration in serum (Cmax),"The maximum drug concentration in serum (Cmax) was reduced from 7.22 +/- 4.0 to 3.51 +/- 1.9 microM, and the area under the concentration-time curve from 0 h to infinity (AUC0-->infinity) was reduced from 22.5 +/- 14 to 14 +/- 5.7 microM.h.",Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980774/),μM,3.51,266505,DB00592,Piperazine
,8980774,area under the concentration-time curve from 0 h to infinity (AUC0-->infinity),"The maximum drug concentration in serum (Cmax) was reduced from 7.22 +/- 4.0 to 3.51 +/- 1.9 microM, and the area under the concentration-time curve from 0 h to infinity (AUC0-->infinity) was reduced from 22.5 +/- 14 to 14 +/- 5.7 microM.h.",Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980774/),h·μM,22.5,266506,DB00592,Piperazine
,8980774,area under the concentration-time curve from 0 h to infinity (AUC0-->infinity),"The maximum drug concentration in serum (Cmax) was reduced from 7.22 +/- 4.0 to 3.51 +/- 1.9 microM, and the area under the concentration-time curve from 0 h to infinity (AUC0-->infinity) was reduced from 22.5 +/- 14 to 14 +/- 5.7 microM.h.",Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980774/),h·μM,14,266507,DB00592,Piperazine
,8980774,Cmax,Reductions in didanosine exposure were observed during concurrent administration with delavirdine with a Cmax reduction from 4.65 +/- 2.0 to 3.22 +/- 0.59 microM and an AUC0-->infinity reduction from 7.93 +/- 3.9 to 6.54 +/- 2.3 microM.h.,Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980774/),μM,4.65,266508,DB00592,Piperazine
,8980774,Cmax,Reductions in didanosine exposure were observed during concurrent administration with delavirdine with a Cmax reduction from 4.65 +/- 2.0 to 3.22 +/- 0.59 microM and an AUC0-->infinity reduction from 7.93 +/- 3.9 to 6.54 +/- 2.3 microM.h.,Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980774/),μM,3.22,266509,DB00592,Piperazine
,8980774,AUC0-->infinity,Reductions in didanosine exposure were observed during concurrent administration with delavirdine with a Cmax reduction from 4.65 +/- 2.0 to 3.22 +/- 0.59 microM and an AUC0-->infinity reduction from 7.93 +/- 3.9 to 6.54 +/- 2.3 microM.h.,Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980774/),h·μM,7.93,266510,DB00592,Piperazine
,8980774,AUC0-->infinity,Reductions in didanosine exposure were observed during concurrent administration with delavirdine with a Cmax reduction from 4.65 +/- 2.0 to 3.22 +/- 0.59 microM and an AUC0-->infinity reduction from 7.93 +/- 3.9 to 6.54 +/- 2.3 microM.h.,Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980774/),h·μM,6.54,266511,DB00592,Piperazine
,23038043,Cmax,"The main pharmacokinetic parameters of eszopiclone after single-dose administration were as follows: doses of 1.5, 3 and 6 mg; Cmax of 18.08±4.65, 38.29±15.41 and 76.38±23.34 ng/ml; Tmax of 0.94±0.39, 1.04±0.63 and 1.08±0.51 h; AUC0-24 of 110.90±23.06, 227.36±62.41 and 504.10±140.13 ng*h/ml; elimination half-lives of 5.84±1.03, 5.53±1.91 and 6.17±1.23 h.",Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038043/),[ng] / [ml],18.08,266565,DB00592,Piperazine
,23038043,Cmax,"The main pharmacokinetic parameters of eszopiclone after single-dose administration were as follows: doses of 1.5, 3 and 6 mg; Cmax of 18.08±4.65, 38.29±15.41 and 76.38±23.34 ng/ml; Tmax of 0.94±0.39, 1.04±0.63 and 1.08±0.51 h; AUC0-24 of 110.90±23.06, 227.36±62.41 and 504.10±140.13 ng*h/ml; elimination half-lives of 5.84±1.03, 5.53±1.91 and 6.17±1.23 h.",Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038043/),[ng] / [ml],38.29,266566,DB00592,Piperazine
,23038043,Cmax,"The main pharmacokinetic parameters of eszopiclone after single-dose administration were as follows: doses of 1.5, 3 and 6 mg; Cmax of 18.08±4.65, 38.29±15.41 and 76.38±23.34 ng/ml; Tmax of 0.94±0.39, 1.04±0.63 and 1.08±0.51 h; AUC0-24 of 110.90±23.06, 227.36±62.41 and 504.10±140.13 ng*h/ml; elimination half-lives of 5.84±1.03, 5.53±1.91 and 6.17±1.23 h.",Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038043/),[ng] / [ml],76.38,266567,DB00592,Piperazine
,23038043,Tmax,"The main pharmacokinetic parameters of eszopiclone after single-dose administration were as follows: doses of 1.5, 3 and 6 mg; Cmax of 18.08±4.65, 38.29±15.41 and 76.38±23.34 ng/ml; Tmax of 0.94±0.39, 1.04±0.63 and 1.08±0.51 h; AUC0-24 of 110.90±23.06, 227.36±62.41 and 504.10±140.13 ng*h/ml; elimination half-lives of 5.84±1.03, 5.53±1.91 and 6.17±1.23 h.",Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038043/),h,0.94,266568,DB00592,Piperazine
,23038043,Tmax,"The main pharmacokinetic parameters of eszopiclone after single-dose administration were as follows: doses of 1.5, 3 and 6 mg; Cmax of 18.08±4.65, 38.29±15.41 and 76.38±23.34 ng/ml; Tmax of 0.94±0.39, 1.04±0.63 and 1.08±0.51 h; AUC0-24 of 110.90±23.06, 227.36±62.41 and 504.10±140.13 ng*h/ml; elimination half-lives of 5.84±1.03, 5.53±1.91 and 6.17±1.23 h.",Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038043/),h,1.04,266569,DB00592,Piperazine
,23038043,Tmax,"The main pharmacokinetic parameters of eszopiclone after single-dose administration were as follows: doses of 1.5, 3 and 6 mg; Cmax of 18.08±4.65, 38.29±15.41 and 76.38±23.34 ng/ml; Tmax of 0.94±0.39, 1.04±0.63 and 1.08±0.51 h; AUC0-24 of 110.90±23.06, 227.36±62.41 and 504.10±140.13 ng*h/ml; elimination half-lives of 5.84±1.03, 5.53±1.91 and 6.17±1.23 h.",Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038043/),h,1.08,266570,DB00592,Piperazine
,23038043,AUC0-24,"The main pharmacokinetic parameters of eszopiclone after single-dose administration were as follows: doses of 1.5, 3 and 6 mg; Cmax of 18.08±4.65, 38.29±15.41 and 76.38±23.34 ng/ml; Tmax of 0.94±0.39, 1.04±0.63 and 1.08±0.51 h; AUC0-24 of 110.90±23.06, 227.36±62.41 and 504.10±140.13 ng*h/ml; elimination half-lives of 5.84±1.03, 5.53±1.91 and 6.17±1.23 h.",Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038043/),[h·ng] / [ml],110.90,266571,DB00592,Piperazine
,23038043,AUC0-24,"The main pharmacokinetic parameters of eszopiclone after single-dose administration were as follows: doses of 1.5, 3 and 6 mg; Cmax of 18.08±4.65, 38.29±15.41 and 76.38±23.34 ng/ml; Tmax of 0.94±0.39, 1.04±0.63 and 1.08±0.51 h; AUC0-24 of 110.90±23.06, 227.36±62.41 and 504.10±140.13 ng*h/ml; elimination half-lives of 5.84±1.03, 5.53±1.91 and 6.17±1.23 h.",Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038043/),[h·ng] / [ml],227.36,266572,DB00592,Piperazine
,23038043,AUC0-24,"The main pharmacokinetic parameters of eszopiclone after single-dose administration were as follows: doses of 1.5, 3 and 6 mg; Cmax of 18.08±4.65, 38.29±15.41 and 76.38±23.34 ng/ml; Tmax of 0.94±0.39, 1.04±0.63 and 1.08±0.51 h; AUC0-24 of 110.90±23.06, 227.36±62.41 and 504.10±140.13 ng*h/ml; elimination half-lives of 5.84±1.03, 5.53±1.91 and 6.17±1.23 h.",Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038043/),[h·ng] / [ml],504.10,266573,DB00592,Piperazine
,23038043,elimination half-lives,"The main pharmacokinetic parameters of eszopiclone after single-dose administration were as follows: doses of 1.5, 3 and 6 mg; Cmax of 18.08±4.65, 38.29±15.41 and 76.38±23.34 ng/ml; Tmax of 0.94±0.39, 1.04±0.63 and 1.08±0.51 h; AUC0-24 of 110.90±23.06, 227.36±62.41 and 504.10±140.13 ng*h/ml; elimination half-lives of 5.84±1.03, 5.53±1.91 and 6.17±1.23 h.",Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038043/),h,5.84,266574,DB00592,Piperazine
,23038043,elimination half-lives,"The main pharmacokinetic parameters of eszopiclone after single-dose administration were as follows: doses of 1.5, 3 and 6 mg; Cmax of 18.08±4.65, 38.29±15.41 and 76.38±23.34 ng/ml; Tmax of 0.94±0.39, 1.04±0.63 and 1.08±0.51 h; AUC0-24 of 110.90±23.06, 227.36±62.41 and 504.10±140.13 ng*h/ml; elimination half-lives of 5.84±1.03, 5.53±1.91 and 6.17±1.23 h.",Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038043/),h,5.53,266575,DB00592,Piperazine
,23038043,elimination half-lives,"The main pharmacokinetic parameters of eszopiclone after single-dose administration were as follows: doses of 1.5, 3 and 6 mg; Cmax of 18.08±4.65, 38.29±15.41 and 76.38±23.34 ng/ml; Tmax of 0.94±0.39, 1.04±0.63 and 1.08±0.51 h; AUC0-24 of 110.90±23.06, 227.36±62.41 and 504.10±140.13 ng*h/ml; elimination half-lives of 5.84±1.03, 5.53±1.91 and 6.17±1.23 h.",Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038043/),h,6.17,266576,DB00592,Piperazine
,23038043,Css_max,"After multiple-dose administration, the steady-state levels of eszopiclone were achieved by the 4th day, and the main pharmacokinetic parameters were Css_max at 33.43±5.63 ng/ml and AUCss (0-24) at 263.30±51.21 ng*h/ml.",Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038043/),[ng] / [ml],33.43,266577,DB00592,Piperazine
,23038043,AUCss (0-24),"After multiple-dose administration, the steady-state levels of eszopiclone were achieved by the 4th day, and the main pharmacokinetic parameters were Css_max at 33.43±5.63 ng/ml and AUCss (0-24) at 263.30±51.21 ng*h/ml.",Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038043/),[h·ng] / [ml],263.30,266578,DB00592,Piperazine
,12121932,peak concentration of drug in plasma (C(max)),"After 15 days of treatment, the peak concentration of drug in plasma (C(max)), the area under the plasma concentration-time curve (AUC) from 0 to 24 h (AUC(0-24)), the concentration in plasma at the end of the dosing interval (predose) (C(min)), and the terminal half-life of itraconazole (ITRA) were (means and standard deviations) 0.604 +/- 0.53 microg/ml, 6.80 +/- 7.4 microg.","Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12121932/),[μg] / [ml],0.604,266704,DB00592,Piperazine
,12121932,AUC-based accumulation factors,"The mean AUC-based accumulation factors for ITRA on day 15 were 4.14 +/- 0.9 and 3.53 +/- 0.6, respectively.","Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12121932/),,4.14,266705,DB00592,Piperazine
,12121932,AUC-based accumulation factors,"The mean AUC-based accumulation factors for ITRA on day 15 were 4.14 +/- 0.9 and 3.53 +/- 0.6, respectively.","Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12121932/),,3.53,266706,DB00592,Piperazine
,12121932,metabolic ratios (AUC,"The mean metabolic ratios (AUC of hydroxyitraconazole/AUC of ITRA) at day 15 were 1.96 +/- 0.1 for the QD regimen and 1.29 +/- 0.2 for the BID regimen, respectively (P < 0.05).","Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12121932/),,1.96,266707,DB00592,Piperazine
,12121932,metabolic ratios (AUC,"The mean metabolic ratios (AUC of hydroxyitraconazole/AUC of ITRA) at day 15 were 1.96 +/- 0.1 for the QD regimen and 1.29 +/- 0.2 for the BID regimen, respectively (P < 0.05).","Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12121932/),,1.29,266708,DB00592,Piperazine
,23669385,time to peak concentration,"Dolutegravir was well tolerated, and absorption of dolutegravir from the suspension formulation was rapid (median time to peak concentration, 0.5 h), declining in a biphasic fashion.","Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23669385/),h,0.5,266812,DB00592,Piperazine
,23669385,terminal plasma half-lives (t1/2),"Dolutegravir and the radioactivity had similar terminal plasma half-lives (t1/2) (15.6 versus 15.7 h), indicating metabolism was formation rate limited with no long-lived metabolites.","Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23669385/),h,15.6,266813,DB00592,Piperazine
,23669385,terminal plasma half-lives (t1/2),"Dolutegravir and the radioactivity had similar terminal plasma half-lives (t1/2) (15.6 versus 15.7 h), indicating metabolism was formation rate limited with no long-lived metabolites.","Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23669385/),h,15.7,266814,DB00592,Piperazine
,26693810,metabolic ratio,"Patients with optimal response to imatinib after 12 months of therapy did not differ in CYP3A activity compared to nonoptimal responders (quinine metabolic ratio of 14.69 and 14.70, respectively; P = 0.966).",In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26693810/),,14.69,266876,DB00592,Piperazine
,26693810,metabolic ratio,"Patients with optimal response to imatinib after 12 months of therapy did not differ in CYP3A activity compared to nonoptimal responders (quinine metabolic ratio of 14.69 and 14.70, respectively; P = 0.966).",In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26693810/),,14.,266877,DB00592,Piperazine
less,32250458,ki,All three compounds showed a strong reversible inhibition on CYP2C8 enzyme with ki of less than 0.5 μmol L-1 .,"Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250458/),[μM] / [l],0.5,267402,DB00592,Piperazine
,32250458,AUC ratio,"The verified PBPK models were able to describe the increase in systemic exposure of midazolam and tacrolimus due to co-administration of S. sphenanthera, consistent with the reported changes in the corresponding clinical interaction study (AUC ratio of 2.0 vs 2.1 and 2.4 vs 2.1, respectively).","Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250458/),,2.0,267403,DB00592,Piperazine
,32250458,AUC ratio,"The verified PBPK models were able to describe the increase in systemic exposure of midazolam and tacrolimus due to co-administration of S. sphenanthera, consistent with the reported changes in the corresponding clinical interaction study (AUC ratio of 2.0 vs 2.1 and 2.4 vs 2.1, respectively).","Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250458/),,2.1,267404,DB00592,Piperazine
,32250458,AUC ratio,"The verified PBPK models were able to describe the increase in systemic exposure of midazolam and tacrolimus due to co-administration of S. sphenanthera, consistent with the reported changes in the corresponding clinical interaction study (AUC ratio of 2.0 vs 2.1 and 2.4 vs 2.1, respectively).","Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250458/),,2.4,267405,DB00592,Piperazine
,32250458,AUC ratio,"The PBPK simulation predicted that at recommended dosing regimens of S. sphenanthera, co-administration would result in an increase in bosutinib exposure (AUC ratio 3.0) but not in imatinib exposure.","Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250458/),,3.0,267406,DB00592,Piperazine
,17978491,absorption lag time (ALAG),"The mean values of the absorption lag time (ALAG) and absorption rate constant (KA) were estimated to be 0.805 h and 2.65 h(-1), respectively.",Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978491/),h,0.805,267522,DB00592,Piperazine
,17978491,absorption rate constant (KA),"The mean values of the absorption lag time (ALAG) and absorption rate constant (KA) were estimated to be 0.805 h and 2.65 h(-1), respectively.",Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978491/),1/[h],2.65,267523,DB00592,Piperazine
,17978491,volume of the central (V(1)/F,"The mean volume of the central (V(1)/F) and peripheral (V(2)/F) compartment was 3.84 and 1.54 l/kg, respectively, and the mean value of inter-compartment clearance (Q/F) was 0.168 l/h/kg.",Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978491/),[l] / [kg],3.84,267524,DB00592,Piperazine
,17978491,peripheral (V(2)/F,"The mean volume of the central (V(1)/F) and peripheral (V(2)/F) compartment was 3.84 and 1.54 l/kg, respectively, and the mean value of inter-compartment clearance (Q/F) was 0.168 l/h/kg.",Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978491/),[l] / [kg],1.54,267525,DB00592,Piperazine
,17978491,inter-compartment clearance (Q/F),"The mean volume of the central (V(1)/F) and peripheral (V(2)/F) compartment was 3.84 and 1.54 l/kg, respectively, and the mean value of inter-compartment clearance (Q/F) was 0.168 l/h/kg.",Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978491/),[l] / [h·kg],0.168,267526,DB00592,Piperazine
,17978491,Oral clearance (CL/F),"Oral clearance (CL/F) was estimated to be 0.0645 l/h/kg in the group with CYP2D6*1/*1, *1/*2 and *2/*2.",Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978491/),[l] / [h·kg],0.0645,267527,DB00592,Piperazine
,17978491,CL/F,"The decrease in CL/F was estimated to be 0.0135 l/h/kg in the group with CYP2D6*1/*5, *1/*10, *2/*5, *2/*10, and *2/*41, and 0.0293 l/h/kg in the group with CYP2D6*5/*10, *10/*10, and *41/*41.",Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978491/),[l] / [h·kg],0.0135,267528,DB00592,Piperazine
,17978491,CL/F,"The decrease in CL/F was estimated to be 0.0135 l/h/kg in the group with CYP2D6*1/*5, *1/*10, *2/*5, *2/*10, and *2/*41, and 0.0293 l/h/kg in the group with CYP2D6*5/*10, *10/*10, and *41/*41.",Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978491/),[l] / [h·kg],0.0293,267529,DB00592,Piperazine
,17978491,CL/F,"The plasma concentration of aripiprazole was increased by coadministration of itraconazole, and the decrease in CL/F was estimated to be 0.0181 l/h/kg.",Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978491/),[l] / [h·kg],0.0181,267530,DB00592,Piperazine
,30485754,DL,"DL and EE values of ITR-M were 5.70 ± 0.12% and 91.30 ± 1.90%, respectively.",Itraconazole-loaded micelles based on linear-dendritic poly (ethylene glycol)-b-poly (ε-caprolactone). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30485754/),%,5.70,267587,DB00592,Piperazine
,30485754,EE,"DL and EE values of ITR-M were 5.70 ± 0.12% and 91.30 ± 1.90%, respectively.",Itraconazole-loaded micelles based on linear-dendritic poly (ethylene glycol)-b-poly (ε-caprolactone). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30485754/),%,91.30,267588,DB00592,Piperazine
up to,30485754,solubility,The micelle formulation enhanced the ITR solubility up to 30.42 μg/mL.,Itraconazole-loaded micelles based on linear-dendritic poly (ethylene glycol)-b-poly (ε-caprolactone). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30485754/),[μg] / [ml],30.42,267589,DB00592,Piperazine
,22538054,Bioavailability,Bioavailability of budesonide without inhibition was 27(12-42)%.,Differentiating mucosal and hepatic metabolism of budesonide by local pretreatment with increasing doses of ketoconazole in the proximal jejunum. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22538054/),%,27,267650,DB00592,Piperazine
,22538054,bioavailability,"At the two highest doses (128 mg and above) bioavailability approached 100%, showing that budesonide was completely absorbed from jejunum.",Differentiating mucosal and hepatic metabolism of budesonide by local pretreatment with increasing doses of ketoconazole in the proximal jejunum. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22538054/),%,100,267651,DB00592,Piperazine
,22538054,extraction ratios,"Applying sigmoid E(max)-models of the mean inhibitions in mucosa and liver indicated that, in this study performed under fed conditions, their uninhibited extraction ratios of budesonide were approximately 0.32 and 0.60, respectively.",Differentiating mucosal and hepatic metabolism of budesonide by local pretreatment with increasing doses of ketoconazole in the proximal jejunum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22538054/),,0.32,267652,DB00592,Piperazine
,22538054,extraction ratios,"Applying sigmoid E(max)-models of the mean inhibitions in mucosa and liver indicated that, in this study performed under fed conditions, their uninhibited extraction ratios of budesonide were approximately 0.32 and 0.60, respectively.",Differentiating mucosal and hepatic metabolism of budesonide by local pretreatment with increasing doses of ketoconazole in the proximal jejunum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22538054/),,0.60,267653,DB00592,Piperazine
,10771454,tmax,The tmax for levonorgestrel was approximately 0.5 h longer.,Ziprasidone and the pharmacokinetics of a combined oral contraceptive. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771454/),h,0.5,267673,DB00592,Piperazine
,17149874,oral bioavailability,"Further optimization with the (N-oxy-2-pyridinyl)piperidine template led to the discovery of compound 6b (ABT-670), which exhibited excellent oral bioavailability in rat, dog, and monkey (68%, 85%, and 91%, respectively) with comparable efficacy, safety, and tolerability to 1a.","Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17149874/),%,68,267817,DB00592,Piperazine
,17149874,oral bioavailability,"Further optimization with the (N-oxy-2-pyridinyl)piperidine template led to the discovery of compound 6b (ABT-670), which exhibited excellent oral bioavailability in rat, dog, and monkey (68%, 85%, and 91%, respectively) with comparable efficacy, safety, and tolerability to 1a.","Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17149874/),%,85,267818,DB00592,Piperazine
,17149874,oral bioavailability,"Further optimization with the (N-oxy-2-pyridinyl)piperidine template led to the discovery of compound 6b (ABT-670), which exhibited excellent oral bioavailability in rat, dog, and monkey (68%, 85%, and 91%, respectively) with comparable efficacy, safety, and tolerability to 1a.","Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17149874/),%,91,267819,DB00592,Piperazine
,19135329,flow rate,"After extraction with ethyl acetate, the chromatographic separation was carried out on a Diamonsil C(18) column (150mmx4.6mm i.d., 5microm particle size, Zhonghuida) protected by a ODS guard column (10mmx4.6mm i.d., 5microm particle size), using acetonitrile-methanol-phosphate buffer (pH 3.0, 30mM) (31:3:66, v/v/v) as mobile phase at a flow rate of 1.0mL/min, and wavelength of the UV detector was set at 281nm.",Development of a high performance liquid chromatography method for quantification of PAC-1 in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135329/),,1.,268096,DB00592,Piperazine
,23417515,occupancies,"Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively.",Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),%,66,268126,DB00592,Piperazine
,23417515,occupancies,"Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively.",Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),%,39,268127,DB00592,Piperazine
,23417515,occupancies,"Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively.",Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),%,2,268128,DB00592,Piperazine
,23417515,occupancies,"Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively.",Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),%,62,268129,DB00592,Piperazine
,23417515,occupancies,"Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively.",Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),%,35,268130,DB00592,Piperazine
,23417515,occupancies,"Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively.",Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),%,-,268131,DB00592,Piperazine
,23417515,occupancies,"Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively.",Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),%,6,268132,DB00592,Piperazine
,23417515,occupancies,"Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively.",Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),%,68,268133,DB00592,Piperazine
,23417515,occupancies,"Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively.",Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),%,47,268134,DB00592,Piperazine
,23417515,occupancies,"Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively.",Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),%,11,268135,DB00592,Piperazine
,23417515,occupancy half-life,The time-course of receptor occupancy across the regions indicated an occupancy half-life of 8.3 h.,Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),h,8.3,268136,DB00592,Piperazine
,14612892,half-life,There was a statistically significant decrease in total-body clearance of drug from the plasma (CL/F) with a mean reduction of 70% for simvastatin (P<0.001): the mean half-life of simvastatin was prolonged from 1.4-2.7 h when given together with imatinib.,"Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14612892/),h,1.4-2.7,268235,DB00592,Piperazine
,3428348,elimination half-life,"The mean elimination half-life of the drug was 3.3 h, and although the ketoconazole was given only once daily, a satisfactory clinical response was obtained in all seven individuals.",The pharmacokinetics of ketoconazole after chronic administration in adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428348/),h,3.3,268382,DB00592,Piperazine
,2906159,Tmax,"5. Pharmacokinetic study From the pharmacokinetic parameters measured, two features were recognized: one was the slowness of Tmax (4-6 hours) and the other was the length of its biological half-life (56-88 hours).","Phase 1 study of a new antipsychotic drug, OPC-4392. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906159/),h,4-6,268579,DB00592,Piperazine
,2906159,biological half-life,"5. Pharmacokinetic study From the pharmacokinetic parameters measured, two features were recognized: one was the slowness of Tmax (4-6 hours) and the other was the length of its biological half-life (56-88 hours).","Phase 1 study of a new antipsychotic drug, OPC-4392. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906159/),h,56-88,268580,DB00592,Piperazine
,17220239,fecal excretion,Mean fecal excretion was 13% of the administered dose.,Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220239/),%,13,268927,DB00592,Piperazine
up to,23837910,loading efficiencies,"High loading efficiencies of itraconazole (up to 20%) and stable liquid formulations were obtained at neutral pH, and full dispersion of itraconazole was reached in 2 h in simulated intestinal fluid (pH 6.8).",PEGylated bile acids for use in drug delivery systems: enhanced solubility and bioavailability of itraconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23837910/),%,20,269256,DB00592,Piperazine
,15963102,C(max),Sildenafil C(max) fell from 759 ng ml(-1) on visit 1 to 333 ng ml(-1) on visit 3 (P < 0.01) and there was a significant decrease in the plasma half-life of sildenafil on the higher bosentan dose (P < 0.05).,Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15963102/),[ng] / [ml],759,269282,DB00592,Piperazine
,15963102,C(max),Sildenafil C(max) fell from 759 ng ml(-1) on visit 1 to 333 ng ml(-1) on visit 3 (P < 0.01) and there was a significant decrease in the plasma half-life of sildenafil on the higher bosentan dose (P < 0.05).,Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15963102/),[ng] / [ml],333,269283,DB00592,Piperazine
,11254202,flow-rate,An aliquot of 25 microl of the mixture was injected onto a BDS Hypersil C18 column (50x2 mm; 3 microm) at a flow-rate of 0.3 ml/min.,Quantitation of itraconazole in rat heparinized plasma by liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11254202/),[ml] / [min],0.3,269294,DB00592,Piperazine
,11254202,extraction recovery,The extraction recovery of ITZ was 96%.,Quantitation of itraconazole in rat heparinized plasma by liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11254202/),%,96,269295,DB00592,Piperazine
,12485722,detection limits,"The detection limits at a signal-to-noise ratio of 3 obtained using spiked plasma and artificial cerebrospinal fluid were 2.1 and 0.7 ng/ml, respectively.",Semi-micro column HPLC of triazolam in rat plasma and brain microdialysate and its application to drug interaction study with itraconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485722/),[ng] / [ml],3,269443,DB00592,Piperazine
,12485722,detection limits,"The detection limits at a signal-to-noise ratio of 3 obtained using spiked plasma and artificial cerebrospinal fluid were 2.1 and 0.7 ng/ml, respectively.",Semi-micro column HPLC of triazolam in rat plasma and brain microdialysate and its application to drug interaction study with itraconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485722/),[ng] / [ml],2.1,269444,DB00592,Piperazine
,12485722,detection limits,"The detection limits at a signal-to-noise ratio of 3 obtained using spiked plasma and artificial cerebrospinal fluid were 2.1 and 0.7 ng/ml, respectively.",Semi-micro column HPLC of triazolam in rat plasma and brain microdialysate and its application to drug interaction study with itraconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485722/),[ng] / [ml],0.7,269445,DB00592,Piperazine
,12485722,signal-to-noise ratio,"The detection limits at a signal-to-noise ratio of 3 obtained using spiked plasma and artificial cerebrospinal fluid were 2.1 and 0.7 ng/ml, respectively.",Semi-micro column HPLC of triazolam in rat plasma and brain microdialysate and its application to drug interaction study with itraconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485722/),[ng] / [ml],3,269446,DB00592,Piperazine
,12485722,signal-to-noise ratio,"The detection limits at a signal-to-noise ratio of 3 obtained using spiked plasma and artificial cerebrospinal fluid were 2.1 and 0.7 ng/ml, respectively.",Semi-micro column HPLC of triazolam in rat plasma and brain microdialysate and its application to drug interaction study with itraconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485722/),[ng] / [ml],2.1,269447,DB00592,Piperazine
,12485722,signal-to-noise ratio,"The detection limits at a signal-to-noise ratio of 3 obtained using spiked plasma and artificial cerebrospinal fluid were 2.1 and 0.7 ng/ml, respectively.",Semi-micro column HPLC of triazolam in rat plasma and brain microdialysate and its application to drug interaction study with itraconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485722/),[ng] / [ml],0.7,269448,DB00592,Piperazine
,7833227,peak time,The peak time of zopiclone concentration was reduced from 2 to 1 h (P < 0.001).,The effect of erythromycin on the pharmacokinetics and pharmacodynamics of zopiclone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833227/),h,2,269776,DB00592,Piperazine
,7833227,peak time,The peak time of zopiclone concentration was reduced from 2 to 1 h (P < 0.001).,The effect of erythromycin on the pharmacokinetics and pharmacodynamics of zopiclone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833227/),h,1,269777,DB00592,Piperazine
,2562944,serum elimination t1/2,"The serum elimination t1/2 of hydroxyzine was 29.3 +/- 10.1 hours; the volume of distribution was 22.5 +/- 6.3 L/kg; the clearance rate was 9.6 +/- 3.2 ml/min/kg, and the AUC was 1383.1 +/- 1039.0 ng.hr/ml.",Pharmacokinetic and pharmacodynamic studies of the H1-receptor antagonist hydroxyzine in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2562944/),h,29.3,269880,DB00592,Piperazine
,2562944,volume of distribution,"The serum elimination t1/2 of hydroxyzine was 29.3 +/- 10.1 hours; the volume of distribution was 22.5 +/- 6.3 L/kg; the clearance rate was 9.6 +/- 3.2 ml/min/kg, and the AUC was 1383.1 +/- 1039.0 ng.hr/ml.",Pharmacokinetic and pharmacodynamic studies of the H1-receptor antagonist hydroxyzine in the elderly. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2562944/),[l] / [kg],22.5,269881,DB00592,Piperazine
,2562944,clearance rate,"The serum elimination t1/2 of hydroxyzine was 29.3 +/- 10.1 hours; the volume of distribution was 22.5 +/- 6.3 L/kg; the clearance rate was 9.6 +/- 3.2 ml/min/kg, and the AUC was 1383.1 +/- 1039.0 ng.hr/ml.",Pharmacokinetic and pharmacodynamic studies of the H1-receptor antagonist hydroxyzine in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2562944/),[ml] / [kg·min],9.6,269882,DB00592,Piperazine
,2562944,AUC,"The serum elimination t1/2 of hydroxyzine was 29.3 +/- 10.1 hours; the volume of distribution was 22.5 +/- 6.3 L/kg; the clearance rate was 9.6 +/- 3.2 ml/min/kg, and the AUC was 1383.1 +/- 1039.0 ng.hr/ml.",Pharmacokinetic and pharmacodynamic studies of the H1-receptor antagonist hydroxyzine in the elderly. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2562944/),[h·ng] / [ml],1383.1,269883,DB00592,Piperazine
,2562944,serum elimination t1/2,"The mean serum elimination t1/2 of cetirizine, the active metabolite of hydroxyzine generated in vivo, was 24.8 +/- 7.7 hours, not significantly different from that of the parent compound (p = 0.05).",Pharmacokinetic and pharmacodynamic studies of the H1-receptor antagonist hydroxyzine in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2562944/),h,24.8,269884,DB00592,Piperazine
,31388783,Size,"Size of the nano-formulations OLA-LP, OLA-NSPSE and OLA-NSPWM were found to be 126.71 ± 4.54, 128.6 ± 2.34 and 531.1 ± 5.34 nm with polydispersity index below 0.3.",Preparation and Comparison of Oral Bioavailability for Different Nano-formulations of Olaparib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31388783/),nm,126.71,270017,DB00592,Piperazine
,31388783,Size,"Size of the nano-formulations OLA-LP, OLA-NSPSE and OLA-NSPWM were found to be 126.71 ± 4.54, 128.6 ± 2.34 and 531.1 ± 5.34 nm with polydispersity index below 0.3.",Preparation and Comparison of Oral Bioavailability for Different Nano-formulations of Olaparib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31388783/),nm,128.6,270018,DB00592,Piperazine
,31388783,Size,"Size of the nano-formulations OLA-LP, OLA-NSPSE and OLA-NSPWM were found to be 126.71 ± 4.54, 128.6 ± 2.34 and 531.1 ± 5.34 nm with polydispersity index below 0.3.",Preparation and Comparison of Oral Bioavailability for Different Nano-formulations of Olaparib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31388783/),nm,531.1,270019,DB00592,Piperazine
,22446981,V,"The final model formula was: CL = 28.2 × [1 - 0.0263 × (HCT - 26.62)] × [1 - 0.0289 × (ALB - 37.63)] × [1 - 0.146 × ITR] (L/h); V = 1,080 (L); K (a) = 1.28 (h⁻¹); F = 0.711.",Population pharmacokinetics of cyclosporine A based on NONMEM in Chinese allogeneic hematopoietic stem cell transplantation recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22446981/),l,"1,080",270121,DB00592,Piperazine
,22446981,K (a),"The final model formula was: CL = 28.2 × [1 - 0.0263 × (HCT - 26.62)] × [1 - 0.0289 × (ALB - 37.63)] × [1 - 0.146 × ITR] (L/h); V = 1,080 (L); K (a) = 1.28 (h⁻¹); F = 0.711.",Population pharmacokinetics of cyclosporine A based on NONMEM in Chinese allogeneic hematopoietic stem cell transplantation recipients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22446981/),h⁻¹,1.28,270122,DB00592,Piperazine
,7785441,central volume of distribution (Vcentr.),"The central volume of distribution (Vcentr.) is large (1.07 +/- 0.14 l/kg in dogs and 2.74 l/kg in rats), the first elimination half-life (t1/2 alpha) is 5.47 +/- 1.67 min in dogs and 13.7 min in rats.",Pharmacokinetic study on a new antiischaemic agent (BRLP-42). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7785441/),[l] / [kg],1.07,270470,DB00592,Piperazine
,7785441,central volume of distribution (Vcentr.),"The central volume of distribution (Vcentr.) is large (1.07 +/- 0.14 l/kg in dogs and 2.74 l/kg in rats), the first elimination half-life (t1/2 alpha) is 5.47 +/- 1.67 min in dogs and 13.7 min in rats.",Pharmacokinetic study on a new antiischaemic agent (BRLP-42). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7785441/),[l] / [kg],2.74,270471,DB00592,Piperazine
,7785441,first elimination half-life (t1/2 alpha),"The central volume of distribution (Vcentr.) is large (1.07 +/- 0.14 l/kg in dogs and 2.74 l/kg in rats), the first elimination half-life (t1/2 alpha) is 5.47 +/- 1.67 min in dogs and 13.7 min in rats.",Pharmacokinetic study on a new antiischaemic agent (BRLP-42). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7785441/),min,5.47,270472,DB00592,Piperazine
,7785441,first elimination half-life (t1/2 alpha),"The central volume of distribution (Vcentr.) is large (1.07 +/- 0.14 l/kg in dogs and 2.74 l/kg in rats), the first elimination half-life (t1/2 alpha) is 5.47 +/- 1.67 min in dogs and 13.7 min in rats.",Pharmacokinetic study on a new antiischaemic agent (BRLP-42). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7785441/),min,13.7,270473,DB00592,Piperazine
,7785441,second elimination half-life (t1/2 beta,The excretion and/or metabolic elimination of BRLP-42 resulted in short second elimination half-life (t1/2 beta = 41.45 +/- 2.34 min in dogs and 43.8 min in rats).,Pharmacokinetic study on a new antiischaemic agent (BRLP-42). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7785441/),min,41.45,270474,DB00592,Piperazine
,7785441,second elimination half-life (t1/2 beta,The excretion and/or metabolic elimination of BRLP-42 resulted in short second elimination half-life (t1/2 beta = 41.45 +/- 2.34 min in dogs and 43.8 min in rats).,Pharmacokinetic study on a new antiischaemic agent (BRLP-42). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7785441/),min,43.8,270475,DB00592,Piperazine
,7785441,t1/2a,The absorption half-life was short (t1/2a = 17.36 +/- 5.90 min in dogs and 2.7 min in rats).,Pharmacokinetic study on a new antiischaemic agent (BRLP-42). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7785441/),min,17.36,270476,DB00592,Piperazine
,7785441,t1/2a,The absorption half-life was short (t1/2a = 17.36 +/- 5.90 min in dogs and 2.7 min in rats).,Pharmacokinetic study on a new antiischaemic agent (BRLP-42). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7785441/),min,2.7,270477,DB00592,Piperazine
,7785441,bioavailability,The bioavailability was 40 +/- 8% in dogs and 28% in rats.,Pharmacokinetic study on a new antiischaemic agent (BRLP-42). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7785441/),%,40,270478,DB00592,Piperazine
,7785441,bioavailability,The bioavailability was 40 +/- 8% in dogs and 28% in rats.,Pharmacokinetic study on a new antiischaemic agent (BRLP-42). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7785441/),%,28,270479,DB00592,Piperazine
,7785441,elimination half-life (t1/2e,The elimination half-life (t1/2e = 28.77 +/- 0.88 min in dogs and 30.1 min in rats) is connected dominantly with metabolic elimination and/or excretion of BRLP-42.,Pharmacokinetic study on a new antiischaemic agent (BRLP-42). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7785441/),min,28.77,270480,DB00592,Piperazine
,7785441,elimination half-life (t1/2e,The elimination half-life (t1/2e = 28.77 +/- 0.88 min in dogs and 30.1 min in rats) is connected dominantly with metabolic elimination and/or excretion of BRLP-42.,Pharmacokinetic study on a new antiischaemic agent (BRLP-42). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7785441/),min,30.1,270481,DB00592,Piperazine
,23815436,lung concentrations,"Upon multiple dose administration of 10% suspension, mean lung concentrations reached 104.9 ± 10.1 μg/g.",A model for treating avian aspergillosis: serum and lung tissue kinetics for Japanese quail (Coturnix japonica) following single and multiple aerosol exposures of a nanoparticulate itraconazole suspension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23815436/),[μg] / [g],104.9,271067,DB00592,Piperazine
,23815436,terminal half-lives,"Drug clearance from the lungs was slow with terminal half-lives of 19.7 h and 35.8 h following inhalation of 1% and 10% suspension, respectively.",A model for treating avian aspergillosis: serum and lung tissue kinetics for Japanese quail (Coturnix japonica) following single and multiple aerosol exposures of a nanoparticulate itraconazole suspension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23815436/),h,19.7,271068,DB00592,Piperazine
,23815436,terminal half-lives,"Drug clearance from the lungs was slow with terminal half-lives of 19.7 h and 35.8 h following inhalation of 1% and 10% suspension, respectively.",A model for treating avian aspergillosis: serum and lung tissue kinetics for Japanese quail (Coturnix japonica) following single and multiple aerosol exposures of a nanoparticulate itraconazole suspension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23815436/),h,35.8,271069,DB00592,Piperazine
,31490561,terminal half-life,"The terminal half-life was 7.41 and 7.13 hr for hydroxyzine and cetirizine, respectively.",Pharmacokinetics of hydroxyzine and cetirizine following oral administration of hydroxyzine to exercised Thoroughbred horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31490561/),h,7.41,271230,DB00592,Piperazine
,31490561,terminal half-life,"The terminal half-life was 7.41 and 7.13 hr for hydroxyzine and cetirizine, respectively.",Pharmacokinetics of hydroxyzine and cetirizine following oral administration of hydroxyzine to exercised Thoroughbred horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31490561/),h,7.13,271231,DB00592,Piperazine
,10586393,total clearance,"Mean (%CV) azimilide parameters were total clearance = 0.143 L/h/kg (38%), renal clearance = 0.014 L/h/kg (35%), steady-state volume of distribution = 13.2 L/kg (23%), and terminal exponential half-life = 78.8 h (44%).",Azimilide pharmacokinetics following intravenous and oral administration of a solution and capsule formulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10586393/),[l] / [h·kg],0.143,271384,DB00592,Piperazine
,10586393,renal clearance,"Mean (%CV) azimilide parameters were total clearance = 0.143 L/h/kg (38%), renal clearance = 0.014 L/h/kg (35%), steady-state volume of distribution = 13.2 L/kg (23%), and terminal exponential half-life = 78.8 h (44%).",Azimilide pharmacokinetics following intravenous and oral administration of a solution and capsule formulation. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10586393/),[l] / [h·kg],0.014,271385,DB00592,Piperazine
,10586393,steady-state volume of distribution,"Mean (%CV) azimilide parameters were total clearance = 0.143 L/h/kg (38%), renal clearance = 0.014 L/h/kg (35%), steady-state volume of distribution = 13.2 L/kg (23%), and terminal exponential half-life = 78.8 h (44%).",Azimilide pharmacokinetics following intravenous and oral administration of a solution and capsule formulation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10586393/),[l] / [kg],13.2,271386,DB00592,Piperazine
,10586393,terminal exponential half-life,"Mean (%CV) azimilide parameters were total clearance = 0.143 L/h/kg (38%), renal clearance = 0.014 L/h/kg (35%), steady-state volume of distribution = 13.2 L/kg (23%), and terminal exponential half-life = 78.8 h (44%).",Azimilide pharmacokinetics following intravenous and oral administration of a solution and capsule formulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10586393/),h,78.8,271387,DB00592,Piperazine
,10586393,times of maximum blood concentration,"In addition, the rate (Cmax) and extent of absorption (AUC) following oral administration of the capsule dosage form were bioequivalent to the oral solution with means for times of maximum blood concentration of 7.08 and 7.18 hours for the oral solution and capsule, respectively.",Azimilide pharmacokinetics following intravenous and oral administration of a solution and capsule formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10586393/),h,7.08,271388,DB00592,Piperazine
,10586393,times of maximum blood concentration,"In addition, the rate (Cmax) and extent of absorption (AUC) following oral administration of the capsule dosage form were bioequivalent to the oral solution with means for times of maximum blood concentration of 7.08 and 7.18 hours for the oral solution and capsule, respectively.",Azimilide pharmacokinetics following intravenous and oral administration of a solution and capsule formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10586393/),h,7.18,271389,DB00592,Piperazine
,18980631,systemic availability,The mean systemic availability of oral hydroxyzine was 72%.,Hydroxyzine and cetirizine pharmacokinetics and pharmacodynamics after oral and intravenous administration of hydroxyzine to healthy dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18980631/),%,72,272329,DB00592,Piperazine
,18980631,peak concentration,"After oral administration of hydroxyzine, the mean peak concentration of cetirizine was approximately 2.2 microg mL(-1) and that of hydroxyzine 0.16 microg mL(-1).",Hydroxyzine and cetirizine pharmacokinetics and pharmacodynamics after oral and intravenous administration of hydroxyzine to healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18980631/),[μg] / [ml],2.2,272330,DB00592,Piperazine
,18980631,peak concentration,"After oral administration of hydroxyzine, the mean peak concentration of cetirizine was approximately 2.2 microg mL(-1) and that of hydroxyzine 0.16 microg mL(-1).",Hydroxyzine and cetirizine pharmacokinetics and pharmacodynamics after oral and intravenous administration of hydroxyzine to healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18980631/),[μg] / [ml],0.16,272331,DB00592,Piperazine
,18980631,terminal half-life,The terminal half-life for cetirizine varied between 10 and 11 h after intravenous and oral administration of hydroxyzine.,Hydroxyzine and cetirizine pharmacokinetics and pharmacodynamics after oral and intravenous administration of hydroxyzine to healthy dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18980631/),h,10 and 11,272332,DB00592,Piperazine
,18980631,Maximum inhibition,"Maximum inhibition (82% and 69% for histamine and anticanine IgE-mediated skin reactions, respectively) was observed during the first 8 h, which correlated with a plasma concentration of cetirizine greater than 1.5 microg mL(-1).",Hydroxyzine and cetirizine pharmacokinetics and pharmacodynamics after oral and intravenous administration of hydroxyzine to healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18980631/),%,82,272333,DB00592,Piperazine
,18980631,Maximum inhibition,"Maximum inhibition (82% and 69% for histamine and anticanine IgE-mediated skin reactions, respectively) was observed during the first 8 h, which correlated with a plasma concentration of cetirizine greater than 1.5 microg mL(-1).",Hydroxyzine and cetirizine pharmacokinetics and pharmacodynamics after oral and intravenous administration of hydroxyzine to healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18980631/),%,69,272334,DB00592,Piperazine
,21741847,IC₅₀,"Synthesis and evaluation of designed compounds revealed 1-[3-(aminomethyl)-4-(4-methylphenyl)-2-(2-methylpropyl)quinolin-6-yl]piperazine-2,5-dione (1) as a potent, selective, and orally active DPP-4 inhibitor (IC₅₀=1.3 nM) with long-lasting ex vivo activity in dogs and excellent antihyperglycemic effects in rats.","Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21741847/),nM,1.3,272450,DB00592,Piperazine
,21148045,terminal half-life,Ketoconazole coadministration decreased the mean apparent clearance of bosutinib approximately 9-fold and increased the mean (SD) terminal half-life from 46.2 (16.4) hours to 69.0 (29.1) hours.,Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21148045/),h,46.2,272526,DB00592,Piperazine
,21148045,terminal half-life,Ketoconazole coadministration decreased the mean apparent clearance of bosutinib approximately 9-fold and increased the mean (SD) terminal half-life from 46.2 (16.4) hours to 69.0 (29.1) hours.,Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21148045/),h,69.0,272527,DB00592,Piperazine
,28703026,fetal/maternal,The fetal/maternal concentration ratio ranged from 0.5 to 0.58 for nilotinib and from 0.05 to 0.22 for imatinib.,Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28703026/),,0.5 to 0.58,272680,DB00592,Piperazine
,28703026,concentration ratio,The fetal/maternal concentration ratio ranged from 0.5 to 0.58 for nilotinib and from 0.05 to 0.22 for imatinib.,Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28703026/),,0.5 to 0.58,272681,DB00592,Piperazine
,28703026,concentration ratio,The fetal/maternal concentration ratio ranged from 0.5 to 0.58 for nilotinib and from 0.05 to 0.22 for imatinib.,Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28703026/),,0.05 to 0.22,272682,DB00592,Piperazine
,8742233,steady-state plasma concentrations,"To make a valid comparison, differences in pharmacokinetic properties between the azoles were accounted for by using an infusion approach to maintain steady-state plasma concentrations over a range of 1-48 mg/liter.",Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Use of steady-state infusion approach to achieve plasma concentration-response relationships. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8742233/),[mg] / [l],1-48,272847,DB00592,Piperazine
,8742233,Ki,"Analysis of these data provided Ki values of 3 and 10 microM, for ketoconazole and fluconazole, respectively, based on plasma concentration of azole.",Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Use of steady-state infusion approach to achieve plasma concentration-response relationships. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8742233/),μM,3,272848,DB00592,Piperazine
,8742233,Ki,"Analysis of these data provided Ki values of 3 and 10 microM, for ketoconazole and fluconazole, respectively, based on plasma concentration of azole.",Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Use of steady-state infusion approach to achieve plasma concentration-response relationships. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8742233/),μM,10,272849,DB00592,Piperazine
,8742233,Ki,"Ki values based on unbound drug concentration are 0.07 and 8.7 microM for ketoconazole and fluconazole, respectively.",Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Use of steady-state infusion approach to achieve plasma concentration-response relationships. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8742233/),μM,0.07,272850,DB00592,Piperazine
,8742233,Ki,"Ki values based on unbound drug concentration are 0.07 and 8.7 microM for ketoconazole and fluconazole, respectively.",Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Use of steady-state infusion approach to achieve plasma concentration-response relationships. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8742233/),μM,8.7,272851,DB00592,Piperazine
,15935603,recoveries,"Mean recoveries from plasma and tissue homogenates were 88 and 90%, respectively.",Rapid and sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in mouse plasma and tissues. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15935603/),%,88,273643,DB00592,Piperazine
,15935603,recoveries,"Mean recoveries from plasma and tissue homogenates were 88 and 90%, respectively.",Rapid and sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in mouse plasma and tissues. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15935603/),%,90,273644,DB00592,Piperazine
,33346335,half-life,"The median predicted infant dolutegravir half-life and median time to protein-adjusted 90% inhibitory concentration (0.064 mg/L) for those above this threshold were 37.9 (range, 22.1-63.5) hours and 108.9 (18.6-129.6) hours (4.5 [0.8-5.4] days) (n = 13), respectively.",Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33346335/),[mg] / [l],0.064,273645,DB00592,Piperazine
,33346335,time to protein-adjusted 90% inhibitory concentration,"The median predicted infant dolutegravir half-life and median time to protein-adjusted 90% inhibitory concentration (0.064 mg/L) for those above this threshold were 37.9 (range, 22.1-63.5) hours and 108.9 (18.6-129.6) hours (4.5 [0.8-5.4] days) (n = 13), respectively.",Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33346335/),[mg] / [l],0.064,273646,DB00592,Piperazine
,33346335,time to protein-adjusted 90% inhibitory concentration,"The median predicted infant dolutegravir half-life and median time to protein-adjusted 90% inhibitory concentration (0.064 mg/L) for those above this threshold were 37.9 (range, 22.1-63.5) hours and 108.9 (18.6-129.6) hours (4.5 [0.8-5.4] days) (n = 13), respectively.",Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33346335/),h,37.9,273647,DB00592,Piperazine
,33346335,time to protein-adjusted 90% inhibitory concentration,"The median predicted infant dolutegravir half-life and median time to protein-adjusted 90% inhibitory concentration (0.064 mg/L) for those above this threshold were 37.9 (range, 22.1-63.5) hours and 108.9 (18.6-129.6) hours (4.5 [0.8-5.4] days) (n = 13), respectively.",Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33346335/),h,108.9,273648,DB00592,Piperazine
,33346335,time to protein-adjusted 90% inhibitory concentration,"The median predicted infant dolutegravir half-life and median time to protein-adjusted 90% inhibitory concentration (0.064 mg/L) for those above this threshold were 37.9 (range, 22.1-63.5) hours and 108.9 (18.6-129.6) hours (4.5 [0.8-5.4] days) (n = 13), respectively.",Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33346335/),d,4.5,273649,DB00592,Piperazine
,11752133,steady-state concentrations,"Four groups of rats each received 1 mg/kg 8-OH-DPAT in 5 min during computer-controlled infusions of physiological saline or WAY-100,635, targeted at steady-state concentrations of 20, 85, and 170 ng/ml.","A competitive interaction model predicts the effect of WAY-100,635 on the time course of R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin-induced hypothermia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752133/),[ng] / [ml],20,273916,DB00592,Piperazine
,11752133,steady-state concentrations,"Four groups of rats each received 1 mg/kg 8-OH-DPAT in 5 min during computer-controlled infusions of physiological saline or WAY-100,635, targeted at steady-state concentrations of 20, 85, and 170 ng/ml.","A competitive interaction model predicts the effect of WAY-100,635 on the time course of R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin-induced hypothermia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752133/),[ng] / [ml],85,273917,DB00592,Piperazine
,11752133,steady-state concentrations,"Four groups of rats each received 1 mg/kg 8-OH-DPAT in 5 min during computer-controlled infusions of physiological saline or WAY-100,635, targeted at steady-state concentrations of 20, 85, and 170 ng/ml.","A competitive interaction model predicts the effect of WAY-100,635 on the time course of R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin-induced hypothermia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752133/),[ng] / [ml],170,273918,DB00592,Piperazine
,11752133,terminal elimination half-life,"Large differences in pharmacokinetics were observed between WAY-100,635 and R-8-OH-DPAT, reflected in values of the terminal elimination half-life of 33 and 143 min, respectively.","A competitive interaction model predicts the effect of WAY-100,635 on the time course of R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin-induced hypothermia. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752133/),min,33,273919,DB00592,Piperazine
,11752133,terminal elimination half-life,"Large differences in pharmacokinetics were observed between WAY-100,635 and R-8-OH-DPAT, reflected in values of the terminal elimination half-life of 33 and 143 min, respectively.","A competitive interaction model predicts the effect of WAY-100,635 on the time course of R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin-induced hypothermia. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752133/),min,143,273920,DB00592,Piperazine
,11752133,binding constant,"The estimated in vivo binding constant of WAY-100,635 was 0.98 ng/ml (2.3 nM), which is very similar to the reported value from in vitro receptor binding assays.","A competitive interaction model predicts the effect of WAY-100,635 on the time course of R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin-induced hypothermia. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752133/),[ng] / [ml],0.98,273921,DB00592,Piperazine
,11752133,binding constant,"The estimated in vivo binding constant of WAY-100,635 was 0.98 ng/ml (2.3 nM), which is very similar to the reported value from in vitro receptor binding assays.","A competitive interaction model predicts the effect of WAY-100,635 on the time course of R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin-induced hypothermia. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11752133/),nM,2.3,273922,DB00592,Piperazine
,29771285,maximum concentration (Cmax),"DTG maximum concentration (Cmax) was significantly higher in patients ≥60 years old versus controls (geometric mean 4246 ng/mL versus 3402 ng/mL, P = .005).","Increased Dolutegravir Peak Concentrations in People Living With Human Immunodeficiency Virus Aged 60 and Over, and Analysis of Sleep Quality and Cognition. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29771285/),[ng] / [ml],4246,274004,DB00592,Piperazine
,29771285,maximum concentration (Cmax),"DTG maximum concentration (Cmax) was significantly higher in patients ≥60 years old versus controls (geometric mean 4246 ng/mL versus 3402 ng/mL, P = .005).","Increased Dolutegravir Peak Concentrations in People Living With Human Immunodeficiency Virus Aged 60 and Over, and Analysis of Sleep Quality and Cognition. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29771285/),[ng] / [ml],3402,274005,DB00592,Piperazine
,8126695,IC50,A number of analogues in the TP series that incorporate a modified or unmodified L-methionine sulfone amide at the C2 endo position on the camphor ring exhibit high affinity for OT receptors (IC50 = 1.3-15 nM) and good selectivity for binding to OT versus arginine vasopressin V1a and V2 receptors.,"1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126695/),nM,1.3-15,274111,DB00592,Piperazine
,8126695,IC50,"Compound 7 (L-368,899) exhibited the best overall profile of OT receptor affinity (IC50 = 8.9 nM, rat uterus; 26 nM, human uterus), potency for inhibition of OT-stimulated contractions of the isolated rat uterus (pA2 = 8.9) and in situ rat uterus (AD50 = 0.35 mg/kg after intravenous (i.v.) administration and 7.0 mg/kg after intraduodenal administration), aqueous solubility (3.7 mg/mL at pH 5.0), and oral bioavailability in several species (35% (rat), 25% (dog), and 21% (chimpanzee) as estimated from radioreceptor determination of drug levels in plasma after oral and i.v. dosing).","1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126695/),nM,8.9,274112,DB00592,Piperazine
,8126695,IC50,"Compound 7 (L-368,899) exhibited the best overall profile of OT receptor affinity (IC50 = 8.9 nM, rat uterus; 26 nM, human uterus), potency for inhibition of OT-stimulated contractions of the isolated rat uterus (pA2 = 8.9) and in situ rat uterus (AD50 = 0.35 mg/kg after intravenous (i.v.) administration and 7.0 mg/kg after intraduodenal administration), aqueous solubility (3.7 mg/mL at pH 5.0), and oral bioavailability in several species (35% (rat), 25% (dog), and 21% (chimpanzee) as estimated from radioreceptor determination of drug levels in plasma after oral and i.v. dosing).","1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126695/),nM,26,274113,DB00592,Piperazine
,8126695,oral bioavailability,"Compound 7 (L-368,899) exhibited the best overall profile of OT receptor affinity (IC50 = 8.9 nM, rat uterus; 26 nM, human uterus), potency for inhibition of OT-stimulated contractions of the isolated rat uterus (pA2 = 8.9) and in situ rat uterus (AD50 = 0.35 mg/kg after intravenous (i.v.) administration and 7.0 mg/kg after intraduodenal administration), aqueous solubility (3.7 mg/mL at pH 5.0), and oral bioavailability in several species (35% (rat), 25% (dog), and 21% (chimpanzee) as estimated from radioreceptor determination of drug levels in plasma after oral and i.v. dosing).","1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126695/),%,35,274114,DB00592,Piperazine
,8126695,oral bioavailability,"Compound 7 (L-368,899) exhibited the best overall profile of OT receptor affinity (IC50 = 8.9 nM, rat uterus; 26 nM, human uterus), potency for inhibition of OT-stimulated contractions of the isolated rat uterus (pA2 = 8.9) and in situ rat uterus (AD50 = 0.35 mg/kg after intravenous (i.v.) administration and 7.0 mg/kg after intraduodenal administration), aqueous solubility (3.7 mg/mL at pH 5.0), and oral bioavailability in several species (35% (rat), 25% (dog), and 21% (chimpanzee) as estimated from radioreceptor determination of drug levels in plasma after oral and i.v. dosing).","1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126695/),%,25,274115,DB00592,Piperazine
,8126695,oral bioavailability,"Compound 7 (L-368,899) exhibited the best overall profile of OT receptor affinity (IC50 = 8.9 nM, rat uterus; 26 nM, human uterus), potency for inhibition of OT-stimulated contractions of the isolated rat uterus (pA2 = 8.9) and in situ rat uterus (AD50 = 0.35 mg/kg after intravenous (i.v.) administration and 7.0 mg/kg after intraduodenal administration), aqueous solubility (3.7 mg/mL at pH 5.0), and oral bioavailability in several species (35% (rat), 25% (dog), and 21% (chimpanzee) as estimated from radioreceptor determination of drug levels in plasma after oral and i.v. dosing).","1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126695/),%,21,274116,DB00592,Piperazine
